<SEC-DOCUMENT>0001213900-26-034447.txt : 20260326
<SEC-HEADER>0001213900-26-034447.hdr.sgml : 20260326
<ACCEPTANCE-DATETIME>20260326100504
ACCESSION NUMBER:		0001213900-26-034447
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260326
DATE AS OF CHANGE:		20260326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Can-Fite BioPharma Ltd.
		CENTRAL INDEX KEY:			0001536196
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36203
		FILM NUMBER:		26794802

	BUSINESS ADDRESS:	
		STREET 1:		26 BEN GURION STREET
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5257346
		BUSINESS PHONE:		972 39241114

	MAIL ADDRESS:	
		STREET 1:		26 BEN GURION STREET
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5257346
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0282586-20f_canfite.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:canf="http://canfite.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title>canf-20251231</title>
    <meta http-equiv="Content-Type" content="text/html"/>
  </head>
  <body>
    <div style="display:none">
      <ix:header>
        <ix:hidden>
          <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="cref_184434641" id="fc_669790381" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="cref_1205104151" id="fc_406290213" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="cref_1997617154" id="fc_972519014" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="cref_678032609" id="fc_213046275" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonNumeric name="canf:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired" contextRef="cref_184434641" id="fc_113611892" xsi:nil="true"></ix:nonNumeric>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="cref_1997617154" id="fc_299793311" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="cref_1997617154" id="fc_1788048371" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="cref_678032609" id="fc_760617434" unitRef="uref_1278442780" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" contextRef="cref_1111035328" id="fc_1111035328" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" contextRef="cref_869951728" id="fc_2026529756" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_692454694" id="fc_2095020479" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1605243859" id="fc_1605243859" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_471624570" id="fc_2039191230" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" contextRef="cref_60220687" id="fc_2144679190" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" contextRef="cref_1111035328" id="fc_425053498" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" contextRef="cref_869951728" id="fc_8299037" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" contextRef="cref_1205104151" id="fc_1843738797" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" contextRef="cref_1743024573" id="fc_3754123" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" contextRef="cref_1111035328" id="fc_1652128422" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" contextRef="cref_869951728" id="fc_609884468" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_1743024573" id="fc_1574677278" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_1111035328" id="fc_536684989" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_869951728" id="fc_1304797919" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1743024573" id="fc_2054232463" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_60220687" id="fc_941212928" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1111035328" id="fc_204867609" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_679399687" id="fc_2021528685" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" contextRef="cref_1743024573" id="fc_964794137" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="cref_1997617154" id="fc_523126391" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="cref_678032609" id="fc_1937695010" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="cref_1997617154" id="fc_1954273020" unitRef="uref_1278442780" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="cref_1997617154" id="fc_172437876" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="cref_678032609" id="fc_438358129" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" contextRef="cref_1743024573" id="fc_101309368" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_679399687" id="fc_1350392693" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodExerciseValue" contextRef="cref_236998777" id="fc_777455571" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodExerciseValue" contextRef="cref_1424085176" id="fc_1424085176" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodExerciseValue" contextRef="cref_1722856177" id="fc_1050864119" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" contextRef="cref_236998777" id="fc_549751167" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" contextRef="cref_1424085176" id="fc_1604115385" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" contextRef="cref_1722856177" id="fc_696482402" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_236998777" id="fc_1466338231" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_1424085176" id="fc_2080488118" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_1722856177" id="fc_443517718" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_236998777" id="fc_1816291455" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1978583206" id="fc_273676464" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1424085176" id="fc_1832570996" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1254970073" id="fc_554639177" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PaymentsForProceedsFromShortTermInvestments" contextRef="cref_184434641" id="fc_1146546674" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="cref_1914073660" id="fc_421221726" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:LeaseLiabilitiesArisingFromObtainingRightofuseassets" contextRef="cref_184434641" id="fc_1937658026" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_180300996" id="fc_1633826125" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="cref_180300996" id="fc_2074154732" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_1997113680" id="fc_1997113680" unitRef="uref_1413771939" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_487311381" id="fc_487311381" unitRef="uref_1413771939" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="cref_1904201796" id="fc_1904201796" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="cref_1856579833" id="fc_1856579833" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="cref_2047207648" id="fc_2047207648" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="cref_736875626" id="fc_736875626" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="cref_2040359165" id="fc_2130825858" unitRef="uref_1278442780" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="cref_1997617154" id="fc_539237308" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="cref_678032609" id="fc_506692405" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1316363029" id="fc_1027623191" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" contextRef="cref_1182592801" id="fc_1004110757" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" contextRef="cref_1605243859" id="fc_1372760715" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" contextRef="cref_847760719" id="fc_1059179270" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="cref_1182592801" id="fc_259543012" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="cref_1605243859" id="fc_546765437" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="cref_847760719" id="fc_548260843" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_1182592801" id="fc_834906283" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_1605243859" id="fc_1025560619" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_847760719" id="fc_1834162276" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1182592801" id="fc_200494866" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="cref_898003050" id="fc_1936936551" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="cref_898003050" id="fc_605971914" unitRef="uref_1413771939" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="cref_184434641" id="fc_1216322058" unitRef="uref_1278442780" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" contextRef="cref_678032609" id="fc_1823340782" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" contextRef="cref_1997617154" id="fc_792382386" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="cref_678032609" id="fc_2016546657" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="cref_1997617154" id="fc_84170453" unitRef="uref_720247910" xsi:nil="true"></ix:nonFraction>
          <ix:nonNumeric name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="cref_184434641" id="fc_698904215">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</ix:nonNumeric>
          <ix:nonNumeric name="dei:AmendmentFlag" contextRef="cref_184434641" id="ixv-15551">false</ix:nonNumeric>
          <ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="cref_184434641" id="ixv-15552">FY</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="cref_184434641" id="ixv-15553">0001536196</ix:nonNumeric>
        </ix:hidden>
        <ix:references>
          <link:schemaRef xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="canf-20251231.xsd" xlink:type="simple"/>
        </ix:references>
        <ix:resources>
          <xbrli:context id="cref_734008993">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1683224475">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-03-04</xbrli:startDate>
              <xbrli:endDate>2026-03-04</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1278442780">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-04</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1272600409">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:ADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-04</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1413771939">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-04</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_100549505">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-04</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1060093280">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-03-04</xbrli:startDate>
              <xbrli:endDate>2026-03-04</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1994543132">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:NewWarrantSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2026-03-04</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1459093040">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-29</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_184434641">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_898003050">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_678032609">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1997617154">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_44387193">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2017Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_697212563">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_616608710">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_248394047">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1914073660">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1205104151">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1894462461">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1202395540">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1132214309">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1398170537">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1190382762">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_42715392">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1607629638">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_907931666">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_520798346">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1055653923">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1803955859">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_342246256">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_583004226">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_219588702">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-12-31</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_109046716">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">canf:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_862142534">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">canf:TwoThousandThirteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2023-08-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1355753607">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2013-11-28</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_202162938">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1358509655">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2025OneMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1019937961">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2025OneMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1665281426">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2025Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1056014996">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2025Member</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1404131453">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_533550791">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1783668540">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2024AgentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_910941741">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2024AgentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_160240094">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_272935354">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1968813787">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:November2023AgentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1043966202">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:November2023AgentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1820958487">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:November2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_797890104">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:November2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1156080072">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2023AgentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1443470887">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2023AgentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_197686924">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1731853064">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_997732034">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-11-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_48256838">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-11-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1936150275">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-11-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_435254208">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-18</xbrli:startDate>
              <xbrli:endDate>2025-11-18</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1116774511">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-11-18</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1336110434">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">canf:InvestorsFromJuly2025OfferingMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-18</xbrli:startDate>
              <xbrli:endDate>2025-11-18</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_801816110">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-05</xbrli:startDate>
              <xbrli:endDate>2026-01-05</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1078174181">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2026-01-02</xbrli:startDate>
              <xbrli:endDate>2026-01-02</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2037786040">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">canf:SpecialGeneralMeetingOfShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-11-10</xbrli:startDate>
              <xbrli:endDate>2025-11-10</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2040359165">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">canf:SpecialGeneralMeetingOfShareholdersMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-11-10</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1554927284">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-08-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1250994810">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-08-01</xbrli:startDate>
              <xbrli:endDate>2025-08-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1465389010">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-28</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1363860027">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-28</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1886921177">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-28</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1755993480">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-28</xbrli:startDate>
              <xbrli:endDate>2025-07-28</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_275892941">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:CommonWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-28</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_421138161">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:CommonWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-28</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2132039962">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:PreFundedWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-28</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1039317372">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-28</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_575156313">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-28</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1839015054">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:PreFundedWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-07-28</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1536062095">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-07-28</xbrli:startDate>
              <xbrli:endDate>2025-07-28</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1249276182">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-06-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_870625474">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-06-30</xbrli:startDate>
              <xbrli:endDate>2025-06-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_487979537">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-04-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1503704402">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-04-30</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_374804358">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-04-14</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_673085692">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-04-14</xbrli:startDate>
              <xbrli:endDate>2025-04-14</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_236998777">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1335503686">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-04-06</xbrli:startDate>
              <xbrli:endDate>2025-04-06</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1743024573">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1329224424">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-08-08</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_889933283">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:NewWarrantsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-08-08</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2133907439">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-08-08</xbrli:startDate>
              <xbrli:endDate>2024-08-08</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1922956513">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-08-08</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2043010181">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-07-03</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_54615801">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-07-03</xbrli:startDate>
              <xbrli:endDate>2024-07-03</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1778457142">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-04-01</xbrli:startDate>
              <xbrli:endDate>2024-04-01</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1677178547">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2023-02-22</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_447010128">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">canf:RegulatoryAuthorityMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_576633015">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">canf:PhaseIIIStudiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_337919505">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">canf:PhaseIIStudiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2059261110">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">canf:PhaseIStudiesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_648214257">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:VetbiolixMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-09-24</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1130319153">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-09-24</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2057783007">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-06-28</xbrli:startDate>
              <xbrli:endDate>2021-06-28</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_344781049">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-06-28</xbrli:startDate>
              <xbrli:endDate>2021-06-28</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_398624799">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_797038194">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-03-16</xbrli:startDate>
              <xbrli:endDate>2021-03-16</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1154935824">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2021-03-16</xbrli:startDate>
              <xbrli:endDate>2021-03-16</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1677665869">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:KyongboPharmCoLtdMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2019-07-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2037445886">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2019-07-31</xbrli:startDate>
              <xbrli:endDate>2019-07-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1089428082">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:SalesMilestonesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_758140809">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:RegulatoryMilestonesMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_112398461">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CMSMedicalVentureInvestmentLimitedMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2018-04-06</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1830464667">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:VetbiolixMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1798028992">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmbHMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1590073223">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1315189725">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-10-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_632092621">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-10-31</xbrli:startDate>
              <xbrli:endDate>2025-10-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_818757102">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">canf:NASHMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-10-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1375081973">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">canf:LiverCancerIndicationMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-10-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_485025225">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2015-03-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1598663686">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2015-03-01</xbrli:startDate>
              <xbrli:endDate>2015-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2046075473">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2015-03-01</xbrli:startDate>
              <xbrli:endDate>2015-03-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1501641585">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_976418671">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1943456894">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1736241007">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1126769489">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_595936047">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_255520659">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_405802932">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_133213812">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_626091944">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_264863037">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1787915782">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1102009625">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1513674">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_656845410">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1010971887">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_940504229">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:VetbiolixMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_401885686">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1969999970">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_707849457">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2073970239">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmbHMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1630416524">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmbHMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1380163261">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmbHMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_262393112">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1752405840">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1051158666">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1756871285">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1085088613">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1329610678">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1707962055">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_794440730">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1654566158">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_180300996">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_385792771">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2023-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_346153289">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1212188529">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1110324969">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1268205755">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1254970073">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1722856177">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1978583206">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1298046308">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_503396369">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1447998007">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_679399687">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_869951728">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_60220687">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_301922635">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2023-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1568626008">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2023-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_713467315">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2023-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_471624570">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2023-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_847760719">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_692454694">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1182592801">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1096639490">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_430322482">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1689545004">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1316363029">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2022-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1741811486">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1111035328">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2024-01-01</xbrli:startDate>
              <xbrli:endDate>2024-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1605243859">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1424085176">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1997113680">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:VetbiolixMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-01-01</xbrli:startDate>
              <xbrli:endDate>2025-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_487311381">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:VetbiolixMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2023-01-01</xbrli:startDate>
              <xbrli:endDate>2023-12-31</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1904201796">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_1856579833">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2025-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_2047207648">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="cref_736875626">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:instant>2024-12-31</xbrli:instant>
            </xbrli:period>
          </xbrli:context>
          <xbrli:unit id="uref_734008993">
            <xbrli:measure>xbrli:shares</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="uref_720247910">
            <xbrli:measure>iso4217:USD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="uref_1278442780">
            <xbrli:divide>
              <xbrli:unitNumerator>
                <xbrli:measure>iso4217:USD</xbrli:measure>
              </xbrli:unitNumerator>
              <xbrli:unitDenominator>
                <xbrli:measure>xbrli:shares</xbrli:measure>
              </xbrli:unitDenominator>
            </xbrli:divide>
          </xbrli:unit>
          <xbrli:unit id="uref_1413771939">
            <xbrli:measure>xbrli:pure</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="uref_2084217627">
            <xbrli:measure>canf:Segment</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="uref_1677178547">
            <xbrli:divide>
              <xbrli:unitNumerator>
                <xbrli:measure>iso4217:ILS</xbrli:measure>
              </xbrli:unitNumerator>
              <xbrli:unitDenominator>
                <xbrli:measure>xbrli:shares</xbrli:measure>
              </xbrli:unitDenominator>
            </xbrli:divide>
          </xbrli:unit>
          <xbrli:unit id="uref_447010128">
            <xbrli:measure>iso4217:EUR</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="uref_1598663686">
            <xbrli:measure>iso4217:CAD</xbrli:measure>
          </xbrli:unit>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fref_223778504" fromRefs="fc_523126391 fc_1954273020 fc_1802511409 fc_718697983 fc_1848454736 fc_760617434 fc_326785155 fc_171354521 fc_112058716 fc_1937695010"/>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fref_71790209" fromRefs="fc_50742992 fc_1621210643 fc_2139747243 fc_977396253 fc_1309137784 fc_1373640430"/>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fref_376288337" fromRefs="fc_1316363029 fc_2108866782 fc_1182592801 fc_834906283 fc_101309368 fc_1350392693 fc_887952012 fc_776479262 fc_41120727 fc_1816291455 fc_554639177 fc_2039191230 fc_462574281 fc_563207362 fc_2054232463 fc_2021528685 fc_964794137 fc_1027623191 fc_1004110757 fc_259543012 fc_200494866 fc_679399687 fc_777455571 fc_549751167 fc_1466338231 fc_1254970073 fc_471624570 fc_761083602 fc_3754123 fc_1574677278 fc_1391618102 fc_1556835653"/>
          <ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fref_49130764" fromRefs="fc_1132214309 fc_1398170537 fc_1202395540"/>
        </ix:resources>
      </ix:header>
    </div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-weight: bold;">UNITED STATES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Washington, D.C. 20549</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: bold;">Form <ix:nonNumeric name="dei:DocumentType" contextRef="cref_184434641" id="ixv-17043">20-F</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-family: Times New Roman, Times, Serif"><span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentRegistrationStatement" contextRef="cref_184434641" format="ixt:fixed-false" id="ixv-17044">&#9744;</ix:nonNumeric></span></span><span style="font-weight: bold;"> REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Or</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-family: Times New Roman, Times, Serif"><span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="cref_184434641" format="ixt:fixed-true" id="ixv-17045">&#9746;</ix:nonNumeric></span></span><span style="font-weight: bold;"> ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: bold;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="cref_184434641" format="ixt:date-monthname-day-year-en" id="ixv-17046"><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="cref_184434641" format="ixt:date-monthname-day-en" id="ixv-17047">December 31</ix:nonNumeric>, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="cref_184434641" format="ixt:num-dot-decimal" id="ixv-17048">2025</ix:nonNumeric></ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Or</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-family: Times New Roman, Times, Serif"><span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="cref_184434641" format="ixt:fixed-false" id="ixv-17049">&#9744;</ix:nonNumeric></span></span><span style="font-weight: bold;"> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Or</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-family: Times New Roman, Times, Serif"><span style="font-weight: bold;"><ix:nonNumeric name="dei:DocumentShellCompanyReport" contextRef="cref_184434641" format="ixt:fixed-false" id="ixv-17050">&#9744;</ix:nonNumeric></span></span><span style="font-weight: bold;"> SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of event requiring this shell company report________________________</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">For the transition period from</span>__________
to ___________</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> Commission File No. <ix:nonNumeric name="dei:EntityFileNumber" contextRef="cref_184434641" id="ixv-17051">001-36203</ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="cref_184434641" id="ixv-17052">Can-Fite BioPharma Ltd.</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Exact name of Registrant as specified in its
charter)</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Can-Fite BioPharma Ltd., an Israeli Limited
Company</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Translation of Registrant&#8217;s name into
English)</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="cref_184434641" format="ixt-sec:edgarprovcountryen" id="ixv-17053">Israel</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Jurisdiction of incorporation or organization)</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="cref_184434641" id="ixv-17054">26 Ben Gurion Street</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="cref_184434641" id="ixv-17055">Ramat Gan</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="cref_184434641" id="ixv-17056">5257346</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="cref_184434641" format="ixt-sec:countrynameen" id="ixv-17057">Israel</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Address of principal executive offices)</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: bold;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="cref_1741811486" id="ixv-17058">Motti Farbstein</ix:nonNumeric></span> <br/><span style="font-weight: bold;">
Chief Executive, Financial and Operating Officer</span><br/> <span style="font-weight: bold;"> Tel: <ix:nonNumeric name="dei:CityAreaCode" contextRef="cref_1741811486" id="ixv-17059">+972</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="cref_1741811486" id="ixv-17060">(3) 924-1114</ix:nonNumeric></span> <br/> <span style="font-weight: bold;"> Fax: <ix:nonNumeric name="dei:ContactPersonnelFaxNumber" contextRef="cref_1741811486" id="ixv-17061">+972 (3) 924-9378</ix:nonNumeric></span> <br/> <span style="font-weight: bold;"> <ix:nonNumeric name="dei:ContactPersonnelEmailAddress" contextRef="cref_1741811486" id="ixv-17062">motti@canfite.co.il</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="cref_1741811486" id="ixv-17063">26 Ben Gurion Street</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="cref_1741811486" id="ixv-17064">Ramat Gan</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="cref_1741811486" id="ixv-17065">5257346</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressCountry" contextRef="cref_1741811486" format="ixt-sec:countrynameen" id="ixv-17066">Israel</ix:nonNumeric> </span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(Name, Telephone, E-mail and/or Facsimile number
and Address of Company Contact Person)</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(b) of the Act:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center">Title of each class</td>
<td style="width: 2%; text-align: center">&#160;</td>
<td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center">Trading Symbol(s)</td>
<td style="width: 2%; text-align: center">&#160;</td>
<td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center">Name of each exchange on which registered</td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="cref_184434641" id="ixv-17067">American Depositary Shares, each representing 2 Ordinary Shares, no par value</ix:nonNumeric> *</span></td><td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="cref_184434641" id="ixv-17068">CANF</ix:nonNumeric></span></td><td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="cref_184434641" format="ixt-sec:exchnameen" id="ixv-17069">NYSE</ix:nonNumeric> American</span></td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(g) of the Act:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">None</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">None</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Ordinary shares not for trading, but only in connection with
the registration of the American Depositary Shares.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report (December 31, 2025): <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="cref_1997617154" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17070">2,618,425</ix:nonFraction> ordinary shares are outstanding. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="cref_184434641" id="ixv-17071">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="cref_184434641" id="ixv-17072">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such a shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="cref_184434641" id="ixv-17073">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="cref_184434641" id="ixv-17074">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of
the Exchange Act.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr> <td style="width: 31%">Large accelerated filer</td><td style="vertical-align: top; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td><td style="width: 25%">Accelerated filer</td><td style="vertical-align: top; width: 6%"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td><td style="width: 25%"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="cref_184434641" format="ixt-sec:entityfilercategoryen" id="ixv-17075">Non-accelerated filer</ix:nonNumeric></td><td style="vertical-align: top; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></td> </tr>
<tr> <td style="vertical-align: top">&#160;</td><td style="vertical-align: top; text-align: center">&#160;</td><td style="vertical-align: top">&#160;</td><td style="vertical-align: top; text-align: center">&#160;</td><td>Emerging growth company</td><td style="vertical-align: top; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="cref_184434641" format="ixt:fixed-false" id="ixv-17076">&#9744;</ix:nonNumeric></span></td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth company
that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use
the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section
13(a) of the Exchange Act <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 24px">&#1006;</td>
<td style="text-align: justify">The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by
    the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="cref_184434641" format="ixt:fixed-false" id="ixv-17077">&#9744;</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant reflect the correction of an error to previously issued financial statements. <span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="cref_184434641" format="ixt:fixed-false" id="ixv-17078">&#9744;</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of
the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark which
basis of accounting the registrant has used to prepare the financial statements included in this filing:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom"> <td style="width: 25%; text-indent: 0.5in"><ix:nonNumeric name="dei:DocumentAccountingStandard" contextRef="cref_184434641" id="ixv-17079">U.S. GAAP</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></td><td style="width: 50%; text-align: center">International Financial Reporting Standards</td><td style="width: 25%; text-align: center">Other <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td> </tr>
<tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td>
<td style="text-align: center">as issued by the International Accounting Standards Board <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td>
<td style="text-align: center">&#160;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If &#8220;Other&#8221; has
been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to
follow. Item 17 <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;Item 18 <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;No <span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric name="dei:EntityShellCompany" contextRef="cref_184434641" format="ixt:fixed-false" id="ixv-17080">&#9746;</ix:nonNumeric></span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 2 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">TABLE OF CONTENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="background-color: rgb(204,238,255)">
<td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_001"><span style="font-weight: bold;">PART I</span></a></td>
<td style="text-align: center">1</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; width: 10%; text-align: justify"><span style="font-weight: bold;">ITEM 1.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; width: 81%; text-align: justify"><a href="#a_002">Identity of Directors, Senior Management and Advisers.</a></td>
<td style="text-align: center; width: 9%">1</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 2.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_003">Offer Statistics and Expected Timetable</a></td>
<td style="text-align: center">1</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 3.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_004">Key Information</a></td>
<td style="text-align: center">1</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 4.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_005">Information on the Company</a></td>
<td style="text-align: center">40</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 4A.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_006">Unresolved Staff Comments</a></td>
<td style="text-align: center">91</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 5.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_007">Operating and Financial Review and Prospects</a></td>
<td style="text-align: center">91</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 6.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_008">Directors, Senior Management and Employees</a></td>
<td style="text-align: center">104</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 7.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_009">Major Shareholders and Related Party Transactions</a></td>
<td style="text-align: center">124</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 8.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_010">Financial Information</a></td>
<td style="text-align: center">125</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 9.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_011">The Offer and Listing</a></td>
<td style="text-align: center">126</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 10.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_012">Additional Information</a></td>
<td style="text-align: center">127</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 11.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_013">Quantitative and Qualitative Disclosures About Market Risk</a></td>
<td style="text-align: center">147</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 12.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_014">Description of Securities Other Than Equity Securities</a></td>
<td style="text-align: center">148</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify">&#160;</td>
<td style="text-align: center">&#160;</td>
</tr>
<tr style="background-color: White">
<td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#a_015"><span style="font-weight: bold;">PART II</span></a></td>
<td style="text-align: center">150</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 13.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_016">Defaults, Dividend Arrearages and Delinquencies</a></td>
<td style="text-align: center">150</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 14.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_017">Material Modifications to the Rights of Security Holders and Use of Proceeds</a></td>
<td style="text-align: center">150</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 15.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_018">Controls and Procedures</a></td>
<td style="text-align: center">150</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 16.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_019">[RESERVED]</a></td>
<td style="text-align: center">151</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 16A.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_020">Audit Committee Financial Expert</a></td>
<td style="text-align: center">151</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 16B.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_021">Code of Ethics</a></td>
<td style="text-align: center">151</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 16C.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_022">Principal Accountant Fees and Services</a></td>
<td style="text-align: center">151</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 16D.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_023">Exemptions from the Listing Standards for Audit Committees</a></td>
<td style="text-align: center">151</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 16E.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_024">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></td>
<td style="text-align: center">151</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 16F.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_025">Change in Registrant&#8217;s Certifying Accountant</a></td>
<td style="text-align: center">151</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 16G.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_026">Corporate Governance</a></td>
<td style="text-align: center">152</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 16H.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_027">Mine Safety Disclosure</a></td>
<td style="text-align: center">152</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 16I.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_028">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
<td style="text-align: center">152</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 16J.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_029">Insider Trading Policies</a></td>
<td style="text-align: center">152</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 16K.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_030">Cybersecurity</a></td>
<td style="text-align: center">152</td>
</tr>
<tr style="background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</td>
<td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
<td style="text-align: center">&#160;</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td colspan="2" style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_031"><span style="font-weight: bold;">PART III</span></a></td>
<td style="text-align: center">153</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 17.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_032">Financial Statements</a></td>
<td style="text-align: center">153</td>
</tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 18.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_033">Financial Statements</a></td>
<td style="text-align: center">153</td>
</tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><span style="font-weight: bold;">ITEM 19.</span></td>
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: justify"><a href="#a_034">Exhibits</a></td>
<td style="text-align: center">153</td>
</tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">INTRODUCTION</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Can-Fite is an advanced clinical-stage
biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and
inflammatory diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target.
A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal cells,
suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline of drug candidates are synthetic,
highly specific agonists and allosteric modulators targeting the A3AR.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since 2005, our ordinary
shares have been trading on the Tel Aviv Stock Exchange, or TASE, and trade under the symbol &#8220;CANF&#8221;. On October 2, 2012,
our ADSs began trading over the counter, or OTC, in the United States and on November 19, 2013, our ADSs began trading on the NYSE American
under the symbol &#8220;CANF.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;Can-Fite&#8221; refer to Can-Fite BioPharma
Ltd. and its consolidated subsidiary. References to &#8220;ordinary shares&#8221;, &#8220;ADSs&#8221;, &#8220;warrants&#8221; and &#8220;share
capital&#8221; refer to the ordinary shares, ADSs, warrants and share capital, respectively, of Can-Fite.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">References to &#8220;U.S.
dollars&#8221;, &#8220;dollars&#8221;, &#8220;USD&#8221;, and &#8220;$&#8221; are to currency of the United States of America, and references
to &#8220;NIS&#8221; are to New Israeli Shekels. References to &#8220;ordinary shares&#8221; are to our ordinary shares, no par value.
We report financial information under generally accepted accounting principles in the United States, or U.S. GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
U.S. dollar translations of NIS amounts presented in this Annual Report on Form 20-F for the year ended on December 31, 2025 are translated
using the rate of NIS 3.19 to $1.00, the exchange rate reported by the Bank of Israel on December 31, 2025, U.S. dollar translations
of NIS amounts presented in this Annual Report on Form 20-F for the year ended on December 31, 2024 are translated using the rate of
NIS 3.467 to $1.00, the exchange rate reported by the Bank of Israel on December 31, 2024, and U.S. dollar translations of NIS amounts
presented in this Annual Report on Form 20-F for the year ended on December 31, 2023 are translated using the rate of NIS 3.627 to $1.00,
the exchange rate reported by the Bank of Israel on December 29, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 2, 2026, we effected
a 1-for-3,000 reverse split of our ordinary shares with the Tel-Aviv Stock Exchange, or TASE, and the newly consolidated ordinary shares
began trading on TASE on January 5, 2026. Concurrently, on January 5, 2026, we effected a change in the ratio of our ADSs to ordinary
shares from one (1) ADS representing three hundred (300) ordinary shares to a new ratio of one (1) ADS representing two (2) ordinary
shares. For ADS holders, the ratio change had the same effect as a one-for-twenty reverse ADS split. All ADS and related option and warrant
information presented in this Annual Report on Form 20-F have been retroactively adjusted to reflect the reduced number of ADSs and the
increase in the ADS price which resulted from this action. Unless otherwise indicated, in this Annual Report on Form 20-F fractional
ADSs have been rounded to the nearest whole number.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><!-- Field: Page; Sequence: 4; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">FORWARD LOOKING STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
20-F contains forward-looking statements, about our expectations, beliefs or intentions regarding, among other things, our product development
efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking
words such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should&#8221;
or &#8220;anticipate&#8221; or their negatives or other variations of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not
limited to, various filings made by us with the U.S. Securities and Exchange Commission, or the SEC, press releases or oral statements
made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected
events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not
yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially
from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results
to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors
summarized below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
20-F identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking
statements, particularly those set forth under the heading &#8220;Risk Factors.&#8221; The risk factors included in this Annual Report
on Form 20-F are not necessarily all of the important factors that could cause actual results to differ materially from those expressed
in any of our forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking
statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking
statements include, but are not limited to:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">our history of losses and needs for additional capital to fund our operations and our inability to
    obtain additional capital on acceptable terms, or at all;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">uncertainties of cash flows and inability to meet working capital needs;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the initiation, timing, progress and results of our preclinical studies, clinical trials and other
    product candidate development efforts;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">our ability to advance our product candidates into clinical trials or to successfully complete our
    preclinical studies or clinical trials;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">our receipt of regulatory approvals for our product candidates, and the timing of other regulatory
    filings and approvals;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the clinical development, commercialization and market acceptance of our product candidates;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">our ability to establish and maintain strategic partnerships and other corporate collaborations;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the implementation of our business model and strategic plans for our business and product candidates;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the scope of protection we are able to establish and maintain for intellectual property rights covering
    our product candidates and our ability to operate our business without infringing the intellectual property rights of others;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">competitive companies, technologies and our industry;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#9679;</td>
<td style="text-align: justify">risks related to not satisfying the continued listing requirements of NYSE American;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">statements as to the impact of the political, economic and security situation in Israel on our business,
    including due to the current security situation in Israel; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">those factors referred to in &#8220;Item 3.D. Risk Factors,&#8221; &#8220;Item 4. Information on
    the Company,&#8221; and &#8220;Item 5. Operating and Financial Review and Prospects&#8221;, as well as in this annual report on Form
    20-F generally.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All forward-looking statements
attributable to us or persons acting on our behalf speak only as of the date of this Annual Report on Form 20-F and are expressly qualified
in their entirety by the cautionary statements included in this Annual Report on Form 20-F. We undertake no obligations to update or
revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated
events. In evaluating forward-looking statements, you should consider these risks and uncertainties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 5; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">EXPLANATORY NOTE</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market data and certain industry
data and forecasts used throughout this Annual Report on Form 20-F were obtained from sources we believe to be reliable, including market
research databases, publicly available information, reports of governmental agencies and industry publications and surveys. We have relied
on certain data from third-party sources, including internal surveys, industry forecasts and market research, which we believe to be
reliable based on our management&#8217;s knowledge of the industry. Forecasts are particularly likely to be inaccurate, especially over
long periods of time. In addition, we do not necessarily know what assumptions regarding general economic growth were used in preparing
the third-party forecasts we cite. Statements as to our market position are based on the most currently available data. While we are
not aware of any misstatements regarding the industry data presented in this Annual Report on Form 20-F, our estimates involve risks
and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221;
in this Annual Report on Form 20-F.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><!-- Field: Page; Sequence: 6; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><span style="font-weight: bold;"><span id="a_001" style="display: inline-block;"></span>PART
I</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 1. </span></span><span style="font-weight: bold;"><span id="a_002" style="display: inline-block;"></span>Identity
of Directors, Senior Management and Advisers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 2. </span></span><span style="font-weight: bold;"><span id="a_003" style="display: inline-block;"></span>Offer
Statistics and Expected Timetable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;"><span id="a_004" style="display: inline-block;"></span>ITEM 3. </span></span><span style="font-weight: bold;">Key
Information.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">A. [Reserved]</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">B. Capitalization and Indebtedness.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">C. Reasons for the Offer and Use of Proceeds.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">D. Risk Factors</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>You should carefully consider
the risks we describe below, in addition to the other information set forth elsewhere in this Annual Report on Form 20-F, including our
consolidated financial statements and the related notes beginning on page F-1, before deciding to invest in our ordinary shares and American
Depositary Shares, or ADSs. These material risks could adversely impact our results of operations, possibly causing the trading price
of our ordinary shares and ADSs to decline, and you could lose all or part of your investment.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Summary Risk Factors</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal factors and
uncertainties that make investing in our ordinary shares risky, include, among others:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Risks Related to Our Financial Position
and Capital Requirements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">We have incurred operating losses since our inception and anticipate that we will continue to incur
    substantial operating losses for the foreseeable future.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">We will need to raise additional capital to meet our business requirements in the future, and such
    capital raising may be costly or difficult to obtain and will dilute current shareholders&#8217; ownership interests.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Risks Related to Our Business and Regulatory
Matters</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">We have not yet commercialized any products or technologies, and we may never become profitable.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Our product candidates are at various stages of clinical and preclinical development and may never
    be commercialized.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">We might be unable to develop product candidates that will achieve commercial success in a timely
    and cost-effective manner, or ever.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">Our current pipeline is based on our platform technology utilizing the Gi protein associated A3AR,
    as a potent therapeutic target and currently includes three molecules, Piclidenoson, Namodenoson and CF602 product candidates, of
    which Piclidenoson is the most advanced. Failure to develop these molecules will have a material adverse effect on us.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Clinical trials are very expensive, time-consuming and difficult to design and implement, and, as
    a result, we may suffer delays or suspensions in future trials which would have a material adverse effect on our ability to generate
    revenues.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">The manufacture of our product candidates is a chemical synthesis process and if one of our materials
    suppliers encounters problems manufacturing our products, our business could suffer.</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#9679;</td>
<td style="text-align: justify">We do not currently have sales, marketing or distribution capabilities or experience, and we are
    unable to effectively sell, market or distribute our product candidates now and we do not expect to be able to do so in the future.
    The failure to enter into agreements with third parties that are capable of performing these functions would have a material adverse
    effect on our business and results of operations.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">We depend on key members of our management and key consultants and will need to add and retain additional
    leading experts. Failure to retain our management and consulting team and add additional leading experts could have a material adverse
    effect on our business, results of operations or financial condition.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Our product candidates will remain subject to ongoing regulatory requirements even if they receive
    marketing approval, and if we fail to comply with these requirements, we could lose these approvals, and the sales of any approved
    commercial products could be suspended.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">We may not be able to successfully grow and expand our business. Failure to manage our growth effectively
    will have a material adverse effect on our business, results of operations and financial condition.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">We or the third parties upon whom we depend may be adversely affected by natural disasters and/or
    health epidemics, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Risks Related to Our Intellectual Property</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">The failure to obtain or maintain patents, licensing agreements, including our current licensing
    agreements, and other intellectual property could impact our ability to compete effectively.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">International patent protection is particularly uncertain, and if we are involved in opposition proceedings
    in foreign countries, we may have to expend substantial sums and management resources.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">We may be unable to protect the intellectual property rights of the third parties from whom we license
    certain of our intellectual property or with whom we have entered into other strategic relationships.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">Under applicable U.S. and Israeli law, we may not be able to enforce covenants not to compete and
    therefore, may be unable to prevent our competitors from benefiting from the expertise of some of our former employees. In addition,
    employees may be entitled to seek compensation for their inventions irrespective of their agreements with us, which in turn could
    impact our future profitability.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 8; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Risks Related to Our Industry</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">We expect the healthcare industry to face increased limitations on reimbursement as a result of healthcare
    reform, which could adversely affect third-party coverage of our products and how much or under what circumstances healthcare providers
    will prescribe or administer our products.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Our employees, principal investigators, consultants, commercial partners or vendors may engage in
    misconduct or other improper activities, including non-compliance with regulatory standards.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Risks Related to Our Operations in Israel</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">We conduct our operations in Israel and therefore our results may be adversely affected by political,
    economic and military instability in Israel and its region.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Because a certain portion of our expenses is incurred in currencies other than U.S. dollars, our
    results of operations may be harmed by currency fluctuations and inflation.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Risks Related to Our Ordinary Shares and
ADSs</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Our business, operating results and growth rates may be adversely affected by current or future unfavorable
    economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Our business could be negatively impacted by unsolicited takeover proposals, by shareholder activism
    or by proxy contests relating to the election of directors or other matters. &#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#9679;</td>
<td style="text-align: justify">Issuance of additional equity securities may adversely affect the market price of our ADSs or ordinary
    shares. &#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#9679;</td>
<td style="text-align: justify">The market price of our ordinary shares and ADSs is subject to fluctuation, which could result in
    substantial losses by our investors. &#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#9679;</td>
<td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We may not currently satisfy the NYSE American requirements for continued
listing. If we cannot satisfy these requirements, the NYSE American could delist our securities. &#160;</p></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#9679;</td>
<td style="text-align: justify">As a foreign private issuer, we are permitted to follow certain home country corporate governance
    practices instead of applicable SEC and NYSE American requirements, which may result in less protection than is accorded to investors
    under rules applicable to domestic issuers.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 9; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Risks Related to Our Financial Position and
Capital Requirements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We have incurred operating
losses since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an advanced clinical-stage
biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and
inflammatory diseases. Since our incorporation in 1994, we have been focused on research and development activities with a view to developing
our product candidates, CF101, also known as Piclidenoson, CF102, also known as Namodenoson, and CF602. We have financed our operations
primarily through the sale of equity securities (both in private placements and in public offerings on the TASE and NYSE American) and
payments received under out-licensing agreements and have incurred losses in each year since our inception in 1994. We have historically
incurred substantial net losses, including net losses of approximately $9.8 million in 2025, $7.9 million in 2024, and $7.6 million in
2023. As of December 31, 2025, we had an accumulated deficit of approximately $176.2 million. We do not know whether or when we will
become profitable. To date, we have not commercialized any products or generated any revenues from product sales and accordingly we do
not have a revenue stream to support our cost structure. Our losses have resulted principally from costs incurred in development and
discovery activities. We expect to continue to incur losses for the foreseeable future, and these losses will likely increase as we:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">initiate and manage pre-clinical development and clinical trials for our current and new product
    candidates;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">seek regulatory approvals for our product candidates;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">implement internal systems and infrastructures;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>seek to license additional technologies to develop;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>hire management and other personnel; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>move towards commercialization.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our product candidates
fail in clinical trials or do not gain regulatory clearance or approval, or if our product candidates do not achieve market acceptance,
we may never become profitable. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly
or annual basis. Our inability to achieve and then maintain profitability would negatively affect our business, financial condition,
results of operations and cash flows. Moreover, our prospects must be considered in light of the risks and uncertainties encountered
by an early-stage company and in highly regulated and competitive markets, such as the biopharmaceutical market, where regulatory approval
and market acceptance of our products are uncertain. There can be no assurance that our efforts will ultimately be successful or result
in revenues or profits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We will need to raise
additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to obtain and
will dilute current shareholders&#8217; ownership interests.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025,
we had cash and cash equivalents of $5.5 million and short-term deposits of $3.0 million. Based on our current projections and plans,
we have concluded that our existing financial resources will be sufficient to meet our requirements for the next twelve months from the
date of issuance of this Annual Report on Form 20-F. We have expended and believe that we will continue to expend substantial resources
for the foreseeable future developing our product candidates. These expenditures will include costs associated with research and development,
manufacturing, conducting preclinical experiments and clinical trials and obtaining regulatory approvals, as well as commercializing
any products approved for sale. Because the outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably
estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. In addition,
other unanticipated costs may arise. As a result of these and other factors currently unknown to us, we will require additional funds,
through public or private equity or debt financings or other sources, such as strategic partnerships and alliances and licensing arrangements.
In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have
sufficient funds for our current or future operating plans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital requirements
will depend on many factors, including the progress and results of our clinical trials, the duration and cost of discovery and preclinical
development, and laboratory testing and clinical trials for our product candidates, the timing and outcome of regulatory review of our
product candidates, the number and development requirements of other product candidates that we pursue, and the costs of activities,
such as product marketing, sales, and distribution. Because of the numerous risks and uncertainties associated with the development and
commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures
associated with our anticipated clinical trials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 10; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital requirements
depend on many factors, including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">the level of research and development investment required to develop our product candidates;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">the failure to obtain regulatory approval or achieve commercial success of our product candidates,
    including Piclidenoson, Namodenoson and CF602;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">the results of our preclinical studies and clinical trials for our earlier stage product candidates,
    and any decisions to initiate clinical trials if supported by the preclinical results;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">the costs, timing and outcome of regulatory review of our product candidates that progress to clinical
    trials;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">our ability to partner or sub-license any of our product candidates;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our
    issued patents and defending intellectual property-related claims;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">the cost of commercialization activities if any of our product candidates are approved for sale,
    including marketing, sales and distribution costs;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">the cost of manufacturing our product candidates and any products we successfully commercialize;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">the timing, receipt and amount of sales of, or royalties on, our future products, if any;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">the expenses needed to attract and retain skilled personnel;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">any product liability or other lawsuits related to our products;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">the extent to which we acquire or invest in businesses, products or technologies and other strategic
    relationships;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">the costs of financing unanticipated working capital requirements and responding to competitive pressures;
    and</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">maintaining minimum shareholders&#8217; equity requirements and complying with other continue listing
    standards under the NYSE American Company Guide</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional funds may not
be available when we need them, on terms that are acceptable to us, or at all. General market conditions may make it very difficult for
us to seek financing from the capital markets and the current war between Israel and Hamas could impact the availability or cost of future
financings. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate preclinical
studies, clinical trials or other research and development activities for one or more of our product candidates or delay, limit, reduce
or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product
candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may incur substantial
costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance
fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain
securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 11; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Raising additional
capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies
or product candidates.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional capital
through a combination of private and public equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of
existing shareholders will be diluted, and the terms may include liquidation or other preferences that adversely affect shareholder rights.
Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions,
such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through strategic partnerships
and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product
candidates, or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt
financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or
grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Risks Related to Our Business and Regulatory
Matters</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We have not yet commercialized
any products or technologies, and we may never become profitable.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not yet commercialized
any products or technologies, and we may never be able to do so. We do not know when or if we will complete any of our product development
efforts, obtain regulatory approval for any product candidates incorporating our technologies or successfully commercialize any approved
products. Even if we are successful in developing products that are approved for marketing, we will not be successful unless these products
gain market acceptance for appropriate indications at favorable reimbursement rates. The degree of market acceptance of these products
will depend on a number of factors, including:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">the timing of regulatory approvals in the countries, and for the uses, we seek;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">the competitive environment;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">the establishment and demonstration in the medical community of the safety and clinical efficacy
    of our products and their potential advantages over existing therapeutic products;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">our ability to enter into distribution and other strategic agreements with pharmaceutical and biotechnology
    companies with strong marketing and sales capabilities;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">the adequacy and success of distribution, sales and marketing efforts; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">the pricing and reimbursement policies of government and third-party payors, such as insurance companies,
    health maintenance organizations and other plan administrators.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Physicians, patients, third-party
payors or the medical community in general may be unwilling to accept, utilize or recommend, and in the case of third-party payors, cover
any of our products or products incorporating our technologies. As a result, we are unable to predict the extent of future losses or the
time required to achieve profitability, if at all. Even if we successfully develop one or more products that incorporate our technologies,
we may not become profitable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Our product candidates
are at various stages of clinical and preclinical development and may never be commercialized.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates are
at various stages of clinical development and may never be commercialized. The progress and results of any future pre-clinical testing
or future clinical trials are uncertain, and the failure of our product candidates to receive regulatory approvals will have a material
adverse effect on our business, operating results and financial condition to the extent we are unable to commercialize any products.
None of our product candidates has received regulatory approval for commercial sale. In addition, we face the risks of failure inherent
in developing therapeutic products. Our product candidates are not expected to be commercially available for several years, if at all.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to receive U.S.
Food and Drug Administration, or FDA, approval or approval from foreign regulatory authorities to market a product candidate or to distribute
our products, we must demonstrate thorough pre-clinical testing and thorough human clinical trials that the product candidate is safe
and effective for its intended uses (e.g., treatment of a specific condition in a specific way subject to contraindications and other
limitations). If the FDA, or foreign regulatory authorities, determine that data from our pre-clinical testing and clinical trials are
not sufficient to support approval, the FDA, or foreign regulatory authorities, may require additional pre-clinical testing or clinical
trials for our product candidates. Even if we comply with all FDA requests, the FDA may ultimately reject one or more of our New Drug
Applications, or NDA, or grant approval for a narrowly intended use that is not commercially feasible. We might not obtain regulatory
approval for our drug candidates in a timely manner, if at all. Failure to obtain FDA approval of any of our drug candidates in a timely
manner or at all will severely undermine our business by reducing the number of salable products and, therefore, corresponding product
revenues.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 12; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Results of earlier
clinical trials may not be predictive of the results of later-stage clinical trials.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of preclinical
studies and early clinical trials of product candidates may not be predictive of the results of later-stage clinical trials. Also, interim
results, if at all, during a clinical trial do not necessarily predict final results. Product candidates in later stages of clinical
trials may fail to show the desired safety and efficacy results despite having progressed through preclinical studies and initial clinical
trials. For example, our former subsidiary OphthaliX Inc, or OphthaliX, announced top-line results of a Phase III study with Piclidenoson
for dry-eye syndrome in which Piclidenoson did not meet the primary efficacy endpoint of complete clearing of corneal staining, nor the
secondary efficacy endpoints, OphthaliX released top-line results from its Phase II clinical trial of Piclidenoson for the treatment
of glaucoma in which no statistically significant differences were found between the Piclidenoson treated group and the placebo group
in the primary endpoint of lowering intraocular pressure, or IOP. In addition, two Phase IIb studies in rheumatoid arthritis, utilizing
Piclidenoson in combination with methotrexate, a generic drug commonly used for treating rheumatoid arthritis patients, or MTX, failed
to reach their primary endpoints and we ended our Phase III ACROBAT study after the independent data monitoring committee, or IDMC recommended
in a pre-planned interim analysis not to continue this study. A Phase II/III study of Piclidenoson for psoriasis did not meet its primary
endpoint although positive data from further analysis of the Phase II/III study suggests Piclidenoson as a potential systemic therapy
for patients with moderate-severe psoriasis. Furthermore, a Phase II study for advanced HCC in subjects with Child-Pugh B who failed
Nexavar as a first line treatment did not meet its primary endpoint although it showed superiority in overall survival in the largest
study subpopulation.</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies in the pharmaceutical
industry have suffered significant setbacks in advanced clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding
promising results in earlier studies. Any delay in, or termination or suspension of, our clinical trials will delay the requisite filings
with the FDA, the European Medicines Agency (EMA) or other foreign regulatory authorities and, ultimately, our ability to commercialize
our product candidates and generate product revenues. If the clinical trials do not support our product claims, the completion of development
of such product candidates may be significantly delayed or abandoned, which will significantly impair our ability to generate product
revenues and will materially adversely affect our results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This drug candidate development
risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are
developed from preclinical through early to late-stage clinical trials towards approval and commercialization, it is customary that various
aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize
processes and results. While these types of changes are common and are intended to optimize the product candidates for late-stage clinical
trials, approval and commercialization, such changes do carry the risk that they will not achieve these intended objectives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in our planned clinical
trials or future clinical trials could cause our product candidates to perform differently, including causing toxicities, which could
delay completion of our clinical trials, delay approval, if any, of our product candidates, and/or jeopardize our ability to commence
product sales and generate revenues.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 13; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We might be unable
to develop product candidates that will achieve commercial success in a timely and cost-effective manner, or ever.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if regulatory authorities
approve our product candidates, they may not be commercially successful. Our product candidates may not be commercially successful because
government agencies and other third-party payors may not cover the product or the coverage may be too limited to be commercially successful;
physicians and others may not use or recommend our products, even following regulatory approval. A product approval, assuming one issues,
may limit the uses for which the product may be distributed thereby adversely affecting the commercial viability of the product. Third
parties may develop superior products or have proprietary rights that preclude us from marketing our products. We also expect that at
least some of our product candidates will be expensive, if approved. Patient acceptance of and demand for any product candidates for
which we obtain regulatory approval or license will depend largely on many factors, including but not limited to the extent, if any,
of reimbursement of costs by government agencies and other third-party payors, pricing, the effectiveness of our marketing and distribution
efforts, the safety and effectiveness of alternative products, and the prevalence and severity of side effects associated with our products.
If physicians, government agencies and other third-party payors do not accept our products, we will not be able to generate significant
revenue. In addition, government regulators and legislative bodies in the U.S. are considering numerous proposals that may result in
limitations on the prices at which we could charge customers for our products if we have products that are ultimately approved for sale.
At this time, we are unable to predict how these potential legislative changes might affect our business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Our current pipeline
is based on our platform technology utilizing the Gi protein associated A3AR, as a potent therapeutic target and currently includes three
molecules, Piclidenoson, Namodenoson and CF602 product candidates, of which Piclidenoson and Namodenoson are the most advanced. Failure
to develop these molecules will have a material adverse effect on us.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current pipeline is based
on a platform technology where we target the A3AR with highly selective ligands, or small signal triggering molecules that bind to specific
cell surface receptors, such as the A3AR, including Piclidenoson, Namodenoson and CF602. A3ARs are structures found in cell surfaces
that record and transfer messages from small molecules or ligands, such as Piclidenoson, Namodenoson and CF602 to the rest of the cell.
Piclidenoson and Namodenoson are the most advanced of our drug candidates. As such, we are currently dependent on only three molecules
for our potential commercial success, and any safety or efficacy concerns related to such molecules would have a significant impact on
our business. Failure to develop our drug candidates, in whole or in part, will have a material adverse effect on us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Clinical trials are
very expensive, time-consuming and difficult to design and implement, and, as a result, we may suffer delays or suspensions in future
trials which would have a material adverse effect on our ability to generate revenues.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials are
very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Regulatory
authorities, such as the FDA, may preclude or prohibit clinical trials from proceeding. Additionally, the clinical trial process is time-consuming,
failure can occur at any stage of the trials, and we may encounter problems that cause us to abandon or repeat clinical trials. The commencement
and completion of clinical trials may be delayed by several factors, including:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">unforeseen safety issues;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">non-acceptance of an IND by the FDA;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">determination of dosing issues;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">lack of effectiveness or efficacy during clinical trials;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">inability to manufacture sufficient quantities of drug candidate;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">changes in formulation or manufacturing changes;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">failure of third-party suppliers to perform final manufacturing steps for the drug substance;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">slower than expected rates of patient recruitment and enrollment;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">inability to retain patients in clinical trials;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">lack of healthy volunteers and patients to conduct trials;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">inability to monitor patients adequately during or after treatment;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>failure to reach an agreement with contract research organizations or clinical trial sites;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 14; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">failure of institutional review boards, or IRBs, to approve our clinical trial protocols or suspension
    or termination of our clinical trial by the IRB, DSMB, or the FDA;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">failure of institutional review boards to approve our clinical trial protocols;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">inability or unwillingness of clinical investigators and institutional review boards to follow our
    clinical trial protocols;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">failure of clinical investigators or sites to maintain necessary licenses or permits or comply with
    good clinical practices, or GCP, or other regulatory requirements;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">debarment of a clinical investigator by FDA or other similar suspension or exclusion by a regulatory
    authority; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>lack of sufficient funding to finance the clinical trials.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have experienced the risks
involved with conducting clinical trials, including but not limited to, increased expense and delay and failure to meet end points of
the trial. For example, OphthaliX, announced top-line results of a Phase III study with Piclidenoson for dry-eye syndrome in which Piclidenoson
did not meet the primary efficacy endpoint of complete clearing of corneal staining, nor the secondary efficacy endpoints and OphthaliX
released top-line results from its Phase II clinical trial of Piclidenoson for the treatment of glaucoma in which no statistically significant
differences were found between the Piclidenoson treated group and the placebo group in the primary endpoint of lowering IOP. In addition,
two Phase IIb studies in rheumatoid arthritis, utilizing Piclidenoson in combination with MTX failed to reach their primary end points
and we ended our Phase III ACROBAT study after the IDMC recommended in a pre-planned interim analysis not to continue this study. A Phase
II/III study of Piclidenoson for psoriasis did not meet its primary endpoint although positive data from further analysis of the Phase
II/III study suggests Piclidenoson as a potential systemic therapy for patients with moderate-severe psoriasis. Furthermore, a Phase
II study of Namodenoson for advanced HCC in subjects with Child-Pugh B who failed Nexavar as a first line treatment did not meet its
primary endpoint although it showed superiority in overall survival in the largest study subpopulation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we or regulatory
authorities may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks
or if the regulatory authorities find deficiencies in our regulatory submissions or the conduct of these trials. Any suspension of clinical
trials will delay possible regulatory approval, if any, increase costs, and adversely impact our ability to develop products and generate
revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We seek to partner
with third-party collaborators with respect to the development and commercialization of Piclidenoson, Namodenoson and for any other product
candidate, and we may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability
to develop and commercialize our product candidates successfully, if at all.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy relies
in part on partnering with pharmaceutical companies to complement our internal development efforts. We will be competing with many other
companies as we seek partners for Piclidenoson, Namodenoson and for any other product candidate and we may not be able to compete successfully
against those companies. If we are not able to enter into collaboration arrangements for Piclidenoson, Namodenoson and for any other
product candidate, we may be required to undertake and fund further development, clinical trials, manufacturing and commercialization
activities solely at our own expense and risk. If we are unable to finance and/or successfully execute those expensive activities, or
we delay such activities due to capital availability, our business could be materially and adversely affected, and potential future product
launch could be materially delayed, be less successful, or we may be forced to discontinue clinical development of these product candidates.
The process of establishing and maintaining collaborative relationships is difficult, time-consuming and involves significant uncertainty,
including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a collaboration partner may shift its priorities and resources away from our product candidates due
    to a change in business strategies, or a merger, acquisition, sale or downsizing;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 15; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory
    clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">a collaboration partner may cease development in therapeutic areas which are the subject of our strategic
    collaboration</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">a collaboration partner may not devote sufficient capital or resources towards our product candidates;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">a collaboration partner may change the success criteria for a drug candidate thereby delaying or
    ceasing development of such candidate;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">a significant delay in initiation of certain development activities by a collaboration partner will
    also delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">a collaboration partner could develop a product that competes, either directly or indirectly, with
    our drug candidate;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">a collaboration partner with commercialization obligations may not commit sufficient financial or
    human resources to the marketing, distribution or sale of a product;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or
    quality issues and be unable to meet demand requirements;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">a partner may exercise a contractual right to terminate a strategic alliance;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">a dispute may arise between us and a partner concerning the research, development or commercialization
    of a drug candidate resulting in a delay in milestones, royalty payments or termination of an alliance and possibly resulting in
    costly litigation or arbitration which may divert management attention and resources; and</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">a partner may use our products or technology in such a way as to invite litigation from a third party.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any collaborative partners
with whom we enter into agreements in the future may shift their priorities and resources away from our product candidates or seek to
renegotiate or terminate their relationships with us. If any collaborator fails to fulfill its responsibilities in a timely manner, or
at all, our research, clinical development, manufacturing or commercialization efforts related to that collaboration could be delayed
or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility
of our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully transition
terminated collaborative agreements, we may have to delay or discontinue further development of one or more of our product candidates,
undertake development and commercialization activities at our own expense or find alternative sources of capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>If we acquire or license
additional technology or product candidates, we may incur a number of costs, may have integration difficulties and may experience other
risks that could harm our business and results of operations.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may acquire and license
additional product candidates and technologies. Any product candidate or technology we license from others or acquire will likely require
additional development efforts prior to commercial sale, including extensive pre-clinical or clinical testing, or both, and approval
by the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks of failure inherent in pharmaceutical
product development, including the possibility that the product candidate or product developed based on licensed technology will not
be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any product
candidate that we develop based on acquired or licensed technology that is granted regulatory approval will be manufactured or produced
economically, successfully commercialized or widely accepted in the marketplace. Moreover, integrating any newly acquired product candidates
could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may not succeed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 16; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>The manufacture of
our product candidates is a chemical synthesis process and if one of our materials suppliers encounters problems manufacturing our products,
our business could suffer.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and foreign regulators
require manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance
with requirements that the FDA or foreign regulators establish. We do not intend to engage in the manufacture of our products other than
for pre-clinical and clinical studies, but we or our materials suppliers may face manufacturing or quality control problems causing product
production and shipment delays or a situation where we or the supplier may not be able to maintain compliance with the FDA&#8217;s or
foreign regulators&#8217; requirements necessary to continue manufacturing our drug substance. Drug manufacturers are subject to ongoing
periodic unannounced inspections by the FDA, the U.S. Drug Enforcement Agency, or DEA, and corresponding foreign regulators to ensure
strict compliance with requirements and other governmental regulations and corresponding foreign standards. Any failure to comply with
DEA requirements or FDA or foreign regulatory requirements could adversely affect our clinical research activities and our ability to
develop our product candidates, and delay possible regulatory approval.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We do not currently
have sales, marketing or distribution capabilities or experience, and we are unable to effectively sell, market or distribute our product
candidates now and we do not expect to be able to do so in the future. The failure to enter into agreements with third parties that are
capable of performing these functions would have a material adverse effect on our business and results of operations.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have,
and we do not expect to develop, sales, marketing and distribution capabilities. If we are unable to enter into agreements with third
parties to perform these functions, we will not be able to successfully market any of our platforms or product candidates. In order to
successfully market any of our platform or product candidates, we must make arrangements with third parties to perform these services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we do not intend to develop
a marketing and sales force with technical expertise and supporting distribution capabilities, we will be unable to market any of our
product candidates directly. To promote any of our potential products through third parties, we will have to locate acceptable third
parties for these functions and enter into agreements with them on acceptable terms, and we may not be able to do so. Any third-party
arrangements we are able to enter into may result in lower revenues than we could achieve by directly marketing and selling our potential
products. In addition, to the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend
upon the efforts of such third parties, as well as the terms of our agreements with such third parties, which cannot be predicted in
most cases at this time. As a result, we might not be able to market and sell our products in the United States or overseas, which would
have a material adverse effect on us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We will to some extent
rely on third parties to implement our manufacturing and supply strategies. Failure of these third parties in any respect could have
a material adverse effect on our business, results of operations and financial condition.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our current and future
manufacturing and supply strategies are unsuccessful, then we may be unable to conduct and complete any future pre-clinical or clinical
trials or commercialize our product candidates in a timely manner, if at all. Completion of any potential future pre-clinical or clinical
trials and commercialization of our product candidates will require access to, or development of, facilities to manufacture a sufficient
supply of our product candidates. We do not have the resources, facilities or experience to manufacture our product candidates for commercial
purposes on our own and do not intend to develop or acquire facilities for the manufacture of product candidates for commercial purposes
in the foreseeable future. We may rely on contract manufacturers to produce sufficient quantities of our product candidates necessary
for any pre-clinical or clinical testing we undertake in the future. Such contract manufacturers may be the sole source of production
and they may have limited experience at manufacturing, formulating, analyzing, filling and finishing our types of product candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also intend to rely on
third parties to supply the requisite materials needed for the manufacturing of our active pharmaceutical ingredients, or API. There
may be a limited supply of these requisite materials. We might not be able to enter into agreements that provide us assurance of availability
of such components in the future from any supplier. Our potential suppliers may not be able to adequately supply us with the components
necessary to successfully conduct our pre-clinical and clinical trials or to commercialize our product candidates. If we cannot acquire
an acceptable supply of the requisite materials to produce our product candidates, we will not be able to complete pre-clinical and clinical
trials delaying possible regulatory approval, and adversely impacting our ability to develop products, and will not be able to market
or commercialize our product candidates, if approved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 17; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We depend on key members
of our management and key consultants and will need to add and retain additional leading experts. Failure to retain our management and
consulting team and add additional leading experts could have a material adverse effect on our business, results of operations or financial
condition.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent on
our executive officers and other key management and technical personnel. Our failure to retain our Executive Chairman and Chief Scientific
Officer, Pnina Fishman, Ph.D., who has developed much of the technology we utilize today, or any other key management and technical personnel,
could have a material adverse effect on our future operations. Our success is also dependent on our ability to attract, retain and motivate
highly trained technical, and management personnel, among others, to continue the development and commercialization, if approved, of
our current and future product candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success also depends
on our ability to attract, retain and motivate personnel required for the development, maintenance and expansion of our activities. There
can be no assurance that we will be able to retain our existing personnel or attract additional qualified employees or consultants. The
loss of key personnel or the inability to hire and retain additional qualified personnel in the future could have a material adverse
effect on our business, financial condition and results of operation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We face significant
competition and continuous technological change, and developments by competitors may render our products or technologies obsolete or
non-competitive. If we cannot successfully compete with new or existing products, our marketing and sales will suffer and we may not
ever be profitable.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will compete against fully
integrated pharmaceutical and biotechnology companies and smaller companies that are collaborating with larger pharmaceutical companies,
academic institutions, government agencies and other public and private research organizations. In addition, many of these competitors,
either alone or together with their collaborative partners, operate larger research and development programs than we do, and have substantially
greater financial resources than we do, as well as significantly greater experience in:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">developing drugs;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">undertaking pre-clinical testing and human clinical trials;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">obtaining FDA approval, addressing various regulatory matters and other regulatory approvals of drugs;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">formulating and manufacturing drugs; and</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">launching, marketing and selling drugs.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our competitors develop
and commercialize products faster than we do, or develop and commercialize products that are superior to our product candidates, our
commercial opportunities will be reduced or eliminated. The extent to which any of our product candidates achieve market acceptance will
depend on competitive factors, many of which are beyond our control. Competition in the biotechnology and biopharmaceutical industry
is intense and has been accentuated by the rapid pace of technology development. Our competitors include large integrated pharmaceutical
companies, biotechnology companies that currently have drug and target discovery efforts, universities, and public and private research
institutions. Almost all of these entities have substantially greater research and development capabilities and financial, scientific,
manufacturing, marketing and sales resources than we do. These organizations also compete with us to:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>attract parties for acquisitions, joint ventures or other collaborations;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>license proprietary technology that is competitive with the technology we are developing;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 18; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>attract funding; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>attract and hire scientific talent and other qualified personnel.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors may succeed
in developing and commercializing products earlier and obtaining regulatory approvals from the FDA or foreign regulators more rapidly
than we do. Our competitors may also develop products or technologies that are superior to those we are developing, and render our product
candidates or technologies obsolete or non-competitive. If we cannot successfully compete with new or existing products, our marketing
and sales will suffer and we may not ever be profitable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors currently
include companies with marketed products and/or an advanced research and development pipeline. The major competitors in the psoriasis
therapeutic field include Amgen, J&amp;J, Pfizer, Novartis, Abbvie, Eli Lilly, Bristol-Myers Squibb, UCB, Takeda, Alumis and more. Competitors
in the HCC field include companies such as Bayer, Exelixis, Merck, Roche, Eisai, AstraZeneca, BeOne Oncology, Novartis, and Bristol-Myers
Squibb. Competitors in the metabolic dysfunction-associated steatohepatitis, or MASH, field include companies such as Madrigal Pharmaceuticals,
Novo Nordisk, Roche, GSK, Sagimet Biosciences, Inventiva SA, Altimmune Inc, and Eli Lilly. Competitors in the pancreatic cancer field
include Bristol-Myers Squibb, Ipsen, Revolution Medicines among others. Competitors in the erectile dysfunction field include Pfizer,
Eli Lilly, Bayer, and Petros Pharmaceuticals. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Competition.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, several companies
have reported the commencement of research projects related to the A3AR. Such companies include CV Therapeutics Inc. (which was acquired
by Gilead), King Pharmaceuticals R&amp;D Inv. (which was acquired by Pfizer), Hoechst Marion Roussel Inc. (which was acquired by Aventis),
Novo Nordisk A/S and Inotek Pharmaceuticals. However, to the best of our knowledge, there is no approved drug currently on the market,
which is similar to our A3AR agonists, nor are we aware of any allosteric modulator in the A3AR product pipeline similar to our allosteric
modulator with respect to chemical profile and mechanism of action.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We may suffer losses
from product liability claims if our product candidates cause harm to patients.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of our product candidates
could cause adverse events. Although a pooled safety analysis from clinical trials encompassing more than 1,700 humans dosed with Piclidenoson
and more than 250 patients treated with Namodenoson through the completion of our Phase II rheumatoid arthritis and psoriasis trials
indicated that Piclidenoson is generally well-tolerated at doses up to 4.0 mg administered twice daily for up to 12-48 weeks, there were
incidences (less than or equal to 5%) of adverse events in eight completed and fully analyzed trials in inflammatory disease. Such adverse
events included nausea, diarrhea, abdominal pain, vomiting, constipation, common bacterial and viral syndromes (such as tonsillitis,
otitis and respiratory and urinary tract infections), abdominal pain, vomiting, myalgia, arthralgia, dizziness, headache and pruritus.
We observed an even lower incidence (less than or equal to 2%) of serious adverse events, although only one type of event was reported
in more than a single Piclidenoson-treated subject, which was exacerbation of chronic obstructive lung disease reported in two subjects.
Notwithstanding the foregoing, the placebo group in such studies had a higher incidence of overall adverse events than the pooled Piclidenoson
groups. In addition, in normal volunteers, Piclidenoson at doses 3-4-fold higher than those to be used in therapeutic trials, but not
at therapeutic doses, was associated with prolongation of the electrocardiographic QT intervals. No new safety concerns have been identified
and no novel or unexpected safety concerns have appeared over 48 weeks of treatment in more recent trials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is also a risk that
certain adverse events may not be observed in clinical trials, but may nonetheless occur in the future. If any of these adverse events
occur, they may render our product candidates ineffective or harmful in some patients, and our sales would suffer, materially adversely
affecting our business, financial condition and results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 19; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, potential adverse
events caused by our product candidates could lead to product liability lawsuits. If product liability lawsuits are successfully brought
against us, we may incur substantial liabilities and may be required to limit the marketing and commercialization of our product candidates.
Our business exposes us to potential product liability risks, which are inherent in the testing, manufacturing, marketing and sale of
pharmaceutical products. We may not be able to avoid product liability claims. Product liability insurance for the pharmaceutical and
biotechnology industries is generally expensive, if available at all. If, at any time, we are unable to obtain sufficient insurance coverage
on reasonable terms or to otherwise protect against potential product liability claims, we may be unable to clinically test, market or
commercialize our product candidates. A successful product liability claim brought against us in excess of our insurance coverage, if
any, may cause us to incur substantial liabilities, and, as a result, our business, liquidity and results of operations would be materially
adversely affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Our product candidates
will remain subject to ongoing regulatory requirements even if they receive marketing approval, and if we fail to comply with these requirements,
we could lose these approvals, and the sales of any approved commercial products could be suspended.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we receive regulatory
approval to market a particular product candidate, the product will remain subject to extensive regulatory requirements, including requirements
relating to manufacturing, labelling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping.
Even if regulatory approval of a product is granted, the approval may be subject to limitations on the uses for which the product may
be marketed or the conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor
the safety or efficacy of the product, which could negatively impact us or our collaboration partners by reducing revenues or increasing
expenses, and cause the approved product candidate not to be commercially viable. In addition, as clinical experience with a drug expands
after approval, typically because it is used by a greater number and more diverse group of patients after approval than during clinical
trials, side effects and other problems may be observed after approval that were not seen or anticipated during pre-approval clinical
trials or other studies. Any adverse effects observed after the approval and marketing of a product candidate could result in limitations
on the use of or withdrawal of any approved products from the marketplace. Absence of long-term safety data may also limit the approved
uses of our products, if any. If we fail to comply with the regulatory requirements of the FDA and other applicable U.S. and foreign
regulatory authorities, or previously unknown problems with any approved commercial products, manufacturers or manufacturing processes
are discovered, we could be subject to administrative or judicially imposed sanctions or other setbacks, including the following:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Restrictions on the products, manufacturers or manufacturing process;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Warning or other enforcement letters;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Civil or criminal penalties, fines and injunctions;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Product seizures or detentions;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Import or export bans or restrictions;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Voluntary or mandatory product recalls and related publicity requirements;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Suspension or withdrawal of regulatory approvals;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Total or partial suspension of production; and</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">Refusal to approve pending applications for marketing approval of new products or supplements to
    approved applications.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or our collaborators
are slow or unable to adapt to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, marketing
approval for our product candidates may be lost or cease to be achievable, resulting in decreased revenue from milestones, product sales
or royalties, which would have a material adverse effect on our results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 20; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We deal with hazardous
materials and must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do business.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our activities and those
of our third-party manufacturers on our behalf involve the controlled storage, use and disposal of hazardous materials, including corrosive,
explosive and flammable chemicals and other hazardous compounds. We and our manufacturers are subject to U.S. federal, state, and local,
and Israeli and other foreign laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous
materials. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed
by these laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials. In addition,
if we develop a manufacturing capacity, we may incur substantial costs to comply with environmental regulations and would be subject
to the risk of accidental contamination or injury from the use of hazardous materials in our manufacturing process.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of an accident,
government authorities may curtail our use of these materials and interrupt our business operations. In addition, we could be liable
for any civil damages that result, which may exceed our financial resources and may seriously harm our business. Although our Israeli
insurance program covers certain unforeseen sudden pollutions, we do not maintain a separate insurance policy for any of the foregoing
types of risks. In addition, although the general liability section of our life sciences policy covers certain unforeseen, sudden environmental
issues, pollution in the United States and Canada is excluded from the policy. In the event of environmental discharge or contamination
or an accident, we may be held liable for any resulting damages, and any liability could exceed our resources. In addition, we may be
subject to liability and may be required to comply with new or existing environmental laws regulating pharmaceuticals or other medical
products in the environment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Scrutiny of sustainability
and environmental, social, and governance, or ESG, initiatives could increase our costs or otherwise adversely impact our business.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Public companies have recently
faced scrutiny related to&#160;ESG&#160;practices and disclosures from certain investors, capital providers, shareholder advocacy groups,
other market participants and other stakeholder groups. Such scrutiny may result in increased costs, enhanced compliance or disclosure
obligations, or other adverse impacts on our business, financial condition or results of operations. If our&#160;ESG&#160;practices and
reporting do not meet investor or other stakeholder expectations, we may be subject to investor or regulator engagement regarding such
matters. Our failure to comply with any applicable ESG rules or regulations could lead to penalties and adversely impact our reputation,
access to capital and employee retention. Such&#160;ESG&#160;matters may also impact our third-party contract manufacturers and other
third parties on which we rely, which may augment or cause additional impacts on our business, financial condition, or results of operations.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Our business and operations
may be materially adversely affected in the event of computer system failures or security breaches.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the implementation
of security measures, our internal computer systems, and those of our contract research organizations, or CROs, and other third parties
on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyber-attacks, natural disasters, fire, terrorism,
war, and telecommunication and electrical failures. If such an event were to occur and interrupt our operations, it could result in a
material disruption of our drug development programs. For example, the loss of clinical trial data from ongoing or planned clinical trials
could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the
extent that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade secrets or inappropriate
disclosure of confidential or proprietary information, including protected health information or personal data of employees or former
employees, access to our clinical data, or disruption of the manufacturing process, we could incur liability and the further development
of our drug candidates could be delayed. We may also be vulnerable to cyber-attacks by hackers or other malfeasance. This type of breach
of our cybersecurity may compromise our confidential information and/or our financial information and adversely affect our business or
result in legal proceedings. Further, these cybersecurity breaches may inflict reputational harm upon us that may result in decreased
market value and erode public trust.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 21; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We may not be able
to successfully grow and expand our business. Failure to manage our growth effectively will have a material adverse effect on our business,
results of operations and financial condition.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to successfully
grow and expand. Successful implementation of our business plan will require management of growth, including potentially rapid and substantial
growth, which will result in an increase in the level of responsibility for management personnel and place a strain on our human and
capital resources. To manage growth effectively, we will be required to continue to implement and improve our operating and financial
systems and controls to expand, train and manage our employee base. Our ability to manage our operations and growth effectively requires
us to continue to expend funds to enhance our operational, financial and management controls, reporting systems and procedures and to
attract and retain sufficient numbers of talented personnel. If we are unable to scale up and implement improvements to our control systems
in an efficient or timely manner, or if we encounter deficiencies in existing systems and controls, then we will not be able to make
available the products required to successfully commercialize our technology. Failure to attract and retain sufficient numbers of talented
personnel will further strain our human resources and could impede our growth or result in ineffective growth. Moreover, the management,
systems and controls currently in place or to be implemented may not be adequate for such growth, and the steps taken to hire personnel
and to improve such systems and controls might not be sufficient. If we are unable to manage our growth effectively, it will have a material
adverse effect on our business, results of operations and financial condition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>If we are unable to
obtain adequate insurance, our financial condition could be adversely affected in the event of uninsured or inadequately insured loss
or damage. Our ability to effectively recruit and retain qualified officers and directors could also be adversely affected if we experience
difficulty in obtaining adequate directors&#8217; and officers&#8217; liability insurance.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to obtain
insurance policies on terms affordable to us that would adequately insure our business and property against damage, loss or claims by
third parties. To the extent our business or property suffers any damages, losses or claims by third parties, which are not covered or
adequately covered by insurance, our financial condition may be materially adversely affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be unable to maintain
sufficient insurance as a public company to cover liability claims made against our officers and directors. Our insurance costs have
increased for directors&#8217; and officers&#8217; liability insurance, and we may be required to incur further substantial increased
costs to maintain the same or similar coverage or be forced to accept reduced coverage in future. If we are unable to adequately ensure
our officers and directors, we may not be able to retain or recruit qualified officers and directors to manage us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We or the third parties
upon whom we depend may be adversely affected by natural disasters and/or health epidemics, and our business continuity and disaster
recovery plans may not adequately protect us from a serious disaster.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Natural disasters could severely
disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects.
If a natural disaster, power outage, health epidemic or other event occurred that prevented us from using all or a significant portion
of our office, manufacturing and/or lab spaces, that damaged critical infrastructure, such as the manufacturing facilities of our third-party
contract manufacturers, CROs, clinical sites, third parties ongoing activities and schedules or that otherwise disrupted operations,
it may be difficult or, in certain cases, impossible for us to continue our plans and business for a substantial period of time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Epidemics can adversely impact
our business and that of third parties with whom we engage as they can cause disruptions, such as travel bans, quarantines, and interruptions
to access the trial sites and supply chain, which could result in material delays and complications with respect to our research and
development programs and clinical trials. Any future epidemics may result in a period of business disruption in these and other areas
impacting our business, including the establishment of contractual relationships with investigators enrolling subjects in our clinical
trials, the continuity of care provided by these institutions to the subjects we seek to enroll and their ability to support industry-funded
research as a means of caring for their subjects, supply of these sites with study materials, and the enrollment of subjects and their
adherence with study requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The disaster recovery and
business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial
expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse
effect on our business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 22; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Risks Related to Our Intellectual Property</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>The expiry of a patent
that we licensed from the National Institute of Health, or NIH, and the consequent loss of composition of matter exclusivity that we
had by virtue of this license may diminish our proprietary position.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the expiry
in June 2015 of a patent that provided composition of matter protection over Piclidenoson and Namodenoson, that we licensed from the
NIH, we no longer enjoy composition of matter patent exclusivity relating to Piclidenoson and Namodenoson. Nevertheless, because Piclidenoson
and Namodenoson may each be a new chemical entity, or NCE, following approval of an NDA, we, if we are the first applicant to obtain
NDA approval, may be entitled to five years of data exclusivity in the United States with respect to such NCEs. Analogous data and market
exclusivity provisions, of varying duration, may be available in Europe and other foreign jurisdictions. We also have rights under our
pharmaceutical use issued patents with respect to Piclidenoson and Namodenoson and under our Piclidenoson manufacturing process patents,
which provide patent exclusivity within our field of activity until the mid- to late-2020s. While we believe that we may be able to protect
our exclusivity through such use patent portfolio and such period of exclusivity, the lack of composition of matter patent protection
may diminish our ability to maintain a proprietary position for our intended uses of Piclidenoson or Namodenoson. Moreover, we cannot
be certain that we will be the first applicant to obtain an FDA approval for any indication of Piclidenoson or Namodenoson and we cannot
be certain that we will be entitled to NCE exclusivity. In addition, we have discontinued the prosecution of a family of pending patent
applications under joint ownership of us and NIH pertaining to the use of A3AR agonists for the treatment of uveitis. Such diminution
of our proprietary position could have a material adverse effect on our business, results of operation and financial condition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>The failure to obtain
or maintain patents, licensing agreements, including our current licensing agreements, and other intellectual property could impact our
ability to compete effectively.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To compete effectively, we
need to develop and maintain a proprietary position with regard to our own technologies, intellectual property, licensing agreements,
product candidates and business. Legal standards relating to the validity and scope of claims in the biotechnology and biopharmaceutical
fields are still evolving. Therefore, the degree of future protection for our proprietary rights in our core technologies and any products
that might be made using these technologies is also uncertain. The risks and uncertainties that we face with respect to our patents and
other proprietary rights include the following:</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">while some of our patents or patents that we in-licensed have issued, the pending patent applications
    we have filed may not result in issued patents or may take longer than we expect to result in issued patents;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">a third party may initiate an inter parties review, or IPR, proceedings in the U.S.;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">we may be subject to interference proceedings in the U.S.;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">a third party may initiate opposition proceedings in foreign countries;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">any patents that are issued may not provide meaningful protection;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">we may not be able to develop additional proprietary technologies that are patentable;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">other companies may challenge patents licensed or issued to us;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="text-align: justify; width: 48px">&#160;</td>
<td style="text-align: justify; width: 24px">&#9679;</td>
<td style="text-align: justify">other companies may independently develop similar or alternative technologies, or duplicate our technologies;</td></tr>
</tbody></table><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>other companies may design around patents we have in-licensed or developed; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>enforcement of patents is complex, uncertain and expensive.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If patent rights covering
our products and methods are not sufficiently broad or not issued at all by the United States Patent and Trademark Office, or the USPTO,
or by other foreign patent offices, we may not have adequate protection against competitors with similar products and technologies. Furthermore,
if the USPTO or other foreign patent offices issue patents to us or our licensors, others may challenge the patents or design around
the patents, or the patent office or the courts may invalidate the patents. Thus, any patents we own or license from third parties may
not provide any protection against our competitors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 23; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain that
patents will be issued as a result of any pending applications, and we cannot be certain that any of our issued patents will give us
adequate protection from competing products. For example, issued patents, including the patents in-licensed by us, may be circumvented
or challenged, declared invalid or unenforceable, or narrowed in scope. In addition, since publication of discoveries in the scientific
or patent literature often lags behind actual discoveries, we cannot be certain that we were the first to make our inventions or to file
patent applications covering those inventions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that
others may obtain issued patents that could prevent us from commercializing our products or require us to obtain licenses requiring the
payment of significant fees or royalties in order to enable us to conduct our business. As to those patents that we have in-licensed,
our rights depend on maintaining our obligations to the licensor under the applicable license agreement, and we may be unable to do so.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patents and
patent applications, we depend upon trade secrets and proprietary know-how to protect our proprietary technology. We require our employees,
consultants, advisors and collaborators to enter into confidentiality agreements that prohibit the disclosure of confidential information
to any other parties. We require our employees and consultants to disclose and assign to us their ideas, developments, discoveries and
inventions. These agreements may not, however, provide adequate protection for our trade secrets, know-how or other proprietary information
in the event of any unauthorized use or disclosure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Costly litigation may
be necessary to protect our intellectual property rights and we may be subject to claims alleging the violation of the intellectual property
rights of others.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may face significant expense
and liability as a result of litigation or other proceedings relating to patents and other intellectual property rights of others. In
the event that another party has also filed a patent application or been issued a patent relating to an invention or technology claimed
by us in pending applications, we may be required to participate in an interference proceeding declared by the USPTO to determine priority
of invention, which could result in substantial uncertainties and costs for us, even if the eventual outcome were favorable to us. We,
or our licensors, also could be required to participate in interference proceedings involving issued patents and pending applications
of another entity. An adverse outcome in an interference proceeding could require us to cease using the technology or to license rights
from prevailing third parties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost to us of any patent
litigation or other proceeding relating to our own or in-licensed patents or patent applications, even if resolved in our favor, could
be substantial. Our ability to enforce our patent protection could be limited by our financial resources, and may be subject to lengthy
delays. If we are unable to effectively enforce our proprietary rights, or if we are found to infringe the rights of others, we may be
in breach of our License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A third party may claim that
we are using inventions claimed by their patents and may go to court to stop us from engaging in our normal operations and activities,
such as research, development and the sale of any future products. Such lawsuits are expensive and would consume time and other resources.
There is a risk that the court will decide that we are infringing the third party&#8217;s patents and will order us to stop the activities
claimed by the patents, redesign our products or processes to avoid infringement or obtain licenses (which may not be available on commercially
reasonable terms). In addition, there is a risk that a court will order us to pay the other party damages for having infringed their
patents and possibly also their legal fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, there is no guarantee
that any prevailing patent owner would offer us a license so that we could continue to engage in activities claimed by the patent, or
that such a license, if made available to us, could be acquired on commercially acceptable terms. In addition, third parties may, in
the future, assert other intellectual property infringement claims against us with respect to our product candidates, technologies or
other matters.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 24; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We rely on confidentiality
agreements that could be breached and may be difficult to enforce, which could result in third parties using our intellectual property
to compete against us.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we believe that
we take reasonable steps to protect our intellectual property, including the use of agreements relating to the non-disclosure of confidential
information to third parties, as well as agreements that purport to require the disclosure and assignment to us of the rights to the
ideas, developments, discoveries and inventions of our employees and consultants while we employ them, the agreements can be difficult
and costly to enforce. Although we seek to obtain these types of agreements from our contractors, consultants, advisors and research
collaborators, to the extent that employees and consultants utilize or independently develop intellectual property in connection with
any of our projects, disputes may arise as to the intellectual property rights associated with our products. If a dispute arises, a court
may determine that the right belongs to a third party. In addition, enforcement of our rights can be costly and unpredictable. We also
rely on trade secrets and proprietary know-how that we seek to protect in part by confidentiality agreements with our employees, contractors,
consultants, advisors or others. Despite the protective measures we employ, we still face the risk that:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in; font-size: 10pt">&#160;</td>
<td style="width: 24px; font-size: 10pt">&#9679;</td>
<td style="font-size: 10pt">these agreements may be breached;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>these agreements may not provide adequate remedies for the applicable type of breach;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>our trade secrets or proprietary know-how will otherwise become known; or</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td>our competitors will independently develop similar technology or proprietary information.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>International patent
protection is particularly uncertain, and if we are involved in opposition proceedings in foreign countries, we may have to spend substantial
sums and management resources.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent law outside the United
States is different than in the United States. Further, the laws of some foreign countries may not protect our intellectual property
rights to the same extent as the laws of the United States, if at all. A failure to obtain sufficient intellectual property protection
in any foreign country could materially and adversely affect our business, results of operations and future prospects. Moreover, we may
participate in opposition proceedings to determine the validity of our foreign patents or our competitors&#8217; foreign patents, which
could result in substantial costs and divert management&#8217;s resources and attention.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although most jurisdictions
in which we have applied for, intend to apply for, or have been issued patents have patent protection laws similar to those of the United
States, some of them do not. For example, we expect to do business in Brazil and India in the future. However, the Brazilian drug regulatory
agency, ENVISA, has the authority to nullify patents on the basis of its perceived public interest and the Indian patent law does not
allow patent protection for new uses of pharmaceuticals (many of our current patent applications are of such nature). Additionally, due
to uncertainty in patent protection law, we have not filed applications in many countries where significant markets exist, including
Indonesia, Pakistan, Russia, African countries and Taiwan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We may be unable to
protect the intellectual property rights of the third parties from whom we license certain of our intellectual property or with whom
we have entered into other strategic relationships.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our intellectual
property rights may be licensed in the future from universities and/or strategic partners. Such third parties may determine not to protect
the intellectual property rights that we license from them and we may be unable to defend such intellectual property rights on our own
or we may have to undertake costly litigation to defend the intellectual property rights of such third parties. There can be no assurances
that we will be able to obtain licenses to such third party intellectual property or otherwise have the right to use through similar strategic
relationships. Any loss or limitations on use with respect to our right to use such intellectual property licensed from third parties
or otherwise obtained from third parties with whom we have entered into strategic relationships could have a material adverse effect on
our business, results of operations and financial condition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 25; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Under applicable U.S.
and Israeli law, we may not be able to enforce covenants not to compete and therefore, may be unable to prevent our competitors from
benefiting from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their
inventions irrespective of their agreements with us, which in turn could impact our future profitability.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally enter into confidentiality
and non-competition agreements with our employees and certain key consultants, or our employment and consulting agreements contain confidentiality
and non-competition provisions. These agreements, to the extent they are in place and in effect, prohibit our employees and certain key
consultants, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period
of time and maintain confidentiality of our know-how and trade secrets, as long as they do not enter the public domain. We may be unable
to enforce these agreements under the laws of the jurisdictions in which our employees work and it may be difficult for us to restrict
our competitors from benefitting from the expertise our former employees or consultants developed while working for us. For example,
Israeli courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive
activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized
by the courts, such as the secrecy of a company&#8217;s confidential commercial information or the protection of its intellectual property.
If we cannot demonstrate that such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise
of our former employees or consultants and our ability to remain competitive may be diminished.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Chapter 8 to
the Israeli Patents Law, 5727-1967, or the Patents Law, deals with inventions made in the course of an employee&#8217;s service and during
his or her term of employment, whether or not the invention is patentable, or service inventions. Section 134 of the Patents Law provides
that if there is no agreement that explicitly determines whether the employee is entitled to compensation for the service inventions
and the extent and terms of such compensation, such determination will be made by the Compensation and Rewards Committee, a statutory
committee of the Israeli Patents Office. Although our employees have agreed to assign to us service invention rights, we may face claims
demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional
remuneration or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect
our business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Intellectual property
rights do not necessarily address all potential threats to our competitive advantage.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future protection
afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Others may be able to make compounds that are the same as or similar to our product candidates but
    that are not covered by the claims of the patents that we own or have exclusively licensed;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">We or our licensors or any future strategic partners might not have been the first to make the inventions
    covered by the issued patent or pending patent application that we own or have exclusively licensed;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">We or our licensors or any future strategic partners might not have been the first to file patent
    applications covering certain of our inventions;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Others may independently develop similar or alternative technologies or duplicate any of our technologies
    without infringing our intellectual property rights;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">It is possible that our pending patent applications will not lead to issued patents;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantages,
    or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Our competitors might conduct research and development activities in countries where we do not have
    patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial
    markets; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">We may not develop additional proprietary technologies that are patentable.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We may be subject to
claims challenging the inventorship of our patents and other intellectual property.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor
or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved
in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship.
If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 26; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Risks Related to Our Industry</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We are subject to government
regulations and we may experience delays in obtaining required regulatory approvals in the United States and the regulatory authorities
in foreign jurisdiction in which we intend to market our proposed product candidates, of which there can be no assurance.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Various aspects of our operations
are subject to foreign, federal, state or local laws, and rules and regulations, any of which may change from time to time. We are not
permitted to market our product candidates as prescription pharmaceutical products in the United States until we receive approval of
a New Drug Application, or NDA, from the FDA or in any foreign countries until we receive the requisite approval from such countries.
Costs arising out of any regulatory developments could be time-consuming and expensive and could divert management resources and attention
and, consequently, could adversely affect our business operations and financial performance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delays in regulatory approval,
limitations in regulatory approval and withdrawals of regulatory approval may have a material adverse effect on us. In the United States,
the FDA generally requires the completion of clinical trials of each drug to establish its safety and efficacy and extensive pharmaceutical
development to ensure its quality before an NDA is approved. If we experience significant delays in testing or receiving approvals or
sign-offs to conduct clinical trials, our product development costs, or our ability to license product candidates, will increase. If
the FDA grants regulatory approval to market a product, this approval will be limited to those disease states and conditions and populations
for which the product has demonstrated, through clinical trials, to be safe and effective. Any product approvals that we receive in the
future could also include significant restrictions on the use or marketing of our products. Product approvals, if granted, can be withdrawn
for failure to comply with regulatory requirements or upon the occurrence of adverse events following commercial introduction of the
products. Failure to comply with applicable FDA or other applicable regulatory requirements may result in criminal prosecution, civil
penalties, recall or seizure of products, total or partial suspension of production or injunction, as well as other regulatory action
against our product candidates or us. If approval is withdrawn for a product, or if a product were seized or recalled, we would be unable
to sell or license that product and our revenues would suffer. In addition, outside the United States, our ability to market any of our
potential products is contingent upon receiving market application authorizations from the appropriate regulatory authorities and these
foreign regulatory approval processes include all of the risks associated with the FDA approval process described above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends on our
receipt of the regulatory approvals described above, and the issuance of such regulatory approvals is uncertain and subject to a number
of risks, including the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">such authorities may disagree with the number, design, size, conduct or implementation of our clinical
    trials or any of our collaborators&#8217; clinical trials;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">such authorities may disagree with our interpretation of data from preclinical studies or clinical
    trials or the use of results from studies that served as precursors to our current or future product candidates;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the results of toxicology studies may not support the filing of an Investigational New Drug Application,
    or IND, or NDA for our product candidates;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the FDA or comparable foreign regulatory authorities or Institutional Review Boards, or IRBs, may
    disagree with the design or implementation of our clinical trials;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">we may not be able to provide acceptable evidence of our product candidates&#8217; safety and efficacy;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the results of our clinical trials may not be satisfactory or may not meet the level of statistical
    or clinical significance required by the FDA, European Medicines Agency, or EMA, or other regulatory agencies for us to receive marketing
    approval for any of our product candidates;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the dosing of our product candidates in a particular clinical trial may not be at an optimal level;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">patients in our clinical trials may suffer adverse effects for reasons that may or may not be related
    to our product candidates;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the data collected from clinical trials may not be sufficient to support the submission of an NDA,
    or other submission to obtain regulatory approval in the United States or elsewhere;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition
    of approval;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes
    or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may
    significantly change in a manner rendering our clinical data insufficient for approval of our product candidates.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 27; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of obtaining
regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon, among
other things, the type, complexity and novelty of the product candidates involved, the jurisdiction in which regulatory approval is sought
and the substantial discretion of the regulatory authorities. Changes in regulatory approval policies during the development period,
changes in or the enactment of additional statutes or regulations, or changes in regulatory review for a submitted product application
may cause delays in the approval or rejection of an application. Regulatory approval obtained in one jurisdiction does not necessarily
mean that a product candidate will receive regulatory approval in all jurisdictions in which we may seek approval, but the failure to
obtain approval in one jurisdiction may negatively impact our ability to seek approval in a different jurisdiction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Clinical testing is
expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome</i></span>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business model depends
entirely on the successful development, regulatory approval and commercialization of our product candidates, which may never occur. We
may not be successful in obtaining approval from the FDA or comparable foreign regulatory authorities to start or continue clinical trials
for any of our product candidates. Moreover, there is no guarantee that we will receive approval to commence human clinical trials or
that our clinical trials will be successful or that we will continue clinical development in support of an approval from the FDA or comparable
foreign regulatory authorities for any indication. We note that most product candidates never reach the clinical development stage and
even those that do commence clinical development have only a small chance of successfully completing clinical development and gaining
regulatory approval. Success in early phases of pre-clinical and clinical trials does not ensure that later clinical trials will be successful,
and interim results of a clinical trial do not necessarily predict final results. A failure of one or more of our clinical trials can
occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process that
could delay or prevent our ability to receive regulatory approval or commercialize our product candidates. Therefore, our business currently
depends entirely on the successful development, regulatory approval and commercialization of our product candidates, which may never occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>The results of previous
clinical trials may not be predictive of future results, our progress in trials for one product candidate may not be indicative of progress
in trials for other product candidates, and our trials may not be designed so as to support regulatory approval.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have no products
approved for sale and we cannot guarantee that we will ever have marketable products. Clinical failure can occur at any stage of clinical
development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may
decide, or regulators may require us, to conduct additional clinical or non-clinical testing. We will be required to demonstrate with
substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for use in a diverse
population before we can obtain regulatory approvals for their commercial sale. Success in early clinical trials does not mean that future
clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety
and efficacy to the satisfaction of the FDA and other regulatory authorities despite having progressed through initial clinical trials.
Product candidates that have shown promising results in early clinical trials may still suffer significant setbacks in subsequent clinical
trials. Similarly, the outcome of non-clinical testing and early clinical trials may not be predictive of the success of later clinical
trials, and interim results of a clinical trial do not necessarily predict final results. Progress in trials of one product candidate
does not indicate that we will make similar progress in additional trials for that product candidate or in trials for our other product
candidates. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have
suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The design of a clinical
trial can determine whether its results will support approval of a product. We may be unable to design and/or execute a clinical trial
to support regulatory approval. Flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced
or completed. In addition, we or our investigators may have little control over whether subjects comply with important aspects of clinical
trial protocols.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some instances,
there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to
numerous factors, including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing
regimen and other trial protocols, modifications in the formulation throughout the course of development and the rate of dropout among
clinical trial participants. While we have not had any serious adverse events in our clinical trials to date that are believed to be
related to our oral product candidates, we may need to change future trial designs in response to adverse events that occur during future
clinical development. We do not know whether any Phase 2, Phase 3 or other clinical trials we or any of our collaborators may conduct
will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 28; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Even if we receive
regulatory approval for any of our product candidates, we may not be able to successfully commercialize the product and the revenue that
we generate from its sales, if any, may be limited</i></span>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If approved for marketing,
the commercial success of our product candidates will depend upon each product&#8217;s acceptance by the medical community, including
physicians, patients and health care payors. The degree of market acceptance for any of our product candidates will depend on a number
of factors, including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">demonstration of clinical safety and efficacy;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">relative convenience, dosing burden and ease of administration;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the prevalence and severity of any adverse effects;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the willingness of physicians to prescribe our product candidates, and the target patient population
    to try new therapies;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">efficacy of our product candidates compared to competing products;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the introduction of any new products that may in the future become available targeting indications
    for which our product candidates may be approved;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">new procedures or therapies that may reduce the incidences of any of the indications in which our
    product candidates may show utility;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">pricing and cost-effectiveness;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the inclusion or omission of our product candidates in applicable therapeutic guidelines;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the effectiveness of our own or any future collaborators&#8217; sales and marketing strategies;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">limitations or warnings contained in approved labeling from regulatory authorities;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">our ability to obtain and maintain sufficient third-party coverage or reimbursement from government
    health care programs, including Medicare and Medicaid, private health insurers and other third-party payors or to receive the necessary
    pricing approvals from government bodies regulating the pricing and usage of therapeutics; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement
    or government pricing approvals.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our product candidates
are approved, but do not achieve an adequate level of acceptance by physicians, health care payors, and patients, we may not generate
sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the medical community and third-party
payors on the benefits of our product candidates may require significant resources and may never be successful.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, even if we obtain
regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize our product candidates
successfully. For example, if the approval process takes too long, we may miss market opportunities and give other companies the ability
to develop competing products or establish market dominance. Any regulatory approval we ultimately obtain may be limited or subject to
restrictions or post-approval commitments that render our product candidates not commercially viable. For example, regulatory authorities
may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend
to charge for any of our product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials,
or may approve any of our product candidates with a label that does not include the labeling claims necessary or desirable for the successful
commercialization of that indication. Further, the FDA or comparable foreign regulatory authorities may place conditions on approvals
or require risk management plans or a REMS to assure the safe use of the drug. Moreover, product approvals may be withdrawn for non-compliance
with regulatory standards or if problems occur following the initial marketing of the product. Any of the foregoing scenarios could materially
harm the commercial success of our product candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 29; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Even if we obtain marketing
approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result
in significant additional expense. Additionally, our product candidates could be subject to labeling and other restrictions and withdrawal
from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated
problems with our product candidates</i></span>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we obtain regulatory
approval for any of our product candidates for an indication, the FDA or foreign equivalent may still impose significant restrictions
on their indicated uses or marketing or the conditions of approval, or impose ongoing requirements for potentially costly and time-consuming
post-approval studies, including Phase 4 clinical trials, and post-market surveillance to monitor safety and efficacy. Our product candidates
will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging, storage, distribution, safety
surveillance, advertising, promotion, recordkeeping and reporting of adverse events and other post-market information. These requirements
include registration with the FDA, as well as continued compliance with current Good Clinical Practices regulations, or cGCPs, for any
clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual
review and periodic inspections by the FDA and other regulatory authorities for compliance with current Good Manufacturing Practices,
or cGMPs, requirements relating to quality control, quality assurance and corresponding maintenance of records and documents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has the authority
to require a REMS as part of an NDA or after approval, which may impose further requirements or restrictions on the distribution or use
of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training,
limiting treatment to patients who meet certain safe-use criteria or requiring patient testing, monitoring and/or enrollment in a registry.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to sales and
marketing activities related to our product candidates, advertising and promotional materials must comply with FDA rules in addition
to other applicable federal, state and local laws in the United States and similar legal requirements in other countries. In the United
States, the distribution of product samples to physicians must comply with the requirements of the U.S. Prescription Drug Marketing Act.
Application holders must obtain FDA approval for product and manufacturing changes, depending on the nature of the change. We may also
be subject, directly or indirectly through our customers and partners, to various fraud and abuse laws, including, without limitation,
the U.S. Anti-Kickback Statute, U.S. False Claims Act, and similar state laws, which impact, among other things, our proposed sales,
marketing, and scientific/educational grant programs. If we participate in the U.S. Medicaid Drug Rebate Program, the Federal Supply
Schedule of the U.S. Department of Veterans Affairs, or other government drug programs, we will be subject to complex laws and regulations
regarding reporting and payment obligations. All of these activities are also potentially subject to U.S. federal and state consumer
protection and unfair competition laws. Similar requirements exist in many of these areas in other countries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if any of our
product candidates are approved for a particular indication, our product labeling, advertising and promotion would be subject to regulatory
requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about prescription products.
In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling.
On September 9, 2025, the FDA began requiring pharmaceutical advertisements to include full safety warnings during direct-to-consumer
advertisements, instead of footnoting such information. Additionally, the FDA expanded its oversight on social medial promotional activities,
including influencer partnerships, algorithm-driven targeted advertising, and AI-generated health content, to ensure compliance with the
FDA&#8217;s advertisement requirements. The FDA has indicated it will begin enforcement actions for any advertisement violations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we receive marketing approval for our product candidates, physicians
may nevertheless legally prescribe our products to their patients in a manner that is inconsistent with the approved label. If we are
found to have promoted such off-label uses, we may become subject to significant liability and government fines. The FDA and other agencies
actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly
promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against
companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested
that companies enter into consent decrees of permanent injunctions under which specified promotional conduct is changed or curtailed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or a regulatory agency
discover previously unknown problems with a product candidate, such as adverse events of unanticipated severity or frequency, problems
with the facility where the product is manufactured, or we or our manufacturers fail to comply with applicable regulatory requirements,
we may be subject to the following administrative or judicial sanctions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the
    market, or voluntary or mandatory product recalls;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">issuance of warning letters or untitled letters;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">clinical holds;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 30; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">injunctions or the imposition of civil or criminal penalties or monetary fines;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">suspension or withdrawal of regulatory approval;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">suspension of any ongoing clinical trials;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">refusal to approve pending applications or supplements to approved applications filed by us, or suspension
    or revocation of product license approvals;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">suspension or imposition of restrictions on operations, including costly new manufacturing requirements;
    or</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">product seizure or detention or refusal to permit the import or export of product.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The occurrence of any event
or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. Adverse regulatory action,
whether pre- or post-approval, can also potentially lead to product liability claims and increase our product liability exposure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the
United States or abroad, and compliance with such regulation may be expensive and consume substantial financial and management resources.
If we or any future marketing collaborators or contract manufacturers are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies or are not able to maintain regulatory compliance, it could delay or prevent the promotion,
marketing or sale of our products, which would adversely affect our business and results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Obtaining and maintaining
regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval
of our product candidates in other jurisdictions</i></span>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining and maintaining
regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory
approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect
on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable
regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate
in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different
from those in the United States, including additional preclinical studies or clinical trials, as clinical studies conducted in one jurisdiction
may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate
must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to
charge for our products is also subject to approval.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining foreign regulatory
approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could
delay or prevent the introduction of our product candidates in certain countries. If we fail to comply with the regulatory requirements
in international markets and/ or to receive applicable marketing approvals, our target market will be reduced and our ability to realize
the full market potential of our product candidates will be harmed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Even though we may
apply for orphan drug designation for a product candidate, we may not be able to obtain orphan drug status or marketing exclusivity.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we have received
orphan drug designation for Namodenoson for certain indications, there is no guarantee that the FDA will grant any future application
for orphan drug designation for any of our product candidates, which would make us ineligible for the additional exclusivity and other
benefits of orphan drug designation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Orphan Drug Act,
the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition
that affects fewer than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing
and making a drug available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan
drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic
agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten
the duration of regulatory review and approval process. In addition to the potential period of exclusivity, orphan designation makes a
company eligible for grant funding of up to $650,000 per year for four years to defray costs of clinical trial expenses, tax credits for
clinical research expenses and potential exemption from the FDA application user fee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 31; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a product that has orphan
designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product
is entitled to orphan drug exclusivity, which means the FDA may not approve any other applications to market the same drug for the same
indication for seven years, except in limited circumstances, such as (i) the drug&#8217;s orphan designation is revoked; (ii) its marketing
approval is withdrawn; (iii) the orphan exclusivity holder consents to the approval of another applicant&#8217;s product; (iv) the orphan
exclusivity holder is unable to assure the availability of a sufficient quantity of drug; or (v) a showing of clinical superiority to
the product with orphan exclusivity by a competitor product. If a drug designated as an orphan product receives marketing approval for
an indication broader than what is designated, it may not be entitled to orphan drug exclusivity. There can be no assurance that we will
receive orphan drug designation for any of our product candidates in the indications for which we think they might qualify, if we elect
to seek such applications.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Current and future
legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and
affect the prices we may obtain</i></span>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States and
some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare
system that could prevent or delay marketing approval for our product candidates, restrict or regulate post-approval activities and affect
our ability to profitably sell our product candidates. Legislative and regulatory proposals have been made to expand post-approval requirements
and restrict sales and promotional activities for pharmaceutical products. We do not know whether additional legislative changes will
be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing
approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval
process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing
testing and other requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare
coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for drugs. In
addition, this legislation authorized Medicare Part D prescription drug plans to use formularies where they can limit the number of drugs
that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal coverage of drug products,
we expect that there will be additional pressure to contain and reduce costs. These cost reduction initiatives and other provisions of
this legislation could decrease the coverage and price that we receive for our product candidates and could seriously harm our business.
While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment
limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA may result in a similar
reduction in payments from private payors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 or, collectively, the ACA,
is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies
against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees
on the health industry and impose additional health policy reforms. The ACA revised the definition of &#8220;average manufacturer price&#8221;
for reporting purposes, which could increase the amount of Medicaid drug rebates to states. Further, the law imposed a significant annual
fee on companies that manufacture or import branded prescription drug products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been proposed and adopted in the United States since the ACA was enacted. In 2011, the U.S. Congress enacted the Budget Control
Act of 2011, or the Budget Control Act, which included provisions intended to reduce the federal deficit. The Budget Control Act resulted
in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to
the statute, will remain in effect through 2031 absent additional congressional action. In January 2013, the American Taxpayer Relief
Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased the statute
of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional
reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved,
and accordingly, our financial operations. If government spending is further reduced, anticipated budgetary shortfalls may also impact
the ability of relevant agencies, such as the FDA, to continue to function at current levels, which may impact the ability of relevant
agencies to timely review and approve research and development, manufacturing and marketing activities, which may delay our ability to
develop, market and sell any product candidates we may develop. In addition, any significant spending reductions affecting Medicare, Medicaid
or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on
us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact
on our anticipated product revenues.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been judicial
and Congressional challenges to certain aspects of the ACA, and we expect such challenges to continue. In 2017, the U.S. Congress enacted
the Tax Cuts and Jobs Act, or the 2017 Tax Act, which eliminated the tax-based shared responsibility payment imposed by the ACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual
mandate.&#8221; On January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed
the implementation of certain fees mandated by the ACA, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored
insurance plans and the annual fee imposed on certain health insurance providers based on market share. The Bipartisan Budget Act of
2018, or the BBA, among other things, amends the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans.
In July 2018, the Centers for Medicare and Medicaid Services, or CMS, published a final rule permitting further collections and payments
to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the
outcome of federal district court litigation, regarding the method CMS uses to determine this risk adjustment. Litigation and legislation
over the ACA are likely to continue, with unpredictable and uncertain results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 32; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, recently there has
been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products. There have been
several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring
more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs
under Medicare, and reform government program reimbursement methodologies for drugs. On September 24, 2020, the FDA released a final rule
providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department
of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical
manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required
by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain
fixed fee arrangements between pharmacy benefit managers and manufacturers. On August 16, 2022, President Biden signed the Inflation Reduction
Act of 2022, which includes several provisions to lower prescription drug costs for people with Medicare, including price negotiation
requirements for drugs covered under Medicare, rebate requirements when drug prices rise faster than inflation, and a cap on out-of-pocket
spending for Medicare Part D enrollees. Additionally, HHS began implementation in 2025 of &#8220;Most Favored Nation&#8221; drug pricing
by setting the Medicare price of single-source brand drugs without generic or biosimilar competition to the lowest price available in
wealthy countries with a per capita GDP of at least 60% of that in the United States. At the state level, legislatures have increasingly
passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 20, 2020, the
HHS Office of Inspector General finalized further modifications to the federal Anti-Kickback Statute. Under the final rules, the HHS Office
of Inspector General added safe harbor protections under the Anti-Kickback Statute for certain coordinated care and value-based arrangements
among clinicians, providers, and others, yet removed safe harbor protection for price reductions from pharmaceutical manufacturers to
plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule
also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements
between pharmacy benefit managers and manufacturers. This rule (with exceptions) became effective January 19, 2021. We continue to evaluate
what effect, if any, these rules will have on our business. CMS issued a final rule, effective on July 9, 2019, that requires direct-to-consumer
advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to
include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product if it is equal to or greater
than $35 for a monthly supply or usual course of treatment. Prescription drugs and biological products that are in violation of these
requirements will be included on a public list. On September 9, 2025, the FDA began requiring pharmaceutical advertisements to include
full safety warnings during direct-to-consumer advertisements, instead of footnoting such information. Additionally, the FDA expanded
its oversight on social medial promotional activities, including influencer partnerships, algorithm-driven targeted advertising, and AI-generated
health content, to ensure compliance with the FDA&#8217;s advertisement requirements. The FDA has indicated it will begin enforcement
actions for any advertisement violations. Any adopted health reform measure could reduce the ultimate demand for our products, if approved,
or put pressure on our product pricing. Individual states in the United States have also become increasingly active in passing legislation
and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints,
discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed
to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals
are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription
drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the EU, a new Regulation
on health technology assessments at EU level was adopted on December 13, 2021, Regulation (EU) 2021/2282 of the European Parliament and
of the Council of December 15, 2021 on health technology assessment and amending Directive 2011/24/EU, or HTA Regulation. The HTA Regulation
entered into force on 11 January 2022 and applies from 12 January 2025. The HTA Regulation stipulates joint clinical assessments at EU
level. A Joint Clinical Assessment (JCA) under the HTA Regulation is a centralized, EU-level evaluation of the comparative clinical effectiveness
and safety of health technologies, including certain medicinal products. The JCA is designed to influence pricing and reimbursement decisions
of EU member states at the national level, although its result does not pre-determine national decisions concerning reimbursement. As
of 2026, JCAs apply on a phased basis to certain centrally authorized medicinal products, initially including new oncology medicines (new
active substances) and advanced therapy medicinal products (ATMPs), with later expansion to orphan medicines (from 13 January 2028) and
other covered medicinal products (from 13 January 2030), subject to possible earlier inclusion by Commission implementing act in specified
circumstances. For in-scope products, the HTA Regulation may affect market access planning by adding EU-level HTA evidence submission
and coordination requirements while not replacing country-specific national HTA and reimbursement processes. The HTA Regulation may increase
compliance costs and adversely affect pricing of in-scope medicinal products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2025, the European Parliament and the Council reached a
political agreement in trilogue on the EU &#8220;pharma package,&#8221; a comprehensive reform intended to replace and revise key elements
of the EU pharmaceutical framework (including the main pharmaceutical EU directives and regulations). The agreement includes a revised
incentives framework for innovative medicines that keeps eight years of regulatory data protection and sets one year of market protection,
with potential extensions for qualifying products. The deal also includes measures to strengthen security of supply, including provisions
allowing member states to require manufacturers to supply sufficient quantities of a medicinal product. The agreement clarifies and broadens
the Bolar exemption, allowing generic and biosimilar companies to complete preparatory steps before patent/SPC expiry to support immediate
entry after expiry. Because the final legal texts reflecting the trilogue agreement had not yet been fully published, we cannot yet determine
with certainty the full legal, operational or financial impact of the new EU pharmaceutical legislation on our business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 33; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The delivery of healthcare
in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively
a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and
approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare
budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant
health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products,
this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our
ability to commercialize any products for which we obtain marketing approval. Both in the United States and in the EU, legislative and
regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical
products. We do not know whether additional legislative changes will be enacted, or whether the regulations, guidance or interpretations
will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Disruptions at the
FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or
deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or
commercialized in a timely manner or at all, which could negatively impact our business.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of the FDA to
review and clear or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory,
regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other
events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated
in recent years as a result. In addition, government funding of other government agencies that fund research and development activities
is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruptions at the FDA and
other agencies may also slow the time necessary for new medical devices or modifications to cleared or approved medical devices to be
reviewed and/or approved by necessary government agencies, which would adversely affect our business. Most recently, the federal government
was shut down for approximately 43 days from October 1 to November 12, 2025, due to a lapse in appropriations, during which federal employees
were furloughed and many agencies, including components of the HHS, operated with reduced staffing or suspended activities. In early 2025,
following the inauguration of President Trump, the Trump Administration began terminating federal government employees, including approximately
3,500 employees at the FDA. Prior shutdowns, such as the 35-day shutdown beginning December 22, 2018, similarly resulted in furloughs
and delays in regulatory review activities. Any future government shutdowns, funding lapses, continuing resolutions, or similar events
could result in reduced agency staffing, delays in regulatory reviews, interruptions to critical government functions, or uncertainty
in agency operations, each of which could materially and adversely affect our business, financial condition, and results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Any termination or
suspension of, or delays in the commencement or completion of, any necessary studies of any of our product candidates for any indications
could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects</i></span>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The commencement and completion
of clinical studies can be delayed for a number of reasons, including delays related to:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the FDA or a comparable foreign regulatory authority failing to grant permission to proceed and placing
    the clinical study on hold;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">subjects for clinical testing failing to enroll or remain enrolled in our trials at the rate we expect;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">a facility manufacturing any of our product candidates being ordered by the FDA or other government
    or regulatory authorities to temporarily or permanently shut down due to violations of cGMP requirements or other applicable requirements,
    or cross-contaminations of product candidates in the manufacturing process;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">any changes to our manufacturing process that may be necessary or desired;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">subjects choosing an alternative treatment for the indications for which we are developing our product
    candidates, or participating in competing clinical studies;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">subjects experiencing severe or unexpected drug-related adverse effects;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">reports from clinical testing on similar technologies and products raising safety and/or efficacy
    concerns;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">third-party clinical investigators losing their license or permits necessary to perform our clinical
    trials, not performing our clinical trials on our anticipated schedule or employing methods consistent with the clinical trial protocol,
    cGMP requirements, or other third parties not performing data collection and analysis in a timely or accurate manner;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">inspections of clinical study sites by the FDA, comparable foreign regulatory authorities, or IRBs
    finding regulatory violations that require us to undertake corrective action, result in suspension or termination of one or more
    sites or the imposition of a clinical hold on the entire study, or that prohibit us from using some or all of the data in support
    of our marketing applications;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 34; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other
    government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor,
    and we may not be able to use some or any of the data produced by such contractors in support of our marketing applications;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">one or more IRBs refusing to approve, suspending or terminating the study at an investigational site,
    precluding enrollment of additional subjects, or withdrawing its approval of the trial, reaching agreement on acceptable terms with
    prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation
    and may vary significantly among different CROs and trial sites;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">deviations of the clinical sites from trial protocols or dropping out of a trial;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">adding new clinical trial sites;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the inability of the CRO to execute any clinical trials for any reason; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">government or regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination
    of a trial.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Product development costs
for any of our product candidates will increase if we have delays in testing or approval or if we need to perform more or larger clinical
studies than planned. Additionally, changes in regulatory requirements and policies may occur and we may need to amend study protocols
to reflect these changes. Amendments may require us to resubmit our study protocols to the FDA, comparable foreign regulatory authorities,
and IRBs for reexamination, which may impact the costs, timing or successful completion of that study. If we experience delays in completion
of, or if we, the FDA or other regulatory authorities, the IRB, or other reviewing entities, or any of our clinical study sites suspend
or terminate any of our clinical studies of any of our product candidates, its commercial prospects may be materially harmed and our
ability to generate product revenues will be delayed. Any delays in completing our clinical trials will increase our costs, slow down
our development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences
may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, termination
or suspension of, or a delay in the commencement or completion of, clinical studies may also ultimately lead to the denial of regulatory
approval of our product candidates. In addition, if one or more clinical studies are delayed, our competitors may be able to bring competing
products to market before we do, and the commercial viability of any of our affected product candidates could be significantly reduced.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>If we or any of our
independent contractors, consultants, collaborators, manufacturers, or service providers fail to comply with healthcare and data privacy
laws and regulations, we or they could be subject to enforcement actions, which could result in penalties and affect our ability to develop,
market and sell our product candidates and may harm our reputation.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are or may in the future
be subject to federal, state, and foreign healthcare and data privacy laws and regulations pertaining to, among other things, fraud and
abuse of patients&#8217; rights. These laws and regulations include:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully soliciting,
    offering, receiving, or paying any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, ordering
    or arranging for or recommending the purchase or order of any item or service for which payment may be made, in whole or in part,
    under a federal healthcare program such as Medicare and Medicaid. Liability may be established without a person or entity having
    actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it. This statute has been interpreted to apply
    broadly to arrangements between pharmaceutical manufacturers on the one hand and prescribers, patients, purchasers and formulary
    managers on the other. In addition, the ACA amended the Social Security Act to provide that the U.S. government may assert that a
    claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent
    claim for purposes of the federal civil False Claims Act, or the FCA. A conviction for violation of the Anti-Kickback Statute requires
    mandatory exclusion from participation in federal healthcare programs. Although there are a number of statutory exemptions and regulatory
    safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and those
    activities may be subject to scrutiny or penalty if they do not qualify for an exemption or safe harbor;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify; font-size: 10pt">&#160;</td>
<td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FCA prohibits, among other things, knowingly presenting, or causing to be presented claims for payment of government funds that are false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to such a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. This statute also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. The FCA prohibits anyone from knowingly presenting, conspiring to present, making a false statement in order to present, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. This law also prohibits anyone from knowingly underpaying an obligation owed to a federal program. Increasingly, U.S. federal agencies are requiring nonmonetary remedial measures, such as corporate integrity agreements in FCA settlements. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of $5,500 to $11,000 per false claim or statement ($14,308 to $28,619 per false claim or statement for penalties assessed after January 15, 2025 for violations occurring after November 2, 2015). Government enforcement agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for a variety of alleged promotional and marketing activities, such as providing free product to customers with the expectation that the customers would bill federal programs for the product; providing consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion for &#8220;off-label&#8221; uses; and submitting inflated best price information to the Medicaid Rebate Program;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 35; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">The federal False Statements Statute prohibits knowingly and willfully falsifying, concealing, or
    covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using
    any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry, in connection
    with the delivery of or payment for healthcare benefits, items, or services;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">The federal Civil Monetary Penalties Law authorizes the imposition of substantial civil monetary
    penalties against an entity, such as a pharmaceutical manufacturer, that engages in activities including, among others (1) knowingly
    presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in
    any way; (2) arranging for or contracting with an individual or entity that is excluded from participation in federal healthcare
    programs to provide items or services reimbursable by a federal healthcare program; (3) violations of the federal Anti-Kickback Statute;
    (4) knowingly offering or transferring remuneration to a Medicare or Medicaid beneficiary or recipient to influence the beneficiary&#8217;s
    or recipient&#8217;s selection of a particular provider, practitioner, or supplier for the order or receipt of any item or service;
    or (5) failing to report and return a known overpayment;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal
    and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program,
    or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection
    with the delivery of, or payment for, healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person
    or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, which
    imposes requirements on certain types of people and entities relating to the privacy, security, and transmission of individually
    identifiable health information, and requires notification to affected individuals and regulatory authorities of certain breaches
    of security of individually identifiable health information;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">The federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices,
    biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance
    Program, to report annually to the Centers for Medicare &amp; Medicaid Services information related to payments and other transfers
    of value to physicians, other healthcare providers and teaching hospitals, and ownership and investment interests held by physicians
    and other healthcare providers and their immediate family members, which is published in a searchable form on an annual basis;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">State laws comparable to each of the above federal laws, such as, for example, anti-kickback and
    false claims laws that may be broader in scope and also apply to commercial insurers and other non-federal payor;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Requirements for mandatory corporate regulatory compliance programs, and laws relating to patient
    data privacy and security. Other state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary
    compliance guidelines and the relevant compliance guidance promulgated by the federal government; require drug manufacturers to report
    information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures;
    and state and foreign laws govern the privacy and security of health information in some circumstances, many of which differ from
    each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">In the European Union, the General Data Protection Regulation, or the GDPR, Regulation EU 2016/679,
    which was adopted in May 2016 and has become applicable on May 25, 2018. The GDPR is further intended to harmonize data protection
    requirements across the European Union member states by establishing new and expanded operational requirements for entities that
    collect, process or use personal data generated in the European Union, including consent requirements for disclosing the way personal
    information will be used, information retention requirements, and notification requirements in the event of a data breach.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify; font-size: 10pt">&#160;</td>
<td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The California Consumer Privacy Act of 2018, or CCPA, effective as of January 1, 2020 as amended by the California Privacy Rights Act on January 1, 2023, gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches, that is expected to increase data breach litigation.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify; font-size: 10pt">&#160;</td>
<td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, failure to comply with the Israeli Privacy Protection Law of 1981, or Privacy Protection Law, and its regulations, as well as the guidelines of the Israeli Privacy Protection Authority, or the PPA, may expose us to administrative fines, civil claims (including class actions), and in certain cases criminal liability. In August 2024, the Israeli Knesset approved Amendment No. 13 to the Privacy Protection Law, or the Amendment, which entered into force on August 14, 2025. The Amendment represents a significant modernization of Israeli data protection law, aligning it more closely with international standards such as the GDPR. Key changes include expanded PPA enforcement powers with authority to impose substantial administrative fines, new requirements for certain organizations to appoint a Data Protection Officer, enhanced data subject rights with statutory damages available without proof of actual damage, revised database registration and notification requirements, and an extended statute of limitations for civil claims from two to seven years. Our failure to comply with these requirements could result in significant administrative fines, civil liability including class actions, reputational harm, and criminal penalties, any of which could materially adversely affect our business, financial condition, and results of operations.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 36; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our operations are found
to be in violation of any such healthcare laws and regulations, we may be subject to penalties, including administrative, civil and criminal
penalties, monetary damages, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain
approvals from the FDA or foreign regulatory authorities, or exclusion from participation in government contracting, healthcare reimbursement
or other government programs, including Medicare and Medicaid, any of which could adversely our financial results. Any action against
us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention
from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable
laws and regulations may be costly to us in terms of money, time and resources.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Our employees, principal
investigators, consultants, commercial partners or vendors may engage in misconduct or other improper activities, including non-compliance
with regulatory standards.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also exposed to the
risk of employees, independent contractors, principal investigators, consultants, commercial partners or vendors engaging in fraud or
other misconduct. Misconduct by employees, independent contractors, principal investigators, consultants, commercial partners and vendors
could include intentional failures to comply with EU regulations, to provide accurate information to the EMA, the European Commission
or EU Member States authorities or to comply with manufacturing or quality standards we have or will have established. In particular,
sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent
fraud, misconduct, kickbacks, self-dealing and other abusive practices such as promotion of products by medical practitioners. The EU
Member States in which we operate have different statutory provisions regulating the cooperation of pharmaceutical companies with healthcare
professionals. In addition to these statutory provisions, codes of conduct issued by business associations or other non-statutory standards
may be applicable to our activities. Both statutory provisions and non-statutory codes or standards restrict payments or other benefits
provided to healthcare professionals, and in case of non-compliance, may result in severe sanctions such as bans, administrative fines,
criminal fines or even imprisonment. The advertising of medicinal products for human use in the EU is regulated by Title VIII of European
Directive 2001/83/EC. These provisions have been implemented into the law of the EU member States. Such laws inter alia restrict or prohibit
a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.
Misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory
sanctions and serious and irreparable harm to our reputation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This could also apply with
respect to data privacy. In the EU, the EU Directive 95/46/EEC was replaced by the GDPR on May 25, 2018. The GDPR as an EU regulation
does not have to be implemented into Member States&#8217; national law, but applies directly in all Member States since May 25, 2018.
It applies to companies with an establishment in the European Economic Area (EEA) and to certain other companies not in the EEA that
offer or provide goods or services to individuals located in the EEA or monitor individuals located in the EEA. The GDPR implements more
stringent operational requirements for controllers of personal data, including, for example, expanded disclosures about how personal
information is to be used, limitations on retention of information, increased requirements pertaining to health data and pseudonymized
(i.e., key-coded) data, increased cyber security requirements, mandatory data breach notification requirements and higher standards for
controllers to demonstrate that they have obtained a valid legal basis for certain data processing activities. The GDPR provides that
EU Member States may continue to make their own further laws and regulations in relation to the processing of genetic, biometric or health
data, which could result in continued or new differences between Member States, limit our ability to use and share personal data or could
cause our costs to increase, and harm our business and financial condition. We are also subject to evolving and strict rules on the transfer
of personal data out of the European Union to the United States. Further prospective revision of the Directive on privacy and electronic
communications (Directive 2002/58/EC), or ePrivacy Directive, may affect our marketing communications.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our actual or alleged failure
to comply with this regulation, or to protect personal data, could result in enforcement actions and significant penalties against us,
which could result in negative publicity, increase our operating costs, subject us to claims or other remedies and have a material adverse
effect on our business, financial condition, and results of operations. It is not always possible to identify and deter misconduct by
employees or other parties. The precautions we take to detect and prevent such activity may not protect us from legal or regulatory action
resulting from a failure to comply with applicable laws or regulations. Misconduct by our employees, principal investigators, consultants,
commercial partners or vendors could result in significant financial penalties, criminal sanctions, civil law claims and/or negative
media coverage, and thus have a material adverse effect on our business, including through the imposition of significant fines or other
sanctions, and our reputation. In particular, failure to comply with EU laws, including failure under the GDPR, ePrivacy Directive and
other laws relating to the security of personal data may result in fines up to &#8364;20,000,000 or up to 4% of the total worldwide annual
turnover of the preceding financial year, if greater, and other administrative penalties including criminal liability, which may be onerous
and adversely affect our business, financial condition, results of operations and prospects. Failure to comply with the GDPR and related
laws may also give risk to increase risk of private actions, including a new form of class action that is available under the GDPR.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 37; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Risks Related to Our Operations in Israel</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We conduct our operations
in Israel and therefore our results may be adversely affected by political, economic and military instability in Israel and its region.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our headquarters are located
in Israel and we conduct operations in Israel. Accordingly, political, economic and military conditions in the Middle East may affect
our business directly. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between Israel
and its neighboring Arab countries, Hamas (an Islamist terrorist militia and political group that controls the Gaza strip), Hezbollah
(an Islamist terrorist militia and political group based in Lebanon) and other terrorist organizations active in the region. These conflicts
have involved missile strikes, hostile infiltrations and terrorism against civilian targets in various parts of Israel, which have negatively
affected business conditions in Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2023, Hamas terrorists
infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas
also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel&#8217;s border with the
Gaza Strip and in other areas within the State of Israel. These attacks resulted in extensive deaths, injuries and kidnapping of civilians
and soldiers. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and a military campaign against these
terrorist organizations commenced in parallel to their continued rocket and terror attacks. In January 2025, Israel and Hamas entered
into a ceasefire agreement, which remained in effect until March 18, 2025, when hostilities resumed. As of October 9, 2025, Israel and
Hamas entered into a renewed ceasefire agreement calling for a permanent end of the war. However, there are no assurances that such as
agreement will hold. While the conflict has created heightened security concerns, disruptions to business operations, and economic instability,
the ceasefire may contribute to improved regional stability. However, the security situation remains fluid, and any renewed military
actions, restrictions, or government-imposed measures could adversely affect our operations, supply chains, and financial condition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
connection with the Israeli security cabinet&#8217;s declaration of war against Hamas and possible hostilities with other organizations,
several hundred thousand Israeli military reservists were drafted to perform immediate military service, including our CEO during which
time he continued to perform his main work duties. Although many of such military reservists have since been released, including our
CEO, they may be called up for additional reserve duty, depending on developments in the war in Gaza and along Israel&#8217;s other borders.
Military service call ups that result in absences of personnel from us for an extended period of time may materially and adversely affect
our business, prospects, financial condition and results of operations. As of the date hereof, we currently have five full-time employees,
all of whom are located in Israel, and two external consultants, both of whom are located in the United States.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
the commencement of these events, there have been continued hostilities along Israel&#8217;s northern border with Lebanon (with the Hezbollah
terror organization) and on other fronts from various extremist groups in the region, such as the Houthis in Yemen and various rebel militia
groups in Syria and Iraq. Israel has carried out a number of targeted strikes on sites belonging to these terror organizations. In October
2024, Israel began limited ground operations against Hezbollah in Lebanon, and in November 2024, a ceasefire was brokered between Israel
and Hezbollah. However, in March 2026, tensions escalated once again as Hezbollah launched an attack on Israel, firing rockets across
the border. In response, Israel carried out targeted airstrikes against Hezbollah positions in Lebanon, raising concerns among the international
community about the potential for a wider conflict. In addition, in April 2024 and October 2024, Iran launched direct attacks on Israel
involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing nuclear
weapons. In addition, in response to ongoing Iranian aggression and support of proxy attacks against Israel, on June 13, 2025, Israel
conducted a series of preemptive defensive air strikes in Iran targeting Iran&#8217;s nuclear program and military commanders. While a
ceasefire was reached in June 2025 following 12 days of hostilities, on February 28, 2026, the United States and Israel launched coordinated
military strikes against Iran, including attacks on strategic military infrastructure and leadership targets, with the stated aim of degrading
Iran&#8217;s capacity to conduct or support hostile operations against them. In response, Iran has fired missiles and drones toward population
centers and military installations in Israel<span style="font-weight: bold;">, </span>Europe and neighboring countries in the Gulf region, and also launched counter-strikes
against U.S. forces and allied bases throughout the Gulf region. Continued military escalation, retaliatory actions, or broader regional
involvement may adversely affect economic conditions, disrupt markets, and create uncertainty that could negatively impact our business,
financial condition and results of operations. Iran is also believed to have a strong influence among extremist groups in the region,
such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia groups in Syria and Iraq. These situations
may potentially escalate in the future to more violent events which may affect Israel and us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
the war broke out on October 7, 2023, our operations have not been adversely affected by this situation, and we have not experienced
disruptions to our clinical studies. Additionally, all of our manufacturing and supply of our drug candidates takes place outside of
Israel. As such, our clinical and business development activities remain on track. While the intensity and duration of the security situation
in Israel have been difficult to predict, as were the economic implications on our business and operations and on Israel&#8217;s economy
in general, the ceasefire marks a potential shift towards stability in the region. If sustained, this could reduce the risk of disruptions
to our business and the Israeli economy in general. However, if the war is renewed or expands to other fronts, such as Lebanon, Syria
and the West Bank, our operations may be harmed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 38; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial insurance
does not cover losses that may occur as a result of events associated with the security situation in the Middle East. Although the Israeli
government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot
assure you that this government coverage will be maintained. Any losses or damages incurred by us could have a material adverse effect
on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could
harm our results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The continued political instability
and hostilities between Israel and its neighbors and any future armed conflict, terrorist activity or political instability in the region
could adversely affect our operations in Israel and adversely affect the market price of our shares of common stock. In addition, several
organizations and countries may restrict doing business with Israel and Israeli companies have been and are today subjected to economic
boycotts. The interruption or curtailment of trade between Israel and its present trading partners could adversely affect our business,
financial condition and results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, political conditions
within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior to October 2023, the
Israeli government pursued extensive changes to Israel&#8217;s judicial system, which sparked extensive political debate and unrest.
Actual or perceived political instability in Israel or any negative changes in the political environment, may individually or in the
aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and growth prospects.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Because a certain portion
of our expenses is incurred in currencies other than U.S. dollars, our results of operations may be harmed by currency fluctuations and
inflation.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Company&#8217;s functional
and presentation currency is U.S. dollar. To date, we have not engaged in hedging transactions. Although the Israeli rate of inflation
has not had a material adverse effect on our financial condition during 2023, 2024 or 2025 to date, we may, in the future, decide to
enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of the currencies
mentioned above in relation to U.S. dollars. These measures, however, may not adequately protect us from material adverse effects.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>It may be difficult
to enforce a U.S. judgment against us and our officers and directors named in this Annual Report on Form 20-F in Israel or the United
States, or to serve process on our officers and directors.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated in Israel.
All of our executive officers and directors listed in this Annual Report on Form 20-F reside outside of the United States, and all of
our assets and most of the assets of our executive officers and directors are located outside of the United States. Therefore, a judgment
obtained against us or most of our executive officers and all of our directors in the United States, including one based on the civil
liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli
court. It also may be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities
law claims in original actions instituted in Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Your rights and responsibilities
as a shareholder will be governed by Israeli law which may differ in some respects from the rights and responsibilities of shareholders
of U.S. companies.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
Israeli law. The rights and responsibilities of the holders of our shareholders are governed by our Amended and Restated Articles of
Association and Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders
in typical U.S.-based corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith toward the company
and other shareholders and to refrain from abusing its power in the company, including, among other things, in voting at the general
meeting of shareholders on matters such as amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized
share capital, mergers and acquisitions and interested party transactions requiring shareholder approval. In addition, a shareholder
who knows that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director
or executive officer in the company has a duty of fairness toward the company. There is limited case law available to assist us in understanding
the implications of these provisions that govern shareholders&#8217; actions. These provisions may be interpreted to impose additional
obligations and liabilities of our shareholders that are not typically imposed on shareholders of U.S. corporations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 39; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Provisions of Israeli
law may delay, prevent or otherwise impede a merger with, or an acquisition of, our Company, which could prevent a change of control,
even when the terms of such a transaction are favorable to us and our shareholders.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli corporate law regulates
mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving
directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions. For
example, a merger may not be consummated unless at least 50 days have passed from the date that a merger proposal was filed by each merging
company with the Israel Registrar of Companies and at least 30 days from the date that the shareholders of both merging companies approved
the merger. In addition, a majority of each class of securities of the target company must approve a merger. Moreover, a full tender
offer can only be completed if the acquirer receives at least 95% of the issued share capital; provided that, pursuant to an amendment
to the Companies Law, 5759-1999, as amended, or the Israeli Companies Law, effective as of May 15, 2011, a majority of the offerees that
do not have a personal interest in such tender offer shall have approved the tender offer; except that, if the total votes to reject
the tender offer represent less than 2% of our issued and outstanding share capital, in the aggregate, approval by a majority of the
offerees that do not have a personal interest in such tender offer is not required to complete the tender offer, and the shareholders,
including those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the
tender offer, petition the court to alter the consideration for the acquisition (unless the acquirer stipulated in the tender offer that
a shareholder that accepts the offer may not seek appraisal rights and the acquirer or the company published all required information
with respect to the tender offer prior to the tender offer&#8217;s response date).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Israeli tax
considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax
treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges
to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes
the deferral contingent on the fulfillment of numerous conditions, including, in some cases, requirement for a holding period of two
years from the date of the transaction during which sales and dispositions of shares of the participating companies are restricted. Moreover,
with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable
even if no actual disposition of the shares has occurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other similar provisions
could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be
beneficial to us or to our shareholders. See &#8220;Description of the Offered Securities&#8212;Articles of Association.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-weight: bold;"><i>Inflation could adversely&#160;affect our
business and results of operations.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While inflation&#160;in the
United States and global markets has been relatively low in recent years, during 2021 and 2022, the economy in the United States and global
markets encountered a material increase in the level of inflation. The geopolitical developments such as the security situation in Israel,
tariff wars and global supply chain disruptions continue to increase uncertainty in the outlook of near-term and long-term economic activity,
including whether inflation will continue and how long, and at what rate. Increases in&#160;inflation raise our costs for commodities,
labor, materials and services and other costs required to grow and operate our business, and failure to secure these on reasonable terms
may adversely&#160;impact our financial condition. Additionally, increases in inflation, geopolitical developments and global supply chain
disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest rate environment,
which may make it more difficult, costly or dilutive for us to secure additional financing. A failure to adequately respond to these risks
could have a material adverse impact on our financial condition, results of operations or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 40; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Risks Related to Our Ordinary Shares and ADSs</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Our business, operating
results and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments
with respect to financial institutions and associated liquidity risk.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business depends on the
economic health of the global economies. If the conditions in the global economies remain uncertain or continue to be volatile, or if
they deteriorate, including as a result of the impact of military conflict, such as the war between Russia and Ukraine and the security
situation in Israel, terrorism or other geopolitical events, our business, operating results and financial condition may be materially
adversely affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, increases in
inflation raise our costs for commodities, labor, materials and services and other costs required to grow and operate our business, and
failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, geopolitical
developments and global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty
about the interest rate environment, which may make it more difficult, costly or dilutive for us to secure additional financing. A failure
to adequately respond to these risks could have a material adverse impact on our financial condition, results of operations or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that future credit and financial market instability and a deterioration in confidence in economic conditions will not occur. Our general
business strategy may be adversely affected by any such economic downturn, liquidity shortages, volatile business environment or continued
unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or if adverse developments are experienced
by financial institutions, it may cause short-term liquidity risk and also make any necessary debt or equity financing more difficult,
more costly, more onerous with respect to financial and operating covenants and more dilutive. Failure to secure any necessary financing
in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock
price and could require us to alter our operating plans. In addition, there is a risk that one or more of our service providers, financial
institutions, manufacturers, suppliers and other partners may be adversely affected by the foregoing risks, which could directly affect
our ability to attain our operating goals on schedule and on budget.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>There can be no assurance
that we will not be a passive foreign investment company, or PFIC, for U.S. federal income tax purposes in 2026 or in any subsequent
year. If we are a PFIC, there may be negative tax consequences for U.S. taxpayers that are holders of our ordinary shares, ADSs, Warrants,
or Pre-funded Warrants.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be treated as a PFIC
for U.S. federal income tax purposes in any taxable year in which either (i) at least 75% of our gross income is &#8220;passive income&#8221;
or (ii) on average at least 50% of our assets by value produce passive income or are held for the production of passive income. Passive
income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities
and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes
amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether a
non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly,
at least a 25% interest (by value) is taken into account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our analysis of
our income, assets, and operations, we may have been a PFIC for 2025. Because the PFIC determination is highly fact intensive, there
can be no assurance that we will not be a PFIC in 2026 or in any other taxable year. Even if we determine that we are not a PFIC after
the close of a taxable year, there can be no assurance that a court or the U.S. Internal Revenue Service, or IRS, will agree with our
conclusion. If we were to be characterized as a PFIC for U.S. federal income tax purposes in any taxable year during which a U.S. shareholder
owns our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, then &#8220;excess distributions&#8221; to such U.S. shareholder, and
any gain realized on the sale or other disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, as applicable, will
be subject to special rules. Under these rules: (i) the excess distribution or gain would be allocated ratably over the U.S. shareholder&#8217;s
holding period for the ordinary shares (or ADSs, Warrants, or Pre-funded Warrants, as the case may be); (ii) the amount allocated to
the current taxable year and any period prior to the first day of the first taxable year in which we were a PFIC would be taxed as ordinary
income; and (iii) the amount allocated to each of the other taxable years would be subject to tax at the highest rate of tax in effect
for the applicable class of taxpayer for that year, and an interest charge for the deemed deferral benefit would be imposed with respect
to the resulting tax attributable to each such other taxable year. Certain of the adverse consequences of PFIC status can be mitigated
if a U.S. shareholder makes an election to treat us as a &#8220;qualified electing fund,&#8221; or QEF, or makes a &#8220;mark-to-market&#8221;
election. In addition, if the IRS, determines that we are a PFIC for a year with respect to which we have determined that we were not
a PFIC, it may be too late for a U.S. shareholder to make a timely QEF or mark-to-market election. U.S. shareholders who hold our ordinary
shares, ADSs, Warrants or Pre-funded Warrants during a period when we are a PFIC will be subject to the foregoing rules, even if we cease
to be a PFIC in subsequent years, subject to exceptions for U.S. shareholders who made a timely QEF or mark-to-market election (to the
extent available). A U.S. shareholder can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance
with the instructions thereto. Upon request, we intend to annually furnish U.S. shareholders with information needed in order to complete
IRS Form 8621 (which form would be required to be filed with the IRS on an annual basis by the U.S. shareholder) and to make and maintain
a valid QEF election for any year in which we are a PFIC. There is no assurance, however, that we will have timely knowledge of our status
as a PFIC, or that the information that we provide will be adequate to allow U.S. shareholders to make a QEF election. For further discussion,
see &#8220;Item 10.E&#8212;Additional Information&#8212;Taxation&#8212;Certain Material U.S. Federal Income Tax Consequences&#8212;Passive
Foreign Investment Company.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 41; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Provisions of our charter
documents and Israeli law may discourage, delay, prevent or otherwise impede a merger with, or an acquisition of, our Company, which
could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions in articles of
association may discourage, delay, prevent or otherwise impede a merger, acquisition or other change in control of us that shareholders
may consider favorable, including transactions in which they might otherwise receive a premium for their ADSs. On February 20, 2020,
we amended our articles of association to establish a staggered board of directors, which divides the board into three groups, with directors
in each group serving a three-year term. The existence of a staggered board can make it more difficult for shareholders to replace or
remove incumbent members of our Board of Directors. As such, these provisions could also limit the price that investors might be willing
to pay in the future for our ADSs, thereby depressing the market price of our ADSs. In addition, because our Board of Directors is responsible
for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our shareholders to replace
or remove our current management by making it more difficult for shareholders to replace members of our Board of Directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Israeli corporate
law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions
involving directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions.
For example, a merger may not be consummated unless at least 50 days have passed from the date that a merger proposal was filed by each
merging company with the Israel Registrar of Companies and at least 30 days from the date that the shareholders of both merging companies
approved the merger. In addition, a majority of each class of securities of the target company must approve a merger. Moreover, a full
tender offer can only be completed if the acquirer receives at least 95% of the issued share capital; provided that, pursuant to an amendment
to the Companies Law, 5759-1999, as amended, or the Israeli Companies Law, effective as of May 15, 2011, a majority of the offerees that
do not have a personal interest in such tender offer shall have approved the tender offer; except that, if the total votes to reject
the tender offer represent less than 2% of our issued and outstanding share capital, in the aggregate, approval by a majority of the
offerees that do not have a personal interest in such tender offer is not required to complete the tender offer, and the shareholders,
including those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the
tender offer, petition the court to alter the consideration for the acquisition (unless the acquirer stipulated in the tender offer that
a shareholder that accepts the offer may not seek appraisal rights).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Israeli tax
considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax
treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges
to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes
the deferral contingent on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction
during which sales and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain share
swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition
of the shares has occurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Our business could
be negatively impacted by unsolicited takeover proposals, by shareholder activism or by proxy contests relating to the election of directors
or other matters.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business could be negatively
affected as a result of an unsolicited takeover proposal, by shareholder activism or a proxy contest. During 2019, an activist shareholder
sought to make changes to our Board of Directors, among other matters, which ultimately resulted in us entering into a settlement agreement
with the shareholder, and for which considerable costs were incurred and absorbed significant time and attention by management and the
Board of Directors. A future proxy contest, unsolicited takeover proposal, or other shareholder activism relating to the election of
directors or other matters would most likely require us to incur significant legal fees and proxy solicitation expenses and require significant
time and attention by management and our Board of Directors. The potential of a proxy contest, unsolicited takeover proposal, or other
shareholder activism could interfere with our ability to execute our strategic plan, give rise to perceived uncertainties as to our future
direction, result in the loss of potential business opportunities or make it more difficult to attract and retain qualified personnel,
any of which could materially and adversely affect our business and operating results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Issuance of additional
equity securities may adversely affect the market price of our ADSs or ordinary shares.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently authorized
to issue 14,000,000 ordinary shares, no par value. As of the date of this Annual Report on Form 20-F, we had 2,618,425 ordinary shares
issued and outstanding and we had no preferred shares outstanding. As of the date of this Annual Report, we also had warrants to purchase
4,232,328 ordinary shares and options to purchase 123,490 ordinary shares outstanding, of which options to purchase 30,424 ordinary shares
are currently fully vested or vest within the next 60 days.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that ADSs or
ordinary shares are issued or options and warrants are exercised, holders of our ADSs and our ordinary shares will experience dilution.
In addition, in the event of any future issuances of equity securities or securities convertible into or exchangeable for ADSs or ordinary
shares, holders of our ADSs or our ordinary shares may experience dilution. We also consider from time to time various strategic alternatives
that could involve issuances of additional ADSs or ordinary shares, including but not limited to acquisitions and business combinations,
but do not currently have any definitive plans to enter into any of these transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 42; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We have no plans to
pay dividends on our ordinary shares, and you may not receive funds without selling our ADSs or ordinary shares.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not declared or paid
any cash dividends on our ordinary shares, nor do we expect to pay any cash dividends on our ordinary shares for the foreseeable future.
We currently intend to retain any additional future earnings to finance our operations and growth and for future stock repurchases and,
therefore, we have no plans to pay cash dividends on our ordinary shares at this time. Any future determination to pay cash dividends
on our ordinary shares will be at the discretion of our Board of Directors and will be dependent on our earnings, financial condition,
operating results, capital requirements, any contractual restrictions, and other factors that our Board of Directors deems relevant.
Accordingly, you may have to sell some or all of our ADSs or ordinary shares in order to generate cash from your investment. You may
not receive a gain on your investment when you sell our ADSs or ordinary shares and may lose the entire amount of your investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>The market price of
our ordinary shares and ADSs is subject to fluctuation, which could result in substantial losses by our investors.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market in general
and the market price of our ordinary shares on the TASE and our ADSs on the NYSE American is subject to fluctuation, and changes in our
share price may be unrelated to our operating performance. The market price of our ordinary shares and ADSs are and will be subject to
a number of factors, including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">announcements of technological innovations or new products by us or others;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">announcements by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures,
    acquisitions or capital commitments;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">expiration or terminations of licenses, research contracts or other collaboration agreements;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">public concern as to the safety of drugs we, our licensees or others develop;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">general market conditions;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the volatility of market prices for shares of biotechnology companies generally;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">success of research and development projects;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">success in clinical and preclinical studies;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">departure of key personnel;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">developments concerning intellectual property rights or regulatory approvals;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">variations in our and our competitors&#8217; results of operations;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares or
    ADSs are covered by analysts;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">changes in government regulations or patent decisions;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">developments by our licensees; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">general market conditions and other factors, including factors unrelated to our operating performance,
    such as natural disasters and political and economic instability, including wars, terrorism, political unrest, results of certain
    elections and votes, emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an
    emergency), boycotts, adoption or expansion of government trade restrictions, and other business restrictions.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors and any corresponding
price fluctuations may materially and adversely affect the market price of our ordinary shares and our ADSs and result in substantial
losses by our investors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 43; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, market prices
for securities of biotechnology and pharmaceutical companies historically have been very volatile. The market for these securities has
from time to time experienced significant price and volume fluctuations for reasons unrelated to the operating performance of any one
company. See also Risk Factors&#8212;Risks Relating to Ownership of Our Ordinary Shares and ADSs &#8220;<i>Our business, operating results
and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments with
respect to financial institutions and associated liquidity risk.</i>&#8221; In the past, following periods of market volatility, shareholders
have often instituted securities class action litigation and we have been named in the past in a lawsuit requesting recognition as a
class action, in which we ultimately prevailed. If we were involved in securities litigation, it could have a substantial cost and divert
resources and attention of management from our business, even if we are successful.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Future sales of our ordinary
shares or ADSs could reduce the market price of our ordinary shares and ADSs. Moreover, actions such as reverse share and ADS splits,
while intended to increase the per-unit trading price of our securities, may adversely affect trading liquidity, reduce the number of
tradable shares, and weaken secondary market depth. There can be no assurance that a reverse split will result in a sustained increase
in market price or that the liquidity of our securities will not be adversely affected. Investors may interpret reverse splits negatively,
potentially resulting in increased volatility and downward pressure on our share price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Substantial sales of
our ordinary shares or our ADSs either on the TASE or on the NYSE American, as applicable, may cause the market price of our ordinary
shares or our ADSs to decline.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales by us or our security-holders
of substantial amounts of our ordinary shares or our ADSs, or the perception that these sales may occur in the future, could cause a
reduction in the market price of our ordinary shares or our ADSs. The issuance of any additional ordinary shares or ADSs, or any securities
that are exercisable for or convertible into our ordinary shares or our ADSs, may have an adverse effect on the market price of our ordinary
shares or our ADSs, as applicable, and will have a dilutive effect on our shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We may not satisfy
the NYSE American requirements for continued listing. If we cannot satisfy these requirements, the NYSE American could delist our securities.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ADSs are listed on the
NYSE American under the symbol &#8220;CANF.&#8221; To continue to be listed on the NYSE American, we are required to satisfy a number
of conditions, including maintaining a share price and shareholders&#8217; equity above certain thresholds. In addition, on March 6, 2026, the NYSE American filed a rule proposal
with the SEC that would permit the immediate suspension and delisting of a company listed on the NYSE American if its market capitalization
remains below $5 million for 30 consecutive trading days. As of the date of this Annual Report, our market capitalization is above $5
million; however, if this rule were to go into effect and we are unable to maintain our market capitalization above $5 million for the
requisite period, we would become subject to immediate suspension and delisting. If we are delisted from the
NYSE American, trading in our securities may be conducted, if available, on the OTC Markets or, if available, via another market. In
the event of such delisting, our shareholders would likely find it significantly more difficult to dispose of, or to obtain accurate
quotations as to the value of our securities, and our ability to raise future capital through the sale of our securities could be severely
limited. In addition, if our securities were delisted from the NYSE American, our ADSs could be considered a &#8220;penny stock&#8221;
under the U.S. federal securities laws. Additional regulatory requirements apply to trading by broker-dealers of penny stocks that could
result in the loss of an effective trading market for our securities. Moreover, if our ADSs were delisted from the NYSE American, we
will no longer be exempt from certain provisions of the Israeli Securities Law, and therefore will have increased disclosure requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>ADS holders are not
shareholders and do not have shareholder rights.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
as Depositary, delivers our ADSs. Each ADS represents two of our ordinary shares. ADS holders will not be treated as shareholders and
do not have the rights of shareholders. The Depositary will be the holder of the shares underlying our ADSs. Holders of ADSs will have
ADS holder rights. A deposit agreement among us, the Depositary, ADS holders and the beneficial owners of ADSs sets out ADS holder rights
as well as the rights and obligations of the Depositary. New York law governs the deposit agreement and our ADSs. Our shareholders have
shareholder rights. Israeli law and our Amended and Restated Articles of Association govern shareholder rights. ADS holders do not have
the same voting rights as our shareholders. Shareholders are entitled to our notices of general meetings and to attend and vote at our
general meetings of shareholders. At a general meeting, every shareholder present (in person or by proxy, attorney or representative)
and entitled to vote has one vote. This is subject to any other rights or restrictions which may be attached to any shares. ADS holders
may instruct the Depositary how to vote the number of deposited shares their ADSs represent.&#160;Otherwise, you won&#8217;t be able
to exercise your right to vote unless you withdraw the shares. However, you may not know about the meeting enough in advance to withdraw
the shares. The Depositary will notify ADS holders of shareholders&#8217; meetings and arrange to deliver our voting materials to them
if we ask it to. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the Depositary how
to vote. For instructions to be valid, they must reach the Depositary by a date set by the Depositary. The Depositary will try, as far
as practical, subject to the laws of Israel and our Amended and Restated Articles of Association or similar documents, to vote or to
have its agents vote the shares or other deposited securities as instructed by ADS holders. The Depositary will only vote or attempt
to vote as instructed. We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the Depositary
to vote your shares. In addition, the Depositary and its agents are not responsible for failing to carry out voting instructions or for
the matter of carrying out voting instructions. This means that you may not be able to exercise your right to vote and there may be nothing
you can do if your shares are not voted as requested.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i></i></p><!-- Field: Page; Sequence: 44; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADS holders do not have the
same rights to receive dividends or other distributions as our shareholders. Subject to any special rights or restrictions attached to
a share, the directors may determine that a dividend will be payable on a share and fix the amount, the time for payment and the method
for payment (although we have never declared or paid any cash dividends on our ordinary shares and we do not anticipate paying any cash
dividends in the foreseeable future). Dividends and other distributions payable to our shareholders with respect to our ordinary shares
generally will be payable directly to them. Any dividends or distributions payable with respect to ordinary shares deposited in the ADS
facility will be paid to the Depositary, which has agreed to pay to ADS holders the cash dividends or other distributions it or the custodian
receives on shares or other deposited securities, after deducting its fees and expenses. ADS holders will receive these distributions
in proportion to the number of ordinary shares their ADSs represent. In addition, there may be certain circumstances in which the Depositary
may not pay ADS holder&#8217;s amounts distributed by us as a dividend or distribution.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Our ordinary shares
and our ADSs are traded on different markets and this may result in price variations.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares have
traded on the TASE since October 2005 and our ADSs have been listed on the NYSE American since November 2013. Trading on these markets
will take place in different currencies (U.S. dollars on the NYSE American and NIS on the TASE), and at different times (resulting from
different time zones, different trading days and different public holidays in the United States and Israel). The trading prices of our
securities on these two markets may differ due to these and other factors. Any decrease in the price of our securities on one of these
markets could cause a decrease in the trading price of our securities on the other market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>We have incurred significant
additional increased costs as a result of the listing of our ADSs for trading on the NYSE American, and our management is required to
devote substantial time to new compliance initiatives as well as to compliance with ongoing U.S. and Israeli reporting requirements.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company in the
United States, we incur additional significant accounting, legal and other expenses that we did not incur before becoming a reporting
company in the United States. We also incur costs associated with corporate governance requirements of the SEC and the NYSE American
Company Guide, as well as requirements under Section 404a and other provisions of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley
Act as a result of our ADSs being listed on the NYSE American. These rules and regulations have increased our legal and financial compliance
costs, introduced new costs such as investor relations, stock exchange listing fees and shareholder reporting, and made some activities
more time consuming and costly. The implementation and testing of such processes and systems may require us to hire outside consultants
and incur other significant costs. Any future changes in the laws and regulations affecting public companies in the United States and
Israel, including Section 404 and other provisions of the Sarbanes-Oxley Act, the rules and regulations adopted by the SEC and the NYSE
American Company Guide, as well as applicable Israeli reporting requirements, for so long as they apply to us, may result in increased
costs to us as we respond to such changes. These laws, rules and regulations could make it more difficult or more costly for us to obtain
certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits
and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements could also
make it more difficult for us to attract and retain qualified persons to serve on our Board of Directors, our Board committees or as
executive officers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>As a foreign private
issuer, we are permitted to follow certain home country corporate governance practices instead of applicable SEC and NYSE American requirements,
which may result in less protection than is accorded to investors under rules applicable to domestic issuers.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we will be permitted to follow certain home country corporate governance practices instead of those otherwise required under the NYSE
American Company Guide for domestic issuers. For instance, we may follow home country practice in Israel with regard to, among other
things, composition and function of the audit committee and other committees of our Board of Directors and certain general corporate
governance matters. In addition, in certain instances we will follow our home country law, instead of the NYSE American Company Guide,
which requires that we obtain shareholder approval for certain dilutive events, such as an issuance that will result in a change of control
of the company, certain transactions other than a public offering, involving issuances of a 20% or more interest in the company and certain
acquisitions of the stock or assets of another company. We comply with the director independence requirements of the NYSE American Company
Guide, including the requirement that a majority of the Board of Directors be independent. Following our home country governance practices
as opposed to the requirements that would otherwise apply to a U.S. company listed on the NYSE American may provide less protection than
is accorded to investors under the NYSE American Company Guide applicable to domestic issuers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 45; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as a foreign
private issuer, we are exempt from the rules and regulations under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange
Act, related to the furnishing and content of proxy statements. Section 8103 of the National Defense Authorization Act for Fiscal Year
2026 named, the &#8220;Holding Foreign Insiders Accountable Act&#8221; was signed into law on December 18, 2025, will require directors
and officers of foreign private issuers to make insider reports under Section 16(a) of the Exchange Act, effective March 18, 2026. Our
principal shareholders continue to remain exempt from the reporting under Section 16(a) of the Exchange Act and our directors, officers
and principal shareholders continue to remain exempt from the short-swing profit recovery provisions contained in Section 16(b) of the
Exchange Act. In addition, we will not be required under the Exchange Act to file annual, quarterly and current reports and financial
statements with the SEC as frequently or as promptly as domestic companies whose securities are registered under the Exchange Act.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Because we became a
reporting company under the Exchange Act by means of filing a Form 20-F, we may have difficulty attracting the attention of research
analysts at major brokerage firms.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we did not become
a reporting company by conducting an underwritten initial public offering in the United States, we may have difficulty attracting the
attention of security analysts at major brokerage firms in order for them to provide coverage of our company. The failure to receive
research coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our
ADSs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>If we are unable to
satisfy the requirements of Section 404 of the Sarbanes-Oxley Act as they apply to a foreign private issuer that is listed on a U.S.
exchange, or our internal control over financial reporting is not effective, the reliability of our financial statements may be questioned
and our share price and the ADS price may suffer.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the requirements
of the Sarbanes-Oxley Act. Section 404 of the Sarbanes-Oxley Act requires companies subject to the reporting requirements of the U.S.
securities laws to do a comprehensive evaluation of its and its subsidiaries&#8217; internal control over financial reporting. To comply
with this statute, we must document and test our internal control procedures and our management and issue a report concerning our internal
control over financial reporting. In addition, as long as we do not become an accelerated or large accelerated filer, we are exempt from
the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act. Under this exemption, our auditor will not be required
to attest to and report on our management&#8217;s assessment of our internal control over financial reporting until the date we are no
longer a non-accelerated filer. We will need to prepare for compliance with Section 404 by strengthening, assessing and testing our system
of internal controls to provide the basis for our report. However, the continuous process of strengthening our internal controls and
complying with Section 404 is complicated and time-consuming. Furthermore, as our business continues to grow both domestically and internationally,
our internal controls will become more complex and will require significantly more resources and attention to ensure our internal controls
remain effective overall. During the course of the testing, our management may identify material weaknesses or significant deficiencies,
which may not be remedied in a timely manner to meet the deadline imposed by the Sarbanes-Oxley Act. If our management cannot favorably
assess the effectiveness of our internal control over financial reporting, or our independent registered public accounting firm identifies
material weaknesses in our internal controls, investor confidence in our financial results may weaken, and the market price of our securities
may suffer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM
4. </span></span><span style="font-weight: bold;"><span id="a_005" style="display: inline-block;"></span>Information on the Company</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">A. History and Development of the Company</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our legal name is Can-Fite
BioPharma Ltd. and our commercial name is &#8220;Can-Fite.&#8221; We are a company limited by shares organized under the laws of the
State of Israel. Our principal executive offices are located at 26 Ben Gurion Street, Ramat Gan 5257346 Israel. Our telephone number
is +972 (3) 924-1114.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were founded on September
11, 1994 by Pnina Fishman, Ph.D., our Executive Chairman and Chief Scientific Officer, and Ilan Cohn, Ph.D., under the name Can-Fite
Technologies Ltd. On January 7, 2001, we changed our name to Can-Fite BioPharma Ltd. We completed our initial public offering in Israel
in October 2005 and our ordinary shares are traded on the TASE under the symbol &#8220;CANF.&#8221; On October 2, 2012, our ADSs began
trading over the counter in the United States and on November 19, 2013, our ADSs began trading on the NYSE American under the symbol
&#8220;CANF.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 46; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2011, through
a series of transactions, we spun-off our activity in the ophthalmic field to our now former subsidiary, OphthaliX, a Delaware corporation
and successor-in-interest to Denali Concrete Management, Inc., a Nevada corporation, whose common shares were traded in the United States
on OTC under the symbol &#8220;OPLI.&#8221; In the spin-off transactions, we granted an exclusive license for the use of our Piclidenoson
drug candidate in the ophthalmic field, or the License Agreement, to Eye-Fite Ltd., an Israel limited company, or Eye-Fite, and transferred
our issued and outstanding ordinary shares in Eye-Fite to OphthaliX in exchange for an 86.7% interest in OphthaliX. In connection with
the spin-off transactions, OphthaliX completed a series of private placement financing transactions. Following the spin-off transactions
and the private placement financing transactions, we held approximately 82% interest in OphthaliX. In July 2016, OphthaliX released top-line
results from its Phase II clinical trial of Piclidenoson for the treatment of glaucoma. In this trial, no statistically significant differences
were found between the Piclidenoson treated group and the placebo group in the primary endpoint of lowering IOP. High IOP is a characteristic
of glaucoma. Piclidenoson was found to have a favorable safety profile and was generally well-tolerated. Based on these overall results,
OphthaliX saw no immediate path forward in glaucoma and ceased active business operations. Subsequently, on May 21, 2017, OphthaliX and
a wholly owned private Israeli subsidiary of OphthaliX, Bufiduck Ltd, or the Merger Sub, and Wize Pharma Ltd., or Wize Israel, an Israeli
company formerly listed on the TASE entered into an Agreement and Plan of Merger, or the Merger Agreement, providing for the merger of
the Merger Sub with and into Wize Israel, with Wize Israel becoming a wholly-owned subsidiary of OphthaliX and the surviving corporation
of the merger, or the Merger. On November 16, 2017, the Merger was completed. As a result of the Merger, our ownership of OphthaliX,
immediately post-Merger, became approximately 8% of the outstanding shares of common stock. In addition, immediately prior to the Merger,
OphthaliX sold on an &#8220;as is&#8221; basis to us all the ordinary shares of Eye-Fite in exchange for the irrevocable cancellation
and waiver of all indebtedness owed by OphthaliX and Eye-Fite to us, including approximately $5 million of deferred payments owed by
OphthaliX and Eye-Fite to us and, as part of the purchase of Eye-Fite, we also assumed certain accrued milestone payments in the amount
of $175,000 under a license agreement previously entered into with NIH. In addition, that certain License Agreement granted to OphthaliX
by us and a related services agreement was terminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our capital expenditures
for the years ended December 31, 2025, 2024 and 2023 were $2,000, $5,000, and $2,000, respectively. Our current capital expenditures
are made solely within Israel and primarily consist of the acquisition of computers and related communications equipment. Such capital
expenditures are financed internally.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use our website (<i>http://www.canfite.com</i>)
as a channel of distribution of Company information. The information we post on our website may be deemed material. Accordingly, investors
should monitor the website, in addition to following our press releases, SEC filings and public conference calls and webcasts. The contents
of our website are not, however, a part of this Annual Report on Form 20-F.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">B. Business Overview</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are an advanced clinical-stage biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the
treatment of cancer, liver and inflammatory diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor,
or A3AR, as a therapeutic target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has
a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline
of drug candidates are synthetic, highly specific agonists and allosteric modulators targeting the A3AR.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
product pipeline is based on the research of Dr. Pnina Fishman, who investigated a clinical observation that tumor metastasis can be
found in most body tissues, but are rarely found in muscle tissue, which constitutes approximately 60% of human body weight. Dr. Fishman&#8217;s
research revealed that one reason that striated muscle tissue is resistant to tumor metastasis is that muscle cells release small molecules
which bind with high selectivity to the A3AR. As part of her research, Dr. Fishman also discovered that A3ARs have significant expression
in tumor and inflammatory cells, whereas normal cells have low or no expression of this receptor. The A3AR agonists and allosteric modulators,
currently our pipeline of drug candidates, bind with high selectivity and affinity to the A3ARs and initiate down-stream signal transduction
pathways resulting in apoptosis, or programmed cell death, of tumor and inflammatory cells and to the inhibition of inflammatory cytokines.
Cytokines are proteins produced by cells that interact with cells of the immune system in order to regulate the body&#8217;s response
to disease and infection. Overproduction or inappropriate production of certain cytokines by the body can result in disease. In addition,
our product candidates also induce the production of positive cytokines such as granulocyte colony stimulating factor (G-CSF) and adiponectin
which are responsible for the chemo-protective and liver-protective effects of the drugs on liver.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 47; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
product candidates, CF101, CF102 and CF602, are being developed to treat oncological and inflammatory diseases, as well as erectile dysfunction.
CF101, also known as Piclidenoson, is in an advanced stage of clinical development for the treatment of psoriasis. CF102, also known as
Namodenoson, is being developed for the treatment of HCC and has orphan drug designation for this indication in the United States and
Europe. Namodenoson was granted Fast Track designation by the FDA for patients with advanced HCC who failed first line treatment. Namodenoson
is also being developed for the treatment of pancreatic cancer based on pre-clinical findings showing robust anti-pancreatic tumor growth.
Due to the liver protective effect of Namodenoson, it is also being developed for the treatment MASH. CF602 is our second generation allosteric
drug candidate for the treatment of erectile dysfunction, which has shown efficacy in the treatment of erectile dysfunction in preclinical
studies and we are investigating additional compounds, targeting A3AR, for the treatment of erectile dysfunction. Preclinical studies
revealed that our drug candidates have potential to treat additional inflammatory diseases, such as Crohn&#8217;s disease, prostate cancer,
oncological diseases, viral diseases, such as the JC virus, obesity and Lowe Syndrome.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe our pipeline of drug candidates represent a significant market opportunity. For instance, according to Grand View Research, the
psoriasis drug market is forecasted to be worth $39 billion by 2030. According to Future Market Insights, the global HCC treatment market
is expected to reach nearly $34 billion by 2035.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have in-licensed an allosteric modulator of the A3AR, CF602 from Leiden University until we terminated the agreement with them in January
2026. In addition, we have out-licensed the following product candidates for indications that we are currently pursuing:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; font-size: 10pt">&#160;</td>
<td style="width: 24px; font-size: 10pt">&#9679;</td>
<td style="font-size: 10pt; text-align: justify">Piclidenoson for the treatment of (i) psoriasis to Cipher Pharmaceuticals, or Cipher, for Canada, (ii) psoriasis to Gebro Holding, or Gebro, for Spain, Switzerland and Austria, (iii) psoriasis to CMS Medical, or CMS, for China (including Hong Kong, Macao and Taiwan), (iv) psoriasis to Kyongbo Pharm Co. Ltd., or Kyongbo Pharm, for South Korea, (v) psoriasis to Ewopharma AG, or Ewopharma, for Central Eastern Europe, and (vi) osteoarthritis in companion animals including dogs and cats to Vetbiolix SAS, or Vetbiolix.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">Namodenoson for the treatment of (i) liver cancer and MASH to Chong Kun Dang Pharmaceuticals, or CKD, for South Korea, (ii) advanced liver cancer and MASH to CMS for China (including Hong Kong, Macao and Taiwan), and (iii) HCC, MASH and pancreatic cancer to Ewopharma, for Central Eastern Europe and Switzerland.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Currently, (i) we initiated
the pivotal Phase III studies for Piclidenoson in the treatment of psoriasis, following meetings with the FDA and EMA, (ii) we are conducting
a pivotal Phase III trial for Namodenoson in the treatment of advanced liver cancer which is enrolling patients, (iii) we are enrolling
patients in a Phase IIb study of Namodenoson in the treatment of MASH, (iv) we completed enrollment of patients in an exploratory Phase
II study of Namodenoson in the treatment of patients with pancreatic cancer, (v) we are undertaking preparatory work for a Phase II study
with Piclidenoson for the treatment of Lowe syndrome, and (vi) we are investigating additional compounds, targeting the A3 adenosine receptor,
for the treatment of erectile dysfunction. Since inception, we have incurred significant losses in connection with our research and development.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Moreover,
we believe characteristics of Piclidenoson, as exhibited in our clinical studies to date, including its good safety profile, clinical
activity, simple and less frequent delivery through oral administration and its low cost of production, position it well against the competition
in psoriasis markets, where treatments, when available, often include injectable drugs, many of which can be highly toxic, expensive and
not always effective.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Like
Piclidenoson, Namodenoson has a good safety profile, is orally administered and has a low cost of goods, which we believe may position
it well in the HCC market, where no drug has yet been approved by the FDA for patients with advanced liver cancer disease defined as Child
Pugh B7. In addition, pre-clinical studies show Namodenoson&#8217;s novel mechanism of action which entails de-regulation of three key
signaling pathways which mediate the etiology and pathology of NAFLD/MASH and are responsible for the anti-inflammatory, anti-steatotic
and anti-fibrotic effect in the liver. Most recently, pre-clinical data support Piclidenoson&#8217;s potential utilization for the treatment
of Lowe Syndrome and Namodenoson&#8217;s potential utilization as an anti-obesity drug.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p><!-- Field: Page; Sequence: 48; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Nevertheless,
other drugs on the market, new drugs under development (including drugs that are in more advanced stages of development in comparison
to our drug candidates) and additional drugs that were originally intended for other purposes, but were found effective for purposes targeted
by us, may all be competitive to the current drugs in our pipeline. In fact, some of these drugs are well established and accepted among
patients and physicians in their respective markets, are orally bioavailable, can be efficiently produced and marketed, and are relatively
safe. None of our product candidates have been approved for sale or marketing and, to date, there have been no commercial sales of any
of our product candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Our Strategy</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our strategy is to build a
fully integrated biotechnology company that discovers, in-licenses and develops an innovative and effective small molecule drug portfolio
of ligands that bind to a specific therapeutic target for the treatment of liver, oncological and inflammatory diseases as well as erectile
dysfunction. We continue to develop and test our existing pipeline, while also testing other indications for our existing drugs and examining,
from time to time, the potential of other small molecules that may fit our platform technology of utilizing small molecules to target
the A3AR. We generally focus on drugs with global market potential and we seek to create global partnerships to effectively assist us
in developing our portfolio and to market our products. Our approach allows us to:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">continue to advance our clinical and preclinical pipeline;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">test our products for additional indications which fit our molecules&#8217; mechanism of action;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">identify other small molecule drugs or ligands;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">focus on our product candidates closest to realizing their potential; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">avoid dependency on a small number of small molecules and indications.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Using this approach, we have
successfully advanced our product candidates for a number of indications into various stages of clinical development. Specific elements
of our current strategy include the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">Successful development
of our existing portfolio of small molecule orally bioavailable drugs for the treatment of various diseases</span>. We intend to continue
to develop our existing portfolio of small molecule orally bioavailable drugs, both for existing targeted diseases, as well as other potential
indications. Our drug development will continue to focus on cancer, liver and inflammatory diseases. We intend to focus most prominently
on advancing our product candidates that are in the most advanced stages, i.e., psoriasis with respect to Piclidenoson, and HCC, MASH
and pancreatic cancer with respect to Namodenoson.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">Use our expertise with
our platform technology to evaluate in-licensing opportunities</span>. We continuously seek attractive product candidates and innovative
technologies to in-license or acquire. We intend to focus on product candidates that would be synergistic with our A3AR expertise. We
believe that by pursuing selective acquisitions of technologies in businesses that complement our own, we will be able to enhance our
competitiveness and strengthen our market position. We intend to utilize our expertise in A3AR and our pharmacological expertise to validate
new classes of small molecule orally bioavailable drugs. We will then seek to grow our product candidate portfolio by attempting to in-license
those various candidates and to develop them for a variety of indications.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">Primarily develop products
that target major global markets</span>. Our existing product candidates are almost all directed at diseases that have major global markets.
Our intent is to continue to develop products that target diseases that affect significant populations using our platform technology.
We believe these arrangements will allow us to share the high development cost, minimize the risk of failure and enjoy our partners&#8217;
marketing capabilities, while also enabling us to treat a more significant number of persons. We believe further that this strategy will
increase the likelihood of advancing clinical development and potential commercialization of our product candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 49; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">Commercialize our product
candidates throughout-licensing arrangements</span>. We have entered into several out-licensing arrangements with leading pharmaceutical
companies in the Far East, Canada and Europe. We intend to continue to commercialize our product candidates throughout-licensing arrangements
with third parties who may perform any or all of the following tasks: completing development, securing regulatory approvals, manufacturing,
marketing and sales. We do not intend to develop our own manufacturing facilities or sales forces. If appropriate, we may enter into co-development
and similar arrangements with respect to any product candidate with third parties or commercialize a product candidate ourselves. We believe
these arrangements will allow us to share the high development cost, minimize the risk of failure and enjoy our partners&#8217; marketing
capabilities. We believe further that this strategy will increase the likelihood of advancing clinical development and potential commercialization
of our product candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Our Product Pipeline</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below sets forth
our current pipeline of product candidates, including the target indication and status of each.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028258601_img1.jpg"/></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 50; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Piclidenoson (CF101)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson, our lead therapeutic
product candidate, is in development for the treatment of inflammatory diseases. Piclidenoson is a highly-selective, orally bioavailable
small molecule synthetic drug, which targets the A3AR. Based on our clinical studies to date, we believe that Piclidenoson has a favorable
safety profile and significant anti-inflammatory effects as a result of its capability to inhibit the production of inflammatory cytokines,
such as TNF-&#945;, IL-6 and IL-1, chemokines and MMPs, by modulating key proteins such as NF-kB-;and PKB/AKT. Overall, these up-stream
events result in apoptosis of inflammatory cells. See Figure 1 below. Piclidenoson&#8217;s anti-inflammatory effect is mediated via the
A3AR, which is highly expressed in inflammatory cells.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028258601_img2.jpg"/></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-weight: bold;">Figure 1: Piclidenoson anti-inflammatory mechanism
of action</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Psoriasis is an inflammatory
hereditary disease that affects the skin. In psoriasis, immune cells move from the dermis to the epidermis, where they stimulate keratinocytes,
or skin cells, to proliferate. DNA acts as an inflammatory stimulus to stimulate receptors which produce cytokines, such as IL-1, IL-6,
and TNF-&#945;, and antimicrobial peptides. These cytokines and antimicrobial peptides signal more inflammatory cells to arrive and produce
further inflammation. In other words, psoriasis occurs when the immune system overreacts and mistakes the skin cells as a pathogen, and
sends out faulty signals that speed up the growth cycle of skin cells. Normally, skin cells grow gradually and flake off approximately
every four weeks. New skin cells grow to replace the outer layers of the skin as they shed. But in psoriasis, new skin cells move rapidly
to the surface of the skin in days rather than weeks. They build up and form thick patches called plaques.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are five types of psoriasis:
plaque, guttate, inverse, pustular and erythrodermic. The most common form, plaque psoriasis, is commonly seen as red and white hues of
scaly patches appearing on the top first layer of the epidermis, or skin. In plaque psoriasis, skin rapidly accumulates at these sites,
which gives it a silvery-white appearance. Plaques frequently occur on the skin of the lower back, elbows and knees, but can affect any
area, including the scalp, palms of hands, soles of feet and genitals. The plaques range in size from small to large. In contrast to eczema,
psoriasis is more likely to be found on the outer side of the joint. Some patients, though, have no dermatological symptoms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 51; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Psoriasis is a chronic recurring
condition that varies in severity from minor localized patches to complete body coverage. Fingernails and toenails are frequently affected,
known as psoriatic nail dystrophy, and can be seen as an isolated symptom. Psoriasis can also cause inflammation of the joints, which
is known as psoriatic arthritis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Pre-Clinical Studies with Piclidenoson</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information below is based
on the various studies conducted with Piclidenoson, including preclinical studies. All of the studies were conducted by Can-Fite and/or
by Can-Fite&#8217;s partners or affiliates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pre-clinical studies are a
set of experiments carried out in animals to show that a certain drug does not evoke toxicity. Based on the animal studies and safety
data, one can approach the FDA and request permission to conduct a Phase I study in human beings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The toxicity of Piclidenoson
has been evaluated following 28-day, 90-day, six-month and nine-month good laboratory practice repeated-dose toxicity studies in male
and female mice (28-day, 90-day and six-month), dogs (single-dose only), and monkeys (28-day, 90-day and nine-month). Even though the
dose of Piclidenoson in these studies was escalated to an exposure that is many folds higher than the dose used in human clinical studies,
no toxic side effects were identified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effects on cardiovascular
parameters were evaluated in conscious instrumented monkeys and anesthetized dogs. These studies demonstrated no significant cardiovascular
risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Genotoxicity studies were
conducted in bacterial and mammalian mutation assays <i>in vitro</i> (i.e., laboratory) and in an <i>in vivo</i> (i.e., animal) mouse
micronucleus assay. These studies were all negative, indicating no deleterious action on cellular genetic material.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reproductive toxicology studies
that we completed in mice and rabbits did not reveal evidence of negative effects on male or female fertility. In mouse teratology studies,
or studies for abnormalities of physiological developments, craniofacial and skeletal abnormalities were observed at doses greater than
10 mg/kg; however, no such effects were observed at 3 mg/kg demonstrating the safety of the drug in this concentration range. Teratogenicity,
or any developmental anomaly in a fetus, was not observed in rabbits given doses (greater than 13 mg/kg) that induced severe maternal
toxicity in such rabbits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Studies of P450 enzymes, or
enzymes that participate in the metabolism of drugs, showed that Piclidenoson caused no P450 enzyme inhibition, or increased drug activity,
or induction, or reduced drug activity. Studies carried out with radiolabeled (C<sup>14</sup>) Piclidenoson in rats showed that the drug
is excreted essentially unchanged. These studies also showed that the drug is widely distributed in all body parts, except the central
nervous system.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In pre-clinical studies with
skin cells, modeling psoriasis in humans, Piclidenoson destroyed pathological skin cells. We observed that in a cell culture of human
HaCaT cells, incubated with Piclidenoson, cell apoptosis was induced with an increase in the caspase protein, known to mediate apoptotic
responses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Clinical Studies with Piclidenoson</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information below is based
on the various studies conducted with Piclidenoson, including clinical studies in patients with autoimmune-inflammatory and ophthalmic
diseases. All of the studies were conducted by Can-Fite and/or by Can-Fite&#8217;s partners or affiliates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 52; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Phase I Clinical Studies of Piclidenoson</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson has been studied
comprehensively in normal volunteer trials to assess safety, pharmacokinetic metabolism and food interaction. Two Phase I studies in 40
healthy volunteers, single dose and repeated dose, indicated that Piclidenoson is rapidly absorbed (reaching a maximal concentration within
one to two hours) with a half-life of eight to nine hours. Some mild adverse events (principally, increased heart rate) were observed
at doses higher than single doses of 10.0 mg and twice-daily doses of 5.0 mg. Such increase in heart rate was not accompanied by any change
in QT intervals. The drug showed linear kinetics, in that the concentration that results from the dose is proportional to the dose and
the rate of elimination of the drug is proportional to the concentration, and low inter-subject variability, meaning that the same dose
of the drug does not produce large differences in pharmacological responses in different individuals. A fed-fast Phase I study (with and
without food) demonstrated that food causes some attenuation in Piclidenoson absorption; accordingly, Piclidenoson is administered to
patients on an empty stomach in our trials. An additional Phase I study of the absorption, metabolism, excretion and mass balance of 4.0
mg (C<sup>14</sup>) Piclidenoson was conducted in six healthy male subjects and demonstrated that Piclidenoson was generally well-tolerated
in this group.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the findings from
Phase I clinical studies, 4.0 mg twice daily, or BID, was selected as the upper limit for initial Phase II clinical trials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in preparation
for Phase III studies of Piclidenoson to establish cardiac safety in humans prior to registration for marketing approval, we conducted
a cardiodynamic trial that was a placebo-controlled crossover study using precise methodology to determine the effect of Piclidenoson
on electrocardiograms of healthy volunteers. The primary objective of the trial was to assess whether Piclidenoson causes a delay in cardiac
repolarization, as manifested by prolongation of the QT interval of the electrocardiogram. A drug-induced delay in cardiac repolarization
creates an electrophysiological environment that can lead to the development of ventricular cardiac arrhythmias. In this study, Piclidenoson
doses were up to 3-fold higher than the highest dose expected to be used in our registration-directed clinical trials. Trial results showed
that our highest projected Piclidenoson dose had no clinically significant adverse electrocardiographic effects.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Phase II, Phase II/III and Phase III Clinical
Studies of Piclidenoson</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson has completed
eleven Phase II studies, one Phase II/III study and three Phase III studies in different clinical indications including psoriasis, rheumatoid
arthritis, glaucoma and dry eye syndrome, or DES, in approximately 1,700 patients. These studies indicate that Piclidenoson has a favorable
safety profile at doses up to 4.0 mg BID for up to 48 weeks. In these studies, we did not observe a dose-response relationship between
Piclidenoson and adverse events. Moreover, we did not observe any clinically significant changes in vital signs, electrocardiograms, blood
chemistry or hematology. Furthermore, no new emergent safety signals have been observed in the completed or ongoing Phase III rheumatoid
arthritis and psoriasis trials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2022, we announced
positive top-line results from our Phase III COMFORT study of Piclidenoson in the treatment of moderate to serious psoriasis in which
Piclidenoson met its primary endpoint. Previously, Piclidenoson given as a standalone therapy reached the primary endpoint in Phase II
clinical studies in DES; however, a Phase III study of Piclidenoson for DES failed to reach the primary endpoint. We have observed positive
data utilizing Piclidenoson as a standalone drug in a Phase IIa clinical study in rheumatoid arthritis. In this study, we also observed
a significant direct correlation between A3AR expression prior to treatment and the patients&#8217; responses to Piclidenoson. However,
we did not fully attain the primary endpoint in this study as we did not observe a significant difference in responses between Piclidenoson
and the placebo (which for this study was 0.1 mg of Piclidenoson). Moreover, two Phase IIb studies in rheumatoid arthritis utilizing Piclidenoson
in combination with MTX, also failed to reach the primary endpoints. Based on this data, we believe that the failures in the Phase IIb
studies in rheumatoid arthritis may have been due to low A3AR expression in the MTX-treated patients. A Phase IIb of Piclidenoson given
as a standalone therapy in patients with A3AR expression levels above a certain threshold reached the primary endpoint in rheumatoid arthritis
in December 2013. Piclidenoson has been tested in Phase II trials to establish dose and activity (first, orally administered capsules
and then tablets in formulations of 1.0, 2.0 and 4.0 mg of Piclidenoson BID) in psoriasis (moderate to severe plaque psoriasis), rheumatoid
arthritis and DES (moderate to severe). A Phase II/III study of Piclidenoson for psoriasis did not meet its primary endpoint although
positive data from further analysis of the Phase II/III study suggested Piclidenoson as a potential systemic therapy for patients with
moderate-severe psoriasis. In addition, a Phase II study of Piclidenoson for glaucoma showed no statistically significant differences
between the Piclidenoson treated group and the placebo group in the primary endpoint of lowering IOP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><!-- Field: Page; Sequence: 53; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Psoriasis</i>: The rationale
for utilizing Piclidenoson to treat psoriasis stems from our pre-clinical pharmacology studies showing that Piclidenoson acts as an anti-inflammatory
agent via the inhibition of inflammatory cytokines, including TNF-&#945;, which plays a major role in the pathogenesis of psoriasis.
In addition, the A3AR is over-expressed in the tissue and PBMCs of patients with psoriasis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We completed an exploratory
Phase II trial in ten European and Israeli medical centers involving 76 patients. This study was a randomized, double-blind, placebo controlled
and included four cohorts of 1.0, 2.0, and 4.0 mg of Piclidenoson and a placebo for a 12-week period. The study objectives were efficacy
and safety of daily doses of Piclidenoson administered orally in patients with moderate-to-severe plaque-type psoriasis and the efficacy
endpoints were improvements in both the Psoriasis Area Sensitivity Index score, or PASI score, and the Physicians&#8217; Global Assessment
score, or PGA score. We concluded that Piclidenoson met such efficacy endpoints and was well-tolerated and effective in ameliorating disease
manifestations in these patients. The patient group receiving 2.0 mg Piclidenoson BID showed progressive improvement over the course of
the 12-week study in the PGA and PASI scores. Analysis of the mean change from baseline in the PASI score at week 12 revealed a statistically
significant difference between the 2.0 mg Piclidenoson BID treated group and the placebo group (p&lt;0.001 versus baseline and p=0.031
versus placebo). Analysis of the PGA score revealed that 23.5% of the patients treated with the 2.0 mg Piclidenoson BID achieved a score
of 0 or 1, in comparison to 0% in the placebo group (p&lt;0.05). The study also demonstrated linear improvement in patients in both PASI
and PGA. See Figure 2. No drug-related serious adverse events were evident during the study.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028258601_img3.jpg"/></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Figure 2: Psoriasis efficacy by PGA and PASI</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 54; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are representative
pictures of a patient with plaque-type psoriasis on the upper and lower back treated with 2.0 mg Piclidenoson BID, both baseline and week
12.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;"><img alt="" src="ea028258601_img4.jpg"/></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">A comparison between baseline and week 12 of
a patient treated with 2.0 mg CF101</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2015, we completed
a Phase II/III randomized, double-blind, placebo-controlled, dose-finding study of the efficacy and safety of Piclidenoson administered
daily orally in patients with moderate-to-severe plaque psoriasis. This clinical trial enrolled 326 patients in 17 clinical centers in
the United States, Europe and Israel, of which 103 patients were enrolled in the first study cohort and were treated for 6 months and
223 patients were enrolled in the second study cohort and were treated for 8 months. The first study cohort was comprised of three arms
with patients receiving: 1.0 mg of Piclidenoson; 2.0 mg of Piclidenoson; and placebo. All patients receiving placebo were switched to
either 1.0 mg or 2.0 mg of Piclidenoson after 12 weeks. Based on a positive safety and efficacy interim analysis of the first 103 patients
who completed 24 weeks of treatment in the trial, we decided to continue patient enrollment for the second stage of the study and the
study protocol was amended to extend the Piclidenoson 2.0 mg BID and placebo administration for a period of 32 weeks. The positive clinical
effects of the Piclidenoson 2.0 mg BID dose relative to a placebo were observed in a variety of standard psoriasis assessment parameters,
including PASI 75 and PGA scores, with the responses accumulating steadily over the 24-week treatment period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 55; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2015, we announced
the study did not meet its primary endpoint of a statistically significant improvement in the PASI 75 score relative to placebo after
12 weeks of treatment. Further analysis of the entire study period revealed that by 32 weeks of treatment with Piclidenoson, 33% of the
patients achieved PASI 75 while the mean percent of improvement in PASI score was 57% (p&lt;0.001). This was a statistically significant
cumulative and linear improvement during weeks 16 to 32. Most significantly, by week 32 of the study, 20% of the study patients reached
PASI 90, a result demonstrating a response rate of 90% clearing of skin lesions. PASI 90 is one of the most stringent and difficult to
meet clinical endpoints for measuring responses to psoriasis treatments. Moreover, the PASI 90 subset analysis further suggests a higher
and significant (p=0.026) Piclidenoson response rate of 27% among patients previously untreated with systemic psoriasis therapy compared
to patients pre-treated with systemic drugs. We believe this presents the opportunity that Piclidenoson can be developed as a first-line
systemic therapy for patients with moderate-severe psoriasis and for patients who do not want to be treated with the current systemic
drugs due to safety issues.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028258601_img5.jpg"/></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-weight: bold;"><i>Figure 3: Proportion of patients achieving
PASI 75 and PGA2 0 or 1 by treatment arm over time (mITT)</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2022, we announced
positive top-line results from our Phase III COMFORT study of Piclidenoson in the treatment of moderate to serious psoriasis in which
Piclidenoson met its primary endpoint. The trial was a Phase III randomized, double-blind, placebo- and active-controlled study of the
efficacy and safety of daily Piclidenoson (CF101) administered orally in patients with moderate-to-severe plaque psoriasis. The primary
objectives of this study were to evaluate the efficacy of oral Piclidenoson 2 mg or 3 mg twice daily (BID) in patients with moderate-to-severe
plaque psoriasis, compared with placebo, as determined by the proportion of subjects who achieve a PASI score response of &#8805;75% (PASI
75) at Week 16 (superiority); and evaluate the safety of oral Piclidenoson in this patient population. The secondary objectives of this
study are to evaluate the efficacy of oral Piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects
who achieve, respectively, PASI 50, Physician Global Assessment (PGA) score of 0 or 1, and improvement on the Psoriasis Disability Index
(PDI) at Week 16 (superiority); evaluate the efficacy of oral Piclidenoson 2 mg or 3 mg BID, compared with Otezla (apremilast), as determined
by the proportion of subjects who achieve PASI 75, PGA score of 0 or 1, PASI 50, and improvement in PDI at Weeks 16 and 32 (non-inferiority);
and evaluate the efficacy and safety data for Piclidenoson through the extension period of up to 48 weeks of treatment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 56; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The study data showed that
patients treated with oral Piclidenoson 2 mg or 3 mg twice daily, had clinically equivalent efficacy responses. At week 16, patients receiving
Piclidenoson 3mg demonstrated statistically significant improvement when compared with placebo, as measured by the PASI 75 response (representing
a 75% reduction in psoriasis severity): Piclidenoson 3mg: 9.7% vs. placebo: 2.6% (P&lt; 0.04). Secondary endpoint parameters at week 32
comparing Piclidenoson to the active control drug, Otezla, revealed inferiority with respect to PASI 75 (17% vs. 26.2%, respectively)
and PASI 50 (34.1% vs. 49.5%, respectively), but revealed superiority of Piclidenoson as compared to Otezla in the Psoriasis Disability
Index (PDI) (20.5% vs. 10.3%, respectively, P&lt;0.05). A linear increase in the response of patients to Piclidenoson was achieved along
the study period, on week 48 reaching PASI 50 in 90% of patients, PASI 90 in 10% of patients and PDI improvement in 60% of patients. Piclidenoson
had an excellent safety profile overlapping that of the placebo treated patients, showing a better safety profile when compared to Otezla.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further analysis of the study
data showed that Piclidenoson had a significantly better tolerability profile than Otezla, as GI-related adverse events were 1% for Piclidenoson
vs. 6% for Otezla, nervous system disorders were 0.7% for Piclidenoson, 9.9% for Otezla and 3.3% for the placebo. The discontinuation
rate was significantly higher for Otezla vs. Piclidenoson. In the secondary endpoint of achieving a PASI 75 response (at week 32, in the
whole patient population, Piclidenoson was inferior to Otezla; however, in a sub-group analysis of patients who had PASI&gt;25 (more severe
psoriasis) at baseline, Piclidenoson had a comparable response to Otezla.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2023, we submitted
a market registration plan to the EMA and FDA for Piclidenoson in the treatment of moderate to severe psoriasis. Following positive responses
from the FDA and EMA for its registration plan and pivotal Phase III study protocol for Piclidenoson in the treatment of moderate to severe
psoriasis, we initiated a Phase III study in the first quarter of 2025.&#160;The study is a randomized, double-blind, placebo-controlled
study aimed at demonstrating clinical safety and efficacy for the treatment of patients with moderate to severe plaque psoriasis. Patients
will be treated with 3 mg twice daily orally Piclidenoson tablets or placebo. The co-primary efficacy objectives of this study are the
proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of &#8805;75% (PASI 75) and the proportion of
subjects who achieve a Static Physician&#8217;s Global Assessment (sPGA) at of 0 or 1 at Week 16. The FDA requested two Phase III safety and
efficacy studies and also encouraged us to enroll adolescent patients due to the strong safety profile of the drug demonstrated over the
development history and prior clinical studies. Based on our current assumptions, interim analysis data is expected to
be released in the second quarter of 2027.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon positive conclusion of
the Phase 3 program, we plan to submit a New Drug Application (NDA) to the FDA and Marketing Authorization Plan (MAA) to the EMA.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">Additional Developments
with Piclidenoson</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>Lowe Syndrome</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical studies, Piclidenoson
has been found to be effective in&#160;Lowe&#160;Syndrome, a rare genetic disease with no treatment available, and an estimated $100 million
treatment market in the U.S. alone.&#160;Lowe&#160;Syndrome usually develops in the first year of life, causing brain abnormalities associated
with intellectual disabilities and a life span shortened to less than 40 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discovery of Piclidenoson&#8217;s
efficacy in&#160;Lowe&#160;Syndrome was made by researchers at the University of Naples Federico II and The Telethon Institute of Genetics
and Medicine in Italy after testing thousands of compounds in search of a treatment. We and Fondazione Telethon signed an agreement outlining
their collaboration for the development of Piclidenoson for the treatment of&#160;Lowe&#160;Syndrome. As a rare genetic disease in dire
need of a treatment,&#160;Lowe&#160;Syndrome may qualify for an accelerated approval path.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, we announced
that we completed a Phase II design for the treatment of Lowe Syndrome and preparatory work is undergoing for the initiation of the clinical
study. Dr. Franchesca Emma from the Division of Nephrology, Bambino Ges&#249; Children&#8217;s Hospital - IRCCS Rome Italy, agreed to be the
principal investigator of the study. The Phase II open study is expected to enroll 5 patients that will be treated twice daily with 3
mg Piclidenoson for 6 months. The study&#8217;s primary end point will be the efficacy of Piclidenoson in increasing 99mTc-DMSA renal
uptake. We plan to submit the study protocol to regulatory authorities in Italy and EMA during the second quarter of 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 57; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify; text-indent: 0in"><span style="font-weight: bold;"><i>Topical Piclidenoson</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2022, we announced
we are developing a topical psoriasis treatment with Piclidenoson. In a preclinical model, imiquimod-induced skin psoriasis, daily treatment
with topical Piclidenoson significantly inhibited the disease as measured by PASI calculated based on observation of erythema, thickness,
scaling, and a score of skin lesions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>Osteoarthritis in Canine</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 28, 2021, we entered
into a Patent and Know-how License Agreement, or the Vetbiolix Agreement, with Vetbiolix, a France-based veterinary biotech company, for
the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. During 2022, Vetbiolix
completed dose-ranging pharmacokinetic (PK) studies in dogs and determined the optimal efficacy and safety dosage for a planned European
multicentric clinical study. Piclidenoson was well tolerated, with the PK data proportional to dose. Pre-clinical studies were also conducted
showing Piclidenoson has a very favorable safety profile. Based on these data, Vetbiolix conducted a clinical study in dogs with osteoarthritis
yielding positive results in the second half of 2024. The study looked at the effect of 90 days treatment with Piclidenoson at 100 &#956;g/kg
and 500 &#956;g/kg twice daily orally in dog patients with osteoarthritis. Including all evaluable patients, the primary objective was the
Liverpool Osteoarthritis in Dogs (LOAD) questionnaire for the assessment of symptoms severity evaluated on dog&#8217;s mobility. The secondary
objectives included Visual Analog Scale (VAS) for pain assessment by pet parents and Numerical Rating Score (NRS) for (i) lameness and
(ii) pain assessment by the veterinarian. The study reached the primary and secondary endpoints with a dose and time dependent inhibitory
effect of Piclidenoson on LOAD and VAS, together with a favorable trend on NRS scores, demonstrating significant improvement in clinical
status and decrease in pain utilizing the 500 &#181;g/kg dose. As a result, Vetbiolix exercised its option to obtain the license from
us in September 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, we announced
Vetbiolix is initiating an advanced clinical study in dogs with osteoarthritis, utilizing oral daily treatment with Piclidenoson. The
study data expected to be released in the third quarter of 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 4. Information
on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements&#8212;Development and Commercialization Agreement
and License Agreement with Vetbiolix&#8221; for additional information.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">Namodenoson (CF102)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Namodenoson is our second
drug candidate and is under development for the treatment of HCC, hepatitis C virus, or HCV, or NAFLD, the precursor to MASH. Namodenoson
is also a small, orally bioavailable molecule, and an A3AR agonist, with high affinity and selectivity to the A3AR. In comparison to the
expression in adjacent normal liver tissue, the A3AR is over-expressed in tumor tissues of patients with HCC, and the over-expression
is also reflected in the patients&#8217; PBMCs. A3AR over-expression in the patients&#8217; tumor cells and PBMCs is attributed to high
expression of certain A3AR transcription factors. The binding of Namodenoson to the A3AR results in down-regulation, or a decrease in
the quantity of a cellular component, such as the number of receptors on a cell&#8217;s surface, of certain A3AR transcription factors.
Our studies have shown that this down-regulation leads to apoptosis of HCC cells. In our pre-clinical and clinical studies, Namodenoson
demonstrated anti-cancer, anti-viral and liver protective effects. As a result, we believe that Namodenoson can be used to treat a variety
of oncological and liver-related diseases and viruses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2012, the FDA
granted an orphan drug status for the active moiety, or the part of the drug that is responsible for the physiological or pharmacological
action of the drug substance, of Namodenoson for the treatment of HCC. Subsequently, in October 2015, the EMA granted Namodenoson orphan
drug designation for the treatment of HCC. In addition, in October 2024, the FDA granted orphan drug designation to Namodenoson for the
treatment of pancreatic cancer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An orphan drug designation
is a special designation for drug approval and marketing. The special designation is granted to companies that develop a given drug for
unique populations and for incurable and relatively rare diseases. The FDA orphan drug designation program provides orphan status to drugs
and biologics, which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect
fewer than 200,000 people in the United States and in the EU not more than 5 per 10,000. Orphan drug designations have enabled companies
to achieve medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development as this
status lessens some of the regulatory burdens, for approval, including statistical requirements for efficacy, safety and stability, in
an effort to maintain development momentum. Orphan drug designation also results in additional marketing exclusivity and could result
in certain financial incentives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 58; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2015, the FDA
granted Fast Track designation to Namodenoson as a second line treatment to improve survival for patients with advanced HCC who have previously
received Nexavar (sorafenib). Fast Track, aimed at getting important new drugs that meet an unmet need to patients earlier, is expected
to expedite the development of Namodenoson. Drugs that receive Fast Track designation benefit from more frequent meetings and communications
with the FDA to review the drug&#8217;s development plan to support approval. It also allows us to submit parts of the NDA on a rolling
basis for review as data becomes available.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israel&#8217;s Ministry of
Health has previously approved Namodenoson for compassionate use for HCC and decompensated liver cirrhosis. In March 2025, we received
a single FDA approval for the compassionate use treatment with Namodenoson of a U.S. based pancreatic cancer patient.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are general
descriptions of the diseases with respect to which Namodenoson has underwent or is currently undergoing or being prepared for clinical
trials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>HCC: </i>HCC is an oncological
disease characterized by malignant tumors that grow on the surface or inside of the liver. This type of tumor is refractory to chemotherapy
and to other anti-cancer agents. HCC, like any other cancer, develops when there is a mutation to the cellular machinery that causes the
cell to replicate at a higher rate and/or results in the cell avoiding apoptosis. Chronic infections of Hepatitis B and/or C can aid the
development of HCC by repeatedly causing the body&#8217;s own immune system to attack the liver cells, some of which are infected by the
virus. While this constant cycle of damage followed by repair can lead to mistakes during repair which in turn lead to carcinogenesis,
this hypothesis is more applicable, at present, to HCV. Chronic HCV causes HCC through cirrhosis. In chronic Hepatitis B, however, the
integration of the virus into infected cells can directly induce a non-cirrhotic liver to develop HCC. Alternatively, repeated consumption
of large amounts of ethanol can have a similar effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>NAFLD/MASH</i>, also called
&#8220;fatty liver disease,&#8221; is a condition in which fat builds up inside the liver causing inflammation. Prior to the presence
of inflammation, the disease was simply referred to as NAFLD, the most common form of liver disorder in the United States. The accumulation
of macroglobular fat inside the liver causes oxidative stress that reduces the efficiency of the liver and can lead to increased liver
enzymes such as alanine aminotransferase and aspartate aminotransferase. Loss of liver efficiency and oxidative stress leads to inflammation,
liver cell ballooning, and the development of MASH. Prolonged inflammation results in cirrhosis (scar tissue), liver failure, or liver
cancer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Pancreatic Cancer:</i>
Pancreatic cancer is one of the most aggressive malignancies with an overall 5-year survival rate of 8%. The primary cause of this low
survival rate is the absence of early detection methods and the vulnerability to early metastasis, resulting in a stage IV diagnosis in
over half of the cases (52%). Another key reason for the low survival rate is the limited effectiveness of the available treatment options,
as the efficacy of gemcitabine alone, or in combination with other chemotherapies is modest, and checkpoint inhibitors failed to show
a significant clinical benefit. Thus, novel and effective therapies for pancreatic cancer are clearly needed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">Pre-Clinical Studies with
Namodenoson</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In pre-clinical pharmacology
studies, Namodenoson inhibited the growth of HCC via the induction of tumor cell apoptosis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical studies, Namodenoson
revealed its capability to act as an anti NAFLD/MASH agent and data has shown as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">In the STAM model, Namodenoson significantly decreased the non-alcoholic fatty liver disease (NAFLd) activity score, NAS, demonstrating anti-inflammatory and anti steatotic effects.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">In the carbon tetrachloride (ccl4) model, Namodenoson reversed alanine aminotransferase (ALT) to normal values and significantly improved liver inflammation and fibrosis, as well as the adiponectin and leptin levels.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Namodenoson mechanism of action entailed de-regulation of the Wnt/&#946;-catenin pathway in the liver extracts of the ccl4 model mice and in the LX2 HScs, manifested by a decreasing the expression of phosphoinositide 3-kinase (PI3K), NF-&#954;B.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 59; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">Clinical Studies of Namodenoson</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>Phase I Clinical Study</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Namodenoson completed a Phase
I double-blind, randomized, placebo-controlled, ascending single dose trial to evaluate the safety, tolerability, and pharmacokinetics
of orally administered Namodenoson in healthy volunteers. The study was conducted in the United States under an open IND. Namodenoson
was found to be safe and well-tolerated with a half-life time of 12 hours. See Figure 4.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="ea028258601_img6.jpg"/></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">Figure 4: Half-life of orally administered Namodenoson
- Phase I Clinical Study</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>Phase I/II and Phase
II Clinical Studies</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="text-decoration:underline">HCC</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Namodenoson completed two
Phase I/II studies in Israel, one in patients with HCC and another in patients with HCV. The HCC Phase I/II study was an open-label, dose-escalation
study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered Namodenoson in patients with advanced
HCC. The primary objectives of the study were to determine the safety and tolerability, dose-limiting toxicities, maximum tolerated dose,
and recommended Phase II dose of orally administered Namodenoson in patients with advanced HCC; and to assess the repeat-dose pharmacokinetics
behavior of Namodenoson in those patients. The secondary objectives were to document any observed therapeutic effect of Namodenoson in
patients with HCC and to evaluate the relationship between PBMCs and the A3AR expression at baseline, as a biomarker, and the effects
of Namodenoson in patients with HCC. The study included 18 patients, nine of which were also carriers of HCV. The initial dose of Namodenoson
was 1.0 mg BID, with planned dose escalations in subsequent cohorts to 5.0 and 25.0 mg BID. This Phase I/II study achieved its objectives,
showing a good safety profile, or no material differences versus a placebo with respect to observed and patient-indicated side effects,
for Namodenoson and a linear pharmacokinetic drug profile, with no dose-limiting toxicities at any dose level. The median overall survival
time for the patients in this study was 7.8 months, which is encouraging data considering that (i) 67% of the patient population in the
study had previously progressed on Nexavar, produced by Onyx Pharmaceuticals and Bayer, and that Namodenoson was a second line therapy
for these patients and (ii) 28% of the patient population were Child-Pugh Class B patients (patients classified on the Child Pugh scoring
system for chronic liver disease as having significantly impaired liver function) whose overall survival time is usually 3.5 to 5.5 months.
Accordingly, we may also consider Namodenoson as a drug to be developed for this patient sub-population of Child-Pugh Class B patients.
Namodenoson had no adverse effect on routine measures of liver function over a six-month period in 12 patients treated for at least that
duration. These findings are consistent with our pre-clinical Namodenoson data which demonstrated a protective effect on normal liver
tissue in an experimental model of liver inflammation. As such, Namodenoson may potentially be a safer alternative to patients with cirrhosis
and/or hepatic impairment. The study also demonstrated a direct relationship between A3AR expression at baseline and patients&#8217; response
to Namodenoson, suggesting A3AR as a predictive biological marker. We also observed a decrease in the viral load of seven out of nine
patients who were also carriers of HCV. The most commonly reported adverse events included loss of appetite, ascites, nausea, diarrhea,
constipation and pain. However, many of these events are expected in a population of patients with advanced HCC. The most frequently reported
drug-related adverse events included diarrhea, fatigue, loss of appetite, pain and weakness.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 60; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our second Phase I/II study
was a randomized, double-blind, placebo-controlled, dose-escalation study evaluating the safety, tolerability, biological activity, and
pharmacokinetics of orally administered Namodenoson in 32 subjects with chronic HCV genotype 1. Eligible subjects were assigned in a 3:1
ratio (eight subjects in each cohort) to receive QD or BID treatment (1.0, 5.0 and 25.0 mg of Namodenoson) for 15 days with oral Namodenoson
or with a placebo. Dose escalation occurred in four sequential cohorts. The study&#8217;s primary objectives were to determine the safety
and tolerability of orally administered Namodenoson in patients with chronic HCV genotype 1, to assess the effects on HCV load during
15 days of treatment with Namodenoson and to assess the repeat-dose pharmacokinetic behavior of Namodenoson under the conditions of this
trial. The secondary objective of this trial was to perform an exploratory evaluation of the relationship between A3AR in PBMCs at baseline
and the clinical effects of Namodenoson on the study&#8217;s patients. Following the decrease in HCV load that had been observed in HCV
patients treated with Namodenoson in the parallel HCC study and the good safety profile of Namodenoson, we received Israeli Institutional
Review Board, or IRB, approval to extend the treatment period of the Phase I/II in patients with HCV to four months with the 1.0 mg dose
vs. the placebo. The results of this Phase I/II HCV study demonstrated a good safety profile and a linear pharmacokinetic drug profile,
however, no significant decrease in the viral load was observed. Notwithstanding, we did observe in the parallel HCC study that seven
out of the nine patients with both HCC and HCV experienced a decrease in viral load and that these seven patients were treated with higher
Namodenoson dosages than what was administered to the patients with chronic HCV genotype 1 only, and not HCC, possibly explaining the
difference in results. The most commonly reported adverse events included loss of appetite, ascites, nausea, diarrhea, constipation and
pain. However, many of these events are expected in a population of patients with advanced HCV. The most frequently reported drug-related
adverse events included diarrhea, fatigue, loss of appetite, pain and weakness.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2019, we completed a Phase
II study in HCC patients. In January 2013, as part of our preparatory work for such study, we announced that we believe that the optimal
drug dose for the upcoming study is Namodenoson 25.0 mg. This dose was found to be the most effective dose out of the three dosages tested
(1.0 mg, 5.0 mg and 25.0 mg) in the previous Phase I/II study. We filed a patent application protecting such optimal dose of Namodenoson
for HCC. A publication summarizing the results of the Phase I/II study was published in &#8220;The Oncologist,&#8221; a leading oncology
scientific journal.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Phase II study was a randomized,
double-blind, placebo controlled trial conducted in the United States, Europe and Israel to evaluate the efficacy and safety of Namodenoson
as a second-line treatment for advanced HCC in subjects with Child-Pugh B who failed Nexavar as a first line treatment. Advanced HCC in
patients with underlying cirrhosis is categorized into three subclasses based on the severity of cirrhosis, starting with Child Pugh A,
or CPA, mostly treated with Nexavar and progressing to Child Pugh B, or CPB, and Child Pugh C, or CPC, for which there are no drugs on
market with proven efficacy. In the study, we enrolled only patients with CPB stage liver cancer with CBP stage patients being further
divided into three categories of increasing severity, namely CPB7, CPB8, and CPB9. These patients already failed first line Nexavar and
were treated with Namodenoson (25mg), or placebo, as a second line treatment, twice daily, using a 2:1 randomization. The primary endpoint
of the study was median overall survival. Secondary endpoints included progression free survival, partial response, and disease control
rate. In March 2014, the study protocol was approved by the IRB at the Rabin Medical Center in Israel and in December 2014, we dosed the
first patient at the study&#8217;s Israeli site. In the third quarter of 2017, we announced that we completed enrollment and randomization
of all 78 patients and in March 2019, we announced top-line results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 61; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the study did not achieve
the primary end point of overall survival in the whole population (n=78), superiority in overall survival was found in the largest study
subpopulation of CPB7 (n=56) and in secondary end points in the whole population, including objective response measured by CT or MRI.
Findings from the study include the following: (i) for the whole population (n=78), median overall survival was 4.1 months for Namodenoson
vs. 4.3 months for placebo (HR: 0.82), (ii) pre-planned subpopulation analysis of the CPB7 patients (n=56), revealed that the Namodenoson
treated group (n=34) showed median overall survival of 6.8 months vs 4.3 months in placebo (n=22) HR: 0.77 (95% CI 0.49-1.40); similarly,
for this subgroup of patients, progression free survival was 3.5 months for the Namodenoson treated group vs 1.9 (HR: 0.87) in the placebo
group; (iv) 1-year survival in the CPB7 population was 44% for the Namodenoson treated group, as compared to 18% for patients dosed with
placebo (p=0.028); (v) objective response in the whole patient population measured by CT or MRI, demonstrated that 9% treated by Namodenoson
achieved partial response vs 0% in the placebo group, (vi) consistent with safety results from previously completed clinical trials, Namodenoson
was generally well-tolerated, with no treated patients being withdrawn for toxicity and no cases of treatment-related deaths, (vii) disease
control rate was 18.0% in the Namodenoson group vs 7.1% in the placebo group (p=0.013) after four months of treatment, (viii) 32.0% of
patients treated with Namodenoson completed at least 12 months of treatment vs 14.3% who were treated with placebo (p=0.058), (vii) as
of March 27, 2019, two patients in the Namodenoson group are ongoing after 30 months of treatment; these patients will continue to receive
Namodenoson, and (ix) all nine patients with CBP9 cirrhosis, the most severe grade allowed into the trial, were randomly assigned to the
Namodenoson treatment group (OS=3.5 months), a fact which has distorted the results in the whole population. Subgroup analyses using a
variety of demographic and baseline disease characteristics, such as sex, performance status, and HCC disease status indicate the overall
survival advantage of Namodenoson over placebo persists in the vast majority of the subgroups.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A paper titled &#8220;Namodenoson
in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial&#8221; was published in
the peer reviewed journal <i>Cancers</i> with respect to the Phase II HCC trial.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, we announced
that two patients continued to receive Namodenoson treatment from our Phase II study of HCC after nearly four years under an open label
extension. Additional findings show disappearance of ascites, normal liver function and good quality of life. In one patient stable disease
has been recorded with disappearance of peritoneal carcinomatosis. Namodenoson continued to demonstrate a good safety profile and was
well tolerated with no severe adverse events reported. Furthermore, in December 2021, we reported that the last patient treated under
the open label extension experienced a complete response and treatment is ongoing under a compassionate use program established in Romania
in August 2022. Under treatment with Namodenoson, we reported that the patient survived eight years, during which time the clinical benefits
of treatment have included the disappearance of ascites, normal liver function, and the disappearance of peritoneal carcinomatosis leading
to complete clearance of all cancer lesions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2019, we held an
End-of-Phase II Meeting with the FDA regarding our Phase II study of Namodenoson in the treatment of HCC. The purpose of the meeting was
to review the Phase II study data with the FDA and to present our proposed Phase III study design to the regulatory agency. The FDA agreed
with our proposed pivotal Phase III trial design to support an NDA submission and approval. Subsequently in June 2020, we concluded a
meeting with the Scientific Advice Working Party of the EMA to discuss our planned Phase III study.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the input received
from the FDA and EMA, are conducting Liveration, a pivotal Phase III, randomized, double blind, placebo controlled trial of Namodenoson,
that will enroll approximately 450 patients with HCC and underlying CPB7 cirrhosis at multiple centers worldwide. Patients will be randomized
to oral treatment with either Namodenoson 25 mg or matching placebo given twice daily. The primary efficacy endpoint of the trial is overall
survival (OS), based on the favorable OS response seen in the Phase II trial in patients with HCC and CPB7 cirrhosis. Other oncology trial
efficacy outcomes, such as tumor radiographic response rates and median progression-free survival, as well as standard safety parameters,
will be assessed. The study is designed to support an NDA submission in the U.S. and a marketing authorization application, or MAA, in
Europe. The Phase III study is currently open for enrollment. Based on our current assumptions, interim analysis data is expected to be released in the second quarter of 2027.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 62; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2019, we initiated
a compassionate use program in Israel for Namodenoson in the treatment of HCC, the most common form of liver cancer. Our compassionate
use program has enrolled and continues to treat one patient. The compassionate use program, which enables liver cancer patients not enrolled
in our clinical study to be treated with Namodenoson, is being administered by Dr. Salomon Stemmer, the Principal Investigator of the
Company&#8217;s prior Phase II liver cancer study, and Professor at the Institute of Oncology, Rabin Medical Center, Israel. In particular,
a patient with advanced liver cancer treated with Namodenoson has reached an overall survival of 9 years to date with complete response
to treatment. In August 2022, Namodenoson was approved for compassionate use in Romania.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Metabolic Dysfunction-Associated Steatohepatitis
(MASH)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted a Phase II double-blind,
placebo-controlled, dose-finding efficacy and safety study that enrolled 60 patients with NAFLD with or without MASH in three clinical
sites in Israel including Hadassah Medical Center, Jerusalem; Rabin Medical Center, Petach Tikva; and Holy Family Hospital, Nazareth;
with Prof. Rifaat Safadi as the Principal Investigator. Patients with evidence of an active inflammation were treated twice daily with
12.5 mg (n=21) or 25 mg (n=19) of oral Namodenoson vs. placebo (n=20). The patients were treated for 12 weeks and followed-up until week
16. The study&#8217;s end points included among others alanine aminotransferase (ALT) and aspartate aminotransferase (AST) blood level,
% of liver fat, liver stiffness, serum adiponectin, leptin and patient&#8217;s weight loss. In April 2020 we announced top-line data and
in June 2020 we announced our final data analysis. As a whole, the data show that Namodenoson at the 25 mg dose produced statistically
significant results in all measures of efficacy, while also having a strong safety profile and well tolerated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therapeutically significant
positive data and trends were found as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Anti-Inflammatory Effect</i>:
Namodenoson significantly reduced two liver enzymes, AST and ALT, which are elevated in a damaged liver, and increased the anti-inflammatory
cytokine adiponectin known also to act as an anti-fibrotic factor. Serum adiponectin levels increased in the 25 mg dose group by 220 ng/mL
and the 12.5 mg dose group by 539 ng/mL (p=0.03). Adiponectin is a cytokine with robust anti-inflammatory and anti-fibrotic effects that
is used as a biomarker in NAFLD/MASH trials. In addition, a dose response decrease compared to placebo was observed, indicating a reduction
of hepatic inflammation was achieved: (i) % of patients who reached ALT normalization at follow up was 36.8% in the 25 mg dose vs. 10%
in the placebo (p=0.038). In the 12.5 mg dose, 23.8% was recorded at follow up, (ii) ALT change from baseline (CFB) and % change from
baseline (PCFB) - in the 25 mg group, CFB decreased by 15.4 U/L (p=0.066) and PCFB by 22% (p=0.079) compared to placebo (1.7 U/L, 3.0%,
respectively); in the 12.5 mg group, a decrease CFB of 10.4 U/L and PCFB of 8.2% was recorded; and, (iii) AST CFB and PCFB - in the 25
mg group, CFB decreased by 8.1 U/L (p=0.03) and PCFB by 17.9% (p=0.05) compared to placebo (increase of 0.3 U/L, decrease of 1.3%, respectively).
In the 12.5 mg group, a decrease in CFB of 7.4 U/L and PCFB of 8.1 % was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Reduction of Liver </i>Steatosis:
In the Namodenoson 25 mg treated group, the proportion of patients with high steatosis scores declined from 37.5% to 13.3% of the population,
as compared to the placebo treated group in which the proportion of patients with high steatosis scores decreased from 37.5% to 35.3%
of the population, with p=0.08. Steatosis was assessed by Controlled Attenuation Parameter (CAP) measurement of the FibroScan, a non-invasive
marker of hepatic steatosis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>MASH - All Cases Resolved</i>:
25% of patients randomized into the Namodenoson 25 mg dosed group had MASH at baseline, as compared to none in the placebo group, which
comprised of patients who had NAFLD without MASH at baseline. Following 12 weeks of treatment, all MASH cases were resolved in patients
treated with 25 mg of Namodenoson, as compared to new MASH that developed in the placebo group representing 5% of that population, with
p&lt;0.009. MASH was evaluated by FibroScan-AST (FAST) score, a noninvasive marker of MASH, the severe form of NAFLD (equivalent to biopsy
findings of NAS&#8805;4, F&#8805;2), measured by FibroScan elastography, CAP and serum AST.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i></i></p><!-- Field: Page; Sequence: 63; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Decrease in Body weight</i>:
A linear decrease in body weight was recorded in the 25 mg and 12.5 mg Namodenoson groups.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>A3 Adenosine Receptor (A3AR)</i>:
The A3AR biomarker was stable, demonstrating the presence of the receptor after chronic treatment and reflecting the validity of the target.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Safety</i>: Namodenoson
continued to be safe and very well tolerated with no drug emergent severe adverse effects and no hepatotoxicity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently conducting
a Phase IIb study Namodenoson in the treatment of MASH, having announced first patient enrollment in January 2022. The Phase IIb trial
is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed MASH. 140 subjects with MASH, as
determined by a histological endpoint. Eligible subjects are randomly assigned in a 2:1 ratio to oral doses of Namodenoson 25 mg every
12 hours or a matching placebo for 36 weeks. In May 2024, we announced that we received IND clearance from the FDA for enrollment of U.S.
patients. The protocol was developed in conjunction with Dr. Scott Friedman, Chief of the Division of Liver Diseases at the Icahn School
of Medicine at Mount Sinai in New York, and Dr. Stephen A. Harrison, Medical Director of Pinnacle Clinical Research, both of whom were
involved in the design of Namodenoson&#8217;s Phase II study in NAFLD/MASH.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="text-decoration:underline">Pancreatic Cancer</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2023, we announced
that in pre-clinical studies, Namodenoson significantly inhibits the growth of pancreatic carcinoma as a stand-alone treatment. In combination
with the leading chemotherapy used in pancreatic cancer, gemcitabine, Namodenoson demonstrated a significant additive effect. These pre-clinical
studies were conducted on advanced pancreatic carcinoma patient cells. Namodenoson&#8217;s molecular mechanism of action in pancreatic
cancer involves the regulation of the NF-&#954;B /I&#954;B /STAT3-mediated pathway.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2024, we
received approval from the Israeli Ministry of Health to conduct an exploratory Phase IIa clinical trial with orally-administered
Namodenoson in the treatment of pancreatic carcinoma. In October 2024, we received orphan drug designation from the FDA for
Namodenoson for the treatment of pancreatic cancer. Subsequently, in November 2024, the first patient was enrolled and completed
enrollment in January 2026. This is an open-label trial in patients with advanced pancreatic adenocarcinoma whose disease has
progressed on at least first line therapy or who refuse standard treatment. The trial is evaluating the safety, clinical activity,
and pharmacokinetics (PK) of Namodenoson in this population. All patients receive oral Namodenoson 25 mg administered twice daily
for consecutive 28-day cycles. Patients are being evaluated regularly for safety. Twenty evaluable patients were enrolled to the
study. The primary objective of this trial is to characterize the safety profile of Namodenoson and the secondary objective is to
evaluate the clinical activity as determined by the Objective Response Rate (ORR) using Response Evaluation Criteria in Solid Tumors
(RECIST 1.1), Progression-Free Survival (PFS), Disease Control Rate (DCR), Duration of Response (DoR), and Overall Survival (OS).
Top line data is expected in the third quarter of 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, we received
a single FDA approval for the compassionate use treatment with Namodenoson of a U.S. based pancreatic cancer patient.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2026, we announced
that study met its primary endpoint, which was safety, demonstrating that Namodenoson was very well tolerated in this heavily pretreated
patient population. No new safety signals were identified, and the safety profile was consistent with the known clinical experience of
Namodenoson in other oncological diseases. Secondary endpoints included overall survival (OS) and progression-free survival (PFS). Survival
follow-up remains ongoing, with 1/3 of patients currently alive at the time of data cut-off. As follow-up continues, survival outcomes
are expected to further mature and will be announced during upcoming scientific meetings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 64; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>Decompensated cirrhosis</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2025, we announced
the disappearance of episodes of decompensated liver cirrhosis following treatment with Namodenoson under a compassionate use program.
Decompensated liver cirrhosis, an advanced stage of cirrhosis often associated with liver failure, currently has no approved therapeutic
options other than liver transplantation. At 20 months into treatment, the patient reported notable improvements in symptoms related to
the disease, such as fatigue and edema. Prior to starting Namodenoson, the patient had experienced an episode of esophageal variceal bleeding,
but no further gastrointestinal bleeding episodes have occurred since beginning therapy. Additionally, moderate ascites that were present
before treatment have gradually resolved, with the patient now off diuretics for over a year. Liver stiffness, measured repeatedly during
the course of treatment, shows a mean decline compared to levels recorded before therapy began. Importantly, elevated globulin levels
&#8211; a marker of advanced liver disease &#8211; have also started to decrease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2026, we announced
that a patient with advanced decompensated liver cirrhosis who was treated with Namodenoson subsequently underwent a successful liver
transplantation. The patient received Namodenoson treatment under a compassionate use framework while suffering from liver disease and
complications consistent with decompensated cirrhosis. Throughout the treatment period, Namodenoson contributed to clinical stabilization,
allowing the patient to remain a suitable candidate for liver transplantation until a compatible donor organ became available, ultimately
resulting in a successful, life-saving liver transplantation. While this is a single case, the outcome suggests a potential supportive
role for Namodenoson in patients with severe liver dysfunction awaiting transplantation. Due to the ongoing shortage of donor organs,
many patients with decompensated cirrhosis deteriorate rapidly and, tragically, do not survive long enough to receive a suitable transplant,
highlighting the importance of therapies that may help maintain stability during this critical period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">Additional Developments
with Namodenoson</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>Anti-Obesity</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2019, we announced
new pre-clinical findings demonstrating that Namodenoson, inhibits lipid production and fat accumulation in adipocytes (lipid producing
cells). More specifically, Namodenoson showed a significant decrease in lipid production and fat accumulation utilizing 3T3-L1 adipocytes,
functioning as lipid producing cells and are also responsible for fat storage. Namodenoson was also shown to inhibit the proliferation
of adipocytes, further hampering the expansion of fat producing cells. These findings, together with the safety profile of Namodenoson,
support its potential utilization as an anti-obesity drug. A patent application for the utilization of Namodenoson as an anti-obesity
drug has been filed. In January 2020, we announced further pre-clinical data generated at the Hadassah Medical Center by Dr. Rifaat Safadi&#8217;s
lab that demonstrated that Namodenoson induces weight loss in experimental models and normalizes glucose levels.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, we reported
that new data on Namodenoson&#8217;s anti-obesity mechanism of action which demonstrated that treatment of fat cells (3T3-L1 adipocytes)
with Namodenoson leads to modulation of proteins that increase adiponectin level. Adiponectin is a regulator of fat production in the
cells, resulting in the inhibition of fat levels. Furthermore, Namodenoson reduced body weight in an experimental animal model of obesity
induced by a high fat diet. In a Phase IIa MASH study, in patients treated with Namodenoson, a 2.1% weight loss was observed after 3 months
of treatment (Safadi at Al) and a significant decrease in serum adiponectin levels was found.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February&#8239;2026, we
received a Notice of Allowance from the Canadian Patent Office for Canadian Patent Application No.&#8239;3,126,002, which covers the use
of Namodenoson as an oral A3 adenosine receptor agonist for reducing fat mass and body weight as an anti-obesity therapy. This allowance
establishes intellectual property protection in Canada for Namodenoson in metabolic indications, complementing corresponding patents we
hold in the United States and Australia and supporting broader development and partnering opportunities in obesity and related metabolic
disorders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2026, we published
the results of a peer-reviewed study in the <i>International Journal of Obesity</i> demonstrating an anti-obesity effect of our drug candidate,
Namodenoson. The study showed that Namodenoson significantly reduced adipocyte proliferation and weight gain in a high-fat-diet animal
model and modulated metabolic pathways associated with fat regulation. These findings are consistent with earlier clinical observations
in metabolic dysfunction-associated steatohepatitis and support the potential of Namodenoson as an oral treatment for obesity and related
metabolic disorders, complementing its ongoing clinical development in other indications.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 65; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2026, the Israeli
Patent Office allowed our patent application No. 284463, titled &#8220;An A3 Adenosine Receptor Ligand for Use for Achieving a Fat Loss
Effect.&#8221; The allowed patent covers the use of A3 adenosine receptor (A3AR) agonists, including our lead drug candidate Namodenoson,
for inducing fat loss and treating obesity and related metabolic disorders. This allowance provides additional intellectual property protection
in Israel for Namodenoson in metabolic indications and further strengthens our global intellectual property portfolio supporting our obesity
franchise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">CF602</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The allosteric modulator,
CF602, is our third drug candidate in its pipeline. CF602 is an orally bioavailable small molecule, which enhances the affinity of the
natural ligand, adenosine, to its A3AR. The advantage of this molecule is its capability to target specific areas where adenosine levels
are increased. Normal body cells and tissues are refractory to allosteric modulators. This approach complements the basic platform technology
of Can-Fite, utilizing the Gi coupled protein A3AR as a potent target in inflammatory diseases. CF602 has demonstrated proof of concept
for anti-inflammatory activity in <i>in vitro</i> and <i>in vivo</i> studies performed by us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During clinical studies conducted
with our product candidates, other than CF602, patients suffering from erectile dysfunction reported that they returned to normal functioning
following the treatment with such drugs. We believe that these findings are correlated with our platform technology, which is the targeting
of the A3AR. Adenosine, like nitric oxide, is a potent and short-lived vaso-relaxant that functions via intracellular signaling (in particular,
through cAMP) to promote smooth muscle relaxation. Recent studies conducted by others show that adenosine functions to relax the corpus
cavernosum and thereby promote penile erection.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CF602 was tested in an experimental
animal model of diabetic rats, which similar to diabetic patients, suffer from erectile dysfunction. Erectile dysfunction was assessed
by monitoring the ratio between intra-cavernosal pressure, or ICP, and mean arterial pressure, or MAP, as a physiological index of erectile
function. The ICP/MAP for the CF602 treated group improved by 118% over the placebo group. This data is similar to that achieved earlier
by sildenafil (Viagra) in preclinical studies. In addition, treatment with CF602 reversed smooth muscle and endothelial damage, in a dose
dependent manner, leading to the improvement in erectile dysfunction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further studies of CF602 have
revealed that CF602 restores the impaired vascular endothelial growth factor system in the penis of diabetes mellitus rats, thereby inducing
an increase in nitric oxide resulting in significant improvement of penile erection compared to placebo. This mechanism of action is similar
to that of sildenafil, with CF602 demonstrating effects on erection superior to that demonstrated by sildenafil in animal studies. Among
the most important factors to affect erectile function is nitric oxide, which is released by endothelial cells that line the corpus cavernosum
and control smooth muscle relaxation and vascular inflow. It has been well established that release of nitric oxide is diminished in diabetes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, CF602 induced
a dose-dependent, linear effect in a diabetic mellitus rat model after treatment with one single dose of CF602. One hour after dosing,
erectile function was measured. Statistically significant full recovery from erectile dysfunction took place in rats treated with a 500
&#181;/kg dose.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2025, we received
a Notice of Allowance from the National Institute of Industrial Property of Brazil for our patent application covering CF602 as an oral
or topical treatment for erectile dysfunction, including patients living with diabetes and those who do not respond to currently marketed
therapies. This patent expands our intellectual property coverage for CF602 beyond the United States and Europe and supports the potential
of CF602 to address a significant unmet medical need in the erectile dysfunction market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, we announced
new data from a preclinical study of CF602 in the treatment of erectile dysfunction, or ED, in a diabetes experimental model. The study
evaluated the efficacy of topically applied CF602 in a 4-cohort study with diabetic Sprague-Dawley (SD) rats receiving placebo; 100nM
CF602; 500nM CF602. Na&#239;ve rats served as a comparative negative control. ED was assessed by tracing ICP under cavernous nerve stimulation.
Treatment with CF602 at a dose of 500 nM resulted in statistically significant improvement of erectile dysfunction compared to vehicle
treated controls when measured in a two-way ANOVA followed by Bonferroni multiple comparisons post-hoc analysis (p&lt;0.001). The improvement
was even better than recorded for the na&#239;ve animals group. Efficacy was dose-dependent.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 66; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the American
Diabetes Association, approximately 30 million children and adults have diabetes mellitus in the United States. It is estimated that 35-75%
of men with diabetes mellitus suffer from erectile dysfunction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2017, a patent
was granted to us by the USPTO covering A3AR ligands for use in the treatment of erectile dysfunction. The patent addresses methods for
treating erectile dysfunction with different A3AR ligands including our erectile dysfunction drug candidate, CF602. With this new broader
patent protection, we made a strategic decision to investigate additional compounds, owned by us, for the most effective and safest profile
in this indication and we are seeking to partner development of CF602. In May 2024, a notice of allowance was received from the European
Patent Office for CF602 as an oral or topical drug for patients such as diabetics, who suffer from erectile dysfunction, and cannot use
the current drugs on the market.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">Commercial Biomarker Test</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2015, we completed
the development of a commercial predictive biomarker blood test kit for A3AR. The biomarker test can be used at any molecular biology
lab, where a small blood sample from a prospective patient would be tested and within just a few hours, results indicate if the patient
would benefit from treatment with our drugs, which are currently in clinical trials for rheumatoid arthritis, psoriasis, and liver cancer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The USPTO previously issued
to us a patent for the utilization of A3AR as a biomarker to predict patient response to our drug Piclidenoson in autoimmune inflammatory
indications.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">In-Licensing Agreements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
description of our in-licensing agreement with Leiden University, which we terminated in January 2026. Our previously granted license
with NIH expired in June 2015 with the expiration of certain patents. The description provided below does not purport to be complete and
is qualified in its entirety by the complete agreement, which is attached as an exhibit to this Annual Report on Form 20-F.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>Leiden University Agreements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 2, 2009, we entered
into a license agreement, or the Leiden University Agreement, with Leiden University. Leiden University is affiliated with NIH and is
the joint owner with NIH of the patents licensed pursuant to the Leiden University Agreement. The Leiden University Agreement grants an
exclusive license for the use of the patents of several compounds, including CF602, that comprise certain allosteric compound drugs, and
for the use, sale, production and distribution of products derived from such patents in the territory, i.e., China and certain countries
in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, Holland and England). Subject to certain conditions,
we may sublicense the Leiden University Agreement. However, the U.S. government has an irrevocable, royalty-free, paid-up right to practice
the patent rights throughout the territory on behalf of itself or any foreign government or international organization pursuant to any
existing or future treaty or agreement to which the U.S. government is a signatory and the U.S. government may require us to grant sublicenses
when necessary to fulfill health or safety needs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Leiden University
Agreement, we are committed to make the following payments: (i) a one-time concession commission of 25,000 Euros; (ii) annual royalties
of 10,000 Euros until clinical trials commence; (iii) 2% to 3% of net sales value, as defined in the Leiden University Agreement, received
by us; (iv) royalties of up to 850,000 Euros based on certain progress milestones in the clinical stages of the products which are the
subject of the patent under the Leiden University Agreement; and (v) if we sublicense the agreement, we will provide Leiden University
royalties at a rate of 2-3% of net sales value, as defined in the Leiden University Agreement, and 10% of certain consideration received
for granting the sublicense. In the event that we transfer to a transferee the aspect of our business involving the Leiden University
Agreement, we must pay to Leiden University an assignment royalty of 10% of the consideration received for the transfer of the agreement.
However, a merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement. In addition, we
have agreed to bear all costs associated with the prosecution of the patents and patent applications to which we are granted a license
under the Leiden University Agreement. As of December 31, 2025, we have paid approximately 165,000 Euros in royalties to Leiden University
in connection with the Leiden University Agreement. In January 2026, we terminated the Leiden University Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 67; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">Out-Licensing and Distribution
Agreements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are summary
descriptions of certain out-licensing and distribution agreements of Piclidenoson and Namodenoson for the indications we are currently
investigating.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>Cipher Pharmaceuticals
Agreement</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 20, 2015, we entered
into a Distribution and Supply Agreement with Cipher granting Cipher the exclusive right to distribute Piclidenoson in Canada for the
treatment of psoriasis and rheumatoid arthritis. In 2020, we ended our development of Piclidenoson for rheumatoid arthritis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Distribution and
Supply Agreement, we are entitled to CAD 1.65 million upon execution of the agreement plus milestone payments upon receipt of regulatory
approval by the Therapeutic Products Directorate of Health Canada, or Health Canada, for Piclidenoson and the first delivery of commercial
launch quantities as follows (i) CAD 1 million upon the first approved indication for either psoriasis or rheumatoid arthritis, and (ii)
CAD 1 million upon the second approved indication for either psoriasis or rheumatoid arthritis. In addition, following regulatory approval,
we shall be entitled to a royalty of 16.5% of net sales of Piclidenoson in Canada and reimbursement for the cost of manufacturing Piclidenoson.
We are also entitled to a royalty payment for any authorized generic of Piclidenoson that Cipher distributes in Canada. To date, we have
received a total of $1.3 million from Cipher in an upfront payment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are responsible for supplying
Cipher with finished product for distribution and conducting product development activities while Cipher is responsible for distributing,
marketing and obtaining applicable regulatory approvals in Canada. The Distribution and Supply Agreement has an initial term of fifteen
years, automatically renewable for additional five-year periods and may be terminated in certain limited circumstances including certain
breaches of the agreement and failure to achieve certain minimum quantities of sales during the contract period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timeline to regulatory
submissions to Health Canada will be determined by the completion of the remaining clinical trial program.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>CKD Agreement</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 25, 2016, we entered
into an exclusive Distribution Agreement with CKD for the exclusive right to distribute Namodenoson for the treatment of liver cancer
in South Korea, upon receipt of regulatory approvals. On February 25, 2019, the Distribution Agreement was amended to expand the exclusive
right to distribute Namodenoson for the treatment of MASH in South Korea. The Distribution Agreement further provides that we will deliver
finished product to CKD and grant CKD a right of first refusal to distribute Namodenoson for other indications for which we develop Namodenoson.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Distribution Agreement
provides for up to $3,000,000 in upfront and milestone payments payable with respect to the liver cancer indication and up to $6,000,000
with respect to the MASH indication. In addition, we are entitled to a transfer price of the higher of the manufacturing cost plus 10%
or 23% of net sales of Namodenoson following commercial launch in South Korea. To date, we have received a total of $2,000,000 from CKD,
$1,500,000 in upfront payments for the expansion of CKD&#8217;s existing agreement with us to include the rights to distribute Namodenoson
for the treatment of MASH in South Korea, and a further $500,000 for a milestone payment received in the third quarter of 2017 upon receipt
by CKD of a positive result from the preliminary review by the MFDS on obtaining orphan drug designation in South Korea.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 68; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Distribution Agreement
has an initial term of 10 years from first commercial sale of Namodenoson for the treatment of liver cancer or SL and is renewable for
additional 3-year periods unless either party gives notice of termination at least 6 months prior to the then-current term. The Distribution
Agreement may be terminated by CKD upon 30 days prior written notice if we fail to successfully complete our ongoing Phase II clinical
trial for Namodenoson and we may terminate the Distribution Agreement upon 30 days prior written notice if certain commercialization milestones
are not met by CKD or certain minimum quantities of sales are not made during the contract period. In addition, either party may terminate
the Distribution Agreement in the event of an uncured material breach or insolvency.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>Gebro Agreement</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 8, 2018, we entered
into a Distribution and Supply Agreement with Gebro, granting Gebro the exclusive right to distribute Piclidenoson in Spain, Switzerland,
Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis. In 2020, we ended our development of Piclidenoson for
rheumatoid arthritis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Distribution and
Supply Agreement, we are entitled to &#8364;1,500,000 upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#8364;300,000 upon initiation of the ACRobat Phase III clinical trial for the treatment of
rheumatoid arthritis and &#8364;300,000 upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii)
between &#8364;750,000 and &#8364;1,600,000 following first delivery of commercial launch quantities of Piclidenson for either the treatment
of rheumatoid arthritis or psoriasis, and (iii) between &#8364;300,000 and up to &#8364;4,025,000 upon meeting certain net sales. In addition,
following regulatory approval, we shall be entitled to double digit percentage royalties on net sales of Piclidenoson in the territories
and payment for the manufacturing Piclidenoson. To date, we have received a total of &#8364; 2,100,000 from Gebro in upfront and milestone
payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are initially responsible
for supplying Gebro with finished product for distribution and obtaining EMA and Swissmedic marketing approval while Gebro is responsible
for distributing, marketing and obtaining pricing and reimbursement approvals in the territories. The Distribution and Supply Agreement
has an initial term of fifteen years, automatically renewable for additional five-year periods and may be terminated in certain limited
circumstances including certain breaches of the agreement and failure to achieve certain minimum quantities of sales during the contract
period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>CMS Medical Agreement</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 6, 2018, we entered
into a License, Collaboration and Distribution Agreement with CMS for the exclusive right to develop, manufacture and commercialize Piclidenoson
for the treatment of rheumatoid arthritis and psoriasis and Namodenoson for the treatment of HCC and MASH in China (including Hong Kong,
Macau and Taiwan).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the License, Collaboration
and Distribution Agreement, we are entitled to $2,000,000 upon execution of the agreement plus milestone payments of up to $14,000,000
upon achieving certain regulatory milestones and payments of up to $58,500,000 upon achieving certain sales milestones, as follows: (i)
$500,000 upon the granting of the marketing authorization of Piclidenoson in the United States for rheumatoid arthritis; (ii) $500,000
upon the granting of the marketing authorization of Piclidenoson in the European Union for rheumatoid arthritis; (iii) $500,000 upon the
granting of the marketing authorization of Piclidenoson in the United States for psoriasis; (iv) $500,000 upon the granting of the marketing
authorization of Piclidenoson in the European Union for psoriasis; (v) $500,000 upon the granting of the marketing authorization of Namodenoson
in the United States for HCC; (vi) $500,000 upon the granting of the marketing authorization of Namodenoson in the European Union for
HCC; (vii) $500,000 upon the granting of the marketing authorization of Namodenoson in the United States for NAFLD/MASH; (viii) $500,000
upon the granting of the marketing authorization of Namodenoson in the European Union for NAFLD/MASH; (ix) $2,500,000 upon the issuance
of an imported drug license permitting the product to be imported into and marketed in China, or the IDL and granting of marketing authorization
of Piclidenoson in China for rheumatoid arthritis; (x) $2,500,000 upon the issuance of the IDL and granting of marketing authorization
of Piclidenoson in China for psoriasis; (xi) $2,500,000 upon the issuance of the IDL and granting of marketing authorization of Namodenoson
in China for HCC; (xii) $2,500,000 upon the issuance of the IDL and granting of marketing authorization of Namodenoson in China for NAFLD/MASH;
and (xiii) between $1,000,000 and up to $30,000,000 upon meeting certain net sales. In addition, following regulatory approval, we shall
be entitled to double-digit percentage royalties on net sales of Piclidenoson and Namodenoson in the licensed territories. To date, we
have received a total of $2,000,000 from CMS in upfront and milestone payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 69; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the agreement,
CMS will be responsible for the development of Piclidenoson and Namodenoson to obtain regulatory approval in China and shall be further
responsible for obtaining and maintaining regulatory approval in China for the indications described above. We may, at the option of CMS,
supply finished product to CMS.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The License, Collaboration
and Distribution Agreement shall continue in force unless earlier terminated and may be terminated in certain limited circumstances including
certain breaches of the agreement and failure to achieve certain minimum quantities of sales during the contract period. Following expiration
of the term of the agreement, the license granted shall become non-exclusive, fully paid, royalty free and irrevocable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>Kyongbo Pharm Agreement</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2019, we entered
into a License and Distribution Agreement with Kyongbo Pharm. Under the terms of agreement, Kyongbo Pharm, in exchange for exclusive distribution
rights to sell Piclidenoson in the treatment of psoriasis in South Korea, made a total upfront payment of $750,000 to us, with additional
payments of up to $3,250,000 upon achievement of certain milestones. We will also be entitled to a transfer price for delivering finished
product to Kyongbo Pharm. To date, we have received a total of $750,000 from Kyongbo Pharm in upfront and milestone payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>Ewopharma Agreement</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, we signed an
exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the
treatment of liver diseases namely, HCC, the most common form of liver cancer, and MASH. Under the terms of the distribution agreement,
Ewopharma we received $2.25 million upfront and are entitled to up to an additional $40.45 million payable upon the achievement of regulatory
and sales milestones plus 17.5% royalties on net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson
in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution
agreement to new indications that we may identify for its drug candidates. We will also be entitled to a transfer price for delivering
finished product to Ewopharma. In January 2024, we entered into an amendment to the distribution agreement with Ewopharma to expand the
distribution to include the indication of pancreatic cancer with respect to Namodenoson. To date, we have received a total of $2.25 million
from Ewopharma in upfront, milestone and royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;"><i>Development and Commercialization
Agreement and License Agreement with Vetbiolix</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 28, 2021, we entered
into the Vetbiolix Agreement with Vetbiolix, a France-based veterinary biotech company and veterinary partner, for the development of
Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. Vetbiolix had the exclusive right to Piclidenoson
in the veterinary osteoarthritis market for two years, during which time Vetbiolix conducted proof-of-concept studies and covered all
associated costs. The option to the licensed know-how and our patents was initially for a period of two years, which such period was extended
by additional 15 months in February 2024. The studies yielded positive data and Vetbiolix exercised its option to obtain the license from
us in September 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following Vetbiolix&#8217;s
activation of its option to obtain the license pursuant to the Vetbiolix Agreement, we granted Vetbiolix an exclusive option to utilize
the licensed know-how and certain of our patents solely for the purpose of supporting Vetbiolix&#8217;s research, development, manufacturing
and commercializing of its compounds and/or products in the field throughout the territory. Vetbiolix is obligated to pay us upfront and
milestone payments of &#8364;250,000 (approximately $271,000), which was received in October 2024. In addition, Vetbiolix agreed to pay
us payments equal to 30% for each upfront and milestone payment received from and sublicensee and 15%-40% royalties on net sales upon
regulatory approval for veterinary use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 70; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">Total Revenues by Category
of Activity and Geographic Markets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, we have generated
revenues from payments received pursuant to our out-licensing agreements with respect to Piclidenoson and Namodenoson. See &#8220;Item
4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2025, we recorded the following revenues: (i) $0.08 million as a result of recognition of a portion of an advance payment received
in January 2018 under the distribution agreement with Gebro; (ii) $0.08 million under the Distribution Agreement with CKD which was due
to the recognition of a portion of the advance payment received in December 2016 and April 2019 under the Distribution Agreement with
CKD; (iii) $0.04 million under the Distribution Agreement with Cipher; and (iv) $0.20 million under the Distribution Agreement with Ewopharma.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2024, we recorded the following revenues: (i) $0.07 million as a result of recognition of a portion of an advance payment received
in January 2018 under the distribution agreement with Gebro; (ii) $0.07 million under the Distribution Agreement with CKD which was due
to the recognition of a portion of the advance payment received in December 2016 and April 2019 under the Distribution Agreement with
CKD; (iii) $0.05 million under the Distribution Agreement with Cipher; (iv) $0.21 million under the Distribution Agreement with Ewopharma;
and (v) $0.27 million under the Vetbiolix Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2023, we recorded the following revenues: (i) $0.13 million as a result of recognition of a portion of an advance payment received
in January 2018 under the distribution agreement with Gebro; (ii) $0.19 million under the Distribution Agreement with CKD which was due
to the recognition of a portion of the advance payment received in December 2016 and April 2019 under the Distribution Agreement with
CKD; (iii) $0.08 million under the Distribution Agreement with Cipher; and (iv) $0.34 million under the Distribution Agreement with Ewopharma.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to generate future
revenues through our current and potential future out-licensing arrangements with respect to Piclidenoson and Namodenoson based on the
progress we make in our clinical trials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">Seasonality</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and operations
are generally not affected by seasonal fluctuations or factors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">Raw Materials and Suppliers</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the raw materials
that we require to manufacture Piclidenoson, Namodenoson and CF602 are widely available from numerous suppliers and are generally considered
to be generic industrial chemical supplies. We do not rely on a single or unique supplier for the current production of any therapeutic
small molecule in our pipeline.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">Manufacturing</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently manufacturing
our API through a leading CRO. The relevant suppliers of our drug products are compliant with both current Good Manufacturing Practices,
or cGMP, and current Good Laboratory Practices, or cGLP, and allow us to manufacture drug products for our current clinical trials. We
anticipate that we will continue to rely on third parties to produce our drug products for clinical trials and commercialization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that our drug candidates, if approved, can be manufactured in sufficient commercial quantities, in compliance with regulatory requirements
and at an acceptable cost. We and our contract manufacturers are, and will be, subject to extensive governmental regulation in connection
with the manufacture of any pharmaceutical products or medical devices. We and our contract manufacturers must ensure that all of the
processes, methods and equipment are compliant with cGMP for drugs on an ongoing basis, as mandated by the FDA and other regulatory authorities,
and conduct extensive audits of vendors, contract laboratories and suppliers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 71; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-align: justify"><span style="font-weight: bold;">Contract Research Organizations</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We outsource certain preclinical
and clinical development activities to CROs, which in pre-clinical studies work according to cGMP and cGLP. We believe our clinical CROs
comply with guidelines from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals
for Human Use, which attempt to harmonize the FDA and the EMA regulations and guidelines. We create and implement the drug development
plans and, during the preclinical and clinical phases of development, manage the CROs according to the specific requirements of the drug
candidate under development.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Marketing and Sales</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have any
marketing or sales capabilities. We intend to license to, or enter into strategic alliances with, larger companies in the pharmaceutical
business, which are equipped to market and/or sell our products, if any, through their well-developed marketing capabilities and distribution
networks. We intend to out-license some or all of our worldwide patent rights to more than one party to achieve the fullest development,
marketing and distribution of any products we develop.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Intellectual Property</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends in part
on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing
the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary
position by, among other filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements
that we believe are important to the development of our business. We also rely on trade secrets, know-how and continuing technological
innovation to develop and maintain our proprietary position.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Patents</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 26, 2026, we owned
13 patent families that, collectively, contain approximately 198 issued patents and pending patent applications in various countries around
the world relating to our two clinical candidates, Piclidenoson and Namodenoson, and our preclinical candidate, CF602. Patents related
to our drug candidates may provide future competitive advantages by providing exclusivity related to the composition of matter, formulation
and method of administration of the applicable compounds and could materially improve their value. The patent positions for our leading
drug candidates are described below. In addition, we filed a patent application which is currently pending in various countries around
the world concerning the use of cannabinoids for treatment of conditions associated with elevated expression of the A<sub>3</sub> adenosine
receptor.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to our product
candidates, we currently own patents and/or have patent applications pending in several countries around the world for the following families
of patents:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Specific dose to protect from psoriasis - a family of patents which pertains to the use of a specific dose level of Piclidenoson (total daily dose of 4.0 mg) for the treatment of psoriasis. Such a patent was granted in Israel, Japan, the United States, South Korea and Europe (by the EPO and validated in Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands, Spain, Sweden, Switzerland and the United Kingdom). The patent is set to expire in 2030, and in 2031 in the U.S. Each of the patents has a filing date of September 6, 2010 and a priority date of September 6, 2009.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Piclidenoson method of synthesis - a family of patents which pertain to the method for producing Piclidenoson. Such patents were granted in the United States, India, China, Japan, Israel and Europe (by the EPO and validated in Austria, Belgium, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Monaco, the Netherlands, Norway, Poland, Portugal, Spain, Sweden, Switzerland, Turkey and the United Kingdom). These patents are set to expire in 2028 and in 2031 in the U.S. Each patent has a filing date of March 13, 2008, and a priority date of March 14, 2007.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 72; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Osteoarthritis (OA) indication - a family of patents which pertain to the use of A3AR agonists for the treatment of OA. Such patents were granted in Europe (by the EPO and validated in Austria, Belgium, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, Netherlands and the United Kingdom), U.S., Australia, Canada, South Korea, China, Israel, Japan and Mexico. The patents are set to expire in November 29, 2026. These patents have a filing date of November 29, 2006, and a priority date of November 30, 2005.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Liver protection- a family of patents which pertains to the use of A3AR agonists for increasing liver cell division, intended to induce liver regeneration following injury or surgery. Such patents were granted in China, Israel, Japan, U.S. and Europe (by the EPO and validated in Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom and Turkey). The patents are set to expire in 2028. Each patent in this family has a filing date of October 22, 2008, and a priority date of October 15, 2007.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Erectile dysfunction - a family of patents which pertain to treatment of erectile dysfunction. This family includes granted patents in the United States, Europe (by the EPO as a unitary patent and also validated in Switzerland, and United Kingdom), Australia, Brazil China, Hong Kong, Canada, South Korea, Israel, Mexico and Japan. The patents have a filing date of August 8, 2013, the earliest priority date is August 8, 2012.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left">&#9679;</td><td style="text-align: justify">NAFLD/NASH - a family of patents which pertain to the use of
A3AR ligands for treatment of ectopic fat accumulation. This family includes granted patents in U.S., Israel, Europe (by the EPO and
validated in Austria, Belgium, Bulgaria, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia,
Lithuania, Luxembourg, the Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden,
Switzerland, United Kingdom and Turkey), South Korea, Hong Kong, China, Japan, Canada and Mexico. The patents have a filing date of November
22, 2016.</td>
</tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Obesity - a family of patents and patent applications which pertains to the use of A3AR ligand for reducing the level of adipocytes and specifically, for treating obesity. This family includes granted patents in Australia and the U.S., and patent applications in Brazil, Canada, China, Europe, Israel, Japan, Mexico, Korea and Hong Kong. These patents and patent applications have a filing date of January 5, 2020.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Cannabinoids - a family of patent applications pertaining to the use of cannabinoids for treating conditions and diseases that involve elevated expression of the A3AR. This family includes patent applications in India, Korea, and Thailand. These patent applications have a filing date of January 14, 2021. </td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Treatment of advanced cancer - a family of patent applications that makes use of A3AR ligands, particularly Namodenoson, for the treatment of advanced solid cancer, including advanced liver cancer. This family includes patent applications in the US, Australia, Brazil, Canada, Turkey, Japan, South Korea and Mexico. The US application was filed on December 28, 2022, claiming priority from a provisional application that was filed on December 29, 2021.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Treatment of joint inflammation - an Israeli patent application that makes use of A3AR ligands for the local treatment of articular arthritis. This patent application was filed on January 9, 2023, and abandoned. A new Israeli application was filed December 17, 2024, and abandoned. A new Israeli application was filed November 26, 2025, setting a new priority date. </td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Treatment of psoriasis - a family of patent applications that makes use of A3AR ligands for the treatment of psoriasis (6mg daily dose). This family includes patent applications in Argentina, Australia, Brazil, Canada, China, Europe, Israel, India, Japan, Mexico, Korea, South Africa, and the US. These patent applications have a filing date of June 29, 2023.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 73; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">Treatment of pancreatic cancer - a family of patent applications that makes use of A3AR ligands for the treatment of pancreatic cancer, including advanced forms. This family includes patent applications in China, Europe, Israel, Japan, Korea, and the US. These patent applications have a filing date of January 21, 2024.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Namodenoson method of synthesis - a family of patent applications which pertain to the method for producing Namodenoson. This family includes a PCT application and patent applications in Argentina, Brazil, China, India and the US. These patent applications have a filing date of March 10, 2025.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently hold an exclusive
license from Fondazione Telethon ETS (Italy) to a family of patent applications that makes use of A3AR ligands for the treatment of diseases
associated with OCRL gene disfunction, e.g., Dent disease and Lowe Syndrome. This family includes patent applications in Australia, Brazil,
Canada, China, Europe, Israel, India, Japan, Mexico, Korea, South Africa, EurAsia, and the US. These patent applications have a filing
date of July 1, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently hold an exclusive
license from Leiden University of the Netherlands to a family of patents and patent applications that relate to the allosteric modulators
of the A3AR, which includes the allosteric modulator CF602. This exclusive license relates to patents that were granted in the United
States, China, Japan, South Korea, India and in Europe (validated in, Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands,
Spain, Sweden, Switzerland and United Kingdom). In view of the approaching expiry date these patents were not renewed except for the US
patents whose latest expiry date is 2029.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our owned
and licensed patents provide broad and comprehensive coverage of our technology, and we intend to aggressively enforce our intellectual
property rights if necessary to preserve such rights and to gain the benefit of our investment. However, as a result of the termination
of the NIH license agreement between Can-Fite and NIH in June 2015 due to patent expiration, we no longer hold rights to a family of composition
of matter patents relating to Piclidenoson and Namodenoson that were licensed from NIH. Nevertheless, because Piclidenoson or Namodenoson
may be a NCE following approval of an NDA, we, if we are the first applicant to obtain NDA approval, may be entitled to five years of
data exclusivity in the United States with respect to such NCEs. Analogous data and market exclusivity provisions, of varying duration,
may be available in Europe and other foreign jurisdictions. However, we cannot be certain that we will be the first applicant to obtain
an FDA approval for any indication of Piclidenoson or Namodenoson and we cannot be certain that we will be entitled to NCE exclusivity.
In addition, we have discontinued the prosecution of a family of pending patent applications under joint ownership of Can-Fite and NIH
pertaining to the use of A3AR agonists for the treatment of uveitis. Such diminution of our proprietary position could have a material
adverse effect on our business, results of operation and financial condition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent positions of companies
like ours are generally uncertain and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary
position for our technology will depend on our success in obtaining effective claims and enforcing those claims once granted. We do not
know whether any of our patent applications or those patent applications that we license will result in the issuance of any patents. Our
issued patents and those that may issue in the future, or those licensed to us, may be challenged, narrowed, circumvented or found to
be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products or the length of term of
patent protection that we may have for our products. Neither we nor our licensors can be certain that we were the first to invent the
inventions claimed in our owned or licensed patents or patent applications. In addition, our competitors may independently develop similar
technologies or duplicate any technology developed by us, and the rights granted under any issued patents may not provide us with any
meaningful competitive advantages against these competitors. Furthermore, because of the extensive time required for development, testing
and regulatory review of a potential product, before any of our products can be commercialized, any related patent may expire or remain
in force for only a short period following commercialization, thereby reducing any advantage of the patent.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 74; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Trade Secrets</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may rely, in some circumstances,
on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology
and processes, in part, by confidentiality agreements and assignment of inventions agreements with our employees, consultants, scientific
advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical
security of our premises and physical and electronic security of our information technology systems. While we have confidence in these
individuals, organizations and systems, such agreements or security measures may be breached, and we may not have adequate remedies for
any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors or others.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Clinical and Scientific Advisory Board</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Clinical Advisory Board,
which consists of six members, an oncologist, dermatologist, and three hepatologists, who play an active role in consulting with us with
respect to clinical drug development. We call for Clinical Advisory Board meetings on an as-needed basis. The following table sets forth
certain information with respect to our Clinical Advisory Board members.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom">
<td style="width: 18%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-weight: bold;">Name</span></td>
<td style="width: 1%; text-align: justify">&#160;</td>
<td style="width: 81%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-weight: bold;">Position/Institutional Affiliation</span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-align: justify">Dr. Kim Papp</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">Head, Probity Medical Research Inc., Ontario, Canada</td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td>Dr. Salomon Stemmer</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva and Sackler Faculty of Medicine, Tel Aviv</td></tr>
<tr style="vertical-align: top; background-color: White">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="text-align: justify">Dr. Ohad Etzion</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">Director, Department of Gastroenterology and Liver Diseases at Soroka Medical Center in Israel</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Competition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmaceutical industry
is characterized by rapidly evolving technology, intense competition and a highly risky, costly and lengthy research and development process.
Adequate protection of intellectual property, successful product development, adequate funding and retention of skilled, experienced and
professional personnel are among the many factors critical to success in the pharmaceutical industry.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our technology platform is
based on the finding that the A3AR is highly expressed in pathological cells, such as various tumor cell types and inflammatory cells.
We believe that targeting the A3AR with synthetic and highly selective A3AR agonists, such as Piclidenoson and Namodenoson, and allosteric
modulators, such as CF602, induces anti-cancer and anti-inflammatory effects. Currently, our drug candidates, Piclidenoson, Namodenoson,
and CF602 are being developed to treat autoimmune inflammatory indications, oncology, and liver diseases as well as erectile dysfunction,
including but not limited to psoriasis, HCC, and NASH. Preclinical studies have also indicated that our drug candidates have the potential
to treat additional inflammatory diseases, such as Lowe Syndrome, Crohn&#8217;s disease, oncological diseases and viral diseases, such
as the JC virus, and obesity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the competition, however,
we believe that our drug candidates have unique characteristics and advantages over certain drugs currently available on the market and
under development to treat these indications. We believe that our pipeline of drug candidates has exhibited a potential for therapeutic
success with respect to the treatment of autoimmune-inflammatory, oncological and liver diseases. We believe that targeting the A3AR with
synthetic and highly selective A3AR agonists, such as Piclidenoson and Namodenoson, and allosteric modulators, such as CF602, induces
anti-cancer and anti-inflammatory effects.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the characteristics
of Piclidenoson, as exhibited in our clinical studies to date, including its good safety profile, clinical activity, simple and less frequent
delivery through oral administration and its low cost of production, position it well against the competition in the autoimmune-inflammatory
markets, including the psoriasis markets, where treatments, when available, often include injectable drugs, many of which can be highly
toxic, expensive and not always effective. For example, while TNF inhibitor therapies transformed the treatment for many patients, a substantial
percentage of patients (40% to 60%) do not respond to either a DMARD or biologic therapies (Simsek, 2010).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 75; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pre-clinical pharmacology
studies in different experimental animal models revealed that Piclidenoson acts as a DMARD, which, when coupled with its good safety profile,
makes it competitive in the psoriasis market. Our recent findings suggest that Piclidenoson might offer a superior efficacy and tolerability
profile, allowing patients to stay on drug longer and potentially leading to an improvement in response rate. Like Piclidenoson, Namodenoson
has a good safety profile, is orally administered and has a low cost of production, which we believe positions it well in the HCC market,
where only a handful of drugs have been approved by the FDA.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our human clinical
data suggests that A3AR may be a biological marker in that high A3AR expression prior to treatment has been predictive of good patient
response to our drug treatment. In fact, as a result of our research we have developed a simple blood assay to test for A3AR expression
as a predictive biological marker. We hold a patent with respect to the intellectual property related to such assay and are currently
analyzing A3AR expression levels in our Phase III psoriasis trial.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the other hand, other drugs
on the market, new drugs under development (including drugs that are in more advanced stages of development in comparison to our drug
pipeline) and additional drugs that were originally intended for other purposes, but were found effective for purposes targeted by us,
may all be competitive to the current drug candidates in our pipeline. In fact, some of these drugs are well established and accepted
among patients and physicians in their respective markets, are orally bioavailable, can be efficiently produced and marketed, and are
relatively safe. Moreover, other companies of various sizes engage in activities similar to ours. Most, if not all, of our competitors
have substantially greater financial and other resources available to them. Competitors include companies with marketed products and/or
an advanced research and development pipeline. The major competitors in the psoriasis therapeutic field include Amgen, J&amp;J, Pfizer,
Novartis, Abbvie, Eli Lilly, Bristol-Myers Squibb, UCB, Takeda, Alumis and more. Competitors in the HCC field include companies such as
Bayer, Exelixis, Merck, Roche, Eisai, AstraZeneca, BeOne Oncology, Novartis, and Bristol-Myers Squibb. Competitors in the metabolic dysfunction-associated
steatohepatitis, or MASH, field include companies such as Madrigal Pharmaceuticals, Novo Nordisk, Roche, GSK, Sagimet Biosciences, Inventiva
SA, Altimmune Inc, and Eli Lilly. Competitors in the pancreatic cancer field include Bristol-Myers Squibb, Ipsen, Revolution Medicines
among others. Competitors in the erectile dysfunction field include Pfizer, Eli Lilly, Bayer, and Petros Pharmaceuticals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, several companies
have reported the commencement of research projects related to the A3AR. Such companies include CV Therapeutics Inc. (which was acquired
by Gilead), King Pharmaceuticals R&amp;D Inv. (which was acquired by Pfizer), Hoechst Marion Roussel Inc., Novo Nordisk A/S and Inotek
Pharmaceuticals. However, to the best of our knowledge, there is no approved drug currently on the market which is similar to our A3AR
agonists, nor are we aware of any allosteric modulator in the A3AR product pipeline similar to our allosteric modulator with respect to
chemical profile and mechanism of action.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Piclidenoson for the Treatment of Psoriasis</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Psoriasis is a skin condition
that affects 2% to 3% of the general population according to the National Psoriasis Foundation. The disease is manifested by scaly plaques
on the skin and in the severe form has a major effect on the physical and emotional well-being of the patients. Topical agents are typically
used for mild disease, phototherapy for moderate disease, and systemic agents for severe disease. For moderate to severe cases, systemic
biologic drugs, delivered via intravenous injection, or IV, have dominated the market. According to the National Psoriasis Foundation,
common side effects of biologics include respiratory infections, flu-like symptoms, and injection site reactions while rare side effects
include serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes, blood disorders,
and certain types of cancer. We believe a significant need remains for novel oral and safe drugs for patients who do not respond to existing
therapies or for whom these therapies are unsuitable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The psoriasis therapeutic
market is dominated by biological drugs that are primarily administered via IV and have potential side effects. In January 2015, the FDA
approved Cosentyx (secukinumab) by Novartis. In March 2016, the FDA approved Taltz (ixekizumab) by Eli Lilly. In April 2019, the FDA approved
Skyrizi (risankizumab) by AbbVie. An oral small molecule inhibitor of phosphodiesterase 4, Otezla (Amgen), has gained sizable market share
as a result in part due to its convenience of oral dose and comparable efficacy to the biologic drugs. Recently, a new oral inhibitor
of TYK2 called SOTYKTU (Bristol) received U.S. FDA approval in September 2022. The psoriasis drug market is forecast to grow to $39 billion
by 2030, according to estimate by Grand View Research.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 76; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current common treatments
for psoriasis include topical and systemic drugs, steroids, immunosuppressive drugs such as Cyclosporine A by Novartis, MTX and biological
drugs. Biological drugs, such as Enbrel (etanercept) by Amgen and Pfizer, Remicade (infliximab) by Centocor, Humira (adalimumab) by Abbvie,
Stelara (ustekinumab) by Janssen, Otezla (aprelimast) byAmgen, Cosentyx (secukinumab) by Novartis and Taltz (ixekizumab) by Eli Lilly
have significant side effects, are expensive and patients are often not responsive. For example, some of these drugs have received an
FDA &#8220;black box&#8221; warning for increased risk of cancer in children and adolescents and risk of infection with Legionella and
Listeria bacteria.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Namodenoson for the Treatment of HCC</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the American
Cancer Society, HCC is the fifth most common form of cancer death in the U.S., the most common form of liver cancer in adults and the
third most common cause of cancer-related mortality worldwide, particularly in Asia. According to the American Cancer Society, more than
800,000 people are diagnosed with liver cancer each year throughout the world and more than 700,000 persons die from liver cancer each
year. Despite several new approvals in the HCC market, including immunotherapy agents, this remains a significant unmet medical need where
five year survival rates remain less than 20%. According to iHealthcareAnalyst, the HCC drug market is expected to reach $6.3 billion
by 2029.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Several therapies are in advanced
clinical development for HCC. Some drugs under development act as a single agent and some act in combination with Nexavar or approved
checkpoint inhibitors pembrolizumab, atezolizumab, and/or nivolumab. Moreover, some are first line treatments while others are second
line treatments. In addition, many existing approaches are used in the treatment of unresectable liver cancer, including alcohol injection,
radiofrequency ablation, chemoembolization, cryoablation and radiation therapy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Namodenoson for the Treatment of NASH (MASH)</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rates of NAFLD and NASH are
increasing in the United States in concert with increasing rates of obesity and diabetes. In fact, NASH is now the third leading cause
of liver transplant in the United States. It is estimated that 17-33% of Americans have fatty liver, with approximately one-third going
on to develop NASH. NASH is believed to affect 2-5% of adult Americans. In March 2024, Madrigal Pharmaceuticals announced FDA approval
of Rezdiffra (resmetirom) for the treatment of NASH with moderate to advanced liver fibrosis. By 2028, Vantage Market Research estimates
the addressable pharmaceutical market for NASH will reach $21.9 billion in size.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Namodenoson for the Treatment of Pancreatic
Cancer</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pancreatic cancer is increasing
in most industrialized countries. The American Cancer Society estimates that in 2024 there will be 66,440 people in the U.S. diagnosed
with pancreatic cancer. It also estimates 51,750 patients with pancreatic cancer will die in 2024. Pancreatic cancer accounts for about
3% of all cancers in the U.S. and about 8.5% of all cancer deaths. We face intense competition in the field of treating pancreatic cancer.
There are dozens of startups, smaller biotech companies, big pharma, and several academic institutions and cancer centers all trying to
improve the outcome for pancreatic cancer patients.&#160;There are several drugs already available and in the pipelines of pharmaceutical
companies worldwide, not the least of which is the combination of the drugs of Abraxane&#174;&#160;and gemcitabine. This is the primary
FDA-approved combination of drugs for treating advanced pancreatic cancer. Recently, the FDA approved Onivyde&#174; (Ipsen) in combination
with 5FU/LV for the treatment of first-line metastatic pancreatic cancer. Onivyde&#174; was previously approved in the second-line setting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Namodenoson for the Treatment of Canine
Arthritis</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The companion animal arthritis market size was valued at USD 3.75 billion
in 2025 and is projected to grow from USD 3.98 billion in 2026 to&#8239;USD 6.18 billion by 2034 at a CAGR of 6.93% during the forecast
period (2026-2034), as per Straits Research Analysis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The American Veterinary Medical
Association (AVMA) reported that 45.5% of U.S. households contained a dog in 2024, a percentage that had steadily increased over the past
three decades. The American Pet Products Association (APPA) estimates there are 65 million dogs in the U.S. and 900 million around the
globe, according to World Atlas, with 54 million in China and 106 million in Europe, according to the European Pet Food Industry. The
UK&#8217;s Canine Arthritis Management notes that 35% of all dogs and up to 80% of dogs over the age of 8 years old suffer from osteoarthritis
(OA). The market leading company is Zoetis, which markets Librela (bedinvetmab injection) for canine OA, which generated $581 million
in revenue in calendar 2024, growing 80% year-over-year from calendar 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 77; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>CF602 for the Treatment of Erectile Dysfunction</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Massachusetts
Male Aging Study in 1994, 52% of the respondents between the ages of 40 and 70 years old reported some degree of erectile dysfunction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The most popular class of
drug to treat erectile dysfunction is the phosphodiesterase type 5, or PDE5, inhibitors. These drugs block the degradative action of cyclic
guanosine monophosphate, or GMP, specific PDE5 on cyclic GMP in the smooth muscle cells lining the blood vessels supplying the corpus
cavernosum of the penis. An erection is caused by increased blood flow into the penis resulting from the relaxation of penile arteries
and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide from nerve terminals and endothelial cells,
which stimulates the synthesis of cyclic GMP in smooth muscle cells. The inhibition of PDE5 enhances erectile function by increasing the
concentration of cyclic GMP in the corpus cavernosum and pulmonary arteries.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unfortunately, the systemic
side effects of PDE5 inhibitors include a decrease in sitting blood pressure. This has resulted in warnings and precautions and contraindications
of use in patients already taking antihypertensive agents like nitrates or alpha-blockers. A study published in the American Journal of
Medicine (Selvin E., et al., 2007) found that persons with a history of heart disease, hypertension, and diabetes had a higher probability
of impotence. A second study published in the same journal (Shah NP., et al, 2015) notes that vascular erectile dysfunction is a powerful
marker of increased cardiovascular risk. We believe a significant market opportunity exists targeting erectile dysfunction patients contraindicated
for use of the market leading products, Viagra and Cialis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market Research Future estimates
the value of the erectile dysfunction therapeutic market to reach approximately $6.1 billion by 2030.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Insurance</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain directors&#8217;
and officers&#8217; liability insurance to protect our directors and officers against certain liabilities that may arise in connection
with their services to the Company. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also maintain worldwide
product and clinical trial liability insurance with coverage of approximately $5 million with respect to the Piclidenoson and Namodenoson
drugs used in clinical trials. We also procure additional insurance for each specific clinical trial which covers a certain number of
trial participants and which varies based on the particular clinical trial. Certain of such policies are based on the Declaration of Helsinki,
which is a set of ethical principles regarding human experimentation developed for the medical community by the World Medical Association,
and certain protocols of the Israeli Ministry of Health.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We procure cargo marine coverage
when we ship substances for our clinical studies. Such insurance is custom-fit to the special requirements of the applicable shipment,
such as temperature and/or climate sensitivity. If required, we ensure the substances to the extent they are stored in central depots
and at clinical sites.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our insurance
policies are adequate and customary for a business of our kind. However, because of the nature of our business, we cannot assure you that
we will be able to maintain insurance on a commercially reasonable basis or at all, or that any future claims will not exceed our insurance
coverage.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 78; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Environmental Matters</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to various
environmental, health and safety laws and regulations, including those governing air emissions, water and wastewater discharges, noise
emissions, the use, management and disposal of hazardous, radioactive and biological materials and wastes and the cleanup of contaminated
sites. We believe that our business, operations and facilities are being operated in compliance in all material respects with applicable
environmental and health and safety laws and regulations. Our laboratory personnel in Israel have ongoing communication with the Israeli
Ministry of Environmental Protection in order to verify compliance with relevant instructions and regulations. In addition, all of our
laboratory personnel participate in instruction on the proper handling of chemicals, including hazardous substances before commencing
employment, and during the course of their employment with us. In addition, all information with respect to any chemical substance that
we use is filed and stored as a Material Safety Data Sheet, as required by applicable environmental regulations. Based on information
currently available to us, we do not expect environmental costs and contingencies to have a material adverse effect on us. The operation
of our testing facilities, however, entails risks in these areas. Significant expenditures could be required in the future if these facilities
are required to comply with new or more stringent environmental or health and safety laws, regulations or requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Government Regulation and Funding</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate in a highly controlled
regulatory environment. Stringent regulations establish requirements relating to analytical, toxicological and clinical standards and
protocols in respect of the testing of pharmaceuticals. Regulations also cover research, development, manufacturing and reporting procedures,
both pre- and post-approval. In many markets, especially in Europe, marketing and pricing strategies are subject to national legislation
or administrative practices that include requirements to demonstrate not only the quality, safety and efficacy of a new product, but also
its cost-effectiveness relating to other treatment options. Failure to comply with regulations can result in stringent sanctions, including
product recalls, withdrawal of approvals, seizure of products and criminal prosecution.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before obtaining regulatory
approvals for the commercial sale of our product candidates, we must demonstrate through preclinical studies and clinical trials that
our product candidates are safe and effective. Historically, the results from preclinical studies and early clinical trials often have
not accurately predicted results of later clinical trials. In addition, a number of pharmaceutical products have shown promising results
in clinical trials but subsequently failed to establish sufficient safety and efficacy results to obtain necessary regulatory approvals.
We have incurred, and will continue to incur substantial expense for and devote a significant amount of time to, preclinical studies and
clinical trials. Many factors can delay the commencement and rate of completion of clinical trials, including the inability to recruit
patients at the expected rate, the inability to follow patients adequately after treatment, the failure to manufacture sufficient quantities
of materials used for clinical trials, and the emergence of unforeseen safety issues and governmental and regulatory delays. If a product
candidate fails to demonstrate safety and efficacy in clinical trials, this failure may delay development of other product candidates
and hinder our ability to conduct related preclinical studies and clinical trials. Additionally, as a result of these failures, we may
also be unable to obtain additional financing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Governmental authorities in
all major markets require that a new pharmaceutical product be approved or exempted from approval before it is marketed and have established
high standards for technical appraisal which can result in an expensive and lengthy approval process. The time to obtain approval varies
by country and some products are never approved. The lengthy process of conducting clinical trials, seeking approval and subsequent compliance
with applicable statutes and regulations, if approval is obtained, are very costly and require the expenditure of substantial resources.
These regulatory requirements impact our operations and differ from one country to another, so that securing the applicable regulatory
approvals of one country does not imply the approval of another country. The approval procedures involve high costs and are manpower intensive,
usually extend over many years and require highly skilled and professional resources.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 79; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the United States,
European Union and Israeli regulatory processes follow below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">United States</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
Public Health Service Act (IPHS) and the Federal Food, Drug, and Cosmetic Act (FDCA), as amended, and the regulations promulgated thereunder,
and other federal and state statutes and regulations govern, among other things, the safety and effectiveness standards for our products
and the raw materials and components used in the production of, testing, manufacture, labeling, storage, record keeping, approval, advertising
and promotion of our products on a product-by-product basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The failure to comply with
the applicable requirements at any time during the product development process, including preclinical testing, clinical testing, the approval
process or post-approval process, may subject an applicant to delays in the conduct of clinical trials, regulatory review and approval,
and/or administrative or judicial sanctions. These sanctions may include, but are not limited to, the FDA&#8217;s refusal to allow an
applicant to proceed with clinical testing, refusal to approve pending applications, license suspension or revocation, withdrawal of an
approval, warning letters, adverse publicity, customer notification, product recalls, product seizures, refusal to grant export or import
approval, total or partial suspension of production or distribution, consent decrees, injunctions, fines, and civil or criminal investigations
and penalties brought by the FDA or the U.S. Department of Justice, or other governmental entities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The steps usually required
to be taken before a new drug may be marketed in the U.S. generally include:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; font-size: 10pt">&#160;</td>
<td style="width: 24px; font-size: 10pt; text-align: justify">&#9679;</td>
<td style="font-size: 10pt; text-align: justify">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices regulation;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">approval by an independent Institutional Review Board, or IRB, or ethics committee at each treatment site before the trial is commenced;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">performance of adequate and well controlled human clinical trials to establish the safety, purity and potency of the proposed drug product candidate for its intended purpose;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">submission of data supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed labeling;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">preparation of and submission to the FDA of a New Drug Application, or NDA, after completion of all pivotal clinical trials;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">satisfactory completion of an FDA Advisory Committee review, if applicable;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP standards and to assure that the facilities, methods and controls are adequate to preserve the drug product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices, or GCP;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">satisfactory completion of any FDA audits of the non-clinical and clinical trial sites to assure compliance with GCP requirement sand the integrity of clinical data in support of the NDA;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">payment of user fees and securing FDA approval of the NDA for the proposed indication for use;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">compliance with any post-approval requirements, including risk evaluation and mitigation strategies, or REMS, and any post-approval studies required by the FDA.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 80; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical tests include
<i>in vitro</i> and <i>in vivo</i> evaluation of the product candidate, its chemistry, formulation and stability, and animal studies to
assess potential safety and efficacy. Certain preclinical tests must be conducted in compliance with good laboratory practice, or GLP,
regulations. Violations of these regulations can, in some cases, lead to invalidation of the studies, requiring them to be replicated.
After laboratory analysis and preclinical testing, a sponsor files an IND application including the results of the preclinical testing,
manufacturing information and analytical data, with FDA. An IND is a request for authorization from FDA to administer an investigational
new drug or biological product to humans to begin human testing. An IND becomes effective 30 days after FDA receives it, unless the FDA
notifies the sponsor that the clinical trial is subject to a clinical hold. FDA also may impose a clinical hold at any time during a clinical
trial. A sponsor may not proceed with a clinical trial that is subject to a clinical hold until the clinical hold has been lifted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials involve the
administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated under the supervision
of a qualified principal investigator in accordance with CGP requirements. Clinical studies are conducted under protocols detailing, among
other things, the objectives of the study, what types of patients may enter the study, schedules of tests and procedures, drugs, dosages,
and length of study, as well as the parameters to be used in monitoring safety, and the efficacy criteria to be evaluated. A protocol
for each clinical study and any subsequent protocol amendments must be submitted to the FDA as part of the IND process.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A sponsor who wishes to conduct
a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a clinical
trial outside the U.S. is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an
NDA so long as the clinical trial is conducted consistent with the spirit of GCP and in compliance with an international guideline for
the ethical conduct of clinical research known as the Declaration of Helsinki and/or the laws and regulations of the country or countries
in which the clinical trial is performed, whichever provides the greater protection to the participants in the clinical trial.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An IRB, either centrally or
individually, must also review each clinical trial at each institution at which the clinical trial will be conducted. The IRB will consider,
among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, the possible liability
of the institution, and, where appropriate, the protection of privacy of the human subjects. An IRB must operate in compliance with the
FDA regulations. The FDA, IRB, or the clinical trial sponsor, or the principal investigator may suspend or discontinue a clinical trial
at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements
or the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and
the requirements for informed consent. Additionally, some clinical studies are overseen by an independent group of qualified experts organized
by the clinical study sponsor, known as a data safety monitoring board or committee. This group recommends whether or not a trial may
move forward at designated check points based on access to certain data from the study. The clinical study sponsor may also suspend or
terminate a clinical trial based on evolving business objectives and/or competitive climate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Typically, clinical trials
are conducted in three sequential phases which are subject to numerous laws and regulatory requirements, including good clinical practice
requirements, or GCP, which include adequate monitoring, reporting, record keeping and informed consent. In Phase I, small clinical trials
are conducted, typically in healthy human volunteers, to determine the safety and proper dose ranges of product candidates. In Phase II,
clinical trials are generally conducted in patients with the targeted disease or condition to identify possible adverse effects and safety
risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimate dosage.
Multiple Phase II clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase
III clinical trials. In Phase III, clinical trials are conducted in an expanded population of patients with the targeted disease or condition
to demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase III trials
are designed to provide sufficient data for the statistically valid evidence of safety and efficacy to support approval, and if approved,
the basis for product labeling. Post-approval studies, sometimes referred to as Phase IV trials, may be conducted, voluntarily or as a
condition of approval, after initial product approval to obtain additional information about the drugs risks and benefits in patients
with the targeted disease or condition. The time and expense required for us to perform this clinical testing can vary and is substantial.
We cannot be certain that we will successfully complete Phase I, Phase II or Phase III testing of our product candidates within any specific
time period, if at all. Furthermore, the FDA, the Institutional Review Board responsible for approving and monitoring the clinical trials
at a given site, the Data Safety Monitoring Board, where one is used, or we may suspend the clinical trials at any time on various grounds,
including a finding that subjects or patients are exposed to unacceptable health risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 81; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the clinical data from
these clinical trials (Phases I, II and III) are deemed to support the safety and effectiveness of the candidate product for its intended
use, then we may proceed to seek to file with the FDA an NDA seeking approval to market a new drug for one or more specified intended
uses. We have not completed our clinical trials for any candidate product for any intended use and therefore, we cannot ascertain whether
the clinical data will support and justify filing an NDA. Nevertheless, if and when we are able to ascertain that the clinical data supports
and justifies filing an NDA, we intend to make such appropriate filings.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of the NDA is
to provide the FDA with sufficient information so that it can assess whether it ought to approve the candidate product for marketing in
the U.S. for specific intended uses. Under the Prescription Drug User Fee Act, or PDUFA, the submission of an NDA requires the payment
of substantial user fees, which the FDA adjusts on an annual basis, unless a waiver is granted. Moreover, no user fees are assessed on
NDAs for products designated as orphan drugs, unless the product as a non-orphan indication for use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NDA normally contains,
among other things, sections describing the chemistry, manufacturing, and controls, non-clinical pharmacology and toxicology, human pharmacokinetics
and bioavailability, microbiology, the results of the clinical trials, and the proposed labeling which contains, among other things, the
intended uses of the candidate product. FDA reviews the information submitted under the NDA to determine, among other things, whether
a product is safe and effective for its intended use and whether its manufacturing is compliant with cGMP requirements to assure and preserve
the product&#8217;s identity, strength, quality and purity. Before accepting an NDA for filing, FDA conducts a preliminary review of the
NDA, within 60 days of submission, to determine whether it is sufficiently complete to permit substantive review. Generally, under PDUFA
guidelines, FDA has a goal of ten months from the date of acceptance of a standard NDA for a new molecular entity to review and act on
the submission. The FDA does not always meet its PDUFA goal dates for standard and priority applications. The review process may often
be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may
be extended by three months if the FDA requests, or the applicant otherwise provides additional information or clarification regarding
information already provided in the submission within the last three months before the PDUFA goal date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may refer an application
for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific
experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions.
The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an
application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect
one or more clinical trial sites to assure compliance with GCP requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Manufacturers cannot take
any action to market any new drug or biologic product in the United States until an appropriate marketing application has been approved
by the FDA. The FDA has substantial discretion over the approval process and may disagree with a manufacturer&#8217;s interpretation of
the data submitted. The process may be significantly extended by requests for additional information or clarification regarding information
already provided. As part of this review, the FDA may refer the application to an appropriate advisory committee. An advisory committee
is a panel comprised of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a
recommendation as to whether an application should be approved and under what conditions. FDA is not bound by the recommendations of an
advisory committee; however, it takes into consideration the advisory committee&#8217;s recommendations when making decisions., typically
a panel of clinicians. As part of the approval process, FDA determines whether the manufacturer&#8217;s facilities and manufacturing processes
are in compliance with cGMP requirements and sufficient to ensure consistent production of the product within required specifications.
Prior to approving an NDA, FDA also may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 82; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the completion of
its evaluation of an NDA, FDA will issue an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercialization
of the drug for specified indications. A CRL informs the manufacturer that the review cycle for an application is complete and that the
application is not ready for approval in its present form. A CRL typically identifies specific deficiencies in the NDA that may require
additional clinical data or other significant requirements related to clinical trials or manufacturing. If FDA issues a CRL, the manufacturer
must resubmit the NDA with all deficiencies addressed or withdraw the NDA. Even if all requested data and information are submitted, FDA
ultimately may not approve the NDA.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Satisfaction of these and
other regulatory requirements typically takes several years, and the actual time required may vary substantially based upon the type,
complexity and novelty of the product. Government regulation may delay or prevent marketing of potential products for a considerable period
of time and impose costly procedures on our activities. We cannot be certain that the FDA or other regulatory agencies will approve any
of our products on a timely basis, if at all. Success in preclinical or early stage clinical trials does not assure success in later-stage
clinical trials. Even if a product receives regulatory approval, the approval may be significantly limited to specific indications or
uses and these limitations may adversely affect the commercial viability of the product. Delays in obtaining, or failures to obtain regulatory
approvals, would have a material adverse effect on our business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA approves a new
product, it may limit the approved indications for use of the product. Additionally, the FDA may call for further clinical trials (i.e.,
Phase IV trials) and require additional data on safety and effectiveness. FDA also may impose other conditions on approval including the
requirement for a risk evaluation and mitigation strategy, or REMS, designed to ensure the safe use of the drug. A REMS could include,
among other things, medication guides, physician communication plans, restricted distribution methods, and patient registries. Any of
these limitations on approval or marketing could restrict our ability to successfully commercialize products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also required to gain
separate approval for the use of an approved product as a treatment for indications other than those initially approved. In addition,
side effects or adverse events that are reported during clinical trials can delay, impede or prevent marketing approval. Similarly, adverse
events that are reported after marketing approval can result in additional limitations being placed on the product&#8217;s use and, potentially,
withdrawal of the product from the market. Any adverse event, either before or after marketing approval, can result in product liability
claims against us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an alternate path for FDA
approval of new indications or new formulations of previously-approved products, a company may file a Section 505(b)(2) NDA, instead of
a &#8220;stand-alone&#8221; or &#8220;full&#8221; NDA. Section 505(b)(2) of the FDCA, was enacted as part of the Drug Price Competition
and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Amendments. Section 505(b)(2) permits the submission of an
NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which
the applicant has not obtained a right of reference. Some examples of products that may be allowed to follow a 505(b)(2) path to approval
are drugs that have a new dosage form, strength, route of administration, formulation or indication. The Hatch-Waxman Amendments permit
the applicant to rely upon certain published nonclinical or clinical studies conducted for an approved product or the FDA&#8217;s conclusions
from prior review of such studies. The FDA may require companies to perform additional studies or measurements to support any changes
from the approved product. The FDA may then approve the new product for all or some of the labeled indications for which the reference
product has been approved, as well as for any new indication supported by the NDA. While references to nonclinical and clinical data not
generated by the applicant or for which the applicant does not have a right of reference are allowed, all development, process, stability,
qualification and validation data related to the manufacturing and quality of the new product must be included in an NDA submitted under
Section 505(b)(2).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that the Section
505(b)(2) applicant is relying on the FDA&#8217;s conclusions regarding studies conducted for an already approved product, the applicant
is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book publication. Specifically,
the applicant must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the
listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed
patent is invalid or will not be infringed by the new product. The Section 505(b)(2) application also will not be approved until any non-patent
exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the reference product
has expired. Thus, the Section 505(b)(2) applicant may invest a significant amount of time and expense in the development of its products
only to be subject to significant delay and patent litigation before its products may be commercialized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 83; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to regulating
and auditing human clinical trials, the FDA regulates and inspects equipment, facilities, laboratories and processes used in the manufacturing
and testing of such products prior to providing approval to market a product. If, after receiving FDA approval, we make a material change
in manufacturing equipment, location or process, additional regulatory review and approval may be required. We also must adhere to cGMP
regulations and product-specific regulations enforced by the FDA through its facilities inspection program. The FDA also conducts regular,
periodic visits to re-inspect our equipment, facilities, laboratories and processes following the initial approval. If, as a result of
these inspections, the FDA determines that our equipment, facilities, laboratories or processes do not comply with applicable FDA regulations
and conditions of product approval, the FDA may seek civil, criminal or administrative sanctions and/or remedies against us, including
the suspension of our manufacturing operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have currently received
no approvals to market our products from the FDA or other foreign regulators.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA is authorized to designate
certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening
disease or condition, or in the event of an emergency. These programs are fast track designation, breakthrough therapy designation and
priority review designation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, the FDA may
designate a product for fast track review if it is intended, whether alone or in combination with one or more other products, for the
treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for
such a disease or condition. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review
of sections of a fast track product&#8217;s application before the application is complete. This rolling review may be available if the
FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The
sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay
applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast track application does not begin until the last section
of the application is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation
is no longer supported by data emerging in the clinical trial process.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2012, Congress enacted
the Food and Drug Administration Safety and Innovation Act, or FDASIA. This law established a new regulatory scheme allowing for expedited
review of products designated as &#8220;breakthrough therapies.&#8221; A product may be designated as a breakthrough therapy if it is
intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition
and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or
more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take
certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process;
providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process;
assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient
manner.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may also designate
a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement
in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement
when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the
treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient
compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority
designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s
goal for taking action on a marketing application from ten months to six months.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 84; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Secretary of Health
and Human Services may additionally authorize unapproved drugs and biologics to be marketed in the event an actual or potential emergency
has been designated by the U.S. government. After an emergency has been designated, the FDA may issue an Emergency Use Authorization,
or EUA, for the use of a specific product based on criteria established by the FDCA. An EUA is product specific and is subject to specific
conditions and restrictions. Once the emergency underlying the EUA ends, then the EUA terminates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once regulatory approval for
marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with post-approval
regulatory requirements, including any post-approval requirements that the FDA may have imposed as a condition of approval. The sponsor
will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information
and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors
are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections
by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain
procedural and documentation requirements upon drug manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue
to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other
regulatory requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A product may also be subject
to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released
for distribution. If the product is subject to official release, the manufacturer must submit samples of each lot, together with a release
protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed
on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots
for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency, and effectiveness of pharmaceutical
products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After an approval is granted,
the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after
the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to
the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks;
or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">fines, warning letters or holds on post-approval clinical trials;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">product seizure or detention, or refusal to permit the import or export of products; or</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">injunctions or the imposition of civil or criminal penalties.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics may be promoted only for
the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the
laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses
may be subject to significant liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i></i></p><!-- Field: Page; Sequence: 85; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Orphan Drug Designation</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Orphan Drug
Act, FDA may grant special status, or orphan designation, to a drug intended to treat a rare disease or condition, which is a defined
as a disease or condition that affects fewer than 200,000 individuals in the United States, or there is no reasonable expectation that
the sales of the product will offset the cost of developing and making the drug available in the United States. A request for orphan drug
designation must be filed before the NDA is filed. Following the grant of orphan designation, FDA will publicly disclose the identity
of the therapeutic drug candidate and its potential orphan use. Orphan designation does not shorten the duration of the regulatory review
and approval process. The fact that the FDA has designated a drug as an orphan drug for a particular intended use does not mean that the
drug has been approved for marketing. Only after an NDA has been approved by the FDA is marketing appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a drug candidate with orphan
designation subsequently receives the first FDA approval for the disease or condition for which it has orphan designation, the drug is
entitled to a seven-year period of market exclusivity subject to certain exceptions (e.g., clinical superiority of a subsequent product).
This means that FDA may not approve another drug application authorizing another manufacturer to market the same drug for the same indication
for seven years. This does not preclude competitors from receiving approval of the same product that has orphan exclusivity for a different
indication or a different product for the same indication for which the orphan product has exclusivity. The orphan designation of a drug
also provides the sponsor with certain financial incentives including tax credit, waiver of PDUFA fees, and access to certain grant funding
for orphan products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2012, the FDA
granted orphan drug status for the active moiety, or the part of the drug that is responsible for the physiological or pharmacological
action of the drug substance, of Namodenoson for the treatment of HCC. In October 2015, the EMA granted Namodenoson orphan drug designation
for the treatment of HCC. Subsequently, in October 2024, the FDA granted orphan drug status for the indication of pancreatic cancer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other U.S. Healthcare Laws and Compliance Requirements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For products distributed in
the United States, we will also be subject to additional healthcare regulation and enforcement by the federal government and the states
in which we conduct our business. Applicable federal and state healthcare laws and regulations include the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">The federal anti-kickback law, which governs federal healthcare programs (e.g., Medicare, Medicaid), makes it illegal to solicit, offer, receive or pay any remuneration in exchange for, or to induce, the referral of business, including the purchase or prescription of a particular drug. Many states have similar laws that are not restricted to federal healthcare programs. A person or entity does not need to have actual knowledge of the federal anti-kickback statute or specific intent to violate it to have committed a violation; in addition, items or services resulting from a violation of the federal anti-kickback statute may constitute a false or fraudulent claim for purposes of the False Claims Act;</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td style="text-align: justify">&#9679;</td>
<td style="text-align: justify">The Ethics in Patient Referrals Act, commonly referred to as the Stark Law, and its corresponding regulations, prohibit physicians from referring patients for designated health services (including outpatient drugs) reimbursed under the Medicare or Medicaid programs to entities with which the physicians or their immediate family members have a financial relationship or an ownership interest, subject to narrow regulatory exceptions, and prohibits those entities from submitting claims to Medicare or Medicaid for payment of items or services provided to a referred beneficiary;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; font-size: 10pt">&#160;</td>
<td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Federal and state false claims laws prohibit anyone
    from knowingly and willingly presenting, or causing to be presented for payment to third party payers (including Medicare and Medicaid),
    claims for reimbursement, including claims for the sale of drugs or services, that are false or fraudulent, claims for items or services
    not provided as claimed, or claims for medically unnecessary items or services. If the government or a whistleblower were to allege that
    we violated these laws there could be a material adverse effect on us, including our stock price. Even an unsuccessful challenge could
    cause adverse publicity and be costly to respond to, which could have a materially adverse effect on our business, results of operations
    and financial condition;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Civil Monetary Penalties Law prohibits, among
    other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or
    for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know
    is likely to influence the beneficiary&#8217;s selection of a particular supplier of items or services reimbursable by a federal or state
    governmental program;&#160;</p></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Health Insurance Portability and Accountability Act of 1996, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. This statute also prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items, or services;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 86; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for health care benefits, items or services;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; font-size: 10pt">&#160;</td>
<td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which requires specified manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other &#8220;transfers of value&#8221; made to physicians and other providers. All such reported information is publicly available; and</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Analogous state laws and regulations, such as state anti-kickback&#160;and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental&#160;third-party&#160;payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of the breadth of
these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our future business
activities could be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements with third parties
will comply with applicable laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude
that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse
or other health care laws and regulations. A finding of liability under these laws can have significant adverse financial implications
for us and can result in payment of large penalties and possible exclusion from federal healthcare programs. We will consult counsel concerning
the potential application of these and other laws to our business and our sales, marketing and other activities and will make good faith
efforts to comply with them. However, given their broad reach and the increasing attention given by law enforcement authorities, we cannot
assure you that some of our activities will not be challenged or deemed to violate some of these laws.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Reimbursement</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of our product candidates
in the United States may depend, in part, on the extent to which the costs of the product candidates may be covered by third-party&#160;payers,
such as government health programs, commercial insurance and managed health care organizations. These third-party&#160;payers are increasingly
challenging the prices charged for medical products and services. Additionally, the containment of health care costs has become a priority
of federal and state governments, and the prices of drugs have been a focus in this effort. The United States government, state legislatures
and foreign governments have shown significant interest in implementing cost-containment&#160;programs, including price controls, restrictions
on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment&#160;measures,
and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and
results. If these third-party&#160;payers do not consider our product candidates to be cost-effective&#160;compared to other available
therapies, they may not cover our product candidates after approval as a benefit under their plans or, if they do, the level of payment
may not be sufficient to allow us to sell our product candidates on a profitable basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to secure coverage
and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order
to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA, EMA or other
comparable regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. A payer&#8217;s decision
to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Third-party reimbursement
may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product
development.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 87; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pricing and reimbursement
schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price
has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product
candidate to currently available therapies. The conduct of such studies could be expensive and result in delays in our commercializing
efforts. The EU provides options for its member states to restrict the range of drug products for which their national health insurance
systems provide reimbursement and to control the prices of medicinal products for human use. EU member states may approve a specific price
for a drug product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product
on the market. Other member states allow companies to fix their own prices for drug products but monitor and control company profits.
The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly
high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets
exert competitive pressure that may reduce pricing within a country. There can be no assurance that any country that has price controls
or reimbursement limitations for drug products will allow favorable reimbursement and pricing arrangements for any of our products.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The marketability of any products
for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate
coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase
the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. Even
if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable
coverage policies and reimbursement rates may be implemented in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Healthcare Reform</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been and continue to be a number of significant legislative initiatives to contain healthcare costs. The ACA was enacted in the United
States in March 2010 and contains provisions that may reduce the profitability of drug products, including, for example, increased rebates
for drugs subject to the Medicaid Drug Rebate Program, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts
for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care
programs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative changes have been proposed and adopted
since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective
April 1, 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through 2031, unless additional Congressional
action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare
payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have
a material adverse effect on customers for our drugs, if approved, and, accordingly, our financial operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, recently there has been heightened governmental scrutiny
over the manner in which manufacturers set prices for their commercial products. There have been several recent U.S. Congressional inquiries
and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review
the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program
reimbursement methodologies for drugs. The FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance
for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department of Health and
Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers
to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The
rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee
arrangements between pharmacy benefit managers and manufacturers. On August 16, 2022, President Biden signed the Inflation Reduction Act
of 2022, which includes several provisions to lower prescription drug costs for people with Medicare, including price negotiation requirements
for drugs covered under Medicare, rebate requirements when drug prices rise faster than inflation, and a cap on out-of-pocket spending
for Medicare Part D enrollees. In 2025, HHS began implementation of &#8220;Most Favored Nation&#8221; drug pricing by setting the Medicare
price of single-source brand drugs without generic or biosimilar competition to the lowest price available in wealthy countries with a
per capita GDP of at least 60% of that in the United States. On February 3, 2026, Congress enacted the Consolidated Appropriations Act
of 2026, which limits the fees charged by pharmacy benefit managers, as well as requiring pharmacy benefit managers to fully pass through
manufacturer rebates to a Medicare Part D plan sponsor. At the state level, legislatures have increasingly passed legislation and implemented
regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage
importation from other countries and bulk purchasing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 88; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although a number of these,
and other proposed measures may require authorization through additional legislation to become effective, Congress has indicated that
it will continue to seek new legislative measures to control drug costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CMS issued a final rule, effective on July 9, 2019, that requires direct-to-consumer
advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to
include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product if it is equal to or greater
than $35 for a monthly supply or usual course of treatment. Prescription drugs and biological products that are in violation of these
requirements will be included on a public list. In addition, in December 2022, the Federal Trade Commission (FTC) released its Health
Products Compliance Guidance that is intended to ensure health-related product claims, including drugs and biologics, are truthful, not
misleading and supported by science. The FTC also updated its Guides Concerning the Use of Endorsements and Testimonials in Advertising
that raises the growth of social media in marketing. On September 9, 2025, the FDA began requiring pharmaceutical advertisements to include
full safety warnings during direct-to-consumer advertisements, instead of footnoting such information. Additionally, the FDA expanded
its oversight on social medial promotional activities, including influencer partnerships, algorithm-driven targeted advertising, and AI-generated
health content, to ensure compliance with the FDA&#8217;s advertisement requirements. The FDA has indicated it will begin enforcement
actions for any advertisement violations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any adopted health reform
measure could reduce the ultimate demand for our products, if approved, or put pressure on our product pricing. Individual states in the
United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical
products and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state
and federal healthcare reform measures will be adopted in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that additional
state and federal healthcare reform measures, as well as legal changes by foreign governments, will be adopted in the future, any of which
could limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our product
candidates or additional pricing pressures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">European Union</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to market any product
outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions
regarding quality, safety and efficacy that govern, among other things, clinical trials, marketing authorization, commercial sales and
distribution of drug products. Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals
by the comparable non-U.S. regulatory authorities before it can commence clinical trials or marketing of the product in those countries
or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing
and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from
and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory
approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the
regulatory process in others.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Regulation and Marketing Authorization in
the European Union</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The European Medicines Agency,
or EMA, is the scientific agency of the European Union, or EU, that coordinates the evaluation and monitoring of new and approved medicinal
products such as drugs and biologics. It is responsible for the scientific evaluation of centralized applications for EU marketing authorizations,
as well as the development of technical guidance and the provision of scientific advice to sponsors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process governing approval of medicinal products in the European
Union follows essentially comparable lines as in the United States and, likewise, generally involves satisfactorily completing each of
the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the applicable E.U. Good Laboratory Practice regulations;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify; font-size: 10pt">&#160;</td>
<td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the relevant national authorities of a clinical trial authorization, or CTA, which must be approved before human clinical trials may begin;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 89; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">submission to the relevant competent authorities of a Marketing Authorisation Application, or MAA, which includes the data supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed labelling;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility or facilities, including those of third parties, at which the product is produced to assess compliance with strictly enforced current cGMP;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">potential audits of the non-clinical and clinical trial sites that generated the data in support of the MAA; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">review and approval by the relevant competent authority of the MAA before any commercial marketing, sale or shipment of the product.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Preclinical Studies</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical tests include
laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal studies, in
order to assess the potential safety and efficacy of the product. The conduct of the preclinical tests and formulation of the compounds
for testing must comply with the relevant EU and/or Member States&#8217; regulations and requirements. The results of the preclinical
tests, together with relevant manufacturing information and analytical data, are submitted as part of the CTA.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical Trial Authorization</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials in the EU
are regulated under Regulation (EU) 536/2014 (CTR), as amended. As opposed to the previous Directive 2001/20/EC (CTD), which as an EU
directive was not directly applicable in the member states, the CTR has immediate effect for the whole EU and did not have to be transposed
into national law. While national laws implementing the CTD varied to a great extent, the CTR provides for a significant further harmonization
of the law governing clinical trials in the EU. After significant delay, the CTR became applicable on January 31, 2022. The CTR harmonizes
the assessment and supervision processes for clinical trials throughout the EU via the Clinical Trials Information System (CTIS), which
includes a centralized EU portal and database for clinical trials. From January 31, 2023&#160;onwards,&#160;clinical trial&#160;sponsors
need to apply to start a&#160;clinical trial&#160;via CTIS. From January 31, 2025, any trials previously approved under the CTD&#160;that
continue to run after such date, will need to comply with CTR and&#160;their sponsors must have recorded the required information on&#160;such
trials in&#160;CTIS. The CTR provides inter alia:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Consistent rules for conducting clinical trials throughout the EU;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Making information on the authorization, conduct and results of each clinical trial carried out in the EU publicly available;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Harmonized electronic submission and assessment process for clinical trials conducted in multiple member states;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Improved collaboration, information sharing and decision-making between and within member states;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Increased transparency of information on clinical trials; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Higher standards of safety for all participants in EU clinical trials.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 90; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The authorization of a clinical
trial (Phase I-III) in an EU member state requires the submission of a CTA via CTIS. The application will be reviewed by the competent
authorities of the member states where the trial is supposed to take place. The application and approval process is conducted by the member
states under the cooperation system set forth in the CTR. Particularities under member states&#8217; national law still apply to some
extent. In general, the CTA should include, among other documents, the study protocol, results of the nonclinical studies and manufacturing
information and analytical results. Also, the sponsor has to suggest one of the concerned member states as reporting member state. The
CTR aims at speeding up the validation and review of clinical trial applications and therefore provides strict deadlines.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Marketing Authorization</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Authorization to market a
product in the member states of the European Union proceeds under one of four procedures: a centralized authorization procedure, a mutual
recognition procedure, a decentralized procedure or a national procedure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Centralized Authorization Procedure</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The centralized procedure
enables applicants to obtain a marketing authorization that is valid in all EU member states based on a single application. Certain medicinal
products, including products developed by means of biotechnological processes, must undergo the centralized authorization procedure for
marketing authorization which, if granted by the European Commission, is automatically valid in all 28 EU member states, as well as member
states of the European Economic Area (EEA). The EMA and the European Commission administer this centralized authorization procedure pursuant
to Regulation (EC) No 726/2004.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Regulation (EC)
No 726/2004, this procedure is inter alia mandatory for:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">medicinal products developed by means of one of the following biotechnological processes:</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">recombinant DNA technology;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including transformed mammalian cells; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">hybridoma and monoclonal antibody methods;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">advanced therapy medicinal products as defined in Article 2 of Regulation (EC) No. 1394/2007 on advanced therapy medicinal products;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">medicinal products for human use containing a new active substance that, on the date of effectiveness of this regulation, was not authorized in the European Union, and for which the therapeutic indication is the treatment of any of the following diseases:</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">acquired immune deficiency syndrome;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">cancer;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">neurodegenerative disorder;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">diabetes;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">auto-immune diseases and other immune dysfunctions;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">viral diseases; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">medicinal products that are designated as orphan medicinal products pursuant to Regulation (EC) No 141/2000.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The centralized authorization
procedure is optional for other medicinal products if they contain a new active substance or if the applicant shows that the medicinal
product concerned constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorization in
accordance with Regulation (EC) No 726/2004 is in the interest of patients' health at EU level.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i></i></p><!-- Field: Page; Sequence: 91; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Administrative Procedure</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the centralized authorization procedure, the EMA&#8217;s Committee
for Human Medicinal Products, or CHMP, serves as the scientific committee that renders opinions about the safety, efficacy and quality
of medicinal products for human use on behalf of the EMA. The CHMP is composed of experts nominated by each member state&#8217;s national
authority for medicinal products, with experts appointed to act as Rapporteur for the co-ordination of the evaluation with the possible
assistance of a further member of the Committee acting as a Co-Rapporteur. After approval, the Rapporteur(s) continue to monitor the product
throughout its life cycle. The CHMP has 210 days to adopt an opinion as to whether a marketing authorization should be granted. The process
usually takes longer in case additional information is requested, which triggers clock-stops in the procedural timelines. The process
is complex and involves extensive consultation with the regulatory authorities of member states and a number of experts. When an application
is submitted for a marketing authorization in respect of a drug that is of major interest from the point of view of public health and
in particular from the viewpoint of therapeutic innovation, the applicant may pursuant to Article 14(9) Regulation (EC) No 726/20042,
as amended, request an accelerated assessment procedure. If the CHMP accepts such request, the time-limit of 210 days will be reduced
to 150 days but it is possible that the CHMP can revert to the standard time-limit for the centralized procedure if it considers that
it is no longer appropriate to conduct an accelerated assessment. Once the procedure is completed, a European Public Assessment Report,
or EPAR, is produced. If the opinion is negative, information is given as to the grounds on which this conclusion was reached. After the
adoption of the CHMP opinion, a decision on the MAA must be adopted by the European Commission, after consulting the EU member states.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Conditional Approval</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In specific circumstances, EU legislation (Article 14a Regulation (EC)
No 726/2004, as amended and Regulation (EC) No 507/2006 on Conditional Marketing Authorisations for Medicinal Products for Human Use)
enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an
application for a full marketing authorization. Such conditional approvals may be granted for medicinal products intended for the treatment,
prevention or medical diagnosis of seriously debilitating or life-threatening diseases (including medicines designated as orphan medicinal
products) if (1) the risk-benefit balance of the product candidate is positive, (2) it is likely that the applicant will be in a position
to provide the required comprehensive clinical trial data post-authorization, (3) the product fulfills unmet medical needs and (4) the
benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in
the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled
by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies with a view to confirming
that the risk-benefit balance is favorable. Conditional marketing authorizations are valid for one year, and may be renewed annually,
if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific
obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications
for a conditional marketing authorization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Marketing Authorization under Exceptional Circumstances</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Article 14(8) Regulation
(EC) No 726/2004, as amended, products for which the applicant can demonstrate that comprehensive data (in line with the requirements
laid down in Annex I of Directive 2001/83/EC, as amended) cannot be provided (for objective, verifiable reasons) might be eligible for
marketing authorization under exceptional circumstances. This type of authorization is reviewed annually to reassess the risk-benefit
balance. The fulfillment of any specific procedures/obligations imposed as part of the marketing authorization under exceptional circumstances
is aimed at the provision of information on the safe and effective use of the product and will normally not lead to a standard marketing
authorization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 92; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Market Authorizations Granted by Authorities
of EU Member States</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, if the centralized
procedure is not followed, there are three alternative procedures as prescribed in Directive 2001/83/EC, as amended:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify; font-size: 10pt">&#160;</td>
<td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The decentralized procedure allows applicants to file identical applications to several EU member states and receive simultaneous national approvals based on the recognition by EU member states of an assessment by a reference member state;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">The national procedure is only available for products intended to be authorized in a single E.U. member state; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify; font-size: 10pt">&#160;</td>
<td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A mutual recognition procedure similar to the decentralized procedure is available when a marketing authorization has already been obtained in at least one EU member state.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A marketing authorization
may be granted only to an applicant established in the European Union.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Pediatric Studies</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to obtaining a marketing
authorization in the European Union, applicants have to demonstrate compliance with all measures included in an EMA-approved Pediatric
Investigation Plan, or PIP, covering all subsets of the paediatric population, unless the EMA has granted a product-specific waiver, a
class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization
procedures are set forth in Regulation (EC) No 1902/2006, which is referred to as the Pediatric Regulation. This requirement also applies
when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized.
The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine
in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when
development of a medicine in children is not needed or is not appropriate, such as for diseases that only occurs in adult populations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before a marketing authorization
application can be filed, or an existing marketing authorization can be amended, the competent authority responsible for granting marketing
authorization verifies whether an application for marketing authorization or variation complies with the requirements laid down in Articles
7 and 8 of the Pediatric Regulation and whether a pediatric use marketing authorization application complies with the agreed pediatric
investigation plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Periods of Authorization and Renewals</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A marketing authorization
is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation
of the risk-benefit balance by the competent authority of the authorizing member state. To this end, the marketing authorization holder
must provide the EMA or the competent authority (with respect to the relevant procedure for marketing authorization) with a consolidated
version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization
was granted, at least nine months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is
valid for an unlimited period, unless the European Commission decides, on justified grounds relating to pharmacovigilance, to proceed
with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the EU market (in
case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid
(the so-called sunset clause).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i></i></p><!-- Field: Page; Sequence: 93; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Orphan Drug Designation and Exclusivity</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Regulation (EC)
No 141/2000, as amended, and Regulation (EC) No. 847/2000, as amended, the European Commission can grant such orphan medicinal product
designation to products for which the sponsor can establish that it is intended for the diagnosis, prevention or treatment of a life-threatening
or chronically debilitating condition affecting not more than five in 10,000 people in the European Union, or a life threatening, seriously
debilitating or serious and chronic condition in the European Union and with regards to that without incentives it is unlikely that sales
of the drug in the European Union would generate a sufficient return to justify the necessary investment. In addition, the sponsor must
establish that there is no other satisfactory method approved in the European Union of diagnosing, preventing or treating the condition,
or if such a method exists, the proposed orphan drug will be of significant benefit to patients.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orphan drug designation is
not a marketing authorization. It is a designation that provides a number of benefits and obligations, including fee reductions, regulatory
assistance, and the obligation to apply for the marketing authorization in the centralized process pursuant to Regulation (EC) No 726/2004
as well as ten years of market exclusivity following a marketing authorization. During this market exclusivity period, neither the EMA,
the European Commission nor the member states can accept an application or grant a marketing authorization for a &#8220;similar medicinal
product.&#8221; A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances
as those contained in an authorized orphan medicinal product and that is intended for the same therapeutic indication. The market exclusivity
period for the authorized therapeutic indication may be reduced to six years if, at the end of the fifth year, it is established that
the orphan designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify
maintenance of market exclusivity. In addition, a competing similar medicinal product may in limited circumstances be authorized prior
to the expiration of the market exclusivity period, including if the marketing authorization holder has given his consent to the second
applicant or the marketing authorization holder is unable to supply sufficient quantities of the product or if the competing product is
shown to be safer, more effective or otherwise clinically superior to the already approved orphan drug. Furthermore, a product can lose
orphan designation, and the related benefits, prior to us obtaining a marketing authorization if it is demonstrated that the orphan designation
criteria are no longer met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the MAA of a medicinal
product designated as an orphan drug includes the results of all studies conducted in compliance with an agreed PIP, and a corresponding
statement is subsequently included in the marketing authorization granted, the ten-year period of market exclusivity will be extended
by two additional years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Regulatory Data and Market Protection; Supplementary
Protection Certificates </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">EU legislation also provides
for a system of regulatory data and market exclusivity. According to Article 14(11) of Regulation (EC) No 726/2004, as amended, and Article
10(1) of Directive 2001/83/EC, as amended, upon receiving marketing authorization, new medicinal products approved on the basis of a complete
independent data package benefit from eight years of data exclusivity and ten years of market exclusivity. Data exclusivity prevents regulatory
authorities in the European Union from referencing the innovator&#8217;s data to assess a generic (abbreviated) application. During the
ten-year period of market exclusivity, a generic marketing authorization can be submitted, and the innovator&#8217;s data may be referenced,
but no generic medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended
to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder, or MAH, obtains an authorization
for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a
significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new medicinal product and
the innovator is able to gain the period of data exclusivity, another company nevertheless could also market another version of the medicinal
product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests,
preclinical tests and clinical trials. However, products designated as orphan medicinal products enjoy, upon receiving marketing authorization,
a period of ten years of orphan market exclusivity-see also &#8220;<i>Orphan Drug Designation and Exclusivity</i>&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depending upon the timing
and duration of the E.U. marketing authorization process, products may be eligible for up to five years&#8217; supplementary protection
certificates, or SPCs, pursuant to Regulation (EC) No 469/2009, as amended. A six-month additional extension is available in accordance
with Regulation (EC) No 1901/2006 if the SPC relates to a medicinal product for children for which data has been submitted according to
a Paediatric Investigation Plan (PIP). Such SPCs extend the rights under the basic patent for the drug (see below sub &#8220;<i>Patent
Term Extension&#8221;</i>).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 94; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Regulatory Requirements After a Marketing Authorization
has been Obtained</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we obtain authorization
for a medicinal product in the European Union, we will be required to comply with a range of requirements applicable to the manufacturing,
marketing, promotion and sale of medicinal products:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Pharmacovigilance and other requirements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will, for example, have to comply with the EU&#8217;s stringent
pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be
imposed. Other requirements relate, for example, to the manufacturing of products and APIs in accordance with good manufacturing practice
standards. EU regulators may conduct inspections to verify our compliance with applicable requirements, and we will have to continue to
expend time, money and effort to remain compliant. Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance,
and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties
in the European Union. Similarly, failure to comply with the EU&#8217;s requirements regarding the protection of individual personal data
can also lead to significant penalties and sanctions. Individual EU member states may also impose various sanctions and penalties in case
we do not comply with locally applicable requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Manufacturing</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacturing of authorized drugs, for which a separate manufacturer&#8217;s
license is mandatory, must be conducted in strict compliance with the European Commission&#8217;s Good Manufacturing Practices, or cGMP,
requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls
used in manufacturing, processing and packing of drugs to assure their safety and identity. Importers, manufacturers and distributors
of active substances who are established in the Union shall register their activity with the competent authority of the Member State in
which they are established. Member States enter the certificates of good manufacturing practice and good distribution practices which
they issue in the EudraGMP database managed by EMA. The EMA may have a coordinating role in inspections concerning the compliance of manufacturers
with regulatory requirements while the responsibility for carrying inspections out rests with the member states' competent authorities
under whose responsibility the manufacturer falls. Failure to comply with these requirements could interrupt supply and result in delays,
unanticipated costs and lost revenues, and could subject the manufacturer to potential legal or regulatory action, including but not limited
to warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil and criminal penalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Marketing and Promotion</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The marketing and promotion
of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs
and/or the general public, are strictly regulated in the European Union under Directive 2001/83/EC, as amended. The applicable regulations
aim to ensure that information provided by holders of marketing authorizations regarding their products is truthful, balanced and accurately
reflects the safety and efficacy claims authorized by the European Commission or by the competent authority of the authorizing member
state. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential
civil and criminal penalties and liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Patent Term Extension</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to compensate the patentee for delays in obtaining a marketing
authorization for a patented product, a supplementary certificate, or SPC, may be granted extending the exclusivity period for that specific
product by up to five years. Applications for SPCs must be made to the relevant competent authority in each EU member state pursuant to
Article 9 of Regulation (EC) No 469/2009 and the granted certificates are valid only in the member state of grant. An application has
to be made by the patent owner within six months of the first marketing authorization being granted in the European Union (assuming the
patent in question has not expired, lapsed or been revoked) or within six months of the grant of the patent (if the marketing authorization
is granted first). In the context of SPCs, the term &#8220;product&#8221; means the active ingredient or combination of active ingredients
for a medicinal product and the term &#8220;basic patent&#8221; means a patent which protects a product as such, a process to obtain a
product or an application of a product, and which is designated by its holder for the purpose of the procedure for grant of a certificate.
The duration of an SPC is calculated as the difference between the patent&#8217;s filing date and the date of the first marketing authorization,
minus five years, subject to a maximum term of five years.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A six month pediatric extension
of an SPC may be obtained where the patentee has carried out an agreed pediatric investigation plan, the authorized product information
includes information on the results of the studies and the product is authorized in all member states of the European Union.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 95; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>United Kingdom</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The withdrawal of the United
Kingdom (U.K.) from the E.U. took effect on January 1, 2021, and there are 27 member states remaining in the E.U. As of January 1, 2021,
the U.K. is a &#8220;third country&#8221; with regard to the EU (subject to the terms of the EU UK Trade Agreement) and EU law ceased
to apply directly in the UK. However, the U.K. has retained the E.U. regulatory regime with certain modifications as standalone U.K. legislation.
Therefore, the U.K. regulatory regime is currently similar to E.U. regulations, but the U.K. may adopt changed regulations that may diverge
from the E.U. legislative regime for medicines and their research, development and commercialization. For a two-year period starting January
1, 2021, the U.K. adopted transitional provisions, which <i>inter alia</i> applied to the importation of medicines into the U.K. and relied
on certain EMA marketing authorization application procedures. Following the end of this transition period,&#160;the U.K. regulatory regime
currently mirrors E.U. regulations, but, it may however, diverge in the future as the U.K. adopts new regulations for medicines and research,
development, and commercialization.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Clinical Testing in Israel</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to conduct clinical
testing on humans in Israel, special authorization must first be obtained from the ethics committee and general manager of the institution
in which the clinical studies are scheduled to be conducted, as required under the Guidelines for Clinical Trials in Human Subjects implemented
pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects), as amended from time to time, and other applicable
legislation. These regulations also require authorization from the Israeli Ministry of Health, except in certain circumstances, and in
the case of genetic trials, special fertility trials and similar trials, an additional authorization of the overseeing institutional ethics
committee. The institutional ethics committee must, among other things, evaluate the anticipated benefits that are likely to be derived
from the project to determine if it justifies the risks and inconvenience to be inflicted on the human subjects, and the committee must
ensure that adequate protection exists for the rights and safety of the participants as well as the accuracy of the information gathered
in the course of the clinical testing. Since we intend to perform a portion of the clinical studies on certain of our product candidates
in Israel, we will be required to obtain authorization from the ethics committee and general manager of each institution in which we intend
to conduct our clinical trials, and in most cases, from the Israeli Ministry of Health.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Israel Ministry of Health</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israel&#8217;s Ministry of
Health, which regulates medical testing, has adopted protocols that correspond, generally, to those of the FDA and the EMA, making it
comparatively straightforward for studies conducted in Israel to satisfy FDA and the European Medicines Agency requirements, thereby enabling
medical technologies subjected to clinical trials in Israel to reach U.S. and EU commercial markets in an expedited fashion. Many members
of Israel&#8217;s medical community have earned international prestige in their chosen fields of expertise and routinely collaborate,
teach and lecture at leading medical centers throughout the world. Israel also has free trade agreements with the United States and the
European Union.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-weight: bold;">Other Countries</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to regulations
in the United States, the EU and Israel, we are subject to a variety of other regulations governing clinical trials and commercial sales
and distribution of drugs in other countries. Whether or not our products receive approval from the FDA, approval of such products must
be obtained by the comparable regulatory authorities of countries other than the United States before we can commence clinical trials
or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter
than that required for FDA approval. The requirements governing the conduct of clinical trials and product licensing vary greatly from
country to country.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The requirements that we and
our collaborators must satisfy to obtain regulatory approval by government agencies in other countries prior to commercialization of our
products in such countries can be rigorous, costly and uncertain. In Canada and Australia, regulatory requirements and approval processes
are similar in principle to those in the United States. For example, in Canada, pharmaceutical product candidates are regulated by the
Food and Drugs Act and the rules and regulations promulgated thereunder, which are enforced by Health Canada. Before commencing clinical
trials in Canada, an applicant must complete preclinical studies and file a clinical trial application with Health Canada. After filing
a clinical trial application, the applicant must receive different clearance authorizations to proceed with Phase 1 clinical trials, which
can then lead to Phase 2 and Phase 3 clinical trials. To obtain regulatory approval to commercialize a new drug in Canada, a new drug
submission, or NDS, must be filed with Health Canada. If the NDS demonstrates that the product was developed in accordance with the regulatory
authorities&#8217; rules, regulations and guidelines and demonstrates favorable safety and efficacy and receives a favorable risk/benefit
analysis, Health Canada issues a notice of compliance which allows the applicant to market the product. Facilities, procedures, operations
and/or testing of products are subject to periodic inspection by Health Canada and the Health Products and Food Branch Inspectorate. In
addition, Health Canada conducts pre-approval and post-approval reviews and plant inspections to determine whether systems are in compliance
with the good manufacturing practices in Canada, Drug Establishment Licensing requirements and other provisions of the Food and Drug Regulations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign governments also have
stringent post-approval requirements including those relating to manufacture, labeling, reporting, record keeping and marketing. Failure
to substantially comply with these on-going requirements could lead to government action against the product, our company and/or our representatives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 96; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-weight: bold;">Related Matters</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, legislation
is drafted, introduced and passed in governmental bodies that could significantly change the statutory provisions governing the approval,
manufacturing and marketing of products regulated by the FDA, the EMA, the Israeli Ministry of Health and other applicable regulatory
bodies to which we are subject. In addition, regulations and guidance are often revised or reinterpreted by the national agency in ways
that may significantly affect our business and our product candidates. It is impossible to predict whether such legislative changes will
be enacted, whether FDA, EMA or Israeli Ministry of Health regulations, guidance or interpretations will change, or what the impact of
such changes, if any, may be. We may need to adapt our business and product candidates and products to changes that occur in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-weight: bold;">C. Organizational Structure</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate structure consists
of Can-Fite and our wholly owned subsidiary, Can-Fite Biopharma Europe, incorporated in France.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-weight: bold;">D. Property, Plants and
Equipment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are headquartered in Ramat
Gan, Israel. We lease office space for NIS 4,000 ($1,253 based on December 31, 2025 exchange rate by Bank of Israel) per month. As of
December 31, 2025, we did not have obligation to any lease payments related to our office space.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM
4A. </span></span><span style="font-weight: bold;"><span id="a_006" style="display: inline-block;"></span>Unresolved Staff Comments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not Applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM
5. </span></span><span style="font-weight: bold;"><span id="a_007" style="display: inline-block;"></span>Operating and Financial Review and Prospects</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in this section
should be read in conjunction with our consolidated financial statements and related notes beginning on page F-1 and the related information
included elsewhere in this Annual Report on Form 20-F. Our financial statements are prepared in accordance with U.S. GAAP. We maintain
our accounting books and records in U.S. dollars and our functional currency is the U.S. dollar. Certain amounts presented herein may
not sum due to rounding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Overview</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are an advanced clinical-stage biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the
treatment of cancer, liver and inflammatory diseases. Our platform technology utilizes the Gi protein associated or A3AR as a therapeutic
target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal
cells, suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline of drug candidates are synthetic,
highly specific agonists and allosteric modulators targeting the A3AR.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 97; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
product pipeline is based on the research of Dr. Pnina Fishman, who investigated a clinical observation that tumor metastasis can be found
in most body tissues, but are rarely found in muscle tissue, which constitutes approximately 60% of human body weight. Dr. Fishman&#8217;s
research revealed that one reason that striated muscle tissue is resistant to tumor metastasis is that muscle cells release small molecules
which bind with high selectivity to the A3AR. As part of her research, Dr. Fishman also discovered that A3ARs have significant expression
in tumor and inflammatory cells, whereas normal cells have low or no expression of this receptor. The A3AR agonists and allosteric modulators,
currently our pipeline of drug candidates, bind with high selectivity and affinity to the A3ARs and upon binding to the receptor initiate
down-stream signal transduction pathways resulting in apoptosis, or programmed cell death, of tumors and inflammatory cells and to the
inhibition of inflammatory cytokines. Cytokines are proteins produced by cells that interact with cells of the immune system in order
to regulate the body&#8217;s response to disease and infection. Overproduction or inappropriate production of certain cytokines by the
body can result in disease. In addition, our product candidateds also induce the production of positive cytokines such as granulocyte
colony stimulating factor (G-CSF) and adiponectin which are responsible for the chemo-protective and liver-protective effects of the drugs
on liver</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
product candidates, CF101, CF102 and CF602, are being developed to treat oncological and inflammatory diseases, as well as erectile dysfunction.
CF101, also known as Piclidenoson, is in an advanced stage of clinical development for the treatment of psoriasis. CF102, also known as
Namodenoson, is being developed for the treatment of HCC and has orphan drug designation for this indication in the United States and
Europe. Namodenoson was granted Fast Track designation by the FDA for patients with advanced HCC. who failed first line treatment. Due
to the liver protective effect of Namidenoson, it is also being developed for the treatment of MASH (also known as MASH). Namodenoson
is also being developed for the treatment of pancreatic cancer based on pre-clinical findings showing robust anti-pancreatic tumor growth.
CF602 is our second generation allosteric drug candidate for the treatment of erectile dysfunction, which has shown efficacy in the treatment
of erectile dysfunction in preclinical studies and we are investigating additional compounds, targeting A3AR, for the treatment of erectile
dysfunction. Preclinical studies revealed that our drug candidates have potential to treat additional inflammatory diseases, such as Crohn&#8217;s
disease, oncological diseases such as prostate cancer, viral diseases, such as the JC virus, obesity and Lowe Syndrome.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe our pipeline of drug candidates represent a significant market opportunity. For instance, according to Grand View Research, the
psoriasis drug market is forecasted to be worth $39 billion by 2030. According to Future Market Insights, the global HCC treatment market
is expected to reach nearly $34 billion by 2035.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, we have out-licensed the following product candidates for indications that we are currently pursuing:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Piclidenoson for the treatment of (i) psoriasis to Cipher Pharmaceuticals, or Cipher, for Canada, (ii) psoriasis to Gebro Holding, or Gebro, for Spain, Switzerland and Austria, (iii) psoriasis to CMS Medical, or CMS, for China (including Hong Kong, Macao and Taiwan), (iv) psoriasis to Kyongbo Pharm Co. Ltd., or Kyongbo Pharm, for South Korea, (v) psoriasis to Ewopharma AG, or Ewopharma, for Central Eastern Europe, and (vi) osteoarthritis in companion animals including dogs and cats to Vetbiolix.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">Namodenoson for the treatment of (i) liver cancer and MASH to Chong Kun Dang Pharmaceuticals, or CKD, for South Korea, (ii) advanced liver cancer and NAFLD/MASH to CMS for China (including Hong Kong, Macao and Taiwan), and (iii) HCC, MASH and pancreatic cancer to Ewopharma, for Central Eastern Europe and Switzerland.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="background-color: white">Currently,
(i) we initiated the pivotal Phase III studies for Piclidenoson in the treatment of psoriasis, following meetings with the FDA and EMA,
(ii) we are conducting a pivotal Phase III trial for Namodenoson in the treatment of advanced liver cancer which is enrolling patients,
(iii) we are enrolling patients in a Phase IIb study of Namodenoson in the treatment of MASH, (iv) we recently completed enrollment in
an exploratory Phase II study of Namodenoson in the treatment of patients with pancreatic cancer, (v) we are undertaking preparatory work
for a Phase II study with Piclidenoson for the treatment of Lowe syndrome, and (vi) we are investigating additional compounds, targeting
the A3 adenosine receptor, for the treatment of erectile dysfunction. Since inception, we have incurred significant losses in connection
with our research and development.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 98; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Moreover,
we believe characteristics of Piclidenoson, as exhibited in our clinical studies to date, including its good safety profile, clinical
activity, simple and less frequent delivery through oral administration and its low cost of production, position it well against the competition
in psoriasis markets, where treatments, when available, often include injectable drugs, many of which can be highly toxic, expensive and
not always effective.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Like
Piclidenoson, Namodenoson has a good safety profile, is orally administered and has a low cost of goods, which we believe may position
it well in the HCC market, where no drug has yet been approved by the FDA for patients with advanced liver cancer disease defined as Child
Pugh B7. In addition, pre-clinical studies show Namodenoson&#8217;s novel mechanism of action which entails de-regulation of three key
signaling pathways which mediate the etiology and pathology of NAFLD/MASH and are responsible for the anti-inflammatory, anti-steatotic
and anti-fibrotic effect in the liver. Most recently, pre-clinical data support Piclidenoson&#8217;s potential utilization for the treatment
of Lowe Syndrome and Namodenoson&#8217;s potential utilization as an anti-obesity drug.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Nevertheless,
other drugs on the market, new drugs under development (including drugs that are in more advanced stages of development in comparison
to our drug candidates) and additional drugs that were originally intended for other purposes, but were found effective for purposes targeted
by us, may all be competitive to the current drugs in our pipeline. In fact, some of these drugs are well established and accepted among
patients and physicians in their respective markets, are orally bioavailable, can be efficiently produced and marketed, and are relatively
safe. None of our product candidates have been approved for sale or marketing and, to date, there have been no commercial sales of any
of our product candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, we have incurred
significant losses in connection with our research and development. As of December 31, 2025, we had an accumulated deficit of approximately
$176.2 million. Although we have recognized revenues in connection with our existing out-licensing agreements with, Cipher, CKD, Gebro,
Ewopharma, Vetbiolix and our historic out-licensing agreement with KD, CMS, Kyongbo and Seikagaku Corporation, or SKK, we expect to generate
losses in connection with the research and development activities relating to our pipeline of drug candidates. Such research and development
activities are budgeted to expand over time and will require further resources if we are to be successful. As a result, we expect to incur
operating losses, which may be substantial over the next several years, and we will need to obtain additional funds to further develop
or research and development programs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have funded our operations
primarily through the sale of equity securities (both in private placements and in public offerings) and payments received under our existing
out-licensing agreements with KD, Cipher, CKD Gebro, CMS, and Kyongbo and our historic out-licensing agreement with SKK. We expect to
continue to fund our operations over the next several years through our existing cash resources, potential future milestone payments that
we expect to receive from our licensees, interest earned on our investments, if any, and additional capital to be raised through public
or private equity offerings or debt financings. As of December 31, 2025, we had approximately $5.5 million of cash and cash equivalents
and $3 million of short-term deposits. A substantial part of this amount is designated for payments to be made in relation to the ongoing
treatment of patients who are currently enrolled in our on-going trials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Revenues</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our revenues to date have
been generated primarily from payments under our existing out-licensing agreements with, Cipher, CKD, Gebro, Kyongbo, Ewophrma and Vetbiolix,
and our historic out-licensing agreement with Kwang Dong and SKK.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Kwang Dong License
Agreement, we are entitled to up-front and milestone payments of up to $1.5 million. In accordance with the Kwang Dong License Agreement,
we received an up-front payment of $0.3 million and a payment of $0.048 million as consideration for Kwang Dong&#8217;s purchase of our
ordinary shares in 2009 and a milestone payment of $0.2 million in 2010. Under the terms of the Kwang Dong License Agreement, in addition
to the payments mentioned above, we are entitled to certain additional payments based on the sale of raw materials, subject to the terms
and conditions of the respective agreements. To date, we have received a total of $0.5 million from Kwang Dong in an upfront payment.
See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 99; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Distribution and
Supply Agreement with Cipher we received CAD 1.65 million upon execution of the agreement and are entitled to milestone payments upon
receipt of regulatory approval by Health Canada for Piclidenoson and the first delivery of commercial launch quantities as follows (i)
CAD 1 million upon the first approved indication for either psoriasis or rheumatoid arthritis, and (ii) CAD 1 million upon the second
approved indication for either psoriasis or rheumatoid arthritis. In addition, following regulatory approval, we shall be entitled to
a royalty of 16.5% of net sales of Piclidenoson in Canada and reimbursement for the cost of manufacturing Piclidenoson. We are also entitled
to a royalty payment for any authorized generic of Piclidenoson that Cipher distributes in Canada. To date, we have received a total
of $1.3 million (CAD 1.65 million) from Cipher in an upfront payment. See &#8220;Item 4. Information on the Company&#8212;B. Business
Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Distribution Agreement
with CKD provides for up to $3,000,000 in upfront and milestone payments payable with respect to the liver cancer indication and up to
$6,000,000 with respect to the MASH indication. In addition, we are entitled to a transfer price of the higher of (a) the manufacturing
cost plus 10% or (b) 23% of net sales of Namodenoson following commercial launch in South Korea. To date, we have received a total of
$2,000,000 from CKD, comprising $1,500,000 in upfront payments for the expansion of CKD&#8217;s existing agreement with us to include
the rights to distribute Namodenoson for the treatment of MASH in South Korea, and a further $500,000 for a milestone payment received
in the third quarter of 2017 upon receipt by CKD of a positive result from the preliminary review by the MFDS, on obtaining orphan drug
designation in South Korea. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution
Agreements&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, we entered
into a Distribution and Supply Agreement with Gebro. The Distribution and Supply Agreement with Gebro provides that we are entitled to
&#8364;1,500,000 upon execution of the agreement plus milestone payments upon achieving certain clinical, launch and sales milestones,
as follows: (i) &#8364;300,000 upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and &#8364;300,000
upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between &#8364;750,000 and &#8364;1,600,000
following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis,
and (iii) between &#8364;300,000 and up to &#8364;4,025,000 upon meeting certain net sales. In addition, following regulatory approval,
we shall be entitled to double digit percentage royalties on net sales of Piclidenoson in the territories and payment for the manufacturing
Piclidenoson. To date, we have received a total of &#8364;2,100,000 from Gebro in upfront and milestone payments. See &#8220;Item 4. Information
on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, we entered
into a License, Collaboration and Distribution Agreement with CMS. Under the License, Collaboration and Distribution Agreement, we are
entitled to $2,000,000 upon execution of the agreement plus milestone payments of up to $14,000,000 upon achieving certain regulatory
milestones and payments of up to $58,500,000 upon achieving certain sales milestones. In addition, following regulatory approval, we shall
be entitled to double-digit percentage royalties on net sales of Piclidenoson and Namodenoson in the licensed territories. To date, we
have received a total of $2,000,000 from CMS in upfront and milestone payments. See &#8220;Item 4. Information on the Company&#8212;B.
Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2019, we entered into
a License and Distribution Agreement with Kyongbo Pharm. Under the terms of agreement, Kyongbo Pharm, in exchange for exclusive distribution
rights to sell Piclidenoson in the treatment of psoriasis in South Korea, made a total upfront payment of $750,000 to us, with additional
payments of up to $3,250,000 upon achievement of certain milestones. We will also be entitled to a transfer price for delivering finished
product to Kyongbo Pharm. To date, we have received a total of $750,000 from Kyongbo Pharm in upfront and milestone payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, we signed an
exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the
treatment of liver diseases namely, HCC, the most common form of liver cancer, and MASH. Under the terms of the distribution agreement,
Ewopharma we received $2.25 million upfront and are entitled to up to an additional $40.45 million payable upon the achievement of regulatory
and sales milestones plus 17.5% royalties on net sales. We will also be entitled to a transfer price for delivering finished product to
Ewopharma. In January 2024, we entered into an amendment to the distribution agreement with Ewopharma to expand the distribution to include
the indication of pancreatic cancer with respect to Namodenoson. To date, we have received a total of $2,250,000 from Ewopharma in upfront,
milestone and royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 100; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terminated SKK
license agreement we received an aggregate of approximately $8.5 million from SKK. See &#8220;Item 4. Information on the Company&#8212;B.
Business&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain payments we have
received from SKK and KD have been subject to a 10% and 5% withholding tax in Japan and Korea, respectively, and certain payments we
may receive in the future, if at all, may also be subject to the same withholding tax in Korea. Receipt of any milestone payment under
our out-licensing agreements depends on many factors, some of which are beyond our control. We cannot assure you that we will receive
any of these future payments. We expect our revenues for the next several years, if any, to be derived primarily from payments under
our current out-license agreements and our public capital raising activities, as well as additional collaborations that we may enter
into in the future with respect to our drug candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 28, 2021, we
entered into the Vetbiolix Agreement with Vetbiolix, a France-based veterinary biotech company and veterinary partner, for the
development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. Vetbiolix had the
exclusive right to Piclidenoson in the veterinary osteoarthritis market for two years, during which time Vetbiolix conducted
proof-of-concept studies and covered all associated costs. The option to the licensed know-how and our patents was initially for a
period of two years, which such period was extended by additional 15 months in February 2024. The studies yielded positive data and
Vetbiolix exercised its option to obtain the license from us in September 2024. Following Vetbiolix&#8217;s activation of its option
to obtain the license pursuant to the Vetbiolix Agreement, we granted Vetbiolix an exclusive option to utilize the licensed know-how
and certain of our patents solely for the purpose of supporting Vetbiolix&#8217;s research, development, manufacturing and
commercializing of its compounds and/or products in the field throughout the territory. Vetbiolix is obligated to pay us upfront and
milestone payments of &#8364;250,000 (approximately $271,000), which was received in October 2024. In addition, Vetbiolix agreed to
pay us payments equal to 30% for each upfront and milestone payment received from and sublicensee and 15%-40% royalties on net sales
upon regulatory approval for veterinary use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Research and Development</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses consist primarily of salaries and related personnel expenses, fees paid to external service providers, up-front and milestone
payments under our license agreements, patent-related legal fees, costs of preclinical studies and clinical trials, drug and laboratory
supplies and costs for facilities and equipment. We charge all research and development expenses to operations as they are incurred.
We expect our research and development expense to remain our primary expense in the near future as we continue to develop our products.
Increases or decreases in research and development expenditures are attributable to the number and/or duration of the pre-clinical and
clinical studies that we conduct.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table identifies
our current major research and development projects:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid; text-align: left; width: 24%"><span style="font-weight: bold;">Project</span></td>
<td style="width: 1%; text-align: center">&#160;</td>
<td style="border-bottom: black 1.5pt solid; width: 36%; text-align: center"><span style="font-weight: bold;">Status</span></td>
<td style="width: 1%; text-align: center">&#160;</td>
<td style="border-bottom: black 1.5pt solid; width: 38%; text-align: center"><span style="font-weight: bold;">Expected or Recent Near Term Milestone</span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="text-align: justify">Piclidenoson</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">COMFORT Phase III study in psoriasis</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">Enrolling patients; Interim analysis data expected in Q2 2027</td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">Lowe Syndrome</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">Submission of the study protocol to regulators is expected in &#160;Q2 of 2026</td></tr>
<tr style="vertical-align: top; background-color: white">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="text-align: justify">Namodenoson</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">LIVERATION Phase III in HCC</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">Enrolling patients; Interim analysis data expected in Q2 2027</td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">Phase IIb study in MASH</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">Enrolling patients</td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">Phase IIa study in pancreatic cancer</td>
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">Completed enrollment; Study met the primary endpoint - safety; Survival follow up is ongoing</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 101; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We record certain costs for
each development project on a &#8220;direct cost&#8221; basis, as they are recorded to the project for which such costs are incurred.
Such costs include, but are not limited to, CRO expenses, drug production for pre-clinical and clinical studies and other pre-clinical
and clinical expenses. However, certain other costs, including but not limited to, salary expenses (including salaries for research and
development personnel), facilities, depreciation, share-based compensation and other overhead costs are recorded on an &#8220;indirect
cost&#8221; basis, i.e., they are shared among all of our projects and are not recorded to the project for which such costs are incurred.
We do not allocate direct salaries to projects due to the fact that our project managers are generally involved in several projects at
different stages of development, and the related salary expense is not significant to the overall cost of the applicable projects. In
addition, indirect labor costs relating to our support of the research and development process, such as manufacturing, controls, pre-clinical
analysis, laboratory testing and initial drug sample production, as well as rent and other administrative overhead costs, are shared
by many different projects and have never been considered by management to be of significance in its decision-making process with respect
to any specific project. Accordingly, such costs have not been specifically allocated to individual projects.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below is a summary
of the gross direct costs allocated to our main projects on an individual basis, as well as the gross direct costs allocated to our less
significant projects on an aggregate basis, for the years ended December 31, 2023, 2024 and 2025; and on an aggregate basis since project
inception:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">($ in thousands)</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Costs<br/> Since</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December&#160;31,</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center">Project</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Inception</td>
<td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>Piclidenoson</td>
<td>&#160;</td>
<td colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td colspan="2">&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 52%">-&#160;&#160;&#160;Psoriasis</td>
<td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 9%; text-align: right">1,444</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 9%; text-align: right">550</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 9%; text-align: right">1,275</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td>
<td style="width: 9%; text-align: right">27,461</td>
<td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">-&#160;&#160;&#160;Lowe syndrome</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">-&#160;&#160;&#160;Dogs osteoarthritis</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1.5pt; text-align: left">-&#160;&#160;&#160;Other project &amp; Pre clinical &amp; API</td>
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">27</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">10</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">2</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">22,434</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-weight: bold;">1,471</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-weight: bold;">560</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,277</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">49,895</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>Namodenoson</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">&#160;</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">-&#160;&#160;&#160;Liver cancer</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,755</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,990</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">2,153</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">17,376</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">-&#160;&#160;&#160;Pancreatic cancer</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">169</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">472</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">641</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>-&#160;&#160;&#160;MASH</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,225</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,230</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,289</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">7,216</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 1.5pt; text-align: left">-&#160;&#160;&#160;Pre clinical &amp; API</td>
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">9</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">202</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">4,671</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-weight: bold;">2,989</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right"><span style="font-weight: bold;">3,389</span></td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">4,116</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">29,904</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">CF602 (erectile dysfunction)</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">-</td>
<td style="text-align: left">&#160;</td>
<td>&#160;</td>
<td style="text-align: left">&#160;</td>
<td style="text-align: right">1,740</td>
<td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 1.5pt; text-align: left">Other projects</td>
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: right">4,129</td>
<td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-bottom: 2.5pt; text-align: left">Total gross direct project costs&#160;<sup>(1)</sup></td>
<td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: right">4,460</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: right">3,949</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: right">5,393</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
<td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: right">85,668</td>
<td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</tbody></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; text-align: justify">(1)</td>
<td style="text-align: justify">Does not include indirect project costs and overhead, such as payroll and related expenses (including
    stock-based compensation), facilities, depreciation and impairment of intellectual property, which are included in total research
    and development expenses in our financial statements.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From our inception through
December 31, 2025, we have incurred research and development expenses of approximately $158.6 million. We expect that a large percentage
of our research and development expense in the future will be incurred in support of our current and future preclinical and clinical
development projects. Due to the inherently unpredictable nature of preclinical and clinical development processes and given the early
stage of our preclinical product development projects, we are unable to estimate with any certainty the costs we will incur in the continued
development of the product candidates in our pipeline for potential commercialization. Clinical development timelines, the probability
of success and development costs can differ materially from expectations. We expect to continue to test our product candidates in preclinical
studies for toxicology, safety and efficacy, and to conduct additional clinical trials for each product candidate. If we are not able
to enter into an out-licensing arrangement with respect to any product candidate prior to the commencement of later stage clinical trials,
we may fund the trials for the product candidates ourselves.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 102; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we are currently focused
on advancing each of our product development projects, our future research and development expenses will depend on the clinical success
of each product candidate, as well as ongoing assessments of each product candidate&#8217;s commercial potential. In addition, we cannot
forecast with any degree of certainty which product candidates may be subject to future out-licensing arrangements, when such out-licensing
arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we obtain results from
clinical trials, we may elect to discontinue or delay clinical trials for certain product candidates or projects in order to focus our
resources on more promising product candidates or projects. Completion of clinical trials by us or our licensees may take several years
or more, but the length of time generally varies according to the type, complexity, novelty and intended use of a product candidate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of clinical trials
may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the number of sites included in the clinical trials;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the length of time required to enroll suitable patients;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the number of patients that participate in the clinical trials;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the duration of patient follow-up;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the development stage of the product candidate; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the efficacy and safety profile of the product candidate.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our research and
development expenses to increase in the future from current levels as we continue the advancement of our clinical trials and preclinical
product development and to the extent we in-license new product candidates. The lengthy process of completing clinical trials and seeking
regulatory approval for our product candidates requires expenditure of substantial resources. Any failure or delay in completing clinical
trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development
expenses to increase and, in turn, have a material adverse effect on our operations. Because of the factors set forth above, we are not
able to estimate with any certainty when we would recognize any net cash inflows from our projects.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">General and Administrative Expenses</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of compensation for employees in executive and operational functions, including accounting, finance, legal,
business development, investor relations, information technology and human resources. Other significant general and administration costs
include facilities costs, professional fees for outside accounting and legal services, travel costs, insurance premiums and depreciation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Financial Expense and Income</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expense and income
consists of interest earned on our cash and cash equivalents; bank fees and other transactional costs; expense or income resulting from
fluctuations of the NIS and other currencies, in which a portion of our assets and liabilities are denominated, against the U.S. dollar
(our functional currency).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 103; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Critical Accounting Policies and Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our accounting policies and
their effect on our financial condition and results of operations are more fully described in our audited consolidated financial statements
included elsewhere in this Annual Report on Form 20-F. The preparation of financial statements in conformity with U.S. GAAP as issued
by the Financial Accounting Standards Board (FASB) requires management to make estimates and assumptions that in certain circumstances
affect the reported amounts of assets and liabilities, revenues and expenses and disclosure of contingent assets and liabilities. These
estimates are prepared using our best judgment, after considering past and current events and economic conditions. While management believes
the factors evaluated provide a meaningful basis for establishing and applying sound accounting policies, management cannot guarantee
that the estimates will always be consistent with actual results. In addition, certain information relied upon by us in preparing such
estimates includes internally generated financial and operating information, external market information, when available, and when necessary,
information obtained from consultations with third party experts. Actual results could differ from these estimates and could have a material
adverse effect on our reported results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the accounting
policies discussed below are critical to our financial results and to the understanding of our past and future performance, as these
policies relate to the more significant areas involving management&#8217;s estimates and assumptions. We consider an accounting estimate
to be critical if: (1) it requires us to make assumptions because information was not available at the time or it included matters that
were highly uncertain at the time we were making our estimate; and (2) changes in the estimate could have a material impact on our financial
condition or results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Functional and Presentation Currency</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our functional and presentation
currency is the U.S. dollar since the USD is the primary currency of the economic environment in which we operate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Principles of Consolidation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our financial statements
reflect the consolidation of the financial statements of companies that we control based on legal control or effective control. We fully
consolidate into our financial statements the results of operations of companies that we control. Legal control exists when we have the
power, directly or indirectly, to govern the financial and operating policies of an entity. The effect of potential voting rights that
are exercisable at the balance sheet date are considered when assessing whether we have legal control. In addition, we consolidate on
the basis of effective control even if we do not have voting control.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generate income from out-licensing
and distribution agreements. See &#8220;Item 4. Information on the Company&#8212;B. Business&#8212;Out-Licensing and Distribution Agreements&#8221;.
Such income comprises of upfront license fees, milestone payments and potential royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize revenue in accordance
with ASC 606, &#8220;Revenue from Contracts with Customers&#8221; pursuant to which each required deliverable is evaluated to determine
whether it qualifies as a separate unit of accounting based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer.
The arrangement&#8217;s consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the
relative selling price of each deliverable which is based on the Estimated Selling Price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contracts generally include
three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of an exclusive
licensing to distribute the product, once available; and, (iii) participation in joint steering committee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contracts also include
development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent that
it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. We
have not yet received the required regulatory approvals for our products and we have not yet recognized any sales-based royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenue from supply and distribution
agreements with customers are recognized over time as we satisfy the performance obligations. We usually accept long-term upfront payment
from our customers. Contract liabilities for those upfront payments are recognized as revenue over time. We have concluded that the performance
obligation in the abovementioned agreements should be combined for a single performance obligation for accounting purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i></i></p><!-- Field: Page; Sequence: 104; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Revenues from milestone payments:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Contingent payments related
to milestones will be recognized upon satisfaction of the milestone and contingent payments related to royalties will be recognized in
the period that the related sales have occurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;Revenues from royalties:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues from royalties will
be recognized as they accrue in accordance with the terms of the relevant agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Share-based Compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for share-based
compensation arrangements in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221;, or ASC 718, which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s
consolidated statement of comprehensive loss. We recognize compensation expenses for the value of its awards granted based on the vesting
acceleration approach over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures
to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We selected the binomial
option pricing model as the most appropriate method for determining the estimated fair value of our share-based awards. The determination
of the grant date fair value of options using an option pricing model is affected by estimates and assumptions regarding a number of
complex and subjective variables. These variables include the expected volatility of our share price over the expected term of the options,
share option exercise and forfeiture rate, risk-free interest rates, expected dividends and the price of our ordinary shares on the TASE.
As our ordinary shares are publicly traded on the TASE, we do not need to estimate the fair value of our ordinary shares. Rather, we
use the actual closing market price of our ordinary shares on the date of grant, as reported by the TASE although in the future may use
the closing market price of our ADSs on the date of grant, as reported by the NYSE American.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the assumptions
used in the binomial option pricing model change significantly, share-based compensation for future awards may differ materially compared
with the awards previously granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As for other service providers,
the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments.
In cases where the fair value of the goods or services received as consideration of equity instruments cannot be measured, they are measured
by reference to the fair value of the equity instruments granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of equity-settled
transactions is recognized in statements of comprehensive loss, together with a corresponding increase in equity, during the period which
the service are to be satisfied, ending on the date on which the relevant employees or other service providers become fully entitled
to the award.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we modify the conditions
on which equity-instruments are granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee or other service provider at the modification date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Recently Issued Accounting Pronouncements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2023, the
FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which requires disaggregated information
about the effective tax rate reconciliation as well as information on income taxes paid. The guidance will be effective for the
Company for annual periods beginning January 1, 2025, with early adoption permitted. The adoption of the standard did not have
a material impact on its financial statement disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2024, the FASB
issued ASU 2024-03&#160;&#8220;Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures&#8221;&#160;(&#8220;ASU
2024-03&#8221;), which requires more detailed information about specified categories of expenses presented on the face of the income
statement, in addition to disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15,
2026, with early adoption permitted. The amendment may be applied either prospectively to financial statements issued for reporting periods
after the effective date or retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating
ASU 2024-03 to determine the impact it may have on its consolidated financial statements and related disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 105; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Recent Offerings</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 30, 2024, we entered
into the ATM Agreement with Wainwright, as sales agent. Pursuant to the ATM Agreement, we may offer and sell our ADSs from time to time
through Wainwright. Wainwright will receive a commission equal to 3.0% of the gross proceeds from the sale of the ADSs and will be reimbursed
for certain specified expenses in connection with entering into the ATM Agreement. As of the date of this Annual Report, we sold 314,867
of our ADSs pursuant to the ATM Agreement for aggregate gross proceeds of approximately $5.7 million and subject to certain standstill
restrictions and General Instruction I.B.5 to Form F-3 (also known as the baby shelf rule), we may currently sell up to an additional
approximately $0.4 million under the ATM program.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 14, 2025, we entered
into a securities purchase agreement pursuant to which we to sold in a registered direct offering an aggregate of 125,000 ADSs at an offering
price of $24.00 per ADS resulting in aggregate gross proceeds of $3.0 million, before deducting fees payable to the placement agent and
other offering expenses payable by us. The offering closed on April 15, 2025. We paid an aggregate of approximately $315,000 in placement
agent fees and expenses and issued unregistered placement agent five-year warrants to purchase 8,750 ADS on the at an exercise price equal
to $30.00 per ADS.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 28, 2025, we offered and sold in a public offering on a best
efforts basis (the &#8220;July Offering&#8221;) (i) 62,500 ADSs, representing 125,000 ordinary share, (ii) 347,167 pre-funded warrants
to purchase up to 347,167 ADSs (the &#8220;July Pre-Funded Warrants&#8221;), and (iii) 833,333 warrants to purchase up to 833,333 ADSs
(the &#8220;July Common Warrants&#8221;, and together with the July Pre-Funded Warrants, the &#8220;July Warrants&#8221;), at a combined
public offering price of $12.0 per ADS and accompanying July Common Warrants, and $11.98 per July Pre-Funded Warrant and accompanying
July Common Warrants. Aggregate gross proceeds from the July Offering
(without taking into account any proceeds from any future exercises of July Warrants) were approximately $5.0 million. The July
Pre-Funded Warrants were immediately exercisable at an exercise price of $0.02 per ADS and may be exercised at any time until
exercised in full. The July Common Warrants have an exercise price of $12 per ADS, are immediately exercisable, and expire on the
two-year anniversary of the date of issuance. We paid an aggregate of approximately $350,000 in placement agent fees and expenses
and issued unregistered placement agent warrants, or the July Placement Agent Warrants, to purchase 29,167 ADS on the same terms as
the July Common Warrants except that the July Placement Agent Warrants have an exercise price equal to $15 per ADS (representing
125% of the combined public offering price per ADS and accompanying July Common Warrant).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2026, we entered
into an inducement offer letter agreement (the &#8220;Inducement Letter&#8221;), with a certain holder (the &#8220;Holder&#8221;), of
certain of our existing warrants to purchase up to 795,869 ADSs representing 1,591,738 ordinary shares issued on July 29, 2025 at an exercise
price of&#160;$9.34 per ADS (the &#8220;Existing Warrant&#8221;). Pursuant to the Inducement Letter, the Holder agreed to exercise for
cash its Existing Warrants to purchase an aggregate of 795,869 of the Company&#8217;s ADSs at a reduced exercise price of $5.00 per ADS
in consideration of the Company&#8217;s agreement to issue new warrants to purchase ADSs (the &#8220;New Warrants&#8221;), to purchase
up to an aggregate of 1,591,738 ADSs, at an exercise price of $5.00 per ADS. We paid an aggregate of approximately $343,347 in placement
agent fees and expenses and issued unregistered placement agent warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase 55,711
ADS on the same terms as the New Warrants except that the Placement Agent Warrants have an exercise price equal to $6.25 per ADS.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">A. Results of Operations</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Comparison of the Year Ended December 31,
2025 to Year Ended December 31, 2024</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Revenues</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues for the year ended
December 31, 2025 were $0.41 million, a decrease of $0.27 million, or 40% compared to $0.67 million for the year ended December 31, 2024.
The decrease in revenues was mainly due to the recognition of a lower portion of advance payments received under the Ewopharma distribution
agreement entered in 2021 and a lower portion of advance payments received under distribution agreements from Gebro, Chong Kun Dung Pharmaceuticals,
and Cipher Pharmaceuticals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Research and development
expenses</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses for the year ended December 31, 2025 were $6.69 million, an increase of $0.9 million, or 16.26% compared to $5.75 million for
the year ended December 31, 2024. Research and development expenses for the year ended December 31, 2025 comprised primarily of expenses
associated with the ongoing of the Phase 3 study of Piclidenoson for the treatment of psoriasis and two ongoing studies for Namodenoson,
a Phase 3 study in the treatment of advanced liver cancer and a Phase 2b study for MASH. The increase is primarily due to acceleration
in expenses associated with both Namodenoson and Piclidenoson.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 106; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>General and administrative
expenses</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses were $3.66 million for the year ended December 31, 2025, an increase of $0.6 million, or 20.2% compared to $3.04 million for
the year ended December 31, 2024. The increase is primarily due to the increase in investors relationship expenses following a one-time
project that occurred during the first half of 2025. We expect that general and administrative expenses will remain at the same level
through 2026.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Financial income, net</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial income, net for
the year ended December 31, 2025 was $0.12 million compared to $0.25 million for the year ended December 31, 2024. The decrease in financial
income, net was mainly due to lower income on short-term deposits.<span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-weight: bold;">Comparison of the
Year Ended December 31, 2024 to Year Ended December 31, 2023</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-weight: bold;"><i>Revenues</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Revenues
for the year ended December 31, 2024 were $0.67 million, a decrease of $0.07 million, or 9.3%, compared to $0.74 million for the year
ended December 31, 2023. The decrease in revenues was mainly due to the recognition a lower portion of advance payments received under
the Ewopharma distribution agreement entered in 2021 and a lower portion of advance payments received under distribution agreements from
Gebro, Chong Kun Dung Pharmaceuticals, and Cipher Pharmaceuticals offset by a recognition of advance payment received under the Vetbiolix
Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-weight: bold;"><i>Research
and development expenses</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Research
and development expenses for the year ended December 31, 2024 were $5.75 million, a decrease of $0.23 million, or 3.8%, compared to $5.98
million for the year ended December 31, 2023. Research and development expenses for the year ended December 31, 2024 comprised primarily
of expenses associated with the completion of the Phase 3 study of Piclidenoson for the treatment of psoriasis and two ongoing studies
for Namodenoson, a Phase 3 study in the treatment of advanced liver cancer and a Phase 2b study for MASH. The decrease is primarily due
to a decrease in expenses associated with Piclidenosnon.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-weight: bold;"><i>General
and administrative expenses</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">General
and administrative expenses were $3.04 million for the year ended December 31, 2024, an increase of $0.09 million, or 3.1%, compared to
$2.95 million for the year ended December 31, 2023. The increase is primarily due to higher public relationship expenses. We expect that
general and administrative expenses will remain at the same level through 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><span style="font-weight: bold;"><i>Financial
income (expenses), net</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Financial
income, net for the year ended December 31, 2024 aggregated $0.25 million compared to $0.56 million for the year ended December 31, 2023.
The decrease in financial income, net was mainly due to decrease interest from deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 107; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">B. Liquidity and Capital Resources</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, we have
funded our operations primarily through public (in Israel and US) and private offerings of our equity securities and payments received
under our strategic licensing arrangements. As of December 31, 2025, we had approximately $8.5 million in cash, cash equivalents and
short-term deposits, and have invested most of our available cash funds in ongoing cash accounts. Our board of directors approved a contingency
plan, to be implemented, in whole or in part, at our discretion, to allow us to continue our operations and meet our cash obligations.
The contingency plan consists of cost reduction, which include mainly deferral and reprioritization of certain research and development
programs that would involve reduced program spend and reduction in compensation paid to key management personnel until additional financing
is obtained. Based on our current projections and plans, we have concluded that our existing capital resources will be adequate to satisfy
our expected liquidity requirements for at least twelve months from the filing date. In March 2026, we received aggregate gross proceeds
of approximately $4.3 million from a warrant inducement transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For information regarding
the revenues and expenses associated with our licensing agreements, see &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing
and Distribution Agreements&#8221;, &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;In-Licensing Agreements&#8221;
and &#8220;Item 5. Operating and Financial Review and Prospects&#8212;Revenues.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Developing drugs, conducting
clinical trials and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic
objectives. Although we believe our existing financial resources as of the date of issuance of this Annual Report on Form 20-F, will
be sufficient to fund our projected cash requirements at least through the next twelve months, we will require significant additional
financing to fund our operations. Additional financing may not be available on acceptable terms, if at all. Our future capital requirements
will depend on many factors, including:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the level of research and development investment required to develop our product candidates;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the failure to obtain regulatory approval or achieve commercial success of our product candidates,
    including Piclidenoson, Namodenoson and CF602;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the results of our preclinical studies and clinical trials for our earlier stage product candidates,
    and any decisions to initiate clinical trials if supported by the preclinical results;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the costs, timing and outcome of regulatory review of our product candidates that progress to clinical
    trials;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">our ability to partner or sub-license any of our product candidates;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our
    issued patents and defending intellectual property-related claims;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the cost of commercialization activities if any of our product candidates are approved for sale,
    including marketing, sales and distribution costs;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the cost of manufacturing our product candidates and any products we successfully commercialize;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the timing, receipt and amount of sales of, or royalties on, our future products, if any;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the expenses needed to attract and retain skilled personnel;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">any product liability or other lawsuits related to our products;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the extent to which we acquire or invest in businesses, products or technologies and other strategic
    relationships;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the costs of financing unanticipated working capital requirements and responding to competitive pressures;
    and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">regaining and maintaining minimum shareholders&#8217; equity requirements and complying with other
    continue listing standards under the NYSE American Company Guide; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify; font-size: 10pt">&#160;</td>
<td style="width: 24px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of the Russian invasion of Ukraine and the security situation in Israel, which may exacerbate the magnitude of the factors discussed above.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until we can generate significant
continuing revenues, we expect to satisfy our future cash needs through payments received under our license agreements, debt or equity
financings, or by out-licensing other product candidates. We cannot be certain that additional funding will be available to us on acceptable
terms, or at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research
or development programs or our commercialization efforts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 108; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">Cash Flows</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following tables sets
forth selected cash flow information for the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">U.S. $ in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 64%; text-align: justify">Cash used in operating activities:</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(8,949</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,637</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(8,440</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify">Cash provided by (used in) investing activities:</td><td>&#160;</td>
<td style="text-align: left">$</td><td style="text-align: right">(2</td><td style="text-align: left">)</td><td>&#160;</td>
<td style="text-align: left">$</td><td style="text-align: right">1,495</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">$</td><td style="text-align: right">498</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">Cash provided by financing activities:</td><td>&#160;</td>
<td style="text-align: left">$</td><td style="text-align: right">9,644</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">$</td><td style="text-align: right">6,711</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">$</td><td style="text-align: right">9,144</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify; padding-bottom: 1.5pt">Exchange differences on balances of cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">98</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">703</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">547</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities was $8.9 million for the year ended December 31, 2025, compared with net cash used in operating activities of $7.6 million
and $8.4 million for the years ended December 31, 2024 and 2023, respectively. The $1.3 million increase in the net cash used in operating
activities during 2025, compared to 2024, was primarily the result of increase in our net loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by investing
activities for the year ended December 31, 2025 was $0.002 million compared to net cash used in investing activities of $1.5 million and
$0.5 million for the years ended December 31, 2024 and December 31, 2023, respectively. The decrease in net cash provided by investing
activities for the year ended December 31, 2025 compared with 2024 was primarily due to no maturity of short-term deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities was $9.6 million for the year ended December 31, 2025, compared to $6.7 million provided by financing activities for the year
ended December 31, 2024 and $9.1 million of net cash provided by financing activities for the year ended December 31, 2023. The increase
in net cash provided by financing activities during 2025 compared to 2024 was due to higher proceeds from issuance of shares and warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our significant contractual obligations in U.S. dollars as of December 31, 2025:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less than <br/> 1&#160;year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">&#160;<span style="font-weight: bold;">1-3&#160;years</span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">&#160;<span style="font-weight: bold;">3-5&#160;years</span></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">More than <br/> 5&#160;years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 40%; text-align: justify">Leiden University milestones<sup>(1)</sup></td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">35,224</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,741</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23,483</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify; padding-bottom: 1.5pt">Car lease obligations</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">92,775</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,339</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,436</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">127,999</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">72,080</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">55,919</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify">(1)</td>
<td style="text-align: justify">The obligations above do not include a potential milestone payment of &#8364;50,000 upon the initiation
    of a Phase I study, &#8364;100,000 upon the initiation of a Phase II study, &#8364;200,000 upon the initiation of a Phase III study
    or &#8364;500,000 upon marketing approval by any regulatory authority.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as described above,
we did not have any material commitments for capital expenditures, including any anticipated material acquisition of plant and equipment
or interests in other companies, as of December 31, 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">C. Research and Development, Patents and Licenses,
Etc.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For information concerning
our research and development policies and a description of the amount spent during each of the last three fiscal years on company-sponsored
research and development activities, see &#8220;Item 5. Operating and Financial Review and Prospects&#8212; Results of Operation.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">D. Trend Information</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development stage
company and it is not possible for us to predict with any degree of accuracy the outcome of our research, development or commercialization
efforts. As such, it is not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments
or events that are reasonably likely to have a material effect on our net sales or revenues, income from continuing operations, profitability,
liquidity or capital resources, or that would cause financial information to not necessarily be indicative of future operating results
or financial condition. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are in this &#8220;Operating
and Financial Review and Prospects.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 109; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">E. Critical Accounting Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We prepare our financial statements
in accordance with U.S. GAAP. In doing so, we must make estimates and assumptions that affect our reported amounts of assets, liabilities
and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different
accounting policies and estimates. Changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly,
actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and
actual results, our financial condition or results of operations will be affected. Significant estimates include, but are not limited
to, those related to deferred revenue (including duration of the services), revenue recognition and stock-based compensation. For further
significant accounting policies please see Note 2 to our audited consolidated financial statements of this annual report. We believe that
our accounting policies contained therein are critical in fully understanding and evaluating our financial condition and operating results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-transform: uppercase"><span style="font-weight: bold;"><span id="a_008" style="display: inline-block;"></span>ITEM
6. </span></span><span style="font-weight: bold;">Directors, Senior Management and Employees</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">A. Directors and Senior Management.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth our directors and senior management:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid; width: 23%"><span style="font-weight: bold;">Member</span></td>
<td style="width: 2%">&#160;</td>
<td style="text-align: center; border-bottom: black 1.5pt solid; width: 8%"><span style="font-weight: bold;">Age</span></td>
<td style="width: 2%">&#160;</td>
<td style="text-align: center; border-bottom: black 1.5pt solid; width: 65%"><span style="font-weight: bold;">Position</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Pnina Fishman, Ph.D.</td>
<td>&#160;</td>
<td style="text-align: center">76</td>
<td>&#160;</td>
<td>Executive Chairman of the Board, Chief Scientific Officer</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Motti Farbstein</td>
<td>&#160;</td>
<td style="text-align: center">62</td>
<td>&#160;</td>
<td>Chief Executive Officer, Chief Financial Officer and Chief Operating Officer</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Sari Fishman, Ph.D.</td>
<td>&#160;</td>
<td style="text-align: center">53</td>
<td>&#160;</td>
<td>VP of Business Development</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Guy Regev(1)(2)(3)(4)(5)</td>
<td>&#160;</td>
<td style="text-align: center">55</td>
<td>&#160;</td>
<td>Director</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Abraham Sartani, M.D.(4)(5)</td>
<td>&#160;</td>
<td style="text-align: center">78</td>
<td>&#160;</td>
<td>Director</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Yoseph Bornstein(1)(2)(4)(5)</td>
<td>&#160;</td>
<td style="text-align: center">67</td>
<td>&#160;</td>
<td>Director</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center">&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Ilan Tamir(1)(2)(3)(4)(5)</td>
<td>&#160;</td>
<td style="text-align: center">67</td>
<td>&#160;</td>
<td>&#160;Director</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify">(1)</td>
<td style="text-align: justify">Member of the Compensation Committee</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">(2)</td>
<td style="text-align: justify">Member of the Audit Committee</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">(3)</td>
<td style="text-align: justify">External Director under Israeli Law</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">(4)</td>
<td style="text-align: justify">Independent Director under Israeli Law</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">(5)</td>
<td style="text-align: justify">Independent Director under the NYSE American rules</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Pnina Fishman,
Ph.D. </i></span>Pnina Fishman, Ph.D. co-founded Can-Fite, has served as our Chief Scientific Officer since June 2023, served on our
Board of Directors since September 2005 and since June 2023 has served as the Executive Chairman of the Can-Fite Board of Directors.
Dr. Fishman also served as our Chief Executive Officer from 2005 to June 2023. Dr. Fishman is the scientific founder of Can-Fite and
was previously a professor of Life Sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical
Research Institute, Rabin Medical Center, Israel. Dr. Fishman has authored or co-authored over 150 publications and presented the
findings of her research at many major scientific meetings. Her past managerial experience included seven years as Chief Executive
Officer of Mor Research Application, the technology transfer arm of Clalit Health Services, the largest healthcare provider in
Israel. Mor Research Application was also the first clinical research organization in Israel. Dr. Fishman currently also serves as a
member of the Board of Directors of F.D Consulting Ltd., Eye-Fite Ltd. and Ultratrend. Dr. Fishman holds a Ph.D. in Immunology from
the Bar Ilan University in Ramat Gan, Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Motti Farbstein</i></span>.
Motti Farbstein has been with Can-Fite since 2003. Mr. Farbstein has served as our Chief Executive Officer since June 2023. Mr. Farbstein
served as our Chief Operating Officer from August 2003 until May 2005 and from that date onwards he served as Chief Operating and Financial
Officer. Mr. Farbstein also serves as a director of Eye-Fite Ltd. since July 2011. Mr. Farbstein&#8217;s past managerial experience includes
seven years as Vice President of Mor Research Application, a company that managed the commercialization of the intellectual property
of all hospitals and research centers affiliated with Clalit Health Services, which is the largest healthcare provider in Israel and
was Israel&#8217;s first clinical CRO. Mr. Farbstein also has extensive experience in the data management of clinical trials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i></i></span></p><!-- Field: Page; Sequence: 110; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Sari Fishman, Ph.D</i>.
</span>Sari Fishman, Ph.D. has served as our Director Clinical Affairs from 2004 to 2014, Director of Business Development from 2014 to
2017 and since 2017 serves as VP of Business Development. Dr. Fishman gained her Ph.D. at the Bar-Ilan University, Ramat-Gan, Israel.
Dr. Sari Fishman is the daughter of Pnina Fishman, our Chief Scientific Officer and the Chairman of our Board of Directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Abraham Sartani, M.D.
</i></span>Abraham Sartani has served on our Board of Directors since 2001. Dr. Sartani has over 30 years of experience in the pharmaceuticals
industry and currently acts as a consultant to pharmaceutical and medical device companies. Dr. Sartani is a member of a number of scientific
and management societies and the author or co-author of numerous publications and patents in the urology, pain treatment and hypertension
fields. Dr. Sartani previously served on the Board of Directors of Akkadeas Pharma Srl (formerly Arkadia Pharma) and was a co-founder.
From 1985 until 2008, Dr. Sartani was the Vice-President of R&amp;D and Licensing and Group coordinator of B&amp;D of Recordati, a European
specialty pharmaceutical company. Prior to joining Recordati, from 1980 until 1985, Dr. Sartani was employed at Farmitalia-Carlo Erba,
serving in a number of capacities, including as the Medical Director for Europe. Currently, Dr. Sartani is a member of the board of directors
of BLV Pharma Group Srl, a privately owned Italian food supplements company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Guy Regev. </i></span>Guy
Regev has over fourteen years of experience in accounting, financial management and control and general management of commercial enterprises.
He has served on our Board of Directors since July 2011 and has served as a member of our Audit Committee and Compensation Committee
since February 2014. Mr. Regev has also been a director of OphthaliX since November 2011. Mr. Regev is currently the Chief Executive
Officer of Gaon Holdings Ltd, a publicly traded Israeli holding company traded on the TASE which focuses on three areas of operation
- Cleantech / Water, Financial Services, Retail/Trading. Mr. Regev is currently also the Chief Executive Officer of Middle East Tube
Company Ltd a publicly traded Israeli company traded on the TASE which focuses on steel pipe manufacturing and galvanization services.
Mr. Regev was the Chief Executive Officer of Shaked Global Group Ltd, a privately-held equity investment firm that provides value added
capital to environmental-related companies and technologies. Prior to joining Shaked, from 2001 to 2008, Mr. Regev was Vice President
of Commercial Business at Housing&amp; Construction Holding, or HCH, Israel&#8217;s largest infrastructure company. His duties included
being responsible for the consolidation and financial recovery of various business units within HCH. Prior to that, Mr. Regev carried
several roles within the group including as a Chief Financial Officer and later the Chief Executive Officer of Blue-Green Ltd., the environmental
services subsidiary of HCH. Between 1999 and 2001, Mr. Regev was a manager at Deloitte &amp; Touche, Israel. Mr. Regev holds an LLB degree
in Law (Israel) and is a licensed attorney and has been a licensed CPA since 1999. Mr. Regev is also a director of, The Green Way Ltd,
Shtang Construction and Engineering Ltd, R.I.B.E. Consulting &amp; Investment Ltd., Middle East Tube Company Ltd, Middle East Tube -
Industries 2001 Ltd, Middle East Tubes - Galvanizing (1994) Ltd, I-Solar Greentech Ltd, Plassim Infrastructure Ltd, Plassim Advanced
Solutions in Sanitation Ltd, Hakohav Valves Industries Metal (1987) Ltd, Metzerplas Agriculture Cooperative Ltd, B. Gaon Retail &amp;
Trading Ltd, Gaon Agro - Rimon Management Services Ltd, B. Gaon Business (2004) Ltd, Gaon Antan Investments Ltd, Or Asaf Investments
Ltd, Hamashbir Holdings (1999) Ltd, and AHAVA Holdings LTD.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Yoseph Borenstein</i>.
</span>Yoseph Bornstein has played key roles in the Israeli biomed industry during the past 35 years. Mr. Bornstein is a co-founder of Microbot
Medical and has been a member of the Board of Directors since Microbot Israel was founded in November 2010. He is also serving as a compensation
committee member and Audit committee member at Microbot Medical. Mr. Bornstein founded Shizim Ltd., a life science holding group in October
2000 and has served as its president since then. Mr. Bornstein is the Chairman of GCP Clinical Studies Ltd., a provider of clinical research
services and educational programs in Israel since January 2002. He is the Chairman of Biotis Ltd., that supplies bio-pharmaceutical industry,
since June 2000. In addition, he is the Chairman of Dolphin Medical Ltd, that supplies medical device industry, since April 2012. Mr.
Bornstein is a co-founder and director of XACT Robotics, developing a novel platform technology for robotic needle steering in minimally
invasive interventional procedures, and is the founder of ShizimXL &amp; ShizimVS, Innovation Centers. In October 1992, Mr. Bornstein
founded Pharmateam Ltd., an Israeli company that specialized in representing international pharmaceutical companies which was sold in
2000. Mr. Bornstein is also a founder of a number of other privately held life-science companies. Mr. Bornstein served as the Biotechnology
Committee Chairman of the United States-Israel Science &amp; Technology Commission, or the USISTC, from September 2002 to February 2005
as well as a consultant for USISTF from September 2002 to February 2005. He is also the founder of ILSI-Israel Life Science Industry
Organization (who was integrated into Israel Advanced Technology Industries) and ITTN-Israel Tech Transfer Organization. Mr. Bornstein
was the General Manager of Bristol-Myers Squibb (Israel), until 1992. Mr. Bornstein holds a Bachelor of Science degree in Agriculture
from the Hebrew University of Jerusalem.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 111; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Ilan
Tamir</i></span>. Ilan Tamir has over 25 years of leadership experience across global technology, healthcare, and capital markets
organizations. He recently joined our Board of Directors in March 2026. Mr. Tamir is currently the Chief Financial Officer at
Serverfarm Israel Infrastructure Ltd. where he oversees financial and operational performance for the company. Previously, Mr. Tamir
was CFO of Behalf Ltd., where he was appointed to lead the company&#8217;s structured wind down, including the closure of operations
in the U.S. and Israel, asset realization, multi million dollar loan repayments, and final shareholder distributions. Before that,
he served as COO and CFO of Matomy Media Group (LSE/TASE), guiding the company through a highly complex multi stakeholder
restructuring, asset divestitures, and comprehensive settlement agreements. Earlier in his career, Mr. Tamir held senior roles
including Interim CFO of Kryon Systems, CFO of BRM Capital, and CFO of Logal Software (NASDAQ: SMPLF). He also co founded, led, and
served on the Board of iMER, an international medical services firm that helped patients access top academic medical centers
worldwide. Mr. Tamir holds a B.Sc. in Computer Science from the Technion &#8211; Israel Institute of Technology and an MBA from Tel
Aviv University.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">B. Compensation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Compensation of Directors and Senior Management</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
in the aggregate all compensation we paid to all of our office holders as a group</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &#8216;office holder&#8217;
as defined in the Companies Law includes a general manager, chief business manager, deputy general manager, vice general manager, any
other person fulfilling or assuming the responsibilities of any of the foregoing positions without regard to such person&#8217;s title,
as well as a director, or a manager directly subordinate to the general manager or the chief executive officer. As of December 31, 2025,
in addition to the five members of the Board of Directors, we consider two other individuals, including our Chief Executive Officer,
who is also our Chief Financial Officer, and its VP Business Development to be office holders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salaries,<br/> fees,<br/> commissions,<br/> bonuses and<br/> options<br/> (thousand<br/> USD)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 88%; text-align: justify">All office holders as a group, consisting of 7 persons</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,804</td><td style="width: 1%; text-align: left">*</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; text-align: justify">*</td>
<td style="text-align: justify">This amount includes approximately $0.06 million set aside or accrued to provide pension, severance,
    retirement or similar benefits or expenses, but does not include business travel, professional and business association dues and
    expenses reimbursed to office holders, and other benefits commonly reimbursed or paid by companies in our industry.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 112; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
information regarding compensation reflected in our financial statements for five most highly compensated office holders, as of December
31, 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value of<br/> Options<br/> Granted(4)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other(5)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name and Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(USD in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 40%; text-align: left; text-indent: -9pt; padding-left: 0.125in">Pnina Fishman<br/> <i>Executive Chairman and Chief
    Scientific Officer</i></td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">351</td><td style="width: 1%; text-align: left">(1)</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">147</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">557</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; text-indent: -9pt; padding-left: 0.125in">Motti Farbstein<br/> <i>Chief Executive Officer, Chief Financial Officer and Chief Operating Officer</i></td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">398</td><td style="text-align: left">(2)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">650</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; text-indent: -9pt; padding-left: 0.125in">Sari Fishman<br/> <i>VP Business Development</i></td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">255</td><td style="text-align: left">(2)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">389</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; text-indent: -9pt; padding-left: 0.125in">Yaacov Goldman (6)<br/> <i>Former External Director</i></td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">(3)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">56</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left; text-indent: -9pt; padding-left: 0.125in">Guy Regev<br/> <i>External Director</i></td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">(3)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">22</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; text-align: justify">(1)</td>
<td style="text-align: justify">Amount represents consulting fee.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; text-align: justify">(2)</td>
<td style="text-align: justify">Salary includes gross salary plus payment of social benefits made by us on behalf of such person.
    Such benefits may include, to the extent applicable, payments, contributions and/or allocations for savings funds (e.g., managers&#8217;
    life insurance policy), education funds (referred to in Hebrew as &#8220;keren hishtalmut&#8221;), pension, severance, risk insurances
    (e.g., life, or work disability insurance), payments for social security payments and tax gross-up payments, vacation, medical insurance
    and benefits, convalescence or recreation pay and other benefits and perquisites consistent with our policies.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; text-align: justify">(3)</td>
<td style="text-align: justify">Amount represents fees for Board service.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; text-align: justify">(4)</td>
<td style="text-align: justify">The value of options is the expense recorded in our financial statements for the period ended December
    31, 2025 with respect to all options granted to such person. Assumptions and key variables used in the calculation of such amounts
    are discussed in Note 9 of our financial statements.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; text-align: justify"><p style="margin-top: 0; margin-bottom: 0">(5)</p>
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>(6)</td>
<td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount represents cost of use of company
    car.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Goldman resigned effective January 14,
    2026.</p></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each director other than
our Chief Executive Officer and Avraham Sartani, is entitled to the payment of annual fee of NIS 53,155 or $16,663 (based on the exchange
rate reported by the Bank of Israel on December 31, 2025), and payment of NIS 3,552 or $1,113 (based on the exchange rate reported by
the Bank of Israel on December 31, 2025) per meeting for participating in meetings of the Board and committees of the Board. The annual
fee shall not exceed the annual fee of an expert external director set forth in the Companies Regulations (Rules regarding Compensation
and Expenses of External Directors) 5760-2000 as adjusted by the Companies Regulations (Relief for Public Companies with Shares Listed
for Trading on a Stock Market Outside of Israel), 5760-2000. The compensation awarded for participating in resolutions that are adopted
without an actual convening (i.e., unanimous written resolutions) and for participating through telephone meetings will be reduced as
follows: (1) for resolutions that will be adopted without an actual convening, the participation compensation will be reduced by 50%;
and (2) for participation through telephone meetings, the participation compensation will be reduced by 40%. The participation compensation
and the annual fee is inclusive of all expenses incurred by our directors in connection with their participation in a meeting held at
our offices or with regard to resolutions resolved by written consent or teleconference. Avraham Sartani is entitled to a fee of $1,000
per meeting. In addition, our directors (other than our Chief Executive Officer and external directors) are entitled to reimbursement
for expenses related to their participation at meetings taking place not at our offices and outside their respective residency area.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 113; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Employment and Consulting Agreements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into employment
or consulting agreements with our directors, senior management and key service providers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of proprietary information and inventions. However, the enforceability
of the noncompetition provisions may be limited under applicable law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are summary
descriptions of certain agreements to which we are a party. The descriptions provided below do not purport to be complete and are qualified
in their entirety by the complete agreements, which are attached as exhibits to this Annual Report on Form 20-F.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Service Management Agreement
with F.D. Consulting:</i>&#160;On June 27, 2002, we entered into a Service Management Agreement with F.D. Consulting, a company partially
owned by Pnina Fishman, pursuant to which Dr. Fishman began serving as our Chief Scientific Officer and later became our Chief Executive
Officer and is a member of our Board of Directors and continues to be retained through this agreement. F.D. Consulting&#8217;s current
gross monthly fee is NIS 100,000 or $31,348 (based on the exchange rate reported by the Bank of Israel on December 31, 2025) which is
linked to the Israeli CPI and fluctuates accordingly. Dr. Fishman, through F.D. Consulting, is also entitled to reimbursement for reasonable
out-of-pocket expenses and use of a company automobile and mobile phone.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of F.D. Consulting&#8217;s
service management agreement is indefinite, unless earlier terminated for cause by us or without cause by either party, subject to three
months&#8217; advanced notice.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Fishman is also entitled
to receive options exercisable into our ordinary shares from time to time. As of the date of this Annual Report, Dr. Fishman has outstanding
options to purchase an aggregate of 23,600,000 ordinary shares, of which (i) 133 options to purchase 133 ordinary shares have an exercise
price of NIS 7,032 per ordinary share or $2,204 per ordinary share (based on the exchange rate reported by the Bank of Israel on December
31, 2025), fully vested as of the date of this Annual Report and expire on January 7, 2029, (ii) 833 options to purchase 833 ordinary
shares have an exercise price of NIS 756 per ordinary share or $237 per ordinary share (based on the exchange rate reported by the Bank
of Israel on December 31, 2025), fully vested as of the date of this Annual Report and expire on May 27, 2030, (iii) 833 options to purchase
833 ordinary shares have an exercise price of NIS 750 per ordinary share or $235 per ordinary share (based on the exchange rate reported
by the Bank of Israel on December 31, 2025), fully vested as of the date of this Annual Report, and expire on April 13, 2031, (iv) 1,000
options to purchase 1,000 ordinary shares have an exercise price of NIS 750 per ordinary share or $235 per ordinary share (based on the
exchange rate reported by the Bank of Israel on December 31, 2025), vesting on a quarterly basis over four years commencing September
5, 2022, and expire on July 16, 2032, (v) 2,500 options to purchase 2,500 ordinary shares have an exercise price of NIS 78.3 per ordinary
share or $24.5 per ordinary share (based on the exchange rate reported by the Bank of Israel on December 31, 2025), vesting on a quarterly
basis over four years commencing May 1, 2023 and expire on April 30, 3033, (vi) 2,500 options to purchase 2,500 ordinary shares have
an exercise price of NIS 82.5 per ordinary share or $25.8 per ordinary share (based on the exchange rate reported by the Bank of Israel
on December 31, 2025), vesting on a quarterly basis over four years commencing August 7, 2024 and expire on May 7, 2034, and (vii) 2,500
options to purchase 2,500 ordinary shares have an exercise price of NIS 54.0 per ordinary share or $16.9 per ordinary share (based on
the exchange rate reported by the Bank of Israel on December 31, 2025), vesting on a quarterly basis over four years commencing June
30, 2025 and expire on April 29, 2035.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Employment and Non-Competition
Agreement with Motti Farbstein:</i>&#160;On September 1, 2003 we entered into an employment and non-competition agreement with Motti
Farbstein pursuant to which Mr. Farbstein began serving as our Director of Clinical Operations and Administrative Affairs on September
1, 2003 and is currently serving as our Chief Executive Financial and Operating Officer. Mr. Farbstein&#8217;s current gross monthly
salary is NIS 80,000 or $25,078 (based on the exchange rate reported by the Bank of Israel on December 31, 2025). Mr. Farbstein is entitled
to an allocation to a manager&#8217;s insurance policy equivalent to an amount up to 13-1/3% of his gross monthly salary, up to 2-1/2%
of his gross monthly salary for disability insurance and 7-1/2% of his gross monthly salary for a study fund. The foregoing amounts are
paid by us. Five percent of his gross monthly salary is deducted for the manager&#8217;s insurance policy and 2-1/2% is deducted for
the study fund. Mr. Farbstein is also entitled to reimbursement for reasonable out-of-pocket expenses, including travel expenses, and
use of a company automobile and mobile phone.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of Mr. Farbstein&#8217;s
employment and non-competition agreement is indefinite, unless earlier terminated for just cause by either party, upon the death, disability
or retirement age, or without cause by either party, subject to 60 days&#8217; advanced notice.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 114; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Farbstein is also entitled
to receive options exercisable into our ordinary shares from time to time. As of the date of this Annual Report, Mr. Farbstein has outstanding
options to purchase an aggregate of 19,960,000 ordinary shares, of which (i) 83 options to purchase 83 ordinary shares at an exercise
price of NIS 7,539 per option or $2,363 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2025),
fully vested and expire on December 28, 2027, (ii) 50 options to purchase 50 ordinary shares at an exercise price of NIS 7,032 per option
or $2,204 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2025), fully vested and expire on January
7, 2029, (iii) 333 options to purchase 333 ordinary shares at an exercise price of NIS 756 per option or $237 per option (based on the
exchange rate reported by the Bank of Israel on December 31, 2025), fully vested and expire on May 27, 2030, (iv) 500 options to purchase
500 ordinary shares at an exercise price of NIS 750 per option or $235 per option (based on the exchange rate reported by the Bank of
Israel on December 31, 2025), vesting on a quarterly basis over four years commencing April 13, 2021 and expire on April 14, 2031; (v)
667 options to purchase 667 ordinary shares at an exercise price of NIS 750 per option or $235 per option (based on the exchange rate
reported by the Bank of Israel on December 31, 2025), vesting on a quarterly basis over four years commencing July 7, 2022 and expire
on July 6, 2032, (vi) 2,500 options to purchase 2,500 ordinary shares have an exercise price of NIS 78.3 per ordinary share or $24.5
per ordinary share (based on the exchange rate reported by the Bank of Israel on December 31, 2025), vesting on a quarterly basis over
four years commencing May 1, 2023 and expire on April 30, 2033, (vii) 2,500 options to purchase 2,500 ordinary shares have an exercise
price of NIS 82.5 per ordinary share or $25.8 per ordinary share (based on the exchange rate reported by the Bank of Israel on December
31, 2025), vesting on a quarterly basis over four years commencing August 7, 2024 and expire on May 7, 2034, and (viii) 2,500 options
to purchase 2,500 ordinary shares have an exercise price of NIS 54.0 per ordinary share or $16.9 per ordinary share (based on the exchange
rate reported by the Bank of Israel on December 31, 2025), vesting on a quarterly basis over four years commencing June 30, 2025 and
expire on April 29, 2035.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Consulting Agreement with
BioStrategics:</i>&#160;On September 27, 2005, we entered into a consulting agreement with BioStrategics through its President, Michael
Silverman pursuant to which Dr. Silverman began serving as our Medical Director. Dr. Silverman has extensive experience in clinical development
acquired through his involvement in clinical development in large pharmaceutical and small biopharmaceutical companies. He was involved
in international clinical research, market-oriented strategic planning, and the challenges of managing research and development portfolios
in various capacities at Sterling Winthrop Research Institute and subsequently at Sandoz Research Institute.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">BioStrategics&#8217; current
fee is $400 per hour with a maximum daily fee of $2,600. In addition, BioStrategics is entitled to reimbursement for reasonable pre-approved
expenses. The term of the consulting agreement is currently on a year-to-year basis, unless earlier terminated by either party upon 30
days&#8217; prior written notice or immediately by either party if such termination is for cause.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Master Services Agreement
with Accellient Partners:</i>&#160;On May 10, 2010, we entered into a Master Services Agreement with Accellient Partners, a company owned
by William Kerns, who currently serves as our current Vice President of Drug Development. Dr. Kerns has over 20 years of experience in
Pharmaceutical Research and Development at SmithKline Beecham and Eisai Pharmaceuticals. As a Senior Executive he has participated in
the development of drugs for over 100 Phase I studies and 13 NDA&#8217;s and/or Marketing Authorization Applications. Dr. Kerns has chaired
an FDA committee on biomarkers and he is an expert in preclinical development and regulatory strategy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the agreement,
consulting services are provided by Accellient Partners&#8217; personnel in accordance with individual work orders that are executed
from time to time. Each individual work order defines the scope of work to be provided and sets forth the fees to be paid to Accellient
Partners.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beginning on May 10, 2012,
the term of the master services agreement is on a month-to-month basis, unless terminated by us upon 30 days&#8217; prior written notice,
by us at any time if Accellient Partners commits a breach and fails to cure, or by Accellient Partners upon 30 days&#8217; prior written
notice if we commit a breach and fail to cure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 115; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">C. Board Practices</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>General</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Israeli
Companies Law, the management of our business is vested in our Board of Directors. Our Board of Directors may exercise all powers and
may take all actions that are not specifically granted to our shareholders. Our executive officers are responsible for our day-to-day
management and have individual responsibilities established by our Board of Directors. Executive officers are appointed by and serve
at the discretion of our Board of Directors, subject to any applicable employment agreements we have entered into with the executive
officers. See &#8220;Item 6. Directors, Senior Management and Employees&#8212;B. Compensation&#8212;Employment and Consulting Agreements.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Election of Directors and Terms of Office</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated
Articles of Association provide that the maximum number of members of the Board of Directors is 13. The Board of Directors is presently
comprised of five members.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2020, a special
general meeting of our shareholders approved an amendment to the our Amended and Restated Articles of Association, according to which
the Board of Directors, excluding the external directors, if any (who shall be elected and serve in office in strict accordance with
the provisions of the Companies Law, if so required by the Companies Law), shall consist of three classes of directors as nearly equal
in number as practicable, which are appointed for fixed terms of office in accordance with the Israeli Companies Law and our Amended
and Restated Articles of Association, as follows: (i) the term of office of the initial Class I directors expired at the first annual
general meeting of our shareholders held in 2020 and when their successors are elected and qualified, (ii) the term of office of the
initial Class II directors shall expire at the first annual general meeting of our shareholders following the annual general meeting
of our shareholders referred to in clause (i) above and when their successors are elected and qualified, and (iii) the term of office
of the initial Class III directors shall expire at the first annual general meeting of our shareholders following the annual general
meeting of our shareholders referred to in clause (ii) above and when their successors are elected and qualified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors (other than external
directors), may be elected only in annual general meetings of our shareholders. At each annual general meeting of our shareholders, commencing
with the annual general meeting of our shareholders held in 2021, each of the successors elected to replace the directors of a class
whose term shall have expired at such annual general meeting of our shareholders shall be elected to hold office until the third annual
general meeting of our shareholders next succeeding his or her election and until his or her respective successor shall have been elected
and qualified. Notwithstanding anything to the contrary, each director shall serve until his or her successor is elected and qualified
or until such earlier time as such director&#8217;s office is vacated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the number of directors
(excluding external directors) that constitutes the Board of Directors is hereafter changed, the then-serving directors shall be re-designated
to other classes and/or any newly created directorships or decrease in directorships shall be apportioned by the Board of Directors among
the classes so as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of Directors
constituting the Board of Directors shall shorten the term of any incumbent director.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors so elected may
not be dismissed from office by the shareholders or by a general meeting of our shareholders prior to the expiration of their term of
office. The directors do not receive any benefits upon the expiration of their term of office.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The three classes of directors
are Class I Directors, Class II Directors and Class III Directors. Abraham Sartani serves as our Class I Director until the close of the
annual meeting to be held in 2026; we currently have a vacancy for our Class II Director; and Dr. Pnina Fishman and Mr. Guy Regev serve
as our Class III Directors until the close of the annual meeting to be held in 2028.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any amendment, replacement
or suspension of our Amended and Restated Articles of Association regarding the election of directors, as described above, require a
majority of 65% of the voting power represented at the general meeting of our shareholders in person or by proxy and voting thereon,
disregarding abstentions from the count of the voting power present and voting, provided that such majority constitutes more than 20%
of our then issued and outstanding share capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 116; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A nominee for service as
a director in a public company may not be elected without submitting a declaration to the company, prior to election, specifying that
he or she has the requisite qualifications to serve as a director, independent director or external director (if required), as applicable,
and the ability to devote the appropriate time to performing his or her duties as such.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director, who ceases to
meet the statutory requirements to serve as a director, external director or independent director, as applicable, must notify the company
to that effect immediately and his or her service as a director will expire upon submission of such notice.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2023, Dr. Pnina
Fishman was appointed as Chairman of the Board, and Ilan Cohn, the former Chairman of the Board, remained as one of our Class II directors
until the close of the annual meeting held in 2024.&#160; On August 5, 2021, at a special meeting of our shareholders Yoseph Bornstein
was elected to serve as one of our external directors for a three-year term ending July 29, 2027. On March 10, 2026, at a special meeting
of our shareholders Mr. Ilan Tamir was elected to serve as one of our external directors for a three-year term ending March 3, 2029.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our directors or
senior management has any family relationship with any other director or senior management except that Sari Fishman is the daughter of
Pnina Fishman. None of our directors have service contracts that provide for benefits upon termination of his or her directorship with
us, other than the payment of salary due, accrued and unpaid as of and through the date of termination. See &#8220;Item 6. Directors,
Senior Management and Employees&#8212;B. Compensation&#8212;Employment and Consulting Agreements.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Chairman of the Board.
Un</i>der the Israeli Companies Law, without shareholder approval, a person cannot hold the role of both chairman of the Board of Directors
and chief executive officer of a company. Furthermore, a person who is directly or indirectly subordinate to a chief executive officer
of a company may not serve as the chairman of the Board of Directors of that company and the chairman of the Board of Directors may not
otherwise serve in any other capacity in a company or in a subsidiary of that company other than as the chairman of the Board of Directors
of such a subsidiary.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that an Israeli company may, under certain circumstances, exculpate an office holder from liability with respect to a breach
of his duty of care toward the company if appropriate provisions allowing such exculpation are included in its articles of association.
Our Amended and Restated Articles of Association permit us to maintain directors&#8217; and officers&#8217; liability insurance and to
indemnify our directors and officers for actions performed on behalf of us, subject to specified limitations. We maintain a directors
and officers insurance policy which covers the liability of our directors and officers as allowed under the Israeli Companies Law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term office holder is
defined in the Israeli Companies Law as a director, general manager, chief business manager, deputy general manager, vice general manager,
executive vice president, vice president, any other manager directly subordinate to the general manager, director, or any other person
assuming the responsibilities of any of the foregoing positions, without regard to such person&#8217;s title.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>External and Independent Directors</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the boards of directors of companies whose shares are publicly traded, either within or outside of Israel, are required to include
at least two members who qualify as external directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">External directors must be
elected by a majority vote of the shares present and voting at a shareholders meeting, provided that either:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the majority of the shares that are voted at the meeting, shall include at least a majority of the
    shares held by non-controlling shareholders and shareholders who do not have a personal interest in the election of the external
    director (other than a personal interest not deriving from a relationship with a controlling shareholder) who voted at the meeting,
    excluding abstentions, vote in favor of the election of the external director; Anyone with a personal interest will be subject to
    the provisions of section 276, mutatis mutandis; or</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 117; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">the total number of shares held by non-controlling, disinterested shareholders (as described in the
    preceding bullet point) that are voted against the election of the external director does not exceed 2% of the aggregate voting rights
    in the company.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &#8220;controlling
shareholder&#8221; means a shareholder with the ability to direct the activities of the company, other than by virtue of being an office
holder. A shareholder is presumed to have &#8220;control&#8221; of the company and thus to be a controlling shareholder of the company
if the shareholder holds 50% or more of the &#8220;means of control&#8221; of the company. &#8220;Means of control&#8221; is defined
as (1) the right to vote at a general meeting of a company or a corresponding body of another corporation; or (2) the right to appoint
directors of the corporation or its general manager. For the purpose of approving related-party transactions, the term also includes
any shareholder that holds 25% or more of the voting rights of the company if the company has no shareholder that owns more than 50%
of its voting rights. For the purpose of determining the holding percentage stated above, two or more shareholders who have a personal
interest in a transaction that is brought for the company&#8217;s approval are deemed as joint holders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person may not serve as
an external director of a company if (i) such person is a relative of a controlling shareholder of a company or (ii) at the date of such
person&#8217;s appointment or within the prior two years, such person, such person&#8217;s relative, partner, employer or any entity
under such person&#8217;s control or anyone to whom such person is subordinate, whether directly or indirectly, has or had any affiliation
with (a) the company, (b) the controlling shareholder or his relative, at the time of such person&#8217;s appointment or (c) any entity
that is either controlled by the company or by its controlling shareholder at the time of such appointment or during the prior two years.
If a company does not have a controlling shareholder or a group of shareholders who have a control block entitling them to vote at least
25% of the votes in a shareholders meeting, then a person may not serve as an external director if, such person or such person&#8217;s
relative, partner, employer or any entity under such person&#8217;s control, has or had, on or within the two years preceding the date
of the person&#8217;s appointment to serve as an external director, any affiliation with the chairman of our Board of Directors, chief
executive officer, a substantial shareholder who holds at least 5% of the issued and outstanding shares of the company or voting rights
which entitle him to vote at least 5% of the votes in a shareholders meeting, or the chief financial officer of the company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term affiliation includes:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">an employment relationship;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">a business or professional relationship even if not maintained on a regular basis (excluding insignificant
    relationships);</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">control; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">service as an office holder, excluding service as a director in a private company prior to the initial
    offering of its shares to the public if such director was appointed as a director of the private company in order to serve as an
    external director following the public offering.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term relative is defined
as a spouse, sibling, parent, grandparent or descendant; a spouse&#8217;s sibling, parent or descendant; and the spouse of each of the
foregoing persons.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, no person may
serve as an external director if that person&#8217;s professional activities create, or may create, a conflict of interest with that
person&#8217;s responsibilities as a director or otherwise interfere with that person&#8217;s ability to serve as an external director
or if the person is an employee of the Israel Securities Authority, or the ISA, or of the TASE. Furthermore, a person may not continue
to serve as an external director if he or she received direct or indirect compensation from the company for his or her role as a director.
This prohibition does not apply to compensation paid or given in accordance with regulations promulgated under the Israeli Companies
Law or amounts paid pursuant to indemnification and/or exculpation contracts or commitments and insurance coverage. If, at the time an
external director is appointed, all current members of the Board of Directors not otherwise affiliated with the company are of the same
gender, then that external director must be of the other gender. In addition, a director of a company may not be elected as an external
director of another company if, at that time, a director of the other company is acting as an external director of the first company.</p><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 118; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the termination
of an external director&#8217;s service on a Board of Directors, such former external director and his or her spouse and children may
not be provided with a direct or indirect benefit by the company, its controlling shareholder or any entity under its controlling shareholder&#8217;s
control. This includes engagement to serve as an executive officer or director of the company or a company controlled by its controlling
shareholder, or employment by, or providing services to, any such company for consideration, either directly or indirectly, including
through a corporation controlled by the former external director, for a period of two years (and for a period of one year with respect
to relatives of the former external director).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that an external director must meet certain professional qualifications or have financial and accounting expertise and that
at least one external director must have financial and accounting expertise. However, if at least one of our other directors (i) meets
the independence requirements of the Securities Exchange Act of 1934, as amended, (ii) meets the standards of the NYSE American rules
for membership on the audit committee and (iii) has financial and accounting expertise as defined in the Israeli Companies Law and applicable
regulations, then neither of our external directors is required to possess financial and accounting expertise as long as both possess
other requisite professional qualifications. Our Board of Directors is required to determine whether a director possesses financial and
accounting expertise by examining whether, due to the director&#8217;s education, experience and qualifications, the director is highly
proficient and knowledgeable with regard to business-accounting issues and financial statements, to the extent that the director is able
to engage in a discussion concerning the presentation of financial information in our financial statements, among others. The regulations
define a director with the requisite professional qualifications as a director who satisfies one of the following requirements: (i) the
director holds an academic degree in either economics, business administration, accounting, law or public administration; (ii) the director
either holds an academic degree in any other field or has completed another form of higher education in our primary field of business
or in an area which is relevant to the office of an external director; or (iii) the director has at least five years of experience serving
in any one of the following, or at least five years of cumulative experience serving in two or more of the following capacities: (a)
a senior business management position in a corporation with a substantial scope of business; (b) a senior position in our primary field
of business; or (c) a senior position in public administration. Yaacov Goldman, who is one of our external directors, meets the required
qualifications and has financial and accounting expertise as required by the Israeli Companies Law, while Guy Regev, an independent director,
also meets the required qualifications and has financial and accounting expertise as required by the Israeli Companies Law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
defines an independent director as a director who complies with the following and was appointed as such in accordance with Chapter 1
of Part 56 of the Israeli Companies Law: (1) the director complies with the qualification to serve as an external director as set out
in Sections 240 (b)-(f) of the Israeli Companies Law and the audit committee has approved such compliance; and (2) the director has not
served as a director of the company for more than nine consecutive years (which, for such purpose, does not include breaks in such service
for periods of less than two year).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an external directorship
becomes vacant and there are less than two external directors on the Board of Directors at the time, then the Board of Directors is required
under the Israeli Companies Law to call a shareholders&#8217; meeting as soon as possible to appoint a replacement external director.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each committee of the Board
of Directors that is authorized to exercise the powers of the Board of Directors must include at least one external director, except
that the audit committee and compensation committee must each include all external directors then serving on the Board of Directors.
Under the Israeli Companies Law, external directors of a company are prohibited from receiving, directly or indirectly, any compensation
for their services as external directors, other than compensation and reimbursement of expenses pursuant to applicable regulations promulgated
under the Israeli Companies Law. Compensation of an external director is determined prior to his or her appointment and may not be changed
during his or her term subject to certain exceptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yoseph Borenstein and
Ilan Tamir serve as external directors on our Board of Directors pursuant to the provisions of the Israeli Companies
Law. They both serve on our audit committee and our compensation committee. Our Board of Directors has determined that Guy Regev
possesses accounting and financial expertise, and that both of our external directors possess the requisite professional
qualifications. In addition to our external directors, Guy Regev and Abraham Sartani serve as independent directors on our Board of
Directors. Guy Regev also serves on our audit committee and our compensation committee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><!-- Field: Page; Sequence: 119; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Audit Committee</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
requires public companies to appoint an audit committee. The responsibilities of the audit committee include identifying irregularities
in the management of our business and approving related party transactions as required by law. An audit committee must consist of at
least three directors, including all of its external directors and a majority of independent directors. The chairman of the Board of
Directors, any director employed by or otherwise providing services to the company, and a controlling shareholder or any relative of
a controlling shareholder, may not be a member of the audit committee. An audit committee may not approve an action or a transaction
with a controlling shareholder, or with an office holder, unless at the time of approval two external directors are serving as members
of the audit committee and at least one of the external directors was present at the meeting in which an approval was granted.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee is currently
comprised of three independent non-executive directors. The audit committee is chaired by Guy Regev, who serves as the audit committee
financial expert, with Yoseph Borenstein and Ilan Tamir as members. Our audit committee meets at least four times a year and monitors
the adequacy of our internal controls, accounting policies and financial reporting. It regularly reviews the results of the ongoing risk
self-assessment process, which we undertake, and our interim and annual reports prior to their submission for approval by the full Board
of Directors. The audit committee oversees the activities of the internal auditor, sets its annual tasks and goals and reviews its reports.
The audit committee reviews the objectivity and independence of the external auditors and also considers the scope of their work and
fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee provides
assistance to our Board of Directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing,
financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants
and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our audit committee
also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that
the accountants are independent of management.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, our audit committee is responsible for (i) determining whether there are deficiencies in the business management practices of our
company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the Board of Directors
to improve such practices and amend such deficiencies, (ii) determining whether certain related party transactions (including transactions
in which an office holder has a personal interest) should be deemed as material or extraordinary, and to approve such transactions (which
may be approved according to certain criteria set out by our audit committee on an annual basis) (see &#8220;&#8212;Approval of Related
Party Transactions under the Israeli Companies Law&#8221;); (iii) establishing procedures to be followed in respect of related party
transactions with a controlling shareholder (where such are not extraordinary transactions), which may include, where applicable, the
establishment of a competitive process for such transaction, under the supervision of the audit committee, or individual, or other committee
or body selected by the audit committee, in accordance with criteria determined by the audit committee; (iv) determining procedures for
approving certain related party transactions with a controlling shareholder, which having been determined by the audit committee not
to be extraordinary transactions, were also determined by the audit committee not to be negligible transactions; (v) approving the working
plan of the internal auditor, to examine such working plan before its submission to the Board and proposing amendments thereto, (vi)
examining our internal controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources
and tools to dispose of its responsibilities, (vii) examining the scope of our auditor&#8217;s work and compensation and submitting a
recommendation with respect thereto to our Board of Directors or shareholders, depending on which of them is considering the appointment
of our auditor, and (viii) establishing procedures for the handling of employees&#8217; complaints as to the management of our business
and the protection to be provided to such employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a written
charter for our audit committee, setting forth its responsibilities as outlined by the regulations of the SEC. In addition, our audit
committee has adopted procedures for the receipt, retention and treatment of complaints we may receive regarding accounting, internal
accounting controls or auditing matters and the submission by our employees of concerns regarding questionable accounting or auditing
matters. In addition, SEC rules mandate that the audit committee of a listed issuer consist of at least three members, all of whom must
be independent, as such term is defined by rules and regulations promulgated by the SEC. We are in compliance with the independence requirements
of the SEC rules.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 120; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any person who is not eligible
to serve on the audit committee is further restricted from participating in its meetings and votes, unless the chairman of the audit
committee determines that such person&#8217;s presence is necessary in order to present a certain matter; provided, however, that company
employees who are not controlling shareholders or relatives of such shareholders may be present in the meetings, but not for actual voting,
and likewise, company counsel and secretary who are not controlling shareholders or relatives of such shareholders may be present in
the meetings and for actual voting if such presence is requested by the audit committee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the above,
all such committee&#8217;s members must apply with the following requirements:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; font-size: 10pt; text-align: justify">&#160;</td>
<td style="width: 24px; font-size: 10pt; text-align: justify">&#9679;</td>
<td style="font-size: 10pt; text-align: justify">All members shall be members of the Board of Directors of the company.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px; text-align: justify">&#160;</td>
<td style="width: 24px; text-align: justify">&#9679;</td>
<td style="text-align: justify">At least one of the committee&#8217;s members shall have financial and accounting expertise and the
    rest of the committee&#8217;s members must have the ability to read and understand financial statements.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our company, through our
audit committee, is in full compliance with the above requirements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Financial Statement Examination Committee</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the Board of Directors of a public company must appoint a financial statement examination committee, which consists of members with
accounting and financial expertise or the ability to read and understand financial statements. According to a resolution of our Board
of Directors, the audit committee has been assigned the responsibilities and duties of a financial statements examination committee,
as permitted under relevant regulations promulgated under the Israeli Companies Law. From time to time as necessary and required to approve
our financial statements, the audit committee holds separate meetings, prior to the scheduled meetings of the entire Board of Directors
regarding financial statement approval. The function of a financial statements examination committee is to discuss and provide recommendations
to its Board of Directors (including the report of any deficiency found) with respect to the following issues: (i) estimations and assessments
made in connection with the preparation of financial statements; (ii) internal controls related to the financial statements; (iii) completeness
and propriety of the disclosure in the financial statements; (iv) the accounting policies adopted and the accounting treatments implemented
in material matters of the company; and (v) value evaluations, including the assumptions and assessments on which evaluations are based
and the supporting data in the financial statements. Our independent auditors and our internal auditors are invited to attend all meetings
of audit committee when it is acting in the role of the financial statements examination committee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Compensation Committee</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amendment no. 20 to the Israeli
Companies Law was published on November 12, 2012 and became effective on December 12, 2012, or Amendment no. 20. In general, Amendment
no. 20 requires public companies to appoint a compensation committee and to adopt a compensation policy with respect to its officers,
or the Compensation Policy. In addition, Amendment no. 20 addresses the corporate approval process required for a public company&#8217;s
engagement with its officers (with specific reference to a director, a non-director officer, a chief executive officer and controlling
shareholders and their relatives who are employed by the company).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee
shall be nominated by the Board of Directors and be comprised of its members. The compensation committee must consist of at least three
members. All of the external directors must serve on the compensation committee and constitute a majority of its members. The remaining
members of the compensation committee must be directors who qualify to serve as members of the audit committee (including the fact that
they are independent) and their compensation should be identical to the compensation paid to the external directors of the company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 121; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar to the rules that
apply to the audit committee, the compensation committee may not include the chairman of the board, or any director employed by the Company,
by a controlling shareholder or by any entity controlled by a controlling shareholder, or any director providing services to the company,
to a controlling shareholder or to any entity controlled by a controlling shareholder on a regular basis, or any director whose primary
income is dependent on a controlling shareholder, and may not include a controlling shareholder or any of its relatives. Individuals
who are not permitted to be compensation committee members may not participate in the committee&#8217;s meetings other than to present
a particular issue; provided, however, that an employee that is not a controlling shareholder or relative may participate in the committee&#8217;s
discussions, but not in any vote, and our legal counsel and corporate secretary may participate in the committee&#8217;s discussions
and votes if requested by the committee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The roles of the compensation
committee are, among others, to: (i) recommend to the Board of Directors the Compensation Policy for office holders and recommend to
the board once every three years the extension of a Compensation Policy that had been approved for a period of more than three years;
(ii) recommend to the directors any update of the Compensation Policy, from time to time, and examine its implementation; (iii) decide
whether to approve the terms of office and of employment of office holders that require approval of the compensation committee; and (iv)
decide, in certain circumstances, whether to exempt the approval of terms of office of a chief executive officer from the requirement
of shareholder approval.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy requires
the approval of the general meeting of shareholders with a &#8220;Special Majority&#8221;, which requires a majority of the shareholders
of the company who are not either a controlling shareholder or an &#8220;interested party&#8221; in the proposed resolution, or that
shareholders holding less than 2% of the voting power in the company voted against the proposed resolution at such meeting. However,
under special circumstances, the Board of Directors may approve the compensation policy without shareholder approval, if the compensation
committee and thereafter the Board of Directors decided, based on substantiated reasons after they have reviewed the Compensation Policy
again, that the Compensation Policy is in the best interest of the company. The Compensation Policy is required to be brought before
the shareholders of the Company once every three years for approval.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, our Compensation Policy must generally serve as the basis for corporate approvals with respect to the financial terms of employment
or engagement of office holders, including exemption, insurance, indemnification or any monetary payment or obligation of payment in
respect of employment or engagement. The Compensation Policy must relate to certain factors, including advancement of the company&#8217;s
objective, the company&#8217;s business plan and its long term strategy, and creation of appropriate incentives for office holders. It
must also consider, among other things, the company&#8217;s risk management, size and nature of its operations. The Compensation Policy
must furthermore consider the following additional factors:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">The knowledge, skills, expertise, and accomplishments of the relevant office holder;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">The office holder&#8217;s roles and responsibilities and prior compensation agreements with him or
    her;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">The relationship between the terms offered and the average compensation of the other employees of
    the company, including those employed through manpower companies;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">The impact of disparities in salary upon work relationships in the company;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">The possibility of reducing variable compensation at the discretion of the Board of Directors;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">The possibility of setting a limit on the exercise value of non-cash variable equity-based compensation;
    and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">As to severance compensation, the period of service of the office holder, the terms of his or her
    compensation during such service period, the company&#8217;s performance during that period of service, the person&#8217;s contributions
    towards the company&#8217;s achievement of its goals and the maximization of its profits, and the circumstances under which the person
    is leaving the company.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy must
also include the following principles:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">the link between variable compensation and the long term performance and measurable criteria;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 122; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">the relationship between variable and fixed compensation, and the ceiling for the value of variable
    compensation;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">the conditions under which an office holder would be required to repay compensation paid to him or
    her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in
    the company&#8217;s financial statements;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">the minimum holding or vesting period for variable, equity-based compensation; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">maximum limits for severance compensation.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy was
approved by the general meeting of shareholders on January 19, 2017 after discussions and recommendation of the compensation committee
and approval by the Board of Directors. The Compensation Policy was amended by the general meeting of shareholders on June 7, 2021. Moreover,
the approval of the compensation committee is required in order to approve terms of office and/or employment of office holders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yaacov Goldman is the chairman
of our compensation committee. Guy Regev and Yoseph Bornstein serve as the other members of our compensation committee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Amendment no. 27 to
the Israeli Companies Law, which became effective as of February 17, 2016, the audit committee of an Israeli public company which has
been established and conducts itself also in accordance with provisions governing the composition of the compensation committee as set
forth in the Israeli Companies Law, may act in lieu of a compensation committee with respect to the responsibilities of a compensation
committee which are set forth in the Israeli Companies Law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Approval of Related Party Transactions under the Israeli Companies
Law</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Fiduciary duties of the
office holders</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
imposes a duty of care and a duty of loyalty on all office holders of a company. The duty of care of an office holder is based on the
duty of care set forth in connection with the tort of negligence under the Israeli Torts Ordinance (New Version) 5728-1968. This duty
of care requires an office holder to act with the degree of proficiency with which a reasonable office holder in the same position would
have acted under the same circumstances. The duty of care includes a duty to use reasonable means, in light of the circumstances, to
obtain:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">information on the advisability of a given action brought for his or her approval or performed by
    virtue of his or her position; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">all other important information pertaining to these actions.&#160;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of loyalty requires
an office holder to act in good faith and for the benefit of the company, and includes the duty to:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">refrain from any act involving a conflict of interest between the performance of his or her duties
    in the company and his or her other duties or personal affairs;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">refrain from any activity that is competitive with the business of the company;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">refrain from exploiting any business opportunity of the company for the purpose of gaining a personal
    advantage for himself or herself or others; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">disclose to the company any information or documents relating to our affairs which the office holder
    received as a result of his or her position as an office holder.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 123; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may approve an act performed
in breach of the duty of loyalty of an office holder provided that the office holder acted in good faith, the act or its approval does
not harm the company, and the office holder discloses his or her personal interest, as described below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Disclosure of personal
interests of an office holder and approval of acts and transactions</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy requires
the approval of the general meeting of shareholders with a &#8220;Special Majority&#8221;, which requires a majority of the shareholders
of the company who are not either a controlling shareholder or an &#8220;interested party&#8221; in the proposed resolution, or that
shareholders holding less than 2% of the voting power in the company voted against the proposed resolution at such meeting. However,
under special circumstances, the Board of Directors may approve the compensation policy without shareholder approval, if the compensation
committee and thereafter the Board of Directors decided, based on substantiated reasons after they have reviewed the Compensation Policy
again, that the Compensation Policy is in the best interest of the company. The Compensation Policy is required to be brought before
the shareholders of the Company once every three years for approval.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term personal interest
is defined under the Israeli Companies Law to include the personal interest of a person in an action or in the business of a company,
including the personal interest of such person&#8217;s relative or the interest of any corporation in which the person is an interested
party, but excluding a personal interest stemming solely from the fact of holding shares in the company. A personal interest furthermore
includes the personal interest of a person for whom the office holder holds a voting proxy or the interest of the office holder with
respect to his or her vote on behalf of the shareholder for whom he or she holds a proxy even if such shareholder itself has no personal
interest in the approval of the matter. An office holder is not, however, obliged to disclose a personal interest if it derives solely
from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, an extraordinary transaction which requires approval is defined as any of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a transaction other than in the ordinary course of business;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a transaction that is not on market terms; or</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a transaction that may have a material impact on our profitability, assets or liabilities.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, once an office holder has complied with the disclosure requirement described above, a company may approve a transaction between
the company and the office holder or a third party in which the office holder has a personal interest, or approve an action by the office
holder that would otherwise be deemed a breach of duty of loyalty. However, a company may not approve a transaction or action that is
adverse to our interest or that is not performed by the office holder in good faith.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, unless the articles of association of a company provide otherwise, a transaction with an office holder, a transaction with a third
party in which the office holder has a personal interest, and an action of an office holder that would otherwise be deemed a breach of
duty of loyalty requires approval by the Board of Directors. Our Amended and Restated Articles of Association do not provide otherwise.
If the transaction or action considered is (i) an extraordinary transaction, (ii) an action of an office holder that would otherwise
be deemed a breach of duty of loyalty and may have a material impact on a company&#8217;s profitability, assets or liabilities, (iii)
an undertaking to indemnify or insure an office holder who is not a director, or (iv) for matters considered an undertaking concerning
the terms of compensation of an office holder who is not a director, including, an undertaking to indemnify or insure such office holder,
then approval by the audit committee is required prior to approval by the Board of Directors. Arrangements regarding the compensation,
indemnification or insurance of a director require the approval of the audit committee, Board of Directors and shareholders, in that
order.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director who has a personal
interest in a matter that is considered at a meeting of the Board of Directors or the audit committee may generally not be present at
the meeting or vote on the matter, unless a majority of the directors or members of the audit committee have a personal interest in the
matter or the chairman of the audit committee or Board of Directors, as applicable, determines that he or she should be present to present
the transaction that is subject to approval. If a majority of the directors have a personal interest in the matter, such matter would
also require approval of the shareholders of the company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 124; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Disclosure of personal
interests of a controlling shareholder and approval of transactions</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public company. See &#8220;&#8212;
Audit Committee&#8221; for a definition of controlling shareholder. Extraordinary transactions with a controlling shareholder or in which
a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder has a personal interest,
as well as transactions for the provision of services whether directly or indirectly by a controlling shareholder or his or her relative,
or a company such controlling shareholder controls, and transactions concerning the terms of engagement of a controlling shareholder
or a controlling shareholder&#8217;s relative, whether as an office holder or an employee, require the approval of the audit committee,
the Board of Directors and a majority of the shares voted by the shareholders of the company participating and voting on the matter in
a shareholders&#8217; meeting. In addition, such shareholder approval must fulfill one of the following requirements:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">at least a majority of the shares held by shareholders who have no personal interest in the transaction
    and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">the shares voted by shareholders who have no personal interest in the transaction who vote against
    the transaction represent no more than 2% of the voting rights in the company.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that any such
transaction with a controlling shareholder is for a period extending beyond three years, approval is required once every three years,
unless the audit committee determines that the duration of the transaction is reasonable given the circumstances related thereto.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Duties of shareholders</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an acceptable manner in
exercising its rights and performing its obligations to the company and other shareholders, including, among other things, voting at
general meetings of shareholders on the following matters:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">an amendment to the articles of association;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">an increase in our authorized share capital;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a merger; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">the approval of related party transactions and acts of office holders that require shareholder approval.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A shareholder also has a
general duty to refrain from discriminating against other shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remedies generally available
upon a breach of contract will also apply to a breach of the above mentioned duties, and in the event of discrimination against other
shareholders, additional remedies are available to the injured shareholder.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any controlling
shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under
a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder, or has another power
with respect to a company, is under a duty to act with fairness towards the company. The Israeli Companies Law does not describe the
substance of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of
a breach of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 125; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Exculpation, Insurance and Indemnification of Directors and
Officers</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate
an office holder in advance from liability to us, in whole or in part, for damages caused to us as a result of a breach of duty of care
but only if a provision authorizing such exculpation is included in its articles of association. Our Amended and Restated Articles of
Association include such a provision. We may not exculpate in advance a director from liability arising out of a prohibited dividend
or distribution to shareholders.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law and the Israeli Securities Law, a company may indemnify, or undertake in advance to indemnify, an office holder, provided its articles
of association include a provision authorizing such indemnification, for the following liabilities and expenses imposed on an office
holder or incurred by office holder due to acts performed by him or her as an office holder:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">Financial liability incurred by or imposed on him or her in favor of another person pursuant to a
    judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an office
    holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion
    of the Board of Directors, can be foreseen based on our activities when the undertaking to indemnify is given, and to an amount or
    according to criteria determined by the Board of Directors as reasonable under the circumstances, and such undertaking shall detail
    the abovementioned foreseen events and amount or criteria;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">Reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder as
    a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation
    or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding;
    and (ii) no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation
    or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof
    of criminal intent or as a monetary sanction;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">Reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or
    imposed by a court in proceedings instituted against him or her by us, on our behalf, or by a third party, or in connection with
    criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require
    proof of criminal intent; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">Expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in
    relation to an administrative proceeding instituted against such office holder, or certain compensation payments required to be made
    to an injured party, pursuant to certain provisions of the Israeli Securities Law.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder
if and to the extent provided in the Company&#8217;s articles of association:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a breach of the duty of loyalty to us, provided that the office holder acted in good faith and had
    a reasonable basis to believe that the act would not harm us;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a breach of duty of care to us or to a third party; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a financial liability imposed on the office holder in favor of a third party.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Israeli Companies Law and the Israeli Securities Law, we may also enter into a contract to insure an office holder, in respect
of expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding
instituted against such office holder or payment required to be made to an injured party, pursuant to certain provisions of the Israeli
Securities Law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"></p><!-- Field: Page; Sequence: 126; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nevertheless, under the Israeli
Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a breach of fiduciary duty, except for indemnification and insurance for a breach of the duty of
    loyalty to us in the event office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice
    us;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of
    the negligent conduct of the office holder;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">an act or omission committed with intent to derive unlawful personal benefit; or</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a fine, monetary sanction, penalty or forfeit levied against the office holder.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, exculpation, indemnification and insurance of office holders require the approval of the compensation committee, Board of Directors
and, in certain circumstances, the shareholders. Our Amended and Restated Articles of Association permit us to exculpate, indemnify and
insure our office holders to the fullest extent permitted by the Israeli Companies Law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Approval of Compensation to Our Officers</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
prescribes that compensation to officers must be approved by a company&#8217;s Board of Directors after obtaining the approval of the
compensation committee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As detailed above, our compensation
committee consists of three independent directors: Yoseph Borenstein, Yaacov Goldman and Guy Regev. The responsibilities of the compensation
committee are to set our overall policy on executive remuneration and to decide the specific remuneration, benefits and terms of employment
for directors, officers and the Chief Executive Officer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The objectives of the compensation
committee&#8217;s policies are that such individuals should receive compensation which is appropriate given their performance, level
of responsibility and experience. Compensation packages should also allow us to attract and retain executives of the necessary caliber
while, at the same time, motivating them to achieve the highest level of corporate performance in line with the best interests of shareholders.
In order to determine the elements and level of remuneration appropriate to each executive director, the compensation committee reviews
surveys on executive pay, obtains external professional advice and considers individual performance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Internal Auditor</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the Board of Directors must appoint an internal auditor, nominated by the audit committee. The role of the internal auditor is to
examine, among other matters, whether our actions comply with the law and orderly business procedure. Under the Israeli Companies Law,
an internal auditor may not be:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a person (or a relative of a person) who holds more than 5% of our ordinary shares;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a person (or a relative of a person) who has the power to appoint a director or the general manager
    of the company;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">an executive officer or director of the company (or a relative thereof); or</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a member of our independent accounting firm, or anyone on his or her behalf.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We comply with the requirement
of the Israeli Companies Law relating to internal auditors. Our internal auditors examine whether our various activities comply with
the law and orderly business procedure. Our current internal auditor is Brightman Almagor Zohar &amp; Co. (A Firm in the Deloitte Global
Network).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 127; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">D. Employees.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025,
we had 5 employees, 2 of whom were employed in management and administration, 2 of whom were employed in research and development and
1 of whom was employed in business development. All of these employees were located in Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While none of our employees
are party to any collective bargaining agreements, certain provisions of the collective bargaining agreements between the Histadrut (General
Federation of Labor in Israel) and the Coordination Bureau of Economic Organizations (including the Industrialists&#8217; Associations)
are applicable to our employees by order of the Israel Ministry of Labor. These provisions primarily concern the length of the workday,
minimum daily wages for professional workers, pension fund benefits for all employees, insurance for work-related accidents, procedures
for dismissing employees, determination of severance pay and other conditions of employment. We generally provide our employees with
benefits and working conditions beyond the required minimums. We have never experienced any employment-related work stoppages and believe
our relationship with our employees is good.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">E. Share Ownership.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding the beneficial ownership of our outstanding ordinary shares as of March 25, 2026 by the members of our senior management
and Board of Directors individually and as a group. The beneficial ownership of ordinary shares is based on the 4,285,093 ordinary shares
outstanding as of March 25, 2026 and is determined in accordance with the rules of the SEC and generally includes any ordinary shares
over which a person exercises sole or shared voting or investment power. For purposes of the table below, we deem shares subject to options
or warrants that are currently exercisable or exercisable within 60 days of March 25, 2026, to be outstanding and to be beneficially owned
by the person holding the options or warrants for the purposes of computing the percentage ownership of that person but we do not treat
them as outstanding for the purpose of computing the percentage ownership of any other person.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; white-space: nowrap; text-align: left; font-weight: bold">Name
    of Beneficial Owner</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number of<br/>
    Ordinary <br/>
    Shares*</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Percentage
    of<br/> Class**</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold">Senior Management and Directors</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; text-align: left">Pnina Fishman, Ph.D.</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,356</td><td style="width: 1%; text-align: left">(1)</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">**</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Motti Farbstein</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">5,029</td><td style="text-align: left">(2)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Sari Fishman, Ph.D.</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">3,919</td><td style="text-align: left">(3)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Guy Regev</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">2,932</td><td style="text-align: left">(4)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Abraham Sartani, M.D.</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">2,924</td><td style="text-align: left">(5)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Yoseph Borenstein</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">2,908</td><td style="text-align: left">(6)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Ilan Tamir</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">(7)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Senior Management and Directors as a group (7 persons)</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">24,068</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">1.0</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-weight: bold; text-align: left">Holders of more than 5% of our voting securities</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>None</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px">*</td>
<td style="text-align: justify">U.S. dollar translations of NIS amounts presented in the footnotes to this table are translated using
    the exchange rate reported by the Bank of Israel on December 31, 2025.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px">**</td>
<td style="text-align: justify">Denotes less than 1%</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 88 ordinary shares, (ii) 133 options to purchase 133 ordinary shares at an exercise price of NIS 7,032 per option or $2,204 per option and expire on January 7, 2029, (iii) 833 options to purchase 833 ordinary shares at an exercise price of NIS 750 per option or $235 per option and expire on May 27, 2030; (iv) 833 options to purchase 833 ordinary shares at an exercise price of NIS 756 per option or $237 per option and expire on April 13, 2031;&#160;&#160;(v) 875 options to purchase 875 ordinary shares at an exercise price of NIS 750 per option or $235 per option and expire on July 16, 2032, (vi) 1,875 options to purchase 1,875 ordinary shares at an exercise price of NIS 78.3 per option or $24.5 per option and expire on April 30, 2033, (vii) 1,094 options to purchase 1,094 ordinary shares at an exercise price of NIS 82.5 per option or $25.8 per option and expire on May 7, 2034, and (viii) 625 options to purchase 625 ordinary shares at an exercise price of NIS 54.0 per option or $16.9 per option and expire on April 29, 2033. Excludes 4,031 options to purchase 4,031 ordinary shares that vest in more than 60 days from March 25, 2026.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"></p><!-- Field: Page; Sequence: 128; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i)83 options to purchase 83 ordinary shares at an exercise price of NIS 7,539 per option or $2,363 per option and expire on December 28, 2027, (ii) 50 options to purchase 50 ordinary shares at an exercise price of NIS 7,032 per option or $2,204 per option and expire on January 7, 2029, and (iii) 333 options to purchase 333 ordinary shares at an exercise price of NIS 750 per option or $235 per option and expire on May 27, 2030; (iv) 500 options to purchase 500 ordinary shares at an exercise price of NIS 756 per option or $237 per option and expire on April 13, 2031; (v) 625 options to purchase 625 ordinary shares at an exercise price of NIS 750 per option or $235 per option and expire on July 16, 2032, (vi) 1,719 options to purchase 1,719 ordinary shares at an exercise price of NIS 78.3 per option or $24.5 per option and expire on April 30, 2033, (vii) 1,094 options to purchase 1,094 ordinary shares at an exercise price of NIS 82.5 per option or $25.8 per option and expire on May 7, 2034, and (viii) 625 options to purchase 625 ordinary shares at an exercise price of NIS 54.0 per option or $16.9 per option and expire on April 29, 2035. Excludes 4,103 options to purchase 4,103 ordinary shares that vest in more than 60 days from March 25, 2026.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 27 options to purchase 27 ordinary shares at an exercise price of NIS 10,986 per option or $3,444 per option and expire on March 30, 2027, (ii) 50 options to purchase 50 ordinary shares at an exercise price of NIS 7,539 per option or $2,363 per option and expire on December 30, 2027, (iii) 40 options to purchase 40 ordinary shares at an exercise price of NIS 7,032 per option or $2,204 per option and expire on January 7, 2029, (iv) 333 options to purchase 333 ordinary shares at an exercise price of NIS 750 per option or $235 per option and expire on May 27, 2030, (v) 500 options to purchase 500 ordinary shares at an exercise price of NIS 756 per option or $237 per option and expire on April 13, 2031; (vi) 469 options to purchase 469 ordinary shares at an exercise price of NIS 750 per option or $235 per option and expire on July 16, 2032, (vii) 1,250 options to purchase 1,250 ordinary shares at an exercise price of NIS 78.3 per option or $24.5 per option and expire on April 30, 2033, (viii) 833 options to purchase 833 ordinary shares at an exercise price of NIS 82.5 per option or $25.8 per option and expire on May 7, 2034, and &#160;(ix) 417 options to purchase 417 ordinary shares at an exercise price of NIS 54.0 per option or $16.9 per option and expire on April 29, 2035. Excludes 2,528 options to purchase 2,528 ordinary shares that vest in more than 60 days from March 25, 2026.&#160;</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 8 ordinary shares, (ii) 16 options to purchase 16 ordinary shares at an exercise price of NIS 8,778 per option or $2,752 per option and expire on November 28, 2027, and (iii) 200 options to purchase 200 ordinary shares at an exercise price of NIS 750 per option or $235 per option and expire on June 14, 2030, (iv) 1,625 options to purchase 1,625 ordinary shares at an exercise price of NIS 78.3 per option or $24.5 per option and expire on April 30, 2033, (v) 1,083 options to purchase 1,083 ordinary shares at an exercise price of NIS 82.5 per option or $25.8 per option and expire on May 7, 2034. Excludes 17,625 options to purchase 17,625 ordinary shares that vest in more than 60 days from March 25, 2026.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 16 options to purchase 16 ordinary shares at an exercise price of NIS 8,778 per option or $2,752 per option and expire on November 28, 2027, and (ii) 200 options to purchase 200 ordinary shares at an exercise price of NIS 750 per option or $235 per option and expire on June 14, 2030, (iii) 1,625 options to purchase 1,625 ordinary shares at an exercise price of NIS 78.3 per option or $24.5 per option and expire on April 30, 2033, (iv) 1,083 options to purchase 1,083 ordinary shares at an exercise price of NIS 82.5 per option or $25.8 per option and expire on May 7, 2034. Excludes 17,624 options to purchase 17,624 ordinary shares that vest in more than 60 days from March 25, 2026.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents (i) 200 options to purchase 200 ordinary shares at an exercise price of NIS 750 per option or $235 per option and expire on June 22, 2031, (ii) 1,625 options to purchase 1,625 ordinary shares at an exercise price of NIS 78.3 per option or $24.5 per option and expire on April 30, 2033, and (iv) 1,083 options to purchase 1,083 ordinary shares at an exercise price of NIS 82.5 per option or $25.8 per option and expire on May 7, 2034. Excludes 1,624 options to purchase 1,624 ordinary shares that vest in more than 60 days from March 25, 2026.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
<td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excludes 16,000 options to purchase 16,000 ordinary shares that vest in more than 60 days from March 25, 2026.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
or BNY, is the holder of record for our ADR program, pursuant to which each ADS represents 2 ordinary shares. As of March 18, 2026, BNY
held 3,485,847 ordinary shares representing approximately 81.3% of the outstanding ordinary shares at that date. Certain of these ordinary
shares were held by brokers or other nominees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 129; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, the number of
holders of record or registered holders in the United States is not representative of the number of beneficial holders or of the residence
of beneficial holders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Share Option Plans</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain the following
share option plans for our and our subsidiary&#8217;s employees, directors and consultants. In addition to the discussion below, see
Note 9 of our consolidated financial statements, included elsewhere in this Annual Report on Form 20-F.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors administers
our share option plans and has the authority to designate all terms of the options granted under our plans including the grantees, exercise
prices, grant dates, vesting schedules and expiration dates, which may be no more than ten years after the grant date. Options may not
be granted with an exercise price of less than the fair market value of our ordinary shares on the date of grant, unless otherwise determined
by our Board of Directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025,
options to purchase an aggregate of 49,533 ordinary shares, are outstanding pursuant to the 2013 and 2023 share option plans.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2013 Share Option Plan</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 2013 Plan we granted
options at exercise prices between NIS 750 and NIS 36,000 per ordinary share, no par value. As of December 31, 2025, no options were
available to be granted under the 2013 Plan. As of December 31, 2025, 24,866 options to purchase 24,866 ordinary shares were outstanding.
Options granted to Israeli employees were in accordance with the Tax Ordinance under the capital gains route set forth in section 102(b)(2)
of the Tax Ordinance. The options are non-transferable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The option term is for a
period of ten years from the grant date. The options vest over a four-year period. As of December 31, 2025, options to purchase 18,247
ordinary shares were fully vested.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>2023 Share Option Plan</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2025,
options to purchase up to 8,667 ordinary shares were available to be granted under the 2023 Plan. As of December 31, 2025, 24,667 options
to purchase ordinary shares were outstanding. Options granted to Israeli employees were in accordance with the Tax Ordinance under the
capital gains route set forth in section 102(b)(2) of the Tax Ordinance. The options are non-transferable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The option term is for a
period of ten years from the grant date. The options vest over a four year period. As of December 31, 2025, 7,250 options were fully
vested.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">F. Disclosure of a Registrant&#8217;s Action to Recover Erroneously
Awarded Compensation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There was no erroneously
awarded compensation that was required to be recovered pursuant to the Can-Fite BioPharma Ltd. Executive Officer Clawback Policy during
the fiscal year ended December 31, 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;"><span id="a_009" style="display: inline-block;"></span>ITEM 7. </span></span><span style="font-weight: bold;">Major
Shareholders and Related Party Transactions</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">A. Major Shareholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in &#8220;Item
6. Directors, Senior Management and Employees&#8212;E. Share Ownership,&#8221; to the best of our knowledge, no other person who we know
beneficially owns 5.0% or more of the Company&#8217;s ordinary shares outstanding as of March 25, 2026. None of our shareholders has different
voting rights from other shareholders. Other than as described herein, to the best of our knowledge, we are not owned or controlled, directly
or indirectly, by another corporation, by any foreign government or by any natural person or legal persons, severally or jointly, and
we are not aware of any arrangement that may, at a subsequent date, result in a change of control of our Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 130; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, other than
as disclosed in the table above, our other filings with the SEC and this Annual Report on Form 20-F, there has been no significant change
in the percentage ownership held by any major shareholder since January 1, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">B. Related Party Transactions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description
of the transactions with related parties to which we, or our subsidiary, are party, and which were in effect since January 1, 2025. The
descriptions provided below are summaries of the terms of such agreements, do not purport to be complete and are qualified in their entirety
by the complete agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we have executed
all of our transactions with related parties on terms no less favorable to us than those we could have obtained from unaffiliated third
parties. We are required by Israeli law to ensure that all future transactions between us and our officers, directors and principal shareholders
and their affiliates are approved by a majority of our Board of Directors, including a majority of the independent and disinterested
members of our Board of Directors, and that they are on terms no less favorable to us than those that we could obtain from unaffiliated
third parties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Employment and Consulting Agreements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have or have had employment,
consulting or related agreements with each member of our senior management. See &#8220;Item 6. Directors, Senior Management and Employees&#8212;Compensation&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We employ Zivit Harpaz as
Director of Regulatory and Clinical Operations. For fiscal years 2025, 2024 and 2023, Ms. Harpaz received salary, bonus and benefits
totaling approximately $296,000, $270,000, and $262,000, respectively. During fiscal years 2025, 2024 and 2023, we awarded to Ms. Harpaz
options to purchase 1,333, 1,333, and 1,000 ordinary shares, respectively. Ms. Harpaz is the daughter of Pnina Fishman.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Options</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have granted options to
purchase our ordinary shares to certain of our senior management and directors. See &#8220;Item 6. B.&#8212;Compensation&#8221; and &#8220;Item
6. Directors, Senior Management and Employees&#8212;Share Ownership&#8221;. We describe our option plans under &#8220;Item 6. Directors,
Senior Management and Employees&#8212;Share Ownership&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Indemnification Agreements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated
Articles of Association permit us to exculpate, indemnify and insure our directors and officeholders to the fullest extent permitted
by the Israeli Companies Law. We have obtained directors&#8217; and officers&#8217; insurance for each of our officers and directors
and have entered into indemnification agreements with all of our current officers and directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">C. Interests of Experts and Counsel.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_010" style="display: inline-block;"></span><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 8. </span></span><span style="font-weight: bold;">Financial
Information</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">A. Consolidated Financial Statements and Other Financial Information</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 18. Financial
Statements&#8221; for a list of all financial statements filed as part of this Annual Report on Form 20-F.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 131; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">Legal Matters</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not involved in any
legal or arbitration proceedings that may have or have had in the recent past, significant effects on our financial position or profitability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">Dividend Policy</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends to our shareholders. Currently we do not intend to pay cash dividends. We intend to reinvest any earnings in developing
and expanding our business. Any future determination relating to our dividend policy will be at the discretion of our Board of Directors
and will depend on a number of factors, including future earnings, our financial condition, operating results, contractual restrictions,
capital requirements, business prospects, applicable Israeli Companies Law and other factors our Board of Directors may deem relevant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">B. Significant Changes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Note 14:&#8212;Subsequent
Events&#8221; to our consolidated financial statements included in this Annual Report beginning on page F-34 for a discussion of significant
events that have occurred since December 31, 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;"><span id="a_011" style="display: inline-block;"></span>ITEM 9. </span></span><span style="font-weight: bold;">The
Offer and Listing</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">A. Offer and Listing Details</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Ordinary Shares</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares have
been trading on the TASE under the symbol &#8220;CFBI&#8221; since October 2005.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>ADSs</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 2, 2012, our ADSs
began trading OTC in the United States under the symbol &#8220;CANFY&#8221; and on November 19, 2013, our ADSs began trading on the NYSE
American under the symbol &#8220;CANF.&#8221; One ADS represents three hundred (300) ordinary shares. See &#8220;Item 12. Description
of Securities Other Than Equity Securities&#8212;D. American Depositary Shares&#8221; for a description of the rights attaching to our
ADSs. See &#8220;Item 12. Description of Securities Other Than Equity Securities&#8212;D. American Depositary Shares&#8221; for a description
of the rights attaching to our ADSs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">B. Plan of Distribution.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">C. Markets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;&#8212;Offer and
Listing Details&#8221; above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">D. Selling Shareholders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">E. Dilution.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">F. Expenses of the Issue.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 132; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;"><span id="a_012" style="display: inline-block;"></span>ITEM 10. </span></span><span style="font-weight: bold;">Additional
Information</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">A. Share Capital.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">B. Memorandum and Articles of Association.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our number with the Israeli
Registrar of Companies is 512022153. Our purpose is set forth in Section 3 of our Articles of Association and is to carry out any lawful
business.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 10, 2025, our
shareholders increased our authorized share capital by 20,000,000,000 shares, such that our authorized share capital is equal to 42,000,000,000
shares, with no par value. Following our 1 for 3,000 reverse split effected on January 2, 2026, our authorized share capital was proportionately
decreased to 14,000,000 ordinary shares, no par value. Our ordinary shares that are fully paid for are issued in registered form and may
be freely transferred under our Amended and Restated Articles of Association, unless the transfer is restricted or prohibited by applicable
law or the rules of a stock exchange on which the shares are traded. The ownership or voting of our ordinary shares by non-residents of
Israel is not restricted in any way by our Amended and Restated Articles of Association or the laws of the State of Israel, except for
ownership by nationals of some countries that are, or have been, in a state of war with Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Israeli Companies
Law and our Amended and Restated Articles of Association, our Board of Directors may exercise all powers and take all actions that are
not required under law or under our Amended and Restated Articles of Association to be exercised or taken by our shareholders, including
the power to borrow money for company purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated
Articles of Association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli
Companies Law and must be approved by a resolution duly passed by our shareholders at a general or special meeting by voting on such
change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends
in the absence of sufficient retained earnings and profits and an issuance of shares for less than their nominal value, require a resolution
of our Board of Directors and court approval.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Dividends</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may declare a dividend
to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Israeli Companies Law, dividend
distributions are determined by the Board of Directors and do not require the approval of the shareholders of a company unless such company&#8217;s
articles of association provide otherwise. Our Amended and Restated Articles of Association provide that decisions on the distribution
of dividends will be made by the Board of Directors and do not require shareholder approval.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Israeli Companies
Law, we may only distribute dividends from our profits accrued over the previous two years, as defined in the Israeli Companies Law,
according to our then last reviewed or audited financial reports, or we may distribute dividends with court approval. In each case, we
are only permitted to pay a dividend if there is no reasonable concern that payment of the dividend will prevent us from satisfying our
existing and foreseeable obligations as they become due.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Election of Directors</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Articles
of Association provide that the maximum number of members of the Board of Directors is 13, plus the number of external directors whose
appointment is legally required. The Board of Directors is presently comprised of six members.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2020, a special
general meeting of our shareholders approved an amendment to the our Amended and Restated Articles of Association, according to which
the Board of Directors, excluding the external directors, if any (who shall be elected and serve in office in strict accordance with
the provisions of the Companies Law, if so required by the Companies Law), shall consist of three classes of directors as nearly equal
in number as practicable, which are appointed for fixed terms of office in accordance with the Israeli Companies Law and our Amended
and Restated Articles of Association, as follows: (i) the term of office of the initial Class I directors shall expire at the first annual
general meeting of our shareholders held in 2020 and when their successors are elected and qualified, (ii) the term of office of the
initial Class II directors shall expire at the first annual general meeting of our shareholders following the annual general meeting
of our shareholders referred to in clause (i) above and when their successors are elected and qualified, and (iii) the term of office
of the initial Class III directors shall expire at the first annual general meeting of our shareholders following the annual general
meeting of our shareholders referred to in clause (ii) above and when their successors are elected and qualified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 133; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors (other than external
directors), may be elected only in annual general meetings of our shareholders. At each annual general meeting of our shareholders, commencing
with the annual general meeting of our shareholders held in 2020, each of the successors elected to replace the directors of a class
whose term shall have expired at such annual general meeting of our shareholders shall be elected to hold office until the third annual
general meeting of our shareholders next succeeding his or her election and until his or her respective successor shall have been elected
and qualified. Notwithstanding anything to the contrary, each director shall serve until his or her successor is elected and qualified
or until such earlier time as such director&#8217;s office is vacated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the number of directors
(excluding external directors) that constitutes the Board of Directors is hereafter changed, the then-serving directors shall be re-designated
to other classes and/or any newly created directorships or decrease in directorships shall be apportioned by the Board of Directors among
the classes so as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of Directors
constituting the Board of Directors shall shorten the term of any incumbent director.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors so elected may not
be dismissed from office by the shareholders or by a general meeting of our shareholders prior to the expiration of their term of office,
and the provisions of Section 230(a) of the Companies Law in this regard shall not apply. The directors do not receive any benefits upon
the expiration of their term of office.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The three classes of directors
are Class I Directors, Class II Directors and Class III Directors. Dr. Pnina Fishman and Mr. Guy Regev serve as our Class III Directors
until the close of the annual meeting to be held in 2025; Abraham Sartani serves as our Class I Director until the close of the annual
meeting to be held in 2026; and we currently have a vacancy for our Class II Director.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any amendment, replacement
or suspension of our Amended and Restated Articles of Association regarding the election of directors, as described above, requires a
majority of 65% of the voting power represented at the general meeting of our shareholders in person or by proxy and voting thereon, disregarding
abstentions from the count of the voting power present and voting, provided that such majority constitutes more than 20% of our then issued
and outstanding share capital.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A nominee for service as
a director in a public company may not be elected without submitting a declaration to the company, prior to election, specifying that
he or she has the requisite qualifications to serve as a director, independent director or external director (if required), as applicable,
and the ability to devote the appropriate time to performing his or her duties as such.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director, who ceases to
meet the statutory requirements to serve as a director, external director or independent director, as applicable, must notify the company
to that effect immediately and his or her service as a director will expire upon submission of such notice.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6. Directors,
Senior Management and Employees&#8212;C. Board Practices&#8212;External Directors.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Shareholder Meetings</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Israeli Companies Law,
we are required to hold an annual general meeting of our shareholders once every calendar year that must be no later than 15 months after
the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to as
extraordinary meetings. Our Board of Directors may call extraordinary meetings whenever it sees fit, at such time and place, within or
outside of Israel, as it may determine. In addition, the Israeli Companies Law and our Amended and Restated Articles of Association provide
that our Board of Directors is required to convene an extraordinary meeting upon the written request of (i) any two of our directors or
one quarter of our Board of Directors or (ii) one or more shareholders holding, in the aggregate, either (1) 5% of our outstanding shares
and 1% of our outstanding voting power or (2) 5% of our outstanding voting power.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 134; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Israeli Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings
are the shareholders of record on a date to be decided by the Board of Directors, which may be between four and forty days prior to the
date of the meeting. Furthermore, the Israeli Companies Law and our Amended and Restated Articles of Association require that resolutions
regarding the following matters must be passed at a general meeting of our shareholders:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">amendments to our Amended and Restated Articles of Association;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">appointment or termination of our auditors;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">appointment of directors and appointment and dismissal of external directors;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">approval of acts and transactions requiring general meeting approval pursuant to the Israeli Companies
    Law;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">director compensation, indemnification and change of the principal executive officer;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">increases or reductions of our authorized share capital;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">a merger; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">the exercise of our Board of Director&#8217;s powers by a general meeting, if our Board of Directors
    is unable to exercise its powers and the exercise of any of its powers is required for our proper management.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
requires that a notice of any annual or special shareholders meeting be provided at least 21 days prior to the meeting and if the agenda
of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related
parties, or an approval of a merger, notice must be provided at least 35 days prior to the meeting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
does not allow shareholders of publicly traded companies to approve corporate matters by written consent. Consequently, our Amended and
Restated Articles of Association do not allow shareholders to approve corporate matters by written consent.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our Amended and
Restated Articles of Association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted
to a vote before the shareholders at a general meeting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Quorum</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The quorum required for our
general meetings of shareholders consists of at least two shareholders present in person, by proxy or written ballot who hold or represent
between them at least 25% of the total outstanding voting rights.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A meeting adjourned for lack
of a quorum is adjourned to the same day in the following week at the same time and place, or to a later date if so specified in the notice
of the meeting. At the reconvened meeting, any number of our shareholders present in person or by proxy shall constitute a lawful quorum.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Resolutions</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated
Articles of Association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by
applicable law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 135; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law provides that
a shareholder of a public company may vote in a meeting and in a class meeting by means of a written ballot in which the shareholder
indicates how he or she votes on resolutions relating to the following matters:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">an appointment or removal of directors;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">an approval of transactions with office holders or interested or related parties;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">an approval of a merger or any other matter in respect of which there is a provision in the articles
    of association providing that decisions of the general meeting may also be passed by written ballot;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">authorizing the chairman of the Board of Directors or his relative to act as our chief executive
    officer or act with such authority; or authorize our chief executive officer or his relative to act as the chairman of the Board
    of Directors or act with such authority; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 48px">&#160;</td>
<td style="width: 24px">&#9679;</td>
<td style="text-align: justify">other matters which may be prescribed by Israel&#8217;s Minister of Justice.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision allowing the
vote by written ballot does not apply where the voting power of the controlling shareholder is sufficient to determine the vote. Our
Amended and Restated Articles of Association provide that our Board of Directors may prevent voting by means of a written ballot and
this determination is required to be stated in the notice convening the general meeting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that a shareholder, in exercising his or her rights and performing his or her obligations toward the company and its other shareholders,
must act in good faith and in a customary manner, and avoid abusing his or her power. This is required when voting at general meetings
on matters such as changes to the articles of association, increasing our registered capital, mergers and approval of related party transactions.
A shareholder also has a general duty to refrain from depriving any other shareholder of its rights as a shareholder. In addition, any
controlling shareholder, any shareholder who knows that its vote can determine the outcome of a shareholder vote and any shareholder
who, under such company&#8217;s articles of association, can appoint or prevent the appointment of an office holder, is required to act
with fairness towards the company. The Israeli Companies Law does not describe the substance of this duty except to state that the remedies
generally available upon a breach of contract will also apply to a breach of the duty to act with fairness, and, to the best of our knowledge,
there is no binding case law that addresses this subject directly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, unless provided otherwise in a company&#8217;s articles of association, a resolution at a shareholders meeting requires approval
by a simple majority of the voting rights represented at the meeting, in person, by proxy or written ballot, and voting on the resolution.
A resolution for the voluntary winding up of the company requires the approval of holders of 75% of the voting rights represented at
the meeting, in person, by proxy or by written ballot and voting on the resolution.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of our liquidation,
after satisfaction of liabilities to creditors, our surplus assets will be distributed to the holders of our ordinary shares pari passu
in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential
dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 136; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Access to Corporate Records</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, all shareholders of a company generally have the right to review minutes of our general meetings, its shareholders register and
principal shareholders register, articles of association, financial statements and any document it is required by law to file publicly
with the Israeli Companies Registrar and the Israel Securities Authority. Any of our shareholders may request access to review any document
in our possession that relates to any action or transaction with a related party, interested party or office holder that requires shareholder
approval under the Israeli Companies Law. We may deny a request to review a document if we determine that the request was not made in
good faith, that the document contains a commercial secret or a patent or that the document&#8217;s disclosure may otherwise prejudice
our interests.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Acquisitions under Israeli Law</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Full Tender Offer</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person wishing to acquire
shares of a public Israeli company and who would as a result hold over 90% of the target company&#8217;s issued and outstanding share
capital is required by the Israeli Companies Law to make a tender offer to all of our shareholders for the purchase of all of the issued
and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result hold
over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders
who hold shares of the same class for the purchase of all of the issued and outstanding shares of the same class. If the shareholders
who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class,
all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law (provided that a majority
of the offerees that do not have a personal interest in such tender offer shall have approved the tender offer except that if the total
votes to reject the tender offer represent less than 2% of the company&#8217;s issued and outstanding share capital, in the aggregate,
approval by a majority of the offerees that do not have a personal interest in such tender offer is not required to complete the tender
offer). However, a shareholder that had its shares so transferred may petition the court within six months from the date of acceptance
of the full tender offer, whether or not such shareholder agreed to the tender or not, to determine whether the tender offer was for
less than fair value and whether the fair value should be paid as determined by the court unless the acquirer stipulated in the tender
offer that a shareholder that accepts the offer may not seek appraisal rights. If the shareholders who did not accept the tender offer
hold 5% or more of the issued and outstanding share capital of the company or of the applicable class, the acquirer may not acquire shares
of the company that will increase its holdings to more than 90% of our issued and outstanding share capital or of the applicable class
from shareholders who accepted the tender offer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Special Tender Offer</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that an acquisition of shares of a public Israeli company must be made by means of a special tender offer if as a result of
the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company, unless one of the exemptions
in the Israeli Companies Law is met. This rule does not apply if there is already another holder of at least 25% of the voting rights
in the company. Similarly, the Israeli Companies Law provides that an acquisition of shares in a public company must be made by means
of a tender offer if as a result of the acquisition the purchaser would become a holder of 45% or more of the voting rights in the company,
if there is no other shareholder of the company who holds 45% or more of the voting rights in the company, unless one of the exemptions
in the Israeli Companies Law is met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A special tender offer must
be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting
power attached to our outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated
only if (i) at least 5% of the voting power attached to our outstanding shares will be acquired by the offeror and (ii) the number of
shares tendered in the offer exceeds the number of shares whose holders objected to the offer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a special tender offer
is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling
person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger
with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook
to effect such an offer or merger in the initial special tender offer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Merger</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
permits merger transactions if approved by each party&#8217;s Board of Directors and, unless certain requirements described under the
Israeli Companies Law are met, a majority of each party&#8217;s shares voted on the proposed merger at a shareholders&#8217; meeting
called with at least 35 days&#8217; prior notice.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 137; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the shareholder
vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares represented at the shareholders
meeting that are held by parties other than the other party to the merger, or by any person who holds 25% or more of the outstanding
shares or the right to appoint 25% or more of the directors of the other party, vote against the merger. If the transaction would have
been approved but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a
court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds
that the merger is fair and reasonable, taking into account the value of the parties to the merger and the consideration offered to the
shareholders.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the request of a creditor
of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of any of the parties to the merger,
and may further give instructions to secure the rights of creditors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a merger may
not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed by each party
with the Israeli Registrar of Companies and 30 days have passed from the date the merger was approved by the shareholders of each party.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Antitakeover Measures</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain
preferred rights, distributions or other matters and shares having preemptive rights. As of the date of this Annual Report on Form 20-F,
we do not have any authorized or issued shares other than our ordinary shares. In the future, if we do create and issue a class of shares
other than ordinary shares, such class of shares, depending on the specific rights that may be attached to them, may delay or prevent
a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The
authorization of a new class of shares will require an amendment to our Amended and Restated Articles of Association which requires the
prior approval of the holders of a majority of our shares at a general meeting. In addition, the rules and regulations of the TASE also
limit the terms permitted with respect to a new class of shares and prohibit any such new class of shares from having voting rights.
Shareholders voting in such meeting will be subject to the restrictions provided in the Israeli Companies Law as described above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Borrowing Powers</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law and our Amended and Restated Articles of Association, our Board of Directors may exercise all powers and take all actions that are
not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders or other
corporate bodies, including the power to borrow money for company purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Changes in Capital</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated
Articles of Association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli
Companies Law and must be approved by a resolution duly passed by our shareholders at a general meeting by voting on such change in the
capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the
absence of sufficient retained earnings or profits and, in certain circumstances, an issuance of shares for less than their nominal value,
require the approval of both our Board of Directors and an Israeli court.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">C. Material Contracts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are summary
descriptions of certain material agreements to which we are a party. The descriptions provided below do not purport to be complete and
are qualified in their entirety by the complete agreements, which may be attached as exhibits to this Annual Report on Form 20-F.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>License Agreements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 4. Information
on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 138; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Employment and Consulting Agreements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6. Directors,
Senior Management and Employees&#8212;B. Compensation&#8212;Employment and Consulting Agreements&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">D. Exchange Controls</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no Israeli government
laws, decrees or regulations that restrict or that affect our export or import of capital or the remittance of dividends, interest or
other payments to non-resident holders of our securities, including the availability of cash and cash equivalents for use by us and our
wholly-owned subsidiary, except or otherwise as set forth under &#8220;Item 10. Additional Information&#8212;E. Taxation.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">E. Taxation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following description
is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our
ordinary shares, ADSs, Warrants or Pre-funded Warrants. You should consult your own tax advisor concerning the tax consequences of your
particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign, or other taxing jurisdiction.</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Certain Israeli Tax Considerations</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a brief
summary of the material Israeli tax laws applicable to us and certain Israeli Government programs that benefit us. This section also
contains a discussion of material Israeli tax consequences concerning the ownership and disposition of our ordinary shares. This summary
does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment
circumstances or to some types of investors subject to special treatment under Israeli law. Examples of such investors include residents
of Israel or traders in securities who are subject to special tax regimes not covered in this discussion. To the extent that the discussion
is based on new tax legislation that has not yet been subject to judicial or administrative interpretation, we cannot assure you that
the appropriate tax authorities or the courts will accept the views expressed in this discussion. The discussion below is subject to
change, including due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations of Israeli
law, which change could affect the tax consequences described below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">You are urged to consult
your own tax advisor as to the Israeli and other tax consequences of the purchase, ownership and disposition of our ADSs, including,
in particular, the effect of any non-Israeli, state or local taxes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>General Corporate Tax Structure in Israel</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli resident (as defined
below) companies, such as us, are generally subject to corporate tax at the rate of 23% since 2018. However, the effective tax rate imposed
on a company that derives income from a Preferred Enterprise or a Preferred Technology Enterprise (as discussed below) may be considerably
lower. Capital gains derived by an Israeli company are generally subject to tax at the prevailing corporate tax rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Law for the Encouragement of Capital Investments, 5719-1959</i></span><i>:</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tax Benefits for Income from
Preferred Enterprise</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Law for the Encouragement
of Capital Investments, 5719-1959 (the &#8220;Investment Law&#8221;), currently provides certain tax benefits for income generated by
&#8220;Preferred Companies&#8221; from their &#8220;Preferred Enterprises.&#8221; The definition of a Preferred Company includes, inter
alia, a company incorporated in Israel and that is not wholly owned by a governmental entity, which:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in; font-size: 10pt">&#9679;</td>
<td style="font-size: 10pt; text-align: justify">owns a Preferred Enterprise, which is defined as an &#8220;Industrial Enterprise&#8221;
    (as defined under the Investment Law) that is classified as either a &#8220;Competitive Enterprise&#8221; (as defined under the Investment
    Law) or a &#8220;Competitive Enterprise in the Field of Renewable Energy&#8221; (as defined under the Investment Law);</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 139; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in; font-size: 10pt">&#9679;</td>
<td style="font-size: 10pt; text-align: justify">is controlled and managed from Israel;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in; font-size: 10pt">&#9679;</td>
<td style="font-size: 10pt; text-align: justify">is not a &#8220;Family Company,&#8221; a &#8220;Home Company,&#8221; or a &#8220;Kibbutz&#8221;
    (collective community) as defined under the Income Tax Ordinance;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in; font-size: 10pt">&#9679;</td>
<td style="font-size: 10pt; text-align: justify">keeps acceptable ledgers and files reports in accordance with the provisions of
    the Investment Law and the Income Tax Ordinance; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in; font-size: 10pt">&#9679;</td>
<td style="font-size: 10pt; text-align: justify">was not, and certain officers of which were not, convicted of certain crimes in
    the 10 years prior to the tax year with respect to which benefits are being claimed.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 1, 2017, a
Preferred Company is currently entitled to a reduced corporate tax rate of 16% with respect to its income derived by its Preferred Enterprise,
unless the Preferred Enterprise is located in development area A, in which case the rate is currently 7.5% (our operations are currently
not located in development area A).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends paid out of income
attributed to a Preferred Enterprise are generally subject to tax at the rate of 20% or such lower rate as may be provided in an applicable
tax treaty. However, if such dividends are paid to an Israeli company, such dividends should be exempt from tax (although, if such dividends
are subsequently distributed to non-Israeli individuals or a non-Israeli company, tax at a rate of 20% or such lower rate as may be provided
in an applicable tax treaty will apply).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If in the future we generate
taxable income, to the extent that we qualify as a &#8220;Preferred Company,&#8221; the benefits provided under the Investment Law could
potentially reduce our corporate tax liabilities. Therefore, the termination or substantial reduction of the benefits available under
the Investment Law could materially increase our tax liabilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tax Benefits for Income from
Preferred Technology Enterprise</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An amendment to the Investment
Law was enacted as part of the Economic Efficiency Law that was published on December 29, 2016, and entered into effect as of January
1, 2017 (the &#8220;2017 Amendment&#8221;). The 2017 Amendment provides additional tax benefits to Preferred Companies for &#8220;Technology
Enterprises,&#8221; as described below, and is in addition to the Preferred Enterprise regime provided under the Investment Law.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2017 Amendment provides
that a technology company satisfying certain conditions will qualify as a &#8220;Preferred Technology Enterprise&#8221; and may thereby
enjoy a reduced corporate tax rate of 12% on income that qualifies as &#8220;Preferred Technology Income,&#8221; as defined in the Investment
Law. The tax rate is further reduced to 7.5% for a Preferred Technology Enterprise located in development area A. In addition, a Preferred
Technology Enterprise may enjoy a reduced capital gains tax rate of 12% on capital gain derived from the sale of certain &#8220;Benefited
Intangible Assets&#8221; (as defined in the Investment Law) to a related foreign company if the Benefited Intangible Assets were acquired
from a foreign company on or after January 1, 2017 for at least NIS 200 million, pending that the sale receives is pre-approved by the
IIA.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends distributed by
a Preferred Technology Enterprise that are paid out of Preferred Technology Income are subject to tax at the rate of 20%, but if they
are distributed to a foreign company and at least 90% of the shares of the distributing company are held by foreign resident companies
then the tax rate may be as low as 4%, subject to the fulfillment of certain conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><!-- Field: Page; Sequence: 140; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Pre-Ruling from the Israeli Income Tax Authorities</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the spin-off,
we received a pre-ruling decision from the Israeli Income Tax Authority which confirms: (i) that the grant of the license to Eye-Fite
is not liable for tax pursuant to the provisions of section 104a to the Income Tax Ordinance (New Version), 1961, or the Ordinance; (ii)
that OphthaliX is considered the receiving company pursuant to section 103c(7)(b) to the Ordinance; (iii) that the sale of Eye-Fite shares
to OphthaliX as consideration for OphthaliX shares does not create liability for tax pursuant to the provisions of section 103t to the
Ordinance, or change in structure; and (iv) the date for the change in structure was determined. According to the tax pre-ruling, the
date of change in structure shall also be the date of exchange of shares with respect to the spin-off and notification to the tax assessor.
We and Eye-Fite presented to the tax assessor and the merger and spin-off department of the tax assessor the forms required by the Ordinance
and the regulations thereunder. The tax pre-ruling further provides that the grant of a license to Eye-Fite as consideration for the
issuance of Eye-Fite shares to us does not create liability for tax pursuant to the provisions of section 104a to the Ordinance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the pre-ruling,
we must not sell more than 10% of our common stock holdings in OphthaliX issued in connection with the change in structure for at least
two years from the date of the change (i.e., November 21, 2011), OphthaliX must not sell more than 10% of its ordinary share holdings
in Eye-Fite received in connection with the change in structure for at least two years from the date of the change and Eye-Fite must
retain the assets received from us in connection with the change in structure for at least two years from the date of the change.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of Eye-Fite which
were transferred to OphthaliX in connection with the change in structure will be held in escrow. The sale of these shares will be deemed
as a sale by an Israeli company and will be taxed accordingly. The trustee will withhold tax at the source.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of OphthaliX which
were transferred to us in connection with the change in structure will be held in escrow. The sale of these shares will be deemed as
a sale by an Israeli company and will be taxed accordingly. The trustee will withhold tax at the source.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any dividend distributed
by Eye-Fite to OphthaliX will be taxed in Israel in accordance with paragraph 125b(5) of the Israeli Tax Ordinance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A description of the terms
of the pre-ruling is also included in the notes to the financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><span style="font-weight: bold;"><i>The Encouragement
of Research, Development and Technological Innovation in the Industry Law 5744-1984</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under
the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984 (formerly known as the Law for
the Encouragement of Research and Development in Industry 5744-1984), or the Innovation Law, and the regulations and guidelines promulgated
thereunder, research and development programs which meet specified criteria and are approved by a committee of the IIA, are eligible
for grants. The grants awarded are typically up to 50% of the project&#8217;s expenditures, as determined by the research committee.
The grantee is required to pay royalties to the State of Israel from the sale of products developed under the program. Regulations under
the Innovation Law generally provide for the payment of royalties of 3% to 6% on income generated from products and services based on
technology developed using grants, until 100% of the grant, linked to the dollar and bearing interest at the LIBOR rate, is repaid. In
July 2017, new regulations came into force. According to the new regulations, the royalties range between 1.3-5% depending on the company&#8217;s
size and sector. The terms of the IIA participation also require that products developed with IIA grants be manufactured in Israel and
that the know-how developed thereunder may not be transferred outside of Israel, unless approval is received from the IIA and additional
payments are made to the IIA. However, this does not restrict the export of products that incorporate the funded know-how. The royalty
repayment ceiling can reach up to three times the amount of the grant received (plus interest) if manufacturing is transferred outside
of Israel, and repayment of up to six times the amount of the grant (plus interest) may be required if the technology itself is transferred
outside of Israel or license to use it was granted to a foreign entity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><!-- Field: Page; Sequence: 141; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Taxation of our Shareholders</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Capital Gains Tax</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law generally imposes
a capital gains tax (i) on the sale of any capital assets by residents of Israel, as defined for Israeli tax purposes, and (ii) on the
sale of capital assets located in Israel, including shares of Israeli companies, by non-residents of Israel, unless a specific exemption
is available or unless a tax treaty between Israel and the shareholder&#8217;s country of residence provides otherwise. The law distinguishes
between real gain and inflationary surplus. The inflationary surplus is a portion of the total capital gain that is equivalent to the
increase of the relevant asset&#8217;s purchase price which is attributable to the increase in the Israeli consumer price index or a
foreign currency exchange rate between the date of purchase and the date of sale. The real gain is the excess of the total capital gain
over the inflationary surplus.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Israeli Residents</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, as of January
1, 2012 and thereafter, the tax rate applicable to real capital gains derived from the sale of shares, whether listed on a stock market
or not, is 25% for Israeli individuals, unless such shareholder claims a deduction for financing expenses in connection with such shares,
in which case the gain will generally be taxed at a rate of 30%. Additionally, if such shareholder is considered a &#8220;substantial
shareholder&#8221; (SSH) at the time of the sale or at any time during the 12-month period preceding such sale, the tax rate will be
30%. A &#8220;substantial shareholder&#8221; is defined as one who holds, directly or indirectly, alone or &#8220;together with another&#8221;
(i.e., together with a relative, or together with someone who is not a relative but with whom, according to an agreement, there is regular
cooperation in material matters of the company, directly or indirectly), directly or indirectly, at least 10% of any of the &#8220;means
of control&#8221; in the company. &#8220;Means of control&#8221; generally include the right to vote, receive profits, nominate a director
or an executive officer, receive assets upon liquidation, or instruct someone who holds any of the aforementioned rights regarding the
manner in which such rights are to be exercised. However, different tax rates will apply to dealers in securities. Israeli companies
are subject to capital gains tax at the regular corporate tax rate (i.e., 23% for the tax year 2018 and thereafter) on real capital gains
derived from the sale of listed shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 1, 2024, Israeli
resident shareholders who are individuals with taxable income that exceeds NIS 721,560 in a tax year (linked to the Israeli consumer
price index each year) will be subject to an additional tax at the rate of 3% on the portion of their taxable income for such tax year
that is in excess of NIS 721,560 (linked to the Israeli consumer price index each year). For this purpose, taxable income includes taxable
capital gains from the sale of our shares and taxable income from dividend distributions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some instances where our
shareholders are liable for Israeli tax on the sale of their ordinary shares, the payment of the consideration may be subject to the
withholding of Israeli tax at source.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Non-Israeli Residents</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>A non-Israeli resident
who derives capital gains from the sale of shares in an Israeli resident company that were </i>purchased after the company was listed
for trading on a stock exchange outside of Israel will be exempt from Israeli tax so long as the shares were not held through a permanent
establishment that the non-resident maintains in Israel. However, non-Israeli resident corporations will not be entitled to the foregoing
exemption if (i) an Israeli resident has a controlling interest, directly or indirectly, alone, &#8220;together with another&#8221; (as
defined above), or together with another Israeli resident, of more than 25% in one or more of the &#8220;means of control&#8221; (as
defined above) in such non-Israeli resident corporation, or (ii) Israeli residents are the beneficiaries of, or are entitled to, 25%
or more of the revenues or profits of such non-Israeli resident corporation, whether directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a sale of securities
by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example,
pursuant to the provisions of the Convention between the Government of the United States of America and the Government of the State of
Israel with respect to Taxes on Income, as amended (the &#8220;U.S.-Israel Tax Treaty&#8221;), capital gains arising from the sale, exchange
or disposition of our ordinary shares by (i) a person who qualifies as a resident of the United States within the meaning of the U.S.-Israel
Tax Treaty, (ii) who holds the shares as a capital asset, and (iii) who is entitled to claim the benefits afforded to such person by
the U.S.-Israel Tax Treaty generally is generally exempt from Israeli capital gains tax. Such exemption will not apply if: (i) such person
holds, directly or indirectly, shares representing 10% or more of our voting power during any part of the 12-month period preceding such
sale, exchange, or disposition, subject to particular conditions; (ii) the capital gains from such sale, exchange, or disposition are
attributable to a permanent establishment in Israel; or (iii) such person is an individual and was present in Israel for 183 days or
more during the relevant tax year. In such case, the capital gain arising from the sale, exchange, or disposition of our ordinary shares
would be subject to Israeli tax, to the extent applicable; however, under the U.S.-Israel Tax Treaty, the taxpayer may be permitted to
claim a credit for such taxes against the U.S. federal income tax imposed with respect to such sale, exchange, or disposition, subject
to the limitations under U.S. law applicable to foreign tax credits. The U.S.-Israel Tax Treaty does not relate to U.S. state or local
taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 142; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders may be required
to demonstrate that they are exempt from tax on their capital gains in order to refrain from withholding at source at the time of sale.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It should be noted that in
the event that the real capital gain realized by an individual shareholder is not exempt from tax in Israel, the tax rates applicable
to Israeli resident individual shareholders should generally apply.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some instances where our
shareholders may be liable for Israeli tax on the sale of their ordinary shares, the payment of the consideration may be subject to the
withholding of Israeli tax at source.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Taxation of Dividend Distributions</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Israeli Residents</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli resident individuals
are generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares, other than bonus shares (share dividends).
As of January 1, 2012 and thereafter, the tax rate applicable to such dividends is generally 25%. With respect to a person who is a &#8220;substantial
shareholder&#8221; (as defined above) at the time the dividend is received or at any time during the preceding 12-month period, the applicable
tax rate is 30%. Dividends paid from income derived from Preferred Enterprises and Preferred Technology Enterprises will generally be
subject to income tax at a rate of 20%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of January 1, 2024, Israeli
resident shareholders who are individuals with taxable income that exceeds NIS 721,560 in a tax year (linked to the Israeli consumer
price index each year) will be subject to an additional tax at the rate of 3% on the portion of their taxable income for such tax year
that is in excess of NIS 721,560 (linked to the Israeli consumer price index each year). For this purpose, taxable income includes taxable
capital gains from the sale of our shares and taxable income from dividend distributions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends paid to an Israeli
resident individual shareholder on our ordinary shares will generally be subject to withholding tax at the rates corresponding with the
income tax rates detailed above unless we are provided in advance with a withholding tax certificate issued by the Israel Tax Authority
stipulating a different rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
dividends paid to an Israeli resident &#8220;substantial shareholder&#8221; (as defined above) on publicly traded shares, like our ordinary
shares, which are held via a &#8220;nominee company&#8221; (as defined under the Israeli Securities Law), are generally subject to Israeli
withholding tax at a rate of 25%, unless a different rate is provided under an applicable tax treaty, provided that a certificate from
the Israel Tax Authority allowing for a reduced withholding tax rate is obtained in advance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the dividend is attributable
partly to income derived from a Preferred Enterprise or a Preferred Technology Enterprise and partly to other sources of income, the
tax rate will be a blended rate reflecting the relative portions of the various types of income. We cannot assure you that we will designate
the profits that are being distributed in a way that will reduce shareholders&#8217; tax liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli resident companies
are generally exempt from tax on the receipt of dividends paid on our ordinary shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>Non-Israeli Residents</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless a tax relief is provided
by a treaty between Israel and the shareholder&#8217;s country of residence, non-Israeli residents are generally subject to Israeli income
tax on the receipt of dividends paid on our ordinary shares at the rate of 25%. With respect to a person (including a corporation) who
is a &#8220;substantial shareholder&#8221; (as defined above) at the time of receiving the dividend or at any time during the preceding
12-month period, absent treaty relief as mentioned above, the applicable Israeli income tax rate is 30%. Notwithstanding the above, dividends
paid from income derived from Preferred Enterprises will be subject to Israeli income tax at a rate of 20%. In addition, dividends distributed
by a Preferred Technology Enterprise that are paid out of Preferred Technology Income are subject to tax at the rate of 20%, but if they
are distributed to a foreign company and at least 90% of the shares of the distributing company are held by foreign resident companies
then the tax rate may be as low as 4%, subject to the fulfillment of certain conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 143; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In this regard, dividends
paid to a non-Israeli resident shareholder on our ordinary shares will generally be subject to withholding tax at the rates corresponding
with the income tax rates detailed above unless we are provided in advance with a withholding tax certificate issued by the Israel Tax
Authority stipulating a different rate (e.g., in accordance with the provisions of an applicable tax treaty).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the above,
dividends paid to a non-Israeli resident &#8220;substantial shareholder&#8221; (as defined above) on publicly traded shares, like our
ordinary shares, which are held via a &#8220;nominee company&#8221; (as defined under the Israeli Securities Law), are generally subject
to Israeli withholding tax at a rate of 25%, unless a different rate is provided under an applicable tax treaty, provided that a certificate
from the Israel Tax Authority allowing for a reduced withholding tax rate is obtained in advance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, it should be
noted that an additional 3% tax might be applicable to individual shareholders if certain conditions are met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the U.S.-Israel Tax
Treaty, the maximum Israeli tax on dividends paid to a holder of ordinary shares who qualifies as a resident of the United States within
the meaning of the U.S.-Israel Tax Treaty is 25%. Such tax rate is generally reduced to 12.5% if: (i) the shareholder is a U.S. corporation
and holds at least 10% of the outstanding shares of our voting stock during the part of our tax year that precedes the date of payment
of the dividends and during the whole of our prior tax year; (ii) not more than 25% of our gross income in the tax year preceding the
payment of the dividends consists of interest or dividends, other than dividends or interest received from subsidiary corporations 50%
or more of the outstanding shares of voting stock of which is owned by us at the time such dividends or interest are received by us;
and (iii) the dividends are not sourced from income derived during a period for which we were entitled to the reduced tax rate applicable
to a Preferred Enterprise under the Investment Law. If the dividends are sourced from income derived during a period for which we are
entitled to the reduced tax rate applicable to a Preferred Enterprise or a Preferred Technology Enterprise under the Investment Law,
to the extent that the first two conditions detailed above are met, the Israeli tax rate applicable to such dividends should be 15%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the dividend is attributable
partly to income derived from a Preferred Enterprise or a Preferred Technology Enterprise and partly to other sources of income, the
tax rate will be a blended rate reflecting the relative portions of the various types of income. We cannot assure you that we will designate
the profits that are being distributed in a way that will reduce shareholders&#8217; tax liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Estate and gift tax</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law presently does
not impose estate tax.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law also does not
presently impose gift taxes upon the transfer of assets to Israeli resident individuals so long as it is demonstrated to the satisfaction
of the Israel Tax Authority that the transfer was executed in good faith.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 144; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Certain Material U.S. Federal Income Tax Consequences</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a general
summary of certain material U.S. federal income tax consequences relating to the purchase, ownership and disposition of our ordinary
shares, ADSs, Warrants, and Pre-funded Warrants by U.S. Holders (as defined below) that hold such ordinary shares, ADSs, Warrants, or
Pre-funded Warrants as capital assets (generally, property held for investment). This summary is based on the Internal Revenue Code of
1986, as amended, or the Code, the regulations of the U.S. Department of the Treasury issued pursuant to the Code, or the Treasury Regulations,
administrative and judicial interpretations thereof, and the U.S.-Israel Income Tax Treaty, all as in effect on the date hereof and all
of which are subject to change, possibly with retroactive effect, or to different interpretation. No ruling has been sought from the
IRS, with respect to any United States federal income tax consequences described below, and there can be no assurance that the IRS or
a court will not take a contrary position. This summary does not address all of the tax considerations that may be relevant to specific
U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax
law, including but not limited to, (1) a bank, insurance company, regulated investment company, or other financial institution or &#8220;financial
services entity&#8221;; (2) a broker or dealer in securities or foreign currency; (3) a person who acquired our ordinary shares, ADSs,
Warrants, or Pre-funded Warrants in connection with employment or other performance of services; (4) a U.S. Holder that is subject to
the U.S. alternative minimum tax; (5) a U.S. Holder that holds our ordinary shares, ADSs, Warrants, or Pre-funded Warrants as a hedge
or as part of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for U.S. federal income
tax purposes; (6) a retirement plan or tax-exempt entity; (7) real estate investment trusts or grantor trusts; (8) a U.S. Holder that
expatriates out of the United States or a former long-term resident of the United States; or (9) a U.S. Holder having a functional currency
other than the U.S. dollar. This discussion does not address the U.S. federal income tax treatment of a U.S. Holder that owns, directly
or constructively, at any time, ordinary shares or ADSs representing 10% or more of our voting power or value (including by treating
U.S. Holders of Warrants, Pre-funded Warrants, or other options to acquire our ordinary shares or ADSs as owning such ordinary shares
or ADSs). Additionally, this summary does not address any U.S. state or local or non-U.S. tax considerations or any U.S. federal estate,
gift or alternative minimum tax considerations or any U.S. federal tax consequences other than U.S. federal income tax consequences.
In addition, this discussion assumes that a U.S. Holder will not be entitled to a fractional share upon the exercise of a Warrant or
Pre-funded Warrant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this summary,
the term &#8220;U.S. Holder&#8221; means a beneficial owner of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants that is, for
U.S. federal income tax purposes, (i) an individual citizen or resident of the United States, (ii) a corporation, or other entity taxable
as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state thereof,
or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income tax regardless of its source or (iv)
a trust with respect to which a court within the United States is able to exercise primary supervision over its administration and one
or more U.S. persons have the authority to control all of its substantial decisions, or that has a valid election in effect under applicable
Treasury Regulations to be treated as a &#8220;United States person.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an entity or arrangement
treated as a partnership for U.S. federal income tax purposes holds our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, the
tax treatment of such partnership and each person or entity treated as a partner thereof will generally depend upon the status and activities
of the partnership and such partner. A holder that is treated as a partnership for U.S. federal income tax purposes should consult its
own tax advisor regarding the U.S. federal income tax considerations applicable to it and its partners of the purchase, ownership and
disposition of its ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discussions under &#8220;&#8212;
Distributions&#8221; and under &#8220;&#8212; Sale, Exchange or Other Disposition of Ordinary Shares, ADSs, Warrants, and Pre-funded
Warrants&#8221; below assume that we will not be treated as a passive foreign investment company, or PFIC, for U.S. federal income tax
purposes. Based on our analysis of our income, assets, and operations, we believe that we may have been a PFIC for 2025. Because the
PFIC determination is highly fact intensive, there can be no assurance that we will not be a PFIC for 2026 or for any other taxable year.
For a discussion of the rules that would apply if we are treated as a PFIC, see the discussion under &#8220;&#8212; Passive Foreign Investment
Company.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">This summary is not intended
to be, and should not be considered to be, legal or tax advice. Investors should be aware that this summary does not address the tax
consequences to investors who are not U.S. Holders, except to the limited extent discussed below. Investors should consult their own
tax advisors as to the particular tax considerations applicable to them relating to the purchase, ownership and disposition of their
ordinary shares, ADSs, Warrants, or Pre-funded Warrants, including the applicability of U.S. federal, state and local tax laws and non-U.S.
tax laws.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Tax Characterization of Pre-funded Warrants</i>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the appropriate
characterization of Pre-funded Warrants under the tax law is unsettled, it is likely that the Pre-funded Warrants will be treated as
a class of our ordinary shares for U.S. federal income tax purposes. However, it is possible that the IRS could treat the Pre-funded
Warrants as warrants to acquire our ADSs. If the Pre-funded Warrants are not treated as a class of our ordinary shares for U.S. federal
income tax purposes and are instead treated as warrants to acquire our ADSs, then the U.S. federal income tax treatment of Pre-Funded
Warrants generally should be the same as the treatment of Warrants as described below and the holding period of an ADS acquired pursuant
to the exercise of a Pre-funded Warrant would not include the period during which the Pre-funded Warrant was held. U.S. Holders should
consult their own tax advisors regarding the U.S. federal income tax consequences of an investment in our Pre-funded Warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 145; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Ownership of ADSs</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For U.S. federal income tax
purposes, we expect that a holder of ADSs generally should be treated as the owner of the ordinary shares represented by such ADSs. As
a result, gain or loss is generally not expected to be recognized on account of exchanges of ordinary shares for ADSs, or of ADSs for
ordinary shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Distributions.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no current plans
to pay dividends. To the extent we pay any dividends, a U.S. Holder will be required to include in gross income as a taxable dividend
the amount of any distributions made on the ordinary shares or ADSs, including the amount of any Israeli taxes withheld, to the extent
that those distributions are paid out of our current and/or accumulated earnings and profits as determined for U.S. federal income tax
purposes. Any distributions in excess of our earnings and profits will be applied against and will reduce the U.S. Holder&#8217;s tax
basis in its ordinary shares or ADSs and to the extent they exceed that tax basis, will be treated as gain from the sale or exchange
of those ordinary shares or ADSs. If we were to pay dividends, we expect to pay such dividends in NIS with respect to the ordinary shares
and in U.S. dollars with respect to ADSs. A dividend paid in NIS, including the amount of any Israeli taxes withheld, will be includible
in a U.S. Holder&#8217;s income as a U.S. dollar amount calculated by reference to the exchange rate in effect on the date such dividend
is received, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted to U.S. dollars on
the date of receipt, a U.S. Holder generally will not recognize a foreign currency gain or loss. However, if the U.S. Holder converts
the NIS into U.S. dollars on a later date, the U.S. Holder must include, in computing its income, any gain or loss resulting from any
exchange rate fluctuations. The gain or loss will be equal to the difference between (i) the U.S. dollar value of the amount included
in income when the dividend was received and (ii) the amount received on the conversion of the NIS into U.S. dollars. Such gain or loss
will generally be ordinary income or loss and United States source for U.S. foreign tax credit purposes. U.S. Holders should consult
their own tax advisors regarding the tax consequences to them if we pay dividends in NIS or any other non-U.S. currency.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to certain significant
conditions and limitations, including potential limitations under the U.S.-Israel Tax Treaty, any Israeli taxes paid on or withheld from
distributions from us and not refundable to a U.S. Holder may be credited against the investor&#8217;s U.S. federal income tax liability
or, alternatively, may be deducted from the investor&#8217;s taxable income. The election to credit or deduct foreign taxes is made on
a year-by-year basis and applies to all foreign taxes paid by a U.S. Holder or withheld from a U.S. Holder that year. Dividends paid
on the ordinary shares generally will constitute income from sources outside the United States and be categorized as &#8220;passive category
income&#8221; or, in the case of some U.S. Holders, as &#8220;general category income&#8221; for U.S. foreign tax credit purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of recent changes
to the U.S. foreign tax credit rules, a withholding tax may need to satisfy certain additional requirements in order to be considered
a creditable tax for a U.S. Holder. We have not determined whether these requirements have been met and, accordingly, no assurance can
be given that any withholding tax on dividends paid by us will be creditable. Because the rules governing foreign tax credits are complex,
U.S. Holders should consult their own tax advisor regarding the availability of foreign tax credits in their particular circumstances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends paid on the ordinary
shares and ADSs will not be eligible for the &#8220;dividends-received&#8221; deduction generally allowed to corporate U.S. Holders with
respect to dividends received from U.S. corporations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain distributions treated
as dividends that are received by an individual U.S. Holder from &#8220;qualified foreign corporations&#8221; generally qualify for a
20% tax rate so long as certain holding period and other requirements are met. A non-U.S. corporation (other than a corporation that
is treated as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to
be a qualified foreign corporation (i) if it is eligible for the benefits of a comprehensive tax treaty with the United States which
the Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange
of information program, or (ii) with respect to any dividend it pays on stock (or ADSs in respect of such stock) which is readily tradable
on an established securities market in the United States. Dividends paid by us in a taxable year in which we are not a PFIC and with
respect to which we were not a PFIC in the preceding taxable year are expected to be eligible for the 20% tax rate, although we can offer
no assurances in this regard. However, any dividend paid by us in a taxable year in which we are a PFIC or were a PFIC in the preceding
taxable year will be subject to tax at regular ordinary income rates. Because the PFIC determination is highly fact intensive, there
can be no assurance that we will not be a PFIC in 2025 or in any other taxable year. The additional 3.8% &#8220;net investment income
tax&#8221; (described below) may apply to dividends received by certain U.S. Holders who meet certain modified adjusted gross income
thresholds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><!-- Field: Page; Sequence: 146; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Adjustments with respect to Warrants and
Pre-funded Warrants</i>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of the Warrants
and Pre-funded Warrants provide for an adjustment to the number of ordinary shares for which the warrant may be exercised or to the exercise
price of the warrant in certain events. An adjustment that has the effect of preventing dilution generally is not taxable. However, the
U.S. Holders of the Warrants or Pre-funded Warrants would be treated as receiving a constructive distribution from us if, for example,
the adjustment increases the warrant holders&#8217; proportionate interest in our assets or earnings and profits (e.g., through a decrease
in the exercise price of the Warrants or Pre-funded Warrants) as a result of a distribution of cash to the holders of our ordinary shares
or ADSs, which is taxable to the U.S. Holders of such ordinary shares or ADSs as described under &#8220;&#8212;Distributions&#8221; above.
Such constructive distribution would be subject to tax as described under that section in the same manner as if the U.S. Holders of the
Warrants or Pre-funded Warrants received a cash distribution from us equal to the fair market value of such increased interest. U.S.
Holders of Warrants and Pre-funded Warrants are urged to consult their own tax advisors on these issues<span style="font-weight: bold;">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Sale, Exchange or Other Disposition of
Ordinary Shares, ADSs, Warrants, and Pre-funded Warrants.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussion
under &#8220;&#8212; Passive Foreign Investment Company&#8221; below, a U.S. Holder generally will recognize capital gain or loss upon
the sale, exchange or other taxable disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants in an amount equal to
the difference between the amount realized on the sale, exchange or other disposition and the U.S. Holder&#8217;s adjusted tax basis
in such securities. This capital gain or loss will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period in our
securities exceeds one year. Preferential tax rates for long-term capital gain (currently, with a maximum rate of 20%) will apply to
individual U.S. Holders. The deductibility of capital losses is subject to limitations. The gain or loss will generally be income or
loss from sources within the United States for U.S. foreign tax credit purposes, subject to certain exceptions in the U.S.-Israel Tax
Treaty. The additional 3.8% &#8220;net investment income tax&#8221; (described below) may apply to gains recognized upon the sale, exchange,
or other taxable disposition of our securities by certain U.S. Holders who meet certain modified adjusted gross income thresholds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders should consult
their own tax advisors regarding the U.S. federal income tax consequences of receiving currency other than U.S. dollars upon the disposition
of their ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Exercise or Lapse of a Warrant and Pre-funded
Warrants</i>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the discussion
under &#8220;&#8212;Passive Foreign Investment Company&#8221; below, a U.S. Holder generally will not recognize gain or loss upon the
exercise of a Warrant or Pre-funded Warrant for cash. An ADS acquired pursuant to the exercise of a Warrant or Pre-funded Warrant for
cash generally will have a tax basis equal to the U.S. Holder&#8217;s tax basis in the Warrant or Pre-funded Warrant, increased by the
amount paid to exercise the Warrant or Pre-funded Warrant. The holding period of an ADS acquired pursuant to the exercise of a Warrant
generally would begin on the day after the date of exercise of the Warrant. Subject to the discussion above regarding the tax characterization
of the Pre-funded Warrants, the holding period of a Pre-funded Warrant should carry over to an ADS acquired pursuant to the exercise
of a Pre-funded Warrant. If a Warrant or Pre-funded Warrant is allowed to lapse unexercised, a U.S. Holder generally will recognize a
capital loss equal to such holder&#8217;s tax basis in the warrant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax consequences of a
cashless exercise of Warrants are unclear and could differ from the consequences described above. It is possible that a cashless exercise
could be a taxable event. U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of the
cashless exercise of Warrants, including with respect to whether the exercise is a taxable event, and their holding period and tax basis
in the ADSs received.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><!-- Field: Page; Sequence: 147; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Passive Foreign Investment Company</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, a corporation
organized outside the United States will be treated as a PFIC for U.S. federal income tax purposes in any taxable year in which either
(i) at least 75% of its gross income is &#8220;passive income&#8221; or (ii) on average at least 50% of its assets (by value) produce
passive income or are held for the production of passive income. Passive income for this purpose generally includes, among other things,
certain dividends, interest, royalties, rents and gains from commodities and securities transactions and from the sale or exchange of
property that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary investment of funds,
including those raised in the public offering. Assets that produce or are held for the production of passive income may include cash,
even if held as working capital or raised in a public offering, as well as marketable securities and other assets that may produce passive
income. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in
which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the tests described
above, whether or not we are a PFIC will be determined annually based upon the composition of our income and the composition and valuation
of our assets, all of which are subject to change.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our analysis of
our income, assets, and operations, we believe that we may have been a PFIC for 2025. Because the PFIC determination is highly fact intensive,
there can be no assurance that we will not be a PFIC in 2026 or in any other taxable year. Even if we determine that we are not a PFIC
after the close of a taxable year, there can be no assurance that a court or the IRS will agree with our conclusion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Default PFIC Rules</i>.
If we are a PFIC for any tax year, a U.S. Holder who does not make a timely QEF election or a mark-to-market election, referred to in
this disclosure as a &#8220;Non-Electing U.S. Holder,&#8221; will be subject to special rules with respect to (i) any &#8220;excess distribution&#8221;
(generally, the portion of any distributions received by the Non-Electing U.S. Holder on the ordinary shares or ADSs (or warrants, to
the extent applicable) in a taxable year in excess of 125% of the average annual distributions received by the Non-Electing U.S. Holder
in the three preceding taxable years, or, if shorter, the Non-Electing U.S. Holder&#8217;s holding period for the ordinary shares or
ADSs), and (ii) any gain realized on the sale or other disposition of ordinary shares, ADSs, Warrants, or Pre-funded Warrants. Under
these rules:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in; font-size: 10pt">&#160;</td>
<td style="width: 0.25in; font-size: 10pt">&#9679;</td>
<td style="font-size: 10pt; text-align: justify">the excess distribution or gain would be allocated ratably over the Non-Electing
    U.S. Holder&#8217;s holding period for such ordinary shares, ADSs, Warrants, or Pre-funded Warrants;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in; font-size: 10pt">&#160;</td>
<td style="width: 0.25in; font-size: 10pt">&#9679;</td>
<td style="font-size: 10pt; text-align: justify">the amount allocated to the current taxable year and any year prior to us becoming
    a PFIC would be taxed as ordinary income; and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in; font-size: 10pt">&#160;</td>
<td style="width: 0.25in; font-size: 10pt">&#9679;</td>
<td style="font-size: 10pt; text-align: justify">the amount allocated to each of the other taxable years would be subject to tax
    at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge for the deemed deferral
    benefit would be imposed with respect to the resulting tax attributable to each such other taxable year.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a Non-Electing U.S. Holder
who is an individual dies while owning our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, the Non-Electing U.S. Holder&#8217;s
successor would be ineligible to receive a step-up in tax basis of such ordinary shares, ADSs, Warrants, or Pre-funded Warrants. Non-Electing
U.S. Holders should consult their tax advisors regarding the application of the &#8220;net investment income tax&#8221; (described below)
to their specific situation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent a distribution
on our ordinary shares or ADSs (or warrants, to the extent applicable) does not constitute an excess distribution to a Non-Electing U.S.
Holder, such Non-Electing U.S. Holder generally will be required to include the amount of such distribution in gross income as a dividend
to the extent of our current and/or accumulated earnings and profits (as determined for U.S. federal income tax purposes) that are not
allocated to excess distributions. The tax consequences of such distributions are discussed above under &#8220;Distributions.&#8221;
Each U.S. Holder is encouraged to consult its own tax advisor with respect to the appropriate U.S. federal income tax treatment of any
distribution on our ordinary shares or ADSs (or warrants, to the extent applicable).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are treated as a PFIC
for any taxable year during the holding period of a Non-Electing U.S. Holder, we will continue to be treated as a PFIC for all succeeding
years during which the Non-Electing U.S. Holder is treated as a direct or indirect Non-Electing U.S. Holder even if we are not a PFIC
for such years. A U.S. Holder is encouraged to consult its tax advisor with respect to any available elections that may be applicable
in such a situation, including the &#8220;deemed sale&#8221; election of Code Section 1298(b)(1) (which will be taxed under the adverse
tax rules described above).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 148; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder that owns (or
is deemed to own) shares in a PFIC during any taxable year of the U.S. Holder generally is required to file an IRS Form 8621 with such
U.S. Holder&#8217;s U.S. federal income tax return and provide such other information as the IRS may require. Failure to file IRS Form
8621 for each applicable taxable year may result in substantial penalties and result in the U.S. Holder&#8217;s taxable years being open
to audit by the IRS until such forms are properly filed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may invest in the equity
of foreign corporations that are PFICs or may own subsidiaries that own PFICs. If we are classified as a PFIC, under attribution rules
U.S. Holders will be subject to the PFIC rules with respect to their indirect ownership interests in such PFICs, such that a disposition
of the shares of the PFIC or receipt by us of a distribution from the PFIC generally will be treated as a deemed disposition of such
shares or the deemed receipt of such distribution by the U.S. Holder, subject to taxation under the PFIC rules. There can be no assurance
that a U.S. Holder will be able to make a QEF election or a mark-to-market election with respect to PFICs in which we invest. Each U.S.
Holder is encouraged to consult its own tax advisor with respect to tax consequences of an investment by us in a corporation that is
a PFIC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">QEF Election</span>. Certain
adverse consequences of PFIC status can be mitigated for holders of our ordinary shares, ADSs, and Pre-funded Warrants if a U.S. Holder
makes a QEF election. A U.S. Holder may not make a QEF election with respect to our Warrants. A U.S. Holder who makes a timely QEF election,
referred to in this disclosure as an &#8220;Electing U.S. Holder,&#8221; with respect to us must report for U.S. federal income tax purposes
his pro rata share of our ordinary earnings and net capital gain, if any, for our taxable year that ends with or within the taxable year
of the Electing U.S. Holder. The &#8220;net capital gain&#8221; of a PFIC is the excess, if any, of the PFIC&#8217;s net long-term capital
gains over its net short-term capital losses. The amount so included in income generally will be treated as ordinary income to the extent
of such Electing U.S. Holder&#8217;s allocable share of the PFIC&#8217;s ordinary earnings and as long-term capital gain to the extent
of such Electing U.S. Holder&#8217;s allocable share of the PFIC&#8217;s net capital gains. Such Electing U.S. Holder generally will
be required to translate such income into U.S. dollars based on the average exchange rate for the PFIC&#8217;s taxable year with respect
to the PFIC&#8217;s functional currency. Such income generally will be treated as income from sources outside the United States for U.S.
foreign tax credit purposes. Amounts previously included in income by such Electing U.S. Holder under the QEF rules generally will not
be subject to tax when they are distributed to such Electing U.S. Holder. The Electing U.S. Holder&#8217;s tax basis in our ordinary
shares, ADSs, or Pre-funded Warrants generally will increase by any amounts so included under the QEF rules and decrease by any amounts
not included in income when distributed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Electing U.S. Holder will
be subject to U.S. federal income tax on such amounts for each taxable year in which we are a PFIC, regardless of whether such amounts
are actually distributed to such Electing U.S. Holder. However, an Electing U.S. Holder may, subject to certain limitations, elect to
defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If an Electing U.S. Holder is an individual,
any such interest will be treated as non-deductible &#8220;personal interest.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any net operating losses
or net capital losses of a PFIC will not pass through to the Electing U.S. Holder and will not offset any ordinary earnings or net capital
gain of a PFIC recognized by Electing U.S. Holder in subsequent years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">So long as an Electing U.S.
Holder&#8217;s QEF election with respect to us is in effect with respect to the entire holding period for our ordinary shares, ADSs,
or Pre-funded Warrants, any gain or loss recognized by such Electing U.S. Holder on the sale, exchange or other disposition of such shares,
ADSs, or Pre-funded Warrants generally will be long-term capital gain or loss if such Electing U.S. Holder has held such shares, ADSs,
or Pre-funded Warrants for more than one year at the time of such sale, exchange or other disposition. Preferential tax rates for long-term
capital gain (currently, a maximum rate of 20%) will apply to individual U.S. Holders. The deductibility of capital losses is subject
to limitations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 149; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, a U.S. Holder
must make a QEF election on or before the due date for filing its income tax return for the first year to which the QEF election is to
apply. A U.S. Holder makes a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions
thereto. Upon request, we intend to annually furnish U.S. Holders with information needed in order to complete IRS Form 8621 (which form
would be required to be filed with the IRS on an annual basis by the U.S. Holder) and to make and maintain a valid QEF election for any
year in which we are a PFIC. There is no assurance, however, that we will have timely knowledge of our status as a PFIC, or that the
information that we provide will be adequate to allow U.S. Holders to make a QEF election. A QEF election will not apply to any taxable
year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become a PFIC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder may not make
a QEF election with respect to our Warrants. As a result, if a U.S. Holder sells or otherwise disposes of such Warrants (other than upon
exercise thereof), any gain recognized generally will be subject to special tax and interest charge rules treating the gain as an excess
distribution, as described above, if we were a PFIC at any time during the period the U.S. Holder held the Warrants. If a U.S. Holder
that exercises such Warrants properly makes a QEF election with respect to the newly acquired ADSs (or has previously made a QEF election
with respect to our ADSs), the QEF election will apply to the newly acquired ADSs, but the adverse tax consequences attributable to the
period prior to exercise of the Warrants, adjusted to take into account the current income inclusions resulting from the QEF election,
will continue to apply with respect to such newly acquired ADSs, unless the U.S. Holder makes a &#8220;purging election&#8221; that creates
a deemed sale of such ADSs at their fair market value. The gain recognized by the purging election will be subject to the special tax
and interest charge rules treating the gain as an excess distribution, as described above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each U.S. Holder should consult
its own tax advisor with respect to the advisability of, the tax consequences of, and the procedures for making a QEF election with respect
to us.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mark-to-Market Election.&#160;</i>Alternatively,
if our ordinary shares or ADSs are treated as &#8220;marketable stock,&#8221; a U.S. Holder would be allowed to make a &#8220;mark-to-market&#8221;
election with respect to our ordinary shares or ADSs, provided the U.S. Holder completes and files IRS Form 8621 in accordance with the
relevant instructions and related Treasury Regulations. If the election is made, the U.S. Holder generally would include as ordinary
income in each taxable year the excess, if any, of the fair market value of our ordinary shares or ADSs at the end of the taxable year
over such holder&#8217;s adjusted tax basis in such shares or ADSs. The U.S. Holder would also be permitted an ordinary loss in respect
of the excess, if any, of the U.S. Holder&#8217;s adjusted tax basis in our ordinary shares or ADSs over their fair market value at the
end of the taxable year, but only to the extent of the net amount previously included in income as a result of the mark-to-market election.
A U.S. Holder&#8217;s tax basis in our ordinary shares or ADSs would be adjusted to reflect any such income or loss amount. Gain realized
on the sale, exchange or other disposition of our ordinary shares or ADSs would be treated as ordinary income, and any loss realized
on the sale, exchange or other disposition of our ordinary shares or ADSs would be treated as ordinary loss to the extent that such loss
does not exceed the net mark-to-market gains previously included in income by the U.S. Holder, and any loss in excess of such amount
will be treated as capital loss. Amounts treated as ordinary income will not be eligible for the favorable tax rates applicable to qualified
dividend income or long-term capital gains.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, stock will be
considered marketable stock if it is &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221; within the meaning of applicable
Treasury Regulations. A class of stock is regularly traded on an exchange during any calendar year during which such class of stock is
traded, other than in&#160;<i>de minimis&#160;</i>quantities, on at least 15 days during each calendar quarter. To be marketable stock,
our ordinary shares and ADSs must be regularly traded on a qualifying exchange (i) in the United States that is registered with the SEC
or a national market system established pursuant to the Exchange Act or (ii) outside the United States that is properly regulated and
meets certain trading, listing, financial disclosure and other requirements. Our ordinary shares should constitute &#8220;marketable
stock&#8221; as long as they remain listed on the TASE and are regularly traded. Our ADSs will be listed on the OTC and/or the NYSE American.
While we believe that our ordinary shares and ADSs may be treated as marketable stock for purposes of the PFIC rules so long as they
are listed on the TASE and the OTC and/or the NYSE American, as applicable, and are regularly traded, the IRS has not provided a list
of the exchanges that meet the foregoing requirements and thus no assurance can be provided that our ordinary shares and/or ADSs will
be (or will remain) treated as marketable stock for purposes of the PFIC rules.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A mark-to-market election
will not apply to our ordinary shares or ADSs held by a U.S. Holder for any taxable year during which we are not a PFIC, but will remain
in effect with respect to any subsequent taxable year in which we become a PFIC. Such election will not apply to any PFIC subsidiary
that we own. Each U.S. Holder is encouraged to consult its own tax advisor with respect to the availability and tax consequences of a
mark-to-market election with respect to our ordinary shares and ADSs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 150; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, U.S. Holders
should consult their tax advisors regarding the IRS information reporting and filing obligations that may arise as a result of the ownership
of ordinary shares in a PFIC, including IRS Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or
Qualified Electing Fund.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>The U.S. federal income
tax rules relating to PFICs, QEF elections, and mark-to market elections are complex. U.S. Holders are urged to consult their own tax
advisors with respect to the purchase, ownership and disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, any
elections available with respect to such shares, ADSs, Warrants, or Pre-funded Warrants, and the IRS information reporting obligations
with respect to the purchase, ownership and disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Certain Reporting Requirements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S. Holders may
be required to file IRS Form 926, Return by U.S. Transferor of Property to a Foreign Corporation, reporting transfers of cash or other
property to us and information relating to the U.S. Holder and us. Substantial penalties may be imposed upon a U.S. Holder that fails
to comply. See also the discussion regarding Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or
Qualified Electing Fund, above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, certain U.S.
Holders must report information on IRS Form 8938, Statement of Specified Foreign Financial Assets, with respect to their investments
in certain &#8220;specified foreign financial assets,&#8221; which would include an investment in our securities, if the aggregate value
of all of those assets exceeds $50,000 on the last day of the taxable year (and in some circumstances, a higher threshold). This reporting
requirement applies to individuals and certain U.S. entities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who fail to
report required information could become subject to substantial penalties. U.S. Holders should consult their tax advisors regarding the
possible implications of these reporting requirements arising from their investment in our securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Backup Withholding Tax and Information Reporting Requirements</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, information reporting
requirements will apply to distributions on our ordinary shares or ADSs (or warrants, to the extent applicable) or proceeds on the disposition
of our securities paid within the United States (and, in certain) proceeds on the disposition of our securities paid within the United
States (and, in certain cases, outside the United States) to U.S. Holders other than certain exempt recipients, such as corporations.
Furthermore, backup withholding (currently at 24%) may apply to such amounts if the U.S. Holder fails to (i) provide a correct taxpayer
identification number, (ii) report interest and dividends required to be shown on its U.S. federal income tax return, or (iii) make other
appropriate certifications in the required manner. U.S. Holders who are required to establish their exempt status generally must provide
such certification on IRS Form W-9.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Backup withholding is not
an additional tax. Amounts withheld as backup withholding from a payment may be credited against a U.S. Holder&#8217;s U.S. federal income
tax liability and such U.S. Holder may obtain a refund of any excess amounts withheld by filing the appropriate claim for refund with
the IRS and furnishing any required information in a timely manner.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><i>Tax on Net Investment Income</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S. persons, including
individuals, estates and trusts are generally subject to an additional 3.8% Medicare tax. For individuals, the additional Medicare tax
applies to the lesser of (i) &#8220;net investment income&#8221; or (ii) the excess of &#8220;modified adjusted gross income&#8221; over
$200,000 ($250,000 if married and filing jointly or $125,000 if married and filing separately). &#8220;Net investment income&#8221; generally
equals the taxpayer&#8217;s gross investment income reduced by the deductions that are allocable to such income. Investment income generally
includes passive income such as interest, dividends, annuities, royalties, rents, and capital gains. U.S. Holders are urged to consult
their own tax advisors regarding the implications of the additional Medicare tax resulting from their ownership and disposition of our
securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 151; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"><i>Tax Consequences for Non-U.S. Holders of Ordinary Shares, ADSs,
Warrants, or Pre-funded Warrants</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided below,
an individual, corporation, estate or trust that is not a U.S. Holder, referred to below as a non-U.S. Holder, generally will not be
subject to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the disposition of, our ordinary
shares, ADSs, Warrants, or Pre-funded Warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-U.S. Holder may be
subject to U.S. federal income tax on a dividend paid on our ordinary shares or ADSs (or warrants, to the extent applicable) or gain
from the disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants if: (1) such item is effectively connected with the
conduct by the non-U.S. Holder of a trade or business in the United States and, if required by an applicable income tax treaty is attributable
to a permanent establishment or fixed place of business in the United States; or (2) in the case of a disposition of our ordinary shares,
ADSs, Warrants, or Pre-funded Warrants, the individual non-U.S. Holder is present in the United States for 183 days or more in the taxable
year of the disposition and other specified conditions are met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, non-U.S. Holders
will not be subject to backup withholding with respect to the payment of dividends on our ordinary shares or ADSs (or warrants, to the
extent applicable) if payment is made through a paying agent, or office of a foreign broker outside the United States. However, if payment
is made in the United States or by a U.S. related person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S.
Holder provides an applicable IRS Form W-8 (or a substantially similar form) certifying its foreign status, or otherwise establishes
an exemption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of any backup
withholding from a payment to a non-U.S. Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability
and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>The discussion above
is a general summary and is not intended to constitute a complete analysis of all tax consequences relating to the purchase, ownership
and disposition of our ordinary shares, ADSs, Warrants or Pre-funded Warrants. It does not cover all tax matters that may be of importance
to a U.S. Holder. U.S. Holders should consult their own tax advisors concerning the tax consequences relating to the purchase, ownership
and </i></span>disposition <span style="font-weight: bold;"><i>of our ordinary shares, ADSs, Warrants or Pre-funded Warrants.</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">F. Dividends and Paying Agents.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">G. Statements by Experts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">H. Documents on Display.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements will file reports with
the SEC. The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically
with the SEC. You may read and copy this annual report, including the related exhibits and schedules, and any document we file with the
SEC at http://www.sec.gov.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 152; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements. Section 8103 of the National
Defense Authorization Act for Fiscal Year 2026 named, the &#8220;Holding Foreign Insiders Accountable Act&#8221; was signed into law
on December 18, 2025, will require directors and officers of foreign private issuers to make insider reports under Section 16(a) of the
Exchange Act, effective March 18, 2026. Our principal shareholders continue to remain exempt from the reporting under Section 16(a) of
the Exchange Act and our directors, officers and principal shareholders continue to remain exempt from the short-swing profit recovery
provisions contained in Section 16(b) of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly
and current reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are
registered under the Exchange Act. However, we file with the SEC, within four months after the end of each fiscal year, or such applicable
time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public
accounting firm, and submit to the SEC, on a Form 6-K, unaudited quarterly financial information for the first three quarters of each
fiscal year within 60 days after the end of each such quarter, or such applicable time as required by the SEC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0.5in; text-align: justify">In
addition, because our ordinary shares are traded on the TASE, we have filed Hebrew language periodic and immediate reports with, and
furnish information to, the TASE and the ISA, as required under Chapter Six of the Israel Securities Law. Copies of our filings with
the ISA can be retrieved electronically through the MAGNA distribution site of the ISA (<i>www.magna.isa.gov.il</i>) and the TASE website
(<i>www.maya.tase.co.il</i>).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
at&#160;<i>www.canfite.com. In</i>formation contained on, or that can be accessed through, our website does not constitute a part of
this Annual Report on Form 20-F. We have included our website address in this Annual Report on Form 20-F solely as an inactive textual
reference.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">I. Subsidiary Information.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">J. Annual Report to Security Holders.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;"><span id="a_013" style="display: inline-block;"></span>ITEM 11. </span></span><span style="font-weight: bold;">Quantitative
and Qualitative Disclosures About Market Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market risk is the risk of
loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that may adversely
impact our consolidated financial position, results of operations or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>&#160;</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Interest Rate Risk</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not anticipate undertaking
any significant long-term borrowings. At present, our investments consist primarily of cash and cash equivalents. We may invest in investment-grade
marketable securities with maturities of up to three years, including commercial paper, money market funds, and government/non-government
debt securities. The primary objective of our investment activities is to preserve principal while maximizing the income that we receive
from our investments without significantly increasing risk and loss. Our investments are exposed to market risk due to fluctuation in
interest rates, which may affect our interest income and the fair market value of our investments, if any. We manage this exposure by
performing ongoing evaluations of our investments. Due to the short-term maturities, if any, of our investments to date, their carrying
value has always approximated their fair value. If we decide to invest in investments other than cash and cash equivalents, it will be
our policy to hold such investments to maturity in order to limit our exposure to interest rate fluctuations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><!-- Field: Page; Sequence: 153; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-weight: bold;"><i>Foreign Currency Exchange
Risk</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our foreign currency exposures
give rise to market risk associated with exchange rate movements of the U.S. dollar, our functional and reporting currency, mainly against
the NIS and the euro. Although the U.S. dollar is our functional currency, a portion of our expenses are denominated in both NIS and
euro and currently all of our revenues are denominated in dollars. Our U.S. dollar and euro expenses consist principally of payments
made to sub-contractors and consultants for preclinical studies, clinical trials and other research and development activities, Our NIS
expenses consist principally of salary related payments. We anticipate that a sizable portion of our expenses will continue to be denominated
in currencies other than the NIS. If the U.S. dollar fluctuates significantly against either the NIS or the euro, it may have a negative
impact on our results of operations. To date, fluctuations in the exchange rates have not materially affected our results of operations
or financial condition for the periods under review.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not engaged
in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from
fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us from
the material adverse effects of such fluctuations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;"><span id="a_014" style="display: inline-block;"></span>ITEM 12. </span></span><span style="font-weight: bold;">Description
of Securities Other Than Equity Securities</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">A. Debt Securities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">B. Warrants and Rights.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">C. Other Securities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">D. American Depositary Shares</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
as Depositary, will register and deliver American Depositary Shares, or ADSs. Each ADS will represent two (2) ordinary shares (or a right
to receive two (2) ordinary shares) deposited with the principal Tel Aviv office of Bank Hapoalim, as custodian for the Depositary. Each
ADS will also represent any other securities, cash or other property which may be held by the Depositary. The Depositary&#8217;s corporate
trust office at which the ADSs will be administered is located at 101 Barclay Street, New York, New York 10286. The Bank of New York
Mellon&#8217;s principal executive office is located at One Wall Street, New York, New York 10286.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The form of the deposit agreement
for our ADSs and the form of American Depositary Receipt that represents an ADS have been incorporated by reference as exhibits to this
Annual Report on Form 20-F.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;"></span></p><!-- Field: Page; Sequence: 154; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Fees and Expenses</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: bottom">
<td style="border-bottom: black 1.5pt solid"><span style="font-weight: bold;">Persons depositing or withdrawing shares or ADS holders must pay:</span></td>
<td>&#160;</td>
<td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-weight: bold;">For:</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 50%">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</td>
<td style="width: 2%">&#160;</td>
<td style="width: 3%">&#9679;</td>
<td style="width: 45%; text-align: justify">Issuance of ADSs, including issuances resulting from a distribution of shares or rights
    or other property</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#9679;</td>
<td style="text-align: justify">Cancellation of ADSs for the purpose of withdrawal, including if the Deposit Agreement terminates</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td>$.05 (or less) per ADS</td>
<td>&#160;</td>
<td>&#9679;</td>
<td style="text-align: justify">Any cash distribution to ADS holders</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">A fee equivalent to the fee that would be payable if securities distributed to you had been shares
    and the shares had been deposited for issuance of ADSs</td>
<td>&#160;</td>
<td>&#9679;</td>
<td style="text-align: justify">Distribution of securities distributed to holders of deposited securities which are distributed by
    the Depositary to ADS holders</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td>$.05 (or less) per ADSs per calendar year</td>
<td>&#160;</td>
<td>&#9679;</td>
<td style="text-align: justify">Depositary services</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td>Registration or transfer fees</td>
<td>&#160;</td>
<td>&#9679;</td>
<td style="text-align: justify">Transfer and registration of shares on our share register to or from the name of the Depositary or
    its agent when you deposit or withdraw shares</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td>Expenses of the Depositary</td>
<td>&#160;</td>
<td>&#9679;</td>
<td style="text-align: justify">Cable, telex and facsimile transmissions (when expressly provided in the Deposit Agreement)</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#9679;</td>
<td style="text-align: justify">Converting foreign currency to U.S. dollars</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify">Taxes and other governmental charges the Depositary or the custodian have to pay on any ADS or share
    underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes</td>
<td>&#160;</td>
<td>&#9679;</td>
<td style="text-align: justify">As necessary</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td>Any charges incurred by the Depositary or its agents for servicing the deposited securities</td>
<td>&#160;</td>
<td>&#9679;</td>
<td style="text-align: justify">As necessary</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Depositary collects its
fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal
or from intermediaries acting for them. The Depositary collects fees for making distributions to investors by deducting those fees from
the amounts distributed or by selling a portion of distributable property to pay the fees. The Depositary may collect its annual fee
for depositary services by deduction from cash distributions, by directly billing investors or by charging the book-entry system accounts
of participants acting for them. The Depositary may generally refuse to provide fee-attracting services until its fees for those services
are paid.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Depositary
may make payments to us to reimburse us for expenses and/or share revenue with us from the fees collected from ADS holders, or waive
fees and expenses for services provided, generally relating to costs and expenses arising out of the establishment and maintenance of
the ADS program. In performing its duties under the Deposit Agreement, the Depositary may use brokers, dealers or other service providers
that are affiliates of the Depositary and that may earn or share fees or commissions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 155; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-transform: uppercase"><span style="font-weight: bold;"><span id="a_015" style="display: inline-block;"></span>PART
II</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_016" style="display: inline-block;"></span><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 13. </span></span><span style="font-weight: bold;">Defaults,
Dividend Arrearages and Delinquencies</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_017" style="display: inline-block;"></span><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 14. </span></span><span style="font-weight: bold;">Material
Modifications to the Rights of Security Holders and Use of Proceeds</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_018" style="display: inline-block;"></span><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 15. </span></span><span style="font-weight: bold;">Controls
and Procedures</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Disclosure controls and procedures</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, including
our chief executive officer, or CEO, who is also our chief financial officer, or CFO, is responsible for establishing and maintaining
our disclosure controls and procedures (within the meaning of Rule 13a-15(e) of the Exchange Act). These controls and procedures were
designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated
and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.
We evaluated these disclosure controls and procedures under the supervision of our CEO and CFO as of December 31, 2025. Based upon that
evaluation, our management, including our CEO and CFO, concluded that our disclosure controls and procedures as of December 31, 2025
were effective.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Management&#8217;s annual report on internal control over financial
reporting</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, including
our CEO, and our CFO, is responsible for establishing and maintaining adequate internal control over our financial reporting, as defined
in Rules 13a-15(f) and 15d-15(f) of the Exchange Act of 1934, as amended. Our internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes
policies and procedures that:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in">&#9679;</td>
<td style="text-align: justify">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our
    transactions and asset dispositions;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in">&#9679;</td>
<td style="text-align: justify">provide reasonable assurance that transactions are recorded as necessary to permit the preparation
    of our financial statements in accordance with generally accepted accounting principles;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in">&#9679;</td>
<td style="text-align: justify">provide reasonable assurance that receipts and expenditures are made only in accordance with authorizations
    of our management and board of directors (as appropriate); and</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in">&#9679;</td>
<td style="text-align: justify">provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition,
    use or disposition of assets that could have a material effect on our financial statements.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to its inherent limitations,
internal controls over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the supervision and
with the participation of our management, including our CEO, and our CFO, we assessed the effectiveness of our internal control over
financial reporting as of December 31, 2025 based on the framework for Internal Control-Integrated Framework set forth by The Committee
of Sponsoring Organizations of the Treadway Commission (COSO) (2013).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our assessment and
this framework, our management concluded that our internal control over financial reporting were effective as of December 31, 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Attestation Report of Registered Public Accounting Firm</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This annual report does not include an attestation report of the Company&#8217;s
independent registered public accounting firm regarding internal control over financial reporting since the Company is a non-accelerated
filer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><!-- Field: Page; Sequence: 156; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Changes in internal control over financial reporting</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes in
our internal control over financial reporting, other than as described above, that occurred during the year ended December 31, 2025 that
have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 16. </span></span><span style="font-weight: bold;"><span id="a_019" style="display: inline-block;"></span>[RESERVED]</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_020" style="display: inline-block;"></span><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 16A. </span></span><span style="font-weight: bold;">Audit
Committee Financial Expert</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
determined that Guy Regev is an audit committee financial expert, as defined by applicable SEC regulations. Mr. Regev qualified as an
&#8220;independent director,&#8221; as that term is defined under NYSE American rules.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_021" style="display: inline-block;"></span><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 16B. </span></span><span style="font-weight: bold;">Code
of Ethics</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a code of
ethics, referred to as a Code of Business Conduct, applicable to our directors, officers and all other employees. Our code of ethics
is publicly available on our website at&#160;<i>www.canfite.com</i>. If we make any amendment to the code of ethics or grant any waivers,
including any implicit waiver, from a provision of the code of ethics, which applies to our chief executive officer, chief financial
officer, chief accounting officer or controller, or persons performing similar functions, we will disclose the nature of such amendment
or waiver on our website.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 16C. </span></span><span style="font-weight: bold;"><span id="a_022" style="display: inline-block;"></span>Principal
Accountant Fees and Services</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets
forth, for each of the years indicated, the fees billed by our independent registered public accounting firm.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="font-weight: bold; border-bottom: Black 1.5pt solid">Services Rendered</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(USD in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%">Audit (1)</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">212</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
<td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">198</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Audit related services</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>Tax</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1.5pt">All other fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">216</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
<td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">198</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.25in">(1)</td>
<td style="text-align: justify">Audit fees consist of services that would normally be provided in connection with statutory and regulatory
    filings or engagements, including services that generally only the independent accountant can reasonably provide.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Audit Committee Pre-Approval Policies and
Procedures</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee&#8217;s
specific responsibilities in carrying out its oversight of the quality and integrity of the accounting, auditing and reporting practices
of us include the approval of audit and non-audit services to be provided by the external auditor. The audit committee approves in advance
the particular services or categories of services to be provided to us during the following yearly period and also sets forth a specific
budget for such audit and non-audit services. Additional non-audit services may be pre-approved by the audit committee.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 16D. </span></span><span style="font-weight: bold;"><span id="a_023" style="display: inline-block;"></span>Exemptions
from the Listing Standards for Audit Committees</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_024" style="display: inline-block;"></span><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 16E. </span></span><span style="font-weight: bold;">Purchases
of Equity Securities by the Issuer and Affiliated Purchasers</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_025" style="display: inline-block;"></span><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 16F. </span></span><span style="font-weight: bold;">Change
in Registrant&#8217;s Certifying Accountant</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><!-- Field: Page; Sequence: 157; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;"><span id="a_026" style="display: inline-block;"></span>ITEM 16G. </span></span><span style="font-weight: bold;">Corporate
Governance</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a foreign private
issuer whose ordinary shares are listed on the NYSE American. As such, we are required to comply with U.S. federal securities laws, including
the Sarbanes-Oxley Act, and the NYSE American rules, including the NYSE American corporate governance requirements. The NYSE American
rules provide that foreign private issuers may follow home country practice in lieu of certain qualitative listing requirements subject
to certain exceptions and except to the extent that such exemptions would be contrary to U.S. federal securities laws, so long as the
foreign issuer discloses that it does not follow such listing requirement and describes the home country practice followed in its reports
filed with the SEC. Below is a concise summary of the significant ways in which our corporate governance practices differ from the corporate
governance requirements of NYSE American applicable to domestic U.S. listed companies:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in">&#9679;</td>
<td style="text-align: justify">The NYSE American rules recommend that an issuer have a quorum requirement for shareholders meetings
    of at least one-third of the outstanding shares of the issuer&#8217;s common voting stock. We have chosen to follow home country
    practice with respect to the quorum requirements of our shareholders meeting and our adjourned shareholders meeting. Our Amended
    and Restated Articles of Association, as permitted under the Israeli Companies Law and Israeli practice, provide that the quorum
    requirements for a shareholders meeting are the presence of at least two shareholders who represent at least 25% of the outstanding
    shares of the issuer&#8217;s common voting stock, and in the event of an adjourned meeting, the presence of a minimum of two shareholders
    present in person.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 0.5in">&#160;</td>
<td style="width: 0.25in">&#9679;</td>
<td style="text-align: justify">We have chosen to follow our home country practice in lieu of the requirements of the NYSE American
    rules relating to shareholder approval required prior to the issuance of securities (i) when a stock option or purchase plan is to
    be established or materially amended or other equity compensation arrangement made or materially amended, pursuant to which stock
    may be acquired by officers, directors, employees or consultants and (ii) in connection with a transaction, other than a public offering,
    involving the issuance or potential issuance by the Company of ordinary shares (or their equivalent) equal to 20% or more of the
    ordinary shares or 20% voting power outstanding before the issuance for or at a price less than the greater of book or market value
    of the shares. We follow the provisions of the Israeli Companies Law with regard to transactions with our affiliates, i.e., our controlling
    shareholder and our directors and officers, including private placement transactions.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 16H. </span></span><span style="font-weight: bold;"><span id="a_027" style="display: inline-block;"></span>Mine
Safety Disclosure</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_028" style="display: inline-block;"></span><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 16I. </span></span><span style="font-weight: bold;">Disclosure
Regarding Foreign Jurisdictions that Prevent Inspections</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Not applicable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="a_029" style="display: inline-block;"></span><span style="font-weight: bold;">ITEM&#160;16J. INSIDER TRADING POLICIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have <ix:nonNumeric name="ecd:InsiderTrdPoliciesProcAdoptedFlag" contextRef="cref_184434641" format="ixt:fixed-true" id="ixv-17081">adopted</ix:nonNumeric> an insider trading policy, which includes trading policies that governs the trading in our securities by our directors, officers and certain other covered persons, and which is reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and any listing standards applicable to the Company. A copy of our insider trading policy is included as Exhibit 11.1 to this annual report. In addition, with regard to any trading in our own securities, it is our policy to comply with the federal securities laws and the applicable exchange listing requirements.&#160; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;"><span id="a_030" style="display: inline-block;"></span>ITEM&#160;16K. CYBERSECURITY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:nonNumeric name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" contextRef="cref_184434641" escape="true" id="ixv-9031"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have developed and maintain a cybersecurity risk management program, consisting of cybersecurity policies, procedures, compliance and awareness programs to mitigate risk&#160;and to ensure compliance with security, availability and confidentiality trust principles.&#160;<ix:nonNumeric name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" contextRef="cref_184434641" escape="true" id="ixv-17082">The cybersecurity process has been <ix:nonNumeric name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" contextRef="cref_184434641" format="ixt:fixed-true" id="ixv-17083">integrated</ix:nonNumeric> into our overall risk management system and process, and is solely internally managed.</ix:nonNumeric> Management is responsible for identifying risks that threaten achievement of the control activities stated in the management&#8217;s description of the services organizations systems. Management has implemented a process for identifying relevant risks that could affect the organization&#8217;s ability to provide secure and reliable service to its users. The risk assessment occurs annually, or as business needs change, and covers identification of risks that could act against the company&#8217;s objectives as well as specific risks related to a compromise to the security of data.&#160;See &#8220;Item 3.D Risk Factors&#8212; Risks Related to Our Business and Regulatory Matters&#8212; Our business and operations may be materially adversely affected in the event of computer system failures or security breaches.&#8221; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <ix:nonNumeric name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" contextRef="cref_184434641" escape="true" id="ixv-17084">The oversight of cybersecurity threats is undertaken by our Chief Executive Officer who and is supported by outside IT consultants. <ix:nonNumeric name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" contextRef="cref_184434641" escape="true" id="ixv-17085">Our audit committee is <ix:nonNumeric name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" contextRef="cref_184434641" format="ixt:fixed-true" id="ixv-17086">responsible</ix:nonNumeric> for cybersecurity oversight and monitoring risk.</ix:nonNumeric> <ix:nonNumeric name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" contextRef="cref_184434641" escape="true" id="ixv-17087">Management informs the <ix:nonNumeric name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" contextRef="cref_184434641" format="ixt:fixed-true" id="ixv-17088">audit committee</ix:nonNumeric> of such risk by committee meetings.</ix:nonNumeric></ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of the date of this report, <ix:nonNumeric name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" contextRef="cref_184434641" escape="true" id="ixv-17089">we are <ix:nonNumeric name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" contextRef="cref_184434641" format="ixt:fixed-false" id="ixv-17090">not</ix:nonNumeric> aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition.</ix:nonNumeric> </p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><!-- Field: Page; Sequence: 158; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></p></div></ix:exclude></ix:nonNumeric><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><span style="font-weight: bold;"><span id="a_031" style="display: inline-block;"></span>PART III</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_032" style="display: inline-block;"></span><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 17. </span></span><span style="font-weight: bold;">Financial
Statements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have responded to Item
18 in lieu of responding to this item.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_033" style="display: inline-block;"></span><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 18. </span></span><span style="font-weight: bold;">Financial
Statements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please refer to the financial
statements beginning on page F-1.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><span style="font-weight: bold;">&#160;</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_034" style="display: inline-block;"></span><span style="text-transform: uppercase"><span style="font-weight: bold;">ITEM 19. </span></span><span style="font-weight: bold;">Exhibits</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Index to Exhibits</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 9%; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">Exhibit&#160;No.</span></td>
<td style="width: 1%">&#160;</td>
<td style="width: 90%; border-bottom: black 1.5pt solid; text-align: justify"><span style="font-weight: bold;">Description</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">1.1*</span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="text-decoration: none;text-decoration:underline"><a href="ea028258601ex1-1.htm">Amended and Restated Articles of Association of Can-Fite BioPharma Ltd</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">2.1*</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="ea028258601ex2-1.htm">Description of Securities Registered under Section 12</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">2.2</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413062206/v359878_ex4-2.htm">Form of Amended and Restated Deposit Agreement, by and among Can-Fite BioPharma Ltd., The Bank of New York Mellon and the Owners and Holders of American Depositary Shares, dated September 11, 2013 (incorporated herein by reference to the Registration Statement on Form 8-A filed with the SEC on November 15,
2013.)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.1#</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-3.htm">Employment and Non-Competition Agreement with Motti Farbstein, dated June 10, 2003 (incorporated herein by reference to Amendment No. 1 to the Registration Statement on Form 20-F filed with the
SEC on September 10, 2013)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.2</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-4.htm">Consulting Agreement with BioStrategics Consulting, Ltd, dated September 27, 2005 (incorporated herein by reference to Amendment No. 1 to the Registration Statement on Form 20-F filed with the
SEC on September 10, 2013)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.3</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-5.htm">Service Management Agreement with F.D. Consulting International and Marketing Ltd., dated June 27, 2002 (incorporated herein by reference to Amendment No. 1 to the Registration Statement on Form 20-F filed with the
SEC on September 10, 2013)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.4</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-6.htm">Master Services Agreement with Accellient Partners, dated May 10, 2010 (incorporated herein by reference to Amendment No. 1 to the Registration Statement on Form 20-F filed with the
SEC on September 10, 2013)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.5</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-10.htm">License Agreement, by and between The University of Leiden and Can-Fite BioPharma Ltd., dated November 2, 2009 (incorporated herein by reference to Amendment No. 1 to the Registration Statement on Form 20-F filed with the
SEC on September 10, 2013)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.6</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-15.htm">License Agreement, by and between Kwang Dong Pharmaceutical Co., Ltd. and Can-Fite BioPharma Ltd., dated December 14, 2008 (incorporated herein by reference to Amendment No. 1 to the Registration Statement on Form 20-F filed with the
SEC on September 10, 2013)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.7#</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-25.htm">Can-Fite BioPharma Ltd. 2003 Israeli Share Option Plan (incorporated herein by reference to Amendment No. 1 to the Registration Statement on Form 20-F filed with the
SEC on September 10, 2013)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.8#</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390015002133/f20f2014ex4xiii_canfitebio.htm">Can-Fite BioPharma Ltd. 2013 Israeli Share Option Plan (incorporated herein by reference to Annual Report on Form 20-F filed with the SEC on March 27, 2015)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.9#</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390024026947/ea020248201ex4-9_canfite.htm">Can-Fite BioPharma Ltd. 2023 Israeli Share Option Plan (incorporated herein by reference to the Annual Report on Form 20-F filed with the SEC on March 28, 2024)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.10#</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390025031298/ea023509301ex4-10_canfite.htm">Compensation
    Policy of Can-Fite BioPharma Ltd. (incorporated herein by reference to the Annual Report on Form 20-F filed with the SEC on April
    14, 2025)</a></td></tr>
</tbody></table><p style="margin: 0">&#160;</p><p style="margin: 0"></p><!-- Field: Page; Sequence: 159; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="font-weight: bold; width: 9%"><span style="font-weight: bold;">4.11&#8224;</span></td>
<td style="width: 1%">&#160;</td>
<td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390015002133/f20f2014ex4xxxiv_canfitebio.htm">Distribution and Supply Agreement between Can-Fite BioPharma Ltd. and Cipher Pharmaceuticals Inc. dated as of March 20, 2015 (incorporated herein by reference to Annual Report on Form 20-F filed with the SEC on March 27, 2015)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.12&#8224;</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390017003022/f20f2016ex4xxxi_canfitebio.htm">Distribution Agreement between Can-Fite BioPharma Ltd. and Chong Kun Dang Pharmaceutical Corp. dated as of October 25, 2016 (incorporated herein by reference to the Annual Report on Form 20- F filed with the SEC on March 30, 2017)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.13</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390021042704/ea145842ex10-4_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on August 16, 2021 (incorporated herein by reference to the Report on Form 6-K filed with the SEC on August 16, 2021)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.14</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390023089590/ea188904ex10-2_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on November 24, 2023 (incorporated herein by reference to the Report on Form 6-K filed with the SEC on November 22, 2023)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.15</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390023089590/ea188904ex10-3_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on November 24, 2023 (incorporated herein by reference to the Report on Form 6-K filed with the SEC on November 22, 2023)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.16</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390024067357/ea021093201ex10-2_canfite.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on August 12, 2024 (incorporated herein by reference to the Report on Form 6-K filed with the SEC on August 12, 2024)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.17</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390024067357/ea021093201ex10-3_canfite.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on August 12, 2024 (incorporated herein by reference to the Report on Form 6-K filed with the SEC on August 12, 2024)</a></td></tr>
</tbody></table><p style="margin: 0">&#160;</p><p style="margin: 0"></p><!-- Field: Page; Sequence: 160; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">4.18</span></span></td>
<td style="width: 1%">&#160;</td>
<td style="width: 90%; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390024074547/ea021264201ex10-1_canfite.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of At The Market Offering Agreement, dated August 30, 2024, between Can-Fite BioPharma Ltd. and H.C. Wainwright &amp; Co., LLC (incorporated herein by reference to the Report on Form 6-K filed with the SEC on August 30, 2024)</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.19</span></td>
<td>&#160;</td>
<td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1536196/000121390025031855/ea023825201ex10-1_canfite.htm">Form of Securities Purchase Agreement, dated April 14, 2025, by and between the Company and the investor party thereto (incorporated herein by reference to the Report on Form 6-K filed with the SEC on April 15, 2025)</a></p></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-weight: bold;">4.20</span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390025031855/ea023825201ex10-2_canfite.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on April
15, 2025 (incorporated herein by reference to the Report on Form 6-K filed with the SEC on April 15, 2025)</a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">4.21</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390025068477/ea025049801ex10-1_canfite.htm">Form of Securities Purchase Agreement, dated July 28, 2025, by and between the Company and the investor party thereto (incorporated herein by reference to the Report on Form 6-K filed with the SEC on July 29, 2025)</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">4.22</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390025068477/ea025049801ex4-1_canfite.htm">Form
    of Warrant issued by Can-Fite BioPharma Ltd. on July 29, 2025 (incorporated herein by reference to the Report on Form 6-K filed with
    the SEC on July 29, 2025)</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">4.23</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390025068477/ea025049801ex4-2_canfite.htm">Form of Pre-Funded Warrant issued by Can-Fite BioPharma Ltd. on July 29, 2025 (incorporated herein by reference to the Report on Form 6-K filed with the SEC on July 29, 2025)</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">4.24</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390025068477/ea025049801ex4-3_canfite.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on July 29, 2025 (incorporated herein by reference to the Report on Form 6-K filed with the SEC on July 29, 2025)</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">4.25</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: none;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390026023873/ea028009801ex10-1.htm">Form
    of Inducement Letter dated March 4, 2026 (incorporated herein by reference to the Report on Form 6-K filed with the SEC on March 5,
    2026)</a></span></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">4.26</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: none;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390026023873/ea028009801ex10-2.htm">Form
    of New Warrant issued by Can-Fite BioPharma Ltd. on March 5, 2026 (i<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ncorporated
    herein by reference to the Report on Form 6-K filed with the SEC on March 5, 2026</span>)</a></span></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">4.27</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: none;text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390026023873/ea028009801ex10-3.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on March 5, 2026 (i<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ncorporated herein by reference to
the Report on Form 6-K filed with the SEC on March 5, 2026</span>)</a></span></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">8.1</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390022014672/f20f2021ex8-1_canfitebio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries of Can-Fite BioPharma Ltd. (incorporated herein by reference to the Annual Report on Form 20-F filed with the SEC on March 24, 2022)</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">11.1+</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390025031298/ea023509301ex11-1_canfite.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insider Trading Policy (incorporated herein by reference to the Annual Report on Form 20-F filed with the SEC on April 14, 2025)</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">12.1*</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028258601ex12-1.htm">Certification by Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">13.1*</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028258601ex13-1.htm">Certification by Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">15.1*</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028258601ex15-1.htm">Consent of Independent Registered Public Accounting Firm</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">97.1#</span></span></td>
<td>&#160;</td>
<td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390024026947/ea020248201ex97-1_canfite.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Officer Clawback Policy (incorporated herein by reference to the Annual Report on Form 20-F filed with the SEC on March 28, 2024)</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
<tr style="vertical-align: top; background-color: White">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
<td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
<td style="text-align: right">&#160;</td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
</tbody></table><p style="margin: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td style="width: 34px">*</td>
<td style="text-align: justify">Filed Herewith.</td></tr>
<tr style="vertical-align: top">
<td>#</td>
<td style="text-align: justify">Management contract or compensatory plan.</td></tr>
<tr style="vertical-align: top">
<td>+</td>
<td style="text-align: justify">English translation of original Hebrew document.</td></tr>
<tr style="vertical-align: top">
<td>&#8224;</td>
<td style="text-align: justify">Certain confidential information contained in this exhibit was omitted by means of redacting a portion
    of the text and replacing it with [...]. This exhibit has been filed separately with the Commission without the redaction pursuant
    to a Confidential Treatment Request under Rule 24b-2 of the Securities Exchange Act of 1934 and Rule 406 of the Securities Act.</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><!-- Field: Page; Sequence: 161; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">SIGNATURES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
Annual Report on its behalf.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
<td>&#160;</td>
<td colspan="2"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD.</span></td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td colspan="2">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="width: 60%">Date: March 26, 2026</td>
<td style="width: 3%">By:</td>
<td style="width: 37%; border-bottom: black 1.5pt solid">/s/ Motti Farbstein</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>Motti Farbstein</td></tr>
<tr style="vertical-align: top">
<td>&#160;</td>
<td>&#160;</td>
<td>Chief Executive Officer and <br/>
    Chief Financial Officer</td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 162; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-weight: bold;">CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-weight: bold;">AS OF DECEMBER 31, 2025</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-weight: bold;">INDEX</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr> <td style="vertical-align: top; width: 89%">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Page</span></span></td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><a href="#a_035"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric name="dei:AuditorFirmId" contextRef="cref_184434641" id="ixv-17091">1281</ix:nonNumeric>)</span></span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">F-2 - F-3</span></span></td></tr> <tr style="background-color: White"> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><a href="#a_036"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Consolidated Balance Sheets</span></span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">F-4 - F-5</span></span></td></tr> <tr style="background-color: White"> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><a href="#a_037"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Consolidated Statements of Operating Loss</span></span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">F-6</span></span></td></tr> <tr style="background-color: White"> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><a href="#a_038"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Consolidated Statements of Changes in Shareholders&#8217; Equity</span></span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">F-7 - F-8</span></span></td></tr> <tr style="background-color: White"> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><a href="#a_040"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Consolidated Statements of Cash Flows</span></span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">F-9</span></span></td></tr> <tr style="background-color: White"> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: rgb(204,238,255)"> <td style="vertical-align: top"><a href="#a_041"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Notes to Consolidated Financial Statements</span></span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">F-10&#160;-&#160;F-34</span></span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 163; Options: NewSection; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="a_035" style="display: inline-block;"></span>&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 33%; padding-top: 2pt; font-size: 10pt"><img alt="" src="ea028258601_img7.jpg"/></td> <td style="width: 34%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Kost Forer Gabbay &amp; Kasierer</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">144 Menachem Begin Road, Building</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A Tel-Aviv 6492102, Israel&#160;</p></td> <td style="width: 33%"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel: +972-3-6232525</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fax: +972-3-5622555</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ey.com&#160;</p></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-weight: bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-weight: bold;">To the Shareholders and the Board of Directors of</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><ix:nonNumeric name="dei:AuditorOpinionTextBlock" contextRef="cref_184434641" escape="true" id="ixv-9721"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Opinion on the Financial Statements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.95pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying consolidated balance sheets of Can-Fite BioPharma Ltd. and its subsidiary (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, the related consolidated statements of operating loss, changes in shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.95pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Basis for Opinion</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.95pt; text-align: justify; text-indent: 35.95pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 164; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">Critical Audit Matter</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 18%; text-align: justify">&#160;</td> <td style="width: 1%; text-align: justify">&#160;</td> <td style="width: 81%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Liquidity and Capital Resources</span></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Matter</i></span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed in Note 1 to the consolidated financial statements, the Company has incurred operating losses and negative cash-flow from operations since inception. The Company&#8217;s operations are dependent on its ability to raise additional funds. This dependency will continue until the Company will be able to completely finance its operations by generating revenue from its product candidates. Management has concluded that, based on its current projections and contingency plan, the Company will be able to satisfy its liquidity requirements for at least twelve months from the date these financial statements were issued.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Auditing the assessment of liquidity and the Company&#8217;s ability to continue as a going concern was subjective due to the judgments required of management to conclude whether the Company would have sufficient liquidity to sustain itself for at least twelve months from the date of the issuance of the consolidated financial statements. This in turn led to a high degree of auditor judgment to evaluate the audit evidence supporting the liquidity conclusions. </span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How We Addressed the Matter in Our Audit</i></span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">To test the assessment of liquidity and the Company&#8217;s ability to continue as a going concern our audit procedures to audit judgments made by management included, testing the reasonableness of forecasted research and development costs, comparison of prior period forecasts to actual results, evaluating the fluctuations in forecasted clinical trial expenses and payments thereof as compared to historic amounts and the underlying management assumptions, evaluating the reasonableness of the amounts and timing of payments of forecasted general and administrative expenses and other income, net, and considering positive and negative evidence impacting management&#8217;s forecasts. In addition, we assessed the adequacy of the Company&#8217;s going concern disclosures included in Note 1 to the consolidated financial statements.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> /s/ <ix:nonNumeric name="dei:AuditorName" contextRef="cref_184434641" id="ixv-17092">KOST FORER GABBAY&amp; KASIERER</ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">A Member of EY Global</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&#8217;s auditor since at least 2001, but we are unable to determine the specific year.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> <ix:nonNumeric name="dei:AuditorLocation" contextRef="cref_184434641" id="ixv-17093">Tel-Aviv, Israel</ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="background-color: white">March 26, 2026</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><!-- Field: Page; Sequence: 165; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;"><span id="a_036" style="display: inline-block;"></span>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">CONSOLIDATED
BALANCE SHEETS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
<td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: justify">ASSETS</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: justify">CURRENT ASSETS:</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: justify; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td><td style="width: 7%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17094">5,528</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17095">4,825</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 9pt">Short-term deposits</td><td>&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsCurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17096">3,011</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsCurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17097">3,057</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9pt">Prepaid expenses, and other current assets</td><td>&#160;</td><td style="text-align: center">3</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17098">900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17099">1,095</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">6</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17100">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17101">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: none; text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> current assets</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17102">9,440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17103">8,982</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify">NON-CURRENT ASSETS:</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9pt">Operating lease right of use assets</td><td>&#160;</td><td style="text-align: center">10</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17104">69</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17105">111</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Property, plant and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">4</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17106">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17107">27</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: none; text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17108">74</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17109">138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: none; text-align: justify; padding-bottom: 4pt"><span style="text-decoration:underline">Total</span> assets</td><td style="padding-bottom: 4pt">&#160;</td><td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17110">9,514</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17111">9,120</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part of
the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 166; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">CONSOLIDATED
BALANCE SHEETS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>CURRENT LIABILITIES:</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left; padding-left: 0.2in">Trade payables</td><td style="width: 1%">&#160;</td><td style="width: 7%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17112">1,161</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableTradeCurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17113">618</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.2in">Current maturity of operating lease liability</td><td>&#160;</td><td style="text-align: center">10</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17114">56</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17115">53</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.2in">Deferred revenues</td><td>&#160;</td><td style="text-align: center">7</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17116">405</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17117">405</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.2in">Other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">5</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17118">1,109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableOtherCurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17119">976</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: none; text-align: left; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17120">2,731</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17121">2,052</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.2in">Long-term operating lease liability</td><td>&#160;</td><td style="text-align: center">10</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17122">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17123">51</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.2in">Deferred revenues</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">7</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17124">1,176</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17125">1,581</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: none; text-align: left; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17126">1,191</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17127">1,632</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">CONTINGENT LIABILITIES AND COMMITMENTS</td><td>&#160;</td><td style="text-align: center">8</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_172437876">&#160;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_438358129">&#160;</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">SHAREHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
<td style="text-align: center">9</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 0.5in">Ordinary shares of <span style="-sec-ix-hidden:fc_1954273020"><span style="-sec-ix-hidden:fc_760617434">no</span></span> par value - Authorized: <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="fc_326785155" contextRef="cref_1997617154" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">14,000,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="fc_1802511409" contextRef="cref_678032609" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">3,333,334</ix:nonFraction> shares at December 31, 2025 and 2024, respectively; Issued and outstanding: <ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="fc_171354521" contextRef="cref_1997617154" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="fc_718697983" contextRef="cref_1997617154" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">2,618,425</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="fc_112058716" contextRef="cref_678032609" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="fc_1848454736" contextRef="cref_678032609" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">994,394</ix:nonFraction></ix:nonFraction> shares as of December 31, 2025 and 2024, respectively (*)</td><td>&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_523126391">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1937695010">-</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.2in">Additional paid-in capital</td><td>&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17134">180,654</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17135">170,670</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.2in">Accumulated other comprehensive income</td><td>&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17136">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17137">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.2in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17138">176,189</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17139">166,361</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: none; text-align: left; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17140">5,592</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17141">5,436</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: none; text-align: left; padding-bottom: 4pt"><span style="text-decoration:underline">Total</span> liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td><td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17142">9,514</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17143">9,120</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tbody><tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="fref_223778504" xml:lang="en-US">Retroactively adjusted to give effect to the reverse share split, see also note 9.</ix:footnote></span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part of
the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 167; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;"><span id="a_037" style="display: inline-block;"></span>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">CONSOLIDATED
STATEMENTS OF OPERATING LOSS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
<td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; padding-bottom: 1.5pt">Revenues</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 7%; text-align: center; padding-bottom: 1.5pt">7</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17145">405</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17146">674</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17147">743</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development expenses</td><td>&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17148">6,693</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17149">5,757</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17150">5,983</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17151">3,662</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17152">3,047</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17153">2,955</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td>&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17154">10,355</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17155">8,804</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17156">8,938</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Operating loss</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17157">9,950</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17158">8,130</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17159">8,195</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total financial income, net</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">11</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17160">122</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17161">250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17162">561</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Loss before taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17163">9,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17164">7,880</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17165">7,634</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17166">9,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17167">7,880</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17168">7,634</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: center">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Basic and diluted net loss per share</td><td style="padding-bottom: 4pt">&#160;</td><td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="fc_872966651" contextRef="cref_184434641" unitRef="uref_1278442780" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="cref_184434641" unitRef="uref_1278442780" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-17170">5.97</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="cref_1205104151" unitRef="uref_1278442780" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-17171"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="cref_1205104151" unitRef="uref_1278442780" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-17172">10.86</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="cref_1914073660" unitRef="uref_1278442780" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-17173"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="cref_1914073660" unitRef="uref_1278442780" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-17174">17.92</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted average number of ordinary shares used in computing basic and diluted net loss per share (*)</td><td style="padding-bottom: 4pt">&#160;</td><td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="fc_2139747243" contextRef="cref_184434641" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="fc_1309137784" contextRef="cref_184434641" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">1,646,208</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="fc_50742992" contextRef="cref_1205104151" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="fc_1621210643" contextRef="cref_1205104151" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">725,309</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="fc_977396253" contextRef="cref_1914073660" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="fc_1373640430" contextRef="cref_1914073660" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">426,111</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tbody><tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="fref_71790209" xml:lang="en-US">Retroactively adjusted to give effect to the reverse share split, see also note 9.</ix:footnote></span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part of
the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 168; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;"><span id="a_038" style="display: inline-block;"></span>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="6" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary shares (*)</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Additional <br/>
paid-in</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Accumulated <br/>
other <br/>
comprehensive</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Accumulated</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total <br/>
shareholders&#8217;</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">capital</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">deficit</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">equity</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%">Balance as of December 31, 2022</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" id="fc_1316363029" contextRef="cref_1316363029" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">271,916</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_1027623191">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1689545004" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17183">154,192</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_430322482" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17184">1,127</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1096639490" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17185">150,847</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_346153289" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17186">4,472</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares and warrants, net of issuance costs of $ <ix:nonFraction name="canf:NetOfIssuanceCostsOfOrdinarySharesAndWarrants" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17187">973</ix:nonFraction></td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" id="fc_2108866782" contextRef="cref_1182592801" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1004110757">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" contextRef="cref_692454694" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17189">6,526</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1372760715">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1059179270">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17190">6,526</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares due to exercise of warrants net of issuance expenses of $ <ix:nonFraction name="canf:NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17191">386</ix:nonFraction></td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="fc_1182592801" contextRef="cref_1182592801" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">151,363</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_259543012">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="cref_692454694" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17193">2,618</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_546765437">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_548260843">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17194">2,618</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based payments</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_834906283">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_692454694" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17195">261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1025560619">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1834162276">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17196">261</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_200494866">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_2095020479">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1605243859">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_847760719" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17197">7,634</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17198">7,634</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in">Balance as of December 31, 2023</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" id="fc_471624570" contextRef="cref_471624570" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">453,279</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_2039191230">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_713467315" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17200">163,597</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1568626008" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17201">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_301922635" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17202">158,481</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_385792771" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17203">6,243</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Release of ordinary shares that were previously held in abeyance</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" id="fc_761083602" contextRef="cref_1743024573" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">151,364</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_101309368">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_2144679190">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_425053498">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_8299037">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1843738797">-</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares and warrants, net of issuance costs of $ <ix:nonFraction name="canf:NetOfIssuanceCostsOfOrdinarySharesAndWarrants" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17205">512</ix:nonFraction> (refer to note 9(b)(3))</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" id="fc_1556835653" contextRef="cref_1743024573" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">285,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_964794137">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" contextRef="cref_60220687" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17207">4,488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1111035328">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_2026529756">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17208">4,488</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares due to ATM, net of issuance costs $<ix:nonFraction name="canf:NetOfIssuanceCostsOrdinarySharesDueToATM" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17209">152</ix:nonFraction> (refer to note 9(b)(4))</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" id="fc_462574281" contextRef="cref_1743024573" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">99,037</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_3754123">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" contextRef="cref_60220687" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17211">2,223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1652128422">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_609884468">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17212">2,223</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based payments (refer to note 9(b)(1))</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" id="fc_563207362" contextRef="cref_1743024573" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1574677278">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_60220687" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17214">362</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_536684989">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1304797919">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17215">362</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_2054232463">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_941212928">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_204867609">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_869951728" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17216">7,880</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17217">7,880</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt">Balance as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" id="fc_1391618102" contextRef="cref_679399687" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">994,394</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_2021528685">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1447998007" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17219">170,670</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_503396369" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17220">1,127</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1298046308" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17221">166,361</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17222">5,436</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tbody><tr style="vertical-align: top">
<td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td>
<td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retroactively adjusted to give effect to the reverse share split, see also note 9.</span></td></tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are
an integral part of the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><!-- Field: Page; Sequence: 169; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;"><span id="a_039" style="display: inline-block;"></span>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in; white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="6" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary shares (*)</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Additional<br/>
 paid-in</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Accumulated <br/>
other <br/>
comprehensive</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Accumulated</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total<br/>
 shareholders&#8217;</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">capital</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">deficit</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">equity</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%">Balance as of January 1, 2025</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" id="fc_679399687" contextRef="cref_679399687" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">994,394</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_1350392693">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1447998007" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17224">170,670</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_503396369" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17225">1,127</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1298046308" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17226">166,361</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17227">5,436</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares and warrants and exercise of pre-funded warrants, net of issuance costs of $<ix:nonFraction name="canf:NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17228">1,289</ix:nonFraction></td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:StockIssuedDuringPeriodSharesExercised" id="fc_887952012" contextRef="cref_236998777" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">1,083,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_777455571">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:StockIssuedDuringPeriodExerciseValue" contextRef="cref_1978583206" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17230">6,711</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1424085176">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1050864119">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:StockIssuedDuringPeriodExerciseValue" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17231">6,711</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issuance of ordinary shares due to ATM, net of issuance costs of $<ix:nonFraction name="canf:NetOfIssuanceCostsOrdinarySharesDueToATM" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17232">367</ix:nonFraction> (refer to note 9(b)(5))</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" id="fc_776479262" contextRef="cref_236998777" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">530,698</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_549751167">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" contextRef="cref_1978583206" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17234">2,933</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1604115385">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_696482402">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17235">2,933</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share-based payments</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" id="fc_41120727" contextRef="cref_236998777" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_1466338231">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_1978583206" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17237">340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_2080488118">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_443517718">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17238">340</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1816291455">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_273676464">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1832570996">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1722856177" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17239">9,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17240">9,828</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt">Balance as of December 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" id="fc_1254970073" contextRef="cref_1254970073" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">2,618,425</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_554639177">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1268205755" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17242">180,654</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1110324969" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17243">1,127</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1212188529" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17244">176,189</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17245">5,592</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tbody><tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="fref_376288337" xml:lang="en-US">Retroactively adjusted to give effect to the reverse share split, see also note 9.</ix:footnote></span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part of
the consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 170; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-size: 10pt"><span style="font-weight: bold;"><span id="a_040" style="display: inline-block;"></span>CAN-FITE
BIOPHARMA LTD. AND ITS SUBSIDIARY</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">CONSOLIDATED
STATEMENTS OF CASH FLOWS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tbody><tr style="vertical-align: bottom">
<td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
<td><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
<td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
<td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17247">9,828</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17248">7,880</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17249">7,634</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Adjustments required to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Depreciation of property, plant and equipment</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17250">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17251">7</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17252">15</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Reduction in the carrying amount of operating lease right of use asset</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17253">42</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17254">37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17255">94</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Share-based payment</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17256">340</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17257">362</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17258">261</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Changes in fair value of short-term investment</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:ChangesInFairValueOfShortTermInvestment" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17259">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:ChangesInFairValueOfShortTermInvestment" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17260">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="canf:ChangesInFairValueOfShortTermInvestment" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17261">11</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Financial expenses (income), net</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" id="fc_2046050939" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" id="fc_2109237782" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" id="fc_1764296517" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal">222</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in prepaid expenses, and other current assets</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17265">195</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17266">109</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17267">184</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Decrease in operating lease liability</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17268">33</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17269">32</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17270">84</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Increase (decrease) in trade payable</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17271">543</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17272">191</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17273">469</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Decrease in deferred revenues</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17274">405</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17275">349</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17276">743</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Increase (decrease) in other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17277">133</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17278">32</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17279">169</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17280">8,949</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17281">7,637</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17282">8,440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-decoration: underline; text-align: justify">Cash flows from investing activities:</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Purchase of property, plant and equipment</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17283">2</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17284">5</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17285">2</ix:nonFraction></td><td style="text-align: left">)</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Maturity of short-term deposits, net</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1146546674">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromShortTermInvestments" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17286">1,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsForProceedsFromShortTermInvestments" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17287">500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Net cash provided by investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17288">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17289">1,495</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17290">498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-decoration: underline; text-align: justify">Cash flows from financing activities:</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td>&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Issuance of ordinary shares due to ATM, net of issuance costs</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17291">2,933</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17292">2,223</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_421221726">-</span></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Issuance of ordinary shares and warrants, net of issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17293">6,711</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17294">4,488</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17295">9,144</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17296">9,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17297">6,711</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17298">9,144</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Exchange differences on balances of cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17299">10</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17300">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17301">98</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Increase (decrease) in cash and cash equivalents</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17302">703</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17303">547</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17304">1,300</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Cash and cash equivalents at the beginning of the year</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17305">4,825</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_385792771" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17306">4,278</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_346153289" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17307">2,978</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Cash and cash equivalents at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17308">5,528</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17309">4,825</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="cref_385792771" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17310">4,278</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-decoration: underline; text-align: justify">Non-cash activities:</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: justify">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
<td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Lease liabilities arising from obtaining right-of-use-assets</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1937658026">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="canf:LeaseLiabilitiesArisingFromObtainingRightofuseassets" id="fc_1942140320" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="canf:LeaseLiabilitiesArisingFromObtainingRightofuseassets" id="fc_1991396066" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr>
</tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part of
the consolidated financial statements.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 171; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;"><span id="a_041" style="display: inline-block;"></span>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: bold;">&#160;</span></p> <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12460"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 1:-&#160;GENERAL</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company description:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Can-Fite Biopharma Ltd. (the &#8220;Company&#8221;) was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, MASH, pancreatic cancer and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. The Company&#8217;s pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators at the A3AR.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> The Company&#8217;s ordinary shares have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#8220;CFBI&#8221; and the Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) began public trading on the over the counter market in the U.S. in October 2012 and since November 2013 the Company&#8217;s ADSs have been publicly traded on the NYSE American under the symbol &#8220;CANF&#8221;. Each ADS represents <ix:nonFraction name="canf:NumberOfOrdinaryShares" contextRef="cref_1997617154" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17313">2</ix:nonFraction> ordinary shares of the Company. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under&#160;Accounting Standard Codification (&#8220;ASC&#8221;)&#160;Subtopic 205-40,&#160;Presentation of Financial Statements&#8212;Going Concern&#160;(&#8220;ASC 205-40&#8221;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its obligations as they become due within one year after the date that the financial statements are issued. As required under ASC 205-40, management&#8217;s evaluation should initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in; background-color: white"><i>Evaluation of Substantial Doubt Raised</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 43.05pt; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">In performing the first step of the evaluation, the Company concluded that the following conditions raised substantial doubt about its ability to continue as a going concern:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">History of net losses of&#160;$<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17314">9,828</ix:nonFraction>, $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17315">7,880</ix:nonFraction> and $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17316">7,634</ix:nonFraction>&#160;for the years ended December 31, 2025, 2024 and 2023, respectively. The accumulated deficit for the years ended December 31, 2025, was $176,189.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="background-color: transparent; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating cash outflow of&#160;$<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17317">8,949</ix:nonFraction>, $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17318">7,637</ix:nonFraction> and $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17319">8,440</ix:nonFraction> for the years ended December 31, 2025, 2024 and 2023, respectively.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reliance on additional financing in order to execute its research and development plans.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in; background-color: white"><i>Consideration&#160;of Management&#8217;s Plans</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 0.75in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"> In performing the second step of this assessment, the Company is required to evaluate whether it is probable that the Company&#8217;s plans will be effectively implemented within one year after the financial statements are issued and whether it is probable those plans will alleviate the substantial doubt raised about the Company&#8217;s ability to continue as a going concern. As of December 31, 2025, the Company had $<ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17320">8,539</ix:nonFraction>&#160;in available cash, cash equivalents and short-term deposits. Subsequent to balance sheet date, the Company raised gross proceeds of approximately $<ix:nonFraction name="canf:GrossProceeds" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17321">4,350</ix:nonFraction>, refer to Note 15. </p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">&#160;</p><!-- Field: Page; Sequence: 172; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 1:-&#160;GENERAL (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">Liquidity resources suffice for at least twelve months from the date that the consolidated financial statements were issued, nevertheless the Company has committed to implement a contingency plan, as required, in order to allow it to continue its operations and meet its cash obligations. The contingency plan consists of cost reduction, which include mainly deferral and reprioritization of certain research and development programs that would involve reduced program spend and reduction in compensation paid to key management personnel until additional financing is obtained.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in; background-color: white"><i>Management&#160;Assessment&#160;of Ability to Continue as a Going Concern</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 0.75in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">The Company has a history of operating losses and negative cash flows from operations. However, despite these conditions, the Company believes management&#8217;s plans, as described more fully above, will provide sufficient liquidity to meet its financial obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">Therefore, management concluded these plans alleviate the substantial doubt that was raised about the Company&#8217;s ability to continue as a going concern for at least twelve months from the date that the consolidated financial statements were issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in; background-color: white"><i>Future Plans and Considerations</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 0.75in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">Although not considered for purposes of the Company&#8217;s assessment of whether substantial doubt was alleviated, the Company has plans to improve operating cash flows by entering into strategic partnerships with other companies that can provide access to additional customers and new markets. The Company may also seek to raise additional funds through the issuance of debt and/or equity securities or otherwise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">The Company&#8217;s plans are subject to inherent risks and uncertainties. Accordingly, there can be no assurance that the Company&#8217;s plans can be effectively implemented and, therefore, that the conditions can be effectively mitigated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Until such time, if ever, that the Company can generate revenue sufficient to achieve profitability, the Company expects to finance its operations through equity or debt financings, which may not be available to the Company on the timing needed or on terms that the Company deems to be favorable. To the extent that the Company raises additional capital through the sale of equity or debt securities, the ownership interest of its stockholders will be diluted. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected.</p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 173; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12573"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="cref_184434641" escape="true" id="ixv-12579"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12591"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12603"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment Information</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company&#8217;s operations and manage its business in&#160;one&#160;operating segment which is the research and development of the Company&#8217;s drug candidates.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12615"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency, reporting currency and foreign currency:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The functional currency of the Company is the U.S. dollar. Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars in accordance with Accounting Standard Codification (&#8220;ASC&#8221;) No. 830 &#8220;Foreign Currency Matters.&#8221; All transaction gains and losses of the re-measured monetary balance sheet items are reflected in the consolidated statements of comprehensive loss as financial income or expenses, as appropriate.&#160;&#160;</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12627"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Cash equivalents are short-term, highly liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash equivalents.</p></ix:nonNumeric><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><!-- Field: Page; Sequence: 174; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="canf:ShorttermBankDepositsPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12657"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term bank deposits:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -21.25pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2025 and 2024, the Company&#8217;s bank deposits are denominated in U.S. dollars and bears yearly interest at weighted average rates of&#160;<ix:nonFraction name="canf:ShortTermBankDepositsYearlyInterestRatePercentage" contextRef="cref_184434641" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17322">4.30</ix:nonFraction>% and&#160;<ix:nonFraction name="canf:ShortTermBankDepositsYearlyInterestRatePercentage" contextRef="cref_1205104151" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17323">5.25</ix:nonFraction>%. Short-term bank deposits are presented at their cost, including accrued interest. </p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="canf:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12669"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses, and other current assets</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Prepaid expenses are composed mainly from prepayments to suppliers and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and no longer have an alternative future use.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12681"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with ASU No. 2016-02, &#8220;Leases (Topic 842)&#8221;, the Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12697"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Property and equipment are stated at cost, net of accumulated depreciation. <ix:nonNumeric name="canf:ScheduleOfUsefulLivesOfTheAssetTableTextBlock" contextRef="cref_184434641" continuedAt="continuation_1087196286" escape="true" id="ixv-17324">Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</ix:nonNumeric> </p><ix:continuation id="continuation_1087196286"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Mainly<br/>  %</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td><td style="width: 9%; text-align: center"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="cref_180300996" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17325">10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 9%; text-align: center"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="cref_180300996" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17326">10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="cref_1654566158" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17327">6</ix:nonFraction> - <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="cref_794440730" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17328">33</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: center"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" contextRef="cref_1707962055" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17329">33</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr> </tbody></table></ix:continuation></ix:nonNumeric><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 175; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12771"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of long-lived assets:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Property and equipment and ROU assets are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment,&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets (assets group) to be held and used is measured by a comparison of the carrying amount of an asset (assets group) to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. As of December 31, 2025, and 2024, <span style="-sec-ix-hidden:fc_669790381"><span style="-sec-ix-hidden:fc_406290213">no</span></span> impairment indicators have been identified. </p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12785"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes revenue in accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#8220;ASC 606&#8221;) and determines revenue recognition through the following steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the contract, or contracts, with a customer;</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the performance obligations in the contract;</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination of the transaction price;</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of the transaction price to the performance obligations in the contract; and</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition of revenue when, or as, the performance obligations are satisfied.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company generates revenues from supply and distribution agreements. The consideration under these agreements comprises of upfront fees, milestone payments and potential royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf of third parties (such as taxes).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts generally include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has concluded that the abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded based on the term of the research and development services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts also include development milestones payments and future sales-based royalties.</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 176; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Development milestones payments are recognized only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with those milestones is subsequently resolved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Sales based royalties are recognized only when the subsequent sale occurs. As of December 31, 2025, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any sales-based royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The prepayments terms from the Company&#8217;s contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing from the customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="text-decoration:underline">Revenue Recognition &#8211; Contract Balances </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Contract liabilities, due to the upfront payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2025 and December 31, 2024 contract liabilities and remaining performance obligation amounted to $<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17330">1,581</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17331">1,986</ix:nonFraction>, respectively and are presented under deferred revenues. During the year ended December 31, 2025, the Company recognized revenues in the amount of $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17332">405</ix:nonFraction> which have been included in the contract liabilities at December&#160;31, 2024. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred revenue and remaining performance obligation that is anticipated to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded as non-current deferred revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="cref_184434641" escape="true" id="ixv-12883"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Cipher Pharmaceuticals (Canada)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_1329610678" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17333">11</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_1085088613" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17334">7</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_1756871285" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17335">11</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp. (South Korea)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_1051158666" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17336">19</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_1752405840" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17337">11</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_262393112" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17338">25</ix:nonFraction></td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Gebro Holding GmbH (Austria)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_1380163261" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17339">19</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_1630416524" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17340">11</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_2073970239" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17341">18</ix:nonFraction></td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Ewopharma AG (Switzerland)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_707849457" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17342">51</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_1969999970" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17343">30</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_401885686" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17344">46</ix:nonFraction></td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Vetbiolix (France)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1997113680">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_940504229" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17345">41</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_487311381">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_1010971887" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17346">100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_656845410" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17347">100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="cref_1513674" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17348">100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td> </tr> </tbody></table></ix:nonNumeric></ix:nonNumeric><p style="margin-top: 0; margin-bottom: 0">&#160;</p><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="cref_184434641" escape="true" id="ixv-13016"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Research and development costs are expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization, rent, and utilities.</p></ix:nonNumeric><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 177; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13044"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;). Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent from the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 - Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The carrying amounts of cash and cash equivalents, short term deposit, prepaid expenses and other currents assets, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The Company has an investment in marketable equity security classified within level 1 in the fair value hierarchy.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="cref_184434641" escape="true" id="ixv-13066"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration of Credit Risk:&#160;</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="canf:LegalAndOtherContingenciesPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13078"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for its contingent liabilities in accordance with ASC 450, Contingencies (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss.</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 178; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2025, and 2024, the Company is not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position, results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="canf:SeverancePayPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13109"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance pay<span style="text-transform: uppercase">:</span></span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> The Company&#8217;s liability for severance pay is pursuant to Section 14 of the Israeli Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant to which all the Company&#8217;s employees are included under Section 14, and are entitled only to monthly deposits, at a rate of <ix:nonFraction name="canf:PercentageOfDepositsOnMonthlySalary" contextRef="cref_184434641" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17349">8.33</ix:nonFraction>% of their monthly salary, made in the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.&#160;Severance pay expense for the year ended December 31, 2025, 2024 and 2023 amounted to $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17350">53</ix:nonFraction>, $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17351">49</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17352">47</ix:nonFraction>, respectively. </p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="cref_184434641" escape="true" id="ixv-13122"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions<span style="text-transform: uppercase">:</span></span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for share-based compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s consolidated statement of comprehensive loss, based on acceleration method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes compensation expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company estimates the fair value of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility, early exercise factor and the expected option term. Expected volatility was calculated based upon historical volatility of the Company and early exercise factor was calculated based on statistical studies in the U.S market. The risk-free interest rate is based on the yield from government bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13139"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2025, and 2024, a full valuation allowance was provided by the Company.</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 179; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than <ix:nonFraction name="canf:PercentageOfRealizationOnUltimateSettlement" contextRef="cref_184434641" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17353">50</ix:nonFraction>% likely to be realized upon ultimate settlement. As of December 31, 2025, and 2024, <span style="-sec-ix-hidden:fc_972519014"><span style="-sec-ix-hidden:fc_213046275">no</span></span> liability for unrecognized tax benefits was recorded.&#160; </p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="canf:WarrantsToPurchaseOrdinarySharesPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13174"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase ordinary shares:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13188"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per share<span style="text-transform: uppercase">:</span></span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Basic and diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. The Company include in the basic net loss per share calculation, pre-funded warrants that are exercisable for a nominal consideration. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#8220;Earnings per Share&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13201"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants for the years ended December 31, 2025, 2024 and 2023 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. The potential ordinary shares and warrants that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Options</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_1102009625" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17354">49,533</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_1787915782" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17355">41,610</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_264863037" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17356">27,492</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_626091944" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17357">2,604,096</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_133213812" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17358">886,599</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_405802932" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17359">617,337</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_184434641" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17360">2,653,629</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_1205104151" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17361">928,209</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="cref_1914073660" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17362">644,829</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tbody><tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retroactively adjusted to give effect to the reverse share split, see also note 9.</span></td></tr> </tbody></table></ix:nonNumeric></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13298"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently adopted accounting pronouncements:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="background-color: white">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which requires disaggregated information about the effective tax rate reconciliation as well as information on income taxes paid. The guidance will be effective for the Company for annual periods beginning January 1, 2025, with early adoption permitted. The adoption of the standard <span style="background-color: white">did not </span> have material impact on its financial statement disclosures.</span></p></ix:nonNumeric><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><!-- Field: Page; Sequence: 180; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><ix:nonNumeric name="canf:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13330"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 47px">&#160;</td> <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">v.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Recently issued accounting pronouncements not yet adopted</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In November 2024, the FASB issued ASU 2024-03<i>&#160;&#8220;Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures&#8221;</i>&#160;(&#8220;ASU 2024-03&#8221;), which requires more detailed information about specified categories of expenses presented on the face of the income statement, in addition to disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. The amendment may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating ASU 2024-03 to determine the impact it may have on its consolidated financial statements and related disclosures.</p></ix:nonNumeric></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p> <ix:nonNumeric name="us-gaap:OtherCurrentAssetsTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13343"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 3:-&#160; PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:nonNumeric name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13348"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="canf:GovernmentAuthorities" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17363">74</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="canf:GovernmentAuthorities" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17364">77</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and others</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17365">826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17366">1,018</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17367">900</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17368">1,095</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table></ix:nonNumeric></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13413"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 4:-&#160;PROPERTY, PLANT AND EQUIPMENT, NET </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -56.7pt">&#160;</p><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13417"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Cost:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_1633826125">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_255520659" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17369">64</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Computers, office furniture and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_595936047" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17370">17</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_1126769489" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17371">15</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17372">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17373">79</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Laboratory equipment</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_2074154732">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="cref_255520659" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17374">43</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Computers, office furniture and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="cref_595936047" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17375">12</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="cref_1126769489" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17376">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17377">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17378">52</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17379">5</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17380">27</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -20.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Depreciation expenses for the years ended December 31, 2025, 2024 and 2023 amounted to $<ix:nonFraction name="us-gaap:Depreciation" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17381">24</ix:nonFraction>, $<ix:nonFraction name="us-gaap:Depreciation" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17382">7</ix:nonFraction> and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17383">15</ix:nonFraction>, respectively. </p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 181; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-weight: bold;">&#160;</span></p> <ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13587"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 5:-</span>&#160;<span style="font-weight: bold;">OTHER ACCOUNTS PAYABLE</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><ix:nonNumeric name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13593"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Employees and payroll accruals</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17384">811</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17385">675</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17386">298</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17387">301</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17388">1,109</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17389">976</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table></ix:nonNumeric></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13658"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 6:- FAIR VALUE MEASUREMENTS </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 820 &#8220;Fair Value Measurements and Disclosures&#8221;, the Company measures its short-term investment at fair value. Short-term investments are classified within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13664"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="cref_1736241007" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17390">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="cref_1943456894" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17391">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_1904201796">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_1856579833">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: left; font-weight: bold">Description</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair value</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="cref_976418671" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17392">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="cref_1501641585" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17393">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_2047207648">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_736875626">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table></ix:nonNumeric></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 182; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13810"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 7:- REVENUES&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><i><span style="text-decoration:underline">Cipher Pharmaceuticals</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#8220;Cipher&#8221;). As part of the distribution agreement, Cipher will distribute Can-Fite&#8217;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> Under the terms of the agreement, Cipher made an upfront payment of $<ix:nonFraction name="canf:UpfrontPayment" contextRef="cref_2046075473" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17394">1,292</ix:nonFraction> (<ix:nonFraction name="canf:UpfrontPayment" contextRef="cref_2046075473" unitRef="uref_1598663686" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17395">1,650</ix:nonFraction> CAD thousands) to the Company in March 2015. In addition, the agreement provides that an additional payments of up to <ix:nonFraction name="us-gaap:PaymentsForRoyalties" contextRef="cref_1598663686" unitRef="uref_1598663686" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17396">2,000</ix:nonFraction> thousands Canadian Dollar will be received by the Company upon the achievement of certain milestones plus royalty payments of <ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligationPercentage" contextRef="cref_485025225" unitRef="uref_1413771939" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-17397">16.5</ix:nonFraction>% of net sales of Piclidenoson in Canada. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the agreement, the Company shall be responsible for conducting product development activities including management of the clinical studies required in order to secure regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form a joint steering committee with Cipher which will oversee the progress of the clinical studies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2025, the Company estimates that such services will be completed by December 31, 2029 and therefore revenues from such up-front payment are recognized over such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><i><span style="text-decoration:underline">Chong Kun Dang Pharmaceuticals Corp.</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#8220;CKD&#8221;). As part of the distribution agreement, CKD will have exclusive rights to distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals. On February 25, 2019, distribution agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition to liver cancer in South Korea.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> According to the distribution agreement, the Company is entitled to receive an amounts of up to $<ix:nonFraction name="canf:UpfrontAndMilestonePaymentsPayable" contextRef="cref_1375081973" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17398">3,000</ix:nonFraction> in upfront and milestone payments payable with respect to the liver cancer indication and additional $<ix:nonFraction name="canf:UpfrontAndMilestonePaymentsPayable" contextRef="cref_818757102" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17399">6,000</ix:nonFraction> in upfront and milestone payments payable with respect to NASH indication. In addition, the Company will also be entitled to a transfer price for delivering finished product to CKD following commercial launch at a cost plus <ix:nonFraction name="canf:TransferPriceRate" contextRef="cref_632092621" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17400">10</ix:nonFraction>% basis or <ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligationPercentage" contextRef="cref_1315189725" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17401">23</ix:nonFraction>% of net sales of Namodenoson following commercial launch in South Korea. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the agreement, the Company shall be responsible for conducting product development activities including management of the clinical studies required in order to secure regulatory approvals and shall use commercially reasonable efforts in conducting such activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> As of December 31, 2025, the Company received an amount of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="cref_1590073223" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17402">1,500</ix:nonFraction> for up-front payment and additional $<ix:nonFraction name="canf:AdditionalRevenueReceivedForAchievedMilestone" contextRef="cref_1590073223" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17403">500</ix:nonFraction> for achieved milestone. </p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 183; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 7:-&#160;REVENUES (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2025, the Company estimates that such services will be completed by June 30, 2029 and therefore revenues from such up-front payment are recognized over such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Gebro Holding GmBH</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On January 8, 2018, the Company entered into a Distribution and Supply Agreement with Gebro Holding GmBH (&#8220;Gebro&#8221;), granting Gebro the exclusive right to distribute Piclidenoson in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> <ix:nonNumeric name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" contextRef="cref_1798028992" id="ixv-17404">Under the Distribution and Supply Agreement, the Company is entitled to &#8364; 1,500 thousands upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) &#8364; 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and &#8364; 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between &#8364; 750 thousand and &#8364; 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364; 300 thousand and up to &#8364;4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.</ix:nonNumeric>&#160; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> As of December 31, 2025, the Company received an amount of &#8364; <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="cref_1798028992" unitRef="uref_447010128" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17405">1,500</ix:nonFraction> thousands (approximately $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="cref_1798028992" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17406">1,850</ix:nonFraction>) for up-front payment and additional &#8364; <ix:nonFraction name="canf:AdditionalRevenueReceivedForAchievedMilestone" contextRef="cref_1798028992" unitRef="uref_447010128" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17407">600</ix:nonFraction> thousands (approximately $<ix:nonFraction name="canf:AdditionalRevenueReceivedForAchievedMilestone" contextRef="cref_1798028992" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17408">720</ix:nonFraction>) for achieved milestone. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2025, the Company estimates that such services will be completed by December 31, 2029 and therefore revenues from such up-front payment are recognized over such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">CMS Medical Venture Investment Limited </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> <ix:nonNumeric name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" contextRef="cref_1830464667" id="ixv-17409">On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#8220;CMS Medical&#8221;) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan).</ix:nonNumeric> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> Under the License, Collaboration and Distribution Agreement, the Company is entitled to receive an up-front amount of $<ix:nonFraction name="canf:UpfrontAndMilestonePaymentsPayable" contextRef="cref_112398461" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17410">2,000</ix:nonFraction> upon execution of the agreement. In addition, the Company is also entitle to received an amount of up to $<ix:nonFraction name="canf:AdditionalRevenueReceivedForAchievedMilestone" contextRef="cref_758140809" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17411">14,000</ix:nonFraction> for milestone payments upon achieving certain regulatory milestones and up to $<ix:nonFraction name="canf:AdditionalRevenueReceivedForAchievedMilestone" contextRef="cref_1089428082" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17412">58,500</ix:nonFraction> for milestone payments upon achieving certain sales milestones. In addition, following regulatory approval, the Company shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing of Piclidenoson and Namodenoson. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> As of December 31, 2025, the Company received an amount of $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17413">2,000</ix:nonFraction> for up-front payment which was previously recognized in revenues. </p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 184; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 7:-&#160;REVENUES (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Kyongbo Pharm Co., Ltd.</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On July 31, 2019, the Company signed a distribution agreement with Kyongbo Pharm Co., Ltd. (&#8220;Kyongbo Pharm&#8221;), to distribute Piclidenoson, for the treatment of psoriasis in South Korea, upon receipt of regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> Under the terms of the distribution agreement, Kyongbo Pharm, in exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea, is required to make a total a payment of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="cref_2037445886" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17414">750</ix:nonFraction> for access to information and clinical study data. In addition, the Company will also be also entitled to additional payments of up to $<ix:nonFraction name="canf:AdditionalRevenueReceivedForAchievedMilestone" contextRef="cref_2037445886" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17415">3,250</ix:nonFraction> upon achievement of certain milestones. The Company will also be entitled to a transfer price for delivering finished product to Kyongbo Pharm upon commercial launch. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> In 2019, the Company received an amount of $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="cref_1677665869" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17416">750</ix:nonFraction> for up-front payment which recognized as revenues upon the Company providing access to information and clinical study data. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><i><span style="text-decoration:underline">Ewopharma</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> On March 16, 2021, the Company signed an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the treatment of liver diseases namely, hepatocellular carcinoma (HCC) the most common form of liver cancer and non-alcoholic steatohepatitis (NASH). Under the terms of the distribution agreement, Ewopharma paid Can-Fite non-refundable upfront payment in an amount of $<ix:nonFraction name="canf:NonRefundablePayment" contextRef="cref_1154935824" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17417">2,250</ix:nonFraction> and is entitled to up to an additional $<ix:nonFraction name="canf:AdditionalRevenueReceivedForAchievedMilestone" contextRef="cref_1154935824" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17418">40,450</ix:nonFraction> payable upon the achievement of regulatory and sales milestones and <ix:nonFraction name="canf:PercentageOfRoyaltiesOnNetSales" id="fc_797038194" contextRef="cref_797038194" unitRef="uref_1413771939" scale="-2" decimals="3" format="ixt:num-dot-decimal">17.5</ix:nonFraction>% royalties on net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution agreement to new indications that Can-Fite may identify for its drug candidates. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> As of December 31, 2025, the Company received an amount of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="cref_398624799" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17420">2,250</ix:nonFraction> for up-front payment. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2025, the Company estimates that such services will be completed by December 31, 2029 and therefore revenues from such up-front payment are recognized over such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">On January 30, 2024, the Company entered into an amendment to its distribution agreement with Ewopharma, to add the rights to the Company&#8217;s pancreatic cancer indication for an additional immaterial up-font payment and further milestones payments.&#160;</p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 185; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 7:-&#160;REVENUES (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><i><span style="text-decoration:underline">Vetbiolix</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 28, 2021, the Company entered into a Patent and Know-how License Agreement with Vetbiolix (the &#8220;License Agreement&#8221;), a France-based veterinary pharmaceutical company. According to the agreement, the Company has granted Vetbiolix an exclusive option to utilize the licensed Know-How and the Company&#8217;s patents solely for the purpose of supporting Vetbiolix&#8217;s research, development, manufacturing and commercializing of its compounds and/or products in the field throughout the territory, all as defined in the License Agreement. The option to the licensed Know-How and the Company&#8217;s patents is for a period of two years from the signature date (after which such period was extended by additional 15 months), during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> Upon Vetbiolix exercise of its option to acquire the licensed Know-How and the Company&#8217;s patents, then Vetbiolix will be obligated to pay Can-Fite a non-refundable upfront payment in an amount of euro <ix:nonFraction name="canf:NonRefundablePayment" contextRef="cref_184434641" unitRef="uref_447010128" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17421">250</ix:nonFraction>. In addition, Vetbiolix will also pay the Company with payment equal to <ix:nonFraction name="canf:MilestonePaymentPercentage" contextRef="cref_184434641" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17422">30</ix:nonFraction>% for each upfront and milestone payment received from and sublicensee and <ix:nonFraction name="canf:PercentageOfRoyaltiesOnNetSales" id="fc_344781049" contextRef="cref_344781049" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction>%-<ix:nonFraction name="canf:PercentageOfRoyaltiesOnNetSales" id="fc_2057783007" contextRef="cref_2057783007" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal">40</ix:nonFraction>% royalties on net sales upon regulatory approval for veterinary use. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> On September 24, 2024, Vetbiolix exercised its option and acquired licensed know-how and the Company&#8217;s patents for euro <ix:nonFraction name="us-gaap:FiniteLivedPatentsGross" contextRef="cref_1130319153" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17425">250</ix:nonFraction> thousands and therefore the Company recorded equivalent revenues of $ <ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="cref_648214257" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17426">271</ix:nonFraction> in the year ended December 31, 2024. </p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="cref_184434641" escape="true" id="ixv-13948"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities to pay royalties:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company is committed to pay royalties as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A one-time concession commission of &#8364;<ix:nonFraction name="us-gaap:NoninterestExpenseCommissionExpense" contextRef="cref_184434641" unitRef="uref_447010128" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17427">25</ix:nonFraction> thousand;</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual royalties of &#8364;<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="cref_184434641" unitRef="uref_447010128" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17428">10</ix:nonFraction> thousand until the clinical trials commence;</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="canf:PercentageOfNetSales" contextRef="cref_583004226" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17429">3</ix:nonFraction>)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2%-<ix:nonFraction name="canf:PercentageOfNetSales" contextRef="cref_342246256" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17430">3</ix:nonFraction>% of net sales (as defined in the agreement) received by the Company;</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties in a total amount of up to &#8364;<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="cref_342246256" unitRef="uref_447010128" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17431">850</ix:nonFraction> thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#8364;<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="cref_2059261110" unitRef="uref_447010128" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17432">50</ix:nonFraction> thousand upon initiation of Phase I studies; (ii) &#8364;<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="cref_337919505" unitRef="uref_447010128" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17433">100</ix:nonFraction> thousand upon initiation of Phase II studies; (iii) &#8364;<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="cref_576633015" unitRef="uref_447010128" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17434">200</ix:nonFraction> thousand upon initiation of Phase III studies; and (iv) &#8364;<ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="cref_447010128" unitRef="uref_447010128" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17435">500</ix:nonFraction> thousand upon marketing approval by any regulatory authority.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of <ix:nonFraction name="canf:RoyaltyPaymentsPercentage" contextRef="cref_184434641" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17436">10</ix:nonFraction>%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in"> As of December 31, 2025 and 2024, <span style="-sec-ix-hidden:fc_1823340782"><span style="-sec-ix-hidden:fc_792382386">no</span></span> accrual has been recorded with respect to Leiden University. </p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in">&#160;</p><!-- Field: Page; Sequence: 186; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="cref_184434641" escape="true" id="ixv-14033"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 22, 2023, the Company&#8217;s shareholders approved a change in the Company&#8217;s ordinary shares par value from NIS <ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="cref_1677178547" unitRef="uref_1677178547" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17437">0.25</ix:nonFraction> per share to no par value. All par value data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the change.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All ordinary shares have equal rights for all intent and purposes and each ordinary share confers its holder:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to be invited and participate in all the Company&#8217;s general meetings, both annual and regular, and the right to <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="cref_184434641" id="ixv-17438">one</ix:nonNumeric> vote per ordinary share owned in all votes and in all Company&#8217;s general meeting participated.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to participate in the distribution of the Company&#8217;s assets upon liquidation.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of ordinary shares and warrants:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 1, 2024 the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="fc_1778457142" contextRef="cref_1778457142" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction> ordinary shares to certain service provider in exchange for it services. The shares issued were valued at the amount of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" id="fc_611616676" contextRef="cref_1743024573" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction> which were recorded to general and administrative expenses during the year ended December 31, 2024</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 3, 2024, the Company&#8217;s shareholders meeting approved the increase of the Company&#8217;s authorized share capital by additional <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="cref_54615801" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17441">1,666,667</ix:nonFraction> such that following the increase, the authorized share capital was <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="cref_2043010181" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17442">3,333,334</ix:nonFraction> ordinary shares. </span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 8, 2024, the Company entered into an inducement offer letter with certain existing warrants holder, according to which, the holder has exercised <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1922956513" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17443">285,714</ix:nonFraction> of his warrants for an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1922956513" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17444">17.50</ix:nonFraction> per share into Company&#8217;s ordinary shares, totaling a $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" id="fc_1850396623" contextRef="cref_2133907439" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction> gross consideration. Total issuance expenses were $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="cref_2133907439" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17446">512</ix:nonFraction>. As part of the inducement letter, the Company issued to the holder new warrants to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_889933283" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17447">571,429</ix:nonFraction> of the Company&#8217;s ordinary shares for an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_889933283" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17448">22.50</ix:nonFraction> per share. In addition, the Company has also issued warrants to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1329224424" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17449">20,000</ix:nonFraction> of its ordinary shares for an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1329224424" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17450">21.90</ix:nonFraction> per share as issuance costs.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 30, 2024, the Company entered into at-the-market     offering agreement with H.C. Wainwright &amp; Co (the &#8220;Agent&#8221;), according to which the Company may offer and sell, from time     to time, its ordinary shares represented as ADSs, through the Agent in an at the market offering (&#8220;ATM&#8221;), as defined in Rule     415(a)(4) promulgated under the Securities Act of 1933, as amended.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, the Company issued <ix:nonFraction name="canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" contextRef="cref_1743024573" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17451">99,037</ix:nonFraction>     ordinary shares for net proceeds of $<ix:nonFraction name="canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17452">2,223</ix:nonFraction> through the ATM.</p></td></tr> </tbody> </table><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 187; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px"/><td style="width: 24px">5.</td><td style="text-align: justify">During 2025, the Company issued <ix:nonFraction name="canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" contextRef="cref_236998777" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17453">530,698</ix:nonFraction> ordinary shares for net proceeds of $<ix:nonFraction name="canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17454">2,933</ix:nonFraction> through its ATM.</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px"/><td style="width: 24px">6.</td><td style="text-align: justify">On April 6, 2025 the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="fc_1335503686" contextRef="cref_1335503686" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> ordinary shares to certain service provider in exchange for its services. The shares issued were valued at the amount of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="cref_236998777" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17456">141</ix:nonFraction> which were recorded to general and administrative expenses during the year ended December 31, 2025.</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px"/><td style="width: 24px">7.</td><td style="text-align: justify">On April 14, 2025, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) pursuant to which the Company agreed to sell and issue in a registered direct offering (the &#8220;April 2025 Offering&#8221;) an aggregate of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="cref_673085692" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17457">250,000</ix:nonFraction> ordinary shares of the Company at an offering price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" id="fc_374804358" contextRef="cref_374804358" unitRef="uref_1278442780" scale="0" decimals="1" format="ixt:num-dot-decimal">12.0</ix:nonFraction> per share (the &#8220;Ordinary Shares&#8221;).</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> Aggregate gross proceeds to the Company were approximately $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" id="fc_583619321" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,000</ix:nonFraction>, before deducting fees payable to the placement agent and other offering expenses payable by the Company. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> As part of the April 2025 Offering, the Company incurred an aggregate issuance costs of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17460">452</ix:nonFraction> recorded net of the Company&#8217;s additional paid in capital. The Company also issued to the placement agent warrants equal to <ix:nonFraction name="canf:ClassOfWarrantOrRightPercentage" id="fc_462856129" contextRef="cref_487979537" unitRef="uref_1413771939" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.0</ix:nonFraction>% of the aggregate number of ordinary Shares represented by ADSs, or <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1503704402" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17462">17,500</ix:nonFraction> ordinary Shares represented by <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="fc_487979537" contextRef="cref_487979537" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">8,750</ix:nonFraction> ADSs, at an exercise price of $<ix:nonFraction name="us-gaap:StockOptionExercisePriceIncrease" contextRef="cref_184434641" unitRef="uref_1278442780" scale="0" decimals="1" format="ixt:num-dot-decimal" id="ixv-17464">30.0</ix:nonFraction> per ADS and a term expiring on April 14, 2030. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company accounted for the aforementioned warrants as freestanding instrument classified at part of the Company&#8217;s permanent equity in accordance with ASC-480 and ASC-815-40. The Company accounted for the reduction in the warrants exercise price as issuance costs to be recorded in the Company&#8217;s additional paid in capital in accordance with ASC 815-40, following the adoption of ASU 2021-04.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"> <tbody><tr style="vertical-align: top"> <td style="width: 0.75in"/><td style="width: 0.25in">8.</td><td style="text-align: justify">On June 30, 2025, the Company&#8217;s shareholders meeting approved the increase of the Company&#8217;s authorized share capital by an additional <ix:nonFraction name="canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" contextRef="cref_870625474" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17465">3,333,334</ix:nonFraction> such that following the increase, the authorized share capital was <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="cref_1249276182" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17466">6,666,667</ix:nonFraction> ordinary shares.</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"> <tbody><tr style="vertical-align: top"> <td style="width: 0.75in"/><td style="width: 0.25in">9.</td><td style="text-align: justify">On July 28, 2025, the Company completed a public offering (the &#8220;July 2025 Offering&#8221;) for aggregate gross proceeds (without taking into account any from any future exercises of warrants) of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="fc_31012697" contextRef="cref_1536062095" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction> gross proceeds (approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="cref_1536062095" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17468">4,200</ix:nonFraction> net of issuance cost). The Company issued to the holder from the July 2025 Offering (i) <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1039317372" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17469">125,000</ix:nonFraction> ordinary shares (represented by <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1465389010" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17470">62,500</ix:nonFraction>ADSs, (ii) <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_2132039962" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17471">354,167</ix:nonFraction> pre-funded warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1839015054" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17472">708,334</ix:nonFraction> of the Company&#8217;s ordinary shares (represented by <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_2132039962" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17473">354,167</ix:nonFraction> ADSs (the &#8220;Pre-Funded Warrants&#8221;), and (iii) <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_575156313" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17474">833,333</ix:nonFraction> warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1039317372" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17475">1,666,667</ix:nonFraction> of the Company&#8217;s ordinary shares (represented by <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_275892941" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17476">833,333</ix:nonFraction> ADSs (the &#8220;Common Warrants&#8221; and together with the Pre-Funded Warrants, the &#8220;Warrants&#8221;).</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> The Pre-Funded Warrants will be immediately exercisable at a nominal exercise price ($<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="cref_2132039962" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17477">11.98</ix:nonFraction> per ADS) and may be exercised at any time until exercised in full. The Common Warrants have an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_421138161" unitRef="uref_1278442780" scale="0" decimals="1" format="ixt:num-dot-decimal" id="ixv-17478">6.0</ix:nonFraction> per share ($<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_275892941" unitRef="uref_1278442780" scale="0" decimals="1" format="ixt:num-dot-decimal" id="ixv-17479">12.0</ix:nonFraction> per ADS), are immediately exercisable, and expire on the two-year anniversary of the date of issuance. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> As part of the July 2025 Offering, the Company incurred an aggregate issuance cost of $<ix:nonFraction name="canf:CashPlacementFee" contextRef="cref_1755993480" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17480">837</ix:nonFraction> recorded net of the Company&#8217;s additional paid in capital. </p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 188; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> The Company also issued to the placement agent warrants equal to <ix:nonFraction name="canf:ClassOfWarrantOrRightPercentage" contextRef="cref_1886921177" unitRef="uref_1413771939" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-17481">7.0</ix:nonFraction>% of the aggregate number of ordinary Shares represented by <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1886921177" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17482">58,334</ix:nonFraction> ordinary Shares (represented by <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="fc_658807105" contextRef="cref_1465389010" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">29,167</ix:nonFraction> ADSs), at an exercise price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="cref_1363860027" unitRef="uref_1278442780" scale="0" decimals="1" format="ixt:num-dot-decimal" id="ixv-17484">7.5</ix:nonFraction> per share ($<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="cref_1465389010" unitRef="uref_1278442780" scale="0" decimals="1" format="ixt:num-dot-decimal" id="ixv-17485">15.0</ix:nonFraction> per ADS) and a term expiring on July 28, 2029. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px"/><td style="width: 24px">10.</td><td style="text-align: justify">In August and September 2025, the investors from July 2025 Offering exercised <ix:nonFraction name="canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" contextRef="cref_1250994810" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17486">125,000</ix:nonFraction> pre-funded ADSs into <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1554927284" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17487">250,000</ix:nonFraction> ordinary shares.</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tbody><tr style="vertical-align: top"> <td style="width: 72px"/><td style="width: 24px">11.</td><td style="text-align: justify">On November 10, 2025, a Special General Meeting of Shareholders of the Company approved to:</td></tr></tbody></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <tbody><tr style="vertical-align: top"> <td style="width: 1in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Increase authorized share capital by <ix:nonFraction name="canf:IncreaseAuthorizedShareCapital" contextRef="cref_2040359165" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17488">7,333,333</ix:nonFraction> so following the resolution, Company&#8217;s authorized share capital is <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="cref_2040359165" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17489">14,000,000</ix:nonFraction> ordinary shares, <span style="-sec-ix-hidden:fc_2130825858">no</span> par value per share.&#160;</span></td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <tbody><tr style="vertical-align: top"> <td style="width: 1in"/><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Perform a reverse split at a ratio of <ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="cref_2037786040" id="ixv-17490">1:3,000</ix:nonNumeric>.</span></td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> Concurrently with the reverse split, the Company effected a corresponding change in the ratio of ordinary shares underlying each of the Company&#8217;s American Depositary Shares (ADSs), such that its ratio of ADSs to ordinary shares will change from one (1) ADS representing three hundred (<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" contextRef="cref_1078174181" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17491">300</ix:nonFraction>) ordinary shares to a new ratio of one (1) ADS representing two (<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" contextRef="cref_801816110" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17492">2</ix:nonFraction>) ordinary shares and no adjustment will be made to the outstanding number of the ADSs of the Company. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For accounting purposes, all share and per share amounts for ordinary share, preferred shares, warrants, options and loss per share amounts have been adjusted to give retroactive effect to the forward and reverse share splits for all periods presented in these financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Any fractional shares of more than one-half of one whole share that resulted from the reverse share splits have been rounded up to the nearest whole share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px"/><td style="width: 24px">12.</td><td style="text-align: justify">On November 18, 2025, the investors from July 2025 Offering exercised <ix:nonFraction name="canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" contextRef="cref_1336110434" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17493">229,167</ix:nonFraction> pre-funded ADSs into <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1116774511" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17494">458,334</ix:nonFraction> ordinary shares.</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px"/><td style="width: 24px">13.</td><td style="text-align: justify">On November 18, 2025, the Company entered into an agreement with the holder of warrants to purchase <ix:nonFraction name="canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" contextRef="cref_435254208" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17495">833,333</ix:nonFraction> ADS previously issued on July 29, 2025 to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1936150275" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17496">1,666,667</ix:nonFraction> ordinary shares, pursuant to which in consideration for the holder&#8217;s waiver of certain standstill provisions, the Company reduced the exercise price of such warrants from $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_48256838" unitRef="uref_1278442780" scale="0" decimals="1" format="ixt:num-dot-decimal" id="ixv-17497">12.0</ix:nonFraction> per ADS to $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_997732034" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17498">9.34</ix:nonFraction> per ADS.</td></tr></tbody> </table><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 189; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase ordinary share:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="cref_184434641" escape="true" id="ixv-14281"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table summarizes information regarding outstanding warrants to purchase the Company&#8217;s ordinary shares as of December 31, 2025:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Issuance date</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Number of <br/> outstanding <br/> Warrants</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Exercise <br/> price per <br/> warrant</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify"><ix:nonNumeric name="canf:IssuanceDate" contextRef="cref_1731853064" id="ixv-17499">December 2021</ix:nonNumeric></td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_197686924" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17500">3,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_197686924" unitRef="uref_1278442780" scale="0" decimals="1" format="ixt:num-dot-decimal" id="ixv-17501">200.0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><ix:nonNumeric name="canf:IssuanceDate" contextRef="cref_1443470887" id="ixv-17502">January 2023 agent</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1156080072" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17503">9,545</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1156080072" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17504">68.75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><ix:nonNumeric name="canf:IssuanceDate" contextRef="cref_797890104" id="ixv-17505">November 2023</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1820958487" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17506">243,377</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1820958487" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17507">17.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><ix:nonNumeric name="canf:IssuanceDate" contextRef="cref_1043966202" id="ixv-17508">November 2023 agent</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1968813787" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17509">13,746</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1968813787" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17510">19.13</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><ix:nonNumeric name="canf:IssuanceDate" contextRef="cref_272935354" id="ixv-17511">August 2024</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_160240094" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17512">571,429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_160240094" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17513">22.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><ix:nonNumeric name="canf:IssuanceDate" contextRef="cref_910941741" id="ixv-17514">August 2024 agent</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1783668540" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17515">20,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1783668540" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17516">21.90</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><ix:nonNumeric name="canf:IssuanceDate" contextRef="cref_533550791" id="ixv-17517">April 2025</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1404131453" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17518">17,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1404131453" unitRef="uref_1278442780" scale="0" decimals="1" format="ixt:num-dot-decimal" id="ixv-17519">15.0</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><ix:nonNumeric name="canf:IssuanceDate" contextRef="cref_1056014996" id="ixv-17520">July 2025</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1665281426" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17521">1,666,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1665281426" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17522">4.67</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"><ix:nonNumeric name="canf:IssuanceDate" contextRef="cref_1019937961" id="ixv-17523">July 2025</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_1358509655" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17524">58,333</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1358509655" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17525">7.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="cref_202162938" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17526">2,604,097</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </tbody> </table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2025 and 2024, all of the Company&#8217;s outstanding warrants are classified as part of the Company&#8217;s equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share options plan:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> On November 28, 2013, the board of directors approved the adoption of the 2013 Share Option Plan (the &#8220;2013 Plan&#8221;). Under the Company&#8217;s 2013 Plan, in May 2023, the Company&#8217;s Board of Directors approved to increase number of ordinary shares reserved for issuance to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="cref_1355753607" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17527">28,333</ix:nonFraction>. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> On August 30, 2023, the Company&#8217;s board of directors approved the adoption on a new 2023 Share Option Plan (the &#8220;2023 Plan&#8221;) and approved the reserve of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="fc_862142534" contextRef="cref_862142534" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal">33,333</ix:nonFraction> of the Company&#8217;s ordinary shares to issuance under the 2023 Plan. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Under the Company&#8217;s Plans, the Company may grant its officers, directors, employees and consultants, share options. Each share option granted shall be exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will be granted with a term in excess of <ix:nonNumeric name="canf:GrantedExcessYears" contextRef="cref_1997617154" format="ixt-sec:duryear" id="ixv-17529">10</ix:nonNumeric> years. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> As of December 31, 2025, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="cref_109046716" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17530">8,667</ix:nonFraction> shares available for future grant under the Company&#8217;s 2023 Plans. </p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 190; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions granted by the Company:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="cref_184434641" escape="true" id="ixv-14451"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table summarizes Company&#8217;s option activity during the year ended December 31, 2025:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> options</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> average <br/> exercise <br/> price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> average <br/> remaining <br/> contractual <br/> terms <br/> (in years)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> intrinsic <br/> value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Outstanding at December 31, 2024</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="cref_678032609" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17531">41,610</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="cref_678032609" unitRef="uref_1278442780" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17532">90</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="fc_219588702" contextRef="cref_219588702" format="ixt-sec:duryear">7.1</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_2016546657">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Grants</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="cref_184434641" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17534">8,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="cref_184434641" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17535">16.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric name="canf:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants" contextRef="cref_184434641" format="ixt-sec:duryear" id="ixv-17536">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="cref_184434641" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17537">77</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1216322058">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_113611892">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Outstanding at December 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="cref_1997617154" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17538">49,533</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="cref_1997617154" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17539">87.31</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="cref_184434641" format="ixt-sec:duryear" id="ixv-17540">6.6</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_84170453">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest at December 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="cref_1997617154" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17541">49,533</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="cref_1997617154" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17542">87.31</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="cref_184434641" format="ixt-sec:duryear" id="ixv-17543">6.6</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_299793311">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Exercisable at December 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="cref_1997617154" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17544">25,497</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="cref_1997617154" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17545">143.98</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="cref_184434641" format="ixt-sec:duryear" id="ixv-17546">5.7</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1788048371">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </tbody> </table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life for the shares subject to options outstanding as of December&#160;31, 2025, 2024 and 2023 was <ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="cref_184434641" format="ixt-sec:duryear" id="ixv-17547">6.6</ix:nonNumeric> years, <ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="cref_1205104151" format="ixt-sec:duryear" id="ixv-17548">7.1</ix:nonNumeric> years and <ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="cref_1914073660" format="ixt-sec:duryear" id="ixv-17549">5.88</ix:nonNumeric> years, respectively.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average grant date fair value in 2025 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="cref_184434641" unitRef="uref_1278442780" scale="0" decimals="1" format="ixt:num-dot-decimal" id="ixv-17550">8.0</ix:nonFraction>, in 2024 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="cref_1205104151" unitRef="uref_1278442780" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17551">60</ix:nonFraction> and in 2023 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="cref_1914073660" unitRef="uref_1278442780" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17552">30</ix:nonFraction> and the remaining compensation costs not yet recognized as of December 31, 2025 is $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17553">133</ix:nonFraction> with a weighted average period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="cref_184434641" format="ixt-sec:duryear" id="ixv-17554">7.6</ix:nonNumeric> years to recognize these expenses.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="cref_184434641" escape="true" id="ixv-14683"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The fair value of the Company&#8217;s share options granted was estimated using the binomial option pricing model using the following range assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 61%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Description</span></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">2025</span></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">2024</span></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">2023</span></span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center">&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center">&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="cref_583004226" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17555">4.04</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="cref_342246256" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17556">4.21</ix:nonFraction>%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="cref_520798346" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17557">4.64</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="cref_907931666" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17558">5.09</ix:nonFraction>%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="cref_1803955859" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17559">3.95</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="cref_1055653923" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17560">3.96</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="cref_583004226" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17561">79.56</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="cref_342246256" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17562">79.82</ix:nonFraction>%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="cref_520798346" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17563">83.40</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="cref_907931666" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17564">83.94</ix:nonFraction>%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="cref_1803955859" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17565">84.30</ix:nonFraction>%-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="cref_1055653923" unitRef="uref_1413771939" scale="-2" decimals="4" format="ixt:num-dot-decimal" id="ixv-17566">84.76</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td> <td style="text-align: center">&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="cref_184434641" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17567">0</ix:nonFraction>%</span></td> <td style="text-align: center">&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="cref_1205104151" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17568">0</ix:nonFraction>%</span></td> <td style="text-align: center">&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="cref_1914073660" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17569">0</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual life (in years)</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="cref_184434641" format="ixt-sec:duryear" id="ixv-17570">10</ix:nonNumeric></span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="cref_520798346" format="ixt-sec:duryear" id="ixv-17571">9.75</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="cref_907931666" format="ixt-sec:duryear" id="ixv-17572">10</ix:nonNumeric></span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="cref_1914073660" format="ixt-sec:duryear" id="ixv-17573">10</ix:nonNumeric></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early Exercise Multiple (Suboptimal Factor)</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" contextRef="cref_184434641" unitRef="uref_1413771939" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-17574">2.5</ix:nonFraction></span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" contextRef="cref_1205104151" unitRef="uref_1413771939" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-17575">2.5</ix:nonFraction></span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" contextRef="cref_1914073660" unitRef="uref_1413771939" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-17576">2.5</ix:nonFraction></span></td></tr> </tbody> </table></ix:nonNumeric><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 191; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="cref_184434641" continuedAt="continuation_1712149008" escape="true" id="ixv-17577">Expenses recognized in the financial statements:</ix:nonNumeric></span></td></tr> </tbody> </table><ix:continuation id="continuation_1712149008"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Research and development</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_1607629638" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17578">57</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_42715392" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17579">75</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_1190382762" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17580">83</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative (*)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="fc_1398170537" contextRef="cref_1398170537" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal">283</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="fc_1132214309" contextRef="cref_1132214309" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal">287</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="fc_1202395540" contextRef="cref_1202395540" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal">178</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17584">340</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17585">362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17586">261</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tbody><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="fref_49130764" xml:lang="en-US">Including $<ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" id="fc_756498042" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal">141</ix:nonFraction> and $<ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" id="fc_532889771" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction> share based compensation for services provided in 2025 and 2024, refer to note 9(b)(6) and note 9(b)(1), respectively.</ix:footnote></td> </tr></tbody> </table></ix:continuation></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p> <ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="cref_184434641" escape="true" id="ixv-14877"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 10:- LEASES:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> The Company has lease contracts for motor vehicles used in its operations. Leases of motor vehicles have lease terms of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="cref_1894462461" format="ixt-sec:duryear" id="ixv-17590">3</ix:nonNumeric> years. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="cref_184434641" continuedAt="continuation_1600789674" escape="true" id="ixv-14883"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a summary of weighted average remaining lease terms and discount rate for all of the Company&#8217;s operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2025</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">weighted average remaining lease term (years)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="cref_1997617154" format="ixt-sec:duryear" id="ixv-17591">1.52</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="cref_678032609" format="ixt-sec:duryear" id="ixv-17592">2.49</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>weighted average discount rate</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="cref_1997617154" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17593">13</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="cref_678032609" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17594">13</ix:nonFraction></td><td style="text-align: left">%</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">The components of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2025 and 2024 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2025</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2024</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Components of lease expense:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17595">53</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17596">44</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17597">56</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table></ix:nonNumeric><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><!-- Field: Page; Sequence: 192; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 10:- LEASES (Cont.):</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&#160;</p><ix:continuation id="continuation_1600789674"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, <br/> 2025</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, <br/> 2024</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Supplemental cash flow information</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17598">56</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17599">42</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table></ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="cref_184434641" escape="true" id="ixv-15017"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">Maturities of lease liabilities as of December 31, 2025 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2026</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17600">60</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17601">32</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total operating lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17602">92</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17603">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Present value of lease liability</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17604">71</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table></ix:nonNumeric></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <ix:nonNumeric name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" contextRef="cref_184434641" escape="true" id="ixv-15053"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 11:-&#160;FINANCE INCOME (EXPENSE), NET</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" contextRef="cref_184434641" escape="true" id="ixv-15057"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Interest income</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17605">284</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17606">291</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17607">506</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Bank commissions</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="canf:BankCommissions" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17608">14</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="canf:BankCommissions" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17609">14</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="canf:BankCommissions" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17610">14</ix:nonFraction></td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exchange rate fluctuations and others</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="canf:ExchangeRateFluctuationsAndOthers" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17611">144</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="canf:ExchangeRateFluctuationsAndOthers" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17612">13</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:ExchangeRateFluctuationsAndOthers" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17613">58</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">short-term investment revaluation</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="canf:OtherGainFromShortTermInvestmentRemeasurement" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17614">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="canf:OtherGainFromShortTermInvestmentRemeasurement" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17615">14</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="canf:OtherGainFromShortTermInvestmentRemeasurement" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17616">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total financial income (expenses), net</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="cref_184434641" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17617">122</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="cref_1205104151" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17618">250</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="cref_1914073660" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17619">561</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table></ix:nonNumeric></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="cref_184434641" escape="true" id="ixv-15158"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">NOTE 12:-</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">SEGMENT REPORTING </span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> ASC 280, &#8220;Segment Reporting,&#8221; establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (&#8220;CODM&#8221;) in deciding how to allocate resources and in assessing performance. The Company&#8217;s business is comprised of&#160;<ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="cref_184434641" unitRef="uref_2084217627" scale="0" decimals="0" format="ixt-sec:numwordsen" id="ixv-17620">one</ix:nonFraction>&#160;operating segment. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: -0.7in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> The Company&#8217;s CODM is its <span style="-sec-ix-hidden:fc_698904215">Chief Executive Officer</span> (&#8220;CEO&#8221;), who reviews financial information presented on a consolidated basis. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: -0.7in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> <ix:nonNumeric name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription" contextRef="cref_184434641" id="ixv-17621">The CODM uses consolidated net income to measure segment profit or loss, to allocate resources and assess performance. Further, the CODM reviews and utilizes functional expenses (research and development and general and administrative) at the consolidated level to manage the Company&#8217;s operations and evaluate return on total assets in deciding whether to invest in the development and expansion of the Company&#8217;s consolidated operations.</ix:nonNumeric> </p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 193; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="cref_184434641" escape="true" id="ixv-15185"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 13:-&#160;TAXES ON INCOME</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate tax rates:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Israeli taxation:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Corporate tax rate in Israel in 2025, 2024 and 2023 was <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="cref_248394047" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17622"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="cref_616608710" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17623"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="cref_697212563" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17624">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>%. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Law for the Encouragement of Capital Investments, 1959:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Law for Encouragement of Capital Investments, 1959 (the &#8220;Investment Law&#8221;) provides tax benefits for Israeli companies meeting certain requirements and criteria. The Investment Law has undergone certain amendments and reforms in recent years.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Israeli parliament enacted a reform to the Investment Law, effective January 2011 (which was amended in August 2013). According to the reform, a flat rate tax applies to Preferred Income of companies eligible for the &#8220;Preferred Enterprise&#8221; status. In order to be eligible for Preferred Enterprise status, a company must meet minimum requirements to establish that it contributes to the country&#8217;s economic growth and is a competitive factor for the gross domestic product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Benefits granted to a Preferred Enterprise include reduced tax rates. As part of the Economic Efficiency Law (Legislative Amendments for Accomplishment of Budgetary Targets for Budget Years 2017-2018), 5777-2016, the tax rate is&#160;<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" id="fc_405959774" contextRef="cref_184434641" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal">16</ix:nonFraction>% for all areas other than Development Area A (which was&#160;<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="cref_44387193" unitRef="uref_1413771939" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-17626">7.5</ix:nonFraction>% from 2017 onward). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final tax assessments:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s tax return up until the year ended December 31, 2020 are considered final.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating carryforward losses for tax purposes and other temporary differences:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> As of December 31, 2025, the Company had carryforward losses amounting to approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17627">205,100</ix:nonFraction> that can be carryforward indefinitely </p><ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 194; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 13:-&#160;TAXES ON INCOME (Cont.)</span></p></ix:exclude><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="cref_184434641" escape="true" id="ixv-15260"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax assets:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17628">32,815</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17629">26,998</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences mainly relating to Research and Development</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17630">1,279</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17631">1,062</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax asset before valuation allowance</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17632">34,094</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17633">28,060</ix:nonFraction></td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="cref_1997617154" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17634">34,094</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="cref_678032609" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17635">28,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_539237308">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_506692405">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table></ix:nonNumeric><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation of the theoretical tax expense to the actual tax expense:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes and the company&#8217;s preferred enterprise tax rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="cref_184434641" escape="true" id="ixv-15360"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">A reconciliation of the provision for income taxes to the amount computed by applying the&#160;23% statutory Israeli income tax rate to income before income taxes after the adoption of ASU 2023-09 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Tax at Israeli Statutory Rate</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="cref_898003050" unitRef="uref_720247910" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal" id="ixv-17636">2,260</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="cref_898003050" unitRef="uref_1413771939" scale="-2" decimals="2" format="ixt:num-dot-decimal" id="ixv-17637">23</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Effect of benefitted income preferred technological enterprise in Israel</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="canf:EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount" contextRef="cref_898003050" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17638">688</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="canf:EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael" contextRef="cref_898003050" unitRef="uref_1413771939" scale="-2" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-17639">7</ix:nonFraction></td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.25in">Changes in Valuation Allowances</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="cref_898003050" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17640">1,524</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="cref_898003050" unitRef="uref_1413771939" scale="-2" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-17641">16</ix:nonFraction></td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Share-based payment awards</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="cref_898003050" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17642">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" contextRef="cref_898003050" unitRef="uref_1413771939" scale="-2" decimals="2" sign="-" format="ixt:num-dot-decimal" id="ixv-17643">0</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Effective Tax Rate</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1936936551">-</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_605971914">-</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> </tbody></table></ix:nonNumeric></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><!-- Field: Page; Sequence: 195; Value: 1 --><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-weight: bold;">CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border-bottom: black 1.5pt solid"><span style="font-weight: bold;">NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">(U.S. dollars in thousands except for share and per share data)</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="cref_184434641" escape="true" id="ixv-15452"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 14:- SUBSEQUENT EVENTS </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> On March 4, 2026, the Company entered into an inducement offer letter agreement (the &#8220;Inducement Letter&#8221;) with a certain holder (the &#8220;Holder&#8221;) of certain of the Company&#8217;s existing warrants to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="cref_1272600409" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17644">795,869</ix:nonFraction> of the Company&#8217;s American Depositary Shares (&#8220;ADS&#8221;), each ADS representing two ordinary shares, no par value, issued on July 29, 2025 at an exercise price of&#160;$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1459093040" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17645">9.34</ix:nonFraction> per ADS (the &#8220;Existing Warrants&#8221;). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Pursuant to the Inducement Letter, the Holder agreed to exercise for cash its Existing Warrants to purchase an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1413771939" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17646">795,869</ix:nonFraction> of the Company&#8217;s ADSs at a reduced exercise price of $<ix:nonFraction name="us-gaap:WarrantExercisePriceDecrease" contextRef="cref_1060093280" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17647">5.00</ix:nonFraction> per ADS in consideration of the Company&#8217;s agreement to issue new warrants to purchase ADSs (the &#8220;New Warrants&#8221;), as described below, to purchase up to an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="cref_1994543132" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17648">1,591,738</ix:nonFraction> ADSs (the &#8220;New Warrant Shares&#8221;), at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="cref_1994543132" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17649">5.00</ix:nonFraction> per ADS. The Company received aggregate gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="cref_1060093280" unitRef="uref_720247910" scale="6" decimals="-5" format="ixt:num-dot-decimal" id="ixv-17650">4.0</ix:nonFraction> million from the exercise of the Existing Warrants by the Holder, before deducting placement agent fees and other offering expenses payable by the Company. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> The Company also agreed to pay the placement agent a cash fee equal to <ix:nonFraction name="canf:ClassOfWarrantOrRightPercentage" contextRef="cref_100549505" unitRef="uref_1413771939" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-17651">7.0</ix:nonFraction>% of the aggregate gross proceeds received from the Holder&#8217;s exercise of the Existing Warrants, as well as a management fee equal to <ix:nonFraction name="canf:ClassOfWarrantOrRightPercentage" contextRef="cref_1413771939" unitRef="uref_1413771939" scale="-2" decimals="3" format="ixt:num-dot-decimal" id="ixv-17652">1.0</ix:nonFraction>% of the gross proceeds from the exercise of the Existing Warrants. The Company has also agreed to issue to the placement agent to purchase up to <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="cref_1272600409" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17653">55,711</ix:nonFraction> ADSs which will have the same terms as the New Warrants except that the Placement Agent Warrants will have an exercise price equal to $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="cref_1278442780" unitRef="uref_1278442780" scale="0" decimals="2" format="ixt:num-dot-decimal" id="ixv-17654">6.25</ix:nonFraction> per ADS. Similar to the New Warrants, the Placement Agent Warrants will be immediately exercisable from the date of issuance until the two year anniversary of the effective date of the resale registration statement. In addition, the Company has also agreed to pay the placement agent $<ix:nonFraction name="us-gaap:OtherExpenses" contextRef="cref_1683224475" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17655">91</ix:nonFraction> for other fees. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> As part of the Inducement letter, the Company also received gross proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="cref_734008993" unitRef="uref_720247910" scale="3" decimals="-3" format="ixt:num-dot-decimal" id="ixv-17656">350</ix:nonFraction> following the exercise of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="cref_734008993" unitRef="uref_734008993" scale="0" decimals="0" format="ixt:num-dot-decimal" id="ixv-17657">37,465</ix:nonFraction> Existing Warrants. </p></ix:nonNumeric> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">F-34</p><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea028258601ex1-1.htm
<DESCRIPTION>AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF CAN-FITE BIOPHARMA LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 1.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Articles of Association<BR>
Pursuant to the Companies Law, 1999, of a Company Limited by Shares<BR>
CAN FITE BIOPHARMA LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 7%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 83%; text-align: justify"><B>Clause</B></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: center"><B>Page</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>1</TD>
    <TD STYLE="text-align: justify">Interpretation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>2</TD>
    <TD STYLE="text-align: justify">Company Name</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>3</TD>
    <TD STYLE="text-align: justify">Company Purposes</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>4</TD>
    <TD STYLE="text-align: justify">Company Intent</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>5</TD>
    <TD STYLE="text-align: justify">Authorised Share Capital</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>6</TD>
    <TD STYLE="text-align: justify">Shareholder Liability</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>7</TD>
    <TD STYLE="text-align: justify">Public Company</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>8</TD>
    <TD STYLE="text-align: justify">Shares</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>9</TD>
    <TD STYLE="text-align: justify">Share Certificate; Share Warrant</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>10</TD>
    <TD STYLE="text-align: justify">Call on Shares</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>11</TD>
    <TD STYLE="text-align: justify">Share Forfeiture and Mortgage</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>12</TD>
    <TD STYLE="text-align: justify">Share Transfer and Delivery</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>13</TD>
    <TD STYLE="text-align: justify">Redeemable Shares</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>14</TD>
    <TD STYLE="text-align: justify">Recapitalisation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>15</TD>
    <TD STYLE="text-align: justify">General Meetings</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>16</TD>
    <TD STYLE="text-align: justify">General Meeting Resolutions</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>17</TD>
    <TD STYLE="text-align: justify">Shareholders&rsquo; Vote</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>18</TD>
    <TD STYLE="text-align: justify">Voting Rights</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>19</TD>
    <TD STYLE="text-align: justify">Board of Directors</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">16</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>20</TD>
    <TD STYLE="text-align: justify">Board&rsquo;s Authority</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>21</TD>
    <TD STYLE="text-align: justify">Board Meetings</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">20</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>22</TD>
    <TD STYLE="text-align: justify">Board Committee</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">21</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>23</TD>
    <TD STYLE="text-align: justify">Minutes</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">23</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>24</TD>
    <TD STYLE="text-align: justify">CEO</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">23</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>25</TD>
    <TD STYLE="text-align: justify">Local Management</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>26</TD>
    <TD STYLE="text-align: justify">Registry of Shareholders</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">24</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>27</TD>
    <TD STYLE="text-align: justify">Company Officers</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>28</TD>
    <TD STYLE="text-align: justify">Distribution</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>29</TD>
    <TD STYLE="text-align: justify">The Internal Auditor</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">26</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>30</TD>
    <TD STYLE="text-align: justify">The Auditing Accountant</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">26</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>31</TD>
    <TD STYLE="text-align: justify">Transactions Requiring Special Authorisation</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>32</TD>
    <TD STYLE="text-align: justify">Merger</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>33</TD>
    <TD STYLE="text-align: justify">Notices</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">27</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>34</TD>
    <TD STYLE="text-align: justify">Liquidation of the Company</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">28</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>35</TD>
    <TD STYLE="text-align: justify">Exemption from Liability</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">28</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>36</TD>
    <TD STYLE="text-align: justify">Liability Insurance</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">29</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>37</TD>
    <TD STYLE="text-align: justify">Indemnity</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">29</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>38</TD>
    <TD STYLE="text-align: justify">Binding the Company</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">30</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>39</TD>
    <TD STYLE="text-align: justify">Amendment of these Articles of Association</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">30</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>1.</B></TD><TD STYLE="text-align: justify"><B><U>Interpretation</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.1.</TD><TD STYLE="text-align: justify">In these Articles, unless the wording demands a different interpretation, the following words and expressions
shall bear the following meanings:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;&#8239;</TD>
    <TD STYLE="width: 2in; text-align: justify">&ldquo;<B>The Stock Exchange</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify">The Tel Aviv Stock Exchange Ltd.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;<B>The Board</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify">The Board of Directors duly elected pursuant to the provisions hereof.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;<B>Director</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify">A member of the Company&rsquo;s Board and any person who acts as a Director in actual fact, be his/her title what it may.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;<B>The Securities Law</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify">The Securities Law, 1968, as amended from time to time, and the regulations promulgated thereunder.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;<B>The Companies Law</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify">The Companies Law 1999, as amended from time to time, and the regulations promulgated thereunder.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;<B>The Law</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify">The Companies Law, the Securities Law and any other legislation in effect, pertaining to companies, applicable to the Company at that time.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;<B>The Company</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify">The abovementioned Company.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;<B>The Ledger</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify">The members&rsquo; ledger that must be kept pursuant to Section 127 of the Companies Law, the Material Shareholders Ledger that must be kept pursuant to Section 128 of the Companies Law, and in the event that the Company maintains an additional Ledger outside of Israel, any other Ledger, as the case may be.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;<B>The Office</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify">The Company&rsquo;s Registered Office, at any particular time.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;<B>Writing</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify">Printed matter, lithograph, photograph, telegram, telex, facsimile, email and any other form of imprint or formation of words in visible form.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;<B>Securities</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify">Including, Shares, Bonds, Capital Notes, other Certificates and Documents that bestow a right to sell, convert or sell any such.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2in">&ldquo;<B>The Companies Ordinance</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify"> The Companies Ordinance [New Version], 1983, as periodically amended.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;<B>The Articles</B>&rdquo; &ndash;</TD>
    <TD STYLE="text-align: justify">The Company&rsquo;s Articles of Association in its current version, or as shall be amended from time to time.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.2.</TD><TD STYLE="text-align: justify">Sections 2, 3, 4, 5, 6, 7, 8, 10 of the Interpretation Law, 1981-5741, shall apply, <I>mutatis mutandis</I>,
to the interpretation hereof, in the absence of any other provision relating to the subject matter, and in the absence of anything in
the subject matter, or its context, that does not fit the said application.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.3.</TD><TD STYLE="text-align: justify">Except as provided for herein this article, every word and expression in these Articles, shall bear the
meaning ascribed to them in the Companies Law, unless such would contradict the subject matter or its contents.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.4.</TD><TD STYLE="text-align: justify">Subject to this article, in these Articles &ndash; unless the wording demands a different interpretation,
the phrases defined in the Companies Law, shall bear the meanings ascribed to them therein; and words put forth in the singular shall
include the plural, and vice versa, and words in the masculine shall include the feminine, and words which mean individuals shall include
corporations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>2.</B></TD><TD STYLE="text-align: justify"><B><U>The Company Name</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&rsquo;s name is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In Hebrew: <B>&#1499;&#1503;-&#1508;&#1497;&#1497;&#1496;
&#1489;&#1497;&#1493;&#1508;&#1512;&#1502;&#1492; &#1489;&#1506;&quot;&#1502;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In English: <B>CAN FITE BIOPHARMA
LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>3.</B></TD><TD STYLE="text-align: justify"><B><U>The Company Purposes</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To carry out any lawful business</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>4.</B></TD><TD STYLE="text-align: justify"><B><U>The Company Intent</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&rsquo;s intent is to Law
pursuant to commercial considerations to maximise its profits, however, the Company is entitled to donate a reasonable sum for a worthy
goal, even if the donation is otherwise than in the framework of said commercial considerations, and pursuant to the discretion of the
Company Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>5.</B></TD><TD STYLE="text-align: justify"><B><U>The Authorised Share Capital</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.1.</TD><TD STYLE="text-align: justify">The Company&rsquo;s Authorised Share Capital is divided into 14,000,000 ordinary shares with no nominal
value (hereinafter: &ldquo;<B>Ordinary Shares</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.2.</TD><TD STYLE="text-align: justify">All Ordinary Shares shall be of equal rights vis-&agrave;-vis each other for all intents and purposes,
and each Ordinary Share shall bestow on its holder:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">The right to be invited to and participate in all the Company&rsquo;s General Meetings, both annual and
regular, and a right to one vote on account of each Ordinary Share in his possession, at every ballot, in any General Meeting of the Company
in which he participated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">A right to receive Dividends, if and when such are distributed, and a right to receive Bonus Shares, if
distributed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">A right to participate in the distribution of the Company&rsquo;s assets upon liquidation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>6.</B></TD><TD STYLE="text-align: justify"><B><U>Shareholder Liability</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The liability of holders of Ordinary
Shares shall be limited so that each Shareholder shall be liable to settle and pay exclusively an amount equal to the aggregate proceeds
received by Company for his Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>7.</B></TD><TD STYLE="text-align: justify"><B><U>Public Company</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Upon the registration of the Shares
for trading on the Stock Exchange, the Company shall become a public company, and shall maintain a Ledger of Material Shareholders, as
defined in the Companies Law, in addition to the Ledger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>8.</B></TD><TD STYLE="text-align: justify"><B><U>Shares</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.1.</TD><TD STYLE="text-align: justify">Notwithstanding the previous privileges granted to shareholders of the Company , the Company is entitled
to issue Shares with preferential rights or Shares with deferred rights or to issue, from the unissued Capital, Redeemable Securities,
subject to Section 309a of the Companies Law, or to issue Shares with other special limited rights or upon limitations as to the distribution
of Dividends, voting rights, or other matters, as the Company may from time to time decide by resolution adopted at a General Meeting
by an ordinary majority of Shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.2.</TD><TD STYLE="text-align: justify">If at any time the Share Capital is divided into different classes of Shares, the Company is entitled,
by resolution adopted at a General Meeting by an ordinary majority of Shareholders, unless the terms and conditions of the issuance of
that Class of Shares stipulates otherwise, to convert, expand, add or otherwise change the rights, privileges, advantages, limitations
and provisions, related or unrelated at that time to one of the Classes, or as shall be resolved by resolution adopted at a General Meeting
by an ordinary majority of Shareholders of that Class.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.3.</TD><TD STYLE="text-align: justify">The special rights granted to shareholders or a Shares of different Class, including Shares with preference
rights or other special rights, shall not be deemed altered in any way by the creation or issue of additional Shares of equal ranking
thereto, unless the terms and conditions of the issue of those Shares stipulates otherwise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The provisions hereof relating to General
Meetings shall apply, <I>mutatis mutandis</I>, to any and every meeting of a said Class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.4.</TD><TD STYLE="text-align: justify">The Company&rsquo;s unissued Shares shall be under the supervision of the Board, which may allocate them,
up to the limit of the Company&rsquo;s Authorised Share Capital, to such persons, in consideration of cash or non-cash consideration,
on such terms and conditions and limitations, and at such times and dates that the Board deems fit, and the Board shall have the authority
to present any person with a Call on the Share for whichever such Shares, for such times and for such consideration and terms and conditions
as the Board deems fit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.5.</TD><TD STYLE="text-align: justify">Upon the allocation of Shares, the Board is entitled to differentiate as amongst Shareholders in relation
to the amounts of the Call on the Share and/or times of settlement thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.6.</TD><TD STYLE="text-align: justify">If, according to the terms and conditions of the issuance of any Shares, payment of the consideration
on account of such Shares, in whole or in part, is by instalments, then each instalment shall be paid to the Company at its time of settlement
by that person who is the registered a shareholder at that time or by his administrators.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.7.</TD><TD STYLE="text-align: justify">The Company is entitled to pay, at any time, a commission, to any person for his function as an underwriter
or his consent to serve as an underwriter, conditionally or unconditionally, for any Security, including Bond Stock in the Company or
his consent to underwrite, conditionally or unconditionally, any Security, Bond or Stock of Bonds in the Company. On each event the commission
may be paid or settled in cash or Securities or Bonds or Stock of Bonds in the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>9.</B></TD><TD STYLE="text-align: justify"><B><U>Share Certificate; Share Warrant</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.1.</TD><TD STYLE="text-align: justify">Subject to the provisions of the Companies Law and pursuant thereto, a Share Certificate shall bear the
seal or stamp or the Company, and the signatures of two Directors, or as the Board may determine.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.2.</TD><TD STYLE="text-align: justify">Any Shareholder registered in the Ledger of Members is entitled to receive one Share Certificate on account
of the Shares registered to his name, or, if the Board approves (following payment of the sum determined by the Board from time to time),
several Share Certificates, each for one or more such Shares; every Share Certificate shall mention the number of Shares on account of
which it was issued and the serial numbers thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">A Share Certificate registered in the
name of two or more persons, shall be handed over to that person, from amongst the joint owners, whose name appears first in the Ledger
of Members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.3.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company is entitled to deliver a Share Certificate on account of Shares that the full consideration
of which was paid to the Company, which shall grant the holders thereof the rights to the Shares stipulated therein, and the right to
transfer the same by handing over the Share, and the provisions hereof relating to transfer of Shares shall not apply to the Shares set
forth in such Share Certificate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">A Shareholder lawfully possessed of a Share Certificate is entitled to return it to the Company for cancellation
and to turn it into a Share Registered to a Name; and entitled, in consideration of a fee to be determined by the Board, to have his name
registered in the Ledger of Members on account of the Share mentioned in the Share Certificate, and that he be issued with a certificate
of a Share Registered to a Name.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">A holder of a Share Certificate is entitled to deposit the Share Certificate at the Office, and for as
long as it is so deposited, the depositor shall have the right to demand convening a meeting of the Company, subject and pursuant to the
provisions of the Companies Law and these Articles, to be present at such meeting, to vote therein, and to make use of the remaining rights
of a Shareholder at any Meeting convened upon his said demand within 30 days after said deposit, in the same manner as if his name was
registered in the Ledger of Members as the holder of the Shares included in the Share Certificate. Only one person shall be recognised
as the depositor of the Share, and the Company is obliged to return the Share Certificate to the depositor, should he request so in writing
30 days in advance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">In the event that a Share Certificate
was not so deposited, its holder shall not have the rights set forth in this sub-Article (c), and he shall have, subject to the provisions
of these Articles, all the remaining rights bestowed upon a Shareholder in the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.4.</TD><TD STYLE="text-align: justify">In the event that a Share Certificate is lost or destroyed, the Board is entitled to issue a new certificate
or warrant instead, provided that the certificate or warrant was not rescinded by the Company, or it was proven, to the satisfaction of
the Board, that the certificate or warrant were lost or destroyed, and received satisfactory sureties against any possible damages, and
all in consideration of a payment, if the Board resolves to impose such.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>10.</B></TD><TD STYLE="text-align: justify"><B><U>Call on Shares</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.1.</TD><TD STYLE="text-align: justify">The Board may, from time to time, at its discretion, present the Shareholders with a Call on Shares to
pay any outstanding consideration on account of the Shares held by each Shareholder, and which according to the terms and conditions of
the allocation of the Shares they are not to be settled upon fixed times and dates, and each Shareholder is obliged to pay the Company
the sum of the Call presented to him, at the time and place as determined by the Board. A Call on Shares may divide the payment into instalments.
The date of the Call shall be the date of the Board&rsquo;s resolution pertaining to the Call.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.2.</TD><TD STYLE="text-align: justify">A prior notice of fourteen (14) days shall be provided regarding each Call on Shares, which shall mention
the rate of the payment, the place of payment, provided that prior to the time of settlement of such a Call on Shares the Board is entitled,
by written notice to the Shareholders, to cancel the Call or extend its time for settlement, and provided that such resolution was adopted
prior to the time of settlement of the Call.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.3.</TD><TD STYLE="text-align: justify">Joint owners of a Share shall be jointly liable for payment of any instalment and Call on a Share due
on account of such Share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.4.</TD><TD STYLE="text-align: justify">If, according to the terms and conditions of the allocation of any Share, or otherwise, any sum must be
settled on a fixed date or by instalments on fixed dates, then any such sum or instalment shall be settled as if it were a Call on a Share
duly presented by the Board, and for which notice was duly given, and to such sum or instalment all the provisions of these Articles pertaining
to Calls on Shares shall apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.5.</TD><TD STYLE="text-align: justify">In the event that the sum of a Call on Shares or instalment was not paid by or prior to its date of settlement,
the person who is at that time the owner of the Share on account of which the Call was presented or for which the instalment was due,
shall be obliged to pay interest on the said sum, at a rate to be determined by the Board from time to time, or at the rate permitted
at that time by law, from the day fixed for such payment until payment in fact, however the Board is entitled to waive the payment of
interest, in whole or in part.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.6.</TD><TD STYLE="text-align: justify">Should the Board see fit, it is entitled to receive from a Shareholder who wishes to advance monies not
yet Called or that the settlement of which is not yet due, and that have not yet been settled on account of his Shares, or any part thereof.
The Board is entitled to pay the Shareholder for the monies advanced in the abovementioned manner, or for any part thereof, interest to
the day the monies should have been settled had they not been so advanced, at a rate to be agreed upon between the Board and the Shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>11.</B></TD><TD STYLE="text-align: justify"><B><U>Share Forfeiture and Mortgage</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.1.</TD><TD STYLE="text-align: justify">In the event that a Shareholder fails to pay the consideration he committed to, in whole or in part, at
the times and dates and on the terms and conditions determined, whether a Call on Share was issued or not, the Board may at any time provide
notice to that Shareholder and demand he pay the unsettled sum, plus interest accrued and any other expense the Company was made to suffer
on account of such non-settlement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.2.</TD><TD STYLE="text-align: justify">The notice shall set a date, at least fourteen (14) days after the date of the notice, and a place or
places, in which the Call or abovementioned instalment must be paid, plus interest and the abovementioned expenses. The notice shall stipulate,
that in the event of non-payment at the fixed time and date and the place set forth in the notice, the Company may forfeit the Shares
on account of which the Call was made or on account of which the instalments have become conclusively due.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.3.</TD><TD STYLE="text-align: justify">In the event of failure to fulfil the requirements included in the abovementioned notice, then at any
time thereafter, prior to the payment of the Call on the Share or the instalment, interest and expenses due on account of those Shares,
the Board may resolve to forfeit the Shares on account of which the said notice was provided. Such forfeiture shall include all the dividends
declared in respect of the forfeit Shares which have not been distributed in fact prior to the forfeiture.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.4.</TD><TD STYLE="text-align: justify">Any Share thus forfeit shall be deemed the property of the Company, and the Board may, taking account
of the provisions hereof, sell it, reallocate it, or otherwise transfer it, as it deems fit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.5.</TD><TD STYLE="text-align: justify">Forfeit Shares that have not yet been sold shall be treasury stock in accordance with the Companies Law,
and shall not grant any rights whatsoever for as long as they are the property of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.6.</TD><TD STYLE="text-align: justify">The Board may at any time prior to the sale, reallocation or other transfer of any Share forfeited as
abovementioned, rescind the forfeiture on such terms and conditions that the Board deems fit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">Any Shareholder whose Share have been forfeit shall cease to be the owner of the said forfeit Shares,
however he shall continue to be indebted to the Company for all Calls on Shares, payment instalments, interest and expenses due on account
of those Shares or for them, at the time of forfeiture, plus interest at the maximum rate permissible at law at that time, unless the
forfeit Shares have been sold and the Company has received the full consideration to which the Shareholder committed, plus the expenses
accompanying the sale.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">In the event that the consideration received on account of the forfeit Shares was greater than the consideration
to which the owner of the Shares thus forfeit was committed to, the Shareholder is entitled to recoup the partial consideration he gave
for them, if any, subject to the terms and conditions of the allocation, and provided that the consideration remaining in the hands of
the Company shall be no less than the full consideration committed to by the owner the Share thus forfeit, plus the expenses accompanying
the sale.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.7.</TD><TD STYLE="text-align: justify">The provisions hereof pertaining to forfeiture of Shares shall apply also to events of non-payment of
a fixed consideration the time of settlement of which, according to the terms and conditions of the allocation of the Share, is due, as
if it were a sum due for settlement by virtue of a Call on Shares presented and for which notice was given.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.8.</TD><TD STYLE="text-align: justify">The Company shall have the right to a first ranking mortgage over any and all Shares registered to the
name of any Shareholder, except for fully paid up Shares, and over the income from the sale of such Shares, for the settlement of the
debts and liabilities of that Shareholder to the Company, whether individually or jointly with any other person, whether the time for
settlement of such debts or fulfilment of such obligation is due or not, whatever the source of the debts may be, and no rights in Equity
shall be created in any Share. The abovementioned lien and mortgage shall apply to all Dividends declared from time to time for such Shares.
Unless resolved otherwise, registration by the Company of a transfer of Shares shall be deemed a waiver on behalf of the Company of such
lien or mortgage (if any) over the Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.9.</TD><TD STYLE="text-align: justify">To realise the abovementioned mortgage, the Board shall be entitled to sell the Mortgaged Shares in a
manner it deems fit, pursuant to it&rsquo;s discretion; however, no Share may be sold unless the period of time set forth in Article 11.2
above has passed, and the Shareholder (or such person entitled to be given notice following his death or insolvency or liquidation or
the receivership of his assets) was provided written notice stipulating that the Company intends to sell the Share, and the Shareholder
or person so entitled to the Share, has not paid the abovementioned debts or has not met the abovementioned obligations after the passing
of fourteen (14) days from the date the said notice was sent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.10.</TD><TD STYLE="text-align: justify">The proceeds of any such sale, after the expenses of the sale have been settled, shall be used to settle
the debts and fulfil the obligations of the owner of such a Share (including the debts, obligations and liabilities and contracts the
time for settlement or fulfilment of which is not yet due) and the provisions of Article 11.6(b) shall apply, <I>mutatis mutandis</I>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.11.</TD><TD STYLE="text-align: justify">In the event of a sale following forfeiture or for the realisation of a mortgage under the powers and
authorities granted above, the Board shall be entitled to appoint a person to sign a deed of transfer for the sold Shares and to register
the purchaser in the Ledger of Members as the owner of the sold Shares, and the purchaser shall not be obliged to ensure these actions
were duly and properly taken, and it shall be none of his business what the proceeds of sale were used for, and following the registration
of his name in the Ledger of Members on account of those Shares, the validity of the sale shall not be called into question, and the only
remedy available to any person injured as a result of the sale, shall be suing the Company, and only the Company, for damages.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>12.</B></TD><TD STYLE="text-align: justify"><B><U>Share Transfer and Delivery</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.1.</TD><TD STYLE="text-align: justify">A Share transfer shall not be registered unless the Company was provided with the appropriate deed of
transfer. A Company Share deed of transfer shall be signed by the transferor and transferee, and the transferor shall be deemed continuing
to be the Shareholder until such a time as the name of the transferee is recorded in the Ledger of Members on account of the transferred
Share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">A Share deed of transfer shall be drafted
and filled out in the following form, or such similar form, or in the ordinary or customary way approved by the Board:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>&ldquo;I, ____________, of __________
(&ldquo;The Transferor&rdquo;), in consideration of _______________ NIS paid to me by ____________, of __________ (&ldquo;The Transferee&rdquo;),
do hereby transfer to the Transferee _________ shares ___________ , marked numbers _________ to ______________ in _______________ Ltd.,
to be in the hands of the Transferee, his executors, guardians, and attorneys, under all the terms and conditions on which I held them
prior to the execution hereof, and I, the Transferee, do hereby agree to receive the said shares on the abovementioned terms and conditions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><B>And in Witness hereof we have signed
our names this ____ Day of ________ in the year __________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><B>Transferor</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Transferee</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><B>Witness to Transferor&rsquo;s Signature</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Witness to Transferee&rsquo;s Signature&rdquo;</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.2.</TD><TD STYLE="text-align: justify">The Company is entitled to seal the Ledger of Members for such a time that the Board sees fit, provided
that it is does not exceed thirty (30) days a year. The Company shall provide notice to the Shareholders of the sealing of the Ledger
of Members pursuant to the provision hereof, for the purposes of providing notices to the Shareholders. The Company is entitled to fix
a determining date for the purposes of the right to receive invitations to General Meetings, to participate and vote therein, and for
the purposes of the right to receive a Dividend, provided that such date won&rsquo;t be more than seven (7) days prior to the date fixed
for the convention of the General Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.3.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">Any and every deed of transfer shall be handed in to the Office for recording. Deeds of transfer recorded
shall remain in the possession of the Company, but any deed of transfer which the Board refuses to register, shall be, upon demand, returned
to the person who delivered it, together with the Share Certificate (if handed in).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">The Company is entitled to demand payment of a fee for the registration of the transfer, which fee shall
be fixed by the Company Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.4.</TD><TD STYLE="text-align: justify">The administrators and executors of a deceased Shareholder, or, in the absence of administrators or executors,
the persons entitled as the heirs of the deceased Shareholder, shall be the only individuals the Company shall recognise as owners of
rights in the Share that was registered to the name of the deceased.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In the event that a Share is registered
in the name of two or more owners, the Company shall exclusively recognise the surviving partner or partners as those persons who own
the rights to the Share or any beneficial interest therein. In the event that a Share is registered in the name of several owners jointly
as mentioned, each one of them shall be entitled to transfer his right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.5.</TD><TD STYLE="text-align: justify">The Company may recognise the receiver or liquidator of a Shareholder which is a corporation in liquidation
or in the process of winding up or the trustee in bankruptcy or any receiver of a bankrupt Shareholder as owners of the rights in and
to the Shares registered to the name of such Shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.6.</TD><TD STYLE="text-align: justify">Any person who gains an interest in Shares owing to the death of a Shareholder, shall be entitled, on
production of proof of probation of a will or the appointment of an administrator or the granting of an inheritance order, testifying
that he has the right to the Shares of the deceased Shareholder, to be registered as the Shareholder on account of those Shares, or may,
subject to the provisions hereof, transfer those Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.7.</TD><TD STYLE="text-align: justify">The receiver or liquidator of a Shareholder that is a corporation in liquidation or in the process of
winding up, or the trustee in bankruptcy or any receiver of a bankrupt Shareholder, may, having produced such evidence the Board demands
of him, testifying that he has the right to the Shares of the Shareholder in liquidation or winding up or bankruptcy, with the consent
of the Board (which consent the Board may withhold without giving any reasons for its refusal) be registered as the Shareholder on account
of those Shares, or he may, subject to the provisions hereof, transfer those Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">12.8.</TD><TD STYLE="text-align: justify">All the abovementioned pertaining to the transfer of Shares shall apply to the transfer of other Company
Securities, <I>mutatis mutandis</I>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>13.</B></TD><TD STYLE="text-align: justify"><B><U>Redeemable Shares</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.1.</TD><TD STYLE="text-align: justify">The right to redeem shall be limited to the eventuality of a winding up of the Company following the settlement
of all the Company&rsquo;s obligations to its creditors at the time of winding up.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">13.2.</TD><TD STYLE="text-align: justify">Redeemable Shares shall grant the holders thereof the following rights:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">Voting rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">Rights to participate in Dividends.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>14.</B></TD><TD STYLE="text-align: justify"><B><U>Recapitalisation</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">14.1.</TD><TD STYLE="text-align: justify">The Company is entitled, from time to time, by resolution of the General Meeting, passed by an ordinary
majority of Shareholder votes, to increase the Company&rsquo;s Authorised Share Capital in Classes of Shares as it shall determine.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">14.2.</TD><TD STYLE="text-align: justify">Unless stated otherwise in the resolution approving the said Capital increase, the provisions hereof shall
apply to the New Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">14.3.</TD><TD STYLE="text-align: justify">By resolution of the General Meeting passed by an ordinary majority of Shareholder votes, the Company
is entitled:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">To consolidate and distribute its Share Capital into Shares of higher par value than those extant, and
in the event of no par value &ndash; to capital comprising a smaller number of Shares, provided that such will not alter the proportional
respective holdings of the Shareholders in the issued capital.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">For the purposes of carrying out any
such resolution, the Board is entitled to settle in a manner it deems fit any difficulty arising, and <I>inter alia</I>, to issue Certificates
for Share fractions or Certificates in the name of a number of Shareholders that shall include the fractions of Shares to which they are
entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Notwithstanding the foregoing authority
of the Board, in the event that as a result of consolidation there shall be Shareholders, the consolidation of whose Shares leaves fractions,
the Board is entitled, with the consent of the General Meeting passed by ordinary majority of Shareholder votes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">To sell the total number of fractions and for such purposes to appoint a trustee in whose name the Share
Certificates that include fractions shall be made, who shall sell them and the proceeds of sale, after deduction of commissions and expenses,
shall be distributed amongst those entitled; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">To allocate to each Shareholder who is left by the consolidation with fractions, Shares of the Class of
Shares prior to the consolidation, fully paid up, at such a number that their consolidation with the fraction shall be sufficient for
one complete Consolidated Share, and such allocation shall be deemed valid close in time prior to the consolidation; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Determine that Shareholders shall not be entitled to receive a Consolidated Share on account of a Consolidated
Share fraction, arising from the consolidation of half or less of the number of Shares the consolidation of which created one Consolidated
Share, and shall be entitled to receive one Consolidated Share on account of a fraction of a Consolidated Share arising from the consolidation
of more than half the number of Shares the consolidation of which created one Consolidated Share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">In the event that actions pursuant
to the foregoing paragraphs (2) or (3) shall necessitate issuing additional Shares, then the settlement of such shall be done in the same
way as settlement on account of Bonus Shares. Such consolidation and division shall not be deemed an alteration of the rights of the Shares
which are the subject matter of the consolidation and division.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify">To distribute, by way of new distribution of existing Shares, all or part thereof, its Share Capital,
in whole or in part, to Shares of lower par value than the existing Shares, and in the event that its Shares had no par value, to Share
Capital comprising a larger number of Shares, provided that such will not alter the proportional respective holdings of the Shareholders
in the issued Capital.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.5pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify">To cancel any Authorised Share Capital which on the date of the resolution had yet to be allocated, provided
that the Company has no obligations, including no conditional obligations, to allocate the Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>15.</B></TD><TD STYLE="text-align: justify"><B><U>General Meetings</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.1.</TD><TD STYLE="text-align: justify">In addition to the resolutions the authority to adopt which is given to the General Meeting, and set forth
herein these Articles and/or in the Companies Law, the decisions of the Company on the following matters shall be taken at General Meetings
by ordinary majority of votes of participating Shareholders:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">Amendment of these Articles pursuant to Article 39 hereinafter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">Exercising the powers and authorities of the Board in the event that the Assembly has determined that
the Board is prevented from exercising its power and authorities, and that the exercise thereof is essential to the proper management
of the Company pursuant to Section 52(a) of the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify">Appointment of the Company&rsquo;s auditor, fixing his terms of employment and terminating his appointment
pursuant to the provisions of Sections 154 through 167 of the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify">Approval of actions and transactions which require the General Meeting&rsquo;s approval pursuant to the
provisions of Sections 255, 270(1)-(3), 271 through 273 of the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT></TD><TD STYLE="text-align: justify">Increase the Share Capital and cancellation thereof, pursuant to the provisions of Section 286 &amp; 287
of the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT></TD><TD STYLE="text-align: justify">A merger pursuant to Section 320(a) of the Companies Law, and subject to Section 320(A1) of the Companies
Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.2.</TD><TD STYLE="text-align: justify">The General Meeting is entitled to assume powers and authorities granted to another organ.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.3.</TD><TD STYLE="text-align: justify">The Company shall hold an annual General Meeting every year, and no later than after fifteen (15) months
following the preceding annual General Meeting (the &ldquo;<B>Annual General Meeting</B>&rdquo;). A General Meeting that is not an Annual
General Meeting shall be an Extraordinary Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.4.</TD><TD STYLE="text-align: justify">The agenda at the Annual General Meeting shall include the following subjects:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="text-align: justify">Discussion of the Companies audited financial statements, with the enclosed Board report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="text-align: justify">Appointment of Directors pursuant to Article 19, and determining their remuneration as Directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="text-align: justify">Appointment of a financial auditor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="text-align: justify">Matters that one or more Shareholders, representing at least five (5) percent of the issued Capital and
at least one (1) percent of the voting rights in the Company, or one or more Shareholders, who have at least five (5) percent of the voting
rights in the Company, have asked the Board to include, provided that they are matters to be properly discussed at an Annual General Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.5.</TD><TD STYLE="text-align: justify">Any time the Board deems fit, it is entitled to convene an Extraordinary Meeting by resolving to do so,
and Extraordinary Meetings shall be convened pursuant to demands as set forth in the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">15.6.</TD><TD STYLE="text-align: justify">Notice of a General Meeting, on the agenda of which there are no matters for which voting may be by written
ballot under Section 87 of the Companies Law, shall be published up to at least fourteen (14) days prior to the Convention, and notice
on the agenda of which there are such matters, shall be published at least twenty one (21) days before the Convention. Notice shall be
published in no less than two daily newspapers, of wide circulation in Israel, published in Hebrew. In any event, no notice shall be sent
to each one of the Shareholders registered on the Company&rsquo;s Ledger of Members.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The notice shall specify the type of
meeting, the time and place of the meeting, a list of the items on the agenda, an extract of proposed resolutions, the required majority
to adopt the resolutions and the date for the determination of entitlement of Shareholders to vote in the General Meeting, as set forth
in Section 182 of the Companies Law. In the event that an adjourned Meeting is set for a date later than that stipulated for in Section
78(b) of the Companies Law, namely, more than seven (7) days, that date shall be specified in the notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left">15A.</TD><TD STYLE="text-align: justify"><B><U>Shareholder Proposal Request</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">15A.1</TD><TD STYLE="text-align: justify">Any Shareholder or Shareholders of the Company holding at
least one percent (1%) or a higher percent, as may be required by the Companies Law from time to time, of the voting rights of the Company
(the &ldquo;<B>Proposing Shareholder(s)</B>&rdquo;) may request, subject to the Companies Law, that the Board of Directors include a
matter on the agenda of a General Meeting to be held in the future, provided that the Board determines that the matter is appropriate
to be considered in a General Meeting (a &ldquo;<B>Proposal Request</B>&rdquo;). In order for the Board of Directors to consider a Proposal
Request and whether to include the matter stated therein in the agenda of a General Meeting, notice of the Proposal Request must be timely
delivered in accordance with applicable laws, and the Proposal Request must comply with the requirement of these Articles (including
this Article 15A) and any applicable law and stock exchange rules and regulations. The Proposal Request must be in writing, signed by
all of the Proposing Shareholder(s) making such request, delivered, either in person or by certified mail, postage prepaid, and received
by the Secretary (or, in the absence thereof by the Chief Executive Officer of the Company). To be considered timely, a Proposal Request
must be received within the time periods prescribed by applicable law. The announcement of an adjournment or postponement of a General
Meeting shall not commence a new time period (or extend any time period) for the delivery of a Proposal Request as described above. In
addition to any information required to be included in accordance with applicable law, the Proposal Request must include the following:
(i) the name, address, telephone number, fax number and email address of the Proposing Shareholder (or each Proposing Shareholder, as
the case may be) and, if an entity, the name(s) of the person(s) that controls or manages such entity; (ii) the number of Shares held
by the Proposing Shareholder(s), directly or indirectly (and, if any of such Shares are held indirectly, an explanation of how they are
held and by whom), which shall be in such number no less than as is required to qualify as a Proposing Shareholder, accompanied by evidence
satisfactory to the Company of the record holding of such Shares by the Proposing Shareholder(s) as of the date of the Proposal Request,
and a representation that the Proposing Shareholder(s) intends to appear in person or by proxy at the meeting; (iii) the matter requested
to be included on the agenda of a General Meeting, all information related to such matter, the reason that such matter is proposed to
be brought before the General Meeting, the complete text of the resolution that the Proposing Shareholder proposes to be voted upon at
the General Meeting and, if the Proposing Shareholder wishes to have a position statement in support of the Proposal Request, a copy
of such position statement that complies with the requirement of any applicable law (if any), (iv) a description of all arrangements
or understandings between the Proposing Shareholders and any other Person(s) (naming such Person or Persons) in connection with the matter
that is requested to be included on the agenda and a declaration signed by all Proposing Shareholder(s) of whether any of them has a
personal interest in the matter and, if so, a description in reasonable detail of such personal interest; (v) a description of all Derivative
Transactions (as defined below) by each Proposing Shareholder(s) during the previous twelve (12) month period, including the date of
the transactions and the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions;
and (vi) a declaration that all of the information that is required under the Companies Law and any other applicable law and stock exchange
rules and regulations to be provided to the Company in connection with such matter, if any, has been provided to the Company. The Board
of Directors, may, in its discretion, to the extent it deems necessary, request that the Proposing Shareholder(s) provide additional
information necessary so as to include a matter in the agenda of a General Meeting, as the Board of Directors may reasonably require.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">A &ldquo;<B>Derivative Transaction</B>&rdquo;
means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proposing Shareholder
or any of its affiliates or associates, whether of record or beneficial: (1) the value of which is derived in whole or in part from the
value of any class or series of shares or other securities of the Company, (2) which otherwise provides any direct or indirect opportunity
to gain or share in any gain derived from a change in the value of securities of the Company, (3) the effect or intent of which is to
mitigate loss, manage risk or benefit of security value or price changes, or (4) which provides the right to vote or increase or decrease
the voting power of, such Proposing Shareholder, or any of its affiliates or associates, with respect to any shares or other securities
of the Company, which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position,
note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting agreement,
performance-related fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion
in any such class or series), and any proportionate interest of such Proposing Shareholder in the securities of the Company held by any
general or limited partnership, or any limited liability company, of which such Proposing Shareholder is, directly or indirectly, a general
partner or managing member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">15A.2</TD><TD STYLE="text-align: justify">The information required pursuant to this Article shall be
updated as of (i) the record date of the General Meeting, (ii) five business days before the General Meeting, and (iii) as of the General
Meeting, and any adjournment or postponement thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">15A.3</TD><TD STYLE="text-align: justify">The provisions of Articles 15A.1 and 15A.2 shall apply,&nbsp;mutatis
mutandis, on any matter to be included on the agenda of an Extraordinary Meeting which is convened pursuant to a request of a Shareholder
duly delivered to the Company in accordance with the Companies Law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">16.</TD><TD STYLE="text-align: justify"><B><U>General Meeting Resolutions</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.1.</TD><TD STYLE="text-align: justify">No discussion in General Meeting may be commenced unless a legal quorum is present within half an hour
of the time scheduled for the meeting. Unless otherwise provided for by Companies Law or by these regulations, legal quorum will be present
when at least two (2) shareholders holding together twenty five percent (25%) of company&rsquo;s votes are present in person or by their
attorneys.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.2.</TD><TD STYLE="text-align: justify">If half an hour after the time scheduled for the meeting legal quorum is not present, meeting shall be
postponed to same day on following week, same time and place, or to a later date, if specified on notice as to meeting, and if the matters
for which first meeting was called will be covered on postponed meeting. If no legal quorum is present on second meeting half an hour
after the time scheduled for the meeting, then meeting shall take place with any number of attendees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If a General Meeting was convened at
shareholders&rsquo; request as covered in Companies Law, postponed meeting will only be held if the minimum number of shareholders required
for holding a meeting was present, as covered in Section 63 of Companies Law, i.e., one or more shareholders holding at least five (5)
percent of issued capital and one (1) percent at least of the voting rights in the company, or one or more shareholders holding at least
five (5) percent of the company&rsquo;s voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.3.</TD><TD STYLE="text-align: justify">The chairman of the Board will chair every General Meeting. If there is no chairman or if he is not present
within fifteen (15) minutes of the time scheduled for the meeting, or if he does not wish to chair the assembly, the shareholders present
in the meeting will select one of them as chairman.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.4.</TD><TD STYLE="text-align: justify">The General Meeting&rsquo;s chairman shall be permitted, with the consent of the assembly where a legal
quorum is present, to postpone the meeting to another time and location, and must postpone it as above if the assembly instructs him to
do so. At the postponed meeting, only matters on the agenda which discussion was not completed or commenced at the meeting where the postponement
was resolved will be discussed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.5.</TD><TD STYLE="text-align: justify">Subject to the provisions of Companies Law and these Articles that require an extended majority of shareholders,
any proposed resolution brought before the assembly shall be decided upon by simple majority of the votes of shareholders present and
voting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.6.</TD><TD STYLE="text-align: justify">The General Meeting&rsquo;s chairman shall not have an additional or decisive vote.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">16.7.</TD><TD STYLE="text-align: justify">The Chairman&rsquo;s announcement that a resolution was made unanimously or by certain majority or was
rejected, and the meeting&rsquo;s minutes signed by the chairman, will serve as prima facie evidence of contents of minutes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">17.</TD><TD STYLE="text-align: justify"><B><U>Shareholders&rsquo; Vote</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">17.1.</TD><TD STYLE="text-align: justify">Subject to any special provisions, privileges and limitations as to the voting of shareholders involved
at that time with any shares, when voting by counting votes or by secret ballot, every shareholder whether present himself or by attorney
or proxy, will have one vote for each share he owns granting him a voting right.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">17.2.</TD><TD STYLE="text-align: justify">A corporation constituting a company shareholder is permitted, by the decision of its Directors or another
managing body, to authorize any person it may deem fit to serve as its representative at any General Meeting. A person authorized as covered
above will be permitted to use &ndash; on behalf of the corporation he represents &ndash; the same voting rights the corporation itself
may have used were it an individual shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">17.3.</TD><TD STYLE="text-align: justify">Subject to the provisions of Companies Law, General Meeting resolutions on issues listed below will also
be made by proxy:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD><TD STYLE="padding-right: 1in; text-align: justify">Appointing and dismissing Directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD><TD STYLE="padding-right: 1in; text-align: justify">Approving actions or transactions requiring General Meeting&rsquo;s approval as per Sections 255 and 268
to 275 of Companies Law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD><TD STYLE="padding-right: 1in; text-align: justify">Approving merger as per Section 320 of Companies Law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD><TD STYLE="padding-right: 1in; text-align: justify">Issues covered by the Ministry of Justice in the regulations that were set forth or will be set forth
under Section 89 of Companies Law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">Subject to the provisions of Companies
Law, proxy will be deposited in Office or any other location designated for convening the General Meeting at least forty eight (48) hours
prior to the time scheduled for commencing the meeting where person specified in proxy is to vote. However, the General Meeting chairman
is permitted to waive this requirement and accept proxy when meeting commences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">18.</TD><TD STYLE="text-align: justify"><B><U>Voting Rights</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.1.</TD><TD STYLE="text-align: justify">Minor shareholders and shareholders who were declared by court to be incompetent, may vote only through
their guardians, and each guardian as above may vote through an attorney.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.2.</TD><TD STYLE="text-align: justify">In the event of co-owners of a share, the opinion of one co-owner will be accepted, whether given personally
or by attorney &ndash; and the opinion of remaining co-owners will not be accepted. For this purpose, the co-owner whose opinion shall
be heard shall be determined by the order their names are listed in the book of shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.3.</TD><TD STYLE="text-align: justify">Shareholders can vote personally or by attorney, or in the case of a corporation, by representative as
covered in Article 18.4 below or by attorney with proper power of attorney as covered below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.4.</TD><TD STYLE="text-align: justify">Any document appointing an attorney for voting (hereinafter <B>&ldquo;Letter of Appointment&rdquo;</B>)
will be signed by the appointer or his attorney authorized in writing to do so, or if the appointer is a corporation, the appointment
will be done in writing, signed as legally required and stamped with the corporation seal or signed by its authorized attorney.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.5.</TD><TD STYLE="text-align: justify">Letter of appointment and power of attorney (if any) based on which letter of appointment was signed,
or its copy approved to board&rsquo;s satisfaction, will be deposited in office or any other location designated for convening the assembly
at least forty eight (48) hours prior to the time scheduled for commencing the meeting, in which the person specified in letter of appointment
is supposed to vote. However, the General Meeting chairman is permitted to waive this requirement for all attendees of certain meeting
and accept power of attorney when meeting commences.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.6.</TD><TD STYLE="text-align: justify">A Shareholder holding more than one share will be entitled to appointing more than one attorney, subject
to following provisions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Letter of appointment specifies type and number of shares for which it is granted;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Should number of shares of any kind specified in letters of appointment granted by one shareholder exceed
number of shares of that kind held by him, all Letters of Appointment granted by that shareholder for excessive shares shall be canceled,
without detracting from the validity of the vote for shares held by him;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">in case that only an attorney is appointed by a shareholder, but the Letter of Appointment does not specify
the number and type of shares for which it was granted, than such Letter of Appointment shall be deemed as granted for all shares held
by the shareholder on date the letter of appointment was deposited with the company or handed to the General Meeting chairman, as the
case may be. If the Letter of Appointment was granted for a number of shares smaller than number of shares held by shareholder, shareholder
shall be deemed as refraining from voting for remaining shares he holds, and letter of appointment shall be valid only for the number
of shares specified on it.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.7.</TD><TD STYLE="text-align: justify">Any Letter of Appointment for an attorney, whether for a specifically named meeting or otherwise, will
be made as follows, as far as circumstances permit:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;I, ________________, of __________________
shareholder of _____________ Ltd. (hereinafter <B>&ldquo;The Company&rdquo;</B>) hereby appoint _________, whose ID is ____________, of
______________, or in his/her absence, ___________, whose ID is ____________, of ______________, or in his/her absence, ___________, whose
ID is ____________, of ______________, to vote for me and on my behalf for ___ shares of type ____________ held by me, at the company&rsquo;s
annual / extraordinary meeting / at a shareholder meeting of type _____________ to be held on day ____________ of month __________, year
_____________, and at any meeting postponed from that meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In witness whereof I hereby sign on
this day of ____ month _________ year ________.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Signature&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">18.8.</TD><TD STYLE="text-align: justify">Vote based on the provisions of a document appointing an attorney will be valid despite the appointer&rsquo;s
decease or cancellation of the power of attorney or transferring the share for which voting was done as covered above, unless notice in
writing of such decease, cancellation or transfer was received at the office or by the meeting&rsquo;s chairman prior to voting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: justify"><B><U>Board of Directors</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.1.</TD><TD STYLE="text-align: justify">The number of Board members for the Company shall be no more than thirteen (13) (hereinafter <B>&ldquo;Normal
Directors&rdquo;</B>), plus the number of external Directors which appointment is legally required (hereinafter <B>&ldquo;External Directors&rdquo;</B>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.2.</TD><TD STYLE="text-align: justify"><B><U>Election and Removal of Directors</U></B>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 39.9pt">19.2.1.</TD><TD STYLE="text-align: justify">The Directors, excluding the External Directors if any (who shall be elected and serve in office in strict
accordance with the provisions of the Companies Law, if so required by the Companies Law), shall be classified, with respect to the term
for which they each severally hold office, into three classes, as nearly equal in number as practicable, hereby designated as Class I,
Class II and Class III.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">19.2.1.1.</TD><TD STYLE="text-align: justify">The term of office of the initial Class I directors shall expire at the first Annual General Meeting to
be held in 2020 and when their successors are elected and qualified,</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">19.2.1.2.</TD><TD STYLE="text-align: justify">The term of office of the initial Class II directors shall expire at the first Annual General Meeting
following the Annual General Meeting referred to in clause (i) above and when their successors are elected and qualified, and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">19.2.1.3.</TD><TD STYLE="text-align: justify">The term of office of the initial Class III directors shall expire at the first Annual General Meeting
following the Annual General Meeting referred to in clause (ii) above and when their successors are elected and qualified.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.2.</TD><TD STYLE="text-align: justify">Directors (other than External Directors), may be elected only in Annual General Meetings. At each Annual
General Meeting, commencing with the Annual General Meeting to be held in 2020, each of the successors elected to replace the Directors
of a Class whose term shall have expired at such Annual General Meeting shall be elected to hold office until the third Annual General
Meeting next succeeding his or her election and until his or her respective successor shall have been elected and qualified. Notwithstanding
anything to the contrary, each Director shall serve until his or her successor is elected and qualified or until such earlier time as
such Director&rsquo;s office is vacated.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.3.</TD><TD STYLE="text-align: justify">If the number of Directors (excluding External Directors) that constitutes the Board of Directors is hereafter
changed, the then-serving Directors shall be re-designated to other Classes and/or any newly created directorships or decrease in directorships
shall be apportioned by the Board of Directors among the classes so as to make all classes as nearly equal in number as is practicable,
provided that no decrease in the number of Directors constituting the Board of Directors shall shorten the term of any incumbent Director.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.4.</TD><TD STYLE="text-align: justify">Prior to every Annual General Meeting of the Company at which Directors are to be elected, and subject
to Articles 19.2.1 and 19.2.8 of this Article, the Board of Directors (or a Committee thereof) shall select, by a resolution adopted by
a majority of the Board of Directors (or such Committee), a number of Persons to be proposed to the Shareholders for election as Directors
at such Annual General Meeting (the &ldquo;<B>Nominees</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.5.</TD><TD STYLE="text-align: justify">Any Proposing Shareholder requesting to include on the agenda of an Annual General Meeting a nomination
of a Person to be proposed to the Shareholders for election as Director (such person, an &ldquo;<B>Alternate Nominee</B>&rdquo;), may
so request provided that it complies with this Article 19.2.5 and Article 15A&nbsp;and applicable law. Unless otherwise determined by
the Board, a Proposal Request relating to Alternate Nominee is deemed to be a matter that is appropriate to be considered only in an Annual
General Meeting. In addition to any information required to be included in accordance with applicable law, such a Proposal Request shall
include information required pursuant to Article 15A, and shall also set forth: (i) the name, address, telephone number, fax number and
email address of the Alternate Nominee and all citizenships and residencies of the Alternate Nominee; (ii) a description of all arrangements,
relations or understandings between the Proposing Shareholder(s) or any of its affiliates and each Alternate Nominee; (iii) a declaration
signed by the Alternate Nominee that he consents to be named in the Company&rsquo;s notices and proxy materials relating to the Annual
General Meeting, if provided or published, and, if elected, to serve on the Board of Directors and to be named in the Company&rsquo;s
disclosures and filings, (iv) a declaration signed by each Alternate Nominee as required under the Companies Law and any other applicable
law and stock exchange rules and regulations for the appointment of such an Alternate Nominee and an undertaking that all of the information
that is required under law and stock exchange rules and regulations to be provided to the Company in connection with such an appointment
has been provided (including, information in respect of the Alternate Nominee as would be provided in response to the applicable disclosure
requirements under Form 20-F or any other applicable form prescribed by the U.S. Securities and Exchange Commission or applicable Israeli
rules and regulations under the Company Law or Israeli Securities Laws); (v) a declaration made by the Alternate Nominee of whether he
or she meets the criteria for an independent director and/or External Director of the Company under the Companies Law and/or under any
applicable law, regulation or stock exchange rules, and if not, then an explanation of why not; and (vi) any other information required
at the time of submission of the Proposal Request by applicable law, regulations or stock exchange rules. In addition, the Proposing Shareholder
shall promptly provide any other information reasonably requested by the Company. The Board of Directors may refuse to acknowledge the
nomination of any person not made in compliance with the foregoing. The Company shall be entitled to publish any information provided
by a Proposing Shareholder pursuant to this Article 19.2.5 and Article 15A, and the Proposing Shareholder shall be responsible for the
accuracy and completeness thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.6.</TD><TD STYLE="text-align: justify">The Nominees or Alternate Nominees shall be elected by a resolution adopted at the Annual General Meeting
at which they are subject to election.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.7.</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary herein, this Article 19.2 and Article 15A may only be amended,
replaced or suspended by a resolution adopted at a General Meeting by a majority of [65%] of the voting power represented at the General
Meeting in person or by proxy and voting thereon, disregarding abstentions from the count of the voting power present and voting, provided
that such majority constitutes more than [20%] of the Company&rsquo;s then issued and outstanding share capital.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.8.</TD><TD STYLE="text-align: justify">Notwithstanding anything to the contrary in these Articles, the election, qualification, removal or dismissal
of External Directors shall be only in accordance with the applicable provisions set forth in the Companies Law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.9.</TD><TD STYLE="text-align: justify">Directors whose terms of office have expired or terminated may be re-elected. The aforesaid will not apply
to external directors, whose reappointment shall be in accordance with the provisions of the Companies Law and the regulations promulgated
thereunder.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.10.</TD><TD STYLE="text-align: justify">Election of Board members as detailed above will be done by shareholders present at the Annual General
Meeting, personally or by attorney, or, subject to the provisions of Companies Law, by proxy, by simple majority of shareholder votes.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.11.</TD><TD STYLE="text-align: justify">A Director&rsquo;s tenure will commence on the date of his appointment by the Annual General Meeting in
which he was appointed as above. A Director appointed as above by the Annual General Meeting shall serve until the end of the next applicable
Annual General Meeting in which such Director&rsquo;s term expires in accordance with the relevant classification in Article 19.2.1 above.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">19.2.12.</TD><TD STYLE="text-align: justify">Notwithstanding the aforesaid, Directors may not be dismissed from office by the Shareholders or by a
General Meeting prior to expiration of their term of office pursuant to Articles 19.2.1 and 19.2.2 above, and the provisions of Section
230(a) of the Companies Law in this regard shall not apply.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.3.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">At any time, a Director may appoint a person to serve as his substitute Director, subject to the provisions
of Companies Law (hereinafter <B>&ldquo;Alternative Director&rdquo;</B>). Any person disqualified to be appointed as Director, or serving
as Director or alternative Director shall not be appointed as alternative Director. So long as the alternative Director&rsquo;s appointment
is effective, he shall be entitled to be invited to all board meetings (without revoking the Director&rsquo;s right to be invited) and
attend and vote at any board meeting from which appointing Director is absent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Alternative Director shall have, subject to the provisions of his Letter of Appointment, all rights held
by the Director he substitutes, and he shall be treated as Director.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Director appointing Alternative Director shall be permitted to cancel appointment at any time. Alternative
Director&rsquo;s tenure shall be terminated if the Director appointing him notifies the company in writing of his resignation or if his
tenure as Director was otherwise terminated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Any appointment of an Alternative Director and cancellation of his appointment shall be done by notifying
the company in writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.4.</TD><TD STYLE="text-align: justify">A Director ceasing to serve in such position can be reappointed, but in the event of termination of his
tenure due to being convicted of an offense as specified in Article 19.6 (c) below, he can be reappointed only if five (5) years have
passed since the date of his conviction as covered in Section 226 of Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.5.</TD><TD STYLE="text-align: justify">A Director&rsquo;s position shall automatically become vacant under any one of the following conditions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">If he resigns from his position as covered in Section 229 of Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If he is convicted of an offense as covered in Section 232 of Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">If the court decides to direct his tenure to be terminated as covered in Section 233 of Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">If he declares bankruptcy, and if a corporation, if it has decided on voluntary liquidation or liquidation
order is issued on it.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">In event of his decease.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">If he becomes incompetent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.6.</TD><TD STYLE="text-align: justify">Notwithstanding anything herein to the contrary, if a Director&rsquo;s office becomes vacant, then the
remaining Directors shall be permitted to take any action, so long as their number is minimally three. Additionally, the remaining Directors
shall be permitted to appoint a Director in place of the Director whose tenure was terminated, who will serve in his office until the
next Annual General Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">19.7.</TD><TD STYLE="text-align: justify">Directors shall not be paid wages with company funds, unless the company resolves as covered in Sections
270 (3) and 273 of Companies Law. A Director shall be entitled to have his reasonable transportation expenses reimbursed, as well as other
expenses connected to his attending board meetings and fulfilling his duties as board member. Reward and expenses for outside Directors
shall be paid according to Company Regulations (Rules for Reward and Expenses for Outside Director), 2000, or any other regulations replacing
these in the future.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: justify"><B><U>Board&rsquo;s Authority</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">20.1.</TD><TD STYLE="text-align: justify">In addition to the powers generated to the Board according to the Companies Law and these Articles, and
without detracting from such, the Board shall outline the Company&rsquo;s policy and shall supervise the execution of the CEO&rsquo;s
duties and actions, including:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Determining the Company&rsquo;s plans, principles for their funding, and priorities among them;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Reviewing the Company&rsquo;s financial condition and determining the limit for credit it may use;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Determining organizational structure and wage policy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Being permitted to decide on issuing a series of bonds;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Responsibility for preparing financial statements and for their approval as per Section 171 of the Companies
Law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Appointing and dismissing CEO as covered in Section 250 of the Companies Law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">Deciding on actions and transactions requiring his approval as per Sections 253 and 268 to 275 of the
Companies Law and the provisions of these Articles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">Being permitted to allocate shares and convertible securities up to the Company&rsquo;s registered share
capital as per Section 288 of the Companies Law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Being permitted to distribute as covered in Sections 307 and 308 of the Companies Law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">Voicing his opinion to the General Meeting as to a special acquisition offer as per Section 329 of the
Companies Law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">Being permitted to determine, from time to time, who would be authorized to sign bills of exchange, promissory
notes, invoices, acceptance documents, endorsements, checks, contracts and any kind of other documents on behalf of the company, but such
authorized signatories would be obligated to sign with the company seal, or next to its printed or written name.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">20.2.</TD><TD STYLE="text-align: justify">The board will act, on any of the matters listed in Article 20.1 above, according to the Companies Law
and these Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">20.3.</TD><TD STYLE="text-align: justify">The Board&rsquo;s powers according to Article 20.1 (a) to (j) above cannot be delegated to the CEO, except
as covered in Section 288 (b) (2) of the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">20.4.</TD><TD STYLE="text-align: justify">Recommendations, reports and approvals to be given by the board as per regulation 20.1 above shall be
accompanied by the Board&rsquo;s explanations to the recommendation, report or approval, as the case may be.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">20.5.</TD><TD STYLE="text-align: justify">Chairman of the Board shall direct Board meetings. On first Board meeting after each Annual General Meeting,
the Board will elect one of its members to serve as chairman of the board. Appointment of chairman of the board shall remain in effect
until the first Annual General Meeting after his appointment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21.</TD><TD STYLE="text-align: justify"><B><U>Board Meetings</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.1.</TD><TD STYLE="text-align: justify">The Board shall convene for meetings as per Company&rsquo;s needs, and at least once every three (3) months.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.2.</TD><TD STYLE="text-align: justify">The Chairman of the Board shall be permitted to convene the Board at any time. Additionally, any two Directors
(and if number of board members does not exceed five (5) &ndash; any one Director) shall be permitted to demand a Board meeting on a specified
subject.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.3.</TD><TD STYLE="text-align: justify">Any notice of a board meeting can be communicated verbally, by telephone, in writing (including fax or
e-mail) or by telegram, so long as notice is given at least 12 hours prior to the time established for the meeting, unless all board members
or their replacements (if any) have agreed on shorter notice or on convening without notice. A Director travelling or staying outside
of Israel at any time, shall not be entitled to be provided with notice of a board meeting for the length of his trip, so long as if he
has appointed an alternative Director as per these regulations, such notice would be sent to that alternative Director.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.4.</TD><TD STYLE="text-align: justify">Notice of a Board meeting shall specify its date and place and contain reasonable details of all issues
on the agenda.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The agenda shall include all issues
established as per Article 21.2 above, and any issue a Director or the CEO requested the chairman to add to the agenda within a reasonable
period of the board meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.5.</TD><TD STYLE="text-align: justify">Until board resolves otherwise, most Board members for that time, who are not legally prevented from participating
and voting at the Board meeting, shall constitute a legal quorum for Board meetings and its decisions. Legal quorum shall be examined
when meeting commences and each time Board makes a resolution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Notwithstanding the above, the legal
quorum for the Board&rsquo;s resolution to terminate internal auditor&rsquo;s tenure shall not in any event be less than most Board members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.6.</TD><TD STYLE="text-align: justify">Board resolutions will be based on simple majority of attending, voting Directors. Each Director shall
have one vote.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.7.</TD><TD STYLE="text-align: justify">The chairman of the Board shall chair each Board meeting. If the chairman of Board is absent, within fifteen
(15) minutes of time scheduled for meeting, or if he does not wish to chair the meeting, the Board members present at meeting shall elect
one of them to serve as chairman, direct meeting and sign meeting minutes. However, when board votes, the person elected shall not have
an additional or decisive vote.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.8.</TD><TD STYLE="text-align: justify">Each Board meeting where a legal quorum is present shall be permitted to fulfil every authority, power
of attorney and judgment that according to these regulations are given to board at that time or that are normally utilized by the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">21.9.</TD><TD STYLE="text-align: justify">The Board shall be permitted to make resolutions without actually convening, with the consent of all Directors
entitled to participating in the discussion and voting as to the resolution. In such an event, the chairman of board shall prepare minutes
and attach Directors&rsquo; signatures.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">21.10.</TD><TD STYLE="text-align: justify">Subject to the provisions of any law, all actions taken by
board or under its decision, or by meeting of a board committee or by person serving as board member, shall be valid even if it is later
discovered that there has been some flaw in electing these board members or the persons serving as above, or that all or one of them
are invalid, just as though each of them were legally elected and had the necessary qualifications for becoming a member of the board
or of said committee.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">21.11.</TD><TD STYLE="text-align: justify">A resolution signed by all Directors (or their alternative
Directors) or agreed to in writing (including fax) by all Directors (or their alternative Directors) who are not legally prevented from
participating in such resolution; and resolutions made by using any means of communication that allow all Directors who are not legally
prevented from participating in such resolution to hear the other Directors simultaneously &ndash; shall be valid for all intents just
as though they had been made at a properly convened board meeting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">22.</TD><TD STYLE="text-align: justify"><B><U>Board Committee</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">22.1.</TD><TD STYLE="text-align: justify">Board shall be permitted, by a resolution of the majority of Directors constituting Board at that time,
to establish committees and appoint Board members as committee members. Subject to the provisions of Companies Law and these Articles,
Board may delegate its powers or any part thereof to above committees, and for a special matter, can cancel such delegation from time
to time. At least two (2) Directors shall serve on each committee. At least one (1) External Director shall serve on any committee permitted
to utilize any of the Board&rsquo;s powers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">22.2.</TD><TD STYLE="text-align: justify">When using its powers, any committee established as covered in Article 22.1 above must fulfil all provisions
established by the Board. Meetings and actions of each committee shall be conducted according to the provisions contained in these articles
as far as Board&rsquo;s meetings and actions, so long as they are suitable and so long as no provisions by the Board have replaced them.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">22.3.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">A Resolution made or action taken by board committee according to a power delegated to it by the Board,
shall be the same as a board&rsquo;s resolution or action.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Notwithstanding this section, on the issues listed below a Board committee shall not be permitted to make
resolutions but recommendations only:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">Establishing general Company policy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Distribution, with the exception of acquiring Company shares according to framework formerly outlined
by Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">Establishing Board&rsquo;s position as to an action requiring General Meeting&rsquo;s approval, or as
to providing an opinion as per Section 329 of Companies Law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(4)</TD><TD STYLE="text-align: justify">Appointing Directors, if the Board is permitted to do so;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(5)</TD><TD STYLE="text-align: justify">Allocating shares or securities convertible to shares or which can be realized as shares &ndash; or a
series of bonds &ndash; unless the share distribution is due to realizing or converting Company securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(6)</TD><TD STYLE="text-align: justify">Approving financial statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(7)</TD><TD STYLE="text-align: justify">Approving transactions and actions requiring Board&rsquo;s approval as per Sections 255 and 268 to 275
of Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">22.4.</TD><TD STYLE="text-align: justify">A Board committee shall report to board on ongoing basis of its resolutions or recommendations as determined
by Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">22.5.</TD><TD STYLE="text-align: justify">The Board may cancel resolution of committee appointed by it, but such cancellation shall not detract
from the validity of a committee resolution acted upon by company towards another person not knowing of its cancellation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">However, all actions taken in good
faith at board meeting or by a Board committee or by any person serving as Director shall be valid even it is later discovered that there
has been some flaw in appointing such Director or person acting as above, or that all or one of them are invalid, just as though each
of them were legally appointed and had the necessary qualifications for becoming a Director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">23.</TD><TD STYLE="text-align: justify"><B><U>Minutes</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">23.1.</TD><TD STYLE="text-align: justify">The Company shall document minutes of General Meetings, class meetings, Board meetings and Board committee
meetings, and shall keep them in its office for a period of seven (7) years of the General Meeting or meeting, as the case may be.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">23.2.</TD><TD STYLE="text-align: justify">Minutes will always contain the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Day and place where meeting or assembly took place;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Names of attendees, and if they are attorneys or alternative participants, names of those granting power
of attorney or appointing, and for a shareholders&rsquo; meeting, number and types of shares based on which voting is conducted;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Summary of discussions, course of discussions and resolutions made;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Instructions given by board to board committees or CEO;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Documents, reports, approvals, opinions, etc. presented, discussed and/or attached.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Such General Meeting minutes signed
by the General Meeting&rsquo;s chairman shall serve as prima facie proof of its contents, and such board or board committee meeting minutes
approved and signed by meeting chairman or board chairman shall serve as prima facie proof of its contents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Above provisions shall also apply to
written resolutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">24.</TD><TD STYLE="text-align: justify"><B><U>CEO</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">24.1.</TD><TD STYLE="text-align: justify">The CEO shall be appointed, whether for a fixed or limited period, and dismissed by board through majority
of board members.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">24.2.</TD><TD STYLE="text-align: justify">The CEO shall be responsible for ongoing management of company&rsquo;s affairs as part of policy established
by board and subject to its directions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">24.3.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The CEO shall have all management and execution powers not granted by Companies Law or by these regulations
to any other company agency, and shall be supervised by board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The CEO may delegate some of his powers, with board&rsquo;s approval, to anyone under him. Approval can
be general and granted in advance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">24.4.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The CEO shall notify the chairman of Board immediately of any exceptional matter meaningful to the Company,
and shall submit to board reports on such matters, at such times and at such extent as the board sees fit. Should the Company not have
a chairman of the Board, or should he be prevented from fulfilling his duties, CEO shall notify all Board members of such circumstance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Chairman of Board shall be permitted, as his own initiative or at board&rsquo;s decision, to demand
of CEO to report on the Company&rsquo;s affairs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Should such notice or report require board&rsquo;s action, chairman of board shall immediately summon
a board meeting to discuss notice or resolve upon required action.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>25.</B></TD><TD STYLE="text-align: justify"><B><U>Local Management</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">25.1.</TD><TD STYLE="text-align: justify">The Board may arrange, from time to time, arrangements for the management of the Company&rsquo;s business
in any specific location; whether in Israel or abroad, as it sees fit, and the provisions set forth in Article 25.2, below, shall not
derogate from the general authorisations granted the Board under this Article.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">25.2.</TD><TD STYLE="text-align: justify">The Board may, at any time and from time to time, establish any local management or local agency to manage
the business of the Company in any specific location, in Israel or abroad and can appoint any person to be a member of said local management,
or any manager or agent and may determine their salary. The Board may, from time to time, grant any person so appointed any power, authority
and freedom of discretion that are granted at that time to the Board, and he may empower any person who is at that time serving as a local
member of management to continue in his position even though a position has been vacated there, and any such appointment or such authorisation
may be made under the same terms and conditions that the Board will see fit and the Board may at any time terminate the employment of
any person who was so appointed and to cancel or amend any such authorisation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>26.</B></TD><TD STYLE="text-align: justify"><B><U>Registry of Shareholders</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">26.1.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company shall administer a registry of shareholders (the &ldquo;<B>Primary Registry</B>&rdquo;) and
will record in it the following details:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">For registered share -</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Name, I.D. number and address of every shareholder, all as
was provided to the Company; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Amount of shares and types of shares held by each shareholder, listing their par value, if existent, and
if any amount has yet to be paid in consideration for such shares - the amount yet to be paid; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Date of allocation of the shares or the date of transfer to the shareholders, whichever relevant; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">If the shares have been marked with serial numbers, the Company shall note, next to the name of each shareholder,
the serial numbers of the shares registered in the shareholder&rsquo;s name; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">All other details that, by the Companies Law or these Articles of Association, are required or permitted
to be registered in the Primary Registry.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Bearer Shares -</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Notification of the facts that bearer shares have been allocated, their date of allocation and the amount
of shares that have been allocated; and -</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The numbering of the bearer shares and of the share certificates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 2.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If the share certificate is cancelled
by request of the shareholder, the name of the shareholder and the number of shares registered in his name will be registered in the Primary
Registry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Dormant Shares - Their numbers and the date they became dormant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 141.75pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">The Company may, subject to and in accordance with the provisions
of sections 138 and 139 of the Companies Law, maintain an additional shareholders registry outside of Israel.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>27.</B></TD><TD STYLE="text-align: justify"><B><U>Company Officers</U></B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">27.1.</TD><TD STYLE="text-align: justify">The Company&rsquo;s CEO may, from time to time, appoint officers (except for Directors and a CEO) to the
Company to permanent, temporary or special positions, as the CEO so decides from time to time, and similarly, the CEO may terminate the
services of one or more of the aforementioned from time to time and at any time, in his absolute discretion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">27.2.</TD><TD STYLE="text-align: justify">The CEO can determine, subject to the provisions of the Companies Law, the authority and the role of each
officer he so appoints, as well as the terms under which they will fulfil of their position and may demand collateral in the cases and
in the amounts he deems necessary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>28.</B></TD><TD STYLE="text-align: justify"><B><U>Distribution</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.1.</TD><TD STYLE="text-align: justify">Subject to all special rights or restrictions granted to particular shares, dividends or share dividends
will be distributed and paid to the shareholders relative to the number of Ordinary Shares held by them.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.2.</TD><TD STYLE="text-align: justify">Decisions on the distribution of dividends will be made by the Company Board. All profits made that are
worthy of being distributed as dividends, subject to accepted accounting principles and to the provisions of the Companies Law, will be
distributed by the Company to the shareholders, whether as a dividend or by means of the purchase of shares from all shareholders by the
Company or a corporation in its control, and this with their being actually received by the Company, and subject to all applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.3.</TD><TD STYLE="text-align: justify">The Board may delay any dividend, benefit, rights or sums about to be paid for shares in which the Company
has a lien and/or charge, and to use any such amount or to realise any benefit and any right and to use the consideration from such realisation
to pay off the debts for which the Company holds liens or charges.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.4.</TD><TD STYLE="text-align: justify">The transfer of a share shall not entitle the recipient of the share the right to a dividend or to any
other distribution that was decreed after the transfer but before the transfer was registered, however, if the transfer is subject to
the Board&rsquo;s approval, the date of approval shall be used instead of the date the transfer was registered.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.5.</TD><TD STYLE="text-align: justify">In the event of a dividend whose payment is not demanded within seven (7) years from the date of the decision
on its distribution, the person entitled to said payment will be deemed to have ceded same and it shall be returned to the Company&rsquo;s
ownership.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If not deemed otherwise, any dividend
may be paid by cheque or payment order to be sent by mail to the registered address of the Company or individual thereto entitled or,
in the event of registration of joint ownership, to that member whose name in the registry is registered first with respect the joint
ownership. Any such cheque will be written to the order of the person to whom it is sent. The receipt of the person whose name, on the
date of decree of dividend, is listed in the members&rsquo; registry as a shareholder or, in the event of joint ownership, as one of the
joint owners, will serve as release with respect to all the payments made in connection with that given share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.6.</TD><TD STYLE="text-align: justify">The Board is entitled to deduct from any dividend, grant or other distribution to be made in connection
with shares held by a shareholder, whether held solely or jointly with another shareholder, any sum of money due from him which he must
pay by himself or together with another to the Company, against demands for payment or similar.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">28.7.</TD><TD STYLE="text-align: justify">Subject to Article 28.2, the Board may, in its own discretion, set aside in special funds any sum from
the Company&rsquo;s profits, or the revaluation of its assets, or the relative portion of the assets of the companies connected with it,
and to determine the designation of these funds.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>29.</B></TD><TD STYLE="text-align: justify"><B><U>The Internal Auditor</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">29.1.</TD><TD STYLE="text-align: justify">The Company&rsquo;s Board shall appoint an internal auditor, according to the recommendation of the auditing
committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">29.2.</TD><TD STYLE="text-align: justify">The organisational superior of the internal auditor shall be the Chairman of the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">29.3.</TD><TD STYLE="text-align: justify">The internal auditor shall submit, for the approval of the Board, a proposal for an annual, or periodic,
work plan and the Board shall approve same with the amendments it sees fit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">29.4.</TD><TD STYLE="text-align: justify">The internal auditor shall operate in accordance with the provisions of the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>30.</B></TD><TD STYLE="text-align: justify"><B><U>The financial Auditor</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">30.1.</TD><TD STYLE="text-align: justify">A financial auditor shall be appointed in every Annual General Meeting and shall serve in this position
until the end of the following Annual General Meeting. Notwithstanding the above, the General Meeting may, in a majority decision of the
shareholders, appoint a financial auditor for a longer period that shall not exceed the end of the third Annual General Meeting following
the meeting in which he was appointed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">30.2.</TD><TD STYLE="text-align: justify">The General Meeting may terminate the appointment of the financial auditor. The fee of the financial auditor
for auditing activity will be set by the General Meeting and in accordance with Section 165 of the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">30.3.</TD><TD STYLE="text-align: justify">The fee of the accountant for additional services to the Company which are not auditing activities will
be set by the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>31.</B></TD><TD STYLE="text-align: justify"><B><U>Transactions Requiring Special Authorisation</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">31.1.</TD><TD STYLE="text-align: justify">A transaction of the Company with one of its officers and a transaction of the Company with another person
with whom a Company Officer has a personal interest, and which is not an irregular transaction, requires authorisation of the Board alone,
all subject to the fifth chapter of the sixth part of the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">31.2.</TD><TD STYLE="text-align: justify">The Company is not allowed to enter into a transaction with related parties for a period of three years
commencing on the date said related party became a controlling holder in the Company, this unless as a result of the completion of the
transaction the related party becomes a controlling holder holding no less than 75% of the Company&rsquo;s share capital, and all subject
to the fifth chapter of the sixth part of the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For this purpose, &ldquo;Control&rdquo;
as defined in the Securities Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>32.</B></TD><TD STYLE="text-align: justify"><B><U>Merger</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The authorisation of a merger requires
a regular majority of shareholder votes and subject to the provisions of Section 320(A1) of the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>33.</B></TD><TD STYLE="text-align: justify"><B><U>Notices</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">33.1.</TD><TD STYLE="text-align: justify">Subject to the provisions of Article 15.6 of these Articles, a notice on the General Meeting shall be
given only to shareholders registered in the primary registry and entitled to participate in the general assemblies, who have provided
addresses in Israel. Any other person shall not be entitled to receive notices about general assemblies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">33.2.</TD><TD STYLE="text-align: justify">When the Company has grounds to assume that the address provided by a shareholder is no longer his address,
such a shareholder shall be deemed as not having provided an address to the Company, in each of the following cases:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">When the Company sent him to the address he provided a registered letter in which he was requested to
either confirm that the said address is still his address or to notify the Company of a new address, and the Company did not receive a
reply within thirty (30) days of the date the letter was posted by the Company at the post office.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">When the Company posted a registered letter to the address he provided and the Postal Authority, whether
with or without the return of the letter, notified the Company that the letter was not delivered to the given address because he is unknown
at that address or for any other reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">33.3.</TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.7pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Company may deliver any notice and any document to a shareholder by hand delivery or by delivering
via mail to the address provided to the Company. If a notice was sent by mail, the notice shall be deemed fully performed if the letter
containing the notice bore the address provided to the Company and if it was sent with appropriate postage, and as long as the opposite
has not been proved, it shall be deemed delivered within seventy-two (72) hours of posting at the post office by the Company when the
address is in Israel, and when the address is abroad - within ten (10) days from posting at the post office by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.7pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.7pt; text-align: justify; text-indent: -27pt"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.7pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Company may send notices to shareholders whether they are holders of registered shares and whether
they are holders of bearer shares, by publication of the notice at least once in two daily newspapers of broad circulation in the Hebrew
language as set forth in Article 15.6 above, and the date of publication in the newspaper shall be deemed the date the notice was received
by the shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.7pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Nothing in the above paragraphs (a) and (b) shall be deemed as imposing any obligation on the Company
to give a notice to whoever did not provide the Company with an address in Israel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">33.4.</TD><TD STYLE="text-align: justify">The Company may give notice to partners in a share by sending the notice to the partner whose name first
appears in the Shareholders Registry for that share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">33.5.</TD><TD STYLE="text-align: justify">Any and all documents or notices sent by the Company in accordance with the provisions of this article
shall be deemed properly sent despite the death, bankruptcy or liquidation of said shareholder (whether or not the Company knew), as long
as no other was registered as a shareholder in his place, and sending and delivery as set forth above shall for all purposes be deemed
sufficient for all parties interested in those shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">33.6.</TD><TD STYLE="text-align: justify">The unwitting failure to send notice to a shareholder, or the non-receipt of such a notice by a shareholder
shall not derogate from the validity of any resolution accepted in such an assembly.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>34.</B></TD><TD STYLE="text-align: justify"><B><U>Liquidation of the Company</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In the event of liquidation of the
Company, whether willingly or otherwise, the following provisions shall apply, unless specifically set forth otherwise in these Articles
or in the terms under which a given share was issued:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The liquidator shall first use all of the Company&rsquo;s assets for the payment of its debts (the Company&rsquo;s
remaining assets after the payment of its debts shall hereinafter be referred to as the &ldquo;<B>Surplus Assets</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Subject to any special rights attached to shares, the liquidator shall distribute the Surplus Assets <I>pari
passu</I> amongst the shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">With the Company&rsquo;s permission by a resolution that was accepted in the General Meeting by a regular
majority of shareholders&rsquo; votes, the liquidator may distribute the Surplus Assets of the Company, or any portion thereof, in their
original physical form amongst the shareholders, and may also transfer any asset of the Surplus Assets to a trustee in a trust for the
benefit of the shareholders, all as the liquidator deems fit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>35.</B></TD><TD STYLE="text-align: justify"><B><U>Exemption from Liability</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company may, by resolution reached
in the manner set forth in the Companies Law, exempt in advance any of its officers from all or part of their responsibilities due to
breach of their duty of care to it, however, in accordance with Sections 259(b) and 311 of the Companies Law, the Company may not exempt
in advance a Director from its responsibilities to it due to a breach of the duty of care in distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>36.</B></TD><TD STYLE="text-align: justify"><B><U>Liability Insurance</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Subject to the provisions of the Companies
Law, the Company may, by resolution reached in the manner set forth in the Companies Law, obtain liability insurance for an officer of
the Company due to liability he may incur as the result of an action performed in his position as an officer, entirely or partially, in
each of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Breach of duty of care towards the Company or towards another person;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Breach of his duty of trust to the Company, as long as the officer acted in good faith and had a reasonable
basis to presume that his action will not be detrimental to the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">A financial obligation that he will be subject to for the benefit of another person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>37.</B></TD><TD STYLE="text-align: justify"><B><U>Indemnity</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Subject to the provisions of the Companies
Law, the Company may, by resolution reached in the way set forth in the Companies Law, indemnify an officer for a financial obligation
or expense as set forth in paragraphs (a), (b) and (c) below, which the officer made or was subject to due to an action performed in his
position as an officer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">A financial obligation he was subjected to for the benefit of another person by court ruling, including
court rulings made following a compromise or an arbitrator&rsquo;s ruling authorized by a court, as long as the commitment to indemnify
be limited to events that, in the Board&rsquo;s opinion, are expected in light of the Company&rsquo;s actual activities when the commitment
to indemnify was given, and to a sum or to a degree that the Board deemed reasonable under the circumstances, and that in the commitment
to indemnify will be stated those events that in the Board&rsquo;s opinion are to be expected in light of the Company&rsquo;s actual activities
at the time the commitment was made and also the sum or the degree which the Board deemed reasonable under the circumstances;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Reasonable litigation expenses including lawyer&rsquo;s fees, which the officer incurred as a result of
an investigation or a procedure held against him by an authority authorized to conduct such investigation or procedure, and that were
concluded without the filing of an indictment against him but with the imposition of a financial liability instead of criminal procedures
for offences that do not require proof of criminal intent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In this article - the conclusion of
procedures without the filing of an indictment in a matter for which a criminal investigation was opened - means the closing of a case
in accordance with Section 62 of the Criminal Procedure Law (combined version), 1982 (hereinafter in this paragraph: the &ldquo;<B>Criminal
Procedure Law</B>&rdquo;) or stay of procedures by the Attorney General under Section 231 of the Criminal Procedure Law. &ldquo;A financial
liability instead of criminal proceedings&rdquo; - A financial liability imposed by law as an alternative to criminal proceedings, including
an administrative fine under the Administrative Offences Law, 1985, a fine for an offence deemed a finable offence under the provisions
of the Criminal Procedure Law, a financial sanction or a financial penalty;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Reasonable litigation expenses including lawyer&rsquo;s fees, which the officer incurred or that a court
ruled he must pay, in a procedure instigated against him by the Company or in its name or by another person, or in a criminal charge from
which he was found cleared, or in a criminal charge in which he was convicted for a crime that does not require proof of criminal intent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>38.</B></TD><TD STYLE="text-align: justify"><B><U>Binding the Company</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">38.1.</TD><TD STYLE="text-align: justify">The signature of any person who has been appointed by the Board from time to time, either generally or
for a specific case, whether by himself or together with additional persons, together with the Company&rsquo;s seal or stamp will bind
the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">38.2.</TD><TD STYLE="text-align: justify">The Board may determine different signatory rights for different dealings of the Company and set the financial
limitations for which each signatory is authorised to sign.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>39.</B></TD><TD STYLE="text-align: justify"><B><U>Amendment of these Articles of Association</U></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">These Articles of Association may
be amended by resolution the shareholders in the General Meeting, by regular majority of votes of the participating shareholders, and
notwithstanding all of the above in these Articles of Association, the passing of a resolution that constitutes an amendment of a provision
of these Articles of Association, directly or indirectly, will require the resolution of the shareholders in the General Meeting, in a
regular majority of the votes of the participating shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify"></P>

<!-- Field: Page; Sequence: 31; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.55in; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>3
<FILENAME>ea028258601ex2-1.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTERED UNDER SECTION 12 OF THE EXCHANGE
ACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Can-Fite BioPharma Ltd. is
currently authorized to issue 14,000,000 ordinary shares, no par value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NYSE American </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 19, 2013, our
ADSs began trading on the NYSE American under the symbol &ldquo;CANF.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Memorandum and Articles of Association</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our number with the Israeli
Registrar of Companies is 512022153. Our purpose is set forth in Section 3 of our Articles of Association and includes every lawful purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized share capital
is divided into 14,000,000 ordinary shares with no par value. Our ordinary shares that are fully paid for are issued in registered
form and may be freely transferred under our Amended and Restated Articles of Association, unless the transfer is restricted or prohibited
by applicable law or the rules of a stock exchange on which the shares are traded. The ownership or voting of our ordinary shares by non-residents
of Israel is not restricted in any way by our Amended and Restated Articles of Association or the laws of the State of Israel, except
for ownership by nationals of some countries that are, or have been, in a state of war with Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Israeli Companies
Law and our Amended and Restated Articles of Association, our Board of Directors may exercise all powers and take all actions that are
not required under law or under our Amended and Restated Articles of Association to be exercised or taken by our shareholders, including
the power to borrow money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Articles
of Association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies
Law and must be approved by a resolution duly passed by our shareholders at a general or special meeting by voting on such change in the
capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence
of sufficient retained earnings and profits and an issuance of shares for less than their nominal value, require a resolution of our Board
of Directors and court approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may declare a dividend
to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Israeli Companies Law, dividend
distributions are determined by the Board of Directors and do not require the approval of the shareholders of a company unless such company&rsquo;s
articles of association provide otherwise. Our Amended and Restated Articles of Association do not require shareholder approval of a dividend
distribution and provide that dividend distributions may be determined by our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Israeli Companies
Law, we may only distribute dividends from our profits accrued over the previous two years, as defined in the Israeli Companies Law, according
to our then last reviewed or audited financial reports, or we may distribute dividends with court approval. In each case, we are only
permitted to pay a dividend if there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing
and foreseeable obligations as they become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Articles
of Association provide that the maximum number of members of the Board of Directors is 13, plus the number of external directors required
by the Israeli Companies Law. The Board of Directors is presently comprised of six members, of which two are external directors as required
by the Israeli Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2020, a special
general meeting of our shareholders approved an amendment to our Amended and Restated Articles of Association, according to which the
Board of Directors, excluding the External Directors, if any (who shall be elected and serve in office in strict accordance with the provisions
of the Companies Law), shall consist of three classes of directors as nearly equal in number as practicable, which are appointed for fixed
terms of office in accordance with the Israeli Companies Law and our Amended and Restated Articles of Association, as follows: (i) the
term of office of the initial Class I directors shall expire at the first annual general meeting of our shareholders to be held in 2020
and when their successors are elected and qualified, (ii) the term of office of the initial Class II directors shall expire at the first
annual general meeting of our shareholders following the annual general meeting of our shareholders referred to in clause (i) above and
when their successors are elected and qualified, and (iii) the term of office of the initial Class III directors shall expire at the first
annual general meeting of our shareholders following the annual general meeting of our shareholders referred to in clause (ii) above and
when their successors are elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors (other than external
directors), may be elected only in annual general meetings of our shareholders. At each annual general meeting of our shareholders, commencing
with the annual general meeting of our shareholders held in 2020, each of the successors elected to replace the directors of a class whose
term shall have expired at such annual general meeting of our shareholders shall be elected to hold office until the third annual general
meeting of our shareholders next succeeding his or her election and until his or her respective successor shall have been elected and
qualified. Notwithstanding anything to the contrary, each director shall serve until his or her successor is elected and qualified or
until such earlier time as such director&rsquo;s office is vacated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">External directors are elected
for an initial term of three years and may be reelected for up to two additional three-year terms (for a maximum of nine consecutive years
of service). The reappointment of an external director requires approval by the general meeting under specific voting procedures set forth
in the Israeli Companies Law. As a company traded on stock markets outside of Israel, pursuant to the Israeli Companies Regulations (Relief
for Public Companies Traded on Stock Markets Outside of Israel), 5760-2000, we may reappoint an external director for additional three-year
terms if our audit committee and board of directors confirm that such reappointment is in the company&rsquo;s best interest given the director&rsquo;s
expertise and contribution, and such determination is presented to the general meeting for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the number of directors
(excluding external directors) that constitutes the Board of Directors is hereafter changed, the then-serving directors shall be re-designated
to other classes and/or any newly created directorships or decrease in directorships shall be apportioned by the Board of Directors among
the classes so as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of Directors
constituting the Board of Directors shall shorten the term of any incumbent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors so elected may not
be dismissed from office by the shareholders or by a general meeting of our shareholders prior to the expiration of their term of office.
The directors do not receive any benefits upon the expiration of their term of office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The three classes of directors
are Class I Directors, Class II Directors and Class III Directors. Abraham Sartani serves as our Class I Director until the close of the
annual meeting to be held in 2026; Ilan Cohn serves as our Class II Director until the close of the annual meeting to be held in 2024;
and Dr. Pnina Fishman and Mr. Guy Regev serve as our Class III Directors until the close of the annual meeting to be held in 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any amendment, replacement
or suspension of our Amended and Restated Articles of Association regarding the election of directors, as described above, require a majority
of 65% of the voting power represented at the general meeting of our shareholders in person or by proxy and voting thereon, disregarding
abstentions from the count of the voting power present and voting, provided that such majority constitutes more than 20% of our then issued
and outstanding share capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A nominee for service as a
director in a public company may not be elected without submitting a declaration to the company, prior to election, specifying that he
or she has the requisite qualifications to serve as a director, independent director or external director (if required), as applicable,
and the ability to devote the appropriate time to performing his or her duties as such.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director, who ceases to
meet the statutory requirements to serve as a director, external director or independent director, as applicable, must notify the company
to that effect immediately and his or her service as a director will expire upon submission of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shareholder Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Israeli Companies Law,
we are required to hold an annual general meeting of our shareholders once every calendar year that must be no later than 15 months after
the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to as
special meetings. Our Board of Directors may call special meetings whenever it sees fit, at such time and place, within or outside of
Israel, as it may determine. In addition, the Israeli Companies Law and our Amended and Restated Articles of Association provide that
our Board of Directors is required to convene a special meeting upon the written request of (i) any two of our directors or one quarter
of our Board of Directors or (ii) one or more shareholders holding, in the aggregate, either (1) 5% of our outstanding shares and 1% of
our outstanding voting power or (2) 5% of our outstanding voting power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Israeli Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings
are the shareholders of record on a date to be decided by the Board of Directors, which may be between four and forty days prior to the
date of the meeting. Furthermore, the Israeli Companies Law and our Amended and Restated Articles of Association require that resolutions
regarding the following matters must be passed at a general meeting of our shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">amendments to our Amended and Restated Articles of Association;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">appointment or termination of our auditors;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">appointment of directors and appointment and dismissal of
external directors;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">approval of acts and transactions requiring general meeting
approval pursuant to the Israeli Companies Law;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">director compensation, indemnification and change of the
principal executive officer;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">increases or reductions of our authorized share capital;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a merger; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the exercise of our Board of Director&rsquo;s powers by a
general meeting, if our Board of Directors is unable to exercise its powers and the exercise of any of its powers is required for our
proper management.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
requires that a notice of any annual or special shareholders meeting be provided at least 21 days prior to the meeting and if the agenda
of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related
parties, or an approval of a merger, notice must be provided at least 35 days prior to the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
does not allow shareholders of publicly traded companies to approve corporate matters by written consent. Consequently, our Amended and
Restated Articles of Association does not allow shareholders to approve corporate matters by written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our Amended and
Restated Articles of Association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to
a vote before the shareholders at a general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Quorum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The quorum required for our
general meetings of shareholders consists of at least two shareholders present in person, by proxy or written ballot who hold or represent
between them at least 25% of the total outstanding voting rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A meeting adjourned for lack
of a quorum is adjourned to the same day in the following week at the same time and place or on a later date if so specified in the summons
or notice of the meeting. At the reconvened meeting, any number of our shareholders present in person or by proxy shall constitute a lawful
quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Resolutions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Articles
of Association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law provides that
a shareholder of a public company may vote in a meeting and in a class meeting by means of a written ballot in which the shareholder indicates
how he or she votes on resolutions relating to the following matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">an appointment or removal of directors;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">an approval of transactions with office holders or interested
or related parties;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">an approval of a merger or any other matter in respect of
which there is a provision in the articles of association providing that decisions of the general meeting may also be passed by written
ballot;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">authorizing the chairman of the Board of Directors or his
relative to act as our chief executive officer or act with such authority; or authorize our chief executive officer or his relative to
act as the chairman of the Board of Directors or act with such authority; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">other matters which may be prescribed by Israel&rsquo;s Minister
of Justice.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision allowing the
vote by written ballot does not apply where the voting power of the controlling shareholder is sufficient to determine the vote. Our Amended
and Restated Articles of Association provide that our Board of Directors may prevent voting by means of a written ballot and this determination
is required to be stated in the notice convening the general meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that a shareholder, in exercising his or her rights and performing his or her obligations toward the company and its other shareholders,
must act in good faith and in a customary manner, and avoid abusing his or her power. This is required when voting at general meetings
on matters such as changes to the articles of association, increasing our registered capital, mergers and approval of related party transactions.
A shareholder also has a general duty to refrain from depriving any other shareholder of its rights as a shareholder. In addition, any
controlling shareholder, any shareholder who knows that its vote can determine the outcome of a shareholder vote and any shareholder who,
under such company&rsquo;s articles of association, can appoint or prevent the appointment of an office holder, is required to act with
fairness towards the company. The Israeli Companies Law does not describe the substance of this duty except to state that the remedies
generally available upon a breach of contract will also apply to a breach of the duty to act with fairness, and, to the best of our knowledge,
there is no binding case law that addresses this subject directly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, unless provided otherwise in a company&rsquo;s articles of association, a resolution at a shareholders meeting requires approval
by a simple majority of the voting rights represented at the meeting, in person, by proxy or written ballot, and voting on the resolution.
A resolution for the voluntary winding up of the company requires the approval of holders of 75% of the voting rights represented at the
meeting, in person, by proxy or by written ballot and voting on the resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of our liquidation,
after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to
their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution
rights to the holders of a class of shares with preferential rights that may be authorized in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Access to Corporate Records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, all shareholders of a company generally have the right to review minutes of our general meetings, its shareholders register and principal
shareholders register, articles of association, financial statements and any document it is required by law to file publicly with the
Israeli Companies Registrar and the Israel Securities Authority. Any of our shareholders may request access to review any document in
our possession that relates to any action or transaction with a related party, interested party or office holder that requires shareholder
approval under the Israeli Companies Law. We may deny a request to review a document if we determine that the request was not made in
good faith, that the document contains a commercial secret or a patent or that the document&rsquo;s disclosure may otherwise prejudice
our interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Acquisitions under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Full Tender Offer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person wishing to acquire
shares of a public Israeli company and who would as a result hold over 90% of the target company&rsquo;s issued and outstanding share
capital is required by the Israeli Companies Law to make a tender offer to all of our shareholders for the purchase of all of the issued
and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result hold over
90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders
who hold shares of the same class for the purchase of all of the issued and outstanding shares of the same class. If the shareholders
who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, all
of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law (provided that a majority
of the offerees that do not have a personal interest in such tender offer shall have approved the tender offer except that if the total
votes to reject the tender offer represent less than 2% of the company&rsquo;s issued and outstanding share capital, in the aggregate,
approval by a majority of the offerees that do not have a personal interest in such tender offer is not required to complete the tender
offer). However, a shareholder that had its shares so transferred may petition the court within six months from the date of acceptance
of the full tender offer, whether or not such shareholder agreed to the tender or not, to determine whether the tender offer was for less
than fair value and whether the fair value should be paid as determined by the court unless the acquirer stipulated in the tender offer
that a shareholder that accepts the offer may not seek appraisal rights. If the shareholders who did not accept the tender offer hold
5% or more of the issued and outstanding share capital of the company or of the applicable class, the acquirer may not acquire shares
of the company that will increase its holdings to more than 90% of our issued and outstanding share capital or of the applicable class
from shareholders who accepted the tender offer.<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Special Tender Offer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that an acquisition of shares of a public Israeli company must be made by means of a special tender offer if as a result of the
acquisition the purchaser would become a holder of 25% or more of the voting rights in the company, unless one of the exemptions in the
Israeli Companies Law is met. This rule does not apply if there is already another holder of at least 25% of the voting rights in the
company. Similarly, the Israeli Companies Law provides that an acquisition of shares in a public company must be made by means of a tender
offer if as a result of the acquisition the purchaser would become a holder of 45% or more of the voting rights in the company, if there
is no other shareholder of the company who holds 45% or more of the voting rights in the company, unless one of the exemptions in the
Israeli Companies Law is met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A special tender offer must
be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting
power attached to our outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated
only if (i) at least 5% of the voting power attached to our outstanding shares will be acquired by the offeror and (ii) the number of
shares tendered in the offer exceeds the number of shares whose holders objected to the offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a special tender offer
is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling
person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger
with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to
effect such an offer or merger in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Merger</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
permits merger transactions if approved by each party&rsquo;s Board of Directors and, unless certain requirements described under the
Israeli Companies Law are met, a majority of each party&rsquo;s shares voted on the proposed merger at a shareholders&rsquo; meeting called
with at least 35 days&rsquo; prior notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the shareholder
vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares represented at the shareholders
meeting that are held by parties other than the other party to the merger, or by any person who holds 25% or more of the outstanding shares
or the right to appoint 25% or more of the directors of the other party, vote against the merger. If the transaction would have been approved
but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still
approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is
fair and reasonable, taking into account the value of the parties to the merger and the consideration offered to the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the request of a creditor
of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of any of the parties to the merger,
and may further give instructions to secure the rights of creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a merger may
not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed by each party
with the Israeli Registrar of Companies and 30 days have passed from the date the merger was approved by the shareholders of each party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Antitakeover Measures</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain
preferred rights, distributions or other matters and shares having preemptive rights. As of the date hereof, we do not have any authorized
or issued shares other than our ordinary shares. In the future, if we do create and issue a class of shares other than ordinary shares,
such class of shares, depending on the specific rights that may be attached to them, may delay or prevent a takeover or otherwise prevent
our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization of a new class of
shares will require an amendment to our Amended and Restated Articles of Association which requires the prior approval of the holders
of a majority of our shares at a general meeting. In addition, the rules and regulations of the TASE also limit the terms permitted with
respect to a new class of shares and prohibit any such new class of shares from having voting rights. Shareholders voting in such meeting
will be subject to the restrictions provided in the Israeli Companies Law as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Borrowing Powers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law and our Amended and Restated Articles of Association, our Board of Directors may exercise all powers and take all actions that are
not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders or other
corporate bodies, including the power to borrow money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Changes in Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Articles
of Association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies
Law and must be approved by a resolution duly passed by our shareholders at a general meeting by voting on such change in the capital.
In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of
sufficient retained earnings or profits and, in certain circumstances, an issuance of shares for less than their nominal value, require
the approval of both our Board of Directors and an Israeli court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any debt securities
that are registered under Section 12 of the Securities Exchange Act of 1934 (the &ldquo;Securities Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants and Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any warrants
or rights that are registered under Section 12 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any other securities
that are registered under Section 12 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>American Depositary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>Name of the Depositary</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
as Depositary, will register and deliver American Depositary Shares, or ADSs. Each ADS will represent two (2) ordinary shares (or a right
to receive two (2) ordinary shares) deposited with the principal Tel Aviv office of Bank Hapoalim, as custodian for the Depositary. Each
ADS will also represent any other securities, cash or other property which may be held by the Depositary. The Depositary&rsquo;s office
at which our ADSs will be administered is located at the Depositary&rsquo;s principal executive office, at 240 Greenwich Street, New York,
New York, 10286.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The form of the deposit agreement
for our ADSs and the form of American Depositary Receipt that represents an ADS have been incorporated by reference as exhibits in our
most recent Annual Report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Fees and Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify"><B><I>Persons depositing or withdrawing shares or ADS holders must pay:</I></B></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: justify"><B><I>For</I>:</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; width: 48%">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</TD>
    <TD STYLE="text-align: justify; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 2%">&#9679;</TD>
    <TD STYLE="text-align: justify; width: 48%">Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679; </TD>
    <TD STYLE="text-align: justify">Cancellation of ADSs for the purpose of withdrawal, including if the Deposit Agreement terminates</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">$.05 (or less) per ADS</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679; </TD>
    <TD STYLE="text-align: justify">Any cash distribution to ADS holders</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">Distribution of securities distributed to holders of deposited securities which are distributed by the Depositary to ADS holders</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">$.05 (or less) per ADSs per calendar year</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">Depositary services</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Registration or transfer fees</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">Transfer and registration of shares on our share register to or from the name of the Depositary or its agent when you deposit or withdraw shares</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Expenses of the Depositary</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">Cable, telex and facsimile transmissions (when expressly provided in the Deposit Agreement)</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">Converting foreign currency to U.S. dollars</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Taxes and other governmental charges the Depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">As necessary</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Any charges incurred by the Depositary or its agents for servicing the deposited securities</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">As necessary</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Depositary collects its
fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or
from intermediaries acting for them. The Depositary collects fees for making distributions to investors by deducting those fees from the
amounts distributed or by selling a portion of distributable property to pay the fees. The Depositary may collect its annual fee for depositary
services by deduction from cash distributions, by directly billing investors or by charging the book-entry system accounts of participants
acting for them. The Depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Depositary
may make payments to us to reimburse us for expenses and/or share revenue with us from the fees collected from ADS holders, or waive fees
and expenses for services provided, generally relating to costs and expenses arising out of the establishment and maintenance of the ADS
program. In performing its duties under the Deposit Agreement, the Depositary may use brokers, dealers or other service providers that
are affiliates of the Depositary and that may earn or share fees or commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>ea028258601ex12-1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXCHANGE ACT OF 1934 RULES 13A-14(A) AND 15D-14(A),
AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Motti Farbstein, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 20-F of Can-Fite
BioPharma Ltd.;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the
audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 26, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; width: 40%">/s/ Motti Farbstein</TD>
    <TD STYLE="font-size: 10pt; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Motti Farbstein</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">(Principal Executive Officer and Principal Financial Officer)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>ea028258601ex13-1.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT
TO 18 U.S.C. SECTION 1350, AS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to 18 U.S.C. Section
1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Can-Fite BioPharma Ltd. (the &ldquo;Company&rdquo;)
hereby certifies to such officer&rsquo;s knowledge that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) the accompanying Annual
Report on Form 20-F of the Company for the year ended December 31, 2025 (the &ldquo;Report&rdquo;) fully complies with the requirements
of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: March 26, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font-size: 10pt; width: 40%">/s/ Motti Farbstein</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Motti Farbstein</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt">(Principal Executive Officer and Principal Financial Officer)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing certification is being furnished
solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether made before or after
the date hereof, regardless of any general incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>6
<FILENAME>ea028258601ex15-1.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We consent to the incorporation
by reference in the following Registration Statements: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Amendment No. 1 to the Registration Statement (Form F-3 No.
333-276000) of Can-Fite BioPharma Ltd.,</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Registration Statement (Form F-3 No. 333-274316) of Can-Fite
BioPharma Ltd.,</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Registration Statement (Form F-3 No. 333-262055) of Can-Fite
BioPharma Ltd.,</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Registration Statement (Form F-3 No. 333-281872) of Can-Fite
BioPharma Ltd.,</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Registration Statement (Form S-8 No. 333-227753) pertaining
to the 2003 Israeli Share Option Plan and 2013 Global Incentive Option Scheme of Can-Fite BioPharma Ltd.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(6)</TD><TD STYLE="text-align: justify">Registration Statement (Form S-8 No. 333-271384) pertaining
to the 2013 Global Incentive Option Scheme of Can-Fite BioPharma Ltd., and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(7)</TD><TD STYLE="text-align: justify">Registration Statement (Form S-8 No. 333-278525) pertaining
to the 2023 Option Plan of Can-Fite BioPharma Ltd.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">of our report dated March
26, 2026, with respect to the consolidated financial statements of Can-Fite BioPharma Ltd. included in this Annual Report (Form 20-F)
of Can-Fite BioPharma Ltd. for the year ended December 31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Kost Forer Gabbay &amp; Kasierer</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">A Member of EY Global</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Tel-Aviv, Israel</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">March 26, 2026</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ea028258601_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028258601_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %F G # 2(  A$! Q$!_\0
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M%7=]W][)_M[.O^AIC?\ P=_]R/A'_AW1^SI_?^)'_A90?_**C_AW1^SI_?\
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MMFE6KRQ5:--RG''T8WE"6N&;;2E#E_KH_; \-^+?#7[)/_!4+PKJG[,G@/\
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MT+.\%[;VCP3?^TO$I^SPOM%+Z_\ 68_O.7GNL,Y8>WM.2\OA<;-?JKIOPB\
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MFW&#Y&S] OCUI5OH7_!+CX/Z%:/+)::)^U'XYT:T>=@T[VFE>(_BY86S3.
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M^I#IU>S'X/D_U/T_AG_DG</_ (<?_P"G<2?U1W7_ !\W'_7>;_T8U05/=?\
M'S<?]=YO_1C5!6)^1K9>B_)!7[M_\$\_$&C>%?V&/C)XB\1?%O5/@AH6B?M
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MA64,&E.G5Q,*D(5HNDU4E"BIT_:.7.I/XY1?N_JG^S?\#/@[\1OV08['P?\
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M ,J#7R_'_(\=_L_4?^@9J?\ X+KW_P",4?V?J/\ T#-3_P#!=>__ !BO6_\
MAHW]H3_HN?Q:_P#"^\2?_+"C_AHW]H3_ *+G\6O_  OO$G_RPHOB/Y</_P"#
M*W_RH-?+\?\ (\D_L_4?^@9J?_@NO?\ XQ1_9^H_] S4_P#P77O_ ,8KUO\
MX:-_:$_Z+G\6O_"^\2?_ "PH_P"&C?VA/^BY_%K_ ,+[Q)_\L*+XC^7#_P#@
MRM_\J#7R_'_(]._8DL-07]J'X6LVG:BJBX\399]/O%4?\4?KW5F@"C/;)&3Q
M7]"?V2[/2SNS_P!NMQ_\;K\/OV,?C_\ ';4_VF/AC8ZC\9_BC?V4\_B036EY
MXX\0W%M,$\):ZZ>;#+?-&^QU5UW*<.JL.0*_?8?%3XG*<K\1?&RGID>)=6!Q
MZ<7595'B;KW</M_S\K__ "H_,N->7^U,-S.2?U"G;E46K?6,1_-*+O>_2UK:
MG%_8[S_GSO/_  $N/_C='V.\_P"?.\_\!+C_ .-UVW_"UOBC_P!%'\<?^%/J
M_P#\E4?\+6^*/_11_''_ (4^K_\ R547Q/\ +A__  .O_P#*SX^U+^:K_P"
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MJ_\ @-+_ .3..^Q7O_/E>_\ @)<__&J/L5]_SX7_ /X W7_QFNQ_X6A\2_\
MHH7C;_PJ-9_^3*?_ ,+5^)__ $4;QS_X56M__)M%\3_+A_\ P.O_ /*QKV75
MU?\ P&E_\F<7]BOO^?"__P# &Z_^,T?8K[_GPO\ _P  ;K_XS7:?\+5^)_\
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M?8+_ /Z!^H?^ -W_ /&:Z[_A9WQ*_P"BA^./_"JUS_Y.H_X6=\2O^BA^./\
MPJM<_P#DZB^(_EP__@=?_P"5A^Z[U?\ P&G_ /)'(_8-0_Z!^H?^ %W_ /&:
M7^S]1_Z!VH_^ %Y_\9KKA\4/B8IROQ$\<J>F1XKUP'!ZC(OJ=_PM+XG?]%'\
M=_\ A6Z[_P#)U%\3_+A__ Z__P K'^Z[U?\ P&E_\F<?_9^H_P#0.U'_ , +
MS_XS1_9^H_\ 0.U'_P  +S_XS78?\+2^)W_11_'?_A6Z[_\ )U'_  M+XG?]
M%'\=_P#A6Z[_ /)U%\1_+A__  .O_P#*P_<]ZO\ X#2_^3./_L_4?^@=J/\
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M3_\ !=>__&*/[,U/_H%ZG_X+KW_XQ75M\3OB8PPWQ&\>,.N#XO\ $!Y'0_\
M(0IG_"R_B3_T43QW_P"%?X@_^6%%\1_+A_\ P/$?_*Q?NNCJ_P#@-+_Y(Y?^
MS-3_ .@7J?\ X+KW_P",4?V9J?\ T"]3_P#!=>__ !BNH_X67\2?^BB>._\
MPK_$'_RPH_X67\2?^BB>._\ PK_$'_RPHOB/Y</_ .!XC_Y6'[OO5^ZE_P#)
M'+_V9J?_ $"]3_\ !=>__&*4:9JA.!I>J$^@TZ])_P#1%=/_ ,++^)/_ $43
MQW_X5_B#_P"6%*/B7\2@<CXB^/ ?4>+_ ! ".W!&H9%%\1_+A_\ P/$?_*P_
M==ZOW4O_ )(YC^R=6_Z!.J_^"V^_^,4?V3JW_0)U7_P6WW_QBNH_X6=\3/\
MHI'C_P#\++Q'_P#+*C_A9WQ,_P"BD>/_ /PLO$?_ ,LJ+XC^7#_^!XC_ .5C
MM1_FK?\ @-+_ .3.7_LG5O\ H$ZK_P""V^_^,4?V3JW_ $"=5_\ !;??_&*Z
MC_A9WQ,_Z*1X_P#_  LO$?\ \LJ/^%G?$P?\U(\?_P#A9>(__EC1?$_RX?\
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M7OVI/AWX%T[X=Z)J/P$T/2-(M]$G;P=XGU^2)O$UWJ-A<:]:Z=JFHV&LV3W
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M^J.Z_P"/FX_Z[S?^C&J"I[K_ (^;C_KO-_Z,:H*Q/R-;+T7Y(****!A1110
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M!_\ !-XG_P#C5?E=J&F?M9V'["WQ)^+-U>_M$^"_@EXT^!W[#,GAN/\ :/\
MC?<_$C6_'G[2FK?'#X9:AXD^+GPXEL/%?B/Q7X(^$/B7P]>+:WNAW^M:9<:K
M#?I'#HMFT<D4/Z-ZQ^W+\=_AS?\ [3_P/^+_ ,8_!J?&+X<_M/? OX'?!OXF
M_#;]G*PUR;QW=_&7X<7GQ*G\'#X2>(?BCX=\(66JZ38:1K%O8>,/$_Q"TO2(
M;.!;K6$N+@JC#YELU+1Z*UTXM)W5I*R;M)J3Y>TKM0]#%8;BBGS+!9WE683I
MXNKAJU.E@HQJ4U1J8:C5J.%-XV,GAJV(4<92AB)U,/!1J?O/]HIX+MO^':GQ
M$_Z*IX!_\$WB?_XU7S9^U/\ \$8_B]^T#\.=-\$Z#\=/A5X;O+'Q=IOB-[_6
MO#GC6[M)+>QT[5K)[5(M/A:<3R/J,<B.P\L)%(&.XK61>?\ !2G]KF;]FGX(
M_M ZCX@^&7@WX>6/B[]H;PG^TK\3/#'PU\&_$/QAHD'PG^+$GP\\$>/8_@9J
MGQ9T.X'PYUJQMYY?B!JGPQ\0>,KK0==DB@T2:ZL)+5[GW#P3^WK^U9\1?VN_
M$_@[P=X/T35_@KX)_:LTC]G?Q#X/G\*^!] N8?AK>>&-,O9OC7/\1_$GQ8TG
MXACQQJ&HZK9>(_#WPVTGX3:IX=U/PA*UK:ZS=ZK%/+'5IW=NCM=.#LUNM8I-
MKHMFFG>*)I/CW+ZL\=3QV30GELL95G4E'"RI4JV KSPTJ$I5:$*3Q%5RYZ-"
M33=*K0J594U7HI_E+)_P;*_M(3PR(G[5'P$/FJ\*,/!/Q/8%V0@*,6QRP!!*
MCG'.*_831_\ @F)\2M*T/0],F^*W@"1],T;2M*DG30_%2Q3S:9IUM8S2Q!X@
MP1Y("ZJWSHK*KX8&O(?^"D7Q4^)G@WXT_MR:9X2^)7CKPMIWAC_@CMJOQ#\.
M6/AWQ?KVAV7A_P >1_'?6-*3QWHEKIU_;0Z3XN73(H].3Q+91P:PEC&EH+P0
M*(Q]4_L:>-?&WBC]M;]J_P +:YXO\3^(-"T7]F?_ ()^ZOH'A[5_$&IZEH^C
MZUXO^%.J7OB75=)TR\NIK+3=2\3WZQWFNW]K##<:O=(ES?RW$JAZF4I)KFFV
MG&4KN,(I**BW>WE+KHK/Y:YKQ!QIF&34LVQV<Y=5I4,#',:="GD]&C4C'%4\
M!S4W4A+DE)1Q5-.37(G3DXKWHVX3_AVI\1/^BJ> ?_!-XG_^-4?\.U/B)_T5
M3P#_ .";Q/\ _&J\KTS_ (*0_%O7_P!J>Q\'?"KQ;X6^+WP?^(,_[9/AWP;I
M'BKX2:+\)+?0O&/[,_P]\1>)]-M-&\?1?$_7O&WC#2H/%?AV;PKXU\0^,? /
M@C0+NUD;4O#<Y99%M_$?#'_!07]O74/@#X]_:,M_%_@+7_"=AHG['FG^!X?%
MOP'\/_#S1-2^+7Q[^)&AZ#\4?"@CL/%VM>,=6^'O@;2;^+3/#'Q BA@A\2)J
M[:I92W6H:=&I=IW2TWMJXKT^PW=]FEL[-V;7-#"\<25-SQN44'5C@G3AB(0H
MU'4Q\YTJ.'E3EA7.E7C4I58U(U(I+V524'.-.37V%_P[4^(G_15/ /\ X)O$
M_P#\:H_X=J?$3_HJG@'_ ,$WB?\ ^-5Y#\=OVR?V^_@_\=M>_9T\/3_#CXG?
M$3X*?!CX=?%'Q5?Z1\*?!GA+PA\>];^(/CG7(]0TI]0^(OQO\(77P;\ ^$O"
M5E!X6LO$WA(?$/7;[QC93:CK]K907BV-;'A+_@H!^UOXS_:C\>Z+H'PVTW4O
MA#\.OVFM=^ WBSX5OX=\!:7J^A>!]%\&?VM)\0Y?BCJ_Q7L/B!JWQ(N-?>TN
MM.\ :'\(;_PQK?A2Z\S1M6O;V)Y547*24HZIJ+3O%7C)<R>L4[V>B:6F[B]#
M)4^-)8?ZU#,,CG0>"6/C-5,)'FP]24EA6HU:5*<7C(Q<L,ZD:<'=4JTZ-=^R
M7I(_X)H_$@HT@^*/@0QH0KR#1/%!16;[JLPBVJ6P< D$]J9_P[4^(G_15/ /
M_@F\3_\ QJOES]D3]H?XQ_M(_ME_\$]OC!\5?C)\+?%T_P 6_P!E[]K#QQ;_
M  G^%.FW'AA_@Y9S:KX=M+3P+\0K"/Q3K2>*]:T?[$L-IXCU_2M#URVU2WUV
MT6SD@"3IZ'\>?^"AW[3OP<_:'^,7P4C'@:]MO@+\8[#XV^.M0N?!5N)[O_@G
MS>>'?AG<RP6;)J"+;^.;3Q'XS\0Z>?'"+)*8O#,\<MEYRR9(\TG9-7U?1+24
MH-7<%=W@_LI:JUU[STJT.,HX_P#LRCF&65L93R]8_$Q>'A1ITDLQQV65:5*I
M6P\)5_98K!TZ3JJE3A4GC<+['VM*I&O+V,?\$T/B04\P?%'P(8]XCWC0_%)3
M>1D)N$6W>1R%SDCD"C_AVA\2-C2?\+1\";$8([_V)XHV*[9PC-Y6%8X.%)!.
M#@5\->)_VJOVCO&^E>)OCX_B'P_X0\>^+_\ @EY^V7\>/A7XAT'P]JUIJ/A/
MX9:'^T0UA\)[.UT>'Q/!X>N/$5Q\.;2VU.3QK?:%<:]:ZWJEMK,%Q]CLDTN;
MTCQ!XK_:;N_C#^QAKOP\_:D\ ^*/B7;_ /!-S]H_XFZ[\4]5\ V?BCPCJ5EH
M+?#WQ5#X;OOAUX>\;IX=U?QS8+]B\+:KXRUC5Y-342ZMKMQI4.IW:V**4G%)
MN4=>=K73]WNKJ#UOHWHD[^[+E:-GAN*:=E6SK*J,O9XGG4L"YPIU\+@ZV*J0
ME6I8>I35%3HO#.J_WOM5-T\+5A3DSZ<7_@FE\1W;:GQ2\!NQSA5T3Q0S'')X
M$1/ ZT__ (=F_$LEE'Q.\#%E ++_ &%XJRH.<%AY.0#@X)ZX.*X_]J/]HGXF
M?&#_ ((Y_"G]H[2;S4_ WQ+^-.E_LH>(-2B^&WC#6O %PFH_$'XF>$-+\0>'
M_#_C#3;I=9\-:9XA6[NM--ZEQ.VG6>H$RB[CMRLGGGCKP!=:)\:_V$_@)\>/
M'?QO_98\ >*?#'[:?BKQYI"?M[^.?$^LIJGAV#P-J'@G5M7_ &B;O4/"T^O0
MV3R7%[H?AK5[:?3]!6:ZTV&VN()YUD'.RDW)^ZJC:44W^[MS62:;U=DDM7U5
MU?DPU7B*K2J2Q.<8/#5J..SW!5<+3RJGC:Z?#]!UL=4HTZ&(I5<4I37L:,</
M0DG)J52K3YZ<)^X+_P $T?B.[;$^*7@-GY^5=$\4,W')^41$\ $GCC%)_P .
MU/B+G'_"U/ .<XQ_8OB?.?3'E=:_.WQ9^V%\4_B'^QQ^SG\#-:^-WQUO-?\
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M_@NWL]5C=;ZUC\)S:;ITGAT03QG2&T^R^Q&(6T(3M]-_;%_8XT;PWK_@W2/
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MBT/3KF>:WT6W>2UL5BB)!_SL+K_CVN/^N$W_ *+:OZJ/"7_(H^$/^Q2\+_\
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MIVHR^/'\07.OV4UIIT0L(KZ.X>:WLU6VCQ%A*_.G]JW_ )-I^-__ &(.H_\
MI58U^&_[+G_)R'P1_P"RB:'_ #FJU"Z;YI)KL^ROKHV_2]OS/L,E\/\ )<QR
M[-<QQ.-XA>+H4\1056&>XR+J45@JF)=&O)J=2M1E5NYTIU94IJ4E*DW)R?\
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M@9XY\/\ P?TVQ\#^+9K_ $/Q/\'_ (N^,?"OBW_A$_$5Y-8:W-\3/@G8ZO\
M$+PYXBTK3-,@T77HI8]%D^J_AWX+_8TM;K]C;XY>)/A[\%[[PW^W)\5?@[#K
MGPZ\316.F^!_@UX:_9?\*Z[X9_:TL86OYM/@\*^'_C5\<[?PFUG?>;:L?">H
M:QI]M-!,9H+'?$9K##U:U%X:O4E2DXQ=-PDJLEAYXJR]UJ%Z-&NXJ<^>])J5
M./M*+JCE9M6>GXZ7_P _ZL?@O6GJNB:UH3:<FN:/JNBOK&C:9XCTA-6T^[TY
MM5\.ZU$T^C:_IJW<4)OM$U>!&FTO5;42V-_$K26L\J*2/V;^%;_ ?XP?!SX7
M_%=/A9^QSH_[5^K_  N_;,\/?#SX5W^E^ OA[\)?$/CSP/XT^!5Q\&G^(GP[
MUW7]*\"7WC2P^&'BSXT_\*^U7XD7>D:7\1=>\/:/'JDVOZOI-O%/T/[5_C[X
M7^$/!/Q0\52?#W]D3QE\9]!_9X_X)H?"KPUI&DP>"_BUX*^$][J/PU^-]M^T
M#8_!KPY::]JGAFXO_#VI:;H6EZK!!_;N@_#_ %VZTT:?';O;>&KN.?[5FZ\:
M"P=7G]I.E-2JP34U4A2C*#]ER2H<TI.6(;4'RNG"#J)MG-K:W5I_+Y;>?D?A
MA17]"DGP^_9"/Q%\,6OB_P %?L@:?^SE_P -.?L6Z9^R'XD\%^(/ 3>.?B]\
M']9U>T3]H>+]H_4-.\577C:_\.GP5Y]_\2]7^-.F>&K_ ,'_ !#%IH_AF2VL
M[B]M4\G^%WCW]FWXDVG[+FG^-/@1^Q5X7C^-WC7]N/X<?&BYL/!'AGPQJO@[
MX:_##P1:ZC^SI=6.I'Q! ?ASXH77==O%TWXL""P\6_$NYTG3K35=7UU-/:W>
M5G'-'GC@<3**BY3?/27*E"I5Y4G33G4C"E4C5IQ2=+$1^K2E*H^<.;^Z_P"E
M?^O/0_$.BOV(_: T3]F31_V'O!EW\*_@MX'\4V^N?!']FN^TOX^:5\0_@#IO
MQ#\&_'JYATFZ^.MIXV\*6NIQ?M+>)-5U+Q"_C3P9KG@?Q/HD_@/PY8#PSXF\
M+26&DZ;:7-W^.]>AA,4L7"I-4JE%0K5*/+5<.:7LVXN3C%MPNT[PFE.+M?F4
MHR;3O?I9M?<%%%%=0PHHHH ^JOV(_P#DZ+X6?]?'B;_U#]>K^A:OYZ?V(_\
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MI@\Z7_GK)_WVW^-'G2_\]9/^^V_QHU\OQ_R#_7S%?]"W#?\ A1B/_D#^9_\
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M---(_AH)'%%&K22R.0B(K.Q"@FO]+E;BX3.V>9<]=LKC/UPPIWVNZ/6YN/\
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MA%[K:DJCE%RC!RE^,/\ PJ#XN?\ 1*_B1_X0_B;_ .5E'_"H/BY_T2OXD?\
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MO"I>6>?P5XDBBB0 DO([Z:%50 222  .:_IE\Z7_ )ZR?]]M_C1YTPZ2R?\
M?;?XT]?+\?\ (\+_ %\Q7_0MPW_A1B/_ )6?RMD$,RL"KHS(Z,"KHZG#(Z,
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M% $?DP^:9_*C\\C:9O+7S2N,;3)C>1CC&<8XJ2BB@ HHHH **** /JK]B/\
MY.B^%G_7QXF_]0_7J_H7#.C+)$YCEC=)8I!UCEC8/%(/='56&>,CGBOYZ/V(
M_P#DZ+X6?]?'B;_U#]>K^A:LI[KT_5GYAQM_R-,-_P!B^G_ZD8@_H(_9]_:6
M\"?&3PCHWGZ]I.C>/K+3[6T\3^%]3OK?3[PZE;1+!/J6D+=R1#4]+U%T-W#)
M:-++;F5[>ZCBDB);Z/\ MMA_T$-._P#!A9__ !^OY9F56QN4$@Y!(!(/J#U!
M^E+@>_YG_&H^?]?>?B6)X%P]6O4J8?'5,/2G*4XT98>-94^9N3A":JTVX1;:
M@I1YHQM%RERIO^IC[;8?]!#3O_!A9_\ Q^C[;8?]!#3O_!A9_P#Q^OY9\#W_
M #/^-&![_F?\:->_X?\ !,/]0E_T-'_X1K_YI/ZF/MMA_P!!#3O_  86?_Q^
MC[;8?]!#3O\ P86?_P ?K^6? ]_S/^-&![_F?\:->_X?\$/]0E_T-'_X1K_Y
MI/ZF/MMA_P!!#3O_  86?_Q^C[;8?]!#3O\ P86?_P ?K^6? ]_S/^-&![_F
M?\:->_X?\$/]0E_T-'_X1K_YI/ZF/MMA_P!!#3O_  86?_Q^C[;8?]!#3O\
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M=RE"FY2E.=N>I4J-2J5)<MHIR:248KEC&,8J]FV4444'>%%%% 'S_P#M6_\
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MX,_\(72O_CM'_#??[2G_ $'/!G_A"Z5_\=HU[+[_ /@&'^I.<_S8#_PIE_\
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M /PQ\:2?LF1?#S]F7X.>-?V?M8\1Z;\7_@5I?B9_%W[06M^"/$GB-O@7XO\
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MXA^(6DV\>J:W92Z;)X;T9UOIKG68].L[Y3Y6F7%[/^ZIW_#??[2G_0<\&?\
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M3U;QSXMN_"WQ(U^T\&>.]5\.71L9_'-AX[CAL?B-IMQ<6::OJ%QF1?(?'O[
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M_D3NO^%2_%3_ *)MX[_\)36__D*C_A4OQ4_Z)MX[_P#"4UO_ .0JX3[3<_\
M/U=?^!,__P <H^TW/_/U=?\ @3/_ /'*+8C^;#_^"ZW_ ,M#]UVK?^!4O_D#
MN_\ A4OQ4_Z)MX[_ /"4UO\ ^0J/^%2_%3_HFWCO_P )36__ )"KA/M-S_S]
M77_@3/\ _'*/M-S_ ,_5U_X$S_\ QRBV(_FP_P#X+K?_ "T/W7:M_P"!4O\
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ML/R6/LK+2KLOM4NR_N'>?\*E^*G_ $3;QS_X3&K_ /R+1_PJ7XJ?]$V\<_\
MA,:O_P#(M<'Y]Q_S\W/_ ($3?_'*//N/^?FY_P# B;_XY1;$?S8?_P %UO\
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MO_@5+_Y [I?A3\4&(5?AUXU)/  \-ZIS_P"2U2?\*D^*G_1./&W_ (3>I_\
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M_%5G;$?S8?\ \%UO_EI^>WI_RU/_  .G_P#*SN_^%4?%#_HG?C/_ ,)[4O\
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M\5C_ ,TY\8_^".[_ /B*/^%0?%;_ *)SXQ_\$=W_ /$5YYO?_GI)_P!_'_\
MBJ-[_P#/23_OX_\ \56=L3_/A_\ P76_^6GP-Z7\M3_P.G_\@>A_\*@^*W_1
M.?&/_@CN_P#XBC_A4'Q6_P"B<^,?_!'=_P#Q%>>;W_YZ2?\ ?Q__ (JC>_\
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M?WW_ .^V_P :+8G^?#_^"J__ ,N"]'^6K_X'2_\ E1Z)_P *@^*O_1.O%_\
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MHH **** "BBB@#\L/^"G_P#R!O@K_P!A?QU_Z0>'*_++P7_R.O@K_L<O"?\
MZD.G5^IO_!3_ /Y WP5_["_CK_T@\.5^67@O_D=?!7_8Y>$__4ATZMH_!\G^
MI^M\,_\ ).X?_#C_ /T[B3^J.Z_X^;C_ *[S?^C&J"I[K_CYN/\ KO-_Z,:H
M*Q/R-;+T7Y(****!A1110 4444 %%%% !1110 5^?_\ P4C_ .2">'_^RH:!
M_P"F+Q-7Z 5^?_\ P4C_ .2">'_^RH:!_P"F+Q-51^)>O^9Z^0?\CO*_^PRG
M_P"D5S\.+K_CVN/^N$W_ *+:OZJ/"7_(H^$/^Q2\+_\ IAT^OY5[K_CVN/\
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M-E__ (!B?_EY_/Q_PQO^TU_T2?5?_!WX4_\ E]1_PQO^TU_T2?5?_!WX4_\
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M_P#@[\*?_+ZC_AC?]IK_ *)/JO\ X._"G_R^K^@>BC7R_'_,/]><U_Z!LO\
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MK.+QTL#0P4*\JN(G-8+'8V%1NEBJE&,,13R_$PP<75E4Q<E3=%*-6G%_'O\
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M*#:LFX3A./,DE))225[(K\XO^"F/_))/AS_V4N3_ -1/6J_1VOSB_P""F/\
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M'GFDTI-,LC]!=3_X*)_$'Q+\2?COXS\9_"3X4>(_ _Q^C^%T&N?!*PU#XH>
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MJ_\ ?(_PHV)_=7_OD?X4!_J'@_\ H8XO_P $87_,_I)_X7W\#?\ HL7PT_\
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MFSTJ;4+2.)[>:=6_*K8G]U?^^1_A7Y__ /!2-$_X4)H VKC_ (6AH'&T8_Y
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MZU"77?#YL8+;0M0T^U00U%J?[/O_  36UC4/#NH:C<_"^<^%=*^!FAZ1IO\
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MX<^.? 7CW5/ O[5OQ:^!.O?&^[\2^*/!O@/1O#WP<^%&K_$OX@ZEXM\$>(/
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MQ\&C]G_XZ$ CX/\ Q$(/0_\ ",:B/T,0/YBE_P"&?OCK_P!$?^(G_A,:A_\
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M71=.-:CA<31Q>)IT,-5IU7\9?\,S?M#_ /1%_B!_X)3_ /'J</V9?VAR,_\
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M13A^S%^T2W3X,>/OQTE!_.Y%?H/\5/\ @IC\-OA+JGQ!T?6_A;\0M7U+P5\
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M/ _P_P#@QK/A&Y@E\/\ @;PQ9^(_%/P[BLY-!NO#'B/1-8TOXF>)/&NL^)=
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M_&/B.W\4:GH7AJ[T;PCHYU>ZLKZSLK/1-9^((\9ZGI.D6D.G6UQY629_CO\
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MQ3I9M"CEM6O/"4:E6C@U6HXN=&C%8BC2Y*]7+L%[9U(5)N&&A"G4I1G7]O\
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MB@ HHHH *_.+_@IC_P DD^'/_92Y/_43UJOT=K\XO^"F/_))/AS_ -E+D_\
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M_FXJ4?'_ .!;=/C!\.S_ -S1IH_G+7\W.Q/[J_\ ?(_PHV)_=7_OD?X4?/\
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M$\;>*;JVO-16Y\16VH7]Q.B^TZY_P35^$$WAKQEX)\&?M$:9X9\(Z_\ "_\
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M5_ZJJA_2111161^?A1110 4444 %%%% !1110 4444 %?G%_P4Q_Y))\.?\
MLI<G_J)ZU7Z.U^<7_!3'_DDGPY_[*7)_ZB>M54?B7K_F>UP[_P CS+/^PA_^
MF,2?C/IZ6$M_8QZI<W5EIDEW;)J5Y8V<>H7MI8/,BW=S9Z?-=6$5]=00&26W
MLY;ZRCN956%[NW5S*OMLGAW]F1?]7\7_ (T2\XP?@-X6B^7GYB6^-[#/3Y1G
MKUXY\'H4,Z32I'+)%;DBXFCAEDAMRJAF%Q,B-'"54AF\UDVJ0QPIS53@YM-5
M:E.VEJ;@D[OKS4YZ]%9KT;/V8]S_ .$?_9J_Z*S\9_\ PQGA3_Y]E3_\(]^S
M#QGXN_&[.!G_ (L-X0Z]\?\ %].F>E>%K:W;H)4LKYXBN]9DLKMX63&?,69(
M3&T9'S"16*%?F#8YJ*-7F\TPQ33B @3M!#+,D!(# 3O$CK#E2&_>E/E(;[IS
M4>R?_01B/_ Z7_RC_(/O/=7T#]F8'"?%CXVR#')_X47X-3!R>,-\<^>,'(]:
M8-!_9HR,_%3XVXR,X^!O@O.,\X_XOIUQT'<]Q7AG.SS=DGD^:(//\N3[/YY.
M!#Y^WR?.)(41;_,+<;<\4@),1N DAMA)Y+7(BD-JLN_R_*:Y"^0)/,_=E#(&
M\SY,;^*?L9?]!&(_\#I?_,__  ?(/O\ Z^1[W_PC_P"S!_T5CXZ?^&'\#_\
MS^JA;0_V90Q"_%#XZ.HZ-_PH[P*F1_NGX\$CTP2:\+HI>QE_T$8C_P #I?\
MS.'S?]?(]S71/V921O\ B?\ '95YR4^!W@-F''&%;X\JIR<#EAQDU+_8?[+W
M_14_C]_X8GX??_/_ *\'HI^QE_T$8C_P.G_\SA\W_7R/<3HW[,N?^2D_'T^_
M_"DOAT,^^/\ A?O&?2G)HW[,1/[SXE?']5QU3X(?#AVSVX;X_H,>IW9'8&O#
M**/8O_H(Q/\ X,I__,X??]__  #WC^Q?V7?^BF?M"?\ AC/AK_\ 1!U#_9'[
M,?\ T4/]H3_PROPQ_P#H@J\-HI>Q?_01B?\ P93_ /F<+>;_ *^1[JFD?LO8
M/F?$/]HDG(V^7\%OA<HQCG.[X_ODYZ8QQUI7TG]ET#]W\0?VBF;(X?X-?"U1
MCG/*_'ISGI@;>>>17A-%'L7_ -!&)_\ !E/_ .9P^;_#_(]Q_LK]F3_H?OVA
M?_#/?"__ .?M4R:5^RWM'F>/OVC-_.=GP@^%87KQ@-\<F/3KSUZ5X111[%_]
M!&)_\&07_NN&O?\ +_(_13]C73?V;4_:7^&+:-XU^/MU?B?Q+Y,6K?"WX:6-
MDQ_X1+7 WFW-E\8M1N$ C+LNRTES(J(P5&9U_>_[)\)/^AA^)O\ X1?A'_YO
MJ_FF_8C_ .3HOA9_U\>)O_4/UZOZ%JSG1::_?XAZ=:D.[_ZAT?F/&KMFF&O&
M,O\ 8*;O)-O_ 'C$*RM."M\M[ZGHOV3X0=_$'Q2S[>#O!N/PSX\SCTSS33:_
M"+/RZ]\42/?PAX.4Y^@\<M^>?PKSRBH]B_\ G_B/_!D/_E!\C[1?\^J7_@$O
M_EIZ%]E^$?\ T'?BA_X2/@[_ .;>I/LWP>_Z#GQ4_P#"4\&?_-K7G-%'L7_S
M_P 1_P"#(_\ RABYU_S[I?\ @,O_ ):CT-K;X19^76OBB1ZMX7\'*<]^!XQ8
M?K0+;X19&[6?BCCOM\,>#<_AGQ>1^8KSRBCV3_Y_XC_P9#\_8!SK_GW2_P#
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M(?BZ3GG=>> UX]L::^3GZ4W=\'O^??XM_P#@?X%_^5=>>44>Q_Z?8G_P>_\
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M,;U!++G(^\!U'K3Z_<_XD^$O#GQW_9L\,_"7PQ\*_$NG:Q\"_P#@EO\ !_\
M:=^$7P]^'7B7Q9XHG\4_%SQ;\=+#P=\0_%DO@:RL[^X\::A;^#M4\8:QKNI:
M?'?7=_%J$6I7\S:=X9TKR>4U_P#9-_9P^ =O>#XP_ 'XB^-?%9^*7_!.7X0W
M'@K5/C!XK^&R^$-6_:?_ &9+KXJ?&?4-;ET+2KW5KG7[+Q;;&7P?H3O:V>@[
MI-,U%+ZPMGM)"&<46N6=*JJSJ3A&A!TIU'%.?)4NZM.*C.$')R=H1E>FISE%
MW.9?/M_3_P"!T/Q;I-PSMSSC./;D _C@X]<'T-?LM\2OV0?@[^SU<Z1IH_9W
M^)/[2.BWO[5?QW^&'COXVW?C?QYX<\"_ 7PA\$_VF++X3:7X1\:Z7\.='?P_
M:^(=>\ )#XW\7:S\1M:T6.:P\7Z1-X;M+"RM'N;GUSQ-^RE\./%?Q@^(OPCN
MOA3\1O@M\,U_X*9_&[P+H/P"\/\ B?Q)I5KX^T/X7?LU_%GQ_P##O2_ 4OQ
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M_P (]\(X',)\0_V]XFFMQ\IN5T'^S;*.\)P-XMWU,V(4L0AE1PF6$F'MW?\
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M['+PG_ZD.G5^IO\ P4__ .0-\%?^POXZ_P#2#PY7Y9>"_P#D=?!7_8Y>$_\
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M(NC3WTFFQ7IU+2+[22&OHK:\>#R1?&<%;:7>8A&0H<NOW]_P]"U3_HBFE?\
MA=WW_P S%%%)Q3W1YF-R?+<QJQK8S"JO5A35*,G4K0M34I34;4ZL(_%.3NTW
MK:]DDC_AZ%JG_1%-*_\ "[OO_F8H_P"'H6J?]$4TK_PN[[_YF***7)'M^+./
M_5C(O^A?'_P?BO\ YH#_ (>A:I_T132O_"[OO_F8H_X>A:I_T132O_"[OO\
MYF***.2/;\6'^K&1?]"^/_@_%?\ S0'_  ]"U3_HBFE?^%W??_,Q1_P]"U3_
M *(II7_A=WW_ ,S%%%')'M^+#_5C(O\ H7Q_\'XK_P": _X>A:I_T132O_"[
MOO\ YF*/^'H6J?\ 1%-*_P#"[OO_ )F***.2/;\6'^K&1?\ 0OC_ .#\5_\
M- ?\/0M4_P"B*:5_X7=]_P#,Q1_P]"U3_HBFE?\ A=WW_P S%%%')'M^+#_5
MC(O^A?'_ ,'XK_YH#_AZ%JG_ $132O\ PN[[_P"9BC_AZ%JG_1%-*_\ "[OO
M_F8HHHY(]OQ8?ZL9%_T+X_\ @_%?_-!\P?M,?M4W?[2-GX,M+GP/:>#QX.N]
M;NDDM=?N-;.H'6H-.@9'6?2]-%L+8:>&5E,QE,Q!"; 6^8-&U Z1K.C:PL(N
M&T?6-*U=;=G,:W#:7J%O?BW:0*YC6<VXB,@1S&'+A'*[244TDE;H>MAL)A\'
MAXX7#4U2P\%44::E.22JN4I^].4IOF<Y/63M?2R2M^H,O_!475))))#\$]*!
MD=WQ_P )Y?G&]BV,_P#",<XSC-,_X>A:I_T132O_  N[[_YF***7)'M^+/)_
MU7R+_H7Q_P#!^*_^: _X>A:I_P!$4TK_ ,+N^_\ F8H_X>A:I_T132O_  N[
M[_YF***.2/;\6'^K&1?]"^/_ (/Q7_S0'_#T+5/^B*:5_P"%W??_ #,4?\/0
MM4_Z(II7_A=WW_S,444<D>WXL/\ 5C(O^A?'_P 'XK_YH#_AZ%JG_1%-*_\
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M2<ZL.5U(Q4W^ZJ4[W4(KWKVMI:[O?_X>A:I_T132O_"[OO\ YF*/^'H6J?\
M1%-*_P#"[OO_ )F***7)'M^+/._U8R+_ *%\?_!^*_\ F@/^'H6J?]$4TK_P
MN[[_ .9BC_AZ%JG_ $132O\ PN[[_P"9BBBCDCV_%A_JQD7_ $+X_P#@_%?_
M #0'_#T+5/\ HBFE?^%W??\ S,4?\/0M4_Z(II7_ (7=]_\ ,Q111R1[?BP_
MU8R+_H7Q_P#!^*_^: _X>A:I_P!$4TK_ ,+N^_\ F8H_X>A:I_T132O_  N[
M[_YF***.2/;\6'^K&1?]"^/_ (/Q7_S0'_#T+5/^B*:5_P"%W??_ #,4?\/0
MM4_Z(II7_A=WW_S,444<D>WXL/\ 5C(O^A?'_P 'XK_YH#_AZ%JG_1%-*_\
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5$G&7+*-^6=:47I.2M*+6NUTK?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ea028258601_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028258601_img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %[ 08# 2(  A$! Q$!_\0
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MN5N+J1BES)-V^*[UM;RW1^@/_"/:ST'CWQ-]/*\'_P#S-5#_ ,(MKDW)\?\
MBWCIFS\&GTZ_\4UCC Q^'I7YC^$/B%JN@ZQX?G^T76M7!\>?'B]LS=W>L-]@
M_L+1?^0+A@P&0.<@@9..U9ND_'SQ]%XBUGXF:K?Z+J5Q;?!3^V](\)^'KS6#
MIEA_Q.PQ&N;PV?$#9VX'13A=N..6/C-A]'B\IFH:<KY)M63WORZZ+97V.F7
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M?_Z*)XM_\!= _P#F>KT6BO?.$\Z_X1+7_P#HHGBW_P != _^9ZC_ (1+7_\
MHHGBW_P%T#_YGJ]%HH \Z_X1+7_^BB>+?_ 70/\ YGJ/^$2U_P#Z*)XM_P#
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M .BZ* ,__FJ%S_V(>F?^GK7Z]&KSG_FJ%S_V(>F?^GK7Z]&H **** "BBB@
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MJP:/X.%QXHV^%K.\/A'1/[3_ +,<I_;>LZ[EC@O_ &,FT=]R8SN&=F;]G/\
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M7\2^)=9T;5=8\"C43?:HWC95&L%O$*R+KW!.YMI ^Z.2&K^C7X9_L]VWP_\
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M?#^%SV..#U&:_L.^#OQ!T/XJ_##P3X]T _\ $I\9>'-+UNQ88 ,>LZ0KQYX
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MT6OO).^B_(QP^9K%-^\O=;5^9;J^E[_-M'XY?L<?L[_%3X;?M/\ C#XJ>/\
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MV"M5_P#1= &-\/O^10\+_P#8NZ;_ .BZ*/A]_P BAX7_ .Q=TW_T710!G_\
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M!)QGG\OBGX?SZ[-\5//F\1?"\V'B$:JO_"0^'PI\;_$DZ$"?['D&]3H*>$B
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M^^%M]\5)=2\(VN@:G?67@<:KJOV#3V,?A_D(3Y>]20Q7.P,<$$8%?8/_  5
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M!?\ PEOBE,AM:8#Q(#G<""N?X0.&)6@-.NW7TZ_@=K^V-XN_9VO/V;OBA/\
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M14LQ5L*>,M7N7P@_9R^$GP,U/Q9JWPU\*)X:OO'-IX6L_$EX+QI#?KX!T-?
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M:?\ T>;XH_\  WQ7_P#'?8_E2_\ #DW]M/\ Z/-\4?\ @;XK_P#CGL?R-/\
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M_'/QUX6.A>!OBCK&I69UBRT@C5/#_P#;FNHW]M>-V'(!P <$GGU.:]]^(?\
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M4-"^!'A6?XLZM:9L;SQ9=WI\._#70ONA&.NL!_;YP&W#PHKD_*0_RX(!W*_
M[Q7K,IG\;_';XH>(UP/M5IX?N](\$:;[;H] 5=H'INSCTXKYU_:L\"?\*)^
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M6_[!6J_^BZW:PM>_Y VK?]@K5?\ T70!C?#[_D4/"_\ V+NF_P#HNBCX??\
M(H>%_P#L7=-_]%T4 9__ #5"Y_[$/3/_ $]:_7HU><_\U0N?^Q#TS_T]:_7H
MU !1110 4444 %%%% !117EWCSXA>#_AOI0USQQXCM?#6C_:_L1N]5Z7QP.
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M%IMG8V=KI]CI5C;:;IVE?Z#9VEI9?V;IEA@GGD<?X?K7AA\B*W@_X]K<V?\
MRZ?\@S3]+YY/Y>F.GX;&FP^GX_\ US^?3ZCTKIR_:6*?FK/YVT=SGQ/7Y_J=
MAIL/I^/_ -<_GT^H]*["SL_\_GGG\_T.*Q]-A]/Q_P#KG\^GU'I7<6=G_G\\
M\_G^AQ7!BL3J_-M_>_+Y?@!7^Q^W_CU<_>6??Z#^6.?RS^)Q7<?9/^FWZ_\
MUZQ[RS[_ $'\L<_EG\3BN;#8GO\ ?^'7]//38Z'A[)M+9-[>7I^IYOJ4/K^'
M_P!8_EU^I]*\G\8>%=#\8:7_ &'XJTJVUO1[K_G[/_'@>>?[<_YE_P 1<<_U
M%>X:E#Z_A_\ 6/Y=?J?2O-]2A]?P_P#K'\NOU/I7O8>SCI9Z>3Z*VFIP:W.=
M^&?Q:\2_!G6-(\ _%/5CXE^&^J79T7P%\5M5VC5-!U3 _P"*+^*>X$;ASL\4
MMA"2 Y ^9?:_BIX(U?PKXE7XZ?#72WO/$^F6@_X3WP79F2,_$GP1&L;J (T
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MHNOZ"/Z=>^?85Y?\)?@G\:?C-XGM]<T/PK<^$M'TO1S97FK>(;3^S3J&E_\
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MG^T!X])!L+KQUX7^'UH6Z;? >BA7Z<@_\)#KS8]^#P,'OP[E9.6[5W?OI?\
M&Y[+?,W*W+S-RY?Y>9M\O_;M[?(^I****Z!!1110 4444 %86O?\@;5O^P5J
MO_HNMVL+7O\ D#:M_P!@K5?_ $70!C?#[_D4/"__ &+NF_\ HNBCX??\BAX7
M_P"Q=TW_ -%T4 9__-4+G_L0],_]/6OUZ-7G/_-4+G_L0],_]/6OUZ-0 444
M4 %%%% !1110 5\H_M$13^%-1^'7QIM^+;X9^(A:>+@%7YO GC<+H/B"0NO+
M'PJ)(O$@5@"%A)4X-?5U<EK&DZ=K^EWND:E9+J6D:K9O8:K9W0^6^TW6,HP
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M ('+:SKSQKH1VZ&?"_C1F)\N3:X4E2I^A?C-\,8/CE\(/B!\';[Q'=>$M/\
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MZY_6O/OB5J>IV.DV'A?PO")_'WQ$U<^#/"-M>6@4+J6N#.O:V23@#PB,DG.
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M;5O^P5JO_HN@#&^'W_(H>%_^Q=TW_P!%T4?#[_D4/"__ &+NF_\ HNB@#/\
M^:H7/_8AZ9_Z>M?KT:O.?^:H7/\ V(>F?^GK7Z]&H *K^?[?I_\ 7JQ7D?Q;
MO+ZS^%GQ&U+2I+F#5M,\!^*+_23;8_M%-4BT77"A QC.\!E&.&4N""HH ]9W
MCT/Z?XU%Y_M^G_UZ_FN@_;%_;>E^'^D>'M"UK0[;23\'O"WP]/B+Q#X.\9:E
M\33\3O''[)7B+XMCXFG7>I"^)-%8CYN"6(P#7BMM^U[^TC^QY\+M7M[/QAKG
MC_QQJ>C_  )O;*[^(&DZWXATV^+?!5O'7CO15;764^'3XL\0NP!!!!.X8(#
M _JZ,HCZ]_;^O;./?ITJ;>/0_I_C7\Y&I?MZ_MVS^)!XKTJQ^%]M\/Q=^/=9
M'@BZ^''C/_A)?[+\#:UX )T7^V\@9\6?\)QP?O*-!8*>6S?'[>7[;H\=_P#"
M536'PVM?AM_PDDE\?"5I\-_&?_";_P#"":/^T*?@3)HYUHG:68EO%))!*AG
M(5V! /Z*-X]#^G^-0^9#_>@_2OYF-'_X*)?M7?%K6=0M]*\4^&O '@_P)^TC
M\&FO/&__  @6LXO_ (8>.=<\?Z%KG@S7,^),>'OFT/0R#UW<UZ/X(_;[_:\^
M)FL^'_!WA/5/A=<Z_P#$;XD_##PS_:W_  K?QE_9GP(.O:YX_P!#\>?#'QOD
MG_A(/B)X4/@C1#D\#_A(,<#F@#^B#S1_SV'Y#_XBE\Z'_GM_X\?\*_&SP#^V
M[^T3XI^"/[9WQ%U3P!HEKXO_ &31XG^&*Z3I.D:R=,\7?&3P&-?;QQK*Y)/_
M  C@ T1@%^489@!DUY#:?MN_M3ZG=?!_X<^#_%7PE^,>L?M&'QWHWPX^-O@G
MP%XQT[PQH/BGX3YU_P <_P!NZ&03Q\.\.I!!W*"#B@#]V)X()L@>ALOJ?P[Y
MP1^G2OYU?VW?V(?VU?"WQ4\8_%#]BCQY!8^'OBAK!UCQ]\.IKE/#^H#Q0=%7
M0SXPT76Y%*ACL1VC;GY0W(52,#X>_M\_M/P>%/@MX(UOQQX*\:^(==\!>!++
MQ+9#P-XUTSXE?$SQ3X\/C_\ M[6_!&L@A- /PH.BZ(<L"<\]0H'(?"?]N_\
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M_!0/Q+;:A@WMV!\!/@ZVG:AJG'.M(!N8=#\H.1[5^I=59O\ 5Y\WH,@D#O\
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MX(('!KC_ !=\&OAEX]72(/%_@GPYK=OI7B_2OB!9@Z0I*^*M"/\ Q)-9)7S
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M+L+G4[8VAT76+2UL\ZG8Z:Q+'6=#&<X!_AZ%>&R,@:47Q(\$S1\:YQ_=-IK
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MI12DK-)VNK;(^.M(^%/[,^A:Q;^*M+\/^&[?7[3Q)JGB>TU4)J^;+Q/KH/\
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>E6L!\K3-/L;1?M. V$B;.,CKT)Z=<8XHKI** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ea028258601_img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028258601_img3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $' @X# 2(  A$! Q$!_\0
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M/_8N\8?LA?LW^(_%7[+WP3\2:QKWP3\!ZSK&JZMX#T?4M3O]4.BJ<DE2<CG
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M_HTKX!?^&VT7_"ON.B@#X<_X=R_L)?\ 1I7P"_\ #;:+_A1_P[E_82_Z-*^
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MY?V$O^C2O@%_X;;1?\*^XZ* /AS_ (=R_L)?]&E? +_PVVB_X4?\.Y?V$O\
MHTKX!?\ AMM%_P *^XZ* /AS_AW+^PE_T:5\ O\ PVVB_P"%'_#N7]A+_HTK
MX!?^&VT7_"ON.B@#X<_X=R_L)?\ 1I7P"_\ #;:+_A1_P[E_82_Z-*^ 7_AM
MM%_PK[CHH ^'/^'<O["7_1I7P"_\-MHO^%'_  [E_82_Z-*^ 7_AMM%_PK[C
MHH ^'/\ AW+^PE_T:5\ O_#;:+_A1_P[E_82_P"C2O@%_P"&VT7_  K[CHH
M^'/^'<O["7_1I7P"_P##;:+_ (4?\.Y?V$O^C2O@%_X;;1?\*^XZ* /AS_AW
M+^PE_P!&E? +_P -MHO^%'_#N7]A+_HTKX!?^&VT7_"ON.B@#X<_X=R_L)?]
M&E? +_PVVB_X4?\ #N7]A+_HTKX!?^&VT7_"ON.B@#X<_P"'<O["7_1I7P"_
M\-MHO^%'_#N7]A+_ *-*^ 7_ (;;1?\ "ON.B@#X=N_^"=/["7E9N/V2_@&<
M]C\-M$P.G/"*?U[8^OYA_P#!43]B+]C_ ,%?!/P!/X<_97^!-A+J?Q41KQ5^
M&VBV()7PCKI^Z.OS#U(^7@*5.?Z%98@P_3G_ #^((]P:_)+_ (*__P#)$OAA
M_P!E23_U#]=H ^J_^"?W_)D_[+7_ &0KP#_Z9(J^RZ^-?^"??_)DW[+'_9!_
MAC_Z9(J^RJ "BBB@ HHHH **** "BBB@ K/\_P!OT_\ KU8/_+?\/ZU^3W[6
MG_!5?X._L@?&W4?@?XA^%GQK^)'B'0?@^?V@?'>K_"CP<?$NE^ OA@NM_P!@
M?VUKHR,@$$, 1D# (X( /U@,HCZ]_;^O;./?ITJ#SOWO^<]?ICKV_7%?C;\6
MO^"Q?[-GA76=/TGX8^!_CK^TP/\ A7'A?XS^/=6^ W@0^-M-^$WPN\=9&@ZW
MXW(;*L203X8^\><\X(]8^/W_  4Q_97_ &:C^R=#\5?$?B73#^V/XDTS1?A5
MCPX3J%B-=T=3_;?CD95= T#&M*0Q4E#N"D@MD _3KSOWG_3O]/;_  ]^E'G^
MWZ?_ %Z^//V@_P!K7X9?LOZI\#])^(C:T?\ AH+XK:9\(_ MYI%E_:8_X2?7
M-'?7#J^MD-@: N,,0>&'S+G &B/VQ_V5YKZWTF#]HKX.W%_<^)-,\+BS_P"%
MD:)B^\3ZV<)HHPV,$<IT   ;8V%(!]=>:/+SWQCVQ_\ J[?KFCS_ &_3_P"O
M7S;!^TC\!Y_B-_PIZ#XP?"\?% C4C_PK0^+]%_X28_V&3_;H_L+.X$<DAE &
MX'.0P7EKO]L?]EZS\):AXRO_ -H+X/6W@BT\2CP3>>(CX]T/_A&K'QUG'_"'
M?VX'P?$!Y; (;T3<,4 ?77FS?\\3^O\ A4'FS[?.[8QC''TQ]>/7\:\#F^,W
MPTLKK4)IOB-X'M;;0;WPS9:Q=+XBT8'06\0.IT'1]<S(!CQ4"Y\& @NY.5(*
MA7AA_:)^ $DOQ!A@^,_PXNKCX2W@L?B0P\8:,&\":IK9.U==8L3H&2689(&"
M<@'=D ^BH._X_P!*//\ ;]/_ *]?*O@_]J_]FSXA:QHWASP/\?/A-XM\4^*;
M/5#X;TCP]X\T74]3US^P\G7/[$PQ!QP#@D9Y'&2-#3OVGO@#K&@^,/$EC\;_
M (7:GX7\&:P=&\8>(;3Q?HW]F>$]3&/^)+K;$A03G^(KGKD8) !]->?[?I_]
M>K%?G]KO[??[)7AOQ%^S_P"#[WXT>"M;O_VJ/&&I^#/@I_PCVL#4],\6^)]"
MP-=/]N*2!ABJDGY<\ $$&OO"UEW.0<\_S/3CJ/Z#V)H T:*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ IF\>A_3_ !J.;_4GZ#^5?(?[2'[9G[,W
M[*47A@_M!_&GPC\)F\8'55\(CQ S+J6NG0P&UQ=%P&P=NT\@D@E@,$ @'UWY
M_M^G_P!>CS_;]/\ Z]?(NK_M=?LU^'?AMX(^,_B+XX_#;3/AA\3M8TGPWX$\
M?W7B4?\ "-^*]2U]G&@Z/HNM@G_BH)"'"DCDAN=P.WE?CO\ MO?LH?LQ^)O!
MW@#XZ_'CP!\-_%WC,D>&]*\17A#WRC6-H/\ Q(MW]A,6 (+8!4YRV,L ?<GG
M^WZ?_7J7>/0_I_C7@/AKX\?"/QA=_$;2O"OCGPUKES\);S'Q3_LF\S_P@N=%
M&O?\3S';_A','<H/ )XP#70?#?XD>"/BUX-\/^/_ (>>*M$\:^!_%&+WPAXK
M\/7?]IZ7KNF9[$@=,$8/H.%[@'L-%9QF\H>=FW6W/&1G([@Y';C_ .MT-+YW
M_3?_ #_WQ0!H45G"8 8$PN.IP,?3J">OIVS[Y!YO[WR///IGC^?3'XXQQ0!H
MT5GS3?Y/X]/Y 9]23VJM=RX  '%T  .,\?4?J.>.W2@#1\_V_3_Z]()1)T[>
MW]>^,^W7I7&ZSK^E:#I5SKFMWVFZ-IVEVC7NKW>J7@T[3;'3 6)U@Y&U>FWD
MCG*DJ<%H/#FO:3XKL-/\1^'+[3=2T?7K3[;H_B#2;S^TM,UW2\ Y&1[_ "GI
MG</44 >A4444 %%%% !1110 4444 %%%% !7Y!?\%@?._P"%)?##_LJ:],9_
MY$_7NO\ 7WK]>I/N-]*_)'_@K[_R17X:_P#955_]0_7J /J#_@G[_P F3_LL
M?]D(^&'_ *9*^T:^-?\ @G__ ,F6?LM?]D'^%_\ Z8UK[*H **K2GRQGKT_7
MKZ9_2L#^V+#_ %_GW'Y=L?3\,8Z?G0!U%%<M-KUECG^TO;_1,GK]!@_AT_.K
M/]NV7_3Q^9_QH Z"BN6_MZQ_ZB?_ (!__6I?[>L/^HE_WRW^- '445RTNNV(
M_P"@CCT *^XZDG^OID"C^WK'_J)_^ ?_ -:@#H).A_X^.H^[T_\ U?UK\)_V
MC_\ @E'9?M=?\%!-0_:3^..J:E<_ #_AF33?@O\ \(1X&\8^,O!7B;7_ !0/
M&IUW6]%\<?V  /$'P\( ..QR 2!D_MQ+KUB)?]?<C';[)GV SQD^G'6C^WK'
M_I[_ / /_P"M0!_-]^TK_P $S?VQ/#7BW]JG0OV&9OA+IGP _;'\'_#'1O$G
MA3Q!XCUKX3^./V:O'7PFT;^P-!UOP/KOAX >(/AZ?#A!_P"$4QD'=MW*"Q\V
M^+?_  0T_:@_:*EOH/C1^VEK=O#\,/V/_ '[./P4U_P_HNDZEJGBSQUH8;7]
M>^)_CH:^K-X<_P"+B)HH7_A%54-X. C+*Y%?U%_VQ8^5_K[G'3_CS_3Z]LYS
M[8I/[>L?^GO_ , __K4 ?B=\??V&_P!J[]HK]F[]A'P=XP\9> #\:/V<]9^V
M_&#Q!:6?_%,>*R?AAKO@/^V=#'!&1AB"<EFKX'L_^" ?CVS\$:CI,%E\ K;Q
M3<?LD^ _A+I'B"SL=:8Z?\=]#^-/_">:[\3B "?^$C/AP?\ "+CQ/]X]@:_J
MJFUZQQ_R]?\ @'SV[^N,XX^E+_;VE_\ 3S_X!G_"@#^/3X<?\$V_VH/C[^T;
M^UN++X?^"_A?X0T+]N35/B=H_P"T?XK76]._:$UX:#\&5\/GP7X(UX#;KWP[
M\6>(W#?\)02&90Q4'8V/?]9_X(T_&GX<?!+]CVW^%?@[]GKXH_$#X)?#CXR?
M#SXO_!WX@V+:=\(/'GBGXY%BW[06B_(0OQ"\*?VT1N.%.0$;<R$_U!_VQ9>:
M/W]SFU];,_K_ )Z?6K']L:9_SWN/_ 0__$4 ?S6^"/\ @A_\3?#?Q1_8QO==
M^-.E^)/A/\./A;I5A^U_X>!UK3O^%T_&3X4C7C\)_&FC#:-K>$SKI 4DY70%
M.<MM'RQH7_! _P#:+'A;XX>#_$>N?"ZZU?5,V/@_XFW7B[6F/QI\,:Y\9SX\
MUX?%30E!.?\ A' 1CN<*,L0*_KR_MBQ_YXW/_@%4W]O6/_3W_P" ?_UJ /YK
MYO\ @A_XOL_'GBGQ7X _X4[\+KC5/VI_$_Q!\->+/"6BMIWB;PG\&M>^"_\
MP@8T702!_P 2'Q$?$0R=N2HY.!@UX/\ !C_@A!\;]#^#_BCX=>/H/A=;ZO=>
M)/V=/"]Y=_\ "8:SXD\,_%GX8?"?XGGQYKVL^.-#.,>(_%AX(/0@J3QBOZR/
M[>L?^GO_ , __K4?V]8_]/?_ (!__6H _FVB_P""0_QA^'OQR^&/Q<\ Z'\
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MA9\/OAEX\/AKPU8>*==^-'_%U?\ B1]/^$A_X1P'/?'?CC^U\WM]*/).E7(
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MZ?X5%Y'O^O\ ]:I=X]#^G^-/H K^4/+QWQGVQ_\ J[_IFC'_ $P_7_ZU6**
M*^/^F'Z__6H\CW_7_P"M5BB@"OY'O^O_ -:CR/?]?_K58HH 9L'J?T_PJ&2$
MXS%@'KCM^'/XC%6:* *_D>_Z_P#UJ/(]_P!?_K58HH KX_Z8?K_]:C'_ $P_
M7_ZU6** *_D>_P"O_P!:D$0CZ=_?^G;./?IUJS4$W^I/T'\J $\CW_7_ .M7
M/1#RKFWZ8%IJ1^FU@?3'Z5H^=!#B"XZ#I_,_A]/QJ@W_ !_:?_UZ:I0!K_\
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M_P#$Y]_L>?U_/KV]?:MV/[B_2L*$_P#$SN(.QLQZ8Z_@>#SQV'3-;L?W%^E
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M]CU]<<<GG%2^.OB1X!^&&DRZUX_\4:+X2T?: +O5[XZ<;PA3_P @;1F9F?D
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M=_7K7K->+:[K-A:?&3X?Z5/?6XU"Z\.:J+.SZ9[<8YYP,'N,8[5[2?\ EO\
MA_6@#.;_ )#-S_UZ?T%=#7/_ /,=_P"W/_V2MV/[B_2@".;_ %)^@_E7Y(?\
M%?\ _DB7PP_[*DG_ *A^NU^N<GW&^E?DC_P5]_Y(K\-?^RJK_P"H?KU 'U!^
MP#_R9+^RO_V0CX8?^F-*^T:^-?\ @GW_ ,F3?LL?]D'^&/\ Z9(J^RJ ,Z;_
M %4_T_J:_.7]OWXP?'SX'_LM>*/B+^SKI?A"Z^(-I:::5\5^./$FC:9X'\!;
M3M.N:V"2=?\ #J[@#X94C&X$$ @5^C<TV(KCI[=^^..G_P"OZBOSF_X*3:9J
MNI_L&?M(65CX<T3Q(;GX<-_Q*M7Q_9O]E$Y.LYVY_P"$A) Z'/ )S0 G_!-?
MXP?%_P"-?[*'@;XE?&_Q7X(\:?%G7M6U0>.KGP/>_P!H>!]!U),#^QM! (^5
M2ZCC@;@,C-=SXQ_;\_98^'OC$?#_ ,1?%2UM?&%K\5=)^!7_  CUK99_XN?K
MI!T/0\ CDKD Y8 D'!"[3\O?\$;?#=]X5_80^$^DS^#OAOX2T[[7JEYH_P#P
MKWQ)_P )K]NTO/&M>-]< !'Q$/.><C:,#DU] _%O_@G7^SU\9?$^L>*O&.EZ
MW:ZOXG^)'A;XG>)3X?OCIO\ ;OBCP)_R R6.3D#N<Y/4\F@#[HAP-9\C_GUL
MSG'H#T]?I74URUI#Y.I_]P@<$=/F!Q_C^%=30 4444 %%%% !1110 4444 %
M%%% !1110 457\_V_3_Z]'G^WZ?_ %Z )=X]#^G^-02RP ?OL>H!Y_EC]?K4
M,\O_ "PQ]<?F!_/I7@WQF^.?@+X/Z-IU[XJ74]1UC7KO['X/\%>'K,:GXW\6
M:K_=T/0\AB<=]N.^03@@'I'B_P :^%/!&@:OXJ\<:YIOAOPOH&+S6/$.K7IT
M_3; # &6/)(W<DDGKG/6O@>&7XF?MCW8)M_%OP<_9@%IF[X/AOXF?&CJ,C.1
MX>^'FUNH(W D=#BNG\$?!3QO\;/$>D?%3]JB&VMK?0+W[=\-_P!GNUO#J?AC
MP'N^;0]:\;DD'Q#\0\$ ;?E4\#.TJ/T"BAQ_S[GV&<]<9_'N?; H X[P?X4T
M+P3X=TCPIX5T33?#F@:$#96>D:3: :;8!<' !(Z$CG.1D GA:[[8/4_I_A1L
M'J?T_P *?0 4444 -_C_ . _UKES_P AC3O^O74_YBNJKE3_ ,AC3O\ KUU/
M^8H Z.;_ %)^@_E7.69G&FS^1#]IN!=MQT!Z'/L!@^O7GM73R?<;Z5S5F9_[
M,N/(@'VC_/\ (#U/7&.* /YUOVN=3%[_ ,%<?V<-5OO 'C7Q(/ 5IX7L?#>D
M^!M8UGPYXFU[5-<)'_"::[_PCX'_  L#X=^$^X\6#@Y';-?JA^W5^VQX<_85
M^'W@_P"(WC'PKK?C73_&7Q(\,?#ZSM-(Q_Q(CKN1_;6N$]@P/&.3T/!%?D+^
MWK\3[[X$_P#!3WX7?%S3_"WQ;M=/;PSX"T;Q%:^ +O7-1TWXT^&-=UK'_$E4
M[?#0/A(CYE;:V<AL,./W_P#$O@KX=_&;PMH\'C?PIHGC;PO<MI7B;2=*\6Z2
M=0":F5!T-UT1U/\ 814' .-I8D-@AL '9:;J=MJDN@S6!!M]1T@:U:W?_(1%
M]INN!9 "1TX*L>>1VVYKTJN.M,6=Y86,/V> "Q(M+.S&=.LL [N !R><8X)(
MP,'-=C0 4444 %%%% !4$W^I/T'\JGJ";_4GZ#^5 %:K$'?\?Z5X;J^D?;?C
M5X2G_M;6;;[+X0U2\^QVEW_Q++[_ (G"M\XR.><_PY4CZGW&*(*/TX_S^))^
M@H LT456^UP^I_(?XT $LH4?KS_G\ ![DU7BER#-FV&>,@XQQQCKTP>O-8VI
M:]8Z-I]QJFJWNG:?IUK9_;#JMY>_V?IN"#RQ9NFWDY).#@ DBOD;7OVN?"^L
MZU<^%/@MX5\6?'/Q.PP#X2M#I_@>PRO/]N>-V!5,'IPP8]0.<@'VE)*)%G4#
MA1C\!C^GOGK7SK\1?VD?A)\.+E=+USQ5_:7C"[46=GX*\*(?&?B<D]?^)!H)
MWJ?4. 1D <Y \@/PE_:+^,!_XO#\2_\ A4WABY;_ ))]\'>-3O=,"\Z-K?CA
MNQ!V@H#DL0>"Q7Z ^&_P-^%?PEMKBR\$>#=-T2XN03>:N,ZCXEOQ@CYM=)_X
M24E>HR<=\#K0!\;ZGKWQH^+7B:&;3=*\?_ +Q?JMWCX<W7B%='U/2['P%@C7
MM:US0,L= \0GGY<L3D+DYKZ \!_LF^ /"WB/_A,_%7]M_%OXC$9O/&_Q-U8^
M(]4!&XDZ)H1(\,Z!D8VA4R,$DD-@>I:]!-_PN/P!.)O^8-XI&,<8X!'? _ <
M'&,=?:/^6O\ G^]0!5B@$46/*MQY QQ;$' &?D^;CCGY?KWY6'][)GC X/\
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MX&T J@)P,,QVY&" #D?6&@:#HGA72[#2?#NE:=HNCV@Q::5I5F--TVRR.N%
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M0_"S$C0M$&N\_P#"0X"G=XG*\[EP1R*_1**\!X/^?4X'Z#\?>@#/;_D,W/\
MUZ?T%=#7/PR^=K%P/2S'OMS@?YYK>_@_X#_2@!U%,WCT/Z?XU1NYH<#,P'3(
M'Z'/]"3WH O;QZ']/\:?7ANN_&3X<^%=3U#2O%.N?V)]DN]-L;O5=5!TW2_[
M3/(']M949 "CIQA@"-QJU_PNWX+_ /14_ /_ (4FB_X4 >T45X[_ ,+R^#O_
M $5GP'_X4NB?_%T2_''X/2Q_\E4^'^.>GB_1AZ\\L2?;@#D\T >Q5G^?[?I_
M]>OF77_VHO@MX4T_6=4OO'%K=^']"NSHEYX@\/\ _%1Z59:M_P! 0GP_DCQ
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ME@#\#ZE\9/B-^T7J$_@_]FVX/AKP/I-Z=%\7_M,W-J=1TL\,-=T7X(Z&,?\
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M&MW.CVWQLTH_&OP[X>L@/^$L\!X VZ[KH)&@>'LY.>V<"N%_X(]ZB-8_8/\
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M4\.^$M LU_T32/#VBZ1INEV)(R NCZ"%0GKG!XXR5Q7PC^VQ^QQKO[6?B/\
M9_U70_B<? /_  I+QZ?&FL6GV+6=2-_UXT/  _X2'@#)YZ MTH ^KO&OQ:\
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M[9GM[%?3U_3J8A_Y[?\ DX?\:!W?=_>R?R1#)G/& <\\9Z_AU'''M2_\LO\
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M?^>W_DX?\:F^T0?\_MO_ .!HH _&?]M;]E']K#XL^*_B_P",?@5\5-1M=/\
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MM+\6>&=>RVADKE?["1V!)"G+,6PPR37WO)J>DZ;=P07M]:Z?<ZG>8M+2Z/\
M9NH7SJ-I4+N<ZX<$@\'Y3R2>3_+!\-_^"6/_  4R^ .D6&A? _\ :'TO1(-+
M^.^EZ)H]T/$FL:CXH/[,>A8?X5CQQK>OG.O#PGXC.N,/"H!X() !!KH/%/\
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M #H O_V':_\ /&Y_\##_ (4?V':_\\;G_P ##_A4'_"4Z3_S\V_Y_P#UZ/\
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M?[<Z]>>O!R!7C_C;]C3X._$C^R+'7(/%MK./ ?A?X2:/_9)&!X"\"=?[$/\
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MSUP?7GT]3ZS^R7\$_$?P'\!ZQX5\1ZKHFM?:O$@O='\0_P!C?\3/^R_[%_Y
MOCC7,C_A(!_^J@"\?VN_@$-4^(.E:WXPU'1;GX7>+_\ A"_%]W>Z1@:AJO\
MS'/[$(5BOASPH>IP<=0.U>P^*O&WA7P?X<_X3'Q5XDMM-\/ZI_9=E9ZM:_\
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M"KX[ZU8:KXXFUFVU'0O!_P#PAFCWEIC.@Z9KH&NZZ=$(^]XC\6 *.<X  [#
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M?B=XNU'PQX&/C?Q"^E_$GQ;IFB%O[<\9Z%HQ'E^(O#PV$LH8L@VEPH9"W<>
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M'@?5[S13J>O#QWK/_%U_[$T+_F7_ /A%  #D=">.]?8'[1^A?M*P1_#'P/\
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MVO?V@_%EQ9^'/C1XM\.:S<^+],L_$EE:>&QIOAJQ^%_]LC_C(#0B2!D^'?\
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MVEG_ ,3/7O["_P"@YKGMU/ISTK1@AO8)?W\%S]H_Y^[3_B9?;^Q^G_Z^,<4
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M_MDX/';G(^1M"_X*#_$?PYXRUCXC>/O#UMK/AC4_ FDZ->>"?#FL ^!M!^*
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M\_\ I/VBUL^?SZ'_ /7^-$,TWFV\ @SZVG/XX]>GXT ?C_#^Q]^UMX;NO^$
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M)@?Z79_U_P G/TY/W_F];G[1_P ?OVO!]/I^/TH _+?XA_"SXL_M-_&_X_\
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M,U^>G_!3?]OK]EG6?@#\/Y-*^(^N:O OQ?'S7/@+QEI[H?\ A#=>!PI4;@.
0#U.<X&.2BL,1O\_U8'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ea028258601_img4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028258601_img4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %+ G # 2(  A$! Q$!_\0
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M'BWX8^(SX<U.^TH9QVXP/7@9QDX!KA]>_P""&7['DWPX\ >#_ ]AXE\ ^,?
M5YJVM#XKZ1>C_A)_$&J:Z<:X/&^2J^("1C@D $D$X!( /RG\5?\ !<[]L/X@
M_L>?"?XJ?#'X9:'H>OZ_X]U7X?\ Q)^(0']I#PEJNADDG^PAGJ3D]\G/4C/I
M'QF_X+@_&BS^'_[-'PZ^"O\ PK?6_C?\9-&U76?$GQ!^V#4M*T ^!2QU_1O[
M" Y9B>2<].,9;=^D]Q_P10_9MTSX(VWP5\#>(?%O@'3K36-5UIM6\/7N#?ZI
MKA_XG?\ ;8Y!#>I9,<<%L@9'B/\ X(9?L=WOP1^&_P (_!%OK7@#6?A?K/\
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MSG)[T33?NO\ IX&/_K>Y/;]<>F!N;%%9_P"]_P [J2*\@FD.)AP.!P/_ *V
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M7)IO#6^R_NU_(GFCWC\VO\T?YK&I?\'?/[>D.L3V/_"EOA_;7''^A7>3C\<
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M_:?E^'_ /ZR9_P#@\1_X*!3>?!;_  8^%MO<8!XLF&#TYW <\]LXZ=16>/\
M@\1_;TLX_(/PE^&P'8FR..IZ8!/.,>G&,=:_E.AF_>W'_+MVYL_IW'^'ZUS\
M,WDW1G,_VG_/^<]_3UKXC,DL)BVEZ>7E96L>AEZ^MJ^WKKW[_P!?@?UHP_\
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MI]YA]6\O/;_[4_9F/_@X5_X*K2)YQ_:%U(P@G.;(;<C.<')![^@]\5Z+IO\
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MT]\5]$N$,$E\$'Y>SAKIM\*]#SO]9'Y_?_P3]<?^'\O_  5@_P"B_#_P#_\
MKU6_X?V?\%7H8OW'[0MS]?L?/_Z\\\8YX[8'Y/PS0?ZB#]3T[C]>.O\ ];/F
MO)[.(9_+U_QR<9]#Z4O]4<%;_D5Q_P 5HV_Q;?,%GF+TM)>6I^K,W_!P)_P5
M?\SRO^&C-2\_D?\ 'F!S@#'OGCJ.^!UJ?_A_Q_P5EF_<3_M&:CV_TS['V]?U
M_'W-?D//_K?/P#QU]!Q]3^77U]+ AQ:^1/VY^ASZ<?YZG H_U)R?JHI]N5:>
M7P]-C=YYBTM6OO\ R/V(A_X+P?\ !66:*YG_ .&A;FYN/7\__P!77K^55X?^
M"\'_  57AEM_^+_7/^B^MF?;/?C'^<8Y_(^']S^_/VG\/3_(_7TJQ/-!-+83
MP?\ 'QWZ?R]>GH?RKHP_ ^3N_N0N]+.,?/\ NF'^L6,_J_\ F?KA-_P7F_X*
MK_Z/_P 7^N?L_'_+G^9[GZ^W'-=!X;_X+J?\%9;S6=/TJQ^.-S<W&J?].9_/
MKD?3'3J!7X[_ +CS;B#IVZ_0_D..._6ON7_@FOX<TKQY^VY\"?"NN6.FZE87
M?B13>?VM9G4LD$DG'\O3GUKGQ7"&387[,;W?V8KKZ7]##^W<8[^]WZO?[_\
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M]/3/^>U=!X;T?[9=6_V[_CW_ ,\9Z=O?\*KZ;IMO-+Y\\]M;?9<\G.>GI_\
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MYQZ?A[]?ZCH/J,L^U_7<^7Q77Y_^W!-!YW_+?_1^?S_'\^/7ZU7FAGAE_?\
MOV_(^O\ GITJQS##[C\.O]?R.3V-9_G3S?OY_K^1SGOP?\/:O0.<(9O._?F
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M*WKHK]>BOY^15VW9-[NWS?E^I#+$9>0?M/XXZ#VQ]/PIL$4(D(\DW-QGG_\
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M;;3]+UC[;9Y/U[?7Z8[U\W_LW^%)]=^+6GV,$!N;>ZUCPO97EI_S_C/^3_\
MKY%BEK[RU5MT_P#V[0Z/JWE^'_ /[*/^")_@.Q\!_ RWUTV!_M#7B!_I?_(4
MZ?B/IQT'I7[H?V:)K6X@GG^TS_B<9_SV('45^:_[.GA6#P3X2T>#0_\ B6W'
M@/PWI6;2[''7'U]OK],C]$;/Q)_Q1%O?>1_Q,;JS%Z?_ *WM_P#JKG^+SO\
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MQ>WEIGC\CC\OKSFO)]-A^QV&C^)-5L1<Z>219_9.G3I]*]'TW3?.NK?59_\
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M>SP>1;6UO==+O_/'!R.XXP#BNBYS?6%*ZNG?TOK?S\_\PAUZ#7K7]_/QI?\
MQ^9'(Y[_ $S_ /K[%F(--M9_L/\ HWVK_C\'Y'\/?Z^E>+^&[R>+Q1<V/^D_
MV>,9_ X[YZ^W/?BNPFU+SAGTS97F>_\ ^O\ K^7CXG$6?]>G3_(\C$X;^OQZ
M?+\#TB?[#>16_P!N@_M+/_+W[?GZ]N.OTJO#IMC-=V_G_:?[0M>?M>?T_G_.
MN6TW7OL<5Q!!TY^O^1G^M=SH/GWDOD>>/]*PV/S/KC(_'&."<UYZQ.N_X_\
M!,/K+PONZZZ=7OM_5EN=QIL-C#]G_P"/:VM^G3@\X_\ U=N,8XK8FA\F7/\
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M4\72#W_+\\]_7ITXJSY\\T5Q-_R[]?IV/M_GBN?EOTO\K@<]9V<\T6HB>?\
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M/Z5[1_PE7]FRZ?/?'[3;W1'_ !Z9_IUZG'?'?FM\-I:_3?Y6'B>OS_\ ;CZ
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MT^3^X]CZMY?A_P  ZC1]8TJ;7O(G^T^O7\>AY]>_M]?:(=2S:6\]C@G^H/\
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MY_\ D(8U3_ZWIQ[\GCW&>PL]>@F^S_O_ /CZ_LL?3OGV]B?7&*#GQ2WT[_\
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M[4 ./H?IZ^V>*^ RY_[8M?MPZ^9[)_C;V<W^@=?7_.?SY^OM6?-#YL7GF?\
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M3V7:W_UQW[>AK]1\+O\ ??/37J?'\:Z8-]'_ ,-_P3^5&']SGR?;]/IG&/\
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M-^]_'Z<C'X9_0]*^QQ/^Y+_"OR.9.^*7S_KM]Q_03_P1MUB ^"/'-E.3FUO
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MJ5C><^OL,8SZ#W]/SKS\GP_Q<S[MI_-;'L9FMG;MK8]P\*S7VFQ>3?3_ &G
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M?$_BO7I_CE^US;Z5!_I/A_P'9_;>._T';_#@FOTX\'0SWG]G_P#/Q==./?\
M0_X>N*_'_P#8M\-W&O77Q(\?SZK=?\51XE_X^^/\Y/KVX^M?L!X5FGO)?] _
MT:X_L<V7KTQT_(?S^F.5WN[WWZW[LG-8^[MJT^G]U^1],>#YH(;43P0?\>MY
M]BO/M9&?P['I^'OFO8(9O*CMX.EOQZ]O3\?Y\5XOIDM_#$!/SG/?U[]/P]>3
M7M&CS?NK>?V_3\/4_I^-?7+9>B_(^)E\4O\ $_S9U&IZG!#87'D0=/7O^!K\
MX/\ @HUXPL?!/[(/[0&N3P&VN?\ A6_'OWQZ_P \]^]?>\TQ\T3^F,=./Z8.
M<U^*_P#P6V^)$'@G_@GM\:+[7+C_ $CQ1GPQ9]N>.<DX'8]?Z5]KP/\ \CJ/
M^-6VWO';S_ ^4XNTRB5M/=>VG27H?YV]GK'VS]_/]I_X_,G\><^_&".]%Y]A
MFEZ>_P"G;.?2L?0;SR;7R+CU/;TZ_P"3G\:T9H8)OW_Z=?7'KZ#_ #D5_H5P
MO_R)J?\ -RQ]?AC\^WX'\E9IB.;&23?62?WNY6@F@\W_ % _$?G^/Y\^E5YO
ML,4UOP>.P[?E_D=_;0ATSSL]1^/'.?;Z<?4=>*KPV?E77^D?@2<8QG/Z_P#U
M\U]#+X9?X7^3/./8/V>IH9OVI?V<!!V^,'A?T_Z#8QQ_AQZ#FO\ 9]\)^=_P
MA_AGR,9_X1WPOC.,_=3/X]/;K7^+U^S0/)_:E_9PX_T@?&#PN>__ $&\YS^/
MT(.*_P!H[PF<^#?",_\ U+NF?^F4'Z=#[=_:OYM\2?\ ?%_V_P#^DL_6.$_]
MT^[?T-F$^:!9$W-P!_R]D]..YZ#'^>U?E1_P7"\\_P#!+G]KC'^C@^ M4Y]C
M[@9Y([8K]5X2)<0PX'V;Y;NTSUSR0.>^,^GZ5^6'_!;>$0_\$NOVM_\ CVN/
M^+;ZKS=]/\YZ>O7&:_,LN^)_XX_^E,^G>S]'^1_C+PS'[+Y/ ZC/'MU[\Y_4
M58\[R9?P/J.O3\.GL>>:AB_X]A_U]#^0J]:?]//MU_7'^?7%?88G_<E_A7Y'
M"_B?JS]0/^"5/BJ^T?XOZQH<%]:VW]J6?_'I=YZ>O7V'^(K^N?X233V=K;SG
MCTZ^N"./KW[ XK^+'_@GO>"']H'3H//_ ./KUX[GGMT';I['FO[+_@_>3S77
M^G?\>]K9_3I[8/IZ>HR#S7Y?GG^9^BY+_N7R_1GZ(>#[PS6NG]!],?UZCO\
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M/T@_X)IZD-'_ &@K>Q'_ ![W6/\ C[Z#GU_KZ]N.?[(/@/>?;/L\$$&?LO\
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M>I_H@^+6FXT_SQ/<_:/L8_T3'X?AS_AW.?PW_:[T>#7K3QA!/8_:K>Z\-_\
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M_#*>^-L=>\29U>T'8^OX 9X.?;I7]2'C::"&U'_'SZ=,?4>YZ_ATQTK^+?\
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MQQ\)+[_1KBUUC5-:L[0YZ9_#U]Z_4#P'KVJPVNH0?\^IQT'X_E_]<]*_&_\
M;JU.?X&_MD?#_P ?V/\ HWA_QD=+T2\([^_3G_..U?J1X#\7V.I1:AKEC/\
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M3_#C_(KV#08?^6,'MU_$=Q_GO2PV&_K\>OS_ !U.?,Y2NG=].K[G<6?D6?\
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M1'A4>3= >?\ \?5YP!GW/;U[?RKY?\$S_P!I16_[_'?_ $L\=>,]^N/\YKZ
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MWV;OT>]NO]>I[!X;^)WFW_V&"QN3]E]@?H!WQ_\ JKZ?TWQ)!>6&H009MO\
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MRZA/80W(M]4_SV/Y]*S]'^(5Q+%Y%]/<_9[48^R'^O!X''/:N@]?_8_G^O\
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MYQGOTY_VCO X\WP5X/\ 4^&_#?IWT@$=N.H[=J_Q<?V;YS-^UG^S//\ 9_\
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M7'_/UZ^O^1U_&OG_ *M_M5^F^Z[WM_74_0<M?^QRMNDOR/MCP'-_SQG'V?\
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M_!U_I_\ :L]L+?5,"S_(_0XY'7I]*^:/%?@_0H9;?7=*_P!&_P"?RTY_'O\
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M?*'[_K>''3Z^O/\ +\17I83>'K'\XGDYG0^MWEJMWO\ /3T/L?P5_P ?5O/
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M;0_=?X2P7T]M8?N/M/6]O/\ L*<XS^'3_'BOM#P3#]BEM_(M[GO_ )]_S_\
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MT6<_9_R]>"0.G\ZZ#['^ZZ\?K]/R[_KBL?0<_9/W^;GCN/Z_Y_.NHA\CRO\
M1_3MCIG^?T[^]>^>>8\/_$M_Y8=<G^N/Q_KU/ K/@%Q>71^W08N/L7_'W]?P
M_P D=J[&&'SK_P#?]![9X'Y\<?EP1Q6__P (W 9?/N/H1V_7/7Z'_#S\3AOZ
M_'=?Y]CHPW3Y?H?,]Y-_Q-+BW@G^T]/3]/KG/&#[5Y_K^O>=:^18P#C_ (_/
MY]!_7\\5]$?\(?I6FZS<7W^DW/\ IO/\^/\ )'KSD5R^O>&])A/GV\'3_/\
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M.#3?V5=.O>#<77B3_C[]O7@^P[CK7WA\!O&$&@^,O^$5UO[3<_\ $XXM.?\
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M#2%/I[#@=<5_./B>O]LY>MV_P/UCANWU->GXVT_$ZN;_ %7_  '_  K\GO\
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MO>-'U*W@QB'_ #W]N/RX_/U<-B?K3Z;^G7L>-B<-RZ;6_3T_S[&S#IGDR_\
M/UZ]_P#]6,#/'%=/9V?G1?OS_AU_SWP<^]9\,WF_Y_\ U<=>U:$,'G1^0>;?
MT_S_ /6]N:[L3;7Y_J>><_J0^QP\P6WZCZ8YY],YQQZUQ_C#39X;#_B5?Z3<
M?\?W4CMGMV[?T)&*[B6S\Z']Q!WQ^O/7^><<CUK'U/R/LMQ^X^S#Z_R.>O\
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M?9#Z_7Z?G^-?<\/D:]I?D:K_ ,236?\ F#VEI_G'K7B'Q"\*7TWV>^\\]O\
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MN>:L:#H.JSZ-_P 5']EN;@\&TM#C_P"OW[_XBNHAT&QTVU_<0&VM_;TQG/\
MG!QFO1^K7Z7OY7_0\<\/^)VFSC2_(@@MO[0^Q_;>N>G_ -;G., 5_/O_ ,%"
M/A[/>>%_^)1!]IU#['_;7VN[R?L)Z_4<XZ?_ *OZ8->_?V%O!]A^T=3_ *7C
MC_)SWYK\E_VP/A[_ &QX<\46_D?\?5G_ *9=VGI_GC_]=<\O]EOY7\^_]=;7
M/8R7_>OE_F?+_P"R+XV@F^$O@_[=_P ?&E<9_P \]O3!_.O<)K.Q\5:IJ&AS
MZ5<:;_:G75N^,XZ?Y/Y5^7_[)?C&?3=&UCP!/ /M'A;6-4LKR[NSD # !YX/
M''Y\5^D'@G6)_M__ ![_ &G[+Z<_C]?;^8KGP^)5WHM[V7K_ %M]Q]5BK?5G
MW\][:[]3TCX>P^*O!.O?V5/8_:;?_CRL[J[_ .@7SCKQ^'_UJ^Z/!.I?V;JG
MV&>#_B7W63UXX /7'^.?>O)]-_LK7K"WGG_XEMQ]CX/3UYS_ "Z8]ST] T&S
MOIKK3X+&?G/'^?QZ_P!"*]A?[4DKZ-;?UO\ K8^5S.]M+_*_;R/JB: 0Z-_S
M\_:ACZ'OSGZ<8YYKS_\ LWR8A!Y'^CC/_'I_+!S^'N378:9-?0V%O]H/^<\_
M3D'Z=/I7U+6()I;BQ^PVOVC[9_H5W^I_P[?XO"89K&1:OHUMTU_X'0^8Q>(?
MU5O6ZO=V=^OE=G\K_P#P='>"+[7O@W\#_'_V$_\ $KUC^Q?M?0=>"#T]?_K5
M_'AJ,-N(K""";-QC!!)'4$]>Q!].WOQ7]S__  <C:;?:]^P=H]_?P6UK<:7X
M\TO^Q_\ .!Z #I^M?PKPPXM+>?!)&?UZ^W\O\?[^\#<1_P )"3OM'2^NR[O^
MO(_FCQ%?UG&IZJS6MO/J:$/D?Z1Y\_/3']?Y\_XU8_Y??\^E5X+,375Q/Y_^
MCW7?\>G^ R?Z58O+,V?^O_Y>CTR<_E_/O^=?T30U^??Y'Y7B/]Z7R/2?V;OW
MW[57[.$$'?XO^%_TUP>_X_3/K@_[0O@G;_PB?A[_ )]O^$<TO'UVG/Z?C^.:
M_P 6G]EV&>']JK]G"?H?^%O^%O7D_P!MC\_\XXQ7^T?X)A'_  B7AB"8YQX<
MTL$=>< ]?<$?ATQUK^;O%+_D;_)_^DGZIPI_NV]]-CI_- E&1_Q\8(ZGH,=\
M^Q.?RK\H/^"X7G_\.N_VL,8S_P ($<8Z8SS_ /7_  K]8)Y)X>/)-P1Z'!'U
M!!QW^GI7Y3?\%QY,?\$MOVL<' /PVU,"YXPI _#J?8@X[\U^3Y?&^-:_OQ_,
M^F/\;&+_ (]+?_K^_P :K^3YTMP/0_T_6BS\F:V\C/.<_P NGX_CW/2@PP<^
M1]/?Z#N>PQ_CQ^DO#?['?;3M_=V_IG/I];WT[:6Z^?Z'V1^P?9?;/C=;V,'U
M%W^AQTZ=_;&>*_I(LYO[-BM[#2A]IN/; [=,\9_ ?7I\W\Y__!/::"'XW?89
MY_LT]U9XYY&%ZX_,#OC()Q7]'&@PSWG]CCI]JSV/X=?;/;)]<\5^4<289MOU
M:Z]_Z^9]_D=OJB[Z>O4^R/A7IM]#';G58!^?/ITY^O;'TK]$/!.FP6<5OY'^
MC?:K/."?K_4CG@<U^>_PEA^V36_[C/V3/^EW=Y]?T_#\J_1#PWIOG6MO!/\
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MU/;UQDUZ1IMG_H'D9N;8GZ^O/M^E</X;O.TWY_\ UQ7<:;-/-+/_ *1<]?\
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M[VO:^NW9'SOHVFSZQY%C/_RZ_P#+V>W^?YXKH-,T>^T>6X^W?\>]M_S]G/\
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M;PYI0_\ *,!G]?\ ZPXK^;_$_P#Y'"]9'ZOPE_NJ?E^B-B[E$-K.9P?L^/\
MEU^\.F0?Z]J_*;_@MAY,W_!+O]K#[/./^2;ZK]D..X( S] #CMW'2OU8B\^%
MX(-NZ#!/VGU."0O/<XQ^76ORH_X+;?9YO^"7?[6_O\-M5S]DZ=5].G;UZ5^;
MY;=XZ$;O6K3Y;><DON[V/J<3U^?_ +<?X\&FP@:-I\^/^@IQV[]__P!6.U9%
MY^ZQ[6AR?KC/KTQVSU/MCI]-FQHUOG[-G_CR/UY'^3GOGFL#6(/)BM_T]?\
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M7)R:V?L9AAY^TVV#Z^AR.PZ9&0.YZUW&I_\ ".6?VB">^MK:X_Y<[0XZ<?T
M'X?C7'6<WG8@G@_M*Y[_ &2S'/Y]??\ +FNE85W7NO=?9_\ M3SSH=!_T.ZX
M@N;8_P#3WW/Y>F/_ *U>@6<W[KI]I'?'3KSG@_AQS7'?Z##%_P 3S_B6XZ?:
M[SV)Y[X_7'6O-_&'[3G[.?PKM3?>./C3X T33LG/VOQ)]>?7'3]*]_#873Y=
MOG?7^OP1S_6?/\?^"?2]G-!#_P M^/P&>Y&>P]/R^O0V?V>:Z^W_ /+Q:_\
M+W:<_P"<?KWK\)_CE_P7F_88^$MU?V.E:WJ7Q(U"U_Z%[G3._P#A^??M7X__
M !A_X.:OBIK$O]E? CX=6VAZ?==+N[O"._?\NO7'UKOPV2_6;O2WE;_@;F#S
M+#89V;?SOO=VT]3^RCQ5J1T"PU#7+Z_MK;)_Y>_^);Z?IS_@:_)?]JC_ (**
M?LR? '2[C5?%7Q&T36]1[>$[2\_M+\<_Y/XU_%/\>/\ @I_^W!\>/[0G\<?%
MJYTW1[N\_P"03X3O/[-^G3M_]>O@CQ3KOBK6-4T_5?%5]J7B34/^7(7=[W_Q
M]?3^6\LKCA$U9/Y+T^_^O(2S3LM_R9^V'C'_ (*?C]H7]LS3M4L; :'X(NK/
M[%HYN^<_GQ@=.G)Y.<U_1?\ !G6(+S1O/%\?]*_TWOWZ>^/P/K7^?OH]YJL/
MC+POKGAS2KK4O$.@ZP-:O+32?^7#2^F!C^?K^%?VX?L3^)/^$V^%^C^*NMQ=
M:,,VIQGGU[9^E>%B<,N;2RUZ+SOT^7X'T^6XKFMINO7?M;]3]@/"LT%Y:V]A
M[]OY_G_GU] TWR+*(]>G'\SVP>_?BO!_!^O&'[.?/^TV_4>_K^O\R:]0FO)Y
MO]1_G'X?CZ ]:W6&T6G3>WEZ?J=&+VE\_P!3UB'4O)B_Y=L^W_UOZ?K7G_BK
MR)K73[[S[;/V/T[8Y]?;U]^G/06=YI1M;:"?_D(=A^G/3U^M</XVF\FUMX8/
M^?(Y^UY[_P">GYUZ6%P_^VY7YR6O?5.S?_!/GI?#+_"_R9_%'_P6(O/MG[6$
M0G.F_P#('?\ ]"^G'/I^O%?E'7Z:?\%<;L3?M;7EB9S<W&F>&W4_Z9NXW>G.
M2,G^7?G\TX?(FN<3SW/D<\YY)QGU[=NF,_E_;WAQ:.4K5+W8[OR1^!\3_P#(
MVGZ_K(L0Z;/-:W%]_P P_P!<\?EZ]?3ITSS6AH\T^I:AI$$W2TZ?9;/D#MUP
M&/T[]JY_SO/_ ''Z9_3/;'Z_I706=YI4%_!/!_HT']?PZ<<'(_PK]0/EW?6Z
MZZ:>OZ??N?%'C6\/]O:S#C_E\/N..O;CMSVZ9[USQ_Y8'S_4D_SS^AQGZUT'
MBJ'&LZN8/M)[X[?SR1C^6,=*R(OW4<';-F3^'7UQ]3G\S7^;V*PS>*=W[MG;
M735=V_U]#^GL-:RMOI\W9/\ R/O#_@G-K,.A?'W3K&XN#;_VD,"[M.H&>@SV
M]AWR3S7]>_P?\2>3=7$%A[9N_MG-_P#R]>?7(K^)_P#97\2?\(Y\>/AO?^0.
M/$FEZ-_3GGWZ<U_81\/9OL=U<>1!]IMQ>?Z'=^WMG\*_FKQ1PSPN,YVK\U]=
M[]/N_P"&/VC@+$VPKC?9[/?K?0^J=2O/)\46]_!/Q_SZ=SV'?)Q]/2NW_P"$
MDOKRP\B?I]L'_'Y^'U]0/IZ5XO-J?]I?9IYY_M(_Y]+K_P#7_+MWZUV_]L3S
MQ"#UZ?X>_P#(CKC@5^*XCK;Y6^=K6/U ^6/VEO"O_"8:GX?^'.E3BYN/%%Y]
MBUGOU_'/.?\ ]0-?@?\ \%)?V M<_97M?#_CCP/!J6HZ/JG^F^)+OGC_ !Y_
M'KWQ7[[^ ]3_ +>_:,N)]5N.=!_Y V<#]>O7C/-?H#\?OV==#_:Z_9X^('PK
M\C[3X@U2S^V^&[OMVXZG!/3CO7Z#P3Q'_9<H*6SE%.[_ )FD_P S\_XMRUXE
M.4;];6^;_0_SI]'O-*UC[1/!-_9NH<WF+O\ Y!GX\=N,^M:$,-]IL5O?:5]H
MT^X'6[TG_D)D>^,=<]O_ *PZ#XY? WQQ\"/&_C#X9^/]#N=$\0>#M8^Q?9+O
M@#G\.^#QVSZ5YA!K'BG0O[/GAN+>X^R]+3T[XQD=^?;T/;^C8O!9O@XOW7I%
MZ*+5K1?9I[ZK5>1^0R^NX+%2U:BK]U=*_I_FF?J!^SK_ ,%2OVK_ -G672-#
MM_$ESXLT:UQQJUYD#Z''WAW[X'4'@_T4?LN_\%\OV>OB%+I_AWXPV.M_"[QQ
MJF+(^(0O_$LQVR1^1_/K7\6UGXJ\.:E+;_VK_P 2VX'/VNT'MCWX[C\?J.XL
M]'-Y;>1?0?VY;\?Z7:?\A/TZCZ]^P]J^1SKA+*,6W[B7-?:,8WD[MMI*V[V2
M5E9(]; <28S#7NVU>VMWI=I[W/\ 3@\%?&;X9?$[PN=5\#^/_"7B2W_Y]+36
M/^)G_P#6'K]/>K&CWEC9W0GU3_1K?_G[[]./Y]\#BO\ -7\!_%KXT_"76;:^
M^%GQ-\2>&Q:YO;3_ $PC[!^/../3T! SU_6#X&_\%R/VK_AB=/@^(VEZ)\6]
M/M?^//[9_+C_ #Z9YK\WS/PXMK@U?=J__ 5CZ#"\2\WO-KI?6_KI?^KG]W%I
MK'V/1A^__P")A=?\>?V3_E_QG'\N?UKL/#?BJ:\-O8P?:<>GU[^^1^(_2OYP
M/@#_ ,%\?V0O&WVBR^(%OK?PNO[OCQ)]L'X8T/J.F/3IQC -?JO\*_VN_P!F
M7XD?\5'X.^,7ANV/;[7K'(!P!D?YZ=<5\S+@K-HNS=K=$NG3TT]3WEG>$DM'
MNNC6[_X<_5"'4O.EM_W]M[W@[?Y_IBM>SO)_[4\_S[;^S\>WMUQSQCCT[U\(
M6?[47P=TV+_DJG@"YT_I]C_MCO\ Y/4?SK'U/]N3]F2SNC]N^-/@FVM_^?2T
MO.+#T_S[^G%'^J>,_O?^3?Y&/UI-_$M?-=?^WC[OO/'FAV=_;P?Z-=:A<Y]/
MY_3.?Z<U9FU*"8?ZC[-G]<'K_P#K%?E/XV_X*$?L=Z;?_P!N'X[Z)<_9?^?2
M\]LDCUZ_YXKP?7O^"WG[%O@FUU""^\?W/B2X_P"7(Z3U[]23GMSS^1XK>APG
MC+^]S/UYO/\ X;3N;/,HX;JI:;Z.WY_UJ?MAJ4,%Y:_N)_M-OTSUY_P^OZ=^
M/FT>^G_?Z7!]JM^/K[_Y[>YK^8?XS?\ !R]X5TR+^RO@M\%KG6]0Q_H7BO5O
M^);IF.,8_#K]/I7Y0?'[_@N'_P %$?C-%<?8?''ASX;Z?JG^A7FD^'O^): ?
MKGGC^O;->QAN 98EIM--OL_S]>YX^)XDBM%R][:?H?W3ZQXVT/P?%GQ7XJ\-
M^$K?_E\M/$.LCC\O48&.W=?[OQO\3O\ @I9^QI\'[K4+[Q5\=_#?]H:6/^/3
MP]>?VE_D#J?Z\5_GK^-OC9\<?B==7&J_%3XT_$?Q)<9^Q?\ (R?\2S_/M]:\
M'GF,TMQ_:L%SJ7V7_ET[]^1_^OW]S]/AO#"R3EHM-;>GE_70\G_6[S_'_@']
MO'Q:_P"#D#]DGPW^X\#^'/%OC^YM3_Q]W=G_ ,2SMCZ\?7D]^M?E_P#&#_@X
MN_:3\;2W'ASX+?#+1/!-O=?VI_Q]G_B9^_TQS[$<=LU_//90:[!%Y\$&FZ;I
M_P!C_P"/0?\ U^G..OKZD5],?LZ_LQ_%3]KOXC:-\,O@?H>M>+?%%U>:797G
MBRTT?_B6:?T'7UZ\_7->MA^$\'E5]$[7[/5>M^QAB.(Y8NRBW=NRM?\ 0X#X
M^_MC?M7?M%ZU]A^(_P 1O$>M7^J7G_$G\.Z!G%]P?[@!^F!QZ5]G_P#!,>\\
M5_"OX^W&A^,;'4]%N->L_L5Y]KZZ@>?Z\X[Y'?BO[6/V(?\ @A[^S+^R7\*M
M'@^)OA7PWX_^-^J6?VW6-6N[/^TM,T'5/^H'_P#6_H*^%_\ @JA^Q/X5^$MU
MX7^.'@#P=<VVH:#K&EWMY_9&.?\ /4#M7@<2YA@UA'A%&*?>UGLUNEMIU;ZG
MW_"/UJ4E*5W>W?O?KY,[CP3>0>5Y$'^C?9?^?L>O?IW[X/3OQ7TQH.I?Z+Z>
MW]>/H3Z<=^:^)_AOKT'B3PQH^N:5<77_ !-+/2__ -7M]:^F--O9_L%M_IV,
M^IZ_0?3MS7XQ;EQCLK1N_)=?0_5\1A?]C3T;M?OK:_F?1&@ZE/#?P?N,<8^G
M3ZCUXZ_I7T!9WL$V?/\ ]%N#Q]D^O4?S_.OB_P -S7WV^WGG%S_TY]OQY]N
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M #$]0Y'_ # ^OU_ITK] /V5_^"//[7O[5&IZ??7WARY\)?#"Z_X_/%MW9_\
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M]DQ^@[&O%O >O6.I:!I]]8SY^U68UK[9U%^/Z^OI^5>P:;#!>8N/^/;^F/\
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M*?A?/O\ \3L?GT/;/(XK_9]\(S11>#/"PEX/_".Z0<< [1I"EOS4,/?Z"O\
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M/'2O]JZ+_@G+^PL)\#]EGX.X*C/_ !2EK_<!_O>M'_#MC]@SS,_\,I?!K/\
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M5;6)E"FVC\-P>6002?O.S=>^[/O7T7]I2C&ZB]$ETZI'(\!%M/FT;3:U]?\
MAC_$\FU*?_H6];MOM/\ U!SUZ9&>O\P.H]-"'4AYMO\ 9X-;M1<G_C[_ +'_
M %_KG]#W_P!IC4_^"<W["]Y_Q\_LM?!^;AC\_A:W[(3V<5'_ ,.T/V!?^C3?
M@O\ ^$E;?_%U=#-L1!7;;WV?^9N\FP=KN+]Z_2_YG^-U\-_C!X_^#/C+P_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ea028258601_img5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028258601_img5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #* G # 2(  A$! Q$!_\0
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M'X6__,O7V510!\:_\.ZOV _^C)_V4_\ PP/PM_\ F7H_X=U?L!_]&3_LI_\
MA@?A;_\ ,O7V510!\:_\.ZOV _\ HR?]E/\ \,#\+?\ YEZ/^'=7[ ?_ $9/
M^RG_ .&!^%O_ ,R]?95% 'QK_P .ZOV _P#HR?\ 93_\,#\+?_F7H_X=U?L!
M_P#1D_[*?_A@?A;_ /,O7V510!\:_P##NK]@/_HR?]E/_P ,#\+?_F7H_P"'
M=7[ ?_1D_P"RG_X8'X6__,O7V510!\:_\.ZOV _^C)_V4_\ PP/PM_\ F7H_
MX=U?L!_]&3_LI_\ A@?A;_\ ,O7V510!\:_\.ZOV _\ HR?]E/\ \,#\+?\
MYEZ/^'=7[ ?_ $9/^RG_ .&!^%O_ ,R]?95% 'QK_P .ZOV _P#HR?\ 93_\
M,#\+?_F7H_X=U?L!_P#1D_[*?_A@?A;_ /,O7V510!\:_P##NK]@/_HR?]E/
M_P ,#\+?_F7H_P"'=7[ ?_1D_P"RG_X8'X6__,O7V510!\:_\.ZOV _^C)_V
M4_\ PP/PM_\ F7H_X=U?L!_]&3_LI_\ A@?A;_\ ,O7V510!\:_\.ZOV _\
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MPM_^9>OLJB@#XU_X=U?L!_\ 1D_[*?\ X8'X6_\ S+T?\.ZOV _^C)_V4_\
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MNFVBN9[[4+JVL[6.6XGBC?Y%_P""=/\ R8%^Q/\ ]FJ? +_U5_ABN-_X*<>
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M@X0A.4L34E1C3HQC"<G4G+$2A14(*+J3<YPBHTY-RC%2DO#/$OQB^()_9_\
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M-+#ID:HFFHFC7EF@TY4C%CM^R;$,)4 'H5%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\6^#/^4@_P"T)_V:7^RK_P"K6_:RIGCO_E('^S7_ -FN
M?M8?^K%_95I_@S_E(/\ M"?]FE_LJ_\ JUOVLJ9X[_Y2!_LU_P#9KG[6'_JQ
M?V5: /M6BBOB?]G'7_VUO$WC_P 0:A\?M4_9*NOA98Z)XHT"TTO]GG4_'VN^
M)M"^*.B>.EL/[)\6:UXNG-A/'9>$H98]5L+&PTG4-*\3O=V%_9&.&WD(![?\
M7_V=?@C\?3X<_P"%R_#CP]\0U\)1^*XO#D?B&*YGATJ+QSX9OO!GB^.""&Y@
MA=/$/A/4]2\.ZFLZ2BXT?4;^Q($%Y<))3\*_LR? 'P1JG@77?"_PG\':5KOP
MSTS^Q? .NKIOVK6_"FCCPY!X1CTO2-7OI+K4;?3[?PS;1:+:69N6@L[ S16L
M</VBX,ONM% 'SIX.1/\ AJ'X[2;$\P_"K]G]?,V+YFT:S\;R$WXW[,DG;G;G
MG&>:^BZ^=O!W_)SWQV_[)9^S_P#^GCXW5]$T 03W5M:QM+<W$%O$C(KR3S1Q
M1JTLBQ1*SR,JJTDKI&@)!>1U1<LP!\[^+'QC^%WP+\&7GQ#^+_CC0/A]X(L+
M_2M+N_$GB*[^R:;!J&MW\6F:7:/*JR.9KR]GCAC58SM!>60I#%+(DWB_X4>
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MF3F]"_X),?LNQ:-\";;QQ_PF?CSQ#\!/@5X4^ /AWQ')K4'@U-7\*>$-;O\
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MR^._Q!?PK=^-_&7[1VO>+]4^)VK_ !"U:]\5V]WHOC'4=.OK_P "Z#H%\_\
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MG6=+T^3P1\0O%UM;R^&+[1+Z/4K^SU-[J6?2; 1 &YX)_;'_ &5?B1<:/9^
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M^E_ /7/"47PQDU7PXOPMT_X8QP>*=#^)$/@#4OAQ+XJM_B;XA\7ZFOQ8\/\
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MBD\"?"V\LM/\:>%]*ATW6M0N/%%[  ?OO1110!\[>#O^3GOCM_V2S]G_ /\
M3Q\;J^B:^=O!W_)SWQV_[)9^S_\ ^GCXW5]$T >#?%_]F3X'_'7PCXA\$?$G
MP%I>KZ#XJUW2/$^OK8R76A:AJ6OZ%O33-5N=5T6>QU&6\M[>:XLO,>X;?975
MQ;.#'*153XC_ +*OP!^+'A&R\!^.?AKH&L>$;3Q#\,_$D^AF P66M7?P@U&Q
MU/P!8>)%A97\1:%HL^FVD+:'K+WFF7]C&^GW]M<V<TT,GT)10!^:T_\ P26_
M8GF^)6L?%E? ?BJV\9ZVUPEU=6OQ&\91:=;:?J.L>+]6US1-*T?^U6TW1]"U
MZ/QWXJT?4=*TRWM;6+2-7GBTI--O%CODY2Q_X(Q_L%Z7I>F:3I?P\\5:9:Z'
MX3T_PCH']F_$'Q/IYT.VTS5'U&TUG38;*[@M$\2>5+-I5UK,]M<3:CID\ZZB
MEU>RO?']5** /ABV_P"">/[.$7Q4T_XK7/A_4KW4_"NK_#37?AOI$NIW$>F?
M#C4OA?X?^%'AG1Y/#LD;#4)XK_2O@A\,K?4TU>[U"2>'0;NU\[['KFK6]SZ9
M_P ,>?L]1>&]-\&Z=X%;1?"6G_%'5OC._AW1O$/B73]-U3XDZQHVK://XEU@
M1:M]IO[BS;5WUS2+:2Y6RT;Q3INA>)M-M[;6=#TN[MOINB@#X\_9:_8C^#G[
M($^NQ?"!O$T&AZIX1\)>"M-T/Q#K=QK\7A_1?"WB7XA>,76PU"^\S49I=;\3
M?$OQ%J>H"YN'MH2+.#3K:SC2X^T_8=%% !1110 4444 %%%% !1110 45YGX
M\^+W@#X<2V=AXCUP/XBU1&;1/!>A6=[XD\<^(&&X*NA^#]"@O]?U",R+Y<EY
M'8C3[5B'O;RUB#2+YZMY\?OB:R&PLK3]G_P;,5;[9K,>D>,OC#J=J61Q]FT:
M":_\ ^!'G@9@)=4O?'>HP-\EQHVG7*D)VTL!7J4XUZKIX3#2UCB<7*5*%1)V
M?U>FHRQ&*=TU;#4*D.;25>#O;SZV98>G4E0HJIC<5"REA<'%5JE-M72Q%1RC
MAL(FFG?%8BE+E?-&A-6OV.K_ !^^"6B6M]=WOQ5\"3?V=?+I=U8Z3XDTW7]:
M.KM))"FC6N@:#/J6N7^M22PS1Q:/8Z?<ZG+)#,D=JS12!>-/B_XX?$S,7@#P
MC#\(/"LX*KX\^*^GM>^,[N%@ZFX\-_":RO+>73FRH:WNOB!KFC7<!9)+GP;>
M1[HF\:_9%_X)U_ 3]C/QE\6_'_PUN?&7B3Q;\9-7@UGQ+KGQ"O?#VNZG872:
MAX@U.[7P_?:;X:T2ZTV#5KSQ'>2ZO%YLR7SP61<+]G4'[TKU,T?#^ QM2GP]
M5Q6=X6-/#NCF6=8&. DZLL-0GB8PR>EB*]-1H8N5>C2JXS%U_;4J5.N\+!U'
M3CY651XBS'!4ZO$-/"Y'B)5,1&KEF2XV6._=0Q%:&'E4SFK1I5+U\-&C6JTL
M%A:#HU*DZ/UJ7)SOQ7PI\!_!>@ZU;>,/$4VL_$SXA6Q9X/'GQ&O(O$&L:;([
MF1U\+::MM:>&?!%MO9@MMX-T+0T:,[;EKEMTC>U45Q7C/5)HK>VT#3[H66IZ
M^+B-K_>L?]B:':(LFNZ_)(V$A^PVLBP6<DC*G]J7E@&/EB4KX\ZN(QU:+KUI
M5))-*51I4Z-*-Y24*<%"E1I4X\TE3HTJ4%:T8.<DY>U3H87 49+#T(4XWYG&
MFKU*]65HQ=2I.4ZM>M4DXQ=6O6K5'=N4U&+48-)_XJ?Q%<>(V._1M >\T;PT
M,@Q75_N:VU_7DP,.HDC;0].D#$+#!JLT9:+4$-=Y6'H]UX>M]-T:ST6^TLZ;
M)90Q:&EG>VT\-W901*D36$B2N+R(1J"986EW<NSDDD^&S?M@?LMP>!?B#\39
M/C]\*A\/_A3XMF\!_$;Q>GC+1Y-#\'^,H+RUL&\-ZS>Q7+QV^K27E[:V]K:K
MO>\>9?LGGKN(RJU%4E[J<:<$J=*+W4(WLW;3FFW*I-K1SF[:1B;4:;IP]YJ5
M2;<ZLELYRM>U]>6"4:<$]H0C?5R/HZOG?1_^2._"7_L8/A;_ .I;I%4]1_;'
M_95TG4UT?4OV@?A5:7TGCCP_\-8%E\8:2+6Z\=^*--@U?1/"]EJ"SMI][JMS
MIUU:7,\-I=3+IRWEG'J;V<MW;QR7M*5D^#_PG1U*NGB+X7JRL"&5E\7:0&5@
M>00000>01@UF:GT-1110 4444 %?&7_!1O\ Y1]?MR?]FB?M'?\ JH?%]?9M
M?&7_  4;_P"4?7[<G_9HG[1W_JH?%] #O^"=/_)@7[$__9JGP"_]5?X8KV+]
MH;4=:L?@YX[MM!T7QMK&H>(-!U#PHMS\/9_!=MXI\*V_BBTGT.Z\=6,WQ!\0
M>&?"B)X)@O7\37/]J:JD?DZ:VVVNS^X?QW_@G3_R8%^Q/_V:I\ O_57^&*[3
M]L3X1:C\=/V:?C#\,])\1>./#NH^(? _B%+0?#_QMHWPZUGQ--;Z3>3)X&O_
M !IK_ASQ7IGA[PQXX91X7\5:G-HL[VF@ZG?3PRVTL:SH ?EY_P $(]:\7:Q\
M&/BY9^+?BUK7Q)/@OQ3X4\ >'-)G\=_#OQSX?\'^&-"TO6=4TV&QN? _[3W[
M4U[#XFU67Q#=IXJN?$?C+1GN[?2/#EKI&CW%EI;ZK>?M!\4?"^K>-_AG\1?!
M>@ZK;Z%KOB_P)XN\+Z+K=VFI2VFCZMK_ (?U#2M.U6YCT;4]%UB2WT^\NX;N
M9-)UG2=2>.%EL=3L+HQ747Y(?\$6-7BO/A9\5M"\-P?%&/X;^"M1^%/A'PC_
M ,+B^+'P4^)/C+3]8T7X8Z59^.?"UG8_!>.6RT/P5X1UR*/1/!VN>)=3O]9\
M=Z?#-KL7^B11WVI?M30!_/\ ? +_ ())_M%_ VS_ &=]8T7]H7PD/&WPEU;0
M%\=0ZN_CKQMX)^(/A2R^+/B3QK%I=WX<U(Z!HT>M>!] U@3>#M8TG0/"]CJ/
MC>^.O76B>'KGPYI^I:M^N/[06DZAK>M_L\:?I?B;6/"-Y)\<UF37-"MM"N]1
MBCMOA%\6IYK1(?$FD:YI1M]1B1[*[=]/>YCMIY'LI[6Z6*=/I"O"_B__ ,CC
M^SE_V6RY_P#5,_%^@#W2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBN*\=?$3P=\-M$;7O&&LPZ99M<PZ?8VT45QJ&L:WJ]TVRRT/P]H
M>GQ76KZ_KM_(=EEH^D65YJ%R0S1P%$=UNG2J5JD*5&G.K4G)1A3IPE.<I/91
MC%-MZ-]$DFVXQC*4<ZM:E0IRJUZM.C2@G*=2K.,(1BM6W*32TT[MMI)2<HQE
MVM?..J_%KQ'\0]2OO"'[/UMINKFQNI=,\3_&36H)KSX:^#+J%S%>V&@Q6\UK
M+\3O&5CAE;1-"OK;PYH]YMB\4>)["[B.BW>>?"7Q"^.Y^T_$V+5/AK\)IP7L
M_A'I^HBV\:^-+.3_ %;_ !;\1Z/=2+HNDW,/,OPW\)ZBXFCE:W\7>)=3ADNO
M#5O]'Z7I6EZ'IMCHVBZ=8:/I&F6L-EINE:7:6^GZ=I]E;(([>TL;*TCAMK2U
M@C58X;>"*.*-%"(@4 5Z'+AL!K4]ECL:MJ*DJF!PLO\ I_.$K8ZO%[T*4U@J
M<E:MB,4U*D>;SXO,=*7ML!@'O7<72S#%Q_ZAZ<X\V H26V(K0>.J1:E0P^$3
MC5///AU\)/#GP\EU+65N=3\5>//$21#Q;\1_%4\6H>+_ !(T+&2&UFNXX;>T
MT?0+)V(TCPIX?L]*\-:1'_QXZ7%/)<3S^I45RNK>+;*PNVTC3[>YU_Q#L##1
M=*\N2:W5Q^[GU:[D9++1;1B01/J$T3RJ3]C@NY (CQSJ8C&5I5*DIUJK2<I2
MLE&$5RQ6T*5&C3BE&,8JE1I02A"$(I1?=3IX;!48TZ<84*46U&,4[RG-N4GO
M.K6K597G.4G5K59N4YSG)N2ZEF5%9W8*J@LS,0JJJC)9B<   $DD@ #)KP[X
ME^._%L_A+6O^%/:4->UN$+&GB6YN]*TWPII"Q3;[Z[.IZW<VMGJWV:WAE23^
MSS<6ENTJR7-U&8GC/:KX7U'7RMQXWO(;NVW"2+PIIC2Q^'8,,&1=4ED$5WXE
ME4JA87R6^E;\E-(# 2GMC:VS6QLVMX&LVA-L;4Q1FV-N4\OR# 5,1@,?R>45
MV;/E*[>*UHU*&$K4JKITL;.E4C-T:O.\&W!WY*B@Z=3$1;5IQC*E2:NN::;;
MSK0KXNE4I1J5<%"I"4%5I\GUM*2:YZ?,ITZ$EO%R56JG9\L'MYIXUOKK5/@U
MXIU*^LUT^]O_ (=ZQ=W=E'=6U]':W%QH$\LT$5[9RSVMW#'(S+#=6\TD,\02
M5&*N*]+M?^/:W_ZX0_\ HM:\$LU5/V994151$^%&HHB* J(BZ#=*J(J@*J(H
M"JJ@*J@*H  %>]VO_'M;_P#7"'_T6M<DFG*345%.4FHQORQ3;:C'F;ERQ348
M\S;M%7;=V^N*<8QBY.3C&*<I6YI-))RERI+FDUS.R2NW9)62GHHHI#"BBB@#
MXM\&?\I!_P!H3_LTO]E7_P!6M^UE3/'?_*0/]FO_ +-<_:P_]6+^RK3_  9_
MRD'_ &A/^S2_V5?_ %:W[65,\=_\I _V:_\ LUS]K#_U8O[*M 'VJ0""",@\
M$'H1Z&OP;_8J\7_"KX._\% OC/\ LL_ []A+Q/\ "18M1\::?\2_C-I'QR\6
M_$3P--X0\'V5G>?"/Q#=^"]6U+6]*\%W'BFU#:#%HTPT2Z\-VDWA30M!OM?L
MHM9T;PG^\3ARCB-@CE6".R[U1R"%8IN7>%."5W+N QN&<U^+/_!/KPMXD\*_
MMR_M[6&IV'C.[M'\10ZGK'C33/!FM^'_ (&^)/'^O:K#JOBV3PU>^(OB'JMW
M9_$"XN)8]8\4^%-&\#GPWIMEJEC>V/C_ %Y[QX" ?JE\=?A_K7Q8^"WQ7^&'
MASQ3)X(U[XA?#SQ?X+TCQA#%?3S>&-0\2Z%?:1;:Y#%I>J:+J+3:;+=K=1&R
MU:PN5DB5X;E'49_/7]DO_@G/\1/V8OB%\+?'DG[1NK>-8?#W@*+P=\3_  SK
M.F^(-7TKQUJ%EX.MM T[Q;HLGB?Q9KLOA'Q'%=V]C8W=YI:1VUQX7T*QTRTL
M--75M7@;]8** /F#PGIU[)^US\:=537=3M]/M?@U\"[&X\-10:2VD:C=7/B#
MXS30:Q=7$VG2ZW'J&GQ0R6EK#9:M:Z;)!=3O=V-S<K!/%]/U\[>#O^3GOCM_
MV2S]G_\ ]/'QNKZ)H **** "BBB@ HHHH **** "BBB@ HHII900I90S?=4D
M GZ G)_"C^NXFTM6TEW;2WT6[6K>B75Z*[T'45X5XA^/WA.VUB\\)> =.UKX
MO^.K*0VUYX9^'<-KJ-IH=T=ZK'XQ\8WEU9>#/!H210)[?7-<@UCRR7L](OG"
MQ-C'X?\ Q>^)1,WQ4\<_\(%X:F.[_A6?P<U*^LKR>W+!Q:^+/BU<V]AXHU!G
MB9X+NV\#Z;X#@4@I_:.IPGS'[XY?4A&-3&U(8"E-*4/K"E+$U8M73H8&'^U5
M%):PJ58X2A)--5I1?,_.GF=.<I4L#3J9C6C)QE]7<5A:4TVFJ^/J?[)3<6FI
MTZ4L9B(M.+H1EHNN\:?''P)X-U8^%8IM4\:^/FC$D'PZ^'^G/XJ\9%&V;)]1
ML+.1++PQ8.KAQK'B_4?#^B[ Q.H@KBN1.A?'KXG#/B;7;;X$>$9P0WAKP+=V
M/B?XI7]NP=&BUGQ]=VDWA?PD[@(TEIX.T;7M0A#$V7C>&50P]?\ !?@#P7\.
M=(&@^!O#&C>%]*\PSRVVD645LUY=, LE]J5T ;O5-1GQNN=2U*>ZO[E\O<7,
MKDM77U7UO#8;3 X92J+_ )C,=&G7K7_FHX1*6!PW=.<<;66CYTTF3]3Q>*US
M#%.--Z_4LOE5P]"W\M?%MQQ^*722A/ 49:KD<79^>> OA3X ^&<5X/!WARUT
M^_U1A+KGB&[FNM8\5^(KC.XW/B/Q7K,]_P"(M>N"^7635-2NO*)VPB) $'H=
M%%<56K5Q%25:O4J5JL]95*LY5)NRLDY2;=DDE%*T8Q2C&,8I17?1HT</3C1H
M4J=&E"_+3I0C3A&[NVHPC%7;;<I/FE*3<ISG)N3****S-2"YN;>SMKB\NIH[
M>UM89;FYGE8)%#! C2S2R.>%2.-6=V/ 4$GI7R/^T+\!M<_:E_9X^,7PUB\8
M3_#74?CMX=LO!O\ PDW]BV^O7OA?X:76L6#:UIMOHM]-%8W&J^(_"K:\DT.H
M^=I\.IZ[;QZM8:E8:8UA/]!^(,^)-9M?"$7S:;:K;:SXM=<%'LA*S:3H+G!&
M[6+NW>YO8C@G2;&:&0!-2B+=Y6[_ '5)+_EY7BI2[QH7O"/DZTH\\E_S[A33
MTGKSK]]6YO\ EW0;C'M.O:TI>:HQ?)'_ *>SJ/>&GPW\,_\ @GS\ OAA9_LU
MQZ3'XKO=2_99@\7?\*XU&;6;?2[>;4/'NLZGXC\6WVK^'?#VG:1X9%O?ZWK.
MI76FZ%H^D:3X>\-VDT&C^'M+T[2;&SLX/GZS_P""1OPGT?P%XE\ ^'OC;\<-
M$L]9\9>'/&6B:M#+\-;W5?"%Q\/)8;7X3Z5I)U+X>W=EJ&F?#GPU=^+/#%D/
M$%IJU[XCM?&.I:IXLO-9UK3/#]_I7ZRT5@=!^+&G_P#!#7]F+0]3\/7'AKXD
M_'30-#\(_&?PA\9O"WA2T\2>&KC1-"U?P?\ ;;FTAM/MOA2XO)-;N-3U._D?
MQY=W5QXUCT5[/PP-7DT32].MK?\ 2/39#-\(OA5,P56E\2?#&1E080%_%^DL
M0H))"@G"@DX&!DU]"5\[Z/\ \D=^$O\ V,'PM_\ 4MTB@#Z(HHHH **** "O
MC+_@HW_RCZ_;D_[-$_:._P#50^+Z^S:^,O\ @HW_ ,H^OVY/^S1/VCO_ %4/
MB^@!W_!.G_DP+]B?_LU3X!?^JO\ #%>]?''3='UGX*_&#2/$7ASQ%XP\/ZK\
M+OB!INN>$O![F/Q;XIT>^\)ZM:ZGX<\+R+/:F/Q%K=E+/IFB.+FW*ZG=6K">
M$CS%\%_X)T_\F!?L3_\ 9JGP"_\ 57^&*],_:M\ V?Q1_9F^/OP]O]!\3>*K
M;Q9\(O'^D'PKX-\8^)OA_P"*/%$TWAG47M?#>B>-/!K+XH\-WVO74<.DQZGH
MJW%Y"+M@MG?(SV<X!^=__!(?PG\!O#6E?M&:A\!/V?/VB?@!X7\8^,? 7BK3
M+#X\:3I_ANR\7>#KWPI=6GA/Q%\/O"%EI&@W_@O2;RZLO$NHZCX8\8:5;^-[
M<:KI6K:G]GT+6?#&D:3^Q]?B/_P0_P##\^G?!#XB:_J_A37/#GB?Q-J/PU;6
MI/%6A?M46_B1HM$^'MAI&G>';OQA^U+\5/BGJOCO3_!2PW7A[3M8^'UWX?\
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MXOO]/\4>&DU;PQ+IGAS5M4.L+IUI)=#(V/9K7_DV>?\ [)5J?_IBNJ]ZM?\
MCVM_^N$/_HM:\'MU9/V:;E&&&3X5ZHK#(.&70KL$94E3@C&02/0U[Q:_\>UO
M_P!<(?\ T6M $]%%% !1110!\6^#/^4@_P"T)_V:7^RK_P"K6_:RIGCO_E('
M^S7_ -FN?M8?^K%_95I_@S_E(/\ M"?]FE_LJ_\ JUOVLJ9X[_Y2!_LU_P#9
MKG[6'_JQ?V5: /M"=_+AFDWI'LBD?S)%+1Q[4+;W565F1<;F564E00&!.:_
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MHH **** "BBB@ HHHH **** #/./\X]?SXK\F/CQ^QSH_P"WK^TQ\,_C9/\
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ME_LJ_P#JUOVLJ9X[_P"4@?[-?_9KG[6'_JQ?V5:?X,_Y2#_M"?\ 9I?[*O\
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M()?B#_SX^#>I_P"8KK?<_P#8&H^KO_G_ (3_ ,*%_P#*@^L?].,5_P""'_\
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MOBS\//V3?V(?V<_B3HD?A[P5XAF_91TBZM=:N]&\1>'M#\7O'XF'B?\ 9]^
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MVGVMO8V%A9016ME965I$D%K:6EK D<%M;6T$:0P00HD4,2)'&BHH  +5%%%
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M?^&G?CLN3M_X5;^S^V,G&[^V/C<,XZ9QQGKCBOHBOG;P=_R<]\=O^R6?L_\
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MV>?^B%_"'_PW/A'_ .5%<+<?#7]C:V^(FG_"R?X<?L^I\4-2\,WGBNP\%_\
M"#^!7\6/X1M;U+.YULZ<FDM?VNAR:BAMXKFX6&TOKRSN$MC<3:?<_9^??5ZM
MZMO5MO=MN[;?J=%K:+1+1):));))627DD?2O]JZ7_P!!*P_\#+?_ ..4?VKI
M?_02L/\ P,M__CE>2?\ #-O[//\ T0OX0_\ AN?"/_RHH_X9M_9Y_P"B%_"'
M_P -SX1_^5% 'H6N^-O"7AJVL[S7/$&F:?;:AK6A>';.:6Y5UGUKQ-JUIH6A
M:>HA\UA+J.K7]I91.ZK$DDRO-)%$KR+L_P!JZ9_T$K#_ ,#+?_XY7RU\4?!?
M[$'P9T/3?$7QA\&?LU_#GP]JOB#2_#FE:OX[\+?#O0-,O?$FH-++I>FV=SJ^
MGP02:D5M;B^C$;>99VUE=:E(\%M97%S#Z5_PS;^SS_T0OX0_^&Y\(_\ RHH
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MU[JFI37"R16=JKI&TTB6PFG90\B+B.)V)886N _X9M_9Y_Z(7\(?_#<^$?\
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M#P;.NI#QE>:3?H]QHL][8:3%I-[=^)KC2K33;B>  ^Z/[5TO_H)6'_@9;_\
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MR_X*-_\ */K]N3_LT3]H[_U4/B^OLVOC+_@HW_RCZ_;D_P"S1/VCO_50^+Z
M'?\ !.G_ ),"_8G_ .S5/@%_ZJ_PQ7V77QI_P3I_Y,"_8G_[-4^ 7_JK_#%?
M9= !1110 5\=_M,?L8> _P!I_P =_!+QUXN\5>,/#UQ\&]9>[DTCPVVA?V;X
MZ\//XZ^&'Q1_X13Q!)J^CZGJ&E6H^(/P8^'&M_VQX5O-$UXV.DZIH1U#^S]<
MNA']B44 %%%% 'E/QR^&NI_&/X0?$7X5Z1\1?&'PEO\ Q_X5U/PM%\1_  T4
M>-/",6KQ?9;S5/#,GB#3-9TJVU<6;W%O:WMQIUQ+8M/]LLFM[Z"VN8;GP:^&
M>E_!CX2_#;X1Z'+;3Z)\,_!/AKP+HTEGHFD>&[0Z3X7TFUT;3EMM!T"VL]%T
MF&.SLX8X['3;:&T@50D2 #)]*HH **** /D;]E7]C/X;?L@W?QNF^&OBCXF:
M]:?'3XG'XK>(+#XB^+Y?&*Z%XCGT'3-$U&+P]J%[:1:O]CU233CJM])K6H:Q
MJ,U[<LGV\6EO:V\/US110 5\;77[%G@6;]M:R_;?M?&GQ TKQS'\-;/X;ZSX
M*TO5K:T\$>*;32+?Q58:#>^([=;,ZGJ5KH]GXSUVXMO#TE]_8G_"11Z+XG6V
MCU;25DN?LFB@ HHHH ^,?VW?V*/ W[<WP]\%?#GQ]XP\8>#M*\$_$O0_B99W
M?@Y=!:]N]4T72];T>&&4Z]I.JQ6\MO:Z]=WFE:A;)'+IVL6]C=SPZE8QW6EW
MGV8B[$5=S-M55W.<NV !N8X&6.,L<#)).*=7XK?\%4_VB?V[/@5XR^%_@W]C
MUH-2US]I/X;?$'X<_"Y+WX9V_C70/ '[1?@+Q3X$^)EIXL\::D+"Y>W\,^*/
M@)IWQH\.6NG:K<1:4?%.E>'[BV7[?(1( ?M37SK^U;^SU:?M3? [Q7\$;_QK
MK?P]LO%=[X7O)_%?AS1O"^N:WIS>%O%&C^*[4:?9^,-(US0TEN+W1;6"2ZFT
MV:XM[=YFLW@N3'/'^&7PY_X+#_M8S^(_A]?W'[+'B7XA^"/C_P"%OC#^T=\-
M-#UZT'PL^(Q^#^GW_P 3=$^&_P '?AWHUWI<4_BWXH>'K;X3:?XP\::/JFG:
MUXOUBS^,WAV*PM-*L=-L)]4?\!/^"K7[7'Q7_:(_9"O_ !7\&[7PO\'/C[X;
MU[P)XZN] EO/%/PB^'7B&?XN>";/PGX_\2:SH6B:[XT\/>.O$=IJEU\#-%\$
MZSJL.@:+X\U*#Q-X^NO#>B3PQ6@!^RW[,O['?@_]F+Q5\8O%WA_QEXP\8:E\
M7M8M[J2/Q0GAV&U\)>'K3QE\2_B/;>%=$70-$TB:_M8O'OQD^)>N?VQXAFU;
M79+37-.T22_;3]!L%/U]110!%/&TL,T2N(VDBDC60HDH1G0J',<@*2!20VQP
M4?&U@037YN_ C_@G1:?!'Q]\!_&DOQ_^(7Q#TW]G[3?CQ;>#O!'BKP9\)[+P
MQ#K7[0GC?Q+XX\:^,K!/#7@W1K_P]XNBD\37'A/3=5T2\M4M_ D4_AA+9+?7
M/$<VK_I/10 4444 ?F'^U#_P2Y^&?[7'BGXZZS\4/B[\7M(T'XW^%_A+H,_A
M?X<W?A3P4/"FI_!>'Q\O@SQ+9Z]:>&KK6/%-[%<_$[QA>7>G>.)O$6C_ &F?
M0Y[&RL;KPQH=S:?II:6_V2UMK437%P+:WAMQ<7<IGNI_)C6/SKF<@&:XEV[Y
MI2 9)&9R 35BB@ KY0_:B_92T?\ :DF^$D7B'QYXF\':/\+_ !=XI\4W6F^%
M]*\*3W7B^'QA\,_&7PEUG0[W7=?T35=7\/V4G@_X@>*HX[GPQ<Z9?#5+G3=2
MEGF?1[.(?5]% 'S%^R#^R_X>_8^^!OASX%^%O&?C+QSHGAN]U6[L=6\:WEI-
M=VEOJ5R)8-$T73M.MK/2O#WAO2+=(;72M!TJUAL;3;/.B"6[F)^G:** /(OC
M]\);;X]?!'XK_!.^\0ZAX3T_XL> ?$_P]U/Q'I.FZ)JVJZ/I7BW2;G1-4O-,
ML/$EAJFAS:A'I]Y<BR?4M.O+>WN6BN3;R/"@KY@_9A_8 \&?LR_&_P"*'Q[T
MSXF>/?'7C3XL> /AUX!\2Q>)+3PCINERV_P\\/Z!X?L=7-KX:\/Z3OU![;P[
M:"R16AM]-M[S4[5X]0,]K/9??E% !1110!\6^#/^4@_[0G_9I?[*O_JUOVLJ
M9X[_ .4@?[-?_9KG[6'_ *L7]E6G^#/^4@_[0G_9I?[*O_JUOVLJ9X[_ .4@
M?[-?_9KG[6'_ *L7]E6@#[5HHHH **** /%O"_[/'P=\&?&#QW\>O#7@R#3/
MBK\2M-M=*\8>)UU77;E-0M+>+189S9:%>:I<>'=!NM7C\->&!XCO= TG3+SQ
M,_AGP]-K\^HS:/820>TT44 %>1_$WX'?#GXO:Y\+/$?CK3M:O]6^#'CJ'XD?
M#V;3/%_BWPW:Z5XP@TV]T>+4]2TSP[K>EZ9XFC33-2U"SCT_Q/9ZQIT*7MS)
M!:Q3R&6O7** "BBB@#G/%_A#POX_\+^(/!/C?0-)\5>$/%6DWNA>)/#>NV4&
MI:-KFC:E ]M?Z9J=A<I);W=E=V\CPSP3(T<D;%6!!KGOA+\)OAW\"OAQX2^$
M?PF\+V7@OX<^!-+&B^$O"VG3W]S9:+I8N)[H6EO/J=W?7\J?:+F>7?=7<\I:
M1LN1@#T2B@ HHHH \-^'7[-?P1^$OQ*^+7Q>^'G@'3O#/Q%^.6HZ?JWQ1\1V
MEYJT\OB>_P!,-W);3O8WNH7.F:7ONM0U#4+Q-&LM/CU#4[Z[U&^6XO)GF/N5
M%% !7AOQ+_9N^"_Q?^(?P@^*OQ$\&)XB\>? ?6[_ ,1?"O7'UOQ%IX\,:OJ0
ML3=W?]FZ5JUCI.KEY-,T^>.+7+'4HH)K2-H4C#S++[E7\_?B3PG_ ,%P_#OQ
M3^*$_@C5/#_C#X9>']5^)L?PBB\5>,?AI#<>*=,^'.H^./&'PEU3Q-;6D=CJ
M;R?&^W^,ND?#O6="GN=(_P"$>/[+NA7>O:CHVG^.[C4[X _H$HK\&O'6I?\
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M-_\ */K]N3_LT3]H[_U4/B^OLVOC+_@HW_RCZ_;D_P"S1/VCO_50^+Z '_\
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M3_T??^V7_P")0?&[_P";B@#_ %I:*_R6O^'C7_!0G_H^_P#;+_\ $H/C=_\
M-Q1_P\:_X*$_]'W_ +9?_B4'QN_^;B@#_6EHK_):_P"'C7_!0G_H^_\ ;+_\
M2@^-W_S<4?\ #QK_ (*$_P#1]_[9?_B4'QN_^;B@#_6EHK_):_X>-?\ !0G_
M */O_;+_ /$H/C=_\W%'_#QK_@H3_P!'W_ME_P#B4'QN_P#FXH _UI:*_P E
MK_AXU_P4)_Z/O_;+_P#$H/C=_P#-Q1_P\:_X*$_]'W_ME_\ B4'QN_\ FXH
M_P!:6BO\EK_AXU_P4)_Z/O\ VR__ !*#XW?_ #<4?\/&O^"A/_1]_P"V7_XE
M!\;O_FXH _UI:*_R6O\ AXU_P4)_Z/O_ &R__$H/C=_\W%'_  \:_P""A/\
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M#XW?_-Q0!_K2T5_DM?\ #QK_ (*$_P#1]_[9?_B4'QN_^;BC_AXU_P %"?\
MH^_]LO\ \2@^-W_S<4 ?ZTM%?Y+7_#QK_@H3_P!'W_ME_P#B4'QN_P#FXH_X
M>-?\%"?^C[_VR_\ Q*#XW?\ S<4 ?ZTM%?Y+7_#QK_@H3_T??^V7_P")0?&[
M_P";BC_AXU_P4)_Z/O\ VR__ !*#XW?_ #<4 ?ZTM%?Y+7_#QK_@H3_T??\
MME_^)0?&[_YN*/\ AXU_P4)_Z/O_ &R__$H/C=_\W% '^M+17^2U_P /&O\
M@H3_ -'W_ME_^)0?&[_YN*/^'C7_  4)_P"C[_VR_P#Q*#XW?_-Q0!_K2T5_
MDM?\/&O^"A/_ $??^V7_ .)0?&[_ .;BC_AXU_P4)_Z/O_;+_P#$H/C=_P#-
MQ0!_K2T5_DM?\/&O^"A/_1]_[9?_ (E!\;O_ )N*/^'C7_!0G_H^_P#;+_\
M$H/C=_\ -Q0!_K2T5_DM?\/&O^"A/_1]_P"V7_XE!\;O_FXH_P"'C7_!0G_H
M^_\ ;+_\2@^-W_S<4 ?ZTM%?Y+7_  \:_P""A/\ T??^V7_XE!\;O_FXH_X>
M-?\ !0G_ */O_;+_ /$H/C=_\W% '^M+17^2U_P\:_X*$_\ 1]_[9?\ XE!\
M;O\ YN*/^'C7_!0G_H^_]LO_ ,2@^-W_ ,W% '^M+7QG_P %&@3_ ,$^OVY
M 2?^&1/VCC@#)P/A!XO)/X $GT'-?YDW_#QK_@H3_P!'W_ME_P#B4'QN_P#F
MXK%\2?M[?MT>,?#GB#PEXN_;1_:Q\4^%?$^C:CX?\2^&?$?[1?Q@USP_XAT'
J6;:33M7T37-&U/QC=:;JVD:KI]S<6.I:;?VUQ97UG/-:W4,L$KHP!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ea028258601_img6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028258601_img6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %: BT# 2(  A$! Q$!_\0
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MX %YI/VP:CJ0P".F<8P.GX>F #X*_P"'2'[&?_1/_P!*9+_P21_8T\VW)\
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M X'04 6/F\SMY&W\-V/SQ_GI4$)_T;SL8."?J._ ZG\/SH\Z#RO\^GTQ[?\
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MAZX'_P!?^8-?K1^V9^PIXC_:5_:,_9W^./\ PL;^Q/!_P1\2#6O^$>%GQ?\
MX\9SV[^_KX-^V/\ \$U/C%\4_C)?_$7]G3XCVO@GPA\6SI>B?&OPZ?\ F(>&
M,;OE'L 3CT!/:@#X@^)WA7_AKK]BWPO^U[^T9\=_%WP_^'_PO\'ZIHO_  A'
MAZ\_LW_A+?%&A8_L+^P^GZGWZU]$?\$_?V]M*_9+_8/\#_$W]O7QC<^"?#WC
M+QA_8OP?U;5K/.I:]X7_ .8%D9_^OSUKRC_@H;_P1_\ VC/C9%^SQX4^!'CX
M:+^S_P#LZ#2]9'PR-X<_$G5<@[M;P0">J_-N7:QXW;2OZC>&_P!BWPY^TM^S
M]X%\ ?MV_#CPCXM_X00Z5>^'/#UI9D:;H)QUXSN/0<8&.<G&* /Q@_X*9:E^
MU?XP_;)_8^^+6E?&*VTW]E?Q1XD\+WOAJTTD_P!F_P!O:7KOK[CUZ_AT]/\
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M^%H:!_V+:<<\?O4..,^OM7[#3?\ +O\ C7XX?\% HC_PM/0,=/\ A&TZ#/\
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M^O\ ]?I[>U !_KOW&??/I^.>V.GMBI_-/_/$_I_A4'_+3R/U[=/SZ?Y[U8H
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M$2$B;<>PS@GUZXP?R.?6N/L]-UN"U\[[0,XSC()ZXSCK[_YS5G^S)O\ G_\
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M_3-?Q7?"6;P#XD\+_LO_  R\'>'+G3?VN/!OQ@_XNIJQL_\ B9Z]I?/OQG_
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M  50_:]^*LWQH^+_ .R#X TW7/@3\&Q]C\876J_\A7 QS@' P>_'UKZ O/\
M@E+XWU;]EO4?@A?Z[:VMS??%/_A/O$EI:WW+:9G< !W. Q(')7=V&1^,_P"U
MUIOCC]DGQ)\6/V;O@/\ \))HGAGXR:/_ &)>>%+31\'7O%&?^0UTY'L.#Z8H
M.8_K6_83^-WC']IC]EKX<?&'Q58_V;K/BBT-Y>6?K@C<1U[G\L'VK[*'V&SP
M8>#]L&<'G/?KUYR>?RZX_/W_ ()B_#;Q7\'_ -C;X4^#_B!#<V_BG3=)+7=I
M@\ XQG(&,#CMTZ5^A4)!^T0'_EU[^N1[?Y_J $TQ^R_N.WTSS^/MS^I)JMI/
M_+<"S"\@$@CGV.?7KZU9FF\F*X'D''OZ^GU_$>]5]-S-%<?_ *SZ\^^.1_6@
M#0_Y:_Y_O5/+@_N0/O#_ #VZ_P#UL>E03?9X?W_?MU&/:@GSI#">P//Y'_/Z
M<T 3Q#RQCKU_7IZ9_2H//]OT_P#KTG^F^5VS^&<8_/I^&:7]]-;=@?SR!_4?
MB#_LD4 3Q+Y0P(<>XQG_ /5_GFH/-_>_ZG_.?ICK^OM2>1!]JZ<XZ>^/KGK_
M )QS2PS>=%<'TS_+_/% &?>#_CW_ ' N>O\ I??U_K]#V[U^37[<$,W_  M&
MP_<'_D#+C_3]G\:=L$_GTZ?3]=)O]5#Y./(P/_K?U]NN.<5^17[<X_XNI8?N
M,_\ $F7MG^-.?QZ^_6N<#VW_ ()J:;!_PQ;\+H-$^S:;]JT?K:=N"./PSSU/
M.#SS](>*OCQ\"?!.H6_ASQQ\1O".B:^<_P"B7=[SG)QQC'(XZ^O%?(__  3?
MT>WO/V&OA]I5C/<^&]/NM(_T/5OMG3)'?L/7Z9[8/B_QQ_86_9*U.U\7_&/X
MJ>-K?Q'J&F66IWOVL^)1QJF.AY/L#COT..:Z /U9\+:]X;\86'V_P?XC%S;7
M/.;3&![YXQP3S]<=C77_ &."\E$_G_:KBUXZ8_PZCI@?TS^<W_!.?3?#@^%U
M_KGA634F\/6][J0T>ZN[O<+X'J3VP/YGGO7Z%0^1>6-O??\ 'M/P+O@\'H?P
MZ'^8]0#8F U*V,..N,GCMD=!G^AKCO$F@Z)KVC:AI7B*"VUKPQ=V7]C7EG[#
MKT[\XX)[$9SBN_C6&%R >>V?3 _/OS_D0100Q=+.W7UP!P/JRGM]* /A#X8?
M\$]_V0_A)X\N?B-\,O@[X;\)>,+H9U?[(/\ C_\ 3Z_R/3'!KT#P1^RC^SI\
M,?BAXG^,7@?P!HFB>-_%(%C>ZN+,#3,XY''][)'7C]:^J(3/-_U[_GT_S_AQ
MQ5>:"";T^T6N0#]3_GVXH ^9_"W[*_[.GAKXB_\ "S="^'&FZ;XYN?\ B=7G
MB'['C)QQUZ'\#T)Y.57Z/^VWLTNGF& "WN1R3P.!UZC&<9^;GJ#ZUH_ZF+]_
M![G_ #Z#IV].:(8;B&7_ *=_SX]CCZ9Z\COC) /SG\$\?MS>.1>];K1^,^W
M_P#U"OT@/[F6XF/MQ^@Z<_R_P_-_P?-_QG#XX]/L?Z=\=>/U_*OTFEB#*(1T
M()_H?Z$#]: (89O/B/Y@?RZ_U/?GFK'D>_Z__6JL)OWD^<&W &2/7'/;@>OK
MU^J_O_,M\XZ'.<^_ZXS[T 6)^WX?UI)8LQD>@_#_ !QV]2?3K2S3>5_G_/'3
MM5>:'_IOCIU_'G^F/QH KC_56\_7W_PSG_Z_N.FA6/-Y\,5M!9?Z2..3Q_\
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M<\?7'UQC^LC4O"NE:]%<?\2JV/U_ ^OKZ8ZG''7\K_BU_P $J?@M\3O'FO\
MC_Q'8W7]L:KGFTY']#SV _3I7WO#F/R?#)K&16JMLMVO3^OS_5N#,PX=@O\
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M\@?V^X9_^%H:!_Q\_P#(MK_R^?\ 35/\_A^-?K]--/!]GX%SGTX]![>_K7Y
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M[]>F:AFF\FU\_KQW],G'\N3UH KPS032W!AN!T_GZ8/3\.?:K$QGP2( ?\X
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M1G.,<=>>IZ>PI(0(9><G[3SVXP#Z?TS].] "_P"M_P XQC\_7WZ_D>3;X\_
M_P#K9SG\^/TS2"'R!GFX^O7TZ9/Z?7O2PS>?$?S _EU_J>_/- !_I'G?].^/
MP_PQ_GK2&&>:+$V,^GIP/;^G%+#^YBSSGH<X_3C_ .OGCBIS%!,,XXXZ''M[
M_P"3[T +22B&49)!ZY/3(Q[D<>XSZ=<5!Y_M^G_UZ+N?R8OW/;TS_GCTSS0
M P3?ZGJ/R_+G/_UZ0>=Y=OCK_P#KZ^V.F>:)C/-%^X]Q_G/48Z=_3CK8BBQ&
M!ZC\/\<=O4'UZT 0#_77'^>QHAA\K_/_ .OCKWJQ_P M?\_WJ)^WX?UH SX?
M.AE\G^7/Z_3_ /5S5B&'RO\ EOGKZ_\ UOQ_PXH_=?YVT30^;_G^?MG'?K0
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MYY]L>_2@"Q1Y_M^G_P!>D,HCZ]_;^O;./?ITJ&&:";]QU]/PX/KC./\ /!H
MK33^5]G_ ./D_:CV/J._7'!''H1GM7Y _M]B?_A:&@?N3_R+:?\ HU!^603]
M2:_7[S?)B_<?Y[_Y]N:_'C_@H%]H_P"%J:#_ *1<_P#(MI_RY?\ 35/;OUH
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MO[=DT!^)^C?Z1_S+T>?],S_RT7].WX5^P4W^JM_Q_P#0:_'?]O66<_%+1?\
MCW'_ !3L?_+F"?\ 6+U)!)_'OGKV /5O^";5Y-IW[$?@:]TN!;K7[?1VUDVA
MY8G X(/; 8'KD<],X_(']HK6-5U/]H?Q1\3=*\*>-M$\4:I>?Z9I-I9_\?X'
M;OSCGTK]D/\ @F/-JLW['GPO^W?9K;6+JSSK%Y:#G(X!_P #GG^>]XZ_:A^
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M9?#_ ,*_ 'X5^)+:WNO#?_",?;/">?[,_$_GS7ZF_P#!'3]CSQQ^Q=^SU?\
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MEY\T?7 ]?7Z?I0!GRS>3#;F]V_:#GIT_/V/'2OR0_;PE/_"T=&_<#_D7H_\
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M;(65Y=ZL<G(R3GCIT^O.?0_2,$/V.U\^^G^U8[_R!P.O^/2@#0_?>;_^K/\
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MO>K'E3>GZ#_"@ \Z;_GA^@_^)J8?O8Q*H'G <>QST/MCZ9[^SH._X_TILO\
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M9Y_EZ#_/XU6XB(AQDW/0Y]L=?<?3'IQ4$,/E?Y__ %\=>] %B8>;%;CUQ^@
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M"#!QU&,]>0<8[Y_GZ9KS^\TX:G87/A7Q$<W&IV>J*<?\@P:8.QQTXP2.WXT
M?"'PE_X*<?LR?'+X\?$CX ^ /$>F^)-8^%^C_P!M>/-6TG_D&:#COKG/X>OO
M@<>;_"K_ (*V_ #XG_&KQ!\)8(+G1/"&@ZO_ &)9_$2[ TWPU?ZF#T!ZXR.G
MX^M?F--^S?X'^'O[>O[2_A7]FSX97/AH^,OAMXG_ .$EN[,Y'BW53U )QGVP
MHSUX/%?"'CRSG_:*^%_@;]BWX+?#_4O#?QP^%_CS5-:\8:M:6?\ 9I_SG^5
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M-_PG.H_VSJED#>ZJ.H!)P?H=IQZXXZ&ORXUWX V.O?\ !0[P?/H>JW-S\-_
M?_$E^R?\PS]<_C[&OZ!X-"_L*UMK'2IC<?9KL<$8(X) ('?CG!/.1G'-='-;
MJN^OE_7]= _G _;&T+XC?#>+X@:5KFK?\))J'_,'['U^F.<]..M>L?\ !/+X
MJ?M4>&_!NHZYX_\  ^I:EHVJ?\@>TL[/)_3/I^.>]?IQ^V-X.\.S?#[_ (2/
M^Q--_MFUUC2_MAQZ9_NXZ9_3DY)KTB'Q)X<^&/P,T?78+"VML:1]NL])M.M]
MJG&>2.1D9]>?ICN_M"/U7EY8WVV5^WKY>AOA/][7-\-_>[=/^"?S[_\ !9[_
M (*6?$WX,^ ]'\ ?#C0]3T3QQKUG]MUBTN^ATOGW_ ?GQ7L'_!"#]NOQ'^U#
M\,]8\*^*H/L^H>%\\7?)R?I]?KUK8_:N^ ^M_%/0?$/[3/Q;TOPW;>$!X:^Q
M6FD7=IR > 2#D]B.O)SZ&OF;_@GOJ6E?LZ_$'[=X.@T2W\+^/./M9XQCIUZ\
M_P"/ICAWUWOK^I^C/$Y4\G>$7+[3E=G9.TN5];7WZ']4,/\ IG]H3^1_H_V/
M[%W[=Q_+\?K7QO\ LHPF;X@_&">"?[-;_P!L8%IQT/!]O\.>O%?7.@Z]8ZQH
MUO/8ZK;7)_L?'^B<?C[''ZU\B_LOPS_\+/\ BU/!#;"W_P"$C.2"<A<8)'7D
M#\<]CP:YS\SDK2DNTG;TN[?@?=,,5O#]H/G?\?7?'X'K]15>\A\Z6W/_ #Z@
M?CQQSZ8['W]*OPS>;:^?,.N/;T_#OGMZ<5 )H)HKB?\ +/XC.#_GT[T"*YA_
MTG/GVY^U#/J3ZCOG/89Y/YC\Q_\ @H%X#\1P^$O"_C'P/XXN?#?B"U\2:79?
M9/MG_(>^GY_IVZ5^F!EL9KJW(@N<YZD<=>,C/3U_+WK\GO\ @I[\<?AWX)^'
MW@_0_%<.H_:/^$[TK6K*[M  +#3 6R>,X# @*#TQZDT ??'P2\'S^%? >CP:
MKJOVG6->T?2[R\M+P8'^>V<G'YY]XTX[0?W-P,\9/0=^N1^OUKQ?X)?$'P=\
M3OAIX8\5^![BXU+3_P"R-*L[*[U48.< <\G<>O(V\8';YO:8;P3?\M\?3T^@
M//\ G.,4 6)IO*_S_/VSCMUH\[ROQ]O\]<>_3\SSH)I?([\'_)/0GZ?KP9X?
M]5!]/ZB@"O+$(8S-Z8X Z#Z^A_P^E6>/]?QTZ^W3\NW7W]ZKP^=-%R1^??KR
M,9'^<43R^3Y AP<\=^1[]O7Z?2@ \[SHOQ/H>G3\>GN.>:/._P"/C\,?_6_7
M _$U/+$&'Z<_Y_$$>X-5YY?*P8<$W)R#CJ>F?7O^% $$/[_]_C_ZV?\ ZY_Q
M&:L0P@2]O\,>F._Y@]>*)O\ 6V_X_P#H53S$0YF_ C\^_N1C] ,F@" >1%)_
MK_3(X./3''MG(_\ UV/.'E>=@>G?I_CFJWE"+,\Q!/?V^OU';/\ @5GBGFY@
MGXYS_0<#'],\X'< ;))+)%!,H YW'GU]\^Q]O3I5K]]YG;&/;I_A_P"S57_U
MW[C/OGT_'/;'3VQ1B;_GX_E_C0 ?ZK_.<Y_+T]NGYKS##[CZ=_Z_D<GL:3R>
MOG_YZ^_^>3GK5<0>2;?U'3VX^G3D_P#ZJ +'G^WZ?_7H\F;_ )[_ *C_ .*H
M'^NN/\]C1Y)ED@G$QXYP./R^I]>O\P">6(,/TY_S^((]P:H>=YO3[3^///\
MD]!Q4ZDD"XAF\^#!^7.?K\P//!';^=._?S1=K4?J?_K_ -?U $AA\K_/_P"O
MCKWH\[ROQ]O\]<>_3\SR/?\ 7_ZU'^J_Y89[=>N>_P"GK^70 !YWF_\ +"X'
M],?GZYZCTSVI(HILSPG:(,X'KR!G'?'&/U[TLTW[K_GV^N./KC'?':D\H_9O
ML_G?O\>H^]G^[Z?I0! 1/#%Y$_\ I.0.><Y[<]N?Q[]*L?ZK_.<Y_+T]NGYK
MS##[CZ=_Z_D<GL:K0=_Q_I0!8A\C_7\>F?UX'X?X#@U6EA\J7/GX!]>/S_(9
M _QI?.@\[[/^/4XQ]<>O&/3CI4QB@EC \WBVSDCC&!WSV(_7WH 4B>+CSP><
M'/\ /Z\?TX[$/VWRN?L_3C&>GOCC/^3Q2S0?O?/]O;IV^F?P[YZ4D4,WG>><
M8/&,XR,G_(ZCK0 O^M_SC&/S]??K^4W[K_GC^E+#Q&/W6..GKGTSU/KBE_Y9
M?Y_NT 5YO.\PX^S>V?O=3C.><_Y%5_W_ )G[_I[_ *8SVZ9SV]ZOF(2=>WO_
M $[XS[=>M0<33>Q_'I_3\QQW% $\1$T8F[D$CVP?\XQT[<57F_= ></M'L1T
M]\<X_KCMU*S9(Y/V>#N>F3ZXZ8_I4_GCR_._Y8[<^_I^6?UXH H0_N8OW$''
M?K]3^7/'T]LV,_\ 3?\ 3_Z]3_E]GQ_GWQG_ #NJA%Y\W^N_T?Z<>F.N/\Y'
MO0!8F^T9'D_AZ]/;^O;-)-!!^XZ?Z*?EX'''OT]>XYQWXKQ>>)/()QU[^@.>
M.X_3Z=:T8._X_P!* *\TW_3#/3K^/']<_A5C_EE_G^[5:+[7F;.,Y&W..N.U
M+#Y_'X?E_P#K^]0 DDOF@ DP'U)!S^(&/_U<4O\ J8K@8/K_ )YZ?C^AHSY,
M7[_Z]/\ ]?';M^-$/[Z+'.>ISC].?_KYYYH KC_EA^/]*_(?]O 0#XH:+FYM
MA_Q3L?T_UB].:_7B;]Q#!!^'?GI]?KV]C7Y+_M[^?_PL[0,Y_P"1<3I_UTC_
M ,_7- '7_L+:G-H'[ WAZ^@N+CQ'J'ACPYJMY9_9!@L>2 N3UP&8_0G&,X_-
M#0?VP/V_/@S\+OBA\</%6AZ9\4?#]U>:G9?\(1:7@_X2;P%[X_(]AS7Z3_\
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MR\<X&,#ZY]L\ ]3W(H L?Z[/D?CGMUSZ8]NGM1#Y_'X?E_\ K^]4'G>=:_\
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MC&?4'GO]3UJQ%=@B#R1D$8QZCT(_E^)]Z /SP\!_9_\ AM?X@?9_^@/^/O\
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MZ?Y^AVW_ !^Z7_QZ<9Q^OUS],5]0?!GP'X.\-^"/#_\ PBNAVVBW']CZ7Q:
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M_A,O !T2VN/"NL?;+W2;O_E_X[]3^.?:OZR+R&WFM;BX_P"?6S[=!W[XY/\
M@.G)^'_V4I9]2^('Q)OM5G^TW/\ :YY[Y]2.AQG_  [9W^LZ6OI:V]_S;/J,
MOSIX3"-:O=).^UK=_*^J..A\5^(_ =KH]CX_^$GVH:9_H7]K6EGU!_+\^G\Z
M]9L_BS\ K.[MM5G\*V]MJ-R<_:[NR'^@X'3D'@Y_AY]\=?K>73K&.YG-],T]
MO=9_T-N-.4=@1V8>OZ8'/+ZQ\*_AUJ=K<07WAS3,:GUNL<D]1@Y &..Q/T/%
M8-[M^IY^)S+ZV[ZWUZVZWW.>T[QM\.M= 7PYXK\.74%R,'3!=J"3QR 3P<\]
M-OIWQ_-S_P %/?\ @GC^R%X]^(VC_%35I[G3/%(O!D6?_(,_/MP<]#GMV-?O
MQJ_[*/@":U^Q>%;VYT/4.OVJT(R.<8.,CZY)Z?E^)W[8OA#QC\,?!OCCPMJL
M]QXEU>Z\1Z7_ ,(V?$/.<\@@_P"&<^O/"LL3IIKZ=-/G^MCU\ESE81WO=VM9
MVT_KOY^A^B'[-/[/8^'OP7\$6'P6UPZ;X7NK,&\M#TO]Q.,=NQX'Y<BOH'0?
MBWXX\*2BQ^(WAS_N+6G_ "#/\_GBOE_]D3XI_&CX>_ /PP?B;X&N=<@M;,+9
M_9,<]<#(&3\W/YD\U]H:/\;/@M\2;6WL=5-J;_C[99W@YR,]\GT!'''/7MA_
M9MG>^SO]VO<X,YS+ZWBV[)ZZ:76O1WO_ %L>H>%?%?A7Q2/]'U733<8Z6=Y@
MY_'@\#U_#T](^QP6=KB"#[3Z>N![YZ>GY9Z5\C:[^SWH=[J!\1?#+Q3=:)<:
MGTTJTO!_9AX^I.!Z$#\QFL"'XD_&CX67_P#87B3PY<^);8]=7M/^098CIU^A
M^AZ\]:Z+6T['GGV_YO[KR,_O\=/TSU].U6(\X/G8SCGTSWSC_/7VKQ?P?\:_
M _BL6]O_ &YIHUC_ )].AR>_7Z].E>L>=Y)SYWV@W'2UX/48..#@=R#C/TR0
M!;??\?Z1H_ZW_EACMUZ8[_KZ_GT.?,9C="'S[;':T]NOK[]3W/0&I_.\TDPS
M_O\ '_'J3T_+G  ]^_.:7R8?M7G>?_I'3MG\O3]*#G%\[R,>?[?_ *NQ/_ZA
MWJ;F\A[VW\\?H./SQ5>:&#S?/:>X/_3J.A/?CDXXSU/'&35G_CZ]L?\ CO\
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M^/3^0&?4D]JKP^1Q^'Y__J^]0 <0W/G^?BW[CMWSV'KS[Y-3S0^7R.GX^O\
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MD@#ZM@''/>N0_P""F7['^E?M%?"JXO3JO]FZ?X7_ -.UBT'4XQD]!ZXKP?\
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M $0VN3],D\Y/4\],YH.>S[/[F=!5?SIO^>'Z#_XFJ\,!AB\F>^)(S^6?K_\
MJXYJ>:$0YG,]QZ$ YSUZC'^>HH-PA''G;NV,]^_?/Z_7-9$^I6-I%^_FMK:W
M[?:_8=._^&?I6Q/_ *WR,@<=/4<?0_ET]/7\KO\ @I[-/H/P?&N6.J>)+:WM
MKO\ TRZ\/WF2#[]>>?\ #L6/J_\ G_P=CGPZ>(Q6S27W:;6Z'ZCVVI64W'VW
M3[G_ *]R&)^F"W^>..M6N(H>PQ^&"#_/(]N3VK\QO^"<NI:KXK^$MAXCU7^V
M[G3[KFTO-7O.?TQ_+WZ5^G)FAAA@,Q X_(C//K[]>WXT"E6<<3*#3LKK:RT;
M_4L>?[?I_P#7HI(H;/'RXR?4]_I[9_GCO2^5#Z?H?\*!E?SO*_'V_P ]<>_3
M\SRIO3]!_A4\4,/:;)],XQ[Y^G7GTY[4O^M_Y;X[].F.WZ^GY]2 'DS?\]_U
M'_Q55YC/_K_]&_,G_P"O]>IP1Z4?ZW_.,8_/U]^OY$T/^3^/3^8./4$=Z#G$
MEEF$T&!^X/)/]#SS@?7C)QBK$LH4?KS_ )_  >Y-0>3^Z_SCI]<]._Z9J81&
M(#R<"''(SP.QQSTY'Y^G0._W=-O+;\!1-YXQS;_7KZ]<#]/IVI9H?/B'Y$_S
MZ?T'?CFJ\TWF_P"?_P!7/3M4T/\ QZ?Y]Z# =#%^Z_<#[,/YY[^G\^?K1_RT
M\_\ 3MT_/I_GM5F'_4CZ'^55O.@AE\COR?\ )'4CZ?KP "O/_JO/P1S^I_(=
MNWY^MB:'S8O('?G_ "3VZ#Z#M1_RQ_U'M_\ 7_+OZ=J/._Z=_P!: #_EGY'Z
M]^OY=?\ />EF_P!2?H/Y4DT_[WR/;VZ=OKC\>^>M$W^M_P!=CJ,''4?3D<]/
M6@"OYWG1?B?0].GX]/<<\U/$!%# #_R[@@^X(P<<\YY_3BE\F"'IR/\ (Q[^
MN>_OBJ\,\ E/D?Y/X?B/0^G% &A5>:;RO\_S]LX[=:GE/EC/7I^O7TS^E0>;
M^Z_U/^<?3/3]/>@ F_U5O^/_ *#7XW_M^0V__"U=%S<?\R['CCC_ %B=,_K7
M['R^5-%!^_\ L_.1@CKCIDXQ^F0?I7X]?M]''Q0T#G_F6TZWG_35/4_R_,]:
MYP/=O^"8\/D_L6_">&>]_P"7,<_4CIU//!XZ8S7X+?\ !6'7OB+\0?V@A\.)
MOASX<MM0^V"\T;Q#>6A8WX]R<\\=SQGK7[L?\$SIH1^R!\-[C%Q;P70-[=VE
MV1_Q(O;GW X/Z5^.'_!2S]FGXT_%3]H/Q!\?O#GCC1+JW\&_\271_"=IJ_/)
M_P#K>GUP<5T ?N?^PY_:%G^RC\-;+QO8C3;[2]'TVQ;[(#N/3:1C@<YSGC'T
MK[)\F<16_P!A_P!)]?MA)X_S@\]<?A7R/^PM9^*H/V:?A_8_$#_1O$/V/_3+
M2[ZYQW!QQ^7Y9%?7^G2B>*X^Q3#KD9&>?4#U[=: + *Q2VT,QS/U&.>WKU^I
MS_.M&L_,_G8\D?9\9^U9&<9QC&>GOCWS6AYH\W';&/?'_P"OM^N* ,^:&":7
MM[8_KW[_ .'6CR?)_P!=_P >_I^O;_/];$V/,'_/?''TQ_\ JZ<_K1-Q%YT^
M#CMV_3KP/3/X4 'D_P"BXSQC/X?GZ]NM5C%#/=03B?!QQ;'D9QP0/;J3CG^4
M'GV/_(*\_P#TC.._YY]/_P!6<\4D4L!D@$!M[@E3\P.&'')&<X('?&/PH&M]
M#\X-!AFO/VN?B1Y]A]F_XDW![=?Z\Y]S7X/Z_-\%O$G_  43\4:KXQTK3?[1
M_MG_ (^[S\>O^?K7[7^)?BIX ^&/[7'Q _X3CQCIFAZAXH\'BST>TO+P_P"G
M\^W0^@QU(Y&,5_+!XP_9H^*OQL_:J^)'C_P!XJ^S#^V-4^Q_:]8SS_CU']<U
M]APYPI',W];DDE=-WT=NN_DG_D?K/"6$QCAS-2Y&ES.TN5QLKW=K/3S/W8\8
M?\%(/@MX<_:"^'_@>"^_Y%?_ $'^UL_\2SN#W^H'?K^'[7:'\4]*U/0-'U2"
M_P!.^SWEG]LLRI -ZN/O ^W'09Z<=Z_D1\$_\$J?C3K&LZ?XQ\5?\5)X@NM8
MTO\ MC_3,?8!WQ]#QU[]S7]0WPN^"MCX3^'&G>'3!=>?:Z.++[7=@G4P.F2<
M#&.#GIV'(P/I^(\ERC"?V9'#2CT5172OLI<VOKO8]SB7+<F_X3>:24F[3UBF
MK[W5[[M[_HCXH_;I_P""@/PD^&^GCX?^)+BVNM9UZ[%E9Z5:?\A2QQU)''7K
M^>,XX^L?V1?VD/"GQ5^%7A_Q%HA_L[1[6S&C6?VN\!^WD=#VYR,@C'//!K\1
MOVV/^":GQ%^-GQS'Q'T+1-1U._U6R-G]LN\XT$''X<^OITK[1_X)U_LK_%3]
MFKX<W'ASQ5_9NI:AS8Z/JV>-!R/;UZ<XZU./R;)WE*Y91E-]FG*[2[.^_G^9
MAF&2\.O*U&+BY-*UFFTVE9[N757_ *O^H_Q^U_2KSX5_$C2;'4]-.K_\(V?M
MEK=\@?[W(//('7W(S7,?LBS03?!+P]8WU[:_:.MG]DQ_C_3\QBOY]_\ @JM^
MU3\;_A9KNC>#["R%O<:K=_8O$EY:'KI1Z'IW!'3C![D5ZA_P2=_:0\?ZS+XH
ML?'^JZE<Z?:Z/_;6CVEI_P 3+[#I>>O\O3@=ZX/]5(O*7*,HI-76L;VM>WHU
M;7[F?/8C@+!O*7C8VE>S323]+6OY?<?TGW<5A<6E_IMZ1@V?6Z*X.0>._?D$
M>W4U\7_LNPZ'#\2_C!.(+:U-U>BSXYS@C.<^O3Z>XK(_:)_:;_X5M\$=1^(V
ME8U(6NC_ &W')]AMZ=/3W]C7XG_L3_\ !42^^)WQ?U#PK!X5N=$.O:Q]M^U7
M?_0+'3//3_$<UX67<%?[)F>,Y5I=Q_'5=.G0\C#<!K$PY]$DF^:VFB;WVZ;-
MG]7%G-YT7^H_#G/^>_4_3K6/K'@[PYK$5Q]NTK3KDW7?CJ.G; )Y[#G/:N,M
M_&NE010?;M4MK;[5:A@6^F"><GMQGIG/!X/5V>I65Y8?;M$OK7R!UQ=D#CN!
MGCV[]1@=OGL3A?JONM/M97]-_P"OO/F,PR7ZI)IJW*[?<[?ITTU\SQ_Q)\ ?
M ^O2_N+[4M-N+2T/V+[)>$?I_P#JSUXYK^9?_@L-XV_:3T?QEX6\.?!W0_$F
MI:/H-[_IEW_]?!^O'KVK^L>;7;+$%ZMQIUP;;_C\-KS@]N#VX!(/()/%?E_^
MW5^TA\"O#FAP>'-7U;PE;^-O^$CTK[7:7?7^S!NR>,#!&S'&1@\$&BADN-Q>
MN$3?7Y:MM]>YS+AO%YLE]43=][*Z_P"!H6?V+OBG\?M?_9S^&^J^,O#=R=8.
MCZ7F[O,?D<\'TQC&/U^P+WXG>,M-E_XFO@?4M2_Z]/\ #GM^ QUKI_@GX\\'
MZQX#\+6/ANXTVYT;^Q]+^Q_9.>#]!Q@@<]<YQP:]PB,TT0F@-O;D], G@\9]
M/KDCZ@<UABL)C,'HU)/JK6V]4O/\3@EPYB\IQ3YXNST=[VOMV[W/G&'X\3V<
MI^W?#KQ)IMOU_P!+Z#K^/^15_1_C_P"'-8N_(U72O[-Z_P#'WS]<]<#K[^^#
M7O\ ]B@FN;@7D/VBVQ\INL'D=,9X(]<=1^O/W?@_P1KT7[_2K8\\<$'.>G7T
MZ?@<X/'+RXM]%]R#ZOBM7;1/M?3Y+^MSG[3XA> ;NU$XU4::+4\C.,<^P.>O
M^374_P!L6,YT^^L;[3;G3[H@#N>!QP"?UYZ\=#7#S_!3P=-+Y$\!^S^OO]/3
M\O?WYZ]^ 6E>5<06&N7.FW!_X\_],YZ9)P>3T]#W/3-/ZO\ Y_\ !V_$#V&;
M]S==?M/_ .O^7 ]_3TJQ#:8SG_1O^?.TR/3GD^G4_P#UJ^;]2^#7Q%AFN!I7
MC^YMH#=Z80,'D C/'/<CV].!5B'PM\6O#=J()M5_MS4/MGVW[7Z_T_'CT'I7
M1Z&&OG^)]'F'R8M0^W0?:+<]@!T[_>].,]>WTHAF_P!%$]E]HMX%[7>._H"3
M^'UKYON_B#\6K**W(\-W%P2>2.Y]_P ?7Z^U5X/CCXWLKKR/%/@RXM;<XS@
M9^I '7\O:N5U\2W):-7TO;Y:/3;\3O/J&'$,=Q//]FMK?I[=.G(_#_ZU8_\
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M-6LSGGH0-I]CCISZ=/V U[X>_%2&7S_[#\-W/;%IQQS]1CM^'6L#FSO#9/\
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M^/Y]:"?[.C_.OO7^9^L O(+R7]QJEM<]/]$M+SKZ=,G [\_0^FA#^X_<9_\
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M_,_DH_X+M?'+P!\9OC[X&OO@M\3?[-\4:7_H5Y=^';SCCGOV]?QS7Q/^S?\
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M_P!_Y?CJ?IQH_P /K[PII>H6^E>*O[2_X2C5]4-F?MF!U)Z\?YSQ@YK^.?\
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MOH>;$/[(W_!1&&+_ )*KX;ZGC\^GY$#_ .L*W^KX+^:&UK\T?0?UI?S?C_\
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MO);BW@U8:W/:\7G/]H_8#SCOW]/3DYS5?Q5/;PZ%K_GWXMM/M='U3^U[O/\
MQX\$\=O4@#L,U_*=I'[1/Q3_ &8_B_\ %\^%OC?<?&3P_P#%B]U71K+2;3_B
M9_\ "!':03K>>A*[ESP<$CVK#FE_-+[W_F'-+^9_>_\ ,_JY,,$UI;PP:K]I
MN+J\-D;NUO,GWZ9R1W(!]LU8O='M]2%O8W%B-2MK7K]K_ =?;T/OCN*_GO\
M^"6'Q:^,>C_%_4?AGXI^(MK\4O#'B@:IK7VJTO?[1_X1,^F0#CGJ<-@<^U?T
M4:;#-#:B#_GVXQU&?Q&#Q[8XZ5O]9?=_?_P0YI=W][.?$4_F_N(?^/6\^QC\
M>OU![_AC-=-%YWFSY@QU(.<?3OSGJ.3WJU>0CRN,?R_S_,_7%3X'I_RPS^/K
M3YI=W][-7B+JUT]+:OT\RA^_\K_GVS]3GG],X]S^5&)SR9Q;=,\?EP?H,' [
M9YJ]@2Q^5ZC!/YGT_+]:A\K][_KO\Y^N.OZ^U(Q*_G>3%^(]._) ]^O3GWHA
MF_=?A].!G\<?J>E:$T/F_P"?\\=.]5IH1Y4 ],>_;\.WMQCUIW?=@03>?#%.
M>F>G?Z''0^O'_P!>L<ZE_HMO#/G[1=>V?\^W P?K703?OOM$'(R/\X[CW^N1
MDUPVOS_V#8:AXBOI[:YL-"LS>W=H 3C SUP<="1GCZT7?=_>!9O+.QO+7R+[
M[-<:A:_\>?'//7ICCICTZ^M9\T/^E6^K3ZKIMM<:7_R&+2SZ?7C'/<Y'KUK^
M1>T_X+ >/_B%_P %._''@?PKK>I6OPW\&Z/XIL?#FDWG'VW5.>!USVZX.<_W
M>?H__@G;^T'\6]._;2\0:%JOQ&N_BSX7^,E[J9O+13_:.F> \$8Y&."0-PS@
MC*D,"5)=]W][ _J!TTWTT5Q/?# _Y<_ITXY'<=?Q/05HP^?-_KX/?_/M_GKB
MFP\7)ASCKT_7_.3^)K1\T>;CMC'OC_\ 7V_7%<_-+^:7WO\ S S_ "?)_<Y]
M_3KQ^F??U^A#-.99_P#1^A!Z\_S'X]!GCWJQY7_+;]?TSG^OZ]JKPS>;_G_]
M7'7M1S2_FE][_P QW?=_>ROYT\T5O<"#\/\ Z_H/7VS6AQ#-VP/TS_GVQ[8J
M?\OL^/\ /OC/^=U+Y4/I^A_PKHN^[^\1S\T/VR'G'^B]/LG&>Y]O\<>HK'U[
M1])O#;SZMX=MM;-J,_:C:#(Z<_F1GMV'-=1-^YC/[C_/X_Y/YYKPPWWF_P"D
M3YM\]!CW[\=_I^')HYI=W][_ ,QJ4EM*2]&U^31C0S?8P;W_ )!V@6EGQ:VH
MSSZ\8['MVXXY-5XM2TN\D@@O;[3OM%T#_P 2G5,9S[!LC//&1C/K6C>0F&6_
MGGG'_'F!9FZY(/?L!P1CIC)/'3'\A'Q8_:B_:,\$_P#!3KQ'XQ\:^*KG6OA/
MX7LQ::3X4\/]6U3)&B#TSD9'(//8=$%W>]W?O=W^_<_KV@Y']F3C3K;[/=9L
MA:W9! &2,@C<#AOND G@8! QL0S3F$S>1;?:,<X_/U! Y[&OY;OV9_CU\<M8
M_;N\/Z]XQ^)@UKP?\;"MXW@BSN_^0&,]#UY.3SCL3ZBOZBC!/_I'[X$W5IQG
M\1Z''4XZC)..M @FA\[[-/;SCC/;D_Y_09X]?R-_;RAM_P#A9N@?N#_R+B?^
MC$K]<;.86=KY!!R.XZC./IZ_C^-?D5^WI,?^%I:+^_Y_X1Z/./\ KHF,US@?
M1G_!,+R/^&-/A/;P0X%K8MZ=6((.?48/7U!K[YBFFEN#P H'X =_?GZ\GH,5
M^?\ _P $NX<?L<?"_P#Z\B>W;&>W4YR>WI7WSYT$5UUY^QC.,9(&,]?UXZG-
M= %B:;R8L8^T^N?8]^3_ )[58Q_TP_7_ .M2"(1]._O_ $[9Q[].M'F^3%F;
ML/KD9P,T 03P^=%^XG^S?ECL?7C_ #P,4GD3?:O.\X8QC';&/3&/\_C2SS0S
M1<GO_CQGVX)ZXJQ-#YO^?\\=.] %?=-]W/[C&[[3D9^N,[OQZ>^.::3/-^YA
M_P!01G[2#S],9&3U[8Z8XQ5<S>3]HO3,2,?\>O&,]/7@G'7';KVJSCS1;_\
M+OZVIQTSWQ@<>P^G- "_N?*__7C_ #_[+5>6(&3R0001G[)G QG@YZ >_-6/
M._X^/PQ_];]<#\31-F:+O;<^WK[8_EU[D4'.? V@_P#!/[]F71OVA_\ A?\
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M##[CZ=_Z_D<GL:G_ '7^=M5Y^WX?UH.<X[7]"TKQ5X7U#PWJ@\C3]>L]2LL
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MQV/'.!^,/^J_Y89[=>N>_P"GK^70)YT$LI@S.)N_8@C)ZYQP.>@P,9Q3H?\
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M/-\G(@QCW_KT!]?S'N;_ .XBS-TR.W;.>WZ>WXU!_JO\YSG\O3VZ?F 6./\
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MX?KG/Z=/?K4\L-O_ ,M_\\>WMW.?RX"S?N?]3Q_3UQZYYZ_X5/+-%Y9YX(.
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MI^5$/VSSAG;]G[9^G;OC_(YS0!9H\_V_3_Z]5_)G\SMZYSVS]>G?Z\=>:L4
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M_IR.IP<]NE5OL8M(B((.;G@_9<?7N,=.^0._8T ?QH?\$V?^"/'QP^#/QX\
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MF>GZ>]$,/_Z_Z_XG\!5CR/?]?_K4 5O)\T6Y[<G\!S^?![_3GHL/[[[1GO\
MTSUZ]??/6I]DOJ/T_P *6&'RO\__ *^.O>@"OYUOCR,C_P"MG&/SY_7%$,0A
MDN#CC'';KQQ^?KZ< U/Y8\S/E#ZY'IZ_7]:/(_TCSLGICMZ?RS^- &1-+YP_
MX\<>_ /]#_D8]_R/_;W\_P#X6=H&<_\ (N)T_P"ND?\ GZYK]>)Y?^6&/J/R
M/_UN/:OR9_;=BG/Q0L,#_F#+_P OG.-Z8R.,=.,T >G?\$S=8\.:/^QG\)M*
MG\1:)]HM;(_\OG';'?))YQC@#/3@5]WP^-_!\L?GCQ1HQSCG^V$P/7.2ISCT
MS7\4O["/C'Q=_P ,O>!_^*I\1_\ 'F/^8YJ?H?\ IZKU#3O&/B[^S_%'_%4^
M(_\ C\/_ #'-3_NG_IZH##:V^7Z']B7_  F'A7R_^1BT3Z_VPN/7/7=G'X^]
M6)O%GA8@0_\ "0Z,#Z&]3/Z,1QD_Q<CFOXY_^$Q\7?\ 0T^(_P#C\_Z#FI__
M "57.WGC'Q=_;T__ !5/B/M_S'-3_NG_ *>J!XC?Y_YG]E</BK0C(?\ BHM$
M/J/[8![=.>GN3@]Q2?\ "2^%O]?_ ,)%HF/[W]L#'7TS_3K^5?QQV/C'Q=]O
M'_%4^(__  >:G[_]/5:-[XQ\7?9;C_BJ?$?3_H.:GZG_ *>JZ#9;+T7Y']BO
M_"5^&_\ H.Z)_P"#D_X57_X2OPW_ -#'HG_@X-?QQ3^,?%WV^W_XJGQ'_P >
M0_YCFI_WA_T]5MP^+_%GV6V_XJCQ%_Q]C_F-ZEZ_]?- S^P'_A)?#G_0QZ+_
M .#D58_X3'PM_P!#'HO_ (.?_LJ_D$M?&'BWRK__ (JGQ'_X.]3]_P#IZK#F
M\7^+,G_BJ/$74?\ ,;U+T_Z^: /[%O\ A,/#?_0Q:)_X-A1-XK\+&+GQ#HP]
M#_;"X_1B1GKT%?QY_P#"8^+O^AI\1_\ @\U/_P"2J6[\8^+O[+N?^*I\1]1_
MS'-3]1_T]46Z+3T"W1:>A_8'+XK\*Q18_P"$BT4$#!_XG(]>^"3Q^'3ZTI\;
M^%H?]?XCT0<_]!@'\/0^^1Q7\>]IXO\ %G]EZC_Q5'B+_D,:5_S&]2]!_P!/
M-:&L>+_%GE6__%4>(O\ D,'_ )C>I?[7_3S7.!_7O_PE?@[_ *&'1/\ P;__
M %Z)?%?A6:0?\5%HG3H=8!/0>^,?F.>??^/O_A,?%WF_\C3XC_\ !YJ?][_K
MZIFL>+_%G'_%4>(OO?\ 0;U+_P"2: /[#_[>T3_H8K#_ ,#15:'Q5X<$?'BC
M1#R3D:PN/KR0?KV/KQ7\=FI>,?%WE:?_ ,53XC_X]6_YCFI^W_3U5K3?&/B[
M^R[;_BJ?$?\ QY_]!S4_1O\ IZKH _L*_P"$J\*PRY_X2+1 <<YU@9]N1G]#
M[\<58B\8>%?^ABT4_36!]?XC_/\  ]J_D$/C'Q=_:'B#_BJ?$?\ QY'_ )CF
MI^G_ %]5'9^+_%F(/^*H\1?\>9_YC>I?W1_T\US@?U_Q>*_"WE^;_P )#HQ'
M]X:R@ _4-^G/\H?^$K\-_P#0QZ)_X.#7\??_  F/B[^S/^1I\1_=_P"@YJ?K
M_P!?5$WC'Q=]@_Y&GQ'_ .#S4_[P_P"GJ@#^OJ;Q+X<FZ^*=%ST_Y# ^G;OV
MH_X230_,@_XJG13[#6!^F2 ,]\XS7\@?_"8^+O\ H:?$?_@\U/\ ^2JS)_%_
MBSS6_P"*H\1?^#O4O?\ Z>:Z /[%YO%7AR48A\1Z) >I/]K@$XQSC@<=O3\\
MSS>)?#DO_,PZ*.P']L+_ /%'GZ=>>E?QF#QCXN\ZX_XJGQ'_ ,@?_H.:GZ'_
M *>JL6GC'Q=]@U#_ (JGQ'W_ .8YJ?\ L_\ 3U0!_98?%7AR:,?\5#HO/<:P
MH&,=^0?T[]Z7_A+/#G_0Q:+_ .#@?XU_&-#XW\9_9#_Q5WB?_C^7_F/ZK[?]
M/=69?%_BSS;C_BJ/$7_'Y_T&]2]O^GF@#^R>3Q7X5F\C_BHM$YY'_$X49Z=#
MDY)QU.#Z]\G_  DOA;[-_P C%HF/7^V!CT]<Y]L8]\U_'F/&/B[_ (E__%4^
M(_\ CS'_ #'-3]O^GJK'_"8^+O*_Y&GQ'_X/-3_N_P#7U0+$*R:]?_;C^PV'
MQ+H</^N\1Z(>I_Y# &./P[4DOBOP[_T-&BCJ>=8'YX!/T ^N,]*_CS_X3'Q=
M_P!#3XC_ /!YJ?\ \E4S0?%_BS_2?^*H\1?>'_,;U+_Y)I6\_P (_P"1@?V#
MQ>*O"OF<>(M%:X]/[8'? [_R[_K4_P#PDOASS?\ D8=%^G]L+GKCUQ[=>G'O
M7\?$_B_Q;Y2_\51XBZG_ )C>I^O_ %\U'_PF/B[_ *&GQ'_X/-3_ /DJF=!_
M8)_PDGAR::?R/$6B>?\ ]A@<>W7GIR!G^M5SXDT/&9_%.B&W]!>#Z'J0#P?7
MGIBOXZ_^$Q\7>;_R-/B/_P 'FI_WO^OJLB;QCXN_LRY_XJGQ'_Q]G_F.:G_\
ME4 ?V9P>)?#IDG_XJ'1;C[-_U&1E>_/S$9''"D^O-3Q>*O#<0\[_ (2+1?LY
M'!.KJWH/XNN/IW[5_&Z/&/B[[5X@_P"*I\1_\@9?^8YJ?H?^GJJV@>,?%WV:
MW_XJGQ'_ ,@?_H.:GZ'_ *>J /[)(O%_ALR><?$6AD'L=7!''MTQ]>.G7FK'
M_"4^&_,_Y''1>O\ S_:1Z9ZYSC/O7\>'_"7^+?*A_P"*H\1?\@<?\QO4_P#Y
M)K0/B_Q9]KN/^*H\1=_^8WJ7^U_T\T">S]'^1_7@?&/AV;_CW\8Z)Z#_ $S^
M0.!_@.>1@4'Q5H4/_'QXJTSCUO.GX_EUZC\Z_C[TWQCXN\VW_P"*I\1]6_YC
MFI^@_P"GJM2?Q?XL\UO^*H\1?^#O4O?_ *>:/ZZ?H.AU^?Z']>__  E?AV4?
MN/%&C8S_ ,_J\_CN]_IT%+_PE7AW_1_^*CT3U_Y# YQ_]?CG'J,=:_CI_P"$
MQ\7?VGJ/_%4^(_\ CT_Z#FI^W_3U6#IOC'Q=]JT?_BJ?$?3_ *#FI^A_Z>J!
MO=Z]7V[G]G<OBOPY_P!##HJ]",ZP.G3L3WJ";Q?X;SY'_"1:("0!SK SQSU'
M^)^@K^.^7Q?XLQ<?\51XB_X_/^@WJ7]T?]/-)-XO\6?V@?\ BJ/$70?\QO4O
M3_KYKG$?V(S>*O#G)_X2+1 ;89/_ !..>@ZX)SQZ9/?WI(?%/A6(SS'Q'HI%
MR<\ZP.O/N"?P'3.3SS_(!+XP\6^5J/\ Q5'B+_C\;_F-ZG[?]/7N?S-)9>+_
M !9BW_XJCQ%T_P"@WJ7J/^GF@#^P >*_"L,7D0^(M$'0<ZP/7'4$]_I]35G_
M (2SPY_T,6B_^#@?XU_(!-XO\6?:KG_BJ/$74_\ ,;U+T_Z^:CL_&/B[[!<?
M\53XC[?\QS4_[Q_Z>JZ /[ 1XO\ #?EPG_A(M$&<9)U=?FX]B#QTYQS[5#-X
MO\*R\'Q'H8_[C'3_ .O[8QUS7\A\/B_Q9Y5A_P 51XB[_P#,;U+_ .2:PM8\
M8^+OL _XJGQ'_P >?_0<U/\ ^2J!/9^C_(_L4_X3;PI_T-&B?^#@?X57F\5>
M'.9O^$CT3CO_ &Q^([G\S[^^?XRQXQ\7>3<?\53XC_Y#'_0<U/U/_3U720^+
M_%GV6V_XJCQ%_P >0_YC>I>O_7S2MYO[E_D8X??Y_JC^Q'_A+/#G_0Q:+_X.
M!_C1_P )7X<_Z&O1?_!L*_CBU/QCXN_TG_BJ?$?_ !^#_F.:G[_]/59&L>,?
M%WVK4/\ BJ?$?0_\QS4_0?\ 3U3_ *Z?J;XE6O\ /]3^S7_A*_#?_0QZ)_X.
M#1_PE?AO_H8]$_\ !P:_C^L_%_BS.G_\51XB_P"/,?\ ,;U+^]_U\U+>>,?%
MWV"W_P"*I\1]_P#F.:G_ 'A_T]4 ?U]S>*_#G7_A(]%&<?\ ,8[' ]^X I?^
M$DT+_H8]$_\ !U_]>OXTKWQCXN\FX_XJGQ'_ ,>7_0<U/T/_ $]5J'Q?XL^U
MW'_%4>(N_P#S&]2_VO\ IYH _L>_X2;P[^YSXAT;_21Q_P 3E?FR?X?F]?[V
MP]3TR:@BU_P[#Y_G>(M%.>/^0R!CZY(S\N3\N<8'4<U_'O9^,/%N-'_XJCQ%
MP=5Q_P 3O4^.G_3U6'<>,?%WV"Y_XJGQ'_R&!_S'-3]O^GJ@#^RR'Q5X6BX'
MB'1>?^HPAY/L6Y_3KQTJ"7Q)H?\ T,>B=3UUG^N>W0<\YXK^-\^+_%GV_4/^
M*H\1?>/_ #&]2]_^GFMO_A,?%W_0T^(__!YJ?_R50!_8*/%7A6'_ )F/1!]=
M8!]?0_6IYO%?A::(C_A(=&QGK_;*8_0D^G4<&OX^9?%_BSRK;_BJ/$7_ !Y?
M]!O4O7_KYJ_!XO\ %GV2'_BJ/$7?_F-ZE_\ )- ']=W_  DND_\ 0T:'_P"#
MA?\ "K7_  EGAS_H8M%_\' _QK^/:;Q?XM^U#_BJ/$70_P#,;U/T;_IYIMWX
MQ\7>;_R-/B/O_P QS4__ )*I6?=_A_D*S[O\/\C^P/\ X2KPI_T'-#_\"S_A
M7Y@_MD^(/#NH?$?3_P#BH]%'D:.J=<'YG0\X(&>.>37XD7GC'Q=]OTC_ (JG
LQ'_#_P QS4_;_IZKX9_:A\8^+O\ A80_XJGQ'_QYC_F.:GZI_P!/58#/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ea028258601_img7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028258601_img7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !& #P# 2(  A$! Q$!_\0
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M<8N%XQMRWNFGUMU1YJE%3GS3E!<SUBF^;5WNEM]WZG]=_P"U]^QE_P /0O\
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BT?0M.;7=2ECT^T@,UP\K.:^JJ**RNY.3>[EK;3HNQ1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>canf-20251231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><xs:schema targetNamespace="http://canfite.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:canf="http://canfite.com/20251231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025">
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" />
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="canf-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="canf-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label link" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="canf-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="canf-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple" />
      <link:roleType roleURI="http://canfite.com/20251231/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>995300 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/AuditInformation" id="AuditInformation">
        <link:definition>995301 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>995302 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ConsolidatedBalanceSheetsParentheticals" id="ConsolidatedBalanceSheetsParentheticals">
        <link:definition>995303 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss" id="ConsolidatedStatementsofOperatingLoss">
        <link:definition>995304 - Statement - Consolidated Statements of Operating Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity" id="ConsolidatedStatementsofChangesinShareholdersEquity">
        <link:definition>995305 - Statement - Consolidated Statements of Changes in Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquityParentheticals" id="ConsolidatedStatementsofChangesinShareholdersEquityParentheticals">
        <link:definition>995306 - Statement - Consolidated Statements of Changes in Shareholders&#8217; Equity (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows" id="ConsolidatedStatementsofCashFlows">
        <link:definition>995307 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/General" id="General">
        <link:definition>995308 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
        <link:definition>995309 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssets" id="PrepaidExpensesandOtherCurrentAssets">
        <link:definition>995310 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/PropertyPlantandEquipmentNet" id="PropertyPlantandEquipmentNet">
        <link:definition>995311 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/OtherAccountsPayable" id="OtherAccountsPayable">
        <link:definition>995312 - Disclosure - Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>995313 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/Revenues" id="Revenues">
        <link:definition>995314 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ContingentLiabilitiesandCommitments" id="ContingentLiabilitiesandCommitments">
        <link:definition>995315 - Disclosure - Contingent Liabilities and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ShareholdersEquity" id="ShareholdersEquity">
        <link:definition>995316 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/Leases" id="Leases">
        <link:definition>995317 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/FinanceIncomeExpenseNet" id="FinanceIncomeExpenseNet">
        <link:definition>995318 - Disclosure - Finance Income (Expense), Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/SegmentReporting" id="SegmentReporting">
        <link:definition>995319 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/TaxesonIncome" id="TaxesonIncome">
        <link:definition>995320 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>995321 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure" id="CybersecurityRiskManagementandStrategyDisclosure">
        <link:definition>995322 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies" id="AccountingPoliciesbyPolicyPolicies">
        <link:definition>996323 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
        <link:definition>996324 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsTables" id="PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>996325 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/PropertyPlantandEquipmentNetTables" id="PropertyPlantandEquipmentNetTables">
        <link:definition>996326 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/OtherAccountsPayableTables" id="OtherAccountsPayableTables">
        <link:definition>996327 - Disclosure - Other Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>996328 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ShareholdersEquityTables" id="ShareholdersEquityTables">
        <link:definition>996329 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/LeasesTables" id="LeasesTables">
        <link:definition>996330 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/FinanceIncomeExpenseNetTables" id="FinanceIncomeExpenseNetTables">
        <link:definition>996331 - Disclosure - Finance Income (Expense), Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/TaxesonIncomeTables" id="TaxesonIncomeTables">
        <link:definition>996332 - Disclosure - Taxes on Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/GeneralDetails" id="GeneralDetails">
        <link:definition>996333 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails" id="SignificantAccountingPoliciesDetails">
        <link:definition>996334 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails" id="SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails">
        <link:definition>996335 - Disclosure - Significant Accounting Policies - Schedule of Depreciable Rates of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails" id="SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails">
        <link:definition>996336 - Disclosure - Significant Accounting Policies- Schedule of Major Customer Data as a Percentage (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails" id="SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails">
        <link:definition>996337 - Disclosure - Significant Accounting Policies- Schedule of Antidilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" id="PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>996338 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/PropertyPlantandEquipmentNetDetails" id="PropertyPlantandEquipmentNetDetails">
        <link:definition>996339 - Disclosure - Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails" id="PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails">
        <link:definition>996340 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/OtherAccountsPayableScheduleofOtherAccountsPayableDetails" id="OtherAccountsPayableScheduleofOtherAccountsPayableDetails">
        <link:definition>996341 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails" id="FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails">
        <link:definition>996342 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/RevenuesDetails" id="RevenuesDetails">
        <link:definition>996343 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails" id="ContingentLiabilitiesandCommitmentsDetails">
        <link:definition>996344 - Disclosure - Contingent Liabilities and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ShareholdersEquityDetails" id="ShareholdersEquityDetails">
        <link:definition>996345 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails" id="ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails">
        <link:definition>996346 - Disclosure - Shareholders' Equity - Schedule of Information Regarding Outstanding Warrants to Purchase Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails" id="ShareholdersEquityScheduleofCompanysOptionActivityDetails">
        <link:definition>996347 - Disclosure - Shareholders' Equity - Schedule of Company's Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails" id="ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails">
        <link:definition>996348 - Disclosure - Shareholders' Equity - Schedule of Fair value of Company&#8217;s Share Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails" id="ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails">
        <link:definition>996349 - Disclosure - Shareholders' Equity - Schedule of Expenses Recognized Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/LeasesDetails" id="LeasesDetails">
        <link:definition>996350 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/LeasesScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateDetails" id="LeasesScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateDetails">
        <link:definition>996351 - Disclosure - Leases-Schedule of Weighted Average Remaining Lease Terms and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails" id="LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>996352 - Disclosure - Leases-Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/FinanceIncomeExpenseNetScheduleofFinanceIncomeExpenseNetDetails" id="FinanceIncomeExpenseNetScheduleofFinanceIncomeExpenseNetDetails">
        <link:definition>996353 - Disclosure - Finance Income (Expense), Net-Schedule of Finance Income (Expense), Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/SegmentReportingDetails" id="SegmentReportingDetails">
        <link:definition>996354 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/TaxesonIncomeDetails" id="TaxesonIncomeDetails">
        <link:definition>996355 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/TaxesonIncomeScheduleofScheduleofDeferredTaxAssetsandLiabilitiesDetails" id="TaxesonIncomeScheduleofScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>996356 - Disclosure - Taxes on Income- Schedule of Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails" id="TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails">
        <link:definition>996357 - Disclosure - Taxes on Income - Schedule of Reconciliation Statutory Israeli Income Tax Rate  (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://canfite.com/20251231/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
        <link:definition>996358 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock" name="WarrantsToPurchaseOrdinarySharesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_GrossProceeds" name="GrossProceeds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="canf_NumberOfOrdinaryShares" name="NumberOfOrdinaryShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xs:element id="canf_PercentageOfDepositsOnMonthlySalary" name="PercentageOfDepositsOnMonthlySalary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_PercentageOfRealizationOnUltimateSettlement" name="PercentageOfRealizationOnUltimateSettlement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_ShortTermBankDepositsYearlyInterestRatePercentage" name="ShortTermBankDepositsYearlyInterestRatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable" name="FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisAbstract" name="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_CashPlacementFee" name="CashPlacementFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="canf_ClassOfWarrantOrRightPercentage" name="ClassOfWarrantOrRightPercentage" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xs:element id="canf_CommonWarrantsMember" name="CommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_GrantedExcessYears" name="GrantedExcessYears" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xs:element id="canf_IncreaseAuthorizedShareCapital" name="IncreaseAuthorizedShareCapital" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xs:element id="canf_InvestorsFromJuly2025OfferingMember" name="InvestorsFromJuly2025OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" name="IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="canf_NewWarrantsMember" name="NewWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_PreFundedWarrantsMember" name="PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_PurchaseAgreementMember" name="PurchaseAgreementMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_ShareholdersEquityDetailsTable" name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_SpecialGeneralMeetingOfShareholdersMember" name="SpecialGeneralMeetingOfShareholdersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" name="StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" name="StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_TwoThousandThirteenPlanMember" name="TwoThousandThirteenPlanMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_TwoThousandTwentyThreePlanMember" name="TwoThousandTwentyThreePlanMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_ScheduleOfFairValueOfCompanySShareOptionsGrantedAbstract" name="ScheduleOfFairValueOfCompanySShareOptionsGrantedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable" name="ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_ChongKunDangPharmaceuticalsCorpMember" name="ChongKunDangPharmaceuticalsCorpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_CipherPharmaceuticalsMember" name="CipherPharmaceuticalsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_EwopharmaAGMember" name="EwopharmaAGMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_GebroHoldingGmbHMember" name="GebroHoldingGmbHMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_VetbiolixMember" name="VetbiolixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_AdditionalRevenueReceivedForAchievedMilestone" name="AdditionalRevenueReceivedForAchievedMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="canf_CMSMedicalVentureInvestmentLimitedMember" name="CMSMedicalVentureInvestmentLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_EwopharmaMember" name="EwopharmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_KyongboPharmCoLtdMember" name="KyongboPharmCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_LiverCancerIndicationMember" name="LiverCancerIndicationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_MilestonePaymentPercentage" name="MilestonePaymentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_NASHMember" name="NASHMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_NonRefundablePayment" name="NonRefundablePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount" name="EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="canf_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_BankCommissions" name="BankCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="canf_ExchangeRateFluctuationsAndOthers" name="ExchangeRateFluctuationsAndOthers" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_OtherGainFromShortTermInvestmentRemeasurement" name="OtherGainFromShortTermInvestmentRemeasurement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="canf_ScheduleOfExpensesRecognizedFinancialStatementsAbstract" name="ScheduleOfExpensesRecognizedFinancialStatementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" name="StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" name="StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_LegalAndOtherContingenciesPolicyTextBlock" name="LegalAndOtherContingenciesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_SeverancePayPolicyTextBlock" name="SeverancePayPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_ShorttermBankDepositsPolicyTextBlock" name="ShorttermBankDepositsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_ContingentLiabilitiesandCommitmentsDetailsTable" name="ContingentLiabilitiesandCommitmentsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_PercentageOfNetSales" name="PercentageOfNetSales" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_PhaseIIIStudiesMember" name="PhaseIIIStudiesMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_PhaseIIStudiesMember" name="PhaseIIStudiesMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_PhaseIStudiesMember" name="PhaseIStudiesMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_RegulatoryAuthorityMember" name="RegulatoryAuthorityMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_RoyaltyPaymentsPercentage" name="RoyaltyPaymentsPercentage" type="dtr:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_AmericanDepositarySharesMember" name="AmericanDepositarySharesMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael" name="EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock" name="ScheduleOfUsefulLivesOfTheAssetTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants" name="NetOfIssuanceCostsOfOrdinarySharesAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="canf_PercentageOfRoyaltiesOnNetSales" name="PercentageOfRoyaltiesOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_SalesMilestonesMember" name="SalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_TransferPriceRate" name="TransferPriceRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_UpfrontAndMilestonePaymentsPayable" name="UpfrontAndMilestonePaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="canf_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants" name="NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="canf_NetOfIssuanceCostsOrdinarySharesDueToATM" name="NetOfIssuanceCostsOrdinarySharesDueToATM" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants" name="NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="canf_GovernmentAuthorities" name="GovernmentAuthorities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="canf_November2023Member" name="November2023Member" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_IssuanceDate" name="IssuanceDate" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_December2021Member" name="December2021Member" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_April2025Member" name="April2025Member" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_NewWarrantSharesMember" name="NewWarrantSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_StockIssuedDuringPeriodSharesExercised" name="StockIssuedDuringPeriodSharesExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xs:element id="canf_StockIssuedDuringPeriodExerciseValue" name="StockIssuedDuringPeriodExerciseValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="canf_ExistingWarrantsMember" name="ExistingWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" name="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_November2023AgentMember" name="November2023AgentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_July2025OneMember" name="July2025OneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_July2025Member" name="July2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_January2023AgentMember" name="January2023AgentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_August2024Member" name="August2024Member" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_August2024AgentMember" name="August2024AgentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_SubsequentEventsDetailsTable" name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_ADSMember" name="ADSMember" type="dtr:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xs:element id="canf_ChangesInFairValueOfShortTermInvestment" name="ChangesInFairValueOfShortTermInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xs:element id="canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" name="StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xs:element id="canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets" name="LeaseLiabilitiesArisingFromObtainingRightofuseassets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>canf-20251231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ConsolidatedStatementsofOperatingLoss" roleURI="http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails" roleURI="http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ConsolidatedBalanceSheets" roleURI="http://canfite.com/20251231/role/ConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ConsolidatedStatementsofCashFlows" roleURI="http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails" roleURI="http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails" />
  <link:calculationLink xlink:role="http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" order="5.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" order="6.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InvestmentIncomeNet" />
    <link:calculationArc xlink:type="arc" order="7.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" order="237.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:calculationArc xlink:type="arc" order="238.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://canfite.com/20251231/role/ConsolidatedBalanceSheets" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" order="5.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ChangesInFairValueOfShortTermInvestment" xlink:label="canf_ChangesInFairValueOfShortTermInvestment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <link:calculationArc xlink:type="arc" order="10.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:calculationArc xlink:type="arc" order="0.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="canf_ChangesInFairValueOfShortTermInvestment" />
    <link:calculationArc xlink:type="arc" order="6.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" />
    <link:calculationArc xlink:type="arc" order="7.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" order="8.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" order="9.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:calculationArc xlink:type="arc" order="10.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:calculationArc xlink:type="arc" order="11.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails" xlink:type="extended" xlink:title="calculationLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount" xlink:label="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael" xlink:label="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
    <link:calculationArc xlink:type="arc" order="1.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:calculationArc xlink:type="arc" order="2.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount" />
    <link:calculationArc xlink:type="arc" order="3.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" order="4.00" weight="-1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
    <link:calculationArc xlink:type="arc" order="6.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:calculationArc xlink:type="arc" order="7.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael" />
    <link:calculationArc xlink:type="arc" order="8.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" order="9.00" weight="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>canf-20251231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/ShareholdersEquityDetails" xlink:href="canf-20251231.xsd#ShareholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails" xlink:href="canf-20251231.xsd#ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails" xlink:href="canf-20251231.xsd#SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails" xlink:href="canf-20251231.xsd#SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/RevenuesDetails" xlink:href="canf-20251231.xsd#RevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/TaxesonIncomeDetails" xlink:href="canf-20251231.xsd#TaxesonIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity" xlink:href="canf-20251231.xsd#ConsolidatedStatementsofChangesinShareholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/LeasesDetails" xlink:href="canf-20251231.xsd#LeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails" xlink:href="canf-20251231.xsd#ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails" xlink:href="canf-20251231.xsd#ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/SubsequentEventsDetails" xlink:href="canf-20251231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/DocumentAndEntityInformation" xlink:href="canf-20251231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails" xlink:href="canf-20251231.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails" xlink:href="canf-20251231.xsd#ContingentLiabilitiesandCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails" xlink:href="canf-20251231.xsd#TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails" xlink:href="canf-20251231.xsd#PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails" xlink:href="canf-20251231.xsd#SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable" xlink:label="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable_1149" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1155" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1150" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_33935" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_1152" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_1153" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_1154" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_33936" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1151" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_33937" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_1156" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_33936_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1151_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1155" xlink:to="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable_1149" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable_1149" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_1150" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable_1149" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_33935" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1151" xlink:to="us-gaap_FairValueInputsLevel1Member_1152" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1151" xlink:to="us-gaap_FairValueInputsLevel2Member_1153" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1151" xlink:to="us-gaap_FairValueInputsLevel3Member_1154" />
    <link:definitionArc xlink:type="arc" order="326.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_33935" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_33936" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1150" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1151" />
    <link:definitionArc xlink:type="arc" order="327.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_33936" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_33937" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1155" xlink:to="us-gaap_ShortTermInvestments_1156" />
    <link:definitionArc xlink:type="arc" order="326.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_33935" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_33936_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1150" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1151_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/ShareholdersEquityDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_33883" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_33887" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_33881" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_33880" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_33780" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1293" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_33909" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1307" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_33779" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_1318" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1308" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="us-gaap_StockOptionExercisePriceIncrease_33879" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_33897" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_33895" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_33896" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CashPlacementFee" xlink:label="canf_CashPlacementFee_33907" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ClassOfWarrantOrRightPercentage" xlink:label="canf_ClassOfWarrantOrRightPercentage_1312" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CommonWarrantsMember" xlink:label="canf_CommonWarrantsMember_33906" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_GrantedExcessYears" xlink:label="canf_GrantedExcessYears_33886" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_IncreaseAuthorizedShareCapital" xlink:label="canf_IncreaseAuthorizedShareCapital_33898" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_InvestorsFromJuly2025OfferingMember" xlink:label="canf_InvestorsFromJuly2025OfferingMember_33894" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" xlink:label="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_33876" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NewWarrantsMember" xlink:label="canf_NewWarrantsMember_33833" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PreFundedWarrantsMember" xlink:label="canf_PreFundedWarrantsMember_33901" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PurchaseAgreementMember" xlink:label="canf_PurchaseAgreementMember_1292" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShareholdersEquityDetailsTable" xlink:label="canf_ShareholdersEquityDetailsTable_1282" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SpecialGeneralMeetingOfShareholdersMember" xlink:label="canf_SpecialGeneralMeetingOfShareholdersMember_33900" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" xlink:label="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_33875" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" xlink:label="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_1316" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_TwoThousandThirteenPlanMember" xlink:label="canf_TwoThousandThirteenPlanMember_1298" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_TwoThousandTwentyThreePlanMember" xlink:label="canf_TwoThousandTwentyThreePlanMember_1299" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember_1302" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_33890" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_33891" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_33888" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_33889" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1300" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1301" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1291" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_1303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_33828" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1283" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1290" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_33829" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_AmericanDepositarySharesMember" xlink:label="canf_AmericanDepositarySharesMember_1286" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_33831" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_33782" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_33781" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_33905" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_33884" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1295" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_33778" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_1317" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights_1304" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_33911" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_33882" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1294" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_33892" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_33893" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_33904" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_1311" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1296" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1297" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_33941" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_33903" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_33939" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1284" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1309" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_33940" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_33896_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_33889_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1301_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1291_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_33831_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1294_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_33893_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1297_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1284_default" />
    <link:definitionArc xlink:type="arc" order="30.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_33883" />
    <link:definitionArc xlink:type="arc" order="34.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_33887" />
    <link:definitionArc xlink:type="arc" order="27.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_33881" />
    <link:definitionArc xlink:type="arc" order="26.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_33880" />
    <link:definitionArc xlink:type="arc" order="41.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_SharesIssuedPricePerShare_33780" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_StatementEquityComponentsAxis_1293" />
    <link:definitionArc xlink:type="arc" order="50.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_33909" />
    <link:definitionArc xlink:type="arc" order="37.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1307" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_33779" />
    <link:definitionArc xlink:type="arc" order="35.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_1318" />
    <link:definitionArc xlink:type="arc" order="38.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1308" />
    <link:definitionArc xlink:type="arc" order="29.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_StockOptionExercisePriceIncrease_33879" />
    <link:definitionArc xlink:type="arc" order="296.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain_33896" xlink:to="us-gaap_SubsequentEventMember_33897" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_SubsequentEventTypeAxis_33895" />
    <link:definitionArc xlink:type="arc" order="295.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis_33895" xlink:to="us-gaap_SubsequentEventTypeDomain_33896" />
    <link:definitionArc xlink:type="arc" order="49.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_CashPlacementFee_33907" />
    <link:definitionArc xlink:type="arc" order="39.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_ClassOfWarrantOrRightPercentage_1312" />
    <link:definitionArc xlink:type="arc" order="303.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_33831" xlink:to="canf_CommonWarrantsMember_33906" />
    <link:definitionArc xlink:type="arc" order="33.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_GrantedExcessYears_33886" />
    <link:definitionArc xlink:type="arc" order="44.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_IncreaseAuthorizedShareCapital_33898" />
    <link:definitionArc xlink:type="arc" order="293.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember_33893" xlink:to="canf_InvestorsFromJuly2025OfferingMember_33894" />
    <link:definitionArc xlink:type="arc" order="24.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_33876" />
    <link:definitionArc xlink:type="arc" order="264.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_33831" xlink:to="canf_NewWarrantsMember_33833" />
    <link:definitionArc xlink:type="arc" order="265.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_33831" xlink:to="canf_PreFundedWarrantsMember_33901" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1291" xlink:to="canf_PurchaseAgreementMember_1292" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_ShareholdersEquityDetailsTable_1282" />
    <link:definitionArc xlink:type="arc" order="299.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_1301" xlink:to="canf_SpecialGeneralMeetingOfShareholdersMember_33900" />
    <link:definitionArc xlink:type="arc" order="23.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_33875" />
    <link:definitionArc xlink:type="arc" order="43.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_1316" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1297" xlink:to="canf_TwoThousandThirteenPlanMember_1298" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain_1297" xlink:to="canf_TwoThousandTwentyThreePlanMember_1299" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_1301" xlink:to="srt_BoardOfDirectorsChairmanMember_1302" />
    <link:definitionArc xlink:type="arc" order="289.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_33889" xlink:to="srt_MaximumMember_33890" />
    <link:definitionArc xlink:type="arc" order="290.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_33889" xlink:to="srt_MinimumMember_33891" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="srt_RangeAxis_33888" />
    <link:definitionArc xlink:type="arc" order="288.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis_33888" xlink:to="srt_RangeMember_33889" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="srt_TitleOfIndividualAxis_1300" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis_1300" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1301" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis_1290" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1291" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_33828" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1283" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_TypeOfArrangementAxis_1290" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_33831" xlink:to="us-gaap_WarrantMember_33829" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1284" xlink:to="canf_AmericanDepositarySharesMember_1286" />
    <link:definitionArc xlink:type="arc" order="262.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_33828" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_33831" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_33782" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_33781" />
    <link:definitionArc xlink:type="arc" order="48.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_33905" />
    <link:definitionArc xlink:type="arc" order="31.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_33884" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1294" xlink:to="us-gaap_CommonStockMember_1295" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_33778" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_CommonStockSharesAuthorized_1317" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_CommonStockVotingRights_1304" />
    <link:definitionArc xlink:type="arc" order="52.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_33911" />
    <link:definitionArc xlink:type="arc" order="28.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_33882" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis_1293" xlink:to="us-gaap_EquityComponentDomain_1294" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_InvestmentTypeAxis_33892" />
    <link:definitionArc xlink:type="arc" order="292.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis_33892" xlink:to="us-gaap_InvestmentTypeCategorizationMember_33893" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1284" xlink:to="us-gaap_IPOMember_33904" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_1311" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_PlanNameAxis_1296" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis_1296" xlink:to="us-gaap_PlanNameDomain_1297" />
    <link:definitionArc xlink:type="arc" order="53.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_33941" />
    <link:definitionArc xlink:type="arc" order="47.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_33903" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_33939" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1283" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1284" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1309" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_SaleOfStockPricePerShare_33940" />
    <link:definitionArc xlink:type="arc" order="295.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis_33895" xlink:to="us-gaap_SubsequentEventTypeDomain_33896_default" />
    <link:definitionArc xlink:type="arc" order="288.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis_33888" xlink:to="srt_RangeMember_33889_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis_1300" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1301_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis_1290" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1291_default" />
    <link:definitionArc xlink:type="arc" order="262.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_33828" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_33831_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis_1293" xlink:to="us-gaap_EquityComponentDomain_1294_default" />
    <link:definitionArc xlink:type="arc" order="292.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis_33892" xlink:to="us-gaap_InvestmentTypeCategorizationMember_33893_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis_1296" xlink:to="us-gaap_PlanNameDomain_1297_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1283" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1284_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:label="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_1191" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable" xlink:label="canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable_1181" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_1184" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1188" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1190" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1183" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_1185" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1182" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1187" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1189" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1183_default" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" xlink:to="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_1191" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" xlink:to="canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable_1181" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_1183" xlink:to="srt_MaximumMember_1184" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1188" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1190" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis_1182" xlink:to="srt_RangeMember_1183" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_1183" xlink:to="srt_MinimumMember_1185" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable_1181" xlink:to="srt_RangeAxis_1182" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1187" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1189" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis_1182" xlink:to="srt_RangeMember_1183_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ChongKunDangPharmaceuticalsCorpMember" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_33684" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CipherPharmaceuticalsMember" xlink:label="canf_CipherPharmaceuticalsMember_33685" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EwopharmaAGMember" xlink:label="canf_EwopharmaAGMember_33687" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_GebroHoldingGmbHMember" xlink:label="canf_GebroHoldingGmbHMember_33686" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_VetbiolixMember" xlink:label="canf_VetbiolixMember_33688" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_33682" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_33683" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_33675" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_33674" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_33677" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_33680" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_33681" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_33678" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_33679" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_33676" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33672" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_33683_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_33675_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_33678_default" />
    <link:definitionArc xlink:type="arc" order="144.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33683" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember_33684" />
    <link:definitionArc xlink:type="arc" order="145.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33683" xlink:to="canf_CipherPharmaceuticalsMember_33685" />
    <link:definitionArc xlink:type="arc" order="147.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33683" xlink:to="canf_EwopharmaAGMember_33687" />
    <link:definitionArc xlink:type="arc" order="146.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33683" xlink:to="canf_GebroHoldingGmbHMember_33686" />
    <link:definitionArc xlink:type="arc" order="148.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33683" xlink:to="canf_VetbiolixMember_33688" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33672" xlink:to="srt_MajorCustomersAxis_33682" />
    <link:definitionArc xlink:type="arc" order="143.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis_33682" xlink:to="srt_NameOfMajorCustomerDomain_33683" />
    <link:definitionArc xlink:type="arc" order="135.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_33674" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_33675" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33672" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_33674" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33672" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_33677" />
    <link:definitionArc xlink:type="arc" order="141.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems_33680" xlink:to="us-gaap_ConcentrationRiskPercentage1_33681" />
    <link:definitionArc xlink:type="arc" order="138.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_33677" xlink:to="us-gaap_ConcentrationRiskTypeDomain_33678" />
    <link:definitionArc xlink:type="arc" order="139.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain_33678" xlink:to="us-gaap_CustomerConcentrationRiskMember_33679" />
    <link:definitionArc xlink:type="arc" order="136.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_33675" xlink:to="us-gaap_SalesRevenueNetMember_33676" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems_33680" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33672" />
    <link:definitionArc xlink:type="arc" order="143.00" priority="1" xbrldt:closed="true" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis_33682" xlink:to="srt_NameOfMajorCustomerDomain_33683_default" />
    <link:definitionArc xlink:type="arc" order="135.00" priority="1" xbrldt:closed="true" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_33674" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_33675_default" />
    <link:definitionArc xlink:type="arc" order="138.00" priority="1" xbrldt:closed="true" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_33677" xlink:to="us-gaap_ConcentrationRiskTypeDomain_33678_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_33698" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33692" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33697" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_33693" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_33695" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33691" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_33696" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_33693_default" />
    <link:definitionArc xlink:type="arc" order="155.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33697" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_33698" />
    <link:definitionArc xlink:type="arc" order="149.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33691" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33692" />
    <link:definitionArc xlink:type="arc" order="150.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33692" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_33693" />
    <link:definitionArc xlink:type="arc" order="152.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_33693" xlink:to="us-gaap_EmployeeStockMember_33695" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33697" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33691" />
    <link:definitionArc xlink:type="arc" order="153.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_33693" xlink:to="us-gaap_WarrantMember_33696" />
    <link:definitionArc xlink:type="arc" order="150.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33692" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_33693_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/RevenuesDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_AdditionalRevenueReceivedForAchievedMilestone" xlink:label="canf_AdditionalRevenueReceivedForAchievedMilestone_33724" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ChongKunDangPharmaceuticalsCorpMember" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_33757" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CipherPharmaceuticalsMember" xlink:label="canf_CipherPharmaceuticalsMember_33751" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CMSMedicalVentureInvestmentLimitedMember" xlink:label="canf_CMSMedicalVentureInvestmentLimitedMember_33762" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EwopharmaMember" xlink:label="canf_EwopharmaMember_33768" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_GebroHoldingGmbHMember" xlink:label="canf_GebroHoldingGmbHMember_33759" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_KyongboPharmCoLtdMember" xlink:label="canf_KyongboPharmCoLtdMember_33767" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_LiverCancerIndicationMember" xlink:label="canf_LiverCancerIndicationMember_33752" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_MilestonePaymentPercentage" xlink:label="canf_MilestonePaymentPercentage_33731" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NASHMember" xlink:label="canf_NASHMember_33754" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NonRefundablePayment" xlink:label="canf_NonRefundablePayment_33729" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_33711" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PercentageOfRoyaltiesOnNetSales" xlink:label="canf_PercentageOfRoyaltiesOnNetSales_33938" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_RegulatoryMilestonesMember" xlink:label="canf_RegulatoryMilestonesMember_33764" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SalesMilestonesMember" xlink:label="canf_SalesMilestonesMember_33765" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_TransferPriceRate" xlink:label="canf_TransferPriceRate_33720" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_UpfrontAndMilestonePaymentsPayable" xlink:label="canf_UpfrontAndMilestonePaymentsPayable_33719" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_UpfrontPayment" xlink:label="canf_UpfrontPayment_33716" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_VetbiolixMember" xlink:label="canf_VetbiolixMember_33760" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_KR" xlink:label="country_KR_33755" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_33713" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_33923" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_33924" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_33714" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_33709" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_33710" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_33921" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_33922" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_33712" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_33708" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross_33733" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties_33717" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_33722" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_33726" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_33728" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_33718" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_33714_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_33710_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_33922_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_33712_default" />
    <link:definitionArc xlink:type="arc" order="179.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_AdditionalRevenueReceivedForAchievedMilestone_33724" />
    <link:definitionArc xlink:type="arc" order="199.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember_33757" />
    <link:definitionArc xlink:type="arc" order="193.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_CipherPharmaceuticalsMember_33751" />
    <link:definitionArc xlink:type="arc" order="203.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_CMSMedicalVentureInvestmentLimitedMember_33762" />
    <link:definitionArc xlink:type="arc" order="209.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_EwopharmaMember_33768" />
    <link:definitionArc xlink:type="arc" order="201.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_GebroHoldingGmbHMember_33759" />
    <link:definitionArc xlink:type="arc" order="208.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_KyongboPharmCoLtdMember_33767" />
    <link:definitionArc xlink:type="arc" order="194.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain_33710" xlink:to="canf_LiverCancerIndicationMember_33752" />
    <link:definitionArc xlink:type="arc" order="185.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_MilestonePaymentPercentage_33731" />
    <link:definitionArc xlink:type="arc" order="196.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain_33710" xlink:to="canf_NASHMember_33754" />
    <link:definitionArc xlink:type="arc" order="184.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_NonRefundablePayment_33729" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable_33708" xlink:to="srt_StatementGeographicalAxis_33711" />
    <link:definitionArc xlink:type="arc" order="328.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_PercentageOfRoyaltiesOnNetSales_33938" />
    <link:definitionArc xlink:type="arc" order="205.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_RegulatoryMilestonesMember_33764" />
    <link:definitionArc xlink:type="arc" order="206.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_SalesMilestonesMember_33765" />
    <link:definitionArc xlink:type="arc" order="175.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_TransferPriceRate_33720" />
    <link:definitionArc xlink:type="arc" order="174.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_UpfrontAndMilestonePaymentsPayable_33719" />
    <link:definitionArc xlink:type="arc" order="171.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_UpfrontPayment_33716" />
    <link:definitionArc xlink:type="arc" order="202.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_VetbiolixMember_33760" />
    <link:definitionArc xlink:type="arc" order="197.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain_33712" xlink:to="country_KR_33755" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable_33708" xlink:to="srt_MajorCustomersAxis_33713" />
    <link:definitionArc xlink:type="arc" order="320.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_33922" xlink:to="srt_MaximumMember_33923" />
    <link:definitionArc xlink:type="arc" order="321.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_33922" xlink:to="srt_MinimumMember_33924" />
    <link:definitionArc xlink:type="arc" order="169.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis_33713" xlink:to="srt_NameOfMajorCustomerDomain_33714" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable_33708" xlink:to="srt_ProductOrServiceAxis_33709" />
    <link:definitionArc xlink:type="arc" order="165.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis_33709" xlink:to="srt_ProductsAndServicesDomain_33710" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable_33708" xlink:to="srt_RangeAxis_33921" />
    <link:definitionArc xlink:type="arc" order="319.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis_33921" xlink:to="srt_RangeMember_33922" />
    <link:definitionArc xlink:type="arc" order="167.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis_33711" xlink:to="srt_SegmentGeographicalDomain_33712" />
    <link:definitionArc xlink:type="arc" order="163.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_DisaggregationOfRevenueTable_33708" />
    <link:definitionArc xlink:type="arc" order="187.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_FiniteLivedPatentsGross_33733" />
    <link:definitionArc xlink:type="arc" order="172.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_PaymentsForRoyalties_33717" />
    <link:definitionArc xlink:type="arc" order="177.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_33722" />
    <link:definitionArc xlink:type="arc" order="181.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_33726" />
    <link:definitionArc xlink:type="arc" order="183.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_33728" />
    <link:definitionArc xlink:type="arc" order="173.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_33718" />
    <link:definitionArc xlink:type="arc" order="169.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis_33713" xlink:to="srt_NameOfMajorCustomerDomain_33714_default" />
    <link:definitionArc xlink:type="arc" order="165.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis_33709" xlink:to="srt_ProductsAndServicesDomain_33710_default" />
    <link:definitionArc xlink:type="arc" order="319.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis_33921" xlink:to="srt_RangeMember_33922_default" />
    <link:definitionArc xlink:type="arc" order="167.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis_33711" xlink:to="srt_SegmentGeographicalDomain_33712_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/TaxesonIncomeDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_33850" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="us-gaap_IsraelTaxAuthorityMember_33853" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_33915" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_33916" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2017Member" xlink:label="us-gaap_TaxYear2017Member_33917" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_33849" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_33846" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_33848" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_33851" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_33852" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="us-gaap_IncomeTaxExaminationLineItems_33845" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_33916_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_33852_default" />
    <link:definitionArc xlink:type="arc" order="276.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxExaminationLineItems_33845" xlink:to="us-gaap_OperatingLossCarryforwardsTable_33850" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain_33852" xlink:to="us-gaap_IsraelTaxAuthorityMember_33853" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable_33850" xlink:to="us-gaap_TaxPeriodAxis_33915" />
    <link:definitionArc xlink:type="arc" order="313.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis_33915" xlink:to="us-gaap_TaxPeriodDomain_33916" />
    <link:definitionArc xlink:type="arc" order="314.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain_33916" xlink:to="us-gaap_TaxYear2017Member_33917" />
    <link:definitionArc xlink:type="arc" order="275.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems_33845" xlink:to="us-gaap_OperatingLossCarryforwards_33849" />
    <link:definitionArc xlink:type="arc" order="272.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems_33845" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_33846" />
    <link:definitionArc xlink:type="arc" order="274.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExaminationLineItems_33845" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_33848" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable_33850" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_33851" />
    <link:definitionArc xlink:type="arc" order="278.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_33851" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_33852" />
    <link:definitionArc xlink:type="arc" order="313.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis_33915" xlink:to="us-gaap_TaxPeriodDomain_33916_default" />
    <link:definitionArc xlink:type="arc" order="278.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_33851" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_33852_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_33644" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_33645" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_33646" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33635" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33636" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_33638" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_33642" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_33643" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_LaboratoryEquipmentMember" xlink:label="canf_LaboratoryEquipmentMember_33641" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_33638_default" />
    <link:definitionArc xlink:type="arc" order="119.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_33643" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_33644" />
    <link:definitionArc xlink:type="arc" order="120.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_33643" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_33645" />
    <link:definitionArc xlink:type="arc" order="121.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_33643" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_33646" />
    <link:definitionArc xlink:type="arc" order="110.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_33643" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33635" />
    <link:definitionArc xlink:type="arc" order="111.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33635" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33636" />
    <link:definitionArc xlink:type="arc" order="113.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33636" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_33638" />
    <link:definitionArc xlink:type="arc" order="117.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_33638" xlink:to="us-gaap_EquipmentMember_33642" />
    <link:definitionArc xlink:type="arc" order="116.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_33638" xlink:to="canf_LaboratoryEquipmentMember_33641" />
    <link:definitionArc xlink:type="arc" order="113.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33636" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_33638_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_33867" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_33955" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount" xlink:label="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount_33956" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_33957" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_33958" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33866" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael" xlink:label="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael_33948" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33949" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_33950" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_33952" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_33953" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_33954" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_33868" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_33869" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_33953_default" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_33867" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_33955" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount_33956" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_33957" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_33958" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33866" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael_33948" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33949" />
    <link:definitionArc xlink:type="arc" order="336.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_33950" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable_33950" xlink:to="us-gaap_IncomeTaxAuthorityAxis_33952" />
    <link:definitionArc xlink:type="arc" order="339.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis_33952" xlink:to="us-gaap_IncomeTaxAuthorityDomain_33953" />
    <link:definitionArc xlink:type="arc" order="340.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain_33953" xlink:to="us-gaap_ForeignCountryMember_33954" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_33868" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_33869" />
    <link:definitionArc xlink:type="arc" order="339.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis_33952" xlink:to="us-gaap_IncomeTaxAuthorityDomain_33953_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/DocumentAndEntityInformation" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_1399" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_1401" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_1404" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_1405" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement_1365" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_1366" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_1367" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_1369" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_1370" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_1371" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_1374" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_1375" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_1378" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_1380" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_1381" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_1382" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_1383" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress_1384" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName_1386" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_33918" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_1360" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_1362" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_1355" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_1357" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_1359" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_1361" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_1363" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard_1407" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_1356" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_1358" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelFaxNumber" xlink:label="dei_ContactPersonnelFaxNumber_1387" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1388" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1389" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember_1390" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_1391" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_1392" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_1393" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_1394" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_1395" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_1396" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_1397" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_1398" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1389_default" />
    <link:definitionArc xlink:type="arc" order="33.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityFilerCategory_1399" />
    <link:definitionArc xlink:type="arc" order="35.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityEmergingGrowthCompany_1401" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityInteractiveDataCurrent_1404" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_IcfrAuditorAttestationFlag_1405" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentRegistrationStatement_1365" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentAnnualReport_1366" />
    <link:definitionArc xlink:type="arc" order="28.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_CurrentFiscalYearEndDate_1367" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentTransitionReport_1369" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentShellCompanyReport_1370" />
    <link:definitionArc xlink:type="arc" order="26.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityFileNumber_1371" />
    <link:definitionArc xlink:type="arc" order="27.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityIncorporationStateCountryCode_1374" />
    <link:definitionArc xlink:type="arc" order="37.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityAddressAddressLine1_1375" />
    <link:definitionArc xlink:type="arc" order="40.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityAddressCityOrTown_1378" />
    <link:definitionArc xlink:type="arc" order="43.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityAddressCountry_1380" />
    <link:definitionArc xlink:type="arc" order="42.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityAddressPostalZipCode_1381" />
    <link:definitionArc xlink:type="arc" order="47.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_CityAreaCode_1382" />
    <link:definitionArc xlink:type="arc" order="48.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_LocalPhoneNumber_1383" />
    <link:definitionArc xlink:type="arc" order="51.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_ContactPersonnelEmailAddress_1384" />
    <link:definitionArc xlink:type="arc" order="49.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_ContactPersonnelName_1386" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_33918" />
    <link:definitionArc xlink:type="arc" order="24.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityRegistrantName_1360" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentPeriodEndDate_1362" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentInformationTable_1355" />
    <link:definitionArc xlink:type="arc" order="25.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityCentralIndexKey_1357" />
    <link:definitionArc xlink:type="arc" order="22.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentFiscalYearFocus_1359" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_AmendmentFlag_1361" />
    <link:definitionArc xlink:type="arc" order="23.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentFiscalPeriodFocus_1363" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentAccountingStandard_1407" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentType_1358" />
    <link:definitionArc xlink:type="arc" order="50.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_ContactPersonnelFaxNumber_1387" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable_1355" xlink:to="dei_EntityAddressesAddressTypeAxis_1388" />
    <link:definitionArc xlink:type="arc" order="54.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis_1388" xlink:to="dei_AddressTypeDomain_1389" />
    <link:definitionArc xlink:type="arc" order="55.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain_1389" xlink:to="dei_BusinessContactMember_1390" />
    <link:definitionArc xlink:type="arc" order="44.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_Security12bTitle_1391" />
    <link:definitionArc xlink:type="arc" order="45.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_TradingSymbol_1392" />
    <link:definitionArc xlink:type="arc" order="46.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_SecurityExchangeName_1393" />
    <link:definitionArc xlink:type="arc" order="53.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityCommonStockSharesOutstanding_1394" />
    <link:definitionArc xlink:type="arc" order="29.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityWellKnownSeasonedIssuer_1395" />
    <link:definitionArc xlink:type="arc" order="30.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityVoluntaryFilers_1396" />
    <link:definitionArc xlink:type="arc" order="31.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityCurrentReportingStatus_1397" />
    <link:definitionArc xlink:type="arc" order="32.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityShellCompany_1398" />
    <link:definitionArc xlink:type="arc" order="54.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis_1388" xlink:to="dei_AddressTypeDomain_1389_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_1056" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1058" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1062" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" xlink:label="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_1068" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1061" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1069" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_1065" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" xlink:label="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_1067" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1071" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1052" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1054" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_1406" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1063" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1070" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" xlink:label="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_1408" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesExercised" xlink:label="canf_StockIssuedDuringPeriodSharesExercised_33582" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodExerciseValue" xlink:label="canf_StockIssuedDuringPeriodExerciseValue_33583" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1064" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" xlink:label="canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_33927" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1053" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_1055" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_1057" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1059" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1058_default" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1058" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_1056" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis_1053" xlink:to="us-gaap_EquityComponentDomain_1058" />
    <link:definitionArc xlink:type="arc" order="25.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_NetIncomeLoss_1062" />
    <link:definitionArc xlink:type="arc" order="20.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_1068" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_SharesOutstanding_1061" />
    <link:definitionArc xlink:type="arc" order="23.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1069" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_1065" />
    <link:definitionArc xlink:type="arc" order="19.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_1067" />
    <link:definitionArc xlink:type="arc" order="26.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_StockholdersEquity_1071" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_StatementTable_1052" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1058" xlink:to="us-gaap_CommonStockMember_1054" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_1406" />
    <link:definitionArc xlink:type="arc" order="21.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1063" />
    <link:definitionArc xlink:type="arc" order="24.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1070" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_1408" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodSharesExercised_33582" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodExerciseValue_33583" />
    <link:definitionArc xlink:type="arc" order="22.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1064" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_33927" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable_1052" xlink:to="us-gaap_StatementEquityComponentsAxis_1053" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1058" xlink:to="us-gaap_AdditionalPaidInCapitalMember_1055" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain_1058" xlink:to="us-gaap_RetainedEarningsMember_1057" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis_1053" xlink:to="us-gaap_EquityComponentDomain_1058_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/LeasesDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_33835" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33819" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember_33821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_33823" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_33826" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33820" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_33835_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33820" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_33835" />
    <link:definitionArc xlink:type="arc" order="250.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_33823" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33819" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_33835" xlink:to="us-gaap_VehiclesMember_33821" />
    <link:definitionArc xlink:type="arc" order="257.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_33823" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_33826" />
    <link:definitionArc xlink:type="arc" order="251.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33819" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33820" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33820" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_33835_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_1225" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1224" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_1223" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1220" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1221" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_1222" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1219" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1221_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1224" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_1225" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain_1221" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_1223" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1219" xlink:to="us-gaap_IncomeStatementLocationAxis_1220" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis_1220" xlink:to="us-gaap_IncomeStatementLocationDomain_1221" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain_1221" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_1222" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1224" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1219" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="true" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis_1220" xlink:to="us-gaap_IncomeStatementLocationDomain_1221_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/SubsequentEventsDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease_33913" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_33944" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_33947" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses_33925" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_33942" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_33943" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NewWarrantSharesMember" xlink:label="canf_NewWarrantSharesMember_33912" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1331" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_1343" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1332" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_1344" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_1350" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1347" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1348" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1349" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1338" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1337" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_33874" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ExistingWarrantsMember" xlink:label="canf_ExistingWarrantsMember_33873" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SubsequentEventsDetailsTable" xlink:label="canf_SubsequentEventsDetailsTable_1327" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ClassOfWarrantOrRightPercentage" xlink:label="canf_ClassOfWarrantOrRightPercentage_1352" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ADSMember" xlink:label="canf_ADSMember_1334" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_33943_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1332_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1338_default" />
    <link:definitionArc xlink:type="arc" order="310.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_WarrantExercisePriceDecrease_33913" />
    <link:definitionArc xlink:type="arc" order="331.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain_33943" xlink:to="srt_ScenarioForecastMember_33944" />
    <link:definitionArc xlink:type="arc" order="334.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_33947" />
    <link:definitionArc xlink:type="arc" order="322.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_OtherExpenses_33925" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SubsequentEventsDetailsTable_1327" xlink:to="srt_StatementScenarioAxis_33942" />
    <link:definitionArc xlink:type="arc" order="330.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis_33942" xlink:to="srt_ScenarioUnspecifiedDomain_33943" />
    <link:definitionArc xlink:type="arc" order="309.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1338" xlink:to="canf_NewWarrantSharesMember_33912" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SubsequentEventsDetailsTable_1327" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1331" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1331" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1332" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_1344" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_1350" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1347" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1348" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1349" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1337" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1338" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SubsequentEventsDetailsTable_1327" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1337" />
    <link:definitionArc xlink:type="arc" order="286.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1332" xlink:to="us-gaap_PrivatePlacementMember_33874" />
    <link:definitionArc xlink:type="arc" order="285.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1338" xlink:to="canf_ExistingWarrantsMember_33873" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="canf_SubsequentEventsDetailsTable_1327" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="canf_ClassOfWarrantOrRightPercentage_1352" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1332" xlink:to="canf_ADSMember_1334" />
    <link:definitionArc xlink:type="arc" order="330.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis_33942" xlink:to="srt_ScenarioUnspecifiedDomain_33943_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1331" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1332_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1337" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1338_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_33745" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_1228" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1230" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_November2023Member" xlink:label="canf_November2023Member_1234" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_IssuanceDate" xlink:label="canf_IssuanceDate_1238" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_December2021Member" xlink:label="canf_December2021Member_1232" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_April2025Member" xlink:label="canf_April2025Member_1236" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_33872" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_33744" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_1229" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_November2023AgentMember" xlink:label="canf_November2023AgentMember_33747" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_July2025OneMember" xlink:label="canf_July2025OneMember_33750" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_July2025Member" xlink:label="canf_July2025Member_33749" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_January2023AgentMember" xlink:label="canf_January2023AgentMember_33746" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_August2024Member" xlink:label="canf_August2024Member_1235" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_August2024AgentMember" xlink:label="canf_August2024AgentMember_33748" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_1239" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_1237" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1230_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_33872_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_33872" xlink:to="us-gaap_WarrantMember_33745" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1237" xlink:to="us-gaap_ClassOfWarrantOrRightTable_1228" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis_1229" xlink:to="us-gaap_AwardDateDomain_1230" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_November2023Member_1234" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1237" xlink:to="canf_IssuanceDate_1238" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_December2021Member_1232" />
    <link:definitionArc xlink:type="arc" order="17.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_April2025Member_1236" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_33744" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_33872" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1237" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1240" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable_1228" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_33744" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable_1228" xlink:to="us-gaap_AwardDateAxis_1229" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_November2023AgentMember_33747" />
    <link:definitionArc xlink:type="arc" order="192.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_July2025OneMember_33750" />
    <link:definitionArc xlink:type="arc" order="18.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_July2025Member_33749" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_January2023AgentMember_33746" />
    <link:definitionArc xlink:type="arc" order="15.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_August2024Member_1235" />
    <link:definitionArc xlink:type="arc" order="16.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_August2024AgentMember_33748" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1237" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_1239" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis_1229" xlink:to="us-gaap_AwardDateDomain_1230_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_33744" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_33872_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable_1263" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PercentageOfNetSales" xlink:label="canf_PercentageOfNetSales_1277" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PhaseIIIStudiesMember" xlink:label="canf_PhaseIIIStudiesMember_1268" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PhaseIIStudiesMember" xlink:label="canf_PhaseIIStudiesMember_1267" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PhaseIStudiesMember" xlink:label="canf_PhaseIStudiesMember_1266" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_RegulatoryAuthorityMember" xlink:label="canf_RegulatoryAuthorityMember_1269" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_RoyaltyPaymentsPercentage" xlink:label="canf_RoyaltyPaymentsPercentage_1279" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_1273" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_1272" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1270" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1271" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_33756" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1264" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseCommissionExpense" xlink:label="us-gaap_NoninterestExpenseCommissionExpense_1275" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_1274" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_1276" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1271_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems_1274" xlink:to="canf_ContingentLiabilitiesandCommitmentsDetailsTable_1263" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems_1274" xlink:to="canf_PercentageOfNetSales_1277" />
    <link:definitionArc xlink:type="arc" order="13.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" xlink:to="canf_PhaseIIIStudiesMember_1268" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" xlink:to="canf_PhaseIIStudiesMember_1267" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" xlink:to="canf_PhaseIStudiesMember_1266" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" xlink:to="canf_RegulatoryAuthorityMember_1269" />
    <link:definitionArc xlink:type="arc" order="14.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems_1274" xlink:to="canf_RoyaltyPaymentsPercentage_1279" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_1271" xlink:to="srt_MaximumMember_1273" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_1271" xlink:to="srt_MinimumMember_1272" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable_1263" xlink:to="srt_RangeAxis_1270" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis_1270" xlink:to="srt_RangeMember_1271" />
    <link:definitionArc xlink:type="arc" order="198.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems_1274" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_33756" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable_1263" xlink:to="us-gaap_AwardTypeAxis_1264" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems_1274" xlink:to="us-gaap_NoninterestExpenseCommissionExpense_1275" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems_1274" xlink:to="us-gaap_RoyaltyExpense_1276" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis_1264" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis_1270" xlink:to="srt_RangeMember_1271_default" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis_1264" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265_default" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_33702" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_33703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_33704" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33655" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33656" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_33657" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_LaboratoryEquipmentMember" xlink:label="canf_LaboratoryEquipmentMember_33660" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_33664" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_33665" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_33667" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_33834" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_33657_default" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_33834_default" />
    <link:definitionArc xlink:type="arc" order="12.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33655" xlink:to="srt_RangeAxis_33702" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_33834" xlink:to="srt_MaximumMember_33703" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember_33834" xlink:to="srt_MinimumMember_33704" />
    <link:definitionArc xlink:type="arc" order="125.00" priority="1" xbrldt:closed="true" use="optional" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_33665" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33655" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33655" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33656" />
    <link:definitionArc xlink:type="arc" order="127.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33656" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_33657" />
    <link:definitionArc xlink:type="arc" order="10.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_33657" xlink:to="canf_LaboratoryEquipmentMember_33660" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_33657" xlink:to="us-gaap_ComputerEquipmentMember_33664" />
    <link:definitionArc xlink:type="arc" order="133.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_33665" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_33667" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis_33702" xlink:to="srt_RangeMember_33834" />
    <link:definitionArc xlink:type="arc" order="127.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33656" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_33657_default" />
    <link:definitionArc xlink:type="arc" order="11.00" priority="1" xbrldt:closed="false" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis_33702" xlink:to="srt_RangeMember_33834_default" />
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="definitionLink">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" order="0" priority="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>canf-20251231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock" xlink:label="canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:label="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_GrossProceeds" xlink:label="canf_GrossProceeds" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NumberOfOrdinaryShares" xlink:label="canf_NumberOfOrdinaryShares" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PercentageOfDepositsOnMonthlySalary" xlink:label="canf_PercentageOfDepositsOnMonthlySalary" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PercentageOfRealizationOnUltimateSettlement" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShortTermBankDepositsYearlyInterestRatePercentage" xlink:label="canf_ShortTermBankDepositsYearlyInterestRatePercentage" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable" xlink:label="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisAbstract" xlink:label="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="us-gaap_StockOptionExercisePriceIncrease" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CashPlacementFee" xlink:label="canf_CashPlacementFee" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ClassOfWarrantOrRightPercentage" xlink:label="canf_ClassOfWarrantOrRightPercentage" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CommonWarrantsMember" xlink:label="canf_CommonWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_GrantedExcessYears" xlink:label="canf_GrantedExcessYears" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_IncreaseAuthorizedShareCapital" xlink:label="canf_IncreaseAuthorizedShareCapital" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_InvestorsFromJuly2025OfferingMember" xlink:label="canf_InvestorsFromJuly2025OfferingMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" xlink:label="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NewWarrantsMember" xlink:label="canf_NewWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PreFundedWarrantsMember" xlink:label="canf_PreFundedWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PurchaseAgreementMember" xlink:label="canf_PurchaseAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShareholdersEquityDetailsTable" xlink:label="canf_ShareholdersEquityDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SpecialGeneralMeetingOfShareholdersMember" xlink:label="canf_SpecialGeneralMeetingOfShareholdersMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" xlink:label="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" xlink:label="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_TwoThousandThirteenPlanMember" xlink:label="canf_TwoThousandThirteenPlanMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_TwoThousandTwentyThreePlanMember" xlink:label="canf_TwoThousandTwentyThreePlanMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ScheduleOfFairValueOfCompanySShareOptionsGrantedAbstract" xlink:label="canf_ScheduleOfFairValueOfCompanySShareOptionsGrantedAbstract" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:label="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable" xlink:label="canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ChongKunDangPharmaceuticalsCorpMember" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CipherPharmaceuticalsMember" xlink:label="canf_CipherPharmaceuticalsMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EwopharmaAGMember" xlink:label="canf_EwopharmaAGMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_GebroHoldingGmbHMember" xlink:label="canf_GebroHoldingGmbHMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_VetbiolixMember" xlink:label="canf_VetbiolixMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_AdditionalRevenueReceivedForAchievedMilestone" xlink:label="canf_AdditionalRevenueReceivedForAchievedMilestone" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CMSMedicalVentureInvestmentLimitedMember" xlink:label="canf_CMSMedicalVentureInvestmentLimitedMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EwopharmaMember" xlink:label="canf_EwopharmaMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_KyongboPharmCoLtdMember" xlink:label="canf_KyongboPharmCoLtdMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_LiverCancerIndicationMember" xlink:label="canf_LiverCancerIndicationMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_MilestonePaymentPercentage" xlink:label="canf_MilestonePaymentPercentage" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NASHMember" xlink:label="canf_NASHMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NonRefundablePayment" xlink:label="canf_NonRefundablePayment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="us-gaap_IsraelTaxAuthorityMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2017Member" xlink:label="us-gaap_TaxYear2017Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount" xlink:label="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_DocumentAndEntityInformationAbstract" xlink:label="canf_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_BankCommissions" xlink:label="canf_BankCommissions" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ExchangeRateFluctuationsAndOthers" xlink:label="canf_ExchangeRateFluctuationsAndOthers" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_OtherGainFromShortTermInvestmentRemeasurement" xlink:label="canf_OtherGainFromShortTermInvestmentRemeasurement" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ScheduleOfExpensesRecognizedFinancialStatementsAbstract" xlink:label="canf_ScheduleOfExpensesRecognizedFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelFaxNumber" xlink:label="dei_ContactPersonnelFaxNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_LegalAndOtherContingenciesPolicyTextBlock" xlink:label="canf_LegalAndOtherContingenciesPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SeverancePayPolicyTextBlock" xlink:label="canf_SeverancePayPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShorttermBankDepositsPolicyTextBlock" xlink:label="canf_ShorttermBankDepositsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PercentageOfNetSales" xlink:label="canf_PercentageOfNetSales" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PhaseIIIStudiesMember" xlink:label="canf_PhaseIIIStudiesMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PhaseIIStudiesMember" xlink:label="canf_PhaseIIStudiesMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PhaseIStudiesMember" xlink:label="canf_PhaseIStudiesMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_RegulatoryAuthorityMember" xlink:label="canf_RegulatoryAuthorityMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_RoyaltyPaymentsPercentage" xlink:label="canf_RoyaltyPaymentsPercentage" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseCommissionExpense" xlink:label="us-gaap_NoninterestExpenseCommissionExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_AmericanDepositarySharesMember" xlink:label="canf_AmericanDepositarySharesMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired" xlink:label="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants" xlink:label="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael" xlink:label="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLineItems" xlink:label="dei_AuditorLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_LaboratoryEquipmentMember" xlink:label="canf_LaboratoryEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants" xlink:label="canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNetAbstract" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="us-gaap_IncomeTaxExaminationLineItems" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PercentageOfRoyaltiesOnNetSales" xlink:label="canf_PercentageOfRoyaltiesOnNetSales" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_RegulatoryMilestonesMember" xlink:label="canf_RegulatoryMilestonesMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SalesMilestonesMember" xlink:label="canf_SalesMilestonesMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_TransferPriceRate" xlink:label="canf_TransferPriceRate" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_UpfrontAndMilestonePaymentsPayable" xlink:label="canf_UpfrontAndMilestonePaymentsPayable" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_UpfrontPayment" xlink:label="canf_UpfrontPayment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_KR" xlink:label="country_KR" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants" xlink:label="canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NetOfIssuanceCostsOrdinarySharesDueToATM" xlink:label="canf_NetOfIssuanceCostsOrdinarySharesDueToATM" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants" xlink:label="canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_GovernmentAuthorities" xlink:label="canf_GovernmentAuthorities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_November2023Member" xlink:label="canf_November2023Member" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_IssuanceDate" xlink:label="canf_IssuanceDate" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_December2021Member" xlink:label="canf_December2021Member" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_April2025Member" xlink:label="canf_April2025Member" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NewWarrantSharesMember" xlink:label="canf_NewWarrantSharesMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesExercised" xlink:label="canf_StockIssuedDuringPeriodSharesExercised" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodExerciseValue" xlink:label="canf_StockIssuedDuringPeriodExerciseValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ExistingWarrantsMember" xlink:label="canf_ExistingWarrantsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_November2023AgentMember" xlink:label="canf_November2023AgentMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_July2025OneMember" xlink:label="canf_July2025OneMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_July2025Member" xlink:label="canf_July2025Member" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_January2023AgentMember" xlink:label="canf_January2023AgentMember" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_August2024Member" xlink:label="canf_August2024Member" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_August2024AgentMember" xlink:label="canf_August2024AgentMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SubsequentEventsDetailsTable" xlink:label="canf_SubsequentEventsDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ADSMember" xlink:label="canf_ADSMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ChangesInFairValueOfShortTermInvestment" xlink:label="canf_ChangesInFairValueOfShortTermInvestment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" xlink:label="canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets" xlink:label="canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock" xlink:to="canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:to="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GrossProceeds" xlink:to="canf_GrossProceeds_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NumberOfOrdinaryShares" xlink:to="canf_NumberOfOrdinaryShares_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfDepositsOnMonthlySalary" xlink:to="canf_PercentageOfDepositsOnMonthlySalary_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfRealizationOnUltimateSettlement" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShortTermBankDepositsYearlyInterestRatePercentage" xlink:to="canf_ShortTermBankDepositsYearlyInterestRatePercentage_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable" xlink:to="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisAbstract" xlink:to="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashPlacementFee" xlink:to="canf_CashPlacementFee_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ClassOfWarrantOrRightPercentage" xlink:to="canf_ClassOfWarrantOrRightPercentage_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CommonWarrantsMember" xlink:to="canf_CommonWarrantsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GrantedExcessYears" xlink:to="canf_GrantedExcessYears_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseAuthorizedShareCapital" xlink:to="canf_IncreaseAuthorizedShareCapital_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_InvestorsFromJuly2025OfferingMember" xlink:to="canf_InvestorsFromJuly2025OfferingMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" xlink:to="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NewWarrantsMember" xlink:to="canf_NewWarrantsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PreFundedWarrantsMember" xlink:to="canf_PreFundedWarrantsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PurchaseAgreementMember" xlink:to="canf_PurchaseAgreementMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="canf_ShareholdersEquityDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SpecialGeneralMeetingOfShareholdersMember" xlink:to="canf_SpecialGeneralMeetingOfShareholdersMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" xlink:to="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" xlink:to="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TwoThousandThirteenPlanMember" xlink:to="canf_TwoThousandThirteenPlanMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TwoThousandTwentyThreePlanMember" xlink:to="canf_TwoThousandTwentyThreePlanMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfFairValueOfCompanySShareOptionsGrantedAbstract" xlink:to="canf_ScheduleOfFairValueOfCompanySShareOptionsGrantedAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:to="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable" xlink:to="canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CipherPharmaceuticalsMember" xlink:to="canf_CipherPharmaceuticalsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EwopharmaAGMember" xlink:to="canf_EwopharmaAGMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GebroHoldingGmbHMember" xlink:to="canf_GebroHoldingGmbHMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_VetbiolixMember" xlink:to="canf_VetbiolixMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueAbstract" xlink:to="us-gaap_DisaggregationOfRevenueAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AdditionalRevenueReceivedForAchievedMilestone" xlink:to="canf_AdditionalRevenueReceivedForAchievedMilestone_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CMSMedicalVentureInvestmentLimitedMember" xlink:to="canf_CMSMedicalVentureInvestmentLimitedMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EwopharmaMember" xlink:to="canf_EwopharmaMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_KyongboPharmCoLtdMember" xlink:to="canf_KyongboPharmCoLtdMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LiverCancerIndicationMember" xlink:to="canf_LiverCancerIndicationMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_MilestonePaymentPercentage" xlink:to="canf_MilestonePaymentPercentage_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NASHMember" xlink:to="canf_NASHMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NonRefundablePayment" xlink:to="canf_NonRefundablePayment_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2017Member" xlink:to="us-gaap_TaxYear2017Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount" xlink:to="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DocumentAndEntityInformationAbstract" xlink:to="canf_DocumentAndEntityInformationAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_BankCommissions" xlink:to="canf_BankCommissions_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExchangeRateFluctuationsAndOthers" xlink:to="canf_ExchangeRateFluctuationsAndOthers_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherGainFromShortTermInvestmentRemeasurement" xlink:to="canf_OtherGainFromShortTermInvestmentRemeasurement_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfExpensesRecognizedFinancialStatementsAbstract" xlink:to="canf_ScheduleOfExpensesRecognizedFinancialStatementsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelFaxNumber" xlink:to="dei_ContactPersonnelFaxNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LegalAndOtherContingenciesPolicyTextBlock" xlink:to="canf_LegalAndOtherContingenciesPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeverancePayPolicyTextBlock" xlink:to="canf_SeverancePayPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShorttermBankDepositsPolicyTextBlock" xlink:to="canf_ShorttermBankDepositsPolicyTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="canf_ContingentLiabilitiesandCommitmentsDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfNetSales" xlink:to="canf_PercentageOfNetSales_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PhaseIIIStudiesMember" xlink:to="canf_PhaseIIIStudiesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PhaseIIStudiesMember" xlink:to="canf_PhaseIIStudiesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PhaseIStudiesMember" xlink:to="canf_PhaseIStudiesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RegulatoryAuthorityMember" xlink:to="canf_RegulatoryAuthorityMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyPaymentsPercentage" xlink:to="canf_RoyaltyPaymentsPercentage_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseCommissionExpense" xlink:to="us-gaap_NoninterestExpenseCommissionExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AmericanDepositarySharesMember" xlink:to="canf_AmericanDepositarySharesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired" xlink:to="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants" xlink:to="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael" xlink:to="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLineItems" xlink:to="dei_AuditorLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentMember" xlink:to="canf_LaboratoryEquipmentMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants" xlink:to="canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_IncomeTaxesPaidNetAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_IncomeTaxExaminationLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfRoyaltiesOnNetSales" xlink:to="canf_PercentageOfRoyaltiesOnNetSales_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RegulatoryMilestonesMember" xlink:to="canf_RegulatoryMilestonesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SalesMilestonesMember" xlink:to="canf_SalesMilestonesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TransferPriceRate" xlink:to="canf_TransferPriceRate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UpfrontAndMilestonePaymentsPayable" xlink:to="canf_UpfrontAndMilestonePaymentsPayable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UpfrontPayment" xlink:to="canf_UpfrontPayment_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KR" xlink:to="country_KR_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants" xlink:to="canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetOfIssuanceCostsOrdinarySharesDueToATM" xlink:to="canf_NetOfIssuanceCostsOrdinarySharesDueToATM_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants" xlink:to="canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GovernmentAuthorities" xlink:to="canf_GovernmentAuthorities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_November2023Member" xlink:to="canf_November2023Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceDate" xlink:to="canf_IssuanceDate_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_December2021Member" xlink:to="canf_December2021Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_April2025Member" xlink:to="canf_April2025Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NewWarrantSharesMember" xlink:to="canf_NewWarrantSharesMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodSharesExercised" xlink:to="canf_StockIssuedDuringPeriodSharesExercised_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodExerciseValue" xlink:to="canf_StockIssuedDuringPeriodExerciseValue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExistingWarrantsMember" xlink:to="canf_ExistingWarrantsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_November2023AgentMember" xlink:to="canf_November2023AgentMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_July2025OneMember" xlink:to="canf_July2025OneMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_July2025Member" xlink:to="canf_July2025Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2023AgentMember" xlink:to="canf_January2023AgentMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_August2024Member" xlink:to="canf_August2024Member_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_August2024AgentMember" xlink:to="canf_August2024AgentMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SubsequentEventsDetailsTable" xlink:to="canf_SubsequentEventsDetailsTable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ADSMember" xlink:to="canf_ADSMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ChangesInFairValueOfShortTermInvestment" xlink:to="canf_ChangesInFairValueOfShortTermInvestment_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" xlink:to="canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets" xlink:to="canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Ordinary Shares [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of warrants to purchase ordinary shares Policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Functional currency, reporting currency and foreign currency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxes on income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Recently adopted accounting pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Expenses Recognized Financial Statements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Company's Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair value of Company&#8217;s Share Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Information Regarding Outstanding Warrants to Purchase Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_GrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_GrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_GrossProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of gross proceeds.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of ordinary shares in each ADS (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Ordinary Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of ordinary shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net operating cash outflow</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of deposits on monthly salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Deposits On Monthly Salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of deposits on monthly salary.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of realization on ultimate settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Realization On Ultimate Settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of realization on ultimate settlement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ShortTermBankDepositsYearlyInterestRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ShortTermBankDepositsYearlyInterestRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Bank Deposits Yearly Interest Rate Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ShortTermBankDepositsYearlyInterestRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term bank deposits, annual interest rate percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance pay expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Financial Assets And Liabilities Measured At Fair Value Recurring Basis Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Grants (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price, per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse split ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued for services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares issue (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued value for services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price, per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option, Exercise Price, Increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_CashPlacementFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash placement fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_CashPlacementFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Placement Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_CashPlacementFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the amount of cash placement fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ClassOfWarrantOrRightPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate warrants percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ClassOfWarrantOrRightPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ClassOfWarrantOrRightPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of Warrant or Right, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_GrantedExcessYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted excess years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_GrantedExcessYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Granted Excess Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_GrantedExcessYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Granted excess years.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_IncreaseAuthorizedShareCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase authorized share capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_IncreaseAuthorizedShareCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Authorized Share Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_IncreaseAuthorizedShareCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase authorized share capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_InvestorsFromJuly2025OfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investors from July 2025 Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds of ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares due to ATM, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Ordinary Shares Due To ATMNet Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of ordinary shares due to ATM, net of issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NewWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-Funded Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ShareholdersEquityDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_SpecialGeneralMeetingOfShareholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Special General Meeting of Shareholders [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ordinary shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares due to ATM, net of issuance costs (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issuance Of Ordinary Shares Due To ATM</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the number of shares issuance of ordinary shares due to ATM.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares held investors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Release of ordinary shares that were previously held in abeyance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Release Of Ordinary Shares That Were Previously Held In Abeyance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The shares of release of ordinary shares that were previously held in abeyance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_TwoThousandThirteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_TwoThousandThirteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Thirteen Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_TwoThousandTwentyThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_TwoThousandTwentyThreePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Board of Directors [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Board of Directors Chairman [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ScheduleOfFairValueOfCompanySShareOptionsGrantedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Of Company SShare Options Granted Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early Exercise Multiple (Suboptimal Factor)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders' Equity - Schedule of Fair value of Company&#8217;s Share Options Granted (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual life (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary differences mainly relating to Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, gross total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Chong Kun Dang Pharmaceuticals Corp. (South Korea) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chong Kun Dang Pharmaceuticals Corp. [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chong Kun Dang Pharmaceuticals Corp [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_CipherPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cipher Pharmaceuticals (Canada) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_CipherPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cipher Pharmaceuticals [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_EwopharmaAGMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ewopharma AG (Switzerland) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_EwopharmaAGMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ewopharma AG [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_GebroHoldingGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gebro Holding GmbH (Austria) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_GebroHoldingGmbHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gebro Holding GmbH [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_VetbiolixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vetbiolix (France) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_VetbiolixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vetbiolix [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Major Customer Data as a Percentage [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total anti-dilutive shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Shares [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">REVENUES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_AdditionalRevenueReceivedForAchievedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional achieved milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_AdditionalRevenueReceivedForAchievedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Revenue Received for Achieved Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_AdditionalRevenueReceivedForAchievedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of additional revenue received for achieved milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_CMSMedicalVentureInvestmentLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CMS Medical Venture Investment Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_EwopharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ewopharma [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_KyongboPharmCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Kyongbo Pharm Co Ltd [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_LiverCancerIndicationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liver Cancer Indication [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_MilestonePaymentPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_MilestonePaymentPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_MilestonePaymentPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NASHMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NASH [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NonRefundablePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NonRefundablePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-Refundable Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NonRefundablePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of non-refundable payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Israel [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Israel Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PROPERTY, PLANT AND EQUIPMENT, NET</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in Valuation Allowances, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxYear2017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Year 2017 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxYear2017Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2017 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carryforward losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Reconciliation Statutory Israeli Income Tax Rate [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax at Israeli Statutory Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of benefitted income preferred technological enterprise in Israel, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Benefitted Income Preferred Technological Enterprise in Israel, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of income tax expense or benefit benefitted income preferred technological enterprise in Israel, amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in Valuation Allowances, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment awards, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Other Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees and payroll accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Accounts Payable [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LEASES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Average Remaining Lease Terms and Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentRegistrationStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Registration Statement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentShellCompanyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Shell Company Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contact Personnel Email Address</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_ContactPersonnelName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contact Personnel Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT ASSETS:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Other, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_DocumentAndEntityInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label"></link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments required to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONTINGENT LIABILITIES AND COMMITMENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Motor Vehicles [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vehicles [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_BankCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bank commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_BankCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of bank commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ExchangeRateFluctuationsAndOthers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange rate fluctuations and others</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ExchangeRateFluctuationsAndOthers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of exchange rate fluctuations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_OtherGainFromShortTermInvestmentRemeasurement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term investment revaluation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_OtherGainFromShortTermInvestmentRemeasurement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of other gain from short-term investment remeasurement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Nonoperating, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Nonoperating, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial income (expenses), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finance Income (Expense), Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ScheduleOfExpensesRecognizedFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Expenses Recognized Financial Statements Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Arrangement Expensed [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price decrease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant, Exercise Price, Decrease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NON-CURRENT ASSETS:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAccountingStandard_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Accounting Standard</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Trade, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Financial expenses (income), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_ContactPersonnelFaxNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contact Personnel Fax Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Addresses, Address Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AddressTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Address Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_BusinessContactMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Contact</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_BusinessContactMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Contact [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares of no par value - Authorized: 14,000,000 and 3,333,334 shares at December 31, 2025 and 2024, respectively; Issued and outstanding: 2,618,425 and 994,394 shares as of December 31, 2025 and 2024, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total shareholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NON-CURRENT LIABILITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right of use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT LIABILITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current maturity of operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted net loss per share (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, par value (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Price per share (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHAREHOLDERS&#8217; EQUITY:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses, and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares and warrants, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issuance Of Share Capital And Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of share capital and warrants, net of issuance expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">General and administrative expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total financial income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic net loss per share (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of ordinary shares used in computing basic net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Ordinary Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares and warrants, net of issuance costs (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Share Issuance Of Share Capital And Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of issuance of share capital and warrants, net of issuance expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares due to exercise of warrants net of issuance expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before taxes on income, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUBSEQUENT EVENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_LegalAndOtherContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal and other contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_LegalAndOtherContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal And Other Contingencies [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_LegalAndOtherContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of legal and other contingencies policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses, and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The accounting policy for prepaid expenses, and other current assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently issued accounting pronouncements not yet adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of recently issued accounting pronouncements not yet adopted Policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_SeverancePayPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance pay</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_SeverancePayPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Severance Pay [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_SeverancePayPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for severance pay.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ShorttermBankDepositsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term bank deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ShorttermBankDepositsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Bank Deposits [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ShorttermBankDepositsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for segment reporting.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Liabilities and Commitments (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PercentageOfNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage of net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PhaseIIIStudiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase III Studies [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PhaseIIIStudiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phase IIIStudies Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PhaseIIStudiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase II Studies [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PhaseIIStudiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phase IIStudies Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PhaseIStudiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase I Studies [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PhaseIStudiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phase IStudies Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_RegulatoryAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_RegulatoryAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Authority Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_RoyaltyPaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payments, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_RoyaltyPaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payments Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_RoyaltyPaymentsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The royalty payment in percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrual for Taxes Other than Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Liabilities and Commitments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoninterestExpenseCommissionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commission income expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoninterestExpenseCommissionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noninterest Expense Commission Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Liabilities and Commitments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_AmericanDepositarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">American Depositary Shares (ADSs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_AmericanDepositarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">American Depositary Shares Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price per warrant (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants exercise price (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Exercise price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchased ordinary shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Warrant purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary share, voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation for services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefits and Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation costs not yet recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate issuance costs (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares due to ATM, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Exercisable (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Exercisable (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual terms, expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Terms Forfeitedexpired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, options, nonvested options forfeited, weighted average grant date fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual terms, Grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Terms Grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining contractual term for vested portions of options Grants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax at Israeli Statutory Rate, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of benefitted income preferred technological enterprise in Israel, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Benefitted Income Preferred Technological Enterprise in Israel</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) benefitted income preferred technological enterprise in Israel.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory Israeli Income Tax Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate intrinsic value, Ending (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Vested and expected to vest (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual terms, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers, Office Furniture and Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Property, Plant and Equipment, Net [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Depreciable Rates of Property and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Major Customer Data as a Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Antidilutive Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Laboratory equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Depreciable Rates of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Useful Lives of The Asset [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The tabular disclosure for property plant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate tax rate, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Tax Rate, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development area, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carry forward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of issuance costs of ordinary shares and warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net of Issuance Costs of Ordinary Shares and Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the amount of net of issuance costs of ordinary shares and warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Computers, office furniture and equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Prepaid Expenses and Other Current Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual rates of depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Salvage Value, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxes on Income [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TAXES ON INCOME</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation Statutory Israeli Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxes on Income [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PercentageOfRoyaltiesOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalties on net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PercentageOfRoyaltiesOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Royalties on Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_PercentageOfRoyaltiesOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the percentage of royalties on net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_RegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_SalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_TransferPriceRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer price rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_TransferPriceRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transfer Price Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_TransferPriceRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transfer price rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_UpfrontAndMilestonePaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront and milestone payments payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_UpfrontAndMilestonePaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront and Milestone Payments Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_UpfrontAndMilestonePaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of upfront and milestone payments payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the amount of upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_KR_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South Korea [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_KR_lbl" xlink:role="http://www.xbrl.org/2003/role/label">KOREA, REPUBLIC OF</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of issuance expenses of ordinary shares due to exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net of Issuance Expenses of Ordinary Shares Due to Exercise of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the amount of net of issuance expenses of ordinary shares due to exercise of warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NetOfIssuanceCostsOrdinarySharesDueToATM_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of issuance costs ordinary shares due to ATM</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NetOfIssuanceCostsOrdinarySharesDueToATM_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net of Issuance Costs Ordinary Shares Due To ATM</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NetOfIssuanceCostsOrdinarySharesDueToATM_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the amount of net of issuance costs ordinary shares due to ATM.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of issuance costs ordinary shares and warrants and exercise of pre-funded warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net of Issuance Costs Ordinary Shares and Warrants and Exercise of Pre-Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the amount of net of issuance costs ordinary shares and warrants and exercise of pre-funded warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Weighted Average Exercise Prices Share Options [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Vested and expected to vest (in Dollars)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual terms, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, Ending (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Ending</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment awards, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, expired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and others</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_GovernmentAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government authorities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_GovernmentAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Government Authorities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_GovernmentAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of government authorities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Date [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_November2023Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">November 2023 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_November2023Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">November2023 Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_IssuanceDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_IssuanceDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_IssuanceDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the date of issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_December2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2021 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_December2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December2021 Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_April2025Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">April 2025 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_April2025Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">April2025 Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-accountable expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_NewWarrantSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Warrant Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares and warrants, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants represented</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Lease Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of lease expense:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases, Operating [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">weighted average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">weighted average remaining lease term (years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Income (Expense), Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Income (Expense), Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance Income (Expense), Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income and Expense [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Finance Income (Expense), Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of ordinary shares used in computing diluted net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payments (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GENERAL</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodSharesExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares and warrants and exercise of pre-funded warrants, net of issuance costs (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodSharesExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodSharesExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of shares exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FAIR VALUE MEASUREMENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONTINGENT LIABILITIES AND COMMITMENTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodExerciseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares and warrants and exercise of pre-funded warrants, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodExerciseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During period Exercise Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodExerciseValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of shares issued for options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares due to exercise of warrants net of issuance expenses (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEGMENT REPORTING</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ExistingWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Existing Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Date [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Information Regarding Outstanding Warrants To Purchase Shares Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_November2023AgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">November 2023 agent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_July2025OneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">July 2025 One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_July2025Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">July 2025 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_January2023AgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">January 2023 agent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_August2024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August 2024 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_August2024Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">August2024 Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_August2024AgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">August 2024 agent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Outstanding Warrants to Purchase Shares [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived patents, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Patents, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Terms of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of additional payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Performance Obligation, Description of Payment Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenues recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Accounts Payable [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OTHER ACCOUNTS PAYABLE</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Lease Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_SubsequentEventsDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events (Details) [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ADSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ADS [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ADSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ADSMember</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ADSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">American Depository Receipt (or American Depository Share, ADS).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of CODM</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief executive officer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange differences on balances of cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at the beginning of the year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at the end of the year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in the carrying amount of operating lease right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ChangesInFairValueOfShortTermInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value of short-term investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ChangesInFairValueOfShortTermInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes In Fair Value Of Short Term Investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_ChangesInFairValueOfShortTermInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the amount of changes in fair value of short term investment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in prepaid expenses, and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in trade payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in other accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Maturity of short-term deposits, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation of property, plant and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Release of ordinary shares that were previously held in abeyance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Release of Ordinary Shares that were Previously Held in Abeyance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the amount of stock issued during period value release of ordinary shares that were previously held in abeyance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities arising from obtaining right-of-use-assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Liabilities Arising from Obtaining Right-Of-Use-Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent the amount of lease liabilities arising from obtaining right-of-use-assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (decrease) in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional &#8239;paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in deferred revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property, plant and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" />
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>canf-20251231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#DocumentAndEntityInformation" roleURI="http://canfite.com/20251231/role/DocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#AuditInformation" roleURI="http://canfite.com/20251231/role/AuditInformation" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ConsolidatedBalanceSheets" roleURI="http://canfite.com/20251231/role/ConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ConsolidatedBalanceSheetsParentheticals" roleURI="http://canfite.com/20251231/role/ConsolidatedBalanceSheetsParentheticals" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ConsolidatedStatementsofOperatingLoss" roleURI="http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ConsolidatedStatementsofChangesinShareholdersEquity" roleURI="http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ConsolidatedStatementsofChangesinShareholdersEquityParentheticals" roleURI="http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquityParentheticals" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ConsolidatedStatementsofCashFlows" roleURI="http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#General" roleURI="http://canfite.com/20251231/role/General" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#SignificantAccountingPolicies" roleURI="http://canfite.com/20251231/role/SignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#PrepaidExpensesandOtherCurrentAssets" roleURI="http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssets" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#PropertyPlantandEquipmentNet" roleURI="http://canfite.com/20251231/role/PropertyPlantandEquipmentNet" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#OtherAccountsPayable" roleURI="http://canfite.com/20251231/role/OtherAccountsPayable" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#FairValueMeasurements" roleURI="http://canfite.com/20251231/role/FairValueMeasurements" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#Revenues" roleURI="http://canfite.com/20251231/role/Revenues" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ContingentLiabilitiesandCommitments" roleURI="http://canfite.com/20251231/role/ContingentLiabilitiesandCommitments" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ShareholdersEquity" roleURI="http://canfite.com/20251231/role/ShareholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#Leases" roleURI="http://canfite.com/20251231/role/Leases" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#FinanceIncomeExpenseNet" roleURI="http://canfite.com/20251231/role/FinanceIncomeExpenseNet" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#SegmentReporting" roleURI="http://canfite.com/20251231/role/SegmentReporting" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#TaxesonIncome" roleURI="http://canfite.com/20251231/role/TaxesonIncome" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#SubsequentEvents" roleURI="http://canfite.com/20251231/role/SubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#CybersecurityRiskManagementandStrategyDisclosure" roleURI="http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#AccountingPoliciesbyPolicyPolicies" roleURI="http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#SignificantAccountingPoliciesTables" roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsTables" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#PropertyPlantandEquipmentNetTables" roleURI="http://canfite.com/20251231/role/PropertyPlantandEquipmentNetTables" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#OtherAccountsPayableTables" roleURI="http://canfite.com/20251231/role/OtherAccountsPayableTables" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#FairValueMeasurementsTables" roleURI="http://canfite.com/20251231/role/FairValueMeasurementsTables" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ShareholdersEquityTables" roleURI="http://canfite.com/20251231/role/ShareholdersEquityTables" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#LeasesTables" roleURI="http://canfite.com/20251231/role/LeasesTables" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#FinanceIncomeExpenseNetTables" roleURI="http://canfite.com/20251231/role/FinanceIncomeExpenseNetTables" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#TaxesonIncomeTables" roleURI="http://canfite.com/20251231/role/TaxesonIncomeTables" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#GeneralDetails" roleURI="http://canfite.com/20251231/role/GeneralDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#SignificantAccountingPoliciesDetails" roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails" roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails" roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails" roleURI="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#PropertyPlantandEquipmentNetDetails" roleURI="http://canfite.com/20251231/role/PropertyPlantandEquipmentNetDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails" roleURI="http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#OtherAccountsPayableScheduleofOtherAccountsPayableDetails" roleURI="http://canfite.com/20251231/role/OtherAccountsPayableScheduleofOtherAccountsPayableDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails" roleURI="http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#RevenuesDetails" roleURI="http://canfite.com/20251231/role/RevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ContingentLiabilitiesandCommitmentsDetails" roleURI="http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ShareholdersEquityDetails" roleURI="http://canfite.com/20251231/role/ShareholdersEquityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails" roleURI="http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ShareholdersEquityScheduleofCompanysOptionActivityDetails" roleURI="http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails" roleURI="http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails" roleURI="http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#LeasesDetails" roleURI="http://canfite.com/20251231/role/LeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#LeasesScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateDetails" roleURI="http://canfite.com/20251231/role/LeasesScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails" roleURI="http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#FinanceIncomeExpenseNetScheduleofFinanceIncomeExpenseNetDetails" roleURI="http://canfite.com/20251231/role/FinanceIncomeExpenseNetScheduleofFinanceIncomeExpenseNetDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#SegmentReportingDetails" roleURI="http://canfite.com/20251231/role/SegmentReportingDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#TaxesonIncomeDetails" roleURI="http://canfite.com/20251231/role/TaxesonIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#TaxesonIncomeScheduleofScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://canfite.com/20251231/role/TaxesonIncomeScheduleofScheduleofDeferredTaxAssetsandLiabilitiesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails" roleURI="http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails" />
  <link:roleRef xlink:type="simple" xlink:href="canf-20251231.xsd#SubsequentEventsDetails" roleURI="http://canfite.com/20251231/role/SubsequentEventsDetails" />
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock" xlink:label="canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock_33622" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1130" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_33598" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_33612" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_33593" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_33623" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_33611" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_33596" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_33607" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_33621" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_33605" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1133" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_33606" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_33610" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1131" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_33594" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_33620" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_33592" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_LegalAndOtherContingenciesPolicyTextBlock" xlink:label="canf_LegalAndOtherContingenciesPolicyTextBlock_33614" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:label="canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_33604" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_33625" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SeverancePayPolicyTextBlock" xlink:label="canf_SeverancePayPolicyTextBlock_33619" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShorttermBankDepositsPolicyTextBlock" xlink:label="canf_ShorttermBankDepositsPolicyTextBlock_33603" />
    <link:presentationArc xlink:type="arc" order="29.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock_33622" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_33598" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_ConcentrationRiskCreditRisk_33612" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_ConsolidationPolicyTextBlock_33593" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="30.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_33623" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_33611" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_33596" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_33607" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_33621" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_33605" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="31.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1133" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_33606" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_33610" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1131" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_33594" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_33620" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="us-gaap_UseOfEstimates_33592" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="canf_LegalAndOtherContingenciesPolicyTextBlock_33614" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_33604" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="104.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_33625" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="canf_SeverancePayPolicyTextBlock_33619" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1130" xlink:to="canf_ShorttermBankDepositsPolicyTextBlock_33603" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:label="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_1135" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1136" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_1135" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1136" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ShareholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1145" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1144" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1143" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1146" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1142" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1142" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1145" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1142" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1144" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1142" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1143" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1142" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1146" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/GeneralDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_GrossProceeds" xlink:label="canf_GrossProceeds_33584" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NumberOfOrdinaryShares" xlink:label="canf_NumberOfOrdinaryShares_1248" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_1251" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_1250" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_33581" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1242" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1242" xlink:to="canf_GrossProceeds_33584" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1242" xlink:to="canf_NumberOfOrdinaryShares_1248" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1242" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_1251" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1242" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_1250" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1242" xlink:to="us-gaap_NetIncomeLoss_33581" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PercentageOfDepositsOnMonthlySalary" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_33725" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PercentageOfRealizationOnUltimateSettlement" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_33723" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShortTermBankDepositsYearlyInterestRatePercentage" xlink:label="canf_ShortTermBankDepositsYearlyInterestRatePercentage_33727" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1255" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_1256" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1257" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_33919" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1_33721" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_33920" />
    <link:presentationArc xlink:type="arc" order="180.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1255" xlink:to="canf_PercentageOfDepositsOnMonthlySalary_33725" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="178.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1255" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement_33723" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="182.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1255" xlink:to="canf_ShortTermBankDepositsYearlyInterestRatePercentage_33727" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1255" xlink:to="us-gaap_ContractWithCustomerLiability_1256" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1255" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1257" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="316.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1255" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_33919" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="176.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1255" xlink:to="us-gaap_SeveranceCosts1_33721" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="317.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1255" xlink:to="us-gaap_UnrecognizedTaxBenefits_33920" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable" xlink:label="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable_1149" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisAbstract" xlink:label="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisAbstract_1148" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1155" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1150" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_33935" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_1152" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_1153" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_1154" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_33936" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1151" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_33937" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_1156" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisAbstract_1148" xlink:to="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable_1149" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable_1149" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1155" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable_1149" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_1150" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable_1149" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_33935" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1151" xlink:to="us-gaap_FairValueInputsLevel1Member_1152" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1151" xlink:to="us-gaap_FairValueInputsLevel2Member_1153" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1151" xlink:to="us-gaap_FairValueInputsLevel3Member_1154" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="326.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_33935" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_33936" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1150" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1151" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="327.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_33936" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_33937" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1155" xlink:to="us-gaap_ShortTermInvestments_1156" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ShareholdersEquityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_33883" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_33887" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_33881" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_33880" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_33780" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1293" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1281" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_33909" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1307" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_33779" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_1318" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1308" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionExercisePriceIncrease" xlink:label="us-gaap_StockOptionExercisePriceIncrease_33879" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_33897" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_33895" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_33896" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CashPlacementFee" xlink:label="canf_CashPlacementFee_33907" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ClassOfWarrantOrRightPercentage" xlink:label="canf_ClassOfWarrantOrRightPercentage_1312" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CommonWarrantsMember" xlink:label="canf_CommonWarrantsMember_33906" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_GrantedExcessYears" xlink:label="canf_GrantedExcessYears_33886" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_IncreaseAuthorizedShareCapital" xlink:label="canf_IncreaseAuthorizedShareCapital_33898" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_InvestorsFromJuly2025OfferingMember" xlink:label="canf_InvestorsFromJuly2025OfferingMember_33894" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" xlink:label="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_33876" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NewWarrantsMember" xlink:label="canf_NewWarrantsMember_33833" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PreFundedWarrantsMember" xlink:label="canf_PreFundedWarrantsMember_33901" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PurchaseAgreementMember" xlink:label="canf_PurchaseAgreementMember_1292" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShareholdersEquityDetailsTable" xlink:label="canf_ShareholdersEquityDetailsTable_1282" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SpecialGeneralMeetingOfShareholdersMember" xlink:label="canf_SpecialGeneralMeetingOfShareholdersMember_33900" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" xlink:label="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_33875" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" xlink:label="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_1316" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_TwoThousandThirteenPlanMember" xlink:label="canf_TwoThousandThirteenPlanMember_1298" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_TwoThousandTwentyThreePlanMember" xlink:label="canf_TwoThousandTwentyThreePlanMember_1299" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember_1302" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_33890" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_33891" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_33888" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_33889" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1300" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1301" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1291" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_1303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_33828" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1283" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1290" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_33829" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_AmericanDepositarySharesMember" xlink:label="canf_AmericanDepositarySharesMember_1286" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_33831" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_33782" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1315" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_33781" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_33905" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_33884" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1295" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_33778" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_1317" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights_1304" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_33911" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_33882" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1294" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_33892" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_33893" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_33904" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_1311" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1296" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1297" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_33941" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_33903" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_33939" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1284" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1309" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_33940" />
    <link:presentationArc xlink:type="arc" order="30.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_33883" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="34.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_33887" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_33881" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_33880" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="41.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_SharesIssuedPricePerShare_33780" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_StatementEquityComponentsAxis_1293" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="50.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_33909" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="37.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1307" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_33779" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="35.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_1318" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="38.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_1308" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="29.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_StockOptionExercisePriceIncrease_33879" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="296.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_33896" xlink:to="us-gaap_SubsequentEventMember_33897" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_SubsequentEventTypeAxis_33895" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="295.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_33895" xlink:to="us-gaap_SubsequentEventTypeDomain_33896" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="49.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_CashPlacementFee_33907" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="39.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_ClassOfWarrantOrRightPercentage_1312" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="303.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_33831" xlink:to="canf_CommonWarrantsMember_33906" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="33.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_GrantedExcessYears_33886" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="44.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_IncreaseAuthorizedShareCapital_33898" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="293.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember_33893" xlink:to="canf_InvestorsFromJuly2025OfferingMember_33894" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_33876" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="264.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_33831" xlink:to="canf_NewWarrantsMember_33833" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="265.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_33831" xlink:to="canf_PreFundedWarrantsMember_33901" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1291" xlink:to="canf_PurchaseAgreementMember_1292" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1281" xlink:to="canf_ShareholdersEquityDetailsTable_1282" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="299.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_1301" xlink:to="canf_SpecialGeneralMeetingOfShareholdersMember_33900" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_33875" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="43.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_1316" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1297" xlink:to="canf_TwoThousandThirteenPlanMember_1298" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_1297" xlink:to="canf_TwoThousandTwentyThreePlanMember_1299" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_1301" xlink:to="srt_BoardOfDirectorsChairmanMember_1302" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="289.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_33889" xlink:to="srt_MaximumMember_33890" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="290.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_33889" xlink:to="srt_MinimumMember_33891" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="srt_RangeAxis_33888" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="288.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_33888" xlink:to="srt_RangeMember_33889" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="srt_TitleOfIndividualAxis_1300" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_1300" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1301" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_1290" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1291" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_ClassOfStockLineItems_1303" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_33828" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1283" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_TypeOfArrangementAxis_1290" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_33831" xlink:to="us-gaap_WarrantMember_33829" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1284" xlink:to="canf_AmericanDepositarySharesMember_1286" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="262.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_33828" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_33831" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_33782" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="42.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1315" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_33781" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="48.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_33905" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="31.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_33884" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_1294" xlink:to="us-gaap_CommonStockMember_1295" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_33778" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_CommonStockSharesAuthorized_1317" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_CommonStockVotingRights_1304" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="52.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_33911" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_33882" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1293" xlink:to="us-gaap_EquityComponentDomain_1294" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_InvestmentTypeAxis_33892" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="292.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis_33892" xlink:to="us-gaap_InvestmentTypeCategorizationMember_33893" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1284" xlink:to="us-gaap_IPOMember_33904" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_1311" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ShareholdersEquityDetailsTable_1282" xlink:to="us-gaap_PlanNameAxis_1296" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_1296" xlink:to="us-gaap_PlanNameDomain_1297" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="53.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_33941" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="47.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_33903" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_33939" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1283" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1284" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1309" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_1303" xlink:to="us-gaap_SaleOfStockPricePerShare_33940" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ScheduleOfFairValueOfCompanySShareOptionsGrantedAbstract" xlink:label="canf_ScheduleOfFairValueOfCompanySShareOptionsGrantedAbstract_1180" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:label="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_1191" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable" xlink:label="canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable_1181" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_1184" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1188" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1190" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1183" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_1185" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1182" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1187" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1189" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" xlink:to="canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_1191" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ScheduleOfFairValueOfCompanySShareOptionsGrantedAbstract_1180" xlink:to="canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable_1181" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_1183" xlink:to="srt_MaximumMember_1184" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable_1181" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1188" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1190" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_1182" xlink:to="srt_RangeMember_1183" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_1183" xlink:to="srt_MinimumMember_1185" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable_1181" xlink:to="srt_RangeAxis_1182" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1187" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1186" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1189" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/TaxesonIncomeScheduleofScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_33857" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_33858" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_33859" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_33860" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_33855" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_33856" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_33855" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_33857" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_33855" xlink:to="us-gaap_DeferredTaxAssetsGross_33858" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_33855" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_33859" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_33855" xlink:to="us-gaap_DeferredTaxAssetsNet_33860" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_33855" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_33856" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ChongKunDangPharmaceuticalsCorpMember" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_33684" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CipherPharmaceuticalsMember" xlink:label="canf_CipherPharmaceuticalsMember_33685" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EwopharmaAGMember" xlink:label="canf_EwopharmaAGMember_33687" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_GebroHoldingGmbHMember" xlink:label="canf_GebroHoldingGmbHMember_33686" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_VetbiolixMember" xlink:label="canf_VetbiolixMember_33688" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_33682" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_33683" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_33671" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_33675" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_33674" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_33677" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_33680" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_33681" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_33678" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_33679" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_33676" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33672" />
    <link:presentationArc xlink:type="arc" order="144.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33683" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember_33684" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="145.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33683" xlink:to="canf_CipherPharmaceuticalsMember_33685" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="147.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33683" xlink:to="canf_EwopharmaAGMember_33687" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="146.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33683" xlink:to="canf_GebroHoldingGmbHMember_33686" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="148.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33683" xlink:to="canf_VetbiolixMember_33688" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33672" xlink:to="srt_MajorCustomersAxis_33682" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="143.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_33682" xlink:to="srt_NameOfMajorCustomerDomain_33683" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="135.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_33674" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_33675" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33672" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_33674" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33672" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_33677" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33672" xlink:to="us-gaap_ConcentrationRiskLineItems_33680" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="141.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_33680" xlink:to="us-gaap_ConcentrationRiskPercentage1_33681" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="138.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_33677" xlink:to="us-gaap_ConcentrationRiskTypeDomain_33678" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="139.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_33678" xlink:to="us-gaap_CustomerConcentrationRiskMember_33679" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="136.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_33675" xlink:to="us-gaap_SalesRevenueNetMember_33676" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_33671" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33672" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_33690" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_33698" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33692" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33697" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_33693" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_33695" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33691" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_33696" />
    <link:presentationArc xlink:type="arc" order="155.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33697" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_33698" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="149.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33691" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33692" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="154.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33691" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_33697" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="150.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_33692" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_33693" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="152.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_33693" xlink:to="us-gaap_EmployeeStockMember_33695" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_33690" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33691" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="153.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_33693" xlink:to="us-gaap_WarrantMember_33696" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/Revenues" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="us-gaap_DisaggregationOfRevenueAbstract_33700" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_33701" />
    <link:presentationArc xlink:type="arc" order="157.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueAbstract_33700" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_33701" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/RevenuesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_AdditionalRevenueReceivedForAchievedMilestone" xlink:label="canf_AdditionalRevenueReceivedForAchievedMilestone_33724" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ChongKunDangPharmaceuticalsCorpMember" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_33757" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CipherPharmaceuticalsMember" xlink:label="canf_CipherPharmaceuticalsMember_33751" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_CMSMedicalVentureInvestmentLimitedMember" xlink:label="canf_CMSMedicalVentureInvestmentLimitedMember_33762" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EwopharmaMember" xlink:label="canf_EwopharmaMember_33768" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_GebroHoldingGmbHMember" xlink:label="canf_GebroHoldingGmbHMember_33759" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_KyongboPharmCoLtdMember" xlink:label="canf_KyongboPharmCoLtdMember_33767" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_LiverCancerIndicationMember" xlink:label="canf_LiverCancerIndicationMember_33752" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_MilestonePaymentPercentage" xlink:label="canf_MilestonePaymentPercentage_33731" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NASHMember" xlink:label="canf_NASHMember_33754" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NonRefundablePayment" xlink:label="canf_NonRefundablePayment_33729" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_33711" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PercentageOfRoyaltiesOnNetSales" xlink:label="canf_PercentageOfRoyaltiesOnNetSales_33938" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_RegulatoryMilestonesMember" xlink:label="canf_RegulatoryMilestonesMember_33764" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SalesMilestonesMember" xlink:label="canf_SalesMilestonesMember_33765" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_TransferPriceRate" xlink:label="canf_TransferPriceRate_33720" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_UpfrontAndMilestonePaymentsPayable" xlink:label="canf_UpfrontAndMilestonePaymentsPayable_33719" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_UpfrontPayment" xlink:label="canf_UpfrontPayment_33716" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_VetbiolixMember" xlink:label="canf_VetbiolixMember_33760" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_KR" xlink:label="country_KR_33755" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_33713" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_33923" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_33924" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_33714" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_33709" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_33710" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_33921" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_33922" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_33712" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_33708" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross_33733" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties_33717" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_33707" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_33722" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:label="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_33726" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_33728" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_33718" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" />
    <link:presentationArc xlink:type="arc" order="179.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_AdditionalRevenueReceivedForAchievedMilestone_33724" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="199.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember_33757" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="193.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_CipherPharmaceuticalsMember_33751" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="203.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_CMSMedicalVentureInvestmentLimitedMember_33762" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="209.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_EwopharmaMember_33768" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="201.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_GebroHoldingGmbHMember_33759" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="208.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_KyongboPharmCoLtdMember_33767" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="194.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_33710" xlink:to="canf_LiverCancerIndicationMember_33752" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="185.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_MilestonePaymentPercentage_33731" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="196.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_33710" xlink:to="canf_NASHMember_33754" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="184.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_NonRefundablePayment_33729" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_33708" xlink:to="srt_StatementGeographicalAxis_33711" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="328.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_PercentageOfRoyaltiesOnNetSales_33938" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="205.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_RegulatoryMilestonesMember_33764" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="206.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_SalesMilestonesMember_33765" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="175.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_TransferPriceRate_33720" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="174.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_UpfrontAndMilestonePaymentsPayable_33719" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="171.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="canf_UpfrontPayment_33716" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="202.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_33714" xlink:to="canf_VetbiolixMember_33760" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="197.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_33712" xlink:to="country_KR_33755" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_33708" xlink:to="srt_MajorCustomersAxis_33713" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="320.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_33922" xlink:to="srt_MaximumMember_33923" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="321.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_33922" xlink:to="srt_MinimumMember_33924" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="169.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_33713" xlink:to="srt_NameOfMajorCustomerDomain_33714" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_33708" xlink:to="srt_ProductOrServiceAxis_33709" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="165.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_33709" xlink:to="srt_ProductsAndServicesDomain_33710" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_33708" xlink:to="srt_RangeAxis_33921" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="319.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_33921" xlink:to="srt_RangeMember_33922" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="167.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_33711" xlink:to="srt_SegmentGeographicalDomain_33712" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="163.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_33707" xlink:to="us-gaap_DisaggregationOfRevenueTable_33708" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="187.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_FiniteLivedPatentsGross_33733" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="172.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_PaymentsForRoyalties_33717" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="177.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_33722" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="181.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_33726" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="183.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_33728" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="173.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_33718" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_33708" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_33715" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/TaxesonIncomeDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_33850" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IsraelTaxAuthorityMember" xlink:label="us-gaap_IsraelTaxAuthorityMember_33853" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_33915" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_33916" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxYear2017Member" xlink:label="us-gaap_TaxYear2017Member_33917" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_33849" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_33846" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_33848" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_33851" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_33852" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNetAbstract" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract_33844" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="us-gaap_IncomeTaxExaminationLineItems_33845" />
    <link:presentationArc xlink:type="arc" order="276.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract_33844" xlink:to="us-gaap_OperatingLossCarryforwardsTable_33850" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain_33852" xlink:to="us-gaap_IsraelTaxAuthorityMember_33853" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_33850" xlink:to="us-gaap_TaxPeriodAxis_33915" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="313.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis_33915" xlink:to="us-gaap_TaxPeriodDomain_33916" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="314.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain_33916" xlink:to="us-gaap_TaxYear2017Member_33917" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="275.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems_33845" xlink:to="us-gaap_OperatingLossCarryforwards_33849" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="272.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems_33845" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_33846" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="274.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems_33845" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_33848" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_33850" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_33851" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="278.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_33851" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_33852" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_33850" xlink:to="us-gaap_IncomeTaxExaminationLineItems_33845" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_1005" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_1006" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_1007" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_1010" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_1011" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_1012" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_1016" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_1017" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_1019" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_1020" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_1002" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_1004" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_1004" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_1005" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_1005" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_1006" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_1005" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_1007" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_1005" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_1010" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_1005" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_1011" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_1004" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_1012" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_1012" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_1016" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_1012" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_1017" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_1012" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_1019" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_1012" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_1020" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_1002" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_1004" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquityParentheticals" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_33929" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants" xlink:label="canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants_33930" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants" xlink:label="canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants_33931" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NetOfIssuanceCostsOrdinarySharesDueToATM" xlink:label="canf_NetOfIssuanceCostsOrdinarySharesDueToATM_33932" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants" xlink:label="canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants_33933" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_33929" xlink:to="canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants_33930" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_33929" xlink:to="canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants_33931" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_33929" xlink:to="canf_NetOfIssuanceCostsOrdinarySharesDueToATM_33932" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_33929" xlink:to="canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants_33933" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_33644" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_33645" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_33646" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_33634" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33635" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33636" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_33638" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_33642" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_33643" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_LaboratoryEquipmentMember" xlink:label="canf_LaboratoryEquipmentMember_33641" />
    <link:presentationArc xlink:type="arc" order="119.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_33643" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_33644" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="120.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_33643" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_33645" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="121.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_33643" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_33646" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="110.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_33634" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33635" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="111.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33635" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33636" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="113.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33636" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_33638" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="117.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_33638" xlink:to="us-gaap_EquipmentMember_33642" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="118.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33635" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_33643" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="116.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_33638" xlink:to="canf_LaboratoryEquipmentMember_33641" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_33648" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_33649" />
    <link:presentationArc xlink:type="arc" order="123.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_33648" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_33649" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/PropertyPlantandEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_33587" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_33586" />
    <link:presentationArc xlink:type="arc" order="74.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_33586" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_33587" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/PropertyPlantandEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_33590" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_33629" />
    <link:presentationArc xlink:type="arc" order="106.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_33590" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_33629" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_33867" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_33863" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_33955" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount" xlink:label="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount_33956" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_33957" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_33958" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33866" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael" xlink:label="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael_33948" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33949" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_33950" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_33952" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_33953" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_33954" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_33868" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_33869" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_33867" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_33955" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount_33956" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_33957" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_33958" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_33866" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael_33948" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_33949" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="336.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_33863" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_33950" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable_33950" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable_33950" xlink:to="us-gaap_IncomeTaxAuthorityAxis_33952" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="339.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_33952" xlink:to="us-gaap_IncomeTaxAuthorityDomain_33953" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="340.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_33953" xlink:to="us-gaap_ForeignCountryMember_33954" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_33868" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_33951" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_33869" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/OtherAccountsPayableScheduleofOtherAccountsPayableDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_33742" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_33740" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_33743" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_33741" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_33743" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_33742" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_33743" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_33740" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_33743" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_33741" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/Leases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_33763" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_33766" />
    <link:presentationArc xlink:type="arc" order="207.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_33763" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_33766" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/LeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_33775" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_33774" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_33776" />
    <link:presentationArc xlink:type="arc" order="215.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_33774" xlink:to="us-gaap_LeaseCostTableTextBlock_33775" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="216.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_33774" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_33776" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/DocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_1399" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_1401" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_1404" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_1405" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement_1365" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_1366" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_1367" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_1369" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_1370" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_1371" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_1374" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_1375" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_1378" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_1380" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_1381" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_1382" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_1383" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress_1384" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName_1386" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_33918" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_1360" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_1362" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_DocumentAndEntityInformationAbstract" xlink:label="canf_DocumentAndEntityInformationAbstract_1354" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_1355" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_1357" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_1359" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_1361" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_1363" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard_1407" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_1356" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_1358" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_ContactPersonnelFaxNumber" xlink:label="dei_ContactPersonnelFaxNumber_1387" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1388" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1389" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember_1390" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_1391" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_1392" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_1393" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_1394" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_1395" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_1396" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_1397" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_1398" />
    <link:presentationArc xlink:type="arc" order="33.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityFilerCategory_1399" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="35.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityEmergingGrowthCompany_1401" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityInteractiveDataCurrent_1404" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_IcfrAuditorAttestationFlag_1405" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentRegistrationStatement_1365" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentAnnualReport_1366" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="28.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_CurrentFiscalYearEndDate_1367" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentTransitionReport_1369" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentShellCompanyReport_1370" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityFileNumber_1371" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityIncorporationStateCountryCode_1374" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="37.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityAddressAddressLine1_1375" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="40.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityAddressCityOrTown_1378" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="43.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityAddressCountry_1380" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="42.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityAddressPostalZipCode_1381" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="47.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_CityAreaCode_1382" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="48.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_LocalPhoneNumber_1383" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="51.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_ContactPersonnelEmailAddress_1384" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="49.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_ContactPersonnelName_1386" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_33918" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityRegistrantName_1360" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentPeriodEndDate_1362" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_DocumentAndEntityInformationAbstract_1354" xlink:to="dei_DocumentInformationTable_1355" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityCentralIndexKey_1357" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentFiscalYearFocus_1359" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_AmendmentFlag_1361" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentFiscalPeriodFocus_1363" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentAccountingStandard_1407" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_1355" xlink:to="dei_DocumentInformationLineItems_1356" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_DocumentType_1358" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="50.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_ContactPersonnelFaxNumber_1387" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_1355" xlink:to="dei_EntityAddressesAddressTypeAxis_1388" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="54.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis_1388" xlink:to="dei_AddressTypeDomain_1389" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="55.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain_1389" xlink:to="dei_BusinessContactMember_1390" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="44.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_Security12bTitle_1391" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="45.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_TradingSymbol_1392" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="46.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_SecurityExchangeName_1393" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="53.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityCommonStockSharesOutstanding_1394" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="29.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityWellKnownSeasonedIssuer_1395" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="30.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityVoluntaryFilers_1396" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="31.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityCurrentReportingStatus_1397" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="32.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_1356" xlink:to="dei_EntityShellCompany_1398" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_1027" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_1003" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent_1012" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_1018" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_1023" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_1021" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_1022" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_1024" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_1017" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_1009" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_1004" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_1008" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1028" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_1013" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_1015" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_1026" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1002" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_1011" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_1006" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1030" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_1020" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_1010" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1014" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_1016" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_1019" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_1031" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_1029" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_1025" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1007" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments_1005" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1025" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_1027" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_AssetsCurrentAbstract_1003" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_1009" xlink:to="us-gaap_AssetsNoncurrent_1012" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1014" xlink:to="us-gaap_AccountsPayableOtherCurrent_1018" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_1020" xlink:to="us-gaap_LiabilitiesNoncurrent_1023" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_1020" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_1021" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_1020" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_1022" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_CommitmentsAndContingencies_1024" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1014" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_1017" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_AssetsNoncurrentAbstract_1009" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1003" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_1004" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1003" xlink:to="us-gaap_AssetsCurrent_1008" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1025" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1028" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_Assets_1013" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1014" xlink:to="us-gaap_AccountsPayableTradeCurrent_1015" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1025" xlink:to="us-gaap_CommonStockValue_1026" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_1009" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_1011" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1003" xlink:to="us-gaap_DepositsAssetsCurrent_1006" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1025" xlink:to="us-gaap_StockholdersEquity_1030" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_1020" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_1009" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_1010" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_LiabilitiesCurrentAbstract_1014" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1014" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_1016" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1014" xlink:to="us-gaap_LiabilitiesCurrent_1019" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_1031" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_1025" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_1029" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1002" xlink:to="us-gaap_StockholdersEquityAbstract_1025" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1003" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1007" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_1003" xlink:to="us-gaap_ShortTermInvestments_1005" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1045" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_1041" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_1043" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_1047" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_1039" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_1040" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_1042" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet_1044" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_1046" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1048" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_1373" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1385" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1049" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1039" xlink:to="us-gaap_NetIncomeLoss_1045" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1039" xlink:to="us-gaap_ResearchAndDevelopmentExpense_1041" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1039" xlink:to="us-gaap_OperatingIncomeLoss_1043" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1039" xlink:to="us-gaap_EarningsPerShareDiluted_1047" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1039" xlink:to="us-gaap_Revenues_1040" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1039" xlink:to="us-gaap_GeneralAndAdministrativeExpense_1042" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1039" xlink:to="us-gaap_InvestmentIncomeNet_1044" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1039" xlink:to="us-gaap_EarningsPerShareBasic_1046" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1039" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1048" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1039" xlink:to="us-gaap_OperatingExpenses_1373" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1039" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1385" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_1039" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1049" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_1056" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1058" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1062" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM" xlink:label="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_1068" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1061" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1069" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_1065" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts" xlink:label="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_1067" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1071" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1072" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_1052" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1054" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_1406" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1063" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1051" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1070" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" xlink:label="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_1408" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodSharesExercised" xlink:label="canf_StockIssuedDuringPeriodSharesExercised_33582" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodExerciseValue" xlink:label="canf_StockIssuedDuringPeriodExerciseValue_33583" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_1060" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1064" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance" xlink:label="canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_33927" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1053" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_1055" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_1057" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_1059" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1053" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_1056" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1053" xlink:to="us-gaap_EquityComponentDomain_1058" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_NetIncomeLoss_1062" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM_1068" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_SharesOutstanding_1061" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="23.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1069" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_1065" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts_1067" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_StockholdersEquity_1071" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_SharesOutstanding_1072" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1051" xlink:to="us-gaap_StatementTable_1052" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1053" xlink:to="us-gaap_CommonStockMember_1054" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_1406" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_1063" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1070" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_1408" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodSharesExercised_33582" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodExerciseValue_33583" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_StockholdersEquity_1060" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1064" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_1059" xlink:to="canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance_33927" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1052" xlink:to="us-gaap_StatementEquityComponentsAxis_1053" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1053" xlink:to="us-gaap_AdditionalPaidInCapitalMember_1055" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_1053" xlink:to="us-gaap_RetainedEarningsMember_1057" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_1052" xlink:to="us-gaap_StatementLineItems_1059" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_33959" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33631" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1097" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_1099" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_1096" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1101" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1103" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_1078" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1083" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ChangesInFairValueOfShortTermInvestment" xlink:label="canf_ChangesInFairValueOfShortTermInvestment_1085" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1087" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_1089" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_1091" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1093" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="us-gaap_PaymentsForProceedsFromShortTermInvestments_1095" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_1080" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_1082" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_1098" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets" xlink:label="canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets_33934" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_1100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1102" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1104" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_1084" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1088" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_1090" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_1092" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1094" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1079" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1078" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" xlink:to="us-gaap_OtherNoncashIncomeExpense_33959" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1078" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33631" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1078" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1097" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1097" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_1099" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1093" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_1096" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1078" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1101" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1078" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1103" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1083" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" xlink:to="canf_ChangesInFairValueOfShortTermInvestment_1085" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1087" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_1089" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_1091" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1078" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1093" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1093" xlink:to="us-gaap_PaymentsForProceedsFromShortTermInvestments_1095" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1079" xlink:to="us-gaap_NetIncomeLoss_1080" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" xlink:to="us-gaap_DepreciationDepletionAndAmortization_1082" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1097" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_1098" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="324.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33631" xlink:to="canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets_33934" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1097" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1078" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1102" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1078" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1104" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" xlink:to="us-gaap_ShareBasedCompensation_1084" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1088" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="20.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_1090" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1081" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_1092" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1093" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1094" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_1078" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1079" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/LeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_33835" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33819" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember_33821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_33823" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_33818" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_33826" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33820" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33820" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_33835" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="250.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseDescriptionAbstract_33818" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33819" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_33835" xlink:to="us-gaap_VehiclesMember_33821" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="252.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33819" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_33823" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="257.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_33823" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_33826" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="251.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33819" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33820" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/FinanceIncomeExpenseNetScheduleofFinanceIncomeExpenseNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_BankCommissions" xlink:label="canf_BankCommissions_33825" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ExchangeRateFluctuationsAndOthers" xlink:label="canf_ExchangeRateFluctuationsAndOthers_33827" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_OtherGainFromShortTermInvestmentRemeasurement" xlink:label="canf_OtherGainFromShortTermInvestmentRemeasurement_33830" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_33824" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_33832" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_33822" />
    <link:presentationArc xlink:type="arc" order="256.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_33822" xlink:to="canf_BankCommissions_33825" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="258.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_33822" xlink:to="canf_ExchangeRateFluctuationsAndOthers_33827" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="261.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_33822" xlink:to="canf_OtherGainFromShortTermInvestmentRemeasurement_33830" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="255.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_33822" xlink:to="us-gaap_InterestExpenseNonoperating_33824" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="263.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_33822" xlink:to="us-gaap_NonoperatingIncomeExpense_33832" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ScheduleOfExpensesRecognizedFinancialStatementsAbstract" xlink:label="canf_ScheduleOfExpensesRecognizedFinancialStatementsAbstract_1218" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_1225" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1224" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_1223" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1220" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1221" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_1222" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1219" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1224" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_1225" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1219" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1224" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_1221" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_1223" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1219" xlink:to="us-gaap_IncomeStatementLocationAxis_1220" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_1220" xlink:to="us-gaap_IncomeStatementLocationDomain_1221" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_1221" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_1222" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ScheduleOfExpensesRecognizedFinancialStatementsAbstract_1218" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1219" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/SubsequentEventsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease_33913" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_33944" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_33947" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses_33925" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_33942" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_33943" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_NewWarrantSharesMember" xlink:label="canf_NewWarrantSharesMember_33912" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1331" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1326" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_1343" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1332" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_1344" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_1350" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1347" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1348" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1349" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1338" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1337" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_33874" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ExistingWarrantsMember" xlink:label="canf_ExistingWarrantsMember_33873" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SubsequentEventsDetailsTable" xlink:label="canf_SubsequentEventsDetailsTable_1327" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ClassOfWarrantOrRightPercentage" xlink:label="canf_ClassOfWarrantOrRightPercentage_1352" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ADSMember" xlink:label="canf_ADSMember_1334" />
    <link:presentationArc xlink:type="arc" order="310.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_WarrantExercisePriceDecrease_33913" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="331.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_33943" xlink:to="srt_ScenarioForecastMember_33944" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="334.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_33947" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="322.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_OtherExpenses_33925" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_SubsequentEventsDetailsTable_1327" xlink:to="srt_StatementScenarioAxis_33942" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="330.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_33942" xlink:to="srt_ScenarioUnspecifiedDomain_33943" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="309.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1338" xlink:to="canf_NewWarrantSharesMember_33912" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_SubsequentEventsDetailsTable_1327" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_1331" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_SubsequentEventsDetailsTable_1327" xlink:to="us-gaap_SubsequentEventLineItems_1343" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1331" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1332" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_1344" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_1350" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1347" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1348" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1349" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1337" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1338" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_SubsequentEventsDetailsTable_1327" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_1337" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="286.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1332" xlink:to="us-gaap_PrivatePlacementMember_33874" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="285.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_1338" xlink:to="canf_ExistingWarrantsMember_33873" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1326" xlink:to="canf_SubsequentEventsDetailsTable_1327" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_1343" xlink:to="canf_ClassOfWarrantOrRightPercentage_1352" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_1332" xlink:to="canf_ADSMember_1334" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_33745" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_1228" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1230" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_November2023Member" xlink:label="canf_November2023Member_1234" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_IssuanceDate" xlink:label="canf_IssuanceDate_1238" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_December2021Member" xlink:label="canf_December2021Member_1232" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_April2025Member" xlink:label="canf_April2025Member_1236" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_33872" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_33744" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_1229" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract_1227" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_November2023AgentMember" xlink:label="canf_November2023AgentMember_33747" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_July2025OneMember" xlink:label="canf_July2025OneMember_33750" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_July2025Member" xlink:label="canf_July2025Member_33749" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_January2023AgentMember" xlink:label="canf_January2023AgentMember_33746" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_August2024Member" xlink:label="canf_August2024Member_1235" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_August2024AgentMember" xlink:label="canf_August2024AgentMember_33748" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_1239" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_1237" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_33872" xlink:to="us-gaap_WarrantMember_33745" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract_1227" xlink:to="us-gaap_ClassOfWarrantOrRightTable_1228" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis_1229" xlink:to="us-gaap_AwardDateDomain_1230" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_November2023Member_1234" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1237" xlink:to="canf_IssuanceDate_1238" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_December2021Member_1232" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_April2025Member_1236" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_33744" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_33872" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1237" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1240" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_1228" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_33744" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_1228" xlink:to="us-gaap_AwardDateAxis_1229" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_November2023AgentMember_33747" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="192.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_July2025OneMember_33750" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_July2025Member_33749" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_January2023AgentMember_33746" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_August2024Member_1235" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain_1230" xlink:to="canf_August2024AgentMember_33748" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_1237" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_1239" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_1228" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_1237" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ConsolidatedBalanceSheetsParentheticals" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_1035" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_1037" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_1034" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_1036" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1033" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1033" xlink:to="us-gaap_CommonStockSharesAuthorized_1035" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1033" xlink:to="us-gaap_CommonStockSharesOutstanding_1037" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1033" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_1034" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1033" xlink:to="us-gaap_CommonStockSharesIssued_1036" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/SubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1127" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_1128" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1127" xlink:to="us-gaap_SubsequentEventsTextBlock_1128" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable_1263" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PercentageOfNetSales" xlink:label="canf_PercentageOfNetSales_1277" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PhaseIIIStudiesMember" xlink:label="canf_PhaseIIIStudiesMember_1268" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PhaseIIStudiesMember" xlink:label="canf_PhaseIIStudiesMember_1267" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_PhaseIStudiesMember" xlink:label="canf_PhaseIStudiesMember_1266" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_RegulatoryAuthorityMember" xlink:label="canf_RegulatoryAuthorityMember_1269" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_RoyaltyPaymentsPercentage" xlink:label="canf_RoyaltyPaymentsPercentage_1279" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_1273" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_1272" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1270" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1271" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_33756" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1264" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1262" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoninterestExpenseCommissionExpense" xlink:label="us-gaap_NoninterestExpenseCommissionExpense_1275" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_1274" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_1276" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1262" xlink:to="canf_ContingentLiabilitiesandCommitmentsDetailsTable_1263" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_1274" xlink:to="canf_PercentageOfNetSales_1277" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" xlink:to="canf_PhaseIIIStudiesMember_1268" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" xlink:to="canf_PhaseIIStudiesMember_1267" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" xlink:to="canf_PhaseIStudiesMember_1266" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" xlink:to="canf_RegulatoryAuthorityMember_1269" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_1274" xlink:to="canf_RoyaltyPaymentsPercentage_1279" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_1271" xlink:to="srt_MaximumMember_1273" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_1271" xlink:to="srt_MinimumMember_1272" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable_1263" xlink:to="srt_RangeAxis_1270" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_1270" xlink:to="srt_RangeMember_1271" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="198.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_1274" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_33756" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable_1263" xlink:to="us-gaap_AwardTypeAxis_1264" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_1274" xlink:to="us-gaap_NoninterestExpenseCommissionExpense_1275" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable_1263" xlink:to="us-gaap_OtherCommitmentsLineItems_1274" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_1274" xlink:to="us-gaap_RoyaltyExpense_1276" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_1264" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1265" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1212" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1215" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired" xlink:label="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired_1201" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants" xlink:label="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants_1197" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1205" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1207" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1209" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_33758" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1196" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1200" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1208" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1210" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1214" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1202" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1213" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1203" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1195" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1199" />
    <link:presentationArc xlink:type="arc" order="29.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1212" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="32.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1215" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="17.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired_1201" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants_1197" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="22.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1205" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="24.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1207" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="26.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1209" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="21.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_33758" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1196" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="16.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="25.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1208" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="27.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1210" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="31.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1214" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="18.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1202" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="30.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1213" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="19.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1203" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1195" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1194" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1199" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/SignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_33633" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_33639" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33640" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock_33650" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_33633" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_33639" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_33633" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_33640" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_33633" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock_33650" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/AuditInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLineItems" xlink:label="dei_AuditorLineItems_33573" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName_33577" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_33578" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_33579" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock_33580" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorLineItems_33573" xlink:to="dei_AuditorName_33577" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorLineItems_33573" xlink:to="dei_AuditorFirmId_33578" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="14.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorLineItems_33573" xlink:to="dei_AuditorLocation_33579" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="15.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorLineItems_33573" xlink:to="dei_AuditorOpinionTextBlock_33580" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_33702" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_33703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_33704" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_33652" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33655" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33656" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_33657" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_LaboratoryEquipmentMember" xlink:label="canf_LaboratoryEquipmentMember_33660" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_33664" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_33665" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_33667" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_33834" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33655" xlink:to="srt_RangeAxis_33702" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_33834" xlink:to="srt_MaximumMember_33703" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_33834" xlink:to="srt_MinimumMember_33704" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="125.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_33652" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33655" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33655" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33656" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="127.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_33656" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_33657" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_33657" xlink:to="canf_LaboratoryEquipmentMember_33660" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_33657" xlink:to="us-gaap_ComputerEquipmentMember_33664" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_33655" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_33665" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="133.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_33665" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_33667" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_33702" xlink:to="srt_RangeMember_33834" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/PropertyPlantandEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_33654" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_33658" />
    <link:presentationArc xlink:type="arc" order="128.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_33654" xlink:to="us-gaap_Depreciation_33658" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_33661" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_33662" />
    <link:presentationArc xlink:type="arc" order="130.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_33661" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_33662" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_33666" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33668" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_33669" />
    <link:loc xlink:type="locator" xlink:href="canf-20251231.xsd#canf_GovernmentAuthorities" xlink:label="canf_GovernmentAuthorities_33673" />
    <link:presentationArc xlink:type="arc" order="13.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_33666" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33668" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_33666" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_33669" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_33666" xlink:to="canf_GovernmentAuthorities_33673" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/TaxesonIncome" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNetAbstract" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract_33837" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_33838" />
    <link:presentationArc xlink:type="arc" order="266.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract_33837" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_33838" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/TaxesonIncomeTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNetAbstract" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract_33840" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_33841" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_33842" />
    <link:presentationArc xlink:type="arc" order="268.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract_33840" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_33841" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="269.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract_33840" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_33842" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/LeasesScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_33790" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract_33801" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_33802" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_33803" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_33799" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_33798" />
    <link:presentationArc xlink:type="arc" order="234.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_33790" xlink:to="us-gaap_LeasesOperatingAbstract_33801" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="236.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_33801" xlink:to="us-gaap_OperatingLeaseCost_33802" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="237.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract_33801" xlink:to="us-gaap_OperatingLeasePayments_33803" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="233.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_33790" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_33799" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="232.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_33790" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_33798" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/FinanceIncomeExpenseNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_33784" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_33785" />
    <link:presentationArc xlink:type="arc" order="223.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract_33784" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_33785" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/FinanceIncomeExpenseNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_33795" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_33798" />
    <link:presentationArc xlink:type="arc" order="232.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract_33795" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_33798" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/General" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1107" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1106" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1106" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1107" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/SignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1109" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_1110" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1109" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_1110" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_1113" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract" xlink:label="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_1112" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract_1112" xlink:to="us-gaap_FairValueDisclosuresTextBlock_1113" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ContingentLiabilitiesandCommitments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1119" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1118" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1118" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1119" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/ShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1121" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_1122" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1121" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_1122" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/SegmentReporting" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_1125" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1124" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1124" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_1125" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/OtherAccountsPayable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_33732" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_33734" />
    <link:presentationArc xlink:type="arc" order="188.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_33732" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_33734" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/OtherAccountsPayableTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_33736" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_33737" />
    <link:presentationArc xlink:type="arc" order="189.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_33736" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_33737" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_33813" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_33807" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_33808" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_33814" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_33805" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_33815" />
    <link:presentationArc xlink:type="arc" order="246.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_33805" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_33813" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" order="240.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_33805" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_33807" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="241.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_33805" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_33808" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="247.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_33805" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_33814" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:presentationArc xlink:type="arc" order="248.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_33805" xlink:to="us-gaap_OperatingLeaseLiability_33815" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://canfite.com/20251231/role/SegmentReportingDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_33786" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_33791" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_1323" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_1324" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1321" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_1322" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1321" xlink:to="us-gaap_StatementTable_33786" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="229.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_33786" xlink:to="us-gaap_SegmentReportingInformationLineItems_33791" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" order="11.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_33791" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_1323" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="10.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_33791" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_1324" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" order="12.00" priority="1" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_33791" xlink:to="us-gaap_NumberOfOperatingSegments_1322" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Can-Fite BioPharma Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001536196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26 Ben Gurion Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ramat Gan<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5257346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 2 Ordinary Shares, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CANF<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">2,618,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">26 Ben Gurion Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ramat Gan<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5257346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">(3) 924-1114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Motti Farbstein<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">+972 (3) 924-9378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">motti@canfite.co.il<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLineItems', window );"><strong>Auditor [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KOST FORER GABBAY& KASIERER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">Opinion on the Financial Statements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.95pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying consolidated balance sheets of Can-Fite BioPharma Ltd. and its subsidiary (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, the related consolidated statements of operating loss, changes in shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,528<span></span>
</td>
<td class="nump">$ 4,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short-term deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,011<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses, and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">900<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,440<span></span>
</td>
<td class="nump">8,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,514<span></span>
</td>
<td class="nump">9,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,161<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturity of operating lease liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">405<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,731<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">1,581<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,191<span></span>
</td>
<td class="nump">1,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">CONTINGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of no par value - Authorized: 14,000,000 and 3,333,334 shares at December 31, 2025 and 2024, respectively; Issued and outstanding: 2,618,425 and 994,394 shares as of December 31, 2025 and 2024, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">180,654<span></span>
</td>
<td class="nump">170,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(176,189)<span></span>
</td>
<td class="num">(166,361)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,592<span></span>
</td>
<td class="nump">5,436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9,514<span></span>
</td>
<td class="nump">$ 9,120<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively adjusted to give effect to the reverse share split, see also note 9.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">14,000,000<span></span>
</td>
<td class="nump">3,333,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,618,425<span></span>
</td>
<td class="nump">994,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,618,425<span></span>
</td>
<td class="nump">994,394<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively adjusted to give effect to the reverse share split, see also note 9.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operating Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 405<span></span>
</td>
<td class="nump">$ 674<span></span>
</td>
<td class="nump">$ 743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,693)<span></span>
</td>
<td class="num">(5,757)<span></span>
</td>
<td class="num">(5,983)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,662)<span></span>
</td>
<td class="num">(3,047)<span></span>
</td>
<td class="num">(2,955)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,355)<span></span>
</td>
<td class="num">(8,804)<span></span>
</td>
<td class="num">(8,938)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,950)<span></span>
</td>
<td class="num">(8,130)<span></span>
</td>
<td class="num">(8,195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Total financial income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">122<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income, Amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,828)<span></span>
</td>
<td class="num">(7,880)<span></span>
</td>
<td class="num">(7,634)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (9,828)<span></span>
</td>
<td class="num">$ (7,880)<span></span>
</td>
<td class="num">$ (7,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5.97)<span></span>
</td>
<td class="num">$ (10.86)<span></span>
</td>
<td class="num">$ (17.92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5.97)<span></span>
</td>
<td class="num">$ (10.86)<span></span>
</td>
<td class="num">$ (17.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,646,208<span></span>
</td>
<td class="nump">725,309<span></span>
</td>
<td class="nump">426,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,646,208<span></span>
</td>
<td class="nump">725,309<span></span>
</td>
<td class="nump">426,111<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively adjusted to give effect to the reverse share split, see also note 9.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares</div></th>
<th class="th"><div>Additional &#8239;paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 154,192<span></span>
</td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="num">$ (150,847)<span></span>
</td>
<td class="nump">$ 4,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">271,916<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants', window );">Issuance of ordinary shares and warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,526<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants', window );">Issuance of ordinary shares and warrants, net of issuance costs (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">30,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of ordinary shares due to exercise of warrants net of issuance expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,618<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of ordinary shares due to exercise of warrants net of issuance expenses (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">151,363<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">261<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,634)<span></span>
</td>
<td class="num">(7,634)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">163,597<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(158,481)<span></span>
</td>
<td class="nump">6,243<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">453,279<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance', window );">Release of ordinary shares that were previously held in abeyance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance', window );">Release of ordinary shares that were previously held in abeyance (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">151,364<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants', window );">Issuance of ordinary shares and warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,488<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants', window );">Issuance of ordinary shares and warrants, net of issuance costs (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">285,714<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts', window );">Issuance of ordinary shares due to ATM, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,223<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM', window );">Issuance of ordinary shares due to ATM, net of issuance costs (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">99,037<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">362<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payments (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,880)<span></span>
</td>
<td class="num">(7,880)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">170,670<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(166,361)<span></span>
</td>
<td class="nump">5,436<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">994,394<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodExerciseValue', window );">Issuance of ordinary shares and warrants and exercise of pre-funded warrants, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,711<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodSharesExercised', window );">Issuance of ordinary shares and warrants and exercise of pre-funded warrants, net of issuance costs (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,083,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts', window );">Issuance of ordinary shares due to ATM, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,933<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM', window );">Issuance of ordinary shares due to ATM, net of issuance costs (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">530,698<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">340<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payments (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">10,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,828)<span></span>
</td>
<td class="num">(9,828)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 180,654<span></span>
</td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="num">$ (176,189)<span></span>
</td>
<td class="nump">$ 5,592<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,618,425<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively adjusted to give effect to the reverse share split, see also note 9.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares due to ATM, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodExerciseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of shares issued for options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodExerciseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of issuance of share capital and warrants, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodSharesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodSharesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the number of shares issuance of ordinary shares due to ATM.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares of release of ordinary shares that were previously held in abeyance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital and warrants, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of stock issued during period value release of ordinary shares that were previously held in abeyance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders&#8217; Equity (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants', window );">Net of issuance costs of ordinary shares and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
<td class="nump">$ 973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants', window );">Net of issuance expenses of ordinary shares due to exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants', window );">Net of issuance costs ordinary shares and warrants and exercise of pre-funded warrants</a></td>
<td class="nump">$ 1,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NetOfIssuanceCostsOrdinarySharesDueToATM', window );">Net of issuance costs ordinary shares due to ATM</a></td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of net of issuance costs of ordinary shares and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of net of issuance costs ordinary shares and warrants and exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NetOfIssuanceCostsOrdinarySharesDueToATM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of net of issuance costs ordinary shares due to ATM.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NetOfIssuanceCostsOrdinarySharesDueToATM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of net of issuance expenses of ordinary shares due to exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,828)<span></span>
</td>
<td class="num">$ (7,880)<span></span>
</td>
<td class="num">$ (7,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of property, plant and equipment</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the carrying amount of operating lease right of use asset</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based payment</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ChangesInFairValueOfShortTermInvestment', window );">Changes in fair value of short-term investment</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Financial expenses (income), net</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Change in prepaid expenses, and other current assets</a></td>
<td class="nump">195<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in operating lease liability</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase (decrease) in trade payable</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="num">(469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Decrease in deferred revenues</a></td>
<td class="num">(405)<span></span>
</td>
<td class="num">(349)<span></span>
</td>
<td class="num">(743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Increase (decrease) in other accounts payable</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,949)<span></span>
</td>
<td class="num">(7,637)<span></span>
</td>
<td class="num">(8,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromShortTermInvestments', window );">Maturity of short-term deposits, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of ordinary shares due to ATM, net of issuance costs</a></td>
<td class="nump">2,933<span></span>
</td>
<td class="nump">2,223<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of ordinary shares and warrants, net of issuance costs</a></td>
<td class="nump">6,711<span></span>
</td>
<td class="nump">4,488<span></span>
</td>
<td class="nump">9,144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,644<span></span>
</td>
<td class="nump">6,711<span></span>
</td>
<td class="nump">9,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Exchange differences on balances of cash and cash equivalents</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the beginning of the year</a></td>
<td class="nump">4,825<span></span>
</td>
<td class="nump">4,278<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of the year</a></td>
<td class="nump">5,528<span></span>
</td>
<td class="nump">4,825<span></span>
</td>
<td class="nump">4,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets', window );">Lease liabilities arising from obtaining right-of-use-assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ChangesInFairValueOfShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of changes in fair value of short term investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ChangesInFairValueOfShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of lease liabilities arising from obtaining right-of-use-assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 1:-&#160;GENERAL</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company description:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Can-Fite Biopharma Ltd. (the &#8220;Company&#8221;) was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, MASH, pancreatic cancer and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. The Company&#8217;s pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators at the A3AR.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> The Company&#8217;s ordinary shares have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#8220;CFBI&#8221; and the Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) began public trading on the over the counter market in the U.S. in October 2012 and since November 2013 the Company&#8217;s ADSs have been publicly traded on the NYSE American under the symbol &#8220;CANF&#8221;. Each ADS represents 2 ordinary shares of the Company. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under&#160;Accounting Standard Codification (&#8220;ASC&#8221;)&#160;Subtopic 205-40,&#160;Presentation of Financial Statements&#8212;Going Concern&#160;(&#8220;ASC 205-40&#8221;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its obligations as they become due within one year after the date that the financial statements are issued. As required under ASC 205-40, management&#8217;s evaluation should initially not take into consideration the potential mitigating effects of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in; background-color: white"><i>Evaluation of Substantial Doubt Raised</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 43.05pt; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">In performing the first step of the evaluation, the Company concluded that the following conditions raised substantial doubt about its ability to continue as a going concern:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">History of net losses of&#160;$9,828, $7,880 and $7,634&#160;for the years ended December 31, 2025, 2024 and 2023, respectively. The accumulated deficit for the years ended December 31, 2025, was $176,189.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px; background-color: transparent"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="background-color: transparent; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating cash outflow of&#160;$8,949, $7,637 and $8,440 for the years ended December 31, 2025, 2024 and 2023, respectively.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reliance on additional financing in order to execute its research and development plans.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 0.5in; background-color: white"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in; background-color: white"><i>Consideration&#160;of Management&#8217;s Plans</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 0.75in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"> In performing the second step of this assessment, the Company is required to evaluate whether it is probable that the Company&#8217;s plans will be effectively implemented within one year after the financial statements are issued and whether it is probable those plans will alleviate the substantial doubt raised about the Company&#8217;s ability to continue as a going concern. As of December 31, 2025, the Company had $8,539&#160;in available cash, cash equivalents and short-term deposits. Subsequent to balance sheet date, the Company raised gross proceeds of approximately $4,350, refer to Note 15. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">Liquidity resources suffice for at least twelve months from the date that the consolidated financial statements were issued, nevertheless the Company has committed to implement a contingency plan, as required, in order to allow it to continue its operations and meet its cash obligations. The contingency plan consists of cost reduction, which include mainly deferral and reprioritization of certain research and development programs that would involve reduced program spend and reduction in compensation paid to key management personnel until additional financing is obtained.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in; background-color: white"><i>Management&#160;Assessment&#160;of Ability to Continue as a Going Concern</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 0.75in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">The Company has a history of operating losses and negative cash flows from operations. However, despite these conditions, the Company believes management&#8217;s plans, as described more fully above, will provide sufficient liquidity to meet its financial obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">Therefore, management concluded these plans alleviate the substantial doubt that was raised about the Company&#8217;s ability to continue as a going concern for at least twelve months from the date that the consolidated financial statements were issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in; background-color: white"><i>Future Plans and Considerations</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 0.75in; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">Although not considered for purposes of the Company&#8217;s assessment of whether substantial doubt was alleviated, the Company has plans to improve operating cash flows by entering into strategic partnerships with other companies that can provide access to additional customers and new markets. The Company may also seek to raise additional funds through the issuance of debt and/or equity securities or otherwise.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">The Company&#8217;s plans are subject to inherent risks and uncertainties. Accordingly, there can be no assurance that the Company&#8217;s plans can be effectively implemented and, therefore, that the conditions can be effectively mitigated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Until such time, if ever, that the Company can generate revenue sufficient to achieve profitability, the Company expects to finance its operations through equity or debt financings, which may not be available to the Company on the timing needed or on terms that the Company deems to be favorable. To the extent that the Company raises additional capital through the sale of equity or debt securities, the ownership interest of its stockholders will be diluted. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment Information</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company&#8217;s operations and manage its business in&#160;one&#160;operating segment which is the research and development of the Company&#8217;s drug candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency, reporting currency and foreign currency:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The functional currency of the Company is the U.S. dollar. Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars in accordance with Accounting Standard Codification (&#8220;ASC&#8221;) No. 830 &#8220;Foreign Currency Matters.&#8221; All transaction gains and losses of the re-measured monetary balance sheet items are reflected in the consolidated statements of comprehensive loss as financial income or expenses, as appropriate.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Cash equivalents are short-term, highly liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term bank deposits:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -21.25pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2025 and 2024, the Company&#8217;s bank deposits are denominated in U.S. dollars and bears yearly interest at weighted average rates of&#160;4.30% and&#160;5.25%. Short-term bank deposits are presented at their cost, including accrued interest. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses, and other current assets</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Prepaid expenses are composed mainly from prepayments to suppliers and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and no longer have an alternative future use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with ASU No. 2016-02, &#8220;Leases (Topic 842)&#8221;, the Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Mainly<br/>  %</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 - 33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: center">33</td><td style="text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of long-lived assets:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Property and equipment and ROU assets are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment,&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets (assets group) to be held and used is measured by a comparison of the carrying amount of an asset (assets group) to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. As of December 31, 2025, and 2024, <span style="-sec-ix-hidden:fc_669790381"><span style="-sec-ix-hidden:fc_406290213">no</span></span> impairment indicators have been identified. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes revenue in accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#8220;ASC 606&#8221;) and determines revenue recognition through the following steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the contract, or contracts, with a customer;</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the performance obligations in the contract;</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination of the transaction price;</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of the transaction price to the performance obligations in the contract; and</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition of revenue when, or as, the performance obligations are satisfied.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company generates revenues from supply and distribution agreements. The consideration under these agreements comprises of upfront fees, milestone payments and potential royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf of third parties (such as taxes).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts generally include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has concluded that the abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded based on the term of the research and development services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts also include development milestones payments and future sales-based royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Development milestones payments are recognized only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with those milestones is subsequently resolved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Sales based royalties are recognized only when the subsequent sale occurs. As of December 31, 2025, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any sales-based royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The prepayments terms from the Company&#8217;s contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing from the customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="text-decoration:underline">Revenue Recognition &#8211; Contract Balances </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Contract liabilities, due to the upfront payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2025 and December 31, 2024 contract liabilities and remaining performance obligation amounted to $1,581&#160;and $1,986, respectively and are presented under deferred revenues. During the year ended December 31, 2025, the Company recognized revenues in the amount of $405 which have been included in the contract liabilities at December&#160;31, 2024. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred revenue and remaining performance obligation that is anticipated to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded as non-current deferred revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Cipher Pharmaceuticals (Canada)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp. (South Korea)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Gebro Holding GmbH (Austria)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Ewopharma AG (Switzerland)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Vetbiolix (France)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1997113680">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_487311381">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td> </tr> </tbody></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Research and development costs are expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization, rent, and utilities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;). Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent from the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 - Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The carrying amounts of cash and cash equivalents, short term deposit, prepaid expenses and other currents assets, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The Company has an investment in marketable equity security classified within level 1 in the fair value hierarchy.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration of Credit Risk:&#160;</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for its contingent liabilities in accordance with ASC 450, Contingencies (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2025, and 2024, the Company is not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position, results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance pay<span style="text-transform: uppercase">:</span></span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> The Company&#8217;s liability for severance pay is pursuant to Section 14 of the Israeli Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant to which all the Company&#8217;s employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.&#160;Severance pay expense for the year ended December 31, 2025, 2024 and 2023 amounted to $53, $49 and $47, respectively. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions<span style="text-transform: uppercase">:</span></span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for share-based compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s consolidated statement of comprehensive loss, based on acceleration method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes compensation expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company estimates the fair value of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility, early exercise factor and the expected option term. Expected volatility was calculated based upon historical volatility of the Company and early exercise factor was calculated based on statistical studies in the U.S market. The risk-free interest rate is based on the yield from government bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2025, and 2024, a full valuation allowance was provided by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2025, and 2024, <span style="-sec-ix-hidden:fc_972519014"><span style="-sec-ix-hidden:fc_213046275">no</span></span> liability for unrecognized tax benefits was recorded.&#160; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase ordinary shares:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per share<span style="text-transform: uppercase">:</span></span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Basic and diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. The Company include in the basic net loss per share calculation, pre-funded warrants that are exercisable for a nominal consideration. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#8220;Earnings per Share&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants for the years ended December 31, 2025, 2024 and 2023 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. The potential ordinary shares and warrants that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Options</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">49,533</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41,610</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27,492</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,604,096</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">886,599</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">617,337</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,653,629</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">928,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">644,829</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tbody><tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retroactively adjusted to give effect to the reverse share split, see also note 9.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently adopted accounting pronouncements:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="background-color: white">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which requires disaggregated information about the effective tax rate reconciliation as well as information on income taxes paid. The guidance will be effective for the Company for annual periods beginning January 1, 2025, with early adoption permitted. The adoption of the standard <span style="background-color: white">did not </span> have material impact on its financial statement disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 47px">&#160;</td> <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">v.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Recently issued accounting pronouncements not yet adopted</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In November 2024, the FASB issued ASU 2024-03<i>&#160;&#8220;Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures&#8221;</i>&#160;(&#8220;ASU 2024-03&#8221;), which requires more detailed information about specified categories of expenses presented on the face of the income statement, in addition to disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. The amendment may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating ASU 2024-03 to determine the impact it may have on its consolidated financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 3:-&#160; PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and others</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">826</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,018</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">900</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,095</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 4:-&#160;PROPERTY, PLANT AND EQUIPMENT, NET </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Cost:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_1633826125">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">64</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Computers, office furniture and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Laboratory equipment</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_2074154732">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Computers, office furniture and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">52</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -20.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Depreciation expenses for the years ended December 31, 2025, 2024 and 2023 amounted to $24, $7 and $15, respectively. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 5:-</span>&#160;<span style="font-weight: bold;">OTHER ACCOUNTS PAYABLE</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Employees and payroll accruals</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">811</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">675</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">298</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">301</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,109</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">976</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 6:- FAIR VALUE MEASUREMENTS </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 820 &#8220;Fair Value Measurements and Disclosures&#8221;, the Company measures its short-term investment at fair value. Short-term investments are classified within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_1904201796">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_1856579833">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: left; font-weight: bold">Description</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair value</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_2047207648">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_736875626">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 7:- REVENUES&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><i><span style="text-decoration:underline">Cipher Pharmaceuticals</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#8220;Cipher&#8221;). As part of the distribution agreement, Cipher will distribute Can-Fite&#8217;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> Under the terms of the agreement, Cipher made an upfront payment of $1,292 (1,650 CAD thousands) to the Company in March 2015. In addition, the agreement provides that an additional payments of up to 2,000 thousands Canadian Dollar will be received by the Company upon the achievement of certain milestones plus royalty payments of 16.5% of net sales of Piclidenoson in Canada. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the agreement, the Company shall be responsible for conducting product development activities including management of the clinical studies required in order to secure regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form a joint steering committee with Cipher which will oversee the progress of the clinical studies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2025, the Company estimates that such services will be completed by December 31, 2029 and therefore revenues from such up-front payment are recognized over such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><i><span style="text-decoration:underline">Chong Kun Dang Pharmaceuticals Corp.</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#8220;CKD&#8221;). As part of the distribution agreement, CKD will have exclusive rights to distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals. On February 25, 2019, distribution agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition to liver cancer in South Korea.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> According to the distribution agreement, the Company is entitled to receive an amounts of up to $3,000 in upfront and milestone payments payable with respect to the liver cancer indication and additional $6,000 in upfront and milestone payments payable with respect to NASH indication. In addition, the Company will also be entitled to a transfer price for delivering finished product to CKD following commercial launch at a cost plus 10% basis or 23% of net sales of Namodenoson following commercial launch in South Korea. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Under the agreement, the Company shall be responsible for conducting product development activities including management of the clinical studies required in order to secure regulatory approvals and shall use commercially reasonable efforts in conducting such activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> As of December 31, 2025, the Company received an amount of $1,500 for up-front payment and additional $500 for achieved milestone. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2025, the Company estimates that such services will be completed by June 30, 2029 and therefore revenues from such up-front payment are recognized over such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Gebro Holding GmBH</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On January 8, 2018, the Company entered into a Distribution and Supply Agreement with Gebro Holding GmBH (&#8220;Gebro&#8221;), granting Gebro the exclusive right to distribute Piclidenoson in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> Under the Distribution and Supply Agreement, the Company is entitled to &#8364; 1,500 thousands upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) &#8364; 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and &#8364; 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between &#8364; 750 thousand and &#8364; 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364; 300 thousand and up to &#8364;4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.&#160; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> As of December 31, 2025, the Company received an amount of &#8364; 1,500 thousands (approximately $1,850) for up-front payment and additional &#8364; 600 thousands (approximately $720) for achieved milestone. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2025, the Company estimates that such services will be completed by December 31, 2029 and therefore revenues from such up-front payment are recognized over such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">CMS Medical Venture Investment Limited </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#8220;CMS Medical&#8221;) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> Under the License, Collaboration and Distribution Agreement, the Company is entitled to receive an up-front amount of $2,000 upon execution of the agreement. In addition, the Company is also entitle to received an amount of up to $14,000 for milestone payments upon achieving certain regulatory milestones and up to $58,500 for milestone payments upon achieving certain sales milestones. In addition, following regulatory approval, the Company shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing of Piclidenoson and Namodenoson. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> As of December 31, 2025, the Company received an amount of $2,000 for up-front payment which was previously recognized in revenues. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration:underline">Kyongbo Pharm Co., Ltd.</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On July 31, 2019, the Company signed a distribution agreement with Kyongbo Pharm Co., Ltd. (&#8220;Kyongbo Pharm&#8221;), to distribute Piclidenoson, for the treatment of psoriasis in South Korea, upon receipt of regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> Under the terms of the distribution agreement, Kyongbo Pharm, in exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea, is required to make a total a payment of $750 for access to information and clinical study data. In addition, the Company will also be also entitled to additional payments of up to $3,250 upon achievement of certain milestones. The Company will also be entitled to a transfer price for delivering finished product to Kyongbo Pharm upon commercial launch. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> In 2019, the Company received an amount of $750 for up-front payment which recognized as revenues upon the Company providing access to information and clinical study data. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><i><span style="text-decoration:underline">Ewopharma</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> On March 16, 2021, the Company signed an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the treatment of liver diseases namely, hepatocellular carcinoma (HCC) the most common form of liver cancer and non-alcoholic steatohepatitis (NASH). Under the terms of the distribution agreement, Ewopharma paid Can-Fite non-refundable upfront payment in an amount of $2,250 and is entitled to up to an additional $40,450 payable upon the achievement of regulatory and sales milestones and 17.5% royalties on net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution agreement to new indications that Can-Fite may identify for its drug candidates. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> As of December 31, 2025, the Company received an amount of $2,250 for up-front payment. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2025, the Company estimates that such services will be completed by December 31, 2029 and therefore revenues from such up-front payment are recognized over such period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">On January 30, 2024, the Company entered into an amendment to its distribution agreement with Ewopharma, to add the rights to the Company&#8217;s pancreatic cancer indication for an additional immaterial up-font payment and further milestones payments.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><i><span style="text-decoration:underline">Vetbiolix</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 28, 2021, the Company entered into a Patent and Know-how License Agreement with Vetbiolix (the &#8220;License Agreement&#8221;), a France-based veterinary pharmaceutical company. According to the agreement, the Company has granted Vetbiolix an exclusive option to utilize the licensed Know-How and the Company&#8217;s patents solely for the purpose of supporting Vetbiolix&#8217;s research, development, manufacturing and commercializing of its compounds and/or products in the field throughout the territory, all as defined in the License Agreement. The option to the licensed Know-How and the Company&#8217;s patents is for a period of two years from the signature date (after which such period was extended by additional 15 months), during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> Upon Vetbiolix exercise of its option to acquire the licensed Know-How and the Company&#8217;s patents, then Vetbiolix will be obligated to pay Can-Fite a non-refundable upfront payment in an amount of euro 250. In addition, Vetbiolix will also pay the Company with payment equal to 30% for each upfront and milestone payment received from and sublicensee and 15%-40% royalties on net sales upon regulatory approval for veterinary use. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> On September 24, 2024, Vetbiolix exercised its option and acquired licensed know-how and the Company&#8217;s patents for euro 250 thousands and therefore the Company recorded equivalent revenues of $ 271 in the year ended December 31, 2024. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Contingent Liabilities and Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. </span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities to pay royalties:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company is committed to pay royalties as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A one-time concession commission of &#8364;25 thousand;</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual royalties of &#8364;10 thousand until the clinical trials commence;</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2%-3% of net sales (as defined in the agreement) received by the Company;</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties in a total amount of up to &#8364;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#8364;50 thousand upon initiation of Phase I studies; (ii) &#8364;100 thousand upon initiation of Phase II studies; (iii) &#8364;200 thousand upon initiation of Phase III studies; and (iv) &#8364;500 thousand upon marketing approval by any regulatory authority.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in"> As of December 31, 2025 and 2024, <span style="-sec-ix-hidden:fc_1823340782"><span style="-sec-ix-hidden:fc_792382386">no</span></span> accrual has been recorded with respect to Leiden University. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-weight: bold;">NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 22, 2023, the Company&#8217;s shareholders approved a change in the Company&#8217;s ordinary shares par value from NIS 0.25 per share to no par value. All par value data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the change.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All ordinary shares have equal rights for all intent and purposes and each ordinary share confers its holder:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to be invited and participate in all the Company&#8217;s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company&#8217;s general meeting participated.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to participate in the distribution of the Company&#8217;s assets upon liquidation.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of ordinary shares and warrants:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 1, 2024 the Company issued 5,000 ordinary shares to certain service provider in exchange for it services. The shares issued were valued at the amount of $112 which were recorded to general and administrative expenses during the year ended December 31, 2024</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 3, 2024, the Company&#8217;s shareholders meeting approved the increase of the Company&#8217;s authorized share capital by additional 1,666,667 such that following the increase, the authorized share capital was 3,333,334 ordinary shares. </span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 8, 2024, the Company entered into an inducement offer letter with certain existing warrants holder, according to which, the holder has exercised 285,714 of his warrants for an exercise price of $17.50 per share into Company&#8217;s ordinary shares, totaling a $5,000 gross consideration. Total issuance expenses were $512. As part of the inducement letter, the Company issued to the holder new warrants to purchase 571,429 of the Company&#8217;s ordinary shares for an exercise price of $22.50 per share. In addition, the Company has also issued warrants to purchase 20,000 of its ordinary shares for an exercise price of $21.90 per share as issuance costs.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 30, 2024, the Company entered into at-the-market     offering agreement with H.C. Wainwright &amp; Co (the &#8220;Agent&#8221;), according to which the Company may offer and sell, from time     to time, its ordinary shares represented as ADSs, through the Agent in an at the market offering (&#8220;ATM&#8221;), as defined in Rule     415(a)(4) promulgated under the Securities Act of 1933, as amended.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2024, the Company issued 99,037     ordinary shares for net proceeds of $2,223 through the ATM.</p></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px"></td><td style="width: 24px">5.</td><td style="text-align: justify">During 2025, the Company issued 530,698 ordinary shares for net proceeds of $2,933 through its ATM.</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px"></td><td style="width: 24px">6.</td><td style="text-align: justify">On April 6, 2025 the Company issued 10,000 ordinary shares to certain service provider in exchange for its services. The shares issued were valued at the amount of $141 which were recorded to general and administrative expenses during the year ended December 31, 2025.</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px"></td><td style="width: 24px">7.</td><td style="text-align: justify">On April 14, 2025, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) pursuant to which the Company agreed to sell and issue in a registered direct offering (the &#8220;April 2025 Offering&#8221;) an aggregate of 250,000 ordinary shares of the Company at an offering price of $12.0 per share (the &#8220;Ordinary Shares&#8221;).</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> Aggregate gross proceeds to the Company were approximately $3,000, before deducting fees payable to the placement agent and other offering expenses payable by the Company. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> As part of the April 2025 Offering, the Company incurred an aggregate issuance costs of $452 recorded net of the Company&#8217;s additional paid in capital. The Company also issued to the placement agent warrants equal to 7.0% of the aggregate number of ordinary Shares represented by ADSs, or 17,500 ordinary Shares represented by 8,750 ADSs, at an exercise price of $30.0 per ADS and a term expiring on April 14, 2030. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company accounted for the aforementioned warrants as freestanding instrument classified at part of the Company&#8217;s permanent equity in accordance with ASC-480 and ASC-815-40. The Company accounted for the reduction in the warrants exercise price as issuance costs to be recorded in the Company&#8217;s additional paid in capital in accordance with ASC 815-40, following the adoption of ASU 2021-04.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"> <tbody><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">8.</td><td style="text-align: justify">On June 30, 2025, the Company&#8217;s shareholders meeting approved the increase of the Company&#8217;s authorized share capital by an additional 3,333,334 such that following the increase, the authorized share capital was 6,666,667 ordinary shares.</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"> <tbody><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">9.</td><td style="text-align: justify">On July 28, 2025, the Company completed a public offering (the &#8220;July 2025 Offering&#8221;) for aggregate gross proceeds (without taking into account any from any future exercises of warrants) of $5,000 gross proceeds (approximately $4,200 net of issuance cost). The Company issued to the holder from the July 2025 Offering (i) 125,000 ordinary shares (represented by 62,500ADSs, (ii) 354,167 pre-funded warrants to purchase up to 708,334 of the Company&#8217;s ordinary shares (represented by 354,167 ADSs (the &#8220;Pre-Funded Warrants&#8221;), and (iii) 833,333 warrants to purchase up to 1,666,667 of the Company&#8217;s ordinary shares (represented by 833,333 ADSs (the &#8220;Common Warrants&#8221; and together with the Pre-Funded Warrants, the &#8220;Warrants&#8221;).</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> The Pre-Funded Warrants will be immediately exercisable at a nominal exercise price ($11.98 per ADS) and may be exercised at any time until exercised in full. The Common Warrants have an exercise price of $6.0 per share ($12.0 per ADS), are immediately exercisable, and expire on the two-year anniversary of the date of issuance. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> As part of the July 2025 Offering, the Company incurred an aggregate issuance cost of $837 recorded net of the Company&#8217;s additional paid in capital. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> The Company also issued to the placement agent warrants equal to 7.0% of the aggregate number of ordinary Shares represented by 58,334 ordinary Shares (represented by 29,167 ADSs), at an exercise price of $7.5 per share ($15.0 per ADS) and a term expiring on July 28, 2029. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px"></td><td style="width: 24px">10.</td><td style="text-align: justify">In August and September 2025, the investors from July 2025 Offering exercised 125,000 pre-funded ADSs into 250,000 ordinary shares.</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tbody><tr style="vertical-align: top"> <td style="width: 72px"></td><td style="width: 24px">11.</td><td style="text-align: justify">On November 10, 2025, a Special General Meeting of Shareholders of the Company approved to:</td></tr></tbody></table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <tbody><tr style="vertical-align: top"> <td style="width: 1in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Increase authorized share capital by 7,333,333 so following the resolution, Company&#8217;s authorized share capital is 14,000,000 ordinary shares, <span style="-sec-ix-hidden:fc_2130825858">no</span> par value per share.&#160;</span></td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <tbody><tr style="vertical-align: top"> <td style="width: 1in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Perform a reverse split at a ratio of 1:3,000.</span></td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> Concurrently with the reverse split, the Company effected a corresponding change in the ratio of ordinary shares underlying each of the Company&#8217;s American Depositary Shares (ADSs), such that its ratio of ADSs to ordinary shares will change from one (1) ADS representing three hundred (300) ordinary shares to a new ratio of one (1) ADS representing two (2) ordinary shares and no adjustment will be made to the outstanding number of the ADSs of the Company. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For accounting purposes, all share and per share amounts for ordinary share, preferred shares, warrants, options and loss per share amounts have been adjusted to give retroactive effect to the forward and reverse share splits for all periods presented in these financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Any fractional shares of more than one-half of one whole share that resulted from the reverse share splits have been rounded up to the nearest whole share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px"></td><td style="width: 24px">12.</td><td style="text-align: justify">On November 18, 2025, the investors from July 2025 Offering exercised 229,167 pre-funded ADSs into 458,334 ordinary shares.</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px"></td><td style="width: 24px">13.</td><td style="text-align: justify">On November 18, 2025, the Company entered into an agreement with the holder of warrants to purchase 833,333 ADS previously issued on July 29, 2025 to purchase 1,666,667 ordinary shares, pursuant to which in consideration for the holder&#8217;s waiver of certain standstill provisions, the Company reduced the exercise price of such warrants from $12.0 per ADS to $9.34 per ADS.</td></tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase ordinary share:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table summarizes information regarding outstanding warrants to purchase the Company&#8217;s ordinary shares as of December 31, 2025:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Issuance date</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Number of <br/> outstanding <br/> Warrants</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Exercise <br/> price per <br/> warrant</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">December 2021</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200.0</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">January 2023 agent</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,545</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">68.75</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">November 2023</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">243,377</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">17.50</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">November 2023 agent</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">13,746</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">19.13</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">August 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">571,429</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">22.50</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">August 2024 agent</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">21.90</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">April 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">17,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">15.0</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">July 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,666,667</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">4.67</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">July 2025</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">7.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,604,097</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2025 and 2024, all of the Company&#8217;s outstanding warrants are classified as part of the Company&#8217;s equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share options plan:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> On November 28, 2013, the board of directors approved the adoption of the 2013 Share Option Plan (the &#8220;2013 Plan&#8221;). Under the Company&#8217;s 2013 Plan, in May 2023, the Company&#8217;s Board of Directors approved to increase number of ordinary shares reserved for issuance to 28,333. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> On August 30, 2023, the Company&#8217;s board of directors approved the adoption on a new 2023 Share Option Plan (the &#8220;2023 Plan&#8221;) and approved the reserve of 33,333 of the Company&#8217;s ordinary shares to issuance under the 2023 Plan. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Under the Company&#8217;s Plans, the Company may grant its officers, directors, employees and consultants, share options. Each share option granted shall be exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will be granted with a term in excess of 10 years. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> As of December 31, 2025, 8,667 shares available for future grant under the Company&#8217;s 2023 Plans. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions granted by the Company:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table summarizes Company&#8217;s option activity during the year ended December 31, 2025:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> options</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> average <br/> exercise <br/> price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> average <br/> remaining <br/> contractual <br/> terms <br/> (in years)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> intrinsic <br/> value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Outstanding at December 31, 2024</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41,610</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_2016546657">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Grants</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">16.01</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(77</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1216322058">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_113611892">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Outstanding at December 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">49,533</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">87.31</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6.6</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_84170453">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest at December 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">49,533</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">87.31</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6.6</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_299793311">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Exercisable at December 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25,497</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">143.98</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1788048371">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life for the shares subject to options outstanding as of December&#160;31, 2025, 2024 and 2023 was 6.6 years, 7.1 years and 5.88 years, respectively.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average grant date fair value in 2025 was $8.0, in 2024 was $60 and in 2023 was $30 and the remaining compensation costs not yet recognized as of December 31, 2025 is $133 with a weighted average period of 7.6 years to recognize these expenses.</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The fair value of the Company&#8217;s share options granted was estimated using the binomial option pricing model using the following range assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 61%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Description</span></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">2025</span></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">2024</span></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">2023</span></span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center">&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center">&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.04%-4.21%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.64%-5.09%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.95%-3.96%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79.56%-79.82%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83.40%-83.94%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84.30%-84.76%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td> <td style="text-align: center">&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%</span></td> <td style="text-align: center">&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%</span></td> <td style="text-align: center">&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual life (in years)</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.75-10</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early Exercise Multiple (Suboptimal Factor)</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses recognized in the financial statements:</span></td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Research and development</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">83</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative (*)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">283</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">178</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">340</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">362</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">261</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tbody><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Including $141 and $112 share based compensation for services provided in 2025 and 2024, refer to note 9(b)(6) and note 9(b)(1), respectively.</td> </tr></tbody> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 10:- LEASES:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> The Company has lease contracts for motor vehicles used in its operations. Leases of motor vehicles have lease terms of 3 years. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a summary of weighted average remaining lease terms and discount rate for all of the Company&#8217;s operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2025</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">weighted average remaining lease term (years)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.49</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>weighted average discount rate</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">The components of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2025 and 2024 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2025</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2024</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Components of lease expense:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;53</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;44</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;56</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, <br/> 2025</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, <br/> 2024</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Supplemental cash flow information</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;56</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;42</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">Maturities of lease liabilities as of December 31, 2025 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2026</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total operating lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">92</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21</td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Present value of lease liability</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">71</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense), Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Finance Income (Expense), Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">Finance Income (Expense), Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 11:-&#160;FINANCE INCOME (EXPENSE), NET</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Interest income</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">284</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">291</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">506</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Bank commissions</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(14</td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(14</td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(14</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exchange rate fluctuations and others</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(144</td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(13</td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">58</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">short-term investment revaluation</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total financial income (expenses), net</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">122</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">561</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">NOTE 12:-</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">SEGMENT REPORTING </span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> ASC 280, &#8220;Segment Reporting,&#8221; establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (&#8220;CODM&#8221;) in deciding how to allocate resources and in assessing performance. The Company&#8217;s business is comprised of&#160;one&#160;operating segment. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: -0.7in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> The Company&#8217;s CODM is its <span style="-sec-ix-hidden:fc_698904215">Chief Executive Officer</span> (&#8220;CEO&#8221;), who reviews financial information presented on a consolidated basis. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: -0.7in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> The CODM uses consolidated net income to measure segment profit or loss, to allocate resources and assess performance. Further, the CODM reviews and utilizes functional expenses (research and development and general and administrative) at the consolidated level to manage the Company&#8217;s operations and evaluate return on total assets in deciding whether to invest in the development and expansion of the Company&#8217;s consolidated operations. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNetAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 13:-&#160;TAXES ON INCOME</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate tax rates:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Israeli taxation:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Corporate tax rate in Israel in 2025, 2024 and 2023 was 23%. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Law for the Encouragement of Capital Investments, 1959:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Law for Encouragement of Capital Investments, 1959 (the &#8220;Investment Law&#8221;) provides tax benefits for Israeli companies meeting certain requirements and criteria. The Investment Law has undergone certain amendments and reforms in recent years.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Israeli parliament enacted a reform to the Investment Law, effective January 2011 (which was amended in August 2013). According to the reform, a flat rate tax applies to Preferred Income of companies eligible for the &#8220;Preferred Enterprise&#8221; status. In order to be eligible for Preferred Enterprise status, a company must meet minimum requirements to establish that it contributes to the country&#8217;s economic growth and is a competitive factor for the gross domestic product.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Benefits granted to a Preferred Enterprise include reduced tax rates. As part of the Economic Efficiency Law (Legislative Amendments for Accomplishment of Budgetary Targets for Budget Years 2017-2018), 5777-2016, the tax rate is&#160;16% for all areas other than Development Area A (which was&#160;7.5% from 2017 onward). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final tax assessments:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s tax return up until the year ended December 31, 2020 are considered final.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating carryforward losses for tax purposes and other temporary differences:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> As of December 31, 2025, the Company had carryforward losses amounting to approximately $205,100 that can be carryforward indefinitely </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax assets:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,998</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences mainly relating to Research and Development</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,279</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,062</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax asset before valuation allowance</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">34,094</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">28,060</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(34,094</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,060</td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_539237308">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_506692405">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation of the theoretical tax expense to the actual tax expense:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes and the company&#8217;s preferred enterprise tax rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">A reconciliation of the provision for income taxes to the amount computed by applying the&#160;23% statutory Israeli income tax rate to income before income taxes after the adoption of ASU 2023-09 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Tax at Israeli Statutory Rate</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,260</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Effect of benefitted income preferred technological enterprise in Israel</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">688</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.25in">Changes in Valuation Allowances</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">1,524</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(16</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Share-based payment awards</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0</td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Effective Tax Rate</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1936936551">-</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_605971914">-</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-weight: bold;">NOTE 14:- SUBSEQUENT EVENTS </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> On March 4, 2026, the Company entered into an inducement offer letter agreement (the &#8220;Inducement Letter&#8221;) with a certain holder (the &#8220;Holder&#8221;) of certain of the Company&#8217;s existing warrants to purchase up to 795,869 of the Company&#8217;s American Depositary Shares (&#8220;ADS&#8221;), each ADS representing two ordinary shares, no par value, issued on July 29, 2025 at an exercise price of&#160;$9.34 per ADS (the &#8220;Existing Warrants&#8221;). </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Pursuant to the Inducement Letter, the Holder agreed to exercise for cash its Existing Warrants to purchase an aggregate of 795,869 of the Company&#8217;s ADSs at a reduced exercise price of $5.00 per ADS in consideration of the Company&#8217;s agreement to issue new warrants to purchase ADSs (the &#8220;New Warrants&#8221;), as described below, to purchase up to an aggregate of 1,591,738 ADSs (the &#8220;New Warrant Shares&#8221;), at an exercise price of $5.00 per ADS. The Company received aggregate gross proceeds of $4.0 million from the exercise of the Existing Warrants by the Holder, before deducting placement agent fees and other offering expenses payable by the Company. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> The Company also agreed to pay the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds received from the Holder&#8217;s exercise of the Existing Warrants, as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the Existing Warrants. The Company has also agreed to issue to the placement agent to purchase up to 55,711 ADSs which will have the same terms as the New Warrants except that the Placement Agent Warrants will have an exercise price equal to $6.25 per ADS. Similar to the New Warrants, the Placement Agent Warrants will be immediately exercisable from the date of issuance until the two year anniversary of the effective date of the resale registration statement. In addition, the Company has also agreed to pay the placement agent $91 for other fees. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> As part of the Inducement letter, the Company also received gross proceeds of approximately $350 following the exercise of 37,465 Existing Warrants. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We have developed and maintain a cybersecurity risk management program, consisting of cybersecurity policies, procedures, compliance and awareness programs to mitigate risk&#160;and to ensure compliance with security, availability and confidentiality trust principles.&#160;The cybersecurity process has been integrated into our overall risk management system and process, and is solely internally managed. Management is responsible for identifying risks that threaten achievement of the control activities stated in the management&#8217;s description of the services organizations systems. Management has implemented a process for identifying relevant risks that could affect the organization&#8217;s ability to provide secure and reliable service to its users. The risk assessment occurs annually, or as business needs change, and covers identification of risks that could act against the company&#8217;s objectives as well as specific risks related to a compromise to the security of data.&#160;See &#8220;Item 3.D Risk Factors&#8212; Risks Related to Our Business and Regulatory Matters&#8212; Our business and operations may be materially adversely affected in the event of computer system failures or security breaches.&#8221; </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The oversight of cybersecurity threats is undertaken by our Chief Executive Officer who and is supported by outside IT consultants. Our audit committee is responsible for cybersecurity oversight and monitoring risk. Management informs the audit committee of such risk by committee meetings. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of the date of this report, we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">The cybersecurity process has been integrated into our overall risk management system and process, and is solely internally managed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">The oversight of cybersecurity threats is undertaken by our Chief Executive Officer who and is supported by outside IT consultants. Our audit committee is responsible for cybersecurity oversight and monitoring risk. Management informs the audit committee of such risk by committee meetings.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our audit committee is responsible for cybersecurity oversight and monitoring risk.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Management informs the audit committee of such risk by committee meetings.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (9,828)<span></span>
</td>
<td class="num">$ (7,880)<span></span>
</td>
<td class="num">$ (7,634)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment Information</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company&#8217;s operations and manage its business in&#160;one&#160;operating segment which is the research and development of the Company&#8217;s drug candidates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency, reporting currency and foreign currency</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency, reporting currency and foreign currency:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The functional currency of the Company is the U.S. dollar. Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars in accordance with Accounting Standard Codification (&#8220;ASC&#8221;) No. 830 &#8220;Foreign Currency Matters.&#8221; All transaction gains and losses of the re-measured monetary balance sheet items are reflected in the consolidated statements of comprehensive loss as financial income or expenses, as appropriate.&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Cash equivalents are short-term, highly liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShorttermBankDepositsPolicyTextBlock', window );">Short-term bank deposits</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term bank deposits:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -21.25pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2025 and 2024, the Company&#8217;s bank deposits are denominated in U.S. dollars and bears yearly interest at weighted average rates of&#160;4.30% and&#160;5.25%. Short-term bank deposits are presented at their cost, including accrued interest. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock', window );">Prepaid expenses, and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses, and other current assets</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Prepaid expenses are composed mainly from prepayments to suppliers and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and no longer have an alternative future use.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lease</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with ASU No. 2016-02, &#8220;Leases (Topic 842)&#8221;, the Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Mainly<br/>  %</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 - 33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: center">33</td><td style="text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of long-lived assets:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Property and equipment and ROU assets are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment,&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets (assets group) to be held and used is measured by a comparison of the carrying amount of an asset (assets group) to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. As of December 31, 2025, and 2024, <span style="-sec-ix-hidden:fc_669790381"><span style="-sec-ix-hidden:fc_406290213">no</span></span> impairment indicators have been identified. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue recognition:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes revenue in accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#8220;ASC 606&#8221;) and determines revenue recognition through the following steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the contract, or contracts, with a customer;</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification of the performance obligations in the contract;</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination of the transaction price;</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of the transaction price to the performance obligations in the contract; and</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition of revenue when, or as, the performance obligations are satisfied.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company generates revenues from supply and distribution agreements. The consideration under these agreements comprises of upfront fees, milestone payments and potential royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf of third parties (such as taxes).&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts generally include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has concluded that the abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded based on the term of the research and development services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts also include development milestones payments and future sales-based royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Development milestones payments are recognized only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with those milestones is subsequently resolved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Sales based royalties are recognized only when the subsequent sale occurs. As of December 31, 2025, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any sales-based royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The prepayments terms from the Company&#8217;s contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing from the customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="text-decoration:underline">Revenue Recognition &#8211; Contract Balances </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> Contract liabilities, due to the upfront payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2025 and December 31, 2024 contract liabilities and remaining performance obligation amounted to $1,581&#160;and $1,986, respectively and are presented under deferred revenues. During the year ended December 31, 2025, the Company recognized revenues in the amount of $405 which have been included in the contract liabilities at December&#160;31, 2024. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred revenue and remaining performance obligation that is anticipated to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded as non-current deferred revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Cipher Pharmaceuticals (Canada)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp. (South Korea)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Gebro Holding GmbH (Austria)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Ewopharma AG (Switzerland)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Vetbiolix (France)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1997113680">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_487311381">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td> </tr> </tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenditures</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Research and development costs are expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization, rent, and utilities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurement</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;). Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent from the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 - Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The carrying amounts of cash and cash equivalents, short term deposit, prepaid expenses and other currents assets, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The Company has an investment in marketable equity security classified within level 1 in the fair value hierarchy.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concentration of Credit Risk:&#160;</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_LegalAndOtherContingenciesPolicyTextBlock', window );">Legal and other contingencies</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for its contingent liabilities in accordance with ASC 450, Contingencies (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2025, and 2024, the Company is not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position, results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SeverancePayPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance pay<span style="text-transform: uppercase">:</span></span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> The Company&#8217;s liability for severance pay is pursuant to Section 14 of the Israeli Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant to which all the Company&#8217;s employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.&#160;Severance pay expense for the year ended December 31, 2025, 2024 and 2023 amounted to $53, $49 and $47, respectively. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based payment transactions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions<span style="text-transform: uppercase">:</span></span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for share-based compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s consolidated statement of comprehensive loss, based on acceleration method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes compensation expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company estimates the fair value of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility, early exercise factor and the expected option term. Expected volatility was calculated based upon historical volatility of the Company and early exercise factor was calculated based on statistical studies in the U.S market. The risk-free interest rate is based on the yield from government bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Taxes on income</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2025, and 2024, a full valuation allowance was provided by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2025, and 2024, <span style="-sec-ix-hidden:fc_972519014"><span style="-sec-ix-hidden:fc_213046275">no</span></span> liability for unrecognized tax benefits was recorded.&#160; </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock', window );">Warrants to purchase ordinary shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to purchase ordinary shares:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per share<span style="text-transform: uppercase">:</span></span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Basic and diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. The Company include in the basic net loss per share calculation, pre-funded warrants that are exercisable for a nominal consideration. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#8220;Earnings per Share&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants for the years ended December 31, 2025, 2024 and 2023 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. The potential ordinary shares and warrants that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Options</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">49,533</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41,610</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27,492</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,604,096</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">886,599</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">617,337</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,653,629</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">928,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">644,829</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tbody><tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retroactively adjusted to give effect to the reverse share split, see also note 9.</span></td></tr> </tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently adopted accounting pronouncements:</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="background-color: white">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which requires disaggregated information about the effective tax rate reconciliation as well as information on income taxes paid. The guidance will be effective for the Company for annual periods beginning January 1, 2025, with early adoption permitted. The adoption of the standard <span style="background-color: white">did not </span> have material impact on its financial statement disclosures.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently issued accounting pronouncements not yet adopted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="width: 47px">&#160;</td> <td style="width: 28px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">v.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Recently issued accounting pronouncements not yet adopted</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In November 2024, the FASB issued ASU 2024-03<i>&#160;&#8220;Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures&#8221;</i>&#160;(&#8220;ASU 2024-03&#8221;), which requires more detailed information about specified categories of expenses presented on the face of the income statement, in addition to disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. The amendment may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating ASU 2024-03 to determine the impact it may have on its consolidated financial statements and related disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_LegalAndOtherContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of legal and other contingencies policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_LegalAndOtherContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The accounting policy for prepaid expenses, and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of recently issued accounting pronouncements not yet adopted Policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance pay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShorttermBankDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShorttermBankDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of warrants to purchase ordinary shares Policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock', window );">Schedule of Depreciable Rates of Property and Equipment</a></td>
<td class="text">Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Mainly<br/>  %</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 - 33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: center">33</td><td style="text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Major Customer Data as a Percentage</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Cipher Pharmaceuticals (Canada)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp. (South Korea)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Gebro Holding GmbH (Austria)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">11</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">18</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Ewopharma AG (Switzerland)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">30</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">46</td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Vetbiolix (France)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1997113680">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_487311381">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td> </tr> </tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Shares</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants for the years ended December 31, 2025, 2024 and 2023 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. The potential ordinary shares and warrants that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Options</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">49,533</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41,610</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">27,492</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,604,096</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">886,599</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">617,337</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,653,629</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">928,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">644,829</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tbody><tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retroactively adjusted to give effect to the reverse share split, see also note 9.</span></td></tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for property plant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">74</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">77</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and others</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">826</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,018</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">900</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,095</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment, Net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Cost:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_1633826125">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">64</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Computers, office furniture and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">79</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Laboratory equipment</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden:fc_2074154732">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Computers, office furniture and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">12</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">52</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts Payable and Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accounts Payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">Employees and payroll accruals</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">811</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">675</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">298</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">301</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,109</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">976</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_1904201796">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_1856579833">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: left; font-weight: bold">Description</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair value</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_2047207648">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden:fc_736875626">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Information Regarding Outstanding Warrants to Purchase Shares</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table summarizes information regarding outstanding warrants to purchase the Company&#8217;s ordinary shares as of December 31, 2025:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Issuance date</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Number of <br/> outstanding <br/> Warrants</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">Exercise <br/> price per <br/> warrant</td><td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">December 2021</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200.0</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">January 2023 agent</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,545</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">68.75</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">November 2023</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">243,377</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">17.50</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">November 2023 agent</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">13,746</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">19.13</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">August 2024</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">571,429</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">22.50</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">August 2024 agent</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">21.90</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">April 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">17,500</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">15.0</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">July 2025</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,666,667</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">4.67</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">July 2025</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,333</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">7.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,604,097</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </tbody> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Company's Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table summarizes Company&#8217;s option activity during the year ended December 31, 2025:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: justify">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> options</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> average <br/> exercise <br/> price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/> average <br/> remaining <br/> contractual <br/> terms <br/> (in years)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate <br/> intrinsic <br/> value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Outstanding at December 31, 2024</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41,610</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7.1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden:fc_2016546657">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Grants</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">16.01</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(77</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_1216322058">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden:fc_113611892">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Outstanding at December 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">49,533</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">87.31</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6.6</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_84170453">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest at December 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">49,533</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">87.31</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6.6</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_299793311">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Exercisable at December 31, 2025</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">25,497</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">143.98</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.7</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1788048371">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </tbody> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair value of Company&#8217;s Share Options Granted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The fair value of the Company&#8217;s share options granted was estimated using the binomial option pricing model using the following range assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 61%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">Description</span></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">2025</span></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">2024</span></span></td> <td style="white-space: nowrap; width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-weight: bold;">2023</span></span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center">&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center">&#160;</td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.04%-4.21%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.64%-5.09%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.95%-3.96%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">79.56%-79.82%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">83.40%-83.94%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84.30%-84.76%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td> <td style="text-align: center">&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%</span></td> <td style="text-align: center">&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%</span></td> <td style="text-align: center">&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual life (in years)</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.75-10</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early Exercise Multiple (Suboptimal Factor)</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</span></td></tr> </tbody> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Expenses Recognized Financial Statements</a></td>
<td class="text">Expenses recognized in the financial statements:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Research and development</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">83</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative (*)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">283</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">178</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">340</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">362</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">261</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> </tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"> <tbody><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Including $141 and $112 share based compensation for services provided in 2025 and 2024, refer to note 9(b)(6) and note 9(b)(1), respectively.</td> </tr></tbody> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Terms and Discount Rate</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a summary of weighted average remaining lease terms and discount rate for all of the Company&#8217;s operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2025</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2024</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">weighted average remaining lease term (years)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.49</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>weighted average discount rate</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td> </tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">The components of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2025 and 2024 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2025</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2024</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31,<br/> 2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Components of lease expense:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;53</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;44</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;56</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, <br/> 2025</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, <br/> 2024</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Supplemental cash flow information</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;56</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td><td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;42</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">Maturities of lease liabilities as of December 31, 2025 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">2026</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">60</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2027</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total operating lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">92</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21</td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Present value of lease liability</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">71</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense), Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Finance Income (Expense), Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Finance Income (Expense), Net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Interest income</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">284</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">291</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">506</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Bank commissions</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(14</td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(14</td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(14</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Exchange rate fluctuations and others</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(144</td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(13</td><td style="text-align: left">)</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">58</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">short-term investment revaluation</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Total financial income (expenses), net</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">122</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">250</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">561</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNetAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax assets:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,998</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences mainly relating to Research and Development</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,279</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,062</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred tax asset before valuation allowance</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">34,094</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">28,060</td><td style="text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(34,094</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28,060</td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_539237308">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_506692405">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation Statutory Israeli Income Tax Rate</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">A reconciliation of the provision for income taxes to the amount computed by applying the&#160;23% statutory Israeli income tax rate to income before income taxes after the adoption of ASU 2023-09 is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tbody><tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td> <td colspan="2">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Tax at Israeli Statutory Rate</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(2,260</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23</td><td style="width: 1%; text-align: left">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Effect of benefitted income preferred technological enterprise in Israel</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">688</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(7</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.25in">Changes in Valuation Allowances</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">1,524</td><td style="text-align: left">&#160;</td><td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: right">(16</td><td style="text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Share-based payment awards</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0</td><td style="padding-bottom: 1.5pt; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Effective Tax Rate</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_1936936551">-</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td><td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden:fc_605971914">-</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td> </tr> </tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NumberOfOrdinaryShares', window );">Number of ordinary shares in each ADS (in Shares)</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="nump">$ 9,828<span></span>
</td>
<td class="nump">$ 7,880<span></span>
</td>
<td class="nump">$ 7,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net operating cash outflow</a></td>
<td class="nump">8,949<span></span>
</td>
<td class="nump">$ 7,637<span></span>
</td>
<td class="nump">$ 8,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">8,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_GrossProceeds', window );">Gross proceeds</a></td>
<td class="nump">$ 4,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">$ 1,581<span></span>
</td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognized revenues</a></td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance pay expense</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfRealizationOnUltimateSettlement', window );">Maximum percentage of realization on ultimate settlement</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfDepositsOnMonthlySalary', window );">Percentage of deposits on monthly salary</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShortTermBankDepositsYearlyInterestRatePercentage', window );">Weighted average rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment charges</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfDepositsOnMonthlySalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of deposits on monthly salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfDepositsOnMonthlySalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfRealizationOnUltimateSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of realization on ultimate settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfRealizationOnUltimateSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShortTermBankDepositsYearlyInterestRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term bank deposits, annual interest rate percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShortTermBankDepositsYearlyInterestRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Depreciable Rates of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Depreciable Rates of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Depreciable Rates of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Depreciable Rates of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Depreciable Rates of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Annual rates of depreciation</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies- Schedule of Major Customer Data as a Percentage (Details) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Major Customer Data as a Percentage [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Chong Kun Dang Pharmaceuticals Corp. (South Korea) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Major Customer Data as a Percentage [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Cipher Pharmaceuticals (Canada) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Major Customer Data as a Percentage [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Gebro Holding GmbH (Austria) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Major Customer Data as a Percentage [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Ewopharma AG (Switzerland) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Major Customer Data as a Percentage [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Vetbiolix (France) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Major Customer Data as a Percentage [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-18<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_GebroHoldingGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_GebroHoldingGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_EwopharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_EwopharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_VetbiolixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_VetbiolixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies- Schedule of Antidilutive Shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Antidilutive Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive shares</a></td>
<td class="nump">2,653,629<span></span>
</td>
<td class="nump">928,209<span></span>
</td>
<td class="nump">644,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Antidilutive Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive shares</a></td>
<td class="nump">49,533<span></span>
</td>
<td class="nump">41,610<span></span>
</td>
<td class="nump">27,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Antidilutive Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive shares</a></td>
<td class="nump">2,604,096<span></span>
</td>
<td class="nump">886,599<span></span>
</td>
<td class="nump">617,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Schedule of Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses and others</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses, and other current assets</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 1,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of government authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Computers, Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Payable - Schedule of Other Accounts Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Schedule of Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and payroll accruals</a></td>
<td class="nump">$ 811<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Other accounts payable</a></td>
<td class="nump">$ 1,109<span></span>
</td>
<td class="nump">$ 976<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details)<br> &#8364; in Thousands, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 28, 2021</div></th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 24, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 06, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Additional payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Net sales percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_TransferPriceRate', window );">Transfer price rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Terms of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AdditionalRevenueReceivedForAchievedMilestone', window );">Additional achieved milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,450<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenues recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_NonRefundablePayment', window );">Non-refundable payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_MilestonePaymentPercentage', window );">Milestone payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Finite-lived patents, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfRoyaltiesOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfRoyaltiesOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember', window );">Cipher Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
<td class="nump">$ 1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember', window );">Chong Kun Dang Pharmaceuticals Corp. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Terms of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AdditionalRevenueReceivedForAchievedMilestone', window );">Additional achieved milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_GebroHoldingGmbHMember', window );">Gebro Holding GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Terms of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AdditionalRevenueReceivedForAchievedMilestone', window );">Additional achieved milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720<span></span>
</td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Description of additional payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under the Distribution and Supply Agreement, the Company is entitled to &#8364; 1,500 thousands upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) &#8364; 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and &#8364; 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between &#8364; 750 thousand and &#8364; 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364; 300 thousand and up to &#8364;4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.<span></span>
</td>
<td class="text">Under the Distribution and Supply Agreement, the Company is entitled to &#8364; 1,500 thousands upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) &#8364; 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and &#8364; 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between &#8364; 750 thousand and &#8364; 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364; 300 thousand and up to &#8364;4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_VetbiolixMember', window );">Vetbiolix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Description of additional payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#8220;CMS Medical&#8221;) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan).<span></span>
</td>
<td class="text">On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#8220;CMS Medical&#8221;) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenues recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_CMSMedicalVentureInvestmentLimitedMember', window );">CMS Medical Venture Investment Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UpfrontAndMilestonePaymentsPayable', window );">Upfront and milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_RegulatoryMilestonesMember', window );">Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AdditionalRevenueReceivedForAchievedMilestone', window );">Additional achieved milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_SalesMilestonesMember', window );">Sales Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_AdditionalRevenueReceivedForAchievedMilestone', window );">Additional achieved milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_KyongboPharmCoLtdMember', window );">Kyongbo Pharm Co Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenues recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_EwopharmaMember', window );">Ewopharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Terms of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfRoyaltiesOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">South Korea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Net sales percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=canf_LiverCancerIndicationMember', window );">Liver Cancer Indication [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UpfrontAndMilestonePaymentsPayable', window );">Upfront and milestone payments payable</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=canf_NASHMember', window );">NASH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_UpfrontAndMilestonePaymentsPayable', window );">Upfront and milestone payments payable</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AdditionalRevenueReceivedForAchievedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional revenue received for achieved milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AdditionalRevenueReceivedForAchievedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_MilestonePaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_MilestonePaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NonRefundablePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-refundable payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NonRefundablePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the percentage of royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_TransferPriceRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer price rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_TransferPriceRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_UpfrontAndMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of upfront and milestone payments payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_UpfrontAndMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_GebroHoldingGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_GebroHoldingGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_VetbiolixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_VetbiolixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_CMSMedicalVentureInvestmentLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_CMSMedicalVentureInvestmentLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_KyongboPharmCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_KyongboPharmCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_EwopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_EwopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=canf_LiverCancerIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=canf_LiverCancerIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=canf_NASHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=canf_NASHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseCommissionExpense', window );">Commission income expense</a></td>
<td class="nump">&#8364; 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties</a></td>
<td class="nump">&#8364; 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent', window );">Accrual | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties</a></td>
<td class="nump">&#8364; 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_PercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=canf_PhaseIStudiesMember', window );">Phase I Studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties</a></td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=canf_PhaseIIStudiesMember', window );">Phase II Studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=canf_PhaseIIIStudiesMember', window );">Phase III Studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=canf_RegulatoryAuthorityMember', window );">Regulatory Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties</a></td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The royalty payment in percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fees incurred for commissions on mutual funds and insurance products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=canf_PhaseIStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=canf_PhaseIStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=canf_PhaseIIStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=canf_PhaseIIStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=canf_PhaseIIIStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=canf_PhaseIIIStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=canf_RegulatoryAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=canf_RegulatoryAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 02, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 18, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 10, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 28, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 14, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 06, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 03, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 05, 2026 </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 22, 2023 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Nov. 28, 2013 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Ordinary share, voting rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Aggregate issuance costs (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds amount | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,333,334<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issue (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts', window );">Net proceeds of ordinary shares | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,933<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,223<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation costs not yet recognized | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price, per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual terms</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Ordinary shares reserved for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_GrantedExcessYears', window );">Granted excess years</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price, per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance', window );">Shares held investors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_CashPlacementFee', window );">Cash placement fee | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based compensation for services | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds IPO | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,933<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,223<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Aggregate issuance costs (in Dollars) | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Gross proceeds amount | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchased ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ClassOfWarrantOrRightPercentage', window );">Aggregate warrants percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,604,097<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=canf_NewWarrantsMember', window );">New Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchased ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=canf_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchased ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=canf_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=canf_SpecialGeneralMeetingOfShareholdersMember', window );">Special General Meeting of Shareholders [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IncreaseAuthorizedShareCapital', window );">Increase authorized share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse split ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1:3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=canf_TwoThousandThirteenPlanMember', window );">2013 Plan [Member] | Board of Directors [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Ordinary shares reserved for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=canf_TwoThousandTwentyThreePlanMember', window );">2023 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share) | &#8362; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchased ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM', window );">Ordinary shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">530,698<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">99,037<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts', window );">Net proceeds of ordinary shares | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Shares issued value for services | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance', window );">Shares held investors</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">151,364<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchased ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchased ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">708,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=canf_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=canf_AmericanDepositarySharesMember', window );">American Depositary Shares (ADSs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchased ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ClassOfWarrantOrRightPercentage', window );">Aggregate warrants percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price, per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance', window );">Shares held investors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=canf_AmericanDepositarySharesMember', window );">American Depositary Shares (ADSs) [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=canf_AmericanDepositarySharesMember', window );">American Depositary Shares (ADSs) [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=canf_AmericanDepositarySharesMember', window );">American Depositary Shares (ADSs) [Member] | Investors from July 2025 Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance', window );">Shares held investors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=canf_AmericanDepositarySharesMember', window );">American Depositary Shares (ADSs) [Member] | Common Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchased ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=canf_AmericanDepositarySharesMember', window );">American Depositary Shares (ADSs) [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Number of ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net of issuance cost | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds IPO | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="22"></td></tr>
<tr><td colspan="22"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively adjusted to give effect to the reverse share split, see also note 9.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Retroactively adjusted to give effect to the reverse share split, see also note 9.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CashPlacementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of cash placement fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CashPlacementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ClassOfWarrantOrRightPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ClassOfWarrantOrRightPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_GrantedExcessYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Granted excess years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_GrantedExcessYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IncreaseAuthorizedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase authorized share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IncreaseAuthorizedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares due to ATM, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the number of shares issuance of ordinary shares due to ATM.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares of release of ordinary shares that were previously held in abeyance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=canf_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=canf_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=canf_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=canf_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=canf_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=canf_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=canf_SpecialGeneralMeetingOfShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=canf_SpecialGeneralMeetingOfShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=canf_TwoThousandThirteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=canf_TwoThousandThirteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=canf_TwoThousandTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=canf_TwoThousandTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=canf_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=canf_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=canf_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=canf_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=canf_InvestorsFromJuly2025OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=canf_InvestorsFromJuly2025OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Schedule of Information Regarding Outstanding Warrants to Purchase Shares (Details) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Outstanding Warrants to Purchase Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding Warrants</a></td>
<td class="nump">2,604,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_December2021Member', window );">December 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Outstanding Warrants to Purchase Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">December 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding Warrants</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_January2023AgentMember', window );">January 2023 agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Outstanding Warrants to Purchase Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">January 2023 agent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding Warrants</a></td>
<td class="nump">9,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="nump">$ 68.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_November2023Member', window );">November 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Outstanding Warrants to Purchase Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">November 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding Warrants</a></td>
<td class="nump">243,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_November2023AgentMember', window );">November 2023 agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Outstanding Warrants to Purchase Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">November 2023 agent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding Warrants</a></td>
<td class="nump">13,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="nump">$ 19.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_August2024Member', window );">August 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Outstanding Warrants to Purchase Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">August 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding Warrants</a></td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_August2024AgentMember', window );">August 2024 agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Outstanding Warrants to Purchase Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">August 2024 agent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding Warrants</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="nump">$ 21.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_April2025Member', window );">April 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Outstanding Warrants to Purchase Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">April 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding Warrants</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_July2025Member', window );">July 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Outstanding Warrants to Purchase Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">July 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding Warrants</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_July2025OneMember', window );">July 2025 One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Outstanding Warrants to Purchase Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">July 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding Warrants</a></td>
<td class="nump">58,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share)</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the date of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_December2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_December2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_January2023AgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_January2023AgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_November2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_November2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_November2023AgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_November2023AgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_August2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_August2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_August2024AgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_August2024AgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_April2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_April2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_July2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_July2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_July2025OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_July2025OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Schedule of Company's Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Schedule of Weighted Average Exercise Prices Share Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Grants (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants', window );">Weighted average remaining contractual terms, Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options, expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired', window );">Weighted average remaining contractual terms, expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Ending (in Shares)</a></td>
<td class="nump">41,610<span></span>
</td>
<td class="nump">49,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 87.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual terms</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Ending (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, Vested and expected to vest (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual terms, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual terms, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options Grants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, options, nonvested options forfeited, weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Schedule of Fair value of Company&#8217;s Share Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice', window );">Early Exercise Multiple (Suboptimal Factor)</a></td>
<td class="nump">0.025<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
<td class="nump">0.025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.21%<span></span>
</td>
<td class="nump">5.09%<span></span>
</td>
<td class="nump">3.96%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.82%<span></span>
</td>
<td class="nump">83.94%<span></span>
</td>
<td class="nump">84.76%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.04%<span></span>
</td>
<td class="nump">4.64%<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.56%<span></span>
</td>
<td class="nump">83.40%<span></span>
</td>
<td class="nump">84.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Schedule of Expenses Recognized Financial Statements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Share-Based Payment Arrangement Expensed [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 340<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Share-Based Payment Arrangement Expensed [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Share-Based Payment Arrangement Expensed [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Including $141 and $112 share based compensation for services provided in 2025 and 2024, refer to note 9(b)(6) and note 9(b)(1), respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Motor Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease terms</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases-Schedule of Weighted Average Remaining Lease Terms and Discount Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Lease Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">weighted average remaining lease term (years)</a></td>
<td class="text">1 year 6 months 7 days<span></span>
</td>
<td class="text">2 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">weighted average discount rate</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Components of lease expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases-Schedule of Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Maturities of Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense), Net-Schedule of Finance Income (Expense), Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Schedule of Finance Income (Expense), Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest Expense, Nonoperating, Total</a></td>
<td class="nump">$ 284<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
<td class="nump">$ 506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_BankCommissions', window );">Bank commissions</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ExchangeRateFluctuationsAndOthers', window );">Exchange rate fluctuations and others</a></td>
<td class="num">(144)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_OtherGainFromShortTermInvestmentRemeasurement', window );">Short-term investment revaluation</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total financial income (expenses), net</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_BankCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of bank commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_BankCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExchangeRateFluctuationsAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of exchange rate fluctuations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExchangeRateFluctuationsAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherGainFromShortTermInvestmentRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other gain from short-term investment remeasurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherGainFromShortTermInvestmentRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Chief executive officer</a></td>
<td class="text">Chief Executive Officer [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Description of CODM</a></td>
<td class="text">The CODM uses consolidated net income to measure segment profit or loss, to allocate resources and assess performance. Further, the CODM reviews and utilizes functional expenses (research and development and general and administrative) at the consolidated level to manage the Company&#8217;s operations and evaluate return on total assets in deciding whether to invest in the development and expansion of the Company&#8217;s consolidated operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Taxes on Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Development area, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Carryforward losses</a></td>
<td class="nump">$ 205,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2017Member', window );">Tax Year 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Taxes on Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Development area, percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Taxes on Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate, percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes on Income- Schedule of Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 32,815<span></span>
</td>
<td class="nump">$ 26,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Temporary differences mainly relating to Research and Development</a></td>
<td class="nump">1,279<span></span>
</td>
<td class="nump">1,062<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross total</a></td>
<td class="nump">34,094<span></span>
</td>
<td class="nump">28,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(34,094)<span></span>
</td>
<td class="num">(28,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Schedule of Reconciliation Statutory Israeli Income Tax Rate  (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income, Amount</a></td>
<td class="num">$ (9,828)<span></span>
</td>
<td class="num">$ (7,880)<span></span>
</td>
<td class="num">$ (7,634)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Statutory Israeli Income Tax Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at Israeli Statutory Rate, Amount</a></td>
<td class="num">(2,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount', window );">Effect of benefitted income preferred technological enterprise in Israel, Amount</a></td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in Valuation Allowances, Amount</a></td>
<td class="nump">1,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Share-based payment awards, Amount</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at Israeli Statutory Rate, Percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael', window );">Effect of benefitted income preferred technological enterprise in Israel, Percentage</a></td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in Valuation Allowances, Percentage</a></td>
<td class="num">(16.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Share-based payment awards, Percentage</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Tax Rate, Percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit benefitted income preferred technological enterprise in Israel, amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) benefitted income preferred technological enterprise in Israel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,711<span></span>
</td>
<td class="nump">$ 4,488<span></span>
</td>
<td class="nump">$ 9,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ClassOfWarrantOrRightPercentage', window );">Aggregate warrants percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Non-accountable expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=canf_ExistingWarrantsMember', window );">Existing Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercise of warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=canf_ExistingWarrantsMember', window );">Existing Warrants [Member] | Forecast [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">795,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_canf_ClassOfWarrantOrRightPercentage', window );">Aggregate warrants percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Warrant exercise price decrease</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=canf_NewWarrantSharesMember', window );">New Warrant Shares [Member] | Forecast [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants represented</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,591,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=canf_ADSMember', window );">ADS [Member] | Forecast [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants represented</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">795,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Forecast [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Retroactively adjusted to give effect to the reverse share split, see also note 9.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ClassOfWarrantOrRightPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ClassOfWarrantOrRightPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=canf_ExistingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=canf_ExistingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=canf_NewWarrantSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=canf_NewWarrantSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=canf_ADSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=canf_ADSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>189</ContextCount>
  <ElementCount>311</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995300 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995301 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Operating Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss</Role>
      <ShortName>Consolidated Statements of Operating Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Changes in Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995306 - Statement - Consolidated Statements of Changes in Shareholders??? Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquityParentheticals</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders??? Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995307 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995308 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/OtherAccountsPayable</Role>
      <ShortName>Other Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Contingent Liabilities and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ContingentLiabilitiesandCommitments</Role>
      <ShortName>Contingent Liabilities and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Finance Income (Expense), Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/FinanceIncomeExpenseNet</Role>
      <ShortName>Finance Income (Expense), Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996323 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/SignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996324 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/SignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996325 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996326 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996327 - Disclosure - Other Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/OtherAccountsPayableTables</Role>
      <ShortName>Other Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/OtherAccountsPayable</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996328 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996329 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/ShareholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996330 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996331 - Disclosure - Finance Income (Expense), Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/FinanceIncomeExpenseNetTables</Role>
      <ShortName>Finance Income (Expense), Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/FinanceIncomeExpenseNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996332 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/TaxesonIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/TaxesonIncome</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996333 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/General</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996334 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996335 - Disclosure - Significant Accounting Policies - Schedule of Depreciable Rates of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Depreciable Rates of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996336 - Disclosure - Significant Accounting Policies- Schedule of Major Customer Data as a Percentage (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails</Role>
      <ShortName>Significant Accounting Policies- Schedule of Major Customer Data as a Percentage (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996337 - Disclosure - Significant Accounting Policies- Schedule of Antidilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails</Role>
      <ShortName>Significant Accounting Policies- Schedule of Antidilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996338 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996339 - Disclosure - Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/PropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996340 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996341 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/OtherAccountsPayableScheduleofOtherAccountsPayableDetails</Role>
      <ShortName>Other Accounts Payable - Schedule of Other Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996342 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996343 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/Revenues</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996344 - Disclosure - Contingent Liabilities and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails</Role>
      <ShortName>Contingent Liabilities and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/ContingentLiabilitiesandCommitments</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996345 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/ShareholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996346 - Disclosure - Shareholders' Equity - Schedule of Information Regarding Outstanding Warrants to Purchase Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails</Role>
      <ShortName>Shareholders' Equity - Schedule of Information Regarding Outstanding Warrants to Purchase Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996347 - Disclosure - Shareholders' Equity - Schedule of Company's Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails</Role>
      <ShortName>Shareholders' Equity - Schedule of Company's Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996348 - Disclosure - Shareholders' Equity - Schedule of Fair value of Company???s Share Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails</Role>
      <ShortName>Shareholders' Equity - Schedule of Fair value of Company???s Share Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996349 - Disclosure - Shareholders' Equity - Schedule of Expenses Recognized Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails</Role>
      <ShortName>Shareholders' Equity - Schedule of Expenses Recognized Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996350 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/LeasesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996351 - Disclosure - Leases-Schedule of Weighted Average Remaining Lease Terms and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/LeasesScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateDetails</Role>
      <ShortName>Leases-Schedule of Weighted Average Remaining Lease Terms and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996352 - Disclosure - Leases-Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases-Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996353 - Disclosure - Finance Income (Expense), Net-Schedule of Finance Income (Expense), Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/FinanceIncomeExpenseNetScheduleofFinanceIncomeExpenseNetDetails</Role>
      <ShortName>Finance Income (Expense), Net-Schedule of Finance Income (Expense), Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/FinanceIncomeExpenseNetTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996354 - Disclosure - Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/SegmentReportingDetails</Role>
      <ShortName>Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/SegmentReporting</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996355 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/TaxesonIncomeTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996356 - Disclosure - Taxes on Income- Schedule of Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/TaxesonIncomeScheduleofScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Taxes on Income- Schedule of Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996357 - Disclosure - Taxes on Income - Schedule of Reconciliation Statutory Israeli Income Tax Rate  (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails</Role>
      <ShortName>Taxes on Income - Schedule of Reconciliation Statutory Israeli Income Tax Rate  (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ea0282586-20f_canfite.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996358 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://canfite.com/20251231/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://canfite.com/20251231/role/SubsequentEvents</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>canf-20251231.xsd</File>
    <File>canf-20251231_cal.xml</File>
    <File>canf-20251231_def.xml</File>
    <File>canf-20251231_lab.xml</File>
    <File>canf-20251231_pre.xml</File>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="ea0282586-20f_canfite.htm">ea0282586-20f_canfite.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ea028258601_img1.jpg</File>
    <File>ea028258601_img2.jpg</File>
    <File>ea028258601_img3.jpg</File>
    <File>ea028258601_img4.jpg</File>
    <File>ea028258601_img5.jpg</File>
    <File>ea028258601_img6.jpg</File>
    <File>ea028258601_img7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="566">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="45">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0282586-20f_canfite.htm": {
   "nsprefix": "canf",
   "nsuri": "http://canfite.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "canf-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "canf-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "canf-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "canf-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "canf-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0282586-20f_canfite.htm"
     ]
    }
   },
   "keyStandard": 262,
   "keyCustom": 49,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 38,
   "hidden": {
    "total": 84,
    "http://fasb.org/us-gaap/2025": 59,
    "http://canfite.com/20251231": 22,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 189,
   "entityCount": 1,
   "segmentCount": 68,
   "elementCount": 612,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 566,
    "http://xbrl.sec.gov/dei/2025": 45,
    "http://xbrl.sec.gov/cyd/2025": 10,
    "http://xbrl.sec.gov/ecd/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://canfite.com/20251231/role/DocumentAndEntityInformation",
     "longName": "995300 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://canfite.com/20251231/role/AuditInformation",
     "longName": "995301 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://canfite.com/20251231/role/ConsolidatedBalanceSheets",
     "longName": "995302 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://canfite.com/20251231/role/ConsolidatedBalanceSheetsParentheticals",
     "longName": "995303 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "uref_734008993",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "uref_734008993",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss",
     "longName": "995304 - Statement - Consolidated Statements of Operating Loss",
     "shortName": "Consolidated Statements of Operating Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:Revenues",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:Revenues",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity",
     "longName": "995305 - Statement - Consolidated Statements of Changes in Shareholders\u2019 Equity",
     "shortName": "Consolidated Statements of Changes in Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "cref_1689545004",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1689545004",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquityParentheticals",
     "longName": "995306 - Statement - Consolidated Statements of Changes in Shareholders\u2019 Equity (Parentheticals)",
     "shortName": "Consolidated Statements of Changes in Shareholders\u2019 Equity (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "cref_1205104151",
      "name": "canf:NetOfIssuanceCostsOfOrdinarySharesAndWarrants",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1205104151",
      "name": "canf:NetOfIssuanceCostsOfOrdinarySharesAndWarrants",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows",
     "longName": "995307 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://canfite.com/20251231/role/General",
     "longName": "995308 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://canfite.com/20251231/role/SignificantAccountingPolicies",
     "longName": "995309 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssets",
     "longName": "995310 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://canfite.com/20251231/role/PropertyPlantandEquipmentNet",
     "longName": "995311 - Disclosure - Property, Plant and Equipment, Net",
     "shortName": "Property, Plant and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://canfite.com/20251231/role/OtherAccountsPayable",
     "longName": "995312 - Disclosure - Other Accounts Payable",
     "shortName": "Other Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://canfite.com/20251231/role/FairValueMeasurements",
     "longName": "995313 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://canfite.com/20251231/role/Revenues",
     "longName": "995314 - Disclosure - Revenues",
     "shortName": "Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitments",
     "longName": "995315 - Disclosure - Contingent Liabilities and Commitments",
     "shortName": "Contingent Liabilities and Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://canfite.com/20251231/role/ShareholdersEquity",
     "longName": "995316 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://canfite.com/20251231/role/Leases",
     "longName": "995317 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://canfite.com/20251231/role/FinanceIncomeExpenseNet",
     "longName": "995318 - Disclosure - Finance Income (Expense), Net",
     "shortName": "Finance Income (Expense), Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://canfite.com/20251231/role/SegmentReporting",
     "longName": "995319 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://canfite.com/20251231/role/TaxesonIncome",
     "longName": "995320 - Disclosure - Taxes on Income",
     "shortName": "Taxes on Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://canfite.com/20251231/role/SubsequentEvents",
     "longName": "995321 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure",
     "longName": "995322 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies",
     "longName": "996323 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://canfite.com/20251231/role/SignificantAccountingPoliciesTables",
     "longName": "996324 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "canf:ScheduleOfUsefulLivesOfTheAssetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "canf:ScheduleOfUsefulLivesOfTheAssetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "longName": "996325 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetTables",
     "longName": "996326 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://canfite.com/20251231/role/OtherAccountsPayableTables",
     "longName": "996327 - Disclosure - Other Accounts Payable (Tables)",
     "shortName": "Other Accounts Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://canfite.com/20251231/role/FairValueMeasurementsTables",
     "longName": "996328 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://canfite.com/20251231/role/ShareholdersEquityTables",
     "longName": "996329 - Disclosure - Shareholders' Equity (Tables)",
     "shortName": "Shareholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://canfite.com/20251231/role/LeasesTables",
     "longName": "996330 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://canfite.com/20251231/role/FinanceIncomeExpenseNetTables",
     "longName": "996331 - Disclosure - Finance Income (Expense), Net (Tables)",
     "shortName": "Finance Income (Expense), Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://canfite.com/20251231/role/TaxesonIncomeTables",
     "longName": "996332 - Disclosure - Taxes on Income (Tables)",
     "shortName": "Taxes on Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://canfite.com/20251231/role/GeneralDetails",
     "longName": "996333 - Disclosure - General (Details)",
     "shortName": "General (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "cref_1997617154",
      "name": "canf:NumberOfOrdinaryShares",
      "unitRef": "uref_734008993",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1997617154",
      "name": "canf:NumberOfOrdinaryShares",
      "unitRef": "uref_734008993",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails",
     "longName": "996334 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails",
     "longName": "996335 - Disclosure - Significant Accounting Policies - Schedule of Depreciable Rates of Property and Equipment (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Depreciable Rates of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "cref_1654566158",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "uref_1413771939",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1654566158",
      "name": "us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage",
      "unitRef": "uref_1413771939",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails",
     "longName": "996336 - Disclosure - Significant Accounting Policies- Schedule of Major Customer Data as a Percentage (Details)",
     "shortName": "Significant Accounting Policies- Schedule of Major Customer Data as a Percentage (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "cref_1010971887",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "uref_1413771939",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1010971887",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "uref_1413771939",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails",
     "longName": "996337 - Disclosure - Significant Accounting Policies- Schedule of Antidilutive Shares (Details)",
     "shortName": "Significant Accounting Policies- Schedule of Antidilutive Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "uref_734008993",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "uref_734008993",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "longName": "996338 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "cref_1997617154",
      "name": "canf:GovernmentAuthorities",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1997617154",
      "name": "canf:GovernmentAuthorities",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetDetails",
     "longName": "996339 - Disclosure - Property, Plant and Equipment, Net (Details)",
     "shortName": "Property, Plant and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:Depreciation",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:Depreciation",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails",
     "longName": "996340 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details)",
     "shortName": "Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://canfite.com/20251231/role/OtherAccountsPayableScheduleofOtherAccountsPayableDetails",
     "longName": "996341 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)",
     "shortName": "Other Accounts Payable - Schedule of Other Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails",
     "longName": "996342 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1736241007",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://canfite.com/20251231/role/RevenuesDetails",
     "longName": "996343 - Disclosure - Revenues (Details)",
     "shortName": "Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "cref_1598663686",
      "name": "us-gaap:PaymentsForRoyalties",
      "unitRef": "uref_1598663686",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1598663686",
      "name": "us-gaap:PaymentsForRoyalties",
      "unitRef": "uref_1598663686",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails",
     "longName": "996344 - Disclosure - Contingent Liabilities and Commitments (Details)",
     "shortName": "Contingent Liabilities and Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:NoninterestExpenseCommissionExpense",
      "unitRef": "uref_447010128",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:NoninterestExpenseCommissionExpense",
      "unitRef": "uref_447010128",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://canfite.com/20251231/role/ShareholdersEquityDetails",
     "longName": "996345 - Disclosure - Shareholders' Equity (Details)",
     "shortName": "Shareholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails",
     "longName": "996346 - Disclosure - Shareholders' Equity - Schedule of Information Regarding Outstanding Warrants to Purchase Shares (Details)",
     "shortName": "Shareholders' Equity - Schedule of Information Regarding Outstanding Warrants to Purchase Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "cref_202162938",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "uref_734008993",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1731853064",
      "name": "canf:IssuanceDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails",
     "longName": "996347 - Disclosure - Shareholders' Equity - Schedule of Company's Option Activity (Details)",
     "shortName": "Shareholders' Equity - Schedule of Company's Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "uref_734008993",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "uref_1278442780",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails",
     "longName": "996348 - Disclosure - Shareholders' Equity - Schedule of Fair value of Company\u2019s Share Options Granted (Details)",
     "shortName": "Shareholders' Equity - Schedule of Fair value of Company\u2019s Share Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "uref_1413771939",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "uref_1413771939",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails",
     "longName": "996349 - Disclosure - Shareholders' Equity - Schedule of Expenses Recognized Financial Statements (Details)",
     "shortName": "Shareholders' Equity - Schedule of Expenses Recognized Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://canfite.com/20251231/role/LeasesDetails",
     "longName": "996350 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "cref_1894462461",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1894462461",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://canfite.com/20251231/role/LeasesScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateDetails",
     "longName": "996351 - Disclosure - Leases-Schedule of Weighted Average Remaining Lease Terms and Discount Rate (Details)",
     "shortName": "Leases-Schedule of Weighted Average Remaining Lease Terms and Discount Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails",
     "longName": "996352 - Disclosure - Leases-Schedule of Maturities of Lease Liabilities (Details)",
     "shortName": "Leases-Schedule of Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://canfite.com/20251231/role/FinanceIncomeExpenseNetScheduleofFinanceIncomeExpenseNetDetails",
     "longName": "996353 - Disclosure - Finance Income (Expense), Net-Schedule of Finance Income (Expense), Net (Details)",
     "shortName": "Finance Income (Expense), Net-Schedule of Finance Income (Expense), Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:InterestExpenseNonoperating",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:InterestExpenseNonoperating",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://canfite.com/20251231/role/SegmentReportingDetails",
     "longName": "996354 - Disclosure - Segment Reporting (Details)",
     "shortName": "Segment Reporting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://canfite.com/20251231/role/TaxesonIncomeDetails",
     "longName": "996355 - Disclosure - Taxes on Income (Details)",
     "shortName": "Taxes on Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
      "unitRef": "uref_1413771939",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
      "unitRef": "uref_1413771939",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://canfite.com/20251231/role/TaxesonIncomeScheduleofScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "996356 - Disclosure - Taxes on Income- Schedule of Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Taxes on Income- Schedule of Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_1997617154",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails",
     "longName": "996357 - Disclosure - Taxes on Income - Schedule of Reconciliation Statutory Israeli Income Tax Rate  (Details)",
     "shortName": "Taxes on Income - Schedule of Reconciliation Statutory Israeli Income Tax Rate  (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_898003050",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://canfite.com/20251231/role/SubsequentEventsDetails",
     "longName": "996358 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "cref_184434641",
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "unitRef": "uref_720247910",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "cref_100549505",
      "name": "canf:ClassOfWarrantOrRightPercentage",
      "unitRef": "uref_1413771939",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0282586-20f_canfite.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "canf_ADSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ADSMember",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADS [Member]",
        "label": "ADSMember",
        "documentation": "American Depository Receipt (or American Depository Share, ADS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/OtherAccountsPayableScheduleofOtherAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current, Total",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Accounts Payable [Abstract]",
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/OtherAccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS PAYABLE",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r31",
      "r34",
      "r984"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/OtherAccountsPayableScheduleofOtherAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accounts payable",
        "label": "Accounts Payable and Other Accrued Liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accounts payable",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r29"
     ]
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrual",
        "label": "Accrual for Taxes Other than Income Taxes",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r984",
      "r1017"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r104",
      "r512"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r44",
      "r109",
      "r508",
      "r533",
      "r534",
      "r994"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r16",
      "r389",
      "r392",
      "r452",
      "r529",
      "r530",
      "r866",
      "r867",
      "r868",
      "r924",
      "r925",
      "r926",
      "r927"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional \u202fpaid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r924",
      "r925",
      "r926",
      "r927",
      "r995",
      "r1051"
     ]
    },
    "canf_AdditionalRevenueReceivedForAchievedMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "AdditionalRevenueReceivedForAchievedMilestone",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional achieved milestone",
        "label": "Additional Revenue Received for Achieved Milestone",
        "documentation": "Amount of additional revenue received for achieved milestone."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r954"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r776",
      "r786",
      "r819"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r768",
      "r779",
      "r789",
      "r822"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r780",
      "r790",
      "r814",
      "r823",
      "r827",
      "r835"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based expenses",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r329",
      "r338"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "canf_AmericanDepositarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "AmericanDepositarySharesMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American Depositary Shares (ADSs) [Member]",
        "label": "American Depositary Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total anti-dilutive shares",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Shares [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "canf_April2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "April2025Member",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2025 [Member]",
        "label": "April2025 Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r83",
      "r105",
      "r129",
      "r130",
      "r131",
      "r162",
      "r176",
      "r192",
      "r195",
      "r205",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r379",
      "r381",
      "r424",
      "r499",
      "r500",
      "r505",
      "r582",
      "r673",
      "r674",
      "r684",
      "r718",
      "r734",
      "r735",
      "r746",
      "r949",
      "r950",
      "r1007"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r110",
      "r129",
      "r130",
      "r131",
      "r205",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r379",
      "r381",
      "r424",
      "r718",
      "r949",
      "r950",
      "r1007"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r205",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r379",
      "r381",
      "r424",
      "r949",
      "r950",
      "r1007"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT ASSETS:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://canfite.com/20251231/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r772"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://canfite.com/20251231/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r772"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://canfite.com/20251231/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r772"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "canf_August2024AgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "August2024AgentMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August 2024 agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_August2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "August2024Member",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2024 [Member]",
        "label": "August2024 Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "canf_BankCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "BankCommissions",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/FinanceIncomeExpenseNetScheduleofFinanceIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank commissions",
        "documentation": "Amount of bank commissions."
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r772"
     ]
    },
    "canf_CMSMedicalVentureInvestmentLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "CMSMedicalVentureInvestmentLimitedMember",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CMS Medical Venture Investment Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r102",
      "r654"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at the beginning of the year",
        "periodEndLabel": "Cash and cash equivalents at the end of the year",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r55",
      "r126"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r55"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r1018"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_CashPlacementFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "CashPlacementFee",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash placement fee",
        "label": "Cash Placement Fee",
        "documentation": "Represent the amount of cash placement fee."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "canf_ChangesInFairValueOfShortTermInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ChangesInFairValueOfShortTermInvestment",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value of short-term investment",
        "label": "Changes In Fair Value Of Short Term Investment",
        "documentation": "Represent the amount of changes in fair value of short term investment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "canf_ChongKunDangPharmaceuticalsCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ChongKunDangPharmaceuticalsCorpMember",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Chong Kun Dang Pharmaceuticals Corp. (South Korea) [Member]",
        "terseLabel": "Chong Kun Dang Pharmaceuticals Corp. [Member]",
        "label": "Chong Kun Dang Pharmaceuticals Corp [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_CipherPharmaceuticalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "CipherPharmaceuticalsMember",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cipher Pharmaceuticals (Canada) [Member]",
        "label": "Cipher Pharmaceuticals [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r164",
      "r233",
      "r239",
      "r240",
      "r241",
      "r243",
      "r246",
      "r251",
      "r253",
      "r387",
      "r543",
      "r544",
      "r545",
      "r546",
      "r685",
      "r855",
      "r917",
      "r919"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails",
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails",
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails",
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per warrant (in Dollars per share)",
        "verboseLabel": "Warrants exercise price (in Dollars per share)",
        "netLabel": "Exercise price per share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r133",
      "r254"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Outstanding Warrants to Purchase Shares [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants represented",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchased ordinary shares",
        "netLabel": "Warrant purchase",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants outstanding",
        "terseLabel": "Number of outstanding Warrants",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "canf_ClassOfWarrantOrRightPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ClassOfWarrantOrRightPercentage",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate warrants percentage",
        "label": "Class Of Warrant Or Right Percentage",
        "documentation": "Class of Warrant or Right, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r73",
      "r506",
      "r569"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r212",
      "r213",
      "r636",
      "r944",
      "r946"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "netLabel": "Ordinary Shares [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r737",
      "r738",
      "r739",
      "r741",
      "r742",
      "r743",
      "r744",
      "r924",
      "r925",
      "r927",
      "r995",
      "r1049",
      "r1051"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheetsParentheticals",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "verboseLabel": "Price per share (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheetsParentheticals",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r570"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r38",
      "r570",
      "r588",
      "r1051",
      "r1053"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares of no par value - Authorized: 14,000,000 and 3,333,334 shares at December 31, 2025 and 2024, respectively; Issued and outstanding: 2,618,425 and 994,394 shares as of December 31, 2025 and 2024, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r231",
      "r236",
      "r507",
      "r718"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary share, voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "canf_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Computers, office furniture and equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r203",
      "r537",
      "r538",
      "r635",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r203",
      "r537",
      "r538",
      "r635",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r203",
      "r537",
      "r538",
      "r635",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Major Customer Data as a Percentage [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r635",
      "r664",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r203",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r203",
      "r537",
      "r538",
      "r635",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r662"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "canf_ContingentLiabilitiesandCommitmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ContingentLiabilitiesandCommitmentsDetailsTable",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r259",
      "r278"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenues",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r259",
      "r278"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenues",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r259",
      "r278"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized revenues",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r930"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r844"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r845"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r847"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r845"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r841"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r842"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r842"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r840"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r840"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r843"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r843"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/CybersecurityRiskManagementandStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r846"
     ]
    },
    "canf_December2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "December2021Member",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2021 [Member]",
        "label": "December2021 Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Abstract]",
        "terseLabel": "Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, gross total",
        "label": "Deferred Tax Assets, Gross, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary differences mainly relating to Research and Development",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carry forward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term deposits",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expenses",
        "label": "Depreciation, Total",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r23",
      "r122",
      "r655",
      "r656",
      "r658",
      "r660"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation of property, plant and equipment",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r123",
      "r162",
      "r180",
      "r195",
      "r655",
      "r673",
      "r674"
     ]
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "canf_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "DocumentAndEntityInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": ""
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r772"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r772",
      "r815"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r118",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r152",
      "r154",
      "r156",
      "r157",
      "r158",
      "r161",
      "r229",
      "r328",
      "r374",
      "r377",
      "r400",
      "r401",
      "r498",
      "r517",
      "r663"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r118",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r154",
      "r156",
      "r157",
      "r158",
      "r161",
      "r229",
      "r328",
      "r374",
      "r377",
      "r400",
      "r401",
      "r498",
      "r517",
      "r663"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and diluted net loss per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r160"
     ]
    },
    "canf_EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of benefitted income preferred technological enterprise in Israel, Amount",
        "label": "Effect of Benefitted Income Preferred Technological Enterprise in Israel, Amount",
        "documentation": "The amount of income tax expense or benefit benefitted income preferred technological enterprise in Israel, amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences on balances of cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeDetails",
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate tax rate, percentage",
        "totalLabel": "Effective Tax Rate, Percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent, Total",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r701"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation Statutory Israeli Income Tax Rate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax at Israeli Statutory Rate, Percentage",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r132",
      "r346",
      "r366",
      "r701"
     ]
    },
    "canf_EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael": {
     "xbrltype": "percentItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael",
     "calculation": {
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of benefitted income preferred technological enterprise in Israel, Percentage",
        "label": "Effective Income Tax Rate Reconciliation Benefitted Income Preferred Technological Enterprise in Israel",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) benefitted income preferred technological enterprise in Israel."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Valuation Allowances, Percentage",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r701",
      "r917",
      "r922",
      "r985"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347",
      "r701"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development area, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense."
       }
      }
     },
     "auth_ref": [
      "r917",
      "r922",
      "r985",
      "r987"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment awards, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r985",
      "r986"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment awards, Percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r983",
      "r985",
      "r986"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347",
      "r701"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation for services",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/OtherAccountsPayableScheduleofOtherAccountsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and payroll accruals",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Arrangement Expensed [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation costs not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers, Office Furniture and Equipment [Member]",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r91",
      "r92",
      "r93",
      "r114",
      "r115",
      "r116",
      "r135",
      "r136",
      "r137",
      "r139",
      "r146",
      "r148",
      "r150",
      "r163",
      "r206",
      "r207",
      "r208",
      "r228",
      "r255",
      "r328",
      "r364",
      "r365",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r439",
      "r452",
      "r516",
      "r529",
      "r530",
      "r531",
      "r549",
      "r607"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r765",
      "r776",
      "r786",
      "r819"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r773",
      "r783",
      "r816"
     ]
    },
    "canf_EwopharmaAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "EwopharmaAGMember",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ewopharma AG (Switzerland) [Member]",
        "label": "Ewopharma AG [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_EwopharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "EwopharmaMember",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ewopharma [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_ExchangeRateFluctuationsAndOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ExchangeRateFluctuationsAndOthers",
     "presentation": [
      "http://canfite.com/20251231/role/FinanceIncomeExpenseNetScheduleofFinanceIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange rate fluctuations and others",
        "documentation": "Amount of exchange rate fluctuations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "canf_ExistingWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ExistingWarrantsMember",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r414",
      "r709"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r413",
      "r414",
      "r416",
      "r421",
      "r456",
      "r457",
      "r458",
      "r651",
      "r682",
      "r683",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r709",
      "r712",
      "r716"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r407",
      "r709",
      "r999",
      "r1001"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r409",
      "r411",
      "r412",
      "r413",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r497",
      "r709",
      "r713"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r282",
      "r287",
      "r288",
      "r404",
      "r414",
      "r421",
      "r456",
      "r651",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r709",
      "r716"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r282",
      "r287",
      "r288",
      "r290",
      "r404",
      "r405",
      "r414",
      "r421",
      "r457",
      "r651",
      "r682",
      "r683",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r709",
      "r716"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r404",
      "r405",
      "r406",
      "r407",
      "r414",
      "r421",
      "r458",
      "r651",
      "r682",
      "r683",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r709",
      "r712",
      "r716"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r407",
      "r709",
      "r999",
      "r1001"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r413",
      "r414",
      "r416",
      "r421",
      "r456",
      "r457",
      "r458",
      "r651",
      "r682",
      "r683",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r709",
      "r712",
      "r716"
     ]
    },
    "us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsNonrecurringValueMeasurementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001"
     ]
    },
    "canf_FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetailsTable",
     "presentation": [
      "http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair value Recurring Basis (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedPatentsGross",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived patents, gross",
        "label": "Finite-Lived Patents, Gross",
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r943"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory Israeli Income Tax Rate [Member]",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional currency, reporting currency and foreign currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r780",
      "r790",
      "r823"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r780",
      "r790",
      "r823"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r780",
      "r790",
      "r823"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r780",
      "r790",
      "r823"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r780",
      "r790",
      "r823"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "canf_GebroHoldingGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "GebroHoldingGmbHMember",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gebro Holding GmbH (Austria) [Member]",
        "label": "Gebro Holding GmbH [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r591"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "canf_GovernmentAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "GovernmentAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government authorities",
        "label": "Government Authorities",
        "documentation": "The amount of government authorities."
       }
      }
     },
     "auth_ref": []
    },
    "canf_GrantedExcessYears": {
     "xbrltype": "durationItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "GrantedExcessYears",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted excess years",
        "label": "Granted Excess Years",
        "documentation": "Granted excess years."
       }
      }
     },
     "auth_ref": []
    },
    "canf_GrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "GrossProceeds",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "label": "Gross Proceeds",
        "documentation": "Amount of gross proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r772"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r22",
      "r61",
      "r121",
      "r656",
      "r710"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r62"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 7.0
      },
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss",
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before taxes on income, Amount",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r78",
      "r82",
      "r499",
      "r501",
      "r514",
      "r657",
      "r659",
      "r661",
      "r666",
      "r673",
      "r928",
      "r936",
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r383",
      "r384",
      "r385",
      "r386",
      "r408",
      "r410",
      "r415",
      "r425",
      "r426",
      "r427",
      "r526",
      "r528",
      "r592",
      "r648",
      "r651",
      "r702",
      "r703",
      "r707",
      "r708",
      "r711",
      "r716",
      "r992",
      "r993",
      "r1020"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r383",
      "r384",
      "r385",
      "r386",
      "r408",
      "r410",
      "r415",
      "r425",
      "r426",
      "r427",
      "r526",
      "r528",
      "r592",
      "r648",
      "r651",
      "r702",
      "r703",
      "r707",
      "r708",
      "r711",
      "r716",
      "r992",
      "r993",
      "r1020"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r346",
      "r347",
      "r353",
      "r361",
      "r701",
      "r990"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r346",
      "r347",
      "r353",
      "r361",
      "r701",
      "r990"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r990"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r990"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXES ON INCOME",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r132",
      "r342",
      "r346",
      "r350",
      "r351",
      "r352",
      "r355",
      "r360",
      "r367",
      "r368",
      "r369",
      "r370",
      "r504",
      "r536",
      "r548",
      "r701"
     ]
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on Income [Line Items]",
        "label": "Income Tax Examination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes on income",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r344",
      "r345",
      "r355",
      "r356",
      "r359",
      "r363",
      "r542"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Valuation Allowances, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r701",
      "r985"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeScheduleofReconciliationStatutoryIsraeliIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax at Israeli Statutory Rate, Amount",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r701"
     ]
    },
    "us-gaap_IncomeTaxesPaidNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_IncreaseAuthorizedShareCapital": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "IncreaseAuthorizedShareCapital",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase authorized share capital",
        "label": "Increase Authorized Share Capital",
        "documentation": "Increase authorized share capital."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in trade payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in deferred revenues",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r860",
      "r914"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in other accounts payable",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in prepaid expenses, and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r780",
      "r790",
      "r814",
      "r823",
      "r827",
      "r835"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r839"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r839"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r839"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/FinanceIncomeExpenseNetScheduleofFinanceIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Nonoperating, Total",
        "label": "Interest Expense, Nonoperating, Total",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r657",
      "r661",
      "r870"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial income, net",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r53"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r554",
      "r555",
      "r557",
      "r559",
      "r612",
      "r614",
      "r616",
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r739"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r554",
      "r555",
      "r557",
      "r559",
      "r612",
      "r614",
      "r616",
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r739"
     ]
    },
    "canf_InvestorsFromJuly2025OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "InvestorsFromJuly2025OfferingMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investors from July 2025 Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IsraelTaxAuthorityMember",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israel [Member]",
        "label": "Israel Tax Authority [Member]",
        "documentation": "Designated tax department of the government of Israel."
       }
      }
     },
     "auth_ref": []
    },
    "canf_IssuanceDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "IssuanceDate",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance date",
        "label": "Issuance Date",
        "documentation": "Represent the date of issuance."
       }
      }
     },
     "auth_ref": []
    },
    "canf_IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds of ordinary shares",
        "terseLabel": "Issuance of ordinary shares due to ATM, net of issuance costs",
        "label": "Issuance Of Ordinary Shares Due To ATMNet Of Issuance Costs",
        "documentation": "Issuance of ordinary shares due to ATM, net of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "canf_January2023AgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "January2023AgentMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2023 agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_July2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "July2025Member",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_July2025OneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "July2025OneMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 2025 One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_KR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "KR",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "South Korea [Member]",
        "label": "KOREA, REPUBLIC OF"
       }
      }
     },
     "auth_ref": []
    },
    "canf_KyongboPharmCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "KyongboPharmCoLtdMember",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Kyongbo Pharm Co Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory Equipment [Member]",
        "verboseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "LeaseLiabilitiesArisingFromObtainingRightofuseassets",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities arising from obtaining right-of-use-assets",
        "label": "Lease Liabilities Arising from Obtaining Right-Of-Use-Assets",
        "documentation": "Represent the amount of lease liabilities arising from obtaining right-of-use-assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesOperatingAbstract",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of lease expense:",
        "label": "Leases, Operating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_LegalAndOtherContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "LegalAndOtherContingenciesPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal and other contingencies",
        "label": "Legal And Other Contingencies [Policy Text Block]",
        "documentation": "Disclosure of legal and other contingencies policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r451"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r918",
      "r923",
      "r1016"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r918",
      "r923",
      "r1016"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r918",
      "r923",
      "r1016"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 237.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease terms",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r74",
      "r510",
      "r718",
      "r734",
      "r735",
      "r917",
      "r921",
      "r941",
      "r1002"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r101",
      "r129",
      "r130",
      "r131",
      "r205",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r380",
      "r381",
      "r382",
      "r424",
      "r718",
      "r949",
      "r1007",
      "r1008"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r33",
      "r34",
      "r35",
      "r36",
      "r129",
      "r130",
      "r131",
      "r205",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r380",
      "r381",
      "r382",
      "r424",
      "r949",
      "r1007",
      "r1008"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CURRENT LIABILITIES:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_LiverCancerIndicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "LiverCancerIndicationMember",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liver Cancer Indication [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r686",
      "r689",
      "r728",
      "r732",
      "r1019",
      "r1021",
      "r1022",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://canfite.com/20251231/role/RevenuesDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r214",
      "r215",
      "r216",
      "r217",
      "r291",
      "r321",
      "r322",
      "r323",
      "r339",
      "r407",
      "r461",
      "r525",
      "r527",
      "r535",
      "r560",
      "r561",
      "r613",
      "r615",
      "r617",
      "r618",
      "r622",
      "r630",
      "r631",
      "r633",
      "r634",
      "r646",
      "r647",
      "r681",
      "r685",
      "r699",
      "r702",
      "r704",
      "r705",
      "r712",
      "r713",
      "r714",
      "r715",
      "r729",
      "r951",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "canf_MilestonePaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "MilestonePaymentPercentage",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment percentage",
        "label": "Milestone Payment Percentage",
        "documentation": "Milestone payment percentage."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://canfite.com/20251231/role/RevenuesDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r214",
      "r215",
      "r216",
      "r217",
      "r291",
      "r321",
      "r322",
      "r323",
      "r339",
      "r407",
      "r461",
      "r525",
      "r527",
      "r535",
      "r560",
      "r561",
      "r613",
      "r615",
      "r617",
      "r618",
      "r622",
      "r630",
      "r631",
      "r633",
      "r634",
      "r646",
      "r647",
      "r681",
      "r685",
      "r699",
      "r702",
      "r704",
      "r705",
      "r712",
      "r713",
      "r714",
      "r729",
      "r951",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "canf_NASHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "NASHMember",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NASH [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r686",
      "r689",
      "r728",
      "r732",
      "r1019",
      "r1021",
      "r1022",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows",
      "http://canfite.com/20251231/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net operating cash outflow",
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows",
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity",
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss",
      "http://canfite.com/20251231/role/GeneralDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "negatedLabel": "Net losses",
        "totalLabel": "Net loss",
        "netLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r57",
      "r79",
      "r93",
      "r99",
      "r111",
      "r112",
      "r116",
      "r129",
      "r130",
      "r131",
      "r134",
      "r138",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r155",
      "r205",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r229",
      "r232",
      "r234",
      "r237",
      "r328",
      "r374",
      "r377",
      "r401",
      "r424",
      "r515",
      "r589",
      "r605",
      "r606",
      "r657",
      "r659",
      "r661",
      "r745",
      "r949"
     ]
    },
    "canf_NetOfIssuanceCostsOfOrdinarySharesAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "NetOfIssuanceCostsOfOrdinarySharesAndWarrants",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquityParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of issuance costs of ordinary shares and warrants",
        "label": "Net of Issuance Costs of Ordinary Shares and Warrants",
        "documentation": "Represent the amount of net of issuance costs of ordinary shares and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "canf_NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquityParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of issuance costs ordinary shares and warrants and exercise of pre-funded warrants",
        "label": "Net of Issuance Costs Ordinary Shares and Warrants and Exercise of Pre-Funded Warrants",
        "documentation": "Represent the amount of net of issuance costs ordinary shares and warrants and exercise of pre-funded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "canf_NetOfIssuanceCostsOrdinarySharesDueToATM": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "NetOfIssuanceCostsOrdinarySharesDueToATM",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquityParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of issuance costs ordinary shares due to ATM",
        "label": "Net of Issuance Costs Ordinary Shares Due To ATM",
        "documentation": "Represent the amount of net of issuance costs ordinary shares due to ATM."
       }
      }
     },
     "auth_ref": []
    },
    "canf_NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquityParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of issuance expenses of ordinary shares due to exercise of warrants",
        "label": "Net of Issuance Expenses of Ordinary Shares Due to Exercise of Warrants",
        "documentation": "Represent the amount of net of issuance expenses of ordinary shares due to exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recently adopted accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "canf_NewWarrantSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "NewWarrantSharesMember",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Warrant Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_NewWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "NewWarrantsMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r780",
      "r790",
      "r814",
      "r823"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "canf_NonRefundablePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "NonRefundablePayment",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable payment",
        "label": "Non-Refundable Payment",
        "documentation": "The amount of non-refundable payment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_NoninterestExpenseCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoninterestExpenseCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commission income expense",
        "label": "Noninterest Expense Commission Expense",
        "documentation": "Amount of fees incurred for commissions on mutual funds and insurance products."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/FinanceIncomeExpenseNetScheduleofFinanceIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial income (expenses), net",
        "label": "Nonoperating Income (Expense), Total",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finance Income (Expense), Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_November2023AgentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "November2023AgentMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "November 2023 agent [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_November2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "November2023Member",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2023 [Member]",
        "label": "November2023 Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://canfite.com/20251231/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r674",
      "r935"
     ]
    },
    "canf_NumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "NumberOfOrdinaryShares",
     "presentation": [
      "http://canfite.com/20251231/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ordinary shares in each ADS (in Shares)",
        "label": "Number Of Ordinary Shares",
        "documentation": "The number of ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total operating expenses",
        "label": "Operating Expenses, Total",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r657",
      "r661",
      "r666",
      "r928",
      "r936",
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r717"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities of Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 238.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current maturity of operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r446"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right of use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in the carrying amount of operating lease right of use asset",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r717"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "weighted average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r717"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carryforward losses",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r94",
      "r95",
      "r97",
      "r539",
      "r540"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-accountable expenses",
        "label": "Other Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r734",
      "r735"
     ]
    },
    "canf_OtherGainFromShortTermInvestmentRemeasurement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "OtherGainFromShortTermInvestmentRemeasurement",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/FinanceIncomeExpenseNetScheduleofFinanceIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term investment revaluation",
        "documentation": "Amount of other gain from short-term investment remeasurement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Income (Expense), Net [Abstract]",
        "label": "Finance Income (Expense), Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financial expenses (income), net",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/FinanceIncomeExpenseNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Income (Expense), Net",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and others",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r942"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r767",
      "r778",
      "r788",
      "r821"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r781",
      "r791",
      "r824"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r781",
      "r791",
      "r824"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Maturity of short-term deposits, net",
        "label": "Payments for (Proceeds from) Short-Term Investments",
        "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r916"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional payment",
        "label": "Payments for Royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate issuance costs (in Dollars)",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "canf_PercentageOfDepositsOnMonthlySalary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "PercentageOfDepositsOnMonthlySalary",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of deposits on monthly salary",
        "label": "Percentage Of Deposits On Monthly Salary",
        "documentation": "Percentage of deposits on monthly salary."
       }
      }
     },
     "auth_ref": []
    },
    "canf_PercentageOfNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "PercentageOfNetSales",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of net sales",
        "label": "Percentage Of Net Sales",
        "documentation": "The percentage of net sales."
       }
      }
     },
     "auth_ref": []
    },
    "canf_PercentageOfRealizationOnUltimateSettlement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "PercentageOfRealizationOnUltimateSettlement",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of realization on ultimate settlement",
        "label": "Percentage Of Realization On Ultimate Settlement",
        "documentation": "Percentage of realization on ultimate settlement."
       }
      }
     },
     "auth_ref": []
    },
    "canf_PercentageOfRoyaltiesOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "PercentageOfRoyaltiesOnNetSales",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalties on net sales",
        "label": "Percentage of Royalties on Net Sales",
        "documentation": "Represent the percentage of royalties on net sales."
       }
      }
     },
     "auth_ref": []
    },
    "canf_PhaseIIIStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "PhaseIIIStudiesMember",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase III Studies [Member]",
        "label": "Phase IIIStudies Member"
       }
      }
     },
     "auth_ref": []
    },
    "canf_PhaseIIStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "PhaseIIStudiesMember",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase II Studies [Member]",
        "label": "Phase IIStudies Member"
       }
      }
     },
     "auth_ref": []
    },
    "canf_PhaseIStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "PhaseIStudiesMember",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase I Studies [Member]",
        "label": "Phase IStudies Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "canf_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets",
      "http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses, and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses, and other current assets",
        "label": "Prepaid Expenses And Other Current Assets [Policy Text Block]",
        "documentation": "The accounting policy for prepaid expenses, and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds IPO",
        "terseLabel": "Issuance of ordinary shares due to ATM, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows",
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds",
        "terseLabel": "Issuance of ordinary shares and warrants, net of issuance costs",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of issuance cost",
        "label": "Proceeds from Issuance or Sale of Equity, Total",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r543"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r462",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r652",
      "r656",
      "r659",
      "r661",
      "r686",
      "r687",
      "r727",
      "r729",
      "r730",
      "r733",
      "r736",
      "r859",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r947",
      "r948",
      "r1019",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r462",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r652",
      "r656",
      "r659",
      "r661",
      "r686",
      "r687",
      "r727",
      "r729",
      "r730",
      "r733",
      "r736",
      "r859",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r947",
      "r948",
      "r1019",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesDetails",
      "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r450"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/PropertyPlantandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r86",
      "r88",
      "r89"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Property, Plant and Equipment, Gross, Total",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r103",
      "r513"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Property, Plant and Equipment, Net [Line Items]",
        "terseLabel": "Schedule of Depreciable Rates of Property and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets",
      "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net, Total",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r450",
      "r503",
      "r513",
      "r718"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r86",
      "r88",
      "r511"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual rates of depreciation",
        "label": "Property, Plant and Equipment, Salvage Value, Percentage",
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesDetails",
      "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r450"
     ]
    },
    "canf_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Agreement [Member]",
        "label": "Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://canfite.com/20251231/role/RevenuesDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r214",
      "r215",
      "r216",
      "r217",
      "r281",
      "r291",
      "r321",
      "r322",
      "r323",
      "r327",
      "r339",
      "r407",
      "r459",
      "r460",
      "r461",
      "r525",
      "r527",
      "r535",
      "r560",
      "r561",
      "r613",
      "r615",
      "r617",
      "r618",
      "r622",
      "r630",
      "r631",
      "r633",
      "r634",
      "r646",
      "r647",
      "r681",
      "r685",
      "r699",
      "r702",
      "r704",
      "r705",
      "r712",
      "r713",
      "r714",
      "r715",
      "r729",
      "r739",
      "r945",
      "r951",
      "r999",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://canfite.com/20251231/role/RevenuesDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r170",
      "r214",
      "r215",
      "r216",
      "r217",
      "r281",
      "r291",
      "r321",
      "r322",
      "r323",
      "r327",
      "r339",
      "r407",
      "r459",
      "r460",
      "r461",
      "r525",
      "r527",
      "r535",
      "r560",
      "r561",
      "r613",
      "r615",
      "r617",
      "r618",
      "r622",
      "r630",
      "r631",
      "r633",
      "r634",
      "r646",
      "r647",
      "r681",
      "r685",
      "r699",
      "r702",
      "r704",
      "r705",
      "r712",
      "r713",
      "r714",
      "r715",
      "r729",
      "r739",
      "r945",
      "r951",
      "r999",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014"
     ]
    },
    "canf_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently issued accounting pronouncements not yet adopted",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]",
        "documentation": "Disclosure of recently issued accounting pronouncements not yet adopted Policy."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r773",
      "r783",
      "r816"
     ]
    },
    "canf_RegulatoryAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "RegulatoryAuthorityMember",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory Authority [Member]",
        "label": "Regulatory Authority Member"
       }
      }
     },
     "auth_ref": []
    },
    "canf_RegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "RegulatoryMilestonesMember",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r648",
      "r657",
      "r658",
      "r673",
      "r1015"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenditures",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r774",
      "r784",
      "r817"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r775",
      "r785",
      "r818"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r782",
      "r792",
      "r825"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r65",
      "r509",
      "r532",
      "r534",
      "r547",
      "r571",
      "r718"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r135",
      "r136",
      "r137",
      "r139",
      "r146",
      "r148",
      "r150",
      "r206",
      "r207",
      "r208",
      "r228",
      "r328",
      "r364",
      "r365",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r388",
      "r390",
      "r391",
      "r393",
      "r399",
      "r437",
      "r439",
      "r529",
      "r531",
      "r549",
      "r1051"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Terms of agreement",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r162",
      "r177",
      "r178",
      "r191",
      "r195",
      "r199",
      "r201",
      "r203",
      "r275",
      "r276",
      "r277",
      "r462"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r650"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/Revenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUES",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r277",
      "r280"
     ]
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of additional payments",
        "label": "Revenue, Performance Obligation, Description of Payment Terms",
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues recognized",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales percentage",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r117",
      "r129",
      "r130",
      "r131",
      "r162",
      "r177",
      "r178",
      "r191",
      "r195",
      "r199",
      "r201",
      "r203",
      "r205",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r424",
      "r499",
      "r501",
      "r673",
      "r706",
      "r734",
      "r735",
      "r949"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Royalties",
        "label": "Royalty Expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "canf_RoyaltyPaymentsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "RoyaltyPaymentsPercentage",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payments, percentage",
        "label": "Royalty Payments Percentage",
        "documentation": "The royalty payment in percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds amount",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock shares issued",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock price per share",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "canf_SalesMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "SalesMilestonesMember",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r930",
      "r931"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r151",
      "r292",
      "r856"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/OtherAccountsPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Payable",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Antidilutive Shares",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation Statutory Israeli Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r701",
      "r985"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofExpensesRecognizedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expenses Recognized Financial Statements",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "canf_ScheduleOfExpensesRecognizedFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ScheduleOfExpensesRecognizedFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Expenses Recognized Financial Statements Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r997"
     ]
    },
    "canf_ScheduleOfFairValueOfCompanySShareOptionsGrantedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ScheduleOfFairValueOfCompanySShareOptionsGrantedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of Company SShare Options Granted Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueRecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Assets And Liabilities Measured At Fair Value Recurring Basis Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Information Regarding Outstanding Warrants To Purchase Shares Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/FinanceIncomeExpenseNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finance Income (Expense), Net",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesDetails",
      "http://canfite.com/20251231/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentNetDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofDepreciableRatesofPropertyandEquipmentDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r450"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company's Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r67"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair value of Company\u2019s Share Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information Regarding Outstanding Warrants to Purchase Shares",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "canf_ScheduleOfUsefulLivesOfTheAssetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ScheduleOfUsefulLivesOfTheAssetTableTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciable Rates of Property and Equipment",
        "label": "Schedule of Useful Lives of The Asset [Table Text Block]",
        "documentation": "The tabular disclosure for property plant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Major Customer Data as a Percentage",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r934"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r201",
      "r202",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r500",
      "r501",
      "r502",
      "r553",
      "r556",
      "r558",
      "r614",
      "r616",
      "r620",
      "r623",
      "r630",
      "r632",
      "r633",
      "r634",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r653",
      "r664",
      "r686",
      "r688",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r731",
      "r739",
      "r1019",
      "r1021",
      "r1022",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://canfite.com/20251231/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief executive officer",
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r672",
      "r680"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://canfite.com/20251231/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of CODM",
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r669",
      "r677"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT REPORTING",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r162",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r181",
      "r182",
      "r183",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r203",
      "r667",
      "r670",
      "r671",
      "r673",
      "r675",
      "r678",
      "r679"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r198",
      "r201",
      "r668",
      "r669",
      "r676"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance pay expense",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "canf_SeverancePayPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "SeverancePayPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance pay",
        "label": "Severance Pay [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for severance pay."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual terms",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "canf_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice": {
     "xbrltype": "pureItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early Exercise Multiple (Suboptimal Factor)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Exercisable (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r961"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares granted",
        "terseLabel": "Number of options, Grants (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate intrinsic value, Ending (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of options, Ending (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Exercise Prices Share Options [Abstract]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average exercise price, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Vested and expected to vest (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://canfite.com/20251231/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, Grants",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment transactions",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r299",
      "r318",
      "r319",
      "r320",
      "r321",
      "r324",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, Exercisable (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual terms, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual terms",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants": {
     "xbrltype": "durationItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual terms, Grants",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Terms Grants",
        "documentation": "Weighted average remaining contractual term for vested portions of options Grants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual terms, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "canf_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired": {
     "xbrltype": "durationItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofCompanysOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual terms, expired",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Terms Forfeitedexpired",
        "documentation": "Share based compensation arrangement by share based payment award, options, nonvested options forfeited, weighted average grant date fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "canf_ShareholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ShareholdersEquityDetailsTable",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetailsTable",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofFairvalueofCompanysShareOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity - Schedule of Fair value of Company\u2019s Share Options Granted (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price, per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "canf_ShortTermBankDepositsYearlyInterestRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ShortTermBankDepositsYearlyInterestRatePercentage",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average rate",
        "label": "Short Term Bank Deposits Yearly Interest Rate Percentage",
        "documentation": "Short term bank deposits, annual interest rate percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets",
      "http://canfite.com/20251231/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairvalueRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investment",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r864"
     ]
    },
    "canf_ShorttermBankDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "ShorttermBankDepositsPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term bank deposits",
        "label": "Short-term Bank Deposits [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128"
     ]
    },
    "canf_SpecialGeneralMeetingOfShareholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "SpecialGeneralMeetingOfShareholdersMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Special General Meeting of Shareholders [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r38",
      "r41",
      "r42",
      "r91",
      "r92",
      "r93",
      "r114",
      "r115",
      "r116",
      "r135",
      "r136",
      "r137",
      "r139",
      "r146",
      "r148",
      "r150",
      "r163",
      "r206",
      "r207",
      "r208",
      "r228",
      "r255",
      "r328",
      "r364",
      "r365",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r439",
      "r452",
      "r516",
      "r529",
      "r530",
      "r531",
      "r549",
      "r607"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r201",
      "r202",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r500",
      "r501",
      "r502",
      "r553",
      "r556",
      "r558",
      "r614",
      "r616",
      "r620",
      "r623",
      "r630",
      "r632",
      "r633",
      "r634",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r653",
      "r664",
      "r686",
      "r688",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r731",
      "r739",
      "r1019",
      "r1021",
      "r1022",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r163",
      "r230",
      "r231",
      "r233",
      "r235",
      "r439",
      "r462",
      "r541",
      "r550",
      "r551",
      "r562",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r607",
      "r659",
      "r661",
      "r740",
      "r1050"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r151",
      "r292",
      "r856",
      "r857"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity",
      "http://canfite.com/20251231/role/SegmentReportingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r163",
      "r204",
      "r230",
      "r231",
      "r233",
      "r235",
      "r439",
      "r462",
      "r541",
      "r550",
      "r551",
      "r562",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r590",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r607",
      "r659",
      "r661",
      "r740",
      "r1050"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r766",
      "r777",
      "r787",
      "r820"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "canf_StockIssuedDuringPeriodExerciseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "StockIssuedDuringPeriodExerciseValue",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares and warrants and exercise of pre-funded warrants, net of issuance costs",
        "label": "Stock Issued During period Exercise Value",
        "documentation": "The amount of shares issued for options."
       }
      }
     },
     "auth_ref": []
    },
    "canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares and warrants, net of issuance costs (in Shares)",
        "label": "Stock Issued During Period Share Issuance Of Share Capital And Warrants",
        "documentation": "Number of issuance of share capital and warrants, net of issuance expenses."
       }
      }
     },
     "auth_ref": []
    },
    "canf_StockIssuedDuringPeriodSharesExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesExercised",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares and warrants and exercise of pre-funded warrants, net of issuance costs (in Shares)",
        "label": "Stock Issued During Period Shares Exercised",
        "documentation": "The number of shares exercised."
       }
      }
     },
     "auth_ref": []
    },
    "canf_StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Ordinary shares issued",
        "terseLabel": "Issuance of ordinary shares due to ATM, net of issuance costs (in Shares)",
        "label": "Stock Issued During Period Shares Issuance Of Ordinary Shares Due To ATM",
        "documentation": "Represent the number of shares issuance of ordinary shares due to ATM."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued for services",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares issue (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r37",
      "r38",
      "r65",
      "r543",
      "r607",
      "r628"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ordinary shares",
        "label": "Stock Issued During Period, Shares, Period Increase (Decrease)",
        "documentation": "The increase (decrease) during the period in the number of shares issued."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r1051",
      "r1052"
     ]
    },
    "canf_StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity",
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares held investors",
        "verboseLabel": "Release of ordinary shares that were previously held in abeyance (in Shares)",
        "label": "Stock Issued During Period Shares Release Of Ordinary Shares That Were Previously Held In Abeyance",
        "documentation": "The shares of release of ordinary shares that were previously held in abeyance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments (in Shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r37",
      "r38",
      "r65"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares due to exercise of warrants net of issuance expenses (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r37",
      "r38",
      "r65",
      "r305"
     ]
    },
    "canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares and warrants, net of issuance costs",
        "label": "Stock Issued During Period Value Issuance Of Share Capital And Warrants",
        "documentation": "Issuance of share capital and warrants, net of issuance expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued value for services",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "canf_StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Release of ordinary shares that were previously held in abeyance",
        "label": "Stock Issued During Period Value Release of Ordinary Shares that were Previously Held in Abeyance",
        "documentation": "Represent the amount of stock issued during period value release of ordinary shares that were previously held in abeyance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares due to exercise of warrants net of issuance expenses",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r38",
      "r41",
      "r42",
      "r65"
     ]
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, per share",
        "label": "Stock Option, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets",
      "http://canfite.com/20251231/role/ConsolidatedStatementsofChangesinShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r41",
      "r42",
      "r58",
      "r572",
      "r588",
      "r608",
      "r609",
      "r718",
      "r746",
      "r917",
      "r920",
      "r921",
      "r941",
      "r1002",
      "r1051"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r238",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r255",
      "r387",
      "r398",
      "r610",
      "r611",
      "r629"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse split ratio",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r454"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r454"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r454"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r454"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "canf_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r455"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_TaxYear2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxYear2017Member",
     "presentation": [
      "http://canfite.com/20251231/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2017 [Member]",
        "label": "Tax Year 2017 [Member]",
        "documentation": "Identified as tax year 2017."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1006"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://canfite.com/20251231/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "canf_TransferPriceRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "TransferPriceRate",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfer price rate",
        "label": "Transfer Price Rate",
        "documentation": "Transfer price rate."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "canf_TwoThousandThirteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "TwoThousandThirteenPlanMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 Plan [Member]",
        "label": "Two Thousand Thirteen Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "canf_TwoThousandTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "TwoThousandTwentyThreePlanMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Plan [Member]",
        "label": "Two Thousand Twenty Three Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits, Beginning Balance",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r354",
      "r700"
     ]
    },
    "canf_UpfrontAndMilestonePaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "UpfrontAndMilestonePaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront and milestone payments payable",
        "label": "Upfront and Milestone Payments Payable",
        "documentation": "Represents the amount of upfront and milestone payments payable."
       }
      }
     },
     "auth_ref": []
    },
    "canf_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Upfront Payment",
        "documentation": "Represents the amount of upfront payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r165",
      "r168",
      "r169",
      "r170",
      "r499",
      "r501",
      "r665"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VehiclesMember",
     "presentation": [
      "http://canfite.com/20251231/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Motor Vehicles [Member]",
        "label": "Vehicles [Member]",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "canf_VetbiolixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "VetbiolixMember",
     "presentation": [
      "http://canfite.com/20251231/role/RevenuesDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofMajorCustomerDataasaPercentageDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vetbiolix (France) [Member]",
        "label": "Vetbiolix [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://canfite.com/20251231/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price decrease",
        "label": "Warrant, Exercise Price, Decrease",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://canfite.com/20251231/role/ShareholdersEquityDetails",
      "http://canfite.com/20251231/role/ShareholdersEquityScheduleofInformationRegardingOutstandingWarrantstoPurchaseSharesDetails",
      "http://canfite.com/20251231/role/SignificantAccountingPoliciesScheduleofAntidilutiveSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r737",
      "r738",
      "r741",
      "r742",
      "r743",
      "r744"
     ]
    },
    "canf_WarrantsToPurchaseOrdinarySharesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://canfite.com/20251231",
     "localname": "WarrantsToPurchaseOrdinarySharesPolicyTextBlock",
     "presentation": [
      "http://canfite.com/20251231/role/AccountingPoliciesbyPolicyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase ordinary shares",
        "label": "Warrants To Purchase Ordinary Shares [Policy Text Block]",
        "documentation": "Disclosure of warrants to purchase ordinary shares Policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r158"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://canfite.com/20251231/role/ConsolidatedStatementsofOperatingLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares used in computing basic net loss per share",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r158"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(10)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-9"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001213900-26-034447-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-034447-xbrl.zip
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M?2+&/77S/OFN<6,S_ORY^G#U5.46SR.F)IOLRPFE\Z]F C?/7/)HVR^<+.)
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MY7>7MDY:1[TYFL-J<XW?_R]02P,$%     @ H%!Z7#W*KO8N"0  X'T  !4
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M;X3ZM_$EF=.$A"7F%.SK$%H1R//22)HL^/?)##@R-.<PPTH#2XYU%H4)UWV
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MNUHUSG XG!C;5^N ,.JP1_!Z_)V+LD6X>U3OSVON>U*AG/Z*E:P>%XGS!<2
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M,I*J>(*'&OSJQ5VR=I(&ZS\6S5^+8Q,6=>_B26M/IX"%!'^M0+:8PH'J2EZ
M>1:E*1E_7N[3;@(#_JT<D)"D8:NJPH3CK<=X+,-3QJ..@O/=HXGKKASU@M G
MGNB[K,J*DE7 0L:CZ7NXI>WI./46L4J%?S .-BC_$W4;T1O*JT/JE*RF( ;Q
M)$_4>[)\MLC;KVO2,[3_! 2*/"4_MZCZ/8>PI5H+BD>#&>UI45S,%VF^).0S
MR<@DX0Z+N)92PA'Z>5!WQYXT^(K(IGA!3"#STYYXX2(O92P><J;-MO\.B9BO
M>?E/4FX:)VI <?X]KCX]V05[]6A*NTXX%M2H)RG?G.W05"<<#N21-$^0[U)S
MQA3X%!0>%P_E%J9_D+/ER6.\NKU14[_Z.S>1/(E,4]>\"GFHDKJ81V"+\J3]
M(!GP-9JKQ'Y[""Q33P[DB@RE;MD=!-1ZVOIO:1X3,N8%")O$WM86+V- ]QR(
M_5M?PB(BCM;1IMTFS1BN=A[DJ]E7]?(F7 9]J9,QH4VKWY@DS%%A)O%69%86
M?3-Z"3\9YZN><$,I+)6;R19=ZM(V[8,07_*DDK>)6T4.M@JLKS*C*=2^ JQR
M__.'.OP@&<X5B:^S#VZ+*CMHI^0V>]@_@7XR<W[[6OG+T/GENX/0NE^&W'B3
M?GGHW#WSRYZM->Z7ZJY-GW:M#D[#::^A2N@WY.^TR0C^3#MR!M[^U6; ](@[
M#L> &NI8X.CK=#L2V[YZR/2#;2 'UW'8OPVG_9\%]O@3\,C6/#UI2USO2=29
M!@$RQD?J<>"\&^QF;GLB'[G%#G9K:'^*'[FL/KU$A#0= )#"\^XE0F/0,  )
MT\>7!9-!EP&D#37H)6;<IP +2CB6I?84O0 :?.L#I![N:15U:]Z8=%3 RDE?
M6AC59%;#(0H258<&I&<P-(UBT!T"N>D,$P&+5A38:%XXW;T1I?3[N*!;82#1
M" X,C'1@FW @=<30HHO6+3^P&TDX0H$OBCN Q[+5"!*C8<J,HR8FV(AH<" 9
M:%ID'Q4L%,%YR 90&#5Q&=R%+79'?_<A,N@I\S)NUC)0.Q9M;; [E7_CUOZT
M_#Y*[1KJ(!$+9VLW$2#W_7F0IN'+@\ME7Y_!Z7IA'?H>>N;]@P9W^98I#.@F
M18,1"!=:V[(5$E)1?PQC:Q-TW-E% -%?";N9^T_-XCC6-VU"<AS4K9R&D6Q$
MERBLI/>5%E/&K87\"-A5=9]"JK^>\CF=33N^Q56P=TE)!$#%F08#BP990T)G
M93JHN@$=YG1<M-4*JSJCTZR@8;^KL*RMSO.E^"9:85WSVBDP^.Y<@6D;QX'*
MU4.(SE^#<]?0!SSW7#B+IF/8<'9?X*#V)*W:1&I:51.SL"QZYP5,#CN>(9$*
M3L^T0:IM4S1D-'*H]8-V;=60%0R#77)N^K"%900B4%+U&5*BI&CL%E;E8)>B
M8M87#HG+4&O_3=O+#6ZM6,.A[52'/"T3CA%L!D7+%G?8R.7 T>FIUUU@GB>N
M?!EQ_DP ++J'7EA6<J<A"FQ_/FR:*"C?4\Z<#@A\A[^PPEG=!"S6&*G["(9U
M M:Y8C;N1HC$HZ?JPT[5B+;?X1"W&0%3<LX5W1.1YEPX*L)P7=BU7T2&58;J
M_MBV;PPK3>W^,*:#EH]#U"6Z')D2*9/.D8-+H%C+CUV_R<'9:];X(#I7AGMX
M==433+:67)Y>;=>!S$>)E @=FQJI=IQ[T+ RQKNM#7H1,/57)-1R/7G(7ZOP
MZB*!_:($RG4TKJ7X> A!J=#I(@;UHL3'ULM^42!TYA[LH_3WHSV0F$GY9_T7
MP1^:[^ZP"F&BI"0_QOG\:'7[XA'G]3!V=!_/R+A*23Z!-HY/D!/-(3*PB+)E
MP8=O]](DXR;6]&IGVLAS2>" Z_JWL(/_]&J7TE?.[H^T;@NZ[E0Y8J[(_+#?
MT.KK.[>\=_6Q;\?'EI?@JF!Q,;D\D"C%PMD7& !.[S=T>M,YH\W7E0^V K=V
M/?>8<_=B0,73/3DNEV%Q\;P@,92 Y.!4I- ,DNWDKF'#?QEP]74=LVUK8!5W
MT)%6=CEL=Q\$A=KC+?'XRS+8[+J\ TBGY[;/UXGTW,[Y.T:;RWL^,9@)+N7:
MC8PPFCS=/N=TK=\EQ9^7E) KMO%1YC7TI6-$WP5,/=T9UHG^/(?0$+,Y^];;
MV]\%3%U>EN14W[3TO<*I '!FM6P<- ]V_<MH6M/I7'3K5PRF=E5L/.Q&R/6N
MRF#8[5"T?!OP@\MC=CT'_5G]P488M9T3:MM7GA04^1*#*2A Z3:M>Q*6;K,M
MVG.PPPFD1.H_!;8B_"NCWKVMP:S2H<T VC<+; V8%(M@MH5>$TG)-$LF<#J^
M',5Q7F5P7NHV3Y,X(<5&M7V)_I73LZHH\SFAYU$9146T:4,>0B[I;)9GTU^K
M[)R!><M$;A[%I"H98VEQEM.%T-_&/_CM]/2]91Y!1F^RF!&Z]T$%E?+AG#:[
MV)^$MHOO^8)_:?2SG**#09P.N]B4A(Z?R2/-?V&;+9/)G^>/O\B)$8_D%-GE
M.204_4[*QX2MCF<Y*7M#. TN<P+:[-C62BTD(=K#09Q,E\%:#9EU(GU7K<BN
M>I:.Y42[C,@;1$//\@RT7U-2S6R'SR2+9_.(_JF^VECS&+!TV*75%TO+-74"
M0<(^QEGRE(,5T+:J#<)SLU5-]/Z#I^#[ 5G7FB2Q_ &^:ESFU]JPL3$B9'E&
MU2.<%9>E!VU8V=0Z8SG9J8Y^?]BVH"=&&IUZ0)[R'G#-4YPAETD5DT15E$+[
MD">25>0K*95L",=RXGW51S0V]\WDEN8+0LLE%.25HXS?1KW@%8N"LA[3QSF+
MP]SO_=[1WNF^'QAK[35:V^RE__0ER@#=2X.U<"FQP/B_1\4*&%,O%@N'_Z.K
M-G @76@L"/X/JMJ 8.*Z8Y'PWY#&!@E4Y""L9*0V:6)KE^SGR7'Q"JQ\])6J
MU>8+Y8SM F 8 L$*25 WI6+C"(=9"+N@RL#2C^U74KN 35AI+[]PJ2-"6"T4
M3M&./EB$@$4;E\%JI2#NP3"8?00VND@/%AK_E^$8L"C Q29HA,7&O_EKNA\)
M\NGX<)2S)+C?ZQ,M-$^[&)<[&U$,G+42DA4/.+(16X9B$+9B#WCT92NV!4N_
MA?D%R\$6%F"5RHC]?IRD59D\D>;RRSXK4UH'8'?H7[?0OWB.TXJ1"^W-H,JJ
M*OF<W$PN(IHQ'(I5XZ'1')"1A&J=O!MF_O#>QT& \WDI?H$B%=SA%SF0GL[&
MM63K6I-X=O5Z#I&G;+N8ATU7#"/6MYII $N>ZE76O:XW5PA(N!",Y(1[JDKI
M,2%JV<:A-8L[ES5)^-B_T.G]8>/7%[ V6MI=[_RGQ;I2@X<66H<[.M9'"N6R
M0=O%[AQ4\ST?*]E!'''J$27LU.AV5RR^X1S7P/)YB!!ZYWX9L:/N56P[XP$K
M>N$<'+47/81Y$JZF4P5/ E9U?49@FIATOP$5R2&,T7B<U)/>4+7J:'Z9TU$\
M2]@OQU^2E!1EG@G;GQF] &X4.W%[]*?KHTH?WCD]AN/TJ-*'=TY[Y9U]N?]"
MQO")WYDRAEL"UXT]KY,YD^6Q@E#DLT#U>[M@C>Z %>)XU18-=I&W[@Y7?7AG
M5^$MH>C7)1/OQYQ+SEE^72JF3C*4H^14]J^96J!G<*,$A3[6\5:#6!%=BN$<
M+Z=2M%91S<':30)>1)I\-%!V>--O&\J^CNX5\K3Y*\?$J6[]"O=;3*IL#&99
MPZF0!L$XKNE[; 2U[N;\,\FG-%K,0!5)3NQ)QP+1A_<AM8%P(Q@WD[M\&:5@
M>]QD7TG)L],B-#6/\+M%G"JO.S*M4AB]7(NU8D>2C^8*PZD <H8Q1 D'<GJ<
MGN7EO8HG;#^&EE:"+FOB07PIV)T1D]#QVX+9U=QUVE=$!?NOK%&M_BDN_TZW
MH>:;"N6Q.X)3X/^4\8?W#L[T%23^<9H_'?$<*UW6VJOYQT9Y-;_X]NO=/FGK
M/W#-WF-#2OMCSQ^.^^SI:=2[F*G-DV ;C@)Q+D_U]G2 [,-QCT3?TGQ<Q>4-
M;6Z8E<BE:!B0>GBE4N>D\AN":RH**;[2L1S?OEOW:MO0@J3VV)\<W]\3".OQ
M#.9]'8#=MB"E4RP=RZ?84^7">5)$TRDETR;8UD1O5.E?U2-\B7FJ9KF$R!BY
MYO?P,7N+V3,_T[R0U51(1G/'S5,]P<H,N\SIVN*74"\:RL7(4W5'(P-U[!9*
MW.(2;J9:;157&<1VDVPZ*@K"_C=^B)XEG%F\B5O6GM9/0R[SUB8YG?-K,A_3
MI%X:YZ2(:;*H5TDS8]"743:I5N_BS'NJ6UB'>D&+0?F@B'(UL^IG.7.>U F*
M0&E\R/(M? W[99C?^7KQ7!*:1>G&LL_&UWDVY?H2EEY97&N*UFQ?QR'HT<UQ
M: 5WT&N@/Q.S?^(-K;K^"71HW;6LPOH0SBFEMNNZX7%U0MM!XA")X2?_&*(\
MZ3V 6F0HL<#XKY:P L8T*8J\@O'-0.%HE7K%8C/,-83*_&(A\'_&V 8"DXPS
M%HGP>X*(D#!*=&-5:!A=E;11Q#THC'/K2#@^AE,T[MA<,4WY8^7'_TEK&_G1
ME1U@Q<7_ZNE(7/ U$0/M!8()!F\PL2B[P.%R>N)_+^I(A*P*0; [N'\];;.#
MFQ:?8-$(0PF;HF%0]8*--O@7BXX6$[(J!XO3B]VW;(N$L,#Y]Z&Z!4Y9QX15
M1_[/3]FH(U09%=8L#J,)J39SOP6!IEQKH+TFS<T\;&$8UK[S?_N6I-1DGVUM
MM1F68_\Z$L>QOH0-*?3O^PHNVO40Y<*[R[MA5=Q VV.:+WY\]1U6-()HJZIC
M30@"MJ0/>Y9S\,*AJ2)$JL?C8)3% 3\"=E75B=@ET)<MI&58&\'9"_B8U3UB
MX;!M)MC327IW?H5]W24V_.K?RNX.-:,Z3ZS[ZM\SZPXP?&DI%JV7+%[.RE6Q
M:]6_5] YF"X*8+%P^J_UZ!Q.FQ);[-+^R\.G*]T-U_4UZHUL[ONV+'CTX/#)
M ''F\;6#Q(?'H[]\&^?RM!6&_ET?&>=N?9\^VPTQRX,4><8L$K94A]7$^69!
MH&DV4^#,<C^+*%TR10Q7WA>J<VJ:I]@,?'SGZ<[6JX)&)&4S,JK*&9=I9:-2
MV7#.@J?#:HP:MO<E^5C1[7EG#&@"I^<Z;(A5]E/=&\4)]G2RBI'R3Q+1DS?'
M'Y22<3".$^WI$*!\P1FO4)#LMY[NNKV83$@,;>)J5<D@AD(!\.Z2K&+$-E3G
MF8PM_ LXFYY$3$SE'8GS+$[2A!/X-8?]@)DT"5.8%\\+MCNR$063N'C&C)QS
M9B&G^4+0TZ.;CW"X/)V.6S.PUL%@ "N4G_P!KK8]]<464Z54BZI'."N>CMZN
MZ;IXCN9)%C46BO)0HO(9+E[#VZ'\WG#<B4"U\Q=./N@+^;SF!E!2>!B0L#)H
MG?4E[BN0@U$WA]B8F<@#+;9&"L A.@A#'!N$".*>5R5?"O95ACT6@'!J/B5L
M"?G'> E8[1I.=;!S12KV.[# A),6M 2FK>>"!2J<->04*+=^S4"KQ:PW*5.'
M"2ML0=U]JV<2"XS* 0MW,U?="]!F-V_K,?0O)"HDNI&2/K,-.Y=[1%N7>\"Y
MM?7MDJI1PTI12"\S4?6@4S_$)NW]6Y>=-0W8&<5Q-8<S=H3M4PM*XJ0IPEBD
MA"^F;#R:Y[1,_E-GP66,2!AW]7H.D:>(C90H)KNF\\T>X:QX"@7W>!_@:6BS
MM;FXUW32=J_\/?4T=W+(EPMU& [Q)&?,4\!]38[Z9LW=47P5>8I'2_'4!:7U
M#W*V[!*]LDLXHL><\B/4:IS5@SE=GC(9/0A^R[*5W@IV]&XN7L0.#4L;*P4;
M8 TG[-P&H6[-&2R6X50&=R)M4AL)NQH#OWJQ#6CM+# L@*%%FDRY-A VG6V'
MA2RH;(D!MP90Z:Q%+%3AG!(Q8%40&<88I%A,_#>D:86)C?$8[LI2!>SZ65K>
MRH4W$;O=% =40U<PM77Z/=G)A@PK@(?)Z)S-H+#]BAEV$T(I/\Q5GR;Y/4HK
M/F*4IOEW."'2HA[.X"L0U[6\G-%=X<\N]5L)-9[Q^DPR-K?EJ+PD;.5&Z49D
MMA'050JY^ 8D"BSOSY+=.<IG\V;2?)^9__4';^EJZD@\R_(TGT+A_P4S("E3
M6 6;VWJ],*>@$E^'YN;-G&-/<2G)U+5?0NU?S&'QM&HP"J"^Y3IBFQC<@\T$
MG/_VXCDF1<$>6$F[2'BZ^@R'S%<@$,&+G7IQ\&:N@9W>5(@ARE8MR%5--]\#
ML?%;L U%"*O#V?LU+)_))*<;MN$*^I)&S,),LHA-,[C<7QD(<*P[3QEITRM@
MD!2R1=?A%SF009V'V!4057H(_3Q7,IY.9&&(U,7QC=[!F0WF$(#1.895>8;W
MPO\U18;EYIO"$5^GYRZ9&DBFV5G=+5"9X1(-Y:1[*@UP9UHT9^<[-V&:[_"M
M.B@;IK,S9>\];15.5V;+[%LX#<&M]@5!9+&/V$%81:?]@=M#I"&L0R?=0]MY
M(".L7KK>9;5U! 2)9SC%^STJUO;!$FROD[\BNE9!%FR/JI<"J*=H35A]:?O6
MLCU&<Y"'-DX#/]S<H]I01(W"LF/1)2W&7"NL T2\!BMR0?1:QC&( 405_T%"
M\C:<RD4=?X>(X$-*V'LZ@@$C.)-0&7S"W@3SUX 7'\T*5V^9G>IKH[CZ+ 8Z
MS^,*K 0H3F)S5#+SG+="+;<VLA[K>PH2_SC-GX[&)*FCDNR'33"2_>-;3>5E
MDL+UIB69,H]B+P8I&?7M^/23@^ IEL*+.:%3N)&7YM_+&>B1*)-3*AS][?CM
M&P=Y)"S%W(:-^.(]C\KHK&*.Q4$,7S<<:':0OM#3?!5/Z*@:)^P](^80%247
MV<LTF@HHE@\&>AT<7-/3NUIH=V2:%"5=%]D1P6%*[7@FRX=7 '9)]2C+JBB]
M(XN<JHC='@8T.JA0TM/82-YE4C#?%[JA7&3C\\/2$-50H-5!V1 >3WY;(=>:
M6DSWAP*MO>BQ%0'W,Y*FC4K24GLXF-'[P4'JWV1G^%H)LJZB(4!;KQHVSNDB
MWUK,C:%^EH]%XHIX"CCH1=_6M(S&8\J,X.8_8 \>2^D6C 5J>]%;.Q2<L1]O
MZ$/^?3];J1@)E#K(*)M26D^LELSF*L+CTX\]KJSFX[<YVS[3_Y<LE$(K&@ST
M]K+:8!I'E$02"K?_##0Y*';1TW3-WI'>SO),KIWVAP!M#JI8$'@Q]XQ9<LRA
M+?(L(^D%\T729@9%^"F& \V]Z*-](J E"H)6& 8T]F*9K#;%RX3I[7EY06E.
MSW)F@L0*6U7_$.^+TZ-R6IF@62D!630,S)1>E-,*K[ISD-SV$XX#*GM9_JNO
M;[G7HLI*U5!&J^4A!ZM9/R-PZ5%ZQ7S^YU^)?$_:&P=4]FI*;XSY2_8;D;Z2
MC 1*>S&D1^SC8TZ >,7O_!TDLI=-<A>5>E7@$-P:"]3VLD6M/<R8W\.<9--[
M:"L5T;&"W,/!X.[W*IU;B_A:4F2L&PYRVNMV!8<350XI^S/0U,L.M+]_7T;/
M4OM).A8V_%YF?<?V)2O71]*&2/\ T-T+REO?%99U"L< =;WHS\]5P=8"N#U\
M?H4UU=)Q$/;MQ0ZY)W$%D?SCD\<'"(T+"-P? K3UHNL?: 17%=XOYX_Y_E&A
M@[\#5;W81"LX+IYC7N FL2Y%PX#&7O:=QL;)YW.(O>3QGSPW6-Q490%;"@--
M;A@I'@+Z>PS;_$'2]-<L_Y[=DXCI1C*^*HI*$2&3C >J>[1 ?\]3MGM'M,[C
MR-7GWCB@LI?]LIGF.J9<!SMK4Z,4&E&JX4!SCSO4=I162NGV(* O\)VHY1U\
M_FN)D79@PT%NENA$HN"_UJ\%"O@DZF .FK1 PR _.YA:("LX#)._@SG,806&
M>5IY,&<Q6N&AS5PC"[H&JC*,$N.#.4W22B)0>??!E-"W@@*9U$<N$?_G8%I:
M6HK: >RE!$.&P+P> 6E\#AH5;+4##HL BM#;8Z&IID B,5## EVP@81AH/:F
M834($HR!:@IMX0F2_8$:F:CZ%AP$[_RW*;"3 -/2&:1$#-0U1U?G#.9$<"L[
MV[3D!VEM#M010U<5(6$8J,K URTY.QGKY91Q*W!0M5)(.1FHLXZOQD+B,%"+
MTZ3::S"G-*V0T->5(?D?J MF5K4VF"XN[>+<N)*XL)HL=!;BE56R(9V0@>H%
MLSJYL$1!VV\#814H(A2X$CRD>/1E=RM[:Z!9W-L[4-5^2"#"L*AD+.TRCB\B
M1+KF _6^4+6*2 C"F']C"/15D4C^!VHSH LOD6I@H&:D934GTK8>:.3.O$X4
MF00<J$V%KT1%XC!0T]JXR!4)QT"#$<A*VF -2E'3(Z<699^]CIA)5^1I,H;;
M7-<U;T4^J=OK,K./*_99GC*T"[BJK5P71_?8 LFF._O6-;4WY8Q0D#7&"<SB
MJA.7\B8"]//?CM_XNG:JGA"@C&TT6:EL/R\<"[1[NB3@*RDW34<E-.^,8;1:
MGDN6W#W$#1>^.X_/F5&73>MP6&W*P.^A>?3-Y*9I<5K__KPB#_GHX<L>Q>U?
M".QYF@K=^1WI.*#9TZTNH_&_JJ+DVHK!-QXGM6*_C9+Q5786+9(R2L4]"_DL
MW?"-H+@C;%443#7>$_J4Q*2>,.CP-ZVUETPY]/-UP-?N.*&9R$//=+(14$YY
MP\4H&_\14<@U[B_2]B\$]IQ>4:A;8TR?W$Q6@\[R0LR3^5N $4]7[/$)$.[/
M^XOW8""CVD6G)SNJ&U-#=976[B#8JCQ=P;3EYRI-AH-Q0+/=D4:++<OE^L6]
M$-(DGBP?E=[95K$7SX3&24'V6R)8OP>6NJ=KM)3FA7BW,>-:]290%G9GQFVL
MKSN2$D;!O@9^F$7E'X1"C_^G)*^*=/D+2=F..WHD2\$EJIU]!P3?SE:S 4,F
MPP9/?CL]?6?9T\N,XM47^0(RH'?G.4YMD(NLO691O A42Q^[!<>X^Q76YC-0
MVW?BS:)JS(X]C[E07!NI? :L $_2+'%-U($/U3/ BX-V!S:\W)$R2C(ROHAH
MQH2L4#(A'@S4^Y:J=7!4)TI;4=0W+IIR^0LPM;S;T'^.#!-#VT1VW400 SM&
MB;JL!*,&#W'"1R8'4ZVJ7<R'*.ACG8.IS#3@OJ.XZ6 :%E@("BX*.Y@R5@L$
M?$9?!W/JQM$B;!')'4P+%5.H' 6(!],;P$9)X:+-PSZ>8X6+-J8=5G&Q<ZL8
M%R0?3#<JE[:.7<!],$?];-5(Z_#\8,Z$ND/(.)0_F*,^3IT+E_'_P;2 <HJ@
M)L4PN!!/2U 0>8S!'#5UKHW028_ 8E_].%E.4R5A&9'H&Z&%YK'"BD:G6P87
M$#(,-1OG; :W6YD!8I#_"4S9X&[7=1UI[[/F_!K47'$.,Y2NLV"!5Y/?TIRI
ML')YFT;UQ< ,R<7JO+0R+89X$JY]/O645;V/9V1<I6S;D1.JJM%#/@XL'GM*
M8OY.9DF<$G7">'<0D'OBJ3;R&HZ/$+Y(SDD1TV2Q<Z9&0K_F*<Z0IR*$FK3F
MEO-LRFE\('1^,X$#Q="/6\F3ZD'.EJ<21*G ?UY*;K<Q>)(SYN".ED!U7<N*
M@+YB6:BDM\%L'N[(UKL#-A6NSP9[#9TCU9; !6BU\2#E+)Q4NH&<'&*%V=NP
M\A1.8M-:=&RW%2Q$P3G5ADO%0$OI-JQ@];G*M^I'H??I<1T>XEW)1#ZY>(;$
M (3">>'#?\CX,LFB+$ZB=',@>%C.VBCE[R5C<?ZCX5ABP^ >_G9\<N+)8[N8
M+])\259E*V(R&R[83S>3S<S6T49>D:#S)QQ_!?!R<+F;#5X_DXQI>DBCCL9S
M)IGU%2]/I)E)I5>(>A9X\^1:U16#F^AS,QL*WT/Q!/#AR>604*5T-I3/ "^>
M_/<[4A"VX\R8T)R3)Y+F7/UCI WQ)/#EZ13DQHQPHQMP826'WV+8^0I!=2/?
M+;WH<+R;;C8;09K$?F\?7 ()HQX/$;+?\,(R]2V<(_>:YA!>T]TWL)6,BH?I
M>43CHMC+PQ*WSM:CK4GP,@IK^]H7^C,WG"UH\;QT$@_I9D'W&O^H'@OR[PI6
MSM/PPAE-]>^J9.J6,L$\)S&%N*7$=E0]PN]-<>FO%K3<8H/]:\,"^P=;7"2+
MF"1?YI3$45$*72#Y0"#WK:?0@63Y [934D<$-T-NHR7O)O\]HN.O3#7P55E'
MVZXR9D?Q+HGZM@$=?I)#Z>G\,S\!NXHU2GC?&</KVER&V'1BNM)5*S$4!%&D
MXSBR+OURY)KZ+2L6)$XF"1D+?4GE6$ZTG2*0-)SX2KXWFJ>N710N=<5(KII\
MA3?8'I&,$ZB[C, 2X*6:JI8/LO'?CD]/?;75VMWG=#%>V7#&@:5<M.=@@R6T
MUKZ9\"N'HU@;+=$_"//B2;9N:1X3,BXNF5VU.>0CZ<N%>PCFR-.NN'6"ZS:B
M-Y1KQ+J&F=G ?#U+6$(\"2V#/06AS]*H*-8(W]"[9#HKZUM F&35C=\34IPQ
M=X6,/R]7,]$,E$UCR[?"/'O:L@TIOXCBV>Y8-X@<OA<P\=0J54C[CIF]6:*K
M*3PVP4'W+N#=4Q!;2*]2*2N> &T<TAPJ=GKI>.#!T]IDXO'$=.=M&L7<&%7F
ME<2#H0SA\%[R-N;?!<,$*FI60BLW_\0C.45.#5*)XR]*/6G'L]FV;$DF(4XH
M5VP?9/9Z&4V%]&D>@<W3:9>_T?F]?!+7?X1UX-(6Z<_YD6707H:QZY<[]]M%
MNWSG:4 )3XWG=1A/-0_H(4$)X%(55)!B XEIJ! +1#A'W8REH_^@(?:*FG#R
MX<:@(J*181VBU.:\L2;.WEK#!SRQ2RV(?+66-['*0891L5=[A=/]2N^L;0 Q
MCN&&E:[O8*78A86'6-^AXU" B5UL-C!P.MAB+$*\P^O38PJ*;9!X>*UFC)'I
M()0<E@D3 &K(<'-@72/ZPLTJ/!V8(D?M<KJ@+Q(O1; [K(KB#DTBL_@Y\I3E
MQX!V.*QY(S( \)%Y+##AJ!QCC\(D+? R*ES16MDN/3&\-JI&>-BD0\)2N]VH
M%T1Z)MQ0C:@4V6VL9B#GII"=P+IRQU\42N[-N5#.[V_=NWY'IA'TCIQN70ZQ
MVDK+_+:B\2PJ2-.K?H@E\,HJAYTQ;*%_>.OI@+Y0<E2G7>4/P$D)3U4R/#]T
MSE2N,F6[-XK1>^KTELBO^1.?3_:74T4U\<$H(,1I;<LJ/ >\BDC8_CM\W.GU
MD.<D7O%W+$?A<!00XK8>A.GS%'ZMJ K9'0(D>&K0YK8  9P03^7# 10=GKP-
MJ2C7JE@/=@1/%=-K+:D@?&<,Z'VG%[]O:\C15%8PJ!K*\7-:__:/*EW";V\R
M<5L,\2"@P[)"7$.'GH@M))S.SC^BK&(&/&)RQ",Y179:5J;HJVE5E.SW;Q6:
M?F\,J'H[DTM+A 85X4 .2D@EQEM6N8GRVKGI[>0TI.+O:\T!(_5#P(VG\FE[
MX_8EU51RDV8@;GZ[:'-CO!UZ^0BG\64$FE%+$1D%D;NF@0D-*M,G,KP.@< X
MNH.K0! SM1='1CK7@4V]I;Z0KPB<EQ]6G9LK$4!&%@9W-RJ*>4Q ([!I;UGA
MT'C*9C%Q87QD<,DVE]ND550E+,30;=2T=@(2,WFD)JPEUB4P^DC0X(KVC T-
M;> )>[ET.*H%A0$RW#6XN@XCYE5AMK#THS/.#<)Z@ZL\Q5E9F&#BX(K?#5G7
M1B_#V@1[MJ=T@=# /%!<88I]]&%P=RC9U>?8.R-]5NC S3%,+GG)8O28I/Q(
M 9-5.,R2E/W?H2%K.8$F4]HBP_ 53%0/+V1OP\*FO/-F\I644,RVGWZ0CF/$
M?'":PKR%@JJKJZO[LAHGJGYWPH& C=,ZD>8K6&H.B.D &R0M!Z0XS6;>D6F5
MPNCEJ"IG7.')"9(.!K*<IGWO\F64ELOF0'ZA;OTB'0Q"[3(IJ.F^\B5Z3N;5
M7-K%=>?O0%N/K6:_,*6II&W[[T!;CRT[[Z 7@Z2GZ/IO0)/+0AL,35*TMOX*
M='GJ:3F*8UI%Z65.'Z)G4O"N# ^S**L[3//?G564$G[;UM<\B^M_R%*Z=F_C
M7KBG,C9N^ZTN'E-EJM>7DS$]Y:G0B2'&#$!"2;'J4<_-@@(,0/6U6X@G00@]
ME?1R.=FR<*XUA0_2\<"#I[EI-A#U-.P. FH]2;VVI4TAZVFS60O9&&[A@S,.
MZFY:'7P*UF"/S:O-%+GGKF<O8&8[][V]UHKHM-=>_,J%1SBXL*XA1FAO=' U
M)!UJSWT,T3[TX*2I=Q#UKG]@8<3P,-2'+ :7INT/0K,@R^" --P=S&([@]%N
MXB#"AG=<N&@PB@C%KC8"%=;LXMK"V%F N\BH8V#!YO8DC27WN1'PJHBL88M;
MPJGOP"N\3B)Q8>F(?A8-/O87V.+I0IILPX=A"4XGT"!">H$)"/[8QI[8'S+?
M6VPO6 AE[73,=JB!G!(SJ+GQ)SJ]=HY)IEDR2=B DFVX><6WG-L\36*VV6R:
MR)R3!25Q OO,7522(I_<TIQM8N62;4C0<89?.QQ SQ@G259F0KSI,?-KEC$'
MXH)-F0-QONYB7=_1O!)-6%I@'*[E4]5C!_LX8_'].T]91BEEGY>:_"_B2<Z8
MIV2>''+V464&!_$D9\QIY=)U])A3'IQ:?TY>+B0=#'2]]]4UA>U8%3.'U?1K
M1G,&/*UVZ;Q?:S+O^@<Y6Z&M\/LH?8JF9-7E7%P'9OD6SK#+1@O.DM&GIQ^=
M7AP6EDKJ(,WN%OF61GTH(4C;+5X6?Q2:AX,)%$C6F"KJ+C0Y _/LVC*L-V.Q
M4J\_6.6U> ._ 0I<WE9&<EA+I >UT=KZQHI<7QT34($W VX-H-+9\X-11Q:<
M[F6##3V*L)9=5\A8^2K88JIPJJG::&\G;D%@TF20:&W,-GD<6^AMA*N"51'L
M?G3PBSAA:B,DIA%ZH...3'Z __YV=[6F^< QY003,IX?74#8O$B877&157-"
MH_JU1;D.;!@[NO#R8N,0PF=V0_5%,E] @/3(*+G0BHD <P0/\/&;R54V3IZ2
M<16E?R3E[(ZDG/ABEBP>\HN,4;B47BIN_(:^_/^S64(F%\\DKLKDB5$X26)"
MU:$_U1,VJQ[E&KEU_BPG=,>JT,,@TP'-[^'_'J."_-?_ %!+ P04    " "@
M4'I<H <NZ*Z-  !UAP8 %0   &-A;F8M,C R-3$R,S%?;&%B+GAM;.R]:9/C
M.)(@^OV9O?] ZS';K3:+[*K,ZMF>[CG6E'%D:2HR%!-29FU/V[,R!@E)[(((
M-4A&A/K7+QP'+P$@)1Z@JM^'JE1(#H<[3H>?__:_WW;8>T$TB4C\[[]Y_[OO
M?N.A."!A%&_^_3>SY?5\_IO__1__AJ/XES_!_Y[]!'FL29SP/__]-]LTW?_I
MVV]?7U]_]_9,\>\(W7S[X;OOOO]60?]&@K\=P;]^SZ'?__&/?_R6_YJ#)I$.
MD*%]_^W_^7R_#+9HY[^+XB3UXP Z2*(_)?S+>Q+X*>>DD2[/" %_O5-@[^"K
M=^\_O/O^_>_>DO W__'__C^>)\:#$HR>T-J#?[\\S8U]_O%;@/@V1AL_1>&]
M_XPPHYFCV%*TUK?#E%:: 1U_!#K>_R^@XY]TV-+#'OW[;Y)HM\=L5+[M3.J*
M+0O4+[W'*'LGFJ0^[IGH(Y0]$IV>3FMZ3&?:DCP,8/?LDX0$C);-PCN46U-@
MCE)HD*.I]HC>4A2'2.Z2O$\25* P;%)"JRP'?KQF;'WXY_<?Q$[[)_CFYY]\
M2OTX35;D,:/!EFW(!65GDT\/RZU/4?)(<!0<5JSCCPQM3@ZG3R ]'<6WIU,/
M YBP$>2CM_:39SZ$6?)NX_O[;X&M;Q%.$_4-9Y0S*;_X>18$)(M3=NIR<B*4
MS)Z3E/I!6F.I30,7#%S[R786A_#/[=^RZ,7'B(VY?7I.;.N$+<)NF)B-*]PJ
M3U'RRS5%893")Q,SMA:.6$C84(:<H)838FWB@HE;G\9LK2>/B/)=VXZ/QE8N
M6+GS(_K5QQGZC/PDHVC'5HL@K!U3)[1WPAZA*-K$UQFE3) \K-C9F[!3B2VD
MA.UQ_B?FZZKEX= !GPOVY[L]FQ^8DP6]B9(]27R\6-^3>',?O:!PEB2H[;%X
M'BHG3+,7PPZM_+>6C!G!71!_C]A HGNVF9K$B58M7+#P@%Y+\@ E,?L8\(,A
M.>5D.1V-"V8987M$T\,C9E(=.P) 9-@7AV 3D^V;NV#N"27(9U(J(^P&O2!,
M.&FW;WL4)_+Z,O#5JJ4;EEY0G*$[2G9,KN BZD]1NKW.DI2= K3=K)V*Q 6C
M2[2!(7]">T)SP;SEUFO9U@E;(#E]9&==>$UVL)KX;;O8P__98IMS<9==2+"A
M$NL2/0N3"Y:_L#?B^C9)HQU[_B<&;NI 4Y$EDP<24Q0P>8FMH_J/#:_*#OB<
M+,U@B\(,LWG("1=2$5M-]Y'_'.$H92]C26^XB)\4'VP51LG*?\:H<6?VVX?;
M8;K=[3$Y(+1$]"4*D'Y#SC"6:M3%FC%#-G'T=Q2R-U1$&%R2)NV'K/?^W Z?
MGOYERD@3IU@R8R^3ER@]G+BTSD<\E0%Y] _\/'CU:5BF&S:,F.4DR7;BN[,'
MITLGC@<*J-T2'"*:@,29'AY(BI1J<D&?HLWVE(UU,CXG[&N);+B"FAJ=P8A!
MM_R)DB1ASX$ H;!^R>L ^NOY(=L]([I85Q71.A),D*Y4O"7]["R]9LOMH(0"
MBV[7ULC-<SD%LMC,OD0A"C\>F"C'I,\%>Q?Z('S+LS8RBGZG('#$H-"QW+,%
M;.:A#.."S 7=^.RNYR=W1>7,1*M'MLS9@I%BP1U;_'$0^7C)OA%2:<,QTA/N
M_O8\DV?@>>-OV.E]PYYY2<3.Z?@S>\QN\6'I8[:Y=0= JV;#4/F$?"Q'<!%_
MP>*ALT1IBODH-5';V+P_JI=;]FI>(;K[Z,>_J%'Z,_(I/LSC%+'I3I]8YP5U
M.MK/0.+(G'.D_E#O$-/#NZ'-Y-B0VI[B,7 .7QHDC@T"==W]#PB'=X1^24R7
M9\NV;I1=+^RRBP/$7VCOC6JM&I03;0ZH+^0:6/EO'U&,UFQKF]0Z)NC^CBNM
MED7)]J2XD,1,^UH]@Y\"EA? 4E4XW*#4C[!X_NB.N1$[[_& +Y0P5?KT2IA9
MFG-9I<\@- S4AU.-8$LE%0,HZ_<X!_=1C.9,%#)MD9[[<#I,'P_YQQ\B=E;1
M8'NX!_O)["UJY+^AL6/&2AO\CJ*_96 ^;\>5N>5T#! S4'5L.(T?#WH5D5 ?
MS&.V'S-^S"W2+:*KK2]M#LDB2\&'%)Q=?T*@,6';&BZL#=O2.S\"WQ$E8F0^
M!MG0-'@3H_&BIDDR^HFKKN:Q4/QRW4O?@VWKR=F0/3<S\FQ@Y"M[DZ"PMBPX
M=S?LI9)O:-LPCM'[=(96J,]F6<K>>B#@?8E#1$N:9&YYO'UC3[PH08\T"M 3
M#$9I#TK>6V[%#R<-O0/JG$U-,D^2C"TKX$*YY]D&2P_O1JLMU43BZ(8))#'7
M&IGOUH8VTU#.PX.9)HC_L-PS::ZUAE[3TAE+8IW<9"!IB@.^O'[8DUG:(LU3
M=1J2R3'Z@%[Y3V<Q6&H\.<;$YWD<4/"\NT'BWW.X-&&:$,O\ZNRX9DTXG+$I
MKJ?*#:8FP<:9M9D39K+GA#^+TML7]K_/"(QT)@[TL!,@>\6ZLMU9)NB)D'Y#
M0*II3[R"[T\KQ6V V!<NLG=(JVX[ANFQ?^PGR6(MK?[2Z&\W<C0VZ9$ZLMN1
M6+DD:/>(!:Y/,S_#B\+;-W;V<7N.P=9_#-4?#>JX*F1[?A%=^_LH];&.GJ86
M?=+VPAYRA";@7/N?&3X R&*]1G"1F*>M5;,>J637&!@2ZJX0-QE:D=GJ\P-*
M%VL%Q*T-6J+/P-*CVP=Z;=X.&J >S;L4W640H=E,AQ&T1VID/.9L0Q$_'RW4
MF$#[-"*SE5!YUC294II:]$C;'H$]XA.*V8,>?T8(O$RD9YPDP#QV)S3ND>*F
M9Y1M&VJYZ(9P),Z>$(93NT[':NNG/R'*9%?T$I$LP0>PW\[CV3,ZR!P&IS%\
M=C_]C</JE:RVK \_#E?;B*8(<065>1TV-!B&LE=V5AQ6#!RU)T[?IC>Q-Z%I
M2>1E?Q7B+OOCYX\$5*SKFXBB .[7ZRWX !AH;]-@+,(_^V_1+ML9Z:S]/AI9
M46PGJ_K[6&1QU:WF^57[;51RC&-4^74LDE:0:X*)8W$8O41AYNM,LA8X9V2"
M-Q([GT50\C;:K\AMG()PH'NPGH7!28:*PBZ4"(.^7WQ3CLJV:D-.QN+$-TT\
MDOD%?-_@"V& =4AV]6UO4?!8X%VI>*(P EG&ST,<&O13!G@7Y(.*:;$NK6\+
MZ098%V3+V;=NVAK,(&Y=REJ\6(-QS(\/2R[1EBWV*&SIOG4BKIZ?D.<X)I0]
MJF0 4T7=;7Q]#M/9D(_JDJNA\B$D:IX2S3R=_@COUL-%N<XTW4Y](+ZH =&L
M[01R( 1LGK\2D*BX:[B?6IT-ANYY.@XQ+;Q];(R!%XG1]WO #ET,X U:(TJY
M4[CP>YW'/#8P2?2I-PS#<CJ:23!K\\<S 4^"\"(V&&/RJE&VG=1R$BP]H-:+
MBX/V:-/;DGCS8Q;?L#W\R#;OS@]0ED:!CY-K0O<6(U^[ACU2&NVWB-:ZLM!G
M ^^/JMM7LN=]S#Z9:=$ ]6@-1<^4_,#$I2C>?-H]_V FPP39'RU?4?H<$1R]
MF8DX AE/F?E70E5,F<ZUSP0T%H$/_HX]<"H4&!5,%MA))-7\B.)@N_/I+U:?
MCN9FTV#FD--E4[XT-IL(,PU>0M86DV"A48-G:3 )!@KW').H;6\R"28:/;:L
M+9RP($_*(\*LNK+&5D[>?CX&DS&/AV82H=U?40_K-GV.,6FC3BUT>G,G]I0X
MC<((9Y#P;@FAD3QZ\O8MP%F(0I'H<+?/5):*>BKCV0[R=)JL+/W@OL!A^7C0
M([#<8(/V>(%#V'1?]H=^.H,# K+U=FINYB0KNDJO!Z8OZZFNA72BS(@2?[.A
M4%A#)OSC-TU#-I_&5A-,;-LQI6VWW&V&%_<L#",801\7V5$0)!6Y(W06;"/V
M9?@YPN#8&VNM+2<BZ%&?\WGY&86@EOG*[NV,(N%_#)?X?;2+4M:M6;G3NNT
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MI?\3N[Z(NJV-'C26%BY8*%,@1!%)FH$!"_RDR&\0QUJT&Z(VB>PD 0%P$T.
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MQ[[16<2-D,,3.6/]AKQOO4&S]OO8HR:.[';C5H&=@I&PE65;!^Y$(^LG(&+
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M1(54QJFS6EKL+2; $*,'3+'<D:V!$RVH,Q9"%/TL<AO>11A<4=ESD%1+NQM
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MR;A')[4G@B$K%_QH-.STWM/T!S!IX$MXY<]C42F@9K.JI+\Y:U3[ZW[Z0]W
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M0EI@A@[?97LV$CPFAT<9@7$#O05;( ZN"_@;G ?8HN1E6B Y&R@512F3E'
MKE"L%5KW@84!4XS7;=NEA(LJDR)1AUJB.=2&LH77LBJ>7AIS%&MZYP1 O4B)
M79*NC"52]KE]$Z@Q'+ Y_DI@ _$\SG[:,:Q.8/1><I3_6(/1UWJZTE\2B2@,
MS8>X()3GW9]BPB3;.$-BEDX9FJ]K67>XE9([P ^>HVP28S'B4ALXB<X-6B-*
M>0)FD6YU'O/RG$GRA!($"4=G,;LA7Q F^ZZE9U9HMV?/,'KPP@A\O%',^O%
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M?>FC0$^.SA/XQM&"UKE8H;?T(V:'92<3U)>/R]O_^@(1-;=?!ZX%W1L#YGD
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M94SX]"E)X_0QF@9Q'PY/\RS*!2DY]DZU3"@7S*D'PUW7TLXU?S'?+0$8-Q+
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M&CR+&Y)3265E^:[O13=^RR?;T&=U,;>H4FN$=^KR'#*<F8["PT0<%0#>U&F
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M;>EQ3>Y;66](0[8ACWY3R9'+#Q\?)E%Q<'TE_BUL^1\^OGMXKU,NET1"3[(
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M=3TTCW@#Z;(G;__OM]O'T93,@I^C)"^"9 0?R*._Y>R7M^DH*!@Z2KA^$HZ
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MB7;G_*_U+7\:VP8<G=$6Q.@0B.[U02M\-9;K'O)MDGK#S_"CW>G%&T!X?[7
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MRHH(+*?,-<G%7V*$0S,!4EB?U>@\"]#YG<HE$M98A.%X&11D+29EQ.S^ZXS
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MP:G0>_J1/DWIAX(D?)I&64$(,P&*&5,Z 0ZYTYMP^VL_J"Q9/M'A1!]"WAP
MTN6C)L^*+96:_FNC3M-_?/^2@E%[?!EE9 27\\44,CX%"*@GP"O390Z" OIO
MP6LT6\R$P.[\G6D7+LVD*N"B1 [<]M\9<"XMA0K@F-V<\^K;^1O3;ET:#72
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MX<37@&E>\ 2R9/<O$-81';<NH:-XCC@BF_IZZ/NCX3&:)-$8:@D5@]$H722
MS7T:1R/Z(M@\';X%_Y-F%XN\H$^+[#(H@B /-BVF^A&3>#%-D\D_%LDE???=
MTP??+!B114%1B_.+-)MS Q?T)](-_6@9NB6"-YI/25;[H 1*\7 &FYW2)8#M
MZD<Z9U\:?!5#U!C$X+![&@G@^$J>L_3O:0RE1K[.GO\N!H8_DD%D%UHF@.AW
M4CQ']'R\BD&I#6$PN'QQ*0,2M\YJ+HB*:0YB8+J,CU& 628/[ H6EC[ @58X
ME@'M,@C*X+G1E)>*=Y-X J!Q[C)FU0"-BS0!,5YEQ$3YGU](,IK.@NQ/[G;H
M3F,H(3T$F[ MU]!QSH/N-(824O0N![95/K4^-EL9V!_/D4Q8#;!N%>'%X@GL
M\".931I0;;0A482J; I#I2\"8-.55A>3G3ZV'\^1S(NKJZ$!'O>JUIS%$$(R
M*T*V4_Y 7DBR(/2!(D6#.Y8!CQ59OPX]N\]2^DXJEI D70R2$%R?S%3$2P@Q
MG<Y0;*@M^D8CGU8C+55F\^PT?YP@5"YX[]-Z9$5 ];O)OZG29\*Y#=&$3SO_
MI/)I5;,AE?SAZ9]>OINNF-)+\#H^CO@]PTMM-[9'_&;W6N+')^'D:.^21\F(
M7HM&H73LU7S -BW;NJ_Y@P^%MCZ@IGMPJ-&?G5*R;L X]-)F'1"Q83WQKZ&@
M%+15TD&#=AR#C=<[!:4HJ_H4:E"N:2#R2CB?[:D,:, AG)XQRBOQ4.I[:>HC
M30I*[6"''@VO]C!Q"&9XQ[2@84^"&0;T]V$4+XKHA51=V/<L]-FQZ]%I>0L3
M-+8W8MVEY>IU%"\H8:'4(43T+\H=&(ZO@BRA&.2KHE^#&> DPMC%VHPX2-Z,
ME@A\6?(7D'@,._PB(R12\8V6:*G\DZZ69R1"<LKR<=@4M#5"?:L.+J"$%)VQ
M;@^PZ1@CP((SD@&.%+S@T6]F62>N-8H[O1X%>-3[07[\;!]L_P'#&.=:+C0U
M-Z=7'(;K$.-99GH^G)-=YYKT^4[YT'?#5B>[T#A>WLU@'U >B-WSKNY6-=4$
MKUR/81/7)423A!(=Y;AM&I^YEEM3\>*5\S <S_:<Q]7#>FP#JDQ_^V/+N8SR
M8#+)( &-R=P* 54.KGP6='A\AV35J4 I+Y.$@?-'5$Q7INTG2NPO],M_"C#3
MG<Y0;#Q@](\A1L\/S5UKGD)3HO0][6QU2ON1.38(PZC<] JN56.0ZS0;T.VD
MOPR_13&AQ$ZX!<R-%H ].G6;2=9UYMNY9<$+'YEOYQ^<5KN_^/;XC83PB=\I
M"T)OYG53NMMH1KDYE "J.1>@_FAG#57EZVEDZVW!8&?:[BY7[]RR@(< HG\L
M*7L_IXQS+M+;0K)U@J&,2DYY_Y:*A>P",M6SFP1X!>2&&"[)<$8OIURT%E%5
ME:1-O ,/-/%H@.S,Z:F\&SQ*^&GS5T83I[+U#MI$C1=)".^%"E,N#)QQ3-*[
MS!U1I%2NF[E^)>DD"^93$$6"!%#A6 #ZQ.GF;1B#:CSI,HCA[3%,[DC!G/4\
M:BJFL!9=3H77 YDL8AB]7+.UY$82CV8"PRD#,H1U@.(.9/ X30UG?:JH<LD*
M:7/JI/,'L:/@M%O/;W.J6[,W?5T0Y?2_HE8SZEF,_YU>0]4W)<)C=P2# #]I
M_=Q%2:J<C'Z9I"]OF0TG6Y;2J_K'1GA5O_C^CX<Z:.L_,,GNL:6$?1;]^8G/
MKAQ&W8>HV#SM;<L0 ,YE=K6G^@/G)QZ!OL_2<#$JAEG5]5[ E[QAS#3@41FI
M8,BIJ*V@R(7T%8YE]/7=?$?92 8XU6.',?V.0 "8QQ(>CV12UR"%6RP<R[88
M*31(8(^3Q5?(IK CAA0N=DUE:4%N63M;JF\E\MJ@@M'LX884L+-2PZ[3;*WQ
M"Z#G#65LA!0^I;#.*DSYFK,9<_43P9L$_,=1,H&J:/1_4"#-#EG>2NSI@"0@
M*G#I<W2<9C/6=/LYCLJS?TGR41;-2S%0L20T/!!QK=5:#'FD"@YK6S:(:?"_
M\B"7(RN?RY!#DI=:  H-8):K,"&%BS#K('_U6I L">+-TR4);]-DPBZ$LK3A
MK2+LU78Y1H+&.T[;;7>.$3/6%M>-/\_>6^0]/NFS3TIK/;)J9#1R7ODGG^\T
M>6/RJ;UJ'L-B3M_UGEZ&SCVOQ.O[614X'[W2R'?S/U,:R;VB7DG5IQHR/%(I
MO+4^P_D^^RX@IK25U6BEX4'V2:]/&+D8CA4XM>?;O[KANTR6*1LV??1>N0XC
MR<$QU\DB#(ZC:+^&Z75#,ZT@!X\\>':*4;[#,0]JQF7X9L?3=WVJ0LG36-01
M(UX5O#X55>212QK+XO/B.#\ =448C./]UC@_@&M8/X+(/WDQ*FMU0]Y:*)3_
M"\5WQV13"2F(U_+Z]/5=Q5@90[!%HT;@V%$4F#57D<4A;%YU8Y1F[;M1,W6Z
M< +GO)+$M[U231)>N)Y/@?/1MYE;?#AV*:,4WH=>-]=<[LA"%+WRE.^7HPQQ
M+HG$)C:O:>M[P56-&$V?$OO$MWAJ8,LAQJY ]WJRO*N'*FM?S3BHTB:]$@M#
M6S2,/-R0S^2 >C7S8R3UNWL :T;G^K<K8%C[W9-5%C;LGZ:'P:HMXGF]D_S3
M?IO'G,01^R<ZXL7FGNAZ\<P(M13/CXC,S7AJ[UR-41/?[#7D:H_Z7DF(7B@D
M3Q-ZT5",]JV.^W!.H,4!W0&JWET$6;:DW/XCR,)<EH*FF$5W[M,'I-I?-WD6
MD)CNR6!13-G9D!;Y%0UG*"#EH5%HJ(")TE!2*7UG#+RMFQD-GH&5UNFNC6(
M(^4445#^28+L]-W)N90S&N,8T$CI;^(#9WQ"@;/?([43OAJ/R0@J0);"DI(8
M@@% ;8^2!06V@CI-1&CI+\#01&(Q/I0/9)0FHRB.&(!W*8C\!1U&!>;5ZYPD
M.1V14XX;3>FE>$DOS3B=<\IU=/,11BZDO+ U FL9#-X,B? 33V!B&ZFF/!\J
MJ5B436&H("6=KN$B^7T0A7>D4&00BR<PQG)9G\(&C:O78!8E*_5+FE4HG<.0
ML4X=/#W'4-K56]-4V37UNT,O_*QS/)O$4ZF41Q$IK<E!3>IQ%5NO/C0,.P87
M:PEQ=M5HK^3!"* 4X,TE$%]I]QZ^AQ*VJW5YF8C[U6/!/_DPA)8E^<P?)?[)
MB7%JG9*S[</&^ZV+X>JQOG75+RJ?R2'G&'E*:A+HDFU70?3:*7<O>4XF'OIN
M_+]8/L,W63^3)6N3'"3!A,4 !4GX"/V#R61Y&>6C.,T7V=J@[M4QL"Z!N@S+
M9S/]8:OTZ3+\+D'C/DM'X#B'H(72AT[W^B:D?XG&2_"K)R$;3']\HM\.BES4
M7Z.[#WT_>??.@?W;#9UN$KKEL._A=1Q,+&FPNPC@Y\"6Z1J_MAO-60DP=6!C
MM\*42H\HB./E@"D@)!QF#R3(J=Q\CI>WT9\D7CZE]5$/9!*!-24I]#>[_7<H
ME5S4)$6@DB'+./H8T,N!5=B"7E]2>A,.QY=11B%+LWSX0O\>3:9FA%"O A@Z
M,!:WDQ!ISJJ*Y</L(IW-HJ(@)*=:^9S^"O1T"W&HL2)@CBX;%7#:"DK=98$&
M.%*SDN7TRKY)($Z&7LX;^%U0H]4'@"X.7)V=\L8#F:=9\92R,^[^B#26IS2Q
M;(/@CB8KO9BJ=%_3%X@(2D:B?G-ME@)M ELJ<@$4>:%:K078-CQMO;17N$!S
M\Z#L_%UQJ+ESG1/.?(^X[QZ?]/=I=^XU_>M/LD--]</?!&?O0:_I8O_>(NMW
MZ)'*,Q?7NO9+V">-?3K7VE%%_T+0?WD?U<7@G]+U1[[7VF.'0FX75@2O:<2'
M0OCVAHI_7Y9"NX8V[;5NWA:$[MS+2GDDC:,0WB7K&@MY.KZ80H$)JNX]3BF=
MIVE,MS&_^M>"$N">$7Y*RJX">Y./M<9N.'XLZ"G;P4D1A*TUE]7A<-I<]([0
M#][D^0*8ZB+-BWPX'F9AE 39DNT+)/G]$62@"7-;[1HMP J\.FWCNO/Y*I:H
M <'E@CRE5Z\D&T4Y&8ZUT3%<CV'GMF]UD[A-0 9/WS0WACN70>VT#[CJRUL,
M07_<T/$^(]<+.+N&_&:W.,.[D2382U.?E8S8NE^LS^E11+L[HZJEN/!.9(QP
M4L>L*Y5D1U&JLTN"&LO0O@?ZT1?DG&14KXP#%MH'5&(!QE!Y?C0EX2(FZ5@V
M:M]* ^S@,MC"1=;653Z);O9'K&3 P6BTF$$%?!)>$DKU4535JYG'A!W/)!S,
MZ LT^JLL\2%"1("XJ^49B9!R^85 4>XUW6\ZA:&"E((MA$OQAE+. Z3.D%AX
M)6>&8R&8LJH=NM,9BGUCP2_+)_I925*XQDR&6-\8$H"3)HEKS&2((67OK\&1
M5M.HC6*B 2FY74C/6T5JN'HB0\NN:HS@(4QUG#1C75OD=)8/9G US KZ#U6,
MEK?ZU-ZHIF9:B/^G*482>QLZNE9J_%,<P\;2">=NZ5.&5$R+(&Z9RM@KOJUK
M8DTBFBHZ7N/[4*Q^A@0QX,NF=N65FAAV$P-:&!"RJ<UY)21&,6 #6C0)*= H
M_>=Y8R0K=WB@&Y<40BU9E.JF5MRHIW?WV+5^GY%Y$(4KQT.0A,-B2K*+10;T
M*DNR[HW)\K(B,S-(7P3SB*H^T5\DK) <5,B56&V2LA4VH9:K,B9 >IPW]U*4
M?*4Q@R'2"!W0U\51VI&YV;NF_-2@TSZ[-/;FR NE]F8S52QOL@3=VP^?D(K
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M&+W<.Y6.D\YF8"A*1W^632J'BR*'*X423:P8228!_!YM3'^0./Y'DOY('DE
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MGR&U0^.^)E1=+61SX(0CX;+[HGB()E-Z8'_+">,0K5=(;0Z<!/Q]T3,FB"<
M%DAZDN"-)S_8\DF #=()UVZLQVG/1:%&TL.W@*&"7EM*J::!S$*Z)1Z@66A"
MPJL@2RB;Y%NZZ2491Z-(M"_JB2"]D/:I26*E5B*: %@@Z87W&9D'47CU"IV"
M-_T3->YSC9EPNR.]QQ^G:58\D6QVD[R0O#2$B/:%,Q0@;^Q(+\.<M+EKXT,Q
M-LP?1=-,@T<#AY02UX!WZF%T;U48M$04:W@EVK;*[G4Y'&W=CT,NI1_D*-A,
MYRG3))[,!>.=X3!DFQW9=#T^!YW=UHZ$9JXE[X3$:-38ZIY5N[6.30SJ7B &
M_K.C.,\.U#VAMG,4!)2IO!SV,_ 0'H48-",?SSGI77/!D'0VSUHKU^=1W!L.
MA%[EBSTVM=GRG<;Q_AZ),<7XV I<ST=TEQI83S3\P4<AT,QN49D+VCNY?.;D
MM3B60N^W]QL AV M+DP=D\%1W ;&XDW'R^^=<AB68E?\QU=?CN)NM5#BM"(:
MCN+"L"">,)C"^X7ALRRAZP,KB^$X"A^9A:JB'2YRT#6:G'"BDOI'<?N:O2[T
M V*.XNHP(YXD"*<MM7RF]JX/79Z.-UI$FN]/FN\=*38V4D'$U,X8NDOOD8+7
M'B@1*4."8^&2O) X92:0Z@ *8PHE<P 7I"#)-;<HJ<\9"7 C)<BL+MM[DK$R
M(I=1O* '00"[8#3 CQ0H6!)Q?6X5,9R"T:"8(86A/E F3A;"/-#5GX'"2*'Q
M7TE"&3:F!VX0SJ*D:H+V0N3G5#$+\$%*W]G<4"4WB+-V.",!;J3@_OK9^Q+D
MT4CSG+*Q #M2*/\?!&Q )!R\4*:85!T4AN-&X2(93D9K *Y("9%K^5ZQNO(>
M6(V#7C=(M\#F*KJF2F 9E[.@H%4P4@WI"QFG6>5^?0I>27[U2D\T55#IVR1;
MLF(O8""$*)4TCMGM1E4Y>GRDDKB3+T(]/R2-1L"CU36IZFEMN0KP>N/VTGY;
M^&R\HG<--U\7/(7U*,(G3 FEHQUK$NYS2;B$3.!AM'\!.J:D$ZOEOCG-:ZEY
M6W+)7P)'X9DP/YP[NOQ1F.!,::3W;$ 081@F8%/BB=\KWGG-9SE05R)L^Y%T
MT/V1; EF\P(["ENYM:Y1>_I9R;6G_?2TF@NWKA^,WO6\?7A1V+U%]]7G<\$*
MC^=1PA#CUFWHO0=((WZ^[&8@L#YHSZ=[_0')GEAN"4"6)G07RCX.(ELH;RS
MCF0?M/'0?;2SE<,!^'G%^0P(UNR/10>PPN?AY2*CI[9L@U4>9O@]E#<>CH>5
MY"Q_?[D@3^G@Z5L-XO8+ GI(6Z%KD..)N8](CL9!^#^+RL%.R<<O ;%29TD(
M;$]/+A-3;)>&[&[)'P@]%3D5CH\D>XE&I-RP!S)*)PE;420<_'P=Z&OGD#-C
M>9:IL&%0!GF%!7V"_A%DT#:U?DC;+PCHV5FH!>BISAA+EEH-NDAS/D[FJP B
M6!5B6M5_.T<ZO6TDSCF2PW2M(+'>6T(J;P^"ZQ6QUG(E;:1J3F,<P&SGVK6X
M9EW*'+T%H5DC9JE&@:S<OA:N7DDVBG)A](GQ.B">D#RJ6^&;%I7&-.8"NV()
M,9FZQ[_]S794MA((0KM(&!MM^('$D$-0OQ&?ID'Q!\G(?49>HG21Q\N_DYAJ
M0(-GLH13:*PD6WX'#K6=[FQ##-'Y-)CY_>SLPR<?CYG5%WG5DK7G,6C1!$@;
M_>8C4K"8_$"WE_62A0!K'_<WXXSNY4*;SU"^_8S5D6=]>=7L+CDT(55=>+PY
M<-%A58_G/W#EYC/9', %+=AZ-[M&B@1_,$"/S56WJ]9B*E:ZW?0@>_?!/CP*
M-6M4<AR:EGI3N^U1E.FQ(Z7,9.RSJ28JQ>H'J$DFGI7:U(59[%^HE :%G%G%
MCZ(*B '+B2SQ9G2:EQM1!%E+]D.]'=34\FNM]\ZKJ GB=H??R#]P%%%;N@2U
M=DYX#^5"S1;7$*$B?XB-#+U*VL55GO;T#*O\,!BTPJZSJK1%\WB-XQ7RJ$'C
MDLSHS2'R1WF_!# 2@ERHU+H>L*,([36]#RR\:M[IB%I SIJ.&KZLXZIGT^;5
MW,Y-9D;G%Y(]I_L8C>Z$T@V/W5&D*[4D'==Y>!2Y<&W?'Q^-Q: S&T[?+5ZV
MCM#CLN^W,,>T=+(>U_G>?LA)WGN2IX_/YQ_JV3;SWFFXC8\BE\Z.?%*']7$Y
M431/:%U@MCB6:-E:03Z]CM,?^U.=;\<A QZ49!3%9,>/^I0"6O=9^A)1(+\L
M?Z,W^DVRSA@=C(KHI2PQ*P\B[>)3E%4^8=77@Y &2-^D$)<8R.N/"<?#M=V,
M!_$4FUXQ[!HNR-<'2B=A5>-UF^J743Z*TWR1$<56MUV6DN0C5G-IRI \)N3
MK2""^4*4FS\CA3-1*$>$A"R5>6.W%,3^ZTT";)#86D#Z#1^N26^V=YP% $NL
MG-/QF(R*X?CJ=<2RA!_H131, .Y:5[0'"G06C>AE575-V_W%UD@!.3KXTO>3
MDW=()[P+"K6F!7Y6R%IYT4\&:4P!^S%VE4->BX_!+,V*Z"^F@"FN:<-E0 .Q
MVSM!D'>5\4\OBB#*F#D _$>-8M:\P&W-J0 R4LPO57PRH.LE*?][DU1%SB\K
M79];[%RP57:+ ?9XI8%K /.ZNVECRYL,V"%=NDT 2ZKO0JF-'6\R7+;]4@LY
M&H&=6BA9"+!&NAXHW=F#[3K-MI4]7G%]D8ZHOP+@B227;$I@?$+*:+HD\XR,
M(G8)T9]CPJP_2;A].0E0T)D*F"%E2O/?$UMQ*$;OD*UYP%E.LQ)W^CC!4<VB
MG)Y= &#X#(8_^@^F.Z3C14['<FXQZW7 7G"&5/);_TW;^E$,2C'2"6NES)=^
MG.9]-HH7(2NPMGE"E<^J+EX4QD  M;'J(_3Q.89TOLQRU44A/)^0H.<H<?S&
M=_I*('\^X(CTS&S"N'IM5-5TM7&KS8,["DG>"80RQ^YN)M4Y"P"66-I%I8D^
MI8,1/>S@1Q?T/%:HLNH% ,M^W=#F[AKSA<#X8Y_7BMR^7F3*XCG&._-C'47<
M98?T:VZ6TNN&4+D;-:G)A--=N?&.*TS$A,+6/L*CB/&RIDZ3T%JNRJ,(R[&V
M/VISK]A+ZKU%#FH$J(D@Z,[#>EQ)T*;76UN?+4Z(.(K@\*NWV;EACT+3\+(1
M%@[EHY T7D]!*P_WD;QLD#=$XH0_BKQ>9/)+H@2.*S_0P:M3_00XYE>GS0/)
M//@!06AC5"RS-BYSF;D1EN&WYAL*EWJ5NP9Q(]Y%1(_8UYUAJAF[XINN9RC5
M+5Q9G&OOF#9A-L=L%+1A:.,('^]&0=1B(]X,5+8A0-ZW [6\DU=[H;$T<52F
M#>-AXE4_D49"'46],NQGN#1.R[LA!$,G1-X!?C29=\H?O&/".-3-^WW:HP=1
M&YN)=I0=@LD$N>YI:TN?VL[2]W[)[)[)+Z'(2KP_U3:$K/Q$/RKM&:PQDSY8
M/YTAY4\]CJ8D7,1D.!8#*NO5J#D=4#Q!2F_\G4RC44SD;6IV!P&XITCYBK<D
MSPFY+96$?)1%\^HX2)O5*&8QA)!2$4O0=A7-+1@5T<R:LQF#(646\$ $)P%8
M Q-3W'8GLGU#JE(A/-%?EB"[)$VX-&8RQ!I9$[V^QPVPXEJ+=:\!KVV!,'1.
MPR/-L1H8WCH^ZP1B$-2 N9K$Y-]\WM^?'U#22 P9J4D]S7O7/SDQ0JPTB2&B
MHLY%Z)^0*$_&UGQI<%GUN%QCZ7LB._D_]&6\(D\Z%@SP_+P4U!KX$B1_@C\X
MRG.HJEQ3EGA#V);8O00%,&Q[BZ[CQ:A8,/3S5> A%RKE) :G72T> 9QLW:_T
MHA*$V3R0&14*BXR(2B@9+<!N0Z2<W9N$2B4*U(I;TR1=R3V!.BV9P38"*V%U
M"PZ=.IK"\6PWD'*+A4"IDFQ5\]C.-)#2OW8P?-W:2-6B- 12S.M#!L-W9TLO
M;?GJDX(?44(V+2EH)>V]\B-& IL%-0WN&-_^L-./&.$/+6BHO.#:4K!K=9M%
M8^ST4]EHVA4J>=6L]2^RBNL+XDTA]7[HW9O7DQ;0@IN^S5+?3TZQC-&#F*U+
M0GYHC5Q%TYM,L;-\I+2OG#R;Q^F2K/H'\\&LL* _#<>;[2K#ZE@[5Y4SQ?%7
M@%Y(.OI7DE"!!*T+!^$L2B)@SR)Z60DFJ4M,:R[@AN17*D7LI@M%M1L2OX1D
M!N"!]B#D0B7U*DOG "Y(SLL'*NGI70L!E9?DA<0ILSGI<)O&3, +Z9FX=0\X
MD0UZ/G6'WX(;R;[$$X93HQLAW-3:C.Z\H\@IZ)(!F_3O9I\/O368S@70I+7)
ME7X4*:-^65VM?QRZIUI- 6VJ[;"Z3[IA\*G=<=?7J0[ZL#MXR<MB4-Q+CAY[
M9!\7SSGYUP+8Z 7!XM-:D:\*QZTZW-YG=,=6N1@"?5PV!7)-3UR^?_.LV$*#
M_FN# OT'Y3J2!)1GKM.,C(*\X#ZIQ ,!W/>]JI ] -I.2!F9L!E2Y1(,?@19
M>$?/#),*I4GR)J$G<\$.Z;I/L>@EU>$G&2F1VM$P[\=*C EPWQG#&@R[--FI
MV'0E1U=LR#'*",<QRKI\YVN>J=^2?$Y&T3@B(=?V(AW+@';:3NJ._*@D3]E$
MFGO4)2.9:,(RE]!;(@HC:( =P!7)ZB%(#'/"\=]/SK#:2=9O.E5S-<%PB@%6
M '<-))756S2<8F#)V>TQV'##73"C/SY1+L\I557V4?5$X*Q>=<MIV;+S#.M>
MWZIX<A]DPXS)])#5'*3J+9-( I0T9E*\/F#UDHF#/%]3>)BQ,B-W"Q"ME+/(
M:)&Q]+N+((XA/V^U$]5 87^3=JO"/B,I'8:07P6CZ>Y8-Q1IK@LT07*V<F'?
M>2ALCNAJ"T],Z*!:"W#'ZD#-@U<JE"4S0!KW:0\ENHIP/." U@0Z>J&R\SX.
M1DR=EGK:^(,A1N7<[@H1AAY'+(5\Q;1B!98_DD'D5*46&"]XSCCE>-#KG$9
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MQ2G^*Z=BU#YI1UA[YNO[O7%+@GP[U4!4J8J-8Q6O@R2$>Q)":8 (^V:088B
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MVP+51=+=0Z3Z"_S?,WT"_>?_!U!+ P04    " "@4'I<C9GW<GYY! #SG1\
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MZG';NFL&NFE8FQCW[TG&ANEU$OV+C2[#[^]9PH#KY&TC#0+/-3S#L:N1!A[
M+M ->[M&ZGJ^;IFN'E0#A<74;=?TG"<=Z!<\Q=%0C!,/XMN+29@Q9+VCXW0Z
M@_-.A_PH \YRS1 =[^?U+5_#.?YT=!MFH[,948,_6'0]*0 Y(#>$U^P<.&B4
M@," )Q<'4H;Q)<NF.>!IS$ Z&+'OLRACH[4.A&%8KF'X@;ERLF)&ZV\*3>;]
M_?-]OV*^?V,YSC89G7R?L2'\\S+%G\[* KD6BDI'U]<9NPX+=@HK ,PL&OXM
MC,O6H[0,4!-^"BS+V @)>.S>GWQGV3#*0^ 0S;D:ZTW6\'Q?MWW+V\AL88[3
M-+DHTN&WKV%VEET4L$<C&N]7EM%$USJ:GJO#/ "IBX,V3 \0#/_S%*/FAQ,'
M>YKG)1M]*&%]KV&@4<K'C#^CF'0VIJ$?A[.H"&, YA\A;F [183_TRW',GWE
MB-4_/=\>/,ML?#<(',-3)@,C=ATS\!QW$X#ZPHI34(^F[%.:MU+UP+0=VPV4
MTZT'#DA6,)!M&)_AZHYI6[Y38UO]:0/T!P$Q26,0P?(3$/B*><LH;<]P81T]
M75E%*S "D![U%X7L.8L9$,:S\5D&9#_,.*W,+R=A\0?+V->,W41IF<=S%*=.
MDZ,K-N=JS3)00/_37=]3N+]MNS"/H"LS;"$\MNGHCF4'+TMWGFZ*R]3(!V:N
M6UY'YM<B]X/ 9GF6[P7//\>:/S0G\J%DE^G1Y6>@=6=C>=-QFK>S/^#:.M(2
MJYJ"Y3DV4)(=&7\+^P9^9YB^;9J[,87E4P*BE0]BD_NL=$!RG*/1/\J\0#DV
MAS&/1A'>$\9?PPC +X2.=@V!#IF0>\_1.I&#,G/!LIMHR/AY.^?*'MZQ'O8,
MQP,J[X' V/&I+\/6L5S7!]J_$3'CY6:^C'94ZX%> FO?"@EP&91 Y6W3,FUW
M(\:<>T7H1<DH &IMF,'S:BMK+]\RL$&X]UV/U,4MD9]!CK2"H"%=ZJ;AF+[K
M/ZUQ:2,*[#)@ Q=&;!O/*V>UV! >8-1Q3,LP75!:MF2(RS8-([ \%W13XUD5
MCL=98MH,2 $0*P\0L33L)[7%J....",!F**%$Q#-DF'$UC0_ RL B=GW-F*>
M>-AHES%A6[[E^$!LNZ+ M$A@.O#CP-J,[/F#U-JP'-T*3#=X?B5EQ3X(,R];
M14Y,"\0<W_/J,<._;<=QGM>N^Y@A&[9IZSZ(9FZ]SLI/6SIHSS1]!TB* @[=
MT7W7-IY7G'PZ]6\9*HX=>(YAN+MB0F@!CJO#!CC6!L2I)[*"+,'(!2'*AXD]
MJQ'AY=6Q9?09MNM:ED^!2EV>>0ML31U];[YA=-WZL QWV[9@*;S-S/P^);(%
ME+[AFH$!''0;QF<$GN_X%JCA-70\"W1<V]U(%,6]XVNAR#!<Q]-!CMH:N<XP
MD='INB)\.HZ-.J&W$<55>.\Q#.-KE@X9&^4?LW1Z,4FS N,S3I,;)L[GFI$9
MM@OC=[V-8$ =<LT#%36R%;>&#<OMNK7CT#8-TP1Z\/P2WB?463Y%X544 UUB
M^5$&9"NYQO&?714\0N8< V?2<9G#O1AUM=ZZHZ+N^/KSSD%9]QG+BOG7.$P*
MC'D!>,\0)+]E*PXC*)$Z/WB5=(3\U37,C1"SH^&PG)8QFA,^L%G&AA'Q$/AW
MS"BV)1D=30'RT;_H]Y7S6VMJIN[9H-U[UD;$)E#@APQCJO#:>91_ ^:'/X37
M*\-M,'S*UQ7LU#\M6$O0?N8!MH*7&[#M>Q:,SE?""NM?-C#<=4EAH-NF;G@J
MQ)6?-A&TM2;)=ES'"WQ+L78H/VW-.#$:!@X2Z!^J#;WZ:6O&"9S$]QS7K+==
M^65;3::PDKKE!(;K- )+?=,!D6XC)M,/;,RRC.)?>6PQB'-K&LVMP+0\&.PF
MEG?-82X;21W=Q3 O?2/<;3U)TP*6ZUJZJ5CW==-S0<=]7@?$,T4L E@#T]<5
M$4A'>XON.2\;6?-#LVF)N+,\V!P=H+]SL_%MCT:N @V(C1>8WD;<2'?-1[4:
M2+MJ:\SY,K[@;\>V=&,C4MV3S&$95:":@9I@;\8I^A1S6,:28X/:H/OV1H25
MEPR.60*@;]F![II^UV?>0@QUTW$PO+[K<4'+E!,VW7!-<S.NX?L#6Y:I(G#=
MP/;=C8RO'AQ:3+CKN@3"<C:328COV3C-&+\/A#8&Q 4TS51X14X+-LV_@/Z)
M24AI',.CIS#%#.3[MMT(?!UT>T?5E"T7_G_'V8A;X&0\9O#[33V=<Q#NVV:]
MUN#A6(&>'RSGN#V3VORX?"J1%P8#S'E2523F>IKPD[208":9R-<L:O?R+YO,
M3!"(35/?D,9S-!QF91C#O B79\6$99>3,%&P>ER"KD$&)\0H_V.],!W?M"Q;
M]_S-..J>;"8MZAU(B>AW\S=D,WD<2)7LOGN3^EIR.76#;.7/J["\Q%Q;]M6W
M#4^WG:>579IYJ]5,V34._IS-T**+*:>CZ2D,_"8:8=8IYI4#,+^F.;'AL^RW
M+"UG9QF/BRH8^P)O.ZERW$_J%/?UDK4#'^U^H+>]6U40X-^.)Q$; \4:EDC>
MS\9CH%G99S:]8MG]":S-28]8]/8(ICO"*7^,P^O[!QE]OSDP'&1B[\9AG+,?
M^>2'=%C2%Z-\"*(14>2/\-L:W@KY>7/OW<>__\BW3X !%O-CLB''L+'L^U]9
MJ\6C_;O6WCM=UPW' G'27?E]NK"8\H]#RM DQ$ ESAN#Q=(C;W.J% (CT*@4
MR=LP&X*8P=8K<$)/3#(:OEH*X?![/I*7L?S$G_?R:#J+&:]QH(RV;61\Q'E:
M9HL#IG(;;\6BT0()>Z:MZWX06'OJW=7]C-:^>:FZ&(WP\CABF48KP5KKE!R?
M_K6Y XL/KWA[SH_UXE5Q?01C^SZ+HV%4\(.DC:(I'N$T4:RE<9CG9V-ANSC+
MR-5V]#W*]ZCZQ-L3^"=2#&G<D$>R]0-+PWQSQSCEQ;;U$_.;T2%:-?DBS(H/
M(/Z]0UA@\1'=J#Y876M_%HA#_:1A'EA&/9K1\G/RXO)XY!4!FG7@9+@^R%BV
M[3E=PA,0\K=D:<<77 P9Z!91RG%$E\0O("&Q89@76PHC]T"W#G3[!V"T\.0&
M8%1+Y!V"426PE%=Y-(HP;"^,T=2*9@0.I]KC'MW $G^-PR&![D&0ZC2D>5FH
MH@66\LJSPA(D>MT&H?YUP9*XY=&'BQZ&6P'#VH#301@^J]#68W+Y<T^#25UW
M[,#1>[FO1P*PR, RNRF[]=3IU>DB06 [MF58YFO$\Q=V*Z[Q%*,>SUM!8VTG
M !H+FLAKQ.3VFNT43#@'NG=@!AO$1&7^WA)(O%8;:.V*WY*->,JS63E]C\IB
MDF8PDZ;A"NET=)T<\QK3VW,R=Q5,M1MY2\#TA"32;B[F!DAD[:?NWFHZFUY-
M8#<^6J&V92V?DLP!@>-.[B9U@Y__SL(,LWQZTO9HTA9XIF$Z;B<!M,PG,<RD
MB:;3/ M9K-ZSI:"R?AA4UL9!9;BN#F3IE0A?.PPJ^X=!96\:5*;M6X&MVUX/
MJBT'U0ZQ/Z4PP9:@ZK7R#*6D=1=W8H<(K>$'MNV:MKLU._&4E'9EF8GW<VQL
MU22Y?V.3:!@_T."^.>/FIC5WI N!XW33X,U9<.4%^90.>;!^ Q"_L81EE(M[
M-)I&291328T;A@V(DIQM#TYVE@T8EFD:MK4]MK8>8YUC<%;@&Y[N6!U6)3J)
ML5U2+ QL'HFE/EXMQLY9SL)L. &0?6 W+$Y)S-INA.T0I[1-S\"Z/#V^=@A?
MN\0E71VH5^!:?H^P'4+8#O'(0/<"RW!=MTL PWBY<TSOKL/G/H??HVDYW5+
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MTXKS _AVFT]NHER2YV-HNM]-YMX#?/'BDP"<P]3\88";FP.XJ5N>Y[MZM]*
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MS$J.?7*;SB9A-@VW%#P[).YY@:=;OA%T*FAFI\$#R+$.C!\)XEMX<B/M?^W
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MTW$<4W>=UTLQN+$UO$HS"A?;;GQLG'#8NN/K9F!URO%2Y8'#%T917!;1#;M
M42(J(I:??!_&Y8B-/F;I%"O?E 69WL_&)V&6@*R1?V49M6MY/V]_P9:7EVOX
M *T?]L5;+U ]W,0>QCT4NPG%'2H2[9JN'AB!W4D;0P_%78I0,EW;=RV]FWW4
M-@+%D^DL3N>,;5D=NYUETY[O!8;C=2M?J4?D[G)KP]!-70_<[8D7Z1'9O/C:
MF+;A&):[/3UHGQ*.QVDRA%=D!+?S*/_V?OZ>)</)-,P6ND-3EN<YNV%)R;ZP
MYVL=US*B9;.@#$Y9NGE+P;Y# H'KN+[MV-TL)=C#O9<V%O/U#3WP#-_OI$;6
MX[V791;"LVS=T6W3[*0'Z57#?9UA[72&] YQ%5L'CN)L49!^?\JVY915E>B.
M?MO2<[9#R@H@/\#_\WIMI3]H.W?0=HBA>;KGVX'=K0+Q_3E;<U@[?LYV2#TS
M=<\";F9VM%%L?]"Z7X-HE\1'U])MPW6VIY1Q?]KZT]95&=*P?!U.G-FM>I3]
M:5MS6%TX;;LD2;H@1%I&-^.O^\/V^NH0[I)<Z8%(J3N^W9LE^\/7B<.W2V*F
M[AB&X[MN[WSK#U\G#M\.29W ^5S?,\QNEK+J#]\KJ1ZW4\*F[CNZ[[M&I^H0
M]D=NS6%UYLCMDHAIF8%KZ*[G]T>N/W*[>^1V2K#4O< U=:>3@N6#:B+Q!$&6
M;7?MFXW71O("V[9US^J4S:VMA7KX?;M:J+]H#3W7L1W7-9Q.<>*V78^2?M?K
M]G6ZI>M!T$D+7_?*H&T<'Y;O>('I;4\-ZB=<3&OCBVD#>;7,[:E2^H2+:6Z<
M<IGP__F^T\W\NZI+&=*C8HZ":IK GPOE*<Y9$48)&\GB%CW1XG5/#-TR[<!]
MS= X&@[+*;:"9J.S8H+*_'26L0F^[8:=)D/0MGNT<$+B^J ->]W4A]=%RV@4
MH94GC+^&T>@T.0YG41'&/4(X0AP[\+#'ZBM&"/P^39,MJX/TLCT*3--W7,/K
M9";7S@L@.VN>#3S?\2U3[Z1*WA5VM+/H,@-?MUU+[Y25KS-$ZT5;9>B6%;A6
MKS3MH-*T^6YCMNT%0$JZV:"I*USJ)1'B>H$5!&XWJ\%U1&?:."A\-P@<4)QZ
MZ6,;I8]=#2)S=1/4I5=-:;:>%>TJMBS="$S3M5ZS<7A[*=9+>G,-K$IHNOJK
M5J5W56':.%H\P[)=SS)>,QW9>B;UD@"Q/<,U;:>;]1<[HB]M'!2^[7FN[AFO
MV2:WO=+'KN:YN0$0&ML-.EFKJRN\:%?!91B^Z02FKV]-R&C/R'8<47K@NE9@
M!Z]9--I>+OB20<"VI5NF:7>SY6+'5?#-1XR[?N#8CJ[W<L\6RSTOBA#+<"W7
MTE]U3L%6RBXOB@K/-GS#L+O5@V;$HK<G-'(@"1G+<Y:+?]2Y<7C/^S('N2//
MCV%9PN$6I<7M; @>I:=@'EB7X-1EH657?9>&JSNF;?G.:V9GNXNT75+1;=/6
M?<?P.L4B7PW2=HE[!H%G&);K=](8U!>,>DS!J&UON[E#Q\SV/0N.F=])(WY_
MRKI\RG9); ITV]0-KYOE=SZ&4?:W,"[9^WGUS[_ %\-L.)E_@D,5-_%=W72:
MS,HBISO,9SMRRN@^LS O,Y+P/F;LGR70@OF*H2FW ET8EED6)=?;<Q!>MI24
MXSI>X%N=S))_"C!;/9@7-F9KP6SJMF?JGFMWTDC74^97E77E@;KL.:[92QD]
M858O[@"6RR3B0"XYD&U=]X-@A80QY<OV3DQ]$F8LEY^0UUJ^CM^X_],X62\P
M5IB=Y.NC/+5-PWO[^\6'I_JR87J^;</_K/CT*+J!<[9BJ_!57TK0X+"XY0H@
M/W3TBS-8^7YE#!]8DDZC9*U1K+E]B\-8^0EYT_)"/6P?;,/R/"-8U5"Z.?P9
M_/.I$&#J/FZ+:Z[(<)3O)_7\@I_X)T.?"W/V?,=>\>UG0-_IIXL>?8O[8-N>
M;NC&*J?QXAJ>_'[^9 AP M]U0818(3XL?OKXZ(=(7_3];<9BLFGEDVBF ?_.
MTK@I;N"CAVEV_<;4=>N-N./-.!P6!^,T+9*T8'M:D9ZS<?[GO3$='1/.K._H
M]IXVSM*IN#+\;\>T#-.U D.#/XS  ?IJZ:9.?_F@;QB&K0?XEV?X;H!:+;]D
M^S8<!<NE2Z[N&IYMV?B'9;KP'<-QZ#[/L!S;,?G;#5-W?,]P^:<LSPT<V,J]
M-QN8/AS= *85+,Y>]VPS"$P:D8N%5'77IAF:AA5XH/KPOP+/LP+7=/CD+3U
M"NC;_"]8!5NWK<U,!%;-]'W+\A9F4D=L\=%C^Q[8"#ZS*A(=__(M.]#A)7PN
M.LX&,,VGXNA68+H!7?)]+W!,.&FTQ: !>G")_K!Q)SW3XTB =0L,F^^WX]B(
M)8\NF? R(S!,B]!DP_+!8OLT!L>UX T6?QV@PC8M$Y[D?YF&8_JN3R\,\+/(
M;_A@39B]90BPZCH,1/<<_C$'L&N)T<)JVH$-"X!_5/4W^#P\&*KC\5'8@0<
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MJ,@'0Q@N//DSC/552!CW#F3%7NYK\-AIGH4LCK1/T13N& V$M+"!4<.VDBK
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MH$?1KJ*(Q)6:4(@8QX:M2(EL VJ3+N&%]QD%807EPW$9DXL(I!A6T'L$BI:
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MIKCI8SUSQ3KDEHI=]/2V"P 4H5U-B;:<8:G823KE4=\D?XC G#J(.93-J*\
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M,*YC#!.&3>INZMJ%'*4E%67$QC% [,)O#)5R,I:E.44V7LW5DCQ"I<EY(T1
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MAP%M%]0N426=.2NN0$?ARJS<]44)130$DC9;P9[)SQ)SIQ#I.2A5"K:!+*5
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MI&:]S%$]K@^<VH-Q42U>[9[E15M$R["5CEB@@*B\5AI1@5RH+G*!C_.PE._
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M(5M*[\J0%E$OD9@;)Y/?1GA%OHU@["D]M9B>FMHBC6;N#DV\[![YW%I96?:
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M6N:B)%UN[WT,9W'!VG9!?RQ<EWY*"R79;!M4-AVO.LH8(*V%$[58!?XW>=S
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M2!Q%87M>YV!P].<&,7K0QLI2A.**L)H?3L2BZ]H;YOV@<OD$,=17E >G#ON
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M[R&'5@LG=-0A2JB+\["\ 2Q?O2DNZ3][?Q%_"*#U#E-S(7*YTIQOWR5G&.%
MW<+DX&U;_G)7KOQ1_:8L=[IY="5B-]4.2[O"XN9B1ZUJR*-GK_<UQ%B3-W/J
M=*.A+V"9K<AJHKP;]]3H7/*WE;#B'VV[CH08+T#&7*U,PC5P)_[CV0O_7[)0
M9J0)VHJNS!6)&4U:8E-":.H1'$UX*L"\*N&4)FZ)./_R7G[S%?9&,CXBBZQ6
MR$WO2MFKHP+-W:P)&^WC/31./R0<V&&P**1:_>.'%R2G;,R0H<@-":VK'KHT
M^N;A PHF"H6L>@OB3L(UZ_M2[*@!'AL8#]&Z78UTER/9R%_++$+#G'(=,G&4
M[=#834(T2#P6@9CM1]ZCN>,_;IG1I9"=<\,QYNS<75(GM[L$"U67SM+ ^14'
MJ\Y9A]<_#V41. W#R%0Q"Z56-/!5[/N:922/W#)PC,B17((A C;.^2B_7CJF
M,<A=N,\ /H6MZ$^$[/G-5<O"3GI?;'!GB%_],U&\EX50F)Y68+'"K9'K+BX;
M'+5,-^"*44Z\0G>F_9'8Y<_LM=&.0YUK6JIW\?#&/G'->\RD^7@1F1R/%][7
M](2AF)Z#\C[;^H=*/$<LCFZLRX3T XMCIA^_*;T-80F +)>WG;J%N5G"A%13
MA-#T0BY2EY?$86)6"3JQ)1\Y^NV-J'^?V^LXE4"?+YX@(H]>^EW-_))F.<Q>
ME!O^[!KE5,:_'[T"HPHMKQU=FV0Y?PC3<+X:'CFCTIE=^9 'RXMN(>YAHE-.
M?I/I-4Q%$*2#/Y?&,3KF^:6;8A#6/W+:Z'N!ZP+^C(O^#%P.O['#'VO9!Y1_
M*54/\TMY!V6K]59L;DW9,5D4^ R(8J KQC7]N;C @L9D&L<MI\%#*WX$'7"S
M'XW;N3]0S_ZK6KT!@0K-^CAX5X?^]G?_Q*5W$BBS=XXGMN; 1L1WXSV5:7Z%
MRSI+N:S%Z+'AKJ4I,RX4N3 5<N J_XDK+VSZG W5BK6W+W+J X7 4 ;+Q3-K
MX9IMX&5Y@2^\X!^+Z\ZK('L%>8F]>[6Z\G>KR\2:OBUQ?:69_F^PG< DSS<^
M=.MZ(UAG*HCJS4AA?3D(%B)O7G'L*09_"]6,HENS?ZO^(T_[GA\E1LY^XNI:
M'KDO[49#A3EXSM;O-T] [R<[ 0_[H+W_(*U .#D(D355V1N\LI83Z&,\>R!G
M2E=D^:M?XADE#D*J$8\'0:VES>(XCHK$"ZYL9=4=H%-+>G03*3L;B-J#) 8W
M!X^1[&8AYV&BXF0F369F%G#!\^;F6VR:["35H7@D-2E[>DEQ(,"C+[ A0K+T
M OO2SF[=@>[/^5&+[YT;RO.$S0LWD7&BX#F0?YBJS#J)!G 6;T3-2QFKICW+
M4^35(_=3XZU@-Y3$>O77/'OZ^.E7,15PX5=N8]VGE )+IT3&U@^[AG.H&6ID
M'%!@0A;"!\+9T)Z%Q9E>*"?>F[)8$ZMFVP[^G2FC#]\S"2C3E)@^=?GKSD\S
MA@&'*8)49 1QEO4MY?KACG+1,DQEW&ER%Y,#_F8UI72[<$9=53OX-/4EG/6K
M[=FZJXA]F%HHH(]@@VE8V_GS,ZWKQV[O%F'00.>=D/M. S7_,LZ_3)P[.T3)
M[A1-]HIV(TVZ5(/NU)?@_L*XK?C7A3C_FB9*KWU=M;)S'\L^9GD?3(XJ<9L.
M>;?1LW,!TN#GKD8MB3Q+9LN;=^_U0FE4=9F5=0R"/EPS[)FU4_EK@L.8+F7U
M'OP&X3;^%")_G.*KL)/0XFDWFS,N?6)3R6-:EQJ"S/9IDWMUH)>B8GWT##8
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M&)J1!$!7":;) $6,=/EQ[<%SRI"P]_6+;N8"QTBRA-A[8F<FF[2GTP8INHX
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M#!!R!]XLY C4VU'NQ\650.DZ^\A2(?[-/+0/?+LA^S:E)>)GKT5E'%DOL.N
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M#7=^U5R1OX@^X]J?/]*T9-J8_L@3X$.NNOGVGLGV+KGU,!^AG9X4%RG/X9_
M+T",+;Q:<O4A'TR@'Q0U.*)H%U""2[OI]'=H("AE\7,_QY_LUR_VYMX+!O06
M>HF/LA^87HN;8/($Q!@O[8A7XFI$/>=&Z&/Q-+\2A,)?^LLOLC71NN$$^<GO
M-513Q(L$O.63IPK;$8J-(B-983HYDM;6_/]G[UV;XS:R;-'O^!4(W^X;4ER0
M%O6R9<],A"Q+;IUNMW0M]_&=3R=052@2K2J@!D"1JO[U-]?:>^<#A2)IM67)
M(B=BVB*)1R)SY\[]7,M*<.0S;#C:3NI$_J(B<$.W0K9)&U[(M15F(*9W7F_:
MQNJ_M-32PD=F\QL.AE-WRZ5149)9&N'>L-NXLY$MD>QCD0D(EWF<=5-N3R,>
M@5&3KTRO]/L^C<C1D&]A"9.$ODKIVMQ;A3 #"25:O!#9@^+1O7OAPDBR4;Y5
MD_-@.V 51Z@/#QX=+0#!J'^-X%%"5-XW+VL8<K5+W#1;$4EA"D557H\(KN1
MBR;T:2!_B0$PPBC]D01IZ8OI!FEI=+'PJ!P1V9A!R_-"G;+ Q!:[N&RLG&NW
M+EY78 ]WJE]3S3X/ _%MH,,.!X6^,.8?1\X"(A);1H8WHJB%E^[<(HIX1B0I
MZ@'=\I]>8MA#XOQ.(XEP%K/(+POOB_OJ+1J[C6);M)V%W.UZZ)Z@DCT;H<!H
M' ;9ML*V"&5[3V8#VHXD$HD2601P5,&$','MCBFR#XM3VHDHB!$W#]KYY_$2
M2S+9UCA+H.>-0U),;@5;T'+:@,LI1$&)IE:18G\DDXC??,39E9;U>;5:;23#
M_I]?W/N"/[N%G]O/OWID%_5B.,.E]_[L,P DM7:Z^YO<_O7%?V7_,<S:Q<Z-
MH[.7L+C3S;!]R=!N>-W"+M!G/_QZ\V[RF\/W#8NI&^\_O.3&)X^_>K)_Y^3%
M9BIRQ0.OZQ2AHQ4.[@A(HI%!8?0A0$-OI1^TU-64T?J$+'?_1^43BQ[K7L"T
M((-U_].Y$7^IL_DEE_4#R=2M_/PV\J/NFNC_P,FDZ-.1H$@'HD1V61V@+8E"
M6POZ2W+<FI%'C>_1?6[EXX\J'Z#"GLM9/H8\N\R:D, =IR0 ^JB>&@<;J%M"
MQF#,:8Q 0H52ZK*KI2L$VJIL)' 0'$'UY$(I/@&&?OCQ=1J6]P.(*%WC"PH;
MSMR9(/T1$:'-.NNC]-,$04DZ01KON!7]/ZSH-X'[ @61VVYZA1,4NV!YTV[O
MT;AW*P)_5!'PI^/\K&U[): L5TH:?5Z%AC2/+GJ0I8B(6YZ),U:<U#AQ&DS!
MWP1U4%%AM7G>][\&Z_]6O/[PX@4KJ:L1+T22#DG_2B(W8CY5@J]P9-Y:"@%[
M*P!_6 $0M'0-5>]9W^@>T2!BW')A9022;>M*-DY:EX;&YRN4AI;SG:@63>W>
MRLD?54Z&L[I;'.%,V 4QJ9MS",HI3.8^7\GY) E[9]B"(=>,9?3 !,,D2CTR
MZJ;/$Q>?3EPA73)RD1U6*6%O;Z6J,3INC])W=/)# AGVE\)FP%VQJ::O>Q3_
MAG;=$0LP2K1;MV1BA.\9[Z&&(.>,R"EI33UAN*P*#PB3RAU2KG8]LXZA. !1
MD_E\2V=5"@5N]\@?=8_4 E/B/;\T4-770]5'CFAQS6!9K?;8RY^^ZRF4R]HP
MM?VUD<L9HT H^1=[]8;R+:*ZG;4H2CMY$<76XZA_EZ8$ENQF8 *WJS@(^1JS
M.!/J@3)\.2)S5HB%1@>2D+G)4+S9DD6 9_6L)D\9SR!I$V9OLP$12YZ26XK#
M9*&^.,E+=8JB&B_/JOF1-])EU>0/;ZO)?37YU[?5Y!\[2WBK]W\[VP@H$U)>
M)F 6DNJ:E5UG+ 961Y%6(U:&J#41JJ2NB[+KAT.5\/?3^&.2PH\-&8_0"@@)
MHW5H*NGGPQE#2NJ9^T9B9H4/$]-(L?,CRF8CN49_E-??S2[1WQLC'@3$'ZMU
MH_D*ROU34^RWN_7SV:V1)4.;"EU[8G2@"DNJR@K;IEK\%%<B"7HC+#J4\S:1
M$Z18(<XRDBVR<;:6)KLE566%G#&RB 9@I*1=R>L9<!OZI.-!&PK9/8-J&6X*
MWU?8-EHS*IO0#5?0*G4<4LK TGS=;Z&8LNU.2Z,O52#]GUYIB>G(.:+1)V5;
M\HI0L2/I_ZCT4AM:SU.T4],<4!OGK Y)2&X%7B^T\6 D"H7CWW^[^V]W__OO
M?A25AL,QK2>@2R-<6TDL@'[.HFLW&C973A1>="N-M]+X;R3X%AYA94K5W@K7
MK7#]>X59SFA)6VG<B2JG<S7?#M+9. ZK6AVFU.Q]B_/WTY/#6[EX;[DXZ$AJ
M1:;[I>+!)'&\WN!@ K+HP8BA!>?TD#S^].3G=WSK:RW7B3N66+V<+8.'?*"*
MB8VOGK&X7L+EEE;W4)!MN;HN\A<ZO=;\>4NWT.M!G3203Z/,BY7QLB.?>%-@
MQDV16JT29=P7,.HX9B.<-0JUR&TDL0(=$$'SU(_R=E9&S!EBJ"A0LK[S&'RO
M1C4K1*=Q@!LQ[)D5?H^>:6U@OS+BSJ8-NH?"*5V]\S58!S@^N:0%\CJ^8X;P
M7<OM*BV0E\ WATFB4ZU19/8]7MBDXKKP:UKL5[(=RAK@0O<-17PENCC$(QU"
M;B$2PLFLA7K#6;3+JX,W7:?8OZ!_.U5N;V5,4?<'FM*U&'C4IN\K^\>LF+[U
M7 O2I;%F?VX/9!;3;2>= 5Q=]KRAV"\CR6W<@^A)6T.G(7_YSZK=@)SM7]6X
M+\%J[/WH0X_^N&5!.X,,,5KV%8!AJS[#A&&*KFZ(L;R]SG3B>X^Z--=1Y$[;
M917JHB3)/'0(P)Y!E10K?A_AC+M'2FW0N%[[R)XP^8Y#0RE>[>SEBN71U!(D
M"1LANQHM8O3%=9+DVA^%5$]1F@IK%B&9"*9&A=9"H"2*"@53'DA!.#B)?J%8
M5!< 5B@\[$BT(YR?&DRW:#/YKN:)XT+:91"(2<(JVNGU =M7KM=J9.?OQVAI
MOW8_E&CD1"F"3[5BU%Y@GRUBS>X[I$]+1M1I'CJCL92_):AITI"W!UMCQ*S<
M CNI2HB1EM$Y*''S^AS%-&3Z'@'?%3I>)S^[2 *B4%Q $=>T;Y]B$(0<,-,0
M$]@HL=HRQNALS!A]P(:Q>)_745VUV0JRQT>"-_B(QN O4H8)+1,4HC1\9NFJ
M:<>K@ XHOYL9+9>(2#XE(K#_T'\I4>YI<KME5VX7@I8TVPK9@>*>]XH=D'?8
M*RGK_/A%BDKXV_1RR?\>?^5F[CI3?#310G_K)[ZWG_CS50P^OGBCGY8H0 4I
MA#\< &=3"=IA3P\!!Z.V.B#<7PMOXKRJS_E/5B#OK,_#.1C;1IMWBX3<!L4P
M\A-3FO.R/Y-?YV_KAH0CN&0KN$)==5&B:,NCW1?2(6+]9=#ZI).IE06-]XB]
MXH'4]&X^D'?; >U,Y76LYO<94[QMNZ@T =NN%/"(E60R'X*M74YAS1N=H_6J
M3](B@\[7]+6^T8._:8L_@MBE@HZP5@[> %3TN4T%#B[W;JSAJEJ<5MX8O%0B
M\/6&'TQ\V"%TQ#C_=5"RG5XO!_<%0:T\X)-ZAX 7Y3 (#"ILPY>1!DY3)6GE
M$<RZ,ZG 6Q@KP(QGLBFXPB^J,@3!678ZK9-!>/(@>R#$?&0^#L:0O%907/?S
M&V$N>6-(K$\5:%J.?[&G!Z.PC,(R-'A[-QAC(I!BQ%59KV.>$R=N?21OAC).
MV446H]SCFKEB]8A'QW0_T%N6SN;FBO)DV*ZL44K&0;BP;0>.U7[\]+G;PZO\
M!>]_AJM[8;S7<K$7SYX"8MZ][;P.5%A[8YT>HQ$<V<(LQ.]5T$$CNHB:%X2)
M\/!>@FME4.T#26>YGZ+F98_Z$S!IDX.O53&)N*IZC_4;H=)#CS!1&S#7.%;G
MD"$:Z\5H]);DL<*:7EXT>>/V@]N;.W,>W$-LX]KC=?-'1D7@Z^W4UMO!\:'I
MJ !O"CVL8> P&$I:&,H'S4W<'OS37TV7I:__5<E@W]L2F'C2OFNT+-?U:O?-
M53,R,28U,M2LO]K6^*##^5DTSO6-%9P0 NY/C86 AU:'S"K[(P H1+$MQ5"Q
MTHX1NE5$_36A3OG\\.)U^98OE??MO9K CZ0D$U8X/@_622>%97 3]/B0T)G
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MBXK()X#)IOW@YPRZYMM-7@9_95D*<K_9N3"H0QD CWSDM>>H7&BW_<B?"38
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M)T"&Z4_=X56)<8".Y=KY4?*3M*GA@%N%+@'WJJVQJ;;C*2C :4;=YD[_TSI
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M\H74T DP(\N 95.J0HR>BQ0%I!OQO[?N/@F*>UY#0T[AOI\:+RT?2>2S_ 9
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MF=K*LP+5*:$Q+MUC/&[<& 0.EDHYK1;T7.X1='E$T Q$G[H93<)IB\,>%=4
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M9&86U;[!:FC!3S%4^OR]&1LL%&1Q%/?5\M'Q5^;A\\9/8&DX_;1$.V;3VO&
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ML&W4%>\.Q5:E*02UA[H@/-U#58YX4@T@@%B0N4S:34+O;=RJ/DWH.FH]TE;
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M D6FD0T6MNBO?GX&@7Q+-NQN?-%Y7;K!&1@CKH(X9PD.$OTR/_IB NZ94Z'
MC4NG*>"L1\$I]]M],$#!U*V$#4E@I&>"C0!#!&P2_[-M!XU?A4X.X8*?<.<L
M0A\!))*!W"(_UD#F-B[P0;4M9#7QK(!OVD/H@&ZJP$7[7)]COZJ:6M.Q_O)6
MKW^1 351*ZB&=+(#DP<=RL8Y&I1I0M4<1TS*"^S!8%)%-6G)^0C;9"=DJ2)@
MSOZ<=>U;YSXO*C<M@D 5C4%!#@2==QH=LFPBS@%[;A3B'!V:40B@CE .KC>'
M%^"TI!/K7M^ \V)6*6JXW&.*>I.P?L5T"6_"M)$O09N^!2XC,M:" PN "O>Q
MVRZU%FZ=U/<=) ([GG%%*6WW:%ABQH48+%4*+V^>[04GZKNR>0MYQL/_N^W>
MYC]6JQ4@3IRF_+XB6+ES3,A;AI!H'_E@ST&C@HGW7!H]X>"G_;?C/%ZC.&Y$
MU'X!?!XO64(>@BUG-;++U,&A/QB&ZZ$'<(LN<@JW3@6XVL682,?Y7P)BGB@0
MV[E9&+H)2_X4T3B\+W2$*OSS5JW^>/H2^51,"&'-9KR_98;#O[CG&;L=\KWW
M8EDN@*&BU.@Z'SRS9BN-<7L%%49P'!88C )21""/F/B,*$=]S(1+LBZ<D8G]
MD_ =^F<H]QM^_@D,;UCIIQ$)W-.(!$Z&-;4WDPF,A"+S+ OGK203=$+Z?2]8
MLD6QED"<<5B%BA7WU%IQ"7TQ3$7>Y-[8?YD#6/B"D5S@>K*]R_<D]"D"LZ/+
MF">P':(?;+0T=W#DL$<@!IP'Z8H[@YMJ)Z6?>C6#IW>9U(J_B2,DLT##"6*R
ML![COC [1\,MKD /-2.:?K$$V3"X?:_8B\WD[LXDUBO\T"-!A 7NAY:$PDT0
M ^[KX,D%PY<>BZI\-2@OH2 ?72A5\%??2B0:9'(";$V83\$,XM?Y=RM;#.]V
M_M*B<T(;% 24@7H*,;H::)=AWF^UX$.6T<TY+<&:,1\)Q+?^J5G\U"D]!:ES
M'F<LX2/I,0<R$4;BF9Y6$O&D<J8,ZSZP>A6S=]>99J/ZMS"JP=7],\E5PH4<
MS*+JYUT]L^"K\I31E<:T+7)U0JIWFQ6L(BQG//(KEC[3Z1>JE91#7%[B#JX%
M]:<2;W5DZQH]B?1*= N=JC3&[EC;3<WS $4,&K.R@QK=H,T?N?5B3 P/VQ=+
MH!0R[Z7*2 GG_+\2V'!*"EMXX:.?(LE6N,[E*0]/OR>B,"#W9;0SHLKNWL^?
M)*FC99B> /*1V?N5"M$6)'T<D5\UN%5*2@7;@(:[[!BFE 3V2SIB1U*GQ"F"
MH\H'^)L9,Y@6$3^:G=?>X[#(2!)*.HE^"M7VBUDE!=NNK(UM:.XVSHZGJPXZ
MD4)<VW99D'X6#>(6L14F[U*UNJX(AF??&5'R6?#@,H7DO0;3M/"F49%F<^:.
MO7H9SXS_6MF9S'@RJ_XQ*&121^%W?[E_[65E8P]OR\9\V=C7MV5CGX;P'K!L
M&<.C9:M6&4$_1>-&&)O^B #79CW;^C#7A/F;FGS&>GK Z(OL/&/(*Q1<TP I
MR6VMH)V^]L#&YGTP8\-J&Q\F)^)H_4ZH^IB!5!(MG!A+=ISL8MH9IUF'LW:1
MQ7^Z@\IKFET>CA3VVAZ2ZZ^ 8=5XKRX",J0D'N,G"$V!/"D+3[(TYQYPZ]WC
M_'M_52C*3I?)IF:2^FY$8S8QX,RC2.Q-MBR2!N:<]2= JXG<3 ]E[[6C.0JF
MB'ZZ$]]L6<XE5AJ&4?NJP-@-%D\"'@F]S86AO+K_Q-L MXV7;%K0Z\'2TG.W
MQ]I%72+EH*2J;7,M2\H9A<N!?V-6FIS.?6 $,OJ?B0!&9 'U53JR3"*&2%(H
MFFWJ[(SG==+7V;-\@G$P3?P74[C'9I69(ICK\!7J5O2^"L!_@1*D]4+"Y;?T
M2&INPY7O.\A7$YLY[0SH)/ M#A?R'952D$L"1A1C+3HX!-$E_QCZB6]>3'-B
M9C50Y&?35R3U-2R>5^XPPZ:\?^_>H[0](Q2S7I;^E*?\O3TGM3LHY1XX?T"3
M%G)';V4?O>0:!G*CDA"^CE=7RHREC8B)F04:R[H#"+ 8Z]]?OHD_Z6YA_-KA
MH0,G^DXHI4-6(TO_GO^K;3#YT6^C7*Q6Q-J?%!SM# 8O_JH'P3\:ZM4W \NI
M<8OXSW?%&4W***W@*(M+XVVJ$$,V.:>)P3?G"\GIRS5['6EZP%5:P6EUQ],U
MFS0 &B,I[:O,7I>4*>T][8I*4%N() GZ*6J?/X2*-'1^3UX8,^Y%I5XAJ2:,
MAR/:2"E@]14-?F\S)9]LTKVR1%4%4:%WW<>U(MFBHN,>U]-9S / MJ2\KAD.
M)+<,@[0<H(_@M_%%0LW7G+88$[=_V$0UK +8$JR73S*&-TS!/\7Z>GQ&J4Z1
M_9DE&HBU%4+W&$E+W.E2SDDLS3B\L$ &K>(Y'Z5\!L;=@A:4/%'<8"G:D/H?
MOSQ9.JA4+09&)7F.B:QO[J ,S-MNTQ* 7Q(BE(XDZ:Z"C?H><Y$2Z<V>Z2!^
MV#K+K8AE+GF.U &\46K-A_<>EM$<[">\WY3=K'0'Q=&K=ZO*69)S;C%W<-[W
MU:'I)1DN&>U(OP5GE13('SQ:>7"@H&YK7-$Q,,$HI<Y.=;^*,6N#;;",LXT2
MKH&0T^XFV:98 ^L9L%9+)2!ES9> NQOSEE<GWD-(\E4F!X5V RTJH6$01DZ6
MG+*&A9H"Y1K;M5'@820K#5[7X"!?2VI'0^Y#Y=481^O6!TTE-HB=F\>U&80Q
MY^D9_@F6.B<*\L85U)58G"*'2L0:;0[.2D+/$4%%^"#Y>$VD\)]G9+Q#Z^JP
ME9")@HLKZR)Y_)7B*&&$:7EA1[4X-E-[)_-VU>&]$^IPKU#+A<! 2DF)YFIW
MH51FJY7"P7#W<BQ"*A?)JS66+=6)6'=="-L=6(CBP#<;Y^DDD2HH5MNN4K'C
MB$5@I'XJ\Q6*NXT8;'6C?2;Q8EDX2%8*SZX &6'54]$]&EY1!]:];FX,;J@G
MU_88Z?Z?[X3B3624D#0("S)E1 +?<.2B,]+9#I4ITU#_Y5/#42[&'N4W63D?
MO!F8ZD:9.RCK[, $AAF[!B%M+ZPLW;GO3IDBD Z_%WSR02&%RSX3EMZ:_7F<
MY=MRH?<O%\*1A"/</0[F_#G*!,D;V?FJ8*F6U?96::;T49>SELK;60_=;OJX
MUNQB)5DU8$6@KBWH#U,_ARO/V:&F>?>@*)BT=JIP4!WI[!,I=249D/6Q6=.5
MG.^J&\++D3)V7^ F<2YLF3>1MF5*!G0VW-17(9;YV\O!P,Q[:S4,P:D(=9F7
M'$G4.WOKYQ/JHFQ5T>IXDW':D"!.FN+6J.\I%,_0)CSV&9.0(+AR8VC[VILC
MRVUCC.P2R'?GP1#45G1RQZKL4CHNFU8KD_$SFD4SJD4)XQ+:QM]MD\##DZNH
MLX W)S.Q0K5FLB[C&$MJ"^B.U.4*SH$>. D!N^(V2O^(CBSTZIR+E6!6)_>P
M=C/)0\<]FVI[2C>"LU]7F8Y7W8TB-!1$]*2Z %02WFMJ$4Y1]@QT2S/BG7"R
M.I/^S]X\8--FU?LB7?-OH@7+4I(-K;2CU<RS2^K9EKY W., _"*/8P)#>Q:\
M/8'M*JQL![R?R97*U&H+!@HMPG"[Y:G6Y3_;3IM:<<F$2,ZJ:! #=IAUU.])
MTM2.1Y$)2.W[@)"0?$;4F1%4@;<12PD!7*<! QN=UK'3#5/G0W;%^7"%V%]]
M<MR$X^+*XH)'M\4%OKC@R6UQP4<6U^1P+"-3)QN9.F;NQBT/AYWH4>-(U/GP
MW,(C&A4Z>?+@H;Q9RN9\A,@NS.BOCR!DEMNNJ?NS$!%I!FT>8OEKSJH[B7SZ
M,,'7)_<>^#.AU$#?]]42 ;S\Z=896YUU9F%L.)!?U#V0=OZ[*KL,O76"5B+1
M ^V:03$XAO%"+<27TEC3YT\E;$AUZ)YGK8<7*%]W%S(S[KX&1=#NC=]7<\D+
MG7S--KY'A9WM$J+QU119Y#_SB)LV37OI08,_JI3L$H$8Q_).'M\I[]JLQ&M3
M1*TUTE^H(WO,4F^(1X.RAU5:CA"W54I/W[[$^%#(-8?B0^R+R '6&<@$(O]]
MQ]*[11^.>H&_Z=HE$6?H_._B0!*>9$@8\7AG-MXL'N_(Y#3K4FO\)HSXY&,)
M\+."78P&Q@(!@FY $X)(NB(,V6HF0<PLB'V>-'>BFI4U?^R-HZV%SW-3@<?V
MX:P.<;@+^AYQ'2F;D$YA7QP>_6VHX7T'^5TEZ<0+I@L0C@+^@>T4,^\.R,QL
MIT6ET =2P5I"(ZW=ACUZX;T\AL)]7&IGX2BS?A/<(J,BR0S=&=EB&L/:MH<C
M<EEWZQL8$HC6RO(]TI>;10D>OV:SG?7,RG$EBWC1P=5M-.6W&CM=DW'P:RYD
MEBRD07OD5RYD('?61N0UZZ[48PC1U:7'G*=SA@@IZJ:W7145'V8155X(R_;;
M#:9GA.?A>S4CEN[#Z!BCIEN%2@-F& &(1@_-V)WT*>[X/X1:"IWCOK4]BV L
M]ASN."=S.!NXE^DX%&$3Y[?N([]6'-[,TFR%H: P_M (_SH"'P*J&Q)\86.Z
MQV'+>OM&LT%5R$:HB(>;HX-5\Q("2]<ZF\!79(VQ';3L,:)3[K?8WC=/8?YB
M\'9)_TPL.]E!83F^IDSY:%NP8?;>-Y6#LT=2JD:=[1+'4'P+9U@"78%A.>?
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MR#*NM%/-J%&+Z@,;5K_AP%_^_/S'[.%Q/AKZE78Y+Z@7__E%^7_NW7OD>4H
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M66S:6@;I%DALLY>O7L/G.SW#OU@F#QL0*57W=XPT2SXI&0,*>F28Z*$2L/W
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M^(D41;ZO*(K+9H\O6"Z1*TVF4BMI!0:M(F/O$<K_RC6GAS'(LNF5%C2#NKT
MMF!" %QN6O=A;LD9_'#RZ'R_M3BJ9"YP-Q6<ADNFU7@\Z-0W9_7,^POIM;NA
M?0O#XCA[9O\45! Y<'H]Z)0>GD^6DG;H7$#!")(7_Z#^20W/H]+*RM"3P=8*
M=EAJ.:7;3KZ^5''LR6:AIZ-]F$2^CVGXJ-Y1X@&G4K!;-YU$#Z._+0-NK/\J
MK;630XT8)(8ZH"],_?%,C&/1<_'Q(:AFGN(Z?:T@1X#VT+_7CDXX\-M5Z_X
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M )OM+QI*M#,+9OY6P3S  8IV=>Q7:=N[J*+,H:2?0EI1(3KHY&D=<B8(*V,
M$8ZOW0YA@$3!\9F("4=K*=AH/H5E('0LFO-._&;;]5OWA&]^)V4B>#CP=S?X
MP.;T/[^X]X7XOYMR;C__ZE%<U(OA#)?>^[/W2>8@1=CTSC:W?WWQ7]E_#'!@
MW3@Z>XE;+\:U;=3.=N=U"[M G_WPZ\V[;W.F%_KZ7Y6,*WS;L)BZZ?[# S<]
M>?S5D_V[1A<>F,ZKJZ_NU'>#?<GJ]7J#P-3K))(O\1'YDQRWS\JF7)2%NW_\
M@!^J6=?F"G;$^_@;N>W-IJS=DKQQ OVOJEN52GSZ=,M0'1^W-Z ?W^0_5@OA
M5<2;?WRC0SA#I/-.*'7X"YJ)_]KBK3^6\U(:;G\NZXNRN8M'GX^>_->=NW;6
MRK?FS]KC4$&4_$F'[C;5F7N\FSWWL/&SGE]H\B-_^H/4-MHO=+!NOG&&/X?:
M[YI<K&6)X]\Y=]\,!=*6[AA 9QV]!NU.9QE*O18*1(^1W&K2T.U9OO]_5\.L
M=F[TN_S-TS<<@/_-,87'_4_G).A+E>HON;UN]_%5^_@ZV_;P+IV<F]A!.K@G
MQ5-0;P0+#2N?V^&,4KYM\N]+]X_)??K7[Z=$%CO+.U2'G^^VVWOL+LHQ-Z\S
M0 IY&I/:>ZY5O%DNVQN\/5(4'UF,?\?,[S,[<PN*PH5G^P"@  *A]7F+,A<K
MNWUIG@QG,]'Y4XZ9UUM%9!9X(F"/!@:/G,5?/SY5X3&3P$,49>7$6*3T%R.)
M!7UJ(-/"*$XF+-:F<\.CS:)! 3L?#/'!+LA\U(!MX3:6&>=E-_*N)X<">=4C
MXB)NTY)7A#A!])J&C,4HI83'QW=FNA37>F4:Z=C;)W+&>$2=!:+L;\6  S:#
MO/4"].NL;0\UV!R H()<??S33>S538Q.H_=RQL7<G<R5_PH/_4TM3>JX-3%J
MIWA[<F=X:P?\J'9?H2,T3TB^J1!GNW5P#@SG1W=6(.E(O'+SH],"]WY<UL](
M:?6.F2^I;6!+[RC*0H"<<DB E-$[<-JVBU'M>^%OSJP1J #?PD;+XHE(;"B%
M1E6^LS8CUI<X(72>%(K$2@\OCK<1:KWM#?]3\TE%[G'(ZT&#OJ<EW'WM=EQO
MG(0/FF,-=I^2?&EB-0BW_,:]U>I;D$04"#=\.D09:$/"JXG<$,@[&FH-S9,S
M[VX5$T/[#O43PB"D.:>,A*(KIC0]),4'%>L_B@C_K7Y;9:E\QJJ85*'34E?[
MVB23'F;?+4I>)M*#)_06$HTV"Z&S59HRDR;5_XC-B,R8R#2MQ(;P_!V(Y]&\
M(DCO ;3DBMAX<GI:2A<X*HU0>#M+;K7(7F-K?/?5*&"0A+=MIR*X&\^9#ULV
M;E0K9RJ@$+/NUSS#5>-R&BI@GZY Z7H4('XE$-)55?ZVVF62F]=#73+R"O*B
MK2G$6''WL3A++$@IE))#]>F+OWW_I;<N#V5I&9"/([*%_ JX_$.++AWQ/-VO
MEK5S3G'L:BC>R(B8J<U_Q&KC&!-S+)DNI\U*#U,8"YR?KQ QEBJS.*L2J8O,
M#F*+UPJ/Q\0"3#]0X/[Y-18"AE!]KMK@X*NOS&%_?9O#]CGL^Y][#OO3$]Q?
M=8S]'07<3DW V"DRY9JV.I* S%20<4[^( TR<3HY<M_E$J&JH&4O$&%I7KJ7
MKJ#P  M#.=//'6?:=3W*HU@)C7<.HE>QF<.92VYN>+"BF(EM($M/H+W9=H#H
MTE+"J)<SP(_Q\-/+U-]PKC!;<H3VK!1B'6^HG?N,J[6&R)C4-K6D$ ]#E ,5
MPJCG:;OD:LP3CV_@!\Y6=7^FUH#PB^$'L-H$[Y/'U=FNK^<U();E**F[J&,E
MF(PE)V:O$KHPVX^YU5I#[U89)@2 > *PY<,)B),6[3 93)KC_.]*17N@L"JP
M$'M+@^1RY8K(N_("A? K@MT^T&()-S=MC-N#NY6299<=?/>G6?MT55< "IW?
MP)6H3G\/ *R/U\75ZT?F$M2>;6MTD&?+K>W=4X&-=!(;E="G9?Y:MLHF1$M"
M];$#+N1$C3,F2U]!%_;ZJ!. N@86UM*=KRT$RWV*NT/U"PM'B0H<RM?W"O&G
M0Q^T\(KK%0--U0)E2=3B%P])6250TS'P:O5.>3Y-_]!]6&F/I,?*I%:,\W$&
MA.GO5_6$>7M7PE-I3HM,F IJP2#"?R4M'$Q&;$H^>U3!K+7.X/:J9:!3?1+N
M;K$YV6\[?D*K4YV%2F<W(Z%W?=G.MSRY9.AT8#1A;0B#?IQ:#-)7U5OR&;-S
MWZY&\;3V$?.U7G!(3\#FO6T/+UU7P#=?F0A9N:XE^8.:TB81ZD3DQY'5O>B%
MC_&W27K>YD4NRXO$^T?-DC22)+V:H7['MM&W'S(S<+MFEZV9UVU)EU92%A7T
MF#CZIF2\]C#TZXFXPNW*?K25]:"]4V>&>2*=G<:W"_71%LH?K0>L_?D*;M.@
M=5]Z@(M?XL_<;Z%;;Y?P8RUA>=[6,(^5G'(GY!6RY00NE.#F(Z-+K%6O7F].
M?OP?O8APW7MCS6<),T5U$Y?%1S<.[ U)G88ICD\K(HB<EQV 1:+HR%39_G'^
MQKR/:A58*MH(FB)X5IH"2JKR/F!-W:?37'X-1_N-7[QX>FTN@__DC?F];3'9
M72ZGU:07: MLGIZZ]W1?)%A%'T1-TRQR[?[]$15"#8!Q^0=9=&NZ#T4C9J:V
MLWC[TWG1%HX0P"-%0&Q9^^/BVIWSR4S([>P#!BV<L[X1H0**H>RU ':QM]GB
MV",#F'C(*/Y8Y/5Q=5Q$.58EDF8 #0,899Z;12@XRJ8+CL9/B!(KOQ]H_4?$
M,7_/O?@/A6A!VMF=CKW0?V2'X@/PQ87L)BJ/IC3X,OHZW5Z!P@.H /#VC9SL
MO)KL!Z6(6M@H&V*,9G(06[2)M(5SLF),2B_;>J;%\\+P$/I=4W6G+'@(Y21L
M??;S@6?[7@.)1H4J:=_#G* (24=H/'"W%PQAS\8@U4>BH 0W+3!# JE!69.K
MYLQ<Y"P*?!.ZA/"FG@M%Z2TTS"(C&4V,HF",%MP-3KJ]%79Z# <1KN11N>),
M9DA(S%>EL'M<7QL&%AJ.V<(_I%"9U"B1TIV1V(ZT/-(H$80A&XC*:GI^)$^1
M/F=YO1@$N+@2<J_4P/K<8KY7*H'7'AK+ILD<_4P0(R3 *B2!24 O;/57R4$Y
ML:^1AEK):8"N>U*W"M*^C[_R94P]3+WJ.'NE]"?-H*'KJ6"LCU'$0T]?44H1
M0%QAMFDW@:RX]^?;O@H\SGX)92"21RJ[#J!_QK.*0QP6G\04E04.1R%1#^)C
M&U4F18[0[AK;DD ?=?^6K)U*H,CP;_//5N$5-"ZJP90L)''FY4;(ZNJJ3P+.
M%6CZ2!O51QUMDA:,)R"8QVZW]S0UH@]="AF28<N0ADQ-77RP,U%P'/>55E6\
M=;>=H?C&UW]RC%.]L#S-?50XI)JL[.$#)YD^\5/].J2,T1@N*XMX<EL6X<LB
M'MS(LHA/1ZS?\YQZ%FF'*E8+66+AL4 T-,<QQQVIZ-@ZY6&3H(GV%1&6\\/W
MBZ6XJH36(@5#RP+9I/H_+\J.+0^%-E-)M;UVT4^ZG_+O U^:_YHO]:R1W8)'
MA_)X2_5BU?%D8T5JQS-9>QE#N\!0]F_[;ZQ0/NI0%_1C80@C?>:IM$/NM-:
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M-J5BDM4M/&MQ4L#N^7_>RU9>.!P).R7JJ:!6*&]2/0ALWWKO)5YD_K5 F-L
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MGJXU;:8:K?$9.R(7T8JSR-$0%[B P3Z"G^Q\.0>?5_0G*:STJ\TY[=B8!7)
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M$FVK&53GJML"7#6,UGI*B\S<%!B+ 9XT\!'X3JW1%?!> 5-&?E+: E:APBY
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MY1;N&B7+E\]"UH-#36_*N7;086)XL,<EB0<Y,A]+U)712=G9W5Q1Q!ID,#F
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M#)+1U9QK""/^^ \5-\G [5CJK['!#/1S[J<P8F%_W)4U2CH?O%N=BN B"R*
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MI5P%N:-NO,X"NI' 9) <7O>6C"&YY@VV1EKE1U&?DDY%3-T*?G@(5C903A;
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MD9W  6HF'YT'!ITLQDG>PMZE#S/9"4F8\XIYFN'ADJ^X\9Q<N2R(6>-+/Y6
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MW  *-*1@^N7-!Q+D0!7.M0YVIS>8] PV$E\Q7;9V'VSL;*XRPMF\3_JBY!A
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M#$7J:N4D:H^U]2AH-G!=Z(0K-0S\&0W+?_\F+B)OH8P71:)&Y773X!#?BGG
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M?557^:CNN>JOZ^82))AO:_GN6W)4%V>@*%XM!.C +9H/Q=6UPJ#U-QFV8(]
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M%D\;]^[K.\YY^O;@?6077Q,;#6P19X HE@&&QF\ZWXH/W10+_"L\W7\N&4'
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MZ9>KLA2:9G/<.;ASP4 J<\EK^=J"4K?B;&R<#BU\)]ZC,@M);^/@VDPS'NL
MM(6\OQ(NR-RG>$**.8?DI6/GVFE!*1S#3)U7IHY&C2T<R#A=*.<;5\Q,7W6O
M#?S503$6'%*Y3#6Z[.DM80X\O5:*>Z=EW#.#B(N76ED_?;QIQEH@?)QG5O-1
MV,L+%BH8:8QE.'^-!L1T=^COXX=]XE\*?\Q'=S?6!7Z/E7P# X7#^"+L(';W
MJ8P;O&G^@)HGV",;Z(3Z2L-T1)F*&68J1=$\9?2L2JP7Q$ IG68;A,K9YAH4
MZSV:!)AO\TV5SJ5R*8Z",7GSS@8[:C))YR!  4C8:F?]H D!U$MQ;4@-(DH,
M?*>3=/(D;>R.V_M$E8M!XAJ5%I%FY1R\;MF4R]K;MCS1^0U=?V)=;M#LZ+4-
ME-BE)F"D)]]PG_)GN\^VY4+C,L?\HW)I#H3STZ2)@%.N].=NK=JN3>8F,3D8
M#WZ29+9T^1ASGGL;: ;<-+7<#*H9PQEX,_][!U:!B>F:0KC+A=^*<[E06YH1
M%I9SWM=,^+)H(P+1.?(._L4+/[;K>-BJ17E*VA@)HU0_>KGBPFPDZHK:LBOJ
MV= 3#?EJKC-CQ"1?;MX6U^(S!NJ 0-7GQERH*6HK0"'XM\SD<H,00E^+I]-,
M.8F#CMB@ +)(NF!)XIC5H5>Q#KDC>P-^:B7Y 1NZ<2)Z-@%L.S+U\;#:(#*=
MC=] S@O3&Q:>;O\T_Q9U>*'>G!B6#*P;P+X<NW4)$HWA H1;AQV3#/FP&3D^
M4M;0<11"SH[+<_LOHIR#.D7J_,7*PK 3-<BD$ *1 X.T.H5(\F)PG^RP$H)C
MR7ZB3%Q;\[A;.(?"Y:8:FD'=PL4_>MCM,?CD3J4"4O(00LXN.J,09 (#6;%0
M.HGL#BJ5/[)VXMLIM1[_V3/J*YF1E&:4T;[IAZB!8L,-@%#Z).ATH<FQ=Y<=
M;/CS9.1OP>6.=;&/$FQ4V,(^T OA"JNB,B",TDL.Y\61LM Z& KBLW97]5D$
MK_2:^E9NCQ9@MH/O+1H>&^0P+YK:9:]ZT7O=*5]>1+T9+5?IWRM]O>[%$Z5G
MB&%P8* ]>"R+BFD_VJ4Q'^[8TR>32:*ODD)!^DX/RC(X5&K"G7!@FSM4" J3
MYBR<63S @3D:D\5#$5<2%]L"KO+*._44'ZR->D72#-1%)N,KP0H"INSX&AA8
M(^9#J';>4SF=YN>AW BNQW0&CH4&6*^JPX)4*CLE4^9-M9A)#YNK7>J8B4^P
M;V_\KM\D$K7K5TTK.96JSB1E\B],+Y0V$G5MM&@@[LFH&D65PIHCP89&@3F_
M8-B!0*FIH7[5YZ'C+<S&NBK]T)0,LY6BHPJCR".SQ9NE"Q95%PO*B0NC)=A(
MX6;3UL,Z;+HZ EQ5>4$X[$-2;69:(.D"WT<"F^C0M$PYS&ZO/;U<T^ZH-]($
M&&9]<2YH>-[H^+\.U#%71A(8C(S+\F2##!9O4;^SG%N:/EPX+M-.'P^6@Q:-
M(:%N('U\TZ6/S*5V'JU)F,""OFP>EQ854N('5YMMH>B201Y/!MMIOQ,JM+*Y
M"%^@4IBE1T2._<.0^G$//>HWL49RUYLW90?_NX+;JU>0[< , !MT@X_+:TL%
M!!$)"=15L[Z28:(NHU) ,]: [FF/.XG;)-MU.X0CJ,5JLQUB%L'.^[VV";^O
MJ[5EEWA,@ RZ2C;[9NBF=Y;)OKPMDX4RV8/;,MF';KTAS;@!($"3)0GQT"0+
MS:8_UI8&,YB.TYIJ(8!$@8LZ)1?K^C;+>'PER3;?J(SBLQ&"*X0KV26CU&<*
M^>+;,.@R/R<+?.?9Y;<O[X;8XVDY!P4)-S]/\L?M;BEQR44#RJB9?.?IXXMS
M:>8GM<-C^&+PXC-''"_OUDL;4M&68 (4J)I8UX7>3BHG"$&.^"L:ZTQR-\R*
MXY!ZJ>7*-'9Q>;#42709# E$L.CB>E"H9(^*O 5V53Q!7QS(2H=Z8NE/G[VD
MX')=<-62?\W9CX+'%U$80Z8E?UV66_S!'(F)%%9Z9!4RM? RY620S^D$RJ,_
MG4SW)\&U+FX6;\)B-&69';B SMM42!,\>5<LM!U,IOB)OO5)!A^$AC=^^!OO
M06;!L6_3''6\/H?-EF,N:EMZW4M,SK%[[*>2H'@L%9+XUU<\&0#.IXE7IMC!
M0:::?O.O'??7('>H:5QK%PR_P!(UBZWIYE92UNMJ4PFA2"#D"<0(;;G8<>3%
M_CH,5E%GR<-A!XS*]G ;_?<E9LH1;DCXL[9&)3IFI,(X<]7MNJTT]$@M[JJ1
MCQSDGNLL'CLCT5Z7 *),0H$3_3PSI.$%T5?R()<>F3"YZD&*VWX1A\^X9UBV
M6LQLVAY#:3;\+[>2OM%B(\KH*#+'YUDD&@>@#7KSTYVR=W+'(<\DY=ZP$C+[
MKUU(RB\8)R&*>59=5;A'2*XSZ0-M^%*[OJ!Y2OH#8OTI,L.]FP6=:\X9-!V/
M2UZJ97G^P>=U)@VBHI63K%2I2; ;I*"ZOMRRV=@IWE(G\/5(-O7%Z[*V1$<1
M1N[F.DXZ)#T\+XK.ZUJ'T_C7#[B9PD?+':5;SI/5R__]I[,_28<IA?3V\R]>
MV74U[U?\T;,_ASAL1AYOL>TH'K%__>GOV=_Z:3/?TSI:NPD,*)U%>Q**5_"Y
MN7U K_WPB^V;KW*XC$RC).N*S];/Q[YT_^'(EXZXIO_YO[[\C(+0@TN]W[?3
MI+<W.@YUTY<AP2 ,4985W98M0T)$<H38)J)^ACK:9E-\P_VCW\6K7X8*9O2\
MY''H?UIZIK_HYO\%4G K@K]&!-]/XGZ1@(U^F)P+!?09_A^*G UA_NS[QX$2
MB N#TQ)\A7%2MH&N!L4MT5)+G>2G7\UWVWDAB=I:=!ZFE''%PM60>*;E4FN%
MFV)>WLK5'U2N8K:>HRUF1"W906-]\BPR9M+?7XA#^G5#P9?,+GSQ-?Z+'JD.
MY;^*W*^2_7.TA46  J8&JA *66,E:6JK&<YOY></*C]JJ0HM<"9--#S7TR&@
MM&'N (K@2^DQ]B=/G&([S0%(OW[(O3$"%0,TX&P=U"1EF [7)3A3/^?*XZ[E
M+]Q*V1]4RISU8Y8]1MXRTXPBRL8*W44GXD?_G9>]@#8\,CB,EX[E_I IZ@*C
MBL\K^-)Y,OY"\CPBD)8MNI6T/ZBDD:>^=<W!6IH]XGIA5SBMFI_'9 :,XO>/
MSR>*-4DC 2Z[;ZLKI D&FO!69OZ@,M/1>^\$%+4?ONX:PG(^O^*!Q'MF1% O
M21)\5KC71.>M"'RR(L H9S=M%L!K9V52Q+0V/B#V\JU0O89YB1,4#%2G_]0A
M)%QG[ YZAF;,[95@PO7#.X/^""(NMGMLR,-OYHYBBM'C2<<T\L!E)^1GRC9O
MRXII"D4NSM_BX$V4DR3ORK4@_(*.3'*<TL/^EJ=$+N3"OALR(4)\=W%Y>\X^
MQ7.VEUD"NWD5>1GJICX),C3"N^(%:2>-::D@75SZZA/74^8*..W+)>375W+@
MFC*P7KQ36P6Y [<B]P<5N6VQ#T/<.E2YM9X=\&K)(/'XQ@.V/VCJ2,V7*]':
MK53\0:6"W_E(C=:_?K:*S 3:^^:.V*TT""\75C04>B/'XFBR,C[R["N^_ZT4
M_3&E:&AMV(:E" ./?/ P!HQ\+IEI,/9=DJ@%_RBTO\'E>?'D^<N)%IJ&=[":
MDV]@UB#W]..3JX\(H?K%V2U"-2!4']XB5#^PN%X.@$V!;SC[6_5W,AU7%45N
M3)D//6"_NY)?.4TRL$LAJSY!2AWL"<Q=,<$H;M_VS4G\2GI>1TK:?9-IK(98
M3\ QAXG;2.0W!&IUH4*I$*H#(A"HT"5'?I[90F,_"?V^NYQD"0G#3U43>O^M
MMVC0+SN!0\\5U5G1\8MB.ESIOZ-=X[UQVZ:/.U%UJN"T32YXD;:4-&$Y/\W.
MD1UT*RUT:E+@=CY 4Q4Y>,DY*5"MX85R[=<CJ0;==*Z#4M[IX46S-//@<^3R
M%JW)'+&-CN9AV\#L[7SW2MJSZ,!WXL5HH]'/ZNARZ\=3<8<,N ;^FC2B+]99
M0,\TK>><,4%D'@LN('6REURVEH*2/DE8D)2_.U?_?G!&B]]WFI 5UVU6TE_H
MC/23?%?KS'$8O4P 8L;*KAL>,B.#^+'J?&]Y$?_, YQ.)300-M ]T&),CY%^
M: S/&#^2*;WE>5@)7XEA>PGRKABN2YK6W[8X>NR^6J?/A-\SY_B46Q37U8(E
M]69@O2X&94GK!&+ M0=<QJ,^D-^1.B2++$#:^YRGDY,-9B;4IAT,\D3*3#C-
M54^@=%[.==BZ\#]N&>?=*35+(?P")*9S(R=-<F1< #U$#EU\DR0S2/U='/1C
MMEZ_ROTC9X24TD07,7([.T1N-Y WG"VG$O<,4.$31%Z$3+FT'6!QAG?B/]N1
MF9GOUGJ-@))RU!$R!X/^TW0\N41@Z-*()S-#<1U7!53Z6/);,.Y3]MG0X/0L
M3-$?BXFN?]<JBK.V J9<OZH6DWL S\,.98$3-VETW0?7V[7YV7<$=2_09K-P
M*#GU.N7/*DX\;:^(.256==;:>#..:-2!UZN&)+I;2>I.Y34[4(+-KL=,AH"]
M)&$3['/-FI.TZ,0:025SZ V7:V >T?MR,L0 :UMVJK(/;UY)A^+P=!F RUL;
MA9-S[@ 9Q3#A9*CEHW2D2<>BSC@%089GS0T6*O^'MBLNAN'';)J-6TN60QX,
MKL=I4!U8>QBS(A?:!EZ5Y8X>&U-2Z30 R6\TRF/8=V.0R5_7S,J@*SW"T6SL
MN?R1,:8V.QO6%MI8RR?W]C(5=ZB>'&Y%P%PJE@Z-OAPCT]/(HI;0RJVQJ;N"
M<$)A;4#_E*#ZAAS16G!A927]ML)$#!!AQBDMVLR==/5#U<$UTC1:JC;EM1B4
MS UO3HM@0\9QY= -8BV=OK2DP)[!9Y*[ED8:CP87H]=.#SPQ4Z6NL1X5<$>8
M7"LA1M*ZQ)R*<$_5 ]._D@?859P:"X3O67 GPC/"^K 88LXF)VK(Q@>J"R=^
M@!975T6$1J7W%)^8GAZ[[0BJAH>8O1SQBUUL]$I4RR1 _49V7#56^/,19T04
M&K="S+7S(1"9#+5VYOUAMJ=*K*E<QTD6K."^"(UVCOKGK'2%0#()'(?.D3Q^
M=(ZRQCPOV<O$;XNDE-P,TFG%M6;VB=FLW$KV4PGG9(C+Q2#PTK" WXL4M;2+
M'#P&J#KMULK"(I&<ZX "OFT@C4/6# E8Q]P[\/&S?W\(^5RVC1!X1N\2_/9X
M^B5%]#^7\TSS@P,/)PA"T..% K7D/#@7:\H84M'-BH;0:4=R>VZO8UCHO.,3
M@!/:H&V'KB@OE?D^-MQ+1%MPS=<J>CVM\)I)=\]>TTFK,./.6!;YQ73B+VB&
M(36M> P1^O%'DPD8_-:B)&<ZZZL_E.-XYY(C"3QX8!&/3K+QP=.!++FYYJHT
M;O@;8C)>[;?&*34 1&5I, *[RI,'U8/&[(@5IV34( R)WG:;LF7%,?04AOP5
M7J,@?1368<FC+/VX@ @,<Q_&>AD<(HKZ)/+>#=M&U9T:'N)G=7[)SY0_HR.\
M8;386S=EPA&5;!_OCT6;8@5BS#F1/D01UG+88:N$KG-.3K2"ZX^]:H[JQZ_N
MV61(#H7MC\U-R7L[C'=E0%4Y#X$OSD M&@S)-182)KT-%C-E+>T<D6<& M))
MB,G2P.U80A-J-,PN"0ORE3?AT+)MPP;US;H4-GY 5;:]S'&0./0T>\XS";>T
M6MNG(UT7;G]4GX9,4R"G\;DXLJOR-V2^I-N15RP\7QOAU 7!"VZ</3N\<_+Z
MGAV<MOS@M FU3B$(:HRY#$['+WN?V8"92AF&HL =?T>5RQ<ST4K(Z0F/$'*@
MSN2J5#.S2L7C',/C^M,CID)LMCKXGNM+S()9?Q[KTO5ZQ)#O)3%CX13 ^QCV
MN&]"*.9:P_FX+P)ST 16768VH/2K3VX 8EKZ6)5.['H/3=R6B[)M#>QEC_I3
MZ"8>"MI$%0*Y4]+5P[N7Q4/G&!T-NTH"(FK6!A?9<D;IM9+<\93BWP &,XI@
MT(F3BE@(.C_(4?9^<N0HG+#ARG87*I=2*-?".Z]%N,V&.6\P2%T5RO%4=9[T
M".1[.J2#-T]=!4BL#>GH=G E%CO1<P AE5%MAY//4URC_$5RU2.\B[P'.'7[
MH)4R/"L/&&("!Q8?S/8XS9_N6G:,^-R'IFWYQ_&N'1MK"F6*1#W>IMDBYZ =
M^M$=O/)\R30,P$S)S80#6X[ \_A];1*2^(5IFBHA7H#E%+ZVX$.-W"O)B#=U
M" #8/22O<)(=#0".^NK.2S_JHM\,=^N=5>U[MU7M4-5^=%O5_M L.(M40X28
M+9-:[5!UW+F4B(#T,"E=T# ]>W8W%[-?;D0%F'5^*].,I1*#*^*16KZ[+,-L
MC5Y'CK%NL](<WZHL7X.2E$> ^O9M=ER0HAVR 8*$%"-!':$ R&[J,M+<BX&
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MQ?#O$ %HV&W>IR3\U&TQNB_F04NX6$Q,!LQHTIN;/HSXP$FI85&]T1T7RNN
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MC-]!\1P\4:3F^?&;B!-3O.EV"V7)01;KDK^1^"YR+,P$6;ZS^++1C+J9L$R
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ML!WC!-&_Y8@ +V/PO+17@IH#EDOL-MK\TY1%+PH%< :"[H!W"?:OA\"!A&]
MPF4N<38(C_++U@RL,>KG2HQ4@S$?L;B,0T]FNQDC7]C.;HH86TOS@&L.0%+?
M%XQ8#]E$[T&9+3HAII>3I&ODK"H*Z9H]#-8X?UYL@+<0PE3G,-#)@:#+:OVA
M.M.?5\FX\YC_MOGO@\?\]YU$@MX(NO<Y-,QSQ?T:L^C%1ZYF.*=K974LHVLH
MN TC01-KU@^/'X1/=P]Z/KWH:H*G(^XLNYV+6!."L;=/<B/U =U,%Q4\U48[
M-9PP-XSA#;BY19-'81-NWB31Z\#)45XS.N/^DXR&:L#/+;J3+A+V[^EWN/FF
M8B?0X-@NI$MG:S.BI:)[O)BY=N;MT!L'1[C\SQM Y+#O01O[KG_A+=)!>F/J
M?8OM:HAB.>YRQI9</.=?2I=5:,04]7:REC!#'':]BC,!C=C+N_\]%UQGJ/16
M<**K>B(T=2ADG=<E[Z^*J^)^4?R'IMCBN$U-BQ]CA30[Z,!^#5J;;Z,R>:$,
M$2C.J( <1U&@4,6ZGMK](Z>Y&6G!\AMQD25G<7$5%[K67(653C2D8M[#[K^V
M&D+<1:IG1?)YY0SR'P4.'H6$C[F/A;+AP3FN_6]]XRV.KPG(,N;PU>("E5<2
M2&Q\BT7"-B[R"SYUA96RR6$T?6=BDFC%H?[%%9=ZY<.1=1?=4UQ?>*-\KJ@7
M[86D5]>2QQA8<.!UOB!]85S0B;&)$W?->;2@5ZSC<VYJ)9YDSS.,(Y(G*1\O
M$XH-%NG]W"Q! YTQTJI(J6'VPSHFN'5%:E&"R"@NW]Y\9E*7G1*> 7]@ZUEX
MM/"CYG8QGTP=H3!7>O?6J[C$BGE>'[>,_:$*.!9?.(99FQ[QP 6+KD.5KKC_
M3JOHUFT5_9K(O$23NQL8R ;:1WACZ'^0"W>((PTP3_K1Q$TFD4$?)_G8.? 3
MNEZD:D1N$#\AR;6S?&#TK'L'=E22MTON.^= 7&4MJ5/_8$JW.WDR*'MR5U1E
MFU)5WG63<8LW.NZ<MX8><1=/@-H46E93TM5=L=8-%&ML! -9*%"\:(RL%_>]
M =QNX4JXF"_0<$KR<99JJJ2!#N\]@VY%TJN1Y!+PD<P8U_IJ/6^5Y*XH.L%E
M%K@D\C6J2Y_)Y@&O*S>S8ZWG7?3_@0IK-"XT*^3XE]QZNMT+=%_9!T?0AT2)
MC2J'73<<4!=IY<K@^.V\/A;,8'-+YM+W+N!!^%*('_#LR*4+63]E=&:#KI Z
MC<_Q%(0W]#*)7&$FV62]*=BV_I^H&'OIHK&3YN[+@\4G9$4L!*UK1^VXG_[R
M2+J:%9Z@R/","DW<:G6':_?(Z68MMFLTC._DNW.39^!\M3!)C(I2,C0XC=)Z
MBCT*H8ZHV.&'&FJGC1?)A8U#<J%LDDO<355W_^5N3$FFR!AKH>)%X4?P6&<_
M.#%A3_^=(_YXS@6AM"T*@G^+]B)LPST+3Z"@>&O(RPC<7[BE&EO?,$Y6)Q[0
MJI[GG+.QE[6 45NZDM!YY"ICL\9]U^41\]1IG-FK;]O:6N]OS;"@Q@W/UZ\'
M6YMK\NWKT/-16-,Q5$CQ%9G7B)$,?4TE[#712>,88HX JSA+>"FUXCH>?4 L
MS3AN3,_"K1R=0<X?]$\L7R-7F^P#D>;&Y2_>:-5P1SRNFWZ7E@=DP,_&>U6*
MF**T/$T\1H:/< 5<+.X[V8-K\7"(:CEHU?5F-T+K,"3!4IHJ\AY[35K<TNZX
M.W?!F*V1JO#N<12 &(8N2/NJKBTO+Y$QT(9;7,=25I@8V 7#VK..CNYH8ZZ=
MF\8?TVG-AVEKRS.AQW8)R78NJWE;=,1]L+*R3':/@TFOCWZ-U ZI?(=#3(DV
MQ@D'HM\'J$P#1V^@'DN9Q[0U\RROM&P?.=@L9TDFX&I!>05^W,.2&9ASI/=O
M7*:5H7FRD H9:HHJSQ>P:5-S1)'LT@[63-?CP-S]9Y[IE1JRQ9$$M6E/8\-:
M966Z?9(AG1)L,IBBG/F&:*HX12,.A+%N53$R'V\E/KNFC(DHF>=:#.VBS7>=
M0W,VD6RZ5317N%!S@7.J">6BFY!,6G!S.(X)_$J"C0W:"=J"7XN+A'%T7D>_
MY5ARD_S?Q>72:CN(O8UH:$_SALY)W:@2K>?7.,#-,@,:''AP=E/_6Y^S>*3<
M.EQOP'G*1!-8&I"V^6I1ZB 6LM1P),L3"=72?FDW=R@O//B$:0%?^:::](@;
MB0?DF6JLY4[>'N,E5\?+=O</86(<^K8".$*J].,&I_=]0UEIYJ1(W"'>4XY9
M*0=OL(B#=^MP<TMX@]2_I?&IJR@XRAX--.$D@V+W7*:#3RB\=@;0.Q*ZV+.P
MZ$"\=;C8+K0V7",_95T)?+!4>B<I!H7N&=..VU@[(P2=H2!LZ@2G9 VG:)AD
MQ04&XAVEM_SAX#TYT71T=.'TT.#\?/W\^#VM"-]]S(C;C/C3QXSXG3G([WS\
MIK*7=DG-U$BTVN>-FAZKXQR_FH07B25FZYC.?7I\05[W(O$H+)7&BUF<II9?
M* [+.!<[K(&O55=+C5&Q^_,:^4PVQ2-'C<+W[+2P9@SRM&$O\^]7KS#_JM4_
M;6";UY7%7]G5D>._1/HBOL^3CS%<@<C6]OA"*! \ZUE7<X@8+O<.6I!37(+%
M+)F&%)JCK+.D98F)'=,EI+.Q5HZ?.LM+Z9';O&GBJ@=*H#,(WW2V4RVLUB3[
MC@R[.C;:@QC3VU=5T[:3U3@MBG'KJ[,2N3XR_@P+#IS//UTH1DQ<P_Q*7O=,
MC%8V_!B23SY<77:#RNZ4^Y.2L(?1'F['+)UT .+B7(ALD2#)$XN-+83O5LC7
M[ OG S)1\XWV^WD.C<4$-(137++)_KZ4/>#1P$.5=#9E[.I*&[4K#6R/N-A]
M]5V<*X;[)N%Z;)4?-)B@0_@(Y(>T%''&E";]18_AB>3K,G(W)V34 ZQ\]0E8
ML"B:QS+!8Z9;(E,B'3.\E9QZRTP8V,$;!B5_Z'; JK"U4Q0RCO9Q'6(#6QPD
MIX'QSL  V:_SP]RCE;P[(#$:%YS]]"><%=J+NU\"'RJV55ERO+.].O?!^SZ-
MZ"6DX>Y5D>>&QF&5S&)&<;GO)38"&Y#@D-?'L*LIU"*LS,@R.S>R:;A21O..
M_EL 'K'G\!>HXL9VA6]5%4L,8/3+Z[=1T+2<\K$&#SM2S>$BO4*L63PLQ@OC
MYZ;*4J:G)0#2=ARJ9 10GCG&4,]ED8%*7^;<--A,6(3C)3BHY,3I'O#":_B]
MED*#M/1+'H1?A2$)4^XO@%BPOR4R@C'J+=-AC0L)0+TV/@7AW(*#L3V%XI(O
MJ,YB)E,]I4=):"!5G(OD&G7/KJA3\?FD0.!JL9N7[3</FMQ3(3N?BHORLG+T
MW"MN9)XX_]W.7F)0*B6R@0&_GX2K]C"8XS(FZ6%UC? I7D!>(%<MV!X8*(V!
MXN4[&/%4TV\"9D\AL2'_NE=>6Y^96>6=<R+>C@4&BVGDL"&H-.K,\/]J!:#P
MZW+$*"[+2X9_>&\&@K/D.*W=I<;]\;][-@U7IL2 +CC3T'I7TX1"L1,)!]U2
M+Q?>H57KO$D(G/L>E#7"%0(4$?(?<ZES%6X5T4B &1FE,S8=1H6).6?T+V;R
M)]M'32-Y+@GVO[DDJ3U.X"<+S!3604;7-_/(^DTB1F)B."2-9(WF!KF#O,U%
M+!N9)7,Y<55-RYV;R'WK>%=)^M]:*L;5OL'C_\U=(,\3?2,;4:9=P8@.52;3
M*1%J]2V9!W[_VL Q3?ZM\5Y7[2;V%\&Z\$'OG>PAONA2)3UWN:%H:*%%AE]@
MZ<X1R";Y<XF->,SL.Y60I"./SJ;Y!;?"8)-6>>HT88UW!LJPC+\K49[R@$?*
MNHT+/;LTIVHAJ%KTRW7I>]&V#6/4!-AI*.D41YJ.GMR.0$5Z5?>69Y84MR1!
MO:QZ#]%UPYY/?0XHNH1+^NRD)J=9*S.E2T",DGB:9'9)ML8D2Z0M9-)7EHCJ
ML'1:^9NXN+<%],&GE'X&6OIY TW,W5",RF6)H(_(CG(JLZ/M&-NDRLL3()96
MHUR#JW28*.]4F>$?7#9 HDZ2,6DF059'D;V"!(_EQF4!SBMC)DLN*9%DGUSQ
MD+QE"&HDRJH/&+OK-&XE!STST20$H[#%DR1)+V./==&T&H- ?8OADC=!73J8
M[23E $U8','A1+.0UN>9QF,;K[45TGTGFU:"NZ:UO'P_AA88"-7A O2426U:
MC(R9<\-\=K3^3.YA (C^2V%AEQPC.FIB\L_B*A (!4],-95F"8N+'(:CU-8"
M&J[5TA8,#D#+0KQ"@M^9 ???'&MPAZ8&8Z1OI8]RWR@='MML#-L!6(CIYYCV
MA%,79#,6'X!;*JX8IQ0=6*8A?LG:U;AJT G8KB>8YCICQ;4P".<$SY/TM  Y
M23MHXK15>3"EZ<I5HLX:O8RFPACJ@N.%0Z^]7><SU<*,A)$)_]U^DK<Y '/:
M3-Q68ER5!XR.I6V78J6Y4L7K7F//3-$A'&$$G3O"3/ZAM>(>4H1$"U4Y"BZW
M<<&ZY%"7@Y![5 -VXV)?X(4_R,<KT'B0B0<P*,Y&:JLH3](XG1A>T&$ROX#0
M.#&P48@)76 PG;B<3==UK ?G6E&/ A+ANO*42.0<%Q\<QCM%3_2TS=TH];LB
M[[!GTXL'6T1&X'92-;S%1$E92./.@6: EYQ*@QD/O.T>W26)B=J5,2Z]9ZW-
MP +)>YCV/5PY6X=>KJ-5I-+B%V4NM1:+;4\@^ZL[A1T>2F[50Q\8TD%]UO$:
ME;_Q_@VR/;RKX!I[CW -"]<X?(1KW-?#L-R 2&_@NON-KJ5Q,;W#4WIW@198
M?N,ROD 0<&)"W0CQZ:*$:W\.?ANLN]:J#&Z<%\4'+3J#=O]'G-=P.;:B<'MS
M>\OBTK43P/9!2W]+^E4"-NZA1ZS8V\]B##+&((7,:JR1N5IRH#.?EY?&6O/J
M]XV;01[$FF=/&)O/72%_AG_^%KXO8< ?X0Z$][0N@-<_R6*^$-X;0:IS=%9"
M1,Y7^/,W#^9KQWK&O4#U"K8S;,2S3VD/9<@PT& H2BLOXS[!IN1\>@8X.C_5
MJTIA2ZYD5>*]MOL"&'9U64JAE4=H[(]'"KF'VC.;'\3I5&ZF/#H# F?L?U8\
M0GQD# K&TR1H2H<=)M-]\C"\]H?NRD\1=:[(EF,0O9<%UR35-"F1P;9%V"_9
MFI]?%(VB EHD 5JHY 16"NUL3!O5.1G%E0%5V,9 E<ECD4;@8#Q9'&D,;:#L
MGU::4LXO6=O938B^5GBOXP ^OA@P<9+LKB1+KF?P<YRGF+&I39_[Q<0<BC-3
M,86OHD,6BT+@Y&":EB5@&;U"P-7)G-4Q4JV[;"1^4L^YX4'56N"*"PE\.>GN
MNMUOG[$S6K#A7R%&]2W>6L>FRN!](C4?M"^OJC).LI6[P9H1-L$7F2*,8*[+
M@U@(&LU6;J$BB6>ACT:3Q!"1*G%8?1_*JK>$SMZ(>U$K[2[G5S4!(!G2TK8
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MC#J(D .Q.IF+3/P+LN=9$^R,^!DX(.G5BFJ@@]D^/X4QRY&\ML)HNO3*C]G
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M?4Z/1[H8*?D@,\9]H6X-\M_! <U[F07:V!QL?Q;]U;V*(^T^71A'6A#^NSX
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MMKT>CLX =:Q,.-R&('L/#]<R]1@#@3,&I"]LUQ9X]*\T;.%\3VS!6P2G<U&
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MU\!P\;A&2<W$LE7$?LYQ.D-,H/6W^Q<7_R;5PS5MP590;US7*&V)DVT4ROZ
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MTY''3<9?!E[[:<MW(V-YH=7;LHZ7G<%2QK(<X>^N]Y \B]C[:+>J,-29.N4
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M4=.>-L*I)D34>/%=XH&:!;!+Z-.1ILB9FQ_^'M-[=Z>'X_L.Y0P,'MLR+.R
MSC?4OUR(F^*221I7K>O%>/OX+GDN<(IQV0YH'8>NFLHT(V!&G8:(C]KOR(G5
M^]:M(/>ZB[90AR?:ZH0S.L@XS+.4H&1I9A/LR3BV\+"4THMD)]>E]"-EC#*;
MMB*<A::6D=DUJ.V5J5$BC/O;5-\9M1\!TRUOSS/.!8?#^*A*/9L^H<YT)0=K
MBAP[FYI&WW>:DX>JY*/8'':FZ9PO$+=ZX'F$W06IN;%MXT&I+N9^F+R9&MAQ
MVZ/3?>B$K*NU'&L+*,5N'SV';IH23X3@C7F.55)^Y/V[SL&T$'\#[Q/^3-:
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M65"7C@G!K^$J(MO+9WJV=)!H4ZEI-LR*"+19M#R(+CO>Z:&@J,!QNWJGIXS
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MQ[IL>[%G$@VDVXN(NZ8Y*47-)J#B#Z(5&T&><-6Q2.L3'^F])WLK_ 12QG-
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M;]QRB7YDC'ZE1IA*JV!OGGDWLB?,H"QRET6L0SR*@-5[[@XZUD?C2AD[?P8
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MU)[I[E2*&/WH>$8I0!C>D";4*ED5-3'GY+BWQD2MFKUVGO:>RR9+W!:2-1#
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M/2N7D($\3"'$^#V0R/1XPHURXM%AG3&]*!?H3'J"</#TP^</.ZM2M"X*J<*
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MT1W<&<5-4XUFX2AO+X'[Y'#_R>-G#[O=;\:*EM:*EP&(,<\9T#:R+8?=4[R
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MN"4 8QLC;X(.@ 1S0^1H.253#G,"=DYG2_88^OY"](U@6NCX1@6S' #HA-#
M<P5+<M2#Q:?L-C!M(:Z2^U:A (/:KW'N61BDWD3((%L<*#\RZE&'O&1S3-O!
M,T"4/R((SCCX$U;[C%<^[4G=M'BF=)+ #4A62/X TL9FDYO8HF$C;)PWS? T
M&==NL7<5OBKMT=6(OCDO;YMO4B/^(EHP[<62'XF\6.$ [&4:8N!"9E,4H'$O
M=5;'$Q9FX<OS'%/3,[O7"?V><;*26GB:JJ:B2RN31PS([:D[<HH,JXF4]J'J
M2:1'=44C\ R.2UK5B;&!)N]-%?BG-4C-%Q7FX6;!F+,_3'QP7]<Z/3EXJ'G
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MN'.*WJ'X'GM0F%D 72%-<.%I]ME+L;,,4:MW1.5@I1-)1LSARQ?/=1F]:_H
M%S";O2+$5[&0Y'6G]R"$1*P-NI+ ?4PF0,_D%[B+57N"U&23>5$6>( ADYM=
MDW\O)P5V?"G( L^E>!41_$!C(=@!':)1.U&B2MCDD6#"TRGD/BK%:4K/HN3I
M;&:<NQX3K'&-K96NIAC9\YPK<MNZ@@/6#IF>S>PA*NP;CAX2X0DWO@%JDQ%
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M7^_/JG<Q?5NGF1(\EPV7SX%T_7 MFYG^N_^]W:[1%GY\L'\4'V5D)(ZMW;B
MA&YY]M<'!P_P9^N^CN7G*X_HLIBTYW#IP4,7?QE#UF[1Y#\D\J\'/YF_M*-J
MLK+CJ.4EP'5@Y7(FZJBM%GC=1"[@9Z-"@H)3ZZ0W=K5H8/[CVDG_74=#M[U\
M_OW+[GW1A0/Y*=I7G<V/'7) HAS #6+48_1R[2F=00<QBI)'DFT2^[\MI7O;
MGG-]4DC?:_]3VX_^CM?B.Q2*>TG\:B614UQ>UCC1(G1"8<D.N&%6\^$/"RM5
MF+-90D\Z:UV*+(HWX*"[V4>*U$0E+TB+?B]4.R)4Z+0+B5W'=&^&<+TD4<0L
M ?X$..L"P )CT3,#R>FM2*8=OZN]<I&M\IHO8NZ%E 7:AP$@UWGFR\\F>3ZW
MHY^@V9C-<"Q<U.C'2VV:)[VL39X3AZJ_?,]Y-R6DDKN^S$UNC#OORF(2=] B
M!&< F3ET/?"DH)K162[MPSZW=\E&^]'8M8-S'"QG)PVE*V*T*\Q&KOV8ILT7
MCY<+#!2Z5/  CGY[NS"P S9G*==D*'G7*'[U3T?I,6&%?:%TY$RL#4S1FQV)
MQ82LA6%IAN$0S;:>6#+@B3E_6)'!9&6O;8D$/AUQYNJ"E(1PT''LUHGW,2LJ
MO2]B'0RAEWG1,RX&7_F)E(:/MN8T=!DA;LC,H2$3GEC=B60H;E_JOO/%!%[P
MO14(7Q.@O$(R4''_W\"QH!< L$XEA)JRJ+@#:^LCBI&^8TCQRF_9D;)<F= Y
MN1:1W9'-?S+<N,6H0)>WJYD%?0@\-1B+<K%2Z,Q60+/NGEYI/KYF+\03B^K5
MR>SJ$+ /JH&8E8*2*CK!,GQO[N.R4136>:4X'&#,V%KRUTD]3#'3Z\P\'5C8
M.EKUG9,2ALP?5#%!II#&D$D(81XY_WSP<4K-TD_YY\.CER\>C?:@R?,C9A20
M]#6Z1)[,S7Z&/;2I6QI%#R,4TZUNG;60FQ?WD!L/N3GZ]B$WMT20UM\B&0X>
MH,OA76DWOOWMGIQ.A<M:L9;K*-ZJ2Z$:%#-K0V<*KH6UKR#-\]9*8/+B^=$A
M*1[0':8O!#?<'+1=UJ48+U@2KOQ 333#!=CP4E!;/*#]Y*W5;4LB&<:!R:@,
MC@H+GL&,T!V7](?3LTB5ED$7ST5>$J0#1^>O60.R5E[\*$?/RSX$3+IL"85$
M'."'$5KKL)C1I\(G,I,U8CL@46@_Y)H0AG?>1OA38!T77$B.%I-=7*##]%1P
MFKO*FZH@TVA\P2/  (0%+"9%5B.RAG<'72:4U,A<!_$0+ECR  SNPMIZ:P^/
MH-"?[".TD<1O?[Z+/$!G&_AV7A)M:1(Y=G&@[(9P9K5;IN-LSJE_,U+J(<<R
ML_ETZ^ =K AOZ/HRH4W# 9\P;8/;VUN\*C(D+^_U>%CN X,M#&[1%O=F@)]-
M]#/Z<\]FJ)TWF#0<=^ ,Z=:IT<[BD81I)B22U/W$>2?F6KR3C<UW%$M33)1F
M7VU(B'=$:0204[Q@DH]Y1GY ,9I9S_?!3[#N;WAI&5RZGS#]GF%;LS/M*'S<
M-I?%;FZWP!GN#CA0UE-(2-!JB)V@F(8R:T!&FTA(8_L?&4Q]QC^0YUB48$P^
M,G;<@0_(^WI@ ZD)D0%)'S*@%!=@ RP@')6=3"14KW/(XF\5DS!,3(=I/P^'
M"^8\B'] A$X7+V,F'+NTPNO@ON#LQZV#G%L$4:EU?;"^4A1OWP=3($2%"/4
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M4I.0#OU9@J.O77#T/(-T)Y&#B!OSRQ(HT\[R"S3:2FK53-47.(\!M[:=1YW
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M+5=V=2FT,CI(V:WN>WB"15"\/D!3) ([!O%T^ZZ'$C0M]5R)1$! 4HIU+-S
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M(J9*>V9J- C;(<JRJ)M&G8O/H$AFY@'6\4GP?Z*"4&][)1ZKCE%D79,M0SN
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M^7 OW/_\?G]Y=MF[^T>JH2H?(E?0<Y+?+Y#\56PXO;F^O[FZ/.L]G)_]<O\
M__EQ?@WCN+D03O_H7?]^?B]<7@OW,-+S/VZNSL[O[O_S/TQ9,KX)Y__[Y^5#
MI:,L0>ZGG\?WQV \>9X=1HB"%3\%D\CVG4@@KP,"3X&5P'<.1&48D^03J$;[
M<[74;FI)\&D;X"C&$:S;Y*\ITX%MHV4(*V5D,"'9/,@.M&&4OHOC(:A"7T)[
MO%SS3UN!)6_GUL/4O"_*/I@-G0(?<7[_>J0?+7WKZF.> AJ*1GHS4Q)(+:P-
MA[W@O&6.DGW@K[R<OR6YEV7P_=8/OYS\ F2X#LACR\+R+!P,)J.)1\T^QL0
MS,&0_XTF9$B>B!^!E=UR=1.NMEPKS;6'($Y7,M6'/$K!#8:&.5GN0&N;_;#\
MUE?[M%6VH5U/\&RM#/W;RO?A\*0W"B9^W/(DSY,!2[9OF9)G"DOS:7F2YXE#
MAN[ ;5?/%%,(C=O7QY.Z][Z5.2P%S%N]6[8//<2'[D?B$(^;J'CB,ITO]+]L
M?X(>.LL6TN:L4!YP^76A'9Y<4/[0C]]B_+K)\=["O)]<:L_>I?ULSJ0&&<_N
MF?]W9:&D)BJ6K%M+:B .8OR'DHHCJ^53<3X*XQM)I-'*)M(<!-</, U&+Y\&
MLY1=\T'H0Y3Y1I)8C+))+&4YU-9![&V.>TM(2\AAU$',TUBV_0#]0%Y).'!9
M3ZEQ2+I#().4:U&P!6)I#DP:_CSG--P,;T-R00E8!C5MJJJBZFJ=\!I8ERMU
M9'-Q1]<-17>)"&Z*79IPSTG=/],T+$T6I:*J#QD,0\LTC*K=/ZDCFDI'40X0
ME1*8H6J:9DC[CVZS3!H2.: 9<H6=[0U3,Q59U&M<.-A'6.\8TB;=1W<L!I(J
MJZ*I2<9^8?BOZNBFB2;HPD. 9MI*>!M0^HI4B>RV5OW>6FPM(2TA[]&J7]U>
M8$M[?5F'@28TLXQH=_/!QD(X5NV@&PP8!G;'D@M16>NRW35%[.C6 ?:*TE3+
MT"1)/Y1.8M5 LS=BQZL(S6X=HCL'3P%[6%.65=3O'=&ZI:LF^!_[U1BA;DEN
M8NO0*A'DUJC?6X.M):0EY%"-^J(> TWK\RIZ"<"&*XN&7)1O5%O 63S05@*J
MKBN*2:--^[[5[P&8>B/&+O@/((R')TNR:(JJ:4K2?K6E6$XTV'R:9!A[1O.^
MRG\3)K)9@?BW!O+>&C\M(2TAAVD@M[T$WBF&^2H;V91TV9)4;0U0S(_++=E0
M=$,'(Z%E5AG14F3-$"UK29;'!^+6MH#TF"JGZ5*!=U]#TKMB'9U8'5->?5+5
M=A,H,WE;^!9KSYTJUC1WK>.QMT9E2TA+R&$X'ALT$Y@K#WXGF,&+FPG(F&XA
MBM@3N*#Z+?NQTC"_W-$ELZ,BNUO([C(I,9JJ*Q8:9&T[@0IJ.G53%C4#_-#Z
MPJ^J?'0BF6)'U]J>&15.G22)BJQ:M99!JTK;3V =CZ3DHH/_9YJ:O,G,K>^7
MJ(@@H'>D);5>:T_B1^XG(%F6H4N&I*EU+CP-:[$U:W4#['UJ*+ 2_+R))@-"
MR28#>6.ZF28#<^8[)Z>&)@,HY\,@B&G6.+5O44 50Y=-4U&,(^%UY'T%ZQ\8
M3OSNS_MZVA+DB#B9:U(@).(G-"=_^]&Y0"CH7/!+$YT+RK)I68\"0VQ[%&0]
M"LRV1T%=/0JFU-E:'0S4; \IV<'@E_(=# Z]D4'O_@_AXNKF[_=MMX(#[%:P
MP!2N -I3FC:\5B)WEM'C_R!V*!"*MY&/+I8\$*D0V+,^MLG5<ZU,['5=/-B]
M'>G*EK7O9J3*#L1^2BM3RL'9#$*:N?D5<6A"W!5AP["C)V'H!2^1, R#D1"
M]H6+P&BE'H$;NR3Z.A-M+<._E6<HJ\YL]O*96VB>PQC@[IBV_CD8WW=UM1",
M;E$>W78@@']9<+6U$?KB?J4Q&&73&)I$76R8X;*H2:(J:<UPW#PZ,3JFN27
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M][2=R.:B# B;VY'4]?NO[Z9>H@TY'#XA.S,6"D\HBN(,[U<++8A[7B1,J.V
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M_FA"'-(JSG#RV(5%%DTP"X4=V2$-G""*(8<-TA#GE-8M![D>:_P9M* R$+S
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M:H78H4O3D%*9I[^_]UF@B65IL['TP!T/PEA.>U(^GNNZ2,^UW(@UD'02MT_
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M=-G4%ZY00Y'5HY.S'-54 =K>@ ]H$J5M%< SHYX%;;4^ @<G<#+;(-OM)G1
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M8-CL"SC]7Q,>[$T<H5%=><&@ZB@49:H_V Z3MK2 G3>:]/\UXUB@3AHP/H;
M1PZ4A_88;:P0Q4M5+MNN,G7&M2ZHK@O$8UFLJ?,4L'8-0<0,RSPQ7%/1OKU(
MAT.&]L2+DVZQPZE1N_&$;;336)Y))]@,;8TA]G!/ S4[)8,=Q?DTJ,YZWS(
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M3^D6CY8>0WA>F/A+,*QK7=];C5'K).</\<B;T-%FKH-]2V7C:&B)FVLL5_=
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M*-V!4-, )H,@(C'5*P M8>>FGWZPQZ_8TV5-4T15%PUL(M.FO:IBN:AL%5'
MA0_M3%[2+%/7P3C1&Y@]=MT8Z)I8G/WIZ$MZ&W]$6-?L07>S,N!$P*(U,(7P
MEX/\+@O(X7"TL"#,CG";XP=!\>8[3;RQ7. [-@ 4\^>_^L&U_VS/JNJ$,Q1J
MD7:(Z# 0Q1+:I5I,(@R^D([#Q-.=P^3!(XC*N^<<74E8$ ''#RZH%/%!&#M!
M9 /1Y^[, 8W" WHN9LM0"(@,SSE*KJ<A5U2NG3F,!\;KE1/0BL&ZN+R#,\R
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M\;^WGD7<?EX4?TG\6F-T_BQ"YY,0_XTZQK.>O=4-Z"-_D>\LS\=6S<7/E3;
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M0/BI&9GT+<YD9_)S%5NM(8J'I#XGS@"(C6>;>[;#Y=W_8H? G%TK+,M:FE4
M?^](8%G4+%F7)'1AMT=A!*U:JV44\<HY2'@<[_^5@7\WQ%6*84F6)A;Z]S6Y
M9@4UJY<M.K_JQI:M&;JN**+4ZK)5N#Q?NNS,NAE,^F-32\^LL+VE:Q7=RE9
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M00KYLR5#\:R=T.HV#B'?/ETP"*"B5*XEF0="CJV.0V=\[/X\?G G$\?[!-:
M+"FB*6NF!O3V?&Z_9UJ<IDBI*UZ)URCP>RE2+45 7T,>I")NC 0Y0KB8N1$+
MR5*):*8:NVYC[FLV%#M .%SIJ5$, RPS5<PQN@6WA?0I5P$:]Z(L0JJ^\7#Z
MJ<_"45X$RGF2?I#;IQ5< -#=QRQY=^S##\.%SXIB\NV>DVU=S0LAY,S9,VG_
MU""W/#HTHOT ?OOB+/P01&K&M\$M^S0]'@$]DA>2[@R:\^J+*4$@1@%!>\3W
MP&26/E(]5.(N84(_<!SA 6:*8;H/.Z"IL+_'M^ 7I[HJ3#1,X,Q66X18F"M8
M(M@_EH&IV(1[GNYB):V>_&XH9&+_%%UJTSJS$.*R!GG0WO5\WE&;8^6RY).Y
M/4F*Q/TTIRWCMZ3*:.30/-^_P5*[KYBCS[+N"6&"M\8>4//>LG@(P]AA<%MY
MD@_0-IXZ%#6/E8^G)"V*U92Q;9E1:GMAR+0I>M(&'7%M$,$FTR6=R[9X V$>
M\)()[YC,!2(-2V(Q;0!>[*3.A&!8WKJ]P7*W ]GJ$155L/-BSS*((W/$4@ 1
M[:$ .7ZP9]-8F#S!91Z3DV0X_&(YHZK&..F^E.:9]O8^\Y6P1$S\@>?@>Z/L
MV'N@]=MU#,HO<!3D*H!>F4-04?"^494676$6MOJIBF <AD-0@KDA$':;FHF*
M>!F;0EN]0["K@Z[L>M"K.H.M=!?(E%IE*N]J=$'I4@RHBB9KJBP64*L:Y']M
M?2(Y2@(^W3@A((F!63$,Y#Y;QU@@*351-EKT3EGZ^JJ$5>=4$6L.$PRSL%0)
M?@)CP<3T?+(Q7Q4Y,D&41#T>F!YU/025#%'?S',Z83#P*OABL)E,U;1E&UY^
M725+F[*FFTK3D&NYG3$V) _C%G2T7,LR#,RZ;[-9CV5B(7395<77N_:*VEOJ
MTMH,5ZO/<,UDN!KO.,.U0:NQSUSM,U=?T&2LSTA]'U:(:G;?DFV\KQ;*_R@S
M;O)*ZZ?J=GX=MN1>&X4;/X":FX"\YN)Q%W[DK&IHM_"NSS/"05F'@^> 0K;
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M))"SBYSA[VE]MH=82VOZI,3QH5C6PY2C9> A%T=DEN-""1 @%=Y/#PZN$U_
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M>%\'[<+))M6,[2!X!O&.,IFBNW'36>"^Q3)8^*&3J90#'IBCAPC4B8D+%U:
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MS_EU9+T13H)Q>>?(CFWRA,IOPT]Z:DS.5#Q,?T?HZ)GRK+\OJ)%:UGCL6]_
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MUK^8I5WR/J";>S[)3@>IN6RC_#3-PC-0[SQY)FLTG.NSBG8]D@7<R;5(4N-
MUEO2A]T<:!V#.+V^+%?I#NNWKQ=->K>*WC>4.Z-S3P22!=?VJ99,=AH%,]G_
M 5$E]0&?^-T67INQ#IMC 9&3N';X,;L9STGW*$8(>99O8MS;?WIRO&FASJ?
MHZ9TAFM037-#M4Q!Z9?WE;4URK_@BYA'F=V94NU*PN@66/-Y$#W']7NC.35]
MB'Z?UKO9!1>89&A3K?N?$I1XO5T.4O=QT7#2Y;Y,'Y0!^81N.U?8R<CZ[&;<
MH\Q(0:9NAQJA36E+E:E-&\XY_I34GJ-."V1HU8PX.M=0#X&I]GZ''5>3!U56
M;R)OSHAR*#AGVML3I-<$:(F5O,J*[=O"@IW8Q!G!054$%^A*8>LP.[$D)C+<
M64OJY;P"QI#W1?2HS$J\?$*)QR.7[%+'\66'^(_:6Y+SB:=,\:KEY<+Z4C*W
M"BB2'#6IV;:]2MY*T\-OBSK5K?GS.37/IR2DO9H63RXW=+!:**1HRO;5*)KF
M&\1G4\%$V39+7,^9WZR\;GXO+KJJGU5LE586+$ LG1V?FMMLO<X\;4@[9  >
MF@M'F'V&W]^<[#( ?]Q"W]N_1.E*:I8!+=MFI&CY&4\8*M35/;GK8SC0U9OT
MJJY1V<?=N["%5*9U/<A[52[HUY6;)H$_BES))I9S!FNY+."(]#Z!@#[:0\61
M#=81M,!V=*72!SQ;+TGA$HF.FR-R)*Q^U#DKB8NL#E-0,:7NT!-(J[?S5VHF
MK;.KE5=VCZ=JIGC.A&PAGD"::N,,)XVU8AZ['*/A/V"$P(9.>-7(3&TAZ-J1
M<V3_K78(%=.&Y0D.=[4/CW .H70]15W".>$[1.]1S&7.XT/*O3+@DQWW0C\K
MS ]S_>C=NQ8Q2!1$>V+%0&(7G+?1NL3%$<1W,G^AS=<^5B DW3&+F>$::=1O
M\7.EHJ,V\>5!ZZ=-WCZ8=')QO"I*?RL>EGW-LUSQ_+UX.Z^^?#./,G;3$W6&
M'[OY5HH*]0(-U73L#+N-%)5=>IY/+@@Y50G3+F)*RYTN&PV[R?15%QN5G=&1
M5<N[QFWM+BC<E\216F*A.JUE;F?F+J<)7PELF3E Q6&('EA0W.!IH]_<.ENG
MCM P<0X[RQ_5%:-M3MJ_U*YU>;!ESB_F"3L+J-SQ-N[1R/FLF=*W?NO;VKS<
MY>H*HV)*BQH\!EV%75?>TXCHU8'3()G?HYJ1%&)B6,!<03H+J$)5H52HU3J<
M0QL1W$LS.C2VR%^H_?$$JS3$ZF*[0/W#9][ETUZ[D4G!1;Z-!$?!]RD"3!^?
M9DV4;^4P2J'4'G4/K' O 47TZZB+3]0<$;'-2K7#C:=)4^.OGWR[0LW>=JAW
M1H;\UO!D<I(S6^YZ>E\GTF<NWD[T;)+MT46R0;OW[''X$R6=7R 5;[% /O$3
M^#BWAQ7P'D+:,VS] R77F#)^7!\C)LUI9\8J>T(5Z^AFZP8-SS8<ECZM+:1S
M>!:4V)?8=V4[?&OOMG%:T4C!'REUJ9[Y6.)])KG1S=2\<TO+)Z [LUVOPZC&
MTP8O;^TQ%)#EO^T:>LV!],I'1C=C=VG_G;8&>?9$Q$<XU4J)8P5;)?4["W!G
M =$S,/ 9%785U"U!\K8^S.&M!#_.<<*%41I1VO9ER[N!Y2^+ISUK:S4<5!^U
M:_EFM9[._ZPX2J<8A44O1YQ''0$1)<PO6,)B8I#98^+)9D5&"&BPQ\D0IIE!
M$3!N9XH,EC=JDI7X5P28EPCUHUR1;P5JA.=I]8,H%=)(#ED@U8Q -$8J^D@.
M*Q0D_#@YJJ/!N$_C+Z]P)2LE$@6TK[J2141%;M".)#?01#J%F](;"L"'B^LY
M8D,[KYQU[=\_M:S\C(</J88Y_KD08]+  @RKKQ?\6)'#)+* TXJ-;IXTX57R
M]PXY3&RZ\"-/=1V=5V2NA+NTLIQ486W_99L961^GU3^6*]XF%]T6W9J4;3@2
M>7>XZX"%;'>I937>S::W^R*2<'XED*!T6U(]O]<+\[QS5"5:-S;RC(UZUEV*
MM<8Q\O"]%<N>6\-?*DY6)9D56EEG%A=0XC/?+A=N83_WKW50Y>C)M,U.V&0J
M/18D[JE'],$.:=O.H0&4$'6!0#T+O^O1K(),,*@;6^=U&-*VI2[.*::2DRZ<
M$'>B)6?X(5%Z_F6K2@]XYJN\*I;.VZ&O1)Q!:8'!5%<F!XY6THHXUGP*=9':
MT=^.&%>Z 9;P-R>1'"^)S((F/CM[O1S,ME:M\.IEW%(F6[+"UPH_X25ADPK"
MJ/O0VMMT\L64KU_0H@*S(CIJ]JLZ$C1^;"<\02#G+.UYVB/W1+551.R,<NUH
MHRU.5T3W));L;*'@ID3HD3X;$LWI;!3VXI=X0_$X;M&TD03(P>^U#7+!3JYX
M(D\N#1VM:J>M0<(+Z%&(?%UD/RYDP.AIA3+4Y3?>'XN3;(T_EY7-IQ]339 K
M# )SGU&,'Y1_&*9:RVK.E(J?MJ![<2?I\=5Y;N$>)7W4OYEJ4BMGU#OMG8]*
MY7:QSJH(NFU:SDW*TW^N;8'C-#B^_$V&["[[!\XF<EY0TZ@DR?;A/"QL5P#3
MH@*V,=GG:7VK]'S0D 1[K/,KC8W!US;7F4"+::L7?*)*C$F?/;ZMX&<)ZN)6
MA7TS<(ZGIUIJS$%=Z_2=,H4=H,:S>,9)(*[\O/GVV#IN3X.AC'B"IIK#.) 4
MN@.H1]6=4UI;I&))FW%HU_YD%QZJXBN2&3?XM&/,A;^N@5A=36LJ90'W:21L
M>UP!^(C<%RJY9^35[_VP/FJDW=:<!<AD=G7@XYEG!X(W3X!/R9AVG["V'-G1
ML?89:2JSEH+F]:J7BD,9)?C&D95.>=KN9M&U^NJ?34QT9C;G'>G=S<\O5OC@
MB'RBBT>9@[ED_''/"'::67M_;,1YJDO,UVS!%N8Y6FT<@<CI"7=/[/#;?T7:
M-[.J'[S?W,\KM,[L]\BY)OKLOHO,OBGN0DIIGE<Y3M[:6$_CZEY&$<TAK6B/
ML3HQ'&)JV\0"7.]<+I4U."WL=;'(EAY$B;M9D*]]N.RJMD%G[M.B&#/N]:)]
M!+<$>45&$YI;.\O%!%:)A$B(JL7R]LXS^V-:8=S$N6P!%B"&NDT>UQ%>%HC0
MJ:<]S!#%/ZU^49UDVCTY,]LV*J 5%##3-)/@Z5X\XUV>V=3YYKN,U"N&>:MA
MO'9*E\?AU!3_3L,-TPMF@;V//H,TVB=D,EP(DX00Z$H@40>H3CIR,![M.]K&
M@D]O/'$E'2,,E**]I*(^?3 *.E(O;/ORVWXJ5!=>!XX#P/89CJD3,<]/>O=C
M,_F&1OUF8Z!V@"CC^-*(HWOTYI1KE7S/RBU^/2WFU*1E6\>J/9.>,<IO1&PN
ML9@95?/H')BOS"L&]=[$RQ7N<!43[\!_:"E%87=H9+]]W9T59E3)C^7]6!;P
M=:E9 #W6%4?<X1HKV14HQ=5O[]O_B!%!_SD$=9YW=M&[J;'PJ_"Y]*^8J3"2
M*?OI >:Y0T^3N9X$_VX@&BO!_>6!]S:.C.A@ 8_A?!'B#([]5(+9F>F(P9GS
MK^@$VM$F2EB_(-+"VP?6LGNB>D:+AZ'QG. M#2<H5,<0JZCTG/14+V6G\>43
M(:%!?^PG#Q*QLX?!S4[L"92Q*T4I9D9J5%N4W'1![L\@%G!J2>/<D&55S$U"
M2O>NM-3=/V2=)TT4JE=NQL3KNZC\L7ZI:T9]4/L^EJ>:R+>J#COE.J;(,(8E
M^I1?\RXBB_Q0E&P>M5G+4YK:^-I0'SJO_,>ZO\RDAO_61 :7=IM*SAV:V,>A
M'I(NNW!()"FIH.J(:9-#1<%*\:^[*RG18@29O@?[F]JNIG)=+0L][$^3N<TM
M+3JZR\_V#2:^&T(::%G-+;Q>,5[I4[0N&DYT50I,MWB%KF\&0.,]*8;-?B53
M L7^;C^;P4\2A=%]!II_6:V8ZD6'%TEU$'F]'L5$WR)DM&>Z$3)=>DF8HRS
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MAK*U=/>I-'%C]N@V!U.%VFN\3[V?$[I_9,@^FO"*L$.WF$'J?8)JRVQE:K&
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M# _2W[. <E[T4@U^):\5L24-ZC([E#A9P'*,67'1T.(NS+X+T=K- E8W5%C
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M(S*9XC>)H<?66(=A)@^1JSG6N!W\8H77C/I"C^5OI@F(OWEBN%W8+/?C5Q8
MJA-9@,P)%!&VI1VR%H++3_K! FK_8C%=;O,'%;K[000:N32C/6<G><B&9^%B
M3-E^A6;M<2()/I9S/201HRRP%Q3VX<^9HU?(;UA ]$N0X:[>1NGOX W@_:3.
M JC8U68D!I/506<!OTJ)+TS5/NM7W8Q;/0YG'L>S@.ZG"*4N!D9RC_\[ T1
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M%L]@?H(*BB7!ORM@7D*?/RO];P%3#F4WHAV[*YUS"8(?L1WVLWSYYRMO_LX
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MCG8L8?9664UPN=MW%.0C ,<D-<'8>A9JZ@Y-XOMB>#M[-X+GD<VO9Z!E<?O
M8$[PW4/8Z"B.T0[,46&G.84ZJ4.A$MWY-ZDW!#<3=N?HII<7MSNZN1(NC02\
M+!X(P)\'2<*=XK=L>2@?\TC;-V!7C3XD=@GP<LLB"".VH8?P5QGK)3@=K.%
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MDCQ8\A<X59)Q$/8?SRU?Z6))_ 9L;]0=FD")SQ3_CKE!.]2L!)$O^0YMX09
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MD0HT G9;V=R:TNWOZ.WX<#O^;G2&.:TC$9ZF2F5D9B<M'J8LPT+P.Z)$1VI
MU_EW PWAXQ^*W5UN/'"]5UE!65; =,?H/G-K*4XO>[ID9*7MG*U-6!L^MNM>
MK.;.0)Z)VT[-:Y9V=@$^V3X7RY6RLBX][WT2VC;A6F-NPG[A_P U58"2E31.
MYA)O[PHYTYQ\EG_:^JJPZMU^5MGSZSNW"I[^$W"G^\;D! 2P2WA./(8'G*.R
M$ JXHUA#?NP&3'$#%K3,HG=!KSO%\K-4365\<EY,6*L&A0(8,0QVB-QJ=#-6
M:A +#M+E:2OK!E9,PP:'I)L#US[]=F#V"UX3/_6835ENZV,A>$IMY[INDR-:
M-XL"GX/CO)HS,VT>W$0:J/M^AH!3^=BSK5#GK\PH7J&S#-C',(_GMQ]Z\$?S
M,8L;8_$].N>^V8V90!I*>?C7R$>%B2GQ6Y]JO\0^>\KQM\<W8 MO3Z1Z^ZHX
M&WF)SOMKRH<..ASI"LH-=:WTA>_T%'@]TS!WJBIS4M#-;A<BPNV?A/=\Z!+)
M67%/._^"=0'V$3%$3+_(U2U>9>=+:VJ\>DKON4^2$-@B9$V-20 %N[-.68LF
MT,TP-6B\GC7IH7!OM_SO3KNW84VX>%:UX!Z_-9<;121R$7#0JJO5"!J._K@Q
MO"92 22<!@0UH16@,R>/(#QK0FA//.FGB9!KX\P392YA3U :AS_Q:P0IT62?
M^82RQOIM71\6<AP*!RU.<VFLR&4>?"&@5F2Q7FFQA4M,O_GSW%L?"\6-?,UW
M=@>D21D66I7>(8; :L<%,%+(81*:(XLU1D0QO](N XW5/,- SQPWE\,UM1]#
M+\S="K^<X1IM]\K6_V;#T&IB=85E5&G"@>6EGMS2X%1NP4WW^F=562W%ND4.
MFV<DXX"7YA^J?L\-\TIX.*)@;K1KCC8I=#=SEO*0_]17KB3>6<;7& _#N@)J
M=;T*L<[RQ]1O8&3DWLQ#F42X*G+0?HAU HX$P5Y L(ZIUM]]W2O^!&QJJOCE
M\5J4H/1?I_)^A6)T0J2W7DHI?._\ABTK-I[%OR"DF1QL5</0?8!M[6&H/3@=
MC)4#7X(@0O&D36?C2-*AQ?M\7]<83Y8Q%LN]Y[:^/<RC&N@68^;?*/GH=M(^
M.$_I=A$U1%'K>1:;N*1=.!9.G__Y=Q*5=@_K_.QI)>>#A70%1M=C!(*8PA:K
M]J'Y_C&+?*4F1&I#8NCW]6U7FX8"&E_>B1\]W?O6L5M851IJ;29\'>.M4S@R
M=J AR7WDQR\CF(P:_0>,&64+D[#C"ZO;/*6<]<NS:TGP_KBZD8-#C]/*/.7+
M3!9"NN!G[+HK+U8[%S_279*"V&H O+=8A]3#2)-(N3_C%=W]X^Q98)/NO2-V
M_S*YF8_P[</ [I@L_&60=.)[5^XH[2366QB =0,)0G5<+WZ+"3F;K1%EL@'+
MI%'PBXBGH1!R&T'<O1LSSD!I-/L*#^#>KXU2RT46(&D;L7WQ*%IAWH['5I[$
M&+6O=67&5N^XME)DX#AB9'05,_TJD3BP21@QB2D5[QCCHEFEKGS;=)$<_Y@=
MN+,&$@ATFL6QIQUF6<T*PC,AG@;  S$PRVIN3'\2]@O(?[;2<B;IJH-9_S,3
M%1.I'/71[J9\LUO\E]?(L0L%<SS#:XL"_W73S@N\0^K7([T^:G@''F,O'+?)
MNT0Z4'59*Z7]\O2[X8E#[B'<ORH2#UX^V"?A7^2IW_R<^$AT%4J*\Z*+8 Y
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M#)&TBC:RP'Z8R1#A@.!%:Z$-;>$TCSV6)#XJ<BWDZ78(_9P%)8!$QY@HG.O
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M I"&VC^<A/_8< $[5X7;G,*F*862OX_;[:R0>]-^5 D%;WR7$8 N?]+E2]^
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MSN,+?O=G^E]VVL+KAYVVK- /\Z\C2-S,S(Z:?W?(,L3<:L'24J@131:$3[]
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MQ+D2Y+-,%("$,CO9VK=TR4U(=Z"&8#I$&G#L:S_/LLAH198#,9=9T(RZC(3
M:JT:2(SAK]K6KW52> Z;%&I1'KWE?O*XI@M'.].]0-.P;?UFI4-,W8O+T-K,
MEC6KE297W7Z9T\\)JGOV?-B7:N_NEA>/MB_YZ.]6W41'2OOI>[6!F@?#-,,I
M^1_2"($-O9>^[I@G82M<W5V7#HK@DQV-GQA],G:JL6[M.W'AQEAY?K,_T7G$
MQM- )Y3:[%]."AVQ?:_]1TGRZ8?_=O'5RU67H_LN@8KV6O;]ON]D4<<]NY]?
M%2V-;/A^/1(D "G_ILM+61" %FV/N6EPI#@87BQWCS_="-(M ,EK+^&D@%+/
MEPUC,/KAR*46<3 EM[%&LX>8-OH W;#I5E2E^3F-]#G_2U!0^:V&QD9O*:%J
M-Q> *,<Q0C:X;M&J(P ]Q)P0@+Y,FP!\U;3S548!V=?MY)*<OJCIUWF;.627
M?/)9GG:KR6;D^]N8F;NT(F7QT+GF9'XLEOXG^19V6WE&00#J($MBU[YE #>A
MDSA^XF8\F07M1G!;2K\ I>"-)2$@/C/$3@L7_Y>^[]-FV,LPUAM$+8PGN2J.
MG44DDK?"+;CGY9:%.OG72 H"D&- ^9Y#:]RK6)*K+^\G)G\9*@!IP8H6-;;!
MV$DISJU?,\T!&/W9(XN3U9@)AG+#I4=ECU[J5!4^K[KSD^IA4.8>=!H+THMC
M6>.HB!XR*QJM6,N:2$0CH GU,-F%?-EZ>D9*^[YFMFI<G;4 M-R&[#:6S.OE
M-._!I82FR5T5@,S&2&B#D I3PMOW_>8/GSASR3(^2Q\72GOJSDG?/9QJ[/@4
M7AR;ZIM,-(]3R'XYF+/EXW6G0FTXQ3[+H3"G9.IN\CU$CC9\M0Y;:[<<I945
MPA!IE63U(L&NEF?@[<=3>J6LG[E:[ZH*H400^QCEPRL^\197OB8SONF="/\U
MS,5GWULTG [[J-%!%8 2ZY"R:-C@NJ=J%W;O*M\0B&&<' 3RF73/!$K;A6M1
M$IR[S'XCS)Q5*WMWN-^(&;U?IFE4JRK9QD\U\\JL]Y/0\>V%J<"5QHT;_G?C
M%5J?JGV)J'?MW8Q5&[KG$EK"[/]0-O=@%%Z;G..R./(%KW43<VX(4;>-?$B^
M?A31VRP7'3J0P%=L$X!BL^AE")DZQ!%3XUH!:'_#=XJNTK%:UOOJI\;'84DC
MEU-Z==WP&\V==/F;GI[%6FXZ11<;E @1.^?X;YK#.01.WA^8(_Z$R]'4)4^%
MO.3J98FXP >NMZOK.R,8*-N,H ?.<=G;?]8G+U>*A>?Y=WU%3#A75]JX9"!4
MOZO?39?-2@WX\H2H9[N_S%O=21HO:G75QLSI'OSI*0E7M?<V]]X]O<F4%X!D
M:2Q' 6AK%UI& 'I)3B>OQU"$KIDE;QW]\8EW7JP M'%\I)(G2O83@#[2^*(M
MX"X>G$%;D6&9TOD$%H7N$O<<^+#9/:&K9#Q^9EUS_\J94O+X&4VN,D,46>\7
M7.)^M*2+=M6_5++ME<R9/GK;KME-[D'?JX.:W"@ZY \O\3&X.=#'RJ(?Y13N
MB\?H^1EKLQ*Z82D/2GI877/=[0?8#61Z&M:<-5-S%\DK!B<'AVYI7_?>G1>P
M>4X9[U;A-Y5IAQ])7YMTVVPA.]6-[O A;-U=UBKQ2GD2;"U-^XI$RFCW];.O
MK1[[373K;_@/YU@D)<?96D[WHC,L?,-%!KZ*D8"MUP)0]7?L?.]SC4WJ'">8
MEW%]1+$;[B4!N"L]/+GVJZ&E:NKG#,JK3V?>2S^RJ&Y,SK/,M-=OO76RY;RH
MS)_/?-0AX3OG,6_R(Q<>+1KO H((;ZME%*0?)"1_J[HY8:VNC[W>%\9(Q%V;
MR50F< *F@^'F'@D.WD_<>&<*5X>6.4M1L).8^Z^G?LY$3&[AK@EC)?U5K&,^
MT!CM,9+1([)TJ3, L\L>,7@ \:IO&6=,B"CN9-$ZX I?"W?#W=+C]B6&R6^\
MUQ^/*A$CFIJG=&=47)OZS7.WKIS+2\KI,)%EUY#OY.X?#?D*$"(Z=BG-T&Y/
M,$5):92_&V5')Z=C--R/RC&"R] :=&1*_A000O_VW&>X?4JBVM"DJM15S.:0
MS>5-&^6!,<WEE3>Y^>%# 1M#.E&:V.:E?N?J\H\8*(7Q(O+,1><"AOI:%^9#
MVGYG]7M.%58Y>FOFZ$^UE5YIERQ5Y3\0U7H=0M($H.//2?-25WDY6!^C$Q^]
MEF#BAF(ED_+''B+#"B.=AF]3&?.,\<G@#;"DNWO]V,AU36)L?,3GK1-I!<=0
MC9T9^_E"[:9D?!A ,C:CT>+T(&AGD=8$VI%.!K]E+KVWZVCN+:T2<H=M7,Q&
MBT&4LAO;S48[A;@@]\@5WYK5'Q[TV:/,3_77XK<:A!%,?_UT8<%X/[%H7/I2
MGYA#*OM@_P7708)#H?Q8G/HA@D*]MXO30I-YZ>:<@@S^,%ZUWRIH36V:?]X>
MT?02K<2+U\*<6B+O9;!H%&6V'<7XR!#:O1HX9"<9P$+%V+)6$Q%.-LH.F1^B
M'EQ0G]9*J?AD&10\XCEY39BA_! F03XZ;=UM9J3EL1TEVL>&BNNSN'BY;0>$
M2NXV,2'5IVV8.78JYUB*=99]/=NIP?*%C>&C3HFG(RF3A,Q+W@_+PAQ"H!-8
MBRV=B>H\%0_?F 2HL7L^I4AZT30_3:W"L>KI\P^:=?C]-:EX*\O7H_99Y5]+
M5@ 9,\P'-(HUP96:XO@,M<*(W"#61&SK<4A*?1(:-LM3&N]C0%(,/9GB 3-3
M*WD/PN,,Y6:WPF@RJ.A(1=@Z\9>%?)MN%]GES.FW(IE&VV01PST"T&X^L#7[
M7I&QKTL30B>EHC5)2PJX^/7^YV&(0PL*!0#AUY.!&*DFUE=RI3_F1 W;*U6Z
MO8+>\E[KZ(W>(QYV?@W+KS(YT_XT JUQHYTSQO8Y%9>N]WEKN-.V%'_ =ZR"
MYQ+F_5?AI8FOH?B3=.WA+(_!IQ%/BR]1V/K)O*X)OBR_@R_+ACQ$GV(<O4"7
MR&% D_(SDK0S?O:?\#K;NJ\[GQ![!EMG:'/=]W[1R<C#P>N1]VJF32)"@HZ3
M,S753V4YYAJ8,_BG49$<60#&;+&+;]<"]"+O,A4%H!B8=+OAQP6OPS]:*?PZ
M400"#*D!J*&@_)'N<ZTS*JXZ@6KK=A)]4AY+!]9$RE/>!7CT3[P-V-X.\L5,
MH]]YN)K7+73EVC^U#?-W(EJIQQUNSO9[?[G^FMXH7GX$KZ?F),S HL:NEUKP
M !.!$X!8#K"M8T40 >A5\3/L0DKW&.^>'ZV6MAQ%]%<2'YN@DV+J0I@K8I9L
M<-RZG50 E9#0:O_\VI)^5#4^,+C]R&BKM>QSZM.#GCTR?!Q2O'L<?L/:_Q[[
MZ?<90UX"]G=2<KX6GDZ#<)4 .\8TN"L?WTZH]F^<@8[E@L46QUD>%&0(8^\(
MUR?P8MS=HVWOA]4##U&/NQZIN_DB)\!?>[.6NE32XK80&;&%+![*9?,]__CK
MY>,7D\&WZ7'=ZCG']Z-\+Q:KUYTZ/$-0QHPUA\_=#4F)SB;XD;^'_7_WZ. ]
MA+ L5X%31\8?$!G\?MJN6R-U\-PIK_:,/B6-2/%#UT;EB1O]'_DG%(.4_(8>
M9FJ:![I>/7NF]$1[6@SG!B]M6;M0P@\MQFJ>N-PFZZ8;3P*G^MIH./E=3Z?V
MV0QNB*)=@NHC'^V^VR->G]8S_==#BW?+EEK.TL12EV_,F6GH!%^!6C0A"1"R
M?,]V]HGG^(;.*!'#84$6^YL*W9R:O"&^+L@GY@4%*99K.MI/D<JLR\F\9\*
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MF.X5]9/$>LV+PW,+=DFPAH0.A.P"H@X>KYU!A3(P,4PH59>#P(H $PQ20N@
MU79N=CJO%PK&##6K]FA*60$AK"F&7&JK)1M)7XWGAK#X(U[#K9Y!/A5O9S6E
M>JB?7OH]\"''UXO;>W,-2K+7\F547HQ6>N&=F*HN"/B]@AA*LU7@XJ=TZ1G9
MK#0=D2Z'KX6V_OVF.4;!JVMKC;:Y4ZNPJ!]71>PY"\ B&+2'2M#!L/=[=V:_
MIK!].9[ 0P9MLABS!V"A;0%S8U&4>"M4NUT4B&."E9:P/Q'J6;>(*J4A]!U(
M_,QAEH< =# TL$T%(M5Y'>L3<2)B;^&.)?^]KC)=-\;X#'\,IF2L!U32D0G8
M $VL*>_%QE$84P"B++$9V%2W#$H* H168FMNQJ.M!2#Q<Y&L6JLAKA$;TL,_
M+0#%AG3+7C5E#D"FYMT,8+%PCY;77-^2VG3+&(*,PCV2A+,V7M[!<?/I\J=I
MT?=U+VPOH-_>.#$Q[NUVE7#I2.7 ]A:6LM&T([7S.Y_F)<&NSF//_<8K,%9%
M>PP6 S5L 8B#8'\C&.[K-=XWWHJ=)<<B7IDU=B$58&F&)B'5GDO;Q/%B]F7Y
M8/P(U[YZ22$CY03*T)$TO1AN__;2.+"R$S6OR8!1$3V(70*0OUUJ^ /<BN).
M !?$*RTAOQK!* /[>I0D )O9*6@*-9?,PCFP]WPC<=Y".HJ4V>$)QV*L6!]*
M9@ZQG>SN&N=)35+M1+F_EU3+7]S_U+_3W,%I&:=?JNNL:M(WI7=]"G?RY?JG
M^RX>Q'MJO?O4$<,30>MKL ##'VT6?@)\H;VKT9LX"326+4<A_X06YL8]N@!O
MQQ5MP8I/*@Z<D1L*P\;Q=8'W+$0?#%R?9MK9'-:#)R7KM(@K=AJ?&M7D'@_?
MTUVD.+[;7(0^JG.RJ&D).P6=Y1>SEF:?C;=KHDUM+.BXY<*=N_SW#PA=&K@#
MJ"G[D7(VN'>)E$[-Z"(EZAN_SGL%Z&D3K6V ##IY[V+#*_<I(*'KI;NG6';6
MY=I?L$IJ9:]N*Z1=(@44:@_G+#19YW_Z<"_4/?MSJ?2BIY/5:7-_OR.5=M E
M3_"0 #2%Y<0!2/9F!T0T["<VP@T@L9>LQU<M,G20!^8AA]N5T+*(?::S&>+S
MS6:CD/W&ZD"!)VLSMEW3IFKAGFM@(VV/MC":T'IC:#T"M?_B(]EGXY60N3W2
M\/N*XG:BYMJG]2Z9.V8[-<&AAD^W;A0?-C^;<C_6H<X;3S//R8E.5JM^B'/^
M6\T\\4[=R6K-:G0-=#(XJ!I=FFJE24@/D3/$L"QJBXR#4:2YK'^ZK<[M__G1
M-ICTA)XU^85E-\0X=YHOCAN9BVF%EP!+79BC[(R$X.+6(;1%V>2BRX5?WMGO
M'B3@;BV6;<%EY7YV-Z@,GSHIU<5NKO" 6R(^@+N$:H,FVRZAV4/^ ^U^MWPA
M[UY!2N%>/G7JVJ!*T^^[/,6A5].O!7U["CKYNC;0_U:'E/8?-]I(?,553K8
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M;LC_Q=V;1C65=>VBL45IC$@K"-$"I!-B Z* 2=D !10@O;0I6SJ14D "A$1
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MM 3V>P&Z;HFT*CN- $S[T2M[T\\1"N4DL!OGT"L__;%-UIUI?>%A?$_-?:8
M#XRZC4N)E="DS3__'#.Q>XE":#/%][ 6P^CJD!3JQ\Y)8#FFOQ.&A^FBS::$
M_[+41E!/A:J43(P$MKD1LD7;I=YPY3$+V*PE@>5MIF%(*\4OH/D/"&T(/;2U
M^VAMSERZ^'3/W[0Q;TE@(<$2V*+J #3<FE>L$/\ZUBVK)YAWR1+8JP,(L'9M
M-[2W2Q11(2'P^2LD;P,W>/W/,J !OS<A9DSYPPW=7=P: S00@!Q&B%-T.\F@
M*>V(!/9%(]I)4/,H9FH5LNEYV=JI"=HNA.!@^J+R )T7!%'\:T4?!?!C&+A!
M7@+KVO"5-BX.J(+L.XJ'I,_B<92)!,:NYC,D,+T):"&OB>Y+8!,).*@$;//A
MDL3.S)S_Z.P_/LZFBB^;B=>E0);$+X"(E6+(=;)?_H#&1J /ZK&!@0!+H67M
M$A#1"_\ZW/0;=)TI9E4FF 680&O]>]I_?#3ZSYZA5MENX0^$'CH.RB%M&*Z3
MV-7Y;]H\29#FF"(O*@T0> %Q?]C\[Q^KT_YGS_?7>B83Q)WH9PVS&\K$?0C9
ML"5T/$$U8EH]EK1CYUP831U+&QR$B7<PM4Z:M@^?L%*-WNEL]OC33.7!=FG1
M@@26Y,1W$J=2UEY>)?&E)+#=G@NAPAU3YMGX?K2,^](QA_Y/V$*#U<SI"D;B
MTLQ%[VOP+Y@/^2-(]/@\=/7Z;VC@2X!I:N/RXQ'"7BVZ"(<^R'5TFK5$FQ<2
M3E.NV&RL7LJPGK)S7*:]'[1PY55Q$NZ:M1$T*J:3>7F-%*G[+4^D"IP =[("
MM&YW@6D);*M#N 3V2TB:T(\%BCY+8&/ND+=WE<YZ$A:6HR#QZXD KY5\)']M
M@_X$T=K*V7E$XRRD,M9#D?Y;$14TZ(8*_$5'7"247<HA4/UF0FA]!) EL%/C
M# Q@%T(&$WT]AVLDL/%O4/2LKX'L1P1#Q3#Y)1V4?@[IEYPUO!' ]=!Z[5/Y
M]M(=@G>%!#:O"RV0]#,.0:1 UB"P]6L(\W(&H %PK]T /,+OT3V"X*6%%$$9
MHBOW*OK?^XNKG!;COT'^-2"(CUH]0;^#@O(5I"7G7XF8P71 "2T^]8W.=@'=
M(-X(Y=)!'5.Z^$2I6 G9X;2Z=Q2J%%I=?2!$&;!1?9!KT)X80 ']ATO,T M+
MT#3C(7'*?V.4(KZ,%LM40Q:<7/:K(HRYT5<V0'8DV?-=Q:D-6=#X.9"^69$F
M 6YT)?1$X1IY;'6 8OV7JIM"AVY0Y$<8@PH,\!JI]I,$UCW %&_LAI*S7KW6
M"B2( .,&"<P(_ODZ-$"\"V3.-I98R;-= EO57?OEN!7C!;69H]GNH!,TC4@N
M =19(HM/UFC]NY7_/H5_7<>?\--U&% Z'T(@'D]HL1-O!H.9)J3$D!)P#Y#_
MR+2^FGOIN=^A%M2>YOW[ZE&:\K6MHRUOSYW(VD[;H/33B^&K*R1(G@VU"9+3
M.U';\C#Q:!5N&E(%\+;5)A"+]=VR3)B+R]$:607K2_3VO?U!^M[M[Y66HT!%
MP3>^"2&A QEVN@C#.*H?=>U.!Y%XH.AI!K<^QO,+)1$)N8EMPL. /YK"5W8U
MZ4M@2"9. NLX3KD@/WX-?M6[XURT9S-Q"/)[HYBPN"@*2*X64\^NA%WQ)70$
M(#F<L$<NI-B@*8(W$RTMUE4O3$!I )\2+1_(L^,"-D9G=H/1_?8\,B<[P9/-
MR%+=ME5397 _G'(XX?E(52&Y]A.AS(] S1?[!TA@Q9D2F(,!?=C8R:<P6P(+
M^\.C;_[;AQ#TP,=@'NI-E]U+9)W]4S%[E-!:!D#0/37"0 ,_0C0.IMN !I@T
M\J)#$[0*-SLAKONMKF5E&;&P 'V.5R#PWU@*22LK4-2\2J4#7Y3;"8<1D "
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M$@;%@6X=7&SJ3_CZ)J8+XJ3Z/PR^O;8W+>$/BY6A&$+]K^!%?X$P% \!X4O
M/4)K"0"%VRE6)QVR#[%VPJ\;1HDP4?A'*,Q"VB?3D[SR+WUI7J O#&*$0ET)
M3 G*7]U_XM6?/-\/X7420N<S.GHKRD"O"W>47Y!U)W3]BG7<P9YUY+!J,TB]
M=B!6=8OW0Q=I0-$O[ZMR!PDNY8O%4)71X?QU;9?8B__M<2CS @10!<IV>4E0
MKT9.X#8H$D?D1R'?4H!2R.:%3@2@U01Y3N\/Y6(C3AW/0/-LHB6P=L]-_];7
M_Z4S[@MI ^@_F*P5WX_9+#9B046(VKY'^)W \/S\]*O&FX<'ZT<1M+S85.^I
MWU(XF5K[OGVOK;=SMQKH)KI##T /KV<(B,"!Z%B>)R>TK*BA74XYI+"*M#7X
MUO&-=I<^:S\UV>.LHA6N$#]*]Z('#^E *C(8^(0;BM=<U__#=U[KI&8]+!/4
M=XL,>5R!7T&XT :4W\P9(P%G"A";HU,LW_6K[![\Y4RQYQQ[=2VI?*9/3RZ#
M![I$B47S%=Y X8()"TR;NMQK&_3Y6.3(R=74/W;0A:JA=T?Y)/$62&@ :6L[
MZ'I 0 GG(D!Y2$3QE<8+6>(86PAVB#4,QD*^L47/<:&_N!?]KQ4-XIF5@75H
MGCGDG D"[R'*D-#S_ZG3?UW)M$5Z'D4L!1=_O[@9L.7;.JJSQ]-SEMH"&[[G
M,C<%H=FN.$@&E\1Q6* ")#R2HL7CQ_RZ0:@F BK-S)99:QO]EGPDC4,AE3 %
M0>U#,_(/,$-)[Y=C&\1*9FOP&C5:VU&A&UC;OK600Q(IS"E#U%\\#AIV+_]W
M'Z7A!(C1_MBX^3H57"3P_#!B;Y4_YGL$8EPH+,K_@)BP@P[H0@E#^AJH!92O
MC/ 6.A@:5TM]EZ&^HO[:ET=[1!&\R(!5=G8T?W[@SW#H67/66JA&<J $J> +
M^<1D;9.^M;B;AHIJ8"\T B?D_=\8!Q4..+18&DK.70F+A#RJ6 J"=:YFZA\;
MTU)%"E25M2<;H$A*I;Z% P:D1-"3[723+ /)E+V\;T_NQ;WD^#$_TNLNE]4*
M/6^QCV&ZYRU?678;OB6]97P>I=4MCWX5"R4P5JC8= 7RX::#VJ V$'Z;(3;V
M+3ISE]"A6QWQ^DA5>=4"H]C--ZPRR?Q)WOO!:U5ZU:&QE/+AJ5C+8S,0W\R/
MNCNC'UF$V\D1I.0;,[Z3P!3XWASKM*UEOE>R="-_^^U-A9961D:6%>$, 2(W
M<#M)< TP%>KA#*$25V@$B6FER#EE+,97=+>..IS?@C+B)U%3R_MHVW$19-N>
M&O \.Y##^W9K;]HH8I"JV[30/U7//9GH\Z+(N7;G!@E,-U_^SD\%.KM-;C6N
M#[_A]</&,86LZ%>F(J\@.@]#31C5%+V@;0?/]]$T<;Y,^L40^L?$5LQ3XNP!
M'K4]1NJF#K/)E0H<7&YO'$\&+[+1<+/T.4NSJHZ2X$:ZX,+!:>_.S.@H]BRA
M_8.)\GS<+41G=]ZUJHM+U\AA.L0SGZP-DLR4[)4K>N_//,[UK2^*M#S19NME
M(V]7F.U\10)[[%0PV;GJ5]<S>T$4V5" .B5Z1!_[A2!G"6GY3>JB$@GL BF>
M4$ML00]-L\->26!$UD;P+#R-'HK(<"C!A$21E4PT3 M__!#I=ZBU/$S!WRPU
M#/^VWJ/Q\HZ@Z\LQ$==J.5\N:(9"U7++9GIHII.@!%@6:FN$CQ47\I%C3BVD
M;;A8\T$J5R[ B2?53B>B#)A(2_2#8'\9OHEX%V;F]?E^D\_NIF>Y%DCX\3+"
M);^5ON?;H<J6\H30 C'IV0IZD-/(,VXHLX4T;-:VFC^K7K[VJW 2FI_8HKD=
MV(&W! R02?1MBP09+/'5_&= O-Q)V\6[GLB1"[=]T=@P&/&QR:.; A"=7Y*M
M:P<C1,9?-=$<!*A"%/@"\4)G,10FM>N LWR652\Z, S8FT<6[@G$(T*U6F*R
MJMASZ9AA*$^8Q@I%'O-H-:\1IS&+\UQUF9 P>:]O@W-JO=_834:!:GJ%':49
MW"TG%#VD7PJB_=6,ZW7AR=5'OTH?#:EP+59-<:2BZQF=U>:5ED_;:%Y60K.C
MCN6#!.F!!Z*Y*#_P"\')'F1#R6)S+_[C:CE][#/25E2&/EOM<PJX/S:)<^<1
M.M6B.AWPT[9 6W0(Y5TU"PAGTPJE$KY T$$5LA^6\H_-I404H1;:]D^8'< 0
M@A1MF^AW);!+4'3O(<[&"4]@7;WYR<^XY"&6X'K?3\ 09VZHNT69A<!_]QD2
M0<!+?NFKU<$&-G4[8,@NJT^\/\WU>>$D#X3[]$14/+B]-;*K6M<UV_[9\_J^
M\;MQ%;P L8R5T @TIT%$N/_3- H&L"(1H$(A5/9TK#'X3I4?>:Q$'936(([
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M+BO>'L12LXSF<ULEL/4S8A6K*C F;7R,5E<)''+G-Z229N%C(_2;XYS!.Y7
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M?1)!(WOP,N/@?MQ1WK3@, WQ<PS:U7=EWC.Y)L.FK:98P>O*18Z\;?*LUC&
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M12Z)H(%WE[!B4CQ4462!@]J#?N8)(CTPANLWG$/I$$,2H=(M9_Q>S$!5!-'
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MKZ=J81H5*Y7T"D+OMPX_YX2EWO:"^RL;G"@]2C9.">"67"/D\VIPHT=MCNY
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M((;L%;V'UODUQL&/8T( )/> N3)-#5BK?+\_(/;Z_6_CMC7WN;O=/Z0_42O
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MC?-:R$)$G<GRYNY9,GB\1@R96A/4G3#TO1W7K?W+?KF2LW8<V\Y5(1(<PK
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M_M)=! D+&FS?EP-E%_]AG8+NOMP30UJ5DPW[0+@,&D_*@4YX)?Y3R;9O V1
M;E,U;#F(T/<LU)O(UE\8RJA"?U!<GS!:]%W^CI8.N?R\>??3?N["367W6^#S
MLWO"OB_ A_<HAO2IS[JE55O8XMZ;'G7;.-!:\<?G(M42Q/*4AP2, P@]*,HC
M"N\]64ET".48427JTS(:AIMB>-LX +!4.8482W4$>F. ^8[(F*LXU%3';S?Z
M\3#,M2KPSGB',DWI5<:F&.)6W7_4]*1_>& ]%POJ12S0>=!.EI(@F%? [>Y
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MB1*D,G))/7VX,-.L!YDSRP*<T9^^([: &V^:&A=W\+2[-OT?BG9X$3[XR(W
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M!#W9][PR,DQ>P.Z]JJ"=]B/C#(GVNN_O)\]G:)N:=D5GT[OLDV7JT^9_\-H
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M#EFS^:@A)S^H&D0HT,_V3/*X,J"E]T\SH!+YJ+W 6X+JVAY7+&BWAQ<[!'%
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M9$:@9??O\%1W#<_:=IJ5%D[F:!PVE/4]^SK+7,3T;4?>82.BU6(@VWPY!'(
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M2YW;)0Z4?(Q?:])[>?YR<+F_[R'.C609[DMQ+JZ>CXK>N1"%N3>X.W)T?.Q
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M-8WT[11O@67?N'31W^H!9IO,Q_XPB!<BFW7'Y))7K4+:#]K:ECJ$%#>M7PM
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M/-V.<SD+[37G&TR#JUKH69;G]V.\%.4E.J.<[#,4C :/4?0O.GPK:I]XQ:F
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MD.8)CJXV+"M'(<TZVJH61?_G5B6L6V,>Z"+^;S#'/QL;J/U>9+6V+]&>)Q[
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MBX :#W$1\&P"R]K0*P+&7A+*1(!8$ KVSNVX^G^@P_U(A[8-V'DL1)_EQHD
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MD]_;*+6<5-5V]7SJU6NY-ZE4+XX;&\/5XTBF@ &9$*Z^O"?J!2'E9%%1A5+
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M1',N^JZQQV4G@?9GJ:2"H.VQ _"&7QB<PG/"URB/3^+:4_0DM[@Z=Y0T[IS
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M")[PUA'BSV4>]J_'^5<4XM[@"E\MMJSX@;5VK+0?B1<XC"C)]I^4Y1RT8\#
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MM/K:4.>2M!Y!=EE$7V&) +?B2*CG7^<RIYVX90X\N=O&^M[33T"QY7&]A[?
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MJNQD7 ^(:ZRWD8B,^:-=4"X'ASCJ(DRF_V!5R&2="S376*T$183Q5C&>BP#
MQ].D)S8F'^HXJ()B!3T)&_HM?4 ,Q_A&YSK@[E0K/N:PM\>O!/[JAXJ.I;CP
MME'BZ65!"F_O'2OLE;F7!]8YT'W3%**_.ZNOEG']/$H0'&W=]_W"EH?.SD^,
MLM1?I7<Z!XR$6QK/,G'C9$E((6X.H\XF@O)>PXS4]ES;N$<[%?*G<@^;!;:=
M9!E<R0I&@P^N_RA(IQ=%N-_%YW,^Q%X3MCL&1#6IJZJ:-CM&+AE?$]]EJU,:
M, !0/&^+?4\+;24:BX#5?"B3S4@"WWO7H;6@P;T\[%T+U>R6W%^7Q$B<=<(\
ME+A^\0>IZA$=56/^_+Z[7K.@3,:+X"8STYDN;%MUP1U<'NM;:I&/?A"3-("%
MU"EM?6UN[_.81K4F;>,GWTCHHPUO9ROVIAS=UU7AGG.MX]SI% Y:>K+79-DS
MAIVO?NY;<>$]YRZ[[OE\V^/O=KTB[U5,TQUS.ZQ.4/F\JL+-&_ASTNC_[W)]
M1JA@T6\1"4;/+"('\6N@GE'K"I-4K& ;2;.3:,V7/9+L?CC%XU 'NJHX>NVF
M]7TJ6L\/ X2O3&F,2BO;?D;SG,"2:\>+S3^_*QBO^). M<9HI]A+Y_5[YN>_
M#CO'*N6$'3?KM]&LM&95C2:Y-O%UW!)9L<^SQ-Z,N9DD5&*,+KR&9NHW/U]!
MU?:C/VUMQ[*4=IE EXIV?%<]1-G[?&I=RG//2DY:0(9AS.1"<V!*9S4*<GCE
M)-58,;  V>O$&3_WJSI,M&/K_3Q!9ZWM^GI[)[T.>I='YS[ZC=*]H%6C\NZ4
M"_EI*T\E#^/S6+>L9<?-"DNUZP/7$!?_Q%3O(MCO['R=[X:MMQ>46F+9O5-D
MKC9[,1JSE:#70!+GCMS+$3B;>PMTW! QG+^G7O]K6V_LG;R"RJRSO4K8O0/P
M!@D?S%Q:T<WC>CI5!+">I,4E/9*,9T5*.788#?CE,R]V3G4Y=G6%K.T.>?EH
M\_YD8O,/9D.M5<$H81ZQ8KUM(D #,;P82&(0(I[@*;M^Z+IFK'G6*')+6^?7
M";>,BC?5@T8>J,-C-Q73@H%+G!LTJKOF:$?POYF/45H4O;BLCM&O9]OCS97,
M?2T"KA(NCITED.N72YYU$>U?E&V-_L@I7;,UPZI)#)\9_+_=JI BQ]!EB.[V
ML6DJA,D:-]>$DERR@L ,XF, 0DI]?7T!IA[1O*GMO(_ZGUQ8#+U#/2'0TX+V
MP<*6MR4AN"+T=/ @L[_LZ#>+P]S1&A&@:,24%I*G4[&)%AXL!F1KU$K4D+F:
MU*>?\<RL[698*S'T#>*+]A0/D.]YHJ E1'\^<$5 8C&J'\U1;@3EGQH][3W&
M$P%1E1'9?N\@/"ON7H#V#GRL7,<Z<$/L7%H+6_?+KCPOK6:N(;RVC*O-,JAA
M  *MZL*>W\&@)'C%3TN;YWV[THYC(/''G+#__N3O<XNWR>S'&CT*2SQVVU59
M\^G>+MI@"+W4))'N[<?HJV C9D9UMWZE!W>$87N!+92JG["P>_U^?VFYDM&9
M'JN'U9LW!\X./W@JX;R1GF$01^<BR_D]T;,3HRT(H;"5F_UH<4PIXH4<@E<3
M6DI@Q:K-@08<>:883;B.ZQ(3VYLF O!7*S:>JE7KVSV>*M3OH@\^ C=8&',9
M_!<0(@.RXCE^&;+";+RQ@:*L7H.6O(<3O!ZG^)EG3 Q3BLL,C.$N.T]D[+.>
M^_0U4_[]6C;HC8M:=KT-7L6B8,:3:E/N2*9_#M$7*2C2H&SN2LVR32Z+L?HJ
M9@?7),9(5JK&4X:[@R=N<E=P"-= @+(XQPI=A+<RXW9)/7@Z#!VS,=1O9%]6
M9"]=3#E![/775\.[!_GA7.8Q*';RSD^SE;T2]T?TAQ,VY!JW,#ZKFWY>:7](
M50[5NOH!9^_QBA0C4!;F@5<F_4^WL%!WO#]R/<@Q1!-.USU2(]&0Q9 FWX:-
MVDD*DVZJNP[]QLG[1:U_+)Y4M*H9GT0\(OPH6,?[4L]F3/WD.C+9N^-Y,9[O
MH70$#JSFQ-T"PS^'SYZP&5K0.ILYBX"7D#8ND''7JWV=^?JLZS;=SED8)PX*
MVEI 9=/B/=="KTFF/WPR=D!XGAX;;*2L.DN1*\AF(3JU$9KC'!*XK>6D*P2H
MP;>:;4[5;GIHLV\- \\-A=<B]!\'EF33IU5#>0JUN LE4#;/GDT I0D'7+L$
M^'Q*0DLZOK8<?J])-(<UVB2_UWI-'='N70RYE]_94_(X?5<%.N-B@$KEE7V$
M2O>;?U-WV'M>&=YA5[IX?;JL( ^B\0]"#IP!@WYT[:\M7-G%1*-6ZV-0[EM/
M@RA&S )%UH>RMGHUV'@P>%J!$Y>,$B1I;>&=5]O,-04>BHT"KO-SIR::;!%6
MP,*%2^UB__@)!%+6-8_:/9C 8N<FL.: VXX_&[6ZGQ;03U](O$S1_D:ZF/1G
M^Q9P^_/9J CHP9I?^<<6Z0NICC_-]MK8OA8T OJ*E\+)<R)@$IW^G[TBOO0_
M/]R.W"4"&*\%8^*\%([4]#B'#)#Z$,>_=O<FKO=MTAJB.8]92Y81'.%Y)TXM
M/(K@\%QK298\0&U_F>H)Y#:E(/UU\/H&E\(F+_]/1S!1;!2T$UUK1\1S%VOH
MDD1YGA=G@9$P'\J+N[N BR6IBSM"?JPKO,=W!ETX*#5-\ *GP;S=%"C]U*)Q
M_USX9F%,-9H0QW\%5:P<%CA]U+(LY2W&DU9!S36_UE4>-&*(046#H3$E=+G&
MW </A!6[&$;7$L9NF$B>N^_:CC$B-5"*Z,TS=S/60ID\5&V9(=3,:GS9=[6<
M%B>PS2?L^9P-^AO<E8O+SXG9JNW>CFNP$OSUTN9XRD;O+]$%DKE9D?["2*;A
MG LG5* TRA(!]4NP*>$ J[<&O,O<0-I*W%[9A2V<3ZQRM^E"X/]SE\"AW4*<
M+>MGW7O3"B=-B#L'%'SEKKD.J,@C[(?D_&7*;3H:8P =:,!H0BL!KP7J13S'
MH!R7MP2O.D^+]LH-ORQXC.AY8QFJ=GW_1 H[+>WUSCT-^X0?E04;*O@JG;])
MNW"'N1=[]D.?_=Z>(50];W"KH_%#[UKX5IOWN%HCW,<^3-DP+@^E+.+G'&8E
MG4/(Z[F,J5[$\HQ#,3PDZ>X(S :%UF>AS+>0GPNWK/' @6G<&?,K%51,<K56
M3TGI@7;T>HA63_4CI&E\?E#R=Q(:NS&NSE[YB85COIGN\L14Q>3YS%N-[(^\
M,^<^]LO??!Y*?.-A9JGFZAK>OY)6TBM04J_MM:[7VE;%5297*WV'<,TDBPZ,
MKL"(AXLM3K=N5EZ^$L,])SC7_OS(X;]EY9];^6O98BMV:^AM.%EQB9#%Q@HL
MO6K*(<AR$*=.-(6BN#NGKF9LA?QXT7M9Z;;GN ;3:.X'U'2ZPCD9ISCBP5\:
M/9_)(</.TJK[O%P6"Q!Y73TMO&]AM3M__QON$_MN]5-5CW\O3JNUO1,S+XNQ
MK1]_ISJ[G[!ZZ;#]WM-U&?NZ?^/68+T-;E/$C;%*ODQ9HFZ&6C6OE7HG3V!'
M,%"S)E6+M??6P&NV;E318PF_K/G<UG6O(3]<[N?^\?%VCZZ?/MOZ%IQ*RWV)
MV2ORI"]NM!I-UT9X1Z_%CDR!26DWT81%B4,,D'<VX3FL<+J=:)CI9\ZO-J:H
M$[XG$1(;/'?Q),N'[VXJV"-^.0$F^S%G);OI4QO?_JD)?OY+37'PZ_^&HUL/
MJB<C4;/9.7:+ZN/6?<O83R;M2W,<6A-E#5$"\F"#"9ZFW:[VW++8(._NF=^?
MMJZIT;X542IU(TQU4![7/%K'A';0H^:Q S,-N.*FDL&!1'RLVBQX4?;,V$"E
M[?F %V)YY8*/FM8R0TFWK#[3QN9@:9!;U$17Q%Z1M6FN,5?A7:&S#%0)Z]CK
M"'K86<SX+TG>0[]49C1CI7;5FT%#B<,M\I0:XS_[OM\AJC.%E1.W(C;ABEUO
MK(.7[?>1E%69V'\6G'+(DXHM?">W:A60=*U);]BP&LR_W&KF9O!LFVKQL):_
MNIM>\2,!+ (F:.(WSBJ:>ID0IDJ3_7;]WO<IUS$[7#'[3@Y'KR?)M]_N\-'@
ML$Z'\A"7J@="7X()Q^2612BK2KRA7^?N-8/Y*KQ=5TF$7F; WRF./5YG3WQ+
MWM-QOT8A99%TSM4#=:]RKQ'U2T]^TUI5$S,5#;GPP!GR!/@(C=@$&_2 S6*=
MFTD?W=??I?9\W_B3-RQ[=::RIH&UF'7I?7KEL&O :=.5&OYF\G$*][#3@-UV
M#K^=%P?<#*8H1PV4SDU_UY"S[)89W>] F\IYF592X>[A$QP<X9$?6F8],H>6
M)1K5<P+77/@ I[FE/<P9;SI7EK*H^#'-G9IGEO7J;[/J3OSR8\3^]M9;8LOF
M9YP6IF$M)K6P'F3MYS*$DD$S*\CB")S>":J?P@@^6)\II52A%B5>!' -&^D"
M#S1WB#'@1!7L#TW <DT:,T3 ?-=W$9 V"/>VIB#.TQT,G6!8$GQ8N<R&"3\:
MUY/RF)DIM$%LES^+LBSCPX0VSO/YZ$=H[G."-QRC=D,$E-&X6O7SM.$66./Y
MB@_8,0I11( X\:P(:-85 7';X7[<?!BL(P)JF$H@[PMN4M*?A)MZ$P(]R<3Q
MD'A%0%8Z2K!>!'R%LY 9&W/I0DDC1I=@$9V.YJ9".&04;[S3''-AD39,_\<8
M2)4] F7]&<05&222/&PO N0<A,5(9LT1$9F*JM83 9R,YEFD[Y(Y_/)&NN ^
M#8HEJ2$-VY%VT9=A[P5U1,ZH<=@Q$ZH(8/(1;B51*(4-6&X:P9W*YR-I%[7K
M@-#RH- R=RD,R_V+,7#<"S9T;6C&SB^Q9UH>H[.O3&#_P,'$(98] @ZX-)TI
M=:X15C2>XV54A\BY4JV8IMG"PN?9K<+'TUK>Y7U^T,",41UT@56].R"GTHFJ
MZGA4'N?Z./^S5=#$T.-TQH0WK("3X7?/PTXG0KXST%-IX<*(I&].'-RZPGJ_
MT[;OM@QQ)AFXR=IQ7,-,+?B=R4^%&(BM0=7)ZO'S>20R.+AKW4#N<Z:R[W81
M8-XC]O7]EH6ZV;ZM\]K4 3^$.9V%Q1GK_46 /W8C4.,50F.S:@'^_3GR\3#3
M\831N@!)OWC\AO=ENE3=/@?/B4E_^/2W!4.&Q ?MN,+CM2/5FUVH9G7&F\,=
M?BD</?&8?+++"7S$F,#""N ZRE+2^"\ZCPM"%*\EM5"!CJ>*"'C1@ZPAR! !
M\M/P3;VE" 0*.B0$"N'POAD18."Y=UH$!!KTSIHUGOHG2L#YL&K=/RC9* )X
M_>/P]]8RN.7QXHK)S$08 A0+Q#MF9=H/'Q(!;X2V8)W?'SR.,Z$-D555<7\0
ML)86"XX9YHB 03OD:4;&#>-:R (S$WXGTH[!P\*24)$(2#[Q3ZC0Q^8$3G^0
ML@M!RM_T'HT!^(XS,G@2R%:#D$6R-4=#VW%#X GZ?P ]%%Y-&4-1QR<3G""'
M2F0N5O<.B(!53E!(\W@S4L#N!KE#S %[F(QM$ &0.IL!F]D*S SYWY#1N_Z,
M_N=W](E9P@NMO_K</=_C1K!0;+4:V-$6!Z\!1\#C2()F$%S@&/-0(5):@/Q(
M\I /EF7"+1-*!74L?,1SF_%S#W MS0*S _QNI,].GBW2Y_\;D:.P!!R;K_R#
M_8Q=2&FWQ26L^MH"_"7RUQM</N62K\"8^SE;!*ACI)GSP_2VYIG1Z<TKQX@[
M(#$NI1&K8'&9_=S><EW]Z<.MK>59OJ[':J8Z@YYVOS_SH"ZV97U8W6/TYYFI
M1A$@L9GK?>O/CP3^G^+>.ZJIKGT;#*)&I$0ITA,5%!0!"T4@)"*/8@-4% 2$
M/#RH"!%0:0%" B(@S:@H*"V@ J) 1)K4  E$1;H0J2&)=)"$$@ZD,/']K9GY
MWG=FS:Q9:[[?]\=9*SG).6?O?>]]W=>U][WOHR$(X-)C'L>,^2>8M^;="DK4
MWYWL\"> /7W&E$=/_GE?HA&\.3O"#LW [1&3(X,-T!W[2-ZZ8:M;."N[GF\W
M#=N.M<D#.B;'9MU]'F)J[;JB]A\.XCU1W90\=-?J^@[7"<GD%-'V \C6EP8(
M*0#&VYX)L%L=PTBQODX7*AS)7;'5M5;F'360&-%%4S^+[<07H6MWL9DXC^06
MUB(]WN&;&<S(5_6*@_<\IG!?<%'& LEAY?=.9K8D4Z3>OBCX=.4X@^_W?+JO
M<]SQ,4R((I1E?'KC>.G=,"GD1CEN]A.2U"D-1%_@NB<6S+K<8 RJ.;ZY;:CO
M5RRU.TGF:/9QOWO#.T(DHMV>?TZ2EW,$(=YZ/HY8M%%5:46/,P84F*T5''\>
M#KC$6:"&%#CTP_7'[&4P+HN<QU)=RU<OA[:>T/*[]V6:-KJ>VC K-ZHE"TUV
M?>,4;+<^'XZ:P*MY'<<:*!]O/_SR;&&SDH^NK46KC_'^%-O;(R\R7$Q(/QKJ
MP5WX@Y3_A_"W&@B\]3^7SO]S5@'4^7\)>:N;_/=92I#NZ^BNI<?FZ^%=6Z_P
MNJZW_+H^I#>T%./QY/BO)1IB;&F!WND)>(W=[(NM%ZNZB23CC$@PKX#G^+PF
M^EYO^_:B1D)]$C_)*2_FG@#U2F<M(>%JNE74\4OS(EM##TWU,O2504?[FCH7
ME)ZFRG5W"RE5BO2K*WG@\%8EG<T+-:LZFU<KZ6$?!E>SU3'ZC=M ["2Y(UUW
MMQYO/=C1IZED,W;@]IM4R[3A)(VW0\_S='0^^%:%+-W1?9U@YBGX\!OU:_?K
MA /W:6N>JX:+H+<Z(.()^_'S%W#1LT)9Q+4-T$%^VII$2DA\G&14[U38) E'
M+,9NX6-Q/XKYAP7[W9PH#>HUW 5JI^K,[!@CSEVJ)\J)"TX(:CU4.AZV12LP
MSN+3R7=FVA%KAMDWA%U4S58+PFQF$&^ZAVR*''N-+XNC0I*)L@*+$NPN<GFW
MR%AP@+M3S'5'%YQ4>Q96\'-N^)-NZJX:I.?3)2:"9SGOQYZT$Y#'KN4])/8I
M^G]%#-VOK;A93_)?*ET1@ ]5DG>-0TR"V[1<,K +J1F9/@=LADSHO[/.-%TI
M \Q2VXGMY+D5;@AO3IB.,,>T\1YSQ5;G<W6N<?#)ALHN  $=:.QK8<M)BY48
M29;=YW0:J@@JW&)W,?/O3,+<&V9!<CGJ4?9V#CFY7+5E-(7E!CO7'_BA(6-Y
MWA\=*YGSI:GUN&<36V=M/V>B4 P SL :2VC-PW#;&0^Q2GGH5#(G&;.X>J64
M@\ON1ZAXE+F)*-M4&52+:Y%U[U2T;E^T60GB!#!'TII),>Z; '2^5;)6,Q3*
MH<46Q9H;/'SWAA!T@AI&;&X(CV$;?\\OX'[E<[T#3-:*(^A.B\@[ZR?_^6B6
M^2G3S>PN__L+E9[SNXLFLM5VN'^EGUTL'#AEX3.47:S%T,W7L5X1/2"B/-N@
M;6+CXX_^68M)1;;!JO%/Q!]M#N%3D?^U7),S"=:\1^LG'L*_B&@31#:E=_1/
M(/>&7SV\.A81VMG[^.WZ=M8AG#I@1W$BNI1VE;OZGO[E5U=;WA-8_H/$"8A[
M+F?NI0E159V>:K!_ ? W0-F?5Z?7LFW(LV)17I@*S2CS.5I9^+G0920CNNH;
MS5%=^7'SR4#FJ[X8\Z<^=V/./;U\F7_T8J9#KZV#?M&9!*7376"K2/#TY1W;
M:#Z7N@*RS=?YW8[WZ]U&2;6,!0;WOS5N^QANX.9D!+&SBG_Z&.\.R3WKB! I
MTV^71_)V.0$;K!H,RFW%]_Q>H[&GA9;H"9(*5KK/&+]S%F'"J:S82F1](*I,
MB?;OG9JAV9-[ GVU3B3#]Y2\K_SKQI3=^1V':X;C_)R46EKX%IC)RZ+N:&H8
M(_;W;V,F;ZASA[2E)]_A9!^RDEQ%+C4Z-(9OMIA^!KX?]K?D[VW^A[Q48L.]
MO\PF!0GN@WLYLQ<>K'_CV/YR=QV.("Y(W]I<H/[Q[G>(8//3!93,%*H,125O
MGPZ+[!+M]J:;/WZ'M;\9&L2"S*>(><'-61ILZ*8-DO/D5U)*C.K7XUO?>\.&
M8&7406*<)QJO"52Q]#G^<7A(8&UDD'.0I$;T=2ZNHL3,,8["LE:P,+HQYZ!R
M\;?[84@)_!Z;L5U@UC7)54Y<J8U0/N,VXS[=],,0=GM/X$/Y _]8;U(\L%OF
MV2M'Q-YL"X#!/7$8\!X#$.H8EVD[K"_7L3NV&*L>&6BX><^2Q%@D]K(5/.K9
M,:<Z'<X-[\'V*BHC4;2[C+M*;4,?"S:HN(YO5ABSM3SK!05W2VE1?FV)$.GH
MWABI?UGH<-T^ >_S,TC3^F)7PV:,(S[1O"+_CC_<.20,:\&AG^3GJLP6@7EK
MC;Z4YH1?@K?(M@<2PZ3&!:79HZ\$_MPA5MPCNN2\8S:LM@>^,Y_O1SAQ=1"<
M/\?N35BC\XHX.@)=8B1Q%\) @ 2BV/;;@:IF*(1K4N412@+(SMS]:24S-Z63
M==RZ$U\\O3:_O;MP]Q.Y*[O4;C'8"\GY(VQ8LEK:PZ)P#'YL(38N=KD+@@*R
M@4A\\T7PO97EO(PQ2%1%/)[UOH%;14W$KV\&&+3TSGBC3O[CVWABF,0_U;[?
MUGPKLHJG;Q&T@6@F) FQ0Y@LN'R+L]#8AI^#1>E0Q=1,5OG/6D :_PI&-Z5(
MW+&WL*DG'IAZ>0>49SZI6,8W^\>,&G/)S0L@@-(*@S;HN&&B6Z 03G]9>, 8
M<2=!%N/>]KW;^G.WT6'U>)6)ZX4C?=$!UR\PRD3$T *K'!_R3L2A6=RF@SL$
MQGUU9Y!,#=\]S@F%_G57SQ\#G065>3YK3;,%+-]C$/WL\T  %\TB1!I)7TJ&
M-6=#^Y9]SU-<MC^34N6"IN[*0< @WMLW2N7_U,NCGITZKWS(=;7 S+@_(*/*
M5N/MH/MY6Q/+3I%27.N"W-&V,<;CFOS/UV]X(Q7J3.#6!3$J_,&.V*^Z9IWJ
M9]F9@;+XQZ.&'$EM<7V@/@CYWD]#HMV 'CY)I*[K_]RD_*K](P'RXX.K^ZN>
MWFA2_R%#5*_D>LT?&6NG[T+H<5"M>M*80<,YHM*T3A/"5"(.R37MJCIY38%B
M=..)R4>]I^YY8ZA!=&/#D3[P _C-MSXH6='NF7--6"7N9CRUUNTRPB-G]L,&
M2+&?G"FGG+K[[MW#7Q'$[I5D/;>/57U&'X;<[,_5@ ;=G4<JUN6M5$=B)9-^
MR5-WF#^0FC(E6*_CD[$!)*P.%T:Q=9QM993-##5I#B62E+&:M341AHTB_>UO
MR8(]D4SX%O;$C2\O(*DL*X56>*6W90B31,7+"6PXTWW+UCQTABO%HP@3?G4?
MUB8'\_*(>7]BR9Y;$B^NZ1T>F@C:??!U#KCR/]?6_ANB#__]D:$A!,0>#)+9
M\-RX4P/SF$YQ00Z*J'XK[FDTR<B[1\%6M.-39HH2R5POEE(:Q5 *!3SC210.
M)Y(_ @$GRCIYJ636K:]=RQ=#-Q_3U=YD9V99=9<A7;?3-"J7"VXQC$_/JGS#
MA5%Y^"&$&5=V8"0?L#\_J"[:4;\C&\^$<=[X;2[=]^C0V?;0R1BX+1.5O &"
M^1E''&M!:'*]8A$*@#7%?#+*MUSSEK[-!7)?73 SB*BB671T5$EM[UN;S.2[
M4BH(R?O(<IO$$L1^X+M@4[?A$M-W:U\%*=DI..T[;E0EEF-*44C]&\\\))8_
MS=Z/Y2W?;?MU^?GSJS\U($D"=(FHIZHLXG7$>0JJK/5%X)LS/;ZJ1<;(1.U[
MPK(2"X]EP[C0+S*-N_CM#VS#=F5X>7JA"WY..YH,^F7EX7,&!EV<\;>F4U5T
MLFU@S'5Z+&RO'@;)'AP>V "U%0BBC82&V?;CTX^)L:T9D *QX*$CB?;OEDLR
MR=[_$-/+UH9L H@*],GUK-A_^[FYHU,@"IU<$LKIP6SC>L5,:9;86? CS.F>
MEY<(#U]:$\4I-2509P1#^/#%-1S(B0^K$EE>%XX3\3FB:Y.+G:Q[;K0!Y'25
MV-O3B\+;Q*S:2E#:.4ZDLJH__LP6ZUTF?7FIUS.7.9=Q_L;HJ#NQ<&+].8(<
MMP&Z)G+#%?34$5NA2ET"#[$6\P ^G*OL7PXGK?&1W+'027Z Z*98+-_K7%'Z
MK?9OUS NQ]$Y?^;OVT@_UIWJX\H>IX:%(A(&?>ZB [( +RZ:2MX:E*S5B%1<
M\62A8M?S!KJQ6[BN5P>-;<%7&C= "8:L[+'3S(Y.Q<H=SR2?(&[RR G9V_H$
M>JRKP#2'?CZ\4V$Z-5JDP-@R\$H+*8_=J=8Z TH&(1"<!KK_EK*V<O)OE3.?
M0M',P59"'B;M?+^1?L"YBO[EB,O?G=T'Y3+OAF=Z0NM/A<'FFKC25RJJ^W';
M@$E'7VL41_\U&BK'W=(%%LF38^^?44+YC=K'N-L#I]U>/EU\ +Z,+<2*1;>"
M8&"F.&41]71%)[K.XRVP1$E')M29(7G9421G8=69FDFM=U\M(^X)+,NBW*-1
MTE-0+4Z:N%Y)[I8<@P(V3.XV LP]G;0!4BG/<,,[)]JAI&8&6VN%<253@U9?
M9',PZ;<9U$?*+]\^.^%YV3EEKM[B<FE_4>Z/Y5J^[,GF>7RWP;SAUMR"T:V;
M;[HAW _;?*/>B\Y^41U?>TKQHL3_?OP;\ZI"_V?6NJVF_S%E^^8_HD(N;L7_
M&UKT32*7KAC@YZQ[D<LK)/J;__-)?PY4-K&<1.V4$\@ B6^P5X",M\/#&$E;
MCD$ADRCI[N:BP,R )9C_KG@6].D;[028$KD7R'DQ&$=EGHNYA,H-6MQ5QM17
M9H-I$*4I=Q.Q'LG>#H2,(66=(=(S4<:&<J,8(BV9M:N_HR+W2[&Z"M;LS>UP
MR0\&Q@LO3<[\#7F$T\)N ER9^!CB)KCS6/ALA#2[LK (X]D\JB8>,DW(G;)'
M5N:/N= SKG-'GZA3.IRH"#5.56QKY;?#<L-'FO;9[..R605QR!NHF$'$!V:G
MG!LFY2)WDF!$WC*U 1JD$P==LNM9R2&G.GG]U27XG]6Y_,E9=\(;K"K@Q(GF
M/0!*\[!'.25QKS$X.@6G7.]JU9'&1"JB"U"B$5$S39"X!CX)AUQ*870@?1:B
M&@X"PCR!<BDG^$/^5 A"$N R\8\0VGTEG6KXF&5]9?%%YM CQ)U>T$EZ^A+7
ME(XC%Y*/.H:XS(T4"0WF1+8_RW)$/V%2AQJV 7@6@^J_$_!O,F\M9$*D@=YK
MP,VW0(I(WEYC2L=]^K5XV!)R5FCN>M8B=0KO9A>>B=H ^6$(U/1]-*IG%K37
MD0,MRX^(OBH:$C6)6NC(*?'O"01KUN<I_-\;H$@3_.9 ?'2#1D\%3%8,FH9>
M8B#P%'B6?]H )9(]WM]VH?-X,<4P=;$;:L4S=>>'LE\00S= FP>  +:_*A8I
M;O['"'V!"[?J$1P<RHQ \UVIINDFXKM(^2? I=FV>%KZKHJN)?&@:A(%N'<H
M(0O=]%/\[>/L*_*)%M!@'245MI:R[H?Y$)4EI/8(X^NQ+O@6L:S[2_@,>S9'
M<)@>U!Y Q8%^(+3P7V"4T4,<O" RD S8(IF2717U 55Q7!8RX"N2\-;Y3R D
M_M9(F 4!<$)HBX;(/74>8Y:[ED3RG;*S"/5>2$Q=$-MA3*L(T-A)V+&39:E@
M>?]>IRKX:_D"L"^NR3MH07*6S/F(T(H>ZRW\.>#BGJ5^62TN"I(<M '2A&SQ
M@BT:8ARHZ;\_@]U=DR;J7W>*I#(XR+D&Y=(X*@Y)BP[TE[G=[\7W$D6Z&],%
MH=-=0*+KY'37)$%2,<_ 6[<R(^SMX$AQC[F_^KLEFW24C%]UWK3ZB. I WM$
M6(>\A4^:=(ICTA/@IXIGS*\NQ-Z1+68\#"HV8MB4B.UB)8PNEORHP)PPERNK
MI5+?:3QI_[B5 XLG<RX.P3;CVAAEJ_-2>0*C[K/"UX)@!'1J'9P(#X8K,,E2
M&FAV<"T[:?.(F",A,.H1E5QW!E-LSF *,VOUH:%(3F#+-8Q=D36DD&5P4( P
M3^0>$8T"'F/Z 51S9K?9P@9(J9KFOM4FAQM. /8KQ\[709BPN+NB'KS&)&>U
M>4$3]@BU37_!/AK^%T)UYIPQ3]32'8@"3O^9P?X@_'S7_L(1R>S0:A?Z"Y*%
M,3"@7J7<KJ3]*Z7.P;9XV=N$WJ[UE$.:9[*0*KCN])!&59&&P+3;6%P<G"07
M&0^W#N5&B_9[G>?V)PKK_U1![(:V,0178%R[57;5)7?#0MPH;-<$O4$=?Q/7
M$>:7QR&SZ )]B!H&TKJ*5SI6*&X]$G"IM99ME2O^:(*<N+XN>M#02!<#XY"F
M:?,&"*K#(1%6+,^SP:T+8 #5%$9K(:A/K9OD%=XV1T4%.N3BJ031S@W0FA@[
M69ES82OS+E ]83I.U2<$!5XHB+Y<T2N2Q4"H&R!('>SM8$ ^"D"Y=0=")&;?
MBNKQ3UHBY%SR>"ET9OV*RWR$R F>IEMX?I10L[*:FKY"M\\B/(2?Y>.PISCX
M9FG\8\1QX2LR4X.#3T RG691VU?0Y'@U4X$60K]'$%2,_WL*-90^>HS#IZ+8
M*(>I8VBB:H.R&"3>@D4[( FPGR+=>@[^$4X50Q')VQYM7.W&5YECXB@Y> _>
M[)?)@L0IY$?E2*.1K10*[B!0)=8'-C'+LIZ-(:.2G-5$0R/_N4XI#(J)3$96
MU4F/D>>0Z\KBP9XPVL IZT709,D\QQ>^^3_QM!=9^2E>0K%;>8 D%8=^_GJ?
MU9,R?C]L_]KUBJD,6T&*9=)>S)=S%Q.?_UWQ/&*JM>W\YQ$;KUJ;QS 0=EOT
M6 '%?Q#O6,E93<:BQN;1C>[:P!LVX9%YH;_\#/AD\EONZ&/:]6$M.K<8W; /
MJIK6MO7JSZ,]I\C3A(%C[IS)!$^ P$+%V0;=XZ#<N- ,EGUL35;?Z^E!!^7N
M%)%"].N;5N8@KAKS7HSZL.;PX;4AIO(<D^/)HK4N)#4<Y*Y&&J%VS4#E&CB5
M\6\Q#E<OCZI^-.<E&8_X7Q-1W495Z?"_OC>^VG[T/7CX4L+'=?:8;"['*:'A
MF #Z:1.# I7KA^NQ\)M<0&]O9^_B=B2%W'YYZZ84D[!SRF7LXO4G&EO_;GPZ
MI3'9__Q_3/'ZWQ0-_G\\;\F4HH%OGA>^61>;;PBZB7;=4[2CY$CVO?5 'BD?
M/>&[V74*55Y%E3V(56"38D7*7,N7G:>[5K+P5G3SD-U3V/MWPR[N:LA:YB\C
M4'0)& Q_V^/N_=.DL</V 7F$+5,:1!+93*#W"Y+HKLZ%-1%WBKVH @XV4_.B
M*NXW"<FZYQT2*LS+Q_O@NQ0$RP*]N<Z$;J(4KB?[0 V9.%>#?RQ2QJ"I_9YT
M!XXZ$!/TR>;R.=EM;$8>+D)POPX@\$]AWMAPP)%&Q?ZV'%Q::)Z8VS1;?W">
M-?<7QF&]LY&_KBP0^QOPAUF&<_ ;_B_J!DQ*>GH.U%JFN,\O+.[2B3V"=8@.
MO.M<P/OKTZ.:^ /[YD.OY-TDU4WT5843#[EC/K"0\TK<3ALNC+#2*8_Q;UIW
M+WU_NQ(GWQ-$F!LY9K4!RE&>%E;3IY?7U9FH>6L6,=H$JFM>!.,0?[K<GEAL
M.U%>]U7ME99HAQL:GJDA0_28;I$-9Q*2&I0P;6>RUVF7Q%S44&BR1#6W(W0F
M!KR>7=\FR@J?_.F4)M@'Z' +V*;Q\ROMD.8JA'SW<KW&@+O/Z)YR4;MY;-H&
MZ 1J#FDGC B87]]\++, \IRV&IQZ]_7P%;_IRI3Q,%-UMP_3I4")CCYK&'>7
M*^<P_C7/]]>+4U+WJYV-.X/4ZZ$3-@_R@0PNVAW(Y5)H8KM@77U9$.#T<KT_
MLSZO(!Y9AI45II7,NL.Z@AC TPW0CP(";:@XC%?/_T<0W"W:,0.3AIN5N%W/
M<J#B.3'NF-$Y(G 6*_6EX_3=,XV@IYDW-DF8-?XH9Z@(3#F35-AV!D:2FCH8
M6\BL-Z1 (>4]6-.B&9>_^Y!,(]$H\OMZPK)_#+%4IU6(:H3J &4L"]@<0]&G
MBGRG'/ *B2Y$UWC3>!,?AW]#M>X(ZG:$R:OD^"/YGKLI0U)?0VZ&M%6YS:VO
M9:?NNQ>LLU-8^W""P/LK-"+[ W&D;S&BF#CPM!'0L0*2.1G,3HI8K$SA=];Y
M!G$WT9VXXPL$@]\"#W%9O 07"ZQ$HPLK[*>S;B'S]OP0@>V_(L#^;!*%2PBK
MF,@=/L%$/R#Q P:K^V.E7H_O<259$K1#3LKL4,NK2(O@=U^Y^^O90G!3#3+&
MGD)01^..UVR 8G+?N.-;3(LV0+?P-S&S?)#(; -D.5-'_K1*6XA%RF&/L(H#
MFFB7^PT"DR]_Z^CIQI=76((OT -1:YLPP]Q,F?O'HK-#-NE2;\&1\12AL]ZY
MU9K'5>3 .H*AA*C.H_1RNWJ&,\6WX'N?Y<IXR*6*W_4_Y[RFS F$#9"7K)=]
M54_#04Q*RR#NA9AW*2,.U8EZ^:'BF\\OS*'\Y0ARZ%<D)+>*2D@@ED_2&)"9
MAH-T^%EQK1O7(?%(IDHYA_A0<%:8P8.L[[P+$=(B[D-R2RBM(BF@D,MOW0!Q
MH@5(#J)"[&W%N$2+6:GMW#$SB"ACDC_Z%)SJ,M(,T1'E(>VRS"9J"4H"&)?6
MA%2]+0:;)SXNHP1T:-[H+/103R 6[^\=IGQ'#CEAEIUE-N\&7!@Z2&T]8"TZ
MM?.<8W)FSUG\P8G>]G36XF^#;\]++STO\\IT<UET_[;J5+$\7L]#28&;R8,*
MUP$G@U(QHX3QTA*QACS;RZO\_;VB_2XOD4N;-D ZFA&'[?7Y1H 3&S9_BIMR
M4?@&L1=@M]3HB'N$]"Q8[%D?"BR+-$W/T]<C; 1:.>LB3>ZD2(H#:[%/R(9W
M;X"8<IR2O/SI=7?"^VNC;C/]>$[R=-HZBM??8(G,@=,98K?E(6X'NS1_#JD5
MH5'->=JS@&1EU(K$S13OH1F&PV6_X,*=XRE> R6NB=\<'GPC-A2QVR-^/R.8
M+ 1V_H ;L32&HA<S>P]V'"7/QV46WN\XGW[%K*1^X*PIU,XO&:LSM $J.R"/
M]13F7-@L?;,,0-VB+F[--W+#/CLR)P?IW5_OU)P#&<2SBCX^_27NMU4<E1H=
M/MN)"[D0N&:MT)NT[D04T2H+''L:#F!/79;!(8""#WB/Z ?VL77;TY6C'!#1
M:A+L?!O5KR5LYJZ1$!9Q7H+=8_6QADN/$<%<=DU7-8;I.DU_07*>S+83<!!)
M,%EN_,9XK5/(PI]%VNPV;/NWX;KVMK2UT PLF3<_OXAX^SI!+\?J?Y$8U15U
M[[1GVMHPZ:T9./T&5>"1"^;S%E1&8[:I= [PX.1L&VQ[_%[N;D=0S,,7QXU7
M@NZ[M*84H-?=?C\M=#;(>^M3Z>_Q?F $DLJW[3^:!%(9OV^EH;'IZ+8QR7&Q
M'$QI#ADD/0@TC,_>]7#&?3=@7PQ3<G8>W'*I!',M!KJ[6]%0VR12IH@J[WK*
M;)ETJ#<H6<^]NUP8<K:ALKI[Y?R>XMNKP=$BC^M+LS1@LC*"--9?&C$VXK,!
M&H,E&<J.DL:&["L$Q_M*6EU;B#*J?8%'E1ZP41RB(/'^CD8/R??5GL1T;!#3
M&^^%4K0O'&I5'[,AP$\/?JW[-LE$)@3E_UP_(!VU =J^VF)'-=DJ*2]G[D2,
MI^@4/\_BZTP*?0*9I8;;1TJJRU^02#9!],F .G8;U,8.SUY8]TJ:/#[?6Q&X
M;C9EWSM'?#*Y(O+Z7((492-1O1N@8CICM$86ZH^B((7^5,\92[W^-LZW:Y:7
M@VWUWJX%ANM4?35\.L%*XSL\]_2[-5Q4'#Y;7+50W 93;3#!!/ " 7VN))N<
M4%X<<)E#%D.KG$^V+G=?09P8'\OK;/& "/%FNDEI:5>56-[9 #OS,"Y#+3A%
MSD(B/&)+RVI3AJWB=$B8'5$3 ";?H,7P&M6&-E]JK=DYE$N4!KI?$@UL2Q1?
M',3% .V<5LACU#;$;JQF U>3_K!<S.'%T/-/'5>V0' A)DY@1ZA2715NP4;D
MBT7AP0:(-=M0>1;/>3X3X@[F3M*(L3!-0YSJS.#Q'W7'"F:RMW;#K7+$HTKU
M]7TD*Y.+XHU6LPC/%5(U?+^B8$HQ3BGC!)-ZI?6U8#&MNO]NZ*_T$!?M9=?B
M;*$#T@:NQZUM3D^CV$JR0A[O[\8I#,Y6N@3-CQ+8_@H 4J1]Z[)=0G'1U"$M
M[!.38T>V%WUY;=2&_"9&9(&B/1,UQR1A4.<^<TJJN"<9[IP0 F+WJ,^H0C]6
M/7\Z'1P+ER8"=F*%+06.!PNTH7MGQ?JG:F4:/*\O5N"K@"3_)-:,&Q>U7"PW
MQ#0H95L@)::JL@^)>]+#.;CAF!OZ!)U<:F0)(<C<#82'"_7&%^(9G'-\,69!
ME0%[9N=.45>J2.LS@!I#0K':&Z"'<2SE9O)68,B!CMW"KA<WJ8<767 (*;4,
M/0 ==MH%D_VP@N\G!PM7#KR;OWECI-P%W7O>\)G-S-8,UGE#%<QYBDBOIZ%7
M2& 19*?#^HB#<V)4"T("V5-OW+NJ%SK LU/HM!_YPNX.7.="IWBDS:XN.,+U
MF+4P"4"G201ZP+_</R]09Y*E ?=.1RY$+4N4EGN;_!,VY%8V.SV%)O[(7Q$@
MURF+L\N(BN7J^Y>2[8/T6A@CY]8MEYVFZSONV%94E-<7^YH.57UKA=,Z8.1H
M4L$:;Y;87\=G.184_IPV@2ISZO;B8=B_^CJCX5J^H;<5#?)*9&8'![3'(-N2
MG@5$FHW)]'<FU#GE CJG/]/A-L;M%61!J+.+"PQX-0/567@]A2(6D(\KS>'+
M5IMM@RTOL]DV+1:P,@S[>H4MK!FJ<,>328KY9,_3'1:[:258@I0S]O:)B;^D
MJT_/A1X\>)Q^>S%_9*XX O7,/<T<.:'DRMH ?25_7XXXQQ9[J[*TQK;P"'/5
MDCOP+4Q;G9.<E?R0&?/)^*V!;N#38WOT#>HN[LP\W;-5G7H'5@C QC(ZXY!R
M1A YGS3D;>Y.V2*@9OE7!D-IMKI_90+$?M)>-1QX7 =J5?"=J"G2LXJX<^LS
M<)7C3UTKJU.V)>S"_MTUWK:#?,1<^>%K'3\KQXQGN7;=O)MADO_]B8W^AP,1
M#A1P?F!/]OC>*,WXH[O5,>YS/J*MW!LFK\PA\2</CWRKRF#R+*Y2E#;O^F=@
MB^LS#JG%%]+B>0T(X!+/=<.5V8GGK3U9]E+ 0W:S2+]7,7,6 4;L_L(%QUG+
M[) XB-$R(Q6AQR&#<6/CY%9R=+8)IYHC>L72='+LOO&I]%/M@7P?\_R7+2A7
M3MAL[?G;2,Z+O>38>,<KTGK*3GHUAR%) @7F0J*Y)>&Q,3+6?1/45 QF0)H#
M3/I07#R2-0';]$3N<P.X4Y(R2;5Q18 OA_B:@4ILPXC1=5=S@?<4^[Y BX7R
MH9E4HF\9WUD\&K/BA'%&]DM=3BEHD3:7_@!KZ,%$#>RGT"@MZ_G)A9A#6$V
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M(&:TABU(1<&^'CB$5>%9*-BOIM#Z2O1%>R^0V++G%2'^FO]S;'?FJ;U$'[H
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MQ  P'8-JRI7 (K+<!NK4^-'^'VV5;ZJTQP !P@#A+N,=1>:&&BJ!_D3_H2?
MXB<?6#:^;#*/_0C:6H5^>H;-WON9X54XCJQ,8J4#(7,]EZUY?3()*G[-:5T5
MIE#'"]O&\L#N4LJX=(HES=2)OO8WI^PI-&"E!"(AQ1G*\"!^^BK$7X;:J;3O
M.E)</GQ%"60FN0(8X-Z"V(_69LG#N.@#",8I@0[LTSOB49(S\Q56\1\5_A*6
MC(G9N:N3P:-(=GJLE]V&Q4_.>(( *+QGQX]6 I++-),&TBJ)YU4,PN;BC=-#
M#[?2 Q61@!176P,X#EU067 "_;R-?> JQ/N<<%&^*"*R>3XI+>3GEV9@G\<K
M@?RUA,;)8:PMJC4J"HGV(GY7SCI%W"EXVR,ZH"A$"!+N)JE5+-%-Y.HO!)/
M4VPS^J)6SC,[,VK5]$A\I/D".(SNZ*8$+N^9C[OXY2\MPAJX#)O,3O$8],NE
M9L*M\M/^%R7("@4349$[(G-Y"/B@W_ENKJC9S.]8B2)<!"7%53[MP:C"]2LI
MBRGPQGWK:8X:[ZQO4MHILGKF';2RUPP4-X]/RYJ"AJ^1AP<)T^%*H I$2P"&
M%3U"$:<$SHQT6<O.*2[3S<3X^30 \5.D3;!*D:/2F=DL9(^YM94P[I4 '$Z?
M?7[3)J/H"P?S!.$@O(# /(OH/>Y?<9 ^HU3JP1VZ+0 OE[M?L1D*>>0,<2/P
M8C)BE3)2)P*LT#FKA=58HW@A!7M<H]@#3P+"N(31"2S"=-G(8(*8F6TKDV%2
MD0S"ZE!-),@DQQ,D'IRN&/'(L(G\\'7;>%0+I@BUM61?/Y*L_)1 ,72-=[B-
MX^=!\P/5/6M[JQD:O,AN-MU%ZGOELP/RNUK<R=E[S1*94 <D2 2-&:;T.0IF
M &H N\C"X"RIJB"YEIG PI-L$3,XYGA7: W>G)8COGF<7SSO^J@N1[=BB:)X
MDSC62<4D:"'83I#5)Z> 4% JY?!J#,PR6(<*%86/H.9P)J(&(AL!R+Y2 TLS
M N(AX=<3/C5,>L%MV?!M(5C+C"W?%S\,"04A^2ZH(;F!'&OA#6HBI[.TL_QI
MVP<?SK3\.WBFT[L @HT?1;(60U8;VF%Q? SB7D!?7OYQ8OLG&!0%\*Z7/ *-
MZ2L+Z+XD(B^^WD/3#>-EE\_K)?7.6E4W"ZW@E-I O8G-J,I>?G<'.#[YJW(
MU/_;#ZO@RF9NQA(I)1(4[D"6O_@(GH'T$3<)[SKQ]P>EZ2*J)F+,J\38:HVZ
MG9=:E!*80] CZ,U.?[G4R='(7J $U$'!98+).!B#+H9#Q'TDP\,#D]Z6BG2B
M[:50): 95R0BST8.PL<D+-$EZ;?73V'Q>D?N%>0 ;<'X@ESB<<Y3YK^E'.&_
M&/B#24>O1X[!X=)W0F9],] ' 25L/.*(G;Y&WZG(&F?&=^5?;2O^HBH ZR-T
M_2B?RC6ZH&<5[L(5D'"QROJ3236:;PAM<[W=4QM6QR1,3$XV!6*M^RGUW[[2
M3<'Q40(VI+:$(#0>9<2;\R-QQS9>:*4EU;UM[M)Q#[Q9U1N%7*W.3O4N[$=O
ML\B2$079K?IGN^'()N(5&S@C=S%8!<N>GE("K!O.2F#U,)>2(UYKMM'@W<:"
M3ZQI#7%+=$_O?=STM  ;=I:#-<:%YH[]4SX9X&YWTQ;<GNT]KOA^U+Y1"9S#
M*'AS/1:K]I:!_9.WIG3)%ZRXSP@Y9> 7Q$_U_H/,5,66:?S?1\:=Z]KPG_M#
M7<'6U57<!;=OK16S!];6 R$&E)\H,I'8>X8U)@11=;PD\TL/:V*-H17N]2?P
MAA/"I-);U)M9P]/01-_8L0D%&>X NTNHTS.AK\/ZWI0@+,3/PT:IN!TN*OP<
MZ&R+.O>_C'7H&N%@A%2T#QL8E9%%R'25FP;6VW;;*H'>=TK "IH>5V$O/W5]
MTI(PQB7T3O$$5LC<9IF+X@%T&NQFRF9)/:NFNJM(1G (UN^F;>NH23R&GH1:
ME^A2-4U-LK-XD*[O*0&O&BTA6>_<+'5^GO,7DNMI+>?*&O>@4?I*0'#T,:D;
M"][:=VQDMIT*PF!\9$DV4[O\N1<YZIRC_,ZR&F]3J>%0K=P:60C?ESI5KD1;
MIRL+'_5S],'3_&MA;=JJAR0@8G$R*4:$CSU2<>:%Y$RTRKX+?U4&R3?0YRM*
MD$LY" $N*6#4\XMMX\& <&9G,B8(9A144"4#S=6L>:@NW5=*KDD/O%-A(-_3
MQUBHBNJ-Q'O;<!'+'DTX2VCC\\W4E">[(_NR!XU,!F'C)0LK*EV#\S<GA?4$
M3BA<QOK[UQ(N<PH-A_KE&V'W0U@^9P\H 2/4X!!M3[T2,'N*+.TQ*6J9P9I-
M8^^G1.[J*^^Y*:#':0MA9'-6[9E:RU4%&@N,D3 )<P@G#SN(X%N*.?!&Z#0^
M?GJRAAJ)V5I,C67A*^?3)+!_[7[S)3R&'53_40E<)9#AS9#0%.<JY2>!)6/A
M$8M'=]RY )C>.@],-O-,Y:VR+SLC,HQLS@.]5J;X.OFX(]>INA& #/B$BIGR
M]0@.CI)DR0+@=!_Y*;A-P+D&^H-=%JB!;ZUM+,' /G&;B%K'B0,E3[>T>LJ#
M6/!F4&@@)7P9;'OL,Q:A)QF38?41_2?\Q'8.G-= 6@IW/D!.PA2YVND.L,BV
MFV3I6SV/8#3Q)<A;*XLF5N$(%\)72&;+XX5QYC9-K0D!.SV@W9.5<UM*AD/=
MI9OR!8/^Z5#M?'/3CR6'70ER\KHW+IQG;^0O>\U>5G$-.B-*)]&H9 ILY*<*
M3V M2 N=96%82V42YH*^?#SC(T7K+$.CCX]#K9!YL)6TN\&X*4M$3>(7R^(.
MHX87$ZZ+YF$U'1LBJLK>%EV=9O9JK3V^H;ES&SHKY"$M509^&*EPEV\>O(@N
M@8,>T3Z64./+J]N5@' ;VN'M#/])#!<S88\KIK2@F@P3)7#-E[2$&SW6%T3Y
M%%G1WG J=>L+55,5&J[_!N[QY)"?_"*F6]?F,1'M3/Q7J([UC#!<*%45V3<G
M$"/R&!VAH"0=;8.*25>EFP9K("-[IC8-,TZP C[)C$WIB,],P..9<Y$-57]%
MW5T0&<3]@Q8JL$4,DB@)E,+WX!S,JH=VW8FVPN9:%U %+JHM8TEN<6K)^GW>
MJWGNB=AE&E9;<YN1?=XF1D=Z 9U-.E 15,+'6Z"_0])AKL.?7*/OSE)^Z+E/
M<^-&Y>9TYWT-YUY%/ OL"VSC/7*6=F&P/!_3W>SNP;H,_,<2O%X_6$PJ$Q.2
M.I0 1EBB41?:GGUP[M,!;XP]7O8\@E&:V;U8KR%E$"23UU?4HDMV<&H'*1Q(
MLA6O<H:C#1X%.XN$Z"L!9(XL[T T)8/;)$V% N;5!'M;_3Z29<M;XX[S6[J:
M+#O35&\!EBO!!QD1DZG,H;R,>TJ 6=UF-#[(Y*6U\_W:D:?0R<^^KJ2NU5,A
M7,:+YK,[U=][@1V]N</,'?'(F0!Q"\H2'UCIU5.GX;R/RT88OF,"9ABEE'*)
M,SKK)88237SR]L TWZF=ZM^E?1!9^KCB'Z+Q /_L1[!/#^NRLRAE9_CCLS#&
MVP5\&E-PR.AK<ZBL7PGPGE)=]F*XH(FQP150K.T_.RUP]A]Z/_M7[X^5#1]&
MHRA3+EOLO\C<Y'BWF !9X2T7W[]5R[;[E&H#P7:>KKZ/W_."#I*!,NZ""57'
M7B>NTU?%BDOB^YGJ6R9-^BDW61)/ZM1";%TA,1_=F@*]4@*_77S=IF"/, RF
M>ZT^4[,9FZ!JBA+X>I6^0@D\?\B:CA\L5IGP1?1'T.VIL@/8.;R$JP2VW_3L
MW"<-1?3E?RF!N&6*N^!0#&+;  UI\J48+3M5V9HYN[^"/\Z<'A>3*GJGOS^V
M&X$E&$<FW7&M>["X]VQP,6Y\ >0<LP,+A36>.]6B-J:GJP22J?<=SP:UG @6
M9^ FU%H\,-S5)"13SN'H8VU.(]N8T\<P_C21-_4-YH@Y\)+/A&+#.@V23C=R
M_ 7L=I_Q@:!5[$_6A(NJ&-I6W$HU%?<D9M0$%H@%A/BC@;=6G5^L.CW_<C7F
MVDX77R20A98)5N\'0Y0 9@8\'-21'-28^^<I.6GC/<<C^B>3N*Y->,LDQT6E
MQ)NS[S4;X8C2#$[\+JYYNXKOVWB4I@3$.<@9CZM*@(A9#K<S?L4SZY=* RYA
M:HJM! XQ+?C8D@SN8?#P]\J(X\V#"1 KW^4_#]K[BGM? 3:PUL[^Y$KN1PT,
M;X[\</B)U\\4)&?.0G>.2OGS?V[(</I35F*1 "EHR8$'D=9B]$\&1W&&R(1X
MF*;8OQ@;Z\X9Q$1-UIM)!33]\?@UX%3U $26/#YQ6;SRJ/F+83@(3MB7LG@&
MY]>7/!YUQ;36?YGLW^>?^H>E-S98]//YTQ>;7*=#\NS5^ /D%F@I0/YEOZ>K
M[FA!P/310V?<^TNBQKG]ATC!NB*MI)B<,3"^3?I$6PD0NB!%V)D_5+"YED'-
MDWG@.K4N)5!@U9TCCD'#.[C(<TPR?RF W./U?%&6Z\H&ES#I8-MXID[,)*4W
MP+>1]AN7Y5I2&=0QU#LQ'19*^FC_S?)*S;&7&/ZRC@1.71QL6$W!0E*:C.B+
MQ?%<@@G]$,R40*)OV<):\2LP;AXDN>R/+N\8'YF=N*>JO#4@Z%!+^[D E5*!
M*?[>RYU:,S/QW8NIQ!'J.T0)W-[VOD7.RJ$.3J4E?:O@U89Y?8_*HJVO32G(
M)64_/LTP:;/S;_0TDE_,?>#7&> [P+T5^):8=(="D7Z[+3S;#=^N/W3N.HB4
M'])3 OK6:$Z.N"^B^3'N\26N8H<[BUG+/J( FVB/\3<=1J1MC\+EDR/<'= L
MZ?!J$35V4;E\-KJDI+3]G-LK<_./5\T758L)GZZ_T>)NESDU68NH\1S)7M:G
M$5'H%627T$-+1+E2W#VBY6^<$T=TSZ,5U<9O_S"D$\4<?F:?B5<M&$HSU7V]
MV!G?;NOR%Q+!:3X2/HX,77HVC>8@_N(#T%FH\_BR%?ZAA&+/6B;L?K7-)L">
M"F_QE*^1R\^SAN:$U&PF+3B_LMK&P?8OTO$T$*,05$*G+S>%E)X/>XK9E\\5
M*T(;K*K#7 OR(A+)Z!SF,.N[% ,,V7=0N-BGV/;W&&"Q4W.+[:^=H8_7Q _B
MIJE%2J"N/8PP#0U.8>K-S7-<_BXFZ'%U&*YSN$!Z^L)YU1EXW&.<5<*)"Q$T
MH._)ZW]/Q*>[-@)S_^.Q[UORFP33(.0U>0K!TOL7.TU%7X3I<)BXL>%A;X^G
M/=[5TO4U\S9-"PX?Z9N^O^;N"]6D8>[9D''"UHD,SOC8-)3&F*O"^HK9U\L?
MNJ2 2*]?1^1=!%]PMM9<QDXVB70:WH?YL 4THO13<.,Y[J1A_UJ]1O2A C?*
M?DN K2<):@PCZ!T7\;+K70"]OR_2H7&].1(;WF#PKY)!;F"85X6."5BU!/G2
M,[1)25Q%A,)/=8 *6_&1>U9#F(\G",)X]-[NRI;_M"G.9<0,*K2!W1C6[,&H
MMG< TE543(6E&/<>? -M+728SD59[;QJ?NED@GL,JE7M@-A"!+39V+7QT_,.
MTD*ZJZ0G4436/Q##E2VG8VC[VY0@1I24-9^HNQG']PY%GJ5^\B50(.YH[M_]
MZ"M3N4];)&@Z1KG+EVP'C9%-\&TY>(2^'8MQ$FD97.;.JW!_<I!VCB<VN\O$
M=%T#*]MO U0WY!^F[EEG3I#NFO7N)7G'ZC&]Z87X!.*:P-FHA>3ODOI\WB?J
M,IVBAZK'<M.@NF3<C4OSQ>>Y=BHE:,ZA%TX$:2\VEZ<2>"Q@A+3\6MZ"8 ]0
M5J<$7HZ"+?%6.$>9*8.B".M[I 1V,V*F=N)8_N9+GWT@QN3YAYU+#>QI&XX(
M2]#C<[RS<E03!D&C_D.)GV4RYY[KU,"DX+R*TUVWQA?H[M@1R)OM^.WEB 'L
M+FPJ-!YD.#QKW7'_T0R/[WD7[;YL.#K[Q->(H00?I_G]U[X1'02LF"XDJR[L
M0"O1782'4PYBZG=C:#AKSM?>!:%_25E_T)^N3-,ER*W244R'U*9BL'FXB6_=
MC30;2 R1N0ZR=7"J:-FVF@P=N%^8QYY[^E!#;I;W:>/\'%GX03,U_'#-M@#"
M)YSJ7>KZ%Q+WEM5T7_C@2?E5= 7=L71-64K G5YD;\HBJ"2D1CU:Q<:)\<6P
M2*\*O&GNHKC#$=PUGJQ5E7B_$UU,%5R/P'$SK"2<J_9*0!6^&<PWI15Q,YQ.
M.7]/+/!/74^+3;58<"MSL5;,BS)73.2J_1#\I];[2S"V=X?;($]WKT6UX21J
M!4X(PH<>*F+JT)FM'-'+5JA, T=QV71 =TW:8AN5A4:$ I*:(H>D15_?9L?2
MH[F(DB-#7 +"Z\)8<3;-B.7U..FF*YL#=+4[C527W5!1FVD3JC+N/AV:^@,.
MJ*C*&!K4O*,2\13:8UV["-5\*?1G7N;K]<)%N8<.P\VBM94P5:0N'9%1XRI"
MGICYRL/7M]IY9=^Y1R9(;N<%6.I_T_6?7# X?<23<LRXY[HB$W (._AQ//#Q
MI_X_+;Z?6#GKTL)G#X_&69X  DZW$<:9X!"_CS/6WYT!8R#V-:0@^L6PL;_U
M&_;($#6_9!EI$'5=/DQ5S_[TE?!Z[$22BF.#RVVO8"B0\0<PO?A!Y*R?QY,Q
M&0+F ^;_#OH3#?#MNDHS26GR8_\,BX[B+X:;VFSJAWOR\[RU';8_TVY/#R@5
M7&!X[UA!)LY6X.M1$RDC-@>^75/^_;K(0W7/;E"X0/*]Z.&9,&\<SOB-Y4K3
M"W,S,-+24M'Z35RZ<@2K!0J5-_<?Q+ BJ5GD$#5!T#E#6EDJY5S^3B=DSCZ#
MKBF6+KH1G(<?TDL,",D_^VPCL-Q(.RNM<.>EB)PZ6]4>_RZ'^ 529ESS%?MA
MT\%#8'P^<3-87*)MDP:=]8NY+5)Y^U6GD_2'RF#W3R[RX,FW@P_$@ +B\C"6
M_J2BV0M.%9CA#K16+"F@\6LSC*6;7I]:CK@(1W3]G3>E/Z$D5?B]WW?%Y,J7
MZ N; =V-0)CO-'LLK7=T7-8_)>E9(:7$(6:9 ^@2Z?Z\ "%GMI^U[(O/_H\C
M4%%PM^X+M=MP@NSK9./9]4\_#9;OXK3:YI>8.?>=^C"RU6*7W&_@@KNICY5E
M%,_2LZ&<6V5&YE8ZM%?^QOA@;M-60@!H+IX.?&UT[L$>)>"+V$O@UH/7!C,<
M^*_0.7@]U5?OWBQ>(]#.*P:.TJAUYFL4V1/YO@W&AE'?Z4LDF0?[4ZQJF?-H
M!6,'V^@>!3>?YF(JY-V&5F?;>%GYBOT+GBV,M%A4B76[S8:'W#.(<N9S*#O#
MV7P+]UQ06A*9>.T YZ-(0Z.LB5$!O==GFS6$25M$MQ7G<A^2!WW1B-=*X*9X
MKDJ+$GAG.Z;HXK9!8NQWWB2\OT[!P0\>&5_1*)OM!G96-E^\-*$Z'\?.15:/
MW-!FN: 8*3/%V!G&Q)AUN_ C2@!BCDV'@J+5E":0VPWJ]8$23P(.=D0\8(6_
M@'D%DQ%1B-MKB2Q/W.CK 9]D!"\OMZK)Q]>*<RBPQU55HMY; WF 5"Z[ =O*
ME\/N.Z23#>SYAVBX6N>1JW:LF5UG)M/.24GE:UOMSJI$'J!J5<\W^AJXUOQC
MZ-?U3PZSQAEA.KC>F ;0> S")&O-\Z*2#+G(KF=.:5EI\Z>F?,5UQ<.5W21%
M87>!LR=53=:5_C%!-M;UQ2WWD-:[PP6<<VU;XZH'FS2(8V_$;>^02Q)"%6'.
MJ;)4KKF.I*<L,-L'U7M]:(@P[*KUHMH15WI^A^-<E71AQ#9!:59(H"(>C%]6
MX190SY<]Z3>&DMQ<-8WA_HPI8+9I#.4/@FX%UN;44J7QM9M)6K2D\ "'JBY*
M_?">ZOVA#//BCN#&;5YPEI@UI0/5GS-$EP)!;YM--AE<M60\K97;(=9HSPMI
M4IY@V*&^TK$<TR7-NC &]:?/8(V1QY=6CU"L:514,T?BOKF#OI#TJH#6S>TQ
MA"GB-JF+D%*+I;^3A!=908Y69][_&V/.&K#CFP5)%PZ,+R 8$CK#48W.[+YR
M]YKF88Y:/VI4 C_NLHU#UE1:=N#BD"72]<)-"6"9W4ZOFVY:[]07Z+<D'"LW
MXIRTA2U]8\8)F!U& >P ?!S)"ME'D!20%A[R/]24]<B__%['&])LYV]X9 ]?
M<G/&7KUHQN[:6Z27TGA$GRP+DY;5!5AP)SN,O^37Y]1[D$47"X4**[D1S<?[
MH_T'J,S.*VA#%:ZV+BDM8U-8]#E:*JJID/3NDKA74>)()E)F(EU?P.SDB=C(
M,I9.G[%;:T,J^PRK&\].-VR(/\W/]#U0?2178W[1:.Q1_+-O,$O"WL[+D3Q5
M GITU4=PS':,WVV73/"OCU.'78D^N2TOB#XWU+]_$O#<!&P#.*A^FBR;C)EX
M;5@7IIY[T2,C3_CER$!*@+1A,]J]_>ZQ6RM>6DH>?O7\YL EP);)0]W25 SW
M]1D6C0Y7[2C7L&^92"0?ILX[-/#W =J?N>#2.Y8P/6U&O-J,+4X[\\=QB+X2
MD.UJ5P+'FSO%M02U$#ZA"Y;7S6/\]K&"_)26Q-N,OFNCABP+G<EY-GYT5>2P
M6EG R\%K@&+6?[TU&OWKABA@]9-)#M1?.I<C;L2[2^]&"5)C'C<_I66\VUWY
MP60(DMIT<5:JI3_$5SA9 ;<_1_5)&[^Q"URJ+H#&0-E&@W^*I8QKS6.<<#2(
MUY_TFG-DS\E7@&]V)2@>3,R4#C/;<*8))W;.O&H)['")!),Y_=UE9[)Z@T=)
MC5S(#6%2=Z2[VX^RZVR[7@ES8NUO"CUF1;B+F(D2_@D)N?8W^I8GJC>9PZ_]
M?.4J9,M;U5' A0-WA-WK%$\8J]X%8K1L7NXCM-%<H_R+;)EUS0D:4S0AN[M:
M"2S\$DJ0),"05?2^ TGBUT!8W"OQZT7XQ![=#[&568YMR^S)VO[F"XN.G+YK
M7/ JYGX?5^UD$>*N9CI'QVEZT_R<T9>$?IPI :VD(8'3O(:>>3!>,B@L2ZRP
M>$ [!\WQ.CP0LT^ZJ<">/,??^":OY$A@OG]XY>XM3:O6C3>KI<B7$KZ$3R@@
MV_ZU!DK@FXL2. ?)?_])J@_L5 )OCHLGOQ0EX<^EO[K(5<VX4X2?OCD._A6I
MR6EG9:+[?NQHS(24P*V?=R5O00.$ MX@_1\L^P[&:"J5P%L#V%\)G-P'3>!Y
MCU4'H)\<VV&H\"?'9J+W?F,_SQ-3_L/9QS,N_V,F1%%*TD=P<(F$6]7!)^1(
M0\KBB 0IH=:9'U?,PM->P-2=//K.A]KXC<L-3[T6CAXX=C#J[$I@Z *X]I02
MV >V3:?\)/W9-+ V9;*&'(5:2 E#G5)_V1,,:O3%N%CV,M)\NE4'6!2R?9 C
M78AV\; ^LFKD$" '!;@KB%ZX81+=28"/2^'50GA8O\%J0WE1>6O3O4?^73=5
MC9NNW@WH,1?__L(\4H=SFS]7"0CN\LU)2]$/+#W4'JIY+\%'VVGO$5-B*\@"
M):#39YBQ A/D&HLNJS@WO7RP1(/QVUCTOFOGWN#R(S 1H=8-SP>K6)W-J%[X
MB!JR%?:'V/1-4DK""%%/>IA[76I15Z[!*\G<E&3?F$,BF)R/S['4#6<DGB),
M3:*0<*WI<,+J^HBO$:7?Z*>=J:CS =\HQ(M<="&,Y^DP?7N<\%?A872] SC1
MKY@9L!Y]&($?S<3?12W0)G, +GK2-]V;9+?M>F+X5N/3'TH"K.L.-=UKNN*V
M1Y&@L7.N>H^&3>>Z Y#Y!L)SC%]?JC@9*%7U:K,GZ,'=>W'#E0N=FPH?B?\V
MGM]T15-5ZU9$Y=EA@/7T11SU&!R"LF[T/LM"#T*L[RVXK^=B,$<K)+.=N35,
M>#L=$E&-88( K/?R%%&K^?'B3:U$IT=^A^[/-P832ZI?U:'@SBVJ-,# :>;F
M9;<QA59MQ=#RYQB 0C"^+H475^S/OFJ^!$X7D>,NII 2%<D%3+,94.&6KRI8
MZ9E?LM3YLME CJ6K#:=Y\@PG+0C-4EB9N2J"4&@D!4 J>) @?7IVY0S%7=(\
M> ^WS%M/@A^JE6ZDT^G6H<)&D[H42EUQPIL]ZWDJCAA'CR_;VOOW_-YOCAK6
M=:0U4/5OQ/EBOA[]*)PO!*_Q]<:IUWM<*C]6;'OX'&8=</9.?>)_.'ECJPEK
MRG!?>Y;._2BUV::,+__<@;H]*M\$-I>N1"^VX'J5 *+_3G8>3I0O9[ROQ,,N
M4L_Z0U:)="C;W]NJ@^Z>!P?[N]?N![N[/@QF;6QIJ-3LTCIQMT'G0*3Z@$(E
MAB-6+-W;Q^"T[.G[5QM]\J'^SS?CA'A87)9+2C_3.%=EJANK6VU%.C%0?HCQ
M%U^7I(J O&45#F+\?*AF]25?D?9!\K1.Z@/_PY/J?94+&RX$17/GJ\UD7RW&
MPY8=+R6IM2 >,9. LIM2-%DPHM4)C\,<(>NZ;4F$2U77) 859G[O#46,RT1B
M(Y;FDU>(-NI?)2^LJB_[AMTW BL8>TFL^TI@%AM3^<W0> (T49C &KL&H">)
M!"PK:A7Y1 >Y"7):D6X[SHE)-HZO&[E63JF[+]Q&,1K<)N'N;"/J>!HO>LF"
M<P^C\]Y:8[ES\Y7V'VIKOK(/*9(Y@E2PF%K-ZM82XKF0'HU9 TH23D-%K;"/
MU*0.E-SR)UFV<XJP I^#P;I&RX24A<=KIOG6KR?J.&'EN8ZT'>Q3 B\FAML2
M"&C9E+TW];/6=>9X$'K>.8@'WJ5EXGM-1/RA^=@B[N\@F<(UW%I626%[Y8+3
M4''<[7 )':K90'<2WI<[^<7+0X(IIH_5!M&%;YR. \"<'0977LOWHW5=^&&\
M_!*R\B-C"=Q[I.-;,:PG9*OWP-:"B;$SC-_;T,5^E]],\Y/L>ZU0@\E:YI\W
ML$2^S&W0O+SS222^C6U$/P<G2M_5'8JO:>Y,D?5TU*ZKD!/JF%VSOK]WB*NP
M)"-5B%ZT^Q7B!DT@O7NOZ7?5E$DE$ .J59A)R.[E'Q#KDT%!3_UY4( T]+I]
M>/.PK0D\N,\4"ACLZG&SO'W[#; 86/+V*+Y*VP%C)IBG7A+^E>]V'!RCI6>.
MQ+TVPE:0C%A;@W@:U&#\!OW2WE#RUJE:,GFEPO,F:VZ:+LVQT8\VAFK^C7WT
M=YAIFV#W$G4\3*,*RJZ!6$^&/7N,87*HU.*@=-&]S('7H' 6S[Z2?,4(PYQF
M):"UC7UT=12EC7S[QSYHLV+2_9^_K"4T^D:!QPCP4H=8&U2K\R"=4=H63)T!
MW]Z*OFD=85@,FO\&S@ANQ!_JS"]XE5_)AX^8FTNA^/,Q-?E1@B;U,!7%_%H'
MQ,,&[!]HCI%MUXD?-5>X!!T>K5=;K]C(:9%.^V!*@[@3'#5J4P*#6"I;K#4Q
M:#[X[FM_4>$PS=W\:^!44D])J\>O'9&+\W3[HZE6K))>\RS'-S*QJBIA*X!B
M<'_VL!.R!?/]GB)U/%]+1*U+GR-VD_1&V;.-X!T\S];QQM7RU?*S2N 85*/]
MPE?M*]R=IA?]\HBQXJZB$#P!QD*E\;7#)D)F_:O$<W@M/W/;#W0H?<:DW+4I
M+_,N6K>\#OFDIKNZ^K,*$,FY02BAQB'G04$A7R6$ M#-I>SK&WDQ%3;$2R);
M33AU4\!R);"M9>*9X2%IP[5.9WQ\Q9(;J\X?2!-;\L9#Y.RQTDC'8<*V#\70
MD(D)M?BI\SFF(O$4[X!36_ "X)3X%K"K^:C+K._T7SO<!]HN@=W&T'9%8B$S
M%_VS("X2*^1:;-$@:1MJ?_P:P/Y[??\T09+UO[?JZ^<"C3'M*$NXZ]+.:48\
MLK3^OS[?M.^2G$'HN/N+[>W/Q"_B97+K.< M]VF'>.(NY(_@YE*HR;_CMS@^
MX<5E?(&S'A^,-W/Q_,._#:KODA![05^L.*CU:M()F6M$(-<J;6^E,WQ30(@S
MWE[.8R*['L#;W+N 5Q]'DM*H&GN4P(* ^??N30'S3*X2TT;]5#L2_NT)U-Z2
M]%/=[L\RIN7[VH('M0)3WS7N'Y$['E09J#IZPER%.):0D *+*%UX44Y][CD;
MR!>,#:5\0GS$A/KKJX4<U7 LIGV7,'M2ZXC3*FD7U%?H;U?<4@+"WSAE4ORP
ME910QS&QEX:@L<+!4JQ[^!^+4@(KR&I^EK?"YFQY^[40=TOE^)BLY /BGLN'
M08%A3$ES4L;B8B6PH;)< F,3APM+8W.'F^SY)H.<Q4>__.&XX.B)9Q:N#$WD
M-%S\#APVE.X?Z-[T\I4A1Y+#P..'.-H'9KY!&WCT@%@IJ?*"D]$^(ZM(@/T\
MF(KO)YD\*VTENF0?]BO?F%E_]T[VP42''< SQ[^B$@1S@".1COT9&8LO[PC4
M!<1J/LPQK"1<^U3?HN9T:XE[3;ZM'%]%FM=&=,I)FV&7NL#>>C0SO:NC+.[X
M-N!B49I*=7//A*W5)*77C/2RGS_>>&#T_K@"#^_V0)] .1-V*N+I]SN9UU$<
MZ/O6W.1C8,A@.\"H")T8]"[R7E8PN&8>:SZ)T+^'?SAQW6!MRN.BHOZ,SSX9
MYU>$)_B4A&/%=1<#XHG,V=^4P(W&9D48Y.:E':0$QLR40!FHN%7F([\^GJGQ
M[=?NI.?7> 1CN.CFY%J\?"GVX<>,5Y2""Q$-TYY?F8C!)+J974N1+\W[<>'U
M6L).1A4X>H+SG*.XP8PC3/O\\\&Y"(S0WF:\(\C<4*Q5]=]:*E\:N?K1/SGF
MWPH.8P6=#A/DRVA9(MNAP6QXW:!(._M1BF<]PU&Z*/$1C5!U>$=;@?_16R$8
M#RS &.7>A'-JNAH&TPYVGZZ)<\H8L#@'HP4#UF.IZ"R/1V?*64/SY9L/'H"#
M-D@7OH3/\Z5+/TH5J8H_=NPH2G^))</E&\ZF$LU&P K1IXAQ]4H@$7H>'U7Y
M.YTJI4033TM]O3^6N(GS6*H]2L"/1G!KOZTJ-W$#F'>V/19'O9B=P L2$[K'
M9 ?@<+$>QFSJ* ;+ NC'_*6>6V!LO30F\N]"HM[!AV;X]546MUX"?T=:FNJ^
M(K_C2S;QM?DT3YDN3'[8+!B)0^>T5?*>>/LI 0F;CJVO)KN[N$*:3^,? ?2D
MNF,9%]8DZ'A$J$HQ(<^3N])/2DF%(K91?]B7 K8(NFH^#Z-N>X1R,;:6Y^"L
M*M:HZN]).]9^#[K=CM7G]ROG[5D6:,39IL ^/)F2'6+_[M#ZKP/0I(:I7MLW
M'$$,>^Y9.W/NKO]\_..YF_%_;-Y%_O[KMJ[:\RK<2.& 2N^4S\1T^^IW&#=<
M.<']AAOK]]:6IHI9D97XOJZ0D6O)>]I#$L-&AAAXB6?\TX8<,33O#.=+RS@Q
MSLI,)JYT<UQ@?E.D!(SA/=7&ZFP1V]0_!6O&MIG'QPY(=?+#@A5KJF:KW"7>
M<KBPQ:H@J*,2%T>YRBIU_;2(7\_!@:=43J=6XN/0172_@56K;PI'XE,//[8X
M;QGL6,"J)LPD4J5%=6'N]>2N!R;^_A$S)H?YF'#P?76X-A?VJ0JO#, ?DKZT
M).@BZZN!@*F]DM7%CQ4SKIE"S2]E\YN/^$J_1SQ;K)HD@6+M;-7@T,V2G-A@
M#X?:%/7+VG<R;C[L4GGT:69UE5K2Y:2@FS<TA?Z5/V]^SCUKGC..T;.(GW=U
M'+"6(P [7F*EM3#1!7T= GZS?E*P%P-JGQU8IGJ1IZX!??^L,J=3OL9GT0W@
MZ1>& =RU8:9RE9A!7L;'MK>3)OU'/MYCR5>)WT1&9"%8"W8E'_'!*%\(QS]]
MNS?&YX] OMK[Y57F]M(%$H.<V"&ZPT/8Y$ 'W4D4$+Z7ITF0I/AS)$RL5VJI
M"OF7Y<QY.CKN9WD#\<,?Y6=I03(#. +C;E=Z5DH*RL1>8 -E#G&E9+JI;3,7
MV9STZJ:BI$#_TPJBS^T6R4;&.K2'HS]2J89]*YEA2#_2ABR3GN.1J;-AK4U2
M W;D\HE&=P^X39@8>HB+;-D[+&DAS;'XMK^K\\W9%6*,1M55SH)#I:DU741S
M!\FCJV*JUN?2.Z( JZW2<[="@)1[.X,=O/3:,1PPP 'BT\?7'XVKPIU\-'"Q
MZV'Y[ XUDPCWS<8?\_G(Y8VRU(*9-V:X[YA5V'NS^YS_A[RDXOKTOV,30-](
MK3G+;(8:@@=M5%]%XJS2?*(W5U4W7K3[%V3NU8=R03?D2=@_]TCVY^F&(E V
M[1S[8429V/-R#MK1$5#Y3JB]>VSH8C(DM<'$^-6:LJ953KU@[1V+@8B&Q=',
M-N88?(L1'6G3NG&__ @I9Y0@7JOV/); !GLE0/CM?:+D!8VIQS)6Z:SD&@VV
MX=CVB;G^'<YK6(%/SI257V3E'.I4/!LH2^9T3I_3(!:>ZB^[?6N'#F!Y;<K$
M6U% MWTZZ$F:"R\34N;1@Z0NLU6%UNMS8/-:ZV99;^(G@^WF:2M\VG4NJ,C^
MN'5U7HAJK!&B#N94AO&:.'K0:<)EELYRSVT\XCY%MEBK9-Y%QBS) \)\..TV
M#[4TUNS):7=4.Z'2M'9459(LNPY702()LDT)Q'H(KV/ <"M"$IJX8W*[5E-B
M/BQ\I7LQ.A)#UNAZ1B1,E3@(*36'_:_;JM$</%J7+W=S2'G1E"4Z+(TF!02S
MX"U;O+.LS"3.+;B&Z8S7TBP1[^K]5(\/%9!$JWXZOX=D^H46&QQ!WE8HF8>I
M\/R@M>_,5.NL6,DV.]9]_589*2$,I0KP6C0FJ@\:0 '(83AA$Q6K8X?])(N/
M*B97G1==WBQIBKJ9>'^/A=JM]4?#[KY6XTM>("J.J>C1GB5&7".!'E]58FKJ
M8Q:1A1Y2 JR1G3,/9.IM9"[]?$G5]+#N>74&.37):8KQ>NH %+Z(5H7E_03G
MK9&HV"]S1M[V#4ZI$HNQD>^;P+6KSC3N>X6!TU0+3IM-X]9D:,=QT3DL UIH
M;?SN5_/N0I(; ]/D>*C8WB9MIM7?-NM&54_0LU]8IR?Z[OU0'+$<J^J]G-+6
MXNL;OH0^.=*S_%Y.9W#?@<>#54WJ8EXVPQVK'S?HJ*T1^H6@#_HN^YU^BJXO
M80F'1Y(.B[(_/G:.OS*B7F;\**Y\AGZY*_3W;.*VVR77YT0P#BD>@H([2J#D
MXDL!Z\JT80SH]SI(W!OU_3M]Y4D!V,D5^5ZUA[3AXTJ@UMB0\"FE-[%ZMT.O
MA4J\6I%^Y%HP8L2>/,OML9\^GT\[?\8XG?\)<0I]\N4T;@]GL"$F]ET&?M:J
M'2M(QU*[2)QL_\+/2N#D0,K%;*K_I=R#7NF+I"$&SWU>61R867:NZNL:%:/J
M!2L)367U3-C*<_BV%%?++Z3$+'LD:<J$?"'\Z1Y\1\@VSI7I#RQ5./OBH+OH
MW.7-N#HWHJ-AS3MA] I/?YV;W^4YJ&:S?#ER7,%B+&1T]-C ]X1D#;J3A-,
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M][$0KSE((.QJ XWN(Q'$&1FVK?%L8J%5=Z03L057N!_Z60*#W[P@V0-,/WJ
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M\NH6H,?FT8[!J;H-O3-@4!/V"F71Q/282+(5(G1=D[NS18 "IU576K*S$9B
M2UE?"*K2R\S2^F;O/NQ/(\(ENAV]LQ$'6$R)5LFZSE2X<FSA:4&1+OW3X2),
M:I TI^P!G_?-V:'V6?ZUROM_?!T!&7K/)W#$%N'0LDG;A)&',)N+9EO[I#_Y
M7/ @IT=[9D?XX['5DS=.,#>_'V\VTVP0RP,O0)9T+"SB6>.23BW_21$D#Q."
M]JM/<%] (516?>:B^5AE560B2ITQ*:^_71@_UR$SM.\>4:Q:K HC\^[ND?,I
MYHJB*\]3O;:JSN5K/ NC'[C>B(AWG7%C<Y=M8N8=]GG3J?JB,?R;V-QNJ-84
M_+[J\##J+GV['\6[46;"E"WJO5>>P]$'7UIG,@MZK',N/6\_LT%SIX#V9(SS
MFV^3HWMJZL\')7'&Z7&J,AY*1O0>39RY\&E1-6)>K'.\B"=$2*JL=@DCO01Z
M'Y<=-2_'S[NUU^_TO7C%T'$_5IG$$&P^N%>@662XKU^F+MK76DE0O:L]I])3
M/<JN(D[MRC8S]>DG+F>M+FPRG0V=+* Y5Q]U#=LYP"9)R/#"D;YU7?FX&H^]
M&3H/ZL(O>G?UN5PUID9;D'<8%5>G\#O.6I:N;A!<2NL[6Y'6.M&Y\4#O,@C9
M@LILG?E)\5]5R?'X: F?YV1.<U#5,R[0[>!S(EZ E9 2M>3=]H4?NTZ+[NDB
M_'M]]E]9/'C#!W/0KW =:N@WR:"ZWX6?&9/VP "]52KP+Z4KX[PEB%M_+Y:]
M!2C:$/1OO8K+Y^)87_A!GPWOFQX5H3B]W0B0D"J_RGLCY%=]L48@7=P;T;-I
MJ0Y\G4E^ ;T]H0(-5^B+D(U5%RJM=HF*B]1!-2M6 .T]UOFIK5WS#8F^=BXG
MN@X7]KI7=]EOC[T/]GHW&8'%8T] [V,1":@C4/X.;2+_YY"H?")PC!7.N3EJ
M.LR/)9)K0,8A=[@T-_,^[$KN$>H3_^N,B(UL$O'8NL4AIC.BUVMQOD:@AF@$
MOKWE'F?JYIERNX;>SHI+^WM]P[+_URV5MZP9&^00BZ?05RT9B$8FWM01J;F:
MR_ ,R13'FDZL.J@..Y6*Y9?[,06,2O<7P=IPCO#<@QG8AZ%=<"!?_-M8ZJ$4
MS)DYXY)1)? ;MQ7J8,-^WRGZF5JQ](D1*"I@'E?%:MZKQ'U!LE127?EM^R6M
ME6MHF_!1.=!1!8J9XP-25M*V9ZWX93\IR>JL_/L\^[58>*%W+3B'9@EC77F"
M:?J5:B/ >T 4U<7D7AH*)5WBK&S6;Y7%0;ZBOTK+Q9^(]IXT,XFD9 M\^$)U
M4"A09W]%,XPK&<[,TZT@T]]967]M9(:IB[: UGI/B6(>*%FJL@<Z"A19U[.H
ML>[NROL3)5 7,R:E#3R,6FU[9?LW^S5MIZ.@F5 M61;*GJ,(0#GBQ9%ZC/]D
M6I"A3.H$YZWL.,><5#HQ^?C>0W4LT:(C UP!"D9I5=WFK&+=[_X?!'J=@8G@
M84'93MB^JBHT]^XZUA+;Z]HSX4:@5U- M_7.(Z7X3+E=_ZP]-DWV488?; KW
M8Y]6]BF#*E]EMK>W?[2I>/?\>=;>NL-174ESQ@*;?.\?_K;#_$>=,UTV."*(
M8 Z.BNJXLXU L'('_'@7O$3EZ"5$'/1!BY</IQ;().S:M>9!!^#<@M_&';C.
MG/SX_,7A>8_NRDKZKX#3H)-VOCM4V#YY;$07,WE-67GF%1FWW<U_C1/<D=\-
MC04$&B.0 KQ%.\VR\9H.?_T0MUH%=?$3.)/A:&0:&>@YUQZ54*D[QWY^^*1'
M[I75^$4>@M22+^92[%3YV!N;)W\:NV@'@.=6DU_^9(1D/0"EG:_S:"?5EKE2
M$KR%MODY]1.NKRJV[GN:\Z.; !Q=&S^C*]LV)Z;K.0Z=@.0H>)K+40KLRP&&
M<>KMP;"Y0MB!^1@>(/R&]".91(X1D/6WO=B!8=3K7/5FN$%OFME'5#&4/=;&
MFNOS(,D#.DKPFVU5&&2&ORLL*I,C]Q"6(6;5?Q8T0%U^1X61."5GZZ(9^&4Y
MW:5&H .G2@\(\=]S#?G ;?5,?X3-R'P%1"3$K_1^O6%F[=)CQX:,@.. ; Q3
M/_ZY_?\HAP0LRI&_/?@!) >86B;/B6'_ <D+4:J:<"B:'#/;T@@PAY[/(O]-
M:3[^)\PJOOPG9VC?H\N+)A4H^M=M^'<';:WI"=P&O[]]O,#@:CHH'">*&GGT
M;^+?LZ&@?[HR1E&N:U[^=Y+IX[_9\D<B*HPS^::Z/7A48A*8/8C+Y**#WXS
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M@_M63SEU2QLFAU$QM_ 3^8<>[,HT+.<^,53H5J!@<TIIQ?H,A?+"OMY\([M
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M,Y(B6$9=CR2T%^</J) _NCHO0F7N-L;DHH%&?@?RF35C@KRH.)_WZ!LD-ZF
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M7T1C1N9^@$A4A^!D9846>$7%%N.:O0V"Y<7HH0LYF,2WIK(2(:H!Q8L,FZH
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MU:_,TP8L_DW\9'"B9;M>/,P9>M[M+2T/4WVQPKWCSNNV 5\9'8'PYU-3_W?
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MG?7YG9H!1@[34!HMK"AN7L1N$V=R0%0\-;Y+",?@%'^@>N:.=MM>=U&1'O*
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M!+]_W8P@-\.&G;UP*#$$S&<L:9+.4*YWT1&-M[K1%YUT]BB=QJ(>2:9'#EF
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M.)SX>"QQ'7HP.:N;_7A#G"PC81USW<#"Z]UZ:T?VH$JD12/]ZW<GP<T/UE@
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M,WLX"-305JTNIB.:0<>=?F5;F%5(Q[-%C9Y)S9R6^N79][,[' 3C#'M#,DU
MM1:#FV6_L8AN,GNH]7.;D*B/TS@(_Y9D%/8X""_<WY=L]Y3J?;$OP.H$P/ _
M4O4W:Y08+G0O7S$["+_UC><*%7CP1H,?X'>NOY0,O!3CS/S>Q W-G*BJ7J/8
M+FX" PPZ^]PK-"S#01B\.U0"KRM]U=6^63*SL7G Y^7JA=E$HTQ-NPGHC]P'
ME8=XM9D(,WR97O&3RJ#4P :YU.R2LG!+(%G%=:[WW+[PHV^W?/5Q';MINZH
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M2S :/#0F, \<9VX_VD:O:XHQBB;9#].<])4W[@W(IQ11=3T5,S5@'?C'OW8
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MIW@$]3\Q!21HI.O<$CS>'%D>( O[U_L.PFLM""FO)4A9N=Z4]^WHHZ2 HLB
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M#%ZSGCCOY5>_5 &9>Y4EQ.6L(137-_O3EU^EAX 5_F!$^ T36'7*0:B?W03
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MC)[FBO<24D:S7J1C$2@3#?(0C2=6I2S1#\C[4#*Q!Y> PVTQWD$P#W 0-O/
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MR7"2II,>&3*[E1E\=?J+F$KVGWDZ7&DB:#D0(A/5>2.V:7:'!;(Q$= ;JX=
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M:CPV"WS7'7V_P9POC6#PD--.RH&FB)"$%6?4'CB@IBI'QVB;VL,,X;_X7__
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MR30:;6R;SPYYA$5:JQR=C-76Z_HL0V9P'95S)OQ#)>>K3-*EJDPQQ"J# CY
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MW^7/$L/S=.(.%B2K >DVY;)I;^Z:^4EU3 $BL&/(EKZ =;[A=;/T9DL)748
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ML&J)?CU\GMN::1'WTXFGDI',53+3*^7Q;/6I>/'900WN7N,6U,FI*2:HY\
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M)J&3"6*??2^SEA@*6+8:8*GP%D30LD/*K&U!WB7!1$,R\UG@+X>);@/SHE
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M'Z5IC.D'FE&%G5N,7C1*HF7=*[\L*6A<!\OA*K!*N\6QPG$8]:[5O,03Q_#
M\,J&:BEF)"Y?(0I?$S&X&TPZ_&;N-I['917IZ'IR+(A:0@(,%.J@?K'?23G\
ME[]C^3I#\IT1G 84DMER+FLN<#@W)%/E8 AEM$:P\%3U+)B+[:&I?G%20&"@
M'!&R!#8P%M[IODP==3ESY2K+X+7;I'QT(&.9W@,F35_=H@61*^P$O=%]G_08
MW_,@.W^II2B9" 5WIN*^7:$W=/Z-1]Q-K*JAM'H41'&WT5@F:35^.;#WCI\E
M2EX.JV>EP(\^@NJ3)V)]Q=*D)-,#3^H3N=&"@&K)YE6D*X^Q<<3,\0PG98_L
M5&,#[OZ3&."4[BIT?#;/)O4#4*6> ,]]GTTU?(=>'8+EYV1X5HP1B@V)NZ)!
ME5W "=_VY5QD[LJH@8KUH$HJA1CM74<:J,\.F N*TEAQKNXBDD)TM:LG%.S-
MJ#AQI]X,WC /G%IQ[RZZS9I>(P>;H2T9S<\+C3'@"76TG/1X=T@3K[ASQGN9
M7G@N8*V3<I21DO1PT;4<^_@_:+G)VW+&(GPC\E_(_,125IK=NLID'@&WF]_A
M-EN8MJMA24FLM)?U3R2SFAR[-\>WH=E#$( R]6_<;=NF6>MA*4S:094.Y:G4
M=MFWX_WXM;$VQY[WF\7N86U!:CL>;-B/IBH:'0O&WBB]X8KP26ZQ:]_3>[_F
MRH'7C-M-%FBZ@8 CAP @TK?T?ZNT#@0QB%2V:.O"30FCU2)Q=P5=BA?V20D0
MD=WV(MG3-VX7?UXYF5%CVQ;=O@]"#*-I3,S24UO\%B74Q4+T<DM14AS!V>"D
MR#:[&7RZQ3]V9>_Y4S,8;548M/? =F@0=S@(9GF6[<QO$2;1Y/LU)4\<9__+
M7'2<3*<6(W"<QN92\P2NDRB6OVQE;Y_3%[91#5I+?CGU-DE50"[;< %MCIVE
M-ZD0"U-5D&4D(E,N8.FD(?TUD1IGRSYYB*_:];37SU_<#(.17TND0$Y&B5DG
M(^9-'Z[+AK?V ''XRH74T;T0J1$4^M]CP23</5+)!X0G\.7Z"-45O\7@GVSE
M(UI*&P<NYZ832$K8W6Q_O?AJD", MM +6Q71%FV/$E#>= B:C(Q /)MJ\F,9
M-3)-;.Y[#R1[ZJ;J6XI[V2+1 'B%#NL?6H(++Q/<DDR3<-_9XV0$5$U_,*8D
M.&Z"K3:#'<_4N[_;,3YXAJ13,<D",A.-WOA@P-3_Q7N@ /SC-9MM)5Y;9H"5
M:,9TH\<X-XWT@]]?$:6KZM-]-2L+2PY?ITM9R9/@UAXNLTLV2[Z3FU_V5T^K
M<#[= _LWWR;W8K?<Z-6ZQ6EL;_$7<>JBS!\J$V[E]H 21+"3$UZKL:5*MA/K
MG)01E?LRAOL%,!YW)\Y> Y-"K=[B?HO%(NS&-K5?\PTJ@$\ OMM)&92KT+M?
M4IYD8!_3TI)!=(>6902N.T* U9H75/5F)X46DF50]U^8.OGSA@/Y\G[@E9:W
MBDM9M8"?&!+1V-TP1,\T6L!*2"J#N/"-\H7;9A7$4$5=ND9*XN0! GM1:M[Y
M?T><E-\^32C]?RQ]>5A3U_9V^M.*6C1:K^* Q*&5>XM*K2)C<DJMTE8A;;T5
M%2$J550F*2 02$Z5"BI(2JFB#(E*(2IB1(8 0B(RQ D"! D0($" $$),0N:3
M<TZ^$^_W#\^C\"0G>Z_UKO==V?M=W=L%<TO/HA:Q+'_JK:5LY_ZLY=:+O:DH
MI=<1]0B+M:A9.@'?(G-H6A#K9EJ&A0!PC*"1UW.V>CHO0IE2$3^>P3YG#!-V
MHP$D^W 2QF&D4(=7^5L]A4MC8H"Q\\F45;<-?3D!2C298[RL22MS7V F5HI:
MZ.M<^#H'C!UV1<*'^:?S<,A#?@1CPS%)A,SALM4^J[ZK'>#TV@_ZG2// U]>
M'Y5:G1(8R*X*T-/,Y&0WC,Q)*GIFZ4TM64A>(+:X*>O.'UC$=,R6.(<B/S"+
MM4-0O) ]R86=UGX-C-YDU0@XL%LHF?.$A,J<L_6<=P]A-A;0HPQ/=%&D]1@X
ML+OWN8Q)RI1(%93\,5#JQ)EA/ #:2:O]:W16VA-'9*=]4 JIYN12K!+JR['D
M$SS!I%?3?DP:'.TLB)T#75@O':&_4H/[/=*<7O'?RDEU2-;INBJS=HS.TEJ$
M(JGH,;C!CJ 1A$6G[4-&4QEZ5HV)<$5I1M=P9 Y&[!W^DH_%0O!*)#]M=:/]
M7!Y/56KW_9/&*AAO+N:UT<-9,<@1N\*>0 !C'_W/Y*7'HT'YE!1;+WQ0L0Y3
MSS?I20,0QLT907Q&3'$3L-;"&LL6(7])7[)FI6Q7+I=>[",3*[*(^U]AHHM)
M)&+4R9E^W*3<]PN_@Q[Q=HJE!KWI96V3K+Q$C-,)WS%W&I06O*Z/YVFN69)3
M69*<OH>7K@*FJ7>MKNOM R&Q#_YKH&=Q),J3J^9C#T)$66)&,1P=$6L,W5-$
M,!?0GJI%6-H-Z=JH]3>=F-N.FD(]S/G"^IPU<]6B[ETF46*DTL+"BO=SX:<V
MW N"-EA 6.2. >^VQ.L'CU95>RM8+>(1_H]^#IQS3P9GEH'"!P)_,TI!XGOX
MZVRXF(H@\"*_-@#C4W:SXI)DL#U@?[?[0K5:Q-+EO(-R1P&G_IF?SJV=M)\6
M$[WG[!)6:NC%6*:>I[F-E^;3?O[Y1@/7S..SX1VF_I#P+R\T\++4WT?1QDK,
M?Z7<>RL:PK9L..RT#GB#?0R.Z"[GZZY$MVFP!Y!-C2LK(:N>U ^EIO''FO:C
M1!T UV=M'4;30-:=:;?I);O/;+'ZC=,'@ E#)_BR@SH0W:24=!IU[\^?_$W]
M\)E)'(/09=/%"^;:5S<R-BM5YK]HO'].-U$"&KD%(A/A-)9PXGILA]9:I/ZW
M.K;[V7"Q^F="'90J[G+!5]F-;S#627!I!(O 3&<]Y/P5.7^_2MZOU8;2P0>J
MM8ZD X=T3#K&L+<7(<!+P?AW%5EO=N('-XQJ<Z1R*$[*"\B88JZN> +V$ &*
MF#'9T[0IUN Z#=R@SK6D<H(8[/R[.ON$=:3.#,A^_3*%<H8%G!$>M%#C\L0>
MNM,7L3<_R7N(E#9F$0'A);R>(;XK\%<+L2K&"]!PH%/=S#A%#I,59C\*?,Y2
M%+:.4BB2SQ&=G_YLJ@%3=3K2GYHAT@'*S [466:)('#B56N7%H;O"FMDM!3)
M.8"_2K*ID=5R7K@K>!6@-5QLD[+)&AE\S;AD <$2[L"EM"81Y$U;_W?6WH9;
M'Y36^7-#$LV')X^+F#AB/_=8EAJ^!CG3B'3T(X))"1]3#MJ*);O77640,DC\
M"<+KZBT9*7R9#"61!&@ 5N,#K%R6+!7396Y%_5%D@SG1TO1,T3L)YWJ(Q;DB
M$3^FWS!>NVM(P0U+6X%)'B8H#&O:(9;6<98R:!X5K38<^: 8-AE(]ZK@!V,U
MB !.HSE$R210TN/T?BQ"JV<02:0DNL)$&KZ>]49HMM@'6S,X+2(2D\4 &*R9
ML&]WIA 4P)\FA84&LOUWEZ(W8C]N:^-"A]SM\H: T:YP<_G/=2*0%AYN+,P!
MR/)F/\,H)-[]'TX*9+<Z^&&8RGD+^V/@=CO%89SU/*M0K8],9:W8]J<U+.5E
M3)U, ^1\Y<;5T%AY#\]J#E-HA3_6-$[(M]AM^BD:A> '+6C^8E+;J/5\ON1G
M4!_]C:2UX2<KH<SS(S,\C)!N#"6['N95O=MEPV$JH+5E3CE+\P9RA1YS +;@
M4=S]$MHV4'E0_51"^R$DS6TN8AJ\E'8%4$U#-)]XN-(<1_DV^;\IGE_;>S*&
ME.=K3,2F5/ +"]B,P=_9O;%6.\_8[Y<H(T(R>(KW>_<4KR"JV6$0!$2N.L$8
MA7+9"KAW6;9&M %'Z+^1?L]$EKI=V8DR5((#\8:)A+9D?O9&'G#&ZF?FJJ D
MF414FQK\3\J'.WXZK50%YA"!3F+5).IWJ^6V);8&W/J1A&OI.'%+3?C%4C!F
MM-"OF".,ES)?F<.UZ^QCYA:^_P?<+.5;5$7!&@"<3]#\&4G'UO9VX2&4+7))
MUPH/R*QF<VD9IOV2(\;I?Q_W7-O.'NL@[ZNRNLZ?N3:PF2/6CNHHS0XY:0#V
M:IQ6RA4?YU5F;@^\_^&1 ?V&53BNWWEO.<\WP@/9.!IIPT6.H#-P_AXMX5_>
M>3-YW+\0QU<8*RM#;R$IZ"W!@T>61A0DO,'PU!1Y\M\1-U^,Q Q_) @#E_9/
MQX^48Q$9<L45BRB&0.OUV6\.Y"#?1)1;:28]@'R5EK\W84H;8#&+H A+ G(.
M+734A6+RZ$0ALIE]D"FP1%BR7<H_S95/A'MMQF+M>H+/OTB'JNZT[;Z0C@&(
M8,I2):PW-!M<+YUQZDO#8M'LVLYS?SOX^*YPX'H%\V^@Q^)M(##V](J!I(5_
MH.-@]1#B;5AO&64=T(D\*L>_9Z.]=>DO,>451H7"M?)YG/5UCT ?L"8DBU%%
M*\$^DK2,//4QN%2(S 1+;H:HJI]-@P>V7W7/AW<8R+/Q[BSK7AC )#0KCU$3
M_Q>97EPI+ LX4(!V\R-"R:^RA',D49P-MR&$1$2(1 @ZS;_.Z'<-1'N0$K]M
M]M-0?)&(;5'JQ_G8:_QN^C/0"&Z8&A$C>!;'+.?K.!/\55A,L]Q3HD=TV!_0
MQYZ?V_]Q59^Q1S##^-WPG]$G]DY]".NI=;D!+?:EL[X[TD$L"F!NKY)PNYPQ
M+=66)L22>;-U[9!_GYB/TS'C!%- !6UCA*<:!/LOV'"NW-[P'OZV%WH+/;/W
M)#(2ZV8!=PC-+SI3'GG@-U=4,!^@^4*^I1UP%H\#JH..A%-].^R]JD/AL!X!
M;G&&KE-CS3<HJ PH\U*H#6H*5M!J%USR< MAS-XG=>3$*80 RA$7)$=Y[HY\
M7!YHH,1W*=Y4 K/7M^CY$UALU,-*M&/$L[(+B&2M/G,2K#H+E26$^)(M-IP"
M6WYU9X _I6+9"'AZ)G\9V1B]6YJ'7A7_'H"!)D?G 2MGPG:GO\ JK;'Z2UK!
MB+BUCA"Y1KX^7B+2DVY8M64SAWS:^EBT5(=!NC@%J4&O"H QB<MM3NK5WUZ.
M/=GO=$HMRMJ_KR;P;(,X7ORJRN-:7K/TM+I;'<,7/YAU66<NGI(B&9^LRS-2
MCM-_3Q+8< ]Y+%':]Q]/9MR=OP;+7T?\?1)_C+(Z$)\'@J0;F!A&!0P%2BSO
M\5M1ILSH&T^]?G1*R89IV;0 8)PJ]^*\_CS37/RLJ8D2VPL9,HZ>:4@(I5,X
M;Z&2,;ZZ5-1FK(B.9QL:GRF&1FF^'\'/D!UWS,&=?"LM?S"Z0B<< ":Q=>D$
M7,[[!LO!#'6$9IC#,MIP>MI!3_Y$+@I^86)D *O]P!30>'VI0.5#NH%>%A/D
M'/;ZIOTMVW[6U?(>K%]=Q/UVB+IMVV2E*:/PCMGW!9<RR->JXD:ZC!#(E!Z
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M2^&6^M>,UHIA>F0EM%-S4S=+=](@V-_J)O4R3,R0>#701Z/>O &G7+N[+<)
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M$JMM!\?X2Z"DGH_6U\WX7N!HXY!"^4YZ'UCE]\'XH2!W+%9H/9/-;"%P3@@
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MG;,U[:X5Y6:N)_&P^N;>&ESZQXA+)3R>XEV,KQ@Y6C%B=W/ 5]I)#^&0[CD
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MBSN,;T))<8",$:6'@9=M)RX'#K[28[*T(=X^C/#)&8VE.P*(@)N2/UO*ZFS
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M^GFC0+9'J-NLI4$S\@!#W^+O!&6^-(!T8Q9:6KK@]BH6)C'<"=@/1B>XO0G
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MY,=*TJ)I]11.P?V.%:G&8@.HPZ4H%1SVD2$3]=D^C9/VR5VK/$0C\_2N%>=
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M><-LN,OP3@,N&TE-#4;#*[9CMY=')0[Q[)IGUA"D/@I!2> :P\) _GH!"HK
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M\2FR7!NA*'!!S@OOUX5A_-&@1-J:<,=CO_9P5[O)/S?J\DC2@**7*+*F_*6
MC]!I;$A S"5A]^H7^G40:QC5^%= </KM68#?E P45T17@CQ&?X4/%Q<JC9C
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M-XZV"!"K)3[ PLK!C%@0M@<X&H0$4KR$V!!9U:B9R(H"<7_NU7LW 0J6Z;I
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MW+#DLN:#Y-CT*\,]Y16@]-_9&54%R4:PZ#742U3_(C8GV+YJ:U0(=_ Y)+C
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MK"\J38B\:$ACAY+MU;O&/D!X**?1(?[.)'FEJ29R7K<FX#?5O *1<H&-\+7
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M2:E^MLM_]WKR>G3SQ-)DX1/$%O9.9CO&%X^U7%R9WUWVNA)KRVZ[?O$O=R1
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M1;4B^!M=&QX:K[KN54/P@C,>I5D#Y<5PF&XF'M!EQZ59(LGP8M3=Q!%Q0XR
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MPVST1#GZA=4-^7[R24A3E+L52O>",H&*4T#>/5&-.T05>SW>,EVT=XB].?J
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MDS[F5D5*=P<KN'^<'Z)O3D9_:'G);VA!GGV=MF%^*]>@"N<RX'C@KI>SG>K
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M8)W3@X79=@).J6Z!Y5L$RG;(K[O3S Y*?AI*LA'9%NT8D%E-?%_B:(]!P=Y
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MOJ%)BG@O7$5RC=DU8'U8W^+? PU=F41XQM6K!>-U$YELC8^4;C8"PE9!M&/
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MSP4.[]/H3\]1>@_,T>M-GE^=_S#V47SU4$?<H_@[#R EE*R[ ^1F%8KY<]O
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M:=^1>0O?@,]BTV8U-#440]-YW3V6\LV<,9)/#[FY,_+B4$;0^OG5[G-T=F8
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MRD;L-$UU)N*1>,K11W.PZ.O1!34P@\@MR=J%CJZVE'<4C[KGIMZRQ2^0I5^
MV.U^MGK.YJ]/.E=JEF-%7R5>IW>WWJM,/M.J=R*('P<DRX^M%_OG31-,@Y0Z
M(:VSUT>^S/2^GV4= 0RJ@DP$M@H]J=N)6UTPJC>[I!IE/+7U_2P9W\.[HE\[
MN&3?-;Z%N14]:UD7')S4&5E75R<33%)M>^=E*E*E*(-OQ1 DD1W6%&0G4=RR
M?LX;2A&>@>TXK^*"Q!3CU].SQKQ?32#4WKWJ:&FZ:!?L$O<F[N0)8+XW[UB
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M&AYG6(>'8&YX/S$)_^.T1"UB4+/=:RL8LJK-#^CG1RX1V5Q3]ES]V".&#OP
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M:(N73A9')T&MJI)VS]7MNTU5SR'OY,WW]G\]*,D5'Q.]2HEI 9AZ,1:1Z*S
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MODN*YP2KQ<J_@?XA"(UH@:C5G;ACSKRX6#B6]V^5*Q-5 .Q<7R!VO:AC1F3
M(,JTBEYOA?:VU5;%"1*;*])4XUF>6>:\N;0B=$VITTT/283UZQS!K"E6ZF](
MQ,$@V\.[E,W?2O4JU=ZT8$\X_',/(8^#Z]G$V;N <U--R(/(77A]$#J.%9N>
MQV4Z)]09C1$V^87I4Y;$W\\>(K_LW=WC-K*TH;8R4[>F*E1[[J\MS])=//?Y
M=_TQ1%7JV1Y^*FG^-O7M7S]&]ZT02I^K[ 3,[XXK[S4.;U;,;GB5WQ%1BNI&
MLA+.2'M-*K8*[I:\S;EQJU9)^ZH-_55*TR^L6GF=SCZ;AP:Q. 8;-IO*&VWR
MV@O,MT!C21"\U!AI\Y1!YG(BW)-3MADG?I+W/2[0TT0]9_4B,RC;WK[R):-4
M^[+30W1),2?Q\(E+EF+/?Y\>.29?3)T60C8)I$7W3/Y4RQLUZ]:3O,JNNAMD
M#R5_CZJ 20VV%TV&.((^YBF(UQ5<\Y$?XF^4M??&*3!?6[TJP_#'H#[_92=1
MRYX_N4-%$W".Y4NRLPEMD8>9"_.2H&,3RSRW#$Q"]LU=+6?H1BB=K7SX\UPO
M]@5YSYY*6F6L%?EV .UF[N,8$Q@O:ZE^+=/$"-W%)D0)(3OX>P!HR^&!PMQ;
M!: ?Y\?27$]KQ:#VQ1?SCK.^6M2QJ',5M+KTJ5QKY2OFO#5VE&=LA+Z.,YC!
MFVE"*D3"P'9V'%&7V<=7'J=#I[UV O(DY;Z^Z)]3F>3:P4\8["SYWK)]?=S-
M-Z_IY9E*)9IO<FNJTD_DF<,,\'IK]T3"=S1ZQ)"GT#(JAD-Z50)"2//P,>>>
M0+H\$NQHJ4DOIPZBEPP^HQUPGR9FS@6,BU,=+S#AIIS:06HH]GI6:X,J4X^)
MK>CTUSYY(FTM3_ 7;OU2[MJS/0"E#1%GLJ/F-1C$"["N9BR2Y*:<#!_ZC>RL
M![.*T)D.*,:0VK>VXLM7.:.2GOK9&(G^U%;J0$3ZEH$"EV5_P@UKK)P'.:X1
M&CTJ9[+?-"1_V$_>2\]$JI9':N[&WP=0*[:?:./61 F/I*0IY\!4ZG.6"TLJ
MX);)4N*(_7[>]T;H%YTV(:22V#K3F]/.L>#J%*#HO+_Y9CS$_2OU@'ULA76$
M0W.34\JTHGD:1WD3<K,^E;TJ3MK:'" BB8G\T!<X<X3,%#"C22$TG?>M&KW\
M?O6$H(NAS,!O!ZTU91[VX.&\I_?#?K@N/+3ZSJRW9'ZX.:U]:69\^HV7UZB<
MHV1LC'7KE#7TE',I]6,A)9YB-W=(\@7ZETS^TRN[^OMO_HI0T\]?Q*O!G0X&
M<O?-.TO%K]#41S63DK>F24\X)@97=7E9<&T!Z.P/W-U(13R",:<;>F,1(^X)
MM+!^#$XOWQ#WR[0CC1EAC'WBK.,"]>7#1N]C-RQO&!Y.-TMD&LWP NP_7^/E
MXRW6"O24W#O:*L%P=L#8H,X6/+RF]WLOI[I7+&XOL/&CUT& ^FWB>0UF^.O$
M8*M^2$AAC^N^B)1XQA#]7V*^W#>Z#!ZV*L_?F_I6$]!D(QJ%$"BEQ3[>1 G$
MC)4,DJ+<_$LH'OR3@'?_DD^,;GBVLS4O/9^"\YOW[*4D670O:H?-6+ZNZ<-2
M*TK"?X9'2-:U_ SC[O_</';S;V*SX@Y#QUMATY2DE:^/:%6&E)T#.F'3G%CK
MN-IT59G'5]5T$OK;^B@[M6>G+C7DB\'FSA;D,]*HVV9LP/4\,?MZ6Z?E9D58
M4E#!5D*E8,^,\ZC4XJV]W+V^974!Q3,_6.^K376^"#ZF/-W\4&\=FL7UK]!4
MPF&T7@1F6;L'2C5B,'K9]75'RK:FF(KON_5L-OYY_DNY;_^O4J%<*U(NL547
M.%YJKIK!OEARH7B'$')/.J/\W@_*V<S*]&[W6NC=1K:,BX>Z$K03,-0]X/AH
M"?R^(]SMP?1RL5,^UFDNK(XUDHR5Z)>9K@D\Y]ZZ[^?9Y<KI%-.MN@_?S5YK
M*KA58O2*?4$:)V=Z!B#$U%GEHU3V?L:;YD_7J-07NJ -]8N]B]QM?8I1;N12
MYYJ(M8(.]0%,F;9&(F>+&'178C,U5)W&4UJZRILCEJ!7A)!&^KT:N[@\5!6K
MLEP$#U"^$O8R!>4645$5%K.X\!.U=S]&&[,W/?S)M3W2LL&$1XK?3.3Q^FM$
MDR,BJ')NA<70MS1(X(CL_@=\HT(PM3'L&ZDI>[T5K9=O7.Q>RL+T-60\QZ%M
M>@,G<_[*O5$6.*.9=2/T**MI\MRE()C-;[;]3^"/2:;)$5XA111+G$@<8\6?
MYWE]W,+LLH%31:SZMI0( GD '>Q4U9UP;$._FWG^U:+3R1VL8=/]O]QHA'^F
MQD=P,?9O:G1.$AS :;R%20HV@:FM"+$Z,PK.F9.6D\:C-]?"]3@EW(/&9P=/
M]P;Y\(8,_7-+65,8?Q&W&_0O*QZMKT\OT*(<N&'L^,<T6[560A9"/I]M%D+6
M:PLAX+=KH[B.IC!_<AY*0:#:3=6SE_9 NDWJ'YO6?Q]0XH'*Q*]4YDH^NF[S
M<2D,0VWEOD4N!@/PY#N:G_XP*L=A4KI=7^S9R!9H-$)"L(=O BJSY^-ANX+J
M?9I'-U>(=T6O:'.7$Q>SY3^,S+C1&/ZE<,UP%#D+;31S\4UU[XN%P="87J<.
M.%7CT4F3)D%?CQ RJ?9_PC_QGZGW_1_ZX@^*<__ZGD6"'.ASJB?(-L2U?R'9
MP*);=X:+=.I],<_-JV L=.JSW =79XIMLJY45E3$NB=\Q:8?S[\.WUJ]C98_
M9"K7HO@B6^M8ZR[>AXS*CP^;CVJE6-[?U[PO_L-D<ZS#YK'^CTCINHVKBGAU
M!AY1Q+<!W7F.S6X6]^'>[-$X0[T1,J_L9!VCK,YY7)/"J)!46;%&2'H-3BVQ
MR)_1SKU!J3YY)S\5%R'=2]_3-<<J8U:W"SX+)$P0H!YO?JPJ&:^J4D9@_](S
M0L8HVOW-7'GQ.+VGR\?D21GH;M6',1WPFEK)R=9E2K&F:]3)Y!FW"U69YN3+
MX3?7+5;];ZC'HD,$'^S IT\LSMSX&+9I7Q7MGON3X4A%T,')\E(R.2W]>(5/
M^NFBTM/F1-44FMSC.R>-CYT%2-&+[_5P%42I259TYJ97M]AK*.T@<922#9.K
M3=4Y%-CQ<M]:WU?YJB7']^+X#N6/6KA;;J.L&N3:AE($[^BH$/+ N9DD'D0
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M.3C8.Q!&XK(;E3!RPF2'T;,]QTP)WDC8SY@Z9VG:V&D_7;I96NOHYK5),_W
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M<MH_89P#^V_LPLHMC'])FH''&<V,^:<+,IS=<CB;S0R\0 J)KQT%W9?ICVQ
MWO%])L:Q:/Q3<%LF.2U0YBZ@*'5T8P<.0)%8H[_[2R)Q)SSQR)[$>"+"SJFY
M!%CR(]Q=$U\U1%LBKSI][U)WG-5(Z'I$PIM!1L\A/WF]G*XI>^!I X+B6X@L
M!98D;\_(-Q)-WTMA&S ^1E.Y)]AXM!.=F(SYZOM9Q&66R40+;"#P=%BB*_.
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M^KAJ,D(P[4B)3CC\!ZZN&Q/[D]SMTU[YB8:SDR7]-D#5A)<G6HG>FH/>T-,
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M71Z]3$D]L?($!;H: .5OV;R>F">:RZY&8H6NG)Z?A=AN,W@^T&A?(4/Z1S6
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M&(8R&W*Q6#?5SS\[^Y("<Q(>*?UW_:ZBX@9^4:F)C5M5M_>%>6B,)=_@YSO
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MNJ:'Q\PYRJ)XYLLE+BQ_9MSM5QG#9*UN .<()>=+<NOH#WL@D=./'M(D.O8
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MN6R>QE#U]0_OY.*_JEZ82'\8:[!(KL$RG7@I*2(&=UXDL6:Q*9"4J>F'KAN
MCNL3UG3493]])7L2&@SW1V=KYV7<BGZ__.:=Q OCCD77S3Q%[Y!<9=?QPQ!9
M>O+D_-Z_3.U.>U*35/ ZHD@ ]@5/FU3?UO*1=8)@/_!W,FN^?0_Q+%E#@SJ)
M/>Z<Q6RWE*6F@!Z!8^*+_LCMUEDV ,\6C3]$\:SE!VE"!V];_5,\33=[H:QP
M@F;,^5N)TOI9.SX-]+Z>X.7;QT '+TDX[=5W3XM\T&2,!8I,C/KMN6/GZ:TK
M'@:!FS'6TT+B#621=0'6POW6=!$O!Y^?3(PB1;7?,UR^OI.?8PNS\AF2FPCQ
MIR2_K19055&VEG=]WZA/?2=I]FF2NPT,.(];:&GG6*X+(,+(LEX&+R8LZNQW
MYW[!71LDXD1PBIA# ;*Y]CJX-I#]X9/?S*KCC]E>JAJ\@K]!9X'/KO9&J(3]
M_K&(H$X'U>J@AA,FF7@0XJ7$RPQ(L3YW1\;\TW&SX'[HIKVA<.S^/-$Y;!^T
M6/!V6)Y;VI>,"= C#^:A?>;:"N @9T]L5YI2*1D0"'2+=-F9?B*!,LOZ;W5Y
M>4>9,RGC7XOY[N*2A>(DW"]KQ>7;<\F6F.P"B 05@=\"#\%WNT42*>(%8X*G
MBIL[=$F:^F.CKUE6R7+P+M_M7-NR$KS*OX'E<"RG/HHY GB/OG#LG?_:/[OL
M7%E-I DE9H-JP[_VGN]]H6Z?QQ#S(''J?. "J1J2$"QXGE;L&+JI1XFFK8<%
M$O)=+*[ZWXON]J]T$!'2B:D?H3E.1&3XJ5J2"M+$[>?VCPJ7]G#6)2"UROJY
MDZYG6F0, L^!LXFI\5.WI2ZL'3\Y\F\G!!*9EX4[5YHX7PA#2I3&3KK]*ITL
MM>I$9J&B_;?7LW.<9$Y",+.G52>L H+[S&^Z.* 4P?VY]<L#>P?I )/3-"0'
M4>;WIYO=P0'?%DJRC"M_7WS]T%FZWFE1ZL#(>D]@G.$K!/RW:Z<MC\'5&5US
M7U/W>27$RCF1*'OF/)>U-%;(?OQG\WBW5U[[N!^Q&\.@V/61G?<C,[\K3=I/
MX538@'#.$A;ON%\#*"*WXR)\+W8K188$8()U<<W_EG&/ >XZ:N1[WQ9/E1B!
ML?)(6?,S':][]T1?14Y'@IP;^_5$=.C?I/  &;4#+ZH$U&LK\M][,Z,JE]2*
MUG(1>(_.8C5^X>N^).T@A?DG&QJ8LL!XHW*#X[[,85]2D)-HHPCW!E=HX'OP
M<S9(K@/[K*VCUF*/H9K#==@.-B[$S3X"G=;R#9B,)6RPDT-"80\'JU"FF7)+
M)^L.X#(V QF6ET2NG7EM4=TI-S?T T2%8,H9SH\1TX (M\L47U&1GX6X.6C&
M$0&">\]KT%"YWYPHP<D@41CX,BM;RIL>OFE..8K,LG1GB.@B9#ZP%-/7SQ\U
M_L0J)(W"D,!X?K:33A&Z&!5//#E'(SA-R)&7K;4^EZXG:VMJ2%R$*Q"59TS*
MX<= "JFS4=F>.BN7_)$L->()I5]S_>'[K!4WOO@)>:1*$HM:Y5>_<P@G!3I6
MOBUW_^<@%D/5I56I6UA1 /KZ=J5+<B1"&$*4U]O!V/M16!*%:>'"X40=\IQC
M/BS'"IZS<3 Y\KE<<1-[*\:G$9:;6\>\%(?%<#HT0A?Y38HE.S3\QPD'$KV5
MF^\3'S.R>;XM-+>[%A?..NZ"GW8^*/IM!U>0[1\_0*0-A6Z95#=M<YV/Y6>G
M%J([][;8+:U62#X#I/!E,=G;EJQX<-V[:E7!0LX@I*<NF["YPLE)*<U1YF)'
MP*.0:4%"/<T.86E#ZSSL%=O]KU1GH->2DPZ? F5U7%:L4$+>$V%I?%NYX$[T
MFSW0R_L=*&2O5"JR>2[Q"-]4CA///=,B;8 P%\=5)#0B'BV]+\\+"]4'&NWU
M"GIRW74$'I_;L.)(R9\?^32E#MV=X371-=T&'%_M7?[E<YA1M_8>.!AIW7=$
M,*-ZB@GL]3BG+SDNW_G.@UI?; ,.=D;"/&>7[*5> POTA%KP6\25_S'IVRW?
M2L,9D5T<<4??1/:5/AM0)AWD]]!322YOD 7=J@6#SZG7I*K,AQ3LF;XENM]*
M62I<?]41672GZ["$@('45[_4:]3]-&0<'%Z9%+CZ?$W3-.R/G"S^G]LD=U1R
M-"HQ\/"YOQF^?WUV//G5J!N$_,B:[6#GS!=E_3SC7<W$IRFA6OO5VK/7DGN5
M9;V>**^'LBBU+RIB;L2BX=19&6=J'4P^%P31X'N>$)Y,)2$+T&O5/^[JA[^)
M(V?@HBWGTX!D>X1UC0W8TOIX0^+7) +?2?B47PT>X9C<(U,#]VNK;4 O[YP-
M./P=[)"X6T;BW^E,U'5S2WJ#BQ1,[5SM3=UOH2[=HRH//4E)LHYC-X)EF2]=
M[878CZ8\7J+]"PG5_EV@9X_@R9&^4X0L V'6#(>LOO@QU?M,L4.R%X(*2&7N
MM@&GJYW0^U2WQ+N[$P-6FR[9@+'"\W'\4KDU>4VC,ZFR>Y_+R57"71+3'6V9
M3* Z#;L*CM'M@WL6^=22R^"SAKWD6B.DF_HM-\G]9TJ2JV,+[9X?2M=(D"FZ
MVNH?T7P]YZP_^66,:7T*^:%)B,T8S7T0,_%V$?1+SZHWP:+7?O:SX.N3\S/H
MF2.O "NUM!<")VQNBIW)KYM,-L7T5%R(@P;I4SZ:3HIVBE,\H5[(G#:));S9
MOP* -@@TZZ595-#TQDI*F6/Z54M*WLV9%EWM^DOEXS*GEM8QM VKG!R&91IK
MT_K3214SI4/:!'&V;P,KM(+O9.!G"+IAR"&%H?$RKC5%=!/)%<:8K$#//\K"
M3] V+!'TJ+(_;/^TX5/P2PQZS\1(&%8%7@&B<. F2<B<H66[P_")H\+MA38@
M]*RD45<O"H,EB.7@5I9+R.<]8]V?X2S.K]2C+-"CU3ZDQ0;\; ,B$6MD"<T[
M/&X#T;<KHE43VQ'G+'L;;]GT9MJ\?>MD@7&D3V:PB?*LT+YQ>.2%F+7&Y-*T
M)4[]=I9X2_8G0=C1D=?0KNQ9\7GU=6K+1'\2L16?P(U9VO;4B;/+U;#.8!@6
MM3WX%U_^\6]>A ):<AHM7.@AQ3+QXPI@>R59JR9<RI>[4C/31N;?,+)U:SW[
MS]8MDF(#&I\(ALPV8/UF!"/_RA:L]]:PX+18.(Q"J!"4L(/8TGVX16QM7=X9
M@?WPN 6P =Q+,C#L=SLE+OV:/8(E@OWJLT^HTV?ZG[KTL/]+V]>OFE&A!T)O
MFA^Q^\V/F)*>4)6')K([M ZZN$OX8OUNV<QZ_I0CI!_:J5T/=G;JB@ZCSY08
MY(_*<4&\KS;F-OLE/'KPD7>SV]HWI8>-U4^=A92PI8G#E%?\>F(7T_6DR*A\
M&Q@1T0U-.;(+1)(F['YQ"GJ_:Y](CC$W$-2"048/[1O$!RV@DDT!-9..T#O:
M"Z$['SNY/'[%+T*"2U:^I,,K)-FX&WITJ>,2]X,!B<T07S#G&6.J<G7=\C-(
M",%X-2_FE*/_RN(_]J6UGO!KB!6YCK6P0J9]BK\WY)N/X2FS"*X <\6[S3R,
M[:M2(?=%!7T0'X,E(_9BHL'S^HIC<M)UD5XM*3KB7#1T+ 6K3-"_$@[U&0J_
MT30[M'UP.DZ@R1498HW\_8-UD;5S *@%D%<8]+W%(UNYVKY89383]1RN$JQ9
M7:2#WH9G5Z4I4$:K]FO4J-?BL:%JO-+\9(0TA4+\/D?T\JH,UN?K\6I]&/#6
MO5&HM@%M3 /B)82.)]7/I:[HKH QEB?R/%MO9Y9VWZB$NS*%&M$GT:QL\W"@
M5:>^@)+)?TW-Z2+H"&0YYX7 !YD.@!4>V3'K/GPW9TERUDDJW*3GMSF/B,'4
M!>8YT70W,GV(N6_R +,M:8,94G+"*B- &L^5F;P18?D)$18#YNV)EST,B/1.
MBB"%7O:44 0BF3H7*,,J$)D3@K(LV$X)'&4#5@YYJBQ,-LP[4O:E3LG 0[\O
M#AF_D2R=;.0N98C8!+\:8TMRY 4@)&&\9T96;6S^WEUQ(CX@<UWJVZ=9S0M9
M]GL;6X;.&J($";N]3,3CAAX;,)VZ)'%[=TSZ,O+D@2?;?;ZE9B1@UX$^NP_Q
M!&?7THX,::;)V;H%-P?6: :8.NL9Y<\D)%'8:FP&6-3%\RX.8O&_53A3:DF"
MZS*WBF6']LOC4R<*Y CJOS5Q_]05QX]3Q<;LJJ44=OZVS(+/;*I4CC<:>Q_!
MHI;*NDCPV8 (_I,H%'F3X Q>%\HYGW-+YT^I_P#!0]3*;2FMYPX,L9Z"314R
ME>)]JGL>NH5Z*A A8@+]L)+KM2;E',3@5GEU=56PF5K3FYE?;[F!4<L_G%@9
MF\60<'F\1W^<'ON+W%T5:)0!%F@=&M ZR@;\9P_T4E^73(0;!&6D'V)"O5;-
M'AJ3]-1BT"MR+*SDMCH?>#)2@^V%[JE%W@#T1Y)4K^;4(9X8L\TI,G?A^BP+
M\P1%P)OV"/NR4,?-]$5]1[9TLW^,G39UO"S;WR4YV0;DJ(/&K9Y_=N/E8&6.
MV(W4Q_CJI9!,)\"JD>_D_P6_NCA,J?+"$O7X /\MBH/E2:=,N$I7*E79-[Z<
MS]*ML'(86.S;"!X4YM]Q8>%*PET$%+I6!1N409.(!@E97GK+*86OPZ^0\9FE
M(]^;%PW?A2MZT"A[*MG?.07^+%+BIM\0NVUVYM^XW#4K1SP  M5=&'FAYXTW
M-<:,L3MQ$0TD@7JM91/QXVH_KVY-DD'V,%8,RI_KY*>L5'"\3-< MOP0R)^W
M>7GH;X0P0391)K(!#U.]=-Y/KGZ9LI@WL)J:\39K'YO^6T-FWO+8-".TATC?
M UU:NWSVQ6$R7)V<#\$M_]BDU._F<H^>< +?3O$S]E.8$UDZ_3)B0: 73?B5
MX$9AQM<VV@"RW+LT!5U1:?_0\Y6ZIM'%*M,7;P$Z&',WD&IB#?8\>@Q=<S=%
M[4OKBQ5"&RA4GH1W)VS.Y)5!E*40%<YF;)E'34 J6;D?(@OE%,ISB*NW.^ L
M0.EB)+1W/J[#^$<AF4 DZ?+]8^CH+5J _7%_N854X&<8+G9IFJG=K1OYPI6#
M5FUJ=2#1U% +$V5(!(H+<L.Y4&,1+!Y"+,G805UJ-(2.:U;!PH<C8RZPWY%+
MKE @6J14CQLY^M TNU*?K[^(G/H]80D'>^+;^TQ1OF#1\@56Y7>N*[_(;I](
M"HR;FS_1-$O^-OYA^L91'P%0UBL'(ET]A0J55.S+CXP\07TC%TGN(@'RBO!8
M$;0&T#A6^QW>@+.GYF'%<78'N^.8K[/PQ!(_.:>)*[@FU6R0FG[<G@G]PNB.
M)HX++HALV%5]Y<"QXV>I=7?2LE*]*MQY>TXMLP8OSCMXG,?]>UST9<:E2_GY
M+@>9D3H5_1JY'$*F2+I#59$RUO_%U)<X))6W;1]'D[%%;-=2J+')9\9*'2TW
MX-2T6&-I4U.6F5169EIF6JYP-)ML,<AZRG(!FZ:LS!AS+Y7,!9M2+$Q,5%!,
M)$1!%MG.X3O.\[[O]_P#<,Z]7M?YW??UV]A"GG^.7![6_]D,M'A'1:7R&I()
MM$S:6<I/3<RY5X:K-U5V(V1^WYD0P_AR,U"V,@\Y( C4"D\SBE&P/AN,IL\Q
M;=5%#4XX)H5LZZH+@(O_E%Y/UOJ3QFPIM&VD.A5_H=P/VWQ]?BL_Y=+M/]'&
MN>W4&7#DQY@R^$) PS9<<6;CPB_"\L5C;P?)GXL'W;(:%DI#%OO=KLI-;ND?
M2!*II'0J)3B<>J7\@[K$O_1GR@I*WI , ?T@^N30S>95>Z\*[PPDFH%+.(<(
M9\3X_A5Q=ZKL*[0:19=AP9_C#S; ]Z%C>/H=T/[<JX-@H(X^>,VY"(IFC@GS
M]P.157URTP%:#8JO*[F9IA^,051!-V1+]8B^:/)1Q+Z.U6TS^3_L'S #QYFZ
M7[Q6SV<-.$AH_1L,5!22-FZ,A8Y 5W#>.E AT?ZNXSW2!;08(J]XE<8VA>,J
MB.>"Y?>[YO*)?ZVW7#',9T*-@6;@&/VSRU"\R4G)SFX@H;;(5ZY_\5%-QL@,
M.T9!Q9VD"$O:3_ZI"L_6J$+.L'6E<2OU0^8@N9&9#LY$G*.AV5YFP"%)H8MH
M2OFKCMM#6$,D4MBV%TI&R14AI@78%C]\BQFP#DN+ZI2/@T=71\CY>0TEK0_%
M]:ZT5R_Q=X^J,:1[+*&>+<HGE_-;B+.TU$\$5_&BK@KH ODSL\=0S]R1&+N#
M0[#,20_V<:ZV5_RS/..P8Y#=:[FQ1IG1!0VFG409BW?2T@J3Q#E[F)8?XDOT
M;$FPT+MAY)^,:,0V;D*^/S%@JULM-L9FO@QH8OZ>]ZA\Z."1<17R?=[45;#,
M5\I9@>< AQ30;C,@R@8K0EJ$O2XB,BU73*LAQ [1+703NQ6-ROI"AE=]O"_&
MRC8HQ;(ZV]3DB&Q'^J R+@V,;(]$NUHZ=582OID!F;[#]U0SO!6;F=K3]RAF
MP-U1=E?,R&2EV5YB'V"+KD$O)#3PF-MGUD[%5',TO%67V1KNC/0:O_]2;$IB
M! 6S7"Q)PZKU^#+W-S'RTX3L,*&*D2S/S&@%6<5>5;>2/R*(<&S*,>YDDBE%
M4NPKY8]2Q>U=+ID("63X=&!UCG8G.DD?M,%"0[S!@$:BS+ASAO[1W*W^'0&#
MV53G]"3\HQ_2)ERG/.-ST'+S=5BL(8W4[6S$&K $<3%;)^;A&BK^&G)LG![#
M, -WD2SI>IM5 R'CV]H;I5PQ X%].X@S3NQ)0E&6JTDL%-BWV&WT17ERLH1(
M>25AQJ2JBV8M2$:$T_HF-_YVE@D%!FT'T9#P^'">#3N.SU.(#&*T<1&6 *5>
M2 B:YN)A^+&6]( ==B8 =S&RDKH>$1[Y!_N.!YNN19F!!SNI^ZW@;2S^A#?:
MOO 2MEX[PL:!HB(R"E!^?X*B_3_#ID$R<_++-$@6L$,!;:QNY>GL<VX]J8-5
M6:5?<[U_E@7XOB)F63K3_&Q]3"W4[50^>7X=9"2:XKL)6*-;</R0T"[J/*2X
M)5N45\DTK7AY,"LH2:*GN&J$B,VI8\-("WO.L^/UQCUMY>M"<BF&"'ZG^*:?
MAO4>*R@.TD5BY=N*-XCH<W6"3<JW9N!G)=WTW?F+,!O-L<>#/FUO98WB&[X+
M+ QHR;)"X/H*EF#I&V1+[4/HC;=XCMNZ$ ;N(S2,@M-NT=G@4NJ_HRY\>_JY
M!6.X#]=PET@[0V*_YS<*7T2.L10E@\=SBTW;=2$1\8/^UZE<Q&5=(G,2?B)Q
MS%;+.L^-VLZAIC=YM9*%C:=.=9R%PE(2Q4^*9LVG&GX8<<+@>CAJ;C#79>%U
MKS>S8K\SQ.IRK[E5A1\4,X*W:R26+/%;R<^3)P@/;*PE\H,S[COY&^CAX"^<
MK@I72N(6MJ*TL68)9>#&JM/C\+:WELSM# OIK=8Y0%J."!04:\FZ0B74@I]1
M-T-I'TWU49RZ5Z]T>G@/''4\-V4B@DL4L590XQYV9/ 5-NXT"3#YO5 Z=;.C
MD[5N<W7E8V3ECA.DVF6BF\GV #:-_X4S)C-ZFYS@?#0I'[,="3^(4IUB=W>A
MK!C;@A?@EM?5F8$;D J/-'Q"J9$2.QB>970P;=&E@V@-9"O8#3YI1Y4KGQP3
M<ZU"H>9WS8BE*5C? D H1<2"HF)\N?=U,W!BJ1GX7-[T4E2KW/'\N5=@X/,2
M:K.C2.S#=11G'TVA7G8XGO7;VY%>V:(CG>)L:+&33QL!*82NTC/]<IL* W^!
M<TU.]W5G>X7:UXK8EHVIR@OC/.3GR$ YSUFI;H&.&)3*AGS1-:QN\[*J;M,9
MK^ONH0<'9D>E:WRM$AUI?G9]F6V85L2&AZ:2('9H,ZQ$VJMYJVI6JJXA8N?,
MOJ-G*"J>.K)C_C8Z2(-6G9=SJHAZ5AOTN4'%,7#E#Y489#[L-M;;FOL >A2*
MY3I7H]$61V;9Z7&G6B$LFA2,!CWJ_+ESGJA@:IVX)]N 4/][I2-ZG4/SO+MS
M7M<4?+/CX7/ LE9.'_TI9<^]AQ=B&B6GUO6\E=SJI!:^2$WMG$'W:;(C!02_
M8X;[F0%2?]3*RX&+EE^,_[I>9#R*$*-B8Y>57W8PQ+<&2/0XW3.QU_QM.6FS
M%SO37]R:$%K13*(;OD78V^S38%9>9#/^,Y=C6-A86VW<<<<S*ON.I,#60Q_?
MZA>"0CM%$/:SZA?='L7S 6.@<ENWY-7;=;7V.XG)&(8O\#S _ZR-@:,MNGH*
M%'E?'ZQ>.1)_U"\[K@/DLL5AX-BOCV"ZZ$[>:5N7EX1^PS .?H7G?;70M!0\
M6AHV(+A&)D.\"_Y0>OOJ F&,,4#/#=<9/D'^;^\,",$HC9@O-!FU"R/^GCP&
M<_1RA*(K^N;$H0MN0JZ,3F6+N;C;]_]'!\+V>%8?[ ^1WP\G>C$2)T"I4"I'
M</"_ON&,LSMZ@UT!^ZWX88C))\YP0RP_'H(>JY)E2#?XBJ_4%'T+QLVNIV&&
MX_61^J$K=0B$?V<&^%-1W[N'3KI'$HFI1]526C\W],+\874!@U$#IVI!9@I0
M-IL4,KU!IN37!QV9=TX^ ?N+2?TIG^(D3>];!9BOGE^MUTM68+MSD0901!ZF
M$D&<&J!.F<8?(/M0V#:%M@'JP7K_3TG!MSZ>34D1:R9Z$,I73L[$] CP8P %
MZ$(9C-)F(3,V7$/NF#SB3F%(! 2((90\U;NGPL4:J90IZRY6%65-X4QQ2)SA
M7!&P _QWFH[HJ5-KAJ&;)P1FP T'Z:75!JA@5[(GQ(W3IJ6FP'Z1&NU#N*6
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MNL^>\8L7.N,TA!4;SVGG6F_Q9'CH)3ZMV.I00)_YAEW&&9,HIH8NE2F+FQC
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MV8?F=@0#*4KA\QG42&1@$623=M@8&#6P4'=,-+$8>WE=.NJ@B,1!Q^N_F('
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MDG53']7Q%.TK4&]M]U.2DW[,UX56:9J"&I/ T\SKH&7:](R5I<[;&+#C@^8
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MIC(I((?JZ15_%N2IB5PFCIZ$9'E:%!IV=M6Z%XV_LRTN_ R3FG3> [')>PY
M[1[!-+B-/$L7K04344';!^-$."L#AJ4XG!T1(WP8[[V:?]W3*]@$..D> PK:
MT]E^W]A78QT@,_CX[W(HXUSIBH'=Y?KE#]8"@-J^<"M]>W9/U4:M2Z#F2YQ>
MA^(;?1U-Z'(N\(?]S:X?SSY-'L@Y5,G]C2HV0Q9<%47=V@B[HA'6/,5=+M9'
M0I5D)K+4P9/*5QB^(\^DB_?#?8J#@4::IU/02\.OJ%J(VM=^KO666(<S0$@
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MF$V""<&R4&C,+X=B4RO*2M:H#3$D"Z35!"RUY\5-+AAGV2DXUS?5D,V:Z(K
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M3+K5SS58B)'YCE\WJW,X>M+;%Z.=/;!9/@5?HQE+NNWOW6P"^@3(_!)Y^?O
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MW#@B./K0Z$Q?V\B@Y<S;(NJB@6CDP1C$M?$(5F"Z7P<,HXO.,;2R*G"C)-2
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MSFPEB3_$#*Z86M0PC;>GL&T1)ST&"^8/A[ WR--UC6-IXO>5-CJ@^%8UV+6
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ME4Q7:_F[V <K<P&1?;_C?_:T'\/-B62ZN("R+SM,*5;73GPUZTJ/*"VJ@^/
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MY--L":N+X"^^B"_GF]<."S1#.4$T&B ASCH>:>93I*FU#T:=OK+FAWGRD/,
M4S>9/Y'V[B-1 ]6/!N34\P\N,'5K8DZ$<S3_A*EF&TX[S, ##IGU.O^_X$!5
MS6RK0"0#G&ISTB1<(?TWBYF@V4T$-? .XQ>#I Q<G0J,X7E0R12!OX0#=!P
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M7M?K\[Y.GTLZ*IT"-$^X>;@!,C(RP/F- TA9@,O/V[\E/YW\NSYDI.V UF;
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M7)R<E=@CD7U*X_A@4Z0+'0D14 @XQY7KWVRLKP4?[0FX06KY%,9)2ER!K.=
M_>LQR.U"AX5BT0$POZM%0HJO PE!S&1Y'&3$_A/&;V@FL8:'.#?$%]M<>13A
ME%MZ]7M0, K99]\[Q#<?>&M^YQU>*WDKOF._>/?WWBE:)LHX6?;U% 9E/,=,
M*.Q8U_$6,M.2-6TRDG>A)..3FE 5=G3J*G('<X$'19# N,65=O"\G:/=VY=>
M0G*;D;G^Z< Y0MGXZ!I_@2S:A@L#MXNN@8/=X[0N<GJ)[0>JI6B?^.@ -$;D
MUD8M1#JC,I'0 2D0UJO2:2(/9K+KPAEKU*)Z@N ^<XIXA^K)1C>=4J3[!<)O
MBQ&58\@YAY82VJ/I$WI?KI MOU?AKWLL-!4,KWY;97G*KW@IOR8]]FM].>Z7
M8$%V2_X,%C*2-]J%_2IV\A<PG2[1$M0]+W^(C9KT&2);+?6:;/5&C31NC"(L
MQO66WWZ6Q?LJ<H135"IIS#7]OF1NY(V!N.=L39N5,#T5I\A^B6>8V G5">QH
M91#A3A-J9(B/U,_IC4?EEUU*.*L1\VANO( W=)>.#@F5BX9TOWO?<"S+<Q^Y
M8\,_ON,0]?I4].CB2C9H*H1S5Q=$G"04A\:@C7$Y,W>Y2K&>J!3+:K$9,UGE
M"/>E6;>3?6V;4:2^-\CB1J>M_=/"(+ Q:DYJ*G["AQ]*"Q'4IZ*-J=PKL?HY
MEB_1NWL%A1PF+U$PV)4PT^T]AN)$M\,5<(>I(U0T+$>PR%B!J[19S<?#U%(Z
M:1'#$I8(BC5V&S)FC(<5"U6ZQO5*+SX&-8X/;V\<@GJ&DB8"WY#4FP*')S[D
MMSR-#T2N1O%>,B<</9**G8(K^/&A8Y-5P?[5Z[9@3$^RFC"6F;F V\_)44%2
M!<B7&#9>'X%V*JY;:C,6;OUV\R%8V><RHJT8UC!LC7/D$-3G3Y\+DFO&J&&\
M_G%_^N5 0K[5KP4'&(9>!OI!U>V'S!P5Y;:87#XRB_E1LU$44P]\)/UZL -"
M9GO?'5.9I3X9[-\K^1^H5[B>&BD>0MG.(@4*UR:=)D=U%-GC @1)Q&SM/I_6
MHIXI?A<\?8V6VP9@6ST;6ULC_;O:MB46>WJT&J$R..L1ZT7X$.\TO#Q5A[-N
MS)C8*L!W11MBF=SP'IOLY&W"MM**CQ%&;10IH.+.(69!0]BC]C7K5SG?5Q;/
M"B938FW4P*,<MHFQ/DJC>YV(B0S;GAIV]BL+I*!9A?=YUUOKK&MY [-1/K3V
MB4]^- '+E)A %&OFMSN8.(*ON?-P FP7AI9Y!OM=1(=I"153KA$UQ<Z"4!Z_
MNTZ%LZLS<N=JY]6YD3]!8H>I!G4;31.F@DWI),165.5*#'&GA <+8O 500;6
M^O[>&P5@C+-K :.%5>T3-N _A4;,'@QA3(PI.210I/-LV3T9$F-L(CN<P=?$
M10KY]+Z;1I6%M2@,7!FV!=MZ6@B92:.JL2.-_9L)[/<I(>7F%.3>%T\6*W:7
M<O;._6AJB9_.61_]A(E:^[%L:H[R6D<%KQ454<1:\4>$<=GVA02))1C>O59K
M*D,])4C\=2@Z6?42!LTF:R.3>S<647QX]&:<_P>[:JI+?'0IEM+IAU=LY!L&
M%BLM]2N\K$6ZEWZ\%#>RPHK96%G@H]:3[9.-JSS1E,8O\S!E84\G7DN\I0&$
M/)I7F>H62('NOBV[>++<Z#NF)M20&&'ZN5S^F4&8682112%#"6I8BF6$#Y#Y
M=H</C'2NTN/ZPJVK:N[Y,FH_/PZ>Z/?K1_-=7CGZ7$DBQH^]K+]><G?C@U$9
MQ-D+)GT$O43>;BF@20U-J@-179 Z' X\4B$.%KA*&JX+B)QH.N%."R$#9AH,
M4EP( 50PE4/,-EIE\#4\UE]B%&_"+&>1VL.1D*93SB=+.N='F\C@CO0;]1+C
MB+9-_<E6']'CC 9N=&Z;U8C$(J)$YD,3S13DL#C$SDG0;T*W7[)KOFS5JUG(
MHZ1J&UCCW"A\3#07LG<^Z,/#)L%00FLPZ][96M=S!S\V^220="EE@9@G5]TI
MB/EX<E)?/W%T<N4*=?U^L@HQ=:TP V?).75""G#<N\F9"3G,FU!Y4[J&++HE
MO9N8T68.9B>R)Q6PZI#$+CH=J2?@]660^I<@CDV?3@0LB8ZK,C4L'<F/'Y4]
M;<W/3WR!B72R[C:5COT'4$L#!!0    ( *!0>ES#-0AZI((  +7[ P 4
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M*5V6I7X)GT/WXZ.&",GW+B69%QT=/P\]GN",_@8ZLL""G5_^EW7WOL&+#3?
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M)%CV0?*?;^TF-94GR'+L9U_@!VI*2 2')VZR"(\IT<_KC/.1BL@,R;.Z J=
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M(1KV\$0X@KY&/+:A.>-:)Z5?"4CFA-$,@N!61==RP4V]Z+!(V\,5W+G,J2S
M?5F1:<NRT*YK1'X0N3T0N9[9_P"XV,C(>-:K5*GV=) PG7,VQ6^SML5RHRJI
M5@WR%C@FL>EN:%C&Z%KJXDULQ$,+Z8Y;2&^9'!$N!$E@W(*KY\KYDUZM)+31
M4]".IAS2*A23]Q@Z=Z ;34'4=I2!#%9)5IO+X'Y/!%WJ!WMFD'H#YA![)5>/
MP+6/TRR.@4?TG]M:5 /52N!"<XY:,3-_<*D^)<MZZ564I5D' WYL:/4JR_Y
M N)$\ V35YA"6]1LMERHTO4,T0EOT4Y07=EZ\?ZFVJ2U/ 2%1/)Z0(],9;ZA
M&>^$BFE0 %^L IALI0"ZD2>A8%G!:P/AFV&<PODB6G%"2V7MBQ%JR8EI&V12
MAF$!7C$LNC2ENUU/SW%JP$(FT:OF,8$_7,!AD]F@=.IIOOFZU>':#]#6!9_M
M>H>F#5;R"LC#XG#_S0&DX$-&HBOD+78<>/^]&/0+OU"76_!?9L?QC_S3+]#_
MAS[^@[O9S]W<@F:Z3=H3MCKX_N"\ RL(XHS3J'/6 V4S@XM2:N"7#9NS$0%.
M9_Q.*%$KQ,36SJ 5L%<!2)-(^NHFHAT/PV525#(SJ(F?<RBUC:A- FP.IV /
M3L&+[<G6-[&8*&'9DTE12.Q'2 [FPC)SB?"[G722E<\-J$+'&>?$3?6*ZA>1
ML"*A)PR6R+BL5/\WJ, DH]J"Q1BBTFT-+C 0J59K!696)Y69/,/SYQ/MIK3Y
MYK'-/,;0 I N3-362MC8#;B?&^5L7=\P&IJOV0,_QV)41T<+KXS?PCQ)@[\1
MRI//=R*.N: 8,#MB(9-E7A=36PCC"S*1.[]%L(V25 %;^O8_-8W%L9:3YH:Y
MB6+<6T EK$8J/TTT3[:Q<N!K1)07^,'.WHQL,KL]3]/B0GGG#L>CO[.G;V?R
M>1CW8%QY2$3 VFHCQYHW-8T1I%3,FFCXX[PY:%5>^7A$3\DLEOR0!^SM/&HP
MP.W]9(F]!EX\'X 7/8$7SP;@Q6#Z^YG^ESU-?TY9U$309TWDL.@]'REGU:D?
M.%)9"#]C )YVEAU:$APE0@Q>?B$H#AC.DLKV'+N6]%>F&2!&LR5L@#R4A!(]
MWHQ*,+5)3AR*9%0"-(3T_T0(1Y'4+^6$5C@+=N8*8K[E/[#="MSHX3\LW)Y<
M7./S.A9LA'G/P((NI,T$[5<V)1<A3<#6SDRJ6CID.3=0E(MD95#BN*:J?!14
MCYO=JP9!PDDG"9DMM5A6D<GU=Z7!0N8]*+$#&6*S/'A,[XL+OTVF0TZLWV(^
MN-15U^><#^,C=W ?*(+N[DCV>DF8JJY592_W"/IX<GKX]%O5.40TTC_JGFH]
M*TT\P'U]5-9QDF$S+39!GNIV&X+'*UZ71A_A7Z29P;K['FS%ET2YN$VG27,Y
MZYL#-[W)7BP.!;D12$AX#I[HM))\=4?C>-O+[VHU>=1%+0R?]53:LX/)HUX#
M9(<3L@<GY#9@>QGOF_J6QD]*N7X@-N6N5=@%+FZ2[ I,:E$*#YI,1D6Q-:.M
M267?:/!!U*CC71GC@8<.G@%!FYK)C&TH9D-QM-GB%D@WKTD22%,EA*Y@01R7
MX48NS[!LYJ[K47';:SE<0=@K"9JE9N  .#_,4E>.1Y0;H[YCR4S#\V%$JSZ:
M)F0?;Y/);'FTW),:K!CZ(U?&)/LZCO:/+DXZ:IX7IN_9;"EOH(MOR1Y:MM/>
MM,D>IHV^<0DB,4L<*((6$KR3*3?!$74,\8G:Q#R]ZBQ=(\\JA,[P3BY5DA*!
M03AE+\G^71?<!ZXP<*_3RK^?IZ'+VCQK $C"NX2_1:D1UKY!<^VZ^^OX=MU?
M'XP*P"U^PV,"UD/OU[[8H^.^O5]F]HM5Z8'^\#*]7D3F-S*Y0,8 P&B&T*J@
M^<=B,-S,!:*[DJ\+^4G3ICA] BMU_>OF[SF+G/E1>\&/]Y%F9E" %88?0B :
M?EC(/>OB(#(<GY_6CKWQ[J")PA5KJH6'B>Y#?&^N4&"#_<,3O&P>^K.;$4.;
M=WM68' P8\ @^,[4:5W;%HK /UH2*I7CBF0)9JMPOY7/4W5-%12@3V$5\  %
M2NS:S+@*B1%^^%POX@%I7*^_:3K#',QY'/W+^U^,>^%^'(\.Y',8QWVPQ^F[
M@G[YJ'MPQ+_"_T6_G[^WTUV8..*:6T9==]3:WG$\FN54O,7=LH-;.(7A/NXN
MR*.C2_^648POZR-V*<A\+_<GN%)C]?"$S0?ZM9H=QD9O-' *C87$Y-;I3WI:
M\_2^BQH9UE0F_JL"[5]D>EW&XK>;]H#N^J]I9CIG3D6$931XQOA6#.!@'#=>
MXSQNK<N]1NK5]SD6;.*EM"T0'1F>KA4>?FXIWL71Z4MS_&(H=O0L=CP?BAW[
M)^9G&3DR_TPJ"G4%,',E63EVQB!PK0ORB- W2EB31F_4VE?J1D6N<0JJ4Z,/
M\C@WTW;X+GW3Y=]Z#0:H"#&!/:A3\$S4J@19-/_Z"XG0S<X]B5DW"M(\$GB&
MK<_=K""N^_:#W(6\UZT>NO/>N)G.Z["19/\O:1V&G_>PI%O]\IYN?K<=W\OM
M->H%W _?OY0"X7LS"'F+O>^X(OJ/S2N*1]DA'S;H^HQ:Z2M./&S!"[!AZB0-
MS>X.J"VD2!E&OJ!3I]3:5* E+V$:\8E@;)8S0QBAT@B4G&!/V<')$\,Y0$:+
M85$A;$ZN=PW+L,V*8J;>30!K#ZUMSO]R!2#KPYN\.GP21Y+0M7D%>&5>0]FU
MB'#IC?<Z3SXA8-4PZN"EJ/#:=;< (6@"A22[3"JIC<&O_TMG--E9)H,QSS*A
MRZ?)RO 8M*>0S7-7%+C^?LKBS)I$THRIPWM<Y9D<=LI8T51B0H?CW.DL.G@N
M6QM$3?S8"-RU>'>9:^:C;!O/MR^YZF\ZK3G,'M[]7NU9HQZUM=&8^,W919E*
MGF1& _! 2%)]G,;% QZ],34]>P63XS5(6FY8,2&.C'CU=(8M<DUJ[G!MK<EU
M^9@)5/.Z9&UNTNVNJ!8SI2)SD<4R3I"L6F[ 48:L5F8UXU,B_UE^P<ADFY=O
M3R%#R*M],8^&WK8O]LQLU]MVC8<@G'<^?3U-!78H! ^DW:AHF'D1^'D2W_%H
M8NB-&GANGGPRF-/=F].>Y"34)C!#GY%V/V>4B<MSLZ3,-/5 S\(.$(1#6-*@
MDA)]^.GP:C2-PR3-?1YN3S[-L%>=.&>[^Y;!"!S"'[BVCK"$:92ZC'O%>]A)
M#^.1:Z=P"I3<SRO5T0435 K-PG8EY9^[P+=Y[F7BORID\P[?U54N;1@"_2GC
MC@V">,URC;G-HFBK+BYA9R&4P<"#H$.%^:=@BA V8X0)#27<1D"ZO+U^&&4H
MG"?@^H.5Q#991Z',0<QAU/-9H\:C8D""X80(F'06T8!ACZ^")O$(]@CK/=T@
M+>M-8!*6GF.8"KL3!=J3;\>WN<Q!Y@NQ08O[:/+<GW]N:2@$1ZH@6H7860PQ
MR)F'02?<M_%/$:96DK:\2GB&6[TRQ&I5 :O35-&<J.QC4:\J!K03/8]=$B["
M_#TDR?5T9>2=)^HP<R[JIJ9!=RYLB]AGH ;_VCNN7@Y%R)Y%R!=#$7)0\OV4
M?$^&JS.'FD4_@X95@RIT'D3B9M5<>;W_TE?4T/9QV_*#,YTA_B.?U6;T-JKX
M?"[_F'CX\*N$N6\%DH?.AAM)%KK?YF.$$Y?4-2T;')ZD(GHW4@?@F6EZ5"'%
M0,XX[K<*LK>>TK_62V<\C6<7Y$*^C;D. HUNHUKCN)R0GZ2#V] AA[PK[+N=
M^2:.UA9L'GV])"[X7.\D15T^TGCDG*3XGKRDF&DX%XIC%#JZ-$  ?!Y-M8VI
M]I*!G( II4%@Z9^X:(L#%Q !M1X\= 7=4\4N68@@/^WQA?+J#M@!E3]Z?T"7
M%K^+MZ1_('+S@N,R?D^*PB_,(^'P+<IYJO31-@J@15%&6[30_((''?#EZH">
M7"9G I5LX!+;TXLW,D58"HOFIYC4PXYZ?J^G-?=.[:;E;IA?M$T'R\FV'2SO
M-'8%4*\3B\?0M[(ORN"D;]_*AQ O@!OJ_.4T628>;28EZFJX0K4VOK$S@"$_
M3-BSYWIZR?@8K+9\V&*,_)9AF2XYA24EG"</J3/=K0?3LP?2UA.LU-(8(FM,
M9TU5"0$!58*;#7M6.#/VPU!A_5(KK-NA$OZ15V[77PV[_J7N^G9U]7>VG.1C
MX"#\LF1I@].X-T[CT^V=QJE:)95E81A\QGVQXD^W\1D[@"]QUU3LB<P)JJ\!
MA,;",X4?5IEM.45.K'\C]\;:!J"2S$ L+*-DDPSY&,/!D-:?/&/N#ILPC5ZS
MY*$N>9WB+4LOM.4I+.R/V&&9@W.Y!V+9T[D44LRR(GY.-VM'\I.>&'+KLB.D
M3V:>:+! Q=WI+X/("C(@^.:&--C>B$M/:////313MV**;M)+3A>-1YZ"'.*6
M'7NP%'[THWS$W#P6Z$W[A9L61WF)ICVI<J]RL  '5A-Z"JF%:NFCX'0YW$[A
M!#Y"=K3'6GI?^BZ;J7+Q"I6,>$S(R+\">T;5@*A<(BE1(<WXSI!UMGA0%1,[
M=E1J.06+?)47*/PJ1?8BFI^'W2(HS-B&TE$$L1@^F1(M"WM8Z@W<N\^)S;OF
M?K]T=/A,55%072FO95XCO7&G6WRFL%:'%B;&".D3=1" ,O ]08A]G58XQ8LV
MG]M_?CS_B0KBL*6)PE0Z.T2X,3XZO>3.'!GQ5 B+%Y9\_ \U,7:J*58N+Z.,
MDV0F,U**QEW8.E3^) Z:0#8>F6>_9Y#=/HE('W#1T9,!7=037?1R0!?MDW3_
MGE=8EBZI@"?^,[[=BYR,DI EKL-ZM\6M^TC?D ;/F5L9^V'GOTY" Q3;LKK[
M.#&#>B.W4JTNL7_5Z*1@<FT0L#;K]#>[@?U\P/NF03I\OFE+[M>U:WA41,^P
M#ZY='\__X*BW<V=9GZL<W2IGZIP9,Z-;F.':F/N UM-#M+#XD?&T'M-X%!A8
MF6/.)M/=QPHYS@^/">]6RGAW7N/2Y[<-N#(-#3!X>@[&1D.;RM(^@^$'CKT1
M%O[D8[7,P=6KC'<J)^-5A+01#^C3'9T@3^0@T==+]'%OB59FTC"RMJH0!TY"
ME:!:G%>F@RQ4H*0&G;IL@* H54:P+CO@R&L!#ZX4A\-I:."AT S((3-$ TG1
MM0;?E?0)4=$#3E _4\\[=G5@*)3J"@-M&ZC-?!9WOJV;^-1D,B32UVB:YI(A
M2IH#5(/E#0=B+P[$2;\#\<:D;Z/FO*(RY.5L3/83LH2V2#7PL^%'Y%Q8P8U-
MG.9X^5O^"L_4*7@(GYRS9B"_R=,AZ*!,(<*CT+$6.0)='4_F,9O?W/"@]C2V
M'EN^</VSDB/HN"3HL>_K6?FK#UH6ONY8/HSS?;Q-9Z#X$(8'Q;8*.8]\I0IU
M4:C5HHS FJ#$P1DR9T C7A>)2#B?0Q[\C!D)56JS27#!K('BL=U&3JGBYHB7
M7X(;-!X116@9?"D0K9_SK"Y-VCQZ7PL>UNT_9]V$T"4XM69*5<;9K*"+6GJG
M_-054I:3()DAZ ;CNE15Y3C2-]_]GK,5+TX/^R9J1>]]58K^(8$&T^T:^'//
M%:92Y14S\&5P _L7$2[]"7Z!1\32Z'-?"&(4#%HI;N>&8\KR@@>6:L'*XQ<H
M5>>\K!0'#K3SQ;KCIMFL(YBV=\5!S[,@C>SN!/%(5QHYA7V]IRQRU#.);!/?
MDD5^_1FRR%L<NN/G7YUS]9!G;K;MF9MB)U1*N>V-%7I6V$*@2T48H]]=R0Y%
M'8? </^3B8!F+<XR'Y?*TY=\I&D<N?$U6>XX>;'!W/]4Y0=9B\_2]S @D;9!
M(IUNBT1JTJX-2*1]J>&?]D4BG6?68S5ANU,0'%38G#2=X%D.#V_;_WE&G7RQ
M!4JB$,I,R1N/F+4"/UIJ,UV*<FS?NQXX5C,X*^A7=16;GDTWE,I717F3D)_=
M42\E2!-U,(72E-3Q:%,FFK+/U,5JH9/6?1#K^Y6@$+Y%4[LEIQM$73-OK+,O
MMCYUIOPR.GD9L8Q36GF@,?MBQ60[N/7;3[J8<C1 #KT=?A;YL\^"_M5V!((_
MGI6E7DY2=K(L@I+CAT8%;E70=\VT:^V6@*$,+:&Y C.>1FXF7]&V403K>B76
M\)!KR'6OKC1VMV?JPK4?^4K8/P?O-6>Z3H_AH(7:6C3ZWI^)W2VD%^SA:( ]
M](0]'#T9< ^#D=B?5-E9R'S2A;97-75JQDA5:28]\ZP;S)XM5VG.9)BDQLDV
ML&]*(YW=Y<>CC;3>#"[3DO4^.GT*?R[R^F(1'3U[_F4J[$$^[R>M=$:(?LS9
MS",?PD'D!.87'/<5H$L3J00T BLGR^9R#5DDTJ N83P^/8VCX^=/#HX>/3XX
M>83_/K+2>?S\9)#.KTLZ]5;2>>YW*86)3IH#1@G1U,.^82FAEQJ,CE\\B[Y3
MR]4K^-?SAGL[B-F7+F;S[91@M-14S.F*:DZ.GVP*:PQ@QC+_^-\Y.VI_:3QZ
M:+$:\J3]\J1;#(EI8EH;K0BJ+.OEQO#?C#ZGF=;,\I,7%RH;A& /A*!GPYO?
MMLLY9J(90QA%EM4@&4T)X6$0.,F'-4261V"D&,27"?ATGL!_<#[,T>FC: GO
M;$$-)S[[RPHA1S.F,.N\SP%^2L:7T@"]KD]A9<9,,\7IQ\V+&+8Z*D]G$5]D
M/&I^S";7X3-O/X%[:-/HPW2:_9'H;>CT+W0V4X8>J%MVNAJ6K(B*W?M:ZB)[
MNO-[5!=YDY33NF/8#-HY2F)@6AIT0D:T]=1.CHF)TFL7T1D!AV=V] QB8 :"
MFB]6@+:KF#2286\2,'#$4=9553MZR<;3GQ;'^/="+^O,P!=5Z:XS"-(7*TAW
MRJHJ3^U(-G40A2]6%+9+8/XFX ]R8VELB0QS"9L?P=(4FJJ<Z$Y7V.I85B V
MESHZ  =\I8NIEZ(/\97,.6"_A#<Y.&I]Y]+G7 MQ+6MB"MZ\..PSHB'7-RZ,
M;](<#&3OPA<I/^J95W1FMA]TX)K85--?;A$TC CDZF^*'?1D\!$R[L4&PUC*
M/73\>XZ!P0D!U+'EQ,.2)L0RI-9/;O!,TLU!GZ6INA3ZXUD>E7D,IP4L=^<W
M/)B67'P6F'\A()<6",:0=:+$!K'; ['K.9CB=QY:3*:Z!1<4/)_$H[9[B7O9
M43MEN550V%G,?Q9UB\3O($K8@E D\)EL/)H@W+B*Z@Q;.$U&]D5WG=.;<;&J
M)VE2+C3V7U*ZSNKBO"XD5?.T:Y;O:SNWUV1[\&&QV_*&YZ+6 'FRSH78)517
M<(,U6Y[C(UD$PQ0:2SB,Y%V;RV%9V%P/CA&FHFA8.75*7,%Y4V"4L7&C7*D5
M+81(@B':GR;%M);B"GSSO"R43N,HN-S?]*305S21#+-C!$Z*\299N(J(R?Q-
MDZT;+Q;V&'I4_'E@VFR!L361^^N:;W?M#7M!A8X'J%!?J-#1 !7:HP&.F),,
MM :V1,%?F&\"=I(ZZ9?&:EA.<YH7"^)I-8K]B(I 43F?OD(_)U#*J*^16 Q;
M=66"T8JR4QX6/A9P/&$?9A8S3KJ,4?%-\+RAG0A&VYLLANVY%"_+A+ A5U3.
M4^O%[6D#[$L?7X]#G<3*';TX[@9,=(V,Q!: ?^<TSMFO;<F5<9PJ/H!7N.!^
MMBI9H5703//A;CX>/7]Q,-E4*$6*CQ0B%-?2C-,HP:8^9VL6\]7IELYHD 0D
MWB1+DH_[:ROM)_A?"*Y^P\/<IC$HO!3R7Z"W=];/V>,F(9]'XT\Z5R#![U#'
MEE70, 3KV[D/?W**W>IWV_A[W>M7D2='][GQ-_OUF_;^J'> &8Q/*D+5UH"1
M2[=KA$!WEUTQ28^#H[]2Z[VRS)#\!]* XOE;S1R,^!:]TT6LW)FN"9<U'C4J
MJRS C8:@@_*17UN->*PJ"7AK'%2KOTGYTZN"7+@IMBFD<>8^^V8@T0JB)'&S
M #?!J,IY7=5%5\;'AOW29U"ZO\C]$L'Q090#ZI@L'4?K)5Q(Y@JWEW"@6B_,
M/_%^$?H\XWE^UCIVO 9./M =X6;F>N.17)"L[-5"$Z+"9;C\QQ ^XTKZSY(;
MWV)L_ ^1AN9#1$N0<NHO2]"8C4<SG>+P-7DCTRD\% TKI'(7,AW#0<61':FZ
MLFT8FRY+O#QK5RD3N=[0AG1@>V^Q000VS%9-3L\>,0@%3E>X! 8K53DX\OK3
M%$PP.)-%+;UX&'I)L%<>1A^N>WILRT=T"[ZP$DX_G;WQB-KZ_1?7/BZP,Q^Y
M<BQP4CHJ]BW&D4YH/['9G\=8XGBX-005Q =&[E>"(6@.>WM!  DD3(KE 8B?
M948]?A19ZFFA*TP]'72,@#?M+T9M+!(]C][2"'C,O?Z!S$F.XT(4 \CNA^9A
M8&&(/2$U;PP.L+PRLS;:7ED(:25XS"2?45]/.2V2B5 F!_O&VZ&R+*]AX<$,
M37+?^#<%O945J$]7%1'Y'H_"<CXB/9#NC-Z#(M(&;S'XMM IUB)$WI\>>>XL
M[9F,,VJ)"O4QF0>B<6EXZ$%&O)Y3(L'/X()+]HFM(F=U(P>ZQ]&*KSE5G<B%
M'T"_)X_8H51H$F!9\/[1!]6I7BW0!#&M0QS-U2=#\4"L<"B YO/7BCN_1DQV
M=/X931CW=DT1W\K&C$XN2"KM+@4(Z]@N$\^/W) /!_Z"5#<(8U7D:<D#2;%E
MJY3YCG2)5Z MS.,VV8/08M@#L^G8PA$EM9RNF8G#_G3@EKL.!VF7E. 2>V0^
M+^$6!&LN#%KD5[8,@:W"A*NB0W"UR)>/8DF:V9  I('N(D\2I+-P$$$9R-%_
M<.C6?,VDF9OV83H5XTRW-3,QQR,<LU'.%9JC=6C'UXY4 073>C&-5W##:Z7Y
MY7,7*FZP.I),5ZZ$9?#.8K4W7A]9CC&5SN2+6K45*QCY3VL# 9*XF<1%Y$4L
MJ:AJ/3.^@#V<-[LFS/<2'G0.'Y'&V65 39R-<SHCQYSB7!(;G%<Y2*R.)M0C
M4/EIT-:MZ7P9PCOT5SO8,*Y_C^:VIC:&<3EFB!%Y(,V934?('(K-U[S"_"E=
MD0MVJ+I9+UK0# OZ"N$Q&P6#!LRNF#.6Z3;;EQ$% :\ G<]-WD6'LW# QQI.
MX$%R^0BS :305Y;3#'95%05Z$03R@544G',W'+>8H:ZNM)!@=;Z)TKHJ#(W]
MTRJV U!YUE7XT\HL_XMD&]5>)GD/^UPL+L)?(LJ )+=I54+!Y0,VT]-4":S$
M.C;TH!N/&&7UV0EU:F%)C;S@O_-98YY[.X#;.U=&4LH\;KS@)).C0/L!OCJ:
M';O-S<O"D=VT16_ <%\J=&G&HP]^3\\!V>@Y-1I/-!C&1Z3]-AHL?-I977C8
MU,LDKTLL3:18JSXZ%ABK^ H^/8RGXOC(!-U%QB^>(ETFN)3P=?%)G;DJ[4!4
MN.QEGEZ28^!\ZB5FJ1#^ 0HYRY?)U';0Q?S.W'N(_-?PBI7KP67RJ"$ G"-S
M/JVOP7SI(E/#M:9V^!E*]XWN^'C4Z8^[LKQ$<J$MZC@*@5[E@QR34$[P.&ZX
M$/N9%(J12K&QF(R0QA@*0F4$!8!?S?S\,M\2O<7*,? S01YXWK$Y@#VLE:S*
M8]+#U*9[Z?:B<%QH4+,+^I0U$WW,4;DIY.0 7D[=VNSNX<ZR5/M:8CH92DQ]
M2TS'0XEICTI,9UZ&JML@>'DJK#4I,D_@ UP4FMR<V/=Y8F?7F[Y/1#)*1@J5
MMP& @?XU!+8FDIZ ?L*))6BI\%:=^I&<*W$P4 >K^3Q)$Z)'QS^493ZEGV+K
MC< ')3A!3Y_N@?#('PBY1OE/(DRTJ(0$O8$B8;O:HEVT)+7CD?T>+F?*#->%
M,=H\YZO@9;'1\RQWF$N)B5A5^.HJ,W-,K$ I$UQ0-?M!9Y232UQGI@1WH1)R
M#.FVE"N []$OS>/0TL%3YH276 C[%-<M[X3?E)[/[2HJ<9CM2\-@9 G?OZ!:
M65Z2L<00/"J2\J-[^95WL[6Y/487F&_DM94D) =/S4NQKX(<=C-JF@J#M!9I
MC<V1R)[_S<Z59+:9#,8Z0!NBW]YRA6Z%T%2:[,WFK6[2Q9@P?OMSA#;9HA=Q
M$3@LB,9K*X.X@=6O^-]7=%%**4XJ&PU! )WEQ%.:H[]-J+.B2M -,QL"[^A*
MK6)QQS#YK?'!*5K%%X_H'(S$["5Q<W!3S<+!NT)@2NSV:69FKL9F0]S#4V1
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MIS6[UWX2U.TOA@)2ICQ@XGCNAP)?3KC#?M5,RC^/O"FDPAF&KMTC1/Q+]!C
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MF&B\%&%_,*B0&L6\1MDP HDRR*%L$V8@.>'8-!86&MM4K:>(]\/QI,$GI/*
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M7#)H#!=*-Z;]07&A2(*X";1B7:U+1>V8M%).M1VY5*/C^NSZ:V!8]$_W+;$
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M1&M_&#N<^]9S;^YV[M=<X[1QM/&</29J%HE@)*KV^(MS#Q0V)E$9\[%;7":
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ML>TQ,9S25^7L=^?H*W;_!5!+ P04    " "@4'I<>*;'FE8$  "K#@  %0
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M@YV/^Q\.]]^_4^]?JX.]G=\^[A_N[QU<SO0?]W[9/SC<^[BWJWY[M[OW$1=
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M4+1F&J)TKCQ1\[(P2R(R$P+=TI/ZZH9AU/O/'0,1D_0<3$&$KJE(Z"\FSFA
M#( D''0S,?$L/,O84-L WZH!>L?TCXE=U8S_ !3SJ PD]=A6A$1"5LY [CEL
M";$!""]\!JM%(HQ$KLP;6F36$".I*G[6Q0^%6*J.6)7#M5<+ _O+U=P8HK3P
MC:>Y1;ITI$:P-M""_-[V@3QEF>4K1!RC=1>(D.%NS'2*NX6]$9QP:!ECQ!-H
M9CJ9F>3:1<%DH9=P//0AL]TBJV052H\K4TP,'5'53*=V8O%59VIM"]BYT:Z
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MR<2A@@1<T D?-<>V1.Y\4JHE< !8/;"6S$SI1(1SK+DD,!K=Q".ZLC@/O%R
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M3CL<LW<S[]S%:_ :-L.P.!E")WT;)1-QU@=#<D8:RS@"=7Q:K>NFZUGC&43
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M,C R-3$R,S$N>'-D4$L! A0#%     @ H%!Z7#W*KO8N"0  X'T  !4
M         ( !X!(  &-A;F8M,C R-3$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M *!0>EPP1Y184C   +K2 @ 5              "  4$<  !C86YF+3(P,C4Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " "@4'I<H <NZ*Z-  !UAP8 %0
M        @ '&3   8V%N9BTR,#(U,3(S,5]L86(N>&UL4$L! A0#%     @
MH%!Z7%$5J+UG4   P@L% !4              ( !I]H  &-A;F8M,C R-3$R
M,S%?<')E+GAM;%!+ 0(4 Q0    ( *!0>ER-F?=R?GD$ /.='P 9
M      "  4$K 0!E83 R.#(U.#8M,C!F7V-A;F9I=&4N:'1M4$L! A0#%
M  @ H%!Z7*U2E\5=AP$ H*\! !0              ( !]J0% &5A,#(X,C4X
M-C Q7VEM9S$N:G!G4$L! A0#%     @ H%!Z7(!L-N-&@@  4XX  !0
M         ( !A2P' &5A,#(X,C4X-C Q7VEM9S(N:G!G4$L! A0#%     @
MH%!Z7 $!N"[RM   :<0  !0              ( !_:X' &5A,#(X,C4X-C Q
M7VEM9S,N:G!G4$L! A0#%     @ H%!Z7,="U#8*30$ *EX! !0
M     ( !(60( &5A,#(X,C4X-C Q7VEM9S0N:G!G4$L! A0#%     @ H%!Z
M7$C[Y.>"MP  \,\  !0              ( !7;$) &5A,#(X,C4X-C Q7VEM
M9S4N:G!G4$L! A0#%     @ H%!Z7$FVJ06A\0  PO\  !0
M ( !$6D* &5A,#(X,C4X-C Q7VEM9S8N:G!G4$L! A0#%     @ H%!Z7+VL
MA . $@  >!,  !0              ( !Y%H+ &5A,#(X,C4X-C Q7VEM9S<N
M:G!G4$L! A0#%     @ H%!Z7,,U"'JD@@  M?L# !0              ( !
MEFT+ &5A,#(X,C4X-C Q97@Q+3$N:'1M4$L! A0#%     @ H%!Z7&4[FPU\
M!P  :2<  !4              ( !;/ + &5A,#(X,C4X-C Q97@Q,BTQ+FAT
M;5!+ 0(4 Q0    ( *!0>EQXIL>:5@0  *L.   5              "  1OX
M"P!E83 R.#(U.#8P,65X,3,M,2YH=&U02P$"% ,4    " "@4'I<+,QCG= #
M   -&0  %0              @ &D_ L 96$P,C@R-3@V,#%E>#$U+3$N:'1M
M4$L! A0#%     @ H%!Z7#TJ[U@8*0  -_8  !0              ( !IP ,
K &5A,#(X,C4X-C Q97@R+3$N:'1M4$L%!@     2 !( K00  /$I#     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>ea0282586-20f_canfite_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:canf="http://canfite.com/20251231"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="canf-20251231.xsd" xlink:type="simple"/>
    <context id="cref_734008993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1683224475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-04</startDate>
            <endDate>2026-03-04</endDate>
        </period>
    </context>
    <context id="cref_1278442780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-04</instant>
        </period>
    </context>
    <context id="cref_1272600409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-04</instant>
        </period>
    </context>
    <context id="cref_1413771939">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-04</instant>
        </period>
    </context>
    <context id="cref_100549505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-04</instant>
        </period>
    </context>
    <context id="cref_1060093280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-04</startDate>
            <endDate>2026-03-04</endDate>
        </period>
    </context>
    <context id="cref_1994543132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:NewWarrantSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-04</instant>
        </period>
    </context>
    <context id="cref_1459093040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:ExistingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-29</instant>
        </period>
    </context>
    <context id="cref_184434641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_898003050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_678032609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1997617154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_44387193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_697212563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_616608710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_248394047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1914073660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1205104151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1894462461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1202395540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1132214309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1398170537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1190382762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_42715392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1607629638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_907931666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_520798346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1055653923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1803955859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_342246256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_583004226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_219588702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_109046716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">canf:TwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_862142534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">canf:TwoThousandThirteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="cref_1355753607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2013-11-28</instant>
        </period>
    </context>
    <context id="cref_202162938">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1358509655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2025OneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1019937961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2025OneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1665281426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1056014996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1404131453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_533550791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1783668540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2024AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_910941741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2024AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_160240094">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_272935354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1968813787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:November2023AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1043966202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:November2023AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1820958487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:November2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_797890104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:November2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1156080072">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2023AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1443470887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2023AgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_197686924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1731853064">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_997732034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-18</instant>
        </period>
    </context>
    <context id="cref_48256838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-18</instant>
        </period>
    </context>
    <context id="cref_1936150275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-18</instant>
        </period>
    </context>
    <context id="cref_435254208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-18</startDate>
            <endDate>2025-11-18</endDate>
        </period>
    </context>
    <context id="cref_1116774511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-18</instant>
        </period>
    </context>
    <context id="cref_1336110434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">canf:InvestorsFromJuly2025OfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-18</startDate>
            <endDate>2025-11-18</endDate>
        </period>
    </context>
    <context id="cref_801816110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-05</startDate>
            <endDate>2026-01-05</endDate>
        </period>
    </context>
    <context id="cref_1078174181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-02</startDate>
            <endDate>2026-01-02</endDate>
        </period>
    </context>
    <context id="cref_2037786040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">canf:SpecialGeneralMeetingOfShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-10</startDate>
            <endDate>2025-11-10</endDate>
        </period>
    </context>
    <context id="cref_2040359165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">canf:SpecialGeneralMeetingOfShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-10</instant>
        </period>
    </context>
    <context id="cref_1554927284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="cref_1250994810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="cref_1465389010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="cref_1363860027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="cref_1886921177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="cref_1755993480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="cref_275892941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="cref_421138161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="cref_2132039962">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="cref_1039317372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="cref_575156313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="cref_1839015054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-28</instant>
        </period>
    </context>
    <context id="cref_1536062095">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-28</endDate>
        </period>
    </context>
    <context id="cref_1249276182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_870625474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2025-06-30</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_487979537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">canf:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_1503704402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="cref_374804358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-14</instant>
        </period>
    </context>
    <context id="cref_673085692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">canf:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-14</startDate>
            <endDate>2025-04-14</endDate>
        </period>
    </context>
    <context id="cref_236998777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1335503686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-06</startDate>
            <endDate>2025-04-06</endDate>
        </period>
    </context>
    <context id="cref_1743024573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1329224424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-08</instant>
        </period>
    </context>
    <context id="cref_889933283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">canf:NewWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-08</instant>
        </period>
    </context>
    <context id="cref_2133907439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-08</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <context id="cref_1922956513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-08</instant>
        </period>
    </context>
    <context id="cref_2043010181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2024-07-03</instant>
        </period>
    </context>
    <context id="cref_54615801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2024-07-03</startDate>
            <endDate>2024-07-03</endDate>
        </period>
    </context>
    <context id="cref_1778457142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="cref_1677178547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-22</instant>
        </period>
    </context>
    <context id="cref_447010128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">canf:RegulatoryAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_576633015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">canf:PhaseIIIStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_337919505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">canf:PhaseIIStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_2059261110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">canf:PhaseIStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_648214257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:VetbiolixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-24</instant>
        </period>
    </context>
    <context id="cref_1130319153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2024-09-24</instant>
        </period>
    </context>
    <context id="cref_2057783007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-28</startDate>
            <endDate>2021-06-28</endDate>
        </period>
    </context>
    <context id="cref_344781049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-28</startDate>
            <endDate>2021-06-28</endDate>
        </period>
    </context>
    <context id="cref_398624799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_797038194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="cref_1154935824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="cref_1677665869">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:KyongboPharmCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="cref_2037445886">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-07-31</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="cref_1089428082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:SalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_758140809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_112398461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CMSMedicalVentureInvestmentLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-06</instant>
        </period>
    </context>
    <context id="cref_1830464667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:VetbiolixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1798028992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1590073223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1315189725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="cref_632092621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2025-10-31</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="cref_818757102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">canf:NASHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="cref_1375081973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">canf:LiverCancerIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="cref_485025225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="cref_1598663686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="cref_2046075473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="cref_1501641585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_976418671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1943456894">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1736241007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1126769489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_595936047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_255520659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_405802932">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_133213812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_626091944">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_264863037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1787915782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1102009625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1513674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_656845410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1010971887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_940504229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:VetbiolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_401885686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1969999970">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_707849457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_2073970239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1630416524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1380163261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_262393112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1752405840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1051158666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1756871285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1085088613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1329610678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1707962055">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_794440730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1654566158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_180300996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_385792771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="cref_346153289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="cref_1212188529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1110324969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1268205755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1254970073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1722856177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1978583206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1298046308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_503396369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1447998007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_679399687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_869951728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_60220687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_301922635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="cref_1568626008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="cref_713467315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="cref_471624570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="cref_847760719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_692454694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1182592801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1096639490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="cref_430322482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="cref_1689545004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="cref_1316363029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="cref_1741811486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1111035328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="cref_1605243859">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1424085176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1997113680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:VetbiolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_487311381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:VetbiolixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="cref_1904201796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1856579833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_2047207648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_736875626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="uref_734008993">
        <measure>shares</measure>
    </unit>
    <unit id="uref_720247910">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="uref_1278442780">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="uref_1413771939">
        <measure>pure</measure>
    </unit>
    <unit id="uref_2084217627">
        <measure>canf:Segment</measure>
    </unit>
    <unit id="uref_1677178547">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="uref_447010128">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="uref_1598663686">
        <measure>iso4217:CAD</measure>
    </unit>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="cref_184434641"
      id="fc_669790381"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="cref_1205104151"
      id="fc_406290213"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="cref_1997617154"
      id="fc_972519014"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="cref_678032609"
      id="fc_213046275"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsForfeitedexpired
      contextRef="cref_184434641"
      id="fc_113611892"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="cref_1997617154"
      id="fc_299793311"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="cref_1997617154"
      id="fc_1788048371"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_678032609"
      id="fc_760617434"
      unitRef="uref_1278442780"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="cref_1111035328"
      id="fc_1111035328"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="cref_869951728"
      id="fc_2026529756"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_692454694"
      id="fc_2095020479"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1605243859"
      id="fc_1605243859"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_471624570"
      id="fc_2039191230"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance
      contextRef="cref_60220687"
      id="fc_2144679190"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance
      contextRef="cref_1111035328"
      id="fc_425053498"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance
      contextRef="cref_869951728"
      id="fc_8299037"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance
      contextRef="cref_1205104151"
      id="fc_1843738797"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_1743024573"
      id="fc_3754123"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_1111035328"
      id="fc_1652128422"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_869951728"
      id="fc_609884468"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1743024573"
      id="fc_1574677278"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1111035328"
      id="fc_536684989"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_869951728"
      id="fc_1304797919"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1743024573"
      id="fc_2054232463"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_60220687"
      id="fc_941212928"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1111035328"
      id="fc_204867609"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_679399687"
      id="fc_2021528685"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="cref_1743024573"
      id="fc_964794137"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="cref_1997617154"
      id="fc_523126391"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="cref_678032609"
      id="fc_1937695010"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1997617154"
      id="fc_1954273020"
      unitRef="uref_1278442780"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_1997617154"
      id="fc_172437876"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_678032609"
      id="fc_438358129"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance
      contextRef="cref_1743024573"
      id="fc_101309368"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_679399687"
      id="fc_1350392693"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodExerciseValue
      contextRef="cref_236998777"
      id="fc_777455571"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodExerciseValue
      contextRef="cref_1424085176"
      id="fc_1424085176"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodExerciseValue
      contextRef="cref_1722856177"
      id="fc_1050864119"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_236998777"
      id="fc_549751167"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_1424085176"
      id="fc_1604115385"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_1722856177"
      id="fc_696482402"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_236998777"
      id="fc_1466338231"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1424085176"
      id="fc_2080488118"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1722856177"
      id="fc_443517718"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_236998777"
      id="fc_1816291455"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1978583206"
      id="fc_273676464"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1424085176"
      id="fc_1832570996"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_1254970073"
      id="fc_554639177"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="cref_184434641"
      id="fc_1146546674"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1914073660"
      id="fc_421221726"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:LeaseLiabilitiesArisingFromObtainingRightofuseassets
      contextRef="cref_184434641"
      id="fc_1937658026"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_180300996"
      id="fc_1633826125"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="cref_180300996"
      id="fc_2074154732"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1997113680"
      id="fc_1997113680"
      unitRef="uref_1413771939"
      xsi:nil="true"/>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_487311381"
      id="fc_487311381"
      unitRef="uref_1413771939"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1904201796"
      id="fc_1904201796"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1856579833"
      id="fc_1856579833"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="cref_2047207648"
      id="fc_2047207648"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="cref_736875626"
      id="fc_736875626"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_2040359165"
      id="fc_2130825858"
      unitRef="uref_1278442780"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="cref_1997617154"
      id="fc_539237308"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="cref_678032609"
      id="fc_506692405"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_1316363029"
      id="fc_1027623191"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="cref_1182592801"
      id="fc_1004110757"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="cref_1605243859"
      id="fc_1372760715"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="cref_847760719"
      id="fc_1059179270"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_1182592801"
      id="fc_259543012"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_1605243859"
      id="fc_546765437"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_847760719"
      id="fc_548260843"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1182592801"
      id="fc_834906283"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1605243859"
      id="fc_1025560619"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_847760719"
      id="fc_1834162276"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1182592801"
      id="fc_200494866"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="cref_898003050"
      id="fc_1936936551"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="cref_898003050"
      id="fc_605971914"
      unitRef="uref_1413771939"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="cref_184434641"
      id="fc_1216322058"
      unitRef="uref_1278442780"
      xsi:nil="true"/>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent
      contextRef="cref_678032609"
      id="fc_1823340782"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent
      contextRef="cref_1997617154"
      id="fc_792382386"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_678032609"
      id="fc_2016546657"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1997617154"
      id="fc_84170453"
      unitRef="uref_720247910"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration contextRef="cref_184434641" id="fc_698904215">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <dei:AmendmentFlag contextRef="cref_184434641" id="ixv-15551">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="cref_184434641" id="ixv-15552">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="cref_184434641" id="ixv-15553">0001536196</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="cref_184434641" id="ixv-17043">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="cref_184434641" id="ixv-17044">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="cref_184434641" id="ixv-17045">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="cref_184434641" id="ixv-17046">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="cref_184434641" id="ixv-17047">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="cref_184434641" id="ixv-17048">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="cref_184434641" id="ixv-17049">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="cref_184434641" id="ixv-17050">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="cref_184434641" id="ixv-17051">001-36203</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="cref_184434641" id="ixv-17052">Can-Fite BioPharma Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="cref_184434641" id="ixv-17053">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="cref_184434641" id="ixv-17054">26 Ben Gurion Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="cref_184434641" id="ixv-17055">Ramat Gan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="cref_184434641" id="ixv-17056">5257346</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="cref_184434641" id="ixv-17057">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="cref_1741811486" id="ixv-17058">Motti Farbstein</dei:ContactPersonnelName>
    <dei:CityAreaCode contextRef="cref_1741811486" id="ixv-17059">+972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="cref_1741811486" id="ixv-17060">(3) 924-1114</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber contextRef="cref_1741811486" id="ixv-17061">+972 (3) 924-9378</dei:ContactPersonnelFaxNumber>
    <dei:ContactPersonnelEmailAddress contextRef="cref_1741811486" id="ixv-17062">motti@canfite.co.il</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1 contextRef="cref_1741811486" id="ixv-17063">26 Ben Gurion Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="cref_1741811486" id="ixv-17064">Ramat Gan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="cref_1741811486" id="ixv-17065">5257346</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="cref_1741811486" id="ixv-17066">IL</dei:EntityAddressCountry>
    <dei:Security12bTitle contextRef="cref_184434641" id="ixv-17067">American Depositary Shares, each representing 2 Ordinary Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="cref_184434641" id="ixv-17068">CANF</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="cref_184434641" id="ixv-17069">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="cref_1997617154"
      decimals="0"
      id="ixv-17070"
      unitRef="uref_734008993">2618425</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="cref_184434641" id="ixv-17071">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="cref_184434641" id="ixv-17072">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="cref_184434641" id="ixv-17073">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="cref_184434641" id="ixv-17074">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="cref_184434641" id="ixv-17075">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="cref_184434641" id="ixv-17076">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="cref_184434641" id="ixv-17077">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="cref_184434641" id="ixv-17078">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="cref_184434641" id="ixv-17079">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="cref_184434641" id="ixv-17080">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="cref_184434641" id="ixv-17081">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="cref_184434641" id="ixv-9031">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; We have developed and maintain a cybersecurity risk management program, consisting of cybersecurity policies, procedures, compliance and awareness programs to mitigate risk&#160;and to ensure compliance with security, availability and confidentiality trust principles.&#160;The cybersecurity process has been integrated into our overall risk management system and process, and is solely internally managed. Management is responsible for identifying risks that threaten achievement of the control activities stated in the management&#x2019;s description of the services organizations systems. Management has implemented a process for identifying relevant risks that could affect the organization&#x2019;s ability to provide secure and reliable service to its users. The risk assessment occurs annually, or as business needs change, and covers identification of risks that could act against the company&#x2019;s objectives as well as specific risks related to a compromise to the security of data.&#160;See &#x201c;Item 3.D Risk Factors&#x2014; Risks Related to Our Business and Regulatory Matters&#x2014; Our business and operations may be materially adversely affected in the event of computer system failures or security breaches.&#x201d; &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; The oversight of cybersecurity threats is undertaken by our Chief Executive Officer who and is supported by outside IT consultants. Our audit committee is responsible for cybersecurity oversight and monitoring risk. Management informs the audit committee of such risk by committee meetings. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt; As of the date of this report, we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition. &lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="cref_184434641" id="ixv-17082">The cybersecurity process has been integrated into our overall risk management system and process, and is solely internally managed.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="cref_184434641" id="ixv-17083">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="cref_184434641" id="ixv-17084">The oversight of cybersecurity threats is undertaken by our Chief Executive Officer who and is supported by outside IT consultants. Our audit committee is responsible for cybersecurity oversight and monitoring risk. Management informs the audit committee of such risk by committee meetings.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="cref_184434641" id="ixv-17085">Our audit committee is responsible for cybersecurity oversight and monitoring risk.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="cref_184434641" id="ixv-17086">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="cref_184434641" id="ixv-17087">Management informs the audit committee of such risk by committee meetings.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="cref_184434641" id="ixv-17088">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="cref_184434641" id="ixv-17089">we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="cref_184434641" id="ixv-17090">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorFirmId contextRef="cref_184434641" id="ixv-17091">1281</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="cref_184434641" id="ixv-9721">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45.95pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have audited the accompanying consolidated balance sheets of Can-Fite BioPharma Ltd. and its subsidiary (the &#x201c;Company&#x201d;) as of December 31, 2025 and 2024, the related consolidated statements of operating loss, changes in shareholders&#x2019; equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="cref_184434641" id="ixv-17092">KOST FORER GABBAY&amp; KASIERER</dei:AuditorName>
    <dei:AuditorLocation contextRef="cref_184434641" id="ixv-17093">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17094"
      unitRef="uref_720247910">5528000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17095"
      unitRef="uref_720247910">4825000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17096"
      unitRef="uref_720247910">3011000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17097"
      unitRef="uref_720247910">3057000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17098"
      unitRef="uref_720247910">900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17099"
      unitRef="uref_720247910">1095000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17100"
      unitRef="uref_720247910">1000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17101"
      unitRef="uref_720247910">5000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsCurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17102"
      unitRef="uref_720247910">9440000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17103"
      unitRef="uref_720247910">8982000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17104"
      unitRef="uref_720247910">69000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17105"
      unitRef="uref_720247910">111000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17106"
      unitRef="uref_720247910">5000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17107"
      unitRef="uref_720247910">27000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17108"
      unitRef="uref_720247910">74000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17109"
      unitRef="uref_720247910">138000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17110"
      unitRef="uref_720247910">9514000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17111"
      unitRef="uref_720247910">9120000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17112"
      unitRef="uref_720247910">1161000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17113"
      unitRef="uref_720247910">618000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17114"
      unitRef="uref_720247910">56000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17115"
      unitRef="uref_720247910">53000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17116"
      unitRef="uref_720247910">405000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17117"
      unitRef="uref_720247910">405000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17118"
      unitRef="uref_720247910">1109000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17119"
      unitRef="uref_720247910">976000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17120"
      unitRef="uref_720247910">2731000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17121"
      unitRef="uref_720247910">2052000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17122"
      unitRef="uref_720247910">15000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17123"
      unitRef="uref_720247910">51000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17124"
      unitRef="uref_720247910">1176000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17125"
      unitRef="uref_720247910">1581000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17126"
      unitRef="uref_720247910">1191000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17127"
      unitRef="uref_720247910">1632000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1997617154"
      decimals="0"
      id="fc_326785155"
      unitRef="uref_734008993">14000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_678032609"
      decimals="0"
      id="fc_1802511409"
      unitRef="uref_734008993">3333334</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1997617154"
      decimals="0"
      id="fc_171354521"
      unitRef="uref_734008993">2618425</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1997617154"
      decimals="0"
      id="fc_718697983"
      unitRef="uref_734008993">2618425</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_678032609"
      decimals="0"
      id="fc_112058716"
      unitRef="uref_734008993">994394</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_678032609"
      decimals="0"
      id="fc_1848454736"
      unitRef="uref_734008993">994394</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17134"
      unitRef="uref_720247910">180654000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17135"
      unitRef="uref_720247910">170670000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17136"
      unitRef="uref_720247910">1127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17137"
      unitRef="uref_720247910">1127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17138"
      unitRef="uref_720247910">-176189000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17139"
      unitRef="uref_720247910">-166361000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17140"
      unitRef="uref_720247910">5592000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17141"
      unitRef="uref_720247910">5436000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17142"
      unitRef="uref_720247910">9514000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17143"
      unitRef="uref_720247910">9120000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17145"
      unitRef="uref_720247910">405000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17146"
      unitRef="uref_720247910">674000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17147"
      unitRef="uref_720247910">743000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17148"
      unitRef="uref_720247910">6693000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17149"
      unitRef="uref_720247910">5757000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17150"
      unitRef="uref_720247910">5983000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17151"
      unitRef="uref_720247910">3662000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17152"
      unitRef="uref_720247910">3047000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17153"
      unitRef="uref_720247910">2955000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17154"
      unitRef="uref_720247910">10355000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17155"
      unitRef="uref_720247910">8804000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17156"
      unitRef="uref_720247910">8938000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17157"
      unitRef="uref_720247910">-9950000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17158"
      unitRef="uref_720247910">-8130000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17159"
      unitRef="uref_720247910">-8195000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17160"
      unitRef="uref_720247910">122000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17161"
      unitRef="uref_720247910">250000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17162"
      unitRef="uref_720247910">561000</us-gaap:InvestmentIncomeNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17163"
      unitRef="uref_720247910">-9828000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17164"
      unitRef="uref_720247910">-7880000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17165"
      unitRef="uref_720247910">-7634000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17166"
      unitRef="uref_720247910">-9828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17167"
      unitRef="uref_720247910">-7880000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17168"
      unitRef="uref_720247910">-7634000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_184434641"
      decimals="2"
      id="fc_872966651"
      unitRef="uref_1278442780">-5.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_184434641"
      decimals="2"
      id="ixv-17170"
      unitRef="uref_1278442780">-5.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1205104151"
      decimals="2"
      id="ixv-17171"
      unitRef="uref_1278442780">-10.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1205104151"
      decimals="2"
      id="ixv-17172"
      unitRef="uref_1278442780">-10.86</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1914073660"
      decimals="2"
      id="ixv-17173"
      unitRef="uref_1278442780">-17.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1914073660"
      decimals="2"
      id="ixv-17174"
      unitRef="uref_1278442780">-17.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_184434641"
      decimals="0"
      id="fc_2139747243"
      unitRef="uref_734008993">1646208</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_184434641"
      decimals="0"
      id="fc_1309137784"
      unitRef="uref_734008993">1646208</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1205104151"
      decimals="0"
      id="fc_50742992"
      unitRef="uref_734008993">725309</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1205104151"
      decimals="0"
      id="fc_1621210643"
      unitRef="uref_734008993">725309</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1914073660"
      decimals="0"
      id="fc_977396253"
      unitRef="uref_734008993">426111</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1914073660"
      decimals="0"
      id="fc_1373640430"
      unitRef="uref_734008993">426111</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="cref_1316363029"
      decimals="0"
      id="fc_1316363029"
      unitRef="uref_734008993">271916</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1689545004"
      decimals="-3"
      id="ixv-17183"
      unitRef="uref_720247910">154192000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_430322482"
      decimals="-3"
      id="ixv-17184"
      unitRef="uref_720247910">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1096639490"
      decimals="-3"
      id="ixv-17185"
      unitRef="uref_720247910">-150847000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_346153289"
      decimals="-3"
      id="ixv-17186"
      unitRef="uref_720247910">4472000</us-gaap:StockholdersEquity>
    <canf:NetOfIssuanceCostsOfOrdinarySharesAndWarrants
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17187"
      unitRef="uref_720247910">973000</canf:NetOfIssuanceCostsOfOrdinarySharesAndWarrants>
    <canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants
      contextRef="cref_1182592801"
      decimals="0"
      id="fc_2108866782"
      unitRef="uref_734008993">30000</canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="cref_692454694"
      decimals="-3"
      id="ixv-17189"
      unitRef="uref_720247910">6526000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17190"
      unitRef="uref_720247910">6526000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17191"
      unitRef="uref_720247910">386000</canf:NetOfIssuanceExpensesOfOrdinarySharesDueToExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="cref_1182592801"
      decimals="0"
      id="fc_1182592801"
      unitRef="uref_734008993">151363</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_692454694"
      decimals="-3"
      id="ixv-17193"
      unitRef="uref_720247910">2618000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17194"
      unitRef="uref_720247910">2618000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_692454694"
      decimals="-3"
      id="ixv-17195"
      unitRef="uref_720247910">261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17196"
      unitRef="uref_720247910">261000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="cref_847760719"
      decimals="-3"
      id="ixv-17197"
      unitRef="uref_720247910">-7634000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17198"
      unitRef="uref_720247910">-7634000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_471624570"
      decimals="0"
      id="fc_471624570"
      unitRef="uref_734008993">453279</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_713467315"
      decimals="-3"
      id="ixv-17200"
      unitRef="uref_720247910">163597000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1568626008"
      decimals="-3"
      id="ixv-17201"
      unitRef="uref_720247910">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_301922635"
      decimals="-3"
      id="ixv-17202"
      unitRef="uref_720247910">-158481000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_385792771"
      decimals="-3"
      id="ixv-17203"
      unitRef="uref_720247910">6243000</us-gaap:StockholdersEquity>
    <canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance
      contextRef="cref_1743024573"
      decimals="0"
      id="fc_761083602"
      unitRef="uref_734008993">151364</canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance>
    <canf:NetOfIssuanceCostsOfOrdinarySharesAndWarrants
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17205"
      unitRef="uref_720247910">512000</canf:NetOfIssuanceCostsOfOrdinarySharesAndWarrants>
    <canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants
      contextRef="cref_1743024573"
      decimals="0"
      id="fc_1556835653"
      unitRef="uref_734008993">285714</canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="cref_60220687"
      decimals="-3"
      id="ixv-17207"
      unitRef="uref_720247910">4488000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17208"
      unitRef="uref_720247910">4488000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:NetOfIssuanceCostsOrdinarySharesDueToATM
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17209"
      unitRef="uref_720247910">152000</canf:NetOfIssuanceCostsOrdinarySharesDueToATM>
    <canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM
      contextRef="cref_1743024573"
      decimals="0"
      id="fc_462574281"
      unitRef="uref_734008993">99037</canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_60220687"
      decimals="-3"
      id="ixv-17211"
      unitRef="uref_720247910">2223000</canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17212"
      unitRef="uref_720247910">2223000</canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="cref_1743024573"
      decimals="0"
      id="fc_563207362"
      unitRef="uref_734008993">5000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_60220687"
      decimals="-3"
      id="ixv-17214"
      unitRef="uref_720247910">362000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17215"
      unitRef="uref_720247910">362000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="cref_869951728"
      decimals="-3"
      id="ixv-17216"
      unitRef="uref_720247910">-7880000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17217"
      unitRef="uref_720247910">-7880000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_679399687"
      decimals="0"
      id="fc_1391618102"
      unitRef="uref_734008993">994394</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1447998007"
      decimals="-3"
      id="ixv-17219"
      unitRef="uref_720247910">170670000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_503396369"
      decimals="-3"
      id="ixv-17220"
      unitRef="uref_720247910">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1298046308"
      decimals="-3"
      id="ixv-17221"
      unitRef="uref_720247910">-166361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17222"
      unitRef="uref_720247910">5436000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_679399687"
      decimals="0"
      id="fc_679399687"
      unitRef="uref_734008993">994394</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1447998007"
      decimals="-3"
      id="ixv-17224"
      unitRef="uref_720247910">170670000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_503396369"
      decimals="-3"
      id="ixv-17225"
      unitRef="uref_720247910">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1298046308"
      decimals="-3"
      id="ixv-17226"
      unitRef="uref_720247910">-166361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17227"
      unitRef="uref_720247910">5436000</us-gaap:StockholdersEquity>
    <canf:NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17228"
      unitRef="uref_720247910">1289000</canf:NetOfIssuanceCostsOrdinarySharesAndWarrantsAndExerciseOfPreFundedWarrants>
    <canf:StockIssuedDuringPeriodSharesExercised
      contextRef="cref_236998777"
      decimals="0"
      id="fc_887952012"
      unitRef="uref_734008993">1083333</canf:StockIssuedDuringPeriodSharesExercised>
    <canf:StockIssuedDuringPeriodExerciseValue
      contextRef="cref_1978583206"
      decimals="-3"
      id="ixv-17230"
      unitRef="uref_720247910">6711000</canf:StockIssuedDuringPeriodExerciseValue>
    <canf:StockIssuedDuringPeriodExerciseValue
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17231"
      unitRef="uref_720247910">6711000</canf:StockIssuedDuringPeriodExerciseValue>
    <canf:NetOfIssuanceCostsOrdinarySharesDueToATM
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17232"
      unitRef="uref_720247910">367000</canf:NetOfIssuanceCostsOrdinarySharesDueToATM>
    <canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM
      contextRef="cref_236998777"
      decimals="0"
      id="fc_776479262"
      unitRef="uref_734008993">530698</canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_1978583206"
      decimals="-3"
      id="ixv-17234"
      unitRef="uref_720247910">2933000</canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17235"
      unitRef="uref_720247910">2933000</canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="cref_236998777"
      decimals="0"
      id="fc_41120727"
      unitRef="uref_734008993">10000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1978583206"
      decimals="-3"
      id="ixv-17237"
      unitRef="uref_720247910">340000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17238"
      unitRef="uref_720247910">340000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1722856177"
      decimals="-3"
      id="ixv-17239"
      unitRef="uref_720247910">-9828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17240"
      unitRef="uref_720247910">-9828000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_1254970073"
      decimals="0"
      id="fc_1254970073"
      unitRef="uref_734008993">2618425</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1268205755"
      decimals="-3"
      id="ixv-17242"
      unitRef="uref_720247910">180654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1110324969"
      decimals="-3"
      id="ixv-17243"
      unitRef="uref_720247910">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1212188529"
      decimals="-3"
      id="ixv-17244"
      unitRef="uref_720247910">-176189000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17245"
      unitRef="uref_720247910">5592000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17247"
      unitRef="uref_720247910">-9828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17248"
      unitRef="uref_720247910">-7880000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17249"
      unitRef="uref_720247910">-7634000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17250"
      unitRef="uref_720247910">24000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17251"
      unitRef="uref_720247910">7000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17252"
      unitRef="uref_720247910">15000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17253"
      unitRef="uref_720247910">42000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17254"
      unitRef="uref_720247910">37000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17255"
      unitRef="uref_720247910">94000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17256"
      unitRef="uref_720247910">340000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17257"
      unitRef="uref_720247910">362000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17258"
      unitRef="uref_720247910">261000</us-gaap:ShareBasedCompensation>
    <canf:ChangesInFairValueOfShortTermInvestment
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17259"
      unitRef="uref_720247910">4000</canf:ChangesInFairValueOfShortTermInvestment>
    <canf:ChangesInFairValueOfShortTermInvestment
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17260"
      unitRef="uref_720247910">14000</canf:ChangesInFairValueOfShortTermInvestment>
    <canf:ChangesInFairValueOfShortTermInvestment
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17261"
      unitRef="uref_720247910">-11000</canf:ChangesInFairValueOfShortTermInvestment>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="cref_184434641"
      decimals="-3"
      id="fc_2046050939"
      unitRef="uref_720247910">-36000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="cref_1205104151"
      decimals="-3"
      id="fc_2109237782"
      unitRef="uref_720247910">-90000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="cref_1914073660"
      decimals="-3"
      id="fc_1764296517"
      unitRef="uref_720247910">222000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17265"
      unitRef="uref_720247910">-195000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17266"
      unitRef="uref_720247910">109000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17267"
      unitRef="uref_720247910">-184000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17268"
      unitRef="uref_720247910">-33000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17269"
      unitRef="uref_720247910">-32000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17270"
      unitRef="uref_720247910">-84000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17271"
      unitRef="uref_720247910">543000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17272"
      unitRef="uref_720247910">191000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17273"
      unitRef="uref_720247910">-469000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17274"
      unitRef="uref_720247910">-405000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17275"
      unitRef="uref_720247910">-349000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17276"
      unitRef="uref_720247910">-743000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17277"
      unitRef="uref_720247910">133000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17278"
      unitRef="uref_720247910">32000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17279"
      unitRef="uref_720247910">169000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17280"
      unitRef="uref_720247910">-8949000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17281"
      unitRef="uref_720247910">-7637000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17282"
      unitRef="uref_720247910">-8440000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17283"
      unitRef="uref_720247910">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17284"
      unitRef="uref_720247910">5000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17285"
      unitRef="uref_720247910">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17286"
      unitRef="uref_720247910">-1500000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17287"
      unitRef="uref_720247910">-500000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17288"
      unitRef="uref_720247910">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17289"
      unitRef="uref_720247910">1495000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17290"
      unitRef="uref_720247910">498000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17291"
      unitRef="uref_720247910">2933000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17292"
      unitRef="uref_720247910">2223000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17293"
      unitRef="uref_720247910">6711000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17294"
      unitRef="uref_720247910">4488000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17295"
      unitRef="uref_720247910">9144000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17296"
      unitRef="uref_720247910">9644000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17297"
      unitRef="uref_720247910">6711000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17298"
      unitRef="uref_720247910">9144000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17299"
      unitRef="uref_720247910">10000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17300"
      unitRef="uref_720247910">-22000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17301"
      unitRef="uref_720247910">98000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17302"
      unitRef="uref_720247910">703000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17303"
      unitRef="uref_720247910">547000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17304"
      unitRef="uref_720247910">1300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17305"
      unitRef="uref_720247910">4825000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_385792771"
      decimals="-3"
      id="ixv-17306"
      unitRef="uref_720247910">4278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_346153289"
      decimals="-3"
      id="ixv-17307"
      unitRef="uref_720247910">2978000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17308"
      unitRef="uref_720247910">5528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17309"
      unitRef="uref_720247910">4825000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_385792771"
      decimals="-3"
      id="ixv-17310"
      unitRef="uref_720247910">4278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <canf:LeaseLiabilitiesArisingFromObtainingRightofuseassets
      contextRef="cref_1205104151"
      decimals="-3"
      id="fc_1942140320"
      unitRef="uref_720247910">96000</canf:LeaseLiabilitiesArisingFromObtainingRightofuseassets>
    <canf:LeaseLiabilitiesArisingFromObtainingRightofuseassets
      contextRef="cref_1914073660"
      decimals="-3"
      id="fc_1991396066"
      unitRef="uref_720247910">62000</canf:LeaseLiabilitiesArisingFromObtainingRightofuseassets>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="cref_184434641" id="ixv-12460">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 1:-&#160;GENERAL&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company description:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Can-Fite Biopharma Ltd. (the &#x201c;Company&#x201d;) was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, MASH, pancreatic cancer and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. The Company&#x2019;s pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators at the A3AR.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; The Company&#x2019;s ordinary shares have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#x201c;CFBI&#x201d; and the Company&#x2019;s American Depositary Shares (&#x201c;ADSs&#x201d;) began public trading on the over the counter market in the U.S. in October 2012 and since November 2013 the Company&#x2019;s ADSs have been publicly traded on the NYSE American under the symbol &#x201c;CANF&#x201d;. Each ADS represents 2 ordinary shares of the Company. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under&#160;Accounting Standard Codification (&#x201c;ASC&#x201d;)&#160;Subtopic 205-40,&#160;Presentation of Financial Statements&#x2014;Going Concern&#160;(&#x201c;ASC 205-40&#x201d;), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its obligations as they become due within one year after the date that the financial statements are issued. As required under ASC 205-40, management&#x2019;s evaluation should initially not take into consideration the potential mitigating effects of management&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;i&gt;Evaluation of Substantial Doubt Raised&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 43.05pt; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;In performing the first step of the evaluation, the Company concluded that the following conditions raised substantial doubt about its ability to continue as a going concern:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;History of net losses of&#160;$9,828, $7,880 and $7,634&#160;for the years ended December 31, 2025, 2024 and 2023, respectively. The accumulated deficit for the years ended December 31, 2025, was $176,189.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; background-color: transparent"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="background-color: transparent; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net operating cash outflow of&#160;$8,949, $7,637 and $8,440 for the years ended December 31, 2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reliance on additional financing in order to execute its research and development plans.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 0.5in; background-color: white"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in; background-color: white"&gt;&lt;i&gt;Consideration&#160;of Management&#x2019;s Plans&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 0.75in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt; In performing the second step of this assessment, the Company is required to evaluate whether it is probable that the Company&#x2019;s plans will be effectively implemented within one year after the financial statements are issued and whether it is probable those plans will alleviate the substantial doubt raised about the Company&#x2019;s ability to continue as a going concern. As of December 31, 2025, the Company had $8,539&#160;in available cash, cash equivalents and short-term deposits. Subsequent to balance sheet date, the Company raised gross proceeds of approximately $4,350, refer to Note 15. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;Liquidity resources suffice for at least twelve months from the date that the consolidated financial statements were issued, nevertheless the Company has committed to implement a contingency plan, as required, in order to allow it to continue its operations and meet its cash obligations. The contingency plan consists of cost reduction, which include mainly deferral and reprioritization of certain research and development programs that would involve reduced program spend and reduction in compensation paid to key management personnel until additional financing is obtained.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in; background-color: white"&gt;&lt;i&gt;Management&#160;Assessment&#160;of Ability to Continue as a Going Concern&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 0.75in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;The Company has a history of operating losses and negative cash flows from operations. However, despite these conditions, the Company believes management&#x2019;s plans, as described more fully above, will provide sufficient liquidity to meet its financial obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;Therefore, management concluded these plans alleviate the substantial doubt that was raised about the Company&#x2019;s ability to continue as a going concern for at least twelve months from the date that the consolidated financial statements were issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in; background-color: white"&gt;&lt;i&gt;Future Plans and Considerations&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.65pt; text-align: justify; text-indent: 0.75in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;Although not considered for purposes of the Company&#x2019;s assessment of whether substantial doubt was alleviated, the Company has plans to improve operating cash flows by entering into strategic partnerships with other companies that can provide access to additional customers and new markets. The Company may also seek to raise additional funds through the issuance of debt and/or equity securities or otherwise.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;The Company&#x2019;s plans are subject to inherent risks and uncertainties. Accordingly, there can be no assurance that the Company&#x2019;s plans can be effectively implemented and, therefore, that the conditions can be effectively mitigated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Until such time, if ever, that the Company can generate revenue sufficient to achieve profitability, the Company expects to finance its operations through equity or debt financings, which may not be available to the Company on the timing needed or on terms that the Company deems to be favorable. To the extent that the Company raises additional capital through the sale of equity or debt securities, the ownership interest of its stockholders will be diluted. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <canf:NumberOfOrdinaryShares
      contextRef="cref_1997617154"
      decimals="0"
      id="ixv-17313"
      unitRef="uref_734008993">2</canf:NumberOfOrdinaryShares>
    <us-gaap:NetIncomeLoss
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17314"
      unitRef="uref_720247910">-9828000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17315"
      unitRef="uref_720247910">-7880000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17316"
      unitRef="uref_720247910">-7634000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17317"
      unitRef="uref_720247910">-8949000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17318"
      unitRef="uref_720247910">-7637000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17319"
      unitRef="uref_720247910">-8440000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17320"
      unitRef="uref_720247910">8539000</us-gaap:CashEquivalentsAtCarryingValue>
    <canf:GrossProceeds
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17321"
      unitRef="uref_720247910">4350000</canf:GrossProceeds>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="cref_184434641" id="ixv-12573">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use of estimates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principles of consolidation:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Segment Information&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company&#x2019;s operations and manage its business in&#160;one&#160;operating segment which is the research and development of the Company&#x2019;s drug candidates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency, reporting currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The functional currency of the Company is the U.S. dollar. Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars in accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;) No. 830 &#x201c;Foreign Currency Matters.&#x201d; All transaction gains and losses of the re-measured monetary balance sheet items are reflected in the consolidated statements of comprehensive loss as financial income or expenses, as appropriate.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;Cash equivalents are short-term, highly liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash equivalents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term bank deposits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -21.25pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2025 and 2024, the Company&#x2019;s bank deposits are denominated in U.S. dollars and bears yearly interest at weighted average rates of&#160;4.30% and&#160;5.25%. Short-term bank deposits are presented at their cost, including accrued interest. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses, and other current assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Prepaid expenses are composed mainly from prepayments to suppliers and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and no longer have an alternative future use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In accordance with ASU No. 2016-02, &#x201c;Leases (Topic 842)&#x201d;, the Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset for leases with a term of twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from the lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate (&#x201c;IBR&#x201d;) based on the information available at commencement date in determining the present value of lease payments. The Company&#x2019;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, plant and equipment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Mainly&lt;br/&gt;  %&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 78%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-left: 49.65pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6 - 33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of long-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; Property and equipment and ROU assets are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment,&#x201d; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets (assets group) to be held and used is measured by a comparison of the carrying amount of an asset (assets group) to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. As of December 31, 2025, and 2024, &lt;span style="-sec-ix-hidden:fc_669790381"&gt;&lt;span style="-sec-ix-hidden:fc_406290213"&gt;no&lt;/span&gt;&lt;/span&gt; impairment indicators have been identified. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue recognition:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company recognizes revenue in accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#x201c;ASC 606&#x201d;) and determines revenue recognition through the following steps:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification of the contract, or contracts, with a customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification of the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determination of the transaction price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation of the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognition of revenue when, or as, the performance obligations are satisfied.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company generates revenues from supply and distribution agreements. The consideration under these agreements comprises of upfront fees, milestone payments and potential royalty payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf of third parties (such as taxes).&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and distribution agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts generally include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company has concluded that the abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded based on the term of the research and development services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts also include development milestones payments and future sales-based royalties.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Development milestones payments are recognized only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with those milestones is subsequently resolved.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Sales based royalties are recognized only when the subsequent sale occurs. As of December 31, 2025, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any sales-based royalties.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The prepayments terms from the Company&#x2019;s contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing from the customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition &#x2013; Contract Balances &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; Contract liabilities, due to the upfront payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2025 and December 31, 2024 contract liabilities and remaining performance obligation amounted to $1,581&#160;and $1,986, respectively and are presented under deferred revenues. During the year ended December 31, 2025, the Company recognized revenues in the amount of $405 which have been included in the contract liabilities at December&#160;31, 2024. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Deferred revenue and remaining performance obligation that is anticipated to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded as non-current deferred revenue.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Major customer data as a percentage of total revenues:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: justify"&gt;Cipher Pharmaceuticals (Canada)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Chong Kun Dang Pharmaceuticals Corp. (South Korea)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Gebro Holding GmbH (Austria)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Ewopharma AG (Switzerland)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Vetbiolix (France)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1997113680"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_487311381"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Research and development costs are expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization, rent, and utilities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;). Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent from the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 1 - Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The carrying amounts of cash and cash equivalents, short term deposit, prepaid expenses and other currents assets, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The Company has an investment in marketable equity security classified within level 1 in the fair value hierarchy.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Concentration of Credit Risk:&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal and other contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for its contingent liabilities in accordance with ASC 450, Contingencies (&#x201c;ASC 450&#x201d;). A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;As of December 31, 2025, and 2024, the Company is not a party to any litigation that could have a material adverse effect on the Company&#x2019;s business, financial position, results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Severance pay&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; The Company&#x2019;s liability for severance pay is pursuant to Section 14 of the Israeli Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), pursuant to which all the Company&#x2019;s employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee&#x2019;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.&#160;Severance pay expense for the year ended December 31, 2025, 2024 and 2023 amounted to $53, $49 and $47, respectively. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for share-based compensation in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#x2019;s consolidated statement of comprehensive loss, based on acceleration method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company recognizes compensation expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company estimates the fair value of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility, early exercise factor and the expected option term. Expected volatility was calculated based upon historical volatility of the Company and early exercise factor was calculated based on statistical studies in the U.S market. The risk-free interest rate is based on the yield from government bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for income taxes in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2025, and 2024, a full valuation allowance was provided by the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2025, and 2024, &lt;span style="-sec-ix-hidden:fc_972519014"&gt;&lt;span style="-sec-ix-hidden:fc_213046275"&gt;no&lt;/span&gt;&lt;/span&gt; liability for unrecognized tax benefits was recorded.&#160; &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants to purchase ordinary shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#x2019;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net loss per share&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Basic and diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. The Company include in the basic net loss per share calculation, pre-funded warrants that are exercisable for a nominal consideration. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#x201c;Earnings per Share&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;All outstanding share options and warrants for the years ended December 31, 2025, 2024 and 2023 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. The potential ordinary shares and warrants that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49,533&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,610&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,604,096&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;886,599&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;617,337&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,653,629&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;928,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;644,829&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Retroactively adjusted to give effect to the reverse share split, see also note 9.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recently adopted accounting pronouncements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which requires disaggregated information about the effective tax rate reconciliation as well as information on income taxes paid. The guidance will be effective for the Company for annual periods beginning January 1, 2025, with early adoption permitted. The adoption of the standard &lt;span style="background-color: white"&gt;did not &lt;/span&gt; have material impact on its financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 28px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;v.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Recently issued accounting pronouncements not yet adopted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In November 2024, the FASB issued ASU 2024-03&lt;i&gt;&#160;&#x201c;Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures&#x201d;&lt;/i&gt;&#160;(&#x201c;ASU 2024-03&#x201d;), which requires more detailed information about specified categories of expenses presented on the face of the income statement, in addition to disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. The amendment may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating ASU 2024-03 to determine the impact it may have on its consolidated financial statements and related disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="cref_184434641" id="ixv-12579">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use of estimates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="cref_184434641" id="ixv-12591">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principles of consolidation:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="cref_184434641" id="ixv-12603">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Segment Information&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company&#x2019;s operations and manage its business in&#160;one&#160;operating segment which is the research and development of the Company&#x2019;s drug candidates.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="cref_184434641" id="ixv-12615">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency, reporting currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The functional currency of the Company is the U.S. dollar. Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are re-measured into U.S. dollars in accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;) No. 830 &#x201c;Foreign Currency Matters.&#x201d; All transaction gains and losses of the re-measured monetary balance sheet items are reflected in the consolidated statements of comprehensive loss as financial income or expenses, as appropriate.&#160;&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="cref_184434641" id="ixv-12627">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;Cash equivalents are short-term, highly liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <canf:ShorttermBankDepositsPolicyTextBlock contextRef="cref_184434641" id="ixv-12657">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term bank deposits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -21.25pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2025 and 2024, the Company&#x2019;s bank deposits are denominated in U.S. dollars and bears yearly interest at weighted average rates of&#160;4.30% and&#160;5.25%. Short-term bank deposits are presented at their cost, including accrued interest. &lt;/p&gt;</canf:ShorttermBankDepositsPolicyTextBlock>
    <canf:ShortTermBankDepositsYearlyInterestRatePercentage
      contextRef="cref_184434641"
      decimals="4"
      id="ixv-17322"
      unitRef="uref_1413771939">0.043</canf:ShortTermBankDepositsYearlyInterestRatePercentage>
    <canf:ShortTermBankDepositsYearlyInterestRatePercentage
      contextRef="cref_1205104151"
      decimals="4"
      id="ixv-17323"
      unitRef="uref_1413771939">0.0525</canf:ShortTermBankDepositsYearlyInterestRatePercentage>
    <canf:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock contextRef="cref_184434641" id="ixv-12669">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses, and other current assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Prepaid expenses are composed mainly from prepayments to suppliers and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and no longer have an alternative future use.&lt;/p&gt;</canf:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="cref_184434641" id="ixv-12681">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In accordance with ASU No. 2016-02, &#x201c;Leases (Topic 842)&#x201d;, the Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset for leases with a term of twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum lease payments arising from the lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate (&#x201c;IBR&#x201d;) based on the information available at commencement date in determining the present value of lease payments. The Company&#x2019;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="cref_184434641" id="ixv-12697">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, plant and equipment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates: &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Mainly&lt;br/&gt;  %&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 78%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-left: 49.65pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6 - 33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <canf:ScheduleOfUsefulLivesOfTheAssetTableTextBlock contextRef="cref_184434641" id="ixv-17324">Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Mainly&lt;br/&gt;  %&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 78%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-left: 49.65pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6 - 33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</canf:ScheduleOfUsefulLivesOfTheAssetTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="cref_180300996"
      decimals="2"
      id="ixv-17325"
      unitRef="uref_1413771939">0.10</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="cref_180300996"
      decimals="2"
      id="ixv-17326"
      unitRef="uref_1413771939">0.10</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="cref_1654566158"
      decimals="2"
      id="ixv-17327"
      unitRef="uref_1413771939">0.06</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="cref_794440730"
      decimals="2"
      id="ixv-17328"
      unitRef="uref_1413771939">0.33</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage
      contextRef="cref_1707962055"
      decimals="2"
      id="ixv-17329"
      unitRef="uref_1413771939">0.33</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="cref_184434641" id="ixv-12771">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of long-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; Property and equipment and ROU assets are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment,&#x201d; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets (assets group) to be held and used is measured by a comparison of the carrying amount of an asset (assets group) to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. As of December 31, 2025, and 2024, &lt;span style="-sec-ix-hidden:fc_669790381"&gt;&lt;span style="-sec-ix-hidden:fc_406290213"&gt;no&lt;/span&gt;&lt;/span&gt; impairment indicators have been identified. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="cref_184434641" id="ixv-12785">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue recognition:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company recognizes revenue in accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#x201c;ASC 606&#x201d;) and determines revenue recognition through the following steps:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification of the contract, or contracts, with a customer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification of the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determination of the transaction price;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation of the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognition of revenue when, or as, the performance obligations are satisfied.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company generates revenues from supply and distribution agreements. The consideration under these agreements comprises of upfront fees, milestone payments and potential royalty payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts collected on behalf of third parties (such as taxes).&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and distribution agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts generally include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company has concluded that the abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded based on the term of the research and development services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts also include development milestones payments and future sales-based royalties.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Development milestones payments are recognized only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with those milestones is subsequently resolved.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Sales based royalties are recognized only when the subsequent sale occurs. As of December 31, 2025, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any sales-based royalties.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The prepayments terms from the Company&#x2019;s contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing from the customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition &#x2013; Contract Balances &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; Contract liabilities, due to the upfront payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2025 and December 31, 2024 contract liabilities and remaining performance obligation amounted to $1,581&#160;and $1,986, respectively and are presented under deferred revenues. During the year ended December 31, 2025, the Company recognized revenues in the amount of $405 which have been included in the contract liabilities at December&#160;31, 2024. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Deferred revenue and remaining performance obligation that is anticipated to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded as non-current deferred revenue.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Major customer data as a percentage of total revenues:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: justify"&gt;Cipher Pharmaceuticals (Canada)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Chong Kun Dang Pharmaceuticals Corp. (South Korea)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Gebro Holding GmbH (Austria)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Ewopharma AG (Switzerland)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Vetbiolix (France)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1997113680"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_487311381"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17330"
      unitRef="uref_720247910">1581000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17331"
      unitRef="uref_720247910">1986000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17332"
      unitRef="uref_720247910">405000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="cref_184434641" id="ixv-12883">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Major customer data as a percentage of total revenues:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: justify"&gt;Cipher Pharmaceuticals (Canada)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Chong Kun Dang Pharmaceuticals Corp. (South Korea)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Gebro Holding GmbH (Austria)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Ewopharma AG (Switzerland)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Vetbiolix (France)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1997113680"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_487311381"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1329610678"
      decimals="2"
      id="ixv-17333"
      unitRef="uref_1413771939">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1085088613"
      decimals="2"
      id="ixv-17334"
      unitRef="uref_1413771939">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1756871285"
      decimals="2"
      id="ixv-17335"
      unitRef="uref_1413771939">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1051158666"
      decimals="2"
      id="ixv-17336"
      unitRef="uref_1413771939">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1752405840"
      decimals="2"
      id="ixv-17337"
      unitRef="uref_1413771939">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_262393112"
      decimals="2"
      id="ixv-17338"
      unitRef="uref_1413771939">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1380163261"
      decimals="2"
      id="ixv-17339"
      unitRef="uref_1413771939">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1630416524"
      decimals="2"
      id="ixv-17340"
      unitRef="uref_1413771939">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_2073970239"
      decimals="2"
      id="ixv-17341"
      unitRef="uref_1413771939">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_707849457"
      decimals="2"
      id="ixv-17342"
      unitRef="uref_1413771939">0.51</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1969999970"
      decimals="2"
      id="ixv-17343"
      unitRef="uref_1413771939">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_401885686"
      decimals="2"
      id="ixv-17344"
      unitRef="uref_1413771939">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_940504229"
      decimals="2"
      id="ixv-17345"
      unitRef="uref_1413771939">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1010971887"
      decimals="2"
      id="ixv-17346"
      unitRef="uref_1413771939">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_656845410"
      decimals="2"
      id="ixv-17347"
      unitRef="uref_1413771939">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="cref_1513674"
      decimals="2"
      id="ixv-17348"
      unitRef="uref_1413771939">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="cref_184434641" id="ixv-13016">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Research and development costs are expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization, rent, and utilities.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="cref_184434641" id="ixv-13044">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;). Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent from the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 1 - Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 2 - Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The carrying amounts of cash and cash equivalents, short term deposit, prepaid expenses and other currents assets, trade payables and other accounts payable and accrued expenses approximate their fair value due to the short-term maturity of such instruments. The Company has an investment in marketable equity security classified within level 1 in the fair value hierarchy.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="cref_184434641" id="ixv-13066">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Concentration of Credit Risk:&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <canf:LegalAndOtherContingenciesPolicyTextBlock contextRef="cref_184434641" id="ixv-13078">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal and other contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for its contingent liabilities in accordance with ASC 450, Contingencies (&#x201c;ASC 450&#x201d;). A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;As of December 31, 2025, and 2024, the Company is not a party to any litigation that could have a material adverse effect on the Company&#x2019;s business, financial position, results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/p&gt;</canf:LegalAndOtherContingenciesPolicyTextBlock>
    <canf:SeverancePayPolicyTextBlock contextRef="cref_184434641" id="ixv-13109">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Severance pay&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; The Company&#x2019;s liability for severance pay is pursuant to Section 14 of the Israeli Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), pursuant to which all the Company&#x2019;s employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in the employee&#x2019;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.&#160;Severance pay expense for the year ended December 31, 2025, 2024 and 2023 amounted to $53, $49 and $47, respectively. &lt;/p&gt;</canf:SeverancePayPolicyTextBlock>
    <canf:PercentageOfDepositsOnMonthlySalary
      contextRef="cref_184434641"
      decimals="4"
      id="ixv-17349"
      unitRef="uref_1413771939">0.0833</canf:PercentageOfDepositsOnMonthlySalary>
    <us-gaap:SeveranceCosts1
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17350"
      unitRef="uref_720247910">53000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17351"
      unitRef="uref_720247910">49000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17352"
      unitRef="uref_720247910">47000</us-gaap:SeveranceCosts1>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="cref_184434641" id="ixv-13122">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for share-based compensation in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#x2019;s consolidated statement of comprehensive loss, based on acceleration method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company recognizes compensation expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company estimates the fair value of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility, early exercise factor and the expected option term. Expected volatility was calculated based upon historical volatility of the Company and early exercise factor was calculated based on statistical studies in the U.S market. The risk-free interest rate is based on the yield from government bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="cref_184434641" id="ixv-13139">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for income taxes in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2025, and 2024, a full valuation allowance was provided by the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2025, and 2024, &lt;span style="-sec-ix-hidden:fc_972519014"&gt;&lt;span style="-sec-ix-hidden:fc_213046275"&gt;no&lt;/span&gt;&lt;/span&gt; liability for unrecognized tax benefits was recorded.&#160; &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <canf:PercentageOfRealizationOnUltimateSettlement
      contextRef="cref_184434641"
      decimals="2"
      id="ixv-17353"
      unitRef="uref_1413771939">0.50</canf:PercentageOfRealizationOnUltimateSettlement>
    <canf:WarrantsToPurchaseOrdinarySharesPolicyTextBlock contextRef="cref_184434641" id="ixv-13174">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants to purchase ordinary shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#x2019;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.&lt;/p&gt;</canf:WarrantsToPurchaseOrdinarySharesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="cref_184434641" id="ixv-13188">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net loss per share&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Basic and diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. The Company include in the basic net loss per share calculation, pre-funded warrants that are exercisable for a nominal consideration. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#x201c;Earnings per Share&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;All outstanding share options and warrants for the years ended December 31, 2025, 2024 and 2023 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. The potential ordinary shares and warrants that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49,533&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,610&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,604,096&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;886,599&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;617,337&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,653,629&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;928,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;644,829&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Retroactively adjusted to give effect to the reverse share split, see also note 9.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="cref_184434641" id="ixv-13201">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;All outstanding share options and warrants for the years ended December 31, 2025, 2024 and 2023 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. The potential ordinary shares and warrants that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: justify"&gt;Options&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49,533&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,610&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;27,492&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,604,096&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;886,599&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;617,337&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,653,629&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;928,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;644,829&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Retroactively adjusted to give effect to the reverse share split, see also note 9.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1102009625"
      decimals="0"
      id="ixv-17354"
      unitRef="uref_734008993">49533</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1787915782"
      decimals="0"
      id="ixv-17355"
      unitRef="uref_734008993">41610</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_264863037"
      decimals="0"
      id="ixv-17356"
      unitRef="uref_734008993">27492</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_626091944"
      decimals="0"
      id="ixv-17357"
      unitRef="uref_734008993">2604096</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_133213812"
      decimals="0"
      id="ixv-17358"
      unitRef="uref_734008993">886599</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_405802932"
      decimals="0"
      id="ixv-17359"
      unitRef="uref_734008993">617337</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_184434641"
      decimals="0"
      id="ixv-17360"
      unitRef="uref_734008993">2653629</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1205104151"
      decimals="0"
      id="ixv-17361"
      unitRef="uref_734008993">928209</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1914073660"
      decimals="0"
      id="ixv-17362"
      unitRef="uref_734008993">644829</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="cref_184434641" id="ixv-13298">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recently adopted accounting pronouncements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which requires disaggregated information about the effective tax rate reconciliation as well as information on income taxes paid. The guidance will be effective for the Company for annual periods beginning January 1, 2025, with early adoption permitted. The adoption of the standard &lt;span style="background-color: white"&gt;did not &lt;/span&gt; have material impact on its financial statement disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <canf:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="cref_184434641" id="ixv-13330">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 28px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;v.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Recently issued accounting pronouncements not yet adopted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In November 2024, the FASB issued ASU 2024-03&lt;i&gt;&#160;&#x201c;Income Statement (Topic 220): Reporting Comprehensive Income - Expense Disaggregation Disclosures&#x201d;&lt;/i&gt;&#160;(&#x201c;ASU 2024-03&#x201d;), which requires more detailed information about specified categories of expenses presented on the face of the income statement, in addition to disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. The amendment may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating ASU 2024-03 to determine the impact it may have on its consolidated financial statements and related disclosures.&lt;/p&gt;</canf:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="cref_184434641" id="ixv-13343">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 3:-&#160; PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: justify"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;77&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Prepaid expenses and others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;826&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;900&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,095&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="cref_184434641" id="ixv-13348">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: justify"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;77&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Prepaid expenses and others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;826&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;900&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,095&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <canf:GovernmentAuthorities
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17363"
      unitRef="uref_720247910">74000</canf:GovernmentAuthorities>
    <canf:GovernmentAuthorities
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17364"
      unitRef="uref_720247910">77000</canf:GovernmentAuthorities>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17365"
      unitRef="uref_720247910">826000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17366"
      unitRef="uref_720247910">1018000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17367"
      unitRef="uref_720247910">900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17368"
      unitRef="uref_720247910">1095000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="cref_184434641" id="ixv-13413">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 4:-&#160;PROPERTY, PLANT AND EQUIPMENT, NET &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1633826125"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;64&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2074154732"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -20.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt; Depreciation expenses for the years ended December 31, 2025, 2024 and 2023 amounted to $24, $7 and $15, respectively. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="cref_184434641" id="ixv-13417">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1633826125"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;64&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;15&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2074154732"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_255520659"
      decimals="-3"
      id="ixv-17369"
      unitRef="uref_720247910">64000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_595936047"
      decimals="-3"
      id="ixv-17370"
      unitRef="uref_720247910">17000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1126769489"
      decimals="-3"
      id="ixv-17371"
      unitRef="uref_720247910">15000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17372"
      unitRef="uref_720247910">17000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17373"
      unitRef="uref_720247910">79000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="cref_255520659"
      decimals="-3"
      id="ixv-17374"
      unitRef="uref_720247910">43000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="cref_595936047"
      decimals="-3"
      id="ixv-17375"
      unitRef="uref_720247910">12000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="cref_1126769489"
      decimals="-3"
      id="ixv-17376"
      unitRef="uref_720247910">9000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17377"
      unitRef="uref_720247910">12000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17378"
      unitRef="uref_720247910">52000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17379"
      unitRef="uref_720247910">5000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17380"
      unitRef="uref_720247910">27000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17381"
      unitRef="uref_720247910">24000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17382"
      unitRef="uref_720247910">7000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17383"
      unitRef="uref_720247910">15000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="cref_184434641" id="ixv-13587">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 5:-&lt;/span&gt;&#160;&lt;span style="font-weight: bold;"&gt;OTHER ACCOUNTS PAYABLE&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: justify"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;811&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;675&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;301&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,109&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;976&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="cref_184434641" id="ixv-13593">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: justify"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;811&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;675&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;301&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,109&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;976&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17384"
      unitRef="uref_720247910">811000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17385"
      unitRef="uref_720247910">675000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17386"
      unitRef="uref_720247910">298000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17387"
      unitRef="uref_720247910">301000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17388"
      unitRef="uref_720247910">1109000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17389"
      unitRef="uref_720247910">976000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="cref_184434641" id="ixv-13658">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 6:- FAIR VALUE MEASUREMENTS &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 820 &#x201c;Fair Value Measurements and Disclosures&#x201d;, the Company measures its short-term investment at fair value. Short-term investments are classified within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="width: 52%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1904201796"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1856579833"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Fair value&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="width: 52%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_2047207648"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_736875626"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="cref_184434641" id="ixv-13664">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="width: 52%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1904201796"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1856579833"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Fair value&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="width: 52%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_2047207648"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_736875626"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1736241007"
      decimals="-3"
      id="ixv-17390"
      unitRef="uref_720247910">1000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1943456894"
      decimals="-3"
      id="ixv-17391"
      unitRef="uref_720247910">1000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="cref_976418671"
      decimals="-3"
      id="ixv-17392"
      unitRef="uref_720247910">5000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="cref_1501641585"
      decimals="-3"
      id="ixv-17393"
      unitRef="uref_720247910">5000</us-gaap:ShortTermInvestments>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="cref_184434641" id="ixv-13810">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 7:- REVENUES&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Cipher Pharmaceuticals&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#x201c;Cipher&#x201d;). As part of the distribution agreement, Cipher will distribute Can-Fite&#x2019;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; Under the terms of the agreement, Cipher made an upfront payment of $1,292 (1,650 CAD thousands) to the Company in March 2015. In addition, the agreement provides that an additional payments of up to 2,000 thousands Canadian Dollar will be received by the Company upon the achievement of certain milestones plus royalty payments of 16.5% of net sales of Piclidenoson in Canada. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Under the agreement, the Company shall be responsible for conducting product development activities including management of the clinical studies required in order to secure regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form a joint steering committee with Cipher which will oversee the progress of the clinical studies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2025, the Company estimates that such services will be completed by December 31, 2029 and therefore revenues from such up-front payment are recognized over such period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Chong Kun Dang Pharmaceuticals Corp.&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#x201c;CKD&#x201d;). As part of the distribution agreement, CKD will have exclusive rights to distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals. On February 25, 2019, distribution agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition to liver cancer in South Korea.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; According to the distribution agreement, the Company is entitled to receive an amounts of up to $3,000 in upfront and milestone payments payable with respect to the liver cancer indication and additional $6,000 in upfront and milestone payments payable with respect to NASH indication. In addition, the Company will also be entitled to a transfer price for delivering finished product to CKD following commercial launch at a cost plus 10% basis or 23% of net sales of Namodenoson following commercial launch in South Korea. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Under the agreement, the Company shall be responsible for conducting product development activities including management of the clinical studies required in order to secure regulatory approvals and shall use commercially reasonable efforts in conducting such activities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; As of December 31, 2025, the Company received an amount of $1,500 for up-front payment and additional $500 for achieved milestone. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2025, the Company estimates that such services will be completed by June 30, 2029 and therefore revenues from such up-front payment are recognized over such period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Gebro Holding GmBH&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On January 8, 2018, the Company entered into a Distribution and Supply Agreement with Gebro Holding GmBH (&#x201c;Gebro&#x201d;), granting Gebro the exclusive right to distribute Piclidenoson in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; Under the Distribution and Supply Agreement, the Company is entitled to &#x20ac; 1,500 thousands upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) &#x20ac; 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and &#x20ac; 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between &#x20ac; 750 thousand and &#x20ac; 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#x20ac; 300 thousand and up to &#x20ac;4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.&#160; &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; As of December 31, 2025, the Company received an amount of &#x20ac; 1,500 thousands (approximately $1,850) for up-front payment and additional &#x20ac; 600 thousands (approximately $720) for achieved milestone. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2025, the Company estimates that such services will be completed by December 31, 2029 and therefore revenues from such up-front payment are recognized over such period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;CMS Medical Venture Investment Limited &lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#x201c;CMS Medical&#x201d;) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; Under the License, Collaboration and Distribution Agreement, the Company is entitled to receive an up-front amount of $2,000 upon execution of the agreement. In addition, the Company is also entitle to received an amount of up to $14,000 for milestone payments upon achieving certain regulatory milestones and up to $58,500 for milestone payments upon achieving certain sales milestones. In addition, following regulatory approval, the Company shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing of Piclidenoson and Namodenoson. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; As of December 31, 2025, the Company received an amount of $2,000 for up-front payment which was previously recognized in revenues. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Kyongbo Pharm Co., Ltd.&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On July 31, 2019, the Company signed a distribution agreement with Kyongbo Pharm Co., Ltd. (&#x201c;Kyongbo Pharm&#x201d;), to distribute Piclidenoson, for the treatment of psoriasis in South Korea, upon receipt of regulatory approvals.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; Under the terms of the distribution agreement, Kyongbo Pharm, in exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea, is required to make a total a payment of $750 for access to information and clinical study data. In addition, the Company will also be also entitled to additional payments of up to $3,250 upon achievement of certain milestones. The Company will also be entitled to a transfer price for delivering finished product to Kyongbo Pharm upon commercial launch. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; In 2019, the Company received an amount of $750 for up-front payment which recognized as revenues upon the Company providing access to information and clinical study data. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Ewopharma&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; On March 16, 2021, the Company signed an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the treatment of liver diseases namely, hepatocellular carcinoma (HCC) the most common form of liver cancer and non-alcoholic steatohepatitis (NASH). Under the terms of the distribution agreement, Ewopharma paid Can-Fite non-refundable upfront payment in an amount of $2,250 and is entitled to up to an additional $40,450 payable upon the achievement of regulatory and sales milestones and 17.5% royalties on net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution agreement to new indications that Can-Fite may identify for its drug candidates. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; As of December 31, 2025, the Company received an amount of $2,250 for up-front payment. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;As of December 31, 2025, the Company estimates that such services will be completed by December 31, 2029 and therefore revenues from such up-front payment are recognized over such period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"&gt;On January 30, 2024, the Company entered into an amendment to its distribution agreement with Ewopharma, to add the rights to the Company&#x2019;s pancreatic cancer indication for an additional immaterial up-font payment and further milestones payments.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"&gt;&lt;i&gt;&lt;span style="text-decoration:underline"&gt;Vetbiolix&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On June 28, 2021, the Company entered into a Patent and Know-how License Agreement with Vetbiolix (the &#x201c;License Agreement&#x201d;), a France-based veterinary pharmaceutical company. According to the agreement, the Company has granted Vetbiolix an exclusive option to utilize the licensed Know-How and the Company&#x2019;s patents solely for the purpose of supporting Vetbiolix&#x2019;s research, development, manufacturing and commercializing of its compounds and/or products in the field throughout the territory, all as defined in the License Agreement. The option to the licensed Know-How and the Company&#x2019;s patents is for a period of two years from the signature date (after which such period was extended by additional 15 months), during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; Upon Vetbiolix exercise of its option to acquire the licensed Know-How and the Company&#x2019;s patents, then Vetbiolix will be obligated to pay Can-Fite a non-refundable upfront payment in an amount of euro 250. In addition, Vetbiolix will also pay the Company with payment equal to 30% for each upfront and milestone payment received from and sublicensee and 15%-40% royalties on net sales upon regulatory approval for veterinary use. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; On September 24, 2024, Vetbiolix exercised its option and acquired licensed know-how and the Company&#x2019;s patents for euro 250 thousands and therefore the Company recorded equivalent revenues of $ 271 in the year ended December 31, 2024. &lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <canf:UpfrontPayment
      contextRef="cref_2046075473"
      decimals="-3"
      id="ixv-17394"
      unitRef="uref_720247910">1292000</canf:UpfrontPayment>
    <canf:UpfrontPayment
      contextRef="cref_2046075473"
      decimals="-3"
      id="ixv-17395"
      unitRef="uref_1598663686">1650000</canf:UpfrontPayment>
    <us-gaap:PaymentsForRoyalties
      contextRef="cref_1598663686"
      decimals="-3"
      id="ixv-17396"
      unitRef="uref_1598663686">2000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="cref_485025225"
      decimals="3"
      id="ixv-17397"
      unitRef="uref_1413771939">0.165</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <canf:UpfrontAndMilestonePaymentsPayable
      contextRef="cref_1375081973"
      decimals="-3"
      id="ixv-17398"
      unitRef="uref_720247910">3000000</canf:UpfrontAndMilestonePaymentsPayable>
    <canf:UpfrontAndMilestonePaymentsPayable
      contextRef="cref_818757102"
      decimals="-3"
      id="ixv-17399"
      unitRef="uref_720247910">6000000</canf:UpfrontAndMilestonePaymentsPayable>
    <canf:TransferPriceRate
      contextRef="cref_632092621"
      decimals="2"
      id="ixv-17400"
      unitRef="uref_1413771939">0.10</canf:TransferPriceRate>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="cref_1315189725"
      decimals="2"
      id="ixv-17401"
      unitRef="uref_1413771939">0.23</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1590073223"
      decimals="-3"
      id="ixv-17402"
      unitRef="uref_720247910">1500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <canf:AdditionalRevenueReceivedForAchievedMilestone
      contextRef="cref_1590073223"
      decimals="-3"
      id="ixv-17403"
      unitRef="uref_720247910">500000</canf:AdditionalRevenueReceivedForAchievedMilestone>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms contextRef="cref_1798028992" id="ixv-17404">Under the Distribution and Supply Agreement, the Company is entitled to &#x20ac; 1,500 thousands upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) &#x20ac; 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and &#x20ac; 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between &#x20ac; 750 thousand and &#x20ac; 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#x20ac; 300 thousand and up to &#x20ac;4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1798028992"
      decimals="-3"
      id="ixv-17405"
      unitRef="uref_447010128">1500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_1798028992"
      decimals="-3"
      id="ixv-17406"
      unitRef="uref_720247910">1850000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <canf:AdditionalRevenueReceivedForAchievedMilestone
      contextRef="cref_1798028992"
      decimals="-3"
      id="ixv-17407"
      unitRef="uref_447010128">600000</canf:AdditionalRevenueReceivedForAchievedMilestone>
    <canf:AdditionalRevenueReceivedForAchievedMilestone
      contextRef="cref_1798028992"
      decimals="-3"
      id="ixv-17408"
      unitRef="uref_720247910">720000</canf:AdditionalRevenueReceivedForAchievedMilestone>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms contextRef="cref_1830464667" id="ixv-17409">On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#x201c;CMS Medical&#x201d;) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis, psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan).</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <canf:UpfrontAndMilestonePaymentsPayable
      contextRef="cref_112398461"
      decimals="-3"
      id="ixv-17410"
      unitRef="uref_720247910">2000000</canf:UpfrontAndMilestonePaymentsPayable>
    <canf:AdditionalRevenueReceivedForAchievedMilestone
      contextRef="cref_758140809"
      decimals="-3"
      id="ixv-17411"
      unitRef="uref_720247910">14000000</canf:AdditionalRevenueReceivedForAchievedMilestone>
    <canf:AdditionalRevenueReceivedForAchievedMilestone
      contextRef="cref_1089428082"
      decimals="-3"
      id="ixv-17412"
      unitRef="uref_720247910">58500000</canf:AdditionalRevenueReceivedForAchievedMilestone>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17413"
      unitRef="uref_720247910">2000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_2037445886"
      decimals="-3"
      id="ixv-17414"
      unitRef="uref_720247910">750000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <canf:AdditionalRevenueReceivedForAchievedMilestone
      contextRef="cref_2037445886"
      decimals="-3"
      id="ixv-17415"
      unitRef="uref_720247910">3250000</canf:AdditionalRevenueReceivedForAchievedMilestone>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="cref_1677665869"
      decimals="-3"
      id="ixv-17416"
      unitRef="uref_720247910">750000</us-gaap:RevenueRemainingPerformanceObligation>
    <canf:NonRefundablePayment
      contextRef="cref_1154935824"
      decimals="-3"
      id="ixv-17417"
      unitRef="uref_720247910">2250000</canf:NonRefundablePayment>
    <canf:AdditionalRevenueReceivedForAchievedMilestone
      contextRef="cref_1154935824"
      decimals="-3"
      id="ixv-17418"
      unitRef="uref_720247910">40450000</canf:AdditionalRevenueReceivedForAchievedMilestone>
    <canf:PercentageOfRoyaltiesOnNetSales
      contextRef="cref_797038194"
      decimals="3"
      id="fc_797038194"
      unitRef="uref_1413771939">0.175</canf:PercentageOfRoyaltiesOnNetSales>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="cref_398624799"
      decimals="-3"
      id="ixv-17420"
      unitRef="uref_720247910">2250000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <canf:NonRefundablePayment
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17421"
      unitRef="uref_447010128">250000</canf:NonRefundablePayment>
    <canf:MilestonePaymentPercentage
      contextRef="cref_184434641"
      decimals="2"
      id="ixv-17422"
      unitRef="uref_1413771939">0.30</canf:MilestonePaymentPercentage>
    <canf:PercentageOfRoyaltiesOnNetSales
      contextRef="cref_344781049"
      decimals="2"
      id="fc_344781049"
      unitRef="uref_1413771939">0.15</canf:PercentageOfRoyaltiesOnNetSales>
    <canf:PercentageOfRoyaltiesOnNetSales
      contextRef="cref_2057783007"
      decimals="2"
      id="fc_2057783007"
      unitRef="uref_1413771939">0.40</canf:PercentageOfRoyaltiesOnNetSales>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="cref_1130319153"
      decimals="-3"
      id="ixv-17425"
      unitRef="uref_720247910">250000</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="cref_648214257"
      decimals="-3"
      id="ixv-17426"
      unitRef="uref_720247910">271000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="cref_184434641" id="ixv-13948">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a. &lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities to pay royalties:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company is committed to pay royalties as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A one-time concession commission of &#x20ac;25 thousand;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual royalties of &#x20ac;10 thousand until the clinical trials commence;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2%-3% of net sales (as defined in the agreement) received by the Company;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Royalties in a total amount of up to &#x20ac;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#x20ac;50 thousand upon initiation of Phase I studies; (ii) &#x20ac;100 thousand upon initiation of Phase II studies; (iii) &#x20ac;200 thousand upon initiation of Phase III studies; and (iv) &#x20ac;500 thousand upon marketing approval by any regulatory authority.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in"&gt; As of December 31, 2025 and 2024, &lt;span style="-sec-ix-hidden:fc_1823340782"&gt;&lt;span style="-sec-ix-hidden:fc_792382386"&gt;no&lt;/span&gt;&lt;/span&gt; accrual has been recorded with respect to Leiden University. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:NoninterestExpenseCommissionExpense
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17427"
      unitRef="uref_447010128">25000</us-gaap:NoninterestExpenseCommissionExpense>
    <us-gaap:RoyaltyExpense
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17428"
      unitRef="uref_447010128">10000</us-gaap:RoyaltyExpense>
    <canf:PercentageOfNetSales
      contextRef="cref_583004226"
      decimals="2"
      id="ixv-17429"
      unitRef="uref_1413771939">0.03</canf:PercentageOfNetSales>
    <canf:PercentageOfNetSales
      contextRef="cref_342246256"
      decimals="2"
      id="ixv-17430"
      unitRef="uref_1413771939">0.03</canf:PercentageOfNetSales>
    <us-gaap:RoyaltyExpense
      contextRef="cref_342246256"
      decimals="-3"
      id="ixv-17431"
      unitRef="uref_447010128">850000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="cref_2059261110"
      decimals="-3"
      id="ixv-17432"
      unitRef="uref_447010128">50000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="cref_337919505"
      decimals="-3"
      id="ixv-17433"
      unitRef="uref_447010128">100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="cref_576633015"
      decimals="-3"
      id="ixv-17434"
      unitRef="uref_447010128">200000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="cref_447010128"
      decimals="-3"
      id="ixv-17435"
      unitRef="uref_447010128">500000</us-gaap:RoyaltyExpense>
    <canf:RoyaltyPaymentsPercentage
      contextRef="cref_184434641"
      decimals="2"
      id="ixv-17436"
      unitRef="uref_1413771939">0.10</canf:RoyaltyPaymentsPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="cref_184434641" id="ixv-14033">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 9:-&#160;SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 22, 2023, the Company&#x2019;s shareholders approved a change in the Company&#x2019;s ordinary shares par value from NIS 0.25 per share to no par value. All par value data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the change.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;All ordinary shares have equal rights for all intent and purposes and each ordinary share confers its holder:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The right to be invited and participate in all the Company&#x2019;s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company&#x2019;s general meeting participated.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The right to participate in the distribution of the Company&#x2019;s assets upon liquidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of ordinary shares and warrants:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 1, 2024 the Company issued 5,000 ordinary shares to certain service provider in exchange for it services. The shares issued were valued at the amount of $112 which were recorded to general and administrative expenses during the year ended December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 3, 2024, the Company&#x2019;s shareholders meeting approved the increase of the Company&#x2019;s authorized share capital by additional 1,666,667 such that following the increase, the authorized share capital was 3,333,334 ordinary shares. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 8, 2024, the Company entered into an inducement offer letter with certain existing warrants holder, according to which, the holder has exercised 285,714 of his warrants for an exercise price of $17.50 per share into Company&#x2019;s ordinary shares, totaling a $5,000 gross consideration. Total issuance expenses were $512. As part of the inducement letter, the Company issued to the holder new warrants to purchase 571,429 of the Company&#x2019;s ordinary shares for an exercise price of $22.50 per share. In addition, the Company has also issued warrants to purchase 20,000 of its ordinary shares for an exercise price of $21.90 per share as issuance costs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 30, 2024, the Company entered into at-the-market     offering agreement with H.C. Wainwright &amp;amp; Co (the &#x201c;Agent&#x201d;), according to which the Company may offer and sell, from time     to time, its ordinary shares represented as ADSs, through the Agent in an at the market offering (&#x201c;ATM&#x201d;), as defined in Rule     415(a)(4) promulgated under the Securities Act of 1933, as amended.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of December 31, 2024, the Company issued 99,037     ordinary shares for net proceeds of $2,223 through the ATM.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 24px"&gt;5.&lt;/td&gt;&lt;td style="text-align: justify"&gt;During 2025, the Company issued 530,698 ordinary shares for net proceeds of $2,933 through its ATM.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 24px"&gt;6.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On April 6, 2025 the Company issued 10,000 ordinary shares to certain service provider in exchange for its services. The shares issued were valued at the amount of $141 which were recorded to general and administrative expenses during the year ended December 31, 2025.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 24px"&gt;7.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On April 14, 2025, the Company entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) pursuant to which the Company agreed to sell and issue in a registered direct offering (the &#x201c;April 2025 Offering&#x201d;) an aggregate of 250,000 ordinary shares of the Company at an offering price of $12.0 per share (the &#x201c;Ordinary Shares&#x201d;).&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt; Aggregate gross proceeds to the Company were approximately $3,000, before deducting fees payable to the placement agent and other offering expenses payable by the Company. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt; As part of the April 2025 Offering, the Company incurred an aggregate issuance costs of $452 recorded net of the Company&#x2019;s additional paid in capital. The Company also issued to the placement agent warrants equal to 7.0% of the aggregate number of ordinary Shares represented by ADSs, or 17,500 ordinary Shares represented by 8,750 ADSs, at an exercise price of $30.0 per ADS and a term expiring on April 14, 2030. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company accounted for the aforementioned warrants as freestanding instrument classified at part of the Company&#x2019;s permanent equity in accordance with ASC-480 and ASC-815-40. The Company accounted for the reduction in the warrants exercise price as issuance costs to be recorded in the Company&#x2019;s additional paid in capital in accordance with ASC 815-40, following the adoption of ASU 2021-04.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;8.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 30, 2025, the Company&#x2019;s shareholders meeting approved the increase of the Company&#x2019;s authorized share capital by an additional 3,333,334 such that following the increase, the authorized share capital was 6,666,667 ordinary shares.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;9.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On July 28, 2025, the Company completed a public offering (the &#x201c;July 2025 Offering&#x201d;) for aggregate gross proceeds (without taking into account any from any future exercises of warrants) of $5,000 gross proceeds (approximately $4,200 net of issuance cost). The Company issued to the holder from the July 2025 Offering (i) 125,000 ordinary shares (represented by 62,500ADSs, (ii) 354,167 pre-funded warrants to purchase up to 708,334 of the Company&#x2019;s ordinary shares (represented by 354,167 ADSs (the &#x201c;Pre-Funded Warrants&#x201d;), and (iii) 833,333 warrants to purchase up to 1,666,667 of the Company&#x2019;s ordinary shares (represented by 833,333 ADSs (the &#x201c;Common Warrants&#x201d; and together with the Pre-Funded Warrants, the &#x201c;Warrants&#x201d;).&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt; The Pre-Funded Warrants will be immediately exercisable at a nominal exercise price ($11.98 per ADS) and may be exercised at any time until exercised in full. The Common Warrants have an exercise price of $6.0 per share ($12.0 per ADS), are immediately exercisable, and expire on the two-year anniversary of the date of issuance. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt; As part of the July 2025 Offering, the Company incurred an aggregate issuance cost of $837 recorded net of the Company&#x2019;s additional paid in capital. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt; The Company also issued to the placement agent warrants equal to 7.0% of the aggregate number of ordinary Shares represented by 58,334 ordinary Shares (represented by 29,167 ADSs), at an exercise price of $7.5 per share ($15.0 per ADS) and a term expiring on July 28, 2029. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 24px"&gt;10.&lt;/td&gt;&lt;td style="text-align: justify"&gt;In August and September 2025, the investors from July 2025 Offering exercised 125,000 pre-funded ADSs into 250,000 ordinary shares.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 24px"&gt;11.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On November 10, 2025, a Special General Meeting of Shareholders of the Company approved to:&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Increase authorized share capital by 7,333,333 so following the resolution, Company&#x2019;s authorized share capital is 14,000,000 ordinary shares, &lt;span style="-sec-ix-hidden:fc_2130825858"&gt;no&lt;/span&gt; par value per share.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 1in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Perform a reverse split at a ratio of 1:3,000.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt; Concurrently with the reverse split, the Company effected a corresponding change in the ratio of ordinary shares underlying each of the Company&#x2019;s American Depositary Shares (ADSs), such that its ratio of ADSs to ordinary shares will change from one (1) ADS representing three hundred (300) ordinary shares to a new ratio of one (1) ADS representing two (2) ordinary shares and no adjustment will be made to the outstanding number of the ADSs of the Company. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;For accounting purposes, all share and per share amounts for ordinary share, preferred shares, warrants, options and loss per share amounts have been adjusted to give retroactive effect to the forward and reverse share splits for all periods presented in these financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Any fractional shares of more than one-half of one whole share that resulted from the reverse share splits have been rounded up to the nearest whole share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 24px"&gt;12.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On November 18, 2025, the investors from July 2025 Offering exercised 229,167 pre-funded ADSs into 458,334 ordinary shares.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&lt;/td&gt;&lt;td style="width: 24px"&gt;13.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On November 18, 2025, the Company entered into an agreement with the holder of warrants to purchase 833,333 ADS previously issued on July 29, 2025 to purchase 1,666,667 ordinary shares, pursuant to which in consideration for the holder&#x2019;s waiver of certain standstill provisions, the Company reduced the exercise price of such warrants from $12.0 per ADS to $9.34 per ADS.&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants to purchase ordinary share:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table summarizes information regarding outstanding warrants to purchase the Company&#x2019;s ordinary shares as of December 31, 2025:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Issuance date&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Number of &lt;br/&gt; outstanding &lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Exercise &lt;br/&gt; price per &lt;br/&gt; warrant&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: justify"&gt;December 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;January 2023 agent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;68.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;November 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;November 2023 agent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;19.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;August 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;571,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;August 2024 agent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;21.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;April 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;15.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;July 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,666,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;July 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,604,097&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;As of December 31, 2025 and 2024, all of the Company&#x2019;s outstanding warrants are classified as part of the Company&#x2019;s equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share options plan:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; On November 28, 2013, the board of directors approved the adoption of the 2013 Share Option Plan (the &#x201c;2013 Plan&#x201d;). Under the Company&#x2019;s 2013 Plan, in May 2023, the Company&#x2019;s Board of Directors approved to increase number of ordinary shares reserved for issuance to 28,333. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; On August 30, 2023, the Company&#x2019;s board of directors approved the adoption on a new 2023 Share Option Plan (the &#x201c;2023 Plan&#x201d;) and approved the reserve of 33,333 of the Company&#x2019;s ordinary shares to issuance under the 2023 Plan. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; Under the Company&#x2019;s Plans, the Company may grant its officers, directors, employees and consultants, share options. Each share option granted shall be exercisable at such times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will be granted with a term in excess of 10 years. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; As of December 31, 2025, 8,667 shares available for future grant under the Company&#x2019;s 2023 Plans. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions granted by the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table summarizes Company&#x2019;s option activity during the year ended December 31, 2025:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; remaining &lt;br/&gt; contractual &lt;br/&gt; terms &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; intrinsic &lt;br/&gt; value&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: justify"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,610&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2016546657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Forfeited/expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(77&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1216322058"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_113611892"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding at December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;49,533&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;87.31&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_84170453"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Vested and expected to vest at December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;49,533&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;87.31&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_299793311"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable at December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,497&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;143.98&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1788048371"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average remaining contractual life for the shares subject to options outstanding as of December&#160;31, 2025, 2024 and 2023 was 6.6 years, 7.1 years and 5.88 years, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average grant date fair value in 2025 was $8.0, in 2024 was $60 and in 2023 was $30 and the remaining compensation costs not yet recognized as of December 31, 2025 is $133 with a weighted average period of 7.6 years to recognize these expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The fair value of the Company&#x2019;s share options granted was estimated using the binomial option pricing model using the following range assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 61%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-weight: bold;"&gt;Description&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-weight: bold;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-weight: bold;"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.04%-4.21%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.64%-5.09%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.95%-3.96%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;79.56%-79.82%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;83.40%-83.94%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;84.30%-84.76%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0%&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0%&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contractual life (in years)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.75-10&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Early Exercise Multiple (Suboptimal Factor)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenses recognized in the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative (*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;283&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;178&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;340&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;362&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Including $141 and $112 share based compensation for services provided in 2025 and 2024, refer to note 9(b)(6) and note 9(b)(1), respectively.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1677178547"
      decimals="2"
      id="ixv-17437"
      unitRef="uref_1677178547">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights contextRef="cref_184434641" id="ixv-17438">one</us-gaap:CommonStockVotingRights>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="cref_1778457142"
      decimals="0"
      id="fc_1778457142"
      unitRef="uref_734008993">5000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_1743024573"
      decimals="-3"
      id="fc_611616676"
      unitRef="uref_720247910">112000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_54615801"
      decimals="0"
      id="ixv-17441"
      unitRef="uref_734008993">1666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_2043010181"
      decimals="0"
      id="ixv-17442"
      unitRef="uref_734008993">3333334</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1922956513"
      decimals="0"
      id="ixv-17443"
      unitRef="uref_734008993">285714</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1922956513"
      decimals="2"
      id="ixv-17444"
      unitRef="uref_1278442780">17.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="cref_2133907439"
      decimals="-3"
      id="fc_1850396623"
      unitRef="uref_720247910">5000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="cref_2133907439"
      decimals="-3"
      id="ixv-17446"
      unitRef="uref_720247910">512000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_889933283"
      decimals="0"
      id="ixv-17447"
      unitRef="uref_734008993">571429</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_889933283"
      decimals="2"
      id="ixv-17448"
      unitRef="uref_1278442780">22.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1329224424"
      decimals="0"
      id="ixv-17449"
      unitRef="uref_734008993">20000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1329224424"
      decimals="2"
      id="ixv-17450"
      unitRef="uref_1278442780">21.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM
      contextRef="cref_1743024573"
      decimals="0"
      id="ixv-17451"
      unitRef="uref_734008993">99037</canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17452"
      unitRef="uref_720247910">2223000</canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts>
    <canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM
      contextRef="cref_236998777"
      decimals="0"
      id="ixv-17453"
      unitRef="uref_734008993">530698</canf:StockIssuedDuringPeriodSharesIssuanceOfOrdinarySharesDueToATM>
    <canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17454"
      unitRef="uref_720247910">2933000</canf:IssuanceOfOrdinarySharesDueToATMNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="cref_1335503686"
      decimals="0"
      id="fc_1335503686"
      unitRef="uref_734008993">10000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="cref_236998777"
      decimals="-3"
      id="ixv-17456"
      unitRef="uref_720247910">141000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="cref_673085692"
      decimals="0"
      id="ixv-17457"
      unitRef="uref_734008993">250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="cref_374804358"
      decimals="1"
      id="fc_374804358"
      unitRef="uref_1278442780">12</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="cref_184434641"
      decimals="-3"
      id="fc_583619321"
      unitRef="uref_720247910">3000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17460"
      unitRef="uref_720247910">452000</us-gaap:PaymentsOfStockIssuanceCosts>
    <canf:ClassOfWarrantOrRightPercentage
      contextRef="cref_487979537"
      decimals="3"
      id="fc_462856129"
      unitRef="uref_1413771939">0.07</canf:ClassOfWarrantOrRightPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1503704402"
      decimals="0"
      id="ixv-17462"
      unitRef="uref_734008993">17500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_487979537"
      decimals="0"
      id="fc_487979537"
      unitRef="uref_734008993">8750</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="cref_184434641"
      decimals="1"
      id="ixv-17464"
      unitRef="uref_1278442780">30</us-gaap:StockOptionExercisePriceIncrease>
    <canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance
      contextRef="cref_870625474"
      decimals="0"
      id="ixv-17465"
      unitRef="uref_734008993">3333334</canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1249276182"
      decimals="0"
      id="ixv-17466"
      unitRef="uref_734008993">6666667</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1536062095"
      decimals="-3"
      id="fc_31012697"
      unitRef="uref_720247910">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="cref_1536062095"
      decimals="-3"
      id="ixv-17468"
      unitRef="uref_720247910">4200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1039317372"
      decimals="0"
      id="ixv-17469"
      unitRef="uref_734008993">125000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1465389010"
      decimals="0"
      id="ixv-17470"
      unitRef="uref_734008993">62500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_2132039962"
      decimals="0"
      id="ixv-17471"
      unitRef="uref_734008993">354167</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1839015054"
      decimals="0"
      id="ixv-17472"
      unitRef="uref_734008993">708334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_2132039962"
      decimals="0"
      id="ixv-17473"
      unitRef="uref_734008993">354167</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_575156313"
      decimals="0"
      id="ixv-17474"
      unitRef="uref_734008993">833333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1039317372"
      decimals="0"
      id="ixv-17475"
      unitRef="uref_734008993">1666667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_275892941"
      decimals="0"
      id="ixv-17476"
      unitRef="uref_734008993">833333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_2132039962"
      decimals="2"
      id="ixv-17477"
      unitRef="uref_1278442780">11.98</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_421138161"
      decimals="1"
      id="ixv-17478"
      unitRef="uref_1278442780">6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_275892941"
      decimals="1"
      id="ixv-17479"
      unitRef="uref_1278442780">12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:CashPlacementFee
      contextRef="cref_1755993480"
      decimals="-3"
      id="ixv-17480"
      unitRef="uref_720247910">837000</canf:CashPlacementFee>
    <canf:ClassOfWarrantOrRightPercentage
      contextRef="cref_1886921177"
      decimals="3"
      id="ixv-17481"
      unitRef="uref_1413771939">0.07</canf:ClassOfWarrantOrRightPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1886921177"
      decimals="0"
      id="ixv-17482"
      unitRef="uref_734008993">58334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1465389010"
      decimals="0"
      id="fc_658807105"
      unitRef="uref_734008993">29167</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="cref_1363860027"
      decimals="1"
      id="ixv-17484"
      unitRef="uref_1278442780">7.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="cref_1465389010"
      decimals="1"
      id="ixv-17485"
      unitRef="uref_1278442780">15</us-gaap:SharesIssuedPricePerShare>
    <canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance
      contextRef="cref_1250994810"
      decimals="0"
      id="ixv-17486"
      unitRef="uref_734008993">125000</canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1554927284"
      decimals="0"
      id="ixv-17487"
      unitRef="uref_734008993">250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <canf:IncreaseAuthorizedShareCapital
      contextRef="cref_2040359165"
      decimals="0"
      id="ixv-17488"
      unitRef="uref_734008993">7333333</canf:IncreaseAuthorizedShareCapital>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_2040359165"
      decimals="0"
      id="ixv-17489"
      unitRef="uref_734008993">14000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="cref_2037786040" id="ixv-17490">1:3,000</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="cref_1078174181"
      decimals="0"
      id="ixv-17491"
      unitRef="uref_734008993">300</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="cref_801816110"
      decimals="0"
      id="ixv-17492"
      unitRef="uref_734008993">2</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance
      contextRef="cref_1336110434"
      decimals="0"
      id="ixv-17493"
      unitRef="uref_734008993">229167</canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1116774511"
      decimals="0"
      id="ixv-17494"
      unitRef="uref_734008993">458334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance
      contextRef="cref_435254208"
      decimals="0"
      id="ixv-17495"
      unitRef="uref_734008993">833333</canf:StockIssuedDuringPeriodSharesReleaseOfOrdinarySharesThatWerePreviouslyHeldInAbeyance>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1936150275"
      decimals="0"
      id="ixv-17496"
      unitRef="uref_734008993">1666667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_48256838"
      decimals="1"
      id="ixv-17497"
      unitRef="uref_1278442780">12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_997732034"
      decimals="2"
      id="ixv-17498"
      unitRef="uref_1278442780">9.34</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="cref_184434641" id="ixv-14281">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table summarizes information regarding outstanding warrants to purchase the Company&#x2019;s ordinary shares as of December 31, 2025:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Issuance date&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Number of &lt;br/&gt; outstanding &lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Exercise &lt;br/&gt; price per &lt;br/&gt; warrant&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: justify"&gt;December 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;January 2023 agent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;68.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;November 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;November 2023 agent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,746&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;19.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;August 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;571,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;22.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;August 2024 agent&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;21.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;April 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;15.0&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;July 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,666,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;July 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;58,333&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,604,097&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <canf:IssuanceDate contextRef="cref_1731853064" id="ixv-17499">December 2021</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_197686924"
      decimals="0"
      id="ixv-17500"
      unitRef="uref_734008993">3500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_197686924"
      decimals="1"
      id="ixv-17501"
      unitRef="uref_1278442780">200</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_1443470887" id="ixv-17502">January 2023 agent</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1156080072"
      decimals="0"
      id="ixv-17503"
      unitRef="uref_734008993">9545</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1156080072"
      decimals="2"
      id="ixv-17504"
      unitRef="uref_1278442780">68.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_797890104" id="ixv-17505">November 2023</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1820958487"
      decimals="0"
      id="ixv-17506"
      unitRef="uref_734008993">243377</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1820958487"
      decimals="2"
      id="ixv-17507"
      unitRef="uref_1278442780">17.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_1043966202" id="ixv-17508">November 2023 agent</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1968813787"
      decimals="0"
      id="ixv-17509"
      unitRef="uref_734008993">13746</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1968813787"
      decimals="2"
      id="ixv-17510"
      unitRef="uref_1278442780">19.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_272935354" id="ixv-17511">August 2024</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_160240094"
      decimals="0"
      id="ixv-17512"
      unitRef="uref_734008993">571429</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_160240094"
      decimals="2"
      id="ixv-17513"
      unitRef="uref_1278442780">22.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_910941741" id="ixv-17514">August 2024 agent</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1783668540"
      decimals="0"
      id="ixv-17515"
      unitRef="uref_734008993">20000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1783668540"
      decimals="2"
      id="ixv-17516"
      unitRef="uref_1278442780">21.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_533550791" id="ixv-17517">April 2025</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1404131453"
      decimals="0"
      id="ixv-17518"
      unitRef="uref_734008993">17500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1404131453"
      decimals="1"
      id="ixv-17519"
      unitRef="uref_1278442780">15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_1056014996" id="ixv-17520">July 2025</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1665281426"
      decimals="0"
      id="ixv-17521"
      unitRef="uref_734008993">1666667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1665281426"
      decimals="2"
      id="ixv-17522"
      unitRef="uref_1278442780">4.67</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="cref_1019937961" id="ixv-17523">July 2025</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1358509655"
      decimals="0"
      id="ixv-17524"
      unitRef="uref_734008993">58333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1358509655"
      decimals="2"
      id="ixv-17525"
      unitRef="uref_1278442780">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_202162938"
      decimals="0"
      id="ixv-17526"
      unitRef="uref_734008993">2604097</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1355753607"
      decimals="0"
      id="ixv-17527"
      unitRef="uref_734008993">28333</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_862142534"
      decimals="0"
      id="fc_862142534"
      unitRef="uref_734008993">33333</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <canf:GrantedExcessYears contextRef="cref_1997617154" id="ixv-17529">P10Y</canf:GrantedExcessYears>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_109046716"
      decimals="0"
      id="ixv-17530"
      unitRef="uref_734008993">8667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="cref_184434641" id="ixv-14451">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table summarizes Company&#x2019;s option activity during the year ended December 31, 2025:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; remaining &lt;br/&gt; contractual &lt;br/&gt; terms &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate &lt;br/&gt; intrinsic &lt;br/&gt; value&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%; text-align: justify"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;41,610&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_2016546657"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Forfeited/expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(77&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1216322058"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_113611892"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding at December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;49,533&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;87.31&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_84170453"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Vested and expected to vest at December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;49,533&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;87.31&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6.6&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_299793311"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable at December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,497&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;143.98&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.7&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1788048371"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_678032609"
      decimals="0"
      id="ixv-17531"
      unitRef="uref_734008993">41610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_678032609"
      decimals="0"
      id="ixv-17532"
      unitRef="uref_1278442780">90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_219588702" id="fc_219588702">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_184434641"
      decimals="0"
      id="ixv-17534"
      unitRef="uref_734008993">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="cref_184434641"
      decimals="2"
      id="ixv-17535"
      unitRef="uref_1278442780">16.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <canf:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants contextRef="cref_184434641" id="ixv-17536">P10Y</canf:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTermsGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="cref_184434641"
      decimals="0"
      id="ixv-17537"
      unitRef="uref_734008993">77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1997617154"
      decimals="0"
      id="ixv-17538"
      unitRef="uref_734008993">49533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1997617154"
      decimals="2"
      id="ixv-17539"
      unitRef="uref_1278442780">87.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_184434641" id="ixv-17540">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="cref_1997617154"
      decimals="0"
      id="ixv-17541"
      unitRef="uref_734008993">49533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="cref_1997617154"
      decimals="2"
      id="ixv-17542"
      unitRef="uref_1278442780">87.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="cref_184434641" id="ixv-17543">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="cref_1997617154"
      decimals="0"
      id="ixv-17544"
      unitRef="uref_734008993">25497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1997617154"
      decimals="2"
      id="ixv-17545"
      unitRef="uref_1278442780">143.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="cref_184434641" id="ixv-17546">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_184434641" id="ixv-17547">P6Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_1205104151" id="ixv-17548">P7Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="cref_1914073660" id="ixv-17549">P5Y10M17D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="cref_184434641"
      decimals="1"
      id="ixv-17550"
      unitRef="uref_1278442780">8</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="cref_1205104151"
      decimals="0"
      id="ixv-17551"
      unitRef="uref_1278442780">60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="cref_1914073660"
      decimals="0"
      id="ixv-17552"
      unitRef="uref_1278442780">30</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17553"
      unitRef="uref_720247910">133000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="cref_184434641" id="ixv-17554">P7Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="cref_184434641" id="ixv-14683">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The fair value of the Company&#x2019;s share options granted was estimated using the binomial option pricing model using the following range assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 61%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-weight: bold;"&gt;Description&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-weight: bold;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-weight: bold;"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.04%-4.21%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.64%-5.09%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.95%-3.96%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;79.56%-79.82%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;83.40%-83.94%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;84.30%-84.76%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0%&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0%&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Contractual life (in years)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.75-10&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Early Exercise Multiple (Suboptimal Factor)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_583004226"
      decimals="4"
      id="ixv-17555"
      unitRef="uref_1413771939">0.0404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_342246256"
      decimals="4"
      id="ixv-17556"
      unitRef="uref_1413771939">0.0421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_520798346"
      decimals="4"
      id="ixv-17557"
      unitRef="uref_1413771939">0.0464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_907931666"
      decimals="4"
      id="ixv-17558"
      unitRef="uref_1413771939">0.0509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1803955859"
      decimals="4"
      id="ixv-17559"
      unitRef="uref_1413771939">0.0395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1055653923"
      decimals="4"
      id="ixv-17560"
      unitRef="uref_1413771939">0.0396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_583004226"
      decimals="4"
      id="ixv-17561"
      unitRef="uref_1413771939">0.7956</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_342246256"
      decimals="4"
      id="ixv-17562"
      unitRef="uref_1413771939">0.7982</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_520798346"
      decimals="4"
      id="ixv-17563"
      unitRef="uref_1413771939">0.834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_907931666"
      decimals="4"
      id="ixv-17564"
      unitRef="uref_1413771939">0.8394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1803955859"
      decimals="4"
      id="ixv-17565"
      unitRef="uref_1413771939">0.843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1055653923"
      decimals="4"
      id="ixv-17566"
      unitRef="uref_1413771939">0.8476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_184434641"
      decimals="2"
      id="ixv-17567"
      unitRef="uref_1413771939">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_1205104151"
      decimals="2"
      id="ixv-17568"
      unitRef="uref_1413771939">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_1914073660"
      decimals="2"
      id="ixv-17569"
      unitRef="uref_1413771939">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_184434641" id="ixv-17570">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_520798346" id="ixv-17571">P9Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_907931666" id="ixv-17572">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_1914073660" id="ixv-17573">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
      contextRef="cref_184434641"
      decimals="3"
      id="ixv-17574"
      unitRef="uref_1413771939">0.025</canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
      contextRef="cref_1205104151"
      decimals="3"
      id="ixv-17575"
      unitRef="uref_1413771939">0.025</canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
      contextRef="cref_1914073660"
      decimals="3"
      id="ixv-17576"
      unitRef="uref_1413771939">0.025</canf:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="cref_184434641" id="ixv-17577">Expenses recognized in the financial statements:&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative (*)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;283&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;178&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;340&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;362&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Including $141 and $112 share based compensation for services provided in 2025 and 2024, refer to note 9(b)(6) and note 9(b)(1), respectively.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1607629638"
      decimals="-3"
      id="ixv-17578"
      unitRef="uref_720247910">57000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_42715392"
      decimals="-3"
      id="ixv-17579"
      unitRef="uref_720247910">75000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1190382762"
      decimals="-3"
      id="ixv-17580"
      unitRef="uref_720247910">83000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1398170537"
      decimals="-3"
      id="fc_1398170537"
      unitRef="uref_720247910">283000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1132214309"
      decimals="-3"
      id="fc_1132214309"
      unitRef="uref_720247910">287000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1202395540"
      decimals="-3"
      id="fc_1202395540"
      unitRef="uref_720247910">178000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17584"
      unitRef="uref_720247910">340000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17585"
      unitRef="uref_720247910">362000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17586"
      unitRef="uref_720247910">261000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="cref_184434641"
      decimals="-3"
      id="fc_756498042"
      unitRef="uref_720247910">141000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="cref_1205104151"
      decimals="-3"
      id="fc_532889771"
      unitRef="uref_720247910">112000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="cref_184434641" id="ixv-14877">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 10:- LEASES:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt; The Company has lease contracts for motor vehicles used in its operations. Leases of motor vehicles have lease terms of 3 years. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following is a summary of weighted average remaining lease terms and discount rate for all of the Company&#x2019;s operating leases:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;weighted average remaining lease term (years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.49&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;The components of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2025 and 2024 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;Components of lease expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;53&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;44&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;56&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;Supplemental cash flow information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;56&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;42&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;Maturities of lease liabilities as of December 31, 2025 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total operating lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;92&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Present value of lease liability&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;71&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="cref_1894462461" id="ixv-17590">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock contextRef="cref_184434641" id="ixv-14883">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following is a summary of weighted average remaining lease terms and discount rate for all of the Company&#x2019;s operating leases:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;weighted average remaining lease term (years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.49&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;The components of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2025 and 2024 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt; 2025&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;Components of lease expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;53&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;44&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;56&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31, &lt;br/&gt; 2025&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31, &lt;br/&gt; 2024&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;Supplemental cash flow information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;56&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;42&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="cref_1997617154" id="ixv-17591">P1Y6M7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="cref_678032609" id="ixv-17592">P2Y5M26D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="cref_1997617154"
      decimals="2"
      id="ixv-17593"
      unitRef="uref_1413771939">0.13</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="cref_678032609"
      decimals="2"
      id="ixv-17594"
      unitRef="uref_1413771939">0.13</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17595"
      unitRef="uref_720247910">53000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17596"
      unitRef="uref_720247910">44000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17597"
      unitRef="uref_720247910">56000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17598"
      unitRef="uref_720247910">56000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17599"
      unitRef="uref_720247910">42000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="cref_184434641" id="ixv-15017">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"&gt;Maturities of lease liabilities as of December 31, 2025 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;32&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total operating lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;92&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Present value of lease liability&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;71&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17600"
      unitRef="uref_720247910">60000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17601"
      unitRef="uref_720247910">32000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17602"
      unitRef="uref_720247910">92000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17603"
      unitRef="uref_720247910">21000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17604"
      unitRef="uref_720247910">71000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="cref_184434641" id="ixv-15053">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 11:-&#160;FINANCE INCOME (EXPENSE), NET&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: justify"&gt;Interest income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;284&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;291&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Bank commissions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Exchange rate fluctuations and others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(144&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;short-term investment revaluation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total financial income (expenses), net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;122&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;561&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="cref_184434641" id="ixv-15057">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: justify"&gt;Interest income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;284&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;291&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;Bank commissions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Exchange rate fluctuations and others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(144&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;short-term investment revaluation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total financial income (expenses), net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;122&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;250&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;561&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestExpenseNonoperating
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17605"
      unitRef="uref_720247910">284000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17606"
      unitRef="uref_720247910">291000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17607"
      unitRef="uref_720247910">506000</us-gaap:InterestExpenseNonoperating>
    <canf:BankCommissions
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17608"
      unitRef="uref_720247910">-14000</canf:BankCommissions>
    <canf:BankCommissions
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17609"
      unitRef="uref_720247910">-14000</canf:BankCommissions>
    <canf:BankCommissions
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17610"
      unitRef="uref_720247910">-14000</canf:BankCommissions>
    <canf:ExchangeRateFluctuationsAndOthers
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17611"
      unitRef="uref_720247910">-144000</canf:ExchangeRateFluctuationsAndOthers>
    <canf:ExchangeRateFluctuationsAndOthers
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17612"
      unitRef="uref_720247910">-13000</canf:ExchangeRateFluctuationsAndOthers>
    <canf:ExchangeRateFluctuationsAndOthers
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17613"
      unitRef="uref_720247910">58000</canf:ExchangeRateFluctuationsAndOthers>
    <canf:OtherGainFromShortTermInvestmentRemeasurement
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17614"
      unitRef="uref_720247910">-4000</canf:OtherGainFromShortTermInvestmentRemeasurement>
    <canf:OtherGainFromShortTermInvestmentRemeasurement
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17615"
      unitRef="uref_720247910">-14000</canf:OtherGainFromShortTermInvestmentRemeasurement>
    <canf:OtherGainFromShortTermInvestmentRemeasurement
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17616"
      unitRef="uref_720247910">11000</canf:OtherGainFromShortTermInvestmentRemeasurement>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_184434641"
      decimals="-3"
      id="ixv-17617"
      unitRef="uref_720247910">122000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_1205104151"
      decimals="-3"
      id="ixv-17618"
      unitRef="uref_720247910">250000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_1914073660"
      decimals="-3"
      id="ixv-17619"
      unitRef="uref_720247910">561000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="cref_184434641" id="ixv-15158">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 12:-&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-weight: bold;"&gt;SEGMENT REPORTING &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-indent: -0.7in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; ASC 280, &#x201c;Segment Reporting,&#x201d; establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources and in assessing performance. The Company&#x2019;s business is comprised of&#160;one&#160;operating segment. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: -0.7in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; The Company&#x2019;s CODM is its &lt;span style="-sec-ix-hidden:fc_698904215"&gt;Chief Executive Officer&lt;/span&gt; (&#x201c;CEO&#x201d;), who reviews financial information presented on a consolidated basis. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in; text-align: justify; text-indent: -0.7in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; The CODM uses consolidated net income to measure segment profit or loss, to allocate resources and assess performance. Further, the CODM reviews and utilizes functional expenses (research and development and general and administrative) at the consolidated level to manage the Company&#x2019;s operations and evaluate return on total assets in deciding whether to invest in the development and expansion of the Company&#x2019;s consolidated operations. &lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="cref_184434641"
      decimals="0"
      id="ixv-17620"
      unitRef="uref_2084217627">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription contextRef="cref_184434641" id="ixv-17621">The CODM uses consolidated net income to measure segment profit or loss, to allocate resources and assess performance. Further, the CODM reviews and utilizes functional expenses (research and development and general and administrative) at the consolidated level to manage the Company&#x2019;s operations and evaluate return on total assets in deciding whether to invest in the development and expansion of the Company&#x2019;s consolidated operations.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="cref_184434641" id="ixv-15185">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 13:-&#160;TAXES ON INCOME&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate tax rates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Israeli taxation:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; Corporate tax rate in Israel in 2025, 2024 and 2023 was 23%. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Law for the Encouragement of Capital Investments, 1959:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Law for Encouragement of Capital Investments, 1959 (the &#x201c;Investment Law&#x201d;) provides tax benefits for Israeli companies meeting certain requirements and criteria. The Investment Law has undergone certain amendments and reforms in recent years.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Israeli parliament enacted a reform to the Investment Law, effective January 2011 (which was amended in August 2013). According to the reform, a flat rate tax applies to Preferred Income of companies eligible for the &#x201c;Preferred Enterprise&#x201d; status. In order to be eligible for Preferred Enterprise status, a company must meet minimum requirements to establish that it contributes to the country&#x2019;s economic growth and is a competitive factor for the gross domestic product.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; Benefits granted to a Preferred Enterprise include reduced tax rates. As part of the Economic Efficiency Law (Legislative Amendments for Accomplishment of Budgetary Targets for Budget Years 2017-2018), 5777-2016, the tax rate is&#160;16% for all areas other than Development Area A (which was&#160;7.5% from 2017 onward). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Final tax assessments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s tax return up until the year ended December 31, 2020 are considered final.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net operating carryforward losses for tax purposes and other temporary differences:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; As of December 31, 2025, the Company had carryforward losses amounting to approximately $205,100 that can be carryforward indefinitely &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred income taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Temporary differences mainly relating to Research and Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,279&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,062&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Deferred tax asset before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,094&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(34,094&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax asset, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_539237308"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_506692405"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reconciliation of the theoretical tax expense to the actual tax expense:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes and the company&#x2019;s preferred enterprise tax rate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;A reconciliation of the provision for income taxes to the amount computed by applying the&#160;23% statutory Israeli income tax rate to income before income taxes after the adoption of ASU 2023-09 is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;Tax at Israeli Statutory Rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 0.125in"&gt;Effect of benefitted income preferred technological enterprise in Israel&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;688&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 0.25in"&gt;Changes in Valuation Allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Share-based payment awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective Tax Rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1936936551"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_605971914"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="cref_248394047"
      decimals="2"
      id="ixv-17622"
      unitRef="uref_1413771939">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="cref_616608710"
      decimals="2"
      id="ixv-17623"
      unitRef="uref_1413771939">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="cref_697212563"
      decimals="2"
      id="ixv-17624"
      unitRef="uref_1413771939">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="cref_184434641"
      decimals="2"
      id="fc_405959774"
      unitRef="uref_1413771939">0.16</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="cref_44387193"
      decimals="3"
      id="ixv-17626"
      unitRef="uref_1413771939">0.075</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:OperatingLossCarryforwards
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17627"
      unitRef="uref_720247910">205100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="cref_184434641" id="ixv-15260">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Temporary differences mainly relating to Research and Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,279&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,062&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Deferred tax asset before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,094&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,060&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(34,094&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28,060&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax asset, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_539237308"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_506692405"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17628"
      unitRef="uref_720247910">32815000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17629"
      unitRef="uref_720247910">26998000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17630"
      unitRef="uref_720247910">1279000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17631"
      unitRef="uref_720247910">1062000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17632"
      unitRef="uref_720247910">34094000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17633"
      unitRef="uref_720247910">28060000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="cref_1997617154"
      decimals="-3"
      id="ixv-17634"
      unitRef="uref_720247910">34094000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="cref_678032609"
      decimals="-3"
      id="ixv-17635"
      unitRef="uref_720247910">28060000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="cref_184434641" id="ixv-15360">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;A reconciliation of the provision for income taxes to the amount computed by applying the&#160;23% statutory Israeli income tax rate to income before income taxes after the adoption of ASU 2023-09 is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;Tax at Israeli Statutory Rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,260&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 0.125in"&gt;Effect of benefitted income preferred technological enterprise in Israel&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;688&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 0.25in"&gt;Changes in Valuation Allowances&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,524&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"&gt;Share-based payment awards&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Effective Tax Rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_1936936551"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden:fc_605971914"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="cref_898003050"
      decimals="-3"
      id="ixv-17636"
      unitRef="uref_720247910">-2260000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="cref_898003050"
      decimals="2"
      id="ixv-17637"
      unitRef="uref_1413771939">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <canf:EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount
      contextRef="cref_898003050"
      decimals="-3"
      id="ixv-17638"
      unitRef="uref_720247910">688000</canf:EffectOfBenefittedIncomePreferredTechnologicalEnterpriseInIsraelAmount>
    <canf:EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael
      contextRef="cref_898003050"
      decimals="2"
      id="ixv-17639"
      unitRef="uref_1413771939">-0.07</canf:EffectiveIncomeTaxRateReconciliationBenefittedIncomePreferredTechnologicalEnterpriseInIsrael>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="cref_898003050"
      decimals="-3"
      id="ixv-17640"
      unitRef="uref_720247910">1524000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="cref_898003050"
      decimals="2"
      id="ixv-17641"
      unitRef="uref_1413771939">-0.16</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="cref_898003050"
      decimals="-3"
      id="ixv-17642"
      unitRef="uref_720247910">48000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="cref_898003050"
      decimals="2"
      id="ixv-17643"
      unitRef="uref_1413771939">-0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:SubsequentEventsTextBlock contextRef="cref_184434641" id="ixv-15452">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 14:- SUBSEQUENT EVENTS &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; On March 4, 2026, the Company entered into an inducement offer letter agreement (the &#x201c;Inducement Letter&#x201d;) with a certain holder (the &#x201c;Holder&#x201d;) of certain of the Company&#x2019;s existing warrants to purchase up to 795,869 of the Company&#x2019;s American Depositary Shares (&#x201c;ADS&#x201d;), each ADS representing two ordinary shares, no par value, issued on July 29, 2025 at an exercise price of&#160;$9.34 per ADS (the &#x201c;Existing Warrants&#x201d;). &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; Pursuant to the Inducement Letter, the Holder agreed to exercise for cash its Existing Warrants to purchase an aggregate of 795,869 of the Company&#x2019;s ADSs at a reduced exercise price of $5.00 per ADS in consideration of the Company&#x2019;s agreement to issue new warrants to purchase ADSs (the &#x201c;New Warrants&#x201d;), as described below, to purchase up to an aggregate of 1,591,738 ADSs (the &#x201c;New Warrant Shares&#x201d;), at an exercise price of $5.00 per ADS. The Company received aggregate gross proceeds of $4.0 million from the exercise of the Existing Warrants by the Holder, before deducting placement agent fees and other offering expenses payable by the Company. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; The Company also agreed to pay the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds received from the Holder&#x2019;s exercise of the Existing Warrants, as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the Existing Warrants. The Company has also agreed to issue to the placement agent to purchase up to 55,711 ADSs which will have the same terms as the New Warrants except that the Placement Agent Warrants will have an exercise price equal to $6.25 per ADS. Similar to the New Warrants, the Placement Agent Warrants will be immediately exercisable from the date of issuance until the two year anniversary of the effective date of the resale registration statement. In addition, the Company has also agreed to pay the placement agent $91 for other fees. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt; As part of the Inducement letter, the Company also received gross proceeds of approximately $350 following the exercise of 37,465 Existing Warrants. &lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="cref_1272600409"
      decimals="0"
      id="ixv-17644"
      unitRef="uref_734008993">795869</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1459093040"
      decimals="2"
      id="ixv-17645"
      unitRef="uref_1278442780">9.34</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1413771939"
      decimals="0"
      id="ixv-17646"
      unitRef="uref_734008993">795869</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceDecrease
      contextRef="cref_1060093280"
      decimals="2"
      id="ixv-17647"
      unitRef="uref_1278442780">5</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="cref_1994543132"
      decimals="0"
      id="ixv-17648"
      unitRef="uref_734008993">1591738</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1994543132"
      decimals="2"
      id="ixv-17649"
      unitRef="uref_1278442780">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="cref_1060093280"
      decimals="-5"
      id="ixv-17650"
      unitRef="uref_720247910">4000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <canf:ClassOfWarrantOrRightPercentage
      contextRef="cref_100549505"
      decimals="3"
      id="ixv-17651"
      unitRef="uref_1413771939">0.07</canf:ClassOfWarrantOrRightPercentage>
    <canf:ClassOfWarrantOrRightPercentage
      contextRef="cref_1413771939"
      decimals="3"
      id="ixv-17652"
      unitRef="uref_1413771939">0.01</canf:ClassOfWarrantOrRightPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="cref_1272600409"
      decimals="0"
      id="ixv-17653"
      unitRef="uref_734008993">55711</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1278442780"
      decimals="2"
      id="ixv-17654"
      unitRef="uref_1278442780">6.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:OtherExpenses
      contextRef="cref_1683224475"
      decimals="-3"
      id="ixv-17655"
      unitRef="uref_720247910">91000</us-gaap:OtherExpenses>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="cref_734008993"
      decimals="-3"
      id="ixv-17656"
      unitRef="uref_720247910">350000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="cref_734008993"
      decimals="0"
      id="ixv-17657"
      unitRef="uref_734008993">37465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#fc_1937695010"
          xlink:label="fc_1937695010"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_326785155"
          xlink:label="fc_326785155"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_760617434"
          xlink:label="fc_760617434"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1954273020"
          xlink:label="fc_1954273020"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1848454736"
          xlink:label="fc_1848454736"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1802511409"
          xlink:label="fc_1802511409"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_112058716"
          xlink:label="fc_112058716"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_523126391"
          xlink:label="fc_523126391"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_171354521"
          xlink:label="fc_171354521"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_718697983"
          xlink:label="fc_718697983"
          xlink:type="locator"/>
        <link:footnote id="fref_223778504" xlink:label="fref_223778504" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively adjusted to give effect to the reverse share split, see also note 9.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1937695010"
          xlink:to="fref_223778504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_326785155"
          xlink:to="fref_223778504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_760617434"
          xlink:to="fref_223778504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1954273020"
          xlink:to="fref_223778504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1848454736"
          xlink:to="fref_223778504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1802511409"
          xlink:to="fref_223778504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_112058716"
          xlink:to="fref_223778504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_523126391"
          xlink:to="fref_223778504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_171354521"
          xlink:to="fref_223778504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_718697983"
          xlink:to="fref_223778504"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_977396253"
          xlink:label="fc_977396253"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_50742992"
          xlink:label="fc_50742992"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2139747243"
          xlink:label="fc_2139747243"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1373640430"
          xlink:label="fc_1373640430"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1621210643"
          xlink:label="fc_1621210643"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1309137784"
          xlink:label="fc_1309137784"
          xlink:type="locator"/>
        <link:footnote id="fref_71790209" xlink:label="fref_71790209" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively adjusted to give effect to the reverse share split, see also note 9.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_977396253"
          xlink:to="fref_71790209"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_50742992"
          xlink:to="fref_71790209"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2139747243"
          xlink:to="fref_71790209"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1373640430"
          xlink:to="fref_71790209"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1621210643"
          xlink:to="fref_71790209"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1309137784"
          xlink:to="fref_71790209"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_1350392693"
          xlink:label="fc_1350392693"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_41120727"
          xlink:label="fc_41120727"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2021528685"
          xlink:label="fc_2021528685"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1254970073"
          xlink:label="fc_1254970073"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_777455571"
          xlink:label="fc_777455571"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1391618102"
          xlink:label="fc_1391618102"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1466338231"
          xlink:label="fc_1466338231"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_101309368"
          xlink:label="fc_101309368"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1004110757"
          xlink:label="fc_1004110757"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1574677278"
          xlink:label="fc_1574677278"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_3754123"
          xlink:label="fc_3754123"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2054232463"
          xlink:label="fc_2054232463"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_259543012"
          xlink:label="fc_259543012"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2039191230"
          xlink:label="fc_2039191230"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1027623191"
          xlink:label="fc_1027623191"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1816291455"
          xlink:label="fc_1816291455"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_549751167"
          xlink:label="fc_549751167"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_563207362"
          xlink:label="fc_563207362"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_554639177"
          xlink:label="fc_554639177"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_679399687"
          xlink:label="fc_679399687"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1556835653"
          xlink:label="fc_1556835653"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_964794137"
          xlink:label="fc_964794137"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_471624570"
          xlink:label="fc_471624570"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_200494866"
          xlink:label="fc_200494866"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_2108866782"
          xlink:label="fc_2108866782"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_462574281"
          xlink:label="fc_462574281"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_761083602"
          xlink:label="fc_761083602"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1316363029"
          xlink:label="fc_1316363029"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_887952012"
          xlink:label="fc_887952012"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1182592801"
          xlink:label="fc_1182592801"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_834906283"
          xlink:label="fc_834906283"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_776479262"
          xlink:label="fc_776479262"
          xlink:type="locator"/>
        <link:footnote id="fref_376288337" xlink:label="fref_376288337" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retroactively adjusted to give effect to the reverse share split, see also note 9.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1350392693"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_41120727"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2021528685"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1254970073"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_777455571"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1391618102"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1466338231"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_101309368"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1004110757"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1574677278"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_3754123"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2054232463"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_259543012"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2039191230"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1027623191"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1816291455"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_549751167"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_563207362"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_554639177"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_679399687"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1556835653"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_964794137"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_471624570"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_200494866"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2108866782"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_462574281"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_761083602"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1316363029"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_887952012"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1182592801"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_834906283"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_776479262"
          xlink:to="fref_376288337"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_1398170537"
          xlink:label="fc_1398170537"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1132214309"
          xlink:label="fc_1132214309"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_1202395540"
          xlink:label="fc_1202395540"
          xlink:type="locator"/>
        <link:footnote id="fref_49130764" xlink:label="fref_49130764" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Including $141 and $112 share based compensation for services provided in 2025 and 2024, refer to note 9(b)(6) and note 9(b)(1), respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1398170537"
          xlink:to="fref_49130764"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1132214309"
          xlink:to="fref_49130764"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1202395540"
          xlink:to="fref_49130764"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
